CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
3299018,32990183,3,F,19981101.0,20120723.0,19990121,20130610,PER,,1998SUS0117,BRISTOL MYERS SQUIBB,,2.0,YR,,F,Y,13.0,KG,20130610.0,,CN,US,US,SUSTIVA,Pyrexia;Rash maculo-papular;Swelling face,,,,,32990183.0,1.0,19981023.0,19981104.0,,,32990183.0,1.0,HIV infection
3790999,37909993,3,F,20020504.0,20151210.0,20020516,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11854981,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20151217.0,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy,37909993.0,OT,,,37909993.0,1.0,,20020401.0,,,37909993.0,1.0,HIV infection
3812755,38127553,3,F,20020212.0,20151224.0,20020711,20151228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11936044,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20151228.0,,OT,US,US,SUSTIVA,Abortion spontaneous;Placental disorder;Pregnancy,38127553.0,OT,,,,,,,,,38127553.0,1.0,Antiretroviral therapy
3865372,38653722,2,F,2001.0,20151112.0,20021125,20151126,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-11647732,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151126.0,,CN,US,US,SUSTIVA,Pregnancy,,,,,38653722.0,1.0,20011208.0,20011226.0,,,38653722.0,1.0,HIV infection
3927305,39273052,2,F,20030109.0,20151211.0,20030410,20151214,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12231734,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151214.0,,OT,US,US,SUSTIVA,Death;Pregnancy;Stillbirth,39273052.0,OT,,,39273052.0,1.0,20021007.0,20021007.0,,,39273052.0,1.0,HIV infection
3962911,39629114,4,F,20030416.0,20151210.0,20030630,20151221,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12302055,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20151221.0,,CN,US,FR,SUSTIVA,Pregnancy;Stillbirth;Umbilical cord compression,39629114.0,OT,,,39629114.0,1.0,20000303.0,200108.0,,,39629114.0,1.0,HIV infection
3971583,39715832,2,F,2002.0,20030710.0,20030722,20151207,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-12327581,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20151207.0,,MD,ZA,ZA,EFAVIRENZ,Caesarean section;Normal newborn;Pregnancy;Premature rupture of membranes,39715832.0,OT,,,39715832.0,1.0,20020828.0,,,,39715832.0,1.0,HIV infection
3990923,399092311,11,F,20030725.0,20210126.0,20030828,20210207,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12363941,BRISTOL MYERS SQUIBB,"BEGUINOT I, FRANCOZ B, BERNARD?CHABERT A, MOLIA A, BRODARD V, BERGER JL, ET AL. SECOND OBSERVATION OF A FULMINANT HEPATITIS IN A FEMALE PATIENT NOT COINFECTED, UNDER ANTIRETROVIRAL TRITHERAPY INCLUDING EFAVIRENZ. MEDICINE AND INFECTIOUS DISEASE. 2004?34(1):S148",43.0,YR,,F,Y,74.0,KG,20210207.0,,HP,FR,FR,SUSTIVA,Aggression;Ascites;Hepatic necrosis;Hepatitis A;Jaundice;Peritoneal haematoma;Somnolence;Vomiting,399092311.0,HO,,,399092311.0,1.0,20030412.0,20030728.0,,,399092311.0,1.0,HIV infection
3994361,39943612,2,F,19980909.0,20151124.0,20030905,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12370672,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20151208.0,,PH,FR,FR,EFAVIRENZ,Abortion spontaneous;Pregnancy on oral contraceptive;Thrombocytopenia,39943612.0,OT,,,39943612.0,1.0,19980906.0,20030320.0,,,39943612.0,1.0,HIV infection
3998162,39981628,8,F,20030104.0,20070622.0,20030915,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12374377,BRISTOL MYERS SQUIBB,,47.0,YR,,M,Y,,,20170210.0,,OT,JP,JP,EFAVIRENZ,Cerebellar haemorrhage;Hepatic encephalopathy;Hyperammonaemia;Hypertension;Spinal compression fracture,39981628.0,LT,,,39981628.0,1.0,20010906.0,20040704.0,,,39981628.0,1.0,HIV infection
4008254,40082544,4,F,20030520.0,20151125.0,20031006,20151208,EXP,,DK-BRISTOL-MYERS SQUIBB COMPANY-12399515,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20151208.0,,CN,DK,DK,EFAVIRENZ,Abortion missed;Exposure during pregnancy,40082544.0,HO,,,40082544.0,1.0,200109.0,200304.0,,,40082544.0,1.0,HIV infection
4092890,40928902,2,F,2003.0,20040217.0,20040223,20151223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12509352,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151223.0,,CN,US,US,SUSTIVA,Abnormal behaviour;Caesarean section;Live birth;Pregnancy;Premature delivery;Premature rupture of membranes;Suicidal ideation,40928902.0,OT,,,40928902.0,1.0,20031108.0,20031110.0,,,40928902.0,1.0,HIV infection
4102949,41029493,3,F,20040208.0,20040302.0,20040309,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12524641,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,,,20170210.0,,CN,US,JP,EFAVIRENZ,Death;Influenza;Pneumococcal sepsis;Pneumonia pneumococcal;Rash;Septic shock,41029493.0,HO,,,41029493.0,1.0,20040123.0,20040210.0,,,41029493.0,1.0,HIV infection
4116412,41164123,3,F,20040322.0,20160202.0,20040331,20160202,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12543211,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160202.0,,MD,FR,FR,SUSTIVA,Abortion induced;Pregnancy with implant contraceptive,41164123.0,OT,,,41164123.0,1.0,20031117.0,,,,41164123.0,1.0,HIV infection
4150515,41505155,5,F,20020301.0,20231117.0,20040607,20231122,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12605176,BRISTOL MYERS SQUIBB,"Peyriere H, Reynes J, Rouanet I, Daniel N, Merle de Boever C, Mauboussin J, et al. Renal tubular dysfunction associated with tenofovir therapy report of 7 cases. J Acquir Immune Defic Syndr. 2004 Mar 01;35(3):269-73.",56.0,YR,A,F,Y,56.0,KG,20231122.0,,MD,FR,FR,EFAVIRENZ,Pain in extremity;Renal tubular dysfunction,41505155.0,OT,,,41505155.0,1.0,200105.0,2002.0,335.0,DAY,41505155.0,1.0,HIV infection
4159551,41595514,4,F,20040125.0,20180217.0,20040625,20180302,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12618450,BRISTOL MYERS SQUIBB,,19.0,YR,,F,Y,53.0,KG,20180302.0,,OT,FR,FR,SUSTIVA,Abortion induced;Labelled drug-drug interaction medication error;Pregnancy;Pregnancy with implant contraceptive;Therapeutic response decreased,41595514.0,OT,,,41595514.0,1.0,20031215.0,20040322.0,,,41595514.0,1.0,HIV infection
4196147,41961476,6,F,20040323.0,20060324.0,20040825,20150415,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12676359,BRISTOL MYERS SQUIBB,,55.0,YR,,F,Y,,,20150415.0,N,CN,US,JP,EFAVIRENZ,Ascites;Hepatic encephalopathy;Hepatitis fulminant;Immune reconstitution inflammatory syndrome,41961476.0,HO,,,41961476.0,1.0,20040205.0,20040326.0,,,41961476.0,1.0,HIV infection
4201530,42015303,3,F,20040523.0,20151127.0,20040901,20151207,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12499257,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,56.0,KG,20151207.0,,OT,FR,FR,SUSTIVA,Polyhydramnios;Pregnancy;Premature delivery;Premature rupture of membranes,42015303.0,OT,,,42015303.0,1.0,20010401.0,,,,42015303.0,1.0,HIV test positive
4209582,42095823,3,F,20040815.0,20151118.0,20040915,20151124,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12700944,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,66.66,KG,20151124.0,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,42095823.0,OT,,,,,,,,,42095823.0,1.0,HIV infection
5679262,56792624,4,F,20030421.0,20050526.0,20041122,20170206,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12768867,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,,,20170206.0,,CN,US,JP,EFAVIRENZ,Diabetes mellitus,56792624.0,OT,,,56792624.0,1.0,20021217.0,20040524.0,,,56792624.0,1.0,HIV infection
5684101,56841013,3,F,2004.0,20151128.0,20041129,20151214,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-12571378,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,73.01,KG,20151214.0,,MD,US,US,SUSTIVA,Normal newborn;Pain;Pregnancy;Rash,,,,,56841013.0,1.0,20010313.0,20040217.0,,,56841013.0,1.0,HIV infection
5726120,572612011,11,F,20021125.0,20130218.0,20040414,20130221,EXP,,JP-ABBOTT-04P-087-0256455-00,ABBOTT,,33.0,YR,,M,Y,,,20130221.0,,PH,COUNTRY NOT SPECIFIED,JP,EFAVIRENZ,Amylase increased;Appendicitis;Blood triglycerides increased;Bradycardia;Dizziness;Feeling cold;Gamma-glutamyltransferase increased;Gastric ulcer;Herpes zoster;Weight decreased,572612011.0,HO,,,572612011.0,1.0,20021123.0,20021126.0,,,572612011.0,1.0,HIV infection
5760991,57609912,2,F,20030911.0,20130304.0,20050318,20130313,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-12896577,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20130313.0,,CN,ZA,BW,EFAVIRENZ,Anaemia;Neutropenia,57609912.0,HO,,,,,,,,,57609912.0,1.0,HIV infection
5768520,57685202,2,F,20040106.0,20151211.0,20050331,20151222,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-12330361,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20151222.0,,CN,US,CH,EFAVIRENZ,Pregnancy;Stillbirth,57685202.0,OT,,,57685202.0,2.0,20030701.0,20030701.0,,,57685202.0,1.0,HIV infection
5829241,58292412,2,F,200410.0,20150404.0,20050701,20150417,EXP,,LS-BRISTOL-MYERS SQUIBB COMPANY-13019666,BRISTOL MYERS SQUIBB,,28.0,YR,,M,Y,49.0,KG,20150417.0,N,OT,LS,LS,EFAVIRENZ,Anaemia;Hepatotoxicity;Immune reconstitution inflammatory syndrome;Jaundice;Tuberculosis,58292412.0,OT,,,58292412.0,1.0,20041007.0,20050114.0,,,58292412.0,1.0,HIV infection
5858118,58581186,6,F,,20190603.0,20050811,20200306,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13067566,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20200306.0,,HP,US,US,EFAVIRENZ.,Caesarean section;Gestational diabetes;Live birth;Pregnancy;Premature delivery,58581186.0,OT,,,58581186.0,1.0,20030310.0,20040313.0,,,58581186.0,1.0,HIV infection
5933714,59337142,2,F,,20130404.0,20051121,20130419,EXP,,2005US-01137,RANBAXY,,31.0,YR,,F,N,,,20130418.0,,OT,GB,,EFAVIRENZ,Agitation;Anaemia;Apraxia;Asthenia;Cerebellar syndrome;Demyelination;Depression;Dysarthria;Epstein-Barr virus infection;Extensor plantar response;Eye haemorrhage;Headache;Hyperreflexia;Immune reconstitution inflammatory syndrome;Leukopenia;Liver disorder;Lymph node tuberculosis;Lymphadenopathy;Muscular weakness;Nausea;No therapeutic response;Pyramidal tract syndrome;Retinal haemorrhage;Somnolence;Spleen disorder;Upper motor neurone lesion;VIIth nerve paralysis;Vasculitis;Vomiting,59337142.0,HO,59337142.0,HP,59337142.0,10.0,200407.0,,,,59337142.0,1.0,Antiretroviral therapy
5958680,59586803,3,F,20051218.0,20160107.0,20060111,20160112,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13232228,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20160112.0,,CN,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy,59586803.0,OT,,,59586803.0,1.0,20051002.0,20051002.0,,,59586803.0,1.0,Antiretroviral therapy
5959328,59593282,2,F,200311.0,20190911.0,20060112,20190918,EXP,DJ0500887,FR-GLAXOSMITHKLINE-B0405145A,GLAXOSMITHKLINE,,36.0,YR,,F,Y,82.0,KG,20190918.0,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,59593282.0,HO,,,59593282.0,1.0,20051010.0,20051021.0,,,59593282.0,1.0,HIV infection
6013572,60135723,3,F,1994.0,20160824.0,20060328,20160824,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-13309745,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,56.0,KG,20160824.0,,MD,DE,DE,SUSTIVA,Abdominal pain upper;Asthenia;Caesarean section;Diabetes mellitus;Diarrhoea;Drug ineffective;Flatulence;Herpes zoster;Lipodystrophy acquired;Live birth;Myalgia;Oedema peripheral;Pancreatitis acute;Pneumocystis jirovecii pneumonia;Pregnancy;Premature delivery;Pruritus;Urticaria papular,60135723.0,OT,,,60135723.0,1.0,1999.0,200110.0,,,60135723.0,1.0,HIV infection
6019176,60191763,3,F,20060317.0,20160225.0,20060405,20160225,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13322631,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20160225.0,,CN,US,ZA,EFAVIRENZ,Abortion induced;Pregnancy,60191763.0,OT,,,60191763.0,1.0,2005.0,20060316.0,,,60191763.0,1.0,Antiretroviral therapy
6040321,60403212,2,F,20040206.0,20190125.0,20060508,20190201,EXP,,FR-GILEAD-2006-0009517,GILEAD,,35.0,YR,A,M,Y,63.0,KG,20190201.0,,MD,FR,FR,SUSTIVA,Abdominal pain upper;Amylase increased;Cholelithiasis;Hyperbilirubinaemia;Jaundice;Lipase increased;Pancreatitis acute;Pancreatitis chronic;Vomiting,60403212.0,HO,,,60403212.0,1.0,20030416.0,20050901.0,,,60403212.0,1.0,HIV infection
6049025,604902522,22,F,20060216.0,20220428.0,20060519,20220511,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13375589,BRISTOL MYERS SQUIBB,,25.0,YR,A,F,Y,56.0,KG,20220512.0,,MD,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,604902522.0,HO,,,604902522.0,1.0,20050523.0,20050908.0,109.0,DAY,604902522.0,1.0,HIV infection
6049849,60498492,2,F,20050902.0,20200520.0,20060522,20200602,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13378054,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20200602.0,,HP,ZA,ZA,EFAVIRENZ.,Autoimmune haemolytic anaemia,60498492.0,OT,,,60498492.0,1.0,20050801.0,2005.0,,,60498492.0,1.0,HIV infection
6050433,60504335,5,F,20060428.0,20151120.0,20060523,20151124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-13379078,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,77.8,KG,20151124.0,,OT,CA,CA,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,60504335.0,OT,,,60504335.0,1.0,20050422.0,20060324.0,,,60504335.0,1.0,HIV test positive
6054320,60543205,5,F,20060215.0,20190123.0,20060530,20190131,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13386032,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,54.0,KG,20190131.0,,OT,FR,FR,SUSTIVA,Chondropathy;Osteonecrosis,60543205.0,OT,,,60543205.0,1.0,20051117.0,,,,60543205.0,1.0,HIV infection
6056312,60563123,3,F,2006.0,20190125.0,20060601,20190201,EXP,,FR-GILEAD-2006-0009632,GILEAD,,50.0,YR,A,M,Y,54.0,KG,20190201.0,,OT,FR,FR,SUSTIVA,Chondropathy;Osteonecrosis,60563123.0,OT,,,60563123.0,1.0,20051117.0,,,,60563123.0,1.0,HIV infection
6075544,60755442,2,F,20051215.0,20190125.0,20060630,20190201,EXP,,FR-GILEAD-2006-0009794,GILEAD,,51.0,YR,A,M,Y,58.0,KG,20190201.0,,MD,FR,FR,SUSTIVA,Gynaecomastia,60755442.0,HO,,,60755442.0,1.0,20050613.0,20060514.0,,,60755442.0,1.0,HIV infection
6078567,60785672,2,F,,20190125.0,20060707,20190201,EXP,,FR-GILEAD-2006-0009823,GILEAD,,50.0,YR,A,F,Y,45.0,KG,20190201.0,,MD,FR,FR,SUSTIVA,Hyperphosphaturia;Osteomalacia;Osteoporosis;Renal tubular dysfunction,60785672.0,DS,,,60785672.0,1.0,20021008.0,20060413.0,,,60785672.0,1.0,HIV infection
6078570,60785702,2,F,200606.0,20190903.0,20060707,20190905,EXP,,FR-GILEAD-2006-0009829,GILEAD,,43.0,YR,A,F,Y,,,20190905.0,,MD,FR,FR,SUSTIVA,Acute kidney injury;Cholelithiasis;Hepatomegaly;Pyelonephritis acute,60785702.0,HO,,,60785702.0,1.0,,20060607.0,,,60785702.0,1.0,HIV infection
6079477,60794772,2,F,200606.0,20190123.0,20060710,20190205,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13428768,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20190205.0,,OT,FR,FR,SUSTIVA,Acute kidney injury;Cholelithiasis;Hepatomegaly;Pyelonephritis acute,60794772.0,OT,,,60794772.0,1.0,,20060607.0,,,60794772.0,1.0,HIV infection
6089495,60894952,2,F,20041201.0,20190123.0,20060724,20190201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13445606,BRISTOL MYERS SQUIBB,,57.0,YR,,M,Y,49.0,KG,20190201.0,,OT,FR,FR,SUSTIVA,Blood creatinine increased;Fanconi syndrome;Hypophosphataemia,60894952.0,OT,,,60894952.0,1.0,20030901.0,20060408.0,,,60894952.0,1.0,HIV infection
6097869,60978693,3,F,200510.0,20130731.0,20060803,20130812,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13415054,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,70.0,KG,20130812.0,,OT,US,FR,EFAVIRENZ,Calculus urinary;Neurological symptom;Renal colic,60978693.0,HO,,,60978693.0,1.0,200409.0,20060627.0,,,60978693.0,1.0,HIV infection
6118986,61189862,2,F,20060415.0,20190125.0,20060830,20190201,EXP,,FR-GILEAD-2006-0010082,GILEAD,,52.0,YR,A,M,Y,64.0,KG,20190201.0,,MD,FR,FR,SUSTIVA,Cholestasis;Hyperlipidaemia;Hypertension;Renal infarct;Splenic infarction,61189862.0,LT,,,61189862.0,1.0,20040719.0,,,,61189862.0,1.0,Acquired immunodeficiency syndrome
6146531,61465315,5,F,20040929.0,20070328.0,20061013,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13533260,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,,,20170210.0,,CN,US,JP,EFAVIRENZ,Glucose tolerance impaired,61465315.0,OT,,,61465315.0,1.0,20040913.0,20050404.0,,,61465315.0,1.0,HIV infection
6158885,61588852,2,F,20060710.0,20190125.0,20061031,20190205,EXP,,FR-GILEAD-2006-0010537,GILEAD,,41.0,YR,A,M,Y,55.0,KG,20190205.0,,MD,FR,FR,SUSTIVA,Onychomadesis;Pruritus;Rash;Stevens-Johnson syndrome,61588852.0,HO,,,61588852.0,1.0,20060615.0,20060728.0,,,61588852.0,1.0,HIV infection
6158911,61589112,2,F,20060112.0,20151120.0,20061031,20151124,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13242870,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20151124.0,,CN,US,ZA,EFAVIRENZ,Abortion induced;Exposure during pregnancy,61589112.0,OT,,,61589112.0,1.0,200503.0,20060103.0,,,61589112.0,1.0,HIV infection
6161318,61613187,7,F,2006.0,20151214.0,20061103,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13559935,BRISTOL MYERS SQUIBB,,0.0,YR,,M,Y,,,20151218.0,,OT,US,ZA,EFAVIRENZ,Congenital nose malformation;Foetal exposure during pregnancy;Limb deformity;Premature baby;Talipes,61613187.0,OT,,,61613187.0,1.0,20050223.0,20051229.0,,,61613187.0,1.0,HIV infection
6174803,61748032,2,F,20060225.0,20140616.0,20061128,20140618,EXP,,GB-GILEAD-2006-0010708,GILEAD,,39.0,YR,,F,Y,,,20140617.0,N,OT,GB,GB,EFAVIRENZ,Abortion spontaneous;Pregnancy,61748032.0,OT,,,61748032.0,1.0,20050916.0,,,,61748032.0,1.0,HIV infection
6203174,62031742,2,F,2006.0,20151121.0,20061227,20151201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13329677,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20151201.0,,MD,FR,FR,SUSTIVA,Abortion spontaneous;Metrorrhagia;Pregnancy,62031742.0,OT,,,62031742.0,1.0,200512.0,200602.0,,,62031742.0,1.0,HIV infection
6208597,62085972,2,F,2006.0,20140610.0,20070104,20140618,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13627658,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20140618.0,N,CN,US,US,EFAVIRENZ,Haemolytic anaemia,62085972.0,OT,,,62085972.0,1.0,2006.0,2006.0,,,62085972.0,2.0,HIV infection
6238093,62380932,2,F,20060718.0,20070222.0,20070213,20070305,EXP,,PL-JNJFOC-20070200442,JOHNSON AND JOHNSON,,33.0,YR,A,F,Y,71.67,KG,20070305.0,,MD,PL,PL,SUSTIVA,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,62380932.0,HO,62380932.0,HP,,,,,,,62380932.0,1.0,HIV infection
6260112,62601125,5,F,,20160824.0,20070313,20160825,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-13709290,BRISTOL MYERS SQUIBB,,1.0,DY,,,Y,,,20160825.0,,OT,IT,IT,EFAVIRENZ,Foetal exposure during pregnancy;Talipes,62601125.0,OT,,,,,,,,,62601125.0,1.0,HIV infection
6302681,63026812,2,F,,20151125.0,20070502,20151209,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-13765631,BRISTOL MYERS SQUIBB,"STARGARD, M., KEGG, S., BRITISH HIV ASSOCIATION, HIV MEDICINE (8) PAGE 32",,,,F,Y,,,20151209.0,,OT,GB,GB,EFAVIRENZ,Abortion induced;Pregnancy,63026812.0,OT,,,,,,,,,63026812.0,1.0,HIV infection
6305804,630580411,11,F,20000318.0,20170711.0,20070507,20170802,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13769260,BRISTOL MYERS SQUIBB,,24.0,YR,,M,Y,,,20170802.0,,CN,JP,JP,EFAVIRENZ,Dizziness;Palpitations;Pulmonary hypertension,630580411.0,DS,,,630580411.0,1.0,19941119.0,20040514.0,,,630580411.0,1.0,HIV infection
6353942,63539426,6,F,20070704.0,20140606.0,20070710,20140611,EXP,,US-GILEAD-2007-0012626,GILEAD,,0.0,DY,,F,Y,1.11,KG,20140611.0,N,OT,US,US,SUSTIVA,Breech presentation;Dandy-Walker syndrome;Foetal growth restriction;Multiple congenital abnormalities;Stillbirth;Umbilical cord abnormality,63539426.0,OT,,,63539426.0,1.0,20070201.0,20070704.0,,,63539426.0,1.0,HIV infection
6362915,63629152,2,F,,20151119.0,20070720,20151203,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-13692827,BRISTOL MYERS SQUIBB,,,,,F,Y,55.0,KG,20151203.0,,CN,US,DE,SUSTIVA,Medication error;Pregnancy,,,,,63629152.0,1.0,200609.0,200701.0,,,63629152.0,1.0,HIV infection
6411936,64119362,2,F,,20151029.0,20070912,20151113,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13884366,BRISTOL MYERS SQUIBB,,,,,M,Y,3.91,KG,20151113.0,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Hypospadias,64119362.0,CA,,,,,,,,,64119362.0,1.0,HIV infection
6481176,64811762,2,F,,20071203.0,20071205,20151218,EXP,,NL-BRISTOL-MYERS SQUIBB COMPANY-14002315,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151218.0,,OT,NL,NL,EFAVIRENZ,In vitro fertilisation;Premature delivery;Premature rupture of membranes;Twin pregnancy;Virologic failure,64811762.0,OT,,,,,,,,,64811762.0,1.0,HIV infection
6532801,65328013,3,F,2007.0,20160824.0,20080123,20160824,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14046544,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20160824.0,,OT,FR,FR,SUSTIVA,Caesarean section;HELLP syndrome;Mania;Maternal exposure during pregnancy;Pre-eclampsia;Premature delivery;Twin pregnancy,65328013.0,OT,,,65328013.0,1.0,20070328.0,20070808.0,,,65328013.0,1.0,Antiretroviral therapy
6535257,653525712,12,F,200707.0,20150715.0,20080125,20150730,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14053466,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20150730.0,N,CN,GB,GB,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,653525712.0,OT,,,653525712.0,1.0,20021001.0,20070816.0,,,653525712.0,1.0,HIV infection
6612453,66124532,2,F,20080129.0,20151127.0,20080411,20151211,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13854682,BRISTOL MYERS SQUIBB,,17.0,YR,,F,Y,,,20151211.0,,CN,US,ZA,EFAVIRENZ,Caesarean section;Normal newborn;Pregnancy;Vulvovaginal warts,66124532.0,OT,,,66124532.0,1.0,20070322.0,20070618.0,,,66124532.0,1.0,HIV infection
6615249,66152492,2,F,,20151127.0,20080415,20151209,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14148324,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20151209.0,,CN,US,ZA,EFAVIRENZ,Foetal death;Maternal exposure during pregnancy,66152492.0,OT,,,66152492.0,1.0,20051122.0,20071126.0,,,66152492.0,1.0,HIV infection
6619574,66195742,2,F,,20151210.0,20080421,20151217,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-14156657,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151217.0,,CN,IE,IE,EFAVIRENZ,Ectopic pregnancy;Maternal exposure during pregnancy,66195742.0,OT,,,,,,,,,66195742.0,1.0,HIV infection
6621933,66219332,2,F,,20151210.0,20080423,20151217,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-14158273,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151217.0,,CN,IE,IE,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,66219332.0,OT,,,,,,,,,66219332.0,1.0,HIV infection
6621936,66219362,2,F,,20151210.0,20080423,20151215,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-14158299,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151215.0,,CN,IE,IE,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,66219362.0,OT,,,,,,,,,66219362.0,1.0,HIV infection
6631522,66315225,5,F,20080125.0,20150730.0,20080502,20150811,EXP,,FR-GILEAD-2008-0016228,GILEAD,,26.0,YR,A,F,Y,,,20150811.0,N,OT,FR,FR,SUSTIVA,Abortion induced;Congenital anomaly;Ultrasound antenatal screen abnormal,66315225.0,CA,,,66315225.0,1.0,20060101.0,,,,66315225.0,1.0,HIV infection
6635741,66357412,2,F,20080411.0,20151030.0,20080508,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14182448,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20151113.0,,MD,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Selective abortion,66357412.0,OT,,,,,,,,,66357412.0,1.0,HIV infection
6641856,66418561,1,I,,20080506.0,20080516,20080516,EXP,,FR-JNJFOC-20080500998,TIBOTEC,,53.0,YR,A,M,Y,,,20080516.0,,MD,FR,FR,EFAVIRENZ.,Pancytopenia,66418561.0,HO,66418561.0,HP,,,,,,,66418561.0,2.0,HIV infection
6650762,66507623,3,F,20080424.0,20180606.0,20080528,20180611,EXP,,FR-GILEAD-2008-0016477,GILEAD,,31.0,YR,A,F,Y,,,20180611.0,,MD,FR,FR,SUSTIVA,Blood lactate dehydrogenase increased;Erythema;Eyelid oedema;Nausea;Pyrexia;Rash maculo-papular;Toxic skin eruption;Transaminases increased,66507623.0,OT,,,66507623.0,1.0,20080418.0,20080424.0,,,66507623.0,1.0,HIV infection
6656066,66560662,2,F,,20151208.0,20080603,20151209,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14170856,BRISTOL MYERS SQUIBB,,,,,F,Y,83.0,KG,20151209.0,,CN,GB,GB,SUSTIVA,Ectopic pregnancy;Pregnancy with contraceptive device,66560662.0,OT,,,66560662.0,1.0,200311.0,20061025.0,,,66560662.0,1.0,HIV infection
6660466,66604662,2,F,20080526.0,20151026.0,20080609,20151109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14209035,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20151109.0,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,66604662.0,OT,,,66604662.0,1.0,20080512.0,20080512.0,,,66604662.0,1.0,HIV infection
6668479,66684793,3,F,2007.0,20080701.0,20080616,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14152987,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151218.0,,CN,US,ZA,EFAVIRENZ,Caesarean section;Cephalo-pelvic disproportion;Maternal exposure during pregnancy;Normal newborn,66684793.0,OT,,,66684793.0,1.0,20060330.0,20071113.0,,,66684793.0,1.0,HIV infection
6688989,66889893,3,F,200805.0,20151026.0,20080702,20151106,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14245021,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,57.0,KG,20151106.0,,CN,GB,GB,SUSTIVA,Drug interaction;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,66889893.0,OT,,,66889893.0,2.0,2006.0,,,,66889893.0,1.0,HIV test
6694162,66941623,3,F,20070621.0,20151027.0,20080709,20151108,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14251904,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151108.0,,CN,US,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,66941623.0,OT,,,66941623.0,1.0,20060309.0,20070501.0,,,66941623.0,1.0,HIV infection
6695638,66956382,2,F,20080320.0,20151027.0,20080710,20151108,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-14255277,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20151108.0,,CN,CH,CH,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,66956382.0,OT,,,66956382.0,1.0,2007.0,20080305.0,,,66956382.0,1.0,HIV infection
6698357,66983572,2,F,20071122.0,20151027.0,20080714,20151108,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14258685,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20151108.0,,OT,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,66983572.0,OT,,,66983572.0,1.0,20060914.0,20070514.0,,,66983572.0,1.0,HIV infection
6711435,67114352,2,F,20080315.0,20151027.0,20080728,20151108,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14277164,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20151108.0,,CN,GB,GB,SUSTIVA,Abortion spontaneous;Maternal exposure during pregnancy,67114352.0,OT,,,67114352.0,1.0,20070514.0,20080218.0,,,67114352.0,1.0,HIV infection
6723333,67233335,5,F,20080805.0,20151209.0,20080811,20151219,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14292569,BRISTOL MYERS SQUIBB,,0.0,DY,,F,Y,3.81,KG,20151219.0,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Tooth development disorder,67233335.0,CA,,,67233335.0,1.0,,20080805.0,,,67233335.0,1.0,Antiretroviral therapy
6753908,675390823,23,F,20060602.0,20240618.0,20080911,20240621,EXP,,CA-MERCK-0809CAN00002,MERCK,"Harris M, Larsen G, Montaner JSG. Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-2. AIDS. 2008;22 (14):1890-2",44.0,YR,,M,Y,,,20240621.0,,MD,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,675390823.0,HO,,,675390823.0,1.0,20070626.0,20070626.0,2.0,DAY,675390823.0,1.0,HIV infection
6759866,67598662,2,F,,20220921.0,20080916,20221006,EXP,,US-RANBAXY-2008RR-17909,RANBAXY,"Trivedi BS, Libman H. Update: A 39-year-old man with HIV-associated lipodystrophy. JAMA. 2011;Jul 6; 306(1):87",39.0,YR,,M,Y,,,20221006.0,,HP,US,US,EFAVIRENZ,Anaemia;Lipodystrophy acquired;Neuropathy peripheral;Rash,67598662.0,OT,,,67598662.0,2.0,200402.0,2003.0,,,67598662.0,1.0,HIV infection
6793373,67933732,2,F,,20151028.0,20081022,20151108,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14378285,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151108.0,,MD,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,67933732.0,OT,,,,,,,,,67933732.0,1.0,HIV infection
6797602,67976027,7,F,20070611.0,20160822.0,20081028,20160822,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14332951,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,92.0,KG,20160822.0,,MD,FR,FR,SUSTIVA,Abortion induced;Oligohydramnios;Pregnancy on contraceptive,67976027.0,OT,,,67976027.0,1.0,20070217.0,20070703.0,,,67976027.0,1.0,HIV infection
6798575,67985752,2,F,,20190515.0,20081029,20190528,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14385819,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,43.0,KG,20190528.0,,MD,US,US,EFAVIRENZ.,Drug level increased;Status epilepticus,67985752.0,OT,,,,,,,,,67985752.0,1.0,HIV infection
6806942,680694210,10,F,20080422.0,20160824.0,20081110,20160824,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14017800,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,68.0,KG,20160824.0,,CN,GB,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,680694210.0,OT,,,680694210.0,1.0,20051201.0,20071211.0,,,680694210.0,1.0,Antiretroviral therapy
6826111,68261112,2,F,,20151112.0,20081201,20151127,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14083364,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151127.0,,MD,GB,GB,EFAVIRENZ,Ectopic pregnancy;Maternal exposure during pregnancy,68261112.0,OT,,,,,,,,,68261112.0,1.0,Antiretroviral therapy
6831328,68313283,3,F,,20151029.0,20081203,20151113,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14427819,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20151113.0,,MD,DE,DE,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,68313283.0,OT,,,68313283.0,1.0,20060810.0,20070320.0,,,68313283.0,1.0,HIV infection
6866921,68669214,4,F,20081005.0,20151029.0,20081226,20151113,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14410146,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,52.0,KG,20151113.0,,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,68669214.0,OT,,,68669214.0,1.0,2001.0,20081031.0,,,68669214.0,1.0,HIV infection
6870587,687058710,10,F,20060602.0,20220914.0,20081231,20220926,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14457303,BRISTOL MYERS SQUIBB,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008; 22(14): 1890-2. 10.1097/QAD.0b013e32830e0169",44.0,YR,A,M,Y,,,20220926.0,,MD,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,687058710.0,HO,,,687058710.0,2.0,20060602.0,20070522.0,355.0,DAY,687058710.0,1.0,HIV infection
6902323,69023236,6,F,20070614.0,20170407.0,20090205,20170413,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14445084,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20170413.0,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Myasthenia gravis,69023236.0,OT,,,69023236.0,1.0,20030124.0,20100119.0,,,69023236.0,1.0,HIV infection
6902979,69029794,4,F,20080611.0,20171031.0,20090206,20171031,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14230163,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20171031.0,,CN,US,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,69029794.0,OT,,,69029794.0,1.0,20060104.0,20080506.0,,,69029794.0,1.0,HIV infection
6918933,69189334,4,F,20090130.0,20130617.0,20090225,20130628,EXP,,ZM-BRISTOL-MYERS SQUIBB COMPANY-14517114,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,65.0,KG,20130628.0,,CN,US,ZM,EFAVIRENZ,Anaemia;Neutropenia,69189334.0,LT,,,69189334.0,1.0,20090203.0,20090219.0,,,69189334.0,1.0,HIV infection
6927324,69273248,8,F,20050813.0,20200401.0,20090304,20200407,EXP,,FR-GILEAD-2009-0020445,GILEAD,,,,,F,Y,1.19,KG,20200407.0,,MD,FR,FR,SUSTIVA,Anencephaly;Arnold-Chiari malformation;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Foetal malformation;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,69273248.0,DE,,,69273248.0,1.0,20050523.0,20060216.0,,,69273248.0,1.0,HIV infection
6927327,69273277,7,F,20050813.0,20200911.0,20090304,20200914,EXP,,FR-GILEAD-2009-0020444,GILEAD,,25.0,YR,A,F,Y,56.0,KG,20200914.0,,HP,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,69273277.0,OT,,,69273277.0,1.0,20050523.0,20050908.0,,,69273277.0,1.0,HIV infection
6950172,69501723,3,F,,20090325.0,20090324,20151210,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14554364,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20151210.0,,CN,GB,GB,EFAVIRENZ,Anaemia;Blood triglycerides increased;Caesarean section;Hepatic function abnormal;Injection site reaction;Premature delivery;Premature rupture of membranes;Twin pregnancy;Virologic failure,69501723.0,OT,,,,,,,,,69501723.0,1.0,HIV infection
6950326,69503265,5,F,20080401.0,20180202.0,20090324,20180207,EXP,,FR-GILEAD-2009-0020926,GILEAD,,,,,F,Y,,,20180207.0,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,69503265.0,OT,,,69503265.0,1.0,20051201.0,20071211.0,,,69503265.0,1.0,HIV infection
6971454,69714546,6,F,20020909.0,20170518.0,20090417,20170525,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14589196,BRISTOL MYERS SQUIBB,,34.0,YR,,M,Y,,,20170525.0,,CN,JP,JP,EFAVIRENZ,Lipoatrophy;Varices oesophageal,69714546.0,HO,,,69714546.0,1.0,20000901.0,20100711.0,,,69714546.0,1.0,HIV infection
6975594,69755944,4,F,20081001.0,20151026.0,20090422,20151106,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14243208,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,67.0,KG,20151106.0,,MD,DE,DE,SUSTIVA,Caesarean section;Maternal exposure during pregnancy;Premature delivery,69755944.0,OT,,,69755944.0,1.0,20060501.0,20080626.0,,,69755944.0,1.0,HIV infection
7021228,70212282,2,F,20090506.0,20090609.0,20090612,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14655690,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,72.56,KG,20151217.0,,CN,US,US,BLINDED EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and curettage,70212282.0,OT,,,70212282.0,1.0,20051208.0,20090329.0,,,70212282.0,1.0,HIV infection
7033376,70333764,4,F,20090525.0,20151102.0,20090625,20151113,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-14671929,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,,,20151113.0,,MD,BE,BE,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,70333764.0,OT,,,70333764.0,1.0,20070924.0,20090515.0,,,70333764.0,1.0,HIV infection
7057071,70570716,6,F,,20220914.0,20090722,20220922,EXP,,CA-JNJFOC-20090704890,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20220922.0,,MD,CA,CA,EFAVIRENZ,Progressive external ophthalmoplegia,70570716.0,OT,,,70570716.0,3.0,200802.0,,106.0,MON,70570716.0,1.0,HIV infection
7074617,70746173,3,F,20090510.0,20140910.0,20090806,20140915,EXP,,FR-GILEAD-2009-0023412,GILEAD,,37.0,YR,A,F,Y,,,20140915.0,N,OT,FR,FR,SUSTIVA,Cholangitis;Granulomatous liver disease;Hepatitis fulminant;Immune reconstitution inflammatory syndrome,70746173.0,LT,,,70746173.0,1.0,20090503.0,20090516.0,,,70746173.0,1.0,HIV infection
7091132,70911323,3,F,,20151209.0,20090824,20151215,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14743918,BRISTOL MYERS SQUIBB,BERA E.. MATERNAL OUTCOMES FOLLOWING INTRODUCTION OF ANTIRETROVIRAL THERAPY IN THE PUBLIC SECTOR: A PROSPECTIVE STUDY AT A TERTIARY HOSPITAL IN THE EASTERN CAPE.. SOUTH AFRICAN JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 2009?1?15(1)::26-33.,32.0,YR,,F,Y,,,20151215.0,,OT,ZA,ZA,EFAVIRENZ,Hepatic failure;Lactic acidosis;Live birth;Maternal exposure during pregnancy,70911323.0,HO,,,,,,,,,70911323.0,1.0,Antiretroviral therapy
7111460,71114605,5,F,20090930.0,20190123.0,20090911,20190201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14642565,BRISTOL MYERS SQUIBB,,19.0,YR,,F,Y,,,20190201.0,,CN,FR,FR,SUSTIVA,Caesarean section;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive,71114605.0,OT,,,71114605.0,1.0,20080724.0,,,,71114605.0,1.0,HIV infection
7117171,711717119,19,F,,20241115.0,20090917,20241129,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL-MYERS SQUIBB COMPANY,"Pfeffer G, Cote HCF, Montaner JS, Li CC, Jitratkosol M, Mezei MM. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology. 2009 Jul 07;73(1):71-2.doi:10.1212/WNL.0b013e3181aae814.",52.0,YR,A,M,Y,,,20241129.0,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,711717119.0,OT,,,711717119.0,1.0,200802.0,,1189.0,DAY,711717119.0,1.0,HIV infection
7123445,71234453,3,F,,20151111.0,20090921,20151122,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14785612,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151122.0,,MD,ZA,ZA,EFAVIRENZ,Death;Maternal exposure during pregnancy,71234453.0,OT,,,71234453.0,1.0,20051025.0,,,,71234453.0,1.0,Antiretroviral therapy
7124197,71241973,3,F,,20120905.0,20090921,20150722,PER,,US-GILEAD-2009-0023795,GILEAD,,31.0,YR,A,F,Y,,,20150722.0,N,OT,US,US,EFAVIRENZ,Neutropenia,71241973.0,OT,,,71241973.0,1.0,200805.0,,,,71241973.0,1.0,HIV infection
7124632,71246323,3,F,200512.0,20151120.0,20090922,20151201,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14785646,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151201.0,,MD,ZA,ZA,EFAVIRENZ,Death;Maternal exposure during pregnancy,71246323.0,DE,,,71246323.0,1.0,20051122.0,,,,71246323.0,1.0,Antiretroviral therapy
7131602,71316023,3,F,,20130701.0,20090915,20130710,EXP,,AUR-APL-2009-00569,AUROBINDO,,48.0,YR,,M,N,,,20130709.0,,OT,COUNTRY NOT SPECIFIED,,EFAVIRENZ,Drug ineffective;Oesophageal varices haemorrhage;Portal hypertension;Portal hypertensive gastropathy;Splenomegaly,71316023.0,OT,71316023.0,LIT,,,,,,,71316023.0,1.0,HIV infection
7140532,71405322,2,F,20081230.0,20151026.0,20091006,20151106,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14559363,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,92.0,KG,20151106.0,,MD,FR,FR,SUSTIVA,Caesarean section;Maternal exposure during pregnancy;Normal newborn,71405322.0,OT,,,71405322.0,1.0,200807.0,20090317.0,,,71405322.0,1.0,HIV infection
7147274,71472743,3,F,20090515.0,20140910.0,20091013,20140922,EXP,,FR-ROCHE-660784,ROCHE,,36.0,YR,,F,Y,,,20140922.0,N,MD,FR,FR,SUSTIVA,Hepatitis fulminant,71472743.0,LT,,,71472743.0,1.0,20090503.0,20090516.0,,,71472743.0,1.0,HIV test positive
7152253,715225314,14,F,,20220929.0,20091019,20221010,EXP,,CA-PFIZER INC-2009279889,PFIZER,"Pfeffer, G.. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology. 2009;73 (1):71-72",52.0,YR,,M,Y,,,20221010.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,715225314.0,OT,,,715225314.0,1.0,,,274.0,DAY,715225314.0,1.0,HIV infection
7155921,715592116,16,F,,20240611.0,20091022,20240708,EXP,,CA-ROCHE-663583,ROCHE,"PFEFFER G, Pfeffer G, Cote H, Montaner J, Li C, Jitratkosol M and Mezei M. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY 2009 Jul 07;73 (1):71-72.",52.0,YR,A,M,Y,,,20240709.0,,MD,CA,CA,EFAVIRENZ,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,715592116.0,OT,,,715592116.0,1.0,,,457.0,DAY,715592116.0,1.0,HIV infection
7158049,71580492,2,F,,20140412.0,20091008,20140415,EXP,,AUR-APL-2009-00713,AUROBINDO,,52.0,YR,,M,N,,,20140414.0,,,COUNTRY NOT SPECIFIED,,EFAVIRENZ (EFAVIRENZ),Blood lactic acid increased;Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,71580492.0,OT,71580492.0,HP,,,,,,,71580492.0,1.0,HIV infection
7162461,71624612,2,F,,20130701.0,20091019,20130709,EXP,,AUR-APL-2009-00819,AUROBINDO,,53.0,YR,,M,N,,,20130708.0,,OT,COUNTRY NOT SPECIFIED,,EFAVIRENZ,Gait disturbance;Parkinsonism;Rapid eye movements sleep abnormal,71624612.0,OT,71624612.0,LIT,,,,,,,71624612.0,1.0,HIV infection
7167449,71674492,2,F,,20141215.0,20091022,20141231,EXP,,B0598034A,VIIV,,52.0,YR,A,M,N,,,20141230.0,N,,COUNTRY NOT SPECIFIED,,EFAVIRENZ,Blood lactic acid increased;Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,71674492.0,OT,,,,,,,,,71674492.0,1.0,HIV infection
7230481,72304813,3,F,2008.0,20180821.0,20091224,20180823,EXP,,GB-GILEAD-2009-0026167,GILEAD,,33.0,YR,A,F,Y,,,20180823.0,,OT,GB,GB,EFAVIRENZ.,Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Normal newborn;Pregnancy with implant contraceptive,72304813.0,OT,,,72304813.0,4.0,20040811.0,20070716.0,,,72304813.0,1.0,HIV infection
7240788,72407882,2,F,2008.0,20151030.0,20100108,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14922280,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20151113.0,,CN,GB,GB,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn;Pregnancy with implant contraceptive,72407882.0,OT,,,72407882.0,2.0,20040811.0,20080624.0,,,72407882.0,1.0,HIV infection
7258000,72580002,2,F,,20151112.0,20100127,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14940548,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151120.0,,OT,ZA,ZA,EFAVIRENZ,Congenital anomaly;Foetal exposure during pregnancy,72580002.0,CA,,,,,,,,,72580002.0,1.0,Antiretroviral therapy
7277014,72770147,7,F,20090625.0,20131127.0,20100212,20131205,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14962575,BRISTOL MYERS SQUIBB,,49.0,YR,,F,Y,51.0,KG,20131210.0,,CN,US,TH,SUSTIVA TABS,Calculus ureteric;Hydronephrosis;Nephrolithiasis,72770147.0,HO,,,72770147.0,1.0,20090625.0,20100121.0,,,72770147.0,1.0,HIV infection
7294806,72948062,2,F,,20130701.0,20091124,20130715,EXP,,AUR-APL-2009-01268,AUROBINDO,,38.0,YR,,F,N,,,20130712.0,,,COUNTRY NOT SPECIFIED,,EFAVIRENZ,Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;General physical health deterioration;Hepatomegaly;Immune reconstitution inflammatory syndrome;Lymph node tuberculosis;Tuberculosis,72948062.0,HO,72948062.0,LIT,,,,,,,72948062.0,1.0,HIV infection
7301762,73017622,2,F,20080422.0,20180202.0,20100302,20180207,EXP,,FR-GILEAD-2009-0020925,GILEAD,,30.0,YR,A,F,Y,,,20180207.0,,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,73017622.0,OT,,,73017622.0,1.0,20051201.0,20071211.0,,,73017622.0,1.0,HIV infection
7302622,730262249,49,F,,20240618.0,20100302,20240628,EXP,,CA-MERCK-0907CAN00093,MERCK,"Pfeffer G, Mezei MM, Montaner JS, Li CC, Jitratkosol M, Cote HC. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. NEUROLOGY. 2009;73(1):71-2",52.0,YR,,M,Y,,,20240628.0,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262249.0,OT,,,730262249.0,1.0,200802.0,200802.0,91.0,DAY,730262249.0,1.0,HIV infection
7319685,73196852,2,F,,20151029.0,20100315,20151113,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14626725,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151113.0,,PH,DE,DE,SUSTIVA,Abortion;Maternal exposure during pregnancy,73196852.0,OT,,,,,,,,,73196852.0,1.0,Antiretroviral therapy
7325412,73254122,2,F,,20130701.0,20100224,20130715,EXP,,AUR-APL-2010-00411,AUROBINDO,,43.0,YR,,M,N,,,20130712.0,,OT,COUNTRY NOT SPECIFIED,,EFAVIRENZ,Abdominal distension;Abdominal pain;Alcohol abuse;Blood creatinine increased;Body temperature decreased;Cholelithiasis;Chronic hepatitis;Confusional state;Convulsion;Dyspnoea;Gastritis;Haemoglobin decreased;Hepatic cirrhosis;Hepatitis alcoholic;Hepatomegaly;Hypertension;Lactic acidosis;Loss of consciousness;Malaise;Multi-organ failure;Neuropathy peripheral;Oesophageal candidiasis;Somnolence;Tachypnoea,73254122.0,HO,73254122.0,HP,73254122.0,6.0,200609.0,200702.0,,,73254122.0,1.0,HIV infection
7398818,73988183,3,F,20080829.0,20151029.0,20100525,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14478093,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20151113.0,,MD,GB,GB,SUSTIVA,Anaemia;Caesarean section;Normal newborn;Pregnancy on contraceptive,73988183.0,OT,,,73988183.0,1.0,20070808.0,20080206.0,,,73988183.0,1.0,HIV infection
7400044,74000444,4,F,20080521.0,20151112.0,20100526,20151118,EXP,,GB-GILEAD-2010-0029316,GILEAD,,28.0,YR,A,F,Y,104.0,KG,20151118.0,,MD,GB,GB,SUSTIVA,Caesarean section;Maternal exposure during pregnancy,74000444.0,OT,,,74000444.0,1.0,20071024.0,20071011.0,,,74000444.0,1.0,HIV infection
7407379,74073793,3,F,20080707.0,20151117.0,20100602,20151123,EXP,,GB-GILEAD-2010-0029482,GILEAD,,26.0,YR,A,F,Y,,,20151123.0,,MD,GB,GB,SUSTIVA,Anaemia;Caesarean section;Normal newborn;Pregnancy on contraceptive,74073793.0,OT,,,74073793.0,1.0,20070808.0,20080206.0,,,74073793.0,1.0,HIV infection
7408392,74083925,5,F,20100421.0,20160824.0,20100603,20160824,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15126741,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20160824.0,,CN,FR,FR,SUSTIVA,Abortion induced;Bartholinitis;Maternal exposure during pregnancy;Pyelonephritis,74083925.0,OT,,,74083925.0,1.0,20070817.0,20091202.0,,,74083925.0,1.0,HIV infection
7408901,74089012,2,F,,20220125.0,20100603,20220201,EXP,,US-GILEAD-2010-0029436,GILEAD,,52.0,YR,A,M,Y,,,20220201.0,,HP,US,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,74089012.0,OT,,,74089012.0,1.0,,,2470.0,DAY,74089012.0,1.0,HIV infection
7412939,74129392,2,F,,20151123.0,20100608,20151207,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14668420,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151207.0,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,74129392.0,1.0,Antiretroviral therapy
7412942,74129422,2,F,,20151113.0,20100608,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14714265,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118.0,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,74129422.0,1.0,HIV infection
7454279,74542793,3,F,20051226.0,20180719.0,20100706,20180726,EXP,,US-GILEAD-2010-0030154,GILEAD,,0.0,DY,,,Y,,,20180726.0,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,74542793.0,CA,,,,,,,,,74542793.0,1.0,HIV infection
7494744,74947442,2,F,201007.0,20151119.0,20100722,20151129,EXP,,TW-BRISTOL-MYERS SQUIBB COMPANY-15203383,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20151129.0,,MD,TW,TW,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,74947442.0,OT,,,74947442.0,1.0,20100402.0,,,,74947442.0,1.0,HIV infection
7570976,75709767,7,F,2006.0,20151023.0,20100902,20151107,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-15256381,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,54.0,KG,20151107.0,,CN,US,DE,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes;Twin pregnancy;Urinary tract infection;Virologic failure,75709767.0,HO,,,75709767.0,1.0,20071016.0,200610.0,,,75709767.0,1.0,HIV infection
7587496,75874962,2,F,20091212.0,20100909.0,20100915,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15281645,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20151208.0,,CN,FR,FR,SUSTIVA,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and evacuation,75874962.0,OT,,,,,,,,,75874962.0,1.0,HIV infection
7591099,75910992,2,F,,20151028.0,20100917,20151112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-15286461,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151112.0,,CN,GB,GB,SUSTIVA,Maternal exposure during pregnancy;Muscle rupture;Rhabdomyolysis,75910992.0,OT,,,,,,,,,75910992.0,1.0,HIV infection
7609977,760997732,32,F,20061128.0,20240325.0,20100928,20240402,EXP,,JP-JNJFOC-20100907113,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,,,20240402.0,,MD,JP,JP,EFAVIRENZ,Anaemia;Drug resistance;Dyslipidaemia;Hepatocellular carcinoma;Hyperbilirubinaemia;Osteoporosis;Pyelonephritis,760997732.0,HO,,,760997732.0,1.0,20061111.0,20240202.0,7.0,YR,760997732.0,1.0,HIV infection
7671815,76718152,2,F,2009.0,20151028.0,20101116,20151113,EXP,,IT-GILEAD-2010-0032936,GILEAD,,44.0,YR,A,F,Y,,,20151113.0,,MD,IT,IT,SUSTIVA,Caesarean section;Dyslipidaemia;Lactic acidosis;Maternal exposure during pregnancy;Normal newborn;Pregnancy,76718152.0,OT,,,76718152.0,1.0,200904.0,200907.0,,,76718152.0,1.0,HIV infection
7680832,76808325,5,F,,20200831.0,20101123,20200915,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15394901,BRISTOL MYERS SQUIBB,"LAKHI N, GOVIND A. IMPLANON FAILURE IN PATIENTS ON ANTIRETROVIRAL MEDICATION: THE IMPORTANCE OF DISCLOSURE. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE. 2010?36(3):181?2",35.0,YR,,F,Y,,,20200915.0,,MD,US,US,SUSTIVA,Abortion induced;Drug interaction;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,76808325.0,OT,,,,,,,,,76808325.0,1.0,HIV infection
7686793,768679327,27,F,20070423.0,20240902.0,20101130,20240911,EXP,,JP-JNJFOC-20101108379,JOHNSON AND JOHNSON,,28.0,YR,A,M,Y,,,20240911.0,,MD,JP,JP,EFAVIRENZ,Abdominal distension;Atrioventricular block second degree;Blood triglycerides increased;Bradycardia;Campylobacter gastroenteritis;Dyslipidaemia;Gastrointestinal haemorrhage;Haemoglobin decreased;Haemorrhoids;Hepatic function abnormal;Herpes zoster;Liver function test abnormal;Liver function test increased;Malaise;Oropharyngeal discomfort;Tachycardia paroxysmal,768679327.0,HO,,,768679327.0,1.0,20060905.0,20181001.0,12.0,YR,768679327.0,1.0,HIV infection
7725021,77250214,4,F,20090914.0,20130322.0,20101221,20130401,EXP,,JP-ABBOTT-10P-087-0691207-00,ABBOTT,,30.0,YR,,M,Y,,,20130401.0,,MD,COUNTRY NOT SPECIFIED,JP,EFAVIRENZ,Blood alkaline phosphatase increased;Bronchopulmonary aspergillosis;Gamma-glutamyltransferase increased;Lymphoma;Platelet count decreased,77250214.0,HO,,,77250214.0,1.0,20090909.0,20091006.0,,,77250214.0,1.0,HIV infection
7820530,78205302,2,F,,20190204.0,20110221,20190212,EXP,,GR-GILEAD-2011-0036333,GILEAD,,74.0,YR,E,M,Y,,,20190212.0,,MD,GR,GR,EFAVIRENZ.,Acute kidney injury;Drug interaction;Lactic acidosis,78205302.0,OT,,,,,,,,,78205302.0,1.0,HIV infection
7830904,78309042,2,F,,20151125.0,20110227,20151209,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15570898,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20151209.0,,OT,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,78309042.0,OT,,,,,,,,,78309042.0,1.0,HIV infection
7915468,79154682,2,F,,20140303.0,20110426,20140312,EXP,,US-GILEAD-2011-0038765,GILEAD,,42.0,YR,,M,Y,,,20140312.0,N,,COUNTRY NOT SPECIFIED,US,EFAVIRENZ,Renal tubular necrosis;Rhabdomyolysis,79154682.0,HO,,,,,,,,,79154682.0,1.0,HIV infection
7920187,79201873,3,F,200604.0,20151117.0,20110429,20151123,EXP,,GB-GILEAD-E2B_00001248,GILEAD,,44.0,YR,A,F,Y,,,20151123.0,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,79201873.0,OT,,,79201873.0,1.0,200509.0,,,,79201873.0,1.0,HIV infection
7950979,79509792,2,F,2009.0,20130304.0,20110519,20130314,EXP,,IL-BRISTOL-MYERS SQUIBB COMPANY-15754542,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20130314.0,,OT,IL,IL,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculosis,79509792.0,OT,,,,,,,,,79509792.0,1.0,HIV infection
8000228,80002281,1,I,20110419.0,20110607.0,20110621,20110621,EXP,,US-JNJFOC-20110410180,TIBOTEC,,42.0,YR,A,F,Y,62.6,KG,20110621.0,,MD,US,US,EFAVIRENZ.,Acute kidney injury;Lactic acidosis;Septic shock,80002281.0,DS,80002281.0,HP,80002281.0,1.0,20080911.0,20110302.0,,,80002281.0,1.0,HIV infection
8096421,80964213,3,F,,20110929.0,20110818,20170323,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-15952914,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20170323.0,,CN,JP,JP,EFAVIRENZ,Drug resistance;Psychiatric symptom,80964213.0,OT,,,,,,,,,80964213.0,1.0,Antiretroviral therapy
8100228,81002284,4,F,20110608.0,20140612.0,20110822,20140618,EXP,,KE-GLAXOSMITHKLINE-R0015948F,GLAXOSMITHKLINE,,10.0,MON,,M,Y,,,20140618.0,N,MD,KE,KE,EFAVIRENZ,Immune reconstitution inflammatory syndrome,81002284.0,HO,,,81002284.0,1.0,20101111.0,20101111.0,,,81002284.0,4.0,HIV infection
8143762,81437622,2,F,20110821.0,20151123.0,20110920,20151208,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-16072910,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,70.1,KG,20151208.0,,CN,US,ZW,EFAVIRENZ,Foetal death;Maternal exposure during pregnancy,81437622.0,OT,,,81437622.0,1.0,20090603.0,,,,81437622.0,1.0,HIV infection
8161417,81614173,3,F,20110919.0,20131119.0,20110929,20131127,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16091480,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,59.5,KG,20131127.0,,CN,US,MW,EFAVIRENZ,Neutrophil count decreased,81614173.0,LT,,,81614173.0,1.0,20110830.0,,,,81614173.0,1.0,HIV infection
8163168,81631683,3,F,20110914.0,20151126.0,20110930,20151209,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16102360,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,53.5,KG,20151209.0,,CN,US,MW,EFAVIRENZ,Ectopic pregnancy;Neutrophil count decreased;Pregnancy on contraceptive;Upper respiratory tract infection,81631683.0,OT,,,81631683.0,1.0,20110624.0,20110624.0,,,81631683.0,1.0,HIV infection
8299420,82994202,2,F,,20200817.0,20111219,20200908,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16291882,BRISTOL MYERS SQUIBB,"PASSOS L, TALHARI C, SANTOS M, RIBEIRO?RODRIGUES R, FERREIRA LCL, TALHARI S. HISTOPLASMOSIS?ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. ANAIS BRASILEIROS DE DERMATOLOGIA. 2011?86 (4):168?72",27.0,YR,,M,Y,,,20200908.0,,HP,BR,BR,EFAVIRENZ.,No adverse event,,,,,82994202.0,1.0,200709.0,,,,82994202.0,1.0,HIV infection
8310422,83104222,2,F,,20151127.0,20111223,20151209,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16313751,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151209.0,,CN,US,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure timing unspecified,83104222.0,OT,,,,,,,,,83104222.0,1.0,HIV infection
8310423,83104232,2,F,,20151127.0,20111223,20151209,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16307837,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151209.0,,CN,US,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure timing unspecified,83104232.0,OT,,,,,,,,,83104232.0,1.0,HIV infection
8322070,83220702,2,F,,20170307.0,20120105,20190524,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-16315566,BRISTOL MYERS SQUIBB,,4.0,YR,,F,Y,,,20190524.0,,OT,ZA,ZA,EFAVIRENZ.,Drug level increased;Petit mal epilepsy,83220702.0,OT,,,,,,,,,83220702.0,1.0,HIV infection
8443574,84435742,2,F,,20210412.0,20120306,20210423,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-16428351,BRISTOL MYERS SQUIBB,"OGOINA D, ADEKUNLE V, OBIAKO R, UMAR A, AKOLAWOLE M, OVOSI J. DISSEMINATED INFECTIONS DUE TO IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER HIGHLY ACTIVE ANTIRETROVIRAL THERAPY REPORT OF 3 CASES FROM NIGERIA. PAN AFRICAN MEDICAL JOURNAL. 2011?9(38):1?5",19.0,YR,,F,Y,,,20210423.0,,HP,NG,NG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,84435742.0,DE,,,,,,,,,84435742.0,1.0,HIV infection
8457821,84578212,2,F,20120224.0,20151130.0,20120314,20151207,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-16436339,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,47.8,KG,20151207.0,,CN,US,ZW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Neutropenia,84578212.0,OT,,,84578212.0,1.0,20100210.0,20120130.0,,,84578212.0,1.0,HIV infection
8472793,84727939,9,F,20110616.0,20130315.0,20120322,20130325,EXP,,IN-ABBOTT-11P-078-0834565-00,ABBOTT,,46.0,YR,,F,Y,39.0,KG,20130325.0,,MD,COUNTRY NOT SPECIFIED,IN,EFAVIRENZ,Anaemia;Cytomegalovirus chorioretinitis;Drug hypersensitivity;Extrapulmonary tuberculosis;HIV peripheral neuropathy;Lower respiratory tract infection;Pulmonary tuberculosis;Virologic failure,84727939.0,OT,,,84727939.0,1.0,20080922.0,20100325.0,,,84727939.0,1.0,HIV infection
8602105,86021052,2,F,,20141205.0,20120607,20141219,EXP,,GB-RANBAXY-2012R1-56842,RANBAXY,"THNG C, BABIKER ZOE, BROWN B, BABU C. THE PERILS OF RELYING ON ANTI-HEPATITIS B TOTAL CORE ANTIBODY IN SCREENING INDIVIDUALS INFECTED WITH HIV. INT J STD AIDS. 2012;FEB;23(2):149-50",48.0,YR,,M,Y,,,20141219.0,N,MD,GB,GB,Efavirenz,Drug resistance;Gene mutation;Lipoatrophy;Transaminases increased;Vaccination failure,86021052.0,OT,,,86021052.0,1.0,200606.0,,,,86021052.0,1.0,Antiretroviral therapy
8603296,86032963,3,F,,20151030.0,20120607,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16347718,BRISTOL MYERS SQUIBB,,,,,F,Y,93.0,KG,20151118.0,,CN,US,US,SUSTIVA,Decreased appetite;Malaise;Maternal exposure during pregnancy;Migraine;Weight decreased,,,,,,,,,,,86032963.0,1.0,HIV test
8631944,86319442,2,F,,20140717.0,20120625,20140801,EXP,,FR-RANBAXY-2012R1-57179,RANBAXY,,58.0,YR,,M,Y,48.0,KG,20140801.0,N,OT,FR,FR,Efavirenz,Ascites;Gynaecomastia;Lipodystrophy acquired;Nodular regenerative hyperplasia;Osteoporosis;Portal hypertension;Portal vein thrombosis;Protein-losing gastroenteropathy;Varices oesophageal,86319442.0,HO,,,,,,,,,86319442.0,1.0,HIV infection
8691284,869128410,10,F,20090824.0,20170719.0,20120730,20170726,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-16789448,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,,,20170726.0,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,869128410.0,OT,,,869128410.0,1.0,20000901.0,20100711.0,,,869128410.0,1.0,HIV infection
8696154,86961547,7,F,20090824.0,20160412.0,20120801,20160415,EXP,,JP-009507513-1207JPN000172,MERCK,,41.0,YR,,M,Y,,,20160415.0,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,86961547.0,OT,,,86961547.0,1.0,20000901.0,20100711.0,,,86961547.0,1.0,HIV infection
8707608,87076083,3,F,2012.0,20130724.0,20120805,20131101,PER,,US-009507513-1207USA011603,MERCK,,,,,M,Y,107.94,KG,20131101.0,,CN,US,US,SUSTIVA,Drug dose omission;Viral load increased,,,,,87076083.0,1.0,2008.0,,,,87076083.0,1.0,HIV infection
8728787,87287872,2,F,,20151130.0,20120817,20151208,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-16858938,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151208.0,,CN,US,ZA,EFAVIRENZ,Abortion induced;Abortion spontaneous;Maternal exposure during pregnancy,87287872.0,OT,,,,,,,,,87287872.0,1.0,HIV infection
8745672,87456726,6,F,20120603.0,20171107.0,20120826,20171107,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-16861148,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,46.89,KG,20171107.0,,CN,GB,GB,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Off label use,87456726.0,OT,,,,,,,,,87456726.0,1.0,HIV infection
8764293,87642934,4,F,20120227.0,20180216.0,20120831,20180221,EXP,,GB-GILEAD-2012-0060486,GILEAD,,27.0,YR,A,F,Y,46.89,KG,20180221.0,,CN,US,GB,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Off label use,87642934.0,OT,,,87642934.0,1.0,2011.0,,,,87642934.0,1.0,HIV infection
8779602,87796022,2,F,200908.0,20130724.0,20120913,20131105,EXP,,FR-009507513-1201USA02362,MERCK,,61.0,YR,,M,Y,,,20131105.0,,OT,US,FR,SUSTIVA,Cholestasis;Eosinophilia;Glomerulonephritis membranous;Hepatocellular injury;Nephrotic syndrome;Tubulointerstitial nephritis,87796022.0,HO,,,87796022.0,1.0,20090427.0,20111209.0,,,87796022.0,1.0,HIV infection
8784344,87843445,5,F,20120227.0,20180216.0,20120913,20180221,EXP,,GB-GILEAD-2012-0060487,GILEAD,,,,,F,Y,,,20180221.0,,CN,US,GB,SUSTIVA,Foetal exposure during pregnancy;Turner's syndrome,87843445.0,CA,,,87843445.0,1.0,20120227.0,,,,87843445.0,1.0,HIV infection
8786525,87865253,3,F,20120808.0,20120918.0,20120914,20150917,EXP,,TH-GILEAD-2012-0060984,GLAXOSMITHKLINE,,33.0,YR,,F,Y,,,20150917.0,N,MD,TH,TH,EFAVIRENZ,Hypophosphataemia,87865253.0,LT,,,87865253.0,1.0,20120111.0,20120111.0,,,87865253.0,1.0,HIV infection
8802752,88027522,2,F,20100607.0,20130724.0,20120921,20131105,EXP,,FR-009507513-1011USA00651,MERCK,,45.0,YR,,F,Y,,,20131105.0,,OT,US,FR,SUSTIVA,Acute generalised exanthematous pustulosis;Anaphylactic shock;Asthenia;Castleman's disease;Drug resistance;Generalised erythema;Pancytopenia;Weight decreased,88027522.0,HO,,,88027522.0,1.0,20100625.0,20100625.0,,,88027522.0,1.0,HIV infection
8817347,88173476,6,F,20120922.0,20121005.0,20121004,20150928,EXP,,TH-GILEAD-2012-0062224,VIIV,,27.0,YR,,M,Y,,,20150928.0,N,MD,TH,TH,Efavirenz,Electrolyte imbalance,88173476.0,HO,,,88173476.0,4.0,20100925.0,20120219.0,,,88173476.0,2.0,HIV infection
8834763,88347633,3,F,,20121031.0,20121009,20121108,EXP,,AUR-APL-2012-04359,AUROBINDO,,38.0,YR,,M,N,,,20121106.0,,OT,PE,,EFAVIRENZ,Cerebral ischaemia;Cryptococcosis;Headache;Hemiparesis;Immune reconstitution inflammatory syndrome;Pyramidal tract syndrome;Vasculitis cerebral,88347633.0,OT,88347633.0,FGN,,,,,,,88347633.0,1.0,Antiretroviral therapy
8834764,88347643,3,F,,20121031.0,20121009,20121108,EXP,,AUR-APL-2012-04357,AUROBINDO,,29.0,YR,,M,N,,,20121106.0,,OT,PE,,EFAVIRENZ,Encephalitis;Immune reconstitution inflammatory syndrome associated tuberculosis,88347643.0,OT,88347643.0,HP,,,,,,,88347643.0,1.0,Antiretroviral therapy
8843709,88437092,2,F,20120921.0,20130501.0,20121016,20130503,EXP,,PE-GILEAD-2012-0062815,GILEAD,,29.0,YR,,M,Y,,,20130503.0,,MD,PE,PE,EFAVIRENZ,Anaemia,88437092.0,HO,,,88437092.0,1.0,20120904.0,,,,88437092.0,1.0,HIV infection
8848641,88486412,2,F,,20121107.0,20121015,20121108,EXP,,AUR-APL-2012-04354,AUROBINDO,,44.0,YR,,M,N,,,20121031.0,,OT,MX,,EFAVIRENZ,Balance disorder;Cerebral toxoplasmosis;Diplopia;Headache;Hemiparesis;Immune reconstitution inflammatory syndrome;Pyrexia;Somnolence;Vomiting,88486412.0,OT,88486412.0,HP,,,,,,,88486412.0,1.0,Antiretroviral therapy
8848645,88486452,2,F,,20121031.0,20121015,20121109,EXP,,AUR-APL-2012-04358,AUROBINDO,,39.0,YR,,M,N,,,20121108.0,,OT,PE,,EFAVIRENZ,Leukoencephalopathy,88486452.0,OT,88486452.0,FGN,,,,,,,88486452.0,1.0,Antiretroviral therapy
8857607,88576073,3,F,20120524.0,20130902.0,20121024,20130905,EXP,,FR-BMSGILMSD-2012-0063274,GILEAD,,32.0,YR,,F,Y,,,20130905.0,,OT,FR,FR,SUSTIVA,Pyrexia;Renal tubular disorder,88576073.0,HO,,,88576073.0,1.0,20120614.0,20120623.0,,,88576073.0,1.0,HIV infection
8858448,88584484,4,F,20110921.0,20151118.0,20121025,20151130,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-17061169,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20151130.0,,CN,US,AR,EFAVIRENZ,Abortion induced;Herpes zoster;Maternal exposure during pregnancy,88584484.0,OT,,,88584484.0,2.0,20110501.0,,,,88584484.0,1.0,HIV infection
8871346,88713462,2,F,20120901.0,20130430.0,20121023,20130503,EXP,,IT-GILEAD-2012-0063336,GILEAD,,43.0,YR,,M,Y,,,20130503.0,,MD,IT,IT,SUSTIVA,Suicidal ideation,88713462.0,LT,,,88713462.0,1.0,20120808.0,20120902.0,,,88713462.0,1.0,Antiretroviral therapy
8874867,88748672,2,F,20120227.0,20130712.0,20121023,20130718,EXP,,CI-GILEAD-2012-0062733,GILEAD,,34.0,YR,,F,Y,,,20130718.0,,OT,US,CI,EFAVIRENZ,Abortion spontaneous,88748672.0,OT,,,88748672.0,1.0,20110112.0,20120131.0,,,88748672.0,1.0,HIV infection
8879908,88799087,7,F,20110918.0,20230424.0,20121031,20230426,EXP,,JP-GILEAD-2012-0063774,GILEAD,,30.0,YR,A,M,Y,,,20230426.0,,MD,JP,JP,EFAVIRENZ,Gastritis;Gastrooesophageal reflux disease;Intentional overdose;Nicotine dependence;Seasonal allergy;Suicide attempt,88799087.0,LT,,,88799087.0,1.0,20110805.0,20110918.0,44.0,DAY,88799087.0,1.0,HIV infection
8903788,89037883,3,F,20121015.0,20130501.0,20121112,20130506,EXP,,TH-GILEAD-2012-0064446,GILEAD,,31.0,YR,,M,Y,,,20130506.0,,MD,TH,TH,EFAVIRENZ,Liver injury,89037883.0,OT,,,89037883.0,1.0,20120730.0,20120930.0,,,89037883.0,1.0,HIV infection
8917556,89175564,4,F,20120105.0,20180425.0,20121120,20180507,EXP,,JP-GILEAD-2012-0064712,GILEAD,,39.0,YR,A,M,Y,,,20180507.0,,OT,JP,JP,EFAVIRENZ.,Osteoporosis;Osteoporotic fracture,89175564.0,OT,,,89175564.0,1.0,20050621.0,,,,89175564.0,1.0,HIV infection
8934886,89348862,2,F,20111101.0,20130712.0,20121129,20130722,EXP,,CI-ABBOTT-12P-278-1011121-00,ABBOTT,,33.0,YR,,F,Y,,,20130722.0,,MD,COUNTRY NOT SPECIFIED,CI,EFAVIRENZ,Abortion induced,89348862.0,OT,,,89348862.0,1.0,20091104.0,,,,89348862.0,1.0,HIV infection
8949679,89496793,3,F,,20160315.0,20121206,20160318,EXP,,GB-009507513-1109GBR00053,MERCK,,32.0,YR,,F,Y,,,20160318.0,,CN,US,GB,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy;Off label use;Premature delivery;Premature rupture of membranes;Uterine leiomyoma,89496793.0,OT,,,,,,,,,89496793.0,1.0,HIV infection
8954182,89541826,6,F,20121112.0,20130830.0,20121207,20130905,EXP,,ZA-GILEAD-2012-0065587,GILEAD,,34.0,YR,,F,Y,,,20130905.0,,MD,ZA,ZA,EFAVIRENZ,Normochromic normocytic anaemia,89541826.0,OT,,,89541826.0,1.0,20120821.0,20121206.0,,,89541826.0,1.0,HIV infection
8964781,89647813,3,F,20121113.0,20131209.0,20121214,20131218,EXP,,BW-GILEAD-2012-0066154,GILEAD,,27.0,YR,,F,Y,,,20131218.0,,OT,BW,BW,EFAVIRENZ,Abortion spontaneous,89647813.0,HO,,,89647813.0,1.0,201204.0,20120320.0,,,89647813.0,1.0,HIV infection
8967679,89676792,2,F,20110921.0,20130207.0,20121206,20130222,EXP,,ADR-UNK-091,HETERO,,,,,NS,N,,,20130221.0,,OT,US,,"EFAVIRENZ (STOCRIN, EFV)",Abortion induced;Maternal drugs affecting foetus,89676792.0,DE,89676792.0,CSM,89676792.0,1.0,20110201.0,,,,89676792.0,1.0,Acquired immunodeficiency syndrome
8971291,89712913,3,F,201007.0,20130116.0,20121218,20130124,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-17223421,BRISTOL MYERS SQUIBB,,21.0,YR,,M,Y,,,20130124.0,,CN,US,RO,EFAVIRENZ CAPS,Anaemia;Rash,89712913.0,OT,,,89712913.0,1.0,20100531.0,20100710.0,,,89712913.0,1.0,HIV infection
8978383,89783832,2,F,,20121221.0,20121221,20130102,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-17228701,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20130102.0,,CN,US,IN,EFAVIRENZ,Lactic acidosis,89783832.0,LT,,,,,,,,,89783832.0,1.0,HIV infection
8981155,89811552,2,F,201209.0,20130116.0,20121221,20130121,EXP,,GB-VIIV HEALTHCARE LIMITED-A1006126A,GLAXOSMITHKLINE,,45.0,YR,,F,Y,,,20130121.0,,OT,GB,GB,Sustiva,Abortion induced;Ectopic pregnancy;Exposure during pregnancy,89811552.0,OT,,,,,,,,,89811552.0,1.0,Antiretroviral therapy
8982667,89826676,6,F,,20130821.0,20121224,20130823,EXP,,FR-GILEAD-2012-0066741,GILEAD,,79.0,YR,,M,Y,,,20130823.0,,MD,FR,FR,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Rash,89826676.0,OT,,,,,,,,,89826676.0,1.0,HIV infection
8988115,89881157,7,F,20121211.0,20130903.0,20121227,20130910,EXP,,FR-JNJFOC-20121211876,JANSSEN,,76.0,YR,,M,Y,68.0,KG,20130910.0,,OT,GB,FR,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Rash,89881157.0,OT,,,89881157.0,1.0,20121201.0,20121211.0,,,89881157.0,1.0,HIV infection
8988740,89887402,2,F,2008.0,20130122.0,20121228,20130205,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-17227612,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,83.0,KG,20130131.0,,CN,US,AU,EFAVIRENZ CAPS,Deep vein thrombosis,89887402.0,OT,,,,,,,,,89887402.0,1.0,HIV infection
8991024,89910242,2,F,20121220.0,20121231.0,20121221,20130109,EXP,,AUR-APL-2012-05455,AUROBINDO,,30.0,YR,,M,N,,,20130108.0,,OT,US,,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Vitiligo,89910242.0,OT,89910242.0,LIT,,,,,,,89910242.0,1.0,Antiretroviral therapy
8994254,89942543,3,F,20121026.0,20140106.0,20130102,20140110,EXP,,CI-GILEAD-2012-0067134,GILEAD,,36.0,YR,,F,Y,52.0,KG,20140110.0,,OT,US,CI,EFAVIRENZ,Abortion spontaneous;Malaria,89942543.0,OT,,,89942543.0,1.0,20100312.0,20120827.0,,,89942543.0,1.0,HIV infection
8999489,89994891,1,I,,20121224.0,20130103,20130103,EXP,,CM-VIIV HEALTHCARE LIMITED-B0856123A,GLAXOSMITHKLINE,,30.0,YR,,M,Y,,,20130103.0,,MD,CM,CM,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Macule;Rash;Skin hypopigmentation;Skin lesion;Vitiligo,89994891.0,OT,,,,,,,,,89994891.0,1.0,HIV infection
9000058,90000584,4,F,,20130517.0,20130102,20130524,EXP,,FR-ABBOTT-12P-056-1026427-00,ABBOTT,,79.0,YR,,M,Y,,,20130524.0,,MD,FR,FR,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Rash,90000584.0,OT,,,,,,,,,90000584.0,1.0,HIV infection
9008738,90087381,1,I,,20130103.0,20130111,20130111,EXP,,ES-GILEAD-2013-0067448,GILEAD,,,,,NS,Y,,,20130111.0,,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,90087381.0,OT,,,,,,,,,90087381.0,1.0,HIV infection
9009200,90092001,1,I,,20130103.0,20130111,20130111,EXP,,ES-GILEAD-2013-0067622,GILEAD,,,,,NS,Y,,,20130111.0,,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,90092001.0,OT,,,,,,,,,90092001.0,1.0,HIV infection
9018741,90187412,2,F,20070302.0,20130301.0,20130118,20130308,EXP,,JP-ABBOTT-07P-087-0418599-00,ABBOTT,,40.0,YR,,M,Y,,,20130308.0,,MD,COUNTRY NOT SPECIFIED,JP,EFAVIRENZ,Diabetes mellitus;Diabetes mellitus inadequate control,90187412.0,HO,,,90187412.0,1.0,20041221.0,20050121.0,,,90187412.0,1.0,HIV infection
9026361,90263611,1,I,,20121224.0,20130104,20130104,EXP,,B0856195A,GLAXOSMITHKLINE,,5.0,YR,,M,N,,,20120103.0,,OT,ZA,,EFAVIRENZ,Drug interaction;Hypersensitivity;Sepsis,90263611.0,OT,90263611.0,FGN,,,,,,,90263611.0,1.0,HIV infection
9026363,90263632,2,F,200905.0,20130212.0,20130123,20130215,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-17281668,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20130215.0,,CN,FR,US,SUSTIVA,Cholestasis;Granulomatous liver disease;Hepatic encephalopathy;Hepatitis fulminant;Immune reconstitution inflammatory syndrome;Insomnia;Jaundice;Lactic acidosis;Tachypnoea;Tuberculosis liver,90263632.0,LT,,,90263632.0,1.0,20090505.0,20090516.0,,,90263632.0,1.0,HIV infection
9028829,90288291,1,I,,20130114.0,20130124,20130124,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-17288093,BRISTOL MYERS SQUIBB,,40.0,YR,,F,Y,,,20130124.0,,OT,US,US,EFAVIRENZ,Lactic acidosis;Multi-organ failure;Sepsis,90288291.0,HO,,,,,,,,,90288291.0,1.0,Antiretroviral therapy
9031903,90319033,3,F,201201.0,20131025.0,20130125,20131105,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17293119,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,,,20131105.0,,CN,FR,FR,SUSTIVA,Hypertrophic cardiomyopathy,90319033.0,OT,,,,,,,,,90319033.0,1.0,HIV infection
9031911,90319113,3,F,20080918.0,20160316.0,20130125,20160316,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17316886,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160316.0,,CN,US,FR,SUSTIVA,Cholestasis;Gestational diabetes;Live birth;Maternal exposure during pregnancy;Off label use,90319113.0,OT,,,90319113.0,1.0,20060615.0,,,,90319113.0,1.0,HIV infection
9034692,90346923,3,F,2007.0,20131024.0,20130128,20131028,EXP,,FR-VIIV HEALTHCARE LIMITED-B0858613A,GLAXOSMITHKLINE,,,,,F,Y,,,20131028.0,,MD,FR,FR,Sustiva,Aortic bruit;Aortic disorder;Arteriosclerosis;Arteriosclerosis Moenckeberg-type;Cardiac murmur;Dyspnoea exertional;Hypertrophic cardiomyopathy,90346923.0,OT,,,,,,,,,90346923.0,1.0,HIV infection
9050386,90503861,1,I,201301.0,20130124.0,20130205,20130205,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-17318478,BRISTOL MYERS SQUIBB,,55.0,YR,,F,Y,,,20130205.0,,CN,PL,PL,SUSTIVA,Body mass index increased;Cognitive disorder;Depression;Drug resistance;Pruritus,90503861.0,OT,,,90503861.0,1.0,20110608.0,,,,90503861.0,1.0,Antiretroviral therapy
9050446,90504461,1,I,201201.0,20130124.0,20130205,20130205,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17322975,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20130205.0,,CN,FR,FR,SUSTIVA,Bone marrow transplant;Convulsion;Renal impairment,90504461.0,HO,,,,,,,,,90504461.0,1.0,HIV infection
9052864,90528641,1,I,201104.0,20130125.0,20130207,20130207,EXP,,CM-MYLANLABS-2013S1002126,MYLAN,,30.0,YR,,M,Y,,,20130207.0,,OT,CM,CM,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Vitiligo,90528641.0,OT,,,90528641.0,1.0,201103.0,,,,90528641.0,1.0,HIV infection
9053851,90538511,1,I,,20130129.0,20130207,20130207,EXP,,SG-VIIV HEALTHCARE LIMITED-B0865754A,GLAXOSMITHKLINE,,39.0,YR,,M,Y,,,20130207.0,,MD,SG,SG,EFAVIRENZ,Bedridden;Dysarthria;Dysphagia;Hemiparesis;Immune reconstitution inflammatory syndrome;Muscular weakness;Polyomavirus test positive;Progressive multifocal leukoencephalopathy,90538511.0,OT,,,,,,,,,90538511.0,1.0,HIV infection
9056881,90568811,1,I,20120108.0,20130124.0,20130201,20130201,EXP,,FR-VIIV HEALTHCARE LIMITED-B0861973A,GLAXOSMITHKLINE,,54.0,,,M,Y,,,20130201.0,,MD,FR,FR,Sustiva,CSF protein increased;Convulsion;Pyrexia,90568811.0,HO,,,90568811.0,2.0,20120108.0,20120114.0,,,90568811.0,1.0,HIV infection
9060748,90607481,1,I,20130111.0,20130130.0,20130204,20130204,EXP,,CI-GILEAD-2013-0068172,GILEAD,,38.0,,,F,Y,,,20130204.0,,MD,CI,CI,EFAVIRENZ,Abortion spontaneous,90607481.0,OT,,,90607481.0,1.0,20110125.0,,,,90607481.0,1.0,HIV infection
9062536,90625361,1,I,,20120806.0,20130111,20130111,PER,,US-VIIV HEALTHCARE LIMITED-A0989416A,GLAXOSMITHKLINE,,,,,M,Y,,,20130111.0,,OT,US,US,Sustiva,Lymphadenopathy;Night sweats;Pyrexia,,,,,,,,,,,90625361.0,1.0,HIV infection
9062537,90625371,1,I,20120820.0,20120820.0,20130111,20130111,PER,,US-VIIV HEALTHCARE LIMITED-A0990285A,GLAXOSMITHKLINE,,46.0,YR,,F,Y,,,20130111.0,,CN,US,US,Sustiva,Drug screen positive,,,,,90625371.0,1.0,2004.0,,,,90625371.0,1.0,HIV infection
9062539,90625391,1,I,2008.0,20121018.0,20130111,20130111,PER,,US-VIIV HEALTHCARE LIMITED-A1000459A,GLAXOSMITHKLINE,,52.0,YR,,M,Y,86.4,KG,20130111.0,,OT,US,US,Sustiva,Gastrooesophageal reflux disease,,,,,90625391.0,1.0,2008.0,,,,90625391.0,1.0,HIV infection
9068368,90683681,1,I,,20130121.0,20130128,20130128,EXP,,AU-ROCHE-1182193,ROCHE,,64.0,YR,,M,Y,,,20130128.0,,CN,AU,AU,EFAVIRENZ,Anorectal varices;Hepatic fibrosis;Intestinal varices;Oesophageal varices haemorrhage;Portal hypertension;Portal vein occlusion;Splenomegaly,90683681.0,OT,,,,,,,,,90683681.0,1.0,HIV infection
9069469,90694691,1,I,201104.0,20130204.0,20130215,20130215,EXP,,CM-BRISTOL-MYERS SQUIBB COMPANY-17346131,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,,,20130215.0,,OT,CM,CM,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Vitiligo,90694691.0,OT,,,90694691.0,1.0,201103.0,,,,90694691.0,1.0,HIV infection
9075530,90755301,1,I,2010.0,20130124.0,20130131,20130131,EXP,,FR-ABBOTT-13P-056-1041802-00,ABBOTT,,54.0,,,M,Y,,,20130131.0,,MD,FR,FR,SUSTIVA,Bone marrow transplant;Convulsion;Plasmablastic lymphoma;Pyrexia;Renal failure,90755301.0,OT,,,,,,,,,90755301.0,1.0,HIV infection
9092914,90929141,1,I,,20130208.0,20130218,20130218,EXP,,CA-ABBOTT-13P-028-1050909-00,ABBOTT,,,,,M,Y,59.02,KG,20130227.0,,CN,COUNTRY NOT SPECIFIED,CA,SUSTIVA,Aphasia;Cerebrovascular accident;Gait disturbance;Hemiplegia;Paraesthesia,90929141.0,DS,,,90929141.0,1.0,2003.0,,,,90929141.0,1.0,Antiretroviral therapy
9097849,90978492,2,F,201012.0,20130325.0,20130212,20130403,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-17363292,BRISTOL MYERS SQUIBB,,57.0,YR,,M,Y,,,20130403.0,,CN,US,BR,EFAVIRENZ,Drug ineffective;Porphyria non-acute,90978492.0,OT,,,90978492.0,1.0,200808.0,201012.0,,,90978492.0,1.0,HIV infection
9098129,90981291,1,I,20100930.0,20130212.0,20130213,20130213,EXP,,AR-ABBOTT-13P-007-1048863-00,ABBOTT,,35.0,YR,,F,Y,,,20130214.0,,OT,COUNTRY NOT SPECIFIED,AR,EFAVIRENZ,Abortion spontaneous;Hypothyroidism,90981291.0,OT,,,90981291.0,1.0,20100920.0,,,,90981291.0,1.0,Antiretroviral therapy
9098876,90988761,1,I,200905.0,20130131.0,20130213,20130213,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-17363284,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,,,20130213.0,,CN,US,BR,EFAVIRENZ,Drug ineffective;Porphyria non-acute,90988761.0,OT,,,90988761.0,1.0,,200905.0,,,90988761.0,1.0,HIV infection
9099264,90992641,1,I,201105.0,20130131.0,20130213,20130213,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-17362989,BRISTOL MYERS SQUIBB,,49.0,YR,,M,Y,,,20130213.0,,CN,US,BR,EFAVIRENZ,Porphyria non-acute,90992641.0,OT,,,90992641.0,1.0,201103.0,,,,90992641.0,1.0,HIV infection
9099516,90995161,1,I,20110815.0,20130205.0,20130213,20130213,EXP,,FR-GILEAD-2013-0069399,GILEAD,,39.0,YR,,M,Y,,,20130213.0,,PH,FR,FR,SUSTIVA,Immune reconstitution inflammatory syndrome associated tuberculosis;Pericarditis,90995161.0,HO,,,90995161.0,1.0,20110120.0,20110512.0,,,90995161.0,1.0,HIV infection
9109057,91090574,4,F,2012.0,20200213.0,20130222,20200220,EXP,,BR-VIIV HEALTHCARE LIMITED-A1012284A,VIIV,,0.0,YR,,F,Y,2.9,KG,20200220.0,,CN,US,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,91090574.0,CA,,,91090574.0,1.0,20121128.0,20121128.0,,,91090574.0,1.0,HIV infection
9109906,91099063,3,F,2005.0,20200624.0,20130222,20200705,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-17408931,BRISTOL MYERS SQUIBB,,41.0,YR,,F,Y,,,20200705.0,,MD,PT,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,91099063.0,OT,,,91099063.0,1.0,2003.0,2006.0,,,91099063.0,1.0,Antiretroviral therapy
9115540,91155402,2,F,2005.0,20200616.0,20130225,20200622,EXP,,PT-MERCK-1302PRT004051,MERCK,,41.0,YR,,F,Y,,,20200622.0,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,91155402.0,OT,,,91155402.0,1.0,2005.0,2006.0,,,91155402.0,2.0,Antiretroviral therapy
9123104,91231041,1,I,20110910.0,20130114.0,20130131,20130131,EXP,,ADR-2013UNK004,HETERO,,37.0,YR,,M,N,,,20130128.0,,CN,US,,EFAVIRENZ TABS/(UNK MFR),Dermatitis exfoliative,91231041.0,OT,91231041.0,LIT,,,,,,,91231041.0,1.0,Acquired immunodeficiency syndrome
9124221,91242214,4,F,20120521.0,20180703.0,20130227,20180713,EXP,,US-GILEAD-2013-0070291,GILEAD,,0.0,YR,,F,Y,2.88,KG,20180713.0,,OT,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital disorder female,91242214.0,OT,,,91242214.0,1.0,20120521.0,20121128.0,,,91242214.0,1.0,HIV infection
9129625,91296253,3,F,201201.0,20131024.0,20130125,20131031,EXP,,FR-ASTRAZENECA-2013SE03723,ASTRAZENECA,,858.0,MON,,F,Y,,,20131031.0,,MD,FR,FR,SUSTIVA,Hypertrophic cardiomyopathy,91296253.0,OT,,,,,,,,,91296253.0,2.0,HIV infection
9135768,91357681,1,I,20121031.0,20130301.0,20130304,20130304,EXP,,ES-GILEAD-2013-0071000,GILEAD,,33.0,YR,,M,Y,,,20130304.0,,PH,ES,ES,SUSTIVA,Hepatitis cholestatic,91357681.0,HO,,,91357681.0,1.0,20120911.0,20121031.0,,,91357681.0,1.0,HIV infection
9139068,91390683,3,F,,20160316.0,20130305,20160316,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-17423922,BRISTOL MYERS SQUIBB,,41.0,YR,,F,Y,,,20160316.0,,MD,PT,PT,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy;Off label use,91390683.0,OT,,,91390683.0,1.0,201202.0,,,,91390683.0,1.0,HIV infection
9146891,91468912,2,F,20100901.0,20130211.0,20130221,20130221,EXP,,ADR-2013UNK008,HETERO,,56.0,DY,,NS,N,,,20130220.0,,OT,US,,EFAVIRENZ,Abortion spontaneous;Maternal drugs affecting foetus,91468912.0,DE,91468912.0,CSM,,,,,,,91468912.0,1.0,Acquired immunodeficiency syndrome
9148732,91487321,1,I,,20130125.0,20130214,20130214,EXP,,2013HINLIT0011,HETERO,,25.0,YR,,M,N,,,20130208.0,,OT,US,,EFAVIRENZ,Vanishing bile duct syndrome,91487321.0,DE,91487321.0,HP,,,,,,,91487321.0,1.0,Antiretroviral therapy
9148976,91489761,1,I,,20130219.0,20130304,20130304,EXP,,B0871487A,GLAXOSMITHKLINE,,6.0,YR,,M,N,,,20130301.0,,OT,ZA,,EFAVIRENZ,Confusional state;Hepatomegaly;Immune reconstitution inflammatory syndrome;Intracranial pressure increased;Meningism;Musculoskeletal stiffness;Neck pain;Oral candidiasis;Photophobia;Pyrexia;Somnolence;Vomiting,91489761.0,HO,91489761.0,FGN,,,,,,,91489761.0,1.0,HIV infection
9151441,91514412,2,F,20120613.0,20130422.0,20130308,20130502,EXP,,CI-ABBOTT-13P-084-1056493-00,ABBOTT,,39.0,YR,,F,Y,,,20130502.0,,MD,COUNTRY NOT SPECIFIED,CI,EFAVIRENZ,Abortion induced,91514412.0,OT,,,91514412.0,1.0,20120521.0,20120521.0,,,91514412.0,1.0,HIV infection
9155701,91557011,1,I,20101118.0,20130305.0,20130311,20130311,EXP,,BR-GILEAD-2010-0033749,GILEAD,,35.0,YR,,M,Y,,,20130315.0,,PH,BR,BR,EFAVIRENZ,Gastritis;Pneumothorax;Septic shock,91557011.0,LT,,,91557011.0,1.0,20101014.0,20101114.0,,,91557011.0,1.0,HIV infection
9159647,91596471,1,I,,20130205.0,20130219,20130219,EXP,,B0868124A,GLAXOSMITHKLINE,,42.0,YR,,M,N,,,20130215.0,,OT,ZA,,EFAVIRENZ,Hepatitis E;Immune reconstitution inflammatory syndrome;Neuropathy peripheral,91596471.0,OT,91596471.0,LIT,91596471.0,1.0,201003.0,,,,91596471.0,1.0,HIV infection
9159920,91599201,1,I,20130219.0,20130305.0,20130313,20130313,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-06200BP",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,,,20130313.0,,CN,US,US,Sustiva,Abdominal pain;Blood creatinine increased;Constipation,,,,,91599201.0,1.0,2000.0,20130219.0,,,91599201.0,1.0,HIV infection
9161257,91612573,3,F,20130223.0,20130913.0,20130313,20130918,EXP,,US-VIIV HEALTHCARE LIMITED-Z0018939A,GLAXOSMITHKLINE,,37.0,YR,,M,Y,107.0,KG,20130918.0,,MD,US,US,EFAVIRENZ,Suicide attempt,91612573.0,HO,,,91612573.0,1.0,20120918.0,20130304.0,,,91612573.0,1.0,HIV infection
9161258,91612583,3,F,20130303.0,20130913.0,20130313,20130918,EXP,,US-VIIV HEALTHCARE LIMITED-Z0018939B,GLAXOSMITHKLINE,,37.0,YR,,M,Y,107.0,KG,20130918.0,,MD,US,US,EFAVIRENZ,Suicide attempt,91612583.0,LT,,,91612583.0,1.0,20120918.0,20130304.0,,,91612583.0,1.0,HIV infection
9162829,91628291,1,I,,20130215.0,20130225,20130225,EXP,,B0869886A,GLAXOSMITHKLINE,,42.0,YR,,M,N,,,20130222.0,,,ZA,,EFAVIRENZ,Alcohol use;Transaminases increased,,,91628291.0,HP,91628291.0,1.0,201003.0,,,,91628291.0,1.0,HIV infection
9163785,91637851,1,I,2005.0,20130228.0,20130314,20130314,EXP,,US-PFIZER INC-2013082408,PFIZER,,35.0,YR,,M,Y,,,20130314.0,,MD,US,US,EFAVIRENZ,Drug interaction;Retinal toxicity,91637851.0,OT,,,91637851.0,6.0,2002.0,,,,91637851.0,1.0,HIV infection
9164876,91648761,1,I,,20130212.0,20130222,20130222,EXP,,B0868762A,GLAXOSMITHKLINE,,10.0,YR,,F,N,,,20130219.0,,OT,PL,,EFAVIRENZ,Drug resistance;Limb asymmetry;Lipodystrophy acquired;Lipoma;Viral load increased,91648761.0,RI,91648761.0,HP,,,,,,,91648761.0,1.0,HIV infection
9164884,91648841,1,I,,20130208.0,20130228,20130228,EXP,,2013HINLIT0018,HETERO,,40.0,YR,,F,N,,,20130219.0,,OT,US,,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Asthenia;Back pain;Bradycardia;Cardiac enzymes increased;Decreased appetite;Hepatomegaly;Hypoglycaemia;Hypoperfusion;Hypotension;Lactic acidosis;Lethargy;Metabolic acidosis;Multi-organ failure;No therapeutic response;Oxygen saturation decreased;Pain;Sepsis;Staphylococcus test positive,91648841.0,HO,91648841.0,LIT,,,,,,,91648841.0,1.0,Antiretroviral therapy
9168075,91680751,1,I,20110527.0,20130308.0,20130318,20130318,EXP,,FR-009507513-1303FRA005578,MERCK,,46.0,YR,,M,Y,85.0,KG,20130318.0,,MD,FR,FR,SUSTIVA,Drug-induced liver injury;Transaminases increased,91680751.0,OT,,,91680751.0,1.0,20100429.0,20110630.0,,,91680751.0,1.0,HIV infection
9169124,91691242,2,F,201301.0,20130422.0,20130318,20130429,EXP,,FR-VIIV HEALTHCARE LIMITED-B0873365A,GLAXOSMITHKLINE,,34.0,YR,,F,Y,,,20130429.0,,MD,FR,FR,Sustiva,Asthenia;Drug hypersensitivity;Gingival bleeding;Malaise;Palpitations;Paraesthesia,91691242.0,OT,,,91691242.0,1.0,20130116.0,20130126.0,,,91691242.0,1.0,HIV infection
9170190,91701901,1,I,,20130228.0,20130311,20130311,EXP,,AUR-APL-2013-02087,AUROBINDO,,52.0,YR,,M,N,,,20130308.0,,MD,US,,EFAVIRENZ,Chorioretinal atrophy,91701901.0,OT,91701901.0,LIT,,,,,,,91701901.0,1.0,HIV infection
9170211,91702111,1,I,2005.0,20130228.0,20130311,20130311,EXP,,AUR-APL-2013-02084,AUROBINDO,,35.0,YR,,M,N,,,20130308.0,,MD,US,,EFAVIRENZ,Chorioretinal atrophy;Retinal toxicity,91702111.0,OT,91702111.0,LIT,,,,,,,91702111.0,8.0,HIV infection
9171881,91718811,1,I,20120814.0,20130228.0,20130318,20130318,EXP,,ADR-2013UNK045,HETERO,,42.0,DY,,NS,N,,,20130314.0,,,US,,EFAVIRENZ,Maternal exposure during pregnancy;Selective abortion,91718811.0,DE,91718811.0,SDY,91718811.0,1.0,20100211.0,,,,91718811.0,1.0,Acquired immunodeficiency syndrome
9171903,91719032,2,F,20120613.0,20130422.0,20130318,20130510,EXP,,ADR-2013UNK043,HETERO,,77.0,DY,,NS,N,,,20130507.0,,OT,US,,EFAVIRENZ,Abortion induced;Exposure during pregnancy,91719032.0,DE,91719032.0,CSM,91719032.0,1.0,20110516.0,20110521.0,,,91719032.0,1.0,Acquired immunodeficiency syndrome
9172790,91727902,2,F,20100304.0,20130724.0,20120911,20131105,EXP,,US-009507513-1008FRA00062,MERCK,,53.0,YR,,M,Y,,,20131105.0,,OT,FR,FR,SUSTIVA,Dyspnoea;Hepatic failure;Hyperlactacidaemia;Insomnia;Metabolic acidosis;Shock;Ventricular arrhythmia,91727902.0,HO,,,91727902.0,1.0,20100129.0,20100304.0,,,91727902.0,1.0,HIV infection
9173321,91733211,1,I,,20130227.0,20130315,20130315,EXP,,ADR-2013UNK042,HETERO,,,,,NS,N,,,20130312.0,,,US,,EFAVIRENZ TABS/ (UNK MFR),Neuropsychiatric syndrome,91733211.0,OT,91733211.0,LIT,,,,,,,91733211.0,1.0,Acquired immunodeficiency syndrome
9186935,91869351,1,I,,20121026.0,20130325,20130325,EXP,,IN-VIIV HEALTHCARE LIMITED-B0841906A,GLAXOSMITHKLINE,,27.0,YR,,M,Y,,,20121102.0,,MD,IN,IN,EFAVIRENZ,Arthralgia;CD4 lymphocytes;Cellulitis;Dactylitis;Decreased appetite;Deformity;Dyspnoea;Hypokinesia;Immune reconstitution inflammatory syndrome;Joint warmth;Osteomyelitis;Osteoporosis;Pulmonary tuberculosis;Pyrexia;Tachycardia;Ulcer,91869351.0,DE,,,,,,,,,91869351.0,1.0,HIV infection
9188344,91883441,1,I,,20130313.0,20130325,20130325,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17482308,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20130325.0,,CN,GB,GB,SUSTIVA,Dysphagia;Local swelling;Malaise;Treatment noncompliance,91883441.0,HO,,,,,,,,,91883441.0,1.0,HIV infection
9190247,91902471,1,I,,,20130325,20130325,DIR,,,,,59.0,YR,,F,N,60.0,KG,20130322.0,,MD,US,,SUSTIVA,Product substitution issue;Rash,91902471.0,OT,91902471.0,HP,91902471.0,1.0,2012.0,,,,91902471.0,1.0,Acquired immunodeficiency syndrome
9190258,91902581,1,I,,20130305.0,20130322,20130322,EXP,,ADR-2013UNK046,HETERO,,,,,F,N,,,20130319.0,,,US,,EFAVIRENZ TABS/ (UNK MFR),Neuropsychiatric syndrome,91902581.0,OT,91902581.0,LIT,,,,,,,91902581.0,1.0,Acquired immunodeficiency syndrome
9198372,91983721,1,I,20121026.0,20130308.0,20130326,20130326,EXP,,ADR-2013UNK050,HETERO,,119.0,DY,,NS,N,,,20130320.0,,OT,US,,EFAVIRENZ TABS/ (UNK MFR),Abortion spontaneous;Exposure during pregnancy;Malaria;Pregnancy,91983721.0,DE,91983721.0,CSM,91983721.0,1.0,20100312.0,20120827.0,,,91983721.0,1.0,Acquired immunodeficiency syndrome
9204695,92046954,4,F,20070101.0,20220321.0,20130402,20220325,EXP,,JP-GILEAD-2011-0039952,GILEAD,D  Watanabe. Immune reconstitution to parvovirus B19 and resolution of anemia in a patient treated with highly active antiretroviral therapy.. Journal of Infection and Chemotherapy. 2011;17:283 - 287,54.0,YR,A,M,Y,,,20220325.0,,HP,JP,JP,EFAVIRENZ,Aplasia pure red cell;Immune reconstitution inflammatory syndrome,92046954.0,OT,,,92046954.0,1.0,200701.0,,,,92046954.0,1.0,HIV infection
9204808,92048083,3,F,20130318.0,20150317.0,20130402,20150330,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-18723148,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,52.5,KG,20150330.0,N,CN,US,MW,EFAVIRENZ,Meningitis tuberculous,92048083.0,LT,,,92048083.0,1.0,20130116.0,20130718.0,,,92048083.0,1.0,HIV infection
9205163,92051631,1,I,,20130319.0,20130402,20130402,EXP,,BR-MYLANLABS-2013S1006470,MYLAN,,57.0,YR,,M,Y,,,20130402.0,,OT,BR,BR,EFAVIRENZ,Porphyria non-acute,92051631.0,OT,,,92051631.0,1.0,201012.0,201012.0,,,92051631.0,1.0,HIV infection
9205170,92051701,1,I,201010.0,20130319.0,20130402,20130402,EXP,,BR-MYLANLABS-2013S1006473,MYLAN,,46.0,YR,,M,Y,,,20130402.0,,OT,BR,BR,EFAVIRENZ,Porphyria non-acute,92051701.0,OT,,,92051701.0,4.0,200905.0,,,,92051701.0,1.0,HIV infection
9215280,92152802,2,F,20130318.0,20130529.0,20130405,20130606,EXP,,IN-GILEAD-2013-0072479,GILEAD,,38.0,YR,,F,Y,,,20130606.0,,MD,IN,IN,EFAVIRENZ,Influenza,92152802.0,HO,,,92152802.0,1.0,20090626.0,20130309.0,,,92152802.0,1.0,HIV infection
9215956,92159561,1,I,,20130319.0,20130404,20130404,EXP,,2013HINLIT0068,HETERO,,29.0,YR,,M,N,,,20130327.0,,OT,PE,,EFAVIRENZ,Encephalitis;Immune reconstitution inflammatory syndrome associated tuberculosis,92159561.0,OT,92159561.0,FGN,,,,,,,92159561.0,1.0,Antiretroviral therapy
9215959,92159591,1,I,,20130319.0,20130404,20130404,EXP,,2013HINLIT0069,HETERO,,39.0,YR,,M,N,,,20130327.0,,OT,PE,,EFAVIRENZ,Immune reconstitution inflammatory syndrome,92159591.0,OT,92159591.0,LIT,,,,,,,92159591.0,1.0,Antiretroviral therapy
9215963,92159632,2,F,,20130319.0,20130404,20130404,EXP,,2013HINLIT0070,HETERO,,38.0,YR,,M,N,,,20130327.0,,OT,PE,,EFAVIRENZ,Cerebral ischaemia;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Vasculitis cerebral,92159632.0,OT,92159632.0,FGN,,,,,,,92159632.0,1.0,Antiretroviral therapy
9215977,92159771,1,I,,20130319.0,20130404,20130404,EXP,,2013HINLIT0066,HETERO,,44.0,YR,,M,N,,,20130327.0,,OT,PE,,EFAVIRENZ,Cerebral toxoplasmosis;Immune reconstitution inflammatory syndrome,92159771.0,OT,92159771.0,LIT,92159771.0,1.0,,,56.0,DAY,92159771.0,1.0,Antiretroviral therapy
9215995,92159951,1,I,,20130319.0,20130404,20130404,EXP,,2013HINLIT0071,HETERO,,29.0,YR,,F,N,,,20130327.0,,OT,PE,,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,92159951.0,OT,92159951.0,HP,,,,,,,92159951.0,1.0,Antiretroviral therapy
9217681,92176814,4,F,2013.0,20130620.0,20130408,20130701,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18759704,BRISTOL MYERS SQUIBB,,73.0,YR,,NS,Y,,,20130701.0,,CN,GB,GB,SUSTIVA CAPS,Insomnia;Renal failure,92176814.0,OT,,,92176814.0,2.0,,2013.0,,,92176814.0,1.0,HIV infection
9221573,92215731,1,I,,20130326.0,20130408,20130408,EXP,,B0881057A,GLAXOSMITHKLINE,,40.0,YR,,M,N,,,20130405.0,,OT,GB,,EFAVIRENZ,Blood cholesterol increased;Blood triglycerides increased;Dyslipidaemia;Glycosylated haemoglobin increased,92215731.0,OT,92215731.0,LIT,,,,,,,92215731.0,1.0,HIV infection
9223808,92238083,3,F,20130331.0,20130503.0,20130410,20130508,EXP,,TH-GILEAD-2013-0072940,GILEAD,,46.0,YR,,M,Y,,,20130508.0,,MD,TH,TH,EFAVIRENZ,Haemorrhagic stroke,92238083.0,DE,,,92238083.0,1.0,20120618.0,20130330.0,,,92238083.0,1.0,HIV infection
9225072,92250723,3,F,,20130409.0,20130409,20130418,EXP,,AUR-APL-2013-02853,AUROBINDO,,10.0,YR,,F,N,,,20130417.0,,OT,ZA,,EFAVIRENZ,Anaemia;Blood thyroid stimulating hormone increased;Erythropoiesis abnormal;Leukopenia;Neuropathy peripheral;Transaminases increased,92250723.0,OT,92250723.0,SDY,,,,,,,92250723.0,1.0,Antiretroviral therapy
9225433,92254332,2,F,,20130412.0,20130409,20130426,EXP,,AUR-APL-2013-02854,AUROBINDO,,71.0,MON,,F,N,,,20130425.0,,OT,ZA,,EFAVIRENZ,Lactic acidosis;Neuropathy peripheral;Pancreatitis;Rash,92254332.0,HO,92254332.0,LIT,,,,,,,92254332.0,1.0,HIV infection
9225455,92254552,2,F,,20130402.0,20130409,20130417,EXP,,AUR-APL-2013-02686,AUROBINDO,,42.0,YR,,M,N,,,20130415.0,,OT,ZA,,EFAVIRENZ,Hepatitis E;Immune reconstitution inflammatory syndrome;Neuropathy peripheral,92254552.0,OT,92254552.0,HP,92254552.0,1.0,201003.0,,,,92254552.0,1.0,HIV infection
9228651,92286511,1,I,2012.0,20130402.0,20130412,20130412,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18752345,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20130412.0,,CN,FR,FR,SUSTIVA CAPS 200 MG,Decreased appetite;Depression;Dizziness;Morose;Nervousness;Sleep disorder,92286511.0,OT,,,92286511.0,1.0,20120104.0,,,,92286511.0,1.0,HIV infection CDC category A2
9228950,92289501,1,I,20090930.0,20130402.0,20130412,20130412,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-18747501,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20130412.0,,CN,PL,PL,EFAVIRENZ,Aphasia;Breast abscess;Cachexia;Drug resistance;Dyslipidaemia;Headache;Hydronephrosis;Meningitis viral;Oral candidiasis;Pneumonia;Renal hypoplasia;Upper respiratory tract infection;Urinary tract infection,92289501.0,OT,,,92289501.0,1.0,20121215.0,19990303.0,,,92289501.0,1.0,HIV infection
9237304,92373041,1,I,,20130404.0,20130417,20130417,EXP,,ZA-MYLANLABS-2013S1007969,MYLAN,,,,,NS,Y,,,20130417.0,,OT,ZA,ZA,EFAVIRENZ,Liver injury,92373041.0,HO,,,,,,,,,92373041.0,1.0,Antiretroviral therapy
9237311,92373111,1,I,,20130404.0,20130417,20130417,EXP,,ZA-MYLANLABS-2013S1007970,MYLAN,,,,,NS,Y,,,20130417.0,,OT,ZA,ZA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Liver injury;Vomiting,92373111.0,HO,,,,,,,,,92373111.0,1.0,Antiretroviral therapy
9243127,92431272,2,F,200811.0,20130423.0,20130419,20130501,EXP,,BR-ABBOTT-13P-020-1077271-00,ABBOTT,,34.0,YR,,F,Y,,,20130501.0,,CN,BR,BR,EFAVIRENZ,Amaurosis;CD4 lymphocytes decreased;Chorioretinitis;Colitis;Cytomegalovirus infection;Drug intolerance;Pyrexia;Renal impairment;Treatment noncompliance;Viral load increased;Weight decreased,92431272.0,OT,,,92431272.0,1.0,200311.0,2006.0,,,92431272.0,1.0,HIV infection
9247936,92479362,2,F,201301.0,20130516.0,20130423,20130528,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18798454,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,54.0,KG,20130528.0,,CN,FR,FR,SUSTIVA,Adenocarcinoma gastric;Haematemesis,92479362.0,LT,,,92479362.0,1.0,20060711.0,,,,92479362.0,1.0,HIV infection
9251764,92517641,1,I,,20130410.0,20130424,20130424,EXP,,TW-MYLANLABS-2013S1008381,MYLAN,,37.0,YR,,F,Y,,,20130424.0,,MD,TW,TW,EFAVIRENZ,Hypercalcaemia;Immune reconstitution inflammatory syndrome;Lung infection;Mycobacterium avium complex infection;Renal failure acute;Sinus tachycardia,92517641.0,HO,,,,,,,,,92517641.0,1.0,HIV infection
9252649,92526495,5,F,20120803.0,20140822.0,20130424,20140827,EXP,,CO-VIIV HEALTHCARE LIMITED-A1020794A,GLAXOSMITHKLINE,,28.0,YR,,M,Y,,,20140827.0,N,OT,CO,CO,EFAVIRENZ,Depression;Lipodystrophy acquired,92526495.0,OT,,,92526495.0,2.0,20120803.0,20130312.0,,,92526495.0,1.0,HIV infection
9260612,92606122,2,F,,20130507.0,20130429,20130508,EXP,,FR-GILEAD-2013-0074194,GILEAD,,,,,NS,Y,,,20130508.0,,OT,FR,FR,SUSTIVA,Bronchopulmonary dysplasia;Congenital anomaly of adrenal gland;Congenital hydrocephalus;Dysmorphism,92606122.0,CA,,,,,,,,,92606122.0,1.0,HIV infection
9263986,92639862,2,F,20121116.0,20130703.0,20130430,20130710,EXP,,NL-VIIV HEALTHCARE LIMITED-B0888289A,GLAXOSMITHKLINE,,,,,M,Y,68.0,KG,20130710.0,,OT,NL,NL,EFAVIRENZ,Myocardial infarction,92639862.0,HO,,,92639862.0,1.0,200705.0,,,,92639862.0,1.0,HIV infection
9263988,92639882,2,F,201010.0,20130703.0,20130430,20130712,EXP,,NL-VIIV HEALTHCARE LIMITED-B0888290A,GLAXOSMITHKLINE,,,,,M,Y,71.0,KG,20130712.0,,OT,NL,NL,EFAVIRENZ,Angina unstable;Coronary artery thrombosis,92639882.0,HO,,,92639882.0,1.0,200709.0,,,,92639882.0,1.0,HIV infection
9270240,92702401,1,I,20130120.0,20130423.0,20130503,20130503,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18836460,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20130503.0,,CN,FR,FR,SUSTIVA,Gingival bleeding;Malaise;Palpitations;Paraesthesia,92702401.0,OT,,,92702401.0,1.0,20130116.0,20130126.0,,,92702401.0,1.0,HIV infection
9274643,92746431,1,I,,20130416.0,20130429,20130429,EXP,,CIP-2013-00121,CIPLA,,,,,NS,N,,,20130426.0,,,US,,EFAVIRENZ,Paraplegia,92746431.0,OT,92746431.0,HP,,,,,,,92746431.0,1.0,HIV infection
9276918,92769182,2,F,,20130506.0,20130501,20130520,EXP,,AUR-APL-2013-03400,AUROBINDO,,,,,NS,N,,,20130517.0,,OT,ZA,,EFAVIRENZ,Alanine aminotransferase increased;Cough;Diarrhoea;Drug-induced liver injury,92769182.0,OT,92769182.0,FGN,,,,,,,92769182.0,1.0,Antiretroviral therapy
9276921,92769211,1,I,,20130422.0,20130501,20130501,EXP,,AUR-APL-03399,AUROBINDO,,,,,NS,N,,,20130430.0,,OT,ZA,,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Drug-induced liver injury,92769211.0,OT,92769211.0,LIT,,,,,,,92769211.0,1.0,HIV infection
9286463,92864631,1,I,201202.0,20130506.0,20130513,20130513,EXP,,FR-ABBOTT-13P-056-1086790-00,ABBOTT,,51.0,YR,,M,Y,,,20130513.0,,MD,FR,FR,SUSTIVA,Axonal neuropathy;Hypokinesia;Muscular weakness;Pain;Spinal muscular atrophy,92864631.0,DS,,,92864631.0,1.0,2005.0,20111102.0,,,92864631.0,1.0,HIV infection
9287921,92879211,1,I,,20130506.0,20130514,20130514,EXP,,"TW-ROXANE LABORATORIES, INC.-2013-RO-00724RO",ROXANE,,37.0,YR,,F,Y,,,20130514.0,,OT,COUNTRY NOT SPECIFIED,TW,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Mycobacterium avium complex infection,92879211.0,LT,,,,,,,,,92879211.0,1.0,Antiretroviral therapy
9288911,92889111,1,I,20130120.0,20130425.0,20130514,20130514,EXP,,FR-GILEAD-2013-0074964,GILEAD,,34.0,YR,,F,Y,,,20130514.0,,MD,FR,FR,SUSTIVA,Asthenia;Gingival bleeding;Hypersensitivity;Malaise;Osteopenia;Palpitations;Paraesthesia,92889111.0,OT,,,92889111.0,2.0,20130116.0,20130126.0,,,92889111.0,1.0,HIV infection
9291577,92915772,2,F,201202.0,20140715.0,20130515,20140721,EXP,,FR-VIIV HEALTHCARE LIMITED-B0889823A,GLAXOSMITHKLINE,,51.0,YR,,M,Y,,,20140721.0,N,MD,FR,FR,SUSTIVA,Amyotrophy;Axonal neuropathy;Hypokinesia;Muscular weakness;Myalgia,92915772.0,DS,,,92915772.0,1.0,2005.0,20111102.0,,,92915772.0,1.0,HIV infection
9293557,92935571,1,I,2011.0,20130509.0,20130516,20130516,EXP,,LV-VIIV HEALTHCARE LIMITED-B0891700A,GLAXOSMITHKLINE,,41.0,YR,,M,Y,85.0,KG,20130516.0,,MD,LV,LV,EFAVIRENZ,Diabetes mellitus;Thirst;Weight decreased,92935571.0,OT,,,92935571.0,1.0,2009.0,,,,92935571.0,1.0,HIV infection
9296378,92963782,2,F,201202.0,20140715.0,20130517,20140723,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18889139,BRISTOL MYERS SQUIBB,,51.0,YR,,M,Y,,,20140723.0,N,CN,FR,FR,SUSTIVA,Amyotrophy;Axonal neuropathy,92963782.0,DS,,,92963782.0,1.0,2005.0,,,,92963782.0,1.0,HIV infection
9304042,93040421,1,I,201104.0,20130515.0,20130522,20130522,EXP,,"CM-ROXANE LABORATORIES, INC.-2013-RO-00811RO",ROXANE,,30.0,YR,,M,Y,,,20130522.0,,OT,COUNTRY NOT SPECIFIED,CM,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Vitiligo,93040421.0,OT,,,93040421.0,1.0,201103.0,,,,93040421.0,1.0,HIV infection WHO clinical stage I
9304280,93042801,1,I,,20130510.0,20130522,20130522,EXP,,ZA-MYLANLABS-2013S1010376,MYLAN,,6.0,DEC,,F,Y,,,20130522.0,,OT,ZA,ZA,EFAVIRENZ,Condition aggravated;Mycosis fungoides,93042801.0,OT,,,93042801.0,1.0,201003.0,,,,93042801.0,1.0,HIV infection
9304281,93042811,1,I,,20130510.0,20130522,20130522,EXP,,ZA-MYLANLABS-2013S1010376,MYLAN,,6.0,DEC,,F,Y,,,20130522.0,,OT,ZA,ZA,EFAVIRENZ,Condition aggravated;Mycosis fungoides,93042811.0,DE,,,93042811.0,1.0,201003.0,,,,93042811.0,1.0,HIV infection
9306377,93063772,2,F,20121128.0,20130304.0,20130307,20130322,EXP,,ADR-2013UNK020,HETERO,,280.0,DY,,F,N,2.88,KG,20130311.0,,OT,US,,EFAVIRENZ,Congenital anomaly;Genital prolapse;Maternal drugs affecting foetus;Maternal exposure during pregnancy;Muscle disorder,93063772.0,CA,93063772.0,CSM,93063772.0,1.0,20120521.0,,,,93063772.0,1.0,Acquired immunodeficiency syndrome
9306905,93069052,2,F,20110211.0,20130624.0,20130523,20130701,EXP,,FR-GILEAD-2013-0075359,GILEAD,,40.0,YR,,F,Y,,,20130701.0,,OT,FR,FR,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,93069052.0,OT,,,93069052.0,1.0,20110121.0,,,,93069052.0,1.0,HIV infection
9308464,93084643,3,F,20130514.0,20131210.0,20130524,20131218,EXP,,ZM-GILEAD-2013-0075622,GILEAD,,27.0,YR,,F,Y,48.0,KG,20131218.0,,OT,ZM,ZM,EFAVIRENZ,Hepatic enzyme increased,93084643.0,OT,,,93084643.0,1.0,20130506.0,20130520.0,,,93084643.0,1.0,HIV infection
9312611,93126111,1,I,20130521.0,20130517.0,20130528,20130528,EXP,,JP-VIIV HEALTHCARE LIMITED-B0893857A,GLAXOSMITHKLINE,,6.0,DEC,,M,Y,,,20130528.0,,MD,JP,JP,EFAVIRENZ,Cardiac failure;Chest pain,93126111.0,OT,,,93126111.0,1.0,20130516.0,,,,93126111.0,1.0,HIV infection
9312919,93129193,3,F,20130423.0,20130613.0,20130528,20130614,EXP,,BW-GILEAD-2013-0075627,GILEAD,,45.0,YR,,F,Y,,,20130614.0,,MD,BW,BW,EFAVIRENZ,Uterine leiomyoma,93129193.0,HO,,,93129193.0,1.0,20091125.0,,,,93129193.0,1.0,Prophylaxis against HIV infection
9316221,93162211,1,I,,20130513.0,20130522,20130522,EXP,,2013AP005300,APOTEX,,,,,F,N,,,20130517.0,,OT,US,,EFAVIRENZ,Oral mucosal erythema;Oropharyngeal discomfort;Rash maculo-papular;Tongue disorder,93162211.0,HO,93162211.0,LIT,93162211.0,1.0,,,16.0,DAY,93162211.0,1.0,HIV infection
9317994,93179942,2,F,,20160726.0,20130530,20160726,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-18919407,BRISTOL MYERS SQUIBB,,5.0,DEC,,F,Y,,,20160726.0,,OT,ZA,ZA,EFAVIRENZ,Mycosis fungoides,93179942.0,OT,,,93179942.0,1.0,201003.0,,,,93179942.0,1.0,Antiretroviral therapy
9321851,93218511,1,I,201301.0,20130516.0,20130531,20130531,EXP,,FR-009507513-1304FRA013980,MERCK,,56.0,YR,,F,Y,,,20130531.0,,CN,FR,FR,SUSTIVA,Adenocarcinoma gastric;Haematemesis,93218511.0,LT,,,93218511.0,1.0,20060711.0,,,,93218511.0,1.0,HIV infection
9322259,93222592,2,F,20120720.0,20130608.0,20130531,20130624,EXP,,FR-VIIV HEALTHCARE LIMITED-B0863475A,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20130624.0,,MD,FR,FR,Sustiva,Anal cancer recurrent;Constipation;Gastrointestinal stoma necrosis;Pseudomonal sepsis;Respiratory disorder,93222592.0,OT,,,93222592.0,1.0,20080226.0,,,,93222592.0,1.0,HIV infection
9322281,93222813,3,F,200603.0,20130719.0,20130531,20130724,EXP,,JP-VIIV HEALTHCARE LIMITED-B0894854A,GLAXOSMITHKLINE,,39.0,YR,,M,Y,,,20130724.0,,MD,JP,JP,EFAVIRENZ,Anxiety;Blood creatinine increased;Cough;Depression;Depressive symptom;Lipodystrophy acquired;Myositis;Pneumonia;Pyrexia;Rhinorrhoea;Suicide attempt,93222813.0,HO,,,93222813.0,1.0,200609.0,201012.0,,,93222813.0,1.0,HIV infection
9330146,93301463,3,F,20130523.0,20130716.0,20130604,20130718,EXP,,CI-GILEAD-2012-0064378,GILEAD,,42.0,YR,,F,Y,,,20130718.0,,MD,CI,CI,EFAVIRENZ,Stillbirth,93301463.0,OT,,,93301463.0,1.0,20121130.0,20130107.0,,,93301463.0,1.0,HIV infection
9331858,93318581,1,I,,20130520.0,20130603,20130603,EXP,,AUR-APL-2013-04244,AUROBINDO,,55.0,YR,,F,N,,,20130531.0,,,ZA,,EFAVIRENZ,Mycosis fungoides,93318581.0,DE,93318581.0,HP,93318581.0,1.0,201003.0,,,,93318581.0,1.0,HIV infection
9338637,93386371,1,I,,20120517.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16600934,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,,,20130610.0,,CN,US,US,SUSTIVA,Adverse event,,,,,,,,,,,93386371.0,1.0,HIV infection
9338644,93386441,1,I,,20120720.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16787756,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20130610.0,,CN,US,US,SUSTIVA,Insomnia,,,,,93386441.0,1.0,201109.0,,,,93386441.0,1.0,HIV infection
9338652,93386521,1,I,,20121011.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-17038456,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,,,20130610.0,,CN,US,US,SUSTIVA,Malaise,,,,,,,,,,,93386521.0,1.0,HIV infection
9338653,93386531,1,I,2008.0,20121018.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-17054461,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,86.17,KG,20130610.0,,CN,US,US,SUSTIVA,Gastrooesophageal reflux disease,,,,,93386531.0,1.0,2008.0,,,,93386531.0,1.0,HIV infection
9338658,93386581,1,I,,20121130.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-17126723,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,,,20130610.0,,CN,US,US,SUSTIVA,Adverse event,,,,,,,,,,,93386581.0,1.0,HIV infection
9338661,93386611,1,I,,20130221.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-17272923,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,,,20130610.0,,CN,US,US,SUSTIVA,Drug ineffective,93386611.0,OT,,,93386611.0,1.0,,201212.0,,,93386611.0,1.0,HIV infection
9338664,93386641,1,I,,20130212.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-17384140,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20130610.0,,CN,US,US,SUSTIVA,Adverse event,,,,,,,,,,,93386641.0,1.0,HIV infection
9338674,93386741,1,I,,20120524.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16624496,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20130610.0,,CN,US,US,SUSTIVA TABS 600 MG,Dysphagia;Product size issue,,,,,,,,,,,93386741.0,1.0,HIV infection
9338677,93386771,1,I,,20120606.0,20130610,20130610,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16670531,BRISTOL MYERS SQUIBB,,32.0,YR,,M,Y,,,20130610.0,,CN,US,US,SUSTIVA TABS 600 MG,Adverse event,,,,,93386771.0,1.0,20120207.0,,,,93386771.0,1.0,Acquired immunodeficiency syndrome
9344804,93448044,4,F,20110705.0,20160316.0,20130612,20160316,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-18994129,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20160316.0,,MD,PT,PT,EFAVIRENZ,Dizziness;Inappropriate schedule of drug administration;Maternal exposure during pregnancy;Off label use;Premature delivery;Twin pregnancy;Viral load increased,93448044.0,OT,,,93448044.0,1.0,2011.0,,,,93448044.0,1.0,HIV infection
9346429,93464295,5,F,20130518.0,20131008.0,20130613,20131015,EXP,,ZA-GILEAD-2013-0076826,GILEAD,,40.0,YR,,F,Y,,,20131015.0,,MD,ZA,ZA,EFAVIRENZ,Abdominal adhesions;Intestinal obstruction,93464295.0,OT,,,93464295.0,1.0,20130314.0,20130518.0,,,93464295.0,1.0,HIV infection
9349255,93492552,2,F,,20160712.0,20130614,20160714,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-18979351,BRISTOL MYERS SQUIBB,,10.0,YR,,M,Y,,,20160714.0,,OT,IN,IN,EFAVIRENZ,Drug ineffective;Drug resistance,93492552.0,DE,,,93492552.0,1.0,2005.0,,,,93492552.0,1.0,Antiretroviral therapy
9349328,93493281,1,I,20130523.0,20130605.0,20130614,20130614,EXP,,CI-ABBOTT-13P-084-1100732-00,ABBOTT,,42.0,YR,,F,Y,,,20130614.0,,MD,COUNTRY NOT SPECIFIED,CI,EFAVIRENZ,Stillbirth,93493281.0,OT,,,93493281.0,1.0,20121130.0,20130107.0,,,93493281.0,1.0,HIV infection
9351276,93512761,1,I,,20130612.0,20130617,20130617,EXP,,FR-ABBOTT-13P-056-1103824-00,ABBOTT,,60.0,YR,,M,Y,,,20130617.0,,MD,FR,FR,SUSTIVA,Tubulointerstitial nephritis,93512761.0,DS,,,93512761.0,1.0,20090123.0,20130415.0,,,93512761.0,1.0,HIV infection
9351941,93519411,1,I,,20130607.0,20130617,20130617,EXP,,ZA-VIIV HEALTHCARE LIMITED-B0899930A,GLAXOSMITHKLINE,,12.0,YR,,F,Y,,,20130617.0,,MD,ZA,ZA,EFAVIRENZ,Abasia;Anal dilatation;Areflexia;Bladder dilatation;Bladder pain;CD4 lymphocytes decreased;CSF glucose decreased;CSF protein increased;Cerebral infarction;Faecal incontinence;Hyperaesthesia;Hyporeflexia;Hypotonia;Immune reconstitution inflammatory syndrome;Muscle atrophy;Muscle disorder;Muscular weakness;Paraparesis;Pyrexia;Sensory loss;Spinal cord injury;Treatment noncompliance;Tuberculosis of central nervous system;Urinary incontinence;Urinary retention;Urinary tract infection;VIIth nerve paralysis;Viral load decreased,93519411.0,OT,,,93519411.0,1.0,201012.0,,,,93519411.0,1.0,HIV infection
9354221,93542211,1,I,20130429.0,20130612.0,20130618,20130618,EXP,,FR-GILEAD-2013-0077166,GILEAD,,60.0,YR,,M,Y,,,20130618.0,,OT,FR,FR,SUSTIVA,Tubulointerstitial nephritis,93542211.0,LT,,,93542211.0,1.0,20030130.0,20130415.0,,,93542211.0,1.0,HIV infection
9356035,93560352,2,F,20130609.0,20130617.0,20130619,20130624,EXP,,ZW-GILEAD-2013-0077115,GILEAD,,42.0,YR,,F,Y,,,20130624.0,,MD,ZW,ZW,EFAVIRENZ,Deep vein thrombosis,93560352.0,HO,,,93560352.0,1.0,20090514.0,,,,93560352.0,1.0,HIV infection
9357852,93578521,1,I,2012.0,20130611.0,20130620,20130620,EXP,,FR-ABBOTT-13P-056-1104538-00,ABBOTT,,38.0,YR,,F,Y,,,20130620.0,,MD,FR,FR,SUSTIVA,Hepatic cirrhosis,93578521.0,HO,,,93578521.0,1.0,200809.0,20130502.0,,,93578521.0,1.0,HIV infection
9361232,93612321,1,I,20130514.0,20130611.0,20130621,20130621,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-19022912,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20130621.0,,CN,GB,ZW,EFAVIRENZ,Hepatic enzyme increased,93612321.0,OT,,,93612321.0,1.0,20130506.0,,,,93612321.0,1.0,HIV infection
9361759,93617591,1,I,2012.0,20130610.0,20130621,20130621,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-19007400,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20130621.0,,CN,FR,FR,SUSTIVA,Hepatic cirrhosis,93617591.0,HO,,,93617591.0,1.0,200809.0,20130502.0,,,93617591.0,1.0,HIV infection
9361763,93617633,3,F,20090415.0,20150130.0,20130621,20150212,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-19029164,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20150212.0,N,CN,US,JP,EFAVIRENZ,Blood alkaline phosphatase increased;Femur fracture;Gynaecomastia;Hyperthyroidism;White blood cell count increased,93617633.0,HO,,,93617633.0,1.0,20010919.0,20120531.0,,,93617633.0,1.0,HIV infection
9361971,93619712,2,F,,20160721.0,20130621,20160721,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19030071,BRISTOL MYERS SQUIBB,,,,T,,Y,,,20160721.0,,CN,US,ZA,EFAVIRENZ,Lactic acidosis,93619712.0,OT,,,,,,,,,93619712.0,1.0,Antiretroviral therapy
9361978,93619782,2,F,,20160713.0,20130621,20160714,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19030121,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160714.0,,OT,ZA,ZA,EFAVIRENZ,Lactic acidosis,93619782.0,OT,,,,,,,,,93619782.0,1.0,Antiretroviral therapy
9363674,93636741,1,I,,20130517.0,20130529,20130529,EXP,,2013AP005300,APOTEX,,,,,F,N,,,20130528.0,,OT,US,,EFAVIRENZ,Rash maculo-papular;Skin toxicity;Tongue disorder,93636741.0,HO,93636741.0,HP,93636741.0,1.0,,,16.0,DAY,93636741.0,1.0,HIV infection
9365226,93652262,2,F,,20160721.0,20130624,20160721,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19030089,BRISTOL MYERS SQUIBB,,1.0,DEC,,,Y,,,20160721.0,,CN,US,ZA,EFAVIRENZ,Lactic acidosis,93652262.0,OT,,,,,,,,,93652262.0,1.0,Antiretroviral therapy
9365228,93652282,2,F,,20160713.0,20130624,20160714,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19030055,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160714.0,,CN,US,ZA,EFAVIRENZ,Lactic acidosis,93652282.0,OT,,,,,,,,,93652282.0,1.0,Antiretroviral therapy
9367404,93674041,1,I,20120612.0,20130619.0,20130625,20130625,EXP,,GB-GILEAD-2013-0077626,GILEAD,,38.0,YR,,F,Y,,,20130625.0,,OT,GB,GB,SUSTIVA,Abortion spontaneous,93674041.0,OT,,,93674041.0,1.0,20101007.0,,,,93674041.0,1.0,HIV infection
9368913,93689132,2,F,200905.0,20130617.0,20130621,20130701,EXP,,AUR-APL-2013-05030,AUROBINDO,,10.0,YR,,M,N,,,20130628.0,,OT,IN,,EFAVIRENZ,Abdominal lymphadenopathy;Abdominal pain;Cachexia;Drug resistance;Molluscum contagiosum;Oesophageal candidiasis;Oral candidiasis;Treatment failure;Weight decreased,93689132.0,OT,93689132.0,FGN,93689132.0,3.0,2005.0,2005.0,,,93689132.0,1.0,Antiretroviral therapy
9368920,93689202,2,F,20130523.0,20130730.0,20130624,20130816,EXP,,ADR-2013UNK121,HETERO,,273.0,DY,,M,N,3.0,KG,20130813.0,,,US,,EFAVIRENZ TABS/(UNK MFR),Maternal drugs affecting foetus;Stillbirth,93689202.0,DE,93689202.0,HP,93689202.0,1.0,20130517.0,,,,93689202.0,1.0,Acquired immunodeficiency syndrome
9371638,93716382,2,F,,20130916.0,20130627,20130927,EXP,,US-MYLANLABS-2013S1013406,MYLAN,,42.0,YR,,M,Y,,,20130927.0,,OT,US,US,EFAVIRENZ,Renal failure acute;Rhabdomyolysis,93716382.0,HO,,,,,,,,,93716382.0,1.0,HIV infection
9374540,93745401,1,I,,20130610.0,20130624,20130624,EXP,,B0901061A,GLAXOSMITHKLINE,,41.0,YR,,M,N,,,20130620.0,,,JP,,EFAVIRENZ,Amnesia;Basedow's disease;Blood HIV RNA increased;Diplopia;Hypercholesterolaemia;Tremor,93745401.0,OT,93745401.0,FGN,,,,,,,93745401.0,1.0,Acquired immunodeficiency syndrome
9375161,93751612,2,F,201202.0,20130819.0,20130628,20130828,PER,,US-JNJFOC-20130614181,JANSSEN,,44.0,YR,,F,Y,75.0,KG,20130828.0,,MD,US,US,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,93751612.0,HO,,,93751612.0,1.0,201202.0,,,,93751612.0,1.0,HIV infection
9375922,93759223,3,F,20060210.0,20130821.0,20130628,20130828,EXP,,JP-ABBOTT-06P-087-0339386-00,ABBOTT,,19.0,YR,,M,Y,55.0,KG,20130828.0,,MD,JP,JP,EFAVIRENZ,Dermatitis allergic;Diarrhoea;Gastritis;Hypertriglyceridaemia;Liver disorder;Urethritis chlamydial,93759223.0,OT,,,93759223.0,1.0,20060120.0,20110506.0,,,93759223.0,1.0,HIV infection
9377951,93779511,1,I,,20130624.0,20130701,20130701,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19052380,BRISTOL MYERS SQUIBB,,40.0,YR,,F,Y,,,20130701.0,,CN,GB,US,EFAVIRENZ,Bradycardia;Cardiac enzymes increased;Hepatic enzyme increased;Hepatomegaly;Lactic acidosis,93779511.0,HO,,,,,,,,,93779511.0,1.0,HIV infection
9382361,93823611,1,I,20130609.0,20130619.0,20130703,20130703,EXP,,GE-BRISTOL-MYERS SQUIBB COMPANY-19067982,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,,,20130703.0,,CN,US,GE,EFAVIRENZ CAPS,Influenza like illness;Thrombocytosis,93823611.0,HO,,,93823611.0,2.0,20130517.0,,,,93823611.0,1.0,HIV infection
9383833,93838331,1,I,20130609.0,20130619.0,20130704,20130704,EXP,,GE-009507513-1307GEO002259,MERCK,,56.0,YR,,M,Y,,,20131002.0,,CN,GE,GE,EFAVIRENZ,Influenza like illness;Thrombocytosis,93838331.0,HO,,,93838331.0,2.0,20130517.0,,,,93838331.0,1.0,HIV infection
9385078,93850783,3,F,20130401.0,20130812.0,20130705,20130816,EXP,,US-ABBOTT-13P-163-1114646-00,ABBOTT,,26.0,YR,,F,Y,,,20130816.0,,OT,COUNTRY NOT SPECIFIED,US,EFAVIRENZ,Abortion induced,93850783.0,OT,,,93850783.0,1.0,20121001.0,20120930.0,,,93850783.0,1.0,Antiretroviral therapy
9385669,93856691,1,I,20100804.0,20130628.0,20130705,20130705,EXP,,ZW-VIIV HEALTHCARE LIMITED-B0905339A,GLAXOSMITHKLINE,,,,,M,Y,,,20130705.0,,MD,ZW,ZW,EFAVIRENZ,Hepatitis acute,93856691.0,HO,,,93856691.0,1.0,20100721.0,20100817.0,,,93856691.0,1.0,HIV infection
9388752,93887522,2,F,20130520.0,20140108.0,20130708,20140116,EXP,,FR-VIIV HEALTHCARE LIMITED-B0903824A,GLAXOSMITHKLINE,,47.0,YR,,M,Y,,,20140115.0,N,MD,FR,FR,Sustiva,Chest pain;Dyspnoea;Pain in extremity;Pulmonary embolism;Thrombosis,93887522.0,HO,,,93887522.0,1.0,2003.0,20130608.0,,,93887522.0,1.0,HIV infection
9388761,93887611,1,I,201304.0,20130628.0,20130708,20130708,EXP,,FR-VIIV HEALTHCARE LIMITED-B0905235A,GLAXOSMITHKLINE,,47.0,YR,,M,Y,,,20130708.0,,MD,FR,FR,Sustiva,Rectal haemorrhage,93887611.0,OT,,,93887611.0,1.0,2003.0,20130608.0,,,93887611.0,1.0,HIV infection
9396656,93966562,2,F,,20160711.0,20130711,20160713,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19097500,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160713.0,,CN,US,ZA,EFAVIRENZ,Depression,93966562.0,OT,,,,,,,,,93966562.0,1.0,HIV infection
9398294,93982942,2,F,20121022.0,20130718.0,20130712,20130723,EXP,,US-ABBOTT-13P-163-1117196-00,ABBOTT,,22.0,YR,,F,Y,,,20130729.0,,OT,COUNTRY NOT SPECIFIED,US,SUSTIVA,Abortion induced;Complication of pregnancy,93982942.0,OT,,,93982942.0,1.0,20121017.0,20121017.0,,,93982942.0,1.0,Antiretroviral therapy
9398550,93985503,3,F,201111.0,20150803.0,20130712,20150814,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-19099720,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,,,20150814.0,N,CN,US,JP,EFAVIRENZ,Angina pectoris;Movement disorder;Nightmare,93985503.0,OT,,,93985503.0,1.0,20010624.0,20130108.0,,,93985503.0,1.0,HIV infection
9403154,94031542,2,F,20130625.0,20130716.0,20130716,20130718,EXP,,UG-VIIV HEALTHCARE LIMITED-B0907508A,GLAXOSMITHKLINE,,66.0,YR,,M,Y,,,20130718.0,,MD,UG,UG,EFAVIRENZ,Anaemia;Oropharyngeal candidiasis,94031542.0,DE,,,94031542.0,1.0,20130618.0,20130702.0,,,94031542.0,1.0,HIV infection
9405657,94056571,1,I,20130123.0,20130711.0,20130717,20130717,EXP,,UG-ABBOTT-13P-165-1118795-00,ABBOTT,,39.0,YR,,F,Y,,,20130717.0,,MD,COUNTRY NOT SPECIFIED,UG,EFAVIRENZ,Abortion induced,94056571.0,OT,,,94056571.0,1.0,20130109.0,20130108.0,,,94056571.0,1.0,HIV infection
9408296,94082961,1,I,20121022.0,20130708.0,20130718,20130718,EXP,,US-VIIV HEALTHCARE LIMITED-A1033605A,GLAXOSMITHKLINE,,22.0,YR,,F,Y,,,20130718.0,,OT,US,US,Sustiva,Abortion induced;Blighted ovum;Exposure during pregnancy,94082961.0,OT,,,94082961.0,1.0,20121017.0,20121017.0,,,94082961.0,1.0,Antiretroviral therapy
9408475,94084751,1,I,20130425.0,20130712.0,20130718,20130718,EXP,,TH-GILEAD-2013-0079193,GILEAD,,32.0,YR,,M,Y,,,20130718.0,,MD,TH,TH,EFAVIRENZ,Hand fracture,94084751.0,HO,,,94084751.0,1.0,20121107.0,,,,94084751.0,1.0,HIV infection
9410395,94103955,5,F,,20140910.0,20130719,20140916,EXP,,US-VIIV HEALTHCARE LIMITED-A1034012A,GLAXOSMITHKLINE,,53.0,YR,,M,Y,,,20140916.0,N,MD,US,US,SUSTIVA,Diabetes mellitus;Renal transplant;Therapy cessation;Visual acuity reduced,94103955.0,HO,,,94103955.0,1.0,20120417.0,,,,94103955.0,1.0,HIV infection
9413176,94131763,3,F,201304.0,20130809.0,20130717,20130828,EXP,,ADR-2013UNK126,HETERO,,,,,NS,N,,,20130826.0,,OT,US,,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy;Pregnancy,94131763.0,DE,94131763.0,SDY,94131763.0,1.0,20120416.0,20120930.0,,,94131763.0,1.0,Acquired immunodeficiency syndrome
9416650,94166501,1,I,,20130717.0,20130724,20130724,EXP,,"ZA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-21447GD",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,,,20130724.0,,OT,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Abortion induced;Kaposi's sarcoma;Vaginal hyperplasia,94166501.0,OT,,,,,,,,,94166501.0,1.0,HIV infection
9419274,94192741,1,I,,20130718.0,20130723,20130723,EXP,,B0909773A,GLAXOSMITHKLINE,,57.0,YR,,M,N,,,20130722.0,,OT,BR,BR,EFAVIRENZ,Porphyria non-acute,94192741.0,OT,94192741.0,LIT,94192741.0,1.0,200808.0,201012.0,,,94192741.0,1.0,HIV infection
9419331,94193311,1,I,,20130718.0,20130723,20130723,EXP,,B0909795A,GLAXOSMITHKLINE,,46.0,YR,,M,N,,,20130722.0,,OT,BR,BR,EFAVIRENZ,Blister;Hypertrichosis;Milia;Photosensitivity reaction;Porphyria non-acute;Scar;Tanning;Treatment failure,94193311.0,OT,94193311.0,FGN,94193311.0,1.0,200710.0,200905.0,,,94193311.0,1.0,HIV infection
9419351,94193511,1,I,,20130718.0,20130723,20130723,EXP,,B0909720A,GLAXOSMITHKLINE,,49.0,YR,,M,N,,,20130722.0,,OT,BR,BR,EFAVIRENZ,Porphyria non-acute,94193511.0,OT,94193511.0,FGN,94193511.0,1.0,200910.0,,,,94193511.0,1.0,HIV infection
9425792,94257924,4,F,20130709.0,20140224.0,20130729,20140226,EXP,,BW-GILEAD-2013-0079904,GILEAD,,43.0,YR,,F,Y,,,20140226.0,N,MD,BW,BW,EFAVIRENZ,Stillbirth,94257924.0,OT,,,94257924.0,1.0,20110818.0,20130313.0,,,94257924.0,1.0,HIV infection
9429774,94297741,1,I,,20130715.0,20130726,20130726,EXP,,AUR-APL-2013-06116,AUROBINDO,,30.0,YR,,F,N,,,20130725.0,,MD,IN,,EFAVIRENZ (EFAVIRENZ),Body temperature increased;Myalgia;Rash erythematous;Rash maculo-papular;Rash pruritic,94297741.0,HO,94297741.0,HP,,,,,,,94297741.0,1.0,HIV test positive
9429865,94298651,1,I,,20130715.0,20130726,20130726,EXP,,AUR-APL-2013-06122,AUROBINDO,,26.0,YR,,F,N,,,20130725.0,,MD,IN,,EFAVIRENZ (EFAVIRENZ),Pyrexia;Rash erythematous;Rash generalised;Rash maculo-papular;Rash pruritic,94298651.0,HO,94298651.0,FGN,,,,,,,94298651.0,1.0,HIV test positive
9433370,94333702,2,F,20110705.0,20140120.0,20130731,20140130,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-19138148,BRISTOL MYERS SQUIBB,,52.0,YR,,F,Y,,,20140130.0,N,CN,FR,FR,SUSTIVA,Hypercholesterolaemia,94333702.0,OT,,,94333702.0,1.0,20051115.0,20131001.0,,,94333702.0,1.0,HIV infection
9433423,94334232,2,F,,20130729.0,20130731,20130805,EXP,,DE-GILEAD-2013-0080019,GILEAD,,,,,F,Y,,,20130805.0,,MD,DE,DE,EFAVIRENZ,Drug ineffective;Viral mutation identified,94334232.0,OT,,,94334232.0,1.0,201112.0,,,,94334232.0,1.0,HIV infection
9434828,94348281,1,I,,20130726.0,20130801,20130801,EXP,,US-PFIZER INC-2013210341,PFIZER,,36.0,YR,,M,Y,,,20130801.0,,OT,US,US,EFAVIRENZ,Cranial nerve palsies multiple;Headache;Immune reconstitution inflammatory syndrome;Photophobia,94348281.0,OT,,,,,,,,,94348281.0,1.0,HIV infection
9435080,94350801,1,I,20061114.0,20130722.0,20130801,20130801,EXP,,FR-ABBOTT-13P-056-1124242-00,ABBOTT,,47.0,YR,,F,Y,,,20130801.0,,MD,FR,FR,SUSTIVA,Amenorrhoea;Carpal tunnel syndrome;Hypercholesterolaemia;Nervous system disorder;Sexually transmitted disease;Urinary tract infection,94350801.0,OT,,,94350801.0,1.0,20051115.0,20110705.0,,,94350801.0,1.0,HIV infection
9435655,94356551,1,I,20130123.0,20130711.0,20130730,20130730,EXP,,ADR-2013UNK130,HETERO,,49.0,DY,,NS,N,,,20130724.0,,OT,US,US,EFAVIRENZ TABS,Foetal exposure during pregnancy,94356551.0,DE,94356551.0,HP,94356551.0,1.0,20120427.0,20130108.0,,,94356551.0,1.0,Acquired immunodeficiency syndrome
9436946,94369461,1,I,,20130720.0,20130802,20130802,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-19156587,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,,,20130802.0,,CN,US,GB,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma,94369461.0,OT,,,,,,,,,94369461.0,1.0,Antiretroviral therapy
9438099,94380999,9,F,20070101.0,20230417.0,20130802,20230425,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-18931295,BRISTOL MYERS SQUIBB,,,,,,Y,,,20230425.0,,HP,AT,AT,EFAVIRENZ,Neurotoxicity,94380999.0,OT,,,,,,,,,94380999.0,1.0,HIV infection
9441230,94412301,1,I,,20130725.0,20130805,20130805,EXP,,DE-GILEAD-2013-0080310,GILEAD,,47.0,YR,,M,Y,,,20130805.0,,MD,DE,DE,SUSTIVA,CD4 lymphocytes decreased;Optic atrophy,94412301.0,OT,,,,,,,,,94412301.0,1.0,HIV infection
9445733,94457331,1,I,,20130726.0,20130807,20130807,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19168186,BRISTOL MYERS SQUIBB,,,,,NS,Y,,,20130807.0,,CN,US,US,EFAVIRENZ,Homicidal ideation,94457331.0,OT,,,,,,,,,94457331.0,1.0,HIV infection
9458675,94586751,1,I,,20130730.0,20130812,20130812,EXP,,AUR-APL-2013-06444,AUROBINDO,,42.0,YR,,M,N,,,20130809.0,,OT,US,,EFAVIRENZ (EFAVIRENZ),Disease recurrence;Haemodialysis;Muscle abscess;Perineal abscess;Renal failure acute;Rhabdomyolysis,94586751.0,HO,94586751.0,LIT,,,,,,,94586751.0,1.0,Antiretroviral therapy
9462572,94625723,3,F,,20160711.0,20130816,20160713,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19180678,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20160713.0,,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Anaemia macrocytic;Hypertension;Maternal exposure during pregnancy;Renal tubular acidosis,94625723.0,OT,,,,,,,,,94625723.0,1.0,HIV infection
9462593,94625933,3,F,,20160711.0,20130816,20160713,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19180645,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20160713.0,,OT,ZA,ZA,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,94625933.0,OT,,,,,,,,,94625933.0,1.0,HIV infection
9468888,94688885,5,F,,20130822.0,20130821,20150731,EXP,,LS-GILEAD-2013-0081502,VIIV,"SATTI H., MCLAUGHLIN M.M., SEUNG K.J.. SHORT REPORT: DRUG-RESISTANT TUBECULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL RESISTANCE IN HIV COINFECTED PATIENTS: A REPORT OF SIX CASES IN LESOTHO. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2013;89 (1):174-177",45.0,YR,,M,Y,,,20150731.0,N,MD,LS,LS,Efavirenz,Drug resistance;Viral mutation identified,94688885.0,OT,,,,,,,,,94688885.0,2.0,HIV infection
9474608,94746082,2,F,200912.0,20130821.0,20130823,20130829,EXP,,HR-VIIV HEALTHCARE LIMITED-B0917289A,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20130829.0,,MD,HR,HR,EFAVIRENZ,Cardiac failure;Chest X-ray abnormal;Congestive cardiomyopathy;Cough;Dyspnoea;Ejection fraction decreased,94746082.0,OT,,,94746082.0,1.0,200705.0,201002.0,,,94746082.0,1.0,HIV infection
9476567,94765672,2,F,20130815.0,20130828.0,20130826,20130903,EXP,,PE-GILEAD-2013-0081805,GILEAD,,47.0,YR,,M,Y,,,20130903.0,,OT,PE,PE,EFAVIRENZ,Hypophosphataemia,94765672.0,OT,,,94765672.0,1.0,20130219.0,20130815.0,,,94765672.0,1.0,HIV infection
9484917,94849171,1,I,,20130820.0,20130828,20130828,EXP,,ZA-GILEAD-2013-0082019,GILEAD,,,,,F,Y,,,20130828.0,,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous,94849171.0,OT,,,,,,,,,94849171.0,1.0,HIV infection
9485186,94851861,1,I,,20130820.0,20130828,20130828,EXP,,ZA-GILEAD-2013-0082023,GILEAD,,,,,F,Y,,,20130830.0,,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous,94851861.0,OT,,,,,,,,,94851861.0,1.0,HIV infection
9485221,94852211,1,I,,20130820.0,20130828,20130828,EXP,,ZA-GILEAD-2013-0082029,GILEAD,,,,,F,Y,,,20130828.0,,OT,ZA,ZA,EFAVIRENZ,Stillbirth,94852211.0,OT,,,,,,,,,94852211.0,1.0,HIV infection
9485295,94852951,1,I,,20130820.0,20130828,20130828,EXP,,ZA-GILEAD-2013-0082030,GILEAD,,,,,NS,Y,,,20130828.0,,OT,ZA,ZA,EFAVIRENZ,Death neonatal,94852951.0,DE,,,,,,,,,94852951.0,1.0,HIV infection
9485319,94853191,1,I,,20130820.0,20130828,20130828,EXP,,ZA-GILEAD-2013-0082032,GILEAD,,,,,NS,Y,,,20130828.0,,OT,ZA,ZA,EFAVIRENZ,Death neonatal,94853191.0,DE,,,,,,,,,94853191.0,1.0,HIV infection
9485338,94853382,2,F,,20140303.0,20130828,20140313,EXP,,US-GILEAD-2013-0081909,GILEAD,,42.0,YR,,M,Y,,,20140313.0,N,OT,US,US,EFAVIRENZ,Renal tubular necrosis;Rhabdomyolysis,94853382.0,OT,,,,,,,,,94853382.0,1.0,HIV infection
9489698,94896984,4,F,,20130912.0,20130829,20130927,EXP,,IT-009507513-1308ITA006589,MERCK,,38.0,YR,,F,Y,65.0,KG,20130930.0,,CN,IT,IT,EFAVIRENZ,Drug resistance;Virologic failure,94896984.0,OT,,,,,,,,,94896984.0,1.0,HIV infection
9494846,94948461,1,I,,20130828.0,20130903,20130903,EXP,,"LS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-26807GD",BOEHRINGER INGELHEIM,,,,,M,Y,,,20130903.0,,OT,COUNTRY NOT SPECIFIED,LS,EFAVIRENZ,Drug resistance;Tuberculosis;Viral mutation identified,94948461.0,DE,,,,,,,,,94948461.0,1.0,HIV infection
9494914,94949141,1,I,,20130828.0,20130903,20130903,EXP,,"LS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-26813GD",BOEHRINGER INGELHEIM,,,,,M,Y,,,20130903.0,,OT,COUNTRY NOT SPECIFIED,LS,EFAVIRENZ,Drug resistance;Tuberculosis;Viral mutation identified,94949141.0,OT,,,,,,,,,94949141.0,1.0,HIV infection
9494916,94949161,1,I,,20130828.0,20130903,20130903,EXP,,"LS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-26985GD",BOEHRINGER INGELHEIM,,,,,M,Y,,,20130903.0,,OT,COUNTRY NOT SPECIFIED,LS,EFAVIRENZ,Drug ineffective;Drug resistance;Viral mutation identified,94949161.0,OT,,,,,,,,,94949161.0,1.0,HIV infection
9495312,94953121,1,I,,20130827.0,20130903,20130903,EXP,,ZA-PFIZER INC-2013252024,PFIZER,,,,,NS,Y,1.38,KG,20130903.0,,MD,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Microcephaly,94953121.0,OT,,,,,,,,,94953121.0,1.0,Kaposi's sarcoma AIDS related
9495393,94953931,1,I,1998.0,20130829.0,20130903,20130903,EXP,,DE-VIIV HEALTHCARE LIMITED-D0080959A,GLAXOSMITHKLINE,,36.0,YR,,M,Y,,,20130903.0,,MD,DE,DE,EFAVIRENZ,Atypical mycobacterial infection;Blindness;Cytomegalovirus chorioretinitis;Cytomegalovirus oesophagitis;Diarrhoea;Drug intolerance;Lipoatrophy;Multiple-drug resistance;Muscle atrophy;Myocardial infarction;Oesophageal candidiasis;Polyneuropathy;Treatment noncompliance,94953931.0,DS,,,94953931.0,1.0,1998.0,199807.0,,,94953931.0,1.0,HIV infection
9495399,94953992,2,F,20130304.0,20150313.0,20130903,20150320,EXP,,MX-GILEAD-2013-0082261,GILEAD,,41.0,YR,A,M,Y,65.31,KG,20150320.0,N,MD,MX,MX,EFAVIRENZ,Aspartate aminotransferase increased;Blood creatine phosphokinase increased;Blood lactate dehydrogenase increased,94953992.0,OT,,,94953992.0,1.0,20110803.0,20130303.0,,,94953992.0,1.0,HIV infection
9498499,94984992,2,F,20130711.0,20131202.0,20130904,20131209,EXP,,US-VIIV HEALTHCARE LIMITED-A1039883A,GLAXOSMITHKLINE,,56.0,YR,,F,Y,57.3,KG,20131209.0,,CN,US,US,EFAVIRENZ,Blood creatinine increased;Tubulointerstitial nephritis,94984992.0,OT,,,94984992.0,1.0,20130622.0,20130514.0,,,94984992.0,1.0,HIV infection
9499058,94990581,1,I,,20130827.0,20130904,20130904,EXP,,ZA-GILEAD-2013-0082533,GILEAD,,,,,NS,Y,,,20130904.0,,OT,ZA,ZA,EFAVIRENZ,Microcephaly,94990581.0,DE,,,94990581.0,1.0,201202.0,201206.0,,,94990581.0,1.0,HIV infection
9499059,94990591,1,I,2012.0,20130827.0,20130904,20130904,EXP,,ZA-GILEAD-2013-0082332,GILEAD,,24.0,YR,,F,Y,,,20130904.0,,OT,ZA,ZA,EFAVIRENZ,Stillbirth,94990591.0,OT,,,94990591.0,1.0,2012.0,,,,94990591.0,1.0,HIV infection
9499125,94991253,3,F,,20160720.0,20130904,20160720,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340579,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160720.0,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth;Twin pregnancy,94991253.0,OT,,,,,,,,,94991253.0,1.0,HIV infection
9499127,94991273,3,F,,20160720.0,20130904,20160720,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340462,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160720.0,,CN,US,ZA,EFAVIRENZ,Foetal death;Maternal exposure during pregnancy;Twin pregnancy,94991273.0,DE,,,,,,,,,94991273.0,1.0,HIV infection
9499128,94991283,3,F,,20160720.0,20130904,20160720,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340553,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160720.0,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,94991283.0,OT,,,,,,,,,94991283.0,1.0,HIV infection
9499672,94996722,2,F,20130822.0,20130905.0,20130905,20130911,EXP,,KE-009507513-1309GBR000924,MERCK,,35.0,YR,,M,Y,,,20130911.0,,MD,KE,KE,EFAVIRENZ,Acute respiratory distress syndrome;Alanine aminotransferase increased;Hyperkalaemia;Immune reconstitution inflammatory syndrome;Intestinal obstruction;Pulmonary embolism;Pulmonary tuberculosis;Relapsing fever;Renal failure acute;Sepsis,94996722.0,LT,,,94996722.0,1.0,20130815.0,20130824.0,,,94996722.0,1.0,HIV infection
9501431,95014311,1,I,,20130902.0,20130905,20130905,EXP,,CO-VIIV HEALTHCARE LIMITED-A1040138A,GLAXOSMITHKLINE,,48.0,YR,,M,Y,,,20130905.0,,OT,CO,CO,EFAVIRENZ,Angina pectoris;Angioplasty;Infarction,95014311.0,LT,,,95014311.0,1.0,2011.0,,,,95014311.0,1.0,HIV infection
9506651,95066511,1,I,,20130823.0,20130907,20130907,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19357250,BRISTOL MYERS SQUIBB,,32.0,YR,,M,Y,,,20130907.0,,CN,US,US,SUSTIVA,Non-Hodgkin's lymphoma,95066511.0,OT,,,95066511.0,1.0,20121130.0,,,,95066511.0,1.0,HIV infection
9507029,95070292,2,F,,20130909.0,20130904,20130918,EXP,,AUR-APL-2013-07190,AUROBINDO,,49.0,YR,,F,N,,,20130917.0,,OT,GB,,EFAVIRENZ,Acanthosis;Discomfort;Hyperkeratosis,95070292.0,OT,95070292.0,HP,,,,,,,95070292.0,1.0,HIV infection
9508693,95086931,1,I,,20130902.0,20130909,20130909,EXP,,CO-VIIV HEALTHCARE LIMITED-A1040652A,GLAXOSMITHKLINE,,48.0,YR,,M,Y,,,20131122.0,,OT,CO,CO,EFAVIRENZ,Infarction,95086931.0,HO,,,95086931.0,1.0,2011.0,,,,95086931.0,1.0,HIV infection
9511241,95112411,1,I,,20130828.0,20130906,20130906,EXP,,B0920174A,GLAXOSMITHKLINE,,42.0,YR,,M,N,,,20130904.0,,,US,,EFAVIRENZ,Blood culture positive;Muscle abscess;Perineal abscess;Renal failure;Rhabdomyolysis;Staphylococcal infection,95112411.0,HO,95112411.0,HP,,,,,,,95112411.0,1.0,HIV infection
9513285,95132851,1,I,,20130828.0,20130910,20130910,EXP,,BE-WATSON-2013-15622,WATSON,,38.0,YR,,M,Y,57.0,KG,20130910.0,,MD,BE,BE,EFAVIRENZ (UNKNOWN),Cerebral atrophy;Coma;Drug interaction;Drug level increased;Pneumonia aspiration,95132851.0,DE,,,95132851.0,2.0,20090403.0,,,,95132851.0,1.0,HIV infection
9521592,95215921,1,I,,20130904.0,20130911,20130911,EXP,,B0921422A,GLAXOSMITHKLINE,,,,,M,N,,,20130910.0,,,COUNTRY NOT SPECIFIED,,EFAVIRENZ,Erectile dysfunction;Malaise;Myalgia;Myositis;Nausea;Skin irritation;Transaminases increased,95215921.0,RI,95215921.0,LIT,95215921.0,1.0,200501.0,,,,95215921.0,1.0,HIV infection
9523596,95235963,3,F,20130827.0,20130923.0,20130913,20130927,EXP,,KE-009507513-1309KEN002625,MERCK,,24.0,YR,,F,Y,,,20130927.0,,MD,KE,KE,EFAVIRENZ,Anaemia;Lymphopenia;Pulmonary tuberculosis;Renal failure acute,95235963.0,LT,,,95235963.0,1.0,20130822.0,20130830.0,,,95235963.0,1.0,HIV infection
9523742,95237422,2,F,20130822.0,20130905.0,20130914,20130920,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-19357953,BRISTOL MYERS SQUIBB,,35.0,YR,,M,Y,,,20130920.0,,CN,US,KE,EFAVIRENZ CAPS,Acute respiratory distress syndrome;Alanine aminotransferase increased;Cardio-respiratory arrest;Hyperkalaemia;Immune reconstitution inflammatory syndrome;Intestinal obstruction;Pulmonary embolism;Pulmonary tuberculosis;Pyrexia;Renal failure acute;Sepsis,95237422.0,LT,,,95237422.0,1.0,20130815.0,20130824.0,,,95237422.0,2.0,HIV infection
9529730,95297302,2,F,,20130628.0,20130917,20130917,EXP,,JP-VIIV HEALTHCARE LIMITED-B0901061A,GLAXOSMITHKLINE,,41.0,YR,,M,Y,,,20130917.0,,MD,JP,JP,EFAVIRENZ,Amnesia;Basedow's disease;Blood HIV RNA increased;Diplopia;Dysphonia;Exophthalmos;Goitre;Hypercholesterolaemia;Tremor,95297302.0,OT,,,,,,,,,95297302.0,1.0,Acquired immunodeficiency syndrome
9531399,95313992,2,F,,20140428.0,20130918,20140512,PER,,US-009507513-1309USA001797,MERCK,,,,,F,Y,,,20140512.0,N,CN,US,US,EFAVIRENZ,Drug interaction,,,,,,,,,,,95313992.0,1.0,HIV infection
9535504,95355043,3,F,20130826.0,20131021.0,20130918,20131029,EXP,,GB-GILEAD-2013-0083401,GILEAD,,24.0,YR,,F,Y,40.6,KG,20140414.0,N,MD,KE,KE,EFAVIRENZ,Anaemia;Lymphopenia;Pulmonary tuberculosis;Renal failure acute,95355043.0,OT,,,95355043.0,1.0,20130822.0,20130830.0,,,95355043.0,1.0,HIV infection
9536170,95361702,2,F,20130817.0,20131007.0,20130919,20131011,EXP,,UG-MERCK-1309UGA006505,MERCK,,41.0,YR,,M,Y,40.9,KG,20131011.0,,CN,UG,UG,EFAVIRENZ,Dermatomyositis;Drug hypersensitivity;Immune reconstitution inflammatory syndrome;Oesophageal candidiasis,95361702.0,LT,,,95361702.0,1.0,20130805.0,20130904.0,,,95361702.0,1.0,Antiretroviral therapy
9537499,95374992,2,F,,20130919.0,20130919,20130920,EXP,,GB-JNJFOC-20130907472,JANSSEN,,,,,M,Y,,,20130920.0,,MD,GB,GB,EFAVIRENZ,Headache,95374992.0,OT,,,,,,,,,95374992.0,1.0,HIV infection
9537500,95375001,1,I,,20130910.0,20130919,20130919,EXP,,GB-JNJFOC-20130907467,JANSSEN,,,,,M,Y,,,20130919.0,,MD,GB,GB,EFAVIRENZ,"Hallucination, auditory",95375001.0,OT,,,,,,,,,95375001.0,1.0,HIV infection
9538280,95382802,2,F,,20160712.0,20130920,20160714,EXP,,LS-BRISTOL-MYERS SQUIBB COMPANY-19219195,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,,,20160714.0,,CN,US,LS,EFAVIRENZ,Drug resistance,95382802.0,OT,,,,,,,,,95382802.0,1.0,HIV infection
9538927,95389271,1,I,,20130910.0,20130920,20130920,EXP,,GB-JNJFOC-20130907468,JANSSEN,,,,,M,Y,,,20130920.0,,MD,GB,GB,EFAVIRENZ,Hallucination,95389271.0,OT,,,,,,,,,95389271.0,1.0,HIV infection
9543333,95433337,7,F,20130821.0,20140701.0,20130923,20140709,EXP,,KR-ABBVIE-13P-090-1148744-00,ABBVIE,,,,,F,Y,,,20140709.0,N,MD,COUNTRY NOT SPECIFIED,KR,EFAVIRENZ,AIDS related complication;Asthenia;Depressed mood;Hyponatraemia;Immunodeficiency;Nausea;Pancytopenia;Plantar erythema;Pneumonia;Pruritus;Pyrexia;Unevaluable event;Urinary tract infection;Vomiting,95433337.0,OT,,,95433337.0,1.0,20130819.0,20130904.0,,,95433337.0,1.0,HIV infection
9543488,95434883,3,F,20130822.0,20131021.0,20130923,20131029,EXP,,KE-GILEAD-2013-0083408,GILEAD,,35.0,YR,,M,Y,59.9,KG,20131029.0,,MD,KE,KE,EFAVIRENZ,Acute respiratory distress syndrome;Alanine aminotransferase increased;Hyperkalaemia;Immune reconstitution inflammatory syndrome;Intestinal obstruction;Pulmonary embolism;Pulmonary tuberculosis;Pyrexia;Renal failure acute;Sepsis,95434883.0,OT,,,95434883.0,1.0,20130815.0,20130824.0,,,95434883.0,1.0,HIV infection
9547465,95474651,1,I,,20130910.0,20130924,20130924,EXP,,GB-JNJFOC-20130907469,JANSSEN,,,,,M,Y,,,20130924.0,,MD,GB,GB,EFAVIRENZ,Abnormal dreams;Anxiety;Depression;Disturbance in attention;Dizziness;Fatigue;Headache;Insomnia;Nervous system disorder;Nervousness;Somnolence,95474651.0,OT,,,,,,,,,95474651.0,1.0,HIV infection
9549505,95495052,2,F,20130817.0,20131007.0,20130924,20131022,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19437367,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,40.9,KG,20131022.0,,CN,US,UG,EFAVIRENZ CAPS,Dermatomyositis;Drug hypersensitivity;Immune reconstitution inflammatory syndrome;Oesophageal candidiasis,95495052.0,DE,,,95495052.0,1.0,20130805.0,20130904.0,,,95495052.0,1.0,Antiretroviral therapy
9551128,95511282,2,F,20101120.0,20130916.0,20130925,20130925,EXP,,ZW-009507513-1101USA01823,MERCK,,,,,M,Y,,,20130925.0,,CN,US,ZW,EFAVIRENZ,Decreased appetite;Lethargy;Pruritus,95511282.0,HO,,,95511282.0,1.0,20101116.0,20101116.0,,,95511282.0,1.0,HIV infection
9551333,95513331,1,I,,20130910.0,20130925,20130925,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19430396,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20130925.0,,CN,US,US,EFAVIRENZ,Tubulointerstitial nephritis,95513331.0,OT,,,,,,,,,95513331.0,1.0,HIV infection
9554046,95540463,3,F,2013.0,20131106.0,20130925,20131111,EXP,,CN-GILEAD-2013-0083732,GILEAD,,69.0,YR,,F,Y,54.0,KG,20131111.0,,CN,CN,CN,EFAVIRENZ,Cerebral atrophy;Cerebral infarction;Dizziness;Electrolyte imbalance;Encephalopathy;Enuresis;Nightmare;Pollakiuria;Poor quality sleep;Tuberculosis;Type 2 diabetes mellitus,95540463.0,OT,,,95540463.0,1.0,20130506.0,20130529.0,,,95540463.0,1.0,HIV infection
9558370,95583702,2,F,20130902.0,20131104.0,20130926,20131107,EXP,,PE-GILEAD-2013-0083809,GILEAD,,27.0,YR,,M,Y,69.0,KG,20131107.0,,MD,PE,PE,EFAVIRENZ,Acute hepatitis C,95583702.0,OT,,,95583702.0,1.0,20120930.0,20130902.0,,,95583702.0,1.0,HIV infection
9562184,95621841,1,I,20130905.0,20130923.0,20130927,20130927,EXP,,UG-009507513-1309GBR011477,MERCK,,23.0,YR,,M,Y,,,20130927.0,,MD,UG,UG,EFAVIRENZ,Death,95621841.0,HO,,,95621841.0,1.0,20130822.0,20130915.0,,,95621841.0,1.0,HIV infection
9562988,95629882,2,F,20000316.0,20021226.0,20130927,20130927,EXP,,JP-ABBVIE-01P-087-0110654-00,ABBVIE,,36.0,YR,,M,Y,,,20130927.0,,MD,JP,JP,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood triglycerides increased;Decreased appetite;Diarrhoea;Hepatic function abnormal;Hypoaesthesia;Lactic acidosis;Nausea;Vomiting,95629882.0,OT,,,95629882.0,1.0,20000316.0,20010409.0,,,95629882.0,1.0,HIV infection
9564448,95644482,2,F,,20131107.0,20130930,20131114,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19468503,BRISTOL MYERS SQUIBB,,72.0,YR,,M,Y,,,20131114.0,,OT,US,US,SUSTIVA,Death,95644482.0,DE,,,,,,,,,95644482.0,1.0,HIV infection
9565961,95659611,1,I,20130904.0,20130924.0,20130930,20130930,EXP,,UG-GILEAD-2013-0084125,GILEAD,,36.0,YR,,M,Y,,,20130930.0,,MD,UG,UG,EFAVIRENZ,Drug-induced liver injury,95659611.0,HO,,,95659611.0,1.0,20130807.0,,,,95659611.0,1.0,HIV infection
9571878,95718782,2,F,2000.0,20121112.0,20131001,20131001,PER,,US-ABBVIE-10P-163-0680979-00,ABBVIE,,59.0,YR,,M,Y,77.18,KG,20131001.0,,CN,COUNTRY NOT SPECIFIED,US,SUSTIVA,Diabetes mellitus;Diarrhoea;Lipohypertrophy;Nausea;Weight increased,,,,,95718782.0,1.0,1999.0,,,,95718782.0,1.0,HIV infection
9582137,95821371,1,I,2011.0,20130924.0,20131002,20131002,EXP,,FR-GILEAD-2013-0084243,GILEAD,,,,,NS,Y,,,20131002.0,,OT,FR,FR,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,95821371.0,OT,,,,,,,,,95821371.0,1.0,HIV infection
9602933,96029332,2,F,20130912.0,20131113.0,20131007,20131121,EXP,,KE-GILEAD-2013-0084475,GILEAD,,45.0,YR,,M,Y,,,20131121.0,,MD,KE,KE,EFAVIRENZ,Renal failure acute,96029332.0,OT,,,96029332.0,1.0,20130815.0,20130913.0,,,96029332.0,1.0,HIV infection
9605094,96050942,2,F,201002.0,20131011.0,20131008,20131017,EXP,,IT-GILEAD-2013-0084756,GILEAD,,8.0,YR,,F,Y,,,20131017.0,,MD,IT,IT,EFAVIRENZ,Drug level increased;Fanconi syndrome acquired;Genetic polymorphism,96050942.0,OT,,,96050942.0,1.0,200809.0,20120619.0,,,96050942.0,1.0,HIV infection
9605191,96051912,2,F,20130925.0,20131010.0,20131008,20131015,EXP,,UG-009507513-1310UGA003368,MERCK,,30.0,YR,,M,Y,,,20131015.0,,CN,GB,UG,EFAVIRENZ,Cryptococcosis;Dehydration;Pyrexia;Sepsis,96051912.0,OT,,,96051912.0,1.0,20130926.0,20131005.0,,,96051912.0,1.0,Antiretroviral therapy
9607275,96072753,3,F,,20160725.0,20131009,20160725,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19532936,BRISTOL MYERS SQUIBB,"BARNARDT P, ET AL.. MANAGING AIDS-RELATED KAPOSI^S SARCOMA AND PREGNANCY. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2013;14(2):87-8",24.0,YR,,F,Y,1.38,KG,20160725.0,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,96072753.0,OT,,,96072753.0,1.0,2012.0,,,,96072753.0,1.0,HIV infection
9613367,96133671,1,I,,20131001.0,20131008,20131008,EXP,,B0927202A,GLAXOSMITHKLINE,,50.0,YR,,F,N,,,20131007.0,,OT,ZA,,EFAVIRENZ,Dermatitis exfoliative;Disease progression;General physical health deterioration;Lymphadenopathy;Mycosis fungoides stage IV;Neoplasm skin;Nodule;Swelling face,96133671.0,DE,96133671.0,LIT,96133671.0,1.0,201003.0,,,,96133671.0,1.0,HIV infection
9613720,96137201,1,I,20130912.0,20131004.0,20131010,20131010,EXP,,KE-GILEAD-2013-0084935,GILEAD,,35.0,YR,,F,Y,,,20131010.0,,MD,KE,KE,EFAVIRENZ,Anaemia;Death;Pneumonia;Renal failure acute,96137201.0,DE,,,96137201.0,1.0,20130910.0,20130912.0,,,96137201.0,1.0,HIV infection
9614585,96145852,2,F,20130123.0,20131001.0,20131011,20131011,EXP,,UG-ABBVIE-13P-165-1118795-00,ABBVIE,,39.0,YR,,F,Y,,,20131011.0,,MD,COUNTRY NOT SPECIFIED,UG,EFAVIRENZ,Abortion induced,96145852.0,OT,,,96145852.0,1.0,20130109.0,20130108.0,,,96145852.0,1.0,HIV infection
9626829,96268291,1,I,20130830.0,20131010.0,20131016,20131016,EXP,,KE-GILEAD-2013-0085321,GILEAD,,39.0,YR,,M,Y,,,20131016.0,,MD,KE,KE,EFAVIRENZ,Hyperkalaemia;Meningitis cryptococcal;Renal failure acute,96268291.0,HO,,,96268291.0,1.0,20130827.0,20130916.0,,,96268291.0,1.0,HIV infection
9631446,96314461,1,I,,20131007.0,20131011,20131011,EXP,,B0928409A,GLAXOSMITHKLINE,,,,,M,N,,,20131010.0,,,IN,,EFAVIRENZ,Treatment failure,96314461.0,DE,96314461.0,FGN,96314461.0,1.0,2005.0,,,,96314461.0,1.0,HIV infection
9632225,96322252,2,F,,20131104.0,20131018,20131107,EXP,,KE-009507513-1310KEN008169,MERCK,,,,,M,Y,,,20131107.0,,CN,KE,KE,EFAVIRENZ,Malnutrition,96322252.0,DE,,,96322252.0,1.0,20130924.0,20131007.0,,,96322252.0,1.0,HIV infection
9632832,96328321,1,I,2013.0,20131015.0,20131018,20131018,EXP,,FR-GILEAD-2013-0085650,GILEAD,,30.0,YR,,M,Y,,,20131018.0,,MD,FR,FR,EFAVIRENZ,Neutropenia;Transaminases increased,96328321.0,OT,,,96328321.0,1.0,201308.0,20131015.0,,,96328321.0,1.0,HIV infection
9632872,96328722,2,F,20130925.0,20131028.0,20131018,20131104,EXP,,KE-009507513-1310KEN006063,MERCK,,48.0,YR,,M,Y,,,20131103.0,,CN,US,KE,EFAVIRENZ,Anaemia;Meningitis cryptococcal;Renal failure acute;Vomiting,96328722.0,DE,,,96328722.0,1.0,20130924.0,20131009.0,,,96328722.0,1.0,HIV infection
9632961,96329611,1,I,20130925.0,20131004.0,20131018,20131018,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19548338,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,,,20131018.0,,CN,US,UG,EFAVIRENZ TABS,Dehydration;Disseminated cryptococcosis;Pyrexia;Sepsis,96329611.0,LT,,,96329611.0,1.0,20130925.0,20131003.0,,,96329611.0,1.0,Antiretroviral therapy
9635387,96353872,2,F,20130925.0,20131030.0,20131021,20131105,EXP,,UG-GILEAD-2013-0085421,GILEAD,,30.0,YR,,M,Y,,,20131105.0,,MD,UG,UG,EFAVIRENZ,Cryptococcosis;Dehydration,96353872.0,LT,,,96353872.0,1.0,20130926.0,20131005.0,,,96353872.0,1.0,HIV infection
9636581,96365812,2,F,2010.0,20131014.0,20131021,20131021,EXP,,CH-GILEAD-2013-0084155,GILEAD,,,,,F,Y,,,20131021.0,,MD,CH,CH,EFAVIRENZ,Renal failure,96365812.0,OT,,,96365812.0,1.0,2009.0,,,,96365812.0,1.0,HIV infection
9641700,96417002,2,F,,20160720.0,20131023,20160720,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19622133,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,,,20160720.0,,CN,US,ZA,EFAVIRENZ,Drug ineffective;Injection site phlebitis,96417002.0,OT,,,,,,,,,96417002.0,1.0,HIV infection
9643931,96439312,2,F,,20131011.0,20131024,20131024,EXP,,SE-BRISTOL-MYERS SQUIBB COMPANY-19481217,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20131024.0,,CN,US,SE,EFAVIRENZ TABS,Atrial fibrillation;Palpitations,96439312.0,OT,,,,,,,,,96439312.0,1.0,HIV infection
9649296,96492962,2,F,20060210.0,20131018.0,20131028,20131028,EXP,,JP-ABBVIE-06P-087-0339386-00,ABBVIE,,19.0,YR,,M,Y,55.0,KG,20131028.0,,MD,JP,JP,EFAVIRENZ,Dermatitis allergic;Diarrhoea;Gastritis;Hypertriglyceridaemia;Liver disorder;Urethritis chlamydial,96492962.0,OT,,,96492962.0,1.0,20060120.0,20110506.0,,,96492962.0,1.0,HIV infection
9649430,96494304,4,F,20130926.0,20140115.0,20131028,20140123,EXP,,BR-GILEAD-2013-0085928,GILEAD,,38.0,YR,,M,Y,55.7,KG,20140123.0,N,MD,BR,BR,EFAVIRENZ,Pancytopenia,96494304.0,OT,,,96494304.0,1.0,20130805.0,20131003.0,,,96494304.0,1.0,HIV infection
9652894,96528941,1,I,20130918.0,20131021.0,20131029,20131029,EXP,,KE-GILEAD-2013-0086045,GILEAD,,37.0,YR,,M,Y,,,20131029.0,,MD,KE,KE,EFAVIRENZ,Meningitis cryptococcal;Vomiting,96528941.0,HO,,,96528941.0,1.0,20130917.0,20130909.0,,,96528941.0,1.0,HIV infection
9654861,96548612,2,F,20131010.0,20140827.0,20131029,20140904,EXP,,CI-GILEAD-2013-0086165,GILEAD,,37.0,YR,A,F,Y,,,20140904.0,N,MD,CI,CI,EFAVIRENZ,Abortion spontaneous,96548612.0,OT,,,96548612.0,1.0,20081020.0,,,,96548612.0,1.0,HIV infection
9655515,96555151,1,I,20130929.0,20131022.0,20131029,20131029,EXP,,KE-GILEAD-2013-0086052,GILEAD,,43.0,YR,,M,Y,,,20140414.0,N,MD,KE,KE,EFAVIRENZ,Anaemia;Gastroenteritis;Pulmonary tuberculosis;Renal failure acute,96555151.0,HO,,,96555151.0,1.0,20130918.0,20131004.0,,,96555151.0,1.0,HIV infection
9657874,96578743,3,F,20131006.0,20131028.0,20131030,20150303,EXP,,KE-GILEAD-2013-0086214,GILEAD,,48.0,YR,A,M,Y,,,20150303.0,N,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Anaemia;Meningitis cryptococcal,96578743.0,OT,,,96578743.0,1.0,20130924.0,20131009.0,,,96578743.0,1.0,HIV infection
9658001,96580013,3,F,20131006.0,20150511.0,20131030,20150520,EXP,,BR-GILEAD-2013-0086280,GILEAD,,33.0,YR,A,M,Y,79.0,KG,20150520.0,N,MD,BR,BR,EFAVIRENZ,Arthritis reactive,96580013.0,HO,,,96580013.0,1.0,20120924.0,,,,96580013.0,1.0,HIV infection
9663346,96633463,3,F,20130926.0,20140114.0,20131101,20140122,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-19638139,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,55.7,KG,20140122.0,N,CN,US,BR,EFAVIRENZ,Pancytopenia,96633463.0,HO,,,96633463.0,1.0,20130805.0,20131003.0,,,96633463.0,1.0,HIV infection
9665253,96652532,2,F,20070302.0,20131023.0,20131101,20131101,EXP,,JP-ABBVIE-07P-087-0418599-00,ABBVIE,,40.0,YR,,M,Y,,,20131101.0,,MD,COUNTRY NOT SPECIFIED,JP,EFAVIRENZ,Diabetes mellitus;Diabetes mellitus inadequate control,96652532.0,HO,,,96652532.0,1.0,20041221.0,20050121.0,,,96652532.0,1.0,HIV infection
9667907,96679073,3,F,20130917.0,20150504.0,20131104,20150507,EXP,,UG-009507513-1311UGA000967,MERCK,,44.0,YR,,M,Y,,,20150507.0,N,CN,US,UG,EFAVIRENZ,Bronchopneumonia;Cryptosporidiosis infection;Death,96679073.0,LT,,,96679073.0,1.0,20130902.0,20130904.0,,,96679073.0,1.0,HIV infection
9668354,96683541,1,I,2011.0,20130520.0,20131104,20131104,EXP,,CN-GILEAD-2013-0086926,GILEAD,,66.0,YR,,M,Y,,,20131104.0,,OT,CN,CN,EFAVIRENZ,Abnormal dreams;Asphyxia;Dizziness;Dyspnoea;Nasal congestion;Poor quality sleep;Unevaluable event,96683541.0,OT,,,96683541.0,1.0,20111224.0,20111224.0,,,96683541.0,1.0,HIV infection
9669990,96699902,2,F,,20131108.0,20131105,20131119,EXP,,SG-BRISTOL-MYERS SQUIBB COMPANY-19705649,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20131119.0,,CN,US,SG,EFAVIRENZ CAPS,Immune reconstitution inflammatory syndrome;Progressive multifocal leukoencephalopathy,96699902.0,OT,,,,,,,,,96699902.0,1.0,HIV infection
9672506,96725061,1,I,,20131104.0,20131106,20131106,EXP,,KE-GILEAD-2013-0086992,GILEAD,,,,,M,Y,,,20131106.0,,MD,KE,KE,EFAVIRENZ,Malnutrition,96725061.0,DE,,,96725061.0,1.0,20130924.0,20131007.0,,,96725061.0,1.0,HIV infection
9675195,96751951,1,I,,20131014.0,20131105,20131105,EXP,,ADR-2013UNK177,HETERO,,,,,NS,N,,,20131029.0,,CN,US,,EFAVIRENZ,Hepatotoxicity;Metabolic disorder,96751951.0,OT,96751951.0,CR,,,,,,,96751951.0,1.0,Acquired immunodeficiency syndrome
9681745,96817453,3,F,2013.0,20140212.0,20131111,20140221,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-19767201,BRISTOL MYERS SQUIBB,,70.0,YR,,F,Y,54.0,KG,20140221.0,N,CN,GB,CN,EFAVIRENZ,Cerebral atrophy;Cerebral infarction;Dizziness;Electrolyte imbalance;Encephalopathy;Nightmare;Poor quality sleep;Tuberculosis;Type 2 diabetes mellitus,96817453.0,OT,,,96817453.0,1.0,20130506.0,20130521.0,,,96817453.0,1.0,HIV infection
9686383,96863832,2,F,,20131104.0,20131113,20131113,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-19647924,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,,,20131113.0,,CN,US,KE,EFAVIRENZ TABS,Malnutrition,96863832.0,DE,,,96863832.0,1.0,20130924.0,20131007.0,,,96863832.0,1.0,HIV infection
9688979,96889791,1,I,20131010.0,20131105.0,20131114,20131114,EXP,,GB-VIIV HEALTHCARE LIMITED-B0939440A,GLAXOSMITHKLINE,,53.0,YR,,M,Y,,,20131114.0,,PH,GB,GB,Sustiva,Pancreatitis necrotising,96889791.0,HO,,,96889791.0,1.0,2000.0,20131010.0,,,96889791.0,1.0,HIV infection
9691121,96911211,1,I,20131010.0,20131105.0,20131115,20131115,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-19769181,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20131115.0,,CN,GB,GB,SUSTIVA,Pancreatitis necrotising,96911211.0,HO,,,96911211.0,1.0,2000.0,20131010.0,,,96911211.0,1.0,HIV infection
9691863,96918633,3,F,2008.0,20140423.0,20131117,20140501,EXP,,IN-009507513-1106USA03018,MERCK,,46.0,YR,,F,Y,34.0,KG,20140501.0,N,CN,IN,IN,EFAVIRENZ,Anaemia;Cytomegalovirus chorioretinitis;Drug hypersensitivity;Extrapulmonary tuberculosis;HIV peripheral neuropathy;Lower respiratory tract infection;Pulmonary tuberculosis;Virologic failure,96918633.0,OT,,,96918633.0,1.0,20070309.0,20111007.0,,,96918633.0,1.0,HIV infection
9702814,97028143,3,F,200809.0,20170616.0,20131121,20170623,EXP,FR-AFSSAPS-BX20080806,FR-VIIV HEALTHCARE LIMITED-B0546637A,VIIV,,51.0,YR,,F,Y,,,20170623.0,,CN,FR,FR,SUSTIVA,Abnormal sensation in eye;Alopecia;Anxiety;Arthralgia;Asthenia;Cheilitis;Conjunctival disorder;Cough;Depression;Dermatitis bullous;Dry eye;Dry mouth;Dysphagia;Hand deformity;Insomnia;Lacrimation increased;Mental disorder;Mucous membrane disorder;Nail dystrophy;Onycholysis;Orthosis user;Peripheral swelling;Peripheral vascular disorder;Photophobia;Pigmentation disorder;Pyrexia;Toxic epidermal necrolysis,97028143.0,LT,,,97028143.0,1.0,200201.0,20081007.0,,,97028143.0,1.0,HIV infection
9705164,97051641,1,I,20131011.0,20131120.0,20131122,20131122,EXP,,ZW-009507513-1311ZWE009445,MERCK,,41.0,YR,,M,Y,,,20131202.0,,CN,US,ZW,EFAVIRENZ,Cryptococcal fungaemia,97051641.0,DE,,,97051641.0,1.0,20130923.0,,,,97051641.0,1.0,HIV infection
9708222,97082221,1,I,201308.0,20131115.0,20131125,20131125,EXP,,FR-VIIV HEALTHCARE LIMITED-B0946898A,GLAXOSMITHKLINE,,60.0,YR,,M,Y,,,20131125.0,,MD,FR,FR,Sustiva,Fall;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Macrocytosis;Syncope,97082221.0,HO,,,,,,,,,97082221.0,1.0,HIV infection
9709316,97093162,2,F,20130916.0,20131119.0,20131125,20131125,EXP,,FR-BMSGILMSD-2013-0085650,GILEAD,,35.0,YR,,M,Y,61.0,KG,20131125.0,,MD,FR,FR,SUSTIVA,Transaminases increased,,,,,97093162.0,1.0,20130701.0,,,,97093162.0,1.0,HIV infection
9709769,97097691,1,I,201308.0,20131114.0,20131126,20131126,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-19831999,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,,,20131126.0,,CN,FR,FR,SUSTIVA CAPS 600 MG,Fall;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Syncope,97097691.0,HO,,,,,,,,,97097691.0,1.0,HIV infection
9720110,97201102,2,F,,20160720.0,20131128,20160720,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-19859305,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160720.0,,CN,US,CI,EFAVIRENZ,Gastrointestinal disorder,97201102.0,DS,,,,,,,,,97201102.0,1.0,HIV infection
9720114,97201142,2,F,,20160720.0,20131128,20160720,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-19859271,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160720.0,,CN,US,CI,EFAVIRENZ,Nephrotic syndrome;Renal failure,97201142.0,OT,,,,,,,,,97201142.0,1.0,HIV infection
9720115,97201152,2,F,20130801.0,20160203.0,20131128,20160208,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-19839349,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20160208.0,,CN,ES,ES,SUSTIVA,Nephrolithiasis;Off label use,97201152.0,OT,,,97201152.0,1.0,20110418.0,,,,97201152.0,1.0,HIV infection
9722638,97226381,1,I,,20130604.0,20130613,20130613,EXP,,B0898397A,GLAXOSMITHKLINE,,16.0,YR,,M,N,,,20130610.0,,,MY,,EFAVIRENZ,Septic shock;Splenic abscess,97226381.0,HO,97226381.0,HP,97226381.0,2.0,200311.0,,,,97226381.0,1.0,HIV infection
9723226,97232262,2,F,20080804.0,20080923.0,20131202,20150727,PER,,US-GILEAD-2008-0018231,GILEAD,,49.0,YR,A,M,Y,,,20150727.0,N,OT,US,US,SUSTIVA,Acute kidney injury,97232262.0,OT,,,97232262.0,1.0,200703.0,20080807.0,,,97232262.0,1.0,HIV infection
9723230,97232303,3,F,200802.0,20080411.0,20131202,20150727,PER,,US-GILEAD-2008-0015610,GILEAD,,48.0,YR,,F,Y,60.78,KG,20150727.0,N,MD,US,US,SUSTIVA,Oesophageal pain;Oesophageal ulcer,,,,,97232303.0,1.0,2007.0,,,,97232303.0,1.0,Acquired immunodeficiency syndrome
9723394,97233941,1,I,20131109.0,20131119.0,20131202,20131202,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-19873108,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20131202.0,,CN,US,ZW,EFAVIRENZ TABS,Confusional state;Decreased appetite;Diarrhoea;Insomnia;Local swelling,97233941.0,HO,,,97233941.0,1.0,20131029.0,20131030.0,,,97233941.0,1.0,HIV infection
9723402,97234021,1,I,,20131121.0,20131202,20131202,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19867423,BRISTOL MYERS SQUIBB,,11.0,YR,,F,Y,,,20131202.0,,OT,GB,US,EFAVIRENZ,Herpes zoster;Immune reconstitution inflammatory syndrome,97234021.0,OT,,,,,,,,,97234021.0,1.0,HIV infection
9725025,97250251,1,I,20120523.0,20131122.0,20131203,20131203,EXP,,TH-ROCHE-1309127,ROCHE,,56.0,YR,,M,Y,47.7,KG,20131203.0,,MD,TH,TH,Efavirenz,Myocardial ischaemia,97250251.0,DE,,,97250251.0,1.0,20030603.0,20120522.0,,,97250251.0,1.0,HIV infection
9726482,97264824,4,F,20131030.0,20140417.0,20131203,20140425,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-19873157,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,,,20140430.0,N,CN,US,ZW,EFAVIRENZ TABS,Hepatitis;Pulmonary tuberculosis,97264824.0,HO,,,97264824.0,1.0,20131024.0,20131030.0,,,97264824.0,1.0,HIV infection
9726840,97268405,5,F,2008.0,20140523.0,20131203,20140602,EXP,,IN-ABBVIE-11P-078-0834565-00,ABBVIE,,43.0,YR,,F,Y,39.0,KG,20140602.0,N,MD,COUNTRY NOT SPECIFIED,IN,EFAVIRENZ,Anaemia;Cytomegalovirus chorioretinitis;Drug hypersensitivity;Extrapulmonary tuberculosis;HIV peripheral neuropathy;Head injury;Lower respiratory tract infection;Progressive multifocal leukoencephalopathy;Pulmonary tuberculosis;Subdural haematoma;Virologic failure;Vulval cellulitis,97268405.0,HO,,,97268405.0,1.0,20080922.0,20100325.0,,,97268405.0,1.0,HIV infection
9728993,97289932,2,F,200807.0,20131122.0,20131204,20131204,PER,,US-BAYER-2013-144386,BAYER,,19.0,YR,,F,Y,,,20131202.0,,OT,US,US,SUSTIVA,Anxiety;Deep vein thrombosis;Emotional distress;General physical health deterioration;Injury;Pain;Pelvic venous thrombosis,97289932.0,HO,,,97289932.0,1.0,200711.0,,,,97289932.0,6.0,Prophylaxis against HIV infection
9731283,97312832,2,F,20131010.0,20150602.0,20131203,20150615,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19873165,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,,,20150615.0,N,CN,US,UG,EFAVIRENZ,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood bilirubin increased;Hepatomegaly;Nausea;Pyrexia;Vomiting,97312832.0,LT,,,97312832.0,1.0,20131002.0,20131021.0,,,97312832.0,1.0,HIV infection
9731730,97317301,1,I,,20131121.0,20131204,20131204,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19864081,BRISTOL MYERS SQUIBB,,11.0,YR,,F,Y,,,20131204.0,,CN,US,US,EFAVIRENZ,Cerebral infarction;Herpes zoster meningoencephalitis;Immune reconstitution inflammatory syndrome,97317301.0,HO,,,,,,,,,97317301.0,1.0,HIV infection
9733600,97336001,1,I,20131123.0,20131129.0,20131205,20131205,EXP,,KE-VIIV HEALTHCARE LIMITED-B0950259A,GLAXOSMITHKLINE,,45.0,YR,,M,Y,,,20131205.0,,MD,KE,KE,EFAVIRENZ,Death,97336001.0,DE,,,97336001.0,1.0,20131017.0,20131123.0,,,97336001.0,1.0,HIV infection
9734208,97342081,1,I,20131125.0,20131202.0,20131205,20131205,EXP,,GB-GILEAD-2013-0089028,GILEAD,,27.0,YR,,F,Y,,,20131205.0,,MD,GB,GB,EFAVIRENZ,Nephrotic syndrome,97342081.0,OT,,,97342081.0,1.0,20130910.0,,,,97342081.0,1.0,HIV infection
9736102,97361021,1,I,20131123.0,20131129.0,20131206,20131206,EXP,,KE-GLAXOSMITHKLINE-B0950573A,GLAXOSMITHKLINE,,45.0,YR,,M,Y,,,20131206.0,,MD,KE,KE,EFAVIRENZ,Death,97361021.0,DE,,,97361021.0,1.0,20131107.0,20131121.0,,,97361021.0,5.0,HIV infection
9736168,97361681,1,I,20111107.0,20131122.0,20131206,20131206,EXP,,TH-ROCHE-1309156,ROCHE,,50.0,YR,,F,Y,54.1,KG,20131205.0,,MD,TH,TH,EFAVIRENZ,Pyelonephritis acute;Sepsis,97361681.0,DE,,,97361681.0,1.0,20070124.0,20111107.0,,,97361681.0,1.0,HIV infection
9737233,97372333,3,F,20120315.0,20140430.0,20131206,20140509,EXP,,ZA-ABBVIE-12P-143-0918080-00,ABBVIE,,6.0,YR,,F,Y,15.0,KG,20140509.0,N,MD,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Overdose,97372333.0,OT,,,97372333.0,1.0,20120315.0,20120321.0,,,97372333.0,1.0,HIV infection
9742908,97429081,1,I,,20131017.0,20131210,20131210,PER,,US-VIIV HEALTHCARE LIMITED-A1046139A,GLAXOSMITHKLINE,,35.0,YR,,M,Y,,,20131210.0,,OT,US,US,EFAVIRENZ,Insomnia,,,,,97429081.0,1.0,20131002.0,20131012.0,,,97429081.0,1.0,HIV infection
9744065,97440652,2,F,,20160727.0,20131210,20160727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19897594,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20160727.0,,OT,ZA,ZA,EFAVIRENZ,Erythema annulare;Photosensitivity reaction,97440652.0,HO,,,,,,,,,97440652.0,1.0,HIV infection
9744066,97440663,3,F,,20160715.0,20131210,20160715,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19897651,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160715.0,,CN,US,ZA,EFAVIRENZ,Erythema annulare;Maternal exposure during pregnancy;Photosensitivity reaction,97440663.0,HO,,,,,,,,,97440663.0,1.0,HIV infection
9746050,97460502,2,F,20090728.0,20090731.0,20131211,20150722,PER,,GB-GILEAD-2009-0023437,GILEAD,,,,,M,Y,,,20150722.0,N,PH,GB,GB,SUSTIVA,Dizziness;Insomnia,,,,,97460502.0,1.0,20090727.0,,,,97460502.0,1.0,HIV infection
9746075,97460753,3,F,200805.0,20090903.0,20131211,20150722,PER,,FR-GILEAD-2009-0023718,GILEAD,,,,,M,Y,,,20150722.0,N,MD,FR,FR,SUSTIVA,Dermatitis allergic;Toxic skin eruption,,,,,97460753.0,1.0,20090729.0,20090128.0,,,97460753.0,1.0,HIV infection
9746076,97460762,2,F,20081121.0,20090916.0,20131211,20150722,PER,,GB-GILEAD-2009-0024395,GILEAD,,61.0,YR,,M,Y,78.0,KG,20150722.0,N,OT,GB,GB,EFAVIRENZ,Unevaluable event,,,,,97460762.0,1.0,20081120.0,20081130.0,,,97460762.0,1.0,HIV infection
9746085,97460852,2,F,,20090923.0,20131211,20150722,PER,,ES-GILEAD-2009-0024438,GILEAD,,,,A,M,Y,,,20150722.0,N,MD,ES,ES,EFAVIRENZ,Nervous system disorder,,,,,,,,,,,97460852.0,1.0,HIV infection
9746086,97460863,3,F,,20091021.0,20131211,20150722,PER,,PT-GILEAD-2009-0024517,GILEAD,,,,A,M,Y,,,20150722.0,N,MD,PT,PT,EFAVIRENZ,Sleep disorder,,,,,,,,,,,97460863.0,1.0,HIV infection
9746092,97460923,3,F,20090920.0,20091015.0,20131211,20150722,PER,,FR-GILEAD-2009-0024551,GILEAD,,41.0,YR,,F,Y,90.0,KG,20150722.0,N,MD,FR,FR,SUSTIVA,Hypersensitivity,,,,,97460923.0,1.0,20090913.0,20090928.0,,,97460923.0,1.0,HIV infection
9746104,97461043,3,F,,20091130.0,20131211,20150722,PER,,DE-GILEAD-2009-0024394,GILEAD,,,,A,F,Y,,,20150722.0,N,MD,DE,DE,SUSTIVA,Rash pruritic,,,,,,,,,,,97461043.0,1.0,HIV infection
9746116,97461162,2,F,,20091021.0,20131211,20150722,PER,,GB-GILEAD-2009-0024958,GILEAD,,14.0,YR,,M,Y,,,20150722.0,N,OT,GB,GB,EFAVIRENZ,Arthralgia;Dizziness;Nervous system disorder;Off label use,,,,,,,,,,,97461162.0,1.0,HIV infection
9746169,97461693,3,F,,20100111.0,20131211,20150722,PER,,ES-GILEAD-2009-0024809,GILEAD,,,,,M,Y,68.0,KG,20150722.0,N,PH,ES,ES,EFAVIRENZ,Diarrhoea;Gastrointestinal disorder;Weight decreased,,,,,,,,,,,97461693.0,1.0,HIV infection
9746689,97466892,2,F,,20160714.0,20131211,20160714,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19897610,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160714.0,,CN,US,ZA,EFAVIRENZ,Erythema annulare;Photosensitivity reaction,97466892.0,HO,,,,,,,,,97466892.0,1.0,HIV infection
9746692,97466922,2,F,,20160714.0,20131211,20160714,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19897628,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20160714.0,,CN,US,ZA,EFAVIRENZ,Erythema annulare;Photosensitivity reaction,97466922.0,HO,,,,,,,,,97466922.0,1.0,HIV infection
9746710,97467102,2,F,,20160714.0,20131211,20160714,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19897644,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20160714.0,,CN,US,ZA,EFAVIRENZ,Erythema annulare;Photosensitivity reaction,97467102.0,HO,,,,,,,,,97467102.0,1.0,HIV infection
9747068,97470681,1,I,,20131203.0,20131211,20131211,EXP,,US-GILEAD-2013-0089313,GILEAD,,43.0,YR,,M,Y,,,20131211.0,,OT,US,US,EFAVIRENZ,Lipodystrophy acquired;Scleroedema,97470681.0,OT,,,,,,,,,97470681.0,1.0,Acquired immunodeficiency syndrome
9747069,97470691,1,I,,20131203.0,20131211,20131211,EXP,,ZA-GILEAD-2013-0089367,GILEAD,,,,,F,Y,,,20131211.0,,OT,ZA,ZA,EFAVIRENZ,Erythema annulare;Photosensitivity reaction,97470691.0,HO,,,,,,,,,97470691.0,1.0,HIV infection
9747094,97470941,1,I,,20131203.0,20131211,20131211,EXP,,ZA-GILEAD-2013-0089360,GILEAD,,,,,F,Y,,,20131211.0,,OT,ZA,ZA,EFAVIRENZ,Pregnancy;Skin reaction,97470941.0,HO,,,,,,,,,97470941.0,1.0,HIV infection
9747102,97471021,1,I,,20131203.0,20131211,20131211,EXP,,ZA-GILEAD-2013-0089369,GILEAD,,,,,F,Y,,,20131211.0,,OT,ZA,ZA,EFAVIRENZ,Erythema;Photosensitivity reaction,97471021.0,HO,,,,,,,,,97471021.0,1.0,HIV infection
9747103,97471031,1,I,,20131203.0,20131211,20131211,EXP,,ZA-GILEAD-2013-0089368,GILEAD,,,,,F,Y,,,20131211.0,,OT,ZA,ZA,EFAVIRENZ,Erythema annulare;Photosensitivity reaction,97471031.0,HO,,,,,,,,,97471031.0,1.0,HIV infection
9747104,97471041,1,I,,20131203.0,20131211,20131211,EXP,,ZA-GILEAD-2013-0089370,GILEAD,,,,,F,Y,,,20131211.0,,OT,ZA,ZA,EFAVIRENZ,Erythema;Photosensitivity reaction,97471041.0,HO,,,,,,,,,97471041.0,1.0,HIV infection
9747500,97475003,3,F,,20160721.0,20131212,20160721,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-19859917,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160721.0,,CN,US,CI,EFAVIRENZ,Delirium;Dizziness;Nightmare,97475003.0,OT,,,,,,,,,97475003.0,1.0,HIV infection
9750856,97508562,2,F,20131120.0,20131209.0,20131212,20131212,EXP,,MW-GILEAD-2013-0088553,GILEAD,,27.0,YR,,M,Y,,,20131212.0,,MD,MW,MW,EFAVIRENZ,Neutrophil count decreased,97508562.0,LT,,,97508562.0,1.0,20130221.0,,,,97508562.0,1.0,HIV infection
9751606,97516061,1,I,20111228.0,20131127.0,20131212,20131212,EXP,,CN-GILEAD-2013-0089872,GILEAD,,27.0,YR,,M,Y,,,20131212.0,,MD,CN,CN,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Hallucination;Mental status changes;Nervous system disorder,97516061.0,HO,,,,,,,,,97516061.0,1.0,HIV infection
9755933,97559332,2,F,,20160722.0,20131213,20160722,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-19915149,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160722.0,,OT,ES,ES,EFAVIRENZ,Drug interaction;Drug level decreased;Neurological symptom,97559332.0,OT,,,,,,,,,97559332.0,1.0,HIV infection
9757106,97571061,1,I,2004.0,20131211.0,20131213,20131213,EXP,,GB-GILEAD-2013-0089907,GILEAD,,43.0,YR,,F,Y,,,20131213.0,,CN,GB,GB,EFAVIRENZ,Abnormal dreams;Agitation;Hallucination;Insomnia,97571061.0,OT,,,97571061.0,1.0,2004.0,2008.0,,,97571061.0,1.0,HIV infection
9758334,97583341,1,I,20131211.0,,20131213,20131213,DIR,,,,,48.0,YR,,F,N,,,20131212.0,,PH,US,,SUSTIVA,Death;Disease progression;Unevaluable event,97583341.0,DE,97583341.0,HP,97583341.0,1.0,20111129.0,20131211.0,,,97583341.0,1.0,HIV infection
9767542,97675423,3,F,,20090902.0,20131217,20150731,PER,,US-GILEAD-2009-0023022,GILEAD,,40.0,YR,A,M,Y,,,20150731.0,N,MD,US,US,SUSTIVA,Blood creatinine increased,97675423.0,HO,,,,,,,,,97675423.0,1.0,HIV infection
9767580,97675803,3,F,20090629.0,20091104.0,20131217,20150731,PER,,US-GILEAD-2009-0022878,GILEAD,,18.0,YR,,M,Y,,,20150731.0,N,MD,US,US,SUSTIVA,Proteinuria,,,,,97675803.0,1.0,200906.0,,,,97675803.0,1.0,HIV infection
9768104,97681042,2,F,20131203.0,20140207.0,20131217,20140212,EXP,,MW-009507513-1312MWI005537,MERCK,,33.0,YR,,M,Y,,,20140212.0,N,OT,MW,MW,EFAVIRENZ,Disseminated tuberculosis;Pneumonia,97681042.0,HO,,,97681042.0,1.0,20131111.0,20140203.0,,,97681042.0,1.0,HIV infection
9773493,97734931,1,I,,20131216.0,20131219,20131219,EXP,,GB-GILEAD-2013-0090209,GILEAD,,,,,M,Y,,,20131219.0,,CN,GB,GB,EFAVIRENZ,Abnormal dreams;Depression;Suicide attempt,97734931.0,OT,,,97734931.0,1.0,2003.0,,,,97734931.0,1.0,HIV infection
9779819,97798191,1,I,,20131218.0,20131223,20131223,EXP,,HR-VIIV HEALTHCARE LIMITED-B0954926A,GLAXOSMITHKLINE,,48.0,YR,,F,Y,,,20131223.0,,MD,HR,HR,EFAVIRENZ,Basedow's disease;Blood HIV RNA increased;Blood thyroid stimulating hormone decreased;CD4 lymphocytes decreased;Cardiac murmur;Cough;Diarrhoea;Exophthalmos;Goitre;Hyperthyroidism;Immune reconstitution inflammatory syndrome;Oropharyngeal candidiasis;Palpitations;Pyrexia;Seborrhoeic dermatitis;Tachycardia;Thyroxine free increased;Tremor;Tri-iodothyronine increased;Weight decreased,97798191.0,OT,,,,,,,,,97798191.0,1.0,HIV infection
9779830,97798302,2,F,20131112.0,20140113.0,20131223,20140117,EXP,,UG-VIIV HEALTHCARE LIMITED-B0955202A,GLAXOSMITHKLINE,,27.0,YR,,F,Y,,,20140117.0,N,MD,UG,UG,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Stevens-Johnson syndrome,97798302.0,LT,,,97798302.0,1.0,20131003.0,20131120.0,,,97798302.0,1.0,HIV infection
9788545,97885453,3,F,,20160722.0,20131230,20160722,EXP,,TR-BRISTOL-MYERS SQUIBB COMPANY-19951789,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160722.0,,CN,US,TR,EFAVIRENZ,Osteonecrosis,97885453.0,OT,,,,,,,,,97885453.0,1.0,HIV infection
9790710,97907101,1,I,,20131223.0,20131231,20131231,EXP,,IT-VIIV HEALTHCARE LIMITED-B0956446A,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20131231.0,,MD,IT,IT,EFAVIRENZ,Hypertrophic cardiomyopathy,97907101.0,OT,,,,,,,,,97907101.0,1.0,HIV infection
9795981,97959812,2,F,20130523.0,20131224.0,20140103,20140103,EXP,,CI-ABBVIE-13P-084-1100732-00,ABBVIE,,42.0,YR,,F,Y,,,20140103.0,,MD,COUNTRY NOT SPECIFIED,CI,EFAVIRENZ,Stillbirth,97959812.0,OT,,,97959812.0,1.0,20121130.0,20130107.0,,,97959812.0,1.0,HIV infection
9800247,98002471,1,I,,20140101.0,20140106,20140106,EXP,,GB-GILEAD-2014-0091071,GILEAD,,66.0,YR,,M,Y,,,20140106.0,,MD,GB,GB,EFAVIRENZ,Renal tubular disorder,98002471.0,OT,,,98002471.0,1.0,2010.0,20131211.0,,,98002471.0,1.0,HIV infection
9800266,98002661,1,I,20131219.0,20140102.0,20140106,20140106,EXP,,ES-GILEAD-2014-0091087,GILEAD,,39.0,YR,,F,Y,,,20140106.0,,PH,ES,ES,EFAVIRENZ,Peripheral sensory neuropathy,98002661.0,HO,,,98002661.0,1.0,20131219.0,20131221.0,,,98002661.0,1.0,HIV infection
9804855,98048555,5,F,,20140826.0,20140108,20140908,EXP,,US-009507513-1401USA001791,MERCK,,38.0,YR,,F,Y,,,20140908.0,N,CN,US,US,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Mycobacterium avium complex infection,98048555.0,HO,,,,,,,,,98048555.0,1.0,HIV infection
9808286,98082862,2,F,20121022.0,20140106.0,20140110,20140110,EXP,,US-ABBVIE-13P-163-1117196-00,ABBVIE,,22.0,YR,,F,Y,,,20140110.0,,OT,COUNTRY NOT SPECIFIED,US,SUSTIVA,Abortion induced;Complication of pregnancy,98082862.0,OT,,,98082862.0,1.0,20121017.0,20121017.0,,,98082862.0,1.0,Antiretroviral therapy
9808461,98084612,2,F,,20100924.0,20140110,20150731,PER,,US-GILEAD-2010-0032140,GILEAD,,66.0,YR,,F,Y,,,20150731.0,N,MD,US,US,SUSTIVA,Creatinine renal clearance decreased;Fanconi syndrome acquired,98084612.0,OT,,,,,,,,,98084612.0,1.0,HIV infection
9808689,98086894,4,F,20130611.0,20160316.0,20140110,20160316,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18766808,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20160316.0,,OT,GB,GB,EFAVIRENZ,Abnormal dreams;Drug level increased;Maternal exposure during pregnancy;Neurotoxicity;Normal newborn;Off label use;Sleep disorder,98086894.0,OT,,,98086894.0,1.0,20121212.0,,,,98086894.0,1.0,Antiretroviral therapy
9813782,98137822,2,F,,20150807.0,20140113,20150813,EXP,,FR-GILEAD-2014-0091571,GILEAD,,,,,,Y,,,20150813.0,N,MD,FR,FR,SUSTIVA,Ventricular hypoplasia,98137822.0,OT,,,98137822.0,1.0,20130930.0,20130930.0,,,98137822.0,1.0,HIV infection
9813845,98138452,2,F,,20100826.0,20140113,20150727,PER,,US-GILEAD-2010-0031454,GILEAD,,27.0,YR,A,,Y,,,20150727.0,N,MD,US,US,SUSTIVA,Rash,,,,,,,,,,,98138452.0,1.0,HIV infection
9821000,98210003,3,F,20121215.0,20151112.0,20140116,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-18849695,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20151120.0,,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,98210003.0,OT,,,98210003.0,1.0,20121130.0,20121130.0,,,98210003.0,1.0,Antiretroviral therapy
9821985,98219852,2,F,20131010.0,20140212.0,20140116,20140214,EXP,,ZW-009507513-1401ZWE005717,MERCK,,65.0,YR,,M,Y,80.2,KG,20140214.0,N,CN,ZW,ZW,EFAVIRENZ,Cor pulmonale,98219852.0,DE,,,98219852.0,1.0,20110627.0,20131009.0,,,98219852.0,1.0,HIV infection
9822526,98225263,3,F,20131104.0,20140117.0,20140116,20140131,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-19803055,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20140131.0,N,CN,US,GB,SUSTIVA TABS 600 MG,Depression;Drug interaction;Drug level decreased,98225263.0,OT,,,98225263.0,1.0,,201311.0,,,98225263.0,1.0,HIV infection
9827828,98278282,2,F,20100603.0,20140115.0,20140117,20140117,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-15357361,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20140117.0,N,CN,US,IN,SUSTIVA,Anaemia;Lower respiratory tract infection,98278282.0,HO,,,98278282.0,1.0,20070308.0,20080922.0,,,98278282.0,1.0,Antiretroviral therapy
9828052,98280523,3,F,2010.0,20100810.0,20140117,20150722,PER,,US-GILEAD-2010-0030788,GILEAD,,59.0,YR,A,M,Y,,,20150722.0,N,CN,US,US,SUSTIVA,Drug ineffective,,,,,98280523.0,1.0,2010.0,2010.0,,,98280523.0,1.0,HIV infection
9828111,98281112,2,F,,20101025.0,20140117,20150722,PER,,US-GILEAD-2010-0033116,GILEAD,,,,,F,Y,,,20150722.0,N,CN,US,US,SUSTIVA,Blood lactic acid increased;Blood pressure decreased;Dyspnoea,,,,,,,,,,,98281112.0,1.0,HIV infection
9828121,98281212,2,F,,20101028.0,20140117,20150722,PER,,US-GILEAD-2010-0033133,GILEAD,,,,,M,Y,,,20150722.0,N,MD,US,US,SUSTIVA,Mental impairment,,,,,,,,,,,98281212.0,1.0,HIV infection
9828194,98281943,3,F,201009.0,20110602.0,20140117,20150722,PER,,US-GILEAD-2010-0032732,GILEAD,,,,A,M,Y,,,20150722.0,N,OT,US,US,SUSTIVA,Dyspnoea;Tremor,,,,,98281943.0,1.0,201009.0,201009.0,,,98281943.0,1.0,HIV infection
9828915,98289154,4,F,20131227.0,20140919.0,20140118,20140926,EXP,,TH-ABBVIE-14P-155-1190231-00,ABBVIE,,23.0,YR,,M,Y,56.0,KG,20140926.0,N,MD,COUNTRY NOT SPECIFIED,TH,EFAVIRENZ,Nephrotic syndrome,98289154.0,HO,,,98289154.0,1.0,20131225.0,20140102.0,,,98289154.0,1.0,HIV infection
9841653,98416535,5,F,2014.0,20140502.0,20140124,20140505,EXP,,KE-GILEAD-2014-0092331,GILEAD,,36.0,YR,,F,Y,,,20140505.0,N,MD,KE,KE,EFAVIRENZ,Death;Lymph node tuberculosis;Mycobacterium avium complex infection;Sepsis,98416535.0,DE,,,98416535.0,1.0,20130807.0,20140314.0,,,98416535.0,1.0,HIV infection
9844922,98449221,1,I,,20140107.0,20140122,20140122,EXP,,2014HINLIT0005,HETERO,,46.0,YR,,M,N,,,20140120.0,N,OT,IN,,EFAVIRENZ (EFAVIRENZ),Anaemia;Blood pressure systolic increased;Hepatotoxicity;Stevens-Johnson syndrome;Vomiting;White blood cell count decreased,98449221.0,HO,98449221.0,LIT,,,,,,,98449221.0,1.0,HIV infection
9845171,98451711,1,I,,20140113.0,20140127,20140127,EXP,,IN-MYLANLABS-2014S1001180,MYLAN,,5.0,DEC,,M,Y,,,20140127.0,N,OT,IN,IN,EFAVIRENZ,B-cell lymphoma;Gynaecomastia;Multi-organ failure,98451711.0,DE,,,,,,,,,98451711.0,1.0,HIV infection
9846638,98466381,1,I,20131222.0,20140121.0,20140127,20140127,EXP,,UG-VIIV HEALTHCARE LIMITED-B0962911A,GLAXOSMITHKLINE,,30.0,YR,,F,Y,,,20140127.0,N,MD,UG,UG,EFAVIRENZ,Anaemia;Cardiac failure congestive;Pancytopenia;Urinary tract infection,98466381.0,HO,,,98466381.0,1.0,20130703.0,20140105.0,,,98466381.0,1.0,HIV infection
9846648,98466481,1,I,20131222.0,20140121.0,20140127,20140127,EXP,,UG-GLAXOSMITHKLINE-B0963192A,GLAXOSMITHKLINE,,30.0,YR,,F,Y,,,20140127.0,N,OT,UG,UG,EFAVIRENZ,Anaemia;Cardiac failure congestive;Pancytopenia;Urinary tract infection,98466481.0,LT,,,98466481.0,1.0,20130625.0,20140105.0,,,98466481.0,1.0,HIV infection
9850919,98509192,2,F,20061114.0,20140120.0,20140128,20140128,EXP,,FR-ABBVIE-13P-056-1124242-00,ABBVIE,,47.0,YR,,F,Y,,,20140128.0,N,MD,FR,FR,SUSTIVA,Amenorrhoea;Carpal tunnel syndrome;Hypercholesterolaemia;Nervous system disorder;Sexually transmitted disease;Urinary tract infection,98509192.0,OT,,,98509192.0,1.0,20051115.0,20110705.0,,,98509192.0,1.0,HIV infection
9851024,98510242,2,F,20131018.0,20140123.0,20140128,20140128,EXP,,CI-GILEAD-2013-0086179,GILEAD,,36.0,YR,,F,Y,,,20140128.0,N,MD,CI,CI,EFAVIRENZ,Abortion spontaneous,98510242.0,OT,,,98510242.0,1.0,20081002.0,,,,98510242.0,1.0,HIV infection
9856270,98562701,1,I,20130812.0,20140123.0,20140130,20140130,EXP,,CI-GILEAD-2014-0093031,GILEAD,,,,,F,Y,,,20140130.0,N,MD,CI,CI,EFAVIRENZ,Abortion spontaneous,98562701.0,OT,,,98562701.0,1.0,20090810.0,,,,98562701.0,1.0,HIV infection
9859832,98598321,1,I,20120109.0,20140127.0,20140131,20140131,EXP,,FR-GILEAD-2014-0093211,GILEAD,,44.0,YR,,M,Y,,,20140131.0,N,OT,FR,FR,SUSTIVA,Osteopenia,98598321.0,OT,,,98598321.0,1.0,20100510.0,20120101.0,,,98598321.0,1.0,HIV infection
9863873,98638731,1,I,201201.0,20140124.0,20140203,20140203,EXP,,FR-VIIV HEALTHCARE LIMITED-B0963478A,GLAXOSMITHKLINE,,44.0,YR,,M,Y,,,20140203.0,N,MD,FR,FR,Sustiva,Osteopenia,98638731.0,OT,,,98638731.0,1.0,20040607.0,20120109.0,,,98638731.0,1.0,HIV infection CDC category B3
9863919,98639192,2,F,,20140212.0,20140203,20140217,EXP,,US-GILEAD-2014-0093244,GILEAD,,,,,M,Y,77.98,KG,20140217.0,N,CN,US,US,SUSTIVA,Arthropathy,,,,,98639192.0,1.0,20130522.0,,,,98639192.0,1.0,HIV infection
9866992,98669921,1,I,,20140127.0,20140204,20140204,EXP,,"IN-ROXANE LABORATORIES, INC.-2014-RO-00123RO",ROXANE,,48.0,YR,,M,Y,,,20140204.0,N,OT,COUNTRY NOT SPECIFIED,IN,EFAVIRENZ,Diffuse large B-cell lymphoma;Gynaecomastia;Multi-organ failure;Sepsis,98669921.0,DE,,,,,,,,,98669921.0,1.0,HIV test positive
9868376,98683761,1,I,20120109.0,20140124.0,20140204,20140204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-20114427,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20140204.0,N,CN,FR,FR,SUSTIVA TABS 600 MG,Osteopenia,98683761.0,OT,,,98683761.0,1.0,20080303.0,20120109.0,,,98683761.0,1.0,HIV infection
9868958,98689581,1,I,20131215.0,20140130.0,20140205,20140205,EXP,,GB-GILEAD-2014-0093477,GILEAD,,27.0,YR,,F,Y,,,20140204.0,N,MD,GB,GB,EFAVIRENZ,Extrapulmonary tuberculosis,98689581.0,OT,,,98689581.0,1.0,20130923.0,20131231.0,,,98689581.0,1.0,HIV infection
9871069,98710693,3,F,20130206.0,20130306.0,20140205,20150723,PER,,US-GILEAD-2013-0069855,GILEAD,,59.0,YR,A,M,Y,,,20150723.0,N,OT,US,US,SUSTIVA,Anger;Anxiety;Depression;Lethargy;Obsessive thoughts;Somnolence,,,,,98710693.0,1.0,20130201.0,,,,98710693.0,1.0,HIV infection
9871559,98715592,2,F,,20140317.0,20140205,20140327,EXP,,KE-GILEAD-2014-0093518,GILEAD,,,,,M,Y,50.7,KG,20140327.0,N,MD,KE,KE,EFAVIRENZ,Death,98715592.0,DE,,,98715592.0,1.0,20131205.0,20140127.0,,,98715592.0,1.0,HIV infection
9878794,98787942,2,F,201401.0,20140422.0,20140206,20140429,EXP,,MX-VIIV HEALTHCARE LIMITED-A1059868A,GLAXOSMITHKLINE,,22.0,YR,,M,Y,60.0,KG,20140429.0,N,OT,MX,MX,EFAVIRENZ,Feeling abnormal;Histoplasmosis;Jaundice;Liver injury;Ocular icterus;Osteomyelitis;Rash;Transaminases increased,98787942.0,OT,,,98787942.0,1.0,20140102.0,20140120.0,,,98787942.0,1.0,Antiretroviral therapy
9880824,98808241,1,I,,20140128.0,20140205,20140205,EXP,,B0965747A,GLAXOSMITHKLINE,,40.0,YR,,M,N,,,20140204.0,N,,ZA,,EFAVIRENZ (EFAVIRENZ),Conjunctivitis;Immune reconstitution inflammatory syndrome;Ulcerative keratitis,98808241.0,OT,,,,,,,,,98808241.0,1.0,HIV infection
9881761,98817611,1,I,20120831.0,20140127.0,20140207,20140207,EXP,,US-GILEAD-2014-0093983,GILEAD,,,,,NS,Y,83.45,KG,20140207.0,N,OT,US,US,SUSTIVA,Blood creatine phosphokinase increased;CD4 lymphocytes decreased,,,,,98817611.0,1.0,201208.0,201208.0,,,98817611.0,1.0,HIV infection
9881983,98819833,3,F,20131101.0,20140214.0,20140207,20140227,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-20174496,BRISTOL MYERS SQUIBB,,27.0,YR,,M,Y,50.5,KG,20140227.0,N,CN,US,TH,EFAVIRENZ CAPS,Humerus fracture,98819833.0,HO,,,98819833.0,1.0,20130107.0,20130206.0,,,98819833.0,1.0,HIV infection
9882699,98826992,2,F,20140114.0,20140513.0,20140207,20140515,EXP,,CL-GILEAD-2014-0093760,GILEAD,,46.0,YR,,M,Y,69.5,KG,20140514.0,N,MD,CL,CL,EFAVIRENZ,Intentional overdose;Suicide attempt,98826992.0,HO,,,98826992.0,1.0,20140114.0,20140114.0,,,98826992.0,1.0,HIV infection
9885667,98856673,3,F,1999.0,20110921.0,20140210,20150731,PER,,US-GILEAD-2011-0037125,GILEAD,,,,,M,Y,59.87,KG,20150731.0,N,MD,US,US,EFAVIRENZ,Renal failure,98856673.0,OT,,,98856673.0,1.0,201010.0,201010.0,,,98856673.0,1.0,HIV infection
9886722,98867221,1,I,,20140204.0,20140210,20140210,EXP,,ZA-GILEAD-2014-0093854,GILEAD,,34.0,YR,,M,Y,,,20140210.0,N,OT,ZA,ZA,EFAVIRENZ,Drug ineffective;Genotype drug resistance test positive,98867221.0,OT,,,98867221.0,1.0,201009.0,201005.0,,,98867221.0,1.0,Antiretroviral therapy
9887543,98875431,1,I,,20140127.0,20140206,20140206,EXP,,2014HINLIT0089,HETERO,,48.0,YR,,M,N,,,20140205.0,N,OT,IN,,EFAVIRENZ,Diffuse large B-cell lymphoma;Gynaecomastia;Multi-organ failure;Sepsis,98875431.0,OT,98875431.0,HP,98875431.0,1.0,,,365.0,DAY,98875431.0,1.0,Antiretroviral therapy
9889615,98896151,1,I,,20140205.0,20140211,20140211,EXP,,IN-GILEAD-2014-0093935,GILEAD,,37.0,YR,,F,Y,,,20140211.0,N,OT,IN,IN,EFAVIRENZ,Pancreatitis;Shock,98896151.0,OT,,,,,,,,,98896151.0,1.0,Acquired immunodeficiency syndrome
9891927,98919271,1,I,20130925.0,20140205.0,20140212,20140212,EXP,,GB-GILEAD-2014-0094212,GILEAD,,51.0,YR,,M,Y,88.44,KG,20140212.0,N,CN,GB,GB,SUSTIVA,Chest pain;Coronary artery disease;Coronary artery occlusion;Diarrhoea;Dizziness,98919271.0,HO,,,98919271.0,2.0,2009.0,,,,98919271.0,1.0,HIV infection
9892310,98923103,3,F,,20140507.0,20140212,20140512,EXP,,US-009507513-1402USA004802,MERCK,,2.0,YR,,F,Y,,,20140512.0,N,CN,US,US,SUSTIVA,Drug resistance,98923103.0,OT,,,,,,,,,98923103.0,2.0,HIV infection
9892622,98926223,3,F,20131016.0,20140218.0,20140212,20140220,EXP,,KE-GILEAD-2013-0087344,GILEAD,,43.0,YR,,F,Y,60.3,KG,20140220.0,N,MD,KE,KE,EFAVIRENZ,Renal failure chronic,98926223.0,OT,,,98926223.0,1.0,20121210.0,20131015.0,,,98926223.0,1.0,HIV infection
9892631,98926312,2,F,20140116.0,20140422.0,20140212,20140425,EXP,,ZA-GILEAD-2014-0093985,GILEAD,,35.0,YR,,F,Y,101.9,KG,20140425.0,N,MD,ZA,ZA,EFAVIRENZ,Foetal death,98926312.0,OT,,,98926312.0,1.0,20100303.0,,,,98926312.0,1.0,HIV infection
9897411,98974113,3,F,20140116.0,20151210.0,20140214,20151217,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20196218,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20151217.0,,OT,ZA,ZA,EFAVIRENZ,Live birth;Stillbirth;Twin pregnancy,98974113.0,OT,,,98974113.0,1.0,20100303.0,,,,98974113.0,1.0,Prophylaxis against HIV infection
9899895,98998953,3,F,20131121.0,20160428.0,20140214,20160502,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-19888817,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,38.25,KG,20160502.0,,CN,US,TH,EFAVIRENZ,Disease progression;Systemic lupus erythematosus,98998953.0,HO,,,98998953.0,1.0,20120111.0,20140115.0,,,98998953.0,1.0,HIV infection
9900417,99004172,2,F,199806.0,20140303.0,20140217,20140314,EXP,,IT-ROCHE-1348385,ROCHE,,39.0,YR,,F,Y,,,20140314.0,N,OT,IT,IT,EFAVIRENZ,Diarrhoea;Drug level increased;Hepatic cirrhosis;Liver disorder,99004172.0,OT,,,99004172.0,1.0,199803.0,,,,99004172.0,1.0,HIV infection
9907171,99071711,1,I,20131115.0,20140213.0,20140218,20140218,EXP,,UG-009507513-1402UGA007893,MERCK,,30.0,YR,,M,Y,,,20140218.0,N,CN,GB,UG,EFAVIRENZ,Death,99071711.0,LT,,,99071711.0,1.0,20130814.0,20131115.0,,,99071711.0,1.0,HIV infection
9910167,99101672,2,F,20131203.0,20140207.0,20140219,20140219,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-19933522,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,,,20140219.0,N,CN,US,MW,EFAVIRENZ TABS,Disseminated tuberculosis;Pneumonia,99101672.0,HO,,,99101672.0,1.0,20131111.0,20140206.0,,,99101672.0,1.0,HIV infection
9912491,99124911,1,I,20130925.0,20140205.0,20140220,20140220,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-20250379,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,88.43,KG,20140220.0,N,CN,US,GB,SUSTIVA TABS,Chest pain;Coronary artery disease;Coronary artery occlusion;Diarrhoea;Dizziness,99124911.0,HO,,,99124911.0,1.0,2009.0,,,,99124911.0,1.0,HIV infection
9912847,99128471,1,I,,20140204.0,20140212,20140212,EXP,,AUR-APL-2014-01462,AUROBINDO,,48.0,YR,,M,N,,,20140211.0,N,OT,IN,,EFAVIRENZ (EFAVIRENZ),CD4 lymphocytes decreased;Diffuse large B-cell lymphoma;Gynaecomastia;Multi-organ failure;Performance status decreased;Sepsis;Treatment noncompliance,99128471.0,OT,99128471.0,HP,,,,,,,99128471.0,1.0,Antiretroviral therapy
9914678,99146783,3,F,199806.0,20140418.0,20140220,20140422,EXP,,IT-PFIZER INC-2014046216,PFIZER,,39.0,YR,,F,Y,,,20140422.0,N,MD,IT,IT,EFAVIRENZ,Diarrhoea;Drug level increased;Hepatic cirrhosis;Liver disorder,99146783.0,OT,,,99146783.0,1.0,199803.0,,,,99146783.0,1.0,HIV infection
9915649,99156491,1,I,,20140210.0,20140221,20140221,EXP,,US-ROCHE-1348454,ROCHE,,,,,NS,Y,,,20140221.0,N,MD,US,US,EFAVIRENZ (NON-ROCHE NON-COMPARATOR),Gastrointestinal disorder;Hypertriglyceridaemia;Hypophosphataemia,99156491.0,OT,,,,,,,,,99156491.0,1.0,HIV infection
9917029,99170291,1,I,20140209.0,20140214.0,20140221,20140221,EXP,,CO-VIIV HEALTHCARE LIMITED-A1061923A,GLAXOSMITHKLINE,,40.0,YR,,F,Y,64.0,KG,20140221.0,N,PH,CO,CO,EFAVIRENZ,Lip swelling;Rash pruritic,99170291.0,OT,,,99170291.0,1.0,20140201.0,20140212.0,,,99170291.0,1.0,HIV infection
9917852,99178521,1,I,,20140212.0,20140221,20140221,EXP,,MX-VIIV HEALTHCARE LIMITED-A1061965A,GLAXOSMITHKLINE,,,,,M,Y,,,20140222.0,N,MD,MX,MX,EFAVIRENZ,Drug intolerance,99178521.0,OT,,,,,,,,,99178521.0,1.0,HIV infection
9919764,99197642,2,F,,20140424.0,20140224,20140501,EXP,,MX-VIIV HEALTHCARE LIMITED-A1062143A,GLAXOSMITHKLINE,,40.0,YR,,M,Y,,,20140501.0,N,CN,MX,MX,EFAVIRENZ,Virologic failure,99197642.0,OT,,,,,,,,,99197642.0,1.0,HIV infection
9922271,99222713,3,F,20140202.0,20140415.0,20140225,20140422,EXP,,US-VIIV HEALTHCARE LIMITED-A1061360A,GLAXOSMITHKLINE,,60.0,YR,,F,Y,101.8,KG,20140422.0,N,MD,US,US,Sustiva,Bronchitis;Cough;Influenza;Pneumonia,99222713.0,OT,,,99222713.0,1.0,200707.0,,,,99222713.0,1.0,HIV infection
9925715,99257151,1,I,,20140219.0,20140226,20140226,EXP,,IN-VIIV HEALTHCARE LIMITED-B0972269A,GLAXOSMITHKLINE,,41.0,YR,,M,Y,,,20140226.0,N,MD,IN,IN,EFAVIRENZ,Abnormal behaviour;Anaemia;Brain abscess;CSF lymphocyte count increased;CSF protein increased;Dysarthria;Headache;Hemiparesis;Immune reconstitution inflammatory syndrome;Loss of consciousness;Meningitis tuberculous;Tuberculosis,99257151.0,HO,,,99257151.0,2.0,200906.0,,,,99257151.0,1.0,Acquired immunodeficiency syndrome
9929096,99290961,1,I,,20140210.0,20140225,20140225,EXP,,2014HINLIT0151,HETERO,,41.0,YR,,M,N,,,20140224.0,N,PH,CA,,EFAVIRENZ,Drug interaction;Virologic failure,99290961.0,OT,99290961.0,HP,,,,,,,99290961.0,1.0,Antiretroviral therapy
9929489,99294892,2,F,20140206.0,20140310.0,20140227,20140317,EXP,,CO-VIIV HEALTHCARE LIMITED-A1062759A,GLAXOSMITHKLINE,,27.0,YR,,M,Y,71.0,KG,20140317.0,N,CN,CO,CO,EFAVIRENZ,Oedema;Pyrexia;Rash erythematous,99294892.0,HO,,,99294892.0,1.0,20140127.0,20140206.0,,,99294892.0,1.0,Antiretroviral therapy
9931413,99314132,2,F,20071111.0,20140227.0,20140228,20140307,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-20240578,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,,,20140307.0,N,CN,IT,IT,SUSTIVA,Gastric disorder;Nausea,99314132.0,OT,,,99314132.0,1.0,,20140123.0,,,99314132.0,1.0,HIV infection
9934785,99347851,1,I,20140209.0,20140221.0,20140228,20140228,EXP,,CO-VIIV HEALTHCARE LIMITED-A1062769A,GLAXOSMITHKLINE,,23.0,YR,,M,Y,60.0,KG,20140228.0,N,CN,CO,CO,EFAVIRENZ,Chills;Depressed mood;Ear swelling;Eye irritation;Eyelid oedema;Headache;Lip swelling;Myalgia;Pyrexia;Rash generalised,99347851.0,OT,,,99347851.0,1.0,20140209.0,20140219.0,,,99347851.0,1.0,HIV infection
9958776,99587762,2,F,,20140303.0,20140227,20140313,EXP,,AUR-APL-2014-01989,AUROBINDO,,58.0,YR,,M,N,,,20140311.0,N,MD,IN,,EFAVIRENZ (EFAVIRENZ),Decreased appetite;Pulmonary tuberculosis;Skin discolouration;Weight decreased,99587762.0,OT,99587762.0,LIT,,,,,,,99587762.0,1.0,Antiretroviral therapy
9959692,99596921,1,I,,20140218.0,20140227,20140227,EXP,,B0972091A,GLAXOSMITHKLINE,,19.0,YR,,M,N,,,20140225.0,N,OT,CN,,EFAVIRENZ,Cough;Dizziness;Headache;Immune reconstitution inflammatory syndrome;Lymphadenopathy mediastinal;Meningitis cryptococcal;Neck mass,99596921.0,OT,99596921.0,HP,99596921.0,1.0,201109.0,,,,99596921.0,1.0,Antiretroviral therapy
9964018,99640182,2,F,20140120.0,20140401.0,20140305,20140407,EXP,,CO-VIIV HEALTHCARE LIMITED-A1063143A,GLAXOSMITHKLINE,,27.0,YR,,M,Y,76.0,KG,20140407.0,N,OT,CO,CO,EFAVIRENZ,Abdominal pain,99640182.0,OT,,,99640182.0,1.0,20140120.0,20140220.0,,,99640182.0,1.0,HIV infection
9964258,99642582,2,F,,20140307.0,20140305,20140313,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20324000,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,,,20140313.0,N,CN,US,US,SUSTIVA,Cerebrovascular accident,99642582.0,DE,,,,,,,,,99642582.0,1.0,HIV infection
9964259,99642592,2,F,,20160711.0,20140305,20160714,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-20385860,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160714.0,,CN,US,IT,EFAVIRENZ,Death,99642592.0,DE,,,,,,,,,99642592.0,1.0,HIV infection
9964461,99644613,3,F,,20160722.0,20140305,20160722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-20339826,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160722.0,,OT,FR,SN,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,99644613.0,OT,,,,,,,,,99644613.0,1.0,HIV infection
9967074,99670741,1,I,20100721.0,20140226.0,20140305,20140305,EXP,,DE-ABBVIE-14P-062-1207101-00,ABBVIE,,48.0,YR,,M,Y,,,20140305.0,N,MD,COUNTRY NOT SPECIFIED,DE,SUSTIVA,Fall;Femoral neck fracture;Osteoporosis,99670741.0,HO,,,99670741.0,1.0,20020212.0,,,,99670741.0,1.0,HIV infection
9972934,99729341,1,I,,20140211.0,20140306,20140306,EXP,,"ET-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2014-BI-09955GD",BOEHRINGER INGELHEIM,,35.0,YR,,F,Y,,,20140306.0,N,OT,COUNTRY NOT SPECIFIED,ET,EFAVIRENZ,Stillbirth,99729341.0,OT,,,,,,,,,99729341.0,1.0,HIV infection
9973558,99735581,1,I,,20140227.0,20140306,20140306,EXP,,FR-GILEAD-2014-0095891,GILEAD,,,,,M,Y,,,20140306.0,N,OT,FR,FR,SUSTIVA,Nephropathy;Proteinuria,99735581.0,OT,,,99735581.0,1.0,20090706.0,201401.0,,,99735581.0,1.0,HIV infection
9981432,99814323,3,F,20130709.0,20151217.0,20140307,20151218,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-20386363,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20151218.0,,OT,BW,BW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,99814323.0,OT,,,99814323.0,1.0,20110818.0,20130313.0,,,99814323.0,1.0,HIV infection
9981656,99816561,1,I,,,20140306,20140306,DIR,,,,,,,,F,N,,,20140305.0,N,RN,US,,SUSTIVA,Depression;Rash;Viral load increased;Vomiting,99816561.0,OT,99816561.0,HP,99816561.0,1.0,19971201.0,20030101.0,,,99816561.0,1.0,HIV infection
9983796,99837962,2,F,201402.0,20140310.0,20140307,20140317,EXP,,CO-VIIV HEALTHCARE LIMITED-A1063925A,GLAXOSMITHKLINE,,36.0,YR,,M,Y,65.0,KG,20140317.0,N,CN,CO,CO,EFAVIRENZ,Acquired cardiac septal defect;Ejection fraction decreased;Electrocardiogram ST segment abnormal;Myocardial infarction;Ventricular tachycardia,99837962.0,HO,,,,,,,,,99837962.0,1.0,Antiretroviral therapy
9985506,99855062,2,F,20110721.0,20120727.0,20140307,20150727,PER,,MX-GILEAD-2012-0059012,GILEAD,,41.0,YR,A,M,Y,79.5,KG,20150727.0,N,MD,MX,US,EFAVIRENZ,Abnormal dreams;Dizziness;Insomnia,,,,,99855062.0,1.0,20110721.0,,,,99855062.0,1.0,HIV infection
9993662,99936622,2,F,20140129.0,20140502.0,20140310,20140506,EXP,,KE-GILEAD-2014-0096093,GILEAD,,35.0,YR,,F,Y,,,20140506.0,N,MD,KE,KE,EFAVIRENZ,Meningitis bacterial;Meningitis tuberculous;Myelitis transverse;Neuropathy peripheral;Renal failure acute,99936622.0,OT,,,99936622.0,1.0,20140114.0,20140227.0,,,99936622.0,1.0,HIV infection
9998930,99989301,1,I,,20140226.0,20140310,20140310,EXP,,2014ZA00186,CIPLA,,,,,NS,N,,,20140307.0,N,OT,ZA,,EFAVIRENZ (EFAVIRENZ),Lymphoproliferative disorder,99989301.0,DE,99989301.0,LIT,,,,,,,99989301.0,1.0,HIV infection
10004703,100047032,2,F,20140225.0,20140411.0,20140312,20140417,EXP,,KE-GILEAD-2014-0096146,GILEAD,,41.0,YR,,M,Y,60.0,KG,20140417.0,N,MD,KE,KE,EFAVIRENZ,Death,100047032.0,OT,,,100047032.0,1.0,20140128.0,20140224.0,,,100047032.0,1.0,HIV infection
10010232,100102322,2,F,20131228.0,20140324.0,20140313,20140327,EXP,,KE-GILEAD-2014-0096399,GILEAD,,39.0,YR,,M,Y,,,20140327.0,N,MD,KE,KE,EFAVIRENZ,Extrapulmonary tuberculosis;Oral candidiasis,100102322.0,OT,,,100102322.0,1.0,20140113.0,20140218.0,,,100102322.0,1.0,HIV infection
10010257,100102571,1,I,,20140228.0,20140313,20140313,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-20385977,BRISTOL MYERS SQUIBB,,,,,NS,Y,,,20140313.0,N,PH,DE,DE,SUSTIVA TABS 600 MG,Dysphagia,100102571.0,OT,,,,,,,,,100102571.0,1.0,HIV infection
10012525,100125253,3,F,20131028.0,20151217.0,20140314,20151222,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-20448981,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20151222.0,,OT,IN,IN,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,100125253.0,OT,,,100125253.0,1.0,20080331.0,,,,100125253.0,1.0,HIV infection
10012883,100128832,2,F,20140220.0,20140321.0,20140314,20140401,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-20415295,BRISTOL MYERS SQUIBB,,34.0,YR,,M,Y,,,20140401.0,N,CN,US,UG,EFAVIRENZ CAPS,Meningitis cryptococcal,100128832.0,LT,,,100128832.0,1.0,20140127.0,20140227.0,,,100128832.0,1.0,HIV infection
10014408,100144082,2,F,20140202.0,20140429.0,20140317,20140508,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20412458,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,101.58,KG,20140508.0,N,MD,US,US,SUSTIVA,Bronchitis;Influenza;Pneumonia,100144082.0,OT,,,100144082.0,1.0,200707.0,,,,100144082.0,1.0,HIV infection
10016643,100166432,2,F,,20140401.0,20140317,20140408,EXP,,US-GILEAD-2014-0096998,GILEAD,,26.0,YR,,M,Y,,,20140408.0,N,MD,US,US,EFAVIRENZ,Schizoaffective disorder,100166432.0,OT,,,100166432.0,1.0,20070511.0,20070514.0,,,100166432.0,1.0,HIV infection
10016644,100166441,1,I,,20140306.0,20140317,20140317,EXP,,US-GILEAD-2014-0097000,GILEAD,,,,,NS,Y,,,20140317.0,N,MD,US,US,EFAVIRENZ,Kaposi's sarcoma,100166441.0,OT,,,,,,,,,100166441.0,1.0,HIV infection
10016645,100166453,3,F,20070626.0,20140501.0,20140317,20140506,EXP,,US-GILEAD-2014-0097001,GILEAD,,29.0,YR,,F,Y,,,20140506.0,N,MD,US,US,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Pneumocystis jirovecii pneumonia,100166453.0,OT,,,100166453.0,1.0,20070502.0,,,,100166453.0,1.0,HIV infection
10016647,100166471,1,I,,20140306.0,20140317,20140317,EXP,,US-GILEAD-2014-0097002,GILEAD,,,,,NS,Y,,,20140317.0,N,MD,US,US,EFAVIRENZ,Multiple-drug resistance;Virologic failure,100166471.0,OT,,,,,,,,,100166471.0,1.0,HIV infection
10016683,100166834,4,F,,20171102.0,20140317,20171103,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-20545059,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20171103.0,,CN,US,AT,EFAVIRENZ.,Drug interaction;Dyslipidaemia;Gastrointestinal toxicity;Hepatotoxicity;Hypersensitivity;Maternal exposure during pregnancy;Nephropathy toxic;Neurotoxicity;Off label use;Toxicity to various agents;Treatment failure;Virologic failure,100166834.0,OT,,,,,,,,,100166834.0,1.0,HIV infection
10022970,100229704,4,F,20140228.0,20140708.0,20140319,20140709,EXP,,MW-GILEAD-2014-0096862,GILEAD,,44.0,YR,,M,Y,40.8,KG,20140709.0,N,MD,MW,MW,EFAVIRENZ,Death;Immune reconstitution inflammatory syndrome,100229704.0,HO,,,100229704.0,1.0,20140225.0,,,,100229704.0,1.0,HIV infection
10024677,100246771,1,I,,,20140319,20140319,DIR,,,,,,,,F,N,,,20140318.0,N,RN,US,,SUSTIVA,Drug resistance;Nausea;Treatment noncompliance,100246771.0,OT,100246771.0,HP,,,,,,,100246771.0,1.0,HIV infection
10026080,100260801,1,I,,20140307.0,20140320,20140320,EXP,,IN-MYLANLABS-2014S1005388,MYLAN,,44.0,YR,,F,Y,,,20140320.0,N,OT,IN,IN,EFAVIRENZ,Oculomucocutaneous syndrome;Stevens-Johnson syndrome,100260801.0,HO,,,,,,,,,100260801.0,1.0,HIV infection
10026691,100266915,5,F,20140213.0,20160427.0,20140321,20160607,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-20545620,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20160607.0,,CN,US,ZW,EFAVIRENZ,Hyperbilirubinaemia,100266915.0,OT,,,100266915.0,1.0,20131203.0,,,,100266915.0,1.0,HIV infection
10029181,100291812,2,F,,20140319.0,20140321,20140327,EXP,,US-GILEAD-2014-0097257,GILEAD,,,,,M,Y,,,20140327.0,N,OT,US,US,SUSTIVA,Foetal heart rate abnormal,100291812.0,OT,,,100291812.0,1.0,20130125.0,20130228.0,,,100291812.0,1.0,HIV infection
10029213,100292132,2,F,20140308.0,20140502.0,20140321,20140515,EXP,,KE-GILEAD-2014-0096961,GILEAD,,39.0,YR,,M,Y,,,20140514.0,N,MD,KE,KE,EFAVIRENZ,Cerebral toxoplasmosis;Encephalitis viral;Meningitis tuberculous,100292132.0,OT,,,100292132.0,1.0,20140226.0,20140226.0,,,100292132.0,1.0,HIV infection
10033039,100330392,2,F,20130525.0,20140318.0,20140324,20140324,EXP,,CI-GILEAD-2013-0086172,GILEAD,,34.0,YR,,F,Y,,,20140324.0,N,MD,CI,CI,EFAVIRENZ,Stillbirth,100330392.0,OT,,,100330392.0,1.0,20120612.0,20130817.0,,,100330392.0,1.0,HIV infection
10038893,100388931,1,I,20050916.0,20140320.0,20140326,20140326,EXP,,CH-VIIV HEALTHCARE LIMITED-B0979958A,GLAXOSMITHKLINE,,28.0,YR,,M,Y,,,20140331.0,N,MD,CH,CH,EFAVIRENZ,Amylase abnormal;Blood creatine phosphokinase abnormal;Hypertransaminasaemia,100388931.0,OT,,,100388931.0,1.0,20021112.0,20051107.0,,,100388931.0,1.0,HIV carrier
10039042,100390422,2,F,20140221.0,20151211.0,20140326,20151217,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-20566469,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20151217.0,,CN,US,IN,EFAVIRENZ,Abortion induced;Benign hydatidiform mole;Maternal exposure during pregnancy,100390422.0,OT,,,100390422.0,1.0,20080331.0,20140214.0,,,100390422.0,1.0,HIV infection
10039062,100390622,2,F,20140215.0,20140324.0,20140326,20140331,EXP,,TH-GILEAD-2014-0097673,GILEAD,,29.0,YR,,M,Y,56.4,KG,20140331.0,N,MD,TH,TH,EFAVIRENZ,Suicidal ideation,100390622.0,OT,,,100390622.0,1.0,20130322.0,,,,100390622.0,1.0,HIV infection
10041607,100416074,4,F,20130125.0,20141208.0,20140327,20141211,EXP,,US-GILEAD-2014-0097252,GILEAD,,,,,,Y,,,20141217.0,N,MD,US,US,SUSTIVA,Amniotic cavity infection;Delayed delivery;Pregnancy,100416074.0,OT,,,100416074.0,1.0,20120524.0,20130228.0,,,100416074.0,1.0,HIV infection
10042653,100426532,2,F,20140314.0,20140502.0,20140327,20140513,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-20571311,BRISTOL MYERS SQUIBB,,65.0,YR,,M,Y,,,20140513.0,N,CN,US,MW,EFAVIRENZ TABS,Hypoglycaemia,100426532.0,HO,,,100426532.0,1.0,20140217.0,20140314.0,,,100426532.0,1.0,HIV infection
10043168,100431683,3,F,20140228.0,20140417.0,20140328,20140425,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-20552238,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,47.1,KG,20140425.0,N,CN,US,MW,EFAVIRENZ TABS,Immune reconstitution inflammatory syndrome associated tuberculosis;Pneumonia;Pulmonary tuberculosis;Sepsis,100431683.0,DE,,,100431683.0,1.0,20140225.0,,,,100431683.0,1.0,HIV infection
10044899,100448992,2,F,20131028.0,20140423.0,20140328,20140425,EXP,,US-VIIV HEALTHCARE LIMITED-A1066743A,GLAXOSMITHKLINE,,23.0,YR,,F,Y,,,20140425.0,N,OT,US,US,Sustiva,Amniotic cavity infection;Exposure during pregnancy;Gastrooesophageal reflux disease;Labour complication;Live birth,100448992.0,OT,,,100448992.0,1.0,20120524.0,20130228.0,,,100448992.0,1.0,HIV infection
10045772,100457721,1,I,20140310.0,20140324.0,20140328,20140328,EXP,,ZW-GILEAD-2014-0097987,GILEAD,,31.0,YR,,F,Y,,,20140328.0,N,MD,ZW,ZW,EFAVIRENZ,Foetal death,100457721.0,OT,,,100457721.0,1.0,20110929.0,20110929.0,,,100457721.0,1.0,HIV infection
10050930,100509301,1,I,,20140320.0,20140401,20140401,EXP,,CH-JNJFOC-20140313014,JANSSEN,,28.0,YR,,M,Y,,,20140401.0,N,MD,CH,CH,EFAVIRENZ,Amylase abnormal;Blood creatine phosphokinase abnormal;Hypertransaminasaemia;Liver function test abnormal,100509301.0,OT,,,100509301.0,1.0,20090501.0,20051107.0,,,100509301.0,1.0,HIV carrier
10052914,100529141,1,I,,20140318.0,20140331,20140331,EXP,,2014IN00279,CIPLA,,,,,NS,N,,,20140328.0,N,,IN,,EFAVIRENZ (EFAVIRENZ),Anaemia,100529141.0,DE,100529141.0,HP,100529141.0,1.0,,,21.0,DAY,100529141.0,1.0,HIV infection
10053230,100532301,1,I,20130705.0,20140326.0,20140402,20140402,EXP,,FR-VIIV HEALTHCARE LIMITED-B0980210A,GLAXOSMITHKLINE,,71.0,YR,,M,Y,,,20140402.0,N,MD,FR,FR,Sustiva,Pulmonary embolism,100532301.0,HO,,,100532301.0,1.0,20130218.0,20130819.0,,,100532301.0,1.0,HIV infection
10060912,100609124,4,F,20140121.0,20140623.0,20140404,20140627,EXP,,TH-GILEAD-2014-0098209,GILEAD,,46.0,YR,,F,Y,49.45,KG,20140627.0,N,MD,TH,TH,EFAVIRENZ,Pyelonephritis acute;Renal failure,100609124.0,OT,,,100609124.0,1.0,20120105.0,20140120.0,,,100609124.0,1.0,HIV infection
10062515,100625151,1,I,,20140404.0,20140407,20140407,EXP,,UG-009507513-1404GBR003644,MERCK,,,,,F,Y,,,20140407.0,N,MD,UG,UG,EFAVIRENZ,Death;Malnutrition,100625151.0,DE,,,100625151.0,1.0,20140313.0,20140322.0,,,100625151.0,1.0,HIV infection
10063642,100636422,2,F,20070622.0,20140401.0,20140407,20140407,EXP,,US-GILEAD-2014-0096999,GILEAD,,45.0,YR,,F,Y,,,20140407.0,N,MD,US,US,EFAVIRENZ,Dyspepsia;Gastrointestinal disorder,100636422.0,HO,,,100636422.0,1.0,20070608.0,,,,100636422.0,1.0,HIV infection
10066208,100662081,1,I,201402.0,20140402.0,20140408,20140408,EXP,,US-GILEAD-2014-0098714,GILEAD,,55.0,YR,,F,Y,,,20140408.0,N,CN,US,US,SUSTIVA,Abdominal distension;Abnormal dreams;Nausea,,,,,100662081.0,1.0,201402.0,,,,100662081.0,1.0,HIV infection
10067309,100673091,1,I,,20140324.0,20140407,20140407,EXP,,AUR-APL-2014-04025,AUROBINDO,,34.0,YR,,M,N,,,20140404.0,N,OT,ZA,,EFAVIRENZ (EFAVIRENZ),Gene mutation;Haemoglobin decreased;Imprisonment;Multiple-drug resistance;Therapy cessation;Tuberculosis;Virologic failure,100673091.0,OT,100673091.0,HP,,,,,,,100673091.0,1.0,Antiretroviral therapy
10070585,100705854,4,F,20140227.0,20150106.0,20140410,20150123,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-20595633,BRISTOL MYERS SQUIBB,,32.0,YR,,M,Y,65.8,KG,20150123.0,N,CN,US,MW,EFAVIRENZ,Anaemia;Bacterial sepsis;Lymph node tuberculosis,100705854.0,HO,,,100705854.0,1.0,20140219.0,,,,100705854.0,2.0,HIV infection
10071551,100715513,3,F,20140310.0,20140916.0,20140410,20140922,EXP,IT-PVNET-243070,IT-GILEAD-2014-0097683,GILEAD,,37.0,YR,A,M,Y,,,20140922.0,N,MD,IT,IT,SUSTIVA,Pruritus generalised;Toxic skin eruption,100715513.0,OT,,,100715513.0,1.0,20140226.0,20140309.0,,,100715513.0,1.0,HIV infection
10073218,100732181,1,I,201403.0,20140403.0,20140411,20140411,EXP,,US-VIIV HEALTHCARE LIMITED-A1068063A,GLAXOSMITHKLINE,,73.0,YR,,M,Y,,,20140411.0,N,CN,US,US,Sustiva,Abdominal pain upper,100732181.0,HO,,,100732181.0,1.0,2011.0,,,,100732181.0,1.0,HIV infection
10073396,100733962,2,F,20140222.0,20151211.0,20140411,20151217,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-20601571,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151217.0,,CN,CL,CL,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,100733962.0,OT,,,100733962.0,1.0,20130205.0,,,,100733962.0,1.0,Antiretroviral therapy
10081632,100816323,3,F,,20140717.0,20140414,20140725,EXP,,AUR-APL-2014-04268,AUROBINDO,,36.0,YR,,M,N,,,20140724.0,N,OT,IT,,EFAVIRENZ (EFAVIRENZ),Cardiac failure;Cardiac failure chronic;Congestive cardiomyopathy;Heart transplant,100816323.0,OT,100816323.0,FGN,,,,,,,100816323.0,1.0,Antiretroviral therapy
10082079,100820791,1,I,20130923.0,20140404.0,20140416,20140416,EXP,,PE-BRISTOL-MYERS SQUIBB COMPANY-20612941,BRISTOL MYERS SQUIBB,,24.0,YR,,M,Y,47.5,KG,20140416.0,N,CN,US,PE,EFAVIRENZ,Contusion;Fall;Foot fracture,100820791.0,OT,,,100820791.0,1.0,20110210.0,20120515.0,,,100820791.0,1.0,HIV infection
10082356,100823563,3,F,20140303.0,20140508.0,20140416,20140512,EXP,,UG-GILEAD-2014-0099528,GILEAD,,17.0,YR,,F,Y,,,20140512.0,N,MD,UG,UG,EFAVIRENZ,Anaemia;Death,100823563.0,OT,,,100823563.0,1.0,20140221.0,20140315.0,,,100823563.0,1.0,HIV infection
10086726,100867261,1,I,20140313.0,20140404.0,20140418,20140418,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-20613220,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20140418.0,N,CN,US,UG,EFAVIRENZ TABS,Death;Malnutrition,100867261.0,DE,,,100867261.0,1.0,20140313.0,20140322.0,,,100867261.0,1.0,HIV infection
10087245,100872451,1,I,201006.0,20140409.0,20140418,20140418,EXP,,PHHY2014IN044022,SANDOZ,,41.0,YR,,M,Y,,,20140418.0,N,OT,IN,IN,EFAVIRENZ ,Abnormal behaviour;Anaemia;Disease recurrence;Dysarthria;Headache;Hemiparesis;Immune reconstitution inflammatory syndrome associated tuberculosis;Loss of consciousness;Meningitis tuberculous;Tuberculosis of central nervous system,100872451.0,HO,,,,,,,,,100872451.0,1.0,Antiretroviral therapy
10095998,100959981,1,I,201203.0,20140411.0,20140422,20140422,EXP,,PHHY2014CN045230,SANDOZ,,19.0,YR,,M,Y,,,20140422.0,N,OT,CN,CN,EFAVIRENZ ,Central nervous system lesion;Cough;Cryptococcosis;Immune reconstitution inflammatory syndrome;Lymphadenopathy mediastinal;Neck mass;Neurocryptococcosis;Pyrexia,100959981.0,OT,100959981.0,FGN,100959981.0,1.0,201109.0,,,,100959981.0,1.0,Antiretroviral therapy
10101991,101019912,2,F,201105.0,20140402.0,20140424,20140424,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-16261059,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,65.6,KG,20140424.0,N,CN,US,ZW,EFAVIRENZ TABS,Anaemia;Vaginal haemorrhage,101019912.0,LT,,,101019912.0,1.0,20071119.0,,,,101019912.0,1.0,HIV infection
10130579,101305791,1,I,2000.0,20140423.0,20140428,20140428,EXP,,FR-009507513-1404FRA012250,MERCK,,,,,M,Y,,,20140428.0,N,OT,FR,FR,SUSTIVA,Lipodystrophy acquired,101305791.0,HO,,,101305791.0,1.0,20130422.0,20130422.0,,,101305791.0,1.0,HIV infection
10144471,101444711,1,I,20131202.0,20140425.0,20140430,20140430,EXP,,BR-GILEAD-2014-0100962,GILEAD,,30.0,YR,,M,Y,77.5,KG,20140430.0,N,MD,BR,BR,EFAVIRENZ,Fibrosarcoma,101444711.0,HO,,,101444711.0,1.0,20111013.0,20111013.0,,,101444711.0,1.0,HIV infection
10147000,101470001,1,I,2000.0,20140423.0,20140501,20140501,EXP,,FR-VIIV HEALTHCARE LIMITED-B0988054A,GLAXOSMITHKLINE,,,,,M,Y,,,20140501.0,N,MD,FR,FR,Sustiva,Lipodystrophy acquired,101470001.0,HO,,,101470001.0,1.0,19980731.0,2006.0,,,101470001.0,1.0,HIV infection
10148859,101488593,3,F,201007.0,20210615.0,20140502,20210623,EXP,,CA-009507513-1404CAN014456,MERCK,,44.0,YR,,M,Y,,,20210623.0,,CN,CA,CA,EFAVIRENZ.,Asthenia;Drug interaction;Dysarthria;Gait disturbance;Slow speech;Somnolence,101488593.0,HO,,,101488593.0,1.0,200710.0,200810.0,,,101488593.0,1.0,HIV infection
10149412,101494123,3,F,200912.0,20140508.0,20140430,20140520,EXP,,AUR-APL-2014-05072,AUROBINDO,,41.0,YR,,M,N,,,20140519.0,N,MD,IN,,EFAVIRENZ (EFAVIRENZ),Anaemia;Brain abscess;Immune reconstitution inflammatory syndrome;Meningitis tuberculous;Mycobacterium tuberculosis complex test positive,101494123.0,OT,101494123.0,HP,101494123.0,2.0,200906.0,,,,101494123.0,1.0,Antiretroviral therapy
10149577,101495771,1,I,,20140415.0,20140430,20140430,EXP,,2014HINLIT0386,HETERO,,19.0,YR,,M,N,,,20140428.0,N,,CN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Drug interaction;Immune reconstitution inflammatory syndrome,101495771.0,OT,101495771.0,FGN,101495771.0,1.0,201109.0,,,,101495771.0,1.0,Antiretroviral therapy
10150329,101503291,1,I,,20140422.0,20140502,20140502,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-20674081,BRISTOL MYERS SQUIBB,,10.0,YR,,F,Y,19.0,KG,20140502.0,N,MD,DE,DE,SUSTIVA,Encephalopathy;Mycobacterial infection,101503291.0,OT,,,,,,,,,101503291.0,1.0,HIV infection
10163730,101637301,1,I,2008.0,20140502.0,20140509,20140509,EXP,,FR-GILEAD-2014-0101582,GILEAD,,50.0,YR,,M,Y,,,20140509.0,N,OT,FR,FR,SUSTIVA,Fanconi syndrome acquired;Osteoporosis,101637301.0,OT,,,101637301.0,1.0,,20100121.0,,,101637301.0,1.0,HIV infection
10167492,101674924,4,F,20140422.0,20140710.0,20140512,20140716,EXP,,US-GILEAD-2014-0101624,GILEAD,,23.0,YR,,F,Y,,,20140716.0,N,MD,US,US,SUSTIVA,Alanine aminotransferase increased;Aspartate aminotransferase increased,101674924.0,OT,,,101674924.0,1.0,20140407.0,20140422.0,,,101674924.0,1.0,HIV infection
10167630,101676303,3,F,,20231113.0,20140512,20231128,EXP,,KH-BRISTOL-MYERS SQUIBB COMPANY-20721353,BRISTOL MYERS SQUIBB,"Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, et al. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS ONE. 2014 Mar 07;9(3):1-10. doi:10.1371/journal.pone.0090350.",,,,,Y,,,20231128.0,,HP,KH,KH,EFAVIRENZ,Delirium,101676303.0,LT,,,,,,,,,101676303.0,1.0,HIV infection
10167631,101676313,3,F,,20231113.0,20140512,20231121,EXP,,KH-BRISTOL-MYERS SQUIBB COMPANY-20721361,BRISTOL MYERS SQUIBB,"Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, et al. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS ONE. 2014 Mar 07;9(3):1-10. doi:10.1371/journal.pone.0090350.",,,,,Y,,,20231121.0,,HP,KH,KH,EFAVIRENZ,Insomnia,101676313.0,DS,,,,,,,,,101676313.0,1.0,HIV infection
10167637,101676372,2,F,,20160712.0,20140512,20160715,EXP,,KH-BRISTOL-MYERS SQUIBB COMPANY-20721379,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160715.0,,CN,US,KH,EFAVIRENZ,Skin disorder,101676372.0,LT,,,,,,,,,101676372.0,1.0,HIV infection
10175322,101753221,1,I,201202.0,20140510.0,20140515,20140515,EXP,,US-GILEAD-2014-0102324,GILEAD,,54.0,YR,,M,Y,,,20140515.0,N,OT,US,US,EFAVIRENZ,Ankle fracture;Hypophosphataemia;Osteoporosis;Renal failure;Renal failure acute;Renal tubular disorder,101753221.0,OT,,,101753221.0,1.0,200204.0,201202.0,,,101753221.0,1.0,HIV infection
10178681,101786811,1,I,,20140512.0,20140519,20140519,EXP,,US-TEVA-481720USA,TEVA,,12.0,YR,,M,Y,,,20140518.0,N,OT,US,US,efavirenz,Neuropathy peripheral;Respiratory disorder,101786811.0,DE,,,,,,,,,101786811.0,1.0,Antiretroviral therapy
10181438,101814383,3,F,,20150205.0,20140519,20150217,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-20734364,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150217.0,N,CN,US,GB,EFAVIRENZ,Neurotoxicity,101814383.0,OT,,,,,,,,,101814383.0,1.0,HIV infection
10181805,101818051,1,I,,20140506.0,20140519,20140519,EXP,,US-MYLANLABS-2014S1010794,MYLAN,,12.0,YR,,M,Y,,,20140519.0,N,OT,US,US,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Neuropathy peripheral;Respiratory disorder,101818051.0,DE,,,,,,,,,101818051.0,1.0,Antiretroviral therapy
10184594,101845947,7,F,20140125.0,20151028.0,20140521,20151109,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-20777256,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20151109.0,,CN,CI,CI,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,101845947.0,OT,,,101845947.0,1.0,20120612.0,,,,101845947.0,1.0,Antiretroviral therapy
10185368,101853681,1,I,20140407.0,,20140520,20140520,DIR,,,,,33.0,YR,,M,N,,,20140513.0,N,,US,,EFAVIRENZ,Confusional state;Depression;Suicidal ideation;Thinking abnormal,101853681.0,DS,,,101853681.0,1.0,20070407.0,20071231.0,,,101853681.0,1.0,HIV infection
10190837,101908371,1,I,,20140508.0,20140523,20140523,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-20808663,BRISTOL MYERS SQUIBB,,,,,NS,Y,,,20140523.0,N,CN,US,GB,EFAVIRENZ CAPS,Neurotoxicity,101908371.0,OT,,,,,,,,,101908371.0,1.0,Antiretroviral therapy
10192424,101924242,2,F,20140414.0,20140521.0,20140523,20140530,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20775862,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,40.5,KG,20140530.0,N,CN,US,ZA,EFAVIRENZ TABS 600 MG,Diarrhoea;Renal failure acute,101924242.0,HO,,,101924242.0,1.0,20080302.0,20140414.0,,,101924242.0,1.0,HIV infection
10192430,101924301,1,I,20140308.0,20140502.0,20140523,20140523,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-20800637,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20140523.0,N,CN,US,KE,EFAVIRENZ TABS,Cerebral toxoplasmosis;Encephalitis viral;Meningitis tuberculous,101924301.0,HO,,,101924301.0,1.0,20140226.0,20140226.0,,,101924301.0,1.0,HIV infection
10195789,101957892,2,F,,20140610.0,20140522,20140624,EXP,,AUR-APL-2014-05905,AUROBINDO,,12.0,YR,,M,N,,,20140623.0,N,OT,US,,EFAVIRENZ (EFAVIRENZ),Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Lung disorder;Neuropathy peripheral;Pericardial effusion;Respiratory disorder;Skin lesion,101957892.0,OT,101957892.0,HP,,,,,,,101957892.0,1.0,Antiretroviral therapy
10202188,102021881,1,I,20140410.0,20140519.0,20140528,20140528,EXP,,RU-VIIV HEALTHCARE LIMITED-B0997443A,GLAXOSMITHKLINE,,,,,M,Y,,,20140528.0,N,CN,RU,RU,EFAVIRENZ,Chronic hepatitis C;Craniocerebral injury;Drug ineffective;Hypotonia;Mental disorder due to a general medical condition;Onychomycosis,102021881.0,OT,,,102021881.0,1.0,201212.0,,,,102021881.0,1.0,HIV infection
10202751,102027513,3,F,20140518.0,20140610.0,20140528,20140616,EXP,,KE-GILEAD-2014-0103142,GILEAD,,41.0,YR,,F,Y,,,20140616.0,N,MD,KE,KE,EFAVIRENZ,Acute psychosis;Death;Immune reconstitution inflammatory syndrome associated tuberculosis;Malnutrition;Pneumonia;Pulmonary tuberculosis,102027513.0,DE,,,102027513.0,1.0,20140515.0,20140607.0,,,102027513.0,1.0,HIV infection
10207448,102074482,2,F,,20130927.0,20140530,20140530,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-19478353,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20140530.0,N,MD,US,US,SUSTIVA,Rash,,,,,102074482.0,1.0,20130704.0,20130814.0,,,102074482.0,1.0,HIV infection
10207449,102074492,2,F,,20131220.0,20140530,20140530,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-19524453,BRISTOL MYERS SQUIBB,,47.0,YR,,M,Y,74.83,KG,20140530.0,N,CN,US,US,SUSTIVA,Drug screen positive,,,,,,,,,,,102074492.0,1.0,HIV infection
10207454,102074542,2,F,,20140221.0,20140530,20140530,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-19867704,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,,,20140530.0,N,CN,US,US,SUSTIVA,Adverse event,,,,,102074542.0,1.0,20130524.0,201311.0,,,102074542.0,1.0,HIV infection
10207459,102074593,3,F,,20140507.0,20140530,20140815,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-20225124,BRISTOL MYERS SQUIBB,,2.0,YR,,F,Y,,,20140815.0,N,CN,US,US,SUSTIVA TABS,Drug resistance,102074593.0,OT,,,,,,,,,102074593.0,4.0,HIV infection
10207461,102074611,1,I,,20140220.0,20140530,20140530,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-20305223,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,,,20140530.0,N,CN,COUNTRY NOT SPECIFIED,US,SUSTIVA,Drug resistance,102074611.0,OT,,,,,,,,,102074611.0,1.0,HIV infection
10207463,102074631,1,I,20140312.0,20140313.0,20140530,20140530,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-20503017,BRISTOL MYERS SQUIBB,,64.0,YR,,M,Y,84.35,KG,20140530.0,N,CN,US,US,SUSTIVA,Diarrhoea,,,,,,,,,,,102074631.0,1.0,HIV infection
10208082,102080821,1,I,,20130903.0,20140530,20140530,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-19425446,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20140530.0,N,CN,US,US,EFAVIRENZ TABS,Drug interaction,,,,,,,,,,,102080821.0,2.0,HIV infection
10208392,102083922,2,F,20140429.0,20151022.0,20140530,20151103,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20803656,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,114.0,KG,20151103.0,,CN,US,ZA,EFAVIRENZ,Abortion induced;Benign hydatidiform mole;Maternal exposure during pregnancy;Viral load increased,102083922.0,OT,,,102083922.0,1.0,20120905.0,20140327.0,,,102083922.0,1.0,HIV infection
10210353,102103531,1,I,,20140515.0,20140528,20140528,EXP,,B0995671A,GLAXOSMITHKLINE,,30.0,YR,,F,N,,,20140522.0,N,OT,BR,,EFAVIRENZ,Ataxia;Bradyphrenia;Headache;Hydrocephalus;Paraesthesia;Phonophobia;Photophobia;Procedural haemorrhage;Vomiting,102103531.0,HO,102103531.0,LIT,,,,,,,102103531.0,1.0,Antiretroviral therapy
10210570,102105701,1,I,,20140513.0,20140528,20140528,EXP,,2014HINLIT0455,HETERO,,12.0,YR,,M,N,,,20140527.0,N,OT,US,,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Neuropathy peripheral;Pancytopenia,102105701.0,DE,102105701.0,HP,,,,,,,102105701.0,1.0,HIV infection
10211722,102117221,1,I,,20140513.0,20140528,20140528,EXP,,2014HINLIT0450,HETERO,,7.0,YR,,F,N,,,20140527.0,N,MD,IT,,EFAVIRENZ (EFAVIRENZ),Genetic polymorphism;Renal tubular disorder,102117221.0,OT,102117221.0,FGN,102117221.0,1.0,2008.0,,,,102117221.0,1.0,HIV infection
10216890,102168901,1,I,20140425.0,20140523.0,20140604,20140604,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-20861415,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,62.5,KG,20140604.0,N,OT,US,BR,EFAVIRENZ,Depression suicidal,102168901.0,OT,,,102168901.0,1.0,20131202.0,,,,102168901.0,1.0,HIV infection
10216921,102169211,1,I,201403.0,20140530.0,20140604,20140604,EXP,,FR-GILEAD-2014-0103980,GILEAD,,54.0,YR,,F,Y,29.5,KG,20140604.0,N,OT,FR,FR,SUSTIVA,Anaemia;Hypomagnesaemia;Hypophosphataemia;Lipase increased,102169211.0,HO,,,102169211.0,1.0,,20140323.0,,,102169211.0,1.0,HIV infection
10218241,102182411,1,I,,20140521.0,20140605,20140605,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-20810529,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20140812.0,N,CN,US,US,SUSTIVA,Drug resistance;Nephrolithiasis,102182411.0,OT,,,,,,,,,102182411.0,1.0,HIV infection
10222240,102222403,3,F,20140326.0,20140716.0,20140606,20140722,EXP,,US-VIIV HEALTHCARE LIMITED-A1076059A,GLAXOSMITHKLINE,,23.0,YR,,F,Y,,,20140826.0,N,OT,US,US,SUSTIVA,Alanine aminotransferase increased;Aspartate aminotransferase increased;Liver function test abnormal,102222403.0,OT,,,102222403.0,1.0,2012.0,20140407.0,,,102222403.0,1.0,HIV infection
10222284,102222841,1,I,,20140602.0,20140606,20140606,EXP,,PT-VIIV HEALTHCARE LIMITED-B1000911A,GLAXOSMITHKLINE,,36.0,YR,,M,Y,,,20140606.0,N,MD,PT,PT,EFAVIRENZ,Basedow's disease;Blood thyroid stimulating hormone decreased;Diabetic ketoacidosis;Goitre;Immune reconstitution inflammatory syndrome;Insomnia;Neurotoxicity;Physical examination abnormal;Sinus tachycardia;Thyroxine free increased;Tri-iodothyronine increased;Type 1 diabetes mellitus;Weight decreased,102222841.0,OT,,,102222841.0,1.0,2007.0,200903.0,,,102222841.0,1.0,HIV infection
10222410,102224103,3,F,20140429.0,20151022.0,20140606,20151103,EXP,,ZA-ABBVIE-14P-143-1243784-00,ABBVIE,,23.0,YR,,F,Y,114.0,KG,20151103.0,,MD,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Abortion induced;Benign hydatidiform mole;Viral load increased,102224103.0,HO,,,102224103.0,1.0,20120905.0,20140327.0,,,102224103.0,1.0,HIV infection
10222671,102226712,2,F,,20130724.0,20140606,20150727,PER,,US-GILEAD-2013-0080205,GILEAD,,,,,M,Y,,,20150727.0,N,CN,US,US,SUSTIVA,Gynaecomastia,,,,,102226712.0,1.0,,2006.0,,,102226712.0,1.0,HIV infection
10222673,102226733,3,F,,20130925.0,20140606,20150727,PER,,US-GILEAD-2013-0081759,GILEAD,,,,A,M,Y,79.0,KG,20150727.0,N,MD,US,US,SUSTIVA,Drug ineffective,102226733.0,OT,,,102226733.0,1.0,20111103.0,,,,102226733.0,1.0,HIV infection
10224995,102249952,2,F,201403.0,20140604.0,20140609,20140617,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-20928818,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,29.5,KG,20140617.0,N,CN,US,FR,SUSTIVA,Anaemia;Gastrointestinal disorder;Hypomagnesaemia;Hypophosphataemia;Lipase increased,102249952.0,HO,,,102249952.0,2.0,,20140323.0,,,102249952.0,1.0,Antiretroviral therapy
10231152,102311521,1,I,200408.0,20140602.0,20140611,20140611,EXP,,GB-VIIV HEALTHCARE LIMITED-B1001046A,GLAXOSMITHKLINE,,37.0,YR,,F,Y,,,20140611.0,N,MD,GB,GB,EFAVIRENZ,Anaemia;Angioedema;Castleman's disease;Haemolysis;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Marrow hyperplasia;Peripheral swelling;Pruritus;Splenomegaly;Swelling face;Vascular compression,102311521.0,OT,,,102311521.0,1.0,200403.0,,,,102311521.0,1.0,HIV infection
10231181,102311812,2,F,20120227.0,20140605.0,20140611,20140611,EXP,,CI-ABBVIE-12P-278-1001911-00,ABBVIE,,34.0,YR,,F,Y,,,20140611.0,N,MD,COUNTRY NOT SPECIFIED,CI,EFAVIRENZ,Abortion spontaneous,102311812.0,OT,,,102311812.0,1.0,20110112.0,,,,102311812.0,1.0,HIV infection
10231321,102313211,1,I,,20140604.0,20140611,20140611,EXP,,IR-VIIV HEALTHCARE LIMITED-B1002660A,GLAXOSMITHKLINE,,34.0,YR,,F,Y,,,20140611.0,N,MD,IR,IR,EFAVIRENZ,Anaemia;Cytomegalovirus chorioretinitis;Leukopenia;Necrotising retinitis;Retinal haemorrhage;Retinal perivascular sheathing;Vision blurred;Vitritis,102313211.0,HO,,,,,,,,,102313211.0,1.0,HIV infection
10233706,102337062,2,F,200705.0,20140606.0,20140612,20140612,EXP,,US-GILEAD-2007-0012627,GILEAD,,31.0,YR,,F,Y,,,20140612.0,N,MD,US,US,SUSTIVA,Oligohydramnios;Pregnancy;Ultrasound antenatal screen abnormal,102337062.0,OT,,,102337062.0,1.0,20070201.0,20070201.0,,,102337062.0,1.0,HIV infection
10234314,102343142,2,F,20070704.0,20140606.0,20140612,20140612,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2007-BP-16884BP",BOEHRINGER INGELHEIM,,31.0,YR,,F,Y,,,20140613.0,N,MD,COUNTRY NOT SPECIFIED,US,SUSTIVA,Oligohydramnios;Pneumocystis jirovecii pneumonia;Stillbirth,102343142.0,OT,,,102343142.0,1.0,20070201.0,20070201.0,,,102343142.0,1.0,HIV infection
10234683,102346832,2,F,201403.0,20140731.0,20140613,20140808,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20965414,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,,,20140808.0,N,OT,US,US,SUSTIVA,Death;Glioblastoma multiforme,102346832.0,OT,,,,,,,,,102346832.0,1.0,HIV infection
10236118,102361184,4,F,20140529.0,20140714.0,20140613,20140716,EXP,,KE-GILEAD-2014-0104936,GILEAD,,33.0,YR,,F,Y,38.4,KG,20140716.0,N,MD,KE,KE,EFAVIRENZ,Acute psychosis;Cholecystitis;Encephalitis;Malnutrition;Toxoplasmosis,102361184.0,OT,,,102361184.0,1.0,20140528.0,20140603.0,,,102361184.0,1.0,HIV infection
10239897,102398971,1,I,20140607.0,20140612.0,20140616,20140616,EXP,,KE-GILEAD-2014-0105368,GILEAD,,41.0,YR,,F,Y,,,20140616.0,N,MD,KE,KE,EFAVIRENZ,Anaemia;Death;Extrapulmonary tuberculosis;Immune reconstitution inflammatory syndrome associated tuberculosis;Sepsis,102398971.0,OT,,,102398971.0,1.0,20140507.0,20140511.0,,,102398971.0,1.0,HIV infection
10242769,102427692,2,F,,20160712.0,20140617,20160715,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-20782553,BRISTOL MYERS SQUIBB,,1.0,DEC,,,Y,,,20160715.0,,CN,US,NG,EFAVIRENZ,Drug interaction,102427692.0,OT,,,,,,,,,102427692.0,1.0,HIV infection
10244196,102441961,1,I,2014.0,20140612.0,20140618,20140618,EXP,,KE-009507513-1406KEN007564,MERCK,,41.0,YR,,F,Y,,,20140703.0,N,CN,US,KE,EFAVIRENZ,Anaemia;Death;Extrapulmonary tuberculosis;Immune reconstitution inflammatory syndrome associated tuberculosis;Sepsis,102441961.0,DE,,,102441961.0,1.0,20140507.0,20140607.0,,,102441961.0,1.0,HIV infection
10247296,102472961,1,I,,20140613.0,20140619,20140619,EXP,,IN-VIIV HEALTHCARE LIMITED-B1005580A,GLAXOSMITHKLINE,,,,,M,Y,,,20140619.0,N,MD,IN,IN,EFAVIRENZ,B-cell lymphoma;Breast mass;Death;Disease progression;Gynaecomastia;Multi-organ failure;Sepsis,102472961.0,DE,,,,,,,,,102472961.0,1.0,HIV infection
10248742,102487424,4,F,20140124.0,20140804.0,20140620,20140806,EXP,,GB-009507513-1406GBR009389,MERCK,,67.0,YR,,M,Y,62.0,KG,20140806.0,N,CN,US,GB,EFAVIRENZ,Acute generalised exanthematous pustulosis;Off label use,102487424.0,OT,,,102487424.0,1.0,20140124.0,20140711.0,,,102487424.0,1.0,HIV infection
10250545,102505453,3,F,,20160714.0,20140620,20160714,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-20979142,BRISTOL MYERS SQUIBB,,36.0,YR,,M,Y,,,20160714.0,,CN,US,PT,EFAVIRENZ,Gastrointestinal disorder;Neurotoxicity;Skin disorder,102505453.0,OT,,,102505453.0,1.0,2007.0,,,,102505453.0,1.0,HIV infection
10250677,102506772,2,F,2012.0,20140702.0,20140620,20140710,EXP,,CN-VIIV HEALTHCARE LIMITED-B1005837A,GLAXOSMITHKLINE,"LU WL, SHI PR, XU GY. ONE CASE OF BONE MARROW SUPPRESSION CAUSED BY TWO YEARS OF ZIDOVUDINE ANTI-HIV THERAPY. C CHIN J AIDS STD 2013; 1 (19).",31.0,YR,,M,Y,,,20140710.0,N,MD,CN,CN,EFAVIRENZ,Anaemia;Bone marrow failure;Conjunctival pallor;Fatigue;Haemoglobin decreased;Mucosal discolouration;Neutropenia;Neutrophil count decreased;Palpitations;Red blood cell count decreased,102506772.0,HO,,,102506772.0,1.0,201004.0,20130308.0,,,102506772.0,1.0,HIV infection
10255608,102556081,1,I,,20140605.0,20140620,20140620,EXP,,AUR-APL-2014-06500,AUROBINDO,,36.0,YR,,M,N,,,20140619.0,N,OT,PT,,EFAVIRENZ (EFAVIRENZ),Basedow's disease;Blood thyroid stimulating hormone;Diabetic ketoacidosis;Eyelid retraction;Gastrointestinal disorder;Goitre;Hyperthyroidism;Immune reconstitution inflammatory syndrome;Insomnia;Irritability;Neurotoxicity;Sinus tachycardia;Skin disorder;Weight decreased,102556081.0,OT,102556081.0,HP,,,,,,,102556081.0,1.0,Acquired immunodeficiency syndrome
10256630,102566301,1,I,2014.0,20140612.0,20140624,20140624,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-21086632,BRISTOL MYERS SQUIBB,,41.0,YR,,F,Y,,,20140624.0,N,CN,US,KE,EFAVIRENZ TABS,Anaemia;Death;Extrapulmonary tuberculosis;Immune reconstitution inflammatory syndrome associated tuberculosis;Sepsis,102566301.0,DE,,,102566301.0,1.0,20140507.0,20140607.0,,,102566301.0,1.0,HIV infection
10261939,102619391,1,I,2009.0,20140613.0,20140626,20140626,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-21106489,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,65.0,KG,20140626.0,N,CN,US,BR,EFAVIRENZ TABS,Hepatitis C;Hypertension,102619391.0,OT,,,102619391.0,1.0,2005.0,,,,102619391.0,1.0,HIV infection
10268455,102684553,3,F,20140124.0,20140728.0,20140630,20140811,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-21050448,BRISTOL MYERS SQUIBB,,67.0,YR,E,M,Y,62.0,KG,20140811.0,N,OT,GB,GB,EFAVIRENZ TABS,Acute generalised exanthematous pustulosis;Off label use,102684553.0,HO,,,102684553.0,1.0,20140124.0,20140318.0,,,102684553.0,1.0,HIV infection
10268875,102688751,1,I,,20140623.0,20140630,20140630,EXP,,BR-VIIV HEALTHCARE LIMITED-B1008983A,GLAXOSMITHKLINE,,,,,NS,Y,,,20140630.0,N,MD,BR,BR,EFAVIRENZ,Lipodystrophy acquired,102688751.0,OT,,,,,,,,,102688751.0,1.0,HIV infection
10270690,102706902,2,F,20140124.0,20140728.0,20140701,20140811,EXP,,GB-009507513-1407GBR000196,MERCK,,67.0,YR,,M,Y,,,20140811.0,N,OT,GB,GB,EFAVIRENZ,Acute generalised exanthematous pustulosis;Off label use,102706902.0,OT,,,102706902.0,1.0,20140124.0,20140318.0,,,102706902.0,1.0,HIV infection
10273158,102731581,1,I,,20140619.0,20140702,20140702,EXP,,US-MYLANLABS-2014S1015084,MYLAN,"BOSSE KR, RUSSELL EA, CHIKWAVA KR, RUTSTEIN RM, LOWENTHAL E. ACUTE RENAL INJURY IN A 14-YEAR-OLD WITH HIV/AIDS AND TUBERCULOSIS. PEDIATR-INFECT-DIS-J 2013; 32(9) E380-E382",14.0,YR,T,M,Y,,,20140702.0,N,MD,US,US,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Renal failure acute,102731581.0,HO,,,,,,,,,102731581.0,1.0,Acquired immunodeficiency syndrome
10281934,102819341,1,I,20140630.0,20140701.0,20140707,20140707,EXP,,UG-009507513-1407ZAF002351,MERCK,,41.0,YR,,M,Y,37.0,KG,20140707.0,N,OT,UG,UG,EFAVIRENZ,Anaemia;Bronchopneumonia;Dehydration;Leukopenia;Renal failure acute;Thrombocytopenia,102819341.0,HO,,,102819341.0,1.0,20140422.0,20140630.0,,,102819341.0,1.0,HIV infection
10282099,102820992,2,F,20140622.0,20140710.0,20140707,20140716,EXP,,UG-VIIV HEALTHCARE LIMITED-B1011074A,GLAXOSMITHKLINE,,41.0,YR,,M,Y,,,20140716.0,N,MD,UG,UG,EFAVIRENZ,Anaemia;Death;Dehydration;Leukopenia;Pneumonia;Renal failure acute;Thrombocytopenia,102820992.0,DE,,,102820992.0,1.0,20140422.0,20140617.0,,,102820992.0,1.0,HIV infection
10284739,102847391,1,I,20140604.0,20140703.0,20140708,20140708,EXP,,UG-GILEAD-2014-0107820,GILEAD,,51.0,YR,,M,Y,,,20140708.0,N,MD,UG,UG,EFAVIRENZ,Ascites;Diarrhoea;Pancreatitis,102847391.0,HO,,,102847391.0,1.0,20140507.0,20140617.0,,,102847391.0,1.0,HIV infection
10287058,102870581,1,I,,20140619.0,20140707,20140707,EXP,,2014AP003487,APOTEX,,14.0,YR,,M,N,,,20140702.0,N,,US,,EFAVIRENZ (EFAVIRENZ),Hepatosplenomegaly;Immune reconstitution inflammatory syndrome associated tuberculosis;Nephropathy toxic;Neuropathy peripheral;Paradoxical drug reaction;Renal failure acute;Tubulointerstitial nephritis,102870581.0,OT,102870581.0,HP,,,,,,,102870581.0,1.0,Acquired immunodeficiency syndrome
10292565,102925654,4,F,2013.0,20150519.0,20140710,20150527,EXP,,CH-GILEAD-2014-0106572,GILEAD,"WAGNER N, WYLER-LAZAREVIC CA, YERLY S, SAMER C, PEYTAVIN G, POSFAY-BARBE KM, CALMY A, AMBROSIONI J. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY IN A SEVERELY OVERWEIGHT CHILD WITH A MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION. A CASE REPORT AND REVIEW. NEW MICROBES AND NEW INFECTIONS. 2015;6:1-4",11.0,YR,C,M,Y,56.5,KG,20150527.0,N,OT,CH,CH,EFAVIRENZ,Drug ineffective,102925654.0,OT,,,102925654.0,1.0,201305.0,,,,102925654.0,1.0,HIV infection
10297433,102974334,4,F,20140313.0,20140729.0,20140711,20140801,EXP,,ZW-009507513-1403USA010627,MERCK,,37.0,YR,,M,Y,,,20140801.0,N,CN,US,ZW,EFAVIRENZ,Confusional state;Meningitis cryptococcal;Meningitis tuberculous,102974334.0,HO,,,102974334.0,1.0,20140305.0,20140328.0,,,102974334.0,1.0,HIV infection
10302492,103024922,2,F,20140703.0,20140710.0,20140714,20140715,EXP,,KE-009507513-1407KEN004689,MERCK,,46.0,YR,,M,Y,37.7,KG,20140716.0,N,CN,KE,KE,EFAVIRENZ,Abdominal abscess;Death;Diarrhoea;Jaundice;Malnutrition;Meningitis;Oesophageal candidiasis;Sepsis,103024922.0,HO,,,103024922.0,1.0,20140630.0,20140709.0,,,103024922.0,1.0,HIV infection
10305785,103057851,1,I,20140607.0,20140708.0,20140715,20140715,EXP,,KE-GILEAD-2014-0108131,GILEAD,,46.0,YR,,M,Y,37.3,KG,20140714.0,N,MD,KE,KE,EFAVIRENZ,Diarrhoea;Jaundice;Malnutrition;Meningitis;Mesenteric abscess;Oesophageal candidiasis;Sepsis,103057851.0,HO,,,103057851.0,1.0,20140630.0,20140709.0,,,103057851.0,1.0,HIV infection
10305812,103058121,1,I,20140122.0,20140711.0,20140715,20140715,EXP,,MW-GILEAD-2014-0108679,GILEAD,,16.0,YR,,F,Y,,,20140714.0,N,MD,MW,MW,EFAVIRENZ,Abdominal sepsis;Disseminated tuberculosis,103058121.0,OT,,,103058121.0,1.0,20140509.0,20140528.0,,,103058121.0,1.0,HIV infection
10305912,103059122,2,F,20140625.0,20140718.0,20140715,20140724,EXP,,MW-GILEAD-2014-0107993,GILEAD,,46.0,YR,,M,Y,,,20140724.0,N,MD,MW,MW,EFAVIRENZ,Disseminated tuberculosis,103059122.0,OT,,,103059122.0,1.0,20140613.0,20140613.0,,,103059122.0,1.0,HIV infection
10306286,103062861,1,I,20140224.0,20140714.0,20140715,20140715,EXP,,MW-GILEAD-2014-0108824,GILEAD,,40.0,YR,,F,Y,,,20140717.0,N,MD,MW,MW,EFAVIRENZ,Immune reconstitution inflammatory syndrome,103062861.0,OT,,,103062861.0,1.0,20140109.0,,,,103062861.0,1.0,HIV infection
10308846,103088461,1,I,,20140708.0,20140716,20140716,EXP,,UG-GILEAD-2014-0108511,GILEAD,"KIGGUNDU R, RHEIN J, MEYA DB, BOULWARE DR, BAHR NC. UNMASKING CRYPTOCOCCAL MENINGITIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PREGNANCY INDUCED BY HIV ANTIRETROVIRAL THERAPY WITH POSTPARTUM PARADOXICAL EXACERBATION. MEDICAL MYCOLOGY CASE REPORTS. 2014;5 (1):16-19",32.0,YR,,F,Y,,,20140716.0,N,OT,UG,UG,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Pregnancy,103088461.0,OT,,,,,,,,,103088461.0,1.0,HIV infection
10311481,103114811,1,I,,20140708.0,20140717,20140717,EXP,,FR-JNJFOC-20140705079,JANSSEN,"LEPORRIER J, ETIENNE M, CHAPUZET C, PEYTAVIN G, BORD S, LEBAS FB, ET AL. ASSOCIATION OF DOLUTEGRAVIR AND RILPIVIRINE, ENHANCED BY FOSCARNET INDUCTION, IN EFFECTIVE SALVAGE ANTIRETROVIRAL THERAPY. JOURNAL OF CLINICAL VIROLOGY 2014;60(4):428-430.",23.0,YR,A,M,Y,,,20140717.0,N,OT,FR,FR,EFAVIRENZ,Decreased immune responsiveness;No therapeutic response;Treatment noncompliance,103114811.0,OT,,,,,,,,,103114811.0,1.0,HIV infection
10311591,103115911,1,I,,20140708.0,20140717,20140717,EXP,,UG-VIIV HEALTHCARE LIMITED-B1014138A,GLAXOSMITHKLINE,"  KIGGUNDU R, RHEIN J, MEYA DB, BOULWARE DR, BAHR NC. UNMASKINGCRYPTOCOCCALMENINGITISIMMUNERECONSTITUTION INFLAMMATORYSYNDROMEINPREGNANCYINDUCEDBYHIVANTIRETROVIRAL THERAPYWITHPOSTPARTUMPARADOXICALEXACERBATION. MEDICALMYCOLOGYCASEREPORTS 2014; 5: 16-19",32.0,YR,,F,Y,,,20140717.0,N,MD,UG,UG,EFAVIRENZ,Asthenia;Disorientation;Dyspnoea;Exposure during pregnancy;Headache;Hypoaesthesia;Immune reconstitution inflammatory syndrome;Live birth;Meningitis cryptococcal;Mental status changes;Musculoskeletal stiffness;Nuchal rigidity;Pyrexia;Respiratory failure;Rhonchi;Vomiting,103115911.0,DE,,,,,,,,,103115911.0,1.0,HIV infection
10311592,103115921,1,I,,20140708.0,20140717,20140717,EXP,,UG-VIIV HEALTHCARE LIMITED-B1014138B,GLAXOSMITHKLINE,,,,N,F,Y,,,20140717.0,N,MD,UG,UG,EFAVIRENZ,Foetal exposure during pregnancy;Respiratory distress,103115921.0,HO,,,,,,,,,103115921.0,1.0,HIV infection
10312565,103125653,3,F,200906.0,20150727.0,20140718,20150803,EXP,,JP-009507513-1008USA00405,MERCK,,64.0,YR,,M,Y,,,20150803.0,N,CN,US,JP,EFAVIRENZ,Diabetes mellitus;Mycobacterium avium complex infection;Pancytopenia;Tuberculosis,103125653.0,LT,,,103125653.0,1.0,20090217.0,20090624.0,,,103125653.0,1.0,HIV infection
10314343,103143431,1,I,,20140710.0,20140718,20140718,EXP,,FR-VIIV HEALTHCARE LIMITED-B1015516A,GLAXOSMITHKLINE,,23.0,YR,,M,Y,,,20140718.0,N,MD,FR,FR,EFAVIRENZ,Drug ineffective;Drug resistance;Immune system disorder;Nephropathy toxic;Opportunistic infection;Pneumonia;Pyrexia;Treatment noncompliance,103143431.0,HO,,,,,,,,,103143431.0,1.0,HIV infection
10331818,103318182,2,F,20140505.0,20140819.0,20140722,20140820,EXP,,VN-GILEAD-2014-0108954,GILEAD,,40.0,YR,A,M,Y,,,20140820.0,N,MD,VN,VN,EFAVIRENZ,Central nervous system infection,103318182.0,OT,,,103318182.0,1.0,20131226.0,,,,103318182.0,1.0,HIV infection
10331894,103318941,1,I,20140710.0,20140714.0,20140722,20140722,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-21212568,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,43.0,KG,20140718.0,N,CN,US,IN,EFAVIRENZ,Leukopenia;Neutropenia,103318941.0,OT,,,103318941.0,1.0,20120217.0,20140710.0,,,103318941.0,1.0,HIV infection
10331937,103319372,2,F,201202.0,20140715.0,20140722,20140722,EXP,,FR-ABBVIE-13P-056-1086790-00,ABBVIE,,51.0,YR,,M,Y,,,20140722.0,N,MD,FR,FR,SUSTIVA,Axonal neuropathy;Hypokinesia;Muscular weakness;Pain;Spinal muscular atrophy,103319372.0,DS,,,103319372.0,1.0,2005.0,20111102.0,,,103319372.0,1.0,HIV infection
10332141,103321412,2,F,20140703.0,20140710.0,20140722,20140724,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-21212535,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,37.7,KG,20140724.0,N,CN,GB,KE,EFAVIRENZ,Death;Diarrhoea;Immune reconstitution inflammatory syndrome;Jaundice;Malnutrition;Meningitis;Oesophageal candidiasis,103321412.0,DE,,,103321412.0,1.0,20140630.0,20140709.0,,,103321412.0,1.0,Antiretroviral therapy
10332211,103322113,3,F,20140313.0,20140729.0,20140722,20140806,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-20567020,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,,,20140806.0,N,CN,US,ZW,EFAVIRENZ TABS,Extrapulmonary tuberculosis;Meningitis cryptococcal,103322113.0,HO,,,103322113.0,1.0,20140305.0,20140306.0,,,103322113.0,1.0,HIV infection
10337771,103377712,2,F,20131014.0,20150311.0,20140724,20150313,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-21075809,BRISTOL MYERS SQUIBB,,,,I,F,Y,,,20150313.0,N,CN,US,CI,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,103377712.0,OT,,,,,,,,,103377712.0,1.0,Antiretroviral therapy
10355569,103555692,2,F,20140124.0,20140728.0,20140731,20140731,EXP,,GB-GILEAD-2014-0105746,GILEAD,,67.0,YR,,M,Y,62.0,KG,20140731.0,N,CN,GB,GB,EFAVIRENZ,Acute generalised exanthematous pustulosis;Off label use,103555692.0,OT,,,103555692.0,1.0,20140124.0,20140318.0,,,103555692.0,1.0,HIV infection
10360655,103606551,1,I,,20140726.0,20140804,20140804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-21250568,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20140804.0,N,MD,DE,DE,SUSTIVA,Cerebrovascular accident,103606551.0,OT,,,,,,,,,103606551.0,1.0,HIV infection
10360676,103606761,1,I,20140713.0,20140722.0,20140804,20140804,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-21253224,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,,,20140805.0,N,CN,GB,MW,EFAVIRENZ,Anaemia;Sepsis,103606761.0,HO,,,103606761.0,1.0,20140710.0,,,,103606761.0,1.0,HIV infection
10363037,103630372,2,F,,20141015.0,20140805,20141020,EXP,,ZA-GILEAD-2014-0110661,GILEAD,"MOODLEY A, BHOLA S, OMAR F, MOGAMBERY J. FIRST REPORT OF LEBER^S HEREDITARY OPTIC NEUROPATHY: 2 CASE REPORTS. REACTIONS 1522. 2014;UNK:106-11",,,,,Y,,,20141218.0,N,,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Hereditary optic atrophy,103630372.0,OT,,,,,,,,,103630372.0,1.0,HIV infection
10363144,103631442,2,F,,20141015.0,20140805,20141021,EXP,,ZA-GILEAD-2014-0110663,GILEAD,"MOODLEY A, BHOLA S, OMAR F, MOGAMBERY J. FIRST REPORT OF LEBER^S HEREDITARY OPTIC NEUROPATHY: 2 CASE REPORTS. REACTIONS 1522. 2014;UNK:106-11",,,,,Y,,,20141217.0,N,,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Hereditary optic atrophy,103631442.0,OT,,,,,,,,,103631442.0,1.0,HIV infection
10363160,103631602,2,F,20130902.0,20140729.0,20140805,20140805,EXP,,UG-009507513-1309UGA007734,MERCK,,23.0,YR,,F,Y,,,20140805.0,N,MD,UG,UG,EFAVIRENZ,Lymph node tuberculosis;Neuropathy peripheral;Pulmonary tuberculosis,103631602.0,LT,,,103631602.0,1.0,20130815.0,,,,103631602.0,1.0,HIV infection
10363299,103632992,2,F,20090515.0,20140909.0,20140805,20140918,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-21250303,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20140918.0,N,CN,FR,FR,SUSTIVA,Hepatitis fulminant,103632992.0,LT,,,103632992.0,1.0,20090503.0,20090516.0,,,103632992.0,1.0,HIV infection
10363476,103634762,2,F,20131112.0,20140922.0,20140805,20140922,EXP,,CN-VIIV HEALTHCARE LIMITED-B1020155A,GLAXOSMITHKLINE,,76.0,YR,,M,Y,51.0,KG,20140922.0,N,OT,CN,CN,EFAVIRENZ,Renal impairment,103634762.0,OT,,,103634762.0,1.0,20131104.0,20131126.0,,,103634762.0,1.0,HIV infection
10366013,103660133,3,F,20140516.0,20140814.0,20140806,20140820,EXP,,MW-VIIV HEALTHCARE LIMITED-A1084018A,GLAXOSMITHKLINE,,0.0,DY,,M,Y,1.7,KG,20140820.0,N,OT,MW,MW,EFAVIRENZ,Accessory auricle;Foetal exposure during pregnancy;Premature baby,103660133.0,CA,,,103660133.0,1.0,20110608.0,20140410.0,,,103660133.0,1.0,HIV infection
10366053,103660531,1,I,,20140729.0,20140806,20140806,EXP,,ZA-VIIV HEALTHCARE LIMITED-B1020951A,GLAXOSMITHKLINE,"MOODLEY A, BHOLA S, OMAR F, MOGAMBERY J. ANTIRETROVIRAL THERAPY-INDUCED LEBER^S HEREDITARY OPTIC NEUROPATHY. SOUTH AFRICAN JOURNAL OF HIV MEDICINE. 2014; 15(2).",31.0,YR,,M,Y,,,20140806.0,N,MD,ZA,ZA,EFAVIRENZ,Blindness;Optic atrophy;Optic neuropathy,103660531.0,OT,,,,,,,,,103660531.0,1.0,HIV infection
10366054,103660541,1,I,,20140729.0,20140806,20140806,EXP,,ZA-VIIV HEALTHCARE LIMITED-B1020960A,GLAXOSMITHKLINE,"MOODLEY A, BHOLA S, OMAR F, MOGAMBERY J. ANTIRETROVIRAL THERAPY-INDUCED LEBER^S HEREDITARY OPTIC NEUROPATHY. SOUTH AFRICAN JOURNAL OF HIV MEDICINE. 2014; 15(2).",33.0,YR,,M,Y,,,20140806.0,N,MD,ZA,ZA,EFAVIRENZ,Blindness;Optic atrophy;Optic neuropathy;Visual field defect,103660541.0,OT,,,,,,,,,103660541.0,1.0,HIV infection
10371796,103717962,2,F,20140617.0,20140731.0,20140808,20140808,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-21228531,BRISTOL MYERS SQUIBB,,47.0,YR,,M,Y,,,20140808.0,N,CN,KE,KE,EFAVIRENZ,Confusional state;Meningitis tuberculous,103717962.0,DE,,,103717962.0,1.0,20140528.0,20140719.0,,,103717962.0,1.0,Antiretroviral therapy
10376544,103765442,2,F,20140729.0,20141029.0,20140811,20141104,EXP,,ZW-GILEAD-2014-0111207,GILEAD,,48.0,YR,A,F,Y,43.1,KG,20141104.0,N,MD,ZW,ZW,EFAVIRENZ,Anaemia;Renal failure,103765442.0,DE,,,103765442.0,1.0,20131120.0,20140729.0,,,103765442.0,1.0,HIV infection
10377280,103772806,6,F,20060512.0,20170408.0,20140812,20170413,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14021034,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,,,20170413.0,,MD,JP,JP,EFAVIRENZ,Blood glucose increased;Hypercholesterolaemia;Nephrolithiasis,103772806.0,OT,,,103772806.0,1.0,20060125.0,20120523.0,,,103772806.0,1.0,HIV infection
10379836,103798362,2,F,201010.0,20140903.0,20140812,20140909,EXP,,US-GILEAD-2014-0111462,GILEAD,"LINDSEY S, WEISS J, LEE E, ROMANELLI P. TREATMENT OF SEVERE PSORIASIS AND PSORIATIC ARTHRITIS WITH ADALIMUMAB IN AN HIV-POSITIVE PATIENT.. JOURNAL OF DRUGS IN DERMATOLOGY. 2014;13:869-871",49.0,YR,A,M,Y,,,20140909.0,N,MD,US,US,EFAVIRENZ,Drug ineffective;Drug resistance;Psoriasis;Psoriatic arthropathy,103798362.0,OT,,,103798362.0,1.0,201005.0,201010.0,,,103798362.0,1.0,HIV infection
10381275,103812751,1,I,20131124.0,20140806.0,20140813,20140813,EXP,GB-MHRA-EYC 00113380,GB-GILEAD-2014-0111362,GILEAD,,52.0,YR,A,M,Y,67.0,KG,20140813.0,N,MD,GB,GB,EFAVIRENZ,Coagulopathy,103812751.0,OT,,,103812751.0,1.0,20130101.0,20140624.0,,,103812751.0,1.0,HIV antibody positive
10383993,103839931,1,I,,20140731.0,20140814,20140814,EXP,,KR-MYLAN-2014M1001254,MYLAN,"KIM H-S, SHIN H-S. ALOPECIA AREATA ASSOCIATED WITH ABACAVIR THERAPY. INFECT-CHEMOTHERAP 2014; 46(2) 103-105",,,,,Y,,,20140814.0,N,OT,KR,KR,EFAVIRENZ,Abdominal distension;Alopecia areata;Diarrhoea,103839931.0,OT,,,,,,,,,103839931.0,1.0,HIV infection
10391504,103915041,1,I,20140717.0,20140815.0,20140818,20140818,EXP,,UG-GILEAD-2014-0112277,GILEAD,,25.0,YR,A,F,Y,,,20140910.0,N,MD,UG,UG,EFAVIRENZ,Cachexia;Dehydration;Diarrhoea;Oral candidiasis;Pulmonary tuberculosis,103915041.0,OT,,,103915041.0,1.0,20140630.0,20140729.0,,,103915041.0,1.0,HIV infection
10392976,103929761,1,I,,20140804.0,20140815,20140815,EXP,,2014AU01132,CIPLA,,,,,,N,,,20140814.0,N,,AU,,EFAVIRENZ (EFAVIRENZ),Central nervous system lymphoma,103929761.0,DE,103929761.0,HP,,,,,,,103929761.0,1.0,HIV infection
10392993,103929931,1,I,,20140804.0,20140815,20140815,EXP,,2014AU01133,CIPLA,,,,,,N,,,20140814.0,N,,AU,,EFAVIRENZ,Septic shock,103929931.0,DE,103929931.0,FGN,,,,,,,103929931.0,1.0,HIV infection
10393009,103930091,1,I,,20140804.0,20140815,20140815,EXP,,2014AU01135,CIPLA,,,,,,N,,,20140814.0,N,,AU,,EFAVIRENZ,Completed suicide;Poisoning deliberate,103930091.0,DE,103930091.0,HP,,,,,,,103930091.0,1.0,HIV infection
10393062,103930621,1,I,,20140804.0,20140815,20140815,EXP,,2014AU01130,CIPLA,,,,,,N,,,20140814.0,N,,AU,,EFAVIRENZ,Non-Hodgkin's lymphoma,103930621.0,DE,103930621.0,LIT,,,,,,,103930621.0,1.0,HIV infection
10393082,103930821,1,I,,20140804.0,20140815,20140815,EXP,,2014AU01134,CIPLA,,,,,,N,,,20140814.0,N,,AU,,EFAVIRENZ,Acinetobacter infection;Pneumonia,103930821.0,DE,103930821.0,FGN,,,,,,,103930821.0,1.0,HIV infection
10393119,103931191,1,I,,20140804.0,20140815,20140815,EXP,,2014FR01118,CIPLA,,,,,,N,,,20140814.0,N,,FR,,EFAVIRENZ,Gout,103931191.0,OT,103931191.0,FGN,,,,,,,103931191.0,1.0,HIV infection
10393670,103936701,1,I,,20140804.0,20140815,20140815,EXP,,2014FR01120,CIPLA,,,,,,N,,,20140814.0,N,OT,FR,,EFAVIRENZ,Osteoporosis,103936701.0,OT,103936701.0,HP,,,,,,,103936701.0,1.0,HIV infection
10393805,103938051,1,I,,20140804.0,20140815,20140815,EXP,,2014AU01129,CIPLA,,,,,F,N,,,20140814.0,N,,AU,,EFAVIRENZ (EFAVIRENZ),Abortion spontaneous;Maternal exposure during pregnancy,103938051.0,OT,103938051.0,HP,,,,,,,103938051.0,1.0,HIV infection
10396729,103967291,1,I,,20140811.0,20140820,20140820,EXP,,FR-VIIV HEALTHCARE LIMITED-B1022655A,GLAXOSMITHKLINE,,,,,F,Y,,,20140820.0,N,MD,FR,FR,SUSTIVA,Macrocytosis,103967291.0,OT,,,103967291.0,1.0,20001017.0,20080416.0,,,103967291.0,1.0,HIV infection
10398025,103980251,1,I,,20140804.0,20140818,20140818,EXP,,2014AU01127,CIPLA,,,,,F,N,,,20140814.0,N,,AU,,EFAVIRENZ,Abortion induced;Exposure during pregnancy,103980251.0,OT,103980251.0,FGN,,,,,,,103980251.0,1.0,HIV infection
10399711,103997113,3,F,20140710.0,20151209.0,20140821,20151217,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21316401,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20151217.0,,CN,BW,BW,EFAVIRENZ,Live birth;Maternal exposure during pregnancy;Vaginal discharge,103997113.0,OT,,,103997113.0,1.0,20110822.0,20140204.0,,,103997113.0,1.0,HIV infection
10399937,103999372,2,F,20140718.0,20140821.0,20140821,20140822,EXP,,UG-VIIV HEALTHCARE LIMITED-B1025498A,GLAXOSMITHKLINE,,43.0,YR,,F,Y,,,20140822.0,N,MD,UG,UG,EFAVIRENZ,Cardiac failure congestive,103999372.0,DE,,,103999372.0,1.0,20140612.0,20140808.0,,,103999372.0,1.0,HIV infection
10400731,104007311,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112123,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE,TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104007311.0,OT,,,,,,,,,104007311.0,1.0,HIV infection
10400904,104009041,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112122,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009041.0,OT,,,,,,,,,104009041.0,1.0,HIV infection
10400909,104009091,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112291,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009091.0,OT,,,,,,,,,104009091.0,1.0,HIV infection
10400916,104009161,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112292,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009161.0,OT,,,,,,,,,104009161.0,1.0,HIV infection
10400925,104009251,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112293,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009251.0,OT,,,,,,,,,104009251.0,1.0,HIV infection
10400927,104009271,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112294,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009271.0,OT,,,,,,,,,104009271.0,1.0,HIV infection
10400929,104009291,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112295,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009291.0,OT,,,,,,,,,104009291.0,1.0,HIV infection
10400940,104009401,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112434,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE,TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009401.0,OT,,,,,,,,,104009401.0,1.0,HIV infection
10400942,104009421,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112435,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE,TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009421.0,OT,,,,,,,,,104009421.0,1.0,HIV infection
10400946,104009461,1,I,,20140813.0,20140821,20140821,EXP,,ES-GILEAD-2014-0112436,GILEAD,"BARRIOS A, NEGREDO E, DOMINGO P, ESTRADA V, LABARGA P, ASENSI V, MORALES D, SANTOS J, CLOTET B AND SORIANO V.. SIMPLIFICATION THERAPY WITH ONCE-DAILY DIDANOSINE,TENOFOVIR AND EFAVIRENZ IN HIV-1-INFECTED ADULTS WITH VIRAL SUPPRESSION RECEIVING A MORE COMPLEX ANTIRETROVIRAL REGIMEN: FINAL RESULTS OF THE EFADITE TRIAL. ANTIVIRAL THERAPY. 2005;10 (7):825-32",,,A,,Y,,,20140821.0,N,OT,ES,ES,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,104009461.0,OT,,,,,,,,,104009461.0,1.0,HIV infection
10409897,104098972,2,F,20140721.0,20141023.0,20140826,20141030,EXP,,BW-GILEAD-2014-0112399,GILEAD,,0.0,DY,,M,Y,,,20141030.0,N,MD,BW,BW,EFAVIRENZ,Acute respiratory distress syndrome;Premature baby,104098972.0,OT,,,104098972.0,1.0,20140204.0,20140721.0,,,104098972.0,1.0,HIV infection
10410494,104104941,1,I,,20140818.0,20140826,20140826,EXP,,UZ-VIIV HEALTHCARE LIMITED-B1027202A,GLAXOSMITHKLINE,,,,,M,Y,,,20140826.0,N,CN,UZ,UZ,EFAVIRENZ,Diarrhoea;Poisoning,104104941.0,HO,,,,,,,,,104104941.0,1.0,HIV infection
10411030,104110303,3,F,20140703.0,20140912.0,20140826,20140918,EXP,,HT-GILEAD-2014-0108018,GILEAD,,33.0,YR,A,M,Y,,,20140918.0,N,MD,HT,HT,EFAVIRENZ,Anaemia;Renal failure acute;Respiratory tract infection;Sepsis syndrome,104110303.0,LT,,,104110303.0,1.0,20130905.0,20140702.0,,,104110303.0,1.0,HIV infection
10415707,104157071,1,I,,20140819.0,20140828,20140828,EXP,,US-CIPLA LTD.-2014ZM01166,CIPLA,"K. CHERRY LIU, MANSOUR FARAHANI, TSHILILO MASHAMBA, MUTHUHADINI MAWELA, JESSICA JOSEPH, NIENKE VAN SCHAIK, ENGELA HONEY, MICHELLE GILL, WAASILA JASSAT, ELIZABETH M. STRINGER, NAMIWNGA CHINTU AND RICHA. PREGNANCY OUTCOMES AND BIRTH DEFECTS FROM AN ANTIRETROVIRAL DRUG SAFETY STUDY OF WOMEN IN SOUTH AFRICA AND ZAMBIA. AIDS. 2014;28",,,,,Y,,,20140828.0,N,OT,US,ZM,Efavirenz,Foetal exposure during pregnancy;Stillbirth,104157071.0,OT,,,,,,,,,104157071.0,1.0,HIV infection
10415973,104159731,1,I,,20140819.0,20140828,20140828,EXP,,US-CIPLA LTD.-2014ZA01169,CIPLA,"K. CHERRY LIU, MANSOUR FARAHANI, TSHILILO MASHAMBA, MUTHUHADINI MAWELA, JESSICA JOSEPH, NIENKE VAN SCHAIK, ENGELA HONEY, MICHELLE GILL, WAASILA JASSAT, ELIZABETH M. STRINGER, NAMIWNGA CHINTU AND RICHA. PREGNANCY OUTCOMES AND BIRTH DEFECTS FROM AN ANTIRETROVIRAL DRUG SAFETY STUDY OF WOMEN IN SOUTH AFRICA AND ZAMBIA. AIDS. 2014",,,N,,Y,,,20140828.0,N,OT,US,ZA,Efavirenz,Neonatal disorder,104159731.0,DE,,,,,,,,,104159731.0,6.0,HIV infection
10416236,104162362,2,F,,20130724.0,20140828,20150722,PER,,US-GILEAD-2013-0080143,GILEAD,,,,,M,Y,,,20150722.0,N,CN,US,US,SUSTIVA,Depression;Emotional distress;Gynaecomastia,,,,,104162362.0,1.0,2006.0,2006.0,,,104162362.0,1.0,HIV infection
10417473,104174731,1,I,,20140818.0,20140829,20140829,EXP,,US-CIPLA LTD.-2014ZA01188,CIPLA,"K LIU, MANSOUR FARAHANI, TSHILILO MASHAMBA, MUTHUHADINI MAWELA, JESSICA JOSEPH, NIENKE SCHAIK, ENGELA HONEY, MICHELLE GILL, WAASILA JASSAT, ELIZABETH STRINGER, NAMIWNGA CHINTU, RICHARD MARLINK. PREGNANCY OUTCOMES AND BIRTH DEFECTS FROM AN ANTIRETROVIRAL DRUG SAFETY STUDY OF WOMEN IN SOUTH AFRICA AND ZAMBIA. AIDS. 2014",,,,,Y,,,20140829.0,N,OT,US,ZA,Efavirenz,Haemorrhage in pregnancy,104174731.0,OT,,,,,,,,,104174731.0,1.0,HIV infection
10417541,104175411,1,I,,20140818.0,20140829,20140829,EXP,,US-CIPLA LTD.-2014ZA01189,CIPLA,"K LIU, MANSOUR FARAHANI, TSHILILO MASHAMBA, MUTHUHADINI MAWELA, JESSICA JOSEPH, NIENKE SCHAIK, ENGELA HONEY, MICHELLE GILL, WAASILA JASSAT, ELIZABETH STRINGER, NAMIWNGA CHINTU, RICHARD MARLINK. PREGNANCY OUTCOMES AND BIRTH DEFECTS FROM AN ANTIRETROVIRAL DRUG SAFETY STUDY OF WOMEN IN SOUTH AFRICA AND ZAMBIA. AIDS. 2014",,,,,Y,,,20140829.0,N,OT,US,ZA,Efavirenz,Foetal malpresentation,104175411.0,OT,,,,,,,,,104175411.0,1.0,HIV infection
10417544,104175441,1,I,,20140818.0,20140829,20140829,EXP,,US-CIPLA LTD.-2014ZA01191,CIPLA,"K LIU, MANSOUR FARAHANI, TSHILILO MASHAMBA, MUTHUHADINI MAWELA, JESSICA JOSEPH, NIENKE SCHAIK, ENGELA HONEY, MICHELLE GILL, WAASILA JASSAT, ELIZABETH STRINGER, NAMIWNGA CHINTU, RICHARD MARLINK. PREGNANCY OUTCOMES AND BIRTH DEFECTS FROM AN ANTIRETROVIRAL DRUG SAFETY STUDY OF WOMEN IN SOUTH AFRICA AND ZAMBIA. AIDS. 2014",,,,,Y,,,20140829.0,N,OT,US,ZA,Efavirenz,Placenta praevia,104175441.0,OT,,,,,,,,,104175441.0,1.0,HIV infection
10417589,104175892,2,F,,20230530.0,20140829,20230614,EXP,,US-CIPLA LTD.-2014ZA01186,CIPLA,"LiuKC,FarahaniM,MashambaT,MawelaM,JosephJ,SchaikNV,HoneyE,GillM,JassatW,StringerEM,ChintuN,MarlinkRG. Pregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia. AIDS. 2014;28",,,,,Y,,,20230614.0,,HP,US,ZA,EFAVIRENZ,Blepharophimosis;Eyelid ptosis,104175892.0,CA,,,,,,,,,104175892.0,1.0,Antiretroviral therapy
10418598,104185981,1,I,,20140812.0,20140827,20140827,EXP,,2014HINLIT0729,HETERO,,29.0,YR,,F,N,,,20140825.0,N,MD,JP,,EFAVIRENZ,Microcytic anaemia;Pancytopenia,104185981.0,HO,104185981.0,HP,,,,,,,104185981.0,1.0,HIV infection
10419711,104197111,1,I,2014.0,20140815.0,20140829,20140829,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-21316997,BRISTOL MYERS SQUIBB,,25.0,YR,,F,Y,,,20140829.0,N,CN,KE,KE,EFAVIRENZ,Cachexia;Dehydration;Diarrhoea;Meningitis;Oral candidiasis;Pulmonary tuberculosis;Sepsis;Thrombocytopenia,104197111.0,DE,,,104197111.0,1.0,20140630.0,20140729.0,,,104197111.0,1.0,HIV infection
10421024,104210241,1,I,,20140819.0,20140828,20140828,EXP,,2014ZA01167,CIPLA,,,,,F,N,,,20140826.0,N,,ZA,,EFAVIRENZ,Ectopic pregnancy;Exposure during pregnancy,104210241.0,OT,104210241.0,FGN,,,,,,,104210241.0,1.0,HIV infection
10424377,104243772,2,F,20060524.0,20160628.0,20140902,20160630,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-21335153,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,,,20160630.0,,CN,US,JP,EFAVIRENZ,Hypercholesterolaemia;Hyperglycaemia;Nephrolithiasis,104243772.0,HO,,,104243772.0,1.0,20060125.0,20120523.0,,,104243772.0,1.0,HIV infection
10427314,104273141,1,I,,20140826.0,20140903,20140903,EXP,,PHHY2014US106841,SANDOZ,"CIRCO S, DILLARD T, DAVIS W. ENDOBRONCHIAL MASS DUE TO MAC INFECTION DESPITE MACROLIDE PROPHYLAXIS. CHEST. 2013;144(4):1-2",38.0,YR,,F,Y,,,20140903.0,N,OT,US,US,EFAVIRENZ,Cough;Dyspnoea;Excessive granulation tissue;Haemoptysis;Immune reconstitution inflammatory syndrome;Lung infiltration;Mycobacterium avium complex infection;Tracheal mass,104273141.0,OT,,,,,,,,,104273141.0,1.0,HIV infection
10428439,104284392,2,F,20140417.0,20140904.0,20140903,20140908,EXP,,HR-VIIV HEALTHCARE LIMITED-B1029242A,GLAXOSMITHKLINE,,42.0,YR,,M,Y,,,20140908.0,N,OT,HR,HR,EFAVIRENZ,Myocardial infarction,104284392.0,HO,,,104284392.0,1.0,20091116.0,20140427.0,,,104284392.0,1.0,HIV infection
10428443,104284431,1,I,,20140826.0,20140903,20140903,EXP,,ZA-VIIV HEALTHCARE LIMITED-B1029321A,GLAXOSMITHKLINE,"MAZANDERANI AF, PLESSIS NM, THOMAS WN, VENTER E, AVENANT T. LOSS OF DETECTABILITY AND INDETERMINATE RESULTS: CHALLENGES FACING HIV INFANT DIAGNOSIS IN SOUTH AFRICA^S EXPANDING ART PROGRAMME. SAMJ. 2014; 104 (8): 574-577.",,,I,,Y,,,20140903.0,N,MD,ZA,ZA,EFAVIRENZ,Empyema;Exposure during breast feeding;Foetal exposure during pregnancy;HIV infection;Lower respiratory tract infection,104284431.0,OT,,,,,,,,,104284431.0,1.0,HIV infection
10434353,104343532,2,F,20140823.0,20140917.0,20140905,20140924,EXP,,MW-009507513-1409MWI002261,MERCK,,49.0,YR,,M,Y,,,20140924.0,N,CN,US,MW,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Lower respiratory tract infection,104343532.0,DE,,,104343532.0,1.0,20140714.0,20140823.0,,,104343532.0,1.0,HIV infection
10434549,104345492,2,F,20140823.0,20140904.0,20140905,20140909,EXP,,MW-GILEAD-2014-0114119,GILEAD,,26.0,YR,A,F,Y,,,20140909.0,N,MD,MW,MW,EFAVIRENZ,Meningitis cryptococcal,104345492.0,OT,,,104345492.0,1.0,20140821.0,20140829.0,,,104345492.0,1.0,HIV infection
10444858,104448586,6,F,20140903.0,20150109.0,20140910,20150119,EXP,,KE-GILEAD-2014-0114649,GILEAD,,38.0,YR,A,M,Y,,,20150119.0,N,MD,KE,KE,EFAVIRENZ,Anaemia;Aplasia pure red cell;Tuberculosis,104448586.0,HO,,,104448586.0,1.0,20140819.0,20140819.0,,,104448586.0,1.0,HIV infection
10445017,104450171,1,I,,20140901.0,20140910,20140910,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-21372230,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20140910.0,N,CN,US,DE,SUSTIVA,Anal cancer,104450171.0,OT,,,,,,,,,104450171.0,1.0,HIV infection
10446690,104466902,2,F,,20140911.0,20140911,20140919,EXP,,ZA-AUROBINDO-AUR-APL-2014-09342,AUROBINDO,"DU TOIT SH, ET AL. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. REACTIONS WEEKLY. 2014;1516:83",40.0,YR,,M,Y,,,20140919.0,N,OT,ZA,ZA,Efavirenz,Conjunctival hyperaemia;Corneal lesion;Eye pain;Immune reconstitution inflammatory syndrome;Ulcerative keratitis,104466902.0,OT,,,,,,,,,104466902.0,1.0,HIV infection
10449138,104491382,2,F,20140818.0,20140905.0,20140912,20140919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-21366067,BRISTOL MYERS SQUIBB,,34.0,YR,,M,Y,51.8,KG,20140919.0,N,CN,ZA,ZA,EFAVIRENZ,Headache,104491382.0,HO,,,104491382.0,1.0,20131118.0,,,,104491382.0,1.0,HIV infection
10453226,104532261,1,I,20140823.0,20140902.0,20140915,20140915,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-21366125,BRISTOL MYERS SQUIBB,,49.0,YR,,M,Y,,,20140915.0,N,CN,US,MW,EFAVIRENZ,Asthenia;Chills;Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lower respiratory tract infection;Pneumonia;Pyrexia,104532261.0,OT,,,104532261.0,1.0,20140714.0,20140823.0,,,104532261.0,1.0,HIV infection
10457080,104570801,1,I,,20140902.0,20140912,20140912,EXP,,2014HINLIT0797,HETERO,,,,,F,N,,,20140911.0,N,MD,TH,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Drug interaction;Ergot poisoning,104570801.0,LT,104570801.0,LIT,,,,,,,104570801.0,1.0,HIV infection
10457106,104571063,3,F,20130803.0,20141024.0,20140916,20141030,EXP,,US-GILEAD-2014-0114765,GILEAD,,42.0,YR,A,F,Y,52.0,KG,20141030.0,N,MD,UG,UG,EFAVIRENZ,Ascites;Cirrhosis alcoholic;Decreased appetite;Diarrhoea;Glomerulonephritis;Vomiting,104571063.0,OT,,,104571063.0,1.0,20131211.0,20140811.0,,,104571063.0,1.0,HIV infection
10457144,104571442,2,F,20140823.0,20140911.0,20140916,20140922,EXP,,BW-GILEAD-2014-0114939,GILEAD,,31.0,YR,A,F,Y,,,20140922.0,N,MD,BW,BW,EFAVIRENZ,Abortion spontaneous,104571442.0,OT,,,104571442.0,1.0,20110624.0,20140806.0,,,104571442.0,1.0,HIV infection
10457283,104572831,1,I,20140630.0,20140909.0,20140916,20140916,EXP,,MW-GILEAD-2014-0114855,GILEAD,,36.0,YR,A,M,Y,48.7,KG,20140916.0,N,MD,MW,MW,EFAVIRENZ,Jaundice,104572831.0,OT,,,104572831.0,1.0,20140616.0,20140630.0,,,104572831.0,1.0,HIV infection
10457439,104574392,2,F,,20160713.0,20140916,20160715,EXP,,CM-BRISTOL-MYERS SQUIBB COMPANY-21389077,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,,,20160715.0,,OT,AU,CM,EFAVIRENZ,Paradoxical drug reaction,104574392.0,HO,,,104574392.0,1.0,20130119.0,,,,104574392.0,1.0,HIV infection
10458852,104588521,1,I,,20140904.0,20140917,20140917,EXP,,CM-MYLANLABS-2014M1004564,MYLAN,"WANDA F, NKEMENANG P, EHOUNOU G, TCHATON M, COMTE E, TOUTOUS TRELLU L, ET AL. CLINICAL FEATURES AND MANAGEMENT OF A SEVERE PARADOXICAL REACTION ASSOCIATED WITH COMBINED TREATMENT OF BURULI ULCER AND HIV CO-INFECTION. BMC-INFECT-DIS 2014;",,,,,Y,,,20140917.0,N,OT,CM,CM,EFAVIRENZ,Hypersensitivity;Oedema peripheral;Paradoxical drug reaction;Pyrexia;Rash pruritic;Rash pustular;Skin graft;Skin necrosis;Wound necrosis,104588521.0,HO,104588521.0,HP,104588521.0,1.0,20130119.0,,,,104588521.0,1.0,HIV infection
10459347,104593471,1,I,,20140909.0,20140917,20140917,EXP,,TH-GILEAD-2014-0115442,GILEAD,"PORNPRASERT S, WONGNOI R, OBERDORFER P, SIRIVATANAPA P. PREVENTIVE ANTIRETROVIRAL THERAPY IN NON-THALASSEMIA CARRIER INFANTS EXPOSED TO MOTHER-TO-CHILD TRANSMISSION OF HIV DECREASES CORD AND AFTER DELIVERY RED BLOOD PRODUCTION WITHOUT ALTERING THE DEVELOPMENT OF HEMOGLOBIN.. CURRENT HIV RESEARCH. 2014;12(3):227-231",,,I,,Y,,,20140917.0,N,OT,TH,TH,EFAVIRENZ,Anaemia,104593471.0,OT,,,,,,,,,104593471.0,1.0,HIV infection
10459838,104598382,2,F,20140901.0,20141024.0,20140917,20141103,EXP,,MW-GILEAD-2014-0115094,GILEAD,,30.0,YR,A,F,Y,,,20141103.0,N,MD,MW,MW,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,104598382.0,HO,,,104598382.0,1.0,20140812.0,20140909.0,,,104598382.0,1.0,HIV infection
10460363,104603631,1,I,20140612.0,20140908.0,20140917,20140917,EXP,,CI-GILEAD-2014-0114750,GILEAD,,36.0,YR,A,F,Y,54.0,KG,20140917.0,N,MD,CI,CI,EFAVIRENZ,Hypercreatinaemia,104603631.0,OT,,,104603631.0,1.0,201407.0,20131202.0,,,104603631.0,1.0,HIV infection
10465485,104654851,1,I,20140911.0,20140915.0,20140919,20140919,EXP,,KE-GILEAD-2014-0115417,GILEAD,,36.0,YR,A,M,Y,,,20140919.0,N,MD,KE,KE,EFAVIRENZ,Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Bedridden;Blood bilirubin increased;Blood sodium decreased;Body temperature decreased;Cachexia;Dehydration;Diet refusal;Dyspnoea;General physical health deterioration;Hypoglycaemia;Hypovolaemic shock;Malnutrition;Oedema;Oesophageal candidiasis;Oral candidiasis;Pallor;Peripheral coldness;Pulmonary tuberculosis;Renal failure;Renal failure acute,104654851.0,HO,,,104654851.0,1.0,20140819.0,20140910.0,,,104654851.0,1.0,HIV infection
10467125,104671251,1,I,20140825.0,20140916.0,20140922,20140922,EXP,,BW-GILEAD-2014-0115655,GILEAD,,32.0,YR,A,F,Y,,,20140922.0,N,OT,BW,BW,EFAVIRENZ,Abortion spontaneous,104671251.0,OT,,,104671251.0,1.0,20110609.0,20140806.0,,,104671251.0,1.0,HIV infection
10467426,104674262,2,F,20140721.0,20150309.0,20140922,20150323,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-21389200,BRISTOL MYERS SQUIBB,,35.0,YR,,M,Y,,,20150323.0,N,CN,US,MW,EFAVIRENZ,Pleural effusion;Pneumonia,104674262.0,HO,,,104674262.0,1.0,20140717.0,20141009.0,,,104674262.0,1.0,HIV infection
10467464,104674643,3,F,20140825.0,20150610.0,20140922,20150813,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21415971,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20150813.0,N,CN,US,BW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,104674643.0,OT,,,104674643.0,1.0,20110609.0,20140806.0,,,104674643.0,1.0,Antiretroviral therapy
10468955,104689552,2,F,20090515.0,20140909.0,20140923,20140923,EXP,,FR-MERCK-1408FRA002993,MERCK,,37.0,YR,,F,Y,,,20140923.0,N,MD,FR,FR,SUSTIVA,Hepatitis fulminant,104689552.0,LT,,,104689552.0,1.0,20090503.0,20090516.0,,,104689552.0,1.0,HIV infection
10470790,104707901,1,I,,20140915.0,20140923,20140923,EXP,,IN-VIIV HEALTHCARE LIMITED-B1035121A,GLAXOSMITHKLINE,"KRISHNARAJ R, ET AL. RECURRENT IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OF TUBERCULOUS BRAIN INFECTION IN PEOPLE LIVING WITH HIV/AIDS: A CASE REPORT. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE  2014; 13 (1): 15-17.",41.0,YR,,M,Y,,,20140923.0,N,MD,IN,IN,EFAVIRENZ,Abnormal behaviour;Brain abscess;Dysarthria;Headache;Hemiparesis;Loss of consciousness;Meningitis tuberculous,104707901.0,HO,,,,,,,,,104707901.0,1.0,HIV infection
10470801,104708012,2,F,20140528.0,20140925.0,20140923,20140925,EXP,,DE-VIIV HEALTHCARE LIMITED-D0085528A,GLAXOSMITHKLINE,,52.0,YR,,M,Y,95.0,KG,20140925.0,N,OT,DE,DE,SUSTIVA,Adenocarcinoma of colon;Colectomy;Colon cancer;Enterostomy;Gastroenteritis shigella;Incorrect dosage administered;Intestinal ischaemia,104708012.0,DS,,,104708012.0,1.0,1999.0,2014.0,,,104708012.0,1.0,HIV infection
10471306,104713062,2,F,20140721.0,20150402.0,20140923,20150408,EXP,,MW-009507513-1409MWI010789,MERCK,,35.0,YR,,M,Y,,,20150408.0,N,CN,US,MW,EFAVIRENZ,Pleural effusion;Pneumonia,104713062.0,OT,,,104713062.0,1.0,20140717.0,20141009.0,,,104713062.0,1.0,HIV infection
10473973,104739732,2,F,,20141210.0,20140924,20141218,EXP,,CA-GILEAD-2014-0115852,GILEAD,,46.0,YR,A,M,Y,70.0,KG,20141218.0,N,MD,CA,CA,EFAVIRENZ,Blood HIV RNA increased;Drug ineffective;Neuropsychiatric syndrome;Tuberculosis;Viral mutation identified,104739732.0,OT,,,104739732.0,1.0,20140220.0,201406.0,,,104739732.0,1.0,HIV infection
10475669,104756692,2,F,20140825.0,20150611.0,20140925,20150617,EXP,,BW-ABBVIE-14P-019-1285352-00,ABBVIE,,32.0,YR,,F,Y,,,20150617.0,N,MD,COUNTRY NOT SPECIFIED,BW,EFAVIRENZ,Abortion spontaneous,104756692.0,OT,,,104756692.0,1.0,20140806.0,20140806.0,,,104756692.0,1.0,HIV infection
10476477,104764771,1,I,,20140923.0,20140925,20140925,EXP,,CO-VIIV HEALTHCARE LIMITED-A1090931A,GLAXOSMITHKLINE,,29.0,YR,,M,Y,,,20140925.0,N,OT,CO,CO,EFAVIRENZ,Drug hypersensitivity;Local swelling;Malaise;Oedema;Rash,104764771.0,HO,,,,,,,,,104764771.0,1.0,HIV infection
10476531,104765311,1,I,,20140922.0,20140925,20140925,EXP,,UG-VIIV HEALTHCARE LIMITED-B1036950A,GLAXOSMITHKLINE,"VELAMAKANNI SS, BAHR NC, MUSUBIRE AK, BOULWARE DR, RHEIN J, NABETA HW. CENTRAL NERVOUS SYSTEM CRYPTOCOCCOMA IN A UGANDAN PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS. MEDICAL MYCOLOGY CASE REPORTS. 2014; 6: 10-13.?",45.0,YR,,M,Y,,,20140925.0,N,MD,UG,UG,EFAVIRENZ,Anaemia;Asthenia;Cryptococcosis;Decreased appetite;Dehydration;Generalised tonic-clonic seizure;Hemiparesis;Immune reconstitution inflammatory syndrome;Lethargy;Lymphadenopathy;Pneumonia aspiration;Renal failure,104765311.0,DE,,,,,,,,,104765311.0,1.0,HIV infection
10479608,104796081,1,I,,20140909.0,20140925,20140925,EXP,,2014HINLIT0827,HETERO,,11.0,YR,,F,N,,,20140924.0,N,MD,US,,EFV (EFAVIRENZ) (EFV (EFAVIRENZ)),Cushing's syndrome;Drug interaction,104796081.0,OT,104796081.0,LIT,,,,,,,104796081.0,1.0,HIV infection
10480491,104804911,1,I,,20140909.0,20140925,20140925,EXP,,2014HINLIT0848,HETERO,,45.0,YR,,M,N,,,20140924.0,N,MD,US,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Abdominal distension;CD4 lymphocytes decreased;Cushing's syndrome;Drug interaction,104804911.0,OT,104804911.0,HP,104804911.0,4.0,,,20.0,DAY,104804911.0,1.0,HIV infection
10480694,104806941,1,I,,20140909.0,20140925,20140925,EXP,,2014HINLIT0833,HETERO,,16.0,YR,,F,N,,,20140924.0,N,MD,US,,EFV (EFAVIRENZ),Cushing's syndrome;Drug interaction,104806941.0,OT,104806941.0,LIT,104806941.0,4.0,,,91.0,DAY,104806941.0,1.0,HIV infection
10480720,104807201,1,I,,20140909.0,20140925,20140925,EXP,,2014HINLIT0828,HETERO,,12.0,YR,,F,N,,,20140924.0,N,MD,US,,EFV (EFAVIRENZ),Abdominal pain upper;Contusion;Decreased appetite;Diarrhoea;Drug interaction;Hirsutism;Livedo reticularis;Malaise;Nausea;Skin striae;Vomiting;Waist circumference increased;Weight increased,104807201.0,HO,104807201.0,HP,104807201.0,4.0,,,60.0,DAY,104807201.0,1.0,HIV infection
10482741,104827411,1,I,20140828.0,20140922.0,20140929,20140929,EXP,,KE-GILEAD-2014-0116423,GILEAD,,42.0,YR,A,F,Y,,,20140929.0,N,MD,KE,KE,EFAVIRENZ,Anaemia;Extrapulmonary tuberculosis;Liver abscess;Oesophageal candidiasis,104827411.0,OT,,,104827411.0,1.0,20140818.0,20140818.0,,,104827411.0,1.0,HIV infection
10484033,104840331,1,I,,20140909.0,20140926,20140926,EXP,,2014HINLIT0862,HETERO,,52.0,YR,,M,N,,,20140924.0,N,MD,US,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Blood glucose increased;CD4 lymphocytes decreased;Cushing's syndrome;Drug interaction;Dysphonia;Muscle spasms;Oral pain;Oropharyngeal candidiasis,104840331.0,OT,104840331.0,LIT,104840331.0,4.0,,,61.0,DAY,104840331.0,1.0,HIV infection
10484105,104841051,1,I,,20140909.0,20140926,20140926,EXP,,2014HINLIT0859,HETERO,,48.0,YR,,F,N,,,20140924.0,N,MD,US,,EFAVIRENZ,Cushing's syndrome;Drug interaction,104841051.0,OT,104841051.0,LIT,104841051.0,5.0,,,549.0,DAY,104841051.0,1.0,HIV infection
10484820,104848201,1,I,20140714.0,20140718.0,20140930,20140930,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-21230750,BRISTOL MYERS SQUIBB,,36.0,YR,,M,Y,,,20140930.0,N,OT,KE,KE,EFAVIRENZ,Anaemia;Drug resistance;Pneumonia,104848201.0,OT,,,104848201.0,1.0,20130910.0,20140421.0,,,104848201.0,1.0,Antiretroviral therapy
10486199,104861992,2,F,201212.0,20140917.0,20141001,20141001,EXP,,CN-RANBAXY-2014R1-80584,RANBAXY,"HU Z, WEI H, MENG F, XU C, CHENG C, YANG Y. RECURRENT CRYPTOCOCCAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV-INFECTED PATIENT AFTER ANTI-RETROVIRAL THERAPY: A CASE REPORT. ANN-CLIN-MICROBIAL-ANTIMICROB. 2013;12(40):5 PAGES",19.0,YR,,M,Y,,,20141001.0,N,OT,CN,CN,Efavirenz,Central nervous system lesion;Cryptococcosis;Immune reconstitution inflammatory syndrome;Lymphadenopathy mediastinal,104861992.0,OT,,,104861992.0,1.0,201109.0,,,,104861992.0,1.0,Antiretroviral therapy
10487575,104875752,2,F,,20160718.0,20141001,20160718,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-21423868,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160718.0,,CN,ZA,ZA,EFAVIRENZ,Completed suicide;Nervous system disorder,104875752.0,OT,,,,,,,,,104875752.0,1.0,HIV infection
10490934,104909345,5,F,,20150430.0,20141002,20150723,PER,,US-GILEAD-2014-0116844,GILEAD,,53.0,YR,A,F,Y,,,20150723.0,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,104909345.0,OT,,,104909345.0,1.0,20131028.0,20140410.0,,,104909345.0,1.0,HIV infection
10494095,104940952,2,F,20140913.0,20141003.0,20141003,20141017,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-21434980,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,,,20141017.0,N,CN,GB,KE,EFAVIRENZ,Cerebellar infarction;Cerebral toxoplasmosis;Death;Diarrhoea;Meningitis;Oral candidiasis,104940952.0,DE,,,104940952.0,1.0,20140910.0,20140927.0,,,104940952.0,1.0,HIV infection
10495696,104956964,4,F,20140902.0,20151209.0,20141003,20151217,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-21391164,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,66.0,KG,20151217.0,,OT,ZW,ZW,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy;Retained products of conception,104956964.0,OT,,,104956964.0,1.0,20110531.0,20081224.0,,,104956964.0,1.0,HIV infection
10495703,104957033,3,F,,20180207.0,20141003,20180213,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-21429014,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,,,20180213.0,,OT,CA,CA,SUSTIVA,Drug interaction;Virologic failure,104957033.0,OT,,,,,,,,,104957033.0,1.0,HIV infection
10499423,104994232,2,F,,20141015.0,20141006,20141023,EXP,,US-GILEAD-2014-0117321,GILEAD,HENRICH  T ET AL. ANTIRETROVIRAL-FREE HIV-1 REMISSION AND VIRAL REBOUND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. TOPICS IN ANTIVIRAL MEDICINE. 2014;-:471-472,,,C,M,Y,,,20141023.0,N,MD,US,US,EFAVIRENZ,Acute HIV infection;Blood HIV RNA increased;Blood creatinine increased;Drug ineffective;Meningitis,104994232.0,HO,,,,,,,,,104994232.0,1.0,HIV infection
10502435,105024353,3,F,20040216.0,20150827.0,20141007,20150909,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-21452552,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,79.0,KG,20150909.0,N,CN,FR,FR,SUSTIVA,Vertigo,105024353.0,DS,,,105024353.0,1.0,20040216.0,20140912.0,,,105024353.0,1.0,HIV infection
10503124,105031242,2,F,20140917.0,20141029.0,20141007,20141105,EXP,,KE-GILEAD-2014-0117337,GILEAD,,30.0,YR,A,M,Y,,,20141105.0,N,MD,KE,KE,EFAVIRENZ,Cerebellar infarction;Cerebral toxoplasmosis;Diarrhoea;Oral candidiasis,105031242.0,DE,,,105031242.0,1.0,20140910.0,20140927.0,,,105031242.0,1.0,HIV infection
10517572,105175724,4,F,,20160307.0,20141014,20160308,EXP,,CA-ABBVIE-14P-028-1294263-00,ABBVIE,"PFEFFER G, COTE H, MEZEI M, ET AL. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009?73 (1):71-72.",52.0,YR,,M,Y,,,20160308.0,,MD,COUNTRY NOT SPECIFIED,CA,EFAVIRENZ,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,105175724.0,OT,,,105175724.0,2.0,200802.0,,,,105175724.0,1.0,Antiretroviral therapy
10518435,105184353,3,F,20140918.0,20141224.0,20141015,20141229,EXP,,GB-JNJFOC-20141004457,JANSSEN,,60.0,YR,A,F,Y,,,20150113.0,N,PH,GB,GB,EFAVIRENZ,Acute kidney injury,105184353.0,OT,,,,,,,,,105184353.0,1.0,Antiretroviral therapy
10520712,105207121,1,I,201407.0,20141009.0,20141015,20141015,EXP,FR-ANSM-LY20141238,FR-GILEAD-2014-0118249,GILEAD,,30.0,YR,A,M,Y,,,20141015.0,N,OT,FR,FR,SUSTIVA,Osteoporosis,105207121.0,OT,,,105207121.0,1.0,20061114.0,20140803.0,,,105207121.0,1.0,HIV infection
10522442,105224421,1,I,,20140825.0,20141016,20141016,EXP,,US-GILEAD-2014-0118770,GILEAD,"SANGHA MS, CRAWFORD K, KURUVILA A. FANCONI SYNDROME. AMERICAN JOURNAL OF KIDNEY DISEASES. CONFERENCE: NATIONAL KIDNEY FOUNDATION 2014. 2014;63(5):A97",58.0,YR,A,F,Y,,,20141016.0,N,MD,US,US,EFAVIRENZ,Acute kidney injury;Asthenia;Decreased appetite;Fanconi syndrome acquired;Lethargy;Metabolic acidosis;Renal tubular acidosis;Septic shock,105224421.0,OT,,,,,,,,,105224421.0,1.0,HIV infection
10523527,105235272,2,F,20141001.0,20150306.0,20141017,20150312,EXP,,MW-GILEAD-2014-0118743,GILEAD,,30.0,YR,A,M,Y,,,20150312.0,N,MD,MW,MW,EFAVIRENZ,Meningitis cryptococcal,105235272.0,HO,,,105235272.0,1.0,20140801.0,,,,105235272.0,1.0,HIV infection
10525210,105252101,1,I,20131206.0,20141006.0,20141017,20141017,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-21487632,BRISTOL MYERS SQUIBB,,41.0,YR,,F,Y,62.0,KG,20141017.0,N,CN,US,ZW,EFAVIRENZ,Cellulitis,105252101.0,HO,,,105252101.0,1.0,20110621.0,20140902.0,,,105252101.0,1.0,HIV infection
10525222,105252221,1,I,20140922.0,20141006.0,20141017,20141017,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-21477542,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20141021.0,N,CN,US,UG,EFAVIRENZ,Death,105252221.0,DE,,,105252221.0,1.0,20140917.0,20140921.0,,,105252221.0,1.0,HIV infection
10525299,105252994,4,F,201406.0,20141106.0,20141015,20141118,EXP,,JP2014JPN001749,VIIV,,73.0,YR,,M,N,,,20141117.0,N,MD,JP,,STOCRIN (EFAVIRENZ),Eczema;Pain of skin;Pigmentation disorder;Pruritus;Rash macular;Scar;Scratch,,,105252994.0,HP,105252994.0,1.0,201406.0,,,,105252994.0,1.0,HIV infection
10525523,105255233,3,F,20140902.0,20160304.0,20141017,20160310,EXP,,UG-GILEAD-2014-0118171,GILEAD,,20.0,YR,A,M,Y,,,20160310.0,,MD,UG,UG,EFAVIRENZ,Bladder outlet obstruction;Glomerulonephritis,105255233.0,LT,,,105255233.0,1.0,20140811.0,20140909.0,,,105255233.0,1.0,HIV infection
10528620,105286201,1,I,,20141010.0,20141020,20141020,EXP,,PHHY2014MW133329,SANDOZ,"KUDZALA A, CASHMAN J, VAN OOSTERHOUT JJ.. CASE REPORT: A MAN ON ANTIRETROVIRAL THERAPY WITH PAINFUL THIGHS. MALAWI MEDICAL JOURNAL. 2013;25 (1):24-25",54.0,YR,,M,Y,,,20141020.0,N,OT,MW,MW,EFAVIRENZ,Arthralgia;Osteonecrosis;Pain in extremity,105286201.0,OT,,,,,,,,,105286201.0,1.0,Antiretroviral therapy
10530061,105300611,1,I,,20141013.0,20141021,20141021,EXP,,ZA-AUROBINDO-AUR-APL-2014-10972,AUROBINDO,,31.0,YR,,M,Y,,,20141020.0,N,MD,ZA,ZA,Efavirenz,Blindness;Colour blindness;Hereditary optic atrophy;Optic atrophy;Pupillary reflex impaired;Visual acuity tests abnormal;Visual evoked potentials abnormal,105300611.0,OT,,,,,,,,,105300611.0,1.0,HIV infection
10530241,105302411,1,I,,20141013.0,20141021,20141021,EXP,,ZA-AUROBINDO-AUR-APL-2014-11041,AUROBINDO,,33.0,YR,,M,Y,,,20141020.0,N,MD,ZA,ZA,Efavirenz,Blindness;Colour blindness;Hereditary optic atrophy;Optic atrophy;Oscillopsia;Pupillary reflex impaired;Visual evoked potentials abnormal;Visual field defect;Vitamin B12 decreased,105302411.0,OT,,,,,,,,,105302411.0,1.0,HIV infection
10530828,105308281,1,I,20140924.0,20141015.0,20141021,20141021,EXP,,ZW-009507513-1410GBR010088,MERCK,,39.0,YR,,M,Y,,,20141028.0,N,CN,US,ZW,EFAVIRENZ,Hepatitis,105308281.0,HO,,,105308281.0,1.0,20140818.0,20141002.0,,,105308281.0,1.0,Antiretroviral therapy
10531209,105312092,2,F,,20160714.0,20141021,20160715,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-21505896,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20160715.0,,OT,MW,MW,EFAVIRENZ,Neuropathy peripheral;Osteonecrosis,105312092.0,OT,,,,,,,,,105312092.0,1.0,HIV infection
10531593,105315932,2,F,20140913.0,20141003.0,20141021,20141021,EXP,,KE-009507513-1410KEN000218,MERCK,,30.0,YR,,M,Y,,,20141111.0,N,CN,KE,KE,EFAVIRENZ,Cerebellar infarction;Cerebral toxoplasmosis;Death;Diarrhoea;Meningitis;Oral candidiasis,105315932.0,DE,,,105315932.0,1.0,20140910.0,20140927.0,,,105315932.0,1.0,HIV infection
10538399,105383994,4,F,20141001.0,20150115.0,20141023,20150123,EXP,,CA-GLAXOSMITHKLINE-A1087940A,GLAXOSMITHKLINE,,34.0,YR,,F,Y,,,20150123.0,N,CN,US,CA,Efavirenz,Abortion spontaneous;Exposure during pregnancy,105383994.0,OT,,,105383994.0,1.0,,20140916.0,,,105383994.0,1.0,HIV infection
10539266,105392661,1,I,,20141010.0,20141023,20141023,EXP,,MW-MYLANLABS-2014M1008026,MYLAN,"KUDZALA A, CASHMAN J, VAN OOSTERHOUT JJ. CASE REPORT: A MAN ON ANTIRETROVIRAL THERAPY WITH PAINFUL THIGHS. MALAWI-MED-J 2013; 25(1) 24-25",,,,,Y,,,20141023.0,N,OT,MW,MW,EFAVIRENZ,Osteonecrosis,105392661.0,HO,,,,,,,,,105392661.0,1.0,HIV infection
10540677,105406773,3,F,20140929.0,20150430.0,20141022,20150512,EXP,,MW2014GSK005599,VIIV,,12.0,YR,,F,N,15.0,KG,20150508.0,N,MD,MW,,EFAVIRENZ,Anaemia;Malnutrition;Pulmonary tuberculosis,105406773.0,OT,105406773.0,FGN,105406773.0,1.0,20140214.0,,,,105406773.0,1.0,HIV infection
10540810,105408101,1,I,,20141007.0,20141022,20141022,EXP,,2014HINLIT0933,HETERO,,33.0,YR,,M,N,,,20141018.0,N,OT,ZA,,EFAVIRENZ (EFAVIRENZ),Optic neuropathy,105408101.0,OT,105408101.0,HP,,,,,,,105408101.0,1.0,HIV infection
10543395,105433951,1,I,,20141014.0,20141023,20141023,EXP,,2014HINLIT0946,HETERO,,,,,M,N,,,20141021.0,N,MD,US,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Drug interaction;Drug resistance;Meningitis viral;Nervous system disorder;Vomiting,105433951.0,OT,105433951.0,HP,,,,,,,105433951.0,1.0,HIV infection
10543895,105438951,1,I,,20141007.0,20141023,20141023,EXP,,2014HINLIT0932,HETERO,,31.0,YR,,M,N,,,20141018.0,N,MD,ZA,,EFAVIRENZ (EFAVIRENZ),Hereditary optic atrophy,105438951.0,OT,105438951.0,HP,,,,,,,105438951.0,1.0,HIV infection
10544285,105442853,3,F,20141001.0,20150115.0,20141023,20150126,EXP,,A1087940A,VIIV,,34.0,YR,,F,N,,,20150122.0,N,PH,CA,,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy;Maternal exposure during pregnancy;Pregnancy;Rash,105442853.0,OT,105442853.0,HP,105442853.0,2.0,,20140916.0,,,105442853.0,1.0,HIV infection
10544780,105447801,1,I,20140924.0,20141015.0,20141027,20141027,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-21513924,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20141027.0,N,CN,US,ZW,EFAVIRENZ,Hepatitis,105447801.0,DE,,,105447801.0,1.0,20140818.0,20141002.0,,,105447801.0,1.0,Antiretroviral therapy
10551960,105519602,2,F,,20150505.0,20141029,20150513,EXP,,US-PFIZER INC-2014293808,PFIZER,,53.0,YR,,F,Y,,,20150513.0,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105519602.0,OT,,,105519602.0,2.0,20131028.0,20140410.0,,,105519602.0,1.0,HIV infection
10553582,105535821,1,I,20140923.0,20141013.0,20141028,20141028,EXP,,RUS2014GSK007126,VIIV,,,,,M,N,,,20141024.0,N,CN,RU,,EFAVIRENZ,Chest pain;Haemoptysis;Pneumonia;Pyrexia;Rales,105535821.0,OT,105535821.0,CSM,105535821.0,1.0,201406.0,,,,105535821.0,1.0,HIV infection
10557351,105573512,2,F,,20141110.0,20141031,20141121,EXP,,US-JNJFOC-20141019629,JANSSEN,,53.0,YR,A,F,Y,,,20141121.0,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105573512.0,OT,,,105573512.0,1.0,20131028.0,20140410.0,,,105573512.0,1.0,HIV infection
10557837,105578373,3,F,201402.0,20150505.0,20141031,20150512,EXP,,US-ABBVIE-14P-163-1299475-00,ABBVIE,,53.0,YR,,F,Y,,,20150512.0,N,OT,US,US,EFAVIRENZ,Drug ineffective;Gene mutation;Multiple-drug resistance;Pathogen resistance,105578373.0,OT,,,105578373.0,2.0,20131028.0,20140410.0,,,105578373.0,1.0,HIV infection
10558884,105588841,1,I,,20141022.0,20141101,20141101,EXP,,MW-AUROBINDO-AUR-APL-2014-11371,AUROBINDO,,54.0,YR,,M,Y,,,20141101.0,N,OT,MW,MW,Efavirenz,Gait disturbance;Hypoaesthesia;Osteonecrosis;Pain in extremity,105588841.0,OT,,,,,,,,,105588841.0,1.0,HIV infection WHO clinical stage III
10560768,105607682,2,F,,20150505.0,20141103,20150512,EXP,,US-GLAXOSMITHKLINE-US2014GSK014223,GLAXOSMITHKLINE,,53.0,YR,,F,Y,,,20150512.0,N,CN,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105607682.0,OT,,,105607682.0,1.0,1996.0,20140410.0,,,105607682.0,1.0,HIV infection
10561744,105617442,2,F,20141022.0,20141106.0,20141103,20141117,EXP,,DE-GILEAD-2014-0120081,GILEAD,,51.0,YR,A,M,Y,,,20141116.0,N,MD,DE,DE,SUSTIVA,Acute kidney injury,105617442.0,OT,,,105617442.0,1.0,201409.0,201410.0,,,105617442.0,1.0,HIV infection
10565609,105656091,1,I,20131019.0,20141030.0,20141105,20141105,EXP,,IN-GLAXOSMITHKLINE-IN2014GSK016915,GLAXOSMITHKLINE,PRAMOD KA. CASE REPORT: USE OF HYDROXYCHLOROQUINE IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS).. 3RD INTERNATIONAL CONFERENCE AND EXHIBITION ON PHARMACOVIGILANCE + CLINICAL TRIA. 2014,26.0,YR,,F,Y,,,20141105.0,N,OT,IN,IN,Efavirenz,Cough;Dyspnoea exertional;Headache;Immune reconstitution inflammatory syndrome;Pain;Pyrexia,105656091.0,OT,,,105656091.0,1.0,20130522.0,,,,105656091.0,1.0,Antiretroviral therapy
10566372,105663723,3,F,,20150505.0,20141105,20150518,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-21532072,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150518.0,N,CN,US,US,EFAVIRENZ,Drug dose omission;Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105663723.0,OT,,,105663723.0,1.0,1996.0,,,,105663723.0,1.0,HIV infection
10566381,105663811,1,I,20140813.0,20141024.0,20141105,20141105,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-21538392,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,52.0,KG,20141105.0,N,CN,UG,UG,EFAVIRENZ,Acute kidney injury;Ascites;Decreased appetite;Diarrhoea;Glomerulonephritis;Hepatic cirrhosis;Vomiting,105663811.0,HO,,,105663811.0,1.0,20131211.0,20140811.0,,,105663811.0,1.0,HIV infection
10568009,105680092,2,F,,20150505.0,20141104,20150514,EXP,,US2014GSK014223,VIIV,,53.0,YR,,F,N,,,20150512.0,N,OT,US,,EFAVIRENZ (EFAVIRENZ),Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105680092.0,OT,105680092.0,HP,105680092.0,1.0,20131028.0,20140410.0,,,105680092.0,1.0,HIV infection
10568064,105680641,1,I,,20141021.0,20141104,20141104,EXP,,2014HINLIT0961,HETERO,,54.0,YR,,M,N,,,20141031.0,N,OT,MW,,EFAVIRENZ,Drug hypersensitivity;Neuropathy peripheral;Osteonecrosis;Pain in extremity;Rash,105680641.0,OT,105680641.0,LIT,,,,,,,105680641.0,1.0,Antiretroviral therapy
10568506,105685063,3,F,,20150505.0,20141106,20150520,EXP,,US-009507513-1411USA002189,MERCK,,53.0,YR,,F,Y,,,20150520.0,N,CN,US,US,EFAVIRENZ,Drug dose omission;Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105685063.0,OT,,,105685063.0,1.0,1996.0,20140410.0,,,105685063.0,1.0,HIV infection
10569608,105696081,1,I,,20141027.0,20141106,20141106,EXP,,GH-CIPLA LTD.-2014GH01608,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:111400",,,A,,Y,,,20141106.0,N,OT,GH,GH,Efavirenz,Gangrene;Vasculitis,105696081.0,DE,,,,,,,,,105696081.0,1.0,HIV infection
10569651,105696511,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01606,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:111400",,,A,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Systemic candida,105696511.0,DE,,,,,,,,,105696511.0,1.0,HIV infection
10569672,105696721,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01609,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1114000",,,A,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Pancreatitis,105696721.0,DE,,,,,,,,,105696721.0,1.0,HIV infection
10569676,105696761,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01601,CIPLA,"SARFO S, SARFO M, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Acute abdomen,105696761.0,DE,,,,,,,,,105696761.0,2.0,HIV infection
10569694,105696941,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01607,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:111400",,,,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Intestinal tuberculosis,105696941.0,DE,,,,,,,,,105696941.0,1.0,HIV infection
10569709,105697091,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01617,CIPLA,"SARFO FS, SARFO MA, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Strangulated hernia,105697091.0,DE,,,,,,,,,105697091.0,1.0,HIV infection
10569729,105697291,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01619,CIPLA,"SARFO FS, SARFO MA, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Pneumocystis jirovecii pneumonia,105697291.0,DE,,,,,,,,,105697291.0,1.0,HIV infection
10569782,105697821,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01616,CIPLA,"SARFO FS, SARFO MA, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Hyperosmolar hyperglycaemic state,105697821.0,DE,,,,,,,,,105697821.0,1.0,HIV infection
10569798,105697981,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01604,CIPLA,"SARFO S, SARFO M, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Cervix carcinoma,105697981.0,OT,,,,,,,,,105697981.0,1.0,HIV infection
10569849,105698491,1,I,,20141027.0,20141107,20141107,EXP,,GH-CIPLA LTD.-2014GH01618,CIPLA,"SARFO FS, SARFO MA, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141107.0,N,OT,GH,GH,Efavirenz,Otitis media,105698491.0,DE,,,,,,,,,105698491.0,1.0,HIV infection
10573021,105730211,1,I,20131019.0,20141030.0,20141106,20141106,EXP,,IN2014GSK016915,VIIV,,26.0,YR,,F,N,,,20141105.0,N,OT,IN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Headache;Immune reconstitution inflammatory syndrome associated tuberculosis;Pain,105730211.0,HO,105730211.0,LIT,105730211.0,1.0,20130522.0,,,,105730211.0,1.0,Antiretroviral therapy
10573846,105738461,1,I,,20141027.0,20141110,20141110,EXP,,GH-CIPLA LTD.-2014GH01602,CIPLA,"SARFO F, SARFO M, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141110.0,N,OT,GH,GH,Efavirenz,Hepatic amoebiasis,105738461.0,DE,,,,,,,,,105738461.0,1.0,HIV infection
10574892,105748921,1,I,,20141027.0,20141110,20141110,EXP,,GH-CIPLA LTD.-2014GH01603,CIPLA,"SARFO S, SARFO M, NORMAN B, PHILLIPS R, BEDU-ADDO G, CHADWICK D. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:1-12",,,,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Lymphoma,105748921.0,DE,,,,,,,,,105748921.0,1.0,HIV infection
10574918,105749181,1,I,,20141027.0,20141110,20141110,EXP,,GH-CIPLA LTD.-2014GH01613,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;09:10-12",,,,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Hepatitis B,105749181.0,DE,,,,,,,,,105749181.0,1.0,Antiretroviral therapy
10574931,105749311,1,I,,20141027.0,20141110,20141110,EXP,,GH-CIPLA LTD.-2014GH01611,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:E1114000",,,A,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Subcutaneous abscess,105749311.0,DE,,,,,,,,,105749311.0,1.0,Antiretroviral therapy
10574935,105749351,1,I,,20141027.0,20141110,20141110,EXP,,GH-CIPLA LTD.-2014GH01612,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;09:1-12",,,,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Hepatocellular carcinoma,105749351.0,DE,,,,,,,,,105749351.0,1.0,Antiretroviral therapy
10574941,105749411,1,I,,20141027.0,20141110,20141110,EXP,,GH-CIPLA LTD.-2014GH01614,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;09:1-12",,,A,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Non-Hodgkin's lymphoma,105749411.0,DE,,,,,,,,,105749411.0,1.0,Antiretroviral therapy
10574998,105749981,1,I,,20141027.0,20141111,20141111,EXP,,GH-CIPLA LTD.-2014GH01622,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:0111400",,,,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Meningitis cryptococcal,105749981.0,OT,,,,,,,,,105749981.0,1.0,HIV infection
10575000,105750001,1,I,,20141027.0,20141111,20141111,EXP,,GH-CIPLA LTD.-2014GH01623,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:0111400",,,,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Oesophageal carcinoma,105750001.0,OT,,,,,,,,,105750001.0,1.0,HIV infection
10575060,105750601,1,I,,20141027.0,20141111,20141111,EXP,,GH-CIPLA LTD.-2014GH01624,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:0111400",,,,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Lymphoma,105750601.0,OT,,,,,,,,,105750601.0,1.0,HIV infection
10575068,105750681,1,I,,20141027.0,20141111,20141111,EXP,,GH-CIPLA LTD.-2014GH01625,CIPLA,"FRED STEPHEN SARFO,MAAME ANIMA SARFO,BETTY NORMAN,RICHARD PHILLIPS,GEORGE BEDU ADDO,DAVID CHADWICK. RISK OF DEATHS, AIDS-DEFINING AND NON-AIDS DEFINING EVENTS AMONG GHANAIANS ON LONG-TERM COMBINATION ANTIRETROVIRAL THERAPY. PLOS ONE. 2014;9:0111400",,,,,Y,,,20141111.0,N,OT,GH,GH,Efavirenz,Herpes oesophagitis,105750681.0,OT,,,,,,,,,105750681.0,1.0,HIV infection
10580358,105803581,1,I,20141017.0,20141103.0,20141112,20141112,EXP,,BW-GILEAD-2014-0122055,GILEAD,,32.0,YR,A,F,Y,,,20141112.0,N,MD,BW,BW,EFAVIRENZ,Menorrhagia,105803581.0,HO,,,105803581.0,1.0,20110624.0,20140806.0,,,105803581.0,1.0,HIV infection
10583248,105832481,1,I,20140822.0,20141029.0,20141114,20141114,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-21563655,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,48.0,KG,20141113.0,N,CN,US,ZW,EFAVIRENZ,Haemangioma;Meningitis,105832481.0,HO,,,105832481.0,1.0,20140331.0,,,,105832481.0,1.0,HIV infection
10585081,105850811,1,I,20140930.0,20141104.0,20141113,20141113,EXP,,US2014GSK010116,VIIV,,48.0,YR,,M,N,,,20141110.0,N,MD,US,,EFAVIRENZ,Adverse drug reaction;Drug administration error;Drug ineffective;Drug interaction;Hospitalisation,105850811.0,HO,105850811.0,HP,105850811.0,1.0,201002.0,20141004.0,,,105850811.0,1.0,HIV infection
10588613,105886132,2,F,20140815.0,20141120.0,20141117,20141125,EXP,,ZW-GILEAD-2014-0122190,GILEAD,,49.0,YR,A,M,Y,,,20141125.0,N,MD,ZW,ZW,EFAVIRENZ,Death;Headache,105886132.0,DE,,,105886132.0,1.0,20131017.0,,,,105886132.0,1.0,HIV infection
10589464,105894641,1,I,,20141107.0,20141118,20141118,EXP,,NL-CIPLA LTD.-2014NL01963,CIPLA,"ROKX C, FIBRIANI A, VAN DE VIJVER D, VERBON A, SCHUTTEN M, GRAS L, RIJNDERS B. INCREASED VIROLOGICAL FAILURE IN NAIVE HIV-1-INFECTED PATIENTS TAKING LAMIVUDINE COMPARED WITH EMTRICITABINE IN COMBINATION WITH TENOFOVIR AND EFAVIRENZ OR NEVIRAPINE IN THE DUTCH NATIONWIDE ATHENA COHORT. HIV/AIDS. 2014",,,,,Y,,,20141119.0,N,MD,NL,NL,Efavirenz,Virologic failure,105894641.0,OT,,,,,,,,,105894641.0,1.0,HIV infection
10589483,105894833,3,F,20141025.0,20141215.0,20141114,20141223,EXP,,US2014GSK019874,VIIV,,64.0,YR,,M,N,59.0,KG,20141219.0,N,OT,US,,EFAVIRENZ,Eye movement disorder;Seizure;Syncope;Tremor,105894833.0,OT,105894833.0,HP,105894833.0,1.0,20141004.0,20141027.0,,,105894833.0,1.0,HIV infection
10590778,105907782,2,F,20141013.0,20141208.0,20141118,20150126,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-21609235,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20150126.0,N,OT,UG,UG,EFAVIRENZ,Pulmonary tuberculosis;Tuberculosis,105907782.0,HO,,,105907782.0,1.0,20141008.0,20141011.0,,,105907782.0,1.0,HIV test
10590780,105907801,1,I,2014.0,20141103.0,20141118,20141118,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-21570429,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,80.0,KG,20141118.0,N,CN,US,IT,EFAVIRENZ,Acute respiratory failure;Pneumonia aspiration,105907801.0,LT,,,105907801.0,1.0,20130227.0,,,,105907801.0,1.0,HIV infection
10592058,105920581,1,I,,20141107.0,20141119,20141119,EXP,,NL-CIPLA LTD.-2014NL01964,CIPLA,"ROKX C, FIBRIANI A, DAVID A. M. C.,VIJVER VD,VERBON A,SCHUTTEN M,GRAS L,RIJNDERS BJA. INCREASED VIROLOGICAL FAILURE IN NAIVE HIV 1 INFECTED PATIENTS TAKING LAMIVUDINE COMPARED WITH EMTRICITABINE IN COMBINATION WITH TENOFOVIR AND EFAVIRENZ OR NEVIRAPINE IN THE DUTCH NATIONWIDE ATHENA COHORT. HIV/AIDS. 2014;1-11",,,,,Y,,,20141119.0,N,OT,NL,NL,Efavirenz,Gene mutation;Virologic failure,105920581.0,OT,,,,,,,,,105920581.0,1.0,HIV infection
10592332,105923321,1,I,20140501.0,20141106.0,20141117,20141117,EXP,,UG2014GSK021125,VIIV,,36.0,YR,,M,N,,,20141114.0,N,MD,UG,,EFAVIRENZ,Anaemia;Pulmonary tuberculosis;Tuberculosis,105923321.0,HO,105923321.0,SDY,105923321.0,1.0,20140507.0,20140605.0,,,105923321.0,1.0,HIV infection
10592382,105923822,2,F,,20230530.0,20141119,20230613,EXP,,NL-CIPLA LTD.-2014NL01965,CIPLA,"Rokx C, Fibriani A, David A. M. C.,Vijver VD,Verbon A,Schutten M, Gras L, Rijnders BJA,. Increased Virological Failure in Naive HIV 1 Infected Patients Taking Lamivudine Compared With Emtricitabine in Combination With Tenofovir and Efavirenz or Nevirapine in the Dutch Nationwide ATHENA Cohort. HIV/AIDS. 2014;1 to 11",,,,,Y,,,20230613.0,,MD,NL,NL,EFAVIRENZ,Gene mutation;Virologic failure,105923822.0,OT,,,,,,,,,105923822.0,1.0,HIV infection
10592752,105927521,1,I,,20141107.0,20141119,20141119,EXP,,NL-CIPLA LTD.-2014NL01966,CIPLA,"CASPER ROKX,  AZANIA FIBRIANI ,  DAVID A. M. C. VAN DE VIJVER,  ANNELIES VERBON, MARTIN SCHUTTEN,  LUUK GRAS, AND BART J. A. RIJNDERS. INCREASED VIROLOGICAL FAILURE IN NAIVE HIV 1 INFECTED PATIENTS TAKING LAMIVUDINE COMPARED WITH EMTRICITABINE IN COMBINATION WITH TENOFOVIR AND EFAVIRENZ OR NEVIRAPINE IN THE DUTCH NATIONWIDE ATHENA COHORT. HIV/AIDS. 2014;01 TO 11",,,,,Y,,,20141119.0,N,OT,NL,NL,Efavirenz,Gene mutation;Virologic failure,105927521.0,OT,,,,,,,,,105927521.0,1.0,HIV infection
10592816,105928161,1,I,,20141107.0,20141119,20141119,EXP,,NL-CIPLA LTD.-2014NL01973,CIPLA,"ROKX C, FIBRIANI A, VAN DE VIJVER D, VERBON A, SCHUTTEN M, GRAS L ET.AL.. INCREASED VIROLOGICAL FAILURE IN NAIVE HIV-1 INFECTED PATIENTS TAKING LAMIVUDINE COMPARED WITH EMTRICITABINE IN COMBINATION WITH TENOFOVIR AND EFAVIRENZ OR NEVIRAPINE IN THE DUTCH NATIONWIDE ATHENA COHORT. CLINICAL INFECTIOUS DISEASES. 2014",,,,,Y,,,20141119.0,N,OT,NL,NL,Efavirenz,Gene mutation;Virologic failure,105928161.0,OT,,,,,,,,,105928161.0,1.0,HIV infection
10594047,105940471,1,I,,20141111.0,20141119,20141119,EXP,,RO-GLAXOSMITHKLINE-RO2014GSK021254,GLAXOSMITHKLINE,"DUPONT I, RADULESCU MA, ARAMA V. THERAPEUTIC DIFFICULTIES IN A PATIENT WITH HIV INFECTION AND PLEURAL TUBERCULOSIS. PHARMACEUTICA PRACTICE. 2014;7(3)",41.0,YR,,F,Y,,,20141119.0,N,MD,RO,RO,Efavirenz,Anaemia;Hepatitis cholestatic;Immune reconstitution inflammatory syndrome;Lymphadenopathy mediastinal;Metabolic acidosis;Pleurisy;Renal impairment;Transaminases abnormal;Tuberculosis,105940471.0,HO,105940471.0,LIT,105940471.0,1.0,2011.0,,,,105940471.0,1.0,HIV infection
10594549,105945491,1,I,,20141107.0,20141120,20141120,EXP,,NL-CIPLA LTD.-2014NL01962,CIPLA,"ROKX C, FIBRIANI A, DAVID A. M. C.,VIJVER VD,VERBON A,SCHUTTEN M,GRAS L,RIJNDERS BJA. INCREASED VIROLOGICAL FAILURE IN NAIVE HIV 1 INFECTED PATIENTS TAKING LAMIVUDINE COMPARED WITH EMTRICITABINE IN COMBINATION WITH TENOFOVIR AND EFAVIRENZ OR NEVIRAPINE IN THE DUTCH NATIONWIDE ATHENA COHORT. HIV/AIDS. 2014",,,A,M,Y,,,20141120.0,N,OT,NL,NL,Efavirenz,Gene mutation;Virologic failure,105945491.0,OT,,,,,,,,,105945491.0,1.0,HIV infection
10594591,105945911,1,I,,20141107.0,20141120,20141120,EXP,,NL-CIPLA LTD.-2014NL01972,CIPLA,"CASPER ROKX,  AZANIA FIBRIANI ,  DAVID A. M. C. VAN DE VIJVER,  ANNELIES VERBON, MARTIN SCHUTTEN,  LUUK GRAS AND BART J. A. RIJNDERS. INCREASED VIROLOGICAL FAILURE IN NAIVE HIV 1 INFECTED PATIENTS TAKING LAMIVUDINE COMPARED WITH EMTRICITABINE IN COMBINATION WITH TENOFOVIR AND EFAVIRENZ OR NEVIRAPINE IN THE DUTCH NATIONWIDE ATHENA COHORT. HIV/AIDS. 2014;01 TO 11",,,,,Y,,,20141120.0,N,OT,NL,NL,Efavirenz,Gene mutation;Virologic failure,105945911.0,OT,,,,,,,,,105945911.0,1.0,HIV infection
10596382,105963821,1,I,200905.0,20141107.0,20141120,20141120,EXP,,IT-MYLANLABS-2014M1011210,MYLAN,"DURANTE-MANGONI E, MAIELLO C, LIMONGELLI G, SBREGLIA C, PINTO D, AMARELLI C, ET AL. MANAGEMENT OF IMMUNOSUPPRESSION AND ANTIVIRAL TREATMENT BEFORE AND AFTER HEART TRANSPLANT FOR HIV-ASSOCIATED DILATED CARDIOMYOPATHY. INT-J-IMMUNOPATHOL-PHARMACOL 2014; 27(1) 113-120",,,,,Y,,,20141120.0,N,MD,IT,IT,EFAVIRENZ,Bundle branch block left;Cardiac failure;Congestive cardiomyopathy;Mitral valve incompetence;Ventricular extrasystoles,105963821.0,HO,,,105963821.0,1.0,200502.0,,,,105963821.0,1.0,HIV infection
10600390,106003901,1,I,,20141110.0,20141124,20141124,EXP,,GH-CIPLA LTD.-2014GH02047,CIPLA,"FRED STEPHEN SARFO, ADETAYO KASIM, RICHARD PHILLIPS, ANNA MARIA GERETTI, DAVID R. CHADWICK. LONG-TERM RESPONSES TO FIRST-LINE ANTIRETROVIRAL THERAPY IN HIV AND HEPATITIS B CO-INFECTION IN GHANA. JOURNAL OF INFECTION. 2014;69:481-489",,,,,Y,,,20141124.0,N,OT,GH,GH,Efavirenz,Hepatocellular carcinoma,106003901.0,DE,,,,,,,,,106003901.0,1.0,HIV infection
10600792,106007921,1,I,200605.0,20141110.0,20141124,20141124,EXP,,IT-CIPLA LTD.-2014IT01982,CIPLA,"CHESSA L, ONALI S, FIGORILLI F, BALESTRIERI C, SERRA G, CONTI M ET.AL.. CAN ANTIRETEROVIRAL THERAPY MODIFY THE CLINICAL COURSE OF HDV INFECTION IN HIV POSITIVE PATIENTS. ANTIRETEROVIRAL THERAPY. 2014",,,,,Y,,,20141124.0,N,OT,IT,IT,Efavirenz,Lipodystrophy acquired,106007921.0,OT,,,106007921.0,1.0,200412.0,200605.0,,,106007921.0,1.0,Antiretroviral therapy
10601562,106015622,2,F,20140701.0,20141106.0,20141124,20141124,EXP,,ZW-009507513-1407ZWE009199,MERCK,,32.0,YR,,F,Y,,,20141124.0,N,CN,US,ZW,EFAVIRENZ,Anaemia;Gastroenteritis;Immune reconstitution inflammatory syndrome;Meningitis;Pulmonary tuberculosis,106015622.0,HO,,,106015622.0,1.0,20140630.0,20140922.0,,,106015622.0,1.0,Antiretroviral therapy
10602050,106020502,2,F,20141013.0,20141208.0,20141124,20141222,EXP,,UG-009507513-1411UGA010315,MERCK,,39.0,YR,,M,Y,,,20141222.0,N,CN,UG,UG,EFAVIRENZ,Mycobacterium test positive;Tuberculosis,106020502.0,HO,,,106020502.0,1.0,20141008.0,20141012.0,,,106020502.0,1.0,HIV infection
10602200,106022001,1,I,,20141113.0,20141120,20141120,EXP,,JP2014JPN021457,VIIV,,,,,,N,,,20141119.0,N,PH,JP,,STOCRIN (EFAVIRENZ) TABLET,Drug effect incomplete;Renal impairment,106022001.0,OT,106022001.0,FGN,,,,,,,106022001.0,1.0,HIV infection
10602216,106022161,1,I,,20141111.0,20141120,20141120,EXP,,RO2014GSK021254,VIIV,,41.0,YR,,F,N,,,20141119.0,N,,RO,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Anaemia;Hepatitis cholestatic;Immune reconstitution inflammatory syndrome;Lymphadenopathy mediastinal;Metabolic acidosis;Pleurisy;Renal impairment;Transaminases abnormal;Tuberculosis,106022161.0,OT,106022161.0,HP,106022161.0,1.0,2011.0,,,,106022161.0,1.0,HIV infection
10608174,106081741,1,I,,20141114.0,20141125,20141125,EXP,,IN-MYLANLABS-2014M1011824,MYLAN,"SINGH S, SHARMA T, RAI T, PRABHU A. TYPE 2 LEPRA REACTION IN AN IMMUNOCOMPROMISED PATIENT PRECIPITATED BY FILARIASIS. INDIAN-J-SEX-TRANSM-DIS 2014; 35(1) 40-42",,,,,Y,,,20141125.0,N,OT,IN,IN,EFAVIRENZ,Bone marrow failure,106081741.0,OT,,,,,,,,,106081741.0,1.0,Antiretroviral therapy
10611041,106110412,2,F,,20141114.0,20141126,20141126,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-21625264,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20141126.0,N,CN,FR,FR,SUSTIVA,Psychiatric symptom,106110412.0,OT,,,106110412.0,1.0,20060602.0,20071210.0,,,106110412.0,1.0,HIV infection
10611342,106113422,2,F,20131123.0,20141120.0,20141126,20141126,EXP,,KE-GLAXOSMITHKLINE-B0950259A,GLAXOSMITHKLINE,,45.0,YR,,M,Y,,,20141126.0,N,MD,KE,KE,Efavirenz,Death,106113422.0,OT,,,106113422.0,1.0,20131017.0,20131123.0,,,106113422.0,1.0,HIV infection
10615234,106152341,1,I,,20141117.0,20141201,20141201,EXP,,IT-CIPLA LTD.-2014IT02251,CIPLA,"CALZA L, DANESE I, COLANGELI V, VANDI G, MANFREDI R, GIROMETTI N, BORDERI M, APPOLLONI L, PUGGIOLI C, VIALE P. SKELETAL MUSCLE TOXICITY IN HIV 1 INFECTED PATIENTS TREATED WITH A RALTEGRAVIR-CONTAINING ANTIRETROVIRAL THERAPY:A COHORT STUDY. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30",,,,,Y,,,20141201.0,N,OT,IT,IT,Efavirenz,Muscular weakness,106152341.0,OT,,,,,,,,,106152341.0,1.0,HIV infection
10615235,106152351,1,I,,20141117.0,20141201,20141201,EXP,,ES-CIPLA LTD.-2014ES02244,CIPLA,"ASPIROZ EL,FIGUEROA SC, GOMEZ AI, MERINO MV, HURLE AG. CYP3A4 POLYMORPHISM AND LOPINAVIR TOXICITY IN AN HIV INFECTED PREGNANT WOMAN. CLIN DRUG INVESTIG. 2014",37.0,YR,,F,Y,,,20141201.0,N,OT,ES,ES,Efavirenz,Diarrhoea;Drug resistance;Exposure during pregnancy;Gastrointestinal disorder;Haematology test abnormal;Lipids increased;Meningitis aseptic;Poisoning,106152351.0,HO,,,,,,,,,106152351.0,1.0,HIV infection
10619951,106199511,1,I,20131123.0,20141120.0,20141128,20141128,EXP,,B0950259A,VIIV,,45.0,YR,,M,N,,,20141126.0,N,MD,KE,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Death,106199511.0,DE,106199511.0,FGN,106199511.0,1.0,20131017.0,20131123.0,,,106199511.0,1.0,HIV infection
10624899,106248992,2,F,,20141212.0,20141204,20141223,EXP,,GB-AUROBINDO-AUR-APL-2014-12710,AUROBINDO,,11.0,YR,,F,Y,,,20141223.0,N,MD,GB,GB,Efavirenz,Aphasia;Arterial wall hypertrophy;Carotid artery occlusion;Cerebral infarction;Cerebrovascular accident;Hemiplegia;Immune reconstitution inflammatory syndrome;VIIth nerve paralysis;Vascular stenosis,106248992.0,HO,,,,,,,,,106248992.0,1.0,Antiretroviral therapy
10625110,106251101,1,I,20140307.0,20141119.0,20141202,20141202,EXP,,B0982220A,VIIV,,32.0,YR,,M,N,68.0,KG,20141127.0,N,MD,ES,,EFAVIRENZ,Non-Hodgkin's lymphoma,106251101.0,RI,106251101.0,HP,106251101.0,1.0,20130723.0,20140321.0,,,106251101.0,1.0,HIV infection
10625177,106251771,1,I,,20141124.0,20141202,20141202,EXP,,US2014GSK027863,VIIV,,51.0,YR,,M,N,,,20141127.0,N,MD,US,,EFAVIRENZ (EFAVIRENZ),Eyelid ptosis;Mitochondrial myopathy,106251771.0,OT,106251771.0,LIT,,,,,,,106251771.0,1.0,HIV infection
10626324,106263241,1,I,,20141125.0,20141204,20141204,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-21660618,BRISTOL MYERS SQUIBB,,51.0,YR,,M,Y,,,20141204.0,N,OT,US,US,SUSTIVA,Eyelid ptosis;Mitochondrial myopathy,106263241.0,OT,,,,,,,,,106263241.0,1.0,HIV infection
10626920,106269202,2,F,200509.0,20141210.0,20141204,20141211,EXP,,IN-MYLANLABS-2014M1012780,MYLAN,"DUTTA N, DE R, MUKHERJEE P, BHOWMIK A, MODOK D, GUHA SK. A CASE OF RAPID SECOND-LINE ANTI-RETROVIRAL TREATMENT FAILURE: AN ANALYSIS OF POSSIBLE CAUSES AND PREVENTIVES. J-INDIAN-ACAD-CLIN-MED 2014; 15 229-231",,,A,M,Y,,,20141211.0,N,OT,IN,IN,EFAVIRENZ,Anaemia;Gastritis;Treatment failure,106269202.0,OT,,,106269202.0,1.0,200708.0,200911.0,,,106269202.0,1.0,HIV infection
10627100,106271005,5,F,20140918.0,20150216.0,20141204,20150302,EXP,GB-MHRA-ADR 22779254,GB-BRISTOL-MYERS SQUIBB COMPANY-21657739,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20150302.0,N,CN,US,GB,SUSTIVA,Acute kidney injury,106271005.0,HO,,,,,,,,,106271005.0,1.0,Antiretroviral therapy
10627119,106271192,2,F,20141123.0,20150203.0,20141204,20150217,EXP,GB-MHRA-EYC 00117470,GB-BRISTOL-MYERS SQUIBB COMPANY-21664859,BRISTOL MYERS SQUIBB,,21.0,YR,,M,Y,68.0,KG,20150217.0,N,CN,US,GB,EFAVIRENZ,Hypoglycaemia;Overdose,106271192.0,OT,,,106271192.0,1.0,20140801.0,,,,106271192.0,1.0,HIV antibody positive
10627413,106274131,1,I,,20141121.0,20141205,20141205,EXP,,GB-MYLANLABS-2014M1012373,MYLAN,"IRO MA, KIRKHAM FJ, MACDONALD JHM, TEBRUEGGE M, FAUST SN, PATEL SV. VARICELLA ZOSTER VIRUS CENTRAL NERVOUS SYSTEM IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME PRESENTING IN A CHILD. PEDIATR-INFECT-DIS-J 2013; 32(11) 1283-1284",,,,,Y,,,20141205.0,N,OT,GB,GB,EFAVIRENZ,Cerebrovascular accident;Immune reconstitution inflammatory syndrome;Varicella virus test positive,106274131.0,HO,,,,,,,,,106274131.0,1.0,HIV infection CDC Group III
10629061,106290612,2,F,2014.0,20141112.0,20141205,20161201,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-21601083,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20161201.0,,CN,US,US,SUSTIVA,Erythema;Scratch,,,,,,,,,,,106290612.0,1.0,HIV test
10629489,106294891,1,I,20131007.0,20140616.0,20141205,20141205,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-21154208,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20141204.0,N,CN,US,US,EFAVIRENZ TABS,Normal newborn;Pregnancy,,,,,,,,,,,106294891.0,1.0,Antiretroviral therapy
10636090,106360903,3,F,,20150205.0,20141205,20150212,EXP,,DE-GLAXOSMITHKLINE-DE2014GSK031123,GLAXOSMITHKLINE,,,,,F,Y,,,20150212.0,N,MD,DE,DE,SUSTIVA,Pancytopenia;Pyrexia,106360903.0,OT,,,106360903.0,1.0,2008.0,,,,106360903.0,1.0,HIV infection
10639370,106393701,1,I,201411.0,20141202.0,20141208,20141208,EXP,GB-MHRA-EYC 00117470,GB-GILEAD-2014-0125274,GILEAD,,21.0,YR,A,M,Y,68.0,KG,20141208.0,N,MD,GB,GB,EFAVIRENZ,Hypoglycaemia;Intentional overdose,106393701.0,LT,,,106393701.0,1.0,20140801.0,201411.0,,,106393701.0,1.0,HIV infection
10640227,106402272,2,F,,20150128.0,20141205,20150212,EXP,,2014HINOTH1036,HETERO,,35.0,WK,,M,N,,,20150210.0,N,,MW,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Accessory auricle;Foetal exposure during pregnancy;Premature baby,106402272.0,HO,106402272.0,FGN,106402272.0,1.0,20110608.0,,,,106402272.0,1.0,HIV infection
10641652,106416524,4,F,20141117.0,20150112.0,20141209,20150120,EXP,,KE-GILEAD-2014-0125579,GILEAD,,42.0,YR,A,F,Y,,,20150120.0,N,MD,KE,KE,EFAVIRENZ,Cachexia;Death;Gastroenteritis;Oral candidiasis,106416524.0,HO,,,106416524.0,1.0,20141110.0,20141114.0,,,106416524.0,1.0,HIV infection
10641727,106417273,3,F,20140918.0,20150113.0,20141209,20150119,EXP,,GB-ABBVIE-14P-167-1315688-00,ABBVIE,,60.0,YR,,F,Y,,,20150119.0,N,PH,GB,GB,EFAVIRENZ,Acute kidney injury,106417273.0,OT,,,,,,,,,106417273.0,1.0,Antiretroviral therapy
10642361,106423613,3,F,,20150205.0,20141208,20150218,EXP,,DE2014GSK031123,VIIV,,44.0,YR,,F,N,,,20150212.0,N,OT,DE,,SUSTIVA,Pancytopenia;Pyrexia,106423613.0,OT,106423613.0,HP,106423613.0,1.0,2008.0,,,,106423613.0,1.0,HIV infection
10644733,106447331,1,I,,20141203.0,20141211,20141211,EXP,,US-CIPLA LTD.-2014US02339,CIPLA,"HAVLIR DV, COHAN D, NATUREEBA P, KOSS CA, PLENTY A, LUWEDDE F ET.AL.. EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED PREGNANT UGANDAN WOMEN. AIDS. 2014;28:1-9",,,,,Y,,,20141211.0,N,OT,US,US,Efavirenz,Kaposi's sarcoma,106447331.0,OT,,,,,,,,,106447331.0,1.0,HIV infection
10651828,106518281,1,I,,20141125.0,20141211,20141211,EXP,,2014HINLIT1030,HETERO,,35.0,YR,,M,N,,,20141206.0,N,OT,IN,,EFAVIRENZ (EFAVIENZ),Acquired immunodeficiency syndrome;Anaemia;Arthralgia;Bone marrow failure;Cachexia;Filariasis;Haematotoxicity;Hypoaesthesia;Lepromatous leprosy;Lymph node tuberculosis;Rash erythematous,106518281.0,OT,106518281.0,FGN,,,,,,,106518281.0,1.0,HIV infection
10651845,106518451,1,I,,20141125.0,20141211,20141211,EXP,,2014HINLIT1043,HETERO,,11.0,YR,,F,N,,,20141204.0,N,MD,GB,,EFAVIRENZ,Aphasia;Hemiplegia;Herpes zoster;Immune reconstitution inflammatory syndrome;VIIth nerve paralysis,106518451.0,HO,106518451.0,LIT,,,,,,,106518451.0,1.0,Antiretroviral therapy
10655109,106551093,3,F,20141116.0,20150112.0,20141216,20150127,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-21680202,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20150127.0,N,MD,KE,KE,EFAVIRENZ,Cachexia;Death;Gastroenteritis;Oral candidiasis,106551093.0,HO,,,106551093.0,1.0,20141110.0,20141114.0,,,106551093.0,1.0,HIV infection
10659234,106592341,1,I,,20141210.0,20141217,20141217,EXP,,"IN-ROXANE LABORATORIES, INC.-2014-RO-01887RO",ROXANE,"SINGH S,SHARMA T,RAI T,PRABHU A. TYPE 2 LEPRA REACTION IN AN IMMUNOCOMPROMISED PATIENT PRECIPITATED BY FILARIASIS. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES 2014 JAN;35:1:40-42.",35.0,YR,,M,Y,,,20141217.0,N,OT,COUNTRY NOT SPECIFIED,IN,EFAVIRENZ,Filariasis;Type 2 lepra reaction,106592341.0,OT,,,,,,,,,106592341.0,1.0,Antiretroviral therapy
10660054,106600542,2,F,20141106.0,20141211.0,20141217,20141217,EXP,,FR-GLAXOSMITHKLINE-FR2014GSK018422,GLAXOSMITHKLINE,,9.0,YR,,F,Y,28.3,KG,20141217.0,N,MD,FR,FR,SUSTIVA,Fatigue;Rash pruritic;Urticaria,106600542.0,LT,,,106600542.0,1.0,20141027.0,20141106.0,,,106600542.0,1.0,HIV infection
10663053,106630532,2,F,,20141218.0,20141218,20141223,EXP,,DE-BMSGILMSD-2014-0127656,GILEAD,"HINCH M.C., REICHELT D, HUSSTEDT I.W. ACUTE PSYCHOSIS AS A SIDE EFFECT OF EFAVIRENZ THERAPY WITH METABOLIC ANOMALIES. AN IMPORTANT DIFFERENTIAL DIAGNOSIS OF HIV-ASSOCIATED PSYCHOSES. NUEROLOGIST. 2014;85 (10):1304-1308",52.0,YR,A,,Y,,,20141223.0,N,OT,DE,DE,EFAVIRENZ,Acute psychosis,106630532.0,OT,,,,,,,,,106630532.0,1.0,HIV infection
10667064,106670641,1,I,20130125.0,20141208.0,20141218,20141218,EXP,,K201406768,VIIV,,23.0,YR,,F,N,,,20141217.0,N,MD,US,,SUSTIVA,Amniotic cavity infection;Delayed delivery;Gastrooesophageal reflux disease;Maternal exposure during pregnancy;Pregnancy,106670641.0,RI,106670641.0,HP,106670641.0,1.0,20120524.0,20130228.0,,,106670641.0,1.0,HIV infection
10667474,106674741,1,I,,20141015.0,20141218,20141218,EXP,,K201417016,VIIV,,33.0,YR,,M,N,,,20141217.0,N,,ZA,,EFAVIRENZ(EFAVIRENZ,Blindness;Hereditary optic atrophy;Vitamin B12 deficiency,106674741.0,RI,106674741.0,FGN,,,,,,,106674741.0,1.0,HIV infection
10669196,106691961,1,I,20140918.0,20141216.0,20141222,20141222,EXP,,GB-ABBVIE-14P-167-1322591-00,ABBVIE,,60.0,YR,,F,Y,,,20141223.0,N,PH,GB,GB,EFAVIRENZ,Acute kidney injury,106691961.0,HO,,,,,,,,,106691961.0,1.0,Antiretroviral therapy
10670995,106709951,1,I,,20141015.0,20141219,20141219,EXP,,K201417019,VIIV,,31.0,YR,,M,N,,,20141217.0,N,,ZA,,EFAVIRENZ (EFAVIRENZ),Hereditary optic atrophy,106709951.0,RI,106709951.0,HP,,,,,,,106709951.0,1.0,HIV infection
10671033,106710331,1,I,20141106.0,20141211.0,20141219,20141219,EXP,,FR2014GSK018422,VIIV,,9.0,YR,,F,N,28.3,KG,20141217.0,N,MD,FR,,SUSTIVA,Drug hypersensitivity;Fatigue;Rash maculo-papular;Rash pruritic;Urticaria,106710331.0,LT,106710331.0,HP,106710331.0,1.0,20141027.0,20141106.0,,,106710331.0,1.0,HIV infection
10674577,106745774,4,F,20141212.0,20150206.0,20141224,20150213,EXP,,TH-GILEAD-2014-0128093,GILEAD,,40.0,YR,A,M,Y,49.5,KG,20150213.0,N,MD,TH,TH,EFAVIRENZ,Hepatitis alcoholic,106745774.0,OT,,,106745774.0,1.0,20081121.0,,,,106745774.0,1.0,HIV infection
10675079,106750799,9,F,20140207.0,20151001.0,20141224,20151012,EXP,,PE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-000825,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,52.0,KG,20151012.0,,MD,PE,PE,EFAVIRENZ,Anaemia;Diffuse large B-cell lymphoma;Haematochezia;Leukaemia;Multi-organ failure;Non-Hodgkin's lymphoma;Proctalgia;Sepsis;Syphilis,106750799.0,DE,,,106750799.0,1.0,20140131.0,20141203.0,,,106750799.0,1.0,HIV infection
10677646,106776461,1,I,,20141217.0,20141229,20141229,EXP,,CA-ROCHE-1510165,ROCHE,REPORTER KNOWN TO AUTHORITY. UNKNOWN. ;:-.,52.0,YR,,M,Y,,,20141229.0,N,OT,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,106776461.0,OT,,,,,,,,,106776461.0,1.0,HIV infection
10679686,106796863,3,F,20141127.0,20150716.0,20141229,20150720,EXP,,UG-009507513-1412UGA012531,MERCK,,23.0,YR,,F,Y,,,20150720.0,N,CN,US,UG,EFAVIRENZ,HIV associated nephropathy;Sputum abnormal,106796863.0,DE,,,106796863.0,1.0,20141127.0,20141202.0,,,106796863.0,1.0,HIV infection
10681609,106816091,1,I,20140516.0,20141118.0,20141224,20141224,EXP,,A1084018A,VIIV,,1.0,DY,N,M,N,1.7,KG,20141222.0,N,OT,MW,,EFAVIRENZ,Accessory auricle;Maternal drugs affecting foetus;Premature baby,106816091.0,CA,106816091.0,FGN,106816091.0,1.0,20110608.0,20140410.0,,,106816091.0,1.0,HIV infection
10683321,106833212,2,F,,20141215.0,20141230,20141230,EXP,,CA-GLAXOSMITHKLINE-B0598034A,GLAXOSMITHKLINE,,52.0,YR,,M,Y,,,20141230.0,N,MD,CA,CA,Efavirenz,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,106833212.0,OT,,,,,,,,,106833212.0,1.0,HIV infection
10683707,106837072,2,F,20140918.0,20150113.0,20141230,20150119,EXP,,GB-ABBVIE-14P-167-1326700-00,ABBVIE,,60.0,YR,,F,Y,,,20150119.0,N,PH,GB,GB,EFAVIRENZ,Acute kidney injury,106837072.0,HO,,,,,,,,,106837072.0,1.0,Antiretroviral therapy
10685463,106854631,1,I,,20141217.0,20141231,20141231,EXP,,CA-PFIZER INC-2014360685,PFIZER,,52.0,YR,,M,Y,,,20141231.0,N,OT,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,106854631.0,OT,,,,,,,,,106854631.0,1.0,HIV infection
10685908,106859083,3,F,20141211.0,20150112.0,20141231,20150127,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-003489,BRISTOL MYERS SQUIBB,,34.0,YR,,M,Y,58.4,KG,20150127.0,N,CN,US,MW,EFAVIRENZ,Bacterial sepsis;Candida infection,106859083.0,HO,,,106859083.0,1.0,20140505.0,,,,106859083.0,1.0,Antiretroviral therapy
10687390,106873902,2,F,,20150128.0,20141230,20150212,EXP,,2014HINOTH1083,HETERO,,39.0,WK,,M,N,3.1,KG,20150210.0,N,OT,AR,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Maternal drugs affecting foetus;Plagiocephaly,106873902.0,CA,106873902.0,HP,,,,,,,106873902.0,1.0,HIV infection
10688847,106888472,2,F,20140204.0,20141218.0,20150103,20150103,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-20206934,BRISTOL MYERS SQUIBB,,62.0,YR,,M,Y,,,20150103.0,N,CN,US,KE,EFAVIRENZ,Drug-induced liver injury;Enteritis,106888472.0,OT,,,106888472.0,1.0,20140114.0,20140204.0,,,106888472.0,1.0,HIV infection
10692012,106920121,1,I,,20141224.0,20150106,20150106,EXP,,FR-CIPLA LTD.-2014FR03020,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768-1776",,,,,Y,,,20150106.0,N,MD,FR,FR,Efavirenz,Virologic failure,106920121.0,OT,,,,,,,,,106920121.0,1.0,HIV infection
10692105,106921051,1,I,,20141224.0,20150106,20150106,EXP,,FR-CIPLA LTD.-2014FR03001,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN MA, SOGNI P ET.AL.. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768-1776",,,,,Y,,,20150106.0,N,OT,FR,FR,Efavirenz,Cerebral haemorrhage;Immune thrombocytopenic purpura,106921051.0,DE,,,,,,,,,106921051.0,1.0,HIV infection
10692416,106924162,2,F,20141218.0,20150213.0,20150106,20150227,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-005557,BRISTOL MYERS SQUIBB,,29.0,YR,,M,Y,59.0,KG,20150227.0,N,CN,MW,MW,EFAVIRENZ,Pneumonia bacterial,106924162.0,OT,,,106924162.0,1.0,20140513.0,20141218.0,,,106924162.0,1.0,HIV infection
10696879,106968791,1,I,,20141224.0,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03002,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN MA, SOGNI P ET.AL.. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768-1776",,,,,Y,,,20150108.0,N,OT,FR,FR,Efavirenz,Upper gastrointestinal haemorrhage,106968791.0,DE,,,,,,,,,106968791.0,1.0,HIV infection
10696905,106969051,1,I,,20141224.0,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03008,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768 TO 1776",,,,,Y,,,20150108.0,N,OT,FR,FR,Efavirenz,Thrombocytopenia,106969051.0,OT,,,,,,,,,106969051.0,1.0,HIV infection
10696906,106969061,1,I,,20141224.0,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03029,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. CID. 2014;59:1768-1776",,,,,Y,,,20150108.0,N,MD,FR,FR,Efavirenz,Disease recurrence;Hepatitis C,106969061.0,OT,,,,,,,,,106969061.0,1.0,HIV infection
10697107,106971071,1,I,,20141224.0,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03030,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. CID. 2014;59:1768-1776",,,,,Y,,,20150108.0,N,MD,FR,FR,Efavirenz,Psychiatric decompensation,106971071.0,OT,,,,,,,,,106971071.0,1.0,HIV infection
10709794,107097941,1,I,20140121.0,20140131.0,20150114,20150114,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-20173589,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,40.8,KG,20150114.0,N,CN,US,ZW,EFAVIRENZ,Decreased appetite;Dehydration;Diarrhoea;Leukopenia;Myelodysplastic syndrome;Pancytopenia;Vomiting;Weight decreased,107097941.0,LT,,,107097941.0,1.0,20130910.0,,,,107097941.0,1.0,HIV infection
10713649,107136491,1,I,,20141231.0,20150115,20150115,EXP,,US-CIPLA LTD.-2015US00256,CIPLA,"DORSEY G, NATUREEBA P, ADES V, LUWEDDE F, MWESIGWA J, PLENTY A ET.AL.. LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL TREATMENT (ART) VERSUS EFAVIRENZ-BASED ART FOR THE PREVENTION OF MALARIA AMONG HIV-INFECTED PREGNANT WOMEN. THE JOURNAL OF INFECTIOUS DISEASES. 2014;210:1938-45",,,,,Y,,,20150115.0,N,OT,US,US,Efavirenz,Abortion spontaneous,107136491.0,OT,,,,,,,,,107136491.0,1.0,HIV infection
10717844,107178442,2,F,20141117.0,20150210.0,20150116,20150213,EXP,,RW-GILEAD-2015-0130621,GILEAD,,,,,F,Y,,,20150213.0,N,OT,RW,RW,EFAVIRENZ,Bone tuberculosis,107178442.0,OT,,,107178442.0,1.0,20140813.0,20141117.0,,,107178442.0,1.0,HIV infection
10718212,107182121,1,I,,20141219.0,20150118,20150118,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-005107,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150118.0,N,CN,UG,UG,EFAVIRENZ,HIV associated nephropathy;Sputum abnormal,107182121.0,DE,,,107182121.0,1.0,20141127.0,20141202.0,,,107182121.0,1.0,HIV infection
10722382,107223822,2,F,20141121.0,20150203.0,20150119,20150211,EXP,,UG-GILEAD-2015-0132050,GILEAD,,55.0,YR,A,F,Y,55.0,KG,20150211.0,N,MD,UG,UG,EFAVIRENZ,Urinary tract infection,107223822.0,HO,,,107223822.0,1.0,20121115.0,,,,107223822.0,1.0,HIV infection
10722714,107227145,5,F,20140823.0,20150720.0,20150120,20150727,EXP,,RU-GLAXOSMITHKLINE-B1006356A,GLAXOSMITHKLINE,,,,,M,Y,,,20150727.0,N,CN,RU,RU,EFAVIRENZ,Asthenia;Chest pain;Chronic gastritis;Duodenitis;Erosive oesophagitis;Gastric disorder;Gastric polyps;Gastritis haemorrhagic;Gastrooesophageal reflux disease;Head discomfort;Headache;Hiatus hernia;Hyperchlorhydria;Influenza like illness;Initial insomnia;Irritability;Lymph node pain;Musculoskeletal discomfort;Nail discolouration;Nasal obstruction;Nasopharyngitis;Nervousness;Neurosis;Oropharyngeal pain;Pharyngeal disorder;Pharyngeal erosion;Pharyngeal erythema;Pharyngitis;Pyrexia;Respiratory tract infection viral;Rhinorrhoea;Tongue coated;Tonsillar inflammation,107227145.0,OT,,,107227145.0,1.0,201312.0,,,,107227145.0,1.0,HIV infection
10723036,107230361,1,I,,20141202.0,20150114,20150114,EXP,,2014HINLIT1048,HETERO,,51.0,YR,,F,N,,,20141215.0,N,OT,IN,,EFAVIRENZ,Acute kidney injury;Blood glucose decreased;Blood pressure decreased;Cerebral atrophy;Depressed level of consciousness;Drug interaction;Heart rate increased;Hypophagia;Metabolic acidosis;Pallor;Vomiting,107230361.0,HO,107230361.0,HP,,,,,,,107230361.0,1.0,HIV infection
10724570,107245701,1,I,,20150108.0,20150120,20150120,EXP,,IR-MYLANLABS-2015M1000677,MYLAN,"AHMADINEJAD Z, GHETMIRI Z, RASOOLINEJAD M. CYTOMEGALOVIRUS RETINITIS AFTER INITIATION OF ANTIRETROVIRAL THERAPY. ACTA-MED-IRAN 2013; 51(10) 730-732",,,,,Y,,,20150120.0,N,OT,IR,IR,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,107245701.0,HO,,,,,,,,,107245701.0,1.0,HIV infection
10724794,107247942,2,F,20141207.0,20150114.0,20150120,20150129,EXP,,ZW-009507513-1501ZWE006327,MERCK,,43.0,YR,,F,Y,,,20150129.0,N,CN,US,ZW,EFAVIRENZ,Death,107247942.0,DE,,,107247942.0,1.0,20140930.0,,,,107247942.0,1.0,Antiretroviral therapy
10729305,107293051,1,I,,20150109.0,20150122,20150122,EXP,,PT-MYLANLABS-2015M1000957,MYLAN,"ALMEIDA FERREIRA M, CARVALHO AC, SILVA SV, FRANCA M, BORGES F. TWO ENDOCRINE DISEASES IN ONE CASE OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. HIV-AIDS-REV 2014; 13(2) 60-62",,,,,Y,,,20150122.0,N,OT,PT,PT,EFAVIRENZ,Basedow's disease;Diabetic ketoacidosis;Gastrointestinal disorder;Immune reconstitution inflammatory syndrome;Neurotoxicity;Skin disorder;Type 1 diabetes mellitus,107293051.0,HO,,,,,,,,,107293051.0,4.0,Acquired immunodeficiency syndrome
10729425,107294252,2,F,20141031.0,20150112.0,20150122,20150127,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-001948,BRISTOL MYERS SQUIBB,,55.0,YR,,F,Y,55.0,KG,20150127.0,N,CN,US,UG,EFAVIRENZ,Diabetes mellitus;Pelvic inflammatory disease;Urinary tract infection,107294252.0,HO,,,107294252.0,1.0,20121115.0,,,,107294252.0,1.0,HIV infection
10729806,107298061,1,I,20141031.0,20150112.0,20150122,20150122,EXP,,UG-GILEAD-2015-0131848,GILEAD,,55.0,YR,A,F,Y,55.0,KG,20150122.0,N,MD,UG,UG,EFAVIRENZ,Urinary tract infection,107298061.0,HO,,,107298061.0,1.0,20121115.0,,,,107298061.0,1.0,HIV infection
10733173,107331734,4,F,20140823.0,20150518.0,20150120,20150528,EXP,,B1006356A,VIIV,,,,,M,N,,,20150526.0,N,CN,RU,,EFAVIRENZ,Asthenia;Chronic gastritis;Duodenitis;Erosive oesophagitis;Fungal test positive;Gastric disorder;Gastric polyps;Gastritis;Gastritis haemorrhagic;Gastrooesophageal reflux disease;Head discomfort;Hiatus hernia;Hyperchlorhydria;Influenza like illness;Initial insomnia;Lymph node pain;Musculoskeletal discomfort;Nail discolouration;Nasal obstruction;Nasopharyngitis;Nervousness;Neurosis;Oropharyngeal pain;Pharyngeal disorder;Pharyngeal erosion;Pharyngeal erythema;Pharyngeal mucosa atrophy;Pneumonia streptococcal;Pyrexia;Respiratory tract infection viral;Rhinorrhoea;Tongue coated;Tonsillar inflammation,107331734.0,OT,107331734.0,CSM,107331734.0,1.0,201312.0,,,,107331734.0,1.0,HIV infection
10734045,107340451,1,I,20140725.0,20150119.0,20150123,20150123,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK007354,GLAXOSMITHKLINE,,40.0,YR,,M,Y,48.0,KG,20150123.0,N,MD,CN,CN,Efavirenz,Pruritus;Rash,107340451.0,HO,,,107340451.0,1.0,20140514.0,20140725.0,,,107340451.0,1.0,Acquired immunodeficiency syndrome
10734046,107340461,1,I,20140901.0,20150119.0,20150123,20150123,EXP,,CN-GLAXOSMITHKLINE INC.-CN2015GSK007360,GLAXOSMITHKLINE,,57.0,YR,,F,Y,60.0,KG,20150123.0,N,MD,CN,CN,Efavirenz,Hepatocellular injury,107340461.0,OT,,,107340461.0,1.0,20140305.0,20140811.0,,,107340461.0,1.0,Acquired immunodeficiency syndrome
10740435,107404351,1,I,,20150112.0,20150127,20150127,EXP,,TZ-CIPLA LTD.-2015TZ00564,CIPLA,"DAUDI R. MAVURA, E. JOHN MASENGA, ELI MINJA, HENNING GROSSMANN, JOHN A. CRUMP AND JOHN A. BARTLETT. INITIATION OF ANTIRETROVIRAL THERAPY IN HIV INFECTED ADULTS WITH SKIN COMPLAINTS IN NORTHERN TANZANIA. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2015;54:68 TO 73",,,,,Y,,,20150127.0,N,OT,TZ,TZ,Efavirenz,Kaposi's sarcoma,107404351.0,DE,,,,,,,,,107404351.0,1.0,HIV infection
10740490,107404901,1,I,,20150112.0,20150127,20150127,EXP,,TZ-CIPLA LTD.-2015TZ00567,CIPLA,"DAUDI R. MAVURA, E. JOHN MASENGA, ELI MINJA, HENNING GROSSMANN, JOHN A. CRUMP AND JOHN A. BARTLETT. INITIATION OF ANTIRETROVIRAL THERAPY IN HIV INFECTED ADULTS WITH SKIN COMPLAINTS IN NORTHERN TANZANIA. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2015;54:68 TO 73",,,,,Y,,,20150127.0,N,OT,TZ,TZ,Efavirenz,Anaemia,107404901.0,DE,,,,,,,,,107404901.0,1.0,HIV infection
10740927,107409271,1,I,,20150119.0,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00401,AUROBINDO,"SARFO FS, ET AL.. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST AFRICANS NCVIRAPINE^S EPITAPH?. PLOS ONE. 2014;9(4)",,,,F,Y,,,20150127.0,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash generalised;Rash maculo-papular;Rash pruritic,107409271.0,OT,,,,,,,,,107409271.0,1.0,Antiretroviral therapy
10740930,107409301,1,I,,20150119.0,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00404,AUROBINDO,SARFO FS ET AL. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST AFRICANS: NCVIRAPINE^S EPITAPH?. PLOS ONE. 2014;4,,,,F,Y,,,20150127.0,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash;Rash maculo-papular;Rash pruritic,107409301.0,OT,,,,,,,,,107409301.0,1.0,Antiretroviral therapy
10741432,107414321,1,I,,20150119.0,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00402,AUROBINDO,"SARFO FS, ET AL.. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST-AFRICANS: NEVIRAPINE^S EPITAPH?. PLOS ONE. 2015;1534:77",,,,F,Y,,,20150127.0,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash;Rash maculo-papular;Rash pruritic,107414321.0,OT,,,,,,,,,107414321.0,1.0,HIV infection
10743376,107433761,1,I,,20150119.0,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00405,AUROBINDO,"SARFO FS, ET AL.. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST AFRICANS: NEVIRAPINE^S EPITAPH?. PLOS ONE. 2014;9(4)",,,,M,Y,,,20150127.0,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash;Rash maculo-papular;Rash pruritic,107433761.0,OT,,,,,,,,,107433761.0,1.0,HIV infection
10744465,107444651,1,I,20140901.0,20150119.0,20150126,20150126,EXP,,CN2015GSK007360,VIIV,,58.0,YR,,F,N,60.0,KG,20150123.0,N,OT,CN,,EFAVIRENZ,Hepatocellular injury,107444651.0,OT,107444651.0,FGN,107444651.0,1.0,20140305.0,20140811.0,,,107444651.0,1.0,Acquired immunodeficiency syndrome
10744520,107445201,1,I,20140725.0,20150119.0,20150126,20150126,EXP,,CN2015GSK007354,VIIV,,40.0,YR,,M,N,48.0,KG,20150123.0,N,MD,CN,,EFAVIRENZ,Pruritus;Rash,107445201.0,HO,107445201.0,FGN,107445201.0,1.0,20140514.0,20140625.0,,,107445201.0,1.0,Acquired immunodeficiency syndrome
10746595,107465951,1,I,20140817.0,20150119.0,20150128,20150128,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK010273,GLAXOSMITHKLINE,,61.0,YR,,M,Y,52.0,KG,20150128.0,N,MD,CN,CN,Efavirenz,Alcohol poisoning;Asthenia;Dizziness,107465951.0,OT,,,107465951.0,1.0,20140814.0,20140825.0,,,107465951.0,1.0,Acquired immunodeficiency syndrome
10748230,107482301,1,I,,20150114.0,20150129,20150129,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-004623,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150129.0,N,CN,US,ZW,EFAVIRENZ,Death,107482301.0,DE,,,107482301.0,1.0,20140930.0,,,,107482301.0,1.0,Antiretroviral therapy
10749633,107496331,1,I,,20150116.0,20150129,20150129,EXP,,NL-MYLANLABS-2015M1002098,MYLAN,"SCHOUTEN JN, VAN DER ENDE ME, KOETER T, ROSSING HH, KOMUTA M, VERHEIJ J, ET AL. RISK FACTORS AND OUTCOME OF HIV-ASSOCIATED IDIOPATHIC NONCIRRHOTIC PORTAL HYPERTENSION. ALIMENT-PHARMACOL-THER 2012; 36(9) 875-85",,,,,Y,,,20150129.0,N,OT,NL,NL,EFAVIRENZ,Oesophageal varices haemorrhage;Portal hypertension,107496331.0,OT,,,,,,,,,107496331.0,1.0,HIV infection
10749800,107498001,1,I,,20150119.0,20150129,20150129,EXP,,CN-GLAXOSMITHKLINE-CN2015011033,GLAXOSMITHKLINE,,,,,,Y,,,20150129.0,N,OT,CN,CN,Efavirenz,Pruritus;Rash,107498001.0,HO,,,107498001.0,1.0,20140514.0,20140725.0,,,107498001.0,1.0,Acquired immunodeficiency syndrome
10749818,107498182,2,F,201211.0,20150312.0,20150129,20150319,EXP,,JP-GLAXOSMITHKLINE-JP2015JPN009992,GLAXOSMITHKLINE,,37.0,YR,,M,Y,,,20150319.0,N,MD,JP,JP,Efavirenz,Abulia;Brain death;Central nervous system lymphoma;Decreased appetite;Disorientation;Dysarthria;Dyspnoea;Fatigue;Hyperreflexia;JC virus infection;Lethargy;Locked-in syndrome;Progressive multifocal leukoencephalopathy;Pyrexia,107498182.0,DE,,,,,,,,,107498182.0,4.0,HIV infection
10749832,107498321,1,I,20140901.0,20150119.0,20150129,20150129,EXP,,CN-GLAXOSMITHKLINE-CN2015010531,GLAXOSMITHKLINE,,,,,,Y,,,20150129.0,N,OT,CN,CN,Efavirenz,Hepatocellular injury,107498321.0,OT,,,107498321.0,1.0,20140305.0,20140911.0,,,107498321.0,1.0,Acquired immunodeficiency syndrome
10751711,107517113,3,F,20141104.0,20150205.0,20150130,20150213,EXP,,MW-ABBVIE-15P-100-1336374-00,ABBVIE,,31.0,YR,,F,Y,49.0,KG,20150213.0,N,MD,COUNTRY NOT SPECIFIED,MW,EFAVIRENZ,Abortion incomplete,107517113.0,HO,,,107517113.0,1.0,20141014.0,20141014.0,,,107517113.0,1.0,HIV infection
10753551,107535511,1,I,,20150113.0,20150129,20150129,EXP,,2015HINLIT0016,HETERO,,,,A,,N,,,20150127.0,N,OT,GB,,EFAVIRENZ,Neurotoxicity,107535511.0,OT,107535511.0,FGN,,,,,,,107535511.0,1.0,Antiretroviral therapy
10753572,107535721,1,I,,20150113.0,20150129,20150129,EXP,,2015HINLIT0022,HETERO,,34.0,YR,,F,N,,,20150127.0,N,OT,IR,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,107535721.0,OT,107535721.0,LIT,,,,,,,107535721.0,1.0,HIV infection
10753871,107538711,1,I,20140817.0,20150119.0,20150129,20150129,EXP,,CN2015GSK010273,VIIV,,62.0,YR,,M,N,52.0,KG,20150128.0,N,MD,CN,,EFAVIRENZ,Alcohol poisoning;Asthenia;Dizziness,107538711.0,OT,107538711.0,HP,107538711.0,1.0,20140814.0,20140825.0,,,107538711.0,1.0,Acquired immunodeficiency syndrome
10753895,107538952,2,F,20150122.0,20150130.0,20150129,20150212,EXP,,JP2015JPN008882,VIIV,,60.0,YR,,M,N,,,20150209.0,N,MD,JP,,STOCRIN (EFAVIRENZ),Cerebral haemorrhage,107538952.0,HO,107538952.0,FGN,,,,,,,107538952.0,1.0,HIV infection
10757184,107571843,3,F,201211.0,20150312.0,20150130,20150320,EXP,,JP2015JPN009992,VIIV,,37.0,YR,,M,N,,,20150318.0,N,OT,JP,,EFAVIRENZ,Abulia;Bradykinesia;Brain death;Central nervous system lymphoma;Decreased appetite;Disorientation;Dysarthria;Dyspnoea;Fatigue;Haemophilic arthropathy;Hyperreflexia;Immune reconstitution inflammatory syndrome;JC virus infection;Lethargy;Locked-in syndrome;Masked facies;Progressive multifocal leukoencephalopathy;Pyrexia;Treatment noncompliance,107571843.0,HO,107571843.0,FGN,,,,,,,107571843.0,4.0,HIV infection
10757327,107573271,1,I,20140901.0,20150119.0,20150130,20150130,EXP,,CN2015010531,VIIV,,58.0,YR,,F,N,69.0,KG,20150128.0,N,OT,CN,,EFAVIRENZ (EFAVIRENZ),Hepatocellular injury,107573271.0,OT,107573271.0,HP,107573271.0,1.0,20140305.0,20140911.0,,,107573271.0,1.0,Acquired immunodeficiency syndrome
10757353,107573531,1,I,,20150119.0,20150130,20150130,EXP,,CN20154011033,VIIV,,40.0,YR,,M,N,48.0,KG,20150128.0,N,OT,CN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Pruritus;Rash;Scratch,107573531.0,HO,107573531.0,FGN,107573531.0,1.0,20140514.0,20140725.0,,,107573531.0,1.0,Acquired immunodeficiency syndrome
10759720,107597201,1,I,20141201.0,20150128.0,20150203,20150203,EXP,,FR-GLAXOSMITHKLINE-FR2015GSK012400,GLAXOSMITHKLINE,,38.0,YR,,F,Y,,,20150203.0,N,OT,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,107597201.0,OT,,,107597201.0,1.0,20131226.0,20141204.0,,,107597201.0,1.0,HIV infection
10762006,107620061,1,I,,20150128.0,20150204,20150204,EXP,,"IR-ROXANE LABORATORIES, INC.-2015-RO-00170RO",ROXANE,"AHMADINEJAD Z,GHETMIRI Z,RASOOLINEJAD M. CYTOMEGALOVIRUS RETINITIS AFTER INITIATION OF ANTIRETROVIRAL THERAPY. ACTA MEDICA IRANICA 2013;51:10:730-732.",34.0,YR,,F,Y,,,20150204.0,N,OT,COUNTRY NOT SPECIFIED,IR,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,107620061.0,HO,,,,,,,,,107620061.0,1.0,HIV infection
10763660,107636601,1,I,2002.0,20140721.0,20150204,20150204,EXP,,US-GLAXOSMITHKLINE-A1082147A,GLAXOSMITHKLINE,,,,,M,Y,,,20150204.0,N,CN,US,US,SUSTIVA,Burning sensation;Dry skin;Neuropathy peripheral;Pain;Sensory disturbance;Skin discolouration;Visual acuity reduced,,,,,107636601.0,1.0,1999.0,,,,107636601.0,1.0,HIV infection
10770130,107701301,1,I,20141116.0,20141202.0,20150206,20150206,EXP,,KE-009507513-1502KEN002532,MERCK,,42.0,YR,,F,Y,,,20150206.0,N,CN,US,KE,EFAVIRENZ,Cachexia;Death;Gastroenteritis;Oral candidiasis,107701301.0,LT,,,107701301.0,1.0,20141110.0,20141110.0,,,107701301.0,1.0,HIV infection
10770830,107708303,3,F,20141024.0,20150611.0,20150206,20150617,EXP,,MW-ABBVIE-15P-100-1341646-00,ABBVIE,,25.0,YR,,F,Y,,,20150617.0,N,MD,COUNTRY NOT SPECIFIED,MW,SUSTIVA,Abortion spontaneous,107708303.0,OT,,,107708303.0,1.0,20141024.0,20150121.0,,,107708303.0,1.0,HIV infection
10775555,107755551,1,I,20141201.0,20150128.0,20150205,20150205,EXP,,FR2015GSK012400,VIIV,,38.0,YR,,F,N,,,20150203.0,N,OT,FR,,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,107755551.0,OT,107755551.0,HP,107755551.0,1.0,20131225.0,20141204.0,,,107755551.0,1.0,HIV infection
10779918,107799181,1,I,20141024.0,20150130.0,20150206,20150206,EXP,,MW2015GSK014589,VIIV,,25.0,YR,,F,N,,,20150204.0,N,OT,MW,,SUSTIVA,Abortion spontaneous;Exposure during pregnancy;Pregnancy,107799181.0,OT,107799181.0,HP,107799181.0,1.0,20091123.0,20141024.0,,,107799181.0,1.0,HIV infection
10782797,107827973,3,F,,20160316.0,20150210,20160316,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006291,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160316.0,,OT,GB,GB,EFAVIRENZ,Foetal exposure during pregnancy;Off label use;Ultrasound antenatal screen abnormal,107827973.0,OT,,,107827973.0,1.0,20140916.0,20141031.0,,,107827973.0,1.0,Antiretroviral therapy
10783699,107836992,2,F,20141231.0,20150811.0,20150210,20150825,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006543,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,54.2,KG,20150825.0,N,CN,US,ZW,EFAVIRENZ,Anaemia;Dysfunctional uterine bleeding;Polycystic ovaries,107836992.0,LT,,,107836992.0,1.0,20080630.0,,,,107836992.0,1.0,HIV infection
10783942,107839422,2,F,,20150824.0,20150210,20150826,EXP,,IN-AUROBINDO-AUR-APL-2015-01044,AUROBINDO,LINGESWARAN A.. ANTIRETROVIRALS CATATONIA: CASE REPORT. REACTIONS WEEKLY. 2015;1565:36,16.0,YR,,M,Y,,,20150826.0,N,OT,IN,IN,Efavirenz Tablets,Agitation;Catatonia;Drug withdrawal syndrome;Echopraxia;Grimacing;Mutism;Negativism;Poor quality sleep;Posturing,107839422.0,OT,,,,,,,,,107839422.0,1.0,Antiretroviral therapy
10784348,107843481,1,I,20141229.0,20150127.0,20150211,20150211,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006745,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20150211.0,N,CN,US,US,SUSTIVA,Prostate cancer,107843481.0,OT,,,107843481.0,1.0,2001.0,,,,107843481.0,1.0,HIV infection
10787567,107875671,1,I,20141201.0,20150128.0,20150212,20150212,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-005944,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20150212.0,N,CN,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,107875671.0,HO,,,107875671.0,1.0,20140731.0,20141204.0,,,107875671.0,1.0,HIV infection
10793812,107938122,2,F,20141024.0,20151209.0,20150213,20151217,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-008111,BRISTOL MYERS SQUIBB,,25.0,YR,,F,Y,,,20151217.0,,CN,MW,MW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,107938122.0,OT,,,107938122.0,1.0,20140805.0,20141024.0,,,107938122.0,1.0,HIV infection
10803696,108036961,1,I,,20150210.0,20150217,20150217,EXP,,US-GLAXOSMITHKLINE-US2015GSK018734,GLAXOSMITHKLINE,"BOSSE KR, ET AL. ACUTE RENAL INJURY IN A 14-YEAR-OLD WITH HIV/AIDS AND TUBERCULOSIS. PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2013;32;09:E380-E382",14.0,YR,,M,Y,,,20150217.0,N,OT,US,US,Efavirenz,Abdominal pain;Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Kidney enlargement;Lymphadenopathy;Nephropathy toxic;Neuropathy peripheral;Pyrexia;Tubulointerstitial nephritis;Vomiting,108036961.0,HO,,,,,,,,,108036961.0,1.0,HIV infection
10811856,108118561,1,I,,20150127.0,20150212,20150212,EXP,,2015HINLIT0118,HETERO,,33.0,YR,,F,N,,,20150210.0,N,OT,NL,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Oesophageal varices haemorrhage;Portal hypertension,108118561.0,OT,108118561.0,HP,108118561.0,2.0,,,1095.0,DAY,108118561.0,1.0,HIV infection
10812049,108120491,1,I,,20150127.0,20150212,20150212,EXP,,2015HINLIT0114,HETERO,,29.0,YR,,M,N,,,20150210.0,N,OT,NL,,EFAVIRENZ (EFAVIRENZ),Pancytopenia;Portal hypertension,108120491.0,OT,108120491.0,LIT,108120491.0,3.0,,,5475.0,DAY,108120491.0,1.0,HIV infection
10816758,108167581,1,I,,20150204.0,20150218,20150218,EXP,,NL-MYLANLABS-2015M1005167,MYLAN,"ROKX C, VERBON A, RIJNDERS BJA. SUCCESSFUL SWITCH TO RILPIVIRINE/TENOFOVIR/EMTRICITABINE IN HIV-1-INFECTED PATIENTS WITH AN ISOLATED K103N MUTATION ACQUIRED DURING PRIOR NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY. HIV-MED 2014; 15(10):611-614.",,,,,Y,,,20150218.0,N,MD,NL,NL,EFAVIRENZ,Pathogen resistance;Treatment failure;Virologic failure,108167581.0,OT,,,,,,,,,108167581.0,1.0,HIV infection
10817201,108172011,1,I,20150128.0,20150203.0,20150218,20150218,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-007395,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,101.0,KG,20150218.0,N,OT,ZW,ZW,EFAVIRENZ,Hepatotoxicity,108172011.0,LT,,,108172011.0,1.0,20091119.0,20130515.0,,,108172011.0,1.0,HIV infection
10846551,108465511,1,I,,20150208.0,20150220,20150220,EXP,,NG-GLAXOSMITHKLINE-NG2015GSK023178,GLAXOSMITHKLINE,,,,N,F,Y,,,20150220.0,N,OT,NG,NG,Efavirenz,Cleft palate;Foetal exposure during pregnancy;Live birth,108465511.0,OT,,,,,,,,,108465511.0,1.0,HIV infection
10846561,108465611,1,I,,20150208.0,20150220,20150220,EXP,,NG-GLAXOSMITHKLINE-NG2015GSK023192,GLAXOSMITHKLINE,,,,N,F,Y,,,20150220.0,N,OT,NG,NG,Efavirenz,Cleft palate;Foetal exposure during pregnancy;Hearing impaired;Live birth,108465611.0,OT,,,,,,,,,108465611.0,1.0,HIV infection
10847065,108470651,1,I,2012.0,20150116.0,20150220,20150220,EXP,,US-GLAXOSMITHKLINE-US2015005970,GLAXOSMITHKLINE,,,,,M,Y,,,20150220.0,N,CN,COUNTRY NOT SPECIFIED,US,SUSTIVA,Visual acuity reduced,,,,,108470651.0,1.0,2011.0,,,,108470651.0,1.0,HIV infection
10853519,108535191,1,I,,20150209.0,20150223,20150223,EXP,,IN-RANBAXY-2015R1-93256,RANBAXY,"ISAAKIDIS P, PARYANI R, KHAN S, MANSOOR H, MANGLANI M, VALIYAKATH A ET AL. POOR OUTCOMES IN A COHORT OF HIV-INFECTED ADOLESCENTS UNDERGOING TREATMENT FOR MULTIDRUG-RESISTANT TUBERCULOSIS IN MUMBAI, INDIA. PLOS ONE. 2013;JUL;8(7):E68869",14.0,YR,,M,Y,,,20150223.0,N,OT,IN,IN,Efavirenz,Abdominal discomfort;Neuropathy peripheral;Seizure;Tuberculoma of central nervous system,108535191.0,OT,,,108535191.0,4.0,20070727.0,,,,108535191.0,1.0,Antiretroviral therapy
10853561,108535611,1,I,,20150209.0,20150223,20150223,EXP,,IN-RANBAXY-2015R1-93273,RANBAXY,"ISAAKIDIS P, PARYANI R, KHAN S, MANSOOR H, MANGLANI M, VALIYAKATH A ET AL. POOR OUTCOMES IN A COHORT OF HIV-INFECTED ADOLESCENTS UNDERGOING TREATMENT FOR MULTIDRUG-RESISTANT TUBERCULOSIS IN MUMBAI, INDIA. PLOS ONE. 2013;JUL;8(7):E68869",16.0,YR,,F,Y,,,20150223.0,N,OT,IN,IN,Efavirenz,Gastrointestinal infection;Mental disorder;Tuberculoma of central nervous system,108535611.0,OT,,,108535611.0,4.0,20110215.0,,,,108535611.0,1.0,Antiretroviral therapy
10854364,108543641,1,I,,20150216.0,20150223,20150223,EXP,,IN-AUROBINDO-AUR-APL-2015-01368,AUROBINDO,,18.0,YR,,F,Y,,,20150223.0,N,OT,US,IN,Efavirenz,Death;Neuropathy peripheral;Toxicity to various agents,108543641.0,DE,,,108543641.0,4.0,20080619.0,,,,108543641.0,1.0,HIV infection
10855811,108558113,3,F,20150208.0,20150224.0,20150223,20150309,EXP,,UG-009507513-1502UGA007918,MERCK,,30.0,YR,,F,Y,,,20150309.0,N,CN,UG,UG,EFAVIRENZ,Aspartate aminotransferase increased;Hepatotoxicity,108558113.0,HO,,,108558113.0,1.0,20141216.0,20150211.0,,,108558113.0,1.0,HIV infection
10858191,108581912,2,F,,20150310.0,20150223,20150318,EXP,,MX-GILEAD-2015-0138249,GILEAD,"SIERRA-MADERA JG, ELLENBERG SS, RASSOOL MS, ET AL. EFFECT OF THE CCRS ANTAGONIST MARAVIROC ON THE OCCURRENCE OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV (CADIRIS): A DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED TRIAL.. THE LANCET HIV. 2014;1:PP E60-E67",,,A,,Y,,,20150318.0,N,OT,MX,MX,EFAVIRENZ,Hepatitis toxic,108581912.0,OT,,,,,,,,,108581912.0,1.0,HIV infection
10861281,108612812,2,F,20141203.0,20141218.0,20150224,20150226,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-002624,BRISTOL MYERS SQUIBB,,9.0,YR,,F,Y,22.65,KG,20150226.0,N,CN,US,US,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Diarrhoea;Drug eruption;Vomiting,108612812.0,HO,,,108612812.0,1.0,20141118.0,20141204.0,,,108612812.0,1.0,Antiretroviral therapy
10862522,108625221,1,I,,20150210.0,20150219,20150219,EXP,,US2015GSK018734,VIIV,,14.0,YR,,M,N,,,20150217.0,N,OT,US,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Abdominal pain;Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Kidney enlargement;Lymphadenopathy;Nephropathy toxic;Neuropathy peripheral;Pyrexia;Tubulointerstitial nephritis;Vomiting,108625221.0,HO,108625221.0,LIT,,,,,,,108625221.0,1.0,Acquired immunodeficiency syndrome
10866160,108661601,1,I,,20150209.0,20150220,20150220,EXP,,MX2015GSK022049,VIIV,,,,,,N,,,20150218.0,N,MD,MX,,EFAVIRENZ,Hepatitis toxic,108661601.0,OT,108661601.0,HP,,,,,,,108661601.0,1.0,HIV infection
10866843,108668436,6,F,20150114.0,20150310.0,20150225,20150320,EXP,,MW-009507513-1502MWI010173,MERCK,,39.0,YR,,M,Y,,,20150320.0,N,OT,GB,MW,EFAVIRENZ,Meningitis;Sepsis,108668436.0,HO,,,108668436.0,1.0,20141219.0,,,,108668436.0,1.0,HIV infection
10868291,108682912,2,F,20150205.0,20150211.0,20150225,20150327,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010488,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,,,20150327.0,N,CN,GB,ZW,EFAVIRENZ,Deep vein thrombosis,108682912.0,HO,,,108682912.0,1.0,20150108.0,,,,108682912.0,1.0,Antiretroviral therapy
10870030,108700302,2,F,,20150303.0,20150226,20150313,EXP,,NL-AUROBINDO-AUR-APL-2015-01591,AUROBINDO,,23.0,YR,,F,Y,,,20150313.0,N,OT,NL,NL,Efavirenz,Treatment failure,108700302.0,OT,,,,,,,,,108700302.0,1.0,HIV infection
10872255,108722551,1,I,2006.0,20150115.0,20150226,20150226,EXP,,US-GILEAD-2015-0132535,GILEAD,,42.0,YR,A,M,Y,70.3,KG,20150226.0,N,CN,US,US,SUSTIVA,Abnormal dreams;Depressed level of consciousness;Feeling abnormal;Nausea;Renal disorder;Renal impairment;Somnolence,108722551.0,OT,,,108722551.0,1.0,2006.0,2007.0,,,108722551.0,1.0,HIV infection
10872380,108723804,4,F,20150114.0,20150304.0,20150226,20150319,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010566,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20150319.0,N,CN,GB,MW,EFAVIRENZ,Meningitis;Sepsis,108723804.0,HO,,,108723804.0,1.0,20141219.0,,,,108723804.0,1.0,HIV infection
10873013,108730131,1,I,,20150208.0,20150223,20150223,EXP,,NG2015GSK023192,VIIV,,,,,F,N,,,20150220.0,N,OT,NG,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Cleft palate;Hearing impaired;Maternal drugs affecting foetus,108730131.0,OT,108730131.0,SDY,,,,,,,108730131.0,1.0,HIV infection
10873119,108731191,1,I,,20150208.0,20150223,20150223,EXP,,NG2015GSK023178,VIIV,,,,,F,N,,,20150220.0,N,OT,NG,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Cleft palate;Live birth;Maternal drugs affecting foetus,108731191.0,OT,108731191.0,SDY,,,,,,,108731191.0,1.0,HIV infection
10873283,108732832,2,F,20111222.0,20150212.0,20150227,20150227,EXP,,GB-JNJFOC-20150210066,JANSSEN,,57.0,YR,A,M,Y,90.8,KG,20150227.0,N,OT,GB,GB,EFAVIRENZ,Chest pain,108732832.0,OT,,,108732832.0,1.0,20111216.0,20120106.0,,,108732832.0,1.0,HIV infection
10873994,108739942,2,F,20141204.0,20190918.0,20150227,20190923,EXP,,ZA-009507513-1412ZAF004514,MERCK,,9.0,YR,,F,Y,22.65,KG,20190923.0,,CN,ZA,ZA,EFAVIRENZ.,Aspartate aminotransferase increased,108739942.0,OT,,,108739942.0,1.0,20141118.0,20141124.0,,,108739942.0,1.0,Antiretroviral therapy
10880691,108806911,1,I,,20150210.0,20150226,20150226,EXP,,2015HINLIT0175,HETERO,,16.0,YR,,F,N,,,20150224.0,N,OT,IN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Gastrointestinal disorder;Psychotic disorder;Toxicity to various agents;Tuberculoma of central nervous system,108806911.0,OT,108806911.0,HP,108806911.0,4.0,20111215.0,,,,108806911.0,1.0,Antiretroviral therapy
10880695,108806951,1,I,,20150210.0,20150226,20150226,EXP,,2015HINLIT0172,HETERO,,14.0,YR,,M,N,,,20150224.0,N,OT,IN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Gastrointestinal disorder;Neuropathy peripheral;Seizure;Tuberculoma of central nervous system,108806951.0,DE,108806951.0,FGN,108806951.0,5.0,20070727.0,,,,108806951.0,1.0,Antiretroviral therapy
10891605,108916051,1,I,,20150302.0,20150306,20150306,EXP,,IN-GLAXOSMITHKLINE-IN2015GSK029621,GLAXOSMITHKLINE,,14.0,YR,,M,Y,,,20150306.0,N,MD,IN,IN,Efavirenz,Abnormal behaviour;Clumsiness;Disturbance in attention;Dyskinesia;Fall;Myoclonus;Subacute sclerosing panencephalitis,108916051.0,OT,,,,,,,,,108916051.0,1.0,HIV infection
10896658,108966582,2,F,,20150310.0,20150302,20150320,EXP,,MX2015024076,VIIV,,,,,,N,,,20150318.0,N,OT,MX,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Hepatitis toxic,108966582.0,OT,108966582.0,FGN,,,,,,,108966582.0,1.0,HIV infection
10901710,109017102,2,F,20150112.0,20150310.0,20150310,20150325,EXP,,UG-009507513-1502UGA010752,MERCK,,32.0,YR,,F,Y,39.0,KG,20150325.0,N,CN,US,UG,EFAVIRENZ,Sudden death,109017102.0,DE,,,109017102.0,1.0,20150107.0,20150111.0,,,109017102.0,1.0,HIV infection
10902078,109020781,1,I,,20150302.0,20150310,20150310,EXP,,US-JNJFOC-20150302916,JANSSEN,,53.0,YR,A,F,Y,,,20150310.0,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,109020781.0,OT,,,109020781.0,2.0,20131028.0,20140410.0,,,109020781.0,1.0,HIV infection
10902455,109024551,1,I,20150204.0,20150212.0,20150310,20150310,EXP,,UG-009507513-1502UGA012137,MERCK,,30.0,YR,,F,Y,,,20150310.0,N,CN,US,UG,EFAVIRENZ,Coma;Death,109024551.0,DE,,,109024551.0,1.0,20140909.0,20141105.0,,,109024551.0,1.0,HIV infection
10908647,109086471,1,I,20140425.0,20140523.0,20150312,20150312,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20861415,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,62.5,KG,20150312.0,N,OT,US,BR,EFAVIRENZ,Depression suicidal,109086471.0,OT,,,109086471.0,1.0,20131202.0,20140424.0,,,109086471.0,1.0,HIV infection
10911991,109119911,1,I,,20150302.0,20150309,20150309,EXP,,IN2015GSK029621,VIIV,,14.0,YR,,M,N,,,20150306.0,N,MD,IN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Abnormal behaviour;Clumsiness;Disturbance in attention;Dyskinesia;Fall;Myoclonus;Subacute sclerosing panencephalitis,109119911.0,OT,109119911.0,LIT,,,,,,,109119911.0,1.0,HIV infection
10917808,109178082,2,F,20150126.0,20150413.0,20150316,20150420,EXP,,CO-GLAXOSMITHKLINE-CO2015GSK033251,GLAXOSMITHKLINE,,30.0,YR,,M,Y,70.0,KG,20150420.0,N,CN,CO,CO,EFAVIRENZ,Hypersensitivity;Urticaria,109178082.0,OT,,,109178082.0,1.0,20150126.0,20150210.0,,,109178082.0,1.0,HIV test positive
10920208,109202081,1,I,,20150306.0,20150317,20150317,EXP,,ES-CIPLA LTD.-2015ES01987,CIPLA,"PODZAMCZER.D, TIRABOSCHI.JM, MORENO.JA, PUERTAS.MC, VILLAVERDE.C, PRATS.A, FERRER.E, ROZAS.N, MASO.M, OUCHI.D, PICADO.J.. VIRAL AND INFLAMMATORY MARKERS IN CEREBROSPINAL FLUID OF PATIENTS WITH HIV-1-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING ANTIRETROVIRAL TREATMENT SWITCH. HIV MEDICINE. 2015;1-5",,,,,Y,,,20150317.0,N,OT,ES,ES,Efavirenz,Viral load increased,109202081.0,OT,,,,,,,,,109202081.0,1.0,HIV infection
10921481,109214811,1,I,,20150306.0,20150317,20150317,EXP,,ES-CIPLA LTD.-2015ES01985,CIPLA,"PODZAMCZER.D, TIRABOSCHI.JM, MORENO.JA, PUERTAS.MC, VILLAVERDE.C, PRATS.A, FERRER.E, ROZAS.N, MASO.M, OUCHI.D, PICADO.J.. VIRAL AND INFLAMMATORY MARKERS IN CEREBROSPINAL FLUID OF PATIENTS WITH HIV-1-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING ANTIRETROVIRAL TREATMENT SWITCH. HIV MEDICINE. 2015;1-5",,,,,Y,,,20150317.0,N,OT,ES,ES,Efavirenz,Treatment failure,109214811.0,OT,,,,,,,,,109214811.0,1.0,HIV infection
10923869,109238691,1,I,201403.0,20140414.0,20150129,20150129,PER,,K201490302,VIIV,,73.0,YR,,M,N,,,20150125.0,N,CN,US,,SUSTIVA,Abdominal pain upper,109238691.0,HO,109238691.0,CSM,109238691.0,1.0,2011.0,,,,109238691.0,1.0,HIV infection
10925977,109259773,3,F,,20150327.0,20150318,20150402,EXP,,ES-GLAXOSMITHKLINE-ES2015GSK032181,GLAXOSMITHKLINE,,45.0,YR,,F,Y,,,20150402.0,N,MD,ES,ES,Efavirenz,Angina pectoris,109259773.0,OT,,,109259773.0,1.0,20140813.0,,,,109259773.0,1.0,HIV infection
10931227,109312272,2,F,20150126.0,20150413.0,20150317,20150421,EXP,,CO2015GSK033251,VIIV,,30.0,YR,,M,N,70.0,KG,20150419.0,N,PH,CO,,EFAVIRENZ (EFAVIRENZ),Hypersensitivity;Urticaria,109312272.0,RI,109312272.0,HP,109312272.0,1.0,20150126.0,20150210.0,,,109312272.0,1.0,HIV test positive
10932955,109329552,2,F,20141210.0,20150316.0,20150320,20150323,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-015418,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20150323.0,N,CN,ZW,ZW,EFAVIRENZ,Anaemia;HIV infection;Weight decreased,109329552.0,DE,,,109329552.0,1.0,20140108.0,20141209.0,,,109329552.0,1.0,HIV infection
10949295,109492952,2,F,,20150327.0,20150320,20150406,EXP,,ES2015GSK032181,VIIV,,45.0,YR,,F,N,,,20150402.0,N,MD,ES,,EFAVIRENZ (EFAVIRENZ),Angina pectoris,109492952.0,RI,109492952.0,FGN,109492952.0,1.0,20140813.0,,,,109492952.0,1.0,HIV infection
10950692,109506921,1,I,20110120.0,20150311.0,20150324,20150324,EXP,,IN-MYLANLABS-2015M1009374,MYLAN,"KRISHNARAJ R, CHOCKALINGAM C, KRISHNARAJASEKHAR OR, AYYAMPERUMAL M, NARAYANAN R, SATAGOPAN K. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) WITH ACUTE TUBERCULOUS OSTEOMYELITIS AND DISSEMINATED MUTILATING TUBERCULOUS DACTYLITIS IN A PERSON LIVING WITH HIV AND AIDS (PLHA): A CASE REPORT. J-INT-ASSOC-PHYS-AIDS-CARE 2012; 11(5):289-92.",,,,,Y,,,20150324.0,N,MD,IN,IN,EFAVIRENZ,Dactylitis;Immune reconstitution inflammatory syndrome associated tuberculosis;Osteomyelitis acute,109506921.0,OT,,,109506921.0,1.0,20101222.0,,,,109506921.0,1.0,HIV infection
10950906,109509061,1,I,20140610.0,20140613.0,20150324,20150324,EXP,,ZW-GILEAD-2014-0105557,GILEAD,,36.0,YR,A,F,Y,43.0,KG,20150324.0,N,MD,ZW,ZW,EFAVIRENZ,Renal failure,109509061.0,DE,,,109509061.0,1.0,20140127.0,20140609.0,,,109509061.0,1.0,HIV infection
10955026,109550262,2,F,20110531.0,20150909.0,20150325,20150921,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-016752,BRISTOL MYERS SQUIBB,,41.0,YR,,F,Y,,,20150921.0,N,MD,GB,GB,SUSTIVA,Colectomy;Colon cancer,109550262.0,OT,,,109550262.0,1.0,20060214.0,,,,109550262.0,1.0,HIV infection
10958458,109584581,1,I,,20150318.0,20150326,20150326,EXP,,UG-GILEAD-2015-0143659,GILEAD,"NDAGIJE H, NAMBASA V, NAMAGALA E, NASSALI H, KAJUNGU D, SEMATIKO G, OLSSON S AND PAL S. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA.. DRUG SAFETY.. 2015;UNK:UNK",38.0,YR,A,M,Y,,,20150326.0,N,OT,UG,UG,EFAVIRENZ,Death,109584581.0,OT,,,,,,,,,109584581.0,1.0,HIV infection
10960639,109606392,2,F,,20150518.0,20150325,20150528,EXP,,B1027202A,VIIV,,,,,M,N,,,20150522.0,N,CN,UZ,,EFAVIRENZ (EFAVIRENZ),Anxiety;Arthralgia;Conversion disorder;Depression;Diarrhoea;Disturbance in attention;Fear of death;Impaired work ability;Irritability;Neck pain;Poisoning;Renal disorder;Weight decreased,109606392.0,HO,109606392.0,FGN,,,,,,,109606392.0,1.0,HIV infection
10961895,109618951,1,I,20141115.0,20150313.0,20150327,20150327,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-017609,BRISTOL MYERS SQUIBB,,59.0,YR,,F,Y,56.0,KG,20150327.0,N,CN,US,BR,EFAVIRENZ,Acute pulmonary oedema;American trypanosomiasis;Cardiac failure congestive;Cardiomyopathy,109618951.0,DE,,,109618951.0,1.0,20141020.0,,,,109618951.0,1.0,HIV infection
10961951,109619511,1,I,201211.0,20150312.0,20150327,20150327,EXP,,JP-GILEAD-2015-0143616,GILEAD,,37.0,YR,A,M,Y,,,20150327.0,N,MD,JP,JP,EFAVIRENZ,Abulia;Brain death;Central nervous system lymphoma;Decreased appetite;Disorientation;Dysarthria;Dyspnoea;Fatigue;Hyperreflexia;JC virus infection;Lethargy;Locked-in syndrome;Progressive multifocal leukoencephalopathy;Pyrexia,109619511.0,DE,,,,,,,,,109619511.0,1.0,HIV infection
10962723,109627234,4,F,20141013.0,20150821.0,20150327,20150827,EXP,,TR-GILEAD-2015-0137308,GILEAD,,61.0,YR,A,M,Y,80.0,KG,20150827.0,N,MD,TR,TR,EFAVIRENZ,Chronic kidney disease;Nephropathy toxic;Overdose,109627234.0,OT,,,109627234.0,1.0,20140917.0,20141014.0,,,109627234.0,1.0,HIV infection
10965025,109650253,3,F,20110120.0,20231222.0,20150330,20240105,EXP,,IN-AUROBINDO-AUR-APL-2015-02603,AUROBINDO,"Raja Krishnaraj, Chandrasekar Chockalingam, O.R. Krishnarajasekhar, Mahilmaran Ayyamperumal, Ravichandran Narayanan, Kumar Satagopan. Immune Reconstitution Inflammatory Syndrome (IRIS) with acute tuberculous osteomyelitis and disseminated mutilating tuberculous dactylitis in a person living with HIV and AIDS (PLHA): a case report. Journal of the International Association of Physicians in AIDS Care. 2012;11(5):289-292",27.0,YR,,M,Y,,,20240105.0,,MD,IN,IN,EFAVIRENZ,Acid fast bacilli infection;Arthralgia;Cellulitis;Dactylitis;Decreased appetite;Deformity;Disseminated tuberculosis;Dyspnoea;Hypokinesia;Immune reconstitution inflammatory syndrome associated tuberculosis;Joint warmth;Osteomyelitis acute;Pain;Pneumonia klebsiella;Pyrexia;Sepsis;Swelling;Tachycardia;Tenderness;Toxicity to various agents;Ulcer;Ulcer haemorrhage,109650253.0,OT,,,109650253.0,1.0,20101222.0,,,,109650253.0,1.0,HIV infection
10966389,109663892,2,F,20150310.0,20150414.0,20150330,20150427,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-018204,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,70.0,KG,20150427.0,N,CN,MW,MW,EFAVIRENZ,Disseminated tuberculosis;Haemoglobin decreased;Non-Hodgkin's lymphoma,109663892.0,OT,,,109663892.0,1.0,20140515.0,20150309.0,,,109663892.0,1.0,HIV infection
10968451,109684513,3,F,20150129.0,20150325.0,20150330,20150407,EXP,,KE-009507513-1502GBR008935,MERCK,,38.0,YR,,F,Y,52.3,KG,20150407.0,N,MD,KE,KE,EFAVIRENZ,Death;Muscular weakness;Tuberculosis,109684513.0,OT,,,109684513.0,1.0,20141001.0,20141217.0,,,109684513.0,1.0,HIV infection
10968837,109688372,2,F,,20180530.0,20150331,20180614,EXP,,UG-CIPLA LTD.-2015UG02466,CIPLA,"NDAGIJE H, NAMBASA V, NAMAGALA E, NASSALI H, KAJUNGU D, SEMATIKO G ET AL.,. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAFS. 2015",,,,,Y,,,20180614.0,,OT,UG,UG,EFAVIRENZ.,Blood creatinine increased;Lipodystrophy acquired,109688372.0,OT,,,109688372.0,1.0,2006.0,,,,109688372.0,1.0,HIV infection
10968852,109688521,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02482,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015;1-14",,,,,Y,,,20150330.0,N,OT,UG,UG,Efavirenz,Blood creatinine increased,109688521.0,OT,,,,,,,,,109688521.0,1.0,HIV infection
10968912,109689121,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02479,CIPLA,"NDAGIJE H, NAMBASA V, NAMAGALA E, NASSALI H, KAJUNGU D, SEMATIKO G ET.AL.. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAFS. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Neutropenia;Protein urine present,109689121.0,OT,,,,,,,,,109689121.0,1.0,HIV infection
10968950,109689501,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02486,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Blood urine present;Protein urine;Urinary tract infection;White blood cells urine positive,109689501.0,OT,,,,,,,,,109689501.0,1.0,HIV test positive
10968953,109689531,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02497,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Blood creatinine increased,109689531.0,OT,,,,,,,,,109689531.0,1.0,HIV test positive
10968961,109689611,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02498,CIPLA,"NDAGIJE.H, NAMBASA.V, NAMAGALA.E, NASSALI.H, KAJUNGU.D, SEMATIKO.G, OLSSON.S, PAL.S.. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015;1-14",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Anaemia;Death;Hydronephrosis;Oedema peripheral;Protein urine,109689611.0,DE,,,,,,,,,109689611.0,1.0,HIV infection
10969104,109691041,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02502,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Blood creatinine increased,109691041.0,LT,,,,,,,,,109691041.0,1.0,HIV infection
10969109,109691091,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02506,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Protein urine present;Renal tubular necrosis,109691091.0,OT,,,,,,,,,109691091.0,1.0,HIV test positive
10969110,109691101,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02499,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Kaposi's sarcoma,109691101.0,OT,,,,,,,,,109691101.0,1.0,HIV test positive
10969131,109691311,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02509,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Bone density decreased;Bone formation decreased,109691311.0,OT,,,,,,,,,109691311.0,1.0,HIV test positive
10969133,109691331,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02510,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Haematuria,109691331.0,OT,,,,,,,,,109691331.0,1.0,HIV test positive
10969135,109691351,1,I,,20150316.0,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02511,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331.0,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Protein urine present,109691351.0,OT,,,,,,,,,109691351.0,1.0,HIV test positive
10971671,109716711,1,I,200011.0,20150325.0,20150331,20150331,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2015-BI-16629GD",BOEHRINGER INGELHEIM,"RAZONABLE R,AKSAMIT A,WRIGHT A,WILSON J. CIDOFOVIR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. MAYO CLIN PROC 2001 NOV;76:11:1171-1175.",55.0,YR,,M,Y,,,20150331.0,N,OT,COUNTRY NOT SPECIFIED,US,EFAVIRENZ,Immune system disorder;Progressive multifocal leukoencephalopathy,109716711.0,OT,,,109716711.0,1.0,200009.0,200009.0,,,109716711.0,1.0,Acquired immunodeficiency syndrome
10975184,109751842,2,F,20141008.0,20150605.0,20150401,20150610,EXP,,KE-GILEAD-2015-0145425,GILEAD,,30.0,YR,A,M,Y,51.6,KG,20150610.0,N,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Anaemia;Hyponatraemia,109751842.0,OT,,,109751842.0,1.0,20140821.0,20141008.0,,,109751842.0,1.0,HIV infection
10975394,109753941,1,I,200905.0,20150323.0,20150401,20150401,EXP,,BR-GLAXOSMITHKLINE-BR2015GSK043089,GLAXOSMITHKLINE,"GOIS L, BADARO R, SCHOOLEY R AND GRASSI M.F.R. IMMUNE RESPONSE TO LEISHMANIA ANTIGENS IN AN AIDS PATIENT WITH MUCOCUTANEOUS LEISHMANIASIS AS A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS): A CASE REPORT. BMC INFECTIOUS DISEASES. 2015;15:58",29.0,YR,,M,Y,,,20150401.0,N,OT,BR,BR,Efavirenz,Immune reconstitution inflammatory syndrome;Inflammation;Lymphadenopathy;Mucocutaneous leishmaniasis;Myiasis;Nasal obstruction;Skin necrosis;Skin ulcer;Swelling,109753941.0,OT,,,109753941.0,1.0,200812.0,,,,109753941.0,1.0,HIV infection
10975968,109759681,1,I,200209.0,20150320.0,20150401,20150401,EXP,,HR-MYLANLABS-2015M1010534,MYLAN,"VISKOVIC K, STEMBERGER L, BRNIC Z, BEGOVAC J. REPEATED PRESENTATION OF GRAVES^S DISEASE AS A MANIFESTATION OF IMMUNE RECONSTITUTION SYNDROME IN AN HIV-INFECTED PATIENT TAKING HAART: CASE REPORT. ACTA-CLIN-CROAT 2013; 52(1):125-127.",,,,,Y,,,20150401.0,N,MD,HR,HR,EFAVIRENZ,Basedow's disease;Immune reconstitution inflammatory syndrome,109759681.0,OT,,,109759681.0,1.0,200101.0,,,,109759681.0,1.0,HIV infection
10978129,109781291,1,I,,20150322.0,20150402,20150402,EXP,,IN-CIPLA LTD.-2015IN02573,CIPLA,"RAMESH R. ALLAMA, MANOJ V. MURHEKARA, TARUN BHATNAGARA, CHENGAPPA K. UTHAPPAB, C. NALINIB, B. B. REWARIC AND SANJAY M MEHENDALEA. PREDICTORS OF IMMUNOLOGICAL FAILURE AND DETERMINANTS OF SUBOPTIMAL CD4 TESTING AMONG ADULTS WITH HIV ON FIRST-LINE ANTIRETROVIRAL THERAPY IN ANDHRA PRADESH, INDIA, 2008?2011. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 2015;1 TO 9",,,,,Y,,,20150402.0,N,OT,IN,IN,Efavirenz,Death,109781291.0,DE,,,,,,,,,109781291.0,1.0,HIV infection
10978477,109784773,3,F,20150112.0,20160315.0,20150402,20160318,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-019001,BRISTOL MYERS SQUIBB,,12.0,YR,,M,Y,,,20160318.0,,OT,KE,KE,EFAVIRENZ,Gastroenteritis,109784773.0,HO,,,,,,,,,109784773.0,1.0,Antiretroviral therapy
10978739,109787391,1,I,201503.0,20150324.0,20150331,20150331,EXP,,RU2015GSK039343,VIIV,,37.0,YR,,M,N,75.0,KG,20150329.0,N,MD,RU,,STOCRIN (EFAVIRENZ) (EFAVIRENZ) TABLET,Acute myocardial infarction,109787391.0,OT,109787391.0,FGN,109787391.0,1.0,20120411.0,,,,109787391.0,1.0,HIV infection
10980384,109803842,2,F,20150131.0,20150413.0,20150402,20150422,EXP,,KE-GILEAD-2015-0145809,GILEAD,,38.0,YR,A,F,Y,,,20150422.0,N,MD,KE,KE,EFAVIRENZ,Death;Muscular weakness;Pyelonephritis;Tuberculosis,109803842.0,HO,,,109803842.0,1.0,20141001.0,20150323.0,,,109803842.0,1.0,HIV infection
10981008,109810081,1,I,200011.0,20150325.0,20150402,20150402,EXP,,"US-ROXANE LABORATORIES, INC.-2015-BI-16629GD",ROXANE,"RAZONABLE R,AKSAMIT A,WRIGHT A,WILSON J. CIDOFOVIR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. MAYO CLIN PROC 2001 NOV;76:11:1171-1175.",55.0,YR,,M,Y,,,20150403.0,N,OT,COUNTRY NOT SPECIFIED,US,EFAVIRENZ,Immune system disorder;Progressive multifocal leukoencephalopathy,109810081.0,OT,,,109810081.0,1.0,200009.0,200009.0,,,109810081.0,1.0,Acquired immunodeficiency syndrome
10991102,109911021,1,I,20150129.0,20150209.0,20150406,20150406,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-009061,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20150406.0,N,CN,KE,KE,EFAVIRENZ,Death;Muscular weakness;Tuberculosis,109911021.0,DE,,,109911021.0,1.0,20141001.0,,,,109911021.0,1.0,Antiretroviral therapy
10991801,109918012,2,F,20141030.0,20150412.0,20150406,20150420,EXP,,CN-GILEAD-2015-0146232,GILEAD,,64.0,YR,A,F,Y,64.0,KG,20150420.0,N,MD,CN,CN,EFAVIRENZ,Blood creatinine increased;Multi-organ failure;Oliguria,109918012.0,OT,,,109918012.0,1.0,20141030.0,20141111.0,,,109918012.0,1.0,Acquired immunodeficiency syndrome
10993190,109931901,1,I,20141202.0,20150213.0,20150407,20150407,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-011026,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20150407.0,N,OT,UG,UG,EFAVIRENZ,Death;Lymph node tuberculosis;Sepsis,109931901.0,DE,,,109931901.0,1.0,20150107.0,20150112.0,,,109931901.0,1.0,Antiretroviral therapy
10998311,109983111,1,I,200905.0,20150323.0,20150406,20150406,EXP,,BR2015GSK043089,VIIV,,29.0,YR,,M,N,,,20150401.0,N,OT,BR,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Immune reconstitution inflammatory syndrome;Inflammation;Lymphadenopathy;Mucocutaneous leishmaniasis;Myiasis;Nasal obstruction;Skin necrosis;Skin ulcer;Swelling,109983111.0,OT,109983111.0,HP,109983111.0,1.0,200812.0,,,,109983111.0,1.0,HIV infection
11002842,110028422,2,F,20150310.0,20150909.0,20150408,20150921,EXP,,BW-GILEAD-2015-0146397,GILEAD,,39.0,YR,A,M,Y,,,20150921.0,N,MD,BW,BW,EFAVIRENZ,VIIth nerve paralysis,110028422.0,HO,,,110028422.0,1.0,20091118.0,20150226.0,,,110028422.0,1.0,HIV infection
11003783,110037833,3,F,2008.0,20201112.0,20150409,20201118,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-022290,BRISTOL MYERS SQUIBB,"FERNANDO I, SCOTT G. A CASE OF MULTICENTRIC CASTLEMAN^S DISEASE IN HIV INFECTION WITH THE RARE COMPLICATION OF ACQUIRED ANGIOEDEMA. INTERNATIONAL JOURNAL OF STD AND AIDS. 2014;25 (7):523-5",37.0,YR,,F,Y,,,20201118.0,,MD,GB,GB,EFAVIRENZ.,Angioedema;Castleman's disease;Immune reconstitution inflammatory syndrome,110037833.0,HO,,,110037833.0,1.0,200403.0,,,,110037833.0,1.0,HIV infection
11005139,110051392,2,F,,20150417.0,20150409,20150422,EXP,,JP-GLAXOSMITHKLINE-JP2015JPN045663,GLAXOSMITHKLINE,"WADA T, ET AL.. A CASE OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION PRESENTING WITH VARIOUS IMMUNE ABNORMALITIES. THE JOURNAL OF THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES. 2015;89:290",68.0,YR,,M,Y,,,20150422.0,N,MD,JP,JP,Efavirenz,Anaemia;Anti-GAD antibody positive;Antimitochondrial antibody positive;Antinuclear antibody positive;Autoantibody positive;Calculus urinary;Cutaneous lupus erythematosus;DNA antibody positive;Glycosylated haemoglobin increased;Hepatic function abnormal;Immunology test abnormal;Rash;Type 1 diabetes mellitus,110051392.0,OT,,,,,,,,,110051392.0,3.0,Acquired immunodeficiency syndrome
11011237,110112375,5,F,,20150924.0,20150410,20151002,EXP,,CA-ABBVIE-15P-028-1372603-00,ABBVIE,,52.0,YR,,M,Y,,,20151002.0,,OT,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110112375.0,OT,,,,,,,,,110112375.0,1.0,HIV infection
11021180,110211801,1,I,,20150402.0,20150413,20150413,EXP,,BY-CIPLA LTD.-2015BY02778,CIPLA,"SVETLANA SETKINA, MARINA DOTSENKO, SVIATLANA BONDAR, IRYNA CHARNYSH, ALLA KUCHKO, ALENA KAZNACHEEVA, ELENA KOZOREZ, ALENA DODALEVA, NATALIA ROSSA. SAFETY AND EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN TREATMENT-NA??VE HIV PATIENTS: PRELIMINARY FINDINGS OF A COHORT EVENT MONITORING STUDY IN BELARUS. DRUG SAF",,,,,Y,,,20150413.0,N,OT,BY,BY,Efavirenz,Hypoaesthesia oral,110211801.0,OT,,,,,,,,,110211801.0,1.0,HIV infection
11024072,110240723,3,F,,20150924.0,20150413,20151002,EXP,,CA-ABBVIE-15P-028-1372646-00,ABBVIE,,52.0,YR,,M,Y,,,20151002.0,,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110240723.0,OT,,,,,,,,,110240723.0,1.0,HIV infection
11024262,110242621,1,I,20150312.0,20150407.0,20150414,20150414,EXP,,IN-AUROBINDO-AUR-APL-2015-03094,AUROBINDO,,22.0,YR,,F,Y,,,20150413.0,N,MD,IN,IN,EFAVIRENZ TABLETS 600 MG,Rash maculo-papular,110242621.0,OT,,,110242621.0,1.0,20150305.0,20150312.0,,,110242621.0,1.0,HIV infection
11024290,110242901,1,I,,20150402.0,20150414,20150414,EXP,,BY-CIPLA LTD.-2015BY02779,CIPLA,"SVETLANA SETKINA, MARINA DOTSENKO, SVIATLANA BONDAR, IRYNA CHARNYSH, ALLA KUCHKO, ALENA KAZNACHEEVA, ELENA KOZOREZ, ALENA DODALEVA, NATALIA ROSSA. SAFETY AND EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN TREATMENT-NA??VE HIV PATIENTS: PRELIMINARY FINDINGS OF A COHORT EVENT MONITORING STUDY IN BELARUS. DRUG SAF. 2015",,,,,Y,,,20150414.0,N,OT,BY,BY,Efavirenz,Loss of consciousness,110242901.0,OT,,,,,,,,,110242901.0,1.0,HIV infection
11024291,110242911,1,I,,20150402.0,20150414,20150414,EXP,,BY-CIPLA LTD.-2015BY02805,CIPLA,"SVETLANA SETKINA,  MARINA DOTSENKO,  SVIATLANA BONDAR, IRYNA CHARNYSH, ALLA KUCHKO, ALENA KAZNACHEEVA ET AL.. SAFETY AND EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN TREATMENT-NA??VE HIV PATIENTS: PRELIMINARY FINDINGS OF A COHORT EVENT MONITORING STUDY IN BELARUS. DRUG SAF. 2015;1 TO 8",,,,,Y,,,20150414.0,N,OT,BY,BY,Efavirenz,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,110242911.0,OT,,,,,,,,,110242911.0,1.0,HIV test positive
11024851,110248512,2,F,,20150417.0,20150410,20150424,EXP,,JP2015JPN045663,VIIV,,68.0,YR,,M,N,,,20150421.0,N,MD,JP,,EFAVIRENZ (EFAVIRENZ),Anaemia;Anti-GAD antibody positive;Antimitochondrial antibody positive;Antinuclear antibody positive;Autoantibody positive;Calculus urinary;Cutaneous lupus erythematosus;DNA antibody positive;Glycosylated haemoglobin increased;Hepatic function abnormal;Immunology test abnormal;Rash;Type 1 diabetes mellitus,110248512.0,OT,110248512.0,FGN,,,,,,,110248512.0,2.0,Acquired immunodeficiency syndrome
11031902,110319022,2,F,20140814.0,20150422.0,20150415,20150428,EXP,,UG-GLAXOSMITHKLINE-UG2015GSK050860,GLAXOSMITHKLINE,,48.0,YR,,M,Y,,,20150428.0,N,MD,UG,UG,EFAVIRENZ,Anaemia,110319022.0,DE,,,110319022.0,1.0,20140527.0,20140821.0,,,110319022.0,1.0,HIV infection
11044115,110441151,1,I,,20150331.0,20150415,20150415,EXP,,FK201501717,FRESENIUS KABI,,44.0,YR,,M,N,,,20150409.0,N,,US,,EFAVIRENZ,Drug interaction;Febrile neutropenia;Neuropathy peripheral,110441151.0,OT,110441151.0,HP,,,,,,,110441151.0,1.0,HIV infection
11050632,110506322,2,F,20140814.0,20150422.0,20150417,20150430,EXP,,UG2015GSK050860,VIIV,,48.0,YR,,M,N,,,20150427.0,N,MD,UG,,EFAVIRENZ (EFAVIRENZ),Anaemia;Dehydration;Pallor,110506322.0,DE,110506322.0,HP,110506322.0,1.0,20140527.0,20140821.0,,,110506322.0,1.0,HIV infection
11054474,110544742,2,F,,20160117.0,20150422,20160201,EXP,,CH-CIPLA LTD.-2015CH03145,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2015?1 TO 20",,,,,Y,,,20160201.0,,OT,CH,GB,Efavirenz,Hepatic steatosis;Hepatitis C,110544742.0,DE,,,,,,,,,110544742.0,1.0,HIV infection
11054476,110544761,1,I,,20150413.0,20150422,20150422,EXP,,CH-CIPLA LTD.-2015CH03136,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1 TO 20",,,,,Y,,,20150422.0,N,OT,CH,CH,Efavirenz,Sepsis,110544761.0,DE,,,,,,,,,110544761.0,1.0,HIV test positive
11054477,110544772,2,F,,20160117.0,20150422,20160201,EXP,,CH-CIPLA LTD.-2015CH03142,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2015?1 TO 20",,,,,Y,,,20160201.0,,OT,CH,GB,Efavirenz,Lactic acidosis,110544772.0,DE,,,,,,,,,110544772.0,1.0,HIV infection
11055572,110555721,1,I,20150112.0,20150319.0,20150422,20150422,EXP,,US-009507513-1503GBR013971,MERCK,,12.0,YR,,M,Y,,,20150422.0,N,CN,US,KE,EFAVIRENZ,Gastroenteritis,110555721.0,HO,,,,,,,,,110555721.0,1.0,HIV infection
11069569,110695691,1,I,20140816.0,20150420.0,20150427,20150427,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK055115,GLAXOSMITHKLINE,,60.0,YR,,M,Y,,,20150427.0,N,MD,CN,CN,EFAVIRENZ,Hypersensitivity,110695691.0,OT,,,110695691.0,1.0,20140812.0,20140826.0,,,110695691.0,1.0,HIV infection
11070860,110708601,1,I,20150407.0,20150415.0,20150428,20150428,EXP,,TW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-025652,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,,,20150428.0,N,CN,TW,TW,EFAVIRENZ,Abdominal pain;Pyrexia,110708601.0,HO,,,110708601.0,1.0,20141108.0,,,,110708601.0,1.0,HIV infection
11072338,110723381,1,I,20150412.0,20150422.0,20150428,20150428,EXP,,MW-009507513-1504MWI021776,MERCK,,39.0,YR,,F,Y,,,20150428.0,N,CN,MW,MW,EFAVIRENZ,Lower respiratory tract infection,110723381.0,HO,,,110723381.0,1.0,20150324.0,,,,110723381.0,1.0,Antiretroviral therapy
11073050,110730501,1,I,,20150420.0,20150428,20150428,EXP,,UG-GLAXOSMITHKLINE-UG2015GSK057314,GLAXOSMITHKLINE,"MUSUBIRE AK, MEYA DB, LUKANDE R, KAMBUGU A, BOHJANEN PR, BOULWARE DR. GASTROINTESTINALCRYPTOCOCCOMA - IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OR CRYPTOCOCCAL RELAPSE IN A PATIENT WITH AIDS?. MEDICAL MYCOLOGY CASE REPORTS. 2015;8:40-43",37.0,YR,,M,Y,,,20150428.0,N,OT,UG,UG,Efavirenz,Abdominal pain;Abdominal tenderness;Cough;Cryptococcosis;Immune reconstitution inflammatory syndrome;Pyrexia;Tachypnoea;Vomiting,110730501.0,OT,,,110730501.0,1.0,20090611.0,,,,110730501.0,1.0,HIV infection
11075935,110759351,1,I,20140926.0,20150420.0,20150429,20150429,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK054512,GLAXOSMITHKLINE,,36.0,YR,,F,Y,,,20150429.0,N,MD,CN,CN,Efavirenz,Dermatitis allergic,110759351.0,HO,,,110759351.0,1.0,20140905.0,20140928.0,,,110759351.0,1.0,Acquired immunodeficiency syndrome
11075940,110759401,1,I,20140221.0,20150420.0,20150429,20150429,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK054510,GLAXOSMITHKLINE,,61.0,YR,,M,Y,,,20150429.0,N,MD,CN,CN,Efavirenz,Anaemia;Hepatocellular injury;Off label use,110759401.0,OT,,,110759401.0,1.0,20140221.0,20140829.0,,,110759401.0,1.0,Acquired immunodeficiency syndrome
11076644,110766441,1,I,20130917.0,20131001.0,20150429,20150429,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19681527,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20150429.0,N,CN,US,UG,EFAVIRENZ,Bronchopneumonia;Cryptosporidiosis infection;Death,110766441.0,LT,,,110766441.0,1.0,20130902.0,20130904.0,,,110766441.0,1.0,HIV infection
11078607,110786071,1,I,20140816.0,20150420.0,20150428,20150428,EXP,,CN2015GSK055115,VIIV,,60.0,YR,,M,N,,,20150426.0,N,MD,CN,,EFAVIRENZ,Hypersensitivity,110786071.0,OT,110786071.0,HP,110786071.0,1.0,20140812.0,20140826.0,,,110786071.0,1.0,HIV infection
11078929,110789292,2,F,20150412.0,20150511.0,20150430,20150514,EXP,,MW-GILEAD-2015-0150435,GILEAD,,39.0,YR,A,F,Y,,,20150514.0,N,MD,MW,MW,EFAVIRENZ,Lower respiratory tract infection,110789292.0,OT,,,110789292.0,1.0,20150324.0,,,,110789292.0,1.0,HIV infection
11079990,110799903,3,F,20150407.0,20150518.0,20150430,20150601,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-026377,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,61.0,KG,20150601.0,N,CN,MW,MW,EFAVIRENZ,Neutropenia,110799903.0,LT,,,110799903.0,1.0,20140502.0,20150122.0,,,110799903.0,1.0,HIV infection
11082112,110821121,1,I,,20150421.0,20150501,20150501,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK058611,GLAXOSMITHKLINE,"GKENTZI D, TEBRUEGGE M, TUDOR-WILLIAMS G, WALTERS S, LYALL H, SHARLAND M ET AL. INCIDENCE, SPECTRUM AND OUTCOME OF IMMUNE RECONSTITUTION SYNDROME IN HIV-INFECTED CHILDREN AFTER INITIATION OF ANTIRETROVIRAL THERAPY. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2014;33:9",8.0,YR,,F,Y,,,20150501.0,N,MD,GB,GB,Efavirenz,Hepatosplenomegaly;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Mechanical ventilation;Mycobacterium avium complex infection;Respiratory disorder;Tuberculosis,110821121.0,DE,,,,,,,,,110821121.0,1.0,HIV infection
11082121,110821211,1,I,,20150421.0,20150501,20150501,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK059254,GLAXOSMITHKLINE,"GKENTZI D, TEBRUEGGE M, TUDOR-WILLIAMS G, WALTERS S, LYALL H, SHARLAND M ET AL. INCIDENCE, SPECTRUM AND OUTCOME OF IMMUNE RECONSTITUTION SYNDROME IN HIV-INFECTED CHILDREN AFTER INITIATION OF ANTIRETROVIRAL THERAPY. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2014;33:9",14.0,YR,,M,Y,,,20150501.0,N,MD,GB,GB,Efavirenz,Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Granuloma;Hepatomegaly;Immune reconstitution inflammatory syndrome;Lung infiltration;Mycobacterium avium complex infection;Pleural effusion;Pyrexia;Respiratory disorder,110821211.0,DE,,,,,,,,,110821211.0,1.0,HIV infection
11087763,110877631,1,I,,20150424.0,20150430,20150430,EXP,,UG2015GSK057314,VIIV,,37.0,YR,,M,N,,,20150428.0,N,OT,UG,,EFAVIRENZ,Abdominal pain;Abdominal tenderness;Adhesion;Appendix disorder;Cough;Cryptococcosis;Immune reconstitution inflammatory syndrome;Intestinal perforation;Lymphadenopathy;Mass;Peritonitis;Pneumoperitoneum;Pyrexia;Tachypnoea;Vomiting,110877631.0,OT,110877631.0,LIT,110877631.0,1.0,20090611.0,,,,110877631.0,1.0,HIV infection
11088152,110881521,1,I,20140926.0,20150420.0,20150430,20150430,EXP,,CN2015GSK054512,VIIV,,36.0,YR,,F,N,,,20150429.0,N,MD,CN,,EFAVIRENZ,Dermatitis allergic,110881521.0,HO,110881521.0,FGN,110881521.0,1.0,20140905.0,20140928.0,,,110881521.0,1.0,Acquired immunodeficiency syndrome
11088175,110881751,1,I,20140221.0,20150420.0,20150430,20150430,EXP,,CN2015GSK054510,VIIV,,61.0,YR,,M,N,,,20150429.0,N,MD,CN,,EFAVIRENZ (EFAVIRENZ) TABLET,Anaemia;Drug-induced liver injury;Hepatocellular injury;Off label use,110881751.0,HO,110881751.0,HP,110881751.0,1.0,20140221.0,20140829.0,,,110881751.0,1.0,Acquired immunodeficiency syndrome
11092149,110921491,1,I,201502.0,20150422.0,20150505,20150505,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-027008,BRISTOL MYERS SQUIBB,,61.0,YR,,F,Y,,,20150505.0,N,CN,FR,FR,SUSTIVA,Nephropathy,110921491.0,OT,,,110921491.0,1.0,20040614.0,20150224.0,,,110921491.0,1.0,HIV infection
11092387,110923871,1,I,,20150421.0,20150504,20150504,EXP,,GB2015GSK058611,VIIV,,8.0,YR,,F,N,,,20150501.0,N,MD,GB,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,General physical health deterioration;Hepatosplenomegaly;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Multi-organ failure;Mycobacterium avium complex infection;Respiratory disorder;Tuberculosis,110923871.0,OT,110923871.0,LIT,,,,,,,110923871.0,1.0,HIV infection
11092389,110923891,1,I,,20150421.0,20150504,20150504,EXP,,GB2015GSK059254,VIIV,,14.0,YR,,M,N,,,20150501.0,N,,GB,,EFAVIRENZ (EFAVIRENZ),Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Granuloma;Hepatomegaly;Immune reconstitution inflammatory syndrome;Lung infiltration;Mycobacterium avium complex infection;Pleural effusion;Pyrexia;Respiratory disorder,110923891.0,DE,110923891.0,HP,,,,,,,110923891.0,1.0,HIV infection
11092579,110925791,1,I,2009.0,20150420.0,20150504,20150504,EXP,,RU2015GSK054554,VIIV,,,,,F,N,,,20150430.0,N,CN,RU,,STOCRIN (EFAVIRENZ),Abnormal dreams;Caesarean section;Diarrhoea;Dizziness;Exposure during pregnancy;Haemoglobin decreased;Hepatic cirrhosis;Insomnia;Jaundice;Lipodystrophy acquired;Memory impairment;Nausea;Platelet count decreased;Pregnancy;Premature delivery;Toxic skin eruption;Viral load increased,110925791.0,HO,110925791.0,CSM,110925791.0,1.0,2009.0,20150405.0,,,110925791.0,1.0,HIV infection
11092598,110925981,1,I,,20150430.0,20150506,20150506,EXP,,UG-CIPLA LTD.-2015UG03502,CIPLA,,,,,,Y,,,20150506.0,N,OT,UG,UG,Efavirenz,Abnormal behaviour;Aggression;Insomnia;Psychomotor hyperactivity,110925981.0,OT,,,,,,,,,110925981.0,1.0,HIV infection
11092896,110928961,1,I,2002.0,20150422.0,20150504,20150504,EXP,,US2015055006,VIIV,,,,,M,N,,,20150429.0,N,CN,US,,SUSTIVA,Bedridden;Depression;Facial wasting;Fat redistribution;Fatigue;Suicide attempt,110928961.0,OT,110928961.0,CSM,110928961.0,1.0,2001.0,201409.0,,,110928961.0,1.0,HIV infection
11093886,110938864,4,F,,20220321.0,20150506,20220324,EXP,,GB-BMSGILMSD-2015-0151479,GILEAD,"Bulman J, Teo SY, Page E. An uncommon cause of anaemia in pregnancy: A case report of emtricitabine-induced pure red cell aplasia. HIV Medicine. 2015;Volume 16, Sup2:21-24",39.0,YR,A,F,Y,,,20220324.0,,HP,GB,GB,EFAVIRENZ,Aplasia pure red cell;Maternal exposure during pregnancy;Off label use,110938864.0,OT,,,,,,,,,110938864.0,1.0,HIV infection
11094172,110941722,2,F,20150416.0,20150514.0,20150506,20150520,EXP,,CO-GLAXOSMITHKLINE-CO2015GSK060517,GLAXOSMITHKLINE,,20.0,YR,,M,Y,179.0,KG,20150520.0,N,PH,CO,CO,EFAVIRENZ;Efavirenz,Drug hypersensitivity,110941722.0,LT,,,110941722.0,1.0,20150410.0,20150420.0,,,110941722.0,1.0,HIV infection
11100657,111006572,2,F,2015.0,20150521.0,20150508,20150528,EXP,,CA-ABBVIE-15P-028-1386416-00,ABBVIE,,,,,M,Y,72.0,KG,20150528.0,N,MD,COUNTRY NOT SPECIFIED,CA,TEVA EFAVIRENZ,Decreased appetite;Depression;Impaired work ability;Weight decreased,111006572.0,DS,,,111006572.0,1.0,20010712.0,,,,111006572.0,1.0,Antiretroviral therapy
11103782,111037823,3,F,20150429.0,20150522.0,20150511,20150528,EXP,,BR-GILEAD-2015-0152280,GILEAD,,39.0,YR,A,M,Y,,,20150528.0,N,OT,BR,BR,EFAVIRENZ,Kaposi's sarcoma,111037823.0,OT,,,111037823.0,1.0,20150123.0,20150501.0,,,111037823.0,1.0,HIV infection
11104015,111040151,1,I,,20150507.0,20150511,20150511,EXP,,MW-GLAXOSMITHKLINE-MW2015GSK062927,GLAXOSMITHKLINE,"KUDZALA A, ET AL. CASE REPORT: A MAN ON ANTIRETROVIRAL THERAPY WITH PAINFUL THIGHS. MALAWI MEDICAL JOURNAL. 2013;25;1:24-25",54.0,YR,,M,Y,,,20150511.0,N,OT,MW,MW,Efavirenz,Arthropathy;Bone fragmentation;Hypersensitivity;Hypoaesthesia;Neuropathy peripheral;Osteoarthritis;Osteonecrosis;Osteosclerosis;Pain in extremity;Rash,111040151.0,OT,,,,,,,,,111040151.0,1.0,HIV infection
11104430,111044301,1,I,20140926.0,20150420.0,20150511,20150511,EXP,,CN-GLAXOSMITHKLINE-CN2015059462,GLAXOSMITHKLINE,,36.0,YR,,F,Y,38.0,KG,20150511.0,N,OT,CN,CN,Efavirenz,Dermatitis allergic,111044301.0,HO,,,111044301.0,1.0,20140905.0,20140928.0,,,111044301.0,1.0,Acquired immunodeficiency syndrome
11104431,111044311,1,I,20140728.0,20150420.0,20150511,20150511,EXP,,CN-GLAXOSMITHKLINE-CN2015059407,GLAXOSMITHKLINE,,61.0,YR,,M,Y,,,20150511.0,N,OT,CN,CN,Efavirenz,Hepatocellular injury,111044311.0,HO,,,111044311.0,1.0,20140508.0,20140829.0,,,111044311.0,1.0,Acquired immunodeficiency syndrome
11106687,111066871,1,I,,20150427.0,20150508,20150508,EXP,,FR2015GSK061402,VIIV,,23.0,YR,,M,N,,,20150507.0,N,MD,FR,,EFAVIRENZ (EFAVIRENZ),Drug dose omission;Immunodeficiency;Multiple-drug resistance;Nephropathy toxic;No therapeutic response;Pneumonia;Pyrexia,111066871.0,HO,111066871.0,HP,,,,,,,111066871.0,1.0,HIV infection
11106891,111068911,1,I,20140728.0,20150420.0,20150508,20150508,EXP,,CN2015059407,VIIV,,61.0,YR,,M,N,,,20150507.0,N,OT,CN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Alanine aminotransferase increased;Aspartate aminotransferase increased;Bilirubin conjugated increased;Blood albumin decreased;Blood bilirubin increased;Blood bilirubin unconjugated increased;Drug-induced liver injury;Hepatocellular injury,111068911.0,OT,111068911.0,HP,111068911.0,1.0,20140508.0,20140829.0,,,111068911.0,1.0,Acquired immunodeficiency syndrome
11106918,111069181,1,I,201503.0,20150420.0,20150508,20150508,EXP,,RU2015GSK054546,VIIV,,,,,M,N,,,20150507.0,N,CN,RU,,"STOCRIN (EFAVIRENZ, EFAVIRENZ)",Dizziness;Feeling drunk;Mental retardation;Nausea;Vomiting,111069181.0,OT,111069181.0,FGN,111069181.0,1.0,20150326.0,,,,111069181.0,1.0,HIV infection
11106927,111069272,2,F,20150416.0,20150514.0,20150508,20150522,EXP,,CO2015GSK060517,VIIV,,20.0,YR,,M,N,179.0,KG,20150519.0,N,PH,CO,,EFAVIRENZ (EFAVIRENZ),Drug hypersensitivity,111069272.0,LT,111069272.0,HP,111069272.0,1.0,20150410.0,20150420.0,,,111069272.0,1.0,HIV infection
11110455,111104552,2,F,20150417.0,20150728.0,20150513,20150804,EXP,,BR-GILEAD-2015-0152958,GILEAD,,31.0,YR,A,M,Y,53.5,KG,20150804.0,N,MD,BR,BR,EFAVIRENZ,Abscess neck;Peritonsillar abscess,111104552.0,HO,,,111104552.0,1.0,20120106.0,,,,111104552.0,1.0,HIV infection
11110526,111105262,2,F,,20150511.0,20150513,20150518,EXP,,US-CIPLA LTD.-2015JP03695,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10 (5):1 TO 23",,,,,Y,,,20150518.0,N,OT,PL,US,Efavirenz,Lymphoma,111105262.0,DE,,,,,,,,,111105262.0,1.0,HIV infection
11111546,111115462,2,F,,20161122.0,20150514,20161206,EXP,,FR-CIPLA LTD.-2015FR03693,CIPLA,,,,,,Y,,,20161206.0,,OT,PL,FR,Efavirenz,Burkitt's lymphoma,111115462.0,DE,,,,,,,,,111115462.0,1.0,HIV infection
11111547,111115471,1,I,,20150507.0,20150514,20150514,EXP,,ES-CIPLA LTD.-2015JP03699,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015",,,,,Y,,,20150514.0,N,OT,PL,ES,Efavirenz,Adverse event,111115471.0,OT,,,,,,,,,111115471.0,1.0,HIV infection
11113155,111131551,1,I,20140816.0,20150420.0,20150512,20150512,EXP,,CN2015059410,VIIV,,60.0,YR,,M,N,,,20150508.0,N,OT,CN,,STOCRIN (EFAVIRENZ),Drug eruption;Hypersensitivity,111131551.0,OT,111131551.0,FGN,111131551.0,1.0,20140812.0,20140826.0,,,111131551.0,1.0,HIV infection
11113185,111131851,1,I,20140926.0,20150420.0,20150512,20150512,EXP,,CN2015059462,VIIV,,36.0,YR,,F,N,38.0,KG,20150508.0,N,OT,CN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Dermatitis allergic,111131851.0,HO,111131851.0,HP,111131851.0,1.0,20140905.0,20140928.0,,,111131851.0,1.0,Acquired immunodeficiency syndrome
11113560,111135602,2,F,,20150721.0,20150514,20150803,EXP,,US-CIPLA LTD.-2015FR03694,CIPLA,"JOANNA KRYST, PAWEL KAWALEC AND ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;1-23",,,,,Y,,,20150803.0,N,OT,PL,US,Efavirenz,Adverse event,111135602.0,OT,,,,,,,,,111135602.0,1.0,HIV infection
11113913,111139132,2,F,20150407.0,20150521.0,20150514,20150527,EXP,,MW-ABBVIE-15P-100-1388265-00,ABBVIE,,33.0,YR,,M,Y,61.0,KG,20150527.0,N,MD,COUNTRY NOT SPECIFIED,MW,EFAVIRENZ,Neutropenia,111139132.0,OT,,,111139132.0,1.0,20150122.0,20150121.0,,,111139132.0,1.0,HIV infection
11114137,111141373,3,F,20150212.0,20150528.0,20150514,20150603,EXP,,KE-GILEAD-2015-0152379,GILEAD,,46.0,YR,A,F,Y,35.7,KG,20150603.0,N,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Cachexia;Drug-induced liver injury;Hepatitis B;Pulmonary tuberculosis,111141373.0,HO,,,111141373.0,1.0,20150121.0,20150415.0,,,111141373.0,1.0,HIV infection
11114820,111148202,2,F,,20160720.0,20150515,20160720,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-029333,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160720.0,,OT,US,US,EFAVIRENZ,Drug interaction;Medication error,,,,,,,,,,,111148202.0,1.0,Antiretroviral therapy
11115056,111150561,1,I,,20150505.0,20150515,20150515,EXP,,US-JNJFOC-20150503163,JANSSEN,,53.0,YR,A,F,Y,,,20150515.0,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,111150561.0,OT,,,111150561.0,3.0,20131028.0,20140410.0,,,111150561.0,1.0,HIV infection
11115120,111151201,1,I,,20150511.0,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03777,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515.0,N,OT,PL,ES,Efavirenz,Progressive multifocal leukoencephalopathy,111151201.0,OT,,,,,,,,,111151201.0,1.0,HIV infection
11115121,111151211,1,I,,20150511.0,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03780,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515.0,N,OT,PL,ES,Efavirenz,Myocardial infarction,111151211.0,DE,,,,,,,,,111151211.0,1.0,HIV infection
11115125,111151251,1,I,,20150511.0,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03779,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515.0,N,OT,PL,ES,Efavirenz,Progressive multifocal leukoencephalopathy,111151251.0,DE,,,,,,,,,111151251.0,1.0,HIV infection
11115192,111151921,1,I,,20150511.0,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03789,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515.0,N,OT,PL,ES,Efavirenz,Mycobacterium avium complex infection,111151921.0,OT,,,,,,,,,111151921.0,1.0,HIV infection
11115244,111152441,1,I,,20150511.0,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03826,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE.. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515.0,N,OT,US,US,Efavirenz,Toxicity to various agents,111152441.0,OT,,,,,,,,,111152441.0,1.0,HIV infection
11115246,111152461,1,I,,20150511.0,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03829,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE.. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515.0,N,OT,US,US,Efavirenz,Virologic failure,111152461.0,OT,,,,,,,,,111152461.0,1.0,HIV infection
11115284,111152841,1,I,,20150511.0,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03834,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE.. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515.0,N,OT,US,US,Efavirenz,Toxicity to various agents,111152841.0,OT,,,,,,,,,111152841.0,1.0,HIV infection
11115285,111152851,1,I,,20150511.0,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03832,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515.0,N,OT,US,US,Efavirenz,Virologic failure,111152851.0,OT,,,,,,,,,111152851.0,1.0,HIV infection
11117659,111176591,1,I,,20150511.0,20150518,20150518,EXP,,US-CIPLA LTD.-2015US03851,CIPLA,"JOHN A. BARTLETT, JUDY JOHNSON, GISELA HERRERA, NESTOR SOSA, ALAN RODRIGUEZ, QIMING LIAO, SANDY GRIFFITH, DAVID IRLBECK, AND MARK S. SHAEFER. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150518.0,N,OT,US,US,Efavirenz,Toxicity to various agents,111176591.0,OT,,,,,,,,,111176591.0,1.0,HIV infection
11120376,111203761,1,I,20141002.0,20141014.0,20150518,20150518,EXP,,MW-GILEAD-2014-0118698,GILEAD,,38.0,YR,A,M,Y,,,20150518.0,N,MD,MW,MW,EFAVIRENZ,Lymph node tuberculosis,111203761.0,HO,,,111203761.0,1.0,20140918.0,20141028.0,,,111203761.0,1.0,HIV infection
11122358,111223581,1,I,,20150511.0,20150519,20150519,EXP,,ZA-CIPLA LTD.-2015ZA03852,CIPLA,"SONDERUP MW, WAINWRIGHT H, HALL P, HAIRWADZI H, WENDY C, SPEARMAN N. A CLINICOPATHOLOGICAL COHORT STUDY OF LIVER PATHOLOGY IN 301 PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNE DEFICIENCY SYNDROME. HEPATOLOGY. 2015;61:1721-1729",,,,,Y,,,20150519.0,N,OT,ZA,ZA,Efavirenz,Cryptococcosis,111223581.0,OT,,,,,,,,,111223581.0,1.0,Acquired immunodeficiency syndrome
11123708,111237082,2,F,20150429.0,20150522.0,20150519,20150605,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-031554,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20150605.0,N,CN,US,BR,EFAVIRENZ,Kaposi's sarcoma,111237082.0,HO,,,111237082.0,1.0,20150123.0,20150430.0,,,111237082.0,1.0,Acquired immunodeficiency syndrome
11123776,111237762,2,F,,20160720.0,20150519,20160723,PER,,US-009507513-1505USA007383,MERCK,,,,,,Y,,,20160723.0,,CN,US,US,EFAVIRENZ,Drug interaction;Medication error,,,,,,,,,,,111237762.0,1.0,Antiretroviral therapy
11124149,111241491,1,I,201404.0,20150506.0,20150518,20150518,EXP,,MY2015GSK065896,VIIV,,37.0,YR,,M,N,,,20150515.0,N,OT,MY,,EFAVIRENZ,Anaemia;Lactic acidosis,111241491.0,OT,111241491.0,HP,,,,,,,111241491.0,1.0,HIV infection
11124553,111245533,3,F,20150414.0,20150602.0,20150518,20150608,EXP,,UG2015GSK065465,VIIV,,36.0,YR,,M,N,,,20150605.0,N,MD,UG,,EFAVIRENZ (EFAVIRENZ),Anaemia,111245533.0,HO,111245533.0,HP,111245533.0,1.0,20141205.0,20150421.0,,,111245533.0,1.0,HIV infection
11124871,111248711,1,I,,20150507.0,20150518,20150518,EXP,,MW2015GSK062927,VIIV,,54.0,YR,,M,N,,,20150511.0,N,OT,MW,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Arthropathy;Bone fragmentation;Hypersensitivity;Hypoaesthesia;Neuropathy peripheral;Osteoarthritis;Osteonecrosis;Osteosclerosis;Rash,111248711.0,OT,111248711.0,LIT,,,,,,,111248711.0,1.0,HIV infection
11128336,111283361,1,I,,20150429.0,20150521,20150521,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-029103,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150521.0,N,CN,US,US,SUSTIVA,Burning sensation;Foreign body;Product quality issue,,,,,,,,,,,111283361.0,1.0,HIV infection
11135923,111359234,4,F,20150119.0,20150728.0,20150526,20150731,EXP,,UG-GILEAD-2015-0154199,GILEAD,,37.0,YR,A,M,Y,,,20150731.0,N,MD,UG,UG,EFAVIRENZ,Acidosis;Acute kidney injury;Hepatitis acute;Subcutaneous abscess,111359234.0,LT,,,111359234.0,1.0,20150107.0,20150222.0,,,111359234.0,1.0,HIV infection
11139329,111393292,2,F,20150414.0,20150527.0,20150522,20150605,EXP,,FR2015GSK054104,VIIV,,64.0,YR,,M,N,,,20150604.0,N,OT,FR,,SUSTIVA,Arthralgia;Discomfort;Dizziness;Fatigue;Headache;Malaise;Myalgia;Nausea;Paraesthesia;Poor quality sleep;Pruritus,111393292.0,RI,111393292.0,HP,111393292.0,1.0,20150413.0,20150416.0,,,111393292.0,1.0,HIV infection
11142494,111424943,3,F,20140219.0,20150707.0,20150527,20150715,EXP,,KE-GILEAD-2015-0154204,GILEAD,,31.0,YR,A,M,Y,50.3,KG,20150715.0,N,MD,KE,KE,EFAVIRENZ,Peritoneal tuberculosis,111424943.0,HO,,,111424943.0,1.0,20140212.0,20140226.0,,,111424943.0,1.0,HIV infection
11146019,111460191,1,I,20150517.0,20150518.0,20150528,20150528,EXP,,RU-GLAXOSMITHKLINE-RU2015GSK069313,GLAXOSMITHKLINE,,,,,M,Y,,,20150528.0,N,CN,RU,RU,Efavirenz,Depressed level of consciousness,111460191.0,OT,,,111460191.0,1.0,20150517.0,,,,111460191.0,1.0,HIV infection
11146331,111463311,1,I,200704.0,20150519.0,20150526,20150526,EXP,,IT2015GSK069958,VIIV,,36.0,YR,,M,N,,,20150522.0,N,OT,IT,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Bundle branch block left;Cardiac failure chronic;Congestive cardiomyopathy;Regurgitation;Ventricular extrasystoles,111463311.0,HO,111463311.0,HP,,,,,,,111463311.0,1.0,HIV infection
11149326,111493261,1,I,20150212.0,20150430.0,20150529,20150529,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-030457,BRISTOL MYERS SQUIBB,,47.0,YR,,F,Y,31.0,KG,20150529.0,N,CN,US,KE,EFAVIRENZ,Acute kidney injury;Death;Drug-induced liver injury;HIV wasting syndrome;Hepatitis B;Jaundice;Pulmonary tuberculosis,111493261.0,OT,,,111493261.0,1.0,20150121.0,20150415.0,,,111493261.0,1.0,HIV infection
11152013,111520131,1,I,20150522.0,,20150529,20150529,DIR,,,,,78.0,YR,,M,N,,,20150527.0,N,PH,US,,SUSTIVA,Death,111520131.0,DE,111520131.0,HP,111520131.0,1.0,,20150422.0,,,111520131.0,1.0,HIV infection
11153047,111530471,1,I,20150212.0,20150430.0,20150601,20150601,EXP,,KE-009507513-1505KEN000457,MERCK,,46.0,YR,,F,Y,31.0,KG,20150601.0,N,CN,US,KE,EFAVIRENZ,Acute kidney injury;Cachexia;Death;Drug-induced liver injury;Hepatitis B;Jaundice;Pulmonary tuberculosis,111530471.0,HO,,,111530471.0,1.0,20150204.0,20150415.0,,,111530471.0,1.0,HIV infection
11153105,111531051,1,I,,20150527.0,20150601,20150601,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK073606,GLAXOSMITHKLINE,"IRO MA, ET AL.. VARICELLA ZOSTER VIRUS CENTRAL NERVOUS SYSTEM IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME PRESENTING IN A CHILD.. PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2013;32;11:1283-1284",11.0,YR,,F,Y,,,20150601.0,N,OT,GB,GB,Efavirenz,Aphasia;Carotid artery occlusion;Carotid artery stenosis;Cerebral infarction;Cerebrovascular accident;Hemiplegia;Immune reconstitution inflammatory syndrome;VIIth nerve paralysis;Varicella zoster virus infection,111531051.0,OT,,,,,,,,,111531051.0,1.0,HIV infection WHO clinical stage III
11154945,111549451,1,I,2015.0,20150518.0,20150529,20150529,EXP,,RU2015GSK004378,VIIV,,,,,M,N,,,20150527.0,N,CN,RU,,EFAVIRENZ,Abdominal pain;Scleroderma;Viral load increased,111549451.0,OT,111549451.0,FGN,111549451.0,1.0,201310.0,,,,111549451.0,1.0,HIV infection
11154956,111549561,1,I,20150517.0,20150518.0,20150529,20150529,EXP,,RU2015GSK069313,VIIV,,,,,M,N,,,20150527.0,N,CN,RU,,EFAVIRENZ,Condition aggravated;Depressed level of consciousness,111549561.0,OT,111549561.0,CSM,111549561.0,1.0,20150517.0,,,,111549561.0,1.0,HIV infection
11156328,111563282,2,F,20150526.0,20150528.0,20150602,20150610,EXP,,TH-GILEAD-2015-0156142,GILEAD,,55.0,YR,A,M,Y,63.0,KG,20150610.0,N,MD,TH,TH,EFAVIRENZ,Myocardial infarction,111563282.0,OT,,,111563282.0,1.0,20140721.0,20150214.0,,,111563282.0,1.0,HIV infection
11159284,111592841,1,I,200512.0,20150527.0,20150603,20150603,EXP,,IN-GLAXOSMITHKLINE-IN2015GSK074278,GLAXOSMITHKLINE,"DUTTA N, ET AL.. A CASE OF RAPID SECOND-LINE ANTI-RETROVIRAL TREATMENT FAILURE: AN ANALYSIS OF POSSIBLE CAUSES AND PREVENTIVES.. JOURNAL OF THE INDIAN ACADEMY OF CLINICAL MEDICINE. 2014;15;3-4:229-231",45.0,YR,,M,Y,,,20150603.0,N,OT,IN,IN,EFAVIRENZ,Anaemia;Drug resistance;Gastritis;Immune system disorder;Inappropriate schedule of drug administration;Pulmonary tuberculosis;Treatment failure;Underdose,111592841.0,OT,,,,,,,,,111592841.0,1.0,HIV infection
11160250,111602502,2,F,,20150619.0,20150603,20150703,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-035890,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20150703.0,N,CN,US,US,EFAVIRENZ,Basedow's disease;Immune reconstitution inflammatory syndrome,111602502.0,OT,,,,,,,,,111602502.0,1.0,Antiretroviral therapy
11164407,111644071,1,I,1996.0,20150528.0,20150604,20150604,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK075414,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20150604.0,N,CN,GB,GB,Efavirenz,Depression;Diarrhoea;Nephrolithiasis,111644071.0,OT,,,111644071.0,1.0,1996.0,1998.0,,,111644071.0,1.0,HIV infection
11166251,111662511,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04369,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Anaemia,111662511.0,OT,,,,,,,,,111662511.0,1.0,HIV infection
11166967,111669671,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04391,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Adverse drug reaction,111669671.0,OT,,,,,,,,,111669671.0,1.0,HIV infection
11166968,111669681,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04385,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Psychiatric symptom,111669681.0,OT,,,,,,,,,111669681.0,1.0,HIV infection
11166969,111669691,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04400,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Hallucination,111669691.0,OT,,,,,,,,,111669691.0,1.0,HIV infection
11166972,111669721,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04390,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Musculoskeletal disorder,111669721.0,OT,,,,,,,,,111669721.0,1.0,HIV infection
11166974,111669741,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04392,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Haematotoxicity,111669741.0,OT,,,,,,,,,111669741.0,1.0,HIV infection
11166975,111669751,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04378,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Hallucination,111669751.0,OT,,,,,,,,,111669751.0,1.0,HIV infection
11166976,111669761,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04380,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Dermatitis allergic,111669761.0,OT,,,,,,,,,111669761.0,1.0,HIV infection
11166979,111669791,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04403,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Agitation,111669791.0,OT,,,,,,,,,111669791.0,1.0,HIV infection
11166980,111669801,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04377,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Deafness,111669801.0,OT,,,,,,,,,111669801.0,1.0,HIV infection
11168898,111688981,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04402,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150606.0,N,OT,ET,ET,Efavirenz,Memory impairment,111688981.0,OT,,,,,,,,,111688981.0,1.0,HIV infection
11168900,111689001,1,I,,20150529.0,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04399,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150606.0,N,OT,ET,ET,Efavirenz,Psychotic disorder,111689001.0,OT,,,,,,,,,111689001.0,1.0,HIV infection
11169671,111696712,2,F,,20151130.0,20150605,20151207,EXP,,FR-GILEAD-2015-0157176,GILEAD,"GAZAIGNES S, RESCHE-RIGON M, GAFEY CAROLINE, YANG C, DENIS B, FONSART J, DESSEAUX K, GUIONIE M, ROZENBAUM W, DELAUGERRE C, MOLINA JM. EFFICACY AND SAFETY OF A SWITCH TO RILPIVIRINE BASED REGIMENS IN TREATEMENT-EXPERIENCED HIV-1 INFECTED PATIENTS, A COHORT STUDY. ANTIVIRAL THERAPY. 2015?UNK:UNK",28.0,YR,A,M,Y,,,20151207.0,,MD,FR,FR,EFAVIRENZ,Completed suicide,111696712.0,OT,,,111696712.0,1.0,201304.0,,,,111696712.0,1.0,HIV infection
11169682,111696822,2,F,,20151126.0,20150605,20151204,EXP,,FR-GILEAD-2015-0157177,GILEAD,"GAZAIGNES S, RESCHE-RIGON M, GAFEY CAROLINE, YANG C, DENIS B, FONSART J, DESSEAUX K, GUIONIE M, ROZENBAUM W, DELAUGERRE C, MOLINA JM. EFFICACY AND SAFETY OF A SWITCH TO RILPIVIRINE BASED REGIMENS IN TREATEMENT-EXPERIENCED HIV-1 INFECTED PATIENTS, A COHORT STUDY. ANTIVIRAL THERAPY. 2015?UNK:UNK",34.0,YR,A,M,Y,,,20151204.0,,MD,FR,FR,EFAVIRENZ,Completed suicide,111696822.0,DE,,,111696822.0,1.0,201301.0,,,,111696822.0,1.0,HIV infection
11169936,111699361,1,I,,20150529.0,20150608,20150608,EXP,,ET-CIPLA LTD.-2015ET04398,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605.0,N,OT,ET,ET,Efavirenz,Hypoaesthesia,111699361.0,OT,,,,,,,,,111699361.0,1.0,HIV infection
11169947,111699471,1,I,200512.0,20150527.0,20150604,20150604,EXP,,IN2015GSK074278,VIIV,,45.0,YR,,M,N,,,20150603.0,N,,IN,,EFAVIRENZ (EFAVIRENZ),Anaemia;Drug resistance;Gastritis;Immune system disorder;Inappropriate schedule of drug administration;Pulmonary tuberculosis;Treatment failure;Underdose;Virologic failure,111699471.0,OT,111699471.0,HP,,,,,,,111699471.0,1.0,HIV infection
11170562,111705621,1,I,,20150527.0,20150604,20150604,EXP,,GB2015GSK073606,VIIV,,11.0,YR,,F,N,,,20150601.0,N,OT,GB,,EFAVIRENZ,Carotid artery occlusion;Carotid artery stenosis;Cerebral infarction;Cerebrovascular accident;Immune reconstitution inflammatory syndrome;Varicella zoster virus infection,111705621.0,HO,111705621.0,LIT,,,,,,,111705621.0,1.0,HIV infection WHO clinical stage III
11172159,111721592,2,F,,20150429.0,20150608,20150722,PER,,US-GILEAD-2015-0155231,GILEAD,,67.0,YR,E,M,Y,,,20150722.0,N,CN,US,US,SUSTIVA,Dysphagia;Foreign body;Product quality issue;Throat irritation,,,,,111721592.0,3.0,2014.0,,,,111721592.0,1.0,HIV infection
11172357,111723571,1,I,,20150601.0,20150608,20150608,EXP,,CH-CIPLA LTD.-2015CH04426,CIPLA,"MARIO KURZ, FELIX BURKHALTER, MICHAEL DICKENMANN, HELMUT HOPFER, MICHAEL MAYR, LUIGIA ELZI, MANUEL BATTEGAY. ACUTE KIDNEY INJURY KDIGO STAGE 2 TO 3 IN HIV-POSITIVE PATIENTS TREATED WITH CART-A CASE SERIES OVER 11 YEARS IN A COHORT OF 1,153 PATIENTS. SWISS MEDICAL WEEKLY. 2015;165",,,,,Y,,,20150608.0,N,OT,CH,CH,Efavirenz,Acute kidney injury,111723571.0,OT,,,,,,,,,111723571.0,1.0,HIV infection
11172358,111723581,1,I,,20150601.0,20150608,20150608,EXP,,CH-CIPLA LTD.-2015IT04465,CIPLA,"MARIO KURZ, FELIX BURKHALTER, MICHAEL DICKENMANN, HELMUT HOPFER, MICHAEL MAYR, LUIGIA ELZI, MANUEL BATTEGAY. ACUTE KIDNEY INJURY KDIGO STAGE 2 TO 3 IN HIV-POSITIVE PATIENTS TREATED WITH CART - A CASE SERIES OVER 11 YEARS IN A COHORT OF 1,153 PATIENTS. SWISS MEDICAL WEEKLY. 2015;145:1-6",,,,,Y,,,20150608.0,N,OT,CH,CH,Efavirenz,Acute kidney injury,111723581.0,OT,,,,,,,,,111723581.0,1.0,HIV infection
11174166,111741661,1,I,1996.0,20150528.0,20150605,20150605,EXP,,GB2015GSK075414,VIIV,,54.0,YR,,M,N,,,20150604.0,N,MD,GB,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Depression;Diarrhoea;Nephrolithiasis,111741661.0,OT,111741661.0,HP,111741661.0,1.0,1996.0,1998.0,,,111741661.0,1.0,HIV infection
11175471,111754711,1,I,,20150601.0,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04445,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609.0,N,OT,IT,IT,Efavirenz,Genetic polymorphism;Hypophosphataemia;Proteinuria,111754711.0,OT,,,,,,,,,111754711.0,1.0,HIV infection
11175472,111754721,1,I,,20150601.0,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04443,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609.0,N,OT,IT,IT,Efavirenz,Genetic polymorphism;Hypophosphataemia;Proteinuria,111754721.0,OT,,,,,,,,,111754721.0,1.0,HIV infection
11175473,111754731,1,I,,20150601.0,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04440,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609.0,N,OT,IT,IT,Efavirenz,Proteinuria,111754731.0,OT,,,,,,,,,111754731.0,1.0,HIV infection
11175475,111754751,1,I,,20150601.0,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04434,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609.0,N,OT,IT,IT,Efavirenz,Genetic polymorphism;Hypophosphataemia;Proteinuria;Renal failure,111754751.0,OT,,,,,,,,,111754751.0,1.0,HIV infection
11176991,111769911,1,I,,20150601.0,20150610,20150610,EXP,,CH-CIPLA LTD.-2015CH04455,CIPLA,"MARIO KURZ, FELIX BURKHALTER, MICHAEL DICKENMANN, HELMUT HOPFER, MICHAEL MAYR, LUIGIA ELZI, MANUEL BATTEGAY. ACUTE KIDNEY INJURY KDIGO STAGE 2 TO 3 IN HIV-POSITIVE PATIENTS TREATED WITH CART-A CASE SERIES OVER 11 YEARS IN A COHORT OF 1,153 PATIENTS. SWISS MEDICAL WEEKLY. 2015;145",,,,,Y,,,20150610.0,N,OT,CH,CH,Efavirenz,Acute kidney injury;Focal segmental glomerulosclerosis;Multiple-drug resistance,111769911.0,OT,,,,,,,,,111769911.0,1.0,HIV infection
11185556,111855561,1,I,,20150605.0,20150612,20150612,EXP,,CH-GILEAD-2015-0157811,GILEAD,"BIVER E, DOCO-LECOMPTE T. EVENT: 1ST SWISS HIV COHORT STUDY METABOLIC AND AGING WORKSHOP. SLIDE PRESENTATION. 2015;UNK:UNK",57.0,YR,A,M,Y,,,20150612.0,N,OT,CH,CH,EFAVIRENZ,Osteoporosis,111855561.0,OT,,,111855561.0,1.0,2003.0,2013.0,,,111855561.0,1.0,HIV infection
11200743,112007432,2,F,20141122.0,20150629.0,20150618,20150701,EXP,,UG-GILEAD-2015-0145451,GILEAD,,38.0,YR,A,F,Y,,,20150701.0,N,MD,UG,UG,EFAVIRENZ,Cytomegalovirus chorioretinitis;Death,112007432.0,DS,,,112007432.0,1.0,20141023.0,20150414.0,,,112007432.0,1.0,HIV infection
11202620,112026203,3,F,,20160715.0,20150619,20160715,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-037940,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,,,20160715.0,,OT,TN,TN,EFAVIRENZ,Acute coronary syndrome,112026203.0,OT,,,112026203.0,1.0,2008.0,,,,112026203.0,1.0,HIV infection
11202890,112028904,4,F,,20160816.0,20150619,20160822,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-040845,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160822.0,,OT,TN,TN,EFAVIRENZ,Acute coronary syndrome,112028904.0,OT,,,,,,,,,112028904.0,1.0,HIV infection
11209004,112090041,1,I,20090424.0,20150608.0,20150622,20150622,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-040358,BRISTOL MYERS SQUIBB,,4.0,DEC,,M,Y,,,20150622.0,N,CN,US,JP,EFAVIRENZ,Platelet count decreased,112090041.0,DS,,,112090041.0,1.0,20010809.0,20080331.0,,,112090041.0,1.0,HIV infection
11210698,112106981,1,I,,20150609.0,20150622,20150622,EXP,,IT-GILEAD-2015-0158441,GILEAD,"GIACOMET V., NANNINI P., VIGANO A., ERBA P., BENINCASO A., BEDOGNI G., CATTANEO D., FALVELLA F. S., ZUCCOTTI G. V.. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY.. CLINICAL DURG INVESTIGATION. 2015;UNK:UNK",,,C,,Y,,,20150622.0,N,OT,IT,IT,EFAVIRENZ,Renal failure,112106981.0,OT,,,,,,,,,112106981.0,1.0,HIV infection
11213248,112132481,1,I,,20150609.0,20150623,20150623,EXP,,IT-GLAXOSMITHKLINE-IT2015088154,GLAXOSMITHKLINE,"GIACOMET V., NANNINI P., VIGANO A., ERBA P., BENINCASO A., BEDOGNI G., CATTANEO D., FALVELLA F. S., ZUCCOTTI G. V.. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY.. CLINICAL DURG INVESTIGATION. 2015;UNK:UNK",,,C,,Y,,,20150623.0,N,OT,IT,IT,Efavirenz,Renal failure,112132481.0,OT,,,,,,,,,112132481.0,1.0,HIV infection
11213627,112136271,1,I,20140211.0,20150610.0,20150623,20150623,EXP,,MY-MYLANLABS-2015M1020401,MYLAN,,,,,,Y,,,20150623.0,N,OT,MY,MY,EFAVIRENZ,Anaemia;Dyspnoea;Lethargy,112136271.0,OT,,,,,,,,,112136271.0,1.0,HIV infection
11213637,112136371,1,I,20140102.0,20150610.0,20150623,20150623,EXP,,MY-MYLANLABS-2015M1020435,MYLAN,,,,,,Y,,,20150623.0,N,OT,MY,MY,EFAVIRENZ,Anaemia;Dizziness;Dyspnoea,112136371.0,OT,,,,,,,,,112136371.0,1.0,HIV infection
11217131,112171313,3,F,20150520.0,20150527.0,20150624,20150807,EXP,,BR-GILEAD-2015-0156278,GILEAD,,47.0,YR,A,M,Y,,,20150807.0,N,MD,BR,BR,EFAVIRENZ,Decreased appetite;Dehydration;Disseminated tuberculosis;Dysphagia;Hypoaesthesia;Pyrexia,112171313.0,HO,,,112171313.0,1.0,20150513.0,20150521.0,,,112171313.0,1.0,HIV infection
11224138,112241381,1,I,,20150609.0,20150625,20150625,EXP,,IT2015088154,VIIV,,,,,,N,,,20150623.0,N,OT,IT,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Renal failure,112241381.0,OT,112241381.0,HP,,,,,,,112241381.0,1.0,HIV infection
11224618,112246181,1,I,20150614.0,20150615.0,20150625,20150625,EXP,,RU2015GSK086269,VIIV,,,,,,N,,,20150620.0,N,CN,RU,,STOCRIN (EFAVIRENZ),Chest pain;Chromaturia;Faeces discoloured;Pleurisy;Pulmonary tuberculosis;Pyrexia;Rash,112246181.0,OT,112246181.0,CSM,112246181.0,1.0,201502.0,20150601.0,,,112246181.0,1.0,HIV infection
11224691,112246911,1,I,2014.0,20150615.0,20150625,20150625,EXP,,B0987385A,VIIV,,,,,F,N,,,20150619.0,N,CN,RU,,STOCRIN (EFAVIRENZ),Anaemia;Dyspepsia;Fatigue;Feeling hot;Jaundice;Lipodystrophy acquired;Pain;Pyrexia;Red blood cell sedimentation rate increased;Yawning,112246911.0,OT,112246911.0,CSM,112246911.0,1.0,2014.0,,,,112246911.0,1.0,HIV infection
11224736,112247361,1,I,20140610.0,20150611.0,20150625,20150625,EXP,,B1031199A,VIIV,,32.0,YR,,M,N,,,20150619.0,N,MD,UG,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Anaemia,112247361.0,LT,112247361.0,FGN,112247361.0,1.0,20140318.0,20140901.0,,,112247361.0,1.0,HIV infection
11225710,112257103,3,F,20150310.0,20151221.0,20150629,20160105,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-024150,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,,,20160105.0,,CN,US,ZW,EFAVIRENZ,Gastroenteritis;Tuberculosis,112257103.0,OT,,,112257103.0,1.0,20150226.0,20150302.0,,,112257103.0,1.0,HIV infection
11235165,112351652,2,F,20150522.0,20150624.0,20150702,20150709,EXP,,PE-GILEAD-2015-0161248,GILEAD,,41.0,YR,A,M,Y,69.5,KG,20150709.0,N,MD,PE,PE,EFAVIRENZ,Chronic hepatitis B,112351652.0,OT,,,112351652.0,1.0,20150227.0,20150521.0,,,112351652.0,1.0,HIV infection
11235638,112356381,1,I,20140124.0,20150626.0,20150702,20150702,EXP,,ZW-GILEAD-2015-0160757,GILEAD,,46.0,YR,A,M,Y,,,20150702.0,N,MD,ZW,ZW,EFAVIRENZ,Gastroenteritis,112356381.0,HO,,,112356381.0,1.0,20140116.0,20140128.0,,,112356381.0,1.0,HIV infection
11238812,112388122,2,F,,20160510.0,20150706,20160511,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038383,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160511.0,,OT,US,US,SUSTIVA,Off label use;Wrong technique in product usage process,,,,,,,,,,,112388122.0,1.0,HIV infection
11242430,112424302,2,F,20150522.0,20150714.0,20150707,20150813,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-042462,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,70.0,KG,20150813.0,N,OT,PE,PE,EFAVIRENZ,Alanine aminotransferase increased;Chronic hepatitis B,112424302.0,LT,,,112424302.0,1.0,20150227.0,,,,112424302.0,1.0,HIV infection
11246468,112464681,1,I,,20150626.0,20150708,20150708,EXP,,TH-CIPLA LTD.-2015TH05396,CIPLA,"LINDA AURPIBUL, TIM R. CRESSEY, SIRINTIP SRICHAROENCHAI, ORASRI WITTAWATMONGKOL, VIRAT SIRISANTHANA, WANATPREEYA PHONGSAMART ET AL. EFFICACY, SAFETY AND PHARMACOKINETICS OF TENOFOVIR DISOPROXIL FUMARATE IN VIROLOGIC-SUPPRESSED HIV-INFECTED CHILDREN USING WEIGHT-BAND DOSING. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:392-397",,,,,Y,,,20150708.0,N,OT,TH,TH,Efavirenz,Tonsillitis,112464681.0,HO,,,,,,,,,112464681.0,1.0,HIV infection
11246497,112464971,1,I,,20150626.0,20150708,20150708,EXP,,TH-CIPLA LTD.-2015TH05400,CIPLA,"LINDA AURPIBUL, TIM R. CRESSEY, SIRINTIP SRICHAROENCHAI, ORASRI WITTAWATMONGKOL, VIRAT SIRISANTHANA, WANATPREEYA PHONGSAMART ET AL. EFFICACY, SAFETY AND PHARMACOKINETICS OF TENOFOVIR DISOPROXIL FUMARATE IN VIROLOGIC-SUPPRESSED HIV-INFECTED CHILDREN USING WEIGHT-BAND DOSING. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:392-397",,,,,Y,,,20150708.0,N,OT,TH,TH,Efavirenz,Ventriculo-peritoneal shunt,112464971.0,HO,,,,,,,,,112464971.0,1.0,HIV infection
11246498,112464981,1,I,,20150626.0,20150708,20150708,EXP,,TH-CIPLA LTD.-2015TH05398,CIPLA,"LINDA AURPIBUL, TIM R. CRESSEY, SIRINTIP SRICHAROENCHAI, ORASRI WITTAWATMONGKOL, VIRAT SIRISANTHANA, WANATPREEYA PHONGSAMART ET AL. EFFICACY, SAFETY AND PHARMACOKINETICS OF TENOFOVIR DISOPROXIL FUMARATE IN VIROLOGIC-SUPPRESSED HIV-INFECTED CHILDREN USING WEIGHT-BAND DOSING. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:392-397",,,,,Y,,,20150708.0,N,OT,TH,TH,Efavirenz,Influenza,112464981.0,HO,,,,,,,,,112464981.0,1.0,HIV infection
11246510,112465101,1,I,,20150626.0,20150708,20150708,EXP,,US-CIPLA LTD.-2015US05463,CIPLA,"SAEZ-LLORENS X, CASTANO E, RATHORE M, CHURCH J, DEVILLE J, GAUR A, RHEE.M.ET.AL. A RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF SWITCHING STAVUDINE OR ZIDOVUDINE TO TENOFOVIR DISOPROXIL FUMARATE IN HIV-1-INFECTED CHILDREN WITH VIROLOGIC SUPPRESSION. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:376-382",,,,,Y,,,20150708.0,N,OT,US,US,Efavirenz,Bronchitis,112465101.0,OT,,,,,,,,,112465101.0,1.0,HIV infection
11246512,112465121,1,I,,20150626.0,20150708,20150708,EXP,,US-CIPLA LTD.-2015US05465,CIPLA,"SAEZ-LLORENS X, CASTANO E, RATHORE M, CHURCH J, DEVILLE J, GAUR A, RHEE.M.ET.AL. A RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF SWITCHING STAVUDINE OR ZIDOVUDINE TO TENOFOVIR DISOPROXIL FUMARATE IN HIV-1-INFECTED. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:376-382",,,,,Y,,,20150708.0,N,OT,US,US,Efavirenz,Brain neoplasm,112465121.0,OT,,,,,,,,,112465121.0,1.0,HIV infection
11247552,112475521,1,I,,20150625.0,20150706,20150706,EXP,,KZ2015GSK091882,VIIV,,9.0,YR,,M,N,,,20150702.0,N,MD,KZ,,STOCRIN (EFAVIRENZ),Agranulocytosis;Aplastic anaemia;Asthenia;Dermatitis;Developmental delay;Fatigue;Hepatitis toxic;Hypotonia;Lymphadenitis;Mitral valve prolapse;Odynophagia;Oropharyngeal candidiasis,112475521.0,HO,112475521.0,HP,112475521.0,1.0,20150113.0,20150105.0,,,112475521.0,1.0,HIV infection
11248890,112488901,1,I,,20140804.0,20150708,20150708,EXP,,AU-CIPLA LTD.-2014AU01135,CIPLA,"DIANNE CAREY. EFFICACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS 2015. 2015;15:793-802",,,,,Y,,,20150708.0,N,OT,AU,AU,Efavirenz,Completed suicide,112488901.0,DE,,,,,,,,,112488901.0,1.0,HIV infection
11248891,112488911,1,I,,20140804.0,20150708,20150708,EXP,,AU-CIPLA LTD.-2014AU01134,CIPLA,"DIANNE CAREY. EFFICACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS 2015. 2005;15:793-802",,,,,Y,,,20150708.0,N,OT,AU,AU,Efavirenz,Pneumonia bacterial,112488911.0,DE,,,,,,,,,112488911.0,1.0,HIV infection
11256152,112561521,1,I,,20141002.0,20150709,20150709,EXP,,US-VIIV HEALTHCARE LIMITED-US2014GSK017827,VIIV,,,,,M,Y,,,20150709.0,N,OT,US,US,SUSTIVA,Diarrhoea,,,,,112561521.0,1.0,201207.0,201411.0,,,112561521.0,1.0,HIV infection
11256159,112561591,1,I,2012.0,20150116.0,20150709,20150709,EXP,,US-VIIV HEALTHCARE LIMITED-US2015005970,VIIV,,,,,M,Y,,,20150709.0,N,CN,COUNTRY NOT SPECIFIED,US,SUSTIVA,Visual acuity reduced,,,,,112561591.0,1.0,2011.0,,,,112561591.0,1.0,HIV infection
11258240,112582401,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05579,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Pancreatic carcinoma,112582401.0,DE,,,,,,,,,112582401.0,1.0,HIV infection
11258258,112582581,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05577,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Suicide attempt,112582581.0,OT,,,,,,,,,112582581.0,1.0,HIV infection
11258260,112582601,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05576,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Oedema genital;Rash,112582601.0,OT,,,,,,,,,112582601.0,1.0,HIV infection
11258262,112582621,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05578,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Stab wound,112582621.0,DE,,,,,,,,,112582621.0,1.0,HIV infection
11258263,112582631,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05598,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Acute myocardial infarction,112582631.0,DE,,,,,,,,,112582631.0,1.0,HIV infection
11258264,112582641,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05582,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Adverse drug reaction;Septic shock,112582641.0,DE,,,,,,,,,112582641.0,1.0,HIV infection
11258272,112582721,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05599,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Maternal death during childbirth,112582721.0,DE,,,,,,,,,112582721.0,1.0,HIV infection
11258280,112582801,1,I,,20150702.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05601,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710.0,N,OT,AU,AU,Efavirenz,Gun shot wound,112582801.0,DE,,,,,,,,,112582801.0,1.0,HIV infection
11258293,112582931,1,I,,20140804.0,20150710,20150710,EXP,,AU-CIPLA LTD.-2014AU01133,CIPLA,"DIANNE CAREY, REBEKAH PULS, JANAKI AMIN, MARCELO LOSSO, PRAPHAN PHANUPAK, SHARNE FOULKES, LERATO MOHAPI ET AL. EFFICACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793-802",,,,,Y,,,20150710.0,N,MD,AU,AU,Efavirenz,Septic shock,112582931.0,DE,,,,,,,,,112582931.0,1.0,HIV infection
11258366,112583662,2,F,20090428.0,20150710.0,20150710,20150717,EXP,,BR-VIIV HEALTHCARE LIMITED-B0581303A,VIIV,,31.0,YR,,F,Y,58.0,KG,20150717.0,N,MD,BR,BR,Efavirenz,Decreased appetite;Depressed mood;Depression;Fatigue;Homicidal ideation;Loss of libido;Suicidal ideation;Terminal insomnia;Violence-related symptom,112583662.0,LT,,,112583662.0,1.0,20080416.0,20090701.0,,,112583662.0,1.0,Prophylaxis against HIV infection
11259567,112595673,3,F,,20150803.0,20150710,20151023,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-045269,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20151023.0,,OT,TN,TN,EFAVIRENZ,Acute coronary syndrome;Dyslipidaemia,112595673.0,OT,,,,,,,,,112595673.0,1.0,HIV infection
11271089,112710892,2,F,20130603.0,20151008.0,20150714,20151021,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-044918,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20151021.0,,OT,MW,MW,EFAVIRENZ,Death;Upper respiratory tract infection,112710892.0,DE,,,112710892.0,1.0,20130111.0,20130606.0,,,112710892.0,1.0,HIV infection
11273970,112739704,4,F,20150218.0,20151221.0,20150715,20151224,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-045344,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,,,20151224.0,,OT,UG,UG,EFAVIRENZ,Acute hepatic failure;Anaemia;Cardiac failure;Hepatitis acute;Oral candidiasis;Pulmonary tuberculosis,112739704.0,DE,,,112739704.0,1.0,20150121.0,20150407.0,,,112739704.0,1.0,HIV infection
11274251,112742512,2,F,20120908.0,20150928.0,20150715,20151007,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-17079922,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,75.0,KG,20151007.0,,OT,BR,BR,EFAVIRENZ,Anxiety;Hepatotoxicity;Pulmonary tuberculosis;Weight decreased,112742512.0,LT,,,112742512.0,1.0,20100125.0,20121022.0,,,112742512.0,1.0,HIV infection
11276482,112764821,1,I,,20150706.0,20150716,20150716,EXP,,CH-CIPLA LTD.-2015CH05637,CIPLA,"LAURA C, CAVASSINI M, GENNE D, DELHUMEAU C, ELBES R.S, HILL A.ET.AL. SWITCH TO ETRAVIRINE FOR HIV-POSITIVE PATIENTS RECEIVING STATIN TREATMENT: A PROSPECTIVE STUDY. EUR J CLIN INVEST. 2015;45 (7):720-730",,,,,Y,,,20150716.0,N,OT,CH,CH,Efavirenz,Acute kidney injury,112764821.0,OT,,,,,,,,,112764821.0,1.0,HIV infection
11277591,112775911,1,I,,20150709.0,20150716,20150716,EXP,,ZA-GILEAD-2015-0162987,GILEAD,BARNARDT P AND RELLING M. GESTATIONAL TROPHOBLASTIC NEOPLASM AND WOMEN LIVING WITH HIV AND/OR AIDS. S AFR J HIV MED.. 2015;16(1):UNK,33.0,YR,A,F,Y,,,20150716.0,N,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous,112775911.0,OT,,,,,,,,,112775911.0,1.0,Acquired immunodeficiency syndrome
11282210,112822101,1,I,20140922.0,20150707.0,20150720,20150720,EXP,,KE-CIPLA LTD.-2015KE05833,CIPLA,,,,,,Y,,,20150720.0,N,OT,US,KE,Efavirenz,Abortion spontaneous;Exposure during pregnancy,112822101.0,OT,,,112822101.0,1.0,20131014.0,,,,112822101.0,1.0,HIV infection
11283749,112837491,1,I,,20150715.0,20150720,20150720,EXP,,US-VIIV HEALTHCARE LIMITED-US2015102836,VIIV,,,,,M,Y,,,20150720.0,N,CN,US,US,SUSTIVA,Viral load,,,,,,,,,,,112837491.0,1.0,HIV infection
11285494,112854941,1,I,20150308.0,20150714.0,20150720,20150720,EXP,,CL-GILEAD-2015-0163516,GILEAD,,29.0,YR,A,M,Y,78.0,KG,20150720.0,N,MD,CL,CL,EFAVIRENZ,Cholecystitis acute,112854941.0,HO,,,112854941.0,1.0,20130226.0,,,,112854941.0,1.0,HIV infection
11285522,112855221,1,I,20150614.0,20150713.0,20150720,20150720,EXP,,UG-GILEAD-2015-0163190,GILEAD,,39.0,YR,A,M,Y,,,20150720.0,N,OT,UG,UG,EFAVIRENZ,Kaposi's sarcoma,112855221.0,LT,,,112855221.0,1.0,20150128.0,,,,112855221.0,1.0,HIV infection
11308119,113081191,1,I,,20150715.0,20150724,20150724,EXP,,ES-CIPLA LTD.-2015ES05927,CIPLA,"CASADO JL, MARIN A, ROMERO V, BANON S, MORENO A, PEREZ-ELIAS MJ.ET.AL. THE INFLUENCE OF PATIENT BELIEFS AND TREATMENT SATISFACTION ON THE DISCONTINUATION OF CURRENT FIRST-LINE ANTIRETROVIRAL REGIMENS. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150724.0,N,OT,ES,ES,Efavirenz,Jaundice,113081191.0,OT,,,,,,,,,113081191.0,1.0,HIV infection
11308120,113081201,1,I,,20150715.0,20150724,20150724,EXP,,ES-CIPLA LTD.-2015ES05929,CIPLA,"CASADO JL, MARIN A, ROMERO V, BANON S, MORENO A, PEREZ-ELIAS MJ.ET.AL. THE INFLUENCE OF PATIENT BELIEFS AND TREATMENT SATISFACTION ON THE DISCONTINUATION OF CURRENT FIRST-LINE ANTIRETROVIRAL REGIMENS. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150724.0,N,OT,ES,ES,Efavirenz,Nephropathy toxic,113081201.0,OT,,,,,,,,,113081201.0,1.0,HIV infection
11308123,113081231,1,I,,20150715.0,20150724,20150724,EXP,,ES-CIPLA LTD.-2015ES05931,CIPLA,"CASADO JL, MARIN A, ROMERO V, BANON S, MORENO A, PEREZ-ELIAS MJ.ET.AL. THE INFLUENCE OF PATIENT BELIEFS AND TREATMENT SATISFACTION ON THE DISCONTINUATION OF CURRENT FIRST-LINE ANTIRETROVIRAL REGIMENS. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150724.0,N,OT,ES,ES,Efavirenz,Drug interaction,113081231.0,OT,,,,,,,,,113081231.0,1.0,HIV infection
11309489,113094891,1,I,,20150715.0,20150724,20150724,EXP,,LS-GLAXOSMITHKLINE INC.-LS2015GSK105502,GLAXOSMITHKLINE,"SATTI H, MCLAUGHLIN MM, SEUNG KJ.. SHORT REPORT: DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL. AM. J. TROP. MED. HYG. 2013;89 (1):174-177",59.0,YR,,M,Y,,,20150724.0,N,OT,LS,LS,Efavirenz,CD4 lymphocytes decreased;Drug resistance;Viral mutation identified,113094891.0,DE,,,,,,,,,113094891.0,1.0,HIV infection
11309589,113095891,1,I,,20150715.0,20150724,20150724,EXP,,LS-VIIV HEALTHCARE LIMITED-LS2015GSK105502,VIIV,"SATTI H, MCLAUGHLIN MM, SEUNG KJ.. SHORT REPORT: DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL. AM. J. TROP. MED. HYG. 2013;89 (1):174-177",59.0,YR,,M,Y,,,20150724.0,N,OT,LS,LS,Efavirenz,CD4 lymphocytes decreased;Drug resistance;Viral mutation identified,113095891.0,DE,,,,,,,,,113095891.0,1.0,HIV infection
11314307,113143071,1,I,20140823.0,20140617.0,20150727,20150727,EXP,,RU-VIIV HEALTHCARE LIMITED-B1006356A,VIIV,,,,,M,Y,,,20150727.0,N,CN,RU,RU,EFAVIRENZ,Asthenia;Chest pain;Chronic gastritis;Duodenitis;Erosive oesophagitis;Gastric disorder;Gastric polyps;Gastritis haemorrhagic;Gastrooesophageal reflux disease;Head discomfort;Headache;Hiatus hernia;Hyperchlorhydria;Influenza like illness;Initial insomnia;Irritability;Lymph node pain;Musculoskeletal discomfort;Nail discolouration;Nasal obstruction;Nasopharyngitis;Nervousness;Neurosis;Oropharyngeal pain;Pharyngeal disorder;Pharyngeal erosion;Pharyngeal erythema;Pharyngitis;Pyrexia;Respiratory tract infection viral;Rhinorrhoea;Tongue coated;Tonsillar inflammation,113143071.0,OT,,,113143071.0,1.0,201312.0,,,,113143071.0,1.0,HIV infection
11314312,113143121,1,I,2011.0,20150720.0,20150727,20150727,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2015GSK104295,VIIV,,,,,M,Y,,,20150727.0,N,CN,RU,RU,STOCRIN (EFAVIRENZ),Aggression;Depression;Disturbance in attention;Encephalopathy;Headache;Memory impairment;Mood swings;Social avoidant behaviour,113143121.0,OT,,,113143121.0,1.0,2011.0,,,,113143121.0,1.0,HIV infection
11322175,113221751,1,I,20141105.0,20150722.0,20150729,20150729,EXP,,HT-GILEAD-2015-0164906,GILEAD,,30.0,YR,A,F,Y,,,20150729.0,N,MD,HT,HT,EFAVIRENZ,Abortion spontaneous,113221751.0,OT,,,113221751.0,1.0,20140918.0,20140922.0,,,113221751.0,1.0,HIV infection
11322615,113226153,3,F,,20230417.0,20150730,20230428,EXP,,ZA-CIPLA LTD.-2015ZA06047,CIPLA,"Anne Derache, Carole L. Wallis, Saran Vardhanabhuti, John Bartlett, Nagalingeswaran Kumarasamy, David Katzenstein. Phenotype, Genotype and Drug Resistance in Subtype C HIV-1 Infection. 1 to 26",,,,,Y,,,20230428.0,,HP,ZA,ZA,EFAVIRENZ,Drug resistance;Gene mutation;Treatment failure,113226153.0,OT,,,,,,,,,113226153.0,1.0,HIV infection
11323514,113235141,1,I,,20130611.0,20150730,20150730,EXP,,KH-GLAXOSMITHKLINE-B0901849A,GLAXOSMITHKLINE,"OUK V ET AL. THE ADVANTAGE OF VIRAL LOAD IN PREVENTION FROM MOTHER TO CHILD TRANSMISSION. ABSTRACT PRESENTED AT THE 2013 CONFERENCE ON 30 YEARS OF HIV SCIENCE: IMAGINE THE FUTURE, 2013, PARIS, FRANCE:99.",,,,F,Y,,,20150730.0,N,MD,KH,KH,Efavirenz,Abortion spontaneous;Exposure during pregnancy,113235141.0,OT,,,,,,,,,113235141.0,2.0,HIV infection
11323541,113235411,1,I,,20130611.0,20150730,20150730,EXP,,KH-VIIV HEALTHCARE LIMITED-B0901851A,VIIV,"OUK V ET AL. THE ADVANTAGE OF VIRAL LOAD IN PREVENTION FROM MOTHER TO CHILD TRANSMISSION. ABSTRACT PRESENTED AT THE 2013 CONFERENCE ON 30 YEARS OF HIV SCIENCE: IMAGINE THE FUTURE, 2013, PARIS, FRANCE:99.",,,,F,Y,,,20150730.0,N,MD,KH,KH,Efavirenz,Abortion induced;Exposure during pregnancy,113235411.0,OT,,,,,,,,,113235411.0,1.0,HIV infection
11323548,113235481,1,I,,20130611.0,20150730,20150730,EXP,,KH-VIIV HEALTHCARE LIMITED-B0901849A,VIIV,"OUK V ET AL. THE ADVANTAGE OF VIRAL LOAD IN PREVENTION FROM MOTHER TO CHILD TRANSMISSION. ABSTRACT PRESENTED AT THE 2013 CONFERENCE ON 30 YEARS OF HIV SCIENCE: IMAGINE THE FUTURE, 2013, PARIS, FRANCE:99.",,,,F,Y,,,20150730.0,N,MD,KH,KH,Efavirenz,Abortion spontaneous;Exposure during pregnancy,113235481.0,OT,,,,,,,,,113235481.0,2.0,HIV infection
11325265,113252651,1,I,20150216.0,20150721.0,20150730,20150730,EXP,,MW-ABBVIE-15P-100-1431097-00,ABBVIE,,34.0,YR,,F,Y,,,20150730.0,N,MD,COUNTRY NOT SPECIFIED,MW,SUSTIVA,Foetal death,113252651.0,OT,,,113252651.0,1.0,20141119.0,20150216.0,,,113252651.0,1.0,HIV infection
11325759,113257592,2,F,,20150928.0,20150731,20151013,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-048759,BRISTOL MYERS SQUIBB,,,,,F,Y,71.0,KG,20151013.0,,CN,DE,DE,SUSTIVA,Hepatic cirrhosis,113257592.0,DS,,,113257592.0,1.0,2000.0,2003.0,,,113257592.0,1.0,HIV infection
11327055,113270551,1,I,20140807.0,20140815.0,20150731,20150731,EXP,,UG-VIIV HEALTHCARE LIMITED-B1024921A,VIIV,,24.0,YR,,F,Y,,,20150731.0,N,MD,UG,UG,EFAVIRENZ,Anaemia,113270551.0,LT,,,113270551.0,1.0,20140519.0,20140812.0,,,113270551.0,1.0,HIV infection
11327056,113270561,1,I,20140422.0,20140508.0,20150731,20150731,EXP,,UG-VIIV HEALTHCARE LIMITED-B0992543A,VIIV,,36.0,YR,,M,Y,,,20150731.0,N,MD,UG,UG,Efavirenz,Anaemia,113270561.0,LT,,,113270561.0,1.0,20140310.0,20140505.0,,,113270561.0,1.0,HIV infection
11327585,113275851,1,I,,20150722.0,20150731,20150731,EXP,,PHHY2015LS092159,SANDOZ,"SATTI H, MCLAUGHLIN MM, SEUNG KJ. DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL RESISTANCE IN HIV COINFECTED PATIENTS: A REPORT OF SIX CASES IN LESOTHO. AM-J-TROP-MED-HYG. 2013;89(1):174-7",59.0,YR,,M,Y,,,20150731.0,N,OT,LS,LS,EFAVIRENZ,Death;Drug resistance,113275851.0,OT,,,,,,,,,113275851.0,1.0,HIV infection
11328253,113282531,1,I,,20150722.0,20150731,20150731,EXP,,PHHY2015LS092163,SANDOZ,"SATTI H, MCLAUGHLIN MM, SEUNG KJ. DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL RESISTANCE IN HIV COINFECTED PATIENTS: A REPORT OF SIX CASES IN LESOTHO. AM-J-TROP-MED-HYG. 2013;89(1):174-7",45.0,YR,,M,Y,,,20150731.0,N,OT,LS,LS,EFAVIRENZ,Death;Drug resistance,113282531.0,DE,,,,,,,,,113282531.0,1.0,HIV infection
11329320,113293201,1,I,,20150720.0,20150803,20150803,EXP,,ZA-CIPLA LTD.-2015ZA06049,CIPLA,"ANNE DERACHE, CAROLE L. WALLIS, SARAN VARDHANABHUTI, JOHN BARTLETT, NAGALINGESWARAN KUMARASAMY, DAVID KATZENSTEIN. PHENOTYPE, GENOTYPE AND DRUG RESISTANCE IN SUBTYPE C HIV-1 INFECTION. 2015;1 TO 26",,,,,Y,,,20150803.0,N,OT,ZA,ZA,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113293201.0,OT,,,,,,,,,113293201.0,1.0,HIV infection
11329321,113293211,1,I,,20150720.0,20150803,20150803,EXP,,ZA-CIPLA LTD.-2015ZA06051,CIPLA,"ANNE DERACHE, CAROLE L. WALLIS, SARAN VARDHANABHUTI, JOHN BARTLETT, NAGALINGESWARAN KUMARASAMY, DAVID KATZENSTEIN. PHENOTYPE, GENOTYPE AND DRUG RESISTANCE IN SUBTYPE C HIV-1 INFECTION. 2015;1 TO 26",,,,,Y,,,20150803.0,N,OT,ZA,ZA,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113293211.0,OT,,,,,,,,,113293211.0,1.0,HIV infection
11329322,113293221,1,I,,20150720.0,20150803,20150803,EXP,,ZA-CIPLA LTD.-2015ZA06053,CIPLA,"ANNE DERACHE, CAROLE L. WALLIS, SARAN VARDHANABHUTI, JOHN BARTLETT, NAGALINGESWARAN KUMARASAMY, DAVID KATZENSTEIN. PHENOTYPE, GENOTYPE AND DRUG RESISTANCE IN SUBTYPE C HIV-1 INFECTION. 2015;1 TO 26",,,,,Y,,,20150803.0,N,OT,ZA,ZA,Efavirenz,Treatment failure,113293221.0,OT,,,,,,,,,113293221.0,1.0,HIV infection
11329393,113293931,1,I,,20150721.0,20150803,20150803,EXP,,FR-CIPLA LTD.-2015FR06080,CIPLA,"MOLINA J, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, SUPPARATPINYO K, WALMSLEY S.ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238-246",,,,,Y,,,20150803.0,N,MD,FR,FR,Efavirenz,Renal impairment,113293931.0,OT,,,,,,,,,113293931.0,1.0,HIV infection
11329401,113294011,1,I,,20150721.0,20150803,20150803,EXP,,FR-CIPLA LTD.-2015FR06081,CIPLA,"MOLINA J, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, SUPPARATPINYO K, WALMSLEY S.ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238-246",,,,,Y,,,20150803.0,N,OT,FR,FR,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113294011.0,OT,,,,,,,,,113294011.0,1.0,HIV infection
11329403,113294031,1,I,,20150721.0,20150803,20150803,EXP,,FR-CIPLA LTD.-2015FR06083,CIPLA,"MOLINA J, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, SUPPARATPINYO K, WALMSLEY S.ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238-246",,,,,Y,,,20150803.0,N,OT,FR,FR,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113294031.0,OT,,,,,,,,,113294031.0,1.0,HIV infection
11329667,113296671,1,I,,20150721.0,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06095,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803.0,N,OT,PL,US,Efavirenz,Cerebrovascular accident,113296671.0,DE,,,,,,,,,113296671.0,1.0,HIV infection
11329672,113296721,1,I,,20150721.0,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06094,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803.0,N,OT,PL,US,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113296721.0,OT,,,,,,,,,113296721.0,1.0,HIV infection
11329675,113296751,1,I,,20150721.0,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06075,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803.0,N,OT,PL,US,Efavirenz,Cerebral toxoplasmosis;Dysentery,113296751.0,DE,,,,,,,,,113296751.0,1.0,HIV infection
11329677,113296771,1,I,,20150721.0,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06077,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803.0,N,OT,PL,US,Efavirenz,Respiratory failure,113296771.0,DE,,,,,,,,,113296771.0,1.0,HIV infection
11339704,113397041,1,I,,20150724.0,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06187,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. TH E NEW ENGLAND JOURNAL O F MEDICINE. 2015;1-9",,,,,Y,,,20150805.0,N,OT,US,US,Efavirenz,Hepatocellular carcinoma,113397041.0,OT,,,,,,,,,113397041.0,1.0,HIV infection
11339721,113397211,1,I,,20150724.0,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06188,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805.0,N,OT,US,US,Efavirenz,Portal vein thrombosis,113397211.0,OT,,,,,,,,,113397211.0,1.0,HIV infection
11339893,113398931,1,I,,20150724.0,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06209,CIPLA,SUSANNA.?NAGGIE@?DUKE.?EDU.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9,,,,,Y,,,20150805.0,N,OT,US,US,Efavirenz,Death;Endocarditis staphylococcal;Sepsis,113398931.0,DE,,,,,,,,,113398931.0,1.0,HIV infection
11339894,113398941,1,I,,20150724.0,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06206,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV11. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805.0,N,OT,US,US,Efavirenz,Death,113398941.0,DE,,,,,,,,,113398941.0,1.0,HIV infection
11339895,113398952,2,F,,20160229.0,20150805,20160313,EXP,,US-CIPLA LTD.-2015US06208,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV 1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Disease recurrence;Drug resistance;Virologic failure,113398952.0,OT,,,,,,,,,113398952.0,1.0,HIV infection
11339944,113399441,1,I,,20150724.0,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06212,CIPLA,LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV11. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1 TO 9,,,,,Y,,,20150805.0,N,OT,US,US,Efavirenz,Blood creatinine increased,113399441.0,OT,,,,,,,,,113399441.0,1.0,HIV infection
11339946,113399462,2,F,,20160229.0,20150805,20160313,EXP,,US-CIPLA LTD.-2015US06211,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Renal tubular disorder,113399462.0,OT,,,,,,,,,113399462.0,1.0,HIV infection
11339947,113399471,1,I,,20150724.0,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06210,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV11. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1 TO 9",,,,,Y,,,20150805.0,N,OT,US,US,Efavirenz,Hypophosphataemia,113399471.0,OT,,,,,,,,,113399471.0,1.0,HIV infection
11342548,113425481,1,I,,20150728.0,20150805,20150805,EXP,,ET-GILEAD-2015-0165920,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805.0,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113425481.0,OT,,,,,,,,,113425481.0,1.0,HIV infection
11342559,113425593,3,F,2012.0,20151027.0,20150805,20151103,EXP,,BR-ABBVIE-15P-020-1436927-00,ABBVIE,,,,,M,Y,59.0,KG,20151103.0,,CN,BR,BR,EFAVIRENZ,CD4 lymphocytes increased;Colour blindness;Nausea;Vision blurred;Vomiting;Weight decreased,113425593.0,OT,,,113425593.0,1.0,201111.0,,,,113425593.0,1.0,HIV infection
11342666,113426661,1,I,,20150728.0,20150805,20150805,EXP,,ET-GILEAD-2015-0165921,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805.0,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113426661.0,OT,,,,,,,,,113426661.0,1.0,HIV infection
11342835,113428351,1,I,,20150728.0,20150805,20150805,EXP,,ET-GILEAD-2015-0165923,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805.0,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428351.0,OT,,,,,,,,,113428351.0,1.0,HIV infection
11342836,113428361,1,I,,20150728.0,20150805,20150805,EXP,,ET-GILEAD-2015-0165922,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805.0,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428361.0,OT,,,,,,,,,113428361.0,1.0,HIV infection
11342838,113428381,1,I,,20150728.0,20150805,20150805,EXP,,ET-GILEAD-2015-0165924,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805.0,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428381.0,OT,,,,,,,,,113428381.0,1.0,HIV infection
11342839,113428391,1,I,,20150728.0,20150805,20150805,EXP,,ET-GILEAD-2015-0165925,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805.0,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428391.0,OT,,,,,,,,,113428391.0,1.0,HIV infection
11348844,113488443,3,F,20141105.0,20160701.0,20150806,20160713,EXP,,HT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-051188,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20160713.0,,OT,HT,HT,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,113488443.0,OT,,,113488443.0,1.0,20140918.0,20140922.0,,,113488443.0,1.0,HIV infection
11362483,113624833,3,F,20141011.0,20170105.0,20150810,20170110,EXP,,ZW-GILEAD-2015-0156068,GILEAD,,30.0,YR,A,F,Y,,,20170110.0,,OT,ZW,ZW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,113624833.0,OT,,,113624833.0,1.0,20140619.0,20150520.0,,,113624833.0,1.0,HIV infection
11363064,113630641,1,I,,20150730.0,20150810,20150810,PER,,US-GILEAD-2015-0166134,GILEAD,,48.0,YR,A,F,Y,64.0,KG,20150810.0,N,MD,US,US,EFAVIRENZ,Drug ineffective;Drug resistance,113630641.0,OT,,,113630641.0,1.0,20130513.0,,,,113630641.0,1.0,HIV infection
11363742,113637421,1,I,,20150803.0,20150811,20150811,EXP,,BR-ROCHE-1619078,ROCHE,"NEGRA M, CARVALHO A, DE AQUINO M, PINTO J, DA SILVA M, ANDREATTA K, GRAHAM B, LIU Y-P AND QUIRK E LONG-TERM EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN HIV-1-INFECTED ADOLESCENTS FAILING ANTIRETROVIRAL THERAPY: THE FINAL RESULTS OF STUDY GS-US-104-0321. PEDIATRIC INFECTIOUS DISEASE JOURNAL 2015 APR 21;34 (4):398-405.",,,,,Y,,,20150811.0,N,MD,BR,BR,EFAVIRENZ,Abscess;Abscess limb;Anogenital warts;Gastroenteritis;Herpes zoster;Neurocryptococcosis;Overdose;Pneumocystis jirovecii pneumonia;Pneumonia;Psychotic disorder;Pyelonephritis;Respiratory tract infection;Seizure;Sinusitis;Suicide attempt;Urinary tract infection,113637421.0,OT,,,,,,,,,113637421.0,1.0,HIV infection
11364522,113645221,1,I,,20150728.0,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112478,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645221.0,OT,,,,,,,,,113645221.0,1.0,HIV infection
11364523,113645231,1,I,,20150728.0,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112467,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645231.0,OT,,,,,,,,,113645231.0,1.0,HIV infection
11364526,113645261,1,I,,20150728.0,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112480,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645261.0,OT,,,,,,,,,113645261.0,1.0,HIV infection
11364528,113645281,1,I,,20150728.0,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112474,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645281.0,OT,,,,,,,,,113645281.0,1.0,HIV infection
11364530,113645301,1,I,,20150728.0,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112481,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645301.0,OT,,,,,,,,,113645301.0,1.0,HIV infection
11364531,113645311,1,I,,20150728.0,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112479,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645311.0,OT,,,,,,,,,113645311.0,1.0,HIV infection
11364575,113645751,1,I,,20150728.0,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112478,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645751.0,OT,,,,,,,,,113645751.0,1.0,HIV infection
11364578,113645781,1,I,,20150728.0,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112467,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645781.0,OT,,,,,,,,,113645781.0,1.0,HIV infection
11364583,113645831,1,I,,20150728.0,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112480,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645831.0,OT,,,,,,,,,113645831.0,1.0,HIV infection
11364585,113645851,1,I,,20150728.0,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112474,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645851.0,OT,,,,,,,,,113645851.0,1.0,HIV infection
11364587,113645871,1,I,,20150728.0,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112481,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645871.0,OT,,,,,,,,,113645871.0,1.0,HIV infection
11364596,113645961,1,I,,20150728.0,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112479,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811.0,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645961.0,OT,,,,,,,,,113645961.0,1.0,HIV infection
11370858,113708582,2,F,20150616.0,20150824.0,20150812,20150828,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2015GSK113367,VIIV,,53.0,YR,,M,Y,,,20150828.0,N,OT,FR,FR,EFAVIRENZ;SUSTIVA,Depression;Panic attack;Suicidal ideation,113708582.0,OT,,,113708582.0,1.0,20150615.0,20150614.0,,,113708582.0,1.0,HIV infection
11371327,113713272,2,F,20150616.0,20150824.0,20150812,20150901,EXP,,FR-GILEAD-2015-0166665,GILEAD,,53.0,YR,A,M,Y,,,20150901.0,N,CN,FR,FR,SUSTIVA,Depression;Panic attack;Suicidal ideation,113713272.0,OT,,,113713272.0,1.0,20150615.0,2015.0,,,113713272.0,1.0,HIV infection
11381634,113816342,2,F,,20150814.0,20150814,20150827,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-051772,BRISTOL MYERS SQUIBB,,43.0,YR,,M,Y,111.0,KG,20150827.0,N,MD,BR,BR,EFAVIRENZ,Adverse event;Craniocerebral injury;Meningorrhagia,113816342.0,OT,,,113816342.0,1.0,20110727.0,,,,113816342.0,1.0,HIV infection
11384028,113840281,1,I,,20150807.0,20150815,20150815,EXP,,ES-CIPLA LTD.-2015ES06600,CIPLA,"RAMIREZ R., PEDROL E., LLIBRE J.M., TASIAS M., CURRAN A., GUARDIOLA J.M., ET AL.. OUTCOME OF NEUROPSYCHIATRIC SYMPTOMS RELATED TO AN ANTIRETROVIRAL DRUG FOLLOWING ITS SUBSTITUTION BY NEVIRAPINE: THE RELAX STUDY. HIV MEDICINE. 2015;1-7",,,,,Y,,,20150815.0,N,OT,ES,ES,Efavirenz,Nervous system disorder;Palpitations,113840281.0,OT,,,,,,,,,113840281.0,1.0,HIV infection
11389742,113897421,1,I,20120808.0,20150805.0,20150817,20150817,EXP,,TH-GILEAD-2015-0166983,GILEAD,,33.0,YR,A,F,Y,40.65,KG,20150817.0,N,MD,TH,TH,EFAVIRENZ,Hypophosphataemia,113897421.0,LT,,,113897421.0,1.0,20110912.0,20120111.0,,,113897421.0,1.0,HIV infection
11391056,113910561,1,I,,20150807.0,20150818,20150818,EXP,,ES-CIPLA LTD.-2015ES06602,CIPLA,"RAMIREZ R., PEDROL E., LLIBRE J.M., TASIAS M., CURRAN A., GUARDIOLA J.M., ET AL.. OUTCOME OF NEUROPSYCHIATRIC SYMPTOMS RELATED TO AN ANTIRETROVIRAL DRUG FOLLOWING ITS SUBSTITUTION BY NEVIRAPINE: THE RELAX STUDY. HIV MEDICINE. 2015;1-7",,,,,Y,,,20150818.0,N,OT,ES,ES,Efavirenz,Anal pruritus;Nervous system disorder,113910561.0,OT,,,,,,,,,113910561.0,1.0,HIV infection
11391063,113910631,1,I,,20150807.0,20150818,20150818,EXP,,ES-CIPLA LTD.-2015ES06601,CIPLA,"RAMIREZ R., PEDROL E., LLIBRE J.M., TASIAS M., CURRAN A., GUARDIOLA J.M., ET AL.. OUTCOME OF NEUROPSYCHIATRIC SYMPTOMS RELATED TO AN ANTIRETROVIRAL DRUG FOLLOWING ITS SUBSTITUTION BY NEVIRAPINE: THE RELAX STUDY. HIV MEDICINE. 2015;1-7",,,,,Y,,,20150818.0,N,MD,ES,ES,Efavirenz,Arthralgia;Nervous system disorder,113910631.0,OT,,,,,,,,,113910631.0,1.0,HIV infection
11393459,113934591,1,I,,20150805.0,20150818,20150818,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-052669,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20150818.0,N,CN,GB,GB,EFAVIRENZ,Joint swelling,113934591.0,OT,,,113934591.0,2.0,20140826.0,,,,113934591.0,1.0,HIV infection
11394170,113941704,4,F,,20150826.0,20150819,20150909,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-053911,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20150909.0,N,MD,GB,GB,EFAVIRENZ,Joint swelling,113941704.0,OT,,,113941704.0,2.0,20140826.0,,,,113941704.0,1.0,HIV infection
11398182,113981822,2,F,,20150826.0,20150820,20150908,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-053005,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20150908.0,N,MD,GB,GB,SUSTIVA,Joint swelling,113981822.0,OT,,,113981822.0,2.0,20140826.0,,,,113981822.0,1.0,HIV infection
11399626,113996261,1,I,,20150806.0,20150820,20150820,EXP,,IN-MYLANLABS-2015M1027805,MYLAN,LINGESWARAN A. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY. J-PEDIATR-NEUROSCI 2014; 9(3):283-285.,,,,,Y,,,20150820.0,N,MD,IN,IN,EFAVIRENZ,Catatonia,113996261.0,HO,,,,,,,,,113996261.0,1.0,HIV infection
11403790,114037901,1,I,,20150806.0,20150821,20150821,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-055093,BRISTOL MYERS SQUIBB,LINGESWARAN A. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY. JOURNAL PEDIATRIC NEUROSCIENCES. 2014;9(3):283-5,16.0,YR,,M,Y,,,20150821.0,N,MD,IN,IN,EFAVIRENZ,Catatonia,114037901.0,HO,,,,,,,,,114037901.0,1.0,HIV infection
11413937,114139371,1,I,20150411.0,20150820.0,20150824,20150824,EXP,,TH-GLAXOSMITHKLINE-TH2015GSK121047,GLAXOSMITHKLINE,,30.0,YR,,F,Y,,,20150824.0,N,CN,US,TH,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,114139371.0,OT,,,114139371.0,1.0,20140604.0,,,,114139371.0,1.0,HIV infection
11414725,114147252,2,F,,20150915.0,20150825,20150925,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-054201,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150925.0,N,PH,US,US,EFAVIRENZ,Gastrostomy;Neck surgery;Tracheostomy,114147252.0,HO,,,,,,,,,114147252.0,1.0,HIV infection
11415550,114155502,2,F,,20160510.0,20150825,20160513,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2015GSK121403,VIIV,LINGESWARAN A.. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY.. JOURNAL OF PEDIATRIC NEUROSCIENCES. 2014;9;3:283-285,16.0,YR,,M,Y,,,20160513.0,,OT,IN,IN,Efavirenz,Agitation;Brain scan abnormal;Catatonia;Echopraxia;Grimacing;Mutism;Poor quality sleep;Withdrawal syndrome,114155502.0,HO,,,,,,,,,114155502.0,1.0,HIV infection
11415553,114155531,1,I,20150411.0,20150820.0,20150825,20150825,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2015GSK121047,VIIV,,30.0,YR,,F,Y,,,20150825.0,N,CN,US,TH,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,114155531.0,OT,,,114155531.0,1.0,20140604.0,,,,114155531.0,1.0,HIV infection
11417878,114178781,1,I,,20150818.0,20150825,20150825,EXP,,AO-GILEAD-2015-0168532,GILEAD,"MANUEL A, VICTORIO T, GOMES C, MARTINS T, NETO A. VASCULITIS: AN UNUSUAL MANIFESTATION IN AN HIV-INFECTED PATIENT. THE BRAZILIAN JOURNAL OF INFECTIOUS DISEASES. 2015;19(4):439-441",30.0,YR,A,F,Y,,,20150825.0,N,OT,AO,AO,EFAVIRENZ,Vasculitis,114178781.0,OT,,,,,,,,,114178781.0,1.0,HIV infection
11427013,114270131,1,I,20150411.0,20150820.0,20150827,20150827,EXP,,TH-GILEAD-2015-0168983,GILEAD,,30.0,YR,A,F,Y,,,20150827.0,N,OT,TH,TH,EFAVIRENZ,Abortion spontaneous,114270131.0,OT,,,114270131.0,1.0,20140604.0,,,,114270131.0,1.0,HIV infection
11438119,114381191,1,I,,20150821.0,20150901,20150901,EXP,,PHHY2015GB103493,SANDOZ,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL.. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT.. JAMA-NEUROL. 2015;72(5):603-5",63.0,YR,,M,Y,,,20150901.0,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy;Myalgia,114381191.0,OT,,,,,,,,,114381191.0,1.0,HIV infection
11438122,114381221,1,I,,20150821.0,20150901,20150901,EXP,,PHHY2015GB102794,SANDOZ,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL.. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT.. JAMA-NEUROL. 2015;72(5):603-5",55.0,YR,,M,Y,,,20150901.0,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114381221.0,OT,,,,,,,,,114381221.0,1.0,HIV infection
11441892,114418921,1,I,20140717.0,20150824.0,20150901,20150901,EXP,ES-AGEMED-609137244,ES-VIIV HEALTHCARE LIMITED-ES2015120897,VIIV,,39.0,YR,,F,Y,,,20150901.0,N,MD,ES,ES,Efavirenz,Pancreatitis acute;Portal vein thrombosis;Splenic thrombosis,114418921.0,HO,,,114418921.0,1.0,2009.0,20140717.0,,,114418921.0,1.0,HIV infection
11442100,114421001,1,I,20140717.0,20150824.0,20150901,20150901,EXP,ES-AGEMED-609137244,ES-GLAXOSMITHKLINE-ES2015120897,GLAXOSMITHKLINE,,39.0,YR,,F,Y,,,20150901.0,N,MD,ES,ES,Efavirenz,Pancreatitis acute;Portal vein thrombosis;Splenic thrombosis,114421001.0,OT,,,114421001.0,1.0,2009.0,20140717.0,,,114421001.0,1.0,HIV infection
11442450,114424501,1,I,20150330.0,20150407.0,20150901,20150901,EXP,,MW-GILEAD-2015-0147770,GILEAD,,36.0,YR,A,M,Y,,,20150901.0,N,MD,MW,MW,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Pneumonia,114424501.0,DE,,,114424501.0,1.0,20150316.0,,,,114424501.0,1.0,HIV infection
11449230,114492301,1,I,,20150828.0,20150902,20150902,EXP,,UG-ABBVIE-15P-165-1454522-00,ABBVIE,,35.0,YR,,F,Y,,,20150902.0,N,OT,COUNTRY NOT SPECIFIED,UG,SUSTIVA,Abortion induced;Exposure during pregnancy,114492301.0,OT,,,114492301.0,1.0,20070503.0,20080721.0,,,114492301.0,1.0,Antiretroviral therapy
11449260,114492601,1,I,20081101.0,20150828.0,20150902,20150902,EXP,,UG-ABBVIE-15P-165-1454544-00,ABBVIE,,35.0,YR,,F,Y,,,20150902.0,N,OT,COUNTRY NOT SPECIFIED,UG,SUSTIVA,Exposure during pregnancy;Stillbirth,114492601.0,OT,,,114492601.0,1.0,20070828.0,20080904.0,,,114492601.0,1.0,HIV infection
11449274,114492741,1,I,20090315.0,20150828.0,20150902,20150902,EXP,,UG-ABBVIE-15P-165-1454564-00,ABBVIE,,27.0,YR,,F,Y,,,20150902.0,N,OT,COUNTRY NOT SPECIFIED,UG,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,114492741.0,OT,,,114492741.0,1.0,20090303.0,20090303.0,,,114492741.0,1.0,HIV infection
11451882,114518821,1,I,,20150821.0,20150903,20150903,EXP,,GB-MYLANLABS-2015M1029506,MYLAN,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT. JAMA-NEUROL 2015; 72(5):603-5.",,,,,Y,,,20150903.0,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114518821.0,OT,,,,,,,,,114518821.0,1.0,HIV infection
11451908,114519081,1,I,,20150821.0,20150903,20150903,EXP,,GB-MYLANLABS-2015M1029507,MYLAN,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT. JAMA-NEUROL 2015; 72(5):603-5.",,,,,Y,,,20150903.0,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114519081.0,OT,,,,,,,,,114519081.0,1.0,HIV infection
11457592,114575921,1,I,,20150818.0,20150902,20150902,EXP,,2015HINLIT0706,HETERO,,16.0,YR,,M,N,,,20150831.0,N,MD,IN,,EFAVIRENZ (EFAVIRENZ),Catatonia,114575921.0,HO,114575921.0,LIT,,,,,,,114575921.0,1.0,HIV infection
11457705,114577051,1,I,20150411.0,20150824.0,20150904,20150904,EXP,,TH-AUROBINDO-AUR-APL-2015-07787,AUROBINDO,,30.0,YR,,F,Y,,,20150904.0,N,MD,TH,TH,EFAVIRENZ 600MG,Abortion spontaneous;Exposure during pregnancy,114577051.0,OT,,,114577051.0,1.0,20140604.0,,,,114577051.0,1.0,HIV infection
11460939,114609393,3,F,20150411.0,20160621.0,20150904,20160704,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-057252,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20160704.0,,OT,TH,TH,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Off label use,114609393.0,OT,,,114609393.0,1.0,20140604.0,,,,114609393.0,1.0,HIV infection
11463098,114630982,2,F,,20150821.0,20150905,20150908,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-060207,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,,,20150908.0,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114630982.0,OT,,,,,,,,,114630982.0,1.0,HIV infection
11463106,114631062,2,F,,20150821.0,20150905,20150908,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-059139,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20150908.0,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114631062.0,OT,,,,,,,,,114631062.0,1.0,HIV infection
11466628,114666281,1,I,,20150821.0,20150907,20150907,EXP,,GB-009507513-1509GBR003527,MERCK,,63.0,YR,,M,Y,,,20150907.0,N,CN,US,GB,EFAVIRENZ,Mitochondrial myopathy,114666281.0,OT,,,,,,,,,114666281.0,1.0,HIV infection
11493385,114933851,1,I,,20150829.0,20150911,20150911,EXP,,GB-LUPIN PHARMACEUTICALS INC.-2015-02744,LUPIN,"PAYNE B, GARDNER K, HORVATH R, CHINNERY P, BLAKELY E, TAYLOR R, MADDISON P. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT. JAMA NEUROLOGY. 2015 MAY;72(5):603-605.",63.0,YR,,M,Y,,,20150911.0,N,,COUNTRY NOT SPECIFIED,GB,Efavirenz,Mitochondrial myopathy,114933851.0,OT,,,,,,,,,114933851.0,1.0,HIV infection
11500094,115000941,1,I,20140423.0,20150907.0,20150914,20150914,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2015GSK129083,VIIV,,40.0,YR,,,Y,,,20150914.0,N,MD,UG,UG,Efavirenz,Anaemia,115000941.0,LT,,,115000941.0,1.0,20140326.0,20140618.0,,,115000941.0,1.0,HIV infection
11515214,115152141,1,I,2007.0,20150909.0,20150916,20150916,EXP,ES-AGEMED-109233444,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-061619,BRISTOL MYERS SQUIBB,,48.0,YR,,M,Y,,,20150916.0,N,CN,ES,ES,EFAVIRENZ,Cellulitis;Cholesterosis;Haemothorax;Monarthritis;Neutropenia;Pneumonia;Polyarthritis;Type 2 diabetes mellitus,115152141.0,OT,,,115152141.0,1.0,2006.0,20140911.0,,,115152141.0,1.0,HIV infection
11518514,115185141,1,I,,20150908.0,20150917,20150917,EXP,,US-JNJFOC-20150905804,JANSSEN,"STEK A, BEST BM, WANG J, CAPPARELLI EV, BURCHETT SK, KREITCHMANN R, ET AL. PHARMACOKINETICS OF ONCE VERSUS TWICE DAILY DARUNAVIR IN PREGNANT HIV-INFECTED WOMEN. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 01-SEP-2015;70 (1):33-41.",,,,F,Y,,,20150917.0,N,OT,US,US,EFAVIRENZ,Exposure during pregnancy;Foetal growth restriction;Gestational diabetes;Hypercholesterolaemia;Liver function test abnormal;Premature labour,115185141.0,OT,,,,,,,,,115185141.0,1.0,HIV infection
11520454,115204542,2,F,,20210614.0,20150918,20210627,EXP,,GB-AUROBINDO-AUR-APL-2015-08151,AUROBINDO,,63.0,YR,,M,Y,,,20210627.0,,HP,GB,GB,EFAVIRENZ.,Axonal neuropathy;Blood creatine phosphokinase increased;Mitochondrial myopathy;Myalgia,115204542.0,OT,,,,,,,,,115204542.0,1.0,Antiretroviral therapy
11525401,115254011,1,I,,20150908.0,20150918,20150918,EXP,,US-JNJFOC-20150909154,JANSSEN,"STEK A, BEST BM, WANG J, CAPPARELLI EV, BURCHETT SK, KREITCHMANN R, ET AL. PHARMACOKINETICS OF ONCE VERSUS TWICE DAILY DARUNAVIR IN PREGNANT HIV-INFECTED WOMEN. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 01-SEP-2015;70 (1):33-41.",,,,,Y,,,20150918.0,N,MD,US,US,EFAVIRENZ,Atrial septal defect;Cardiac murmur;Foetal exposure during pregnancy,115254011.0,CA,,,,,,,,,115254011.0,1.0,HIV infection
11546172,115461721,1,I,,20150909.0,20150924,20150924,EXP,,IE-CIPLA LTD.-2015IE07429,CIPLA,"SHERIF O, KHOOB S, AND CAROLINE SOLAS. KEY DRUG-DRUG INTERACTIONS WITH DIRECT-ACTING ANTIVIRAL IN HIV-HCV COINFECTION. CURR OPIN HIV AIDS. 2015;10 (5):348-354",,,,,Y,,,20150924.0,N,OT,IE,IE,Efavirenz,Blood creatinine increased,115461721.0,OT,,,,,,,,,115461721.0,1.0,HIV infection
11546193,115461931,1,I,,20150909.0,20150924,20150924,EXP,,IE-CIPLA LTD.-2015IE07428,CIPLA,"SHERIF O, KHOOB S, AND CAROLINE SOLAS. KEY DRUG-DRUG INTERACTIONS WITH DIRECT-ACTING ANTIVIRAL IN HIV-HCV COINFECTION. CURR OPIN HIV AIDS. 2015;10 (5):348-354",,,,,Y,,,20150924.0,N,OT,IE,IE,Efavirenz,Blood creatinine increased,115461931.0,OT,,,,,,,,,115461931.0,1.0,HIV infection
11564310,115643101,1,I,2012.0,20150921.0,20150928,20150928,EXP,,BR-ABBVIE-15P-020-1469315-00,ABBVIE,,,,,F,Y,46.0,KG,20150928.0,N,CN,BR,BR,EFAVIRENZ,Blindness;Dyspnoea;HIV infection;Malaise;Pain in extremity;Rash macular;Sensory disturbance;Skin discolouration;Visual acuity reduced;Weight decreased;Wound,115643101.0,DS,,,115643101.0,1.0,2007.0,2011.0,,,115643101.0,1.0,HIV infection
11567432,115674321,1,I,20150411.0,20150821.0,20150925,20150925,EXP,,2015HINCT 0709,HETERO,,30.0,YR,,F,N,,,20150902.0,N,OT,TH,,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,115674321.0,OT,115674321.0,FGN,115674321.0,1.0,20140604.0,,,,115674321.0,1.0,HIV infection
11590835,115908354,4,F,,20151130.0,20151002,20151207,EXP,,ES-GILEAD-2015-0174266,GILEAD,,,,N,,Y,,,20151207.0,,MD,ES,ES,EFAVIRENZ,Polydactyly,115908354.0,CA,,,,,,,,,115908354.0,1.0,HIV infection
11593294,115932941,1,I,,20150922.0,20151005,20151005,EXP,,US-CIPLA LTD.-2015US07723,CIPLA,"SEEKINS D, PAVIA-RUZ N, ROSSOUW M, SAEZ-LLORENS X, BUNUPURADAH T, TAYLOR M, YANG R ET AL... EFAVIRENZ CAPSULE SPRINKLE AND LIQUID FORMULATIONS WITH DIDANOSINE AND EMTRICITABINE IN HIV-1-INFECTED INFANTS AND CHILDREN 3 MONTHS TO 6 YEARS OF AGE: STUDY AI266-922. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL",,,,,Y,,,20151005.0,,OT,US,US,Efavirenz,Cardiac failure;Pneumonia,115932941.0,DE,,,,,,,,,115932941.0,1.0,HIV infection
11593397,115933971,1,I,,20150922.0,20151005,20151005,EXP,,US-CIPLA LTD.-2015US07720,CIPLA,"SEEKINS D, PAVIA-RUZ N, ROSSOUW M, SAEZ-LLORENS X, BUNUPURADAH T, TAYLOR M, YANG R ET AL... EFAVIRENZ CAPSULE SPRINKLE AND LIQUID FORMULATIONS WITH DIDANOSINE AND EMTRICITABINE IN HIV-1-INFECTED INFANTS AND CHILDREN 3 MONTHS TO 6 YEARS OF AGE: STUDY AI266-922. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL",,,,,Y,,,20151005.0,,OT,US,US,Efavirenz,Bacterial infection,115933971.0,DE,,,,,,,,,115933971.0,1.0,HIV infection
11620599,116205991,1,I,,20150929.0,20151012,20151012,EXP,,TW-MYLANLABS-2015M1034107,MYLAN,"LO CH, LIN TY. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. RESPIR-CARE 2014? 59(10):E160-E162.",,,,,Y,,,20151012.0,,MD,TW,TW,EFAVIRENZ,Immune reconstitution inflammatory syndrome,116205991.0,HO,,,,,,,,,116205991.0,1.0,HIV infection
11625951,116259511,1,I,20150414.0,20150417.0,20151013,20151013,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2015GSK054104,VIIV,,64.0,YR,,M,Y,67.0,KG,20151013.0,,CN,FR,FR,SUSTIVA,Arthralgia;Balance disorder;Dizziness;Fatigue;Headache;Insomnia;Malaise;Myalgia;Nausea;Paraesthesia;Poor quality sleep;Pruritus,116259511.0,HO,,,116259511.0,1.0,20150413.0,20150416.0,,,116259511.0,1.0,HIV infection
11626599,116265992,2,F,,20151109.0,20151013,20151117,EXP,,US-GILEAD-2015-0175886,GILEAD,,54.0,YR,A,M,Y,68.93,KG,20151117.0,,MD,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,116265992.0,OT,,,116265992.0,1.0,200706.0,200706.0,,,116265992.0,1.0,HIV infection
11636385,116363852,2,F,20150411.0,20150820.0,20151016,20151020,EXP,,TH-GLAXOSMITHKLINE-TH2015123185,GLAXOSMITHKLINE,,30.0,YR,,F,Y,,,20151020.0,,OT,TH,TH,Efavirenz,Abortion spontaneous,116363852.0,OT,,,116363852.0,1.0,20140604.0,,,,116363852.0,1.0,HIV infection
11636659,116366591,1,I,,,20151015,20151015,DIR,,,,,,,,M,N,154.0,LBS,20151006.0,N,,US,,SUSTIVA,Abdominal pain upper;Dry eye;Dysuria;Eye irritation;Eye pain;Fatigue;Genital swelling;Headache;Hot flush;Influenza like illness;Joint stiffness;Joint swelling;Libido increased;Loss of consciousness;Macular degeneration;Musculoskeletal stiffness;Myalgia;Nasopharyngitis;Ocular hyperaemia;Oropharyngeal pain;Pain in extremity;Photopsia;Rash;Renal pain;Skin exfoliation;Throat irritation;Tongue disorder,116366591.0,DS,,,,,,,,,116366591.0,1.0,HIV infection
11636674,116366741,1,I,,20151001.0,20151016,20151016,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK147178,VIIV,,44.0,YR,,M,Y,,,20151016.0,,CN,GB,US,SUSTIVA,Gastrointestinal disorder;Treatment failure,,,,,,,,,,,116366741.0,1.0,HIV infection
11636677,116366772,2,F,20150411.0,20150820.0,20151016,20151020,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2015123185,VIIV,,30.0,YR,,F,Y,,,20151020.0,,OT,TH,TH,Efavirenz,Abortion spontaneous,116366772.0,OT,,,116366772.0,1.0,20140604.0,,,,116366772.0,1.0,HIV infection
11640684,116406843,3,F,201402.0,20151218.0,20151019,20151230,EXP,,MX-GILEAD-2015-0177466,GILEAD,,37.0,YR,A,F,Y,,,20151230.0,,MD,MX,MX,EFAVIRENZ W/ZIDOVUDINE,Anaemia;Blood creatinine increased;Creatinine renal clearance decreased,116406843.0,OT,,,116406843.0,1.0,201309.0,201309.0,,,116406843.0,1.0,HIV infection
11641195,116411951,1,I,,20151001.0,20151019,20151019,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK147655,VIIV,,40.0,YR,,M,Y,,,20151019.0,,CN,GB,US,SUSTIVA,Anxiety;Gastrointestinal disorder;Sleep disorder;Treatment failure,,,,,,,,,,,116411951.0,1.0,HIV infection
11641205,116412051,1,I,,20151001.0,20151019,20151019,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK147832,VIIV,,30.0,YR,,M,Y,,,20151019.0,,CN,GB,US,SUSTIVA,Drug effect incomplete;Gastrointestinal disorder,,,,,,,,,,,116412051.0,1.0,HIV infection
11644114,116441143,3,F,201402.0,20151218.0,20151020,20160105,EXP,,MX-VIIV HEALTHCARE LIMITED-MX2015148662,VIIV,,37.0,YR,,F,Y,,,20160105.0,,MD,MX,MX,EFAVIRENZ W/ZIDOVUDINE,Anaemia;Blood creatinine increased;Creatinine renal clearance decreased,116441143.0,OT,,,116441143.0,1.0,201309.0,201309.0,,,116441143.0,1.0,HIV infection
11644453,116444531,1,I,,20151001.0,20151020,20151020,EXP,,US-GLAXOSMITHKLINE-US2015GSK147655,GLAXOSMITHKLINE,,40.0,YR,,M,Y,,,20151020.0,,CN,GB,US,SUSTIVA,Anxiety;Gastrointestinal disorder;Sleep disorder;Treatment failure,,,,,,,,,,,116444531.0,1.0,HIV infection
11653644,116536444,4,F,,20151014.0,20151022,20151106,EXP,,FR-009507513-1509FRA005380,MERCK,,51.0,YR,,F,Y,,,20151106.0,,CN,US,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,116536444.0,HO,,,,,,,,,116536444.0,1.0,HIV infection
11654885,116548851,1,I,20150505.0,20151019.0,20151023,20151023,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2015GSK149663,VIIV,,41.0,YR,,M,Y,57.0,KG,20151023.0,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Off label use;Rash erythematous,116548851.0,OT,,,116548851.0,1.0,20150505.0,,,,116548851.0,1.0,Acquired immunodeficiency syndrome
11655537,116555371,1,I,20150505.0,20151019.0,20151023,20151023,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK149663,GLAXOSMITHKLINE,,41.0,YR,,M,Y,57.0,KG,20151023.0,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Off label use;Rash erythematous,116555371.0,OT,,,116555371.0,1.0,20150505.0,,,,116555371.0,1.0,Acquired immunodeficiency syndrome
11656307,116563071,1,I,,20151012.0,20151023,20151023,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-071521,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151023.0,,OT,US,US,EFAVIRENZ,Drug interaction;Treatment failure,116563071.0,OT,,,,,,,,,116563071.0,1.0,HIV infection
11661955,116619553,3,F,,20151130.0,20151026,20151203,EXP,,LT-009507513-1510LTU007855,MERCK,,,,,,Y,,,20151203.0,,CN,US,LT,EFAVIRENZ,Drug resistance,116619553.0,OT,,,,,,,,,116619553.0,1.0,HIV infection
11662002,116620022,2,F,,20151130.0,20151026,20151203,EXP,,LT-009507513-1510LTU007848,MERCK,,,,,,Y,,,20151203.0,,CN,US,LT,EFAVIRENZ,Drug resistance,116620022.0,OT,,,,,,,,,116620022.0,1.0,HIV infection
11662446,116624463,3,F,,20151130.0,20151027,20151203,EXP,,LT-009507513-1510LTU007668,MERCK,,,,,,Y,,,20151203.0,,CN,US,LT,EFAVIRENZ,Drug resistance,116624463.0,OT,,,,,,,,,116624463.0,1.0,HIV infection
11662589,116625893,3,F,,20151130.0,20151027,20151203,EXP,,LT-009507513-1510LTU007670,MERCK,,,,,,Y,,,20151203.0,,CN,US,LT,EFAVIRENZ,Drug resistance,116625893.0,OT,,,,,,,,,116625893.0,1.0,HIV infection
11663996,116639961,1,I,,20151014.0,20151027,20151027,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-071202,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151027.0,,PH,US,US,SUSTIVA,Medication residue present,,,,,,,,,,,116639961.0,1.0,HIV infection
11678865,116788653,3,F,,20151130.0,20151028,20151203,EXP,,LT-009507513-1510LTU007391,MERCK,,,,,,Y,,,20151203.0,,CN,US,LT,EFAVIRENZ,Drug resistance,116788653.0,OT,,,,,,,,,116788653.0,1.0,HIV infection
11682541,116825411,1,I,2009.0,20151019.0,20151029,20151029,EXP,,MX-GILEAD-2015-0178908,GILEAD,,41.0,YR,A,M,Y,,,20151029.0,,MD,MX,MX,EFAVIRENZ,Neuropathy peripheral;Pulmonary tuberculosis,116825411.0,OT,,,116825411.0,1.0,200903.0,201201.0,,,116825411.0,1.0,HIV infection
11684269,116842691,1,I,,20110711.0,20151029,20151029,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15928070,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151029.0,,OT,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116842691.0,1.0,HIV infection
11684270,116842701,1,I,,20110711.0,20151029,20151029,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15935554,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151029.0,,OT,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116842701.0,1.0,HIV infection
11684968,116849682,2,F,20000609.0,20160825.0,20151030,20160825,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15158538,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160825.0,,OT,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116849682.0,1.0,HIV infection
11685007,116850072,2,F,,20151209.0,20151030,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028640,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116850072.0,1.0,Antiretroviral therapy
11685782,116857822,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028053,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116857822.0,1.0,Antiretroviral therapy
11686093,116860932,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028087,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116860932.0,1.0,Antiretroviral therapy
11686094,116860942,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028178,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116860942.0,1.0,Antiretroviral therapy
11686095,116860952,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028095,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116860952.0,1.0,Antiretroviral therapy
11686906,116869062,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028384,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116869062.0,1.0,Antiretroviral therapy
11687189,116871892,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028079,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116871892.0,1.0,Antiretroviral therapy
11687190,116871902,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028152,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116871902.0,1.0,Antiretroviral therapy
11687386,116873862,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028111,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116873862.0,1.0,Antiretroviral therapy
11687456,116874562,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028160,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116874562.0,1.0,Antiretroviral therapy
11688153,116881531,1,I,,20151020.0,20151030,20151030,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075673,BRISTOL MYERS SQUIBB,,13.0,YR,,F,Y,,,20151030.0,,OT,ZA,ZA,EFAVIRENZ,Ataxia;Drug level increased,116881531.0,OT,,,,,,,,,116881531.0,1.0,HIV infection
11688218,116882181,1,I,,20100308.0,20151030,20151030,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028103,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151030.0,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882181.0,1.0,Antiretroviral therapy
11688223,116882232,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028129,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882232.0,1.0,Antiretroviral therapy
11688225,116882252,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028145,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882252.0,1.0,Antiretroviral therapy
11688226,116882262,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028137,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882262.0,1.0,Antiretroviral therapy
11688232,116882321,1,I,,20151020.0,20151030,20151030,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-074364,BRISTOL MYERS SQUIBB,,6.0,YR,,F,Y,,,20151030.0,,OT,ZA,ZA,EFAVIRENZ,Ataxia;Drug level increased,116882321.0,OT,,,,,,,,,116882321.0,1.0,HIV infection
11688234,116882342,2,F,,20151209.0,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028061,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882342.0,1.0,Antiretroviral therapy
11688467,116884671,1,I,20130412.0,20130425.0,20151101,20151101,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-18844159,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,71.0,KG,20151101.0,,OT,ZW,ZW,EFAVIRENZ,Breech delivery;Hepatotoxicity;Maternal exposure during pregnancy;Stillbirth,116884671.0,OT,,,116884671.0,1.0,20100429.0,20120806.0,,,116884671.0,1.0,HIV infection
11688825,116888251,1,I,20130523.0,20130605.0,20151102,20151102,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-19001783,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20151102.0,,OT,CI,CI,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,116888251.0,OT,,,116888251.0,1.0,20130107.0,20130517.0,,,116888251.0,1.0,Antiretroviral therapy
11688937,116889372,2,F,,20151209.0,20151102,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028624,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116889372.0,1.0,Antiretroviral therapy
11688971,116889712,2,F,,20151209.0,20151102,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028632,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116889712.0,1.0,Antiretroviral therapy
11691963,116919631,1,I,20130506.0,20130523.0,20151103,20151103,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-18972091,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,49.9,KG,20151103.0,,OT,ZW,ZW,EFAVIRENZ,Abortion threatened;Foetal death;Maternal exposure during pregnancy,116919631.0,OT,,,116919631.0,1.0,20110824.0,20121002.0,,,116919631.0,1.0,HIV infection
11695249,116952495,5,F,20090930.0,20190128.0,20151103,20190205,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-009507513-0906USA00645,MERCK,,19.0,YR,,F,Y,,,20190205.0,,MD,FR,FR,SUSTIVA,Caesarean section;Drug ineffective;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,116952495.0,OT,,,116952495.0,1.0,20080215.0,,,,116952495.0,1.0,HIV infection
11699314,116993142,2,F,20110910.0,20160819.0,20151104,20160819,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-16170078,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,55.0,KG,20160819.0,,CN,GB,TH,EFAVIRENZ,Abortion threatened;Caesarean section;Live birth;Maternal exposure during pregnancy;Pregnancy on contraceptive;Premature delivery;Premature rupture of membranes,116993142.0,OT,,,116993142.0,1.0,20101104.0,20110214.0,,,116993142.0,1.0,HIV infection
11699315,116993151,1,I,2008.0,20090902.0,20151104,20151104,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14764369,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,63.94,KG,20151104.0,,CN,US,US,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy,116993151.0,OT,,,116993151.0,1.0,20060509.0,20081116.0,,,116993151.0,1.0,HIV infection
11699785,116997852,2,F,,20151209.0,20151105,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029028,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,CN,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116997852.0,1.0,Antiretroviral therapy
11702579,117025791,1,I,,20151022.0,20151105,20151105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075612,BRISTOL MYERS SQUIBB,,24.0,YR,,F,Y,,,20151105.0,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn;Sepsis;Stevens-Johnson syndrome,117025791.0,HO,,,,,,,,,117025791.0,1.0,HIV infection
11703721,117037211,1,I,,20100602.0,20151106,20151106,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-15133267,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151106.0,,CN,US,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117037211.0,OT,,,117037211.0,1.0,20100215.0,,,,117037211.0,1.0,HIV infection
11703722,117037222,2,F,20080920.0,20160131.0,20151106,20160701,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14902597,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20160701.0,,OT,UG,UG,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117037222.0,OT,,,117037222.0,1.0,20070503.0,20080721.0,,,117037222.0,1.0,Antiretroviral therapy
11703758,117037582,2,F,20040514.0,20160824.0,20151106,20160824,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15152010,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20160824.0,,CN,US,FR,EFAVIRENZ,Amniotic fluid volume increased;Live birth;Maternal exposure during pregnancy;Premature delivery,117037582.0,OT,,,117037582.0,1.0,20010401.0,20040102.0,,,117037582.0,1.0,Antiretroviral therapy
11703759,117037592,2,F,20120612.0,20160316.0,20151106,20160316,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-19034917,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20160316.0,,OT,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Off label use,117037592.0,OT,,,117037592.0,1.0,20101007.0,,,,117037592.0,1.0,Antiretroviral therapy
11705185,117051852,2,F,200805.0,20180806.0,20151106,20180814,EXP,,GB-009507513-0807USA00501,MERCK,,32.0,YR,,F,Y,57.0,KG,20180814.0,,CN,GB,GB,SUSTIVA,Drug interaction;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,117051852.0,OT,,,117051852.0,2.0,2006.0,,,,117051852.0,1.0,HIV test
11707547,117075472,2,F,,20151110.0,20151106,20151120,EXP,GB-MHRA-EYC 00129667,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075172,BRISTOL MYERS SQUIBB,,25.0,YR,,M,Y,,,20151120.0,,CN,GB,GB,EFAVIRENZ,Abdominal pain;Chromaturia;Porphyria acute;Vomiting,117075472.0,HO,,,,,,,,,117075472.0,1.0,HIV infection
11707929,117079291,1,I,,20151029.0,20151106,20151106,EXP,,SG-CIPLA LTD.-2015SG08365,CIPLA,"PATON N.I, STOHR W, ARENAS-PINTO A, FISHER M, WILLIAMS I, JOHNSON M.ET.AL.... PROTEASE INHIBITOR MONOTHERAPY FOR LONG-TERM MANAGEMENT OF HIV INFECTION: A RANDOMISED, CONTROLLED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET HIV. 2015?2:E417-26",,,,,Y,,,20151107.0,,OT,SG,SG,Efavirenz,Adenocarcinoma,117079291.0,DE,,,,,,,,,117079291.0,1.0,HIV infection
11707935,117079351,1,I,,20151029.0,20151106,20151106,EXP,,SG-CIPLA LTD.-2015SG08367,CIPLA,"PATON N.I, STOHR W, ARENAS-PINTO A, FISHER M, WILLIAMS I, JOHNSON M.ET.AL.... PROTEASE INHIBITOR MONOTHERAPY FOR LONG-TERM MANAGEMENT OF HIV INFECTION: A RANDOMISED, CONTROLLED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET HIV. 2015?2:E417-26",,,,,Y,,,20151107.0,,OT,SG,SG,Efavirenz,Renal failure,117079351.0,OT,,,,,,,,,117079351.0,1.0,HIV infection
11708246,117082462,2,F,,20231227.0,20151107,20240107,EXP,,UG-AUROBINDO-AUR-APL-2015-09941,AUROBINDO,"Abdu K.Musubire DavidB.Meya  RobertLukande,  AndrewKambugu, Paul R.Bohjanen,  DavidR.Boulware. Gastrointestinalcryptococcoma ? Immune reconstitution inflammatory syndrome or cryptococcal relapse in a patient with AIDS?. Medical Mycology Case Reports. 2015;8:40-43",37.0,YR,,M,Y,,,20240108.0,,HP,UG,UG,EFAVIRENZ,Abdominal pain lower;Cough;Cryptococcosis;Drug interaction;Gastroenteritis cryptococcal;Ileal perforation;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Pyrexia;Tachypnoea;Virologic failure;Vomiting,117082462.0,OT,,,,,,,,,117082462.0,1.0,Antiretroviral therapy
11708334,117083342,2,F,20120331.0,20160315.0,20151107,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17309105,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20160315.0,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Off label use,117083342.0,OT,,,117083342.0,1.0,20110920.0,,,,117083342.0,1.0,Antiretroviral therapy
11708336,117083363,3,F,20151026.0,20151125.0,20151107,20160118,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075218,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,95.0,KG,20160118.0,,OT,BR,BR,EFAVIRENZ,Hypotension;Maternal exposure during pregnancy;Uterine haemorrhage,117083363.0,OT,,,117083363.0,1.0,20150828.0,,,,117083363.0,1.0,HIV infection
11708346,117083461,1,I,20100930.0,20130205.0,20151107,20151107,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-17359787,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20151107.0,,CN,AR,AR,EFAVIRENZ,Abortion spontaneous;Hypothyroidism;Maternal exposure during pregnancy,117083461.0,OT,,,117083461.0,3.0,20100920.0,,,,117083461.0,1.0,Antiretroviral therapy
11708376,117083761,1,I,20100222.0,20120814.0,20151107,20151107,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16902462,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,65.4,KG,20151107.0,,CN,US,MW,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117083761.0,OT,,,117083761.0,1.0,20091123.0,20091209.0,,,117083761.0,1.0,HIV infection
11708458,117084581,1,I,,20100308.0,20151107,20151107,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028533,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151107.0,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084581.0,1.0,Antiretroviral therapy
11708459,117084592,2,F,,20151209.0,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028491,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084592.0,1.0,Antiretroviral therapy
11708461,117084612,2,F,,20151209.0,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028483,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084612.0,1.0,Antiretroviral therapy
11708463,117084632,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028541,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084632.0,1.0,Antiretroviral therapy
11708466,117084662,2,F,,20151209.0,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028525,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084662.0,1.0,Antiretroviral therapy
11708469,117084692,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028475,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084692.0,1.0,Antiretroviral therapy
11708474,117084742,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028467,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084742.0,1.0,Antiretroviral therapy
11708618,117086182,2,F,,20151209.0,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028509,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117086182.0,1.0,Antiretroviral therapy
11708621,117086212,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028558,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117086212.0,1.0,Antiretroviral therapy
11708624,117086242,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028566,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117086242.0,1.0,Antiretroviral therapy
11708763,117087632,2,F,20100406.0,20160822.0,20151107,20160822,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15323611,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20160822.0,,OT,FR,FR,SUSTIVA,Albuminuria;Anaemia;Blood alkaline phosphatase increased;Blood urea decreased;Live birth;Maternal exposure during pregnancy;Premature delivery;Proteinuria;Uterine disorder,117087632.0,OT,,,117087632.0,1.0,20091119.0,20091001.0,,,117087632.0,1.0,Antiretroviral therapy
11708765,117087652,2,F,,20151209.0,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028517,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087652.0,1.0,Antiretroviral therapy
11708767,117087672,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028608,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087672.0,1.0,Antiretroviral therapy
11708770,117087702,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028590,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087702.0,1.0,Antiretroviral therapy
11708773,117087732,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028582,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087732.0,1.0,Antiretroviral therapy
11708776,117087762,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028574,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087762.0,1.0,Antiretroviral therapy
11708779,117087792,2,F,,20151209.0,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028616,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087792.0,1.0,Antiretroviral therapy
11712990,117129901,1,I,,20010308.0,20151108,20151108,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0965,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151108.0,,OT,FR,FR,EFAVIRENZ,Abortion induced;Pregnancy,117129901.0,OT,,,,,,,,,117129901.0,1.0,HIV infection
11712996,117129961,1,I,20130228.0,20131206.0,20151108,20151108,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-19904374,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151108.0,,OT,CL,CL,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117129961.0,OT,,,117129961.0,1.0,20130205.0,,,,117129961.0,1.0,HIV infection
11713007,117130071,1,I,20001211.0,20010104.0,20151108,20151108,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0006,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151108.0,,MD,DE,DE,SUSTIVA,Drug administration error;Foetal death;Pregnancy,117130071.0,OT,,,117130071.0,1.0,199912.0,200011.0,,,117130071.0,1.0,HIV infection
11713013,117130131,1,I,20001201.0,20010126.0,20151108,20151108,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0062,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,48.0,KG,20151108.0,,MD,FR,FR,SUSTIVA,Abortion spontaneous;Haemorrhage;Pregnancy,117130131.0,HO,,,117130131.0,1.0,20001201.0,20010110.0,,,117130131.0,1.0,HIV infection
11713014,117130141,1,I,20080521.0,20090120.0,20151108,20151108,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14478119,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,104.0,KG,20151108.0,,MD,GB,GB,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Normal newborn,117130141.0,OT,,,117130141.0,1.0,20071009.0,20071011.0,,,117130141.0,1.0,HIV infection
11713022,117130223,3,F,20080807.0,20160621.0,20151108,20160703,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-14902563,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20160703.0,,OT,ZW,ZW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117130223.0,OT,,,117130223.0,1.0,20041228.0,,,,117130223.0,1.0,Antiretroviral therapy
11713041,117130411,1,I,20000603.0,20010209.0,20151109,20151109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0119,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20151109.0,,MD,US,US,EFAVIRENZ,Cervical dysplasia;Haemorrhage;Maternal exposure during pregnancy;Muscle spasms;Pregnancy;Stillbirth,117130411.0,OT,,,117130411.0,1.0,20000424.0,20000712.0,,,117130411.0,1.0,HIV infection
11713089,117130891,1,I,20121022.0,20130708.0,20151109,20151109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19102441,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,,,20151109.0,,OT,US,US,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117130891.0,OT,,,117130891.0,1.0,20121017.0,20121017.0,,,117130891.0,1.0,Antiretroviral therapy
11713090,117130901,1,I,2012.0,20130711.0,20151109,20151109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19118959,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20151109.0,,CN,UG,UG,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117130901.0,OT,,,117130901.0,1.0,20120427.0,20130108.0,,,117130901.0,1.0,Antiretroviral therapy
11713091,117130911,1,I,20130629.0,20130724.0,20151109,20151109,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-19159615,BRISTOL MYERS SQUIBB,,24.0,YR,,F,Y,58.4,KG,20151109.0,,OT,ZW,ZW,EFAVIRENZ,Abortion incomplete;Maternal exposure during pregnancy;Uterine dilation and evacuation,117130911.0,HO,,,117130911.0,1.0,20110728.0,20130628.0,,,117130911.0,1.0,HIV infection
11713127,117131271,1,I,,20010201.0,20151109,20151109,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0089,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20151109.0,,MD,IT,IT,SUSTIVA,Abortion spontaneous;Pregnancy,117131271.0,OT,,,,,,,,,117131271.0,1.0,HIV infection
11713534,117135342,2,F,20121127.0,20160315.0,20151109,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17234345,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,,,20160315.0,,CN,US,GB,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Maternal exposure during pregnancy;Off label use,117135342.0,OT,,,,,,,,,117135342.0,1.0,Antiretroviral therapy
11713594,117135942,2,F,20121127.0,20160315.0,20151109,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17201724,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20160315.0,,CN,US,GB,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Maternal exposure during pregnancy;Off label use,117135942.0,OT,,,,,,,,,117135942.0,1.0,Antiretroviral therapy
11714021,117140212,2,F,20131017.0,20160217.0,20151109,20160222,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-19804897,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,66.5,KG,20160222.0,,OT,MW,MW,EFAVIRENZ,Death;Maternal exposure during pregnancy;Premature delivery,117140212.0,DE,,,117140212.0,1.0,20080917.0,20120926.0,,,117140212.0,1.0,HIV infection
11714701,117147011,1,I,,20151021.0,20151109,20151109,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-073544,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,50.0,KG,20151109.0,,OT,ZA,ZA,EFAVIRENZ,Hepatic cancer metastatic;Live birth;Maternal exposure during pregnancy;Pre-eclampsia;Premature delivery;Premature labour,117147011.0,OT,,,,,,,,,117147011.0,1.0,HIV infection
11717763,117177631,1,I,20130815.0,20151028.0,20151110,20151110,PER,,US-009507513-1511USA000592,MERCK,,18.0,YR,,F,Y,,,20151110.0,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy;No adverse event;Normal newborn,,,,,,,,,,,117177631.0,1.0,Antiretroviral therapy
11721294,117212943,3,F,,20200831.0,20151111,20200915,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15386592,BRISTOL MYERS SQUIBB,"LAKHI N, GOVIND A. IMPLANON FAILURE IN PATIENTS ON ANTIRETROVIRAL MEDICATION: THE IMPORTANCE OF DISCLOSURE. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE. 2010?36(3):181?2",33.0,YR,,F,Y,,,20200915.0,,MD,US,US,SUSTIVA,Drug interaction;Live birth;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,,,,,117212943.0,1.0,200701.0,,,,117212943.0,1.0,HIV infection
11723660,117236601,1,I,,20151104.0,20151111,20151111,EXP,,US-GLAXOSMITHKLINE-US2015158934,GLAXOSMITHKLINE,,,,,F,Y,,,20151111.0,,CN,US,US,SUSTIVA,Arthralgia;Blood creatine phosphokinase increased,,,,,,,,,,,117236601.0,1.0,HIV infection
11724241,117242411,1,I,20080315.0,20080702.0,20151111,20151111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14251607,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20151111.0,,OT,GB,UG,EFAVIRENZ,Abortion spontaneous;Arthralgia;Arthritis;Blepharitis;Conjunctivitis;Dermatitis atopic;Eczema;Excoriation;Keratitis;Maternal exposure during pregnancy;Pain;Pruritus;Seborrhoeic dermatitis;Upper respiratory tract infection,117242411.0,OT,,,117242411.0,1.0,20070514.0,20080218.0,,,117242411.0,1.0,HIV infection
11725755,117257552,2,F,,20151209.0,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029192,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117257552.0,1.0,Antiretroviral therapy
11725766,117257662,2,F,,20151209.0,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029200,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117257662.0,1.0,Antiretroviral therapy
11725824,117258242,2,F,,20151209.0,20151111,20151230,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029218,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151230.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117258242.0,1.0,Antiretroviral therapy
11725868,117258681,1,I,,20091201.0,20151111,20151111,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14890628,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151111.0,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,,,,,,,117258681.0,1.0,HIV infection
11725869,117258692,2,F,,20151209.0,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029234,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117258692.0,1.0,Antiretroviral therapy
11725870,117258702,2,F,,20151209.0,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029226,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117258702.0,1.0,Antiretroviral therapy
11725917,117259171,1,I,20110810.0,20120714.0,20151112,20151112,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-16770240,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20151112.0,,OT,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117259171.0,OT,,,117259171.0,1.0,20110411.0,,,,117259171.0,1.0,HIV infection
11725919,117259192,2,F,,20151209.0,20151112,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029267,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229.0,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117259192.0,1.0,Antiretroviral therapy
11726493,117264932,2,F,,20160202.0,20151112,20160209,PER,,US-009507513-1011USA03114,MERCK,,33.0,YR,,F,Y,,,20160209.0,,CN,US,US,SUSTIVA,Drug interaction;Normal newborn;Pregnancy with implant contraceptive,,,,,117264932.0,1.0,200701.0,,,,117264932.0,1.0,Antiretroviral therapy
11726897,117268972,2,F,20000520.0,20160826.0,20151112,20160826,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0652,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,61.0,KG,20160826.0,,CN,FR,FR,SUSTIVA,Abdominal distension;Anogenital warts;Caesarean section;Live birth;Pregnancy,117268972.0,HO,,,117268972.0,1.0,20000627.0,20000627.0,,,117268972.0,1.0,HIV infection
11727074,117270741,1,I,,20081106.0,20151112,20151112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14398168,BRISTOL MYERS SQUIBB,,,,,F,Y,64.0,KG,20151112.0,,CN,GB,GB,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,117270741.0,OT,,,117270741.0,1.0,200606.0,,,,117270741.0,1.0,HIV infection
11729090,117290901,1,I,,20151104.0,20151112,20151112,EXP,,US-VIIV HEALTHCARE LIMITED-US2015158934,VIIV,,,,,F,Y,,,20151112.0,,CN,US,US,SUSTIVA,Arthralgia;Blood creatine phosphokinase increased,,,,,,,,,,,117290901.0,1.0,HIV infection
11733813,117338131,1,I,,20151029.0,20151113,20151113,EXP,,GB-HETERO LABS LTD-1044148,HETERO,,25.0,YR,,M,Y,,,20151113.0,,MD,GB,GB,Efavirenz,Abdominal pain;Chromaturia;Porphyria acute;Vomiting,117338131.0,HO,,,,,,,,,117338131.0,1.0,HIV infection
11737686,117376861,1,I,20090821.0,20091012.0,20151113,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14815856,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20151113.0,,OT,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117376861.0,OT,,,117376861.0,1.0,20030529.0,,,,117376861.0,1.0,Antiretroviral therapy
11738513,117385131,1,I,200604.0,20110420.0,20151113,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-15690837,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,,,20151113.0,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117385131.0,OT,,,117385131.0,1.0,200403.0,,,,117385131.0,1.0,HIV infection
11739121,117391211,1,I,20090714.0,20110225.0,20151113,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-15583552,BRISTOL MYERS SQUIBB,,14.0,YR,,F,Y,,,20151113.0,,CN,US,GB,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117391211.0,OT,,,117391211.0,1.0,20080702.0,20090706.0,,,117391211.0,1.0,Antiretroviral therapy
11739293,117392932,2,F,2008.0,20160824.0,20151113,20160824,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14652952,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20160824.0,,OT,ZA,ZA,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Stillbirth,117392932.0,OT,,,117392932.0,1.0,20060201.0,,,,117392932.0,1.0,HIV infection
11739296,117392961,1,I,20090609.0,20090610.0,20151113,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14663462,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20151113.0,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117392961.0,OT,,,117392961.0,1.0,20081101.0,,,,117392961.0,1.0,HIV infection
11739603,117396032,2,F,20090315.0,20160131.0,20151113,20160804,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14902605,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20160804.0,,OT,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117396032.0,OT,,,117396032.0,1.0,20060206.0,20081212.0,,,117396032.0,1.0,Antiretroviral therapy
11739719,117397192,2,F,20110910.0,20160819.0,20151113,20160826,EXP,,TH-ABBVIE-11P-155-0866544-00,ABBVIE,,35.0,YR,,F,Y,55.0,KG,20160826.0,,MD,COUNTRY NOT SPECIFIED,TH,EFAVIRENZ,Abortion threatened;Caesarean section;Live birth;Pregnancy;Pregnancy on contraceptive;Premature delivery;Premature rupture of membranes,117397192.0,OT,,,117397192.0,1.0,20101104.0,20110214.0,,,117397192.0,1.0,HIV infection
11739957,117399572,2,F,20081101.0,20160616.0,20151113,20160624,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14902696,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20160624.0,,OT,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117399572.0,OT,,,117399572.0,1.0,20071008.0,20080904.0,,,117399572.0,1.0,Antiretroviral therapy
11740247,117402471,1,I,,20111004.0,20151113,20151113,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16143976,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151113.0,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117402471.0,1.0,HIV infection
11744737,117447371,1,I,,20070815.0,20151116,20151116,EXP,,US-009507513-0708USA04038,MERCK,,,,I,M,Y,3.91,KG,20151116.0,,CN,US,US,SUSTIVA,Foetal exposure during pregnancy;Hypospadias,117447371.0,OT,,,,,,,,,117447371.0,1.0,HIV infection
11744738,117447385,5,F,2008.0,20180808.0,20151116,20180817,EXP,,GB-009507513-1001USA00481,MERCK,,33.0,YR,,F,Y,,,20180817.0,,OT,GB,GB,EFAVIRENZ.,Labelled drug-drug interaction medication error;Normal newborn;Pregnancy with implant contraceptive,117447385.0,OT,,,117447385.0,2.0,20040811.0,20070716.0,,,117447385.0,1.0,HIV infection
11746781,117467811,1,I,,20111214.0,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16318008,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117.0,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,117467811.0,1.0,Antiretroviral therapy
11746826,117468261,1,I,,20111207.0,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16330839,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117468261.0,1.0,HIV infection
11746837,117468371,1,I,,20111207.0,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16330995,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117.0,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,,,,,,,117468371.0,1.0,HIV infection
11747180,117471801,1,I,,20111207.0,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16331019,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117.0,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117471801.0,1.0,HIV infection
11748738,117487381,1,I,20060614.0,20100308.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15025786,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118.0,,CN,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117487381.0,1.0,Antiretroviral therapy
11748933,117489331,1,I,,20100308.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15027873,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118.0,,CN,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117489331.0,1.0,Antiretroviral therapy
11748953,117489532,2,F,,20151209.0,20151118,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028046,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117489532.0,1.0,Antiretroviral therapy
11749253,117492531,1,I,,20110214.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567381,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20151118.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117492531.0,1.0,HIV infection
11749674,117496741,1,I,20080521.0,20151112.0,20151118,20151118,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015161942,VIIV,,28.0,YR,,F,Y,104.0,KG,20151118.0,,MD,GB,GB,Efavirenz,Caesarean section;Maternal exposure during pregnancy;Normal newborn,117496741.0,OT,,,117496741.0,1.0,20071012.0,20071022.0,,,117496741.0,1.0,HIV infection
11749677,117496771,1,I,,20151006.0,20151118,20151118,EXP,,US-VIIV HEALTHCARE LIMITED-US2015164246,VIIV,,,,,M,Y,68.93,KG,20151118.0,,MD,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,117496771.0,OT,,,117496771.0,1.0,200706.0,200706.0,,,117496771.0,1.0,HIV infection
11750777,117507771,1,I,,20110214.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567456,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151118.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117507771.0,1.0,HIV infection
11750955,117509551,1,I,,20110214.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567530,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151118.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117509551.0,1.0,HIV infection
11751036,117510361,1,I,,20110214.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567548,BRISTOL MYERS SQUIBB,,20.0,YR,,F,Y,,,20151118.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117510361.0,1.0,HIV infection
11751565,117515651,1,I,,20110214.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567605,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,,,20151118.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117515651.0,1.0,HIV infection
11752005,117520051,1,I,,20151006.0,20151118,20151118,EXP,,US-GLAXOSMITHKLINE-US2015164246,GLAXOSMITHKLINE,,,,,M,Y,68.93,KG,20151118.0,,MD,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,117520051.0,OT,,,117520051.0,1.0,200706.0,200706.0,,,117520051.0,1.0,HIV infection
11752387,117523872,2,F,,20151209.0,20151118,20151224,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15027980,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151224.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117523872.0,1.0,Antiretroviral therapy
11752484,117524841,1,I,,20100309.0,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15026032,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117524841.0,1.0,Antiretroviral therapy
11752506,117525062,2,F,,20151209.0,20151119,20151224,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15027998,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151224.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117525062.0,1.0,Antiretroviral therapy
11754326,117543261,1,I,20111101.0,20121030.0,20151119,20151119,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17111626,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20151119.0,,CN,US,CI,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117543261.0,OT,,,117543261.0,1.0,20100203.0,,,,117543261.0,1.0,Antiretroviral therapy
11755635,117556352,2,F,201403.0,20151119.0,20151119,20151201,EXP,,FR-GILEAD-2015-0182342,GILEAD,,51.0,YR,A,F,Y,,,20151201.0,,OT,FR,FR,SUSTIVA,Asthenia;Dizziness;Vertigo,117556352.0,OT,,,117556352.0,1.0,20130313.0,20140416.0,,,117556352.0,1.0,HIV infection
11755763,117557631,1,I,20140622.0,20151113.0,20151119,20151119,EXP,,ZW-GILEAD-2015-0182856,GILEAD,,36.0,YR,A,F,Y,,,20151119.0,,MD,ZW,ZW,EFAVIRENZ,Acute kidney injury;Alanine aminotransferase increased;Aspartate aminotransferase increased;Pruritus;Vomiting,117557631.0,HO,,,117557631.0,1.0,20140612.0,20141001.0,,,117557631.0,1.0,HIV infection
11756034,117560341,1,I,,20151006.0,20151119,20151119,EXP,,US-009507513-1510USA006733,MERCK,,54.0,YR,,M,Y,68.93,KG,20151119.0,,CN,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,117560341.0,OT,,,117560341.0,1.0,200706.0,200706.0,,,117560341.0,1.0,HIV infection
11756515,117565152,2,F,,20151209.0,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028012,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565152.0,1.0,Antiretroviral therapy
11756516,117565162,2,F,,20151209.0,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028004,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565162.0,1.0,Antiretroviral therapy
11756523,117565232,2,F,,20151209.0,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028020,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565232.0,1.0,Antiretroviral therapy
11756525,117565252,2,F,,20151209.0,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028038,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565252.0,1.0,Antiretroviral therapy
11758991,117589911,1,I,20080707.0,20151112.0,20151120,20151120,EXP,,GB-ABBVIE-15P-167-1501161-00,ABBVIE,,27.0,YR,,F,Y,,,20151120.0,,MD,GB,GB,SUSTIVA,Anaemia;Caesarean section;Exposure during pregnancy;Normal newborn;Pregnancy on contraceptive,117589911.0,OT,,,117589911.0,1.0,20080206.0,20080206.0,,,117589911.0,1.0,HIV infection
11761092,117610922,2,F,,20151117.0,20151120,20151130,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2015GSK163541,VIIV,"TUDOR AM, MARDARESCU M, ANCA IA, PETRE C, CRISTEA C, DRAGHICENOIU CR ET AL.,. SEVERE BIRTH DEFECTS IN HIV VERTICALLY EXPOSED CHILDREN. CASE SERIES PUBLICATION: ORL. 2015?3(28):6-12",5.0,YR,,M,Y,,,20151130.0,,MD,RO,RO,Efavirenz,Gonadal dysgenesis;Hermaphroditism,117610922.0,OT,,,,,,,,,117610922.0,1.0,HIV infection
11761488,117614882,2,F,,20151117.0,20151120,20151130,EXP,,RO-GLAXOSMITHKLINE-RO2015GSK163541,GLAXOSMITHKLINE,"TUDOR AM, MARDARESCU M, ANCA IA, PETRE C, CRISTEA C, DRAGHICENOIU CR ET AL.,. SEVERE BIRTH DEFECTS IN HIV VERTICALLY EXPOSED CHILDREN. CASE SERIES PUBLICATION: ORL. 2015?3(28):6-12",5.0,YR,,M,Y,,,20151130.0,,MD,RO,RO,Efavirenz,Gonadal dysgenesis;Hermaphroditism,117614882.0,CA,,,,,,,,,117614882.0,1.0,HIV infection
11762825,117628252,2,F,,20160316.0,20151120,20160316,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17372277,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160316.0,,CN,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Off label use,117628252.0,OT,,,,,,,,,117628252.0,1.0,Antiretroviral therapy
11762836,117628362,2,F,20110820.0,20160825.0,20151120,20160825,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-17379041,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,71.0,KG,20160825.0,,OT,IN,IN,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117628362.0,OT,,,117628362.0,1.0,20110805.0,20110805.0,,,117628362.0,1.0,HIV infection
11762838,117628383,3,F,20130411.0,20160825.0,20151120,20160825,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18861518,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20160825.0,,OT,GB,GB,EFAVIRENZ,Live birth;Maternal exposure during pregnancy;Off label use;Premature delivery;Renal impairment,117628383.0,OT,,,117628383.0,1.0,20110102.0,,,,117628383.0,1.0,Antiretroviral therapy
11765868,117658681,1,I,20111212.0,20120113.0,20151122,20151122,PER,,US-009507513-1201USA02584,MERCK,,24.0,YR,,F,Y,,,20151121.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,117658681.0,1.0,20111202.0,20111212.0,,,117658681.0,1.0,Antiretroviral therapy
11765907,117659071,1,I,20090812.0,20090806.0,20151122,20151122,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14732424,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,68.0,KG,20151122.0,,MD,GB,GB,SUSTIVA,Abortion missed;Maternal exposure during pregnancy,117659071.0,OT,,,117659071.0,1.0,20030529.0,20090804.0,,,117659071.0,1.0,HIV infection
11766296,117662961,1,I,20010708.0,20010711.0,20151123,20151123,EXP,,IL-BRISTOL-MYERS SQUIBB COMPANY-10911063,BRISTOL MYERS SQUIBB,,20.0,YR,,F,Y,,,20151123.0,,OT,IL,IL,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,117662961.0,OT,,,117662961.0,1.0,20010529.0,20010624.0,,,117662961.0,1.0,HIV infection
11766523,117665231,1,I,20140823.0,20140908.0,20151123,20151123,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21390984,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20151123.0,,OT,BW,BW,EFAVIRENZ,Abortion incomplete;Pregnancy on oral contraceptive;Uterine dilation and curettage,117665231.0,OT,,,117665231.0,1.0,20110624.0,20140904.0,,,117665231.0,1.0,HIV infection
11767559,117675591,1,I,,20151113.0,20151123,20151123,EXP,GB-MHRA-ADR 23232433,GB-VIIV HEALTHCARE LIMITED-GB2015162800,VIIV,,32.0,YR,,F,Y,64.0,KG,20151123.0,,CN,GB,GB,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,117675591.0,OT,,,117675591.0,1.0,200606.0,,,,117675591.0,1.0,HIV infection
11767621,117676211,1,I,,20151113.0,20151123,20151123,EXP,GB-MHRA-ADR 23232433,GB-GLAXOSMITHKLINE-GB2015162800,GLAXOSMITHKLINE,,32.0,YR,,F,Y,64.0,KG,20151123.0,,CN,GB,GB,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,117676211.0,OT,,,117676211.0,1.0,200606.0,,,,117676211.0,1.0,HIV infection
11770388,117703884,4,F,20140805.0,20160301.0,20151123,20160303,EXP,,UG-GILEAD-2015-0183893,GILEAD,,34.0,YR,A,F,Y,,,20160303.0,,MD,UG,UG,EFAVIRENZ,Anaemia;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,117703884.0,HO,,,117703884.0,1.0,20140729.0,20140822.0,,,117703884.0,1.0,HIV infection
11772370,117723702,2,F,20140805.0,20160107.0,20151124,20160112,EXP,,UG-GLAXOSMITHKLINE-UG2015167028,GLAXOSMITHKLINE,,34.0,YR,,F,Y,,,20160112.0,,MD,UG,UG,Efavirenz,Anaemia;Kaposi's sarcoma,117723702.0,HO,,,117723702.0,1.0,20140729.0,20140822.0,,,117723702.0,1.0,HIV infection
11772506,117725064,4,F,20140805.0,20160301.0,20151124,20160307,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2015167028,VIIV,,34.0,YR,,F,Y,,,20160307.0,,MD,UG,UG,Efavirenz,Anaemia;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,117725064.0,DE,,,117725064.0,1.0,20140729.0,20140822.0,,,117725064.0,1.0,HIV infection
11772510,117725101,1,I,201510.0,20151022.0,20151124,20151124,EXP,,KE-VIIV HEALTHCARE LIMITED-KE2015GSK151481,VIIV,,45.0,YR,,M,Y,,,20151124.0,,MD,KE,KE,EFAVIRENZ,Fatigue;Immune reconstitution inflammatory syndrome;Oral candidiasis,117725101.0,OT,,,117725101.0,1.0,201510.0,,,,117725101.0,1.0,HIV test positive
11775153,117751531,1,I,200105.0,20051227.0,20151124,20151124,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13235460,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151124.0,,CN,US,JP,EFAVIRENZ,Abortion induced;Pregnancy,117751531.0,OT,,,117751531.0,1.0,20001003.0,20041018.0,,,117751531.0,1.0,HIV infection
11780467,117804671,1,I,,20070815.0,20151126,20151126,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13884051,BRISTOL MYERS SQUIBB,,19.0,YR,,F,Y,,,20151126.0,,OT,US,US,EFAVIRENZ,Abortion induced;Pregnancy,117804671.0,OT,,,,,,,,,117804671.0,1.0,HIV infection
11781034,117810341,1,I,20120306.0,20120308.0,20151126,20151126,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16449464,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,72.0,KG,20151126.0,,CN,US,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and curettage,117810341.0,OT,,,117810341.0,1.0,20110915.0,20120202.0,,,117810341.0,1.0,HIV infection
11781093,117810931,1,I,,20010928.0,20151126,20151126,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11005832,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151126.0,,OT,US,FR,EFAVIRENZ,Abortion induced;Haemorrhage;Pregnancy,117810931.0,OT,,,117810931.0,1.0,20000722.0,20010404.0,,,117810931.0,1.0,HIV infection
11781970,117819701,1,I,201403.0,20151119.0,20151126,20151126,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-081866,BRISTOL MYERS SQUIBB,,51.0,YR,,F,Y,,,20151126.0,,CN,FR,FR,SUSTIVA,Asthenia;Dizziness;Vertigo,117819701.0,OT,,,117819701.0,1.0,20130313.0,20150429.0,,,117819701.0,1.0,HIV infection
11783030,117830301,1,I,2007.0,20080617.0,20151127,20151127,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14255954,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151127.0,,CN,US,US,EFAVIRENZ,CD4 lymphocytes decreased;Maternal exposure during pregnancy;Nausea;Nervous system disorder;Normal newborn;Otitis media;Viral load increased,,,,,,,,,,,117830301.0,1.0,HIV infection
11784347,117843471,1,I,,20100716.0,20151129,20151129,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-15198393,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151129.0,,OT,IT,IT,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117843471.0,OT,,,,,,,,,117843471.0,1.0,Antiretroviral therapy
11784460,117844601,1,I,20050912.0,20050921.0,20151129,20151129,EXP,,SN-BRISTOL-MYERS SQUIBB COMPANY-13122759,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,,,20151129.0,,OT,US,US,EFAVIRENZ,Malaria;Pregnancy;Pyrexia;Stillbirth,117844601.0,OT,,,117844601.0,1.0,20041025.0,20050301.0,,,117844601.0,1.0,HIV infection
11784777,117847771,1,I,,20151120.0,20151130,20151130,EXP,,CN-CIPLA LTD.-2015CN08957,CIPLA,"LI J, GUO W, HAN J, ZHUANG D, LIU S, LIU Y, ET.AL. CHARACTERIZATION OF TWO HIV-1 INFECTORS DURING INITIAL ANTIRETROVIRAL TREATMENT, AND THE EMERGENCE OF PHENOTYPIC RESISTANCE IN REVERSE TRANSCRIPTASE-ASSOCIATED MUTATION PATTERNS. GUO ET AL. VIROLOGY JOURNAL. 2015?12:1-9",,,,,Y,,,20151130.0,,OT,CN,CN,Efavirenz,Drug resistance;Viral load increased,117847771.0,OT,,,,,,,,,117847771.0,1.0,HIV infection
11784780,117847801,1,I,,20151120.0,20151130,20151130,EXP,,CN-CIPLA LTD.-2015CN08958,CIPLA,"LI J, GUO W, HAN J, ZHUANG D, LIU S, LIU Y, ET.AL. CHARACTERIZATION OF TWO HIV-1 INFECTORS DURING INITIAL ANTIRETROVIRAL TREATMENT, AND THE EMERGENCE OF PHENOTYPIC RESISTANCE IN REVERSE TRANSCRIPTASE-ASSOCIATED MUTATION PATTERNS. GUO ET AL. VIROLOGY JOURNAL. 2015?12:1-9",,,,,Y,,,20151130.0,,OT,CN,CN,Efavirenz,Drug resistance;Viral load increased,117847801.0,OT,,,,,,,,,117847801.0,1.0,HIV infection
11786175,117861752,2,F,20151106.0,20151201.0,20151130,20151216,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2015GSK168395,VIIV,,39.0,YR,,F,Y,,,20151216.0,,MD,CN,CN,EFAVIRENZ,Tibia fracture,117861752.0,HO,,,117861752.0,1.0,20151010.0,,,,117861752.0,1.0,HIV infection
11787162,117871622,2,F,20151106.0,20151201.0,20151130,20151216,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK168395,GLAXOSMITHKLINE,,39.0,YR,,F,Y,,,20151216.0,,MD,CN,CN,EFAVIRENZ,Tibia fracture,117871622.0,HO,,,117871622.0,1.0,20151010.0,,,,117871622.0,1.0,HIV infection
11788652,117886521,1,I,200112.0,20010919.0,20151201,20151201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0841,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,60.0,KG,20151201.0,,MD,FR,FR,EFAVIRENZ,Caesarean section;Normal newborn;Pregnancy;Uterine hypotonus,117886521.0,OT,,,117886521.0,1.0,20010709.0,200107.0,,,117886521.0,1.0,HIV infection
11788693,117886931,1,I,20050627.0,20050801.0,20151201,20151201,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13059134,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151201.0,,MD,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,117886931.0,OT,,,117886931.0,1.0,20040830.0,20050527.0,,,117886931.0,1.0,HIV infection
11788953,117889532,2,F,20121026.0,20151123.0,20151201,20151201,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17468513,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20151201.0,,OT,CI,CI,EFAVIRENZ,Abortion spontaneous;Malaria;Maternal exposure during pregnancy,117889532.0,OT,,,117889532.0,1.0,20100312.0,20120827.0,,,117889532.0,1.0,Antiretroviral therapy
11790030,117900301,1,I,20110910.0,20111013.0,20151201,20151201,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16159766,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,55.7,KG,20151201.0,,CN,US,MW,EFAVIRENZ,Abortion missed;Haemoglobin decreased;Maternal exposure during pregnancy,117900301.0,LT,,,117900301.0,1.0,20110712.0,20110812.0,,,117900301.0,1.0,HIV infection
11792651,117926511,1,I,,20100716.0,20151202,20151202,EXP,,IT-009507513-1007USA02067,MERCK,,26.0,YR,,F,Y,,,20151202.0,,CN,US,IT,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117926511.0,OT,,,,,,,,,117926511.0,1.0,Antiretroviral therapy
11794582,117945821,1,I,20000414.0,20031031.0,20151202,20151202,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2003-000007,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20151202.0,,CN,FR,FR,EFAVIRENZ,Abortion induced;Oligohydramnios;Placental insufficiency;Pregnancy,117945821.0,OT,,,,,,,,,117945821.0,1.0,Antiretroviral therapy
11796521,117965212,2,F,,20160114.0,20151203,20160120,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2015171688,VIIV,"LO, CHANG HAN AND LIN, TE YU MD. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. RESPIRATORY CARE. 2014?59:160-162",27.0,YR,,M,Y,,,20160120.0,,MD,TW,TW,Efavirenz,Immune reconstitution inflammatory syndrome,117965212.0,HO,,,,,,,,,117965212.0,1.0,HIV infection
11796522,117965221,1,I,20141004.0,20151124.0,20151203,20151203,EXP,,MY-VIIV HEALTHCARE LIMITED-MY2015GSK171562,VIIV,,26.0,YR,,M,Y,,,20151203.0,,OT,MY,MY,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Mouth ulceration,117965221.0,OT,,,,,,,,,117965221.0,1.0,Antiretroviral therapy
11796524,117965242,2,F,,20160114.0,20151203,20160120,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2015GSK170615,VIIV,,27.0,YR,,M,Y,,,20160120.0,,MD,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung infiltration;Pneumocystis jirovecii pneumonia;Pyrexia;Rales,117965242.0,HO,,,,,,,,,117965242.0,1.0,HIV infection
11796615,117966152,2,F,,20160114.0,20151203,20160120,EXP,,TW-GLAXOSMITHKLINE-TW2015GSK170615,GLAXOSMITHKLINE,,27.0,YR,,M,Y,,,20160120.0,,MD,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung infiltration;Pneumocystis jirovecii pneumonia;Pyrexia;Rales,117966152.0,OT,,,,,,,,,117966152.0,1.0,HIV infection
11796666,117966662,2,F,,20160114.0,20151203,20160120,EXP,,TW-GLAXOSMITHKLINE-TW2015171688,GLAXOSMITHKLINE,"LO, CHANG HAN AND LIN, TE YU MD. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. RESPIRATORY CARE. 2014?59:160-162",27.0,YR,,M,Y,,,20160120.0,,MD,TW,TW,Efavirenz,Immune reconstitution inflammatory syndrome,117966662.0,HO,,,,,,,,,117966662.0,1.0,HIV infection
11796667,117966671,1,I,20141004.0,20151124.0,20151203,20151203,EXP,,MY-GLAXOSMITHKLINE-MY2015GSK171562,GLAXOSMITHKLINE,,26.0,YR,,M,Y,,,20151203.0,,OT,MY,MY,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Mouth ulceration,117966671.0,OT,,,,,,,,,117966671.0,1.0,Antiretroviral therapy
11800288,118002881,1,I,2013.0,20151123.0,20151203,20151203,EXP,,PT-GILEAD-2015-0185123,GILEAD,,51.0,YR,A,M,Y,57.0,KG,20151203.0,,MD,PT,PT,EFAVIRENZ,Osteopenia;Osteoporosis,118002881.0,OT,,,118002881.0,1.0,200601.0,,,,118002881.0,1.0,HIV infection
11805673,118056731,1,I,20020222.0,20030108.0,20151207,20151207,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12153615,BRISTOL MYERS SQUIBB,,21.0,YR,,F,Y,58.0,KG,20151207.0,,MD,FR,FR,SUSTIVA,Caesarean section;Live birth;Pregnancy;Premature rupture of membranes,118056731.0,OT,,,118056731.0,1.0,200104.0,20020407.0,,,118056731.0,1.0,HIV test positive
11805704,118057041,1,I,20120814.0,20130228.0,20151207,20151207,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17439225,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20151207.0,,OT,CI,CI,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,118057041.0,OT,,,118057041.0,1.0,20100211.0,,,,118057041.0,1.0,Antiretroviral therapy
11805705,118057051,1,I,20120613.0,20130227.0,20151207,20151207,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17433368,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20151207.0,,MD,CI,CI,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,118057051.0,OT,,,118057051.0,1.0,20110516.0,20120521.0,,,118057051.0,1.0,Antiretroviral therapy
11806344,118063442,2,F,,20160114.0,20151207,20160120,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2015GSK170585,VIIV,"LO CH, ET AL.. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME.. RESPIRATORY CARE. 2014?59?10:E160-E162",27.0,YR,,M,Y,,,20160120.0,,OT,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung disorder;Pyrexia,118063442.0,HO,,,,,,,,,118063442.0,1.0,HIV infection
11806574,118065742,2,F,,20160114.0,20151207,20160120,EXP,,TW-GLAXOSMITHKLINE-TW2015GSK170585,GLAXOSMITHKLINE,"LO CH, ET AL.. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME.. RESPIRATORY CARE. 2014?59?10:E160-E162",27.0,YR,,M,Y,,,20160120.0,,OT,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung disorder;Pyrexia,118065742.0,OT,,,,,,,,,118065742.0,1.0,HIV infection
11809279,118092791,1,I,,20110214.0,20151207,20151207,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567621,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20151207.0,,OT,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,118092791.0,1.0,HIV infection
11809349,118093491,1,I,,20100114.0,20151207,20151207,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948566,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20151207.0,,OT,ZA,ZA,EFAVIRENZ,Induced labour;Maternal exposure during pregnancy;Stillbirth,118093491.0,OT,,,,,,,,,118093491.0,1.0,Antiretroviral therapy
11809380,118093802,2,F,,20160726.0,20151207,20160726,EXP,,ET-BRISTOL-MYERS SQUIBB COMPANY-19912997,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20160726.0,,OT,ET,ET,EFAVIRENZ,Induced labour;Maternal exposure during pregnancy;Stillbirth,118093802.0,OT,,,,,,,,,118093802.0,1.0,HIV infection
11809388,118093881,1,I,200212.0,20030227.0,20151208,20151208,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-12198859,BRISTOL MYERS SQUIBB,,25.0,YR,,F,Y,,,20151207.0,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Pregnancy;Uterine dilation and evacuation,118093881.0,OT,,,118093881.0,1.0,20020627.0,20030131.0,,,118093881.0,1.0,HIV infection
11809885,118098852,2,F,20041129.0,20160824.0,20151208,20160824,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-12911863,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20160824.0,,OT,GB,GB,EFAVIRENZ,Amniotic cavity infection;Placental insufficiency;Pregnancy;Stillbirth,118098852.0,OT,,,,,,,,,118098852.0,1.0,HIV infection
11809886,118098861,1,I,20040702.0,20040707.0,20151208,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12633871,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,,,20151208.0,,OT,US,US,EFAVIRENZ,Pregnancy;Premature separation of placenta;Stillbirth,118098861.0,OT,,,118098861.0,1.0,20030508.0,20031204.0,,,118098861.0,1.0,HIV infection
11809887,118098871,1,I,20041221.0,20050224.0,20151208,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12875852,BRISTOL MYERS SQUIBB,,17.0,YR,,F,Y,,,20151208.0,,OT,US,US,EFAVIRENZ,Live birth;Pre-eclampsia;Pregnancy;Premature delivery,118098871.0,OT,,,118098871.0,1.0,20010126.0,20040610.0,,,118098871.0,1.0,HIV infection
11809888,118098881,1,I,20050623.0,20061207.0,20151208,20151208,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-13606074,BRISTOL MYERS SQUIBB,,25.0,YR,,F,Y,,,20151208.0,,OT,BW,BW,EFAVIRENZ,Pregnancy;Stillbirth,118098881.0,OT,,,118098881.0,1.0,20041011.0,20050106.0,,,118098881.0,1.0,HIV infection
11809890,118098901,1,I,2002.0,20030424.0,20151208,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12254025,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151208.0,,CN,US,US,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Thrombocytopenia;Vaginal haemorrhage,118098901.0,OT,,,118098901.0,1.0,20010912.0,20020722.0,,,118098901.0,1.0,HIV infection
11809891,118098911,1,I,20100705.0,20101029.0,20151208,20151208,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-15371990,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151208.0,,CN,US,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,118098911.0,OT,,,118098911.0,1.0,20100610.0,,,,118098911.0,1.0,Antiretroviral therapy
11809892,118098922,2,F,,20160826.0,20151208,20160826,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0555,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20160826.0,,OT,DE,DE,SUSTIVA,Caesarean section;Live birth;Pregnancy;Premature rupture of membranes,118098922.0,OT,,,118098922.0,2.0,19980501.0,,,,118098922.0,1.0,HIV infection
11809926,118099261,1,I,200502.0,20050228.0,20151208,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12882957,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,57.0,KG,20151208.0,,OT,FR,FR,EFAVIRENZ,Abortion spontaneous;Metrorrhagia;Pregnancy on oral contraceptive,118099261.0,OT,,,118099261.0,1.0,20041018.0,20050225.0,,,118099261.0,1.0,HIV infection
11811823,118118231,1,I,20090609.0,20090609.0,20151208,20151208,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14667505,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151208.0,,CN,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,118118231.0,OT,,,118118231.0,1.0,20081101.0,,,,118118231.0,1.0,HIV infection
11812699,118126992,2,F,,20160315.0,20151208,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17196734,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20160315.0,,OT,GB,GB,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy;Off label use;Premature delivery;Premature rupture of membranes;Uterine leiomyoma,118126992.0,OT,,,,,,,,,118126992.0,1.0,HIV infection
11812801,118128011,1,I,,20030506.0,20151209,20151209,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-12268199,BRISTOL MYERS SQUIBB,,24.0,YR,,F,Y,,,20151209.0,,OT,US,BE,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,118128011.0,OT,,,118128011.0,1.0,20020514.0,20030414.0,,,118128011.0,1.0,HIV infection
11812832,118128321,1,I,20120315.0,20120323.0,20151209,20151209,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-16487563,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20151209.0,,CN,US,BW,EFAVIRENZ,Abortion spontaneous;Genital infection;Maternal exposure during pregnancy,118128321.0,OT,,,118128321.0,1.0,20110607.0,20120124.0,,,118128321.0,1.0,Antiretroviral therapy
11813087,118130871,1,I,,20081001.0,20151209,20151209,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14356554,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20151209.0,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,118130871.0,1.0,20060717.0,,,,118130871.0,1.0,HIV infection
11813216,118132161,1,I,,20081112.0,20151209,20151209,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14405096,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151209.0,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,118132161.0,1.0,Antiretroviral therapy
11813277,118132771,1,I,20091001.0,20111004.0,20151209,20151209,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-16135378,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20151209.0,,CN,AR,AR,EFAVIRENZ,Abortion spontaneous;Hepatotoxicity;Maternal exposure during pregnancy,118132771.0,OT,,,118132771.0,1.0,20090904.0,20090904.0,,,118132771.0,1.0,Antiretroviral therapy
11813286,118132861,1,I,20010811.0,20021204.0,20151209,20151209,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12130142,BRISTOL MYERS SQUIBB,,0.0,DY,,F,Y,2.66,KG,20151209.0,,CN,FR,FR,SUSTIVA,Apnoea;Foetal exposure during pregnancy,118132861.0,OT,,,118132861.0,1.0,20010726.0,20010811.0,,,118132861.0,1.0,HIV infection
11813295,118132951,1,I,20010326.0,20020215.0,20151209,20151209,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-11737376,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20151209.0,,OT,US,CH,EFAVIRENZ,Abortion induced;Pregnancy,118132951.0,OT,,,,,,,,,118132951.0,1.0,HIV infection
11815749,118157492,2,F,20021025.0,20160824.0,20151209,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12155560,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20160824.0,,OT,US,US,EFAVIRENZ,Live birth;Premature delivery;Twin pregnancy,118157492.0,OT,,,118157492.0,1.0,20020318.0,20020523.0,,,118157492.0,1.0,HIV infection
11816005,118160055,5,F,,20180828.0,20151209,20180903,EXP,,US-009507513-1011USA03112,MERCK,,35.0,YR,,F,Y,,,20180903.0,,OT,GB,US,EFAVIRENZ.,Abortion induced;Drug interaction;Pregnancy with implant contraceptive,118160055.0,OT,,,,,,,,,118160055.0,1.0,Antiretroviral therapy
11816446,118164461,1,I,,20030623.0,20151209,20151209,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-12309464,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20151209.0,,OT,US,DE,EFAVIRENZ,Foetal exposure during pregnancy;Limb hypoplasia congenital,118164461.0,CA,,,,,,,,,118164461.0,1.0,Antiretroviral therapy
11822775,118227751,1,I,,20151202.0,20151210,20151210,EXP,,JP-GILEAD-2015-0187524,GILEAD,UNK. UNK. THE JOURNAL OF AIDS RESEARCH. 2015?17 (4):518,62.0,YR,A,M,Y,,,20151210.0,,PH,JP,JP,EFAVIRENZ,Lipodystrophy acquired;Non-alcoholic steatohepatitis,118227751.0,OT,,,,,,,,,118227751.0,1.0,HIV infection
11824339,118243391,1,I,,20151130.0,20151210,20151210,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-083936,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20151210.0,,CN,IT,IT,EFAVIRENZ,Hypertrophic cardiomyopathy,118243391.0,OT,,,,,,,,,118243391.0,1.0,HIV infection
11824708,118247083,3,F,20151028.0,20160222.0,20151210,20160329,EXP,,UG-GILEAD-2015-0186293,GILEAD,,49.0,YR,A,M,Y,69.0,KG,20160329.0,,MD,UG,UG,EFAVIRENZ,Road traffic accident;Soft tissue injury,118247083.0,HO,,,118247083.0,1.0,20130910.0,,,,118247083.0,1.0,HIV infection
11824871,118248711,1,I,2005.0,20050621.0,20151210,20151210,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13013008,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20151210.0,,MD,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy;Retained products of conception;Uterine dilation and curettage,118248711.0,OT,,,118248711.0,1.0,2004.0,20050310.0,,,118248711.0,1.0,HIV infection
11824885,118248851,1,I,2006.0,20070206.0,20151210,20151210,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14293914,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151210.0,,OT,DE,DE,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,118248851.0,OT,,,118248851.0,1.0,20050101.0,20060925.0,,,118248851.0,1.0,HIV infection
11825102,118251021,1,I,19980819.0,19981016.0,20151211,20151211,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-1998SUS0283,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151211.0,,OT,AU,AU,EFAVIRENZ,Abortion induced;Pregnancy,118251021.0,OT,,,118251021.0,1.0,19980622.0,,,,118251021.0,1.0,HIV infection
11825103,118251031,1,I,19990224.0,19990318.0,20151211,20151211,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0275,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,46.0,KG,20151211.0,,OT,GB,GB,EFAVIRENZ,Abortion induced;Unintended pregnancy,118251031.0,OT,,,,,,,,,118251031.0,1.0,HIV infection
11825370,118253701,1,I,20001109.0,20001207.0,20151211,20151211,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-10636975,BRISTOL MYERS SQUIBB,,21.0,YR,,F,Y,,,20151211.0,,OT,AR,AR,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,118253701.0,OT,,,118253701.0,1.0,20000224.0,20001006.0,,,118253701.0,1.0,HIV infection
11825928,118259283,3,F,,20170404.0,20151211,20170417,EXP,,RS-SUN PHARMACEUTICAL INDUSTRIES LTD-2015R1-107725,RANBAXY,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC D. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IRIS AFTER INITIATION OF HAART: CASE REPORT. INT J INFECT DIS. 2015;NOV 18",28.0,YR,,M,Y,,,20170417.0,,OT,RS,RS,Efavirenz,Drug resistance;Immune reconstitution inflammatory syndrome,118259283.0,HO,,,,,,,,,118259283.0,1.0,HIV infection
11827757,118277571,1,I,20141228.0,20150212.0,20151211,20151211,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010429,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,,,20151211.0,,OT,UG,UG,EFAVIRENZ,Death,118277571.0,DE,,,118277571.0,1.0,20141128.0,20141212.0,,,118277571.0,1.0,HIV infection
11828987,118289871,1,I,20010401.0,20010627.0,20151211,20151211,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0573,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20151211.0,,PH,GB,GB,SUSTIVA,Abortion induced;Foetal death;Pregnancy,118289871.0,OT,,,118289871.0,1.0,20010101.0,20010626.0,,,118289871.0,1.0,HIV infection
11829029,118290291,1,I,,20090206.0,20151211,20151211,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14499560,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151211.0,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,,,,,,,118290291.0,1.0,Antiretroviral therapy
11830073,118300731,1,I,,20060926.0,20151213,20151213,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-13522941,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20151213.0,,OT,US,US,SUSTIVA,Caesarean section;Normal newborn;Pregnancy,,,,,,,,,,,118300731.0,1.0,HIV infection
11830700,118307001,1,I,20080916.0,20080917.0,20151214,20151214,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14354096,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151214.0,,OT,US,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn;Pneumonia bacterial,118307001.0,OT,,,118307001.0,2.0,,20080206.0,,,118307001.0,1.0,Antiretroviral therapy
11830764,118307641,1,I,20060218.0,20070202.0,20151214,20151214,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13675079,BRISTOL MYERS SQUIBB,,19.0,YR,,F,Y,,,20151214.0,,OT,US,US,EFAVIRENZ,Live birth;Pre-eclampsia;Pregnancy;Premature delivery,118307641.0,OT,,,118307641.0,1.0,20060217.0,20050727.0,,,118307641.0,1.0,HIV infection
11830876,118308762,2,F,20000501.0,20151216.0,20151214,20151216,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0597,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151216.0,,MD,AT,AT,SUSTIVA,Abortion induced;Pregnancy,118308762.0,OT,,,118308762.0,1.0,19990908.0,20000509.0,,,118308762.0,1.0,HIV infection
11833039,118330392,2,F,2009.0,20151210.0,20151214,20151214,EXP,,"UG-ROXANE LABORATORIES, INC.-2015-RO-02075RO",ROXANE,"MUSUBIRE A,MEYA D,LUKANDE R,KAMBUGU A,ET AL. GASTROINTESTINAL CRYPTOCOCCOMA - IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OR CRYPTOCOCCAL RELAPSE IN A PATIENT WITH AIDS?. MEDICAL MYCOLOGY CASE REPORTS 2015 JUN?8:40-43.",37.0,YR,,M,Y,,,20151214.0,,OT,COUNTRY NOT SPECIFIED,UG,EFAVIRENZ,Cryptococcosis;Intestinal perforation,118330392.0,HO,,,118330392.0,1.0,20090611.0,,,,118330392.0,1.0,HIV test positive
11833040,118330401,1,I,19991209.0,19990610.0,20151214,20151214,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0578,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151214.0,,CN,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,,,,,,,118330401.0,1.0,HIV infection
11835079,118350791,1,I,20001215.0,20001213.0,20151215,20151215,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0964,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20151215.0,,CN,CH,CH,SUSTIVA,Abortion induced;Pregnancy,118350791.0,OT,,,118350791.0,1.0,19980101.0,,,,118350791.0,1.0,HIV infection
11835685,118356851,1,I,,20000629.0,20151215,20151215,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0534,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151215.0,,CN,US,US,SUSTIVA,Pregnancy,,,,,,,,,,,118356851.0,1.0,HIV infection
11836076,118360761,1,I,,20151207.0,20151215,20151215,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK176876,VIIV,,47.0,YR,,M,Y,,,20151215.0,,CN,US,US,SUSTIVA,Seizure,118360761.0,OT,,,,,,,,,118360761.0,1.0,HIV infection
11837969,118379691,1,I,,20151207.0,20151215,20151215,EXP,,US-GLAXOSMITHKLINE-US2015GSK176876,GLAXOSMITHKLINE,,47.0,YR,,M,Y,,,20151215.0,,CN,US,US,SUSTIVA,Seizure,118379691.0,OT,,,,,,,,,118379691.0,1.0,HIV infection
11840219,118402191,1,I,20020808.0,20020730.0,20151216,20151216,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11971330,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20151216.0,,OT,FR,FR,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,118402191.0,OT,,,118402191.0,1.0,20010108.0,20020726.0,,,118402191.0,1.0,HIV infection
11841288,118412881,1,I,20151204.0,20151206.0,20151216,20151216,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-085990,BRISTOL MYERS SQUIBB,,67.0,YR,,M,Y,170.0,KG,20151216.0,,PH,US,US,SUSTIVA,Gastrostomy;Pneumonia,118412881.0,HO,,,,,,,,,118412881.0,1.0,HIV infection
11841621,118416211,1,I,19991203.0,19990713.0,20151216,20151216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0794,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,73.0,KG,20151216.0,,OT,US,US,SUSTIVA,Caesarean section;Normal newborn;Pregnancy,,,,,118416211.0,1.0,19990309.0,19990413.0,,,118416211.0,1.0,HIV infection
11843180,118431801,1,I,2001.0,20020712.0,20151216,20151216,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-11956372,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,,,20151216.0,,OT,BR,BR,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,118431801.0,OT,,,118431801.0,1.0,20010412.0,,,,118431801.0,1.0,HIV infection
11843221,118432211,1,I,,20000317.0,20151216,20151216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0309,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20151216.0,,MD,US,US,SUSTIVA,Pregnancy,,,,,118432211.0,1.0,19990201.0,,,,118432211.0,1.0,HIV infection
11843222,118432221,1,I,19991204.0,20001205.0,20151216,20151216,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10631778,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20151216.0,,MD,US,US,EFAVIRENZ,Abortion induced;Pregnancy,118432221.0,OT,,,118432221.0,1.0,19990806.0,19991007.0,,,118432221.0,1.0,HIV infection
11844171,118441712,2,F,20050804.0,20160225.0,20151217,20160225,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13112461,BRISTOL MYERS SQUIBB,,15.0,YR,,F,Y,,,20160225.0,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy,118441712.0,OT,,,118441712.0,1.0,19991115.0,20050801.0,,,118441712.0,1.0,HIV infection
11844507,118445071,1,I,19990501.0,20010402.0,20151217,20151217,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0300,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151217.0,,OT,US,US,SUSTIVA,Pregnancy,,,,,118445071.0,1.0,19990201.0,19990801.0,,,118445071.0,1.0,HIV infection
11844732,118447322,2,F,200112.0,20160824.0,20151217,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12160255,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20160824.0,,OT,US,US,EFAVIRENZ,Live birth;Pre-eclampsia;Pregnancy,118447322.0,OT,,,118447322.0,1.0,20020105.0,20020124.0,,,118447322.0,1.0,HIV infection
11844743,118447432,2,F,20150101.0,20151214.0,20151217,20211118,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2015GSK177983,VIIV,,,,,F,Y,,,20211118.0,,CN,RU,RU,EFAVIRENZ,Apathy;Dizziness;Memory impairment;Pyrexia;Seizure;Vomiting,118447432.0,OT,,,118447432.0,1.0,201511.0,,,,118447432.0,1.0,HIV infection
11844875,118448751,1,I,20000101.0,20010402.0,20151217,20151217,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0304,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151217.0,,OT,US,US,SUSTIVA,Caesarean section;Normal newborn;Pregnancy,,,,,118448751.0,1.0,20000630.0,20000801.0,,,118448751.0,1.0,HIV infection
11845497,118454971,1,I,199909.0,20020318.0,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11776523,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151217.0,,MD,US,US,EFAVIRENZ,Activated partial thromboplastin time prolonged;Blood bilirubin increased;Jaundice;Live birth;Nausea;Pregnancy;Premature labour;Prothrombin time prolonged;Transaminases increased;Vomiting,118454971.0,HO,,,118454971.0,1.0,199908.0,200001.0,,,118454971.0,1.0,HIV infection
11845498,118454981,1,I,2007.0,20080423.0,20151217,20151217,EXP,,EC-BRISTOL-MYERS SQUIBB COMPANY-14163802,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151217.0,,CN,EC,EC,EFAVIRENZ,Caesarean section;Dysplasia;Normal newborn;Pregnancy on contraceptive,118454981.0,OT,,,118454981.0,1.0,200309.0,20070629.0,,,118454981.0,1.0,Antiretroviral therapy
11846834,118468342,2,F,20150101.0,20151214.0,20151217,20211118,EXP,,RU-GLAXOSMITHKLINE-RU2015GSK177983,GLAXOSMITHKLINE,,,,,F,Y,,,20211118.0,,CN,RU,RU,EFAVIRENZ,Apathy;Dizziness;Memory impairment;Pyrexia;Seizure;Vomiting,118468342.0,OT,,,118468342.0,1.0,201511.0,,,,118468342.0,1.0,HIV infection
11848255,118482552,2,F,2000.0,20160824.0,20151217,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12194932,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20160824.0,,OT,US,US,SUSTIVA,Abortion induced;Anaemia;Pregnancy,118482552.0,OT,,,118482552.0,1.0,200006.0,20001020.0,,,118482552.0,1.0,HIV infection
11848277,118482771,1,I,20000301.0,20000807.0,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0616,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151217.0,,MD,US,US,SUSTIVA,Abortion induced;Pregnancy,118482771.0,OT,,,118482771.0,1.0,199911.0,20000329.0,,,118482771.0,1.0,HIV infection
11848286,118482861,1,I,20071212.0,20080604.0,20151217,20151217,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14223465,BRISTOL MYERS SQUIBB,,40.0,YR,,F,Y,,,20151217.0,,CN,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Premature labour;Respiratory distress;Stillbirth,118482861.0,HO,,,118482861.0,1.0,20071212.0,,,,118482861.0,1.0,HIV infection
11848343,118483431,1,I,19990415.0,19990416.0,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0391,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,65.0,KG,20151217.0,,MD,US,US,SUSTIVA,Abortion spontaneous;Pregnancy,118483431.0,OT,,,118483431.0,1.0,19990414.0,19990416.0,,,118483431.0,1.0,HIV infection
11848810,118488101,1,I,19990712.0,19990809.0,20151218,20151218,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0973,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,63.0,KG,20151218.0,,OT,FR,FR,EFAVIRENZ,Abortion spontaneous;Ectopic pregnancy;Pregnancy,118488101.0,OT,,,118488101.0,1.0,19990428.0,19990804.0,,,118488101.0,1.0,HIV infection
11849030,118490301,1,I,20021202.0,20021202.0,20151218,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-12124038,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,,,20151218.0,,OT,ZA,ZA,EFAVIRENZ,Abortion induced;Pregnancy,118490301.0,OT,,,118490301.0,1.0,20020228.0,20021112.0,,,118490301.0,1.0,HIV infection
11849620,118496201,1,I,,20010301.0,20151218,20151218,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0162,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151218.0,,CN,US,US,SUSTIVA,Pregnancy,,,,,118496201.0,1.0,200007.0,,,,118496201.0,1.0,HIV infection
11851736,118517361,1,I,2005.0,20061206.0,20151218,20151218,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-13644026,BRISTOL MYERS SQUIBB,,21.0,YR,,F,Y,,,20151218.0,,OT,BW,BW,EFAVIRENZ,Abortion spontaneous;Pregnancy,118517361.0,OT,,,118517361.0,1.0,20040526.0,20050210.0,,,118517361.0,1.0,HIV infection
11851941,118519411,1,I,19990902.0,20001003.0,20151218,20151218,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0763,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,,,20151218.0,,OT,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,118519411.0,1.0,19990528.0,19990528.0,,,118519411.0,1.0,HIV infection
11853156,118531561,1,I,20030127.0,20030129.0,20151218,20151218,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-12177291,BRISTOL MYERS SQUIBB,,24.0,YR,,F,Y,,,20151218.0,,CN,US,BR,EFAVIRENZ,Abortion incomplete;Pregnancy;Uterine dilation and curettage,118531561.0,OT,,,118531561.0,1.0,20010412.0,20030106.0,,,118531561.0,1.0,HIV infection
11853159,118531591,1,I,2004.0,20041019.0,20151218,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-12736013,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20151218.0,,OT,ZA,ZA,EFAVIRENZ,Ectopic pregnancy;Pregnancy on contraceptive;Salpingectomy,118531591.0,OT,,,118531591.0,1.0,20020911.0,20041001.0,,,118531591.0,1.0,HIV infection
11853167,118531671,1,I,20120228.0,20120430.0,20151218,20151218,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16567547,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20151218.0,,CN,US,MW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and curettage,118531671.0,OT,,,118531671.0,1.0,20110902.0,20120122.0,,,118531671.0,1.0,HIV infection
11853192,118531922,2,F,20110728.0,20160825.0,20151218,20160825,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16491946,BRISTOL MYERS SQUIBB,,18.0,YR,,F,Y,,,20160825.0,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy;Polyhydramnios;Premature delivery,118531922.0,OT,,,118531922.0,1.0,20081001.0,20110321.0,,,118531922.0,1.0,Antiretroviral therapy
11853428,118534281,1,I,20020730.0,20020315.0,20151218,20151218,EXP,,NZ-BRISTOL-MYERS SQUIBB COMPANY-11788080,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20151218.0,,CN,US,NZ,EFAVIRENZ,Gestational hypertension;Pregnancy;Premature delivery,118534281.0,OT,,,118534281.0,1.0,20020124.0,20020314.0,,,118534281.0,1.0,Antiretroviral therapy
11853446,118534461,1,I,20011216.0,20020121.0,20151218,20151218,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-11676939,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,76.8,KG,20151218.0,,OT,US,BE,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,118534461.0,OT,,,118534461.0,1.0,20010621.0,,,,118534461.0,1.0,HIV infection
11853466,118534662,2,F,,20111004.0,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16156010,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151218.0,,CN,US,US,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,118534662.0,OT,,,,,,,,,118534662.0,1.0,HIV infection
11853478,118534782,2,F,20141104.0,20150202.0,20151218,20151218,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-005274,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,49.0,KG,20151218.0,,CN,MW,MW,EFAVIRENZ,Abortion incomplete;Maternal exposure during pregnancy;Uterine dilation and curettage,118534782.0,HO,,,118534782.0,1.0,20110801.0,,,,118534782.0,1.0,HIV infection
11853482,118534822,2,F,20080208.0,20160202.0,20151218,20160202,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-14092738,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,56.7,KG,20160202.0,,CN,US,AR,BLINDED EFAVIRENZ,Abortion spontaneous;Pregnancy on oral contraceptive,118534822.0,OT,,,118534822.0,1.0,20060403.0,20080203.0,,,118534822.0,1.0,HIV infection
11853499,118534991,1,I,19991025.0,20000626.0,20151218,20151218,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0519,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,90.0,KG,20151218.0,,MD,FR,FR,SUSTIVA,Abortion spontaneous;Pregnancy,118534991.0,OT,,,118534991.0,1.0,19990818.0,200004.0,,,118534991.0,1.0,HIV infection
11853500,118535001,1,I,19981117.0,20000524.0,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0434,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,61.0,KG,20151218.0,,MD,US,US,EFAVIRENZ,Abortion induced;Pregnancy,118535001.0,OT,,,118535001.0,1.0,19980724.0,19980916.0,,,118535001.0,1.0,HIV infection
11853562,118535621,1,I,19991027.0,20000317.0,20151219,20151219,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0310,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20151219.0,,MD,US,US,SUSTIVA,No adverse event;Normal newborn;Pregnancy,,,,,118535621.0,1.0,19980914.0,199903.0,,,118535621.0,1.0,HIV infection
11853583,118535831,1,I,20000201.0,20010402.0,20151219,20151219,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0310,BRISTOL MYERS SQUIBB,,24.0,YR,,F,Y,,,20151219.0,,OT,US,US,SUSTIVA,No adverse event;Normal newborn;Pregnancy,,,,,118535831.0,1.0,20000309.0,20000601.0,,,118535831.0,1.0,HIV infection
11853584,118535841,1,I,20010621.0,20010604.0,20151219,20151219,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10864775,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,,,20151219.0,,OT,US,US,SUSTIVA,Abortion induced;Pregnancy on contraceptive,118535841.0,OT,,,118535841.0,1.0,20001116.0,20010516.0,,,118535841.0,1.0,HIV infection
11853736,118537361,1,I,20080521.0,20080605.0,20151219,20151219,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14217178,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20151219.0,,CN,US,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Vanishing twin syndrome,118537361.0,OT,,,,,,,,,118537361.0,1.0,HIV infection
11853741,118537411,1,I,,20080513.0,20151219,20151219,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14200083,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151219.0,,CN,ZA,ZA,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,118537411.0,OT,,,,,,,,,118537411.0,1.0,HIV infection
11854127,118541271,1,I,200010.0,20010216.0,20151220,20151220,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10721025,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,59.0,KG,20151220.0,,CN,FR,FR,SUSTIVA,Abdominal pain;Abscess;Caesarean section;Hepatic steatosis;Infection;Influenza like illness;Lactic acidosis;Pancreatitis acute;Pregnancy;Premature delivery;Uterine contractions abnormal,118541271.0,HO,,,118541271.0,1.0,200005.0,200102.0,,,118541271.0,1.0,HIV test positive
11854400,118544001,1,I,,20151210.0,20151221,20151221,EXP,,UG-CIPLA LTD.-2015UG09491,CIPLA,"CASTELNUOVO B., KIRAGGA A., MUSAAZI J., SEMPA J., MUBIRU F., WANYAMA J., WANDERA B., ET AL.. OUTCOMES IN A COHORT OF PATIENTS STARTED ON ANTIRETROVIRAL TREATMENT AND FOLLOWED UP FOR A DECADE IN AN URBAN CLINIC IN UGANDA. PLOS ONE. 2015?1 TO 11",,,,,Y,,,20151221.0,,OT,UG,UG,Efavirenz,Accidental death,118544001.0,DE,,,,,,,,,118544001.0,1.0,HIV test positive
11855568,118555681,1,I,2015.0,20151214.0,20151221,20151221,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2015GSK177987,VIIV,,,,,M,Y,,,20151221.0,,CN,RU,RU,STOCRIN (EFAVIRENZ),Rash;Toxic skin eruption,118555681.0,HO,,,118555681.0,1.0,2015.0,,,,118555681.0,1.0,HIV infection
11855793,118557931,1,I,2015.0,20151214.0,20151221,20151221,EXP,,RU-GLAXOSMITHKLINE-RU2015GSK177987,GLAXOSMITHKLINE,,,,,M,Y,,,20151221.0,,CN,RU,RU,STOCRIN (EFAVIRENZ),Rash;Toxic skin eruption,118557931.0,OT,,,118557931.0,1.0,2015.0,,,,118557931.0,1.0,HIV infection
11856980,118569801,1,I,19990115.0,19990208.0,20151221,20151221,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-M093171,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,,,20151221.0,,CN,US,US,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,118569801.0,OT,,,118569801.0,1.0,19981111.0,19981218.0,,,118569801.0,1.0,HIV infection
11858664,118586644,4,F,20010322.0,20201123.0,20151222,20201203,EXP,,US-009507513-01050823,MERCK,,1.0,DY,,M,Y,3.24,KG,20201203.0,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,118586644.0,CA,,,118586644.0,1.0,20001109.0,20000810.0,,,118586644.0,1.0,HIV infection
11861450,118614501,1,I,,20151215.0,20151222,20151222,EXP,,US-GILEAD-2015-0188859,GILEAD,"KAHLON A, GNANABAKTHAN N, SYED W, DHILLON A, SHARMA A. DEVLOPMENT OF FANCONI SYNDROME AFTER ADDITION OF LEDIPASVIR/SOFOSBUVIR IN A PATIENT ON TENOFOVIR. CRITICAL CARE MEDICINE. 2015?43 (12 SUPPL 1):318",63.0,YR,A,M,Y,,,20151222.0,,OT,US,US,EFAVIRENZ,Drug interaction;Fanconi syndrome acquired,118614501.0,OT,,,118614501.0,1.0,2005.0,,,,118614501.0,1.0,HIV infection
11862309,118623091,1,I,20000713.0,20001101.0,20151222,20151222,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0849,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20151222.0,,MD,DE,DE,SUSTIVA,Abortion missed;Pregnancy;Uterine dilation and curettage,118623091.0,OT,,,118623091.0,1.0,19980501.0,20000816.0,,,118623091.0,1.0,HIV infection
11862500,118625001,1,I,20151013.0,20151217.0,20151223,20151223,EXP,,ZW-GILEAD-2015-0189327,GILEAD,,39.0,YR,A,F,Y,,,20151222.0,,MD,ZW,ZW,EFAVIRENZ,Acute kidney injury;Pyelonephritis,118625001.0,OT,,,118625001.0,1.0,20150407.0,20151023.0,,,118625001.0,1.0,HIV infection
11863641,118636411,1,I,19991209.0,19990610.0,20151223,20151223,PER,,US-009507513-99061896,MERCK,,28.0,YR,,F,Y,,,20151223.0,,CN,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,,,,,,,118636411.0,1.0,HIV infection
11863799,118637991,1,I,19990226.0,20001003.0,20151223,20151223,PER,,US-009507513-00121657,MERCK,,22.0,YR,,F,Y,,,20151223.0,,CN,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,118637991.0,1.0,19990528.0,19990528.0,,,118637991.0,1.0,HIV infection
11863851,118638511,1,I,,19991008.0,20151223,20151223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS1187,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151223.0,,OT,US,US,SUSTIVA,Gestational diabetes;Pregnancy,118638511.0,OT,,,118638511.0,1.0,19990824.0,,,,118638511.0,1.0,HIV infection
11864883,118648831,1,I,19981218.0,19990118.0,20151223,20151223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-M092047,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20151223.0,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy;Pyelonephritis,118648831.0,HO,,,118648831.0,1.0,199810.0,19981217.0,,,118648831.0,1.0,HIV infection
11864990,118649901,1,I,200105.0,20011129.0,20151223,20151223,EXP,,SE-BRISTOL-MYERS SQUIBB COMPANY-11612629,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20151223.0,,OT,US,SE,EFAVIRENZ,Abortion induced;Foetal death;Pregnancy,118649901.0,OT,,,118649901.0,1.0,200007.0,20010417.0,,,118649901.0,1.0,HIV infection
11866743,118667431,1,I,,20151215.0,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09633,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151224.0,,OT,IN,IN,Efavirenz,Virologic failure,118667431.0,OT,,,,,,,,,118667431.0,1.0,HIV infection
11866747,118667471,1,I,,20151215.0,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09582,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151224.0,,OT,IN,IN,Efavirenz,Cerebral malaria;Treatment failure,118667471.0,DE,,,,,,,,,118667471.0,1.0,HIV infection
11866759,118667591,1,I,,20151215.0,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09671,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151224.0,,OT,IN,IN,Efavirenz,Cervix carcinoma;Treatment failure,118667591.0,DE,,,,,,,,,118667591.0,1.0,HIV infection
11866763,118667631,1,I,,20151215.0,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09669,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151224.0,,OT,IN,IN,Efavirenz,Virologic failure,118667631.0,OT,,,,,,,,,118667631.0,1.0,HIV infection
11866881,118668811,1,I,2007.0,20100817.0,20151224,20151224,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-15262066,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20151224.0,,OT,TH,TH,EFAVIRENZ,Abortion incomplete;Female sterilisation;Maternal exposure during pregnancy;Uterine dilation and curettage;Uterine haemorrhage,118668811.0,OT,,,118668811.0,1.0,20051013.0,,,,118668811.0,1.0,HIV infection
11866971,118669712,2,F,20140825.0,20160225.0,20151224,20160225,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21576756,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20160225.0,,OT,BW,BW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Menorrhagia;Uterine dilation and curettage,118669712.0,OT,,,118669712.0,1.0,20110624.0,20140806.0,,,118669712.0,1.0,Antiretroviral therapy
11868354,118683548,8,F,20001221.0,20181026.0,20151224,20181107,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11527520,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20181107.0,,OT,FR,FR,EFAVIRENZ.,Gestational diabetes;Normal newborn;Pregnancy,118683548.0,OT,,,118683548.0,1.0,19970902.0,,,,118683548.0,1.0,Antiretroviral therapy
11868390,118683901,1,I,20010503.0,20011115.0,20151224,20151224,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11544715,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151224.0,,OT,US,US,EFAVIRENZ,Abortion induced;Pregnancy,118683901.0,OT,,,118683901.0,1.0,20000310.0,20010312.0,,,118683901.0,1.0,HIV infection
11868474,118684742,2,F,19991110.0,20160824.0,20151225,20160824,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10799815,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20160824.0,,OT,US,US,EFAVIRENZ,Caesarean section;Pregnancy;Premature separation of placenta,118684742.0,HO,,,118684742.0,1.0,19970915.0,19990503.0,,,118684742.0,1.0,HIV infection
11868611,118686111,1,I,,20030124.0,20151225,20151225,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12167631,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20151225.0,,OT,FR,FR,EFAVIRENZ,Abdominal pain upper;Caesarean section;Cellulitis gangrenous;Hepatic steatosis;Lactic acidosis;Pancreatitis necrotising;Pregnancy;Premature delivery;Uterine hypertonus,118686111.0,HO,,,,,,,,,118686111.0,1.0,HIV infection
11868755,118687551,1,I,20010803.0,20010827.0,20151225,20151225,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10970085,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20151225.0,,OT,US,US,SUSTIVA,Abortion induced;Pregnancy,118687551.0,OT,,,,,,,,,118687551.0,1.0,Antiretroviral therapy
11868899,118688991,1,I,20150610.0,20151215.0,20151225,20151225,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090131,BRISTOL MYERS SQUIBB,,23.0,YR,,M,Y,54.0,KG,20151225.0,,CN,CN,CN,EFAVIRENZ,Pruritus;Pyrexia;Rash papular,118688991.0,HO,,,118688991.0,1.0,20150605.0,20150610.0,,,118688991.0,1.0,HIV infection
11869072,118690721,1,I,20051212.0,20061126.0,20151225,20151225,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-13589700,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20151225.0,,CN,BW,BW,EFAVIRENZ,Abortion spontaneous;Pregnancy,118690721.0,OT,,,118690721.0,1.0,20030504.0,20040715.0,,,118690721.0,1.0,HIV infection
11869539,118695391,1,I,,20151215.0,20151228,20151228,EXP,,IN-CIPLA LTD.-2015IN09673,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151228.0,,OT,IN,IN,Efavirenz,Pneumonia bacterial;Treatment failure,118695391.0,OT,,,,,,,,,118695391.0,1.0,HIV infection
11869540,118695401,1,I,,20151215.0,20151228,20151228,EXP,,IN-CIPLA LTD.-2015IN09674,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151228.0,,OT,IN,IN,Efavirenz,Myocardial infarction,118695401.0,DE,,,,,,,,,118695401.0,1.0,HIV infection
11869655,118696551,1,I,20000229.0,20000210.0,20151228,20151228,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10277309,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,73.0,KG,20151228.0,,OT,FR,FR,EFAVIRENZ,Abortion spontaneous;Pregnancy,118696551.0,OT,,,118696551.0,1.0,19991110.0,20000124.0,,,118696551.0,1.0,HIV infection
11870144,118701441,1,I,,20151215.0,20151228,20151228,EXP,,IN-CIPLA LTD.-2015IN09585,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151228.0,,OT,IN,IN,Efavirenz,Blood bilirubin abnormal,118701441.0,OT,,,,,,,,,118701441.0,1.0,HIV infection
11870680,118706801,1,I,20040704.0,20070706.0,20151228,20151228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000019,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20151228.0,,CN,US,US,EFAVIRENZ,Caesarean section;Oligohydramnios;Pregnancy;Stillbirth;Umbilical cord abnormality,118706801.0,OT,,,118706801.0,1.0,20070201.0,20070201.0,,,118706801.0,1.0,Antiretroviral therapy
11871337,118713371,1,I,20010601.0,20001102.0,20151228,20151228,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0851,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,55.0,KG,20151228.0,,MD,FR,FR,SUSTIVA,Caesarean section;Escherichia pyelonephritis;Live birth;Pregnancy;Pyrexia,118713371.0,HO,,,118713371.0,3.0,20001102.0,20001102.0,,,118713371.0,1.0,HIV infection
11873848,118738481,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09595,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229.0,,OT,IN,IN,Efavirenz,Drug resistance;Treatment failure,118738481.0,OT,,,,,,,,,118738481.0,1.0,HIV infection
11873856,118738561,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09596,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151229.0,,MD,IN,IN,Efavirenz,Drug resistance;Treatment failure,118738561.0,OT,,,,,,,,,118738561.0,1.0,HIV infection
11873872,118738721,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09600,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229.0,,OT,IN,IN,Efavirenz,Drug resistance;Treatment failure,118738721.0,OT,,,,,,,,,118738721.0,1.0,HIV infection
11873873,118738731,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09621,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229.0,,OT,IN,IN,Efavirenz,Aspartate aminotransferase;Treatment failure,118738731.0,OT,,,,,,,,,118738731.0,1.0,HIV infection
11873887,118738871,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09623,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229.0,,OT,IN,IN,Efavirenz,Alanine aminotransferase;Treatment failure,118738871.0,OT,,,,,,,,,118738871.0,1.0,HIV infection
11874007,118740071,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09587,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229.0,,OT,IN,IN,Efavirenz,Diarrhoea;Treatment failure,118740071.0,OT,,,,,,,,,118740071.0,1.0,HIV infection
11874027,118740271,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09618,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229.0,,OT,IN,IN,Efavirenz,Discomfort;Treatment failure,118740271.0,OT,,,,,,,,,118740271.0,1.0,HIV infection
11874332,118743321,1,I,,20151215.0,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09584,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229.0,,MD,IN,IN,Efavirenz,Hypophosphataemia;Treatment failure,118743321.0,OT,,,,,,,,,118743321.0,1.0,HIV infection
11877838,118778381,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09744,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118778381.0,OT,,,,,,,,,118778381.0,1.0,HIV infection
11877843,118778431,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09732,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118778431.0,DE,,,,,,,,,118778431.0,1.0,HIV infection
11877848,118778481,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09728,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,COUNTRY NOT SPECIFIED,VN,Efavirenz,Drug resistance;Virologic failure,118778481.0,OT,,,,,,,,,118778481.0,1.0,HIV infection
11877922,118779221,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09758,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Virologic failure,118779221.0,OT,,,,,,,,,118779221.0,1.0,HIV infection
11877928,118779281,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09733,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118779281.0,OT,,,,,,,,,118779281.0,1.0,HIV infection
11877958,118779581,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09739,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118779581.0,OT,,,,,,,,,118779581.0,1.0,HIV infection
11878000,118780001,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09740,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Virologic failure,118780001.0,OT,,,,,,,,,118780001.0,1.0,HIV infection
11878112,118781121,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09751,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118781121.0,OT,,,,,,,,,118781121.0,1.0,HIV infection
11878135,118781351,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09762,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118781351.0,OT,,,,,,,,,118781351.0,1.0,HIV infection
11878475,118784751,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09745,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118784751.0,OT,,,,,,,,,118784751.0,1.0,HIV infection
11878522,118785221,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09729,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118785221.0,OT,,,,,,,,,118785221.0,1.0,HIV infection
11878534,118785341,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09730,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118785341.0,OT,,,,,,,,,118785341.0,1.0,HIV infection
11878535,118785351,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09750,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230.0,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118785351.0,DE,,,,,,,,,118785351.0,1.0,HIV infection
11879089,118790892,2,F,20151215.0,20160127.0,20151230,20160201,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-091778,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,,,20160201.0,,OT,UG,UG,EFAVIRENZ,Bacteraemia;Headache;Malaise;Neck pain;Pyrexia;Vision blurred,118790892.0,OT,,,118790892.0,1.0,20131128.0,20141106.0,,,118790892.0,1.0,HIV infection
11881127,118811271,1,I,,20151216.0,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09731,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118811271.0,OT,,,,,,,,,118811271.0,1.0,HIV infection
11881177,118811771,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09734,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118811771.0,OT,,,,,,,,,118811771.0,1.0,HIV infection
11881185,118811851,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09735,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118811851.0,DE,,,,,,,,,118811851.0,1.0,HIV infection
11881196,118811961,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09736,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118811961.0,OT,,,,,,,,,118811961.0,1.0,HIV infection
11881215,118812151,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09737,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118812151.0,OT,,,,,,,,,118812151.0,1.0,HIV infection
11881235,118812353,3,F,20140220.0,20180614.0,20151231,20180717,PER,,US-009507513-1512USA007300,MERCK,,29.0,YR,,F,Y,,,20180717.0,,CN,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;No adverse event;Normal newborn;Off label use,,,,,,,,,,,118812353.0,1.0,Antiretroviral therapy
11881338,118813381,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09743,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118813381.0,OT,,,,,,,,,118813381.0,1.0,HIV infection
11881344,118813441,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09741,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118813441.0,DE,,,,,,,,,118813441.0,1.0,HIV infection
11881345,118813451,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09742,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118813451.0,OT,,,,,,,,,118813451.0,1.0,HIV infection
11881486,118814861,1,I,,20151216.0,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09738,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231.0,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118814861.0,OT,,,,,,,,,118814861.0,1.0,HIV infection
11882849,118828492,2,F,20140128.0,20160114.0,20151231,20160118,EXP,,NG-GILEAD-2015-0190051,GILEAD,,52.0,YR,A,M,Y,,,20160118.0,,MD,NG,NG,EFAVIRENZ,Intestinal obstruction,118828492.0,OT,,,118828492.0,1.0,20130201.0,,,,118828492.0,1.0,HIV infection
11883063,118830637,7,F,,20190227.0,20151231,20190313,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090408,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20190313.0,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,118830637.0,OT,,,118830637.0,1.0,2007.0,,,,118830637.0,1.0,HIV infection
11883169,118831691,1,I,20151026.0,20151222.0,20151231,20151231,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-091273,BRISTOL MYERS SQUIBB,,41.0,YR,,F,Y,62.5,KG,20151231.0,,MD,CL,CL,EFAVIRENZ,Appendicectomy;Peritonitis,118831691.0,HO,,,118831691.0,1.0,20130401.0,,,,118831691.0,1.0,HIV infection
11885581,118855811,1,I,20010430.0,20010830.0,20160104,20160104,EXP,,FR-009507513-01096030,MERCK,,38.0,YR,,F,Y,55.0,KG,20160104.0,,CN,US,FR,SUSTIVA,Bradycardia;Caesarean section;Escherichia pyelonephritis;Exposure during pregnancy;Lipodystrophy acquired;Live birth;Pregnancy;Pyelonephritis;Pyrexia,118855811.0,HO,,,118855811.0,1.0,20010430.0,20001102.0,,,118855811.0,1.0,HIV infection
11887494,118874941,1,I,,20151221.0,20160105,20160105,EXP,,PHHY2015TH171174,SANDOZ,"CHITASOMBAT MN, WATTANATRANON D.. DISSEMINATED MYCOBACTERIUM SIMIAE WITH PELVIC MALAKOPLAKIA IN AN AIDS PATIENT.. CLIN-MED-INSIGHTS-CASE-REP. 2015?8:89-91",3.0,DEC,,F,Y,,,20160105.0,,OT,TH,TH,EFAVIRENZ,Mycobacterial infection,118874941.0,OT,,,,,,,,,118874941.0,1.0,Acquired immunodeficiency syndrome
11887500,118875001,1,I,,20151221.0,20160105,20160105,EXP,,PHHY2015TH169783,SANDOZ,"CHITASOMBAT MN, WATTANATRANON D.. DISSEMINATED MYCOBACTERIUM SIMIAE WITH PELVIC MALAKOPLAKIA IN AN AIDS PATIENT.. CLIN-MED-INSIGHTS-CASE-REP. 2015?8:89-91",3.0,DEC,,F,Y,,,20160105.0,,OT,TH,TH,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Malacoplakia vesicae;Transaminases increased,118875001.0,OT,,,,,,,,,118875001.0,1.0,Acquired immunodeficiency syndrome
11888519,118885191,1,I,20010430.0,20001102.0,20160105,20160105,EXP,,FR-009507513-1601FRA000401,MERCK,,38.0,YR,,F,Y,55.0,KG,20160105.0,,CN,US,FR,SUSTIVA,Bradycardia;Caesarean section;Escherichia pyelonephritis;Exposure during pregnancy;Lipodystrophy acquired;Live birth;Pregnancy;Pyelonephritis;Pyrexia,118885191.0,OT,,,118885191.0,1.0,20010430.0,20001102.0,,,118885191.0,1.0,HIV infection
11888924,118889241,1,I,,20151228.0,20160105,20160105,EXP,,RS-VIIV HEALTHCARE LIMITED-RS2015GSK184370,VIIV,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC DJ.. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: CASE REPORT. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASE. 2016?42:40-42",28.0,YR,,M,Y,,,20160105.0,,OT,RS,RS,Efavirenz,CD4 lymphocytes decreased;General physical health deterioration;Immune reconstitution inflammatory syndrome;Pyrexia,118889241.0,HO,,,,,,,,,118889241.0,1.0,HIV infection
11890270,118902701,1,I,,20151228.0,20160105,20160105,EXP,,RS-GLAXOSMITHKLINE-RS2015GSK184370,GLAXOSMITHKLINE,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC DJ.. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: CASE REPORT. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASE. 2016?42:40-42",28.0,YR,,M,Y,,,20160105.0,,OT,RS,RS,Efavirenz,CD4 lymphocytes decreased;General physical health deterioration;Immune reconstitution inflammatory syndrome;Pyrexia,118902701.0,HO,,,,,,,,,118902701.0,1.0,HIV infection
11891040,118910401,1,I,,20151222.0,20160106,20160106,EXP,,US-CIPLA LTD.-2015US09995,CIPLA,"SMITH K, GOMES D, NIXON D AND FULCO P. THE USE OF UNBOOSTED DARUNAVIR IN THE SETTING OF RITONAVIR INTOLERANCE: THREE CASE REPORTS. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2015?1-6",,,,,Y,,,20160106.0,,OT,US,US,Efavirenz,Abdominal discomfort;Drug dose omission;Treatment failure;Vomiting,118910401.0,OT,,,,,,,,,118910401.0,1.0,HIV infection
11910157,119101572,2,F,2013.0,20170727.0,20160112,20170811,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2015R1-109170,RANBAXY,"BRAHMACHARI U, SAHA S, GUCHHAIT B, GUHA SK. DISSEMINATED MYCOBACTERIUM SIMIAE MANIFESTED AS IRIS: A CASE REPORT. HIV AIDS REV. 2015;14(3):93-95",32.0,YR,,F,Y,,,20170811.0,,OT,IN,IN,Efavirenz,Bone marrow failure;Death;Drug ineffective;Escherichia urinary tract infection;Immune reconstitution inflammatory syndrome;Mycobacterial infection;Pancytopenia;Pulmonary tuberculosis,119101572.0,OT,,,119101572.0,1.0,20130414.0,2013.0,,,119101572.0,1.0,HIV infection
11911498,119114981,1,I,20000606.0,20000620.0,20160112,20160112,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0501,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,,,20160112.0,,CN,US,US,EFAVIRENZ,Abortion induced;Pregnancy,119114981.0,OT,,,119114981.0,1.0,19990709.0,,,,119114981.0,1.0,HIV infection
11916239,119162391,1,I,20000705.0,20000710.0,20160114,20160114,EXP,,US-VIIV HEALTHCARE LIMITED-A0124113A,VIIV,,42.0,YR,,M,Y,,,20160114.0,,CN,US,US,SUSTIVA,Fatigue;Hypersensitivity;Influenza like illness;Pruritus;Pyrexia;Rash generalised,,,,,119162391.0,1.0,20000613.0,20000710.0,,,119162391.0,1.0,HIV infection
11924828,119248282,2,F,20160112.0,20160129.0,20160118,20160202,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2016GSK005769,VIIV,,0.0,DY,,M,Y,1.96,KG,20160202.0,,MD,BR,BR,Efavirenz,Underweight,119248282.0,LT,,,119248282.0,1.0,20151113.0,20160111.0,,,119248282.0,1.0,Antiretroviral therapy
11926358,119263581,1,I,,20160112.0,20160119,20160119,EXP,,CH-CIPLA LTD.-2016CH00228,CIPLA,"AOURI M, BARCELO C, TERNON B, CAVASSINI M, ANAGNOSTOPOULOS A, DECOSTERD L ET AL. IN VIVO PROFILING AND DISTRIBUTION OF KNOWN AND NOVEL PHASE I AND PHASE II METABOLITES OF EFAVIRENZ IN PLASMA, URINE, AND CEREBROSPINAL FLUID. DRUG METABOLISM AND DISPOSITION. 2016?44:151-161",,,,,Y,,,20160119.0,,OT,CH,CH,Efavirenz,Neurotoxicity,119263581.0,OT,,,,,,,,,119263581.0,1.0,HIV infection
11930792,119307921,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193343,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119307921.0,OT,,,,,,,,,119307921.0,1.0,HIV infection
11931014,119310141,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193342,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119310141.0,OT,,,,,,,,,119310141.0,1.0,HIV infection
11932477,119324771,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193586,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119324771.0,OT,,,,,,,,,119324771.0,1.0,HIV infection
11932540,119325401,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193588,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119325401.0,OT,,,,,,,,,119325401.0,1.0,HIV infection
11932603,119326031,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193590,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119326031.0,OT,,,,,,,,,119326031.0,1.0,HIV infection
11932693,119326931,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193592,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119326931.0,OT,,,,,,,,,119326931.0,1.0,HIV infection
11932702,119327021,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193306,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327021.0,OT,,,,,,,,,119327021.0,1.0,HIV infection
11932708,119327081,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193589,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327081.0,OT,,,,,,,,,119327081.0,1.0,HIV infection
11932739,119327391,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193587,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327391.0,OT,,,,,,,,,119327391.0,1.0,HIV infection
11932775,119327751,1,I,,20160112.0,20160120,20160120,EXP,,CN-GILEAD-2016-0193591,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120.0,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327751.0,OT,,,,,,,,,119327751.0,1.0,HIV infection
11935840,119358401,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007662,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358401.0,OT,,,,,,,,,119358401.0,1.0,HIV infection
11935842,119358421,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007657,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358421.0,OT,,,,,,,,,119358421.0,1.0,HIV infection
11935843,119358431,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007661,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358431.0,OT,,,,,,,,,119358431.0,1.0,HIV infection
11935844,119358441,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007603,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358441.0,OT,,,,,,,,,119358441.0,1.0,HIV infection
11935845,119358451,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007654,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358451.0,OT,,,,,,,,,119358451.0,1.0,HIV infection
11935846,119358461,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007642,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358461.0,OT,,,,,,,,,119358461.0,1.0,HIV infection
11935847,119358471,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007644,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358471.0,OT,,,,,,,,,119358471.0,1.0,HIV infection
11935848,119358481,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007651,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358481.0,OT,,,,,,,,,119358481.0,1.0,HIV infection
11935849,119358491,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007656,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358491.0,OT,,,,,,,,,119358491.0,1.0,HIV infection
11935850,119358501,1,I,,20160112.0,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007600,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358501.0,OT,,,,,,,,,119358501.0,1.0,HIV infection
11936411,119364111,1,I,,20160111.0,20160121,20160121,EXP,,CN-GILEAD-2016-0192361,GILEAD,"LIU, X., WU, H., HUANG, X.. DISSEMINATED PENICILLIUM MARNEFFEI INFECTION WITH IRIS. IDCASES. 2015?2(4):92-93",47.0,YR,A,M,Y,,,20160121.0,,OT,CN,CN,EFAVIRENZ,Acute kidney injury;Fungal infection;Immune reconstitution inflammatory syndrome,119364111.0,OT,,,,,,,,,119364111.0,1.0,HIV infection
11938845,119388451,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007654,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388451.0,OT,,,,,,,,,119388451.0,1.0,HIV infection
11938846,119388461,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007642,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388461.0,OT,,,,,,,,,119388461.0,1.0,HIV infection
11938851,119388511,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007644,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388511.0,OT,,,,,,,,,119388511.0,1.0,HIV infection
11938855,119388551,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007662,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388551.0,OT,,,,,,,,,119388551.0,1.0,HIV infection
11938859,119388591,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007603,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388591.0,OT,,,,,,,,,119388591.0,1.0,HIV infection
11938863,119388631,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007651,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388631.0,OT,,,,,,,,,119388631.0,1.0,HIV infection
11938867,119388671,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007600,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388671.0,OT,,,,,,,,,119388671.0,1.0,HIV infection
11938875,119388751,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007656,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388751.0,OT,,,,,,,,,119388751.0,1.0,HIV infection
11938878,119388781,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007661,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388781.0,OT,,,,,,,,,119388781.0,1.0,HIV infection
11938879,119388791,1,I,,20160112.0,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007657,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121.0,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388791.0,OT,,,,,,,,,119388791.0,1.0,HIV infection
11941324,119413243,3,F,20160119.0,20160323.0,20160122,20160404,EXP,,MX-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-003946,BRISTOL MYERS SQUIBB,,25.0,YR,,M,Y,68.4,KG,20160404.0,,OT,MX,MX,EFAVIRENZ,Ventricular extrasystoles,119413243.0,OT,,,119413243.0,1.0,20151015.0,20160118.0,,,119413243.0,1.0,HIV infection
11964515,119645151,1,I,,20160115.0,20160127,20160127,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-003862,BRISTOL MYERS SQUIBB,,,,,M,Y,86.8,KG,20160127.0,,CN,US,US,SUSTIVA,Incorrect product storage,,,,,119645151.0,1.0,1999.0,,,,119645151.0,1.0,HIV infection
11968401,119684011,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00520,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL  RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128.0,,OT,GB,GB,Efavirenz,Myocardial ischaemia,119684011.0,OT,,,,,,,,,119684011.0,1.0,HIV infection
11969057,119690571,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00486,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128.0,,OT,GB,GB,Efavirenz,Hepatitis A;Lactic acidosis;Treatment failure,119690571.0,OT,,,,,,,,,119690571.0,1.0,HIV infection
11969070,119690701,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00487,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128.0,,OT,GB,GB,Efavirenz,Nervous system disorder;Treatment failure,119690701.0,DE,,,,,,,,,119690701.0,1.0,HIV infection
11969134,119691341,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00488,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING  ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-98",,,,,Y,,,20160128.0,,OT,COUNTRY NOT SPECIFIED,GB,Efavirenz,Encephalopathy;Treatment failure,119691341.0,DE,,,,,,,,,119691341.0,1.0,HIV infection
11969345,119693451,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00522,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL  RANDOMISED TRIAL. LANCET. 2006?368:287-98",,,,,Y,,,20160128.0,,OT,GB,GB,Efavirenz,Lactic acidosis,119693451.0,OT,,,,,,,,,119693451.0,1.0,HIV infection
11969396,119693961,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00527,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING  ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128.0,,OT,GB,GB,Efavirenz,Myocardial infarction;Treatment failure,119693961.0,OT,,,,,,,,,119693961.0,1.0,HIV infection
11969411,119694111,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00528,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING  ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128.0,,OT,GB,GB,Efavirenz,Atypical mycobacterial infection;Treatment failure,119694111.0,DE,,,,,,,,,119694111.0,1.0,HIV infection
11969474,119694741,1,I,,20160117.0,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00529,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE  REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-98",,,,,Y,,,20160128.0,,OT,GB,GB,Efavirenz,Cytomegalovirus infection;Treatment failure,119694741.0,OT,,,,,,,,,119694741.0,1.0,HIV infection
11972261,119722611,1,I,,20160116.0,20160128,20160128,EXP,,IN-MYLANLABS-2016M1003489,MYLAN,"KARADE S, PANDEY S, GIANCHANDANI S, KURLE SN, GHATE M, GAIKWAD NS, ET AL. NEAR FULL-LENGTH GENOMIC CHARACTERIZATION OF A NOVEL CRF 01-AE/C RECOMBINANT FROM WESTERN INDIA. AIDS-RES-HUM-RETROVIRUSES 2015?31(12):1269-1273.",,,,,Y,,,20160128.0,,OT,IN,IN,EFAVIRENZ,Drug resistance;Treatment failure,119722611.0,OT,,,,,,,,,119722611.0,1.0,Antiretroviral therapy
11976292,119762921,1,I,,20160117.0,20160129,20160129,EXP,,GB-CIPLA LTD.-2016GB00489,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160129.0,,OT,GB,GB,Efavirenz,Pulmonary hypertension;Treatment failure,119762921.0,DE,,,,,,,,,119762921.0,1.0,HIV infection
11981281,119812811,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00498,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Pyrexia,119812811.0,DE,,,,,,,,,119812811.0,1.0,HIV infection
11981282,119812821,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00499,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Oedema;Treatment failure,119812821.0,OT,,,,,,,,,119812821.0,1.0,HIV infection
11981283,119812831,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00500,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Death;Treatment failure,119812831.0,OT,,,,,,,,,119812831.0,1.0,HIV infection
11981284,119812841,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00501,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Death;Treatment failure,119812841.0,DE,,,,,,,,,119812841.0,1.0,HIV infection
11981285,119812851,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00503,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Myocardial infarction;Treatment failure,119812851.0,OT,,,,,,,,,119812851.0,1.0,HIV infection
11981286,119812861,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00505,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Angina pectoris;Myocardial ischaemia;Treatment failure,119812861.0,OT,,,,,,,,,119812861.0,1.0,HIV infection
11981287,119812871,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00502,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,CN,GB,GB,Efavirenz,Lactic acidosis;Treatment failure,119812871.0,OT,,,,,,,,,119812871.0,1.0,HIV infection
11981288,119812881,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00504,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Blood cholesterol increased;Blood triglycerides increased;Treatment failure,119812881.0,OT,,,,,,,,,119812881.0,1.0,HIV infection
11981289,119812891,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00506,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,CN,GB,GB,Efavirenz,Blood bilirubin increased;Treatment failure,119812891.0,OT,,,,,,,,,119812891.0,1.0,HIV infection
11981290,119812901,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00508,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Amylase increased;Treatment failure,119812901.0,OT,,,,,,,,,119812901.0,1.0,HIV infection
11981291,119812911,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00510,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Oedema;Treatment failure,119812911.0,OT,,,,,,,,,119812911.0,1.0,HIV infection
11981292,119812921,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00511,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Blood bilirubin increased,119812921.0,OT,,,,,,,,,119812921.0,1.0,HIV infection
11981293,119812931,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00509,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Cardiac failure;Pulmonary oedema;Shock;Treatment failure,119812931.0,OT,,,,,,,,,119812931.0,1.0,HIV infection
11981294,119812941,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00507,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Pancreatitis;Treatment failure,119812941.0,OT,,,,,,,,,119812941.0,1.0,HIV infection
11981295,119812951,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00515,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Respiratory disorder;Treatment failure,119812951.0,OT,,,,,,,,,119812951.0,1.0,HIV infection
11981300,119813001,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00516,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Myocardial infarction,119813001.0,OT,,,,,,,,,119813001.0,1.0,HIV infection
11981306,119813061,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00513,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Genitourinary symptom;Renal disorder,119813061.0,OT,,,,,,,,,119813061.0,1.0,HIV infection
11981307,119813071,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00514,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Lactic acidosis;Treatment failure,119813071.0,OT,,,,,,,,,119813071.0,1.0,HIV infection
11981308,119813081,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00512,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Lactic acidosis,119813081.0,OT,,,,,,,,,119813081.0,1.0,HIV infection
11981309,119813091,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00519,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Myocardial infarction;Treatment failure,119813091.0,OT,,,,,,,,,119813091.0,1.0,HIV infection
11981310,119813101,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00517,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Oedema,119813101.0,OT,,,,,,,,,119813101.0,1.0,HIV infection
11981311,119813111,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00518,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Hyperlactacidaemia;Treatment failure,119813111.0,OT,,,,,,,,,119813111.0,1.0,HIV infection
11981312,119813121,1,I,,20160117.0,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00521,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130.0,,OT,GB,GB,Efavirenz,Oedema,119813121.0,OT,,,,,,,,,119813121.0,1.0,HIV infection
11981807,119818071,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00540,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Pneumocystis jirovecii pneumonia;Treatment failure,119818071.0,DE,,,,,,,,,119818071.0,1.0,HIV infection
11981917,119819171,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00497,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?398:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Homicide,119819171.0,DE,,,,,,,,,119819171.0,1.0,HIV infection
11981926,119819261,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00526,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Myocardial ischaemia;Treatment failure,119819261.0,OT,,,,,,,,,119819261.0,1.0,HIV infection
11981927,119819271,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00525,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Oesophageal candidiasis;Treatment failure,119819271.0,DE,,,,,,,,,119819271.0,1.0,HIV infection
11981929,119819291,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00524,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Cardiac failure;Pulmonary oedema;Shock,119819291.0,OT,,,,,,,,,119819291.0,1.0,HIV infection
11981935,119819351,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00523,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Genitourinary symptom;Renal disorder,119819351.0,OT,,,,,,,,,119819351.0,1.0,HIV infection
11981937,119819371,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00530,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,AIDS dementia complex;Treatment failure,119819371.0,DE,,,,,,,,,119819371.0,1.0,HIV infection
11981940,119819401,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00535,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-296",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,AIDS dementia complex;Treatment failure,119819401.0,DE,,,,,,,,,119819401.0,1.0,HIV infection
11981941,119819411,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00531,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Pneumocystis jirovecii pneumonia;Treatment failure,119819411.0,OT,,,,,,,,,119819411.0,1.0,HIV infection
11981943,119819431,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00532,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Meningitis cryptococcal;Treatment failure,119819431.0,OT,,,,,,,,,119819431.0,1.0,HIV infection
11981948,119819481,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00539,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,AIDS dementia complex,119819481.0,DE,,,,,,,,,119819481.0,1.0,HIV infection
11981949,119819491,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00537,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Progressive multifocal leukoencephalopathy,119819491.0,DE,,,,,,,,,119819491.0,1.0,HIV infection
11981950,119819501,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00536,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Pneumocystis jirovecii pneumonia,119819501.0,DE,,,,,,,,,119819501.0,1.0,HIV infection
11981963,119819631,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00538,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Meningitis cryptococcal,119819631.0,DE,,,,,,,,,119819631.0,1.0,HIV infection
11981967,119819671,1,I,,20160117.0,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00541,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201.0,,OT,GB,GB,Efavirenz,Cryptosporidiosis infection,119819671.0,DE,,,,,,,,,119819671.0,1.0,HIV infection
11991033,1199103322,22,F,,20240927.0,20160202,20241010,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,Literature citation unavailable,54.0,YR,A,M,Y,,,20241010.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Loss of personal independence in daily activities;Off label use;Paranoia;Prescribed overdose;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1199103322.0,HO,,,,,,,,,1199103322.0,1.0,HIV infection
11993203,119932032,2,F,,20160122.0,20160203,20160204,EXP,,CA-TEVA-630951ACC,TEVA,,65.0,YR,,M,Y,,,20160204.0,,MD,CA,CA,SUSTIVA,Palpitations;Product substitution issue,119932032.0,DS,,,,,,,,,119932032.0,1.0,HIV test positive
11996013,119960133,3,F,20160106.0,20161003.0,20160203,20161007,EXP,,BR-GILEAD-2016-0194835,GILEAD,,28.0,YR,A,M,Y,60.0,KG,20161007.0,,MD,BR,BR,EFAVIRENZ,Nephrolithiasis,119960133.0,OT,,,119960133.0,1.0,20130507.0,,,,119960133.0,1.0,HIV infection
12000812,120008121,1,I,,20160126.0,20160204,20160204,EXP,,KR-JNJFOC-20160120632,JANSSEN,"KIM MJ, KIM S, CHANG H, KIM Y, JIN S, JUNG H, ET AL. COMPARISON OF ANTIRETROVIRAL REGIMENS: ADVERSE EFFECTS AND TOLERABILITY FAILURE THAT CAUSE REGIMEN SWITCHING. INFECT CHEMOTHER 2015?47(4):231-238.",,,A,,Y,,,20160204.0,,OT,KR,KR,EFAVIRENZ,Abdominal pain upper;Alanine aminotransferase increased;Aspartate aminotransferase increased;Diabetes mellitus;Diarrhoea;Dizziness;Headache;Hyperbilirubinaemia;Nausea;Pain in extremity;Rash,120008121.0,OT,,,,,,,,,120008121.0,1.0,HIV infection
12009821,120098211,1,I,,20160122.0,20160205,20160205,EXP,,IN-LUPIN PHARMACEUTICALS INC.-2016-00532,LUPIN,"GANGAKHEDKAR R, KARADE S, PANDEY S, GIANCHANDANI S, KURLE S, GHATE M, GAIKWAD N, REWARI B. NEAR FULL-LENGTH GENOMIC CHARACTERIZATION OF A NOVEL CRF 01_AE/C RECOMBINANT FROM WESTERN INDIA. AIDS-RES-HUM-RETROVIRUSES. 2015?31(12):1269-1273.",32.0,YR,,F,Y,,,20160205.0,,OT,IN,IN,EEFAVIRENZ,Drug resistance;Treatment failure,120098211.0,OT,,,,,,,,,120098211.0,1.0,HIV infection
12013178,120131782,2,F,,20160314.0,20160205,20160323,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-005611,BRISTOL MYERS SQUIBB,,66.0,YR,,F,Y,,,20160323.0,,PH,DE,DE,SUSTIVA,Dysphagia;Gastrointestinal tube insertion;Tumour excision,120131782.0,OT,,,,,,,,,120131782.0,1.0,HIV infection
12062313,120623131,1,I,,20160202.0,20160210,20160210,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2016GSK016070,VIIV,,48.0,YR,,M,Y,,,20160210.0,,MD,FR,FR,EFAVIRENZ,Mitochondrial toxicity,120623131.0,OT,,,,,,,,,120623131.0,1.0,HIV infection
12073158,120731581,1,I,,20160129.0,20160212,20160212,EXP,,RS-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-111401,RANBAXY,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC D. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: CASE REPORT. INT-J-INFECT-DIS. 2016?4240-42",28.0,YR,,M,Y,,,20160212.0,,OT,RS,RS,Efavirenz,Condition aggravated;Drug resistance;Immune reconstitution inflammatory syndrome,120731581.0,OT,,,,,,,,,120731581.0,1.0,Antiretroviral therapy
12074101,120741012,2,F,,20160804.0,20160212,20160804,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-009817,BRISTOL MYERS SQUIBB,MYCOBACTERIUM HAEMNOPHILUM BONE AND JOINT INFECTION IN HIV/AIDS: CASE REPORT AND LITERATURE REVIEW,60.0,YR,,M,Y,,,20160804.0,,MD,AU,AU,EFAVIRENZ,Debridement;Haemophilus infection;Immune reconstitution inflammatory syndrome,120741012.0,OT,,,,,,,,,120741012.0,1.0,Antiretroviral therapy
12081585,120815851,1,I,,20160205.0,20160216,20160216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-012079,BRISTOL MYERS SQUIBB,,72.0,YR,,M,Y,,,20160216.0,,OT,US,US,EFAVIRENZ,Drug intolerance,,,,,,,,,,,120815851.0,1.0,HIV infection
12090160,120901601,1,I,,20160205.0,20160218,20160218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-011281,BRISTOL MYERS SQUIBB,,46.0,YR,,F,Y,,,20160218.0,,OT,US,US,EFAVIRENZ,Fanconi syndrome,120901601.0,OT,,,,,,,,,120901601.0,1.0,HIV infection
12090219,120902191,1,I,,20160205.0,20160218,20160218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-012078,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20160218.0,,OT,US,US,EFAVIRENZ,Anxiety;Depression,120902191.0,OT,,,,,,,,,120902191.0,1.0,HIV infection
12095787,120957871,1,I,,20160208.0,20160220,20160220,EXP,,ES-CIPLA LTD.-2016ES01159,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160220.0,,OT,ES,ES,Efavirenz,Blood bilirubin increased,120957871.0,OT,,,,,,,,,120957871.0,1.0,HIV infection
12095793,120957931,1,I,,20160208.0,20160220,20160220,EXP,,ES-CIPLA LTD.-2016ES01161,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160220.0,,OT,ES,ES,Efavirenz,Blood bilirubin increased,120957931.0,OT,,,,,,,,,120957931.0,1.0,HIV infection
12095794,120957941,1,I,,20160208.0,20160220,20160220,EXP,,ES-CIPLA LTD.-2016ES01160,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160220.0,,OT,ES,ES,Efavirenz,Blood bilirubin increased,120957941.0,OT,,,,,,,,,120957941.0,1.0,HIV infection
12098641,120986411,1,I,,20160208.0,20160222,20160222,EXP,,US-CIPLA LTD.-2016US01275,CIPLA,"BARIL J, ANGEL JB, GILL MJ, GATHE J, CAHN P, WYK J AND WALMSLEY S. DUAL THERAPY TREATMENT STRATEGIES FOR THE MANAGEMENT OF PATIENTS INFECTED WITH HIV: A SYSTEMATIC REVIEW OF CURRENT EVIDENCE IN ARV-NAIVE OR ARV-EXPERIENCED, VIROLOGICALLY SUPPRESSED PATIENTS. PLUS ONE. 2016?11 (2):1-32",,,,,Y,,,20160222.0,,OT,CA,US,Efavirenz,Suicidal ideation,120986411.0,OT,,,,,,,,,120986411.0,1.0,HIV infection
12099310,120993101,1,I,,20160208.0,20160222,20160222,EXP,,ES-CIPLA LTD.-2016ES01168,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160222.0,,OT,ES,ES,Efavirenz,Encephalopathy;Haemorrhage,120993101.0,DE,,,,,,,,,120993101.0,1.0,HIV infection
12099433,120994331,1,I,,20160208.0,20160222,20160222,EXP,,ES-CIPLA LTD.-2016ES01169,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160222.0,,OT,ES,ES,Efavirenz,Virologic failure,120994331.0,OT,,,,,,,,,120994331.0,1.0,HIV infection
12101117,121011171,1,I,,20150401.0,20160222,20160222,EXP,,GB-009507513-1506GBR001330,MERCK,,,,,F,Y,,,20160222.0,,CN,US,GB,EFAVIRENZ,Drug resistance;Off label use;Virologic failure,121011171.0,OT,,,121011171.0,1.0,201111.0,,,,121011171.0,1.0,HIV infection
12101719,121017194,4,F,20160113.0,20160405.0,20160222,20160414,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-010797,BRISTOL MYERS SQUIBB,,56.0,YR,,F,Y,55.0,KG,20160414.0,,OT,UG,UG,EFAVIRENZ,Colporrhaphy;Urinary tract infection,121017194.0,HO,,,121017194.0,1.0,20121115.0,,,,121017194.0,1.0,HIV infection
12101742,121017422,2,F,20160125.0,20160225.0,20160222,20160302,EXP,,UG-GILEAD-2016-0197817,GILEAD,,22.0,YR,A,F,Y,,,20160302.0,,MD,UG,UG,EFAVIRENZ,Abortion infected;Anaemia;Malaria;Maternal exposure during pregnancy,121017422.0,HO,,,121017422.0,1.0,20150401.0,20160205.0,,,121017422.0,1.0,HIV infection
12113243,121132431,1,I,,20160211.0,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01404,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225.0,,OT,US,US,Efavirenz,Drug resistance;Treatment failure,121132431.0,OT,,,,,,,,,121132431.0,1.0,HIV infection
12113264,121132641,1,I,,20160211.0,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01412,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225.0,,OT,US,US,Efavirenz,Road traffic accident,121132641.0,DE,,,,,,,,,121132641.0,1.0,HIV infection
12113286,121132861,1,I,,20160211.0,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01411,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225.0,,OT,US,US,Efavirenz,Adenocarcinoma gastric,121132861.0,DE,,,,,,,,,121132861.0,1.0,HIV infection
12113336,121133361,1,I,,20160211.0,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01391,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225.0,,OT,US,US,Efavirenz,Sepsis,121133361.0,DE,,,,,,,,,121133361.0,1.0,HIV infection
12114130,121141301,1,I,,20160211.0,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01444,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225.0,,OT,US,US,Efavirenz,Drowning,121141301.0,DE,,,,,,,,,121141301.0,1.0,HIV infection
12114271,121142711,1,I,,20160211.0,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01372,CIPLA,"RIDDLER S.A, HAUBRICH R, DIRIENZO G, PEEPLES L, POWDERLY W.G, KLINGMAN K.L., ET AL.. CLASS-SPARING REGIMENS FOR INITIAL TREATMENT OF HIV-1 INFECTION. N ENGL J MED. 2008?358 (20):2095-2106",,,,,Y,,,20160225.0,,MD,US,US,Efavirenz,Hepatotoxicity,121142711.0,DE,,,,,,,,,121142711.0,1.0,HIV infection
12114276,121142761,1,I,,20160211.0,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01370,CIPLA,"RIDDLER S.A, HAUBRICH R, DIRIENZO G, PEEPLES L, POWDERLY W.G, KLINGMAN K.L., ET AL.. CLASS-SPARING REGIMENS FOR INITIAL TREATMENT OF HIV-1 INFECTION. N ENGL J MED. 2008?358 (20):2095-2106",,,,,Y,,,20160225.0,,MD,US,US,Efavirenz,Virologic failure,121142761.0,OT,,,,,,,,,121142761.0,1.0,HIV infection
12119854,121198542,2,F,20150726.0,20160310.0,20160226,20160318,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-014171,BRISTOL MYERS SQUIBB,,36.0,YR,,M,Y,72.0,KG,20160318.0,,CN,CN,CN,EFAVIRENZ,Drug eruption,121198542.0,OT,,,121198542.0,1.0,20150704.0,20150728.0,,,121198542.0,1.0,Acquired immunodeficiency syndrome
12123126,121231261,1,I,,20160119.0,20160227,20160227,EXP,,ZA-AUROBINDO-AUR-APL-2016-00768,AUROBINDO,,29.0,YR,,M,Y,,,20160226.0,,OT,ZA,ZA,Efavirenz,Hepatitis B;Hepatomegaly;Immune reconstitution inflammatory syndrome;Jaundice;Lymphadenopathy;Pancytopenia;Splenomegaly,121231261.0,HO,,,121231261.0,4.0,200901.0,,,,121231261.0,1.0,HIV infection
12123141,121231412,2,F,201406.0,20160510.0,20160227,20160513,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-012812,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,,,20160513.0,,OT,GB,GB,SUSTIVA,Gastrostomy,121231412.0,OT,,,121231412.0,1.0,2012.0,,,,121231412.0,1.0,HIV infection
12123559,121235591,1,I,20160110.0,,20160226,20160226,DIR,,,,,56.0,YR,,M,N,,,20160224.0,N,,US,,EFAVIRENZ;SUSTIVA,Rash,121235591.0,OT,,,121235591.0,1.0,20160110.0,20160118.0,,,121235591.0,1.0,HIV infection
12126565,121265651,1,I,20150523.0,20160217.0,20160229,20160229,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-014208,BRISTOL MYERS SQUIBB,,28.0,YR,,M,Y,62.0,KG,20160229.0,,CN,CN,CN,EFAVIRENZ,Delirium,121265651.0,OT,,,121265651.0,1.0,20150514.0,20150524.0,,,121265651.0,1.0,Acquired immunodeficiency syndrome
12127847,121278471,1,I,,20160217.0,20160229,20160229,EXP,,FR-GILEAD-2016-0199656,GILEAD,LORTHOLARY O ET AL. TENOFOVIR DF/EMTRICITABINE AND EFAVIRENZ COMBINATION THERAPY FOR HIV INFECTION IN PATIENTS TREATED FOR TUBERCULOSIS: THE ANRS 129 BKVIR TRIAL.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016?71(3):783-93,,,A,,Y,,,20160229.0,,MD,FR,FR,EFAVIRENZ,Bronchial obstruction;Immune reconstitution inflammatory syndrome,121278471.0,OT,,,,,,,,,121278471.0,1.0,HIV infection
12127891,121278911,1,I,,20160217.0,20160229,20160229,EXP,,FR-GILEAD-2016-0199655,GILEAD,LORTHOLARY O ET AL. TENOFOVIR DF/EMTRICITABINE AND EFAVIRENZ COMBINATION THERAPY FOR HIV INFECTION IN PATIENTS TREATED FOR TUBERCULOSIS: THE ANRS 129 BKVIR TRIAL.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016?71(3):783-93,,,A,,Y,,,20160229.0,,MD,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoma of central nervous system,121278911.0,OT,,,,,,,,,121278911.0,1.0,HIV infection
12127906,121279061,1,I,,20160217.0,20160229,20160229,EXP,,FR-GILEAD-2016-0199654,GILEAD,LORTHOLARY O ET AL. TENOFOVIR DF/EMTRICITABINE AND EFAVIRENZ COMBINATION THERAPY FOR HIV INFECTION IN PATIENTS TREATED FOR TUBERCULOSIS: THE ANRS 129 BKVIR TRIAL.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016?71(3):783-93,,,A,,Y,,,20160229.0,,MD,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoma of central nervous system,121279061.0,OT,,,,,,,,,121279061.0,1.0,HIV infection
12140970,121409702,2,F,20040125.0,20171107.0,20160303,20171115,EXP,,FR-009507513-2004-113821-NL,MERCK,,19.0,YR,,F,Y,53.0,KG,20171115.0,,CN,US,FR,SUSTIVA,Abortion induced;Drug interaction;Pregnancy;Pregnancy on contraceptive;Therapeutic response decreased,121409702.0,OT,,,121409702.0,1.0,20031215.0,20040322.0,,,121409702.0,1.0,HIV infection
12144135,121441351,1,I,,20160202.0,20160304,20160304,EXP,,GB-HETERO LABS LTD-1048675,HETERO,,,,,F,Y,,,20160304.0,,OT,GB,GB,Efavirenz,Drug resistance;Off label use;Virologic failure,121441351.0,OT,,,121441351.0,1.0,201111.0,,,,121441351.0,1.0,HIV infection
12145960,121459602,2,F,20130123.0,20170609.0,20160304,20170616,EXP,,FR-VIIV HEALTHCARE LIMITED-B0871259A,VIIV,,44.0,YR,,M,Y,57.0,KG,20170616.0,,MD,FR,FR,SUSTIVA,Acute coronary syndrome;Hypovolaemia,121459602.0,HO,,,121459602.0,1.0,20121002.0,,,,121459602.0,1.0,HIV infection
12154055,121540552,2,F,,20160317.0,20160307,20160325,EXP,,ES-CIPLA LTD.-2016ES01677,CIPLA,"PALACIOS R, PEREZ-HERNANDEZ IA, MARTINEZ MA, MAYORGA ML, GONZALEZ-DOMENECH CM, OMAR M, ET AL.,. EFFICACY AND SAFETY OF SWITCHING TO ABACAVIR/LAMIVUDINE (ABC/3TC) PLUS RILPIVIRINE (RPV) IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS ON HAART. EUR J CLIN MICROBIOL INFECT DIS. 2016",,,,,Y,,,20160325.0,,OT,ES,ES,Efavirenz,Virologic failure,121540552.0,OT,,,,,,,,,121540552.0,1.0,HIV infection
12154312,121543121,1,I,,20160223.0,20160307,20160307,EXP,,HT-HETERO LABS LTD-1048743,HETERO,,30.0,YR,,F,Y,,,20160307.0,,OT,HT,HT,Efavirenz,Anaemia;Exposure during pregnancy;Stillbirth;Tuberculosis,121543121.0,HO,,,121543121.0,1.0,20140923.0,,,,121543121.0,1.0,HIV infection
12156520,121565201,1,I,20140625.0,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009686,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,EFAVIRENZ MYLAN,Alanine aminotransferase increased;Blood creatine increased;CD4 lymphocytes decreased;Haemoglobin decreased;Ocular icterus;Vomiting,121565201.0,HO,,,121565201.0,1.0,20070705.0,,,,121565201.0,1.0,Antiretroviral therapy
12156702,121567021,1,I,20150722.0,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009701,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,EFAVIRENZ MYLAN 600 MG COMPRIM?S PELLICUL?S,Abdominal pain;Confusional state;Decreased appetite;Hallucination;Insomnia;Nausea;Psychotic disorder;Pyrexia;Vomiting,121567021.0,OT,,,121567021.0,1.0,20150713.0,20150727.0,,,121567021.0,1.0,Antiretroviral therapy
12156703,121567031,1,I,20140410.0,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009706,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,EFAVIRENZ MYLAN 600 MG COMPRIM?S PELLICUL?S,Anaemia;Blood creatine increased;Dizziness;Dyspnoea;Viral load,121567031.0,OT,,,121567031.0,1.0,20080730.0,20131230.0,,,121567031.0,1.0,Antiretroviral therapy
12157583,121575831,1,I,,20160224.0,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01867,CIPLA,"PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L, PATEL F ET AL.,. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308.0,,OT,US,ZA,Efavirenz,Abdominal pain upper;Ataxia;Cogwheel rigidity;Dysarthria;Gait disturbance;Hypotonia;Intention tremor;Nervous system disorder;Urinary tract infection;Vomiting,121575831.0,HO,,,,,,,,,121575831.0,1.0,Perinatal HIV infection
12157589,121575891,1,I,,20160224.0,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01865,CIPLA,"ABRAMS E, PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L ET AL.,. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308.0,,OT,US,ZA,Efavirenz,Aggression;Conjunctivitis allergic;Drug level increased;Generalised tonic-clonic seizure;Pyrexia,121575891.0,OT,,,,,,,,,121575891.0,1.0,Perinatal HIV infection
12157591,121575911,1,I,,20160224.0,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01862,CIPLA,"ABRAMS E, PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L, ET AL.,. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308.0,,OT,US,ZA,Efavirenz,Abnormal behaviour;Drug level increased;Petit mal epilepsy,121575911.0,OT,,,,,,,,,121575911.0,1.0,HIV infection
12157605,121576051,1,I,,20160224.0,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01861,CIPLA,"ABRAMS E, PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L ET AL. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308.0,,OT,US,ZA,Efavirenz,Drug level increased;Encephalitis;Generalised tonic-clonic seizure;Meningism;Pulmonary tuberculosis;Tonsillitis,121576051.0,HO,,,,,,,,,121576051.0,1.0,Perinatal HIV infection
12160761,121607615,5,F,201602.0,20160611.0,20160308,20160616,EXP,,BR-GILEAD-2016-0201948,GILEAD,,49.0,YR,A,M,Y,68.0,KG,20160616.0,,OT,BR,BR,EFAVIRENZ,Hepatic failure;Multiple organ dysfunction syndrome,121607615.0,DE,,,121607615.0,1.0,20151017.0,20160219.0,,,121607615.0,1.0,HIV infection
12161166,121611667,7,F,,20220929.0,20160308,20240418,EXP,,CA-ABBVIE-10P-163-0641882-00,ABBVIE,"Pfeffer G, Cote H, Montaner J, et al. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving hiv therapy. Neurology. 2009;73:71-72.",52.0,YR,,M,Y,,,20240418.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,121611667.0,OT,,,121611667.0,1.0,,200802.0,8.0,YR,121611667.0,1.0,HIV infection
12166837,121668371,1,I,,20160229.0,20160310,20160310,EXP,,CN-CIPLA LTD.-2016CN02081,CIPLA,"LU H, XIAO H, XUE Y, GU S, WANG J, SUN H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCIENCE TRENDS. 2016?P1 TO P5",,,,,Y,,,20160310.0,,OT,CN,CN,Efavirenz,Anaemia;Drug resistance;Haemorrhage;Nightmare;Virologic failure,121668371.0,OT,,,,,,,,,121668371.0,1.0,HIV infection
12166849,121668491,1,I,,20160229.0,20160310,20160310,EXP,,CN-CIPLA LTD.-2016CN02083,CIPLA,"LU H, XIAO H, XUE Y, GU S, WANG J, SUN H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCIENCE TRENDS. 2016?P1 TO P5",,,,,Y,,,20160310.0,,OT,CN,CN,Efavirenz,Depression;Drug resistance;Haemorrhage;Hypoaesthesia;Insomnia;Virologic failure,121668491.0,OT,,,,,,,,,121668491.0,1.0,HIV infection
12166871,121668711,1,I,,20160229.0,20160310,20160310,EXP,,CN-CIPLA LTD.-2016CN02086,CIPLA,"LU H, XIAO H, XUE Y, GU S, WANG J, SUN H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCIENCE TRENDS. 2016?1 TO 5",,,,,Y,,,20160310.0,,OT,CN,CN,Efavirenz,Osteoporosis,121668711.0,OT,,,,,,,,,121668711.0,1.0,Antiretroviral therapy
12166886,121668861,1,I,,20160229.0,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02082,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310.0,,OT,ES,ES,Efavirenz,Hyperbilirubinaemia,121668861.0,OT,,,,,,,,,121668861.0,1.0,HIV infection
12166892,121668921,1,I,,20160229.0,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02084,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310.0,,OT,ES,ES,Efavirenz,Toxicity to various agents,121668921.0,OT,,,,,,,,,121668921.0,1.0,HIV infection
12166893,121668931,1,I,,20160229.0,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02112,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310.0,,OT,ES,ES,Efavirenz,Death,121668931.0,DE,,,,,,,,,121668931.0,1.0,HIV infection
12167073,121670731,1,I,,20160229.0,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02123,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310.0,,OT,ES,ES,Efavirenz,Hypophosphataemia,121670731.0,OT,,,,,,,,,121670731.0,1.0,HIV infection
12167078,121670781,1,I,,20160229.0,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02119,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310.0,,OT,ES,ES,Efavirenz,Osteoporosis,121670781.0,OT,,,,,,,,,121670781.0,1.0,HIV infection
12167082,121670821,1,I,,20160229.0,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02118,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310.0,,OT,ES,ES,Efavirenz,Nephrolithiasis,121670821.0,OT,,,,,,,,,121670821.0,1.0,HIV infection
12167116,121671161,1,I,,20160229.0,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02125,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310.0,,OT,ES,ES,Efavirenz,Thrombocytopenia,121671161.0,OT,,,,,,,,,121671161.0,1.0,HIV infection
12169701,121697011,1,I,20150526.0,20160302.0,20160310,20160310,EXP,,GB-GILEAD-2016-0202208,GILEAD,,74.0,YR,E,M,Y,112.0,KG,20160310.0,,MD,GB,GB,EFAVIRENZ,Chest pain;Palpitations,121697011.0,HO,,,121697011.0,1.0,20120410.0,,,,121697011.0,1.0,HIV infection
12170478,121704782,2,F,,20160510.0,20160311,20160511,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-016764,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160511.0,,OT,TH,TH,EFAVIRENZ,Drug interaction;Ergot poisoning;Off label use,121704782.0,OT,,,,,,,,,121704782.0,1.0,HIV infection
12170481,121704811,1,I,,20160229.0,20160311,20160311,EXP,,US-CIPLA LTD.-2016US02145,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160311.0,,OT,US,US,Efavirenz,Blood creatine phosphokinase abnormal,121704811.0,OT,,,,,,,,,121704811.0,1.0,HIV infection
12170488,121704881,1,I,,20160229.0,20160311,20160311,EXP,,US-CIPLA LTD.-2016US02135,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL O F MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160311.0,,MD,US,US,Efavirenz,Glycosuria;Renal impairment,121704881.0,OT,,,,,,,,,121704881.0,1.0,HIV infection
12170559,121705591,1,I,,20160229.0,20160311,20160311,EXP,,US-CIPLA LTD.-2016US02157,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160311.0,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121705591.0,OT,,,,,,,,,121705591.0,1.0,HIV infection
12171229,121712292,2,F,,20160715.0,20160311,20160715,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-016765,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160715.0,,OT,COUNTRY NOT SPECIFIED,TH,EFAVIRENZ,Hypotension;Labelled drug-drug interaction medication error;Peripheral ischaemia,121712292.0,OT,,,,,,,,,121712292.0,1.0,HIV infection
12174409,121744091,1,I,,20160229.0,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02137,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL O F MEDICINE. 2015?373(8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Haemoglobin abnormal,121744091.0,OT,,,,,,,,,121744091.0,1.0,HIV infection
12174424,121744241,1,I,,20160229.0,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02155,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Infection;Treatment noncompliance;Virologic failure,121744241.0,OT,,,,,,,,,121744241.0,1.0,HIV infection
12174433,121744331,1,I,,20160229.0,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02156,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121744331.0,OT,,,,,,,,,121744331.0,1.0,HIV infection
12174438,121744381,1,I,,20160229.0,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02178,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373(8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Rhabdomyolysis,121744381.0,OT,,,,,,,,,121744381.0,1.0,HIV infection
12174447,121744471,1,I,,20160229.0,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02166,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121744471.0,OT,,,,,,,,,121744471.0,1.0,HIV infection
12174448,121744481,1,I,,20160229.0,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02169,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Disease recurrence;Virologic failure,121744481.0,OT,,,,,,,,,121744481.0,1.0,HIV infection
12174449,121744491,1,I,,20160229.0,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02171,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313.0,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121744491.0,OT,,,,,,,,,121744491.0,1.0,HIV infection
12177888,121778883,3,F,,20160722.0,20160314,20160722,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-018229,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20160722.0,,OT,JP,JP,EFAVIRENZ,Lactic acidosis,121778883.0,OT,,,,,,,,,121778883.0,1.0,HIV infection
12181720,121817201,1,I,,20160307.0,20160315,20160315,EXP,,IN-GILEAD-2016-0203057,GILEAD,"PAIK S, PAL A, SEN S, PRAMANICK N, TRIPHATHI SK. A SUSPECTED CASE OF EFAVIRENZ-INDUCED STEVENS-JOHNSON SYNDROME.. DRUG SAFETY-CASE REPORTS.. 2015?2 (1):PP 1-5",23.0,YR,A,F,Y,,,20160315.0,,OT,IN,IN,EFAVIRENZ,Stevens-Johnson syndrome,121817201.0,OT,,,,,,,,,121817201.0,1.0,HIV infection
12183825,121838251,1,I,,20160303.0,20160316,20160316,EXP,,IT-CIPLA LTD.-2016IT02397,CIPLA,"CALCAGNO A, MONTRUCCHIO C, CAPETTI A, GUARALDI G, CENDERELLO G, CALZA L ET AL.,. RALTEGRAVIR PLUS NEVIRAPINE AS MAINTENANCE ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS: SAFETY, EFFICACY AND PHARMACOKINETICS. CURRENT HIV RESEARCH. 2016?14 (1):54 TO 60",,,,,Y,,,20160316.0,,OT,IT,IT,Efavirenz,Chronic kidney disease,121838251.0,OT,,,,,,,,,121838251.0,1.0,HIV infection
12183908,121839081,1,I,,20160303.0,20160316,20160316,EXP,,IT-CIPLA LTD.-2016IT02400,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160316.0,,OT,IT,BI,Efavirenz,Treatment noncompliance;Viral load increased,121839081.0,OT,,,,,,,,,121839081.0,1.0,Antiretroviral therapy
12185376,121853761,1,I,,20160309.0,20160316,20160316,EXP,,BR-MYLANLABS-2016M1011056,MYLAN,"GOIS L, BADARO R, SCHOOLEY R, GRASSI MF. IMMUNE RESPONSE TO LEISHMANIA ANTIGENS IN AN AIDS PATIENT WITH MUCOCUTANEOUS LEISHMANIASIS AS A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS): A CASE REPORT. BMC-INFECT-DIS 2015?15(38):38.",,,,,Y,,,20160316.0,,OT,BR,BR,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Mucocutaneous leishmaniasis,121853761.0,HO,,,,,,,,,121853761.0,1.0,HIV infection
12186136,121861361,1,I,,20160303.0,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02399,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160317.0,,OT,IT,BI,Efavirenz,Drug level decreased;Treatment noncompliance,121861361.0,OT,,,,,,,,,121861361.0,1.0,Antiretroviral therapy
12186142,121861421,1,I,,20160303.0,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02402,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160317.0,,OT,IT,BI,Efavirenz,Virologic failure,121861421.0,OT,,,,,,,,,121861421.0,1.0,Antiretroviral therapy
12186153,121861531,1,I,,20160303.0,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02420,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160317.0,,OT,IT,BI,Efavirenz,Drug resistance;Virologic failure,121861531.0,OT,,,,,,,,,121861531.0,1.0,Antiretroviral therapy
12186169,121861691,1,I,,20160303.0,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02422,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2016?79 (5):801 TO 808",,,,,Y,,,20160317.0,,OT,IT,BI,Efavirenz,Drug resistance;Virologic failure,121861691.0,OT,,,,,,,,,121861691.0,1.0,HIV infection CDC category A
12187169,121871691,1,I,20140902.0,20141008.0,20160317,20160317,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2014008741,VIIV,,,,,,Y,,,20160317.0,,MD,UG,UG,Efavirenz,Bladder outlet obstruction;Glomerulonephritis,121871691.0,HO,,,121871691.0,1.0,20140811.0,20140909.0,,,121871691.0,1.0,HIV infection
12188132,121881321,1,I,,20160314.0,20160317,20160317,EXP,,RU-GLAXOSMITHKLINE-RU2016GSK037432,GLAXOSMITHKLINE,,,,,M,Y,,,20160317.0,,CN,RU,RU,STOCRIN (EFAVIRENZ),Abnormal faeces;Autonomic nervous system imbalance;Back pain;Biliary dyskinesia;Chromaturia;Constipation;Daydreaming;Dizziness;Fatigue;Flatulence;Influenza like illness;Irritability;Irritable bowel syndrome;Nausea;Oral disorder;Poisoning,121881321.0,OT,,,,,,,,,121881321.0,1.0,HIV infection
12190823,121908231,1,I,,20160314.0,20160318,20160318,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2016GSK037432,VIIV,,,,,M,Y,,,20160318.0,,CN,RU,RU,STOCRIN (EFAVIRENZ),Abnormal faeces;Autonomic nervous system imbalance;Back pain;Biliary dyskinesia;Chromaturia;Constipation;Daydreaming;Dizziness;Fatigue;Flatulence;Influenza like illness;Irritability;Irritable bowel syndrome;Nausea;Oral disorder;Poisoning,121908231.0,OT,,,,,,,,,121908231.0,1.0,HIV infection
12195166,121951661,1,I,,20160310.0,20160321,20160321,EXP,,CH-CIPLA LTD.-2016CH02709,CIPLA,"GUNTHARD HF, YANG WL, KOUYOS RD, SCHERRER AU, BONI J, SHAH C, ET AL.,. ASSESSING EFFICACY OF DIFFERENT NUCLEOS(T)IDE BACKBONES IN NNRTI-CONTAINING REGIMENS IN THE SWISS HIV COHORT STUDY. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?70:3323 TO 3331",,,,,Y,,,20160321.0,,OT,CH,CH,Efavirenz,Virologic failure,121951661.0,OT,,,,,,,,,121951661.0,1.0,HIV infection
12196779,121967792,2,F,20160113.0,20160321.0,20160321,20160325,EXP,,UG-GILEAD-2016-0197688,GILEAD,,56.0,YR,A,F,Y,55.0,KG,20160325.0,,MD,UG,UG,EFAVIRENZ,Cystocele;Urinary tract infection,121967792.0,HO,,,121967792.0,1.0,20121115.0,,,,121967792.0,1.0,HIV infection
12203023,122030233,3,F,,20160715.0,20160323,20160725,EXP,,US-009507513-1603USA008975,MERCK,,58.0,YR,,F,Y,,,20160725.0,,CN,US,US,EFAVIRENZ,Drug ineffective,122030233.0,OT,,,,,,,,,122030233.0,1.0,HIV infection
12209859,122098592,2,F,20131001.0,20220826.0,20160325,20220908,EXP,,US-CIPLA LTD.-2016US02822,CIPLA,"Mikula JM, Manion MM, Maldarelli F, Suarez LM, Norman-Wheeler JF, Ober AG, et al.. Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy. Antiviral Therapy. 2016;1 to 10",54.0,YR,,M,Y,,,20220908.0,,HP,US,US,EFAVIRENZ,Acute kidney injury;Drug resistance;Treatment failure,122098592.0,OT,,,122098592.0,1.0,2013.0,2014.0,,,122098592.0,1.0,HIV infection
12209958,122099581,1,I,,20160315.0,20160325,20160325,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-021595,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160325.0,,CN,US,US,SUSTIVA,Death,122099581.0,OT,,,,,,,,,122099581.0,1.0,Acquired immunodeficiency syndrome
12211624,122116242,2,F,,20160715.0,20160325,20160715,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-022907,BRISTOL MYERS SQUIBB,,58.0,YR,,F,Y,,,20160715.0,,OT,US,US,EFAVIRENZ,Drug ineffective,122116242.0,OT,,,,,,,,,122116242.0,1.0,HIV infection
12212729,122127291,1,I,,20160317.0,20160328,20160328,EXP,,ES-CIPLA LTD.-2016ES03023,CIPLA,"PALACIOS R, PEREZ-HERNANDEZ IA, MARTINEZ MA, MAYORGA ML, GONZALEZ-DOMENECH CM, OMAR M, ET AL.,. EFFICACY AND SAFETY OF SWITCHING TO ABACAVIR/LAMIVUDINE (ABC/3TC) PLUS RILPIVIRINE (RPV) IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS ON HAART. EUR J CLIN MICROBIOL INFECT DIS. 2016",,,,,Y,,,20160328.0,,OT,ES,ES,Efavirenz,Nephropathy toxic,122127291.0,OT,,,,,,,,,122127291.0,1.0,HIV infection
12213462,122134621,1,I,,20160314.0,20160328,20160328,EXP,,BR-LUPIN PHARMACEUTICALS INC.-2016-01124,LUPIN,"RIOS GRASSI M, GOIS L, BADARO R, SCHOOLEY R. IMMUNE RESPONSE TO LEISHMANIA ANTIGENS IN AN AIDS PATIENT WITH MUCOCUTANEOUS LEISHMANIASIS AS A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS): A CASE REPORT. BMC INFECTIOUS DISEASES. 2015?15 (38):1-7.",29.0,YR,,M,Y,,,20160328.0,,OT,BR,BR,Efavirenz,Immune reconstitution inflammatory syndrome;Mucocutaneous leishmaniasis,122134621.0,OT,,,,,,,,,122134621.0,1.0,HIV infection
12233400,122334001,1,I,20100218.0,20160322.0,20160404,20160404,EXP,,UA-CIPLA LTD.-2016UA03161,CIPLA,,,,,,Y,,,20160404.0,,,UA,UA,Efavirenz,Anaemia;Asthenia;Lactic acidosis;Leukopenia;Pallor;Renal failure,122334001.0,LT,,,122334001.0,1.0,20100210.0,,,,122334001.0,1.0,HIV infection
12233409,122334091,1,I,20111017.0,20160322.0,20160404,20160404,EXP,,UA-CIPLA LTD.-2016UA03167,CIPLA,,,,,,Y,,,20160404.0,,,UA,UA,Efavirenz,Renal failure,122334091.0,LT,,,122334091.0,1.0,20101104.0,,,,122334091.0,1.0,HIV infection
12234046,122340461,1,I,20090723.0,20160322.0,20160404,20160404,EXP,,UA-CIPLA LTD.-2016UA03212,CIPLA,,,,,,Y,,,20160404.0,,,UA,UA,Efavirenz,Anaemia,122340461.0,DS,,,122340461.0,1.0,20090328.0,,,,122340461.0,1.0,HIV infection
12236810,122368101,1,I,20100120.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03173,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia,122368101.0,DS,,,122368101.0,1.0,20091212.0,,,,122368101.0,1.0,Antiretroviral therapy
12236814,122368141,1,I,20091016.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03191,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Asthenia;Dyspnoea,122368141.0,DS,,,122368141.0,1.0,20090701.0,,,,122368141.0,1.0,HIV infection
12236815,122368151,1,I,20090909.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03197,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Leukopenia,122368151.0,DS,,,122368151.0,1.0,20090328.0,,,,122368151.0,1.0,HIV infection
12236816,122368161,1,I,20091001.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03190,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Asthenia;Dyspnoea,122368161.0,DS,,,122368161.0,1.0,20090120.0,,,,122368161.0,1.0,HIV infection
12236829,122368291,1,I,20100121.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03179,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia,122368291.0,HO,,,122368291.0,1.0,20080605.0,,,,122368291.0,1.0,HIV infection
12236831,122368311,1,I,20100120.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03168,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia,122368311.0,HO,,,122368311.0,1.0,20091119.0,,,,122368311.0,1.0,HIV infection
12236847,122368471,1,I,20090101.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03210,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Aggression;Mood swings;Pruritus;Sleep disorder;Tearfulness,122368471.0,OT,,,122368471.0,1.0,20081020.0,,,,122368471.0,1.0,HIV infection
12236848,122368481,1,I,20090714.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03215,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Dizziness;Headache;Lethargy;Somnolence,122368481.0,DS,,,122368481.0,1.0,20070116.0,,,,122368481.0,1.0,HIV infection
12236851,122368511,1,I,20081229.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03203,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Dizziness;Gait disturbance;Insomnia,122368511.0,DS,,,122368511.0,1.0,20060412.0,,,,122368511.0,1.0,HIV infection
12236854,122368541,1,I,20081208.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03206,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Coordination abnormal;Disturbance in attention;Dizziness;Memory impairment;Tremor,122368541.0,HO,,,122368541.0,1.0,20081206.0,,,,122368541.0,1.0,Antiretroviral therapy
12236856,122368561,1,I,20090223.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03207,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Dizziness;Somnolence;Yawning,122368561.0,HO,,,122368561.0,1.0,20081206.0,,,,122368561.0,1.0,HIV infection
12236875,122368751,1,I,20090815.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03219,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia;Asthenia;Decreased appetite;Dizziness;Nausea;Tachycardia,122368751.0,DS,,,122368751.0,1.0,20090806.0,,,,122368751.0,1.0,HIV infection
12236953,122369531,1,I,20120329.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03252,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia,122369531.0,HO,,,122369531.0,1.0,20111223.0,,,,122369531.0,1.0,HIV infection
12237035,122370351,1,I,20090806.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03222,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia;Asthenia;Decreased appetite;Dizziness;Nausea;Tachycardia,122370351.0,HO,,,122370351.0,1.0,20090806.0,,,,122370351.0,1.0,HIV infection
12237089,122370891,1,I,20090413.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03242,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia,122370891.0,HO,,,122370891.0,1.0,20090114.0,,,,122370891.0,1.0,HIV infection
12237092,122370921,1,I,20090803.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03230,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia,122370921.0,HO,,,122370921.0,1.0,20090608.0,,,,122370921.0,1.0,HIV infection
12237098,122370981,1,I,20090617.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03235,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia;Leukopenia;Neutropenia,122370981.0,LT,,,122370981.0,1.0,20080521.0,,,,122370981.0,1.0,HIV infection
12237108,122371081,1,I,20090217.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03244,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia,122371081.0,HO,,,122371081.0,1.0,20081017.0,,,,122371081.0,1.0,HIV infection CDC Group IV subgroup E
12237148,122371481,1,I,20090624.0,20160322.0,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03251,CIPLA,,,,,,Y,,,20160405.0,,,UA,UA,Efavirenz,Anaemia;Asthenia;Dizziness;Leukopenia,122371481.0,LT,,,122371481.0,1.0,20090527.0,,,,122371481.0,1.0,HIV infection
12240693,122406932,2,F,,20160422.0,20160406,20160426,EXP,,US-009507513-1603USA013451,MERCK,,,,,M,Y,,,20160426.0,,PH,US,US,SUSTIVA,Cardiac disorder,122406932.0,HO,,,,,,,,,122406932.0,1.0,HIV infection
12246986,122469861,1,I,20150527.0,20150601.0,20160407,20160407,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038163,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,64.0,KG,20160407.0,,OT,RO,RO,BLINDED EFAVIRENZ,Hepatitis C;Hepatitis toxic,122469861.0,HO,,,122469861.0,1.0,20140403.0,20150530.0,,,122469861.0,1.0,HIV infection
12248775,122487751,1,I,20151019.0,20160401.0,20160408,20160408,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026515,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,47.0,KG,20160408.0,,CN,CN,CN,EFAVIRENZ,Hepatic function abnormal,122487751.0,LT,,,122487751.0,1.0,20150513.0,20151110.0,,,122487751.0,1.0,Acquired immunodeficiency syndrome
12249622,122496221,1,I,20150715.0,20160401.0,20160408,20160408,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026563,BRISTOL MYERS SQUIBB,,26.0,YR,,M,Y,,,20160408.0,,CN,CN,CN,EFAVIRENZ,Lung infection,122496221.0,HO,,,122496221.0,1.0,20150428.0,20150728.0,,,122496221.0,1.0,Acquired immunodeficiency syndrome
12251998,122519981,1,I,,20160328.0,20160411,20160411,EXP,,US-CIPLA LTD.-2016ZA03391,CIPLA,"HOFFMANN CJ, FIELDING KL, CHARALAMBOUS S, SULKOWSKI MS, INNES C, THIO CL ET AL.,. ANTIRETROVIRAL THERAPY USING ZIDOVUDINE, LAMIVUDINE, AND EFAVIRENZ IN SOUTH AFRICA: TOLERABILITY AND CLINICAL EVENTS. AIDS. 2008;22 (1):67 TO 74",,,,,Y,,,20160411.0,,OT,US,ZA,Efavirenz,Adverse event;Death,122519981.0,OT,,,,,,,,,122519981.0,1.0,Antiretroviral therapy
12252035,122520351,1,I,,20160328.0,20160411,20160411,EXP,,US-CIPLA LTD.-2016ZA03392,CIPLA,"HOFFMANN CJ, FIELDING KL, CHARALAMBOUS S, SULKOWSKI MS, INNES C, THIO CL ET AL.,. ANTIRETROVIRAL THERAPY USING ZIDOVUDINE, LAMIVUDINE, AND EFAVIRENZ IN SOUTH AFRICA: TOLERABILITY AND CLINICAL EVENTS. AIDS. 2008;22 (1):67 TO 74",,,,,Y,,,20160411.0,,OT,US,ZA,Efavirenz,Neutropenia;Pneumonia,122520351.0,OT,,,,,,,,,122520351.0,1.0,Antiretroviral therapy
12252042,122520421,1,I,,20160328.0,20160411,20160411,EXP,,US-CIPLA LTD.-2016ZA03427,CIPLA,"HOFFMANN CJ, FIELDING KL, CHARALAMBOUS S, SULKOWSKI MS, INNES C, THIO CL ET AL.,. ANTIRETROVIRAL THERAPY USING ZIDOVUDINE, LAMIVUDINE, AND EFAVIRENZ IN SOUTH AFRICA: TOLERABILITY AND CLINICAL EVENTS. AIDS. 2008;22 (1):67 TO 74",,,,,Y,,,20160411.0,,OT,US,ZA,Efavirenz,Extrapulmonary tuberculosis;HIV infection;Neutropenia,122520421.0,DE,,,,,,,,,122520421.0,1.0,Antiretroviral therapy
12252299,122522991,1,I,20151022.0,20160401.0,20160411,20160411,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026647,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,76.0,KG,20160411.0,,CN,CN,CN,EFAVIRENZ,Neurotoxicity,122522991.0,OT,,,122522991.0,1.0,20120101.0,20151022.0,,,122522991.0,1.0,HIV infection
12252364,122523641,1,I,20151123.0,20160401.0,20160411,20160411,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026519,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,62.0,KG,20160411.0,,CN,CN,CN,EFAVIRENZ,Dermatitis,122523641.0,HO,,,122523641.0,1.0,20151014.0,20151123.0,,,122523641.0,1.0,Acquired immunodeficiency syndrome
12253502,122535022,2,F,,20160405.0,20160411,20170620,EXP,,US-GILEAD-2016-0207534,GILEAD,,,,,F,Y,,,20170620.0,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy,,,,,122535022.0,1.0,20160202.0,20160201.0,,,122535022.0,1.0,HIV infection
12256592,122565922,2,F,,20170621.0,20160412,20170621,EXP,,US-VIIV HEALTHCARE LIMITED-US2016048464,VIIV,,,,,F,Y,,,20170621.0,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy,,,,,122565922.0,1.0,20160202.0,20160201.0,,,122565922.0,1.0,HIV infection
12256882,122568822,2,F,,20170621.0,20160412,20170621,EXP,,US-GLAXOSMITHKLINE-US2016048464,GLAXOSMITHKLINE,,,,,F,Y,,,20170621.0,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy,,,,,122568822.0,1.0,20160202.0,20160201.0,,,122568822.0,1.0,HIV infection
12262224,122622241,1,I,20151106.0,20160401.0,20160413,20160413,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026669,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,60.0,KG,20160413.0,,CN,CN,CN,EFAVIRENZ,Fall;Tibia fracture,122622241.0,HO,,,122622241.0,1.0,20151010.0,20151123.0,,,122622241.0,1.0,HIV infection
12262651,122626511,1,I,20151202.0,20160401.0,20160413,20160413,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026673,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,57.0,KG,20160413.0,,CN,CN,CN,EFAVIRENZ,Hepatic function abnormal,122626511.0,LT,,,122626511.0,1.0,20151102.0,20151203.0,,,122626511.0,1.0,HIV infection
12269160,122691601,1,I,20061107.0,20160126.0,20160414,20160414,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-006624,BRISTOL MYERS SQUIBB,,5.0,YR,,M,Y,14.0,KG,20160414.0,,OT,TH,TH,EFAVIRENZ,Hepatitis;Hypoglycaemia;Virologic failure,122691601.0,HO,,,122691601.0,4.0,20060417.0,20061108.0,,,122691601.0,1.0,HIV infection
12272300,122723001,1,I,20151207.0,20160401.0,20160415,20160415,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026657,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,59.0,KG,20160415.0,,CN,CN,CN,EFAVIRENZ,Dermatitis allergic,122723001.0,OT,,,122723001.0,1.0,20151201.0,20151211.0,,,122723001.0,1.0,HIV infection
12282756,122827562,2,F,20150910.0,20160506.0,20160419,20160511,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-029139,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,46.5,KG,20160511.0,,CN,CN,CN,EFAVIRENZ,Liver injury,122827562.0,OT,,,122827562.0,1.0,20150501.0,20150910.0,,,122827562.0,1.0,Acquired immunodeficiency syndrome
12283997,122839972,2,F,20160115.0,20160511.0,20160419,20160520,EXP,,US-GILEAD-2016-0203642,GILEAD,,65.0,YR,E,M,Y,,,20160520.0,,MD,US,US,SUSTIVA,Acute kidney injury;Drug interaction;Rhabdomyolysis,122839972.0,OT,,,122839972.0,1.0,201601.0,201601.0,,,122839972.0,1.0,HIV infection
12285015,122850152,2,F,20060712.0,20160427.0,20160420,20160503,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14230114,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,,,20160503.0,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Oesophageal varices haemorrhage,122850152.0,DE,,,122850152.0,1.0,20040629.0,20110401.0,,,122850152.0,1.0,HIV infection
12285931,122859312,2,F,,20220321.0,20160420,20220331,EXP,,GB-009507513-1505GBR001885,MERCK,"Bulman J. An uncommon cause of anaemia in pregnancy: A case report of emtricitabine-induced pure red cell aplasia. HIV Medicine. 2015;16, Sup2:30-1",39.0,YR,,F,Y,,,20220331.0,,HP,GB,GB,EFAVIRENZ,Aplasia pure red cell;Maternal exposure during pregnancy;Off label use,122859312.0,OT,,,,,,,,,122859312.0,1.0,HIV infection
12286803,122868031,1,I,,20160408.0,20160420,20160420,EXP,,"ZA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-23565BI",BOEHRINGER INGELHEIM,"DENTI P,MARTINSON N,COHN S,MASHABELA F,HOFFMANN J,MSANDIWA R,ET AL. POPULATION PHARMACOKINETICS OF RIFAMPIN IN PREGNANT WOMEN WITH TUBERCULOSIS AND HIV COINFECTION IN SOWETO, SOUTH AFRICA. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2016;60:3:1234-1241.",,,,F,Y,,,20160420.0,,OT,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Haemorrhage in pregnancy,122868031.0,OT,,,,,,,,,122868031.0,1.0,HIV infection
12308409,123084091,1,I,,20160419.0,20160426,20160426,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-031023,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160426.0,,CN,US,US,SUSTIVA,Death,123084091.0,OT,,,123084091.0,1.0,20150513.0,,,,123084091.0,1.0,HIV infection
12338207,123382072,2,F,,20160505.0,20160505,20160513,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-031517,BRISTOL MYERS SQUIBB,,65.0,YR,,M,Y,,,20160513.0,,OT,US,US,EFAVIRENZ,Calculus urinary,123382072.0,OT,,,,,,,,,123382072.0,1.0,HIV infection
12340054,123400541,1,I,,20160421.0,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04480,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506.0,,OT,US,MW,Efavirenz,Neuropathy peripheral,123400541.0,OT,,,,,,,,,123400541.0,1.0,HIV infection
12340110,123401101,1,I,,20160421.0,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04483,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506.0,,OT,US,MW,Efavirenz,Meningitis bacterial,123401101.0,DE,,,,,,,,,123401101.0,1.0,HIV infection
12340116,123401161,1,I,,20160421.0,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04481,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506.0,,OT,US,MW,Efavirenz,Death,123401161.0,DE,,,,,,,,,123401161.0,1.0,HIV infection
12340122,123401221,1,I,,20160421.0,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04484,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506.0,,OT,US,MW,Efavirenz,Malnutrition,123401221.0,DE,,,,,,,,,123401221.0,1.0,HIV infection
12340134,123401341,1,I,,20160421.0,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04482,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM, ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506.0,,OT,US,MW,Efavirenz,Sepsis,123401341.0,DE,,,,,,,,,123401341.0,1.0,HIV infection
12343536,123435361,1,I,2016.0,20160414.0,20160506,20160506,EXP,,FR-GLAXOSMITHKLINE-FR2016GSK050765,GLAXOSMITHKLINE,,,,,M,Y,92.0,KG,20160506.0,,CN,FR,FR,SUSTIVA,Anxiety;Arrhythmia;Chest discomfort;Chest pain;Cough;Dyspnoea;Respiratory disorder;Sleep disorder,123435361.0,OT,,,123435361.0,1.0,2014.0,,,,123435361.0,1.0,HIV infection
12347853,123478531,1,I,2016.0,20160414.0,20160509,20160509,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2016GSK050765,VIIV,,,,,M,Y,92.0,KG,20160509.0,,CN,FR,FR,SUSTIVA,Anxiety;Arrhythmia;Chest discomfort;Chest pain;Cough;Dyspnoea;Respiratory disorder;Sleep disorder,123478531.0,OT,,,123478531.0,1.0,2014.0,,,,123478531.0,1.0,HIV infection
12356305,123563052,2,F,,20160616.0,20160511,20160624,EXP,,GB-GILEAD-2016-0213060,GILEAD,,30.0,YR,A,M,Y,,,20160624.0,,MD,GB,GB,EFAVIRENZ,Decreased appetite;Osteonecrosis;Photosensitivity reaction,123563052.0,OT,,,,,,,,,123563052.0,1.0,HIV infection
12357192,123571922,2,F,20150503.0,20161115.0,20160511,20161124,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-036449,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,,,20161124.0,,CN,FR,FR,SUSTIVA,Arthralgia;CREST syndrome;Portal hypertension,123571922.0,OT,,,123571922.0,1.0,20060216.0,20160112.0,,,123571922.0,1.0,HIV infection
12360105,123601051,1,I,,20160505.0,20160512,20160512,EXP,,US-MYLANLABS-2016M1019798,MYLAN,"KHALIL C, MOHANTY MJ, KAATZ G, ABU-HAMDAN D. EFAVIRENZ-ASSOCIATED URINARY MATRIX STONE - A RARE PRESENTATION. AM-J-MED-SCI 2016;351(2):213-214.",,,,,Y,,,20160512.0,,MD,US,US,EFAVIRENZ,Nephrolithiasis,123601051.0,OT,,,,,,,,,123601051.0,1.0,HIV infection
12364537,123645372,2,F,2010.0,20160602.0,20160512,20160607,EXP,,CA-GILEAD-2016-0213217,GILEAD,,66.0,YR,E,M,Y,105.0,KG,20160607.0,,MD,CA,CA,EFAVIRENZ,Chronic kidney disease;Renal impairment,123645372.0,OT,,,123645372.0,1.0,200310.0,20160531.0,,,123645372.0,1.0,HIV infection
12370754,123707541,1,I,,20160502.0,20160516,20160516,EXP,,FR-CIPLA LTD.-2016FR04930,CIPLA,,,,,,Y,,,20160516.0,,OT,TG,TG,Efavirenz,Drug resistance;Virologic failure,123707541.0,OT,,,,,,,,,123707541.0,1.0,Perinatal HIV infection
12371659,123716591,1,I,,20160419.0,20160516,20160516,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2016GSK055049,VIIV,,75.0,YR,,M,Y,,,20160516.0,,MD,AU,AU,Efavirenz,Renal impairment,123716591.0,OT,,,123716591.0,1.0,20160113.0,,,,123716591.0,1.0,HIV infection
12371899,123718991,1,I,,20160419.0,20160516,20160516,EXP,,AU-GLAXOSMITHKLINE-AU2016GSK055049,GLAXOSMITHKLINE,,75.0,YR,,M,Y,,,20160516.0,,MD,AU,AU,Efavirenz,Renal impairment,123718991.0,OT,,,123718991.0,1.0,20160113.0,,,,123718991.0,1.0,HIV infection
12378500,123785005,5,F,20160426.0,20170109.0,20160517,20170113,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-037701,BRISTOL MYERS SQUIBB,,40.0,YR,,F,Y,50.0,KG,20170113.0,,OT,MZ,MZ,EFAVIRENZ,Back pain;Drug eruption;Gastroenteritis;Transaminases increased,123785005.0,HO,,,123785005.0,1.0,20160418.0,20160508.0,,,123785005.0,1.0,HIV infection
12381322,123813223,3,F,20150503.0,20161107.0,20160518,20161111,EXP,FR-AFSSAPS-TO20160894,FR-VIIV HEALTHCARE LIMITED-FR2016GSK067139,VIIV,,50.0,YR,,M,Y,,,20161111.0,,OT,FR,FR,SUSTIVA,Arthralgia;Scleroderma,123813223.0,OT,,,123813223.0,1.0,20060216.0,20160112.0,,,123813223.0,1.0,HIV infection
12381742,123817423,3,F,20150503.0,20161107.0,20160518,20161111,EXP,FR-AFSSAPS-TO20160894,FR-GLAXOSMITHKLINE-FR2016GSK067139,GLAXOSMITHKLINE,,50.0,YR,,M,Y,,,20161111.0,,OT,FR,FR,SUSTIVA,Arthralgia;Scleroderma,123817423.0,OT,,,123817423.0,1.0,20060216.0,20160112.0,,,123817423.0,1.0,HIV infection
12384542,123845421,1,I,,20160504.0,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116734,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL^90(7):207-13",38.0,YR,,F,Y,,,20160519.0,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect decreased;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123845421.0,HO,,,,,,,,,123845421.0,1.0,HIV infection
12384549,123845491,1,I,,20160504.0,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116718,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",39.0,YR,,F,Y,,,20160519.0,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect decreased;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123845491.0,OT,,,,,,,,,123845491.0,1.0,HIV infection
12384550,123845501,1,I,,20160411.0,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-116801,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK, ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS - A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST-AFR-MED-J. 2013;90 (7):207-13",30.0,YR,,M,Y,,,20160519.0,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug interaction,123845501.0,OT,,,,,,,,,123845501.0,1.0,Antiretroviral therapy
12384551,123845511,1,I,,20160504.0,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116719,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",31.0,YR,,M,Y,,,20160519.0,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect decreased;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123845511.0,OT,,,,,,,,,123845511.0,1.0,HIV infection
12384554,123845541,1,I,,20160504.0,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116736,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",35.0,YR,,F,Y,,,20160519.0,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect increased;International normalised ratio fluctuation;Potentiating drug interaction;Pulmonary embolism,123845541.0,OT,,,,,,,,,123845541.0,1.0,HIV infection
12384560,123845601,1,I,,20160504.0,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116717,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",38.0,YR,,F,Y,,,20160519.0,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect increased;International normalised ratio fluctuation;Potentiating drug interaction,123845601.0,OT,,,,,,,,,123845601.0,1.0,HIV infection
12385093,123850931,1,I,,20160504.0,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116611,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",47.0,YR,,F,Y,,,20160519.0,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123850931.0,HO,,,,,,,,,123850931.0,1.0,HIV infection
12391320,123913203,3,F,20160505.0,20160811.0,20160520,20160816,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-039437,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,54.0,KG,20160816.0,,OT,MZ,MZ,EFAVIRENZ,Acute kidney injury;Neuropathy peripheral;Transaminases increased;Urinary tract infection,123913203.0,HO,,,123913203.0,1.0,20160330.0,20160513.0,,,123913203.0,1.0,HIV infection
12392586,123925861,1,I,,20160509.0,20160523,20160523,EXP,,MX-CIPLA LTD.-2016CZ04938,CIPLA,,,,,,Y,,,20160523.0,,OT,CZ,MX,Efavirenz,Anaemia;Herpes simplex;Intracranial pressure increased;Meningioma;Rubella,123925861.0,HO,,,,,,,,,123925861.0,1.0,Acquired immunodeficiency syndrome
12394795,123947951,1,I,20160512.0,20160517.0,20160523,20160523,EXP,,GB-GILEAD-2016-0214430,GILEAD,,75.0,YR,E,M,Y,111.6,KG,20160523.0,,MD,GB,GB,EFAVIRENZ,Laryngeal cancer,123947951.0,OT,,,123947951.0,1.0,20080310.0,,,,123947951.0,1.0,HIV infection
12399916,123999162,2,F,20160506.0,20160525.0,20160524,20160601,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-039014,BRISTOL MYERS SQUIBB,,52.0,YR,,F,Y,54.0,KG,20160601.0,,MD,UG,UG,EFAVIRENZ,Cardiac arrest;Electrolyte imbalance;Helicobacter infection;Malnutrition;Oesophageal squamous cell carcinoma;Oral candidiasis,123999162.0,OT,,,123999162.0,1.0,20120705.0,20160329.0,,,123999162.0,1.0,HIV infection
12400325,124003251,1,I,20080501.0,,20160524,20160524,DIR,,,,,42.0,YR,,M,N,162.0,LBS,20160523.0,N,,US,,SUSTIVA,Abdominal distension;Anxiety;Condition aggravated;Decreased appetite;Depression;Fatigue;Internal haemorrhage;Rectal haemorrhage,124003251.0,OT,,,124003251.0,1.0,,,10.0,YR,124003251.0,1.0,HIV infection
12408914,124089141,1,I,,20160517.0,20160526,20160526,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2016GSK074061,VIIV,"AMBROSIONI J, COLL S, MANZARDO C, NICOLAS D, AGUERO F, BLANCO JL ET AL. VORICONAZOLE AND COBICISTAT-BOOSTED ANTIRETROVIRAL SALVAGE REGIMEN CO-ADMINISTRATION TO TREAT INVASIVE ASPERGILLOSIS IN AN HIV-INFECTED PATIENT. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016;1125-1127",,,,M,Y,,,20160526.0,,OT,ES,ES,Efavirenz,Multiple-drug resistance;Pathogen resistance;Virologic failure,124089141.0,OT,,,,,,,,,124089141.0,1.0,HIV infection
12408942,124089421,1,I,,20160517.0,20160526,20160526,EXP,,ES-GLAXOSMITHKLINE-ES2016GSK074061,GLAXOSMITHKLINE,"AMBROSIONI J, COLL S, MANZARDO C, NICOLAS D, AGUERO F, BLANCO JL ET AL. VORICONAZOLE AND COBICISTAT-BOOSTED ANTIRETROVIRAL SALVAGE REGIMEN CO-ADMINISTRATION TO TREAT INVASIVE ASPERGILLOSIS IN AN HIV-INFECTED PATIENT. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016;1125-1127",,,,M,Y,,,20160526.0,,OT,ES,ES,Efavirenz,Multiple-drug resistance;Pathogen resistance;Virologic failure,124089421.0,OT,,,,,,,,,124089421.0,1.0,HIV infection
12419585,124195851,1,I,2016.0,20160527.0,20160531,20160531,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2016GSK077058,VIIV,,58.0,YR,,M,Y,,,20160531.0,,CN,FR,FR,EFAVIRENZ,Chest pain;Myocardial infarction,124195851.0,DE,,,124195851.0,1.0,201601.0,2016.0,,,124195851.0,1.0,HIV infection
12419841,124198411,1,I,2016.0,20160527.0,20160531,20160531,EXP,,FR-GLAXOSMITHKLINE-FR2016GSK077058,GLAXOSMITHKLINE,,58.0,YR,,M,Y,,,20160531.0,,CN,FR,FR,EFAVIRENZ,Chest pain;Myocardial infarction,124198411.0,OT,,,124198411.0,1.0,201601.0,2016.0,,,124198411.0,1.0,HIV infection
12436882,124368822,2,F,,20160523.0,20160606,20160606,EXP,,ES-CIPLA LTD.-2016ES06033,CIPLA,"NEUKAM K, ESPINOSA N, COLLADO A, DELGADO-FERNANDEZ M, JIMENEZ-AGUILAR P, RIVERO-JUAREZ A ET AL. HEPATIC SAFETY OF RILPIVIRINE/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE FIXED-DOSE SINGLE-TABLET REGIMEN IN HIV-INFECTED PATIENTS WITH ACTIVE HEPATITIS C VIRUS INFECTION: THE HEPATIC STUDY. PLOS ONE. 2016;11 (5):1 TO 13",,,,,Y,,,20160606.0,,OT,ES,ES,Efavirenz,Gastrointestinal haemorrhage;Portal hypertension,124368822.0,OT,,,,,,,,,124368822.0,1.0,Antiretroviral therapy
12439378,124393781,1,I,20150414.0,20150512.0,20160606,20160606,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2015GSK065465,VIIV,,36.0,YR,,M,Y,,,20160606.0,,MD,UG,UG,EFAVIRENZ,Anaemia,124393781.0,HO,,,124393781.0,1.0,20141205.0,20150421.0,,,124393781.0,1.0,HIV infection
12446686,124466861,1,I,,20160525.0,20160608,20160608,EXP,,US-CIPLA LTD.-2016US06201,CIPLA,"WARRICK BJ, TATARU AP, SMOLINSKE S. A SYSTEMATIC ANALYSIS OF METHYLENE BLUE FOR DRUG-INDUCED SHOCK. CLINICAL TOXICOLOGY. 2016;1 TO 9",,,,,Y,,,20160608.0,,OT,US,US,Efavirenz,Cardiogenic shock;Coma;Lactic acidosis;Overdose;Polyuria;Renal failure,124466861.0,HO,,,,,,,,,124466861.0,1.0,HIV infection
12448035,124480351,1,I,,20160601.0,20160608,20160608,EXP,,FR-GILEAD-2016-0216869,GILEAD,"DE CASTRO N, GAUBE G, GUEGEN A, LASCOUX C, ZAGDANSKI A, ALANIO A, MOLINA J. TREATMENT WITH ADALIMUMAB FOR SEVERE IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV-INFECTED PATIENT PRESENTING WITH CRYPTOCOCCAL MENINGITIS. MEDECINE ET MALADIES INFECTIEUSES. 2016;46(3):154-156",33.0,YR,A,F,Y,,,20160608.0,,OT,FR,FR,EFAVIRENZ,Bipolar disorder,124480351.0,OT,,,124480351.0,1.0,201106.0,201106.0,,,124480351.0,1.0,HIV infection
12455700,124557001,1,I,,20160527.0,20160610,20160610,EXP,,US-CIPLA LTD.-2016US06391,CIPLA,,,,,,Y,,,20160610.0,,OT,US,US,Efavirenz,Adverse event;Drug interaction,124557001.0,OT,,,,,,,,,124557001.0,1.0,HIV infection
12462340,124623402,2,F,,20160606.0,20160613,20160629,EXP,,RU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-045024,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20160629.0,,CN,RU,RU,EFAVIRENZ,Dizziness;Nausea;Nightmare,124623402.0,OT,,,124623402.0,1.0,20160110.0,20160124.0,,,124623402.0,1.0,HIV infection
12463934,124639341,1,I,,20160606.0,20160614,20160614,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK080757,VIIV,,62.0,YR,,,Y,,,20160614.0,,CN,GB,GB,Efavirenz,Arthralgia;Chronic obstructive pulmonary disease;Fatigue;Pancreatic injury;Type 2 diabetes mellitus;Weight decreased,124639341.0,OT,,,,,,,,,124639341.0,1.0,HIV infection
12464219,124642191,1,I,,20160607.0,20160614,20160614,EXP,,CZ-GLAXOSMITHKLINE-CZ2016GSK084203,GLAXOSMITHKLINE,"ROMERO CF, SOTO-HERNANDEZ JL, BONNET C, AND CARDENAS G. MENINGIOMATOSIS IN AN AIDS PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART). THE NEUROLOGIST. 2016;21(3):44-46",27.0,YR,,M,Y,,,20160614.0,,MD,MX,CZ,Efavirenz,Hoffmann's sign;Hyperreflexia;Insomnia;Meningioma;Papilloedema;Weight decreased,124642191.0,OT,,,,,,,,,124642191.0,1.0,Acquired immunodeficiency syndrome
12467582,124675821,1,I,,20160607.0,20160615,20160615,EXP,,CZ-VIIV HEALTHCARE LIMITED-CZ2016GSK084203,VIIV,"ROMERO CF, SOTO-HERNANDEZ JL, BONNET C, AND CARDENAS G. MENINGIOMATOSIS IN AN AIDS PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART). THE NEUROLOGIST. 2016;21(3):44-46",27.0,YR,,M,Y,,,20160615.0,,MD,MX,CZ,Efavirenz,Hoffmann's sign;Hyperreflexia;Insomnia;Meningioma;Papilloedema;Weight decreased,124675821.0,OT,,,,,,,,,124675821.0,1.0,Acquired immunodeficiency syndrome
12474411,124744111,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06876,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Pyrexia;Virologic failure,124744111.0,OT,,,,,,,,,124744111.0,1.0,HIV infection
12474441,124744411,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06880,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Blood alkaline phosphatase increased;Virologic failure,124744411.0,OT,,,,,,,,,124744411.0,1.0,HIV infection
12474456,124744561,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06879,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Hypoalbuminaemia;Virologic failure,124744561.0,OT,,,,,,,,,124744561.0,1.0,HIV infection
12474528,124745281,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06883,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Herpes simplex;Virologic failure,124745281.0,OT,,,,,,,,,124745281.0,1.0,HIV infection
12474536,124745361,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06877,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Cardiac disorder;Virologic failure,124745361.0,OT,,,,,,,,,124745361.0,1.0,HIV infection
12474544,124745441,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06878,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Nervous system disorder;Virologic failure,124745441.0,OT,,,,,,,,,124745441.0,1.0,HIV infection
12474970,124749701,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06888,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Tuberculosis;Virologic failure,124749701.0,DE,,,,,,,,,124749701.0,1.0,HIV infection
12474974,124749741,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06887,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Genitourinary symptom;Renal disorder;Virologic failure,124749741.0,OT,,,,,,,,,124749741.0,1.0,HIV infection
12474979,124749791,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07169,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Gastroenteritis;Virologic failure,124749791.0,OT,,,,,,,,,124749791.0,1.0,HIV infection
12474983,124749831,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07170,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Cerebrovascular accident;Virologic failure,124749831.0,DE,,,,,,,,,124749831.0,1.0,HIV infection
12475358,124753581,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07882,AUROBINDO,,64.0,YR,,M,Y,,,20160616.0,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic;Proteinuria,124753581.0,OT,,,,,,,,,124753581.0,1.0,Antiretroviral therapy
12475439,124754391,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07894,AUROBINDO,,52.0,YR,,M,Y,,,20160616.0,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754391.0,LT,,,,,,,,,124754391.0,1.0,Antiretroviral therapy
12475442,124754421,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07907,AUROBINDO,,38.0,YR,,F,Y,,,20160616.0,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic;Proteinuria,124754421.0,OT,,,,,,,,,124754421.0,1.0,Antiretroviral therapy
12475443,124754431,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07900,AUROBINDO,,28.0,YR,,M,Y,,,20160616.0,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic;Proteinuria;Renal tubular necrosis,124754431.0,OT,,,,,,,,,124754431.0,1.0,Antiretroviral therapy
12475478,124754781,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07960,AUROBINDO,,22.0,YR,,F,Y,,,20160617.0,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754781.0,OT,,,,,,,,,124754781.0,1.0,Antiretroviral therapy
12475486,124754861,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-08026,AUROBINDO,,39.0,YR,,F,Y,,,20160617.0,,OT,BE,UG,Efavirenz,Bone density decreased;Nephropathy toxic,124754861.0,OT,,,,,,,,,124754861.0,1.0,Antiretroviral therapy
12475487,124754871,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-08004,AUROBINDO,,38.0,YR,,M,Y,,,20160617.0,,OT,BE,UG,Efavirenz,Anaemia;Death;Hydronephrosis;Nephropathy toxic;Proteinuria,124754871.0,DE,,,,,,,,,124754871.0,1.0,Antiretroviral therapy
12475492,124754921,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07952,AUROBINDO,,48.0,YR,,F,Y,,,20160617.0,,OT,BE,UG,EFAVIRENZ,Blood creatinine increased;Nephropathy toxic,124754921.0,OT,,,,,,,,,124754921.0,1.0,Antiretroviral therapy
12475493,124754931,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07967,AUROBINDO,,38.0,YR,,F,Y,,,20160617.0,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754931.0,OT,,,124754931.0,1.0,2006.0,,,,124754931.0,1.0,Antiretroviral therapy
12475494,124754941,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07961,AUROBINDO,,52.0,YR,,M,Y,,,20160617.0,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754941.0,OT,,,,,,,,,124754941.0,1.0,Antiretroviral therapy
12475499,124754991,1,I,,20160604.0,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07991,AUROBINDO,,30.0,YR,,F,Y,,,20160617.0,,OT,BE,UG,Efavirenz,Blood urine present;Nephropathy toxic,124754991.0,OT,,,,,,,,,124754991.0,1.0,Antiretroviral therapy
12476247,124762471,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07183,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Treatment noncompliance;Virologic failure,124762471.0,OT,,,,,,,,,124762471.0,1.0,HIV infection
12476249,124762491,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07185,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Virologic failure,124762491.0,OT,,,,,,,,,124762491.0,1.0,HIV infection
12476250,124762501,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06884,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,AIDS dementia complex;Virologic failure,124762501.0,OT,,,,,,,,,124762501.0,1.0,HIV infection
12476252,124762521,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07179,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Herpes simplex;Virologic failure,124762521.0,OT,,,,,,,,,124762521.0,1.0,HIV infection
12476253,124762531,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07296,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Skin reaction;Virologic failure,124762531.0,OT,,,,,,,,,124762531.0,1.0,HIV infection
12476254,124762541,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07297,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Adverse event;Virologic failure,124762541.0,OT,,,,,,,,,124762541.0,1.0,HIV infection
12476255,124762551,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07182,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Depression;Virologic failure,124762551.0,OT,,,,,,,,,124762551.0,1.0,HIV infection
12476256,124762561,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07177,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Cervix carcinoma;Virologic failure,124762561.0,OT,,,,,,,,,124762561.0,1.0,HIV infection
12476257,124762571,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07263,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762571.0,OT,,,,,,,,,124762571.0,1.0,HIV infection
12476258,124762581,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07173,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Carbon dioxide increased;Virologic failure,124762581.0,OT,,,,,,,,,124762581.0,1.0,HIV infection
12476259,124762591,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07178,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Meningitis cryptococcal;Virologic failure,124762591.0,OT,,,,,,,,,124762591.0,1.0,HIV infection
12476261,124762611,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07172,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Blood alkaline phosphatase increased;Virologic failure,124762611.0,OT,,,,,,,,,124762611.0,1.0,HIV infection
12476262,124762621,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06881,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Anaemia;Virologic failure,124762621.0,OT,,,,,,,,,124762621.0,1.0,HIV infection
12476264,124762642,2,F,,20200820.0,20160617,20200902,EXP,,US-CIPLA LTD.-2016US07171,CIPLA,,,,,,Y,,,20200902.0,,HP,US,PE,EFAVIRENZ.,Adverse event;Virologic failure,124762642.0,OT,,,,,,,,,124762642.0,1.0,HIV infection
12476266,124762661,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07262,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762661.0,OT,,,,,,,,,124762661.0,1.0,HIV infection
12476269,124762692,2,F,,20200820.0,20160617,20200903,EXP,,US-CIPLA LTD.-2016US06890,CIPLA,,,,,,Y,,,20200903.0,,HP,US,PE,EFAVIRENZ.,Kaposi's sarcoma AIDS related;Virologic failure,124762692.0,OT,,,,,,,,,124762692.0,1.0,HIV infection
12476270,124762701,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07175,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Pancreatic disorder;Virologic failure,124762701.0,OT,,,,,,,,,124762701.0,1.0,HIV infection
12476272,124762721,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06886,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Deep vein thrombosis;Virologic failure,124762721.0,OT,,,,,,,,,124762721.0,1.0,HIV infection
12476273,124762731,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06885,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Acute myocardial infarction;Virologic failure,124762731.0,OT,,,,,,,,,124762731.0,1.0,HIV infection
12476274,124762741,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06891,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Acute respiratory failure;Virologic failure,124762741.0,OT,,,,,,,,,124762741.0,1.0,HIV infection
12476275,124762751,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07181,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Cerebrovascular accident;Virologic failure,124762751.0,OT,,,,,,,,,124762751.0,1.0,HIV infection
12476280,124762801,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07184,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Virologic failure,124762801.0,OT,,,,,,,,,124762801.0,1.0,HIV infection
12476281,124762811,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07295,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762811.0,OT,,,,,,,,,124762811.0,1.0,HIV infection
12476282,124762821,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06889,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Sepsis;Virologic failure,124762821.0,DE,,,,,,,,,124762821.0,1.0,HIV infection
12476283,124762831,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07261,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762831.0,OT,,,,,,,,,124762831.0,1.0,HIV infection
12476284,124762841,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07176,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Pneumonia bacterial;Virologic failure,124762841.0,OT,,,,,,,,,124762841.0,1.0,HIV infection
12476285,124762851,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07174,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Hyperglycaemia;Virologic failure,124762851.0,OT,,,,,,,,,124762851.0,1.0,HIV infection
12476286,124762861,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07180,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Gastroenteritis;Virologic failure,124762861.0,OT,,,,,,,,,124762861.0,1.0,HIV infection
12476345,124763451,1,I,,20160603.0,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06882,CIPLA,,,,,,Y,,,20160617.0,,OT,PE,US,Efavirenz,Pneumonia bacterial;Virologic failure,124763451.0,OT,,,,,,,,,124763451.0,1.0,HIV infection
12487051,124870512,2,F,,20160610.0,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07220,CIPLA,"SEKAGGYA C, NALWANGA D, BRAUN AV, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL.,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16(16):1 TO 5",,,,,Y,,,20160622.0,,OT,UG,UG,Efavirenz,Anticoagulation drug level below therapeutic;Cryptococcal fungaemia;Drug interaction;International normalised ratio increased,124870512.0,OT,,,,,,,,,124870512.0,1.0,HIV infection
12487439,124874393,3,F,,20190227.0,20160622,20190311,EXP,UG-MLMSERVICE-20170907-0858234-3,UG-CIPLA LTD.-2016UG07222,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J ET AL.. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20190311.0,,OT,UG,UG,EFAVIRENZ.,Drug interaction,,,,,,,,,,,124874393.0,1.0,HIV infection
12487535,124875352,2,F,,20160610.0,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07313,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16:16:1 TO 5",,,,,Y,,,20160622.0,,OT,UG,UG,Efavirenz,Cryptococcal fungaemia;Deep vein thrombosis;Drug interaction;Epistaxis;International normalised ratio increased,124875352.0,OT,,,,,,,,,124875352.0,1.0,HIV infection
12487536,124875362,2,F,,20160610.0,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07310,CIPLA,"SEKAGGYA C, NALWANGA D, BRAUN AV, NAKIJOBA R, KAMBUGU A, FEHR J ET AL.,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20160622.0,,OT,UG,UG,Efavirenz,Deep vein thrombosis;Treatment noncompliance,124875362.0,OT,,,,,,,,,124875362.0,1.0,HIV infection
12487546,124875462,2,F,,20160610.0,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07221,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL.,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16(16):1 TO 5",,,,,Y,,,20160622.0,,OT,UG,UG,Efavirenz,Deep vein thrombosis;Drug interaction;International normalised ratio increased,124875462.0,OT,,,,,,,,,124875462.0,1.0,HIV infection
12487549,124875492,2,F,,20160610.0,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07314,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J, ET.AL,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20160622.0,,OT,UG,UG,Efavirenz,Deep vein thrombosis;Drug interaction;International normalised ratio increased,124875492.0,OT,,,,,,,,,124875492.0,1.0,HIV infection
12487554,124875542,2,F,,20160610.0,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07315,CIPLA,"SEKAGGYA C, NALWANGA D, BRAUN AV, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20160622.0,,OT,UG,UG,Efavirenz,Cryptococcal fungaemia;Deep vein thrombosis;Treatment noncompliance,124875542.0,OT,,,,,,,,,124875542.0,1.0,HIV infection
12493624,124936241,1,I,,20160614.0,20160623,20160623,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2016GSK087530,VIIV,"JOSE. SK, MARFATIA. YS. ERYTHEMA ELEVATUM DIUTINUM IN ACQUIRED IMMUNE DEFICIENCY SYNDROME: CAN IT BE AN IMMUNE. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES. 2016;37:81-84",47.0,YR,,M,Y,,,20160623.0,,MD,IN,IN,Efavirenz,CD4 lymphocytes decreased;Cough;Cutaneous tuberculosis;Dyspnoea;Erythema elevatum diutinum;Fatigue;Fibrosis;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Nodule;Pain;Pruritus;Rash papular;Skin lesion;Weight decreased,124936241.0,OT,,,124936241.0,1.0,2009.0,,,,124936241.0,1.0,HIV infection
12493672,124936721,1,I,,20160614.0,20160623,20160623,EXP,,IN-GLAXOSMITHKLINE-IN2016GSK087530,GLAXOSMITHKLINE,"JOSE. SK, MARFATIA. YS. ERYTHEMA ELEVATUM DIUTINUM IN ACQUIRED IMMUNE DEFICIENCY SYNDROME: CAN IT BE AN IMMUNE. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES. 2016;37:81-84",47.0,YR,,M,Y,,,20160623.0,,MD,IN,IN,Efavirenz,CD4 lymphocytes decreased;Cough;Cutaneous tuberculosis;Dyspnoea;Erythema elevatum diutinum;Fatigue;Fibrosis;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Nodule;Pain;Pruritus;Rash papular;Skin lesion;Weight decreased,124936721.0,OT,,,124936721.0,1.0,2009.0,,,,124936721.0,1.0,HIV infection
12502978,125029783,3,F,20040806.0,20170526.0,20160628,20170602,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13454525,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,,,20170602.0,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Hepatic function abnormal;Hypercholesterolaemia;Hypertriglyceridaemia;Lipoatrophy,125029783.0,OT,,,125029783.0,1.0,20030304.0,20050304.0,,,125029783.0,1.0,HIV infection
12507979,125079791,1,I,,20160623.0,20160629,20160629,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2016GSK089842,VIIV,,40.0,YR,,M,Y,,,20160629.0,,CN,DE,DE,SUSTIVA,Delirium;Drug therapeutic incompatibility;Dysstasia;Malaise;Nightmare,125079791.0,OT,,,,,,,,,125079791.0,1.0,HIV infection
12530506,125305061,1,I,,20160628.0,20160706,20160706,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK095757,GLAXOSMITHKLINE,,61.0,YR,,F,Y,,,20160706.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125305061.0,OT,,,,,,,,,125305061.0,1.0,HIV infection
12531024,125310241,1,I,,20160628.0,20160706,20160706,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK095757,VIIV,,61.0,YR,,F,Y,,,20160706.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125310241.0,OT,,,,,,,,,125310241.0,1.0,HIV infection
12538343,125383433,3,F,20150611.0,20160928.0,20160707,20161004,EXP,,CN-GILEAD-2016-0222113,GILEAD,,56.0,YR,A,M,Y,50.0,KG,20161004.0,,MD,CN,CN,EFAVIRENZ,Blood creatinine increased;Renal disorder,125383433.0,OT,,,125383433.0,1.0,20150611.0,20150922.0,,,125383433.0,1.0,HIV infection
12542248,125422482,2,F,20040331.0,20170920.0,20160708,20170929,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-055352,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,,,20170929.0,,MD,JP,JP,EFAVIRENZ,Hyperlipidaemia;Lipodystrophy acquired;Liver disorder,125422482.0,OT,,,125422482.0,1.0,20000613.0,20010814.0,,,125422482.0,1.0,HIV infection
12544841,125448411,1,I,,20160628.0,20160711,20160711,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK095831,VIIV,,44.0,YR,,M,Y,,,20160711.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125448411.0,OT,,,,,,,,,125448411.0,1.0,HIV infection
12544842,125448421,1,I,,20160628.0,20160711,20160711,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK095830,VIIV,,23.0,YR,,F,Y,,,20160711.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125448421.0,OT,,,,,,,,,125448421.0,1.0,HIV infection
12544843,125448431,1,I,,20160628.0,20160711,20160711,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK095832,VIIV,,23.0,YR,,M,Y,,,20160711.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125448431.0,OT,,,,,,,,,125448431.0,1.0,HIV infection
12546700,125467001,1,I,,20160628.0,20160711,20160711,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK095832,GLAXOSMITHKLINE,,23.0,YR,,M,Y,,,20160711.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125467001.0,OT,,,,,,,,,125467001.0,1.0,HIV infection
12546701,125467011,1,I,,20160628.0,20160711,20160711,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK095830,GLAXOSMITHKLINE,,23.0,YR,,F,Y,,,20160711.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125467011.0,OT,,,,,,,,,125467011.0,1.0,HIV infection
12546702,125467021,1,I,,20160628.0,20160711,20160711,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK095831,GLAXOSMITHKLINE,,44.0,YR,,M,Y,,,20160711.0,,OT,ZA,ZA,EFAVIRENZ,Drug resistance;Hepatitis B;Treatment failure;Virologic failure,125467021.0,OT,,,,,,,,,125467021.0,1.0,HIV infection
12553154,125531541,1,I,20160415.0,20160705.0,20160713,20160713,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-055802,BRISTOL MYERS SQUIBB,,21.0,YR,,M,Y,50.0,KG,20160713.0,,CN,FR,FR,SUSTIVA,Hypoglycaemia;Hypothermia,125531541.0,HO,,,,,,,,,125531541.0,1.0,HIV infection
12553310,125533101,1,I,20160415.0,20160705.0,20160713,20160713,EXP,,FR-JNJFOC-20160703774,JANSSEN,,21.0,YR,A,M,Y,50.0,KG,20160713.0,,OT,FR,FR,SUSTIVA,Hypoglycaemia;Hypothermia,125533101.0,HO,,,,,,,,,125533101.0,1.0,HIV infection
12563120,125631202,2,F,20000322.0,20160715.0,20160715,20160726,EXP,,JP-009507513-01062443,MERCK,,42.0,YR,,M,Y,,,20160726.0,,CN,US,JP,EFAVIRENZ,Hepatic cirrhosis;Hypertriglyceridaemia;Pancytopenia,125631202.0,OT,,,125631202.0,1.0,19990819.0,20040331.0,,,125631202.0,1.0,HIV infection
12563472,125634725,5,F,20000322.0,20171117.0,20160715,20171129,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0617,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20171129.0,,MD,JP,JP,EFAVIRENZ.,Hepatic cirrhosis;Hypertriglyceridaemia;Pancytopenia,125634725.0,OT,,,125634725.0,1.0,19990819.0,20040331.0,,,125634725.0,1.0,HIV infection
12564709,125647092,2,F,,20160704.0,20160718,20160718,EXP,,UG-CIPLA LTD.-2016UG09322,CIPLA,"RHEIN J, MORAWSKI BM, HULLSIEK KH, NABETA HW, KIGGUNDU R, TUGUME L ET AL.,. EFFICACY OF ADJUNCTIVE SERTRALINE FOR THE TREATMENT OF HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS: AN OPEN-LABEL DOSE-RANGING STUDY. LANCET INFECT DIS. 2016;16:809 TO 818",,,,,Y,,,20160718.0,,OT,UG,UG,Efavirenz,Immune reconstitution inflammatory syndrome,125647092.0,OT,,,,,,,,,125647092.0,1.0,Antiretroviral therapy
12564898,125648982,2,F,,20160704.0,20160718,20160718,EXP,,UG-CIPLA LTD.-2016UG09323,CIPLA,"RHEIN J, MORAWSKI BM, HULLSIEK KH, NABETA HW, KIGGUNDU R, TUGUME L ET AL.,. EFFICACY OF ADJUNCTIVE SERTRALINE FOR THE TREATMENT OF HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS: AN OPEN-LABEL DOSE-RANGING STUDY. LANCET INFECT DIS. 2016;16:809 TO18",,,,,Y,,,20160718.0,,OT,UG,UG,Efavirenz,Medication error;Serotonin syndrome,125648982.0,OT,,,,,,,,,125648982.0,1.0,Antiretroviral therapy
12564934,125649342,2,F,,20160704.0,20160718,20160718,EXP,,UG-CIPLA LTD.-2016UG09324,CIPLA,"RHEIN J, MORAWSKI BM, HULLSIEK KH, NABETA HW, KIGGUNDU R, TUGUME L ET AL.,. EFFICACY OF ADJUNCTIVE SERTRALINE FOR THE TREATMENT OF HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS: AN OPEN-LABEL DOSE-RANGING STUDY. LANCET INFECT DIS. 2016;16:809 TO 818",,,,,Y,,,20160718.0,,OT,UG,UG,Efavirenz,Adverse event,125649342.0,DE,,,,,,,,,125649342.0,1.0,Antiretroviral therapy
12564941,125649412,2,F,,20160704.0,20160718,20160718,EXP,,UG-CIPLA LTD.-2016UG09326,CIPLA,"RHEIN J, MORAWSKI BM, HULLSIEK KH, NABETA HW, KIGGUNDU R, TUGUME L ET AL.,. EFFICACY OF ADJUNCTIVE SERTRALINE FOR THE TREATMENT OF HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS: AN OPEN-LABEL DOSE-RANGING STUDY. LANCET INFECT DIS. 2016;16:809 TO 818",,,,,Y,,,20160718.0,,OT,UG,UG,Efavirenz,Adverse event,125649412.0,OT,,,,,,,,,125649412.0,1.0,Antiretroviral therapy
12564969,125649692,2,F,,20160704.0,20160718,20160718,EXP,,UG-CIPLA LTD.-2016UG09366,CIPLA,"RHEIN J, MORAWSKI BM, HULLSIEK KH, NABETA HW, KIGGUNDU R, TUGUME L ET AL.,. EFFICACY OF ADJUNCTIVE SERTRALINE FOR THE TREATMENT OF HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS: AN OPEN-LABEL DOSE-RANGING STUDY. LANCET INFECT DIS. 2016;16:809 TO 818",,,,,Y,,,20160718.0,,OT,UG,UG,Efavirenz,Immune reconstitution inflammatory syndrome,125649692.0,OT,,,,,,,,,125649692.0,1.0,Antiretroviral therapy
12567139,125671391,1,I,20050627.0,20050919.0,20160718,20160718,EXP,,LS-BRISTOL-MYERS SQUIBB COMPANY-13114491,BRISTOL MYERS SQUIBB,,26.0,YR,,M,Y,,,20160718.0,,CN,ZA,LS,EFAVIRENZ,Liver function test increased;Meningitis tuberculous;Tuberculoma of central nervous system,125671391.0,HO,,,125671391.0,1.0,20040826.0,20050908.0,,,125671391.0,1.0,HIV infection
12573141,125731412,2,F,20160115.0,20160722.0,20160720,20160729,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-058241,BRISTOL MYERS SQUIBB,,25.0,YR,,M,Y,67.0,KG,20160729.0,,CN,CN,CN,EFAVIRENZ,Liver injury,125731412.0,HO,,,125731412.0,1.0,20140603.0,20160115.0,,,125731412.0,1.0,HIV infection
12573363,125733632,2,F,,20160722.0,20160720,20160722,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059004,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,63.0,KG,20160722.0,,OT,CI,CI,EFAVIRENZ,Cholestasis;Coagulopathy,125733632.0,OT,,,,,,,,,125733632.0,1.0,HIV infection
12576304,125763041,1,I,,20160708.0,20160720,20160720,EXP,,US-ACTAVIS-2016-15466,WATSON,"KHALIL C, MOHANTY MJ, KAATZ G, ABU-HAMDAN D. EFAVIRENZ-ASSOCIATED URINARY MATRIX STONE - A RARE PRESENTATION. AM J MED SCI. 2016;351(2):213-4",65.0,YR,,M,Y,,,20160720.0,,MD,US,US,Efavirenz (Unknown),Drug resistance;Nephrolithiasis,125763041.0,OT,,,,,,,,,125763041.0,1.0,HIV infection
12581733,125817331,1,I,20160129.0,20160711.0,20160722,20160722,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-058289,BRISTOL MYERS SQUIBB,,34.0,YR,,M,Y,50.0,KG,20160722.0,,CN,CN,CN,EFAVIRENZ,Drug eruption,125817331.0,OT,,,125817331.0,1.0,20160125.0,20160129.0,,,125817331.0,1.0,HIV infection
12584418,125844182,2,F,20160421.0,20160804.0,20160722,20160811,EXP,,US-GILEAD-2016-0224201,GILEAD,,62.0,YR,A,M,Y,58.5,KG,20160811.0,,MD,US,US,EFAVIRENZ,Blood creatinine increased;Glomerular filtration rate decreased,125844182.0,OT,,,125844182.0,1.0,20160314.0,20160502.0,,,125844182.0,1.0,HIV infection
12595732,125957321,1,I,,20160719.0,20160727,20160727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061114,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,,,20160727.0,,OT,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Overlap syndrome,125957321.0,OT,,,,,,,,,125957321.0,1.0,HIV infection
12596861,125968611,1,I,,20160719.0,20160727,20160727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061581,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20160727.0,,OT,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis,125968611.0,OT,,,,,,,,,125968611.0,1.0,HIV infection
12596864,125968641,1,I,,20160719.0,20160727,20160727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061578,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20160727.0,,OT,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis,125968641.0,OT,,,,,,,,,125968641.0,1.0,HIV infection
12596882,125968821,1,I,,20160719.0,20160727,20160727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061579,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20160727.0,,OT,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis,125968821.0,OT,,,,,,,,,125968821.0,1.0,HIV infection
12596893,125968932,2,F,,20181127.0,20160727,20181210,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061580,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20181210.0,,OT,ZA,GB,EFAVIRENZ.,Autoimmune hepatitis,125968932.0,OT,,,,,,,,,125968932.0,1.0,HIV infection
12596900,125969001,1,I,,20160719.0,20160727,20160727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061577,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,,,20160727.0,,OT,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis,125969001.0,OT,,,,,,,,,125969001.0,1.0,HIV infection
12596901,125969011,1,I,,20160719.0,20160727,20160727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061576,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20160727.0,,OT,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Overlap syndrome,125969011.0,OT,,,,,,,,,125969011.0,1.0,HIV infection
12597577,125975771,1,I,,20160719.0,20160726,20160726,EXP,,ZA-MYLANLABS-2016M1030402,MYLAN,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND-J-GASTROENTEROL 2016;51(7):814-818.",,,,,Y,,,20160726.0,,MD,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Immune reconstitution inflammatory syndrome,125975771.0,OT,,,,,,,,,125975771.0,1.0,HIV infection
12597608,125976081,1,I,,20160719.0,20160726,20160726,EXP,,ZA-MYLANLABS-2016M1030423,MYLAN,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND-J-GASTROENTEROL 2016;51(7):814-818.",,,,,Y,,,20160726.0,,MD,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Immune reconstitution inflammatory syndrome,125976081.0,OT,,,,,,,,,125976081.0,1.0,HIV infection
12597611,125976111,1,I,,20160719.0,20160726,20160726,EXP,,ZA-MYLANLABS-2016M1030419,MYLAN,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND-J-GASTROENTEROL 2016;51(7):814-818.",,,,,Y,,,20160726.0,,MD,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Immune reconstitution inflammatory syndrome;Overlap syndrome,125976111.0,OT,,,,,,,,,125976111.0,1.0,HIV infection
12597622,125976221,1,I,,20160719.0,20160726,20160726,EXP,,ZA-MYLANLABS-2016M1030427,MYLAN,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND-J-GASTROENTEROL 2016;51(7):814-818.",,,,,Y,,,20160726.0,,MD,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Immune reconstitution inflammatory syndrome,125976221.0,OT,,,,,,,,,125976221.0,1.0,HIV infection
12597632,125976321,1,I,,20160719.0,20160726,20160726,EXP,,ZA-MYLANLABS-2016M1030429,MYLAN,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND-J-GASTROENTEROL 2016;51(7):814-818.",,,,,Y,,,20160726.0,,MD,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Immune reconstitution inflammatory syndrome,125976321.0,OT,,,,,,,,,125976321.0,1.0,HIV infection
12597659,125976591,1,I,,20160719.0,20160726,20160726,EXP,,ZA-MYLANLABS-2016M1030432,MYLAN,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND-J-GASTROENTEROL 2016;51(7):814-818.",,,,,Y,,,20160726.0,,MD,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Immune reconstitution inflammatory syndrome,125976591.0,OT,,,,,,,,,125976591.0,1.0,HIV infection
12597712,125977121,1,I,,20160719.0,20160726,20160726,EXP,,ZA-MYLANLABS-2016M1030440,MYLAN,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND-J-GASTROENTEROL 2016;51(7):814-818.",,,,,Y,,,20160726.0,,MD,ZA,ZA,EFAVIRENZ,Autoimmune hepatitis;Immune reconstitution inflammatory syndrome;Overlap syndrome,125977121.0,OT,,,,,,,,,125977121.0,1.0,HIV infection
12598946,125989461,1,I,20160128.0,20160711.0,20160726,20160726,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-058297,BRISTOL MYERS SQUIBB,,51.0,YR,,M,Y,65.0,KG,20160726.0,,CN,CN,CN,EFAVIRENZ,Drug eruption,125989461.0,HO,,,125989461.0,1.0,20160125.0,20160201.0,,,125989461.0,1.0,HIV infection
12599069,125990691,1,I,,20160718.0,20160727,20160727,EXP,,IN-STRIDES ARCOLAB LIMITED-2016SP010190,STRIDES,"BUDAMAKUNTLA L, LOGANATHAN E, SURYANARAYAN S, ABHISHEK K, SARVAJNAMURTHY S. NEVIRAPINE INDUCED TOXIC EPIDERMAL NECROLYSIS AND NON-HODGKIN LYMPHOMA IN A HUMAN IMMUNODEFICIENCY VIRUS POSITIVE PATIENT. INDIAN DERMATOL ONLINE J. 2014;5(2):179-181",,,,,Y,,,20160727.0,,MD,IN,IN,EFAVIRENZ,Dermatitis bullous;Drug-induced liver injury;Genital erosion;Leukopenia;Lower respiratory tract infection;Nikolsky's sign;Oral mucosa erosion;Pruritus;Rash maculo-papular;Skin exfoliation;Toxic epidermal necrolysis,125990691.0,HO,,,,,,,,,125990691.0,1.0,HIV infection
12601807,126018071,1,I,20160104.0,20160711.0,20160728,20160728,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-058254,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,54.0,KG,20160728.0,,CN,CN,CN,EFAVIRENZ,Mouth haemorrhage;Mouth ulceration;Rash,126018071.0,OT,,,126018071.0,1.0,20151224.0,20160104.0,,,126018071.0,1.0,Acquired immunodeficiency syndrome
12624428,126244281,1,I,,20160722.0,20160805,20160805,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2016-03399,LUPIN,"MURUNGA E, ANDERSSON M, RENSBURG C. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2016;1-5.",42.0,YR,,F,Y,,,20160805.0,,MD,ZA,ZA,Efavirenz,Autoimmune hepatitis,126244281.0,OT,,,,,,,,,126244281.0,1.0,HIV infection
12624767,126247672,2,F,2012.0,20160726.0,20160805,20160810,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-064179,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,,,20160810.0,,OT,AU,AU,EFAVIRENZ,Progressive multifocal leukoencephalopathy,126247672.0,OT,,,,,,,,,126247672.0,1.0,HIV infection
12624768,126247681,1,I,,20160726.0,20160805,20160805,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-062054,BRISTOL MYERS SQUIBB,,49.0,YR,,M,Y,,,20160805.0,,OT,AU,AU,EFAVIRENZ,Progressive multifocal leukoencephalopathy,126247681.0,OT,,,,,,,,,126247681.0,1.0,HIV infection
12628089,126280891,1,I,,20160725.0,20160808,20160808,EXP,,IN-AUROBINDO-AUR-APL-2016-09913,AUROBINDO,"JOSE SK, ET AL.. ANTIVIRALS : ERYTHEMA ELEVATUM DIUTINUM: CASE REPORT. REACTIONS WEEKLY. 2016;1611:26",,,,,Y,,,20160806.0,,OT,IN,IN,Efavirenz,Cough;Dyspnoea;Erythema;Erythema elevatum diutinum;Fatigue;Nodule;Papule;Skin lesion;Treatment failure;Weight decreased,126280891.0,OT,,,,,,,,,126280891.0,1.0,HIV infection
12629480,126294804,4,F,,20170116.0,20160808,20170116,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK112580,VIIV,"MAHLAB-GURI K, ASHER I, ROSENBERG-BEZALEL S, ELBIRT D, BURKE M, STHOEGER ZM. TWO CASE REPORTS OF SEVERE MYOCARDITIS ASSOCIATED WITH THE INITIATION OF DOLUTEGRAVIR TREATMENT IN HIV PATIENTS. MEDICINE. 2016;95:47",45.0,YR,,F,Y,,,20170116.0,,MD,IL,IL,Efavirenz,Aspartate aminotransferase increased;Blood creatine phosphokinase increased;Cardiac failure;Depression;Diarrhoea;Dyspnoea;Left ventricular dysfunction;Myocarditis;Necrosis;Oedema peripheral;Pyrexia;Troponin T increased,126294804.0,OT,,,,,,,,,126294804.0,1.0,HIV infection
12642922,126429226,6,F,,20180628.0,20160811,20180711,EXP,,US-CIPLA LTD.-2016US17002,CIPLA,,,,,,Y,,,20180711.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury;Drug interaction;Nephropathy toxic,126429226.0,HO,,,,,,,,,126429226.0,1.0,HIV infection
12643972,126439725,5,F,,20190213.0,20160811,20190225,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK112581,VIIV,,51.0,YR,,M,Y,,,20190225.0,,OT,IL,IL,EFAVIRENZ.,Aspartate aminotransferase increased;Blood lactate dehydrogenase increased;Cardiac failure;Coronary artery stenosis;Dyspnoea;Ischaemic stroke;Myocarditis;Oedema peripheral;Sleep disorder;Troponin T increased;Ventricular dysfunction,126439725.0,OT,,,,,,,,,126439725.0,1.0,HIV infection
12647261,126472611,1,I,,20160803.0,20160812,20160812,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-064630,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160812.0,,OT,TH,TH,EFAVIRENZ,Guillain-Barre syndrome,126472611.0,HO,,,,,,,,,126472611.0,1.0,Acute HIV infection
12657550,126575502,2,F,,20160921.0,20160816,20160924,EXP,,US-009507513-1608USA007071,MERCK,,,,,M,Y,,,20160924.0,,MD,US,US,EFAVIRENZ,Nephrolithiasis;Obstructive nephropathy;Renal failure,126575502.0,DS,,,126575502.0,1.0,2014.0,20160810.0,,,126575502.0,1.0,HIV infection
12662266,126622662,2,F,20160617.0,20160926.0,20160817,20160928,EXP,,BR-GILEAD-2016-0228623,GILEAD,,74.0,YR,E,F,Y,67.1,KG,20160928.0,,MD,BR,BR,EFAVIRENZ,Sepsis,126622662.0,DE,,,126622662.0,1.0,20130617.0,20160502.0,,,126622662.0,1.0,HIV infection
12662286,126622862,2,F,20160601.0,20160916.0,20160817,20160926,EXP,,BR-GILEAD-2016-0228729,GILEAD,,74.0,YR,E,F,Y,67.1,KG,20160926.0,,MD,BR,BR,EFAVIRENZ,Diabetes mellitus,126622862.0,OT,,,126622862.0,1.0,20130617.0,20160502.0,,,126622862.0,1.0,HIV infection
12664189,126641891,1,I,,20160809.0,20160818,20160818,EXP,,CH-GLAXOSMITHKLINE-CH2016GSK119198,GLAXOSMITHKLINE,"CALMY A, VAN DELDEN C, GIOSTRA E, JUNET C, BRANDT LR, YERLY S ET AL. HIV-POSITIVE-TO-HIV-POSITIVE LIVER TRANSPLANTATION. AMERICAN JOURNAL OF TRANSPLANTATION. 2016;16:2473-2478",53.0,YR,,M,Y,,,20160818.0,,OT,CH,CH,EFAVIRENZ,Antiviral drug level above therapeutic;Drug level decreased;Drug resistance;Pathogen resistance;Viral mutation identified,126641891.0,OT,,,126641891.0,1.0,1997.0,2001.0,,,126641891.0,1.0,HIV infection
12664221,126642211,1,I,,20160809.0,20160818,20160818,EXP,,CH-VIIV HEALTHCARE LIMITED-CH2016GSK119198,VIIV,"CALMY A, VAN DELDEN C, GIOSTRA E, JUNET C, BRANDT LR, YERLY S ET AL. HIV-POSITIVE-TO-HIV-POSITIVE LIVER TRANSPLANTATION. AMERICAN JOURNAL OF TRANSPLANTATION. 2016;16:2473-2478",53.0,YR,,M,Y,,,20160818.0,,OT,CH,CH,EFAVIRENZ,Antiviral drug level above therapeutic;Drug level decreased;Drug resistance;Pathogen resistance;Viral mutation identified,126642211.0,OT,,,126642211.0,1.0,1997.0,2001.0,,,126642211.0,1.0,HIV infection
12665997,126659972,2,F,20160305.0,20160906.0,20160818,20160914,EXP,,CN-GILEAD-2016-0229003,GILEAD,,52.0,YR,A,M,Y,,,20160914.0,,OT,CN,CN,EFAVIRENZ,Drug-induced liver injury;Hepatic function abnormal;Rash,126659972.0,OT,,,126659972.0,1.0,20160125.0,20160311.0,,,126659972.0,1.0,HIV infection
12670349,126703491,1,I,,20160809.0,20160822,20160822,EXP,,US-GLAXOSMITHKLINE-US2016GSK120368,GLAXOSMITHKLINE,"LAZENBY GB, MMEJE O, FISHER BM, WEINBERG A, AARON EK, KEATING M ET AL. ANTIRETROVIRAL RESISTANCE AND PREGNANCY CHARACTERISTICS OF WOMEN WITH PERINATAL AND NONPERINATAL HIV INFECTION. INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY. 2016;2016:1-8",,,,F,Y,,,20160822.0,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Pathogen resistance,126703491.0,OT,,,,,,,,,126703491.0,1.0,Antiretroviral therapy
12670413,126704131,1,I,,20160809.0,20160822,20160822,EXP,,US-VIIV HEALTHCARE LIMITED-US2016GSK120368,VIIV,"LAZENBY GB, MMEJE O, FISHER BM, WEINBERG A, AARON EK, KEATING M ET AL. ANTIRETROVIRAL RESISTANCE AND PREGNANCY CHARACTERISTICS OF WOMEN WITH PERINATAL AND NONPERINATAL HIV INFECTION. INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY. 2016;2016:1-8",,,,F,Y,,,20160822.0,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Pathogen resistance,126704131.0,OT,,,,,,,,,126704131.0,1.0,Antiretroviral therapy
12671099,126710991,1,I,201510.0,20160810.0,20160822,20160822,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068710,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20160822.0,,OT,CH,CH,EFAVIRENZ,Hepatic cirrhosis;Hepatitis B;Hepatitis D;Hepatocellular injury;Liver transplant,126710991.0,OT,,,,,,,,,126710991.0,1.0,HIV infection
12676060,126760601,1,I,,20160809.0,20160823,20160823,EXP,,ZA-AUROBINDO-AUR-APL-2016-10792,AUROBINDO,,42.0,YR,,F,Y,,,20160823.0,,OT,ZA,ZA,Efavirenz,Autoimmune hepatitis;Hepatic enzyme abnormal;Immune reconstitution inflammatory syndrome,126760601.0,OT,,,,,,,,,126760601.0,1.0,HIV infection
12677474,126774741,1,I,,20160810.0,20160823,20160823,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069628,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160823.0,,OT,ES,ES,EFAVIRENZ,Neurotoxicity,126774741.0,OT,,,,,,,,,126774741.0,1.0,HIV infection
12677475,126774751,1,I,,20160810.0,20160823,20160823,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069630,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160823.0,,OT,ES,ES,EFAVIRENZ,Neurotoxicity,126774751.0,OT,,,,,,,,,126774751.0,1.0,HIV infection
12677489,126774891,1,I,,20160810.0,20160823,20160823,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069629,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160823.0,,OT,ES,ES,EFAVIRENZ,Neurotoxicity,126774891.0,OT,,,,,,,,,126774891.0,1.0,HIV infection
12677501,126775011,1,I,,20160810.0,20160823,20160823,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069631,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160823.0,,OT,ES,ES,EFAVIRENZ,Neurotoxicity,126775011.0,OT,,,,,,,,,126775011.0,1.0,HIV infection
12678862,126788621,1,I,,20160810.0,20160824,20160824,EXP,,KR-CIPLA LTD.-2016KR17421,CIPLA,,,,,,Y,,,20160824.0,,OT,KR,KR,Efavirenz,Somnolence,126788621.0,OT,,,,,,,,,126788621.0,1.0,HIV infection
12679329,126793291,1,I,20011205.0,20020522.0,20160824,20160824,EXP,,SN-BRISTOL-MYERS SQUIBB COMPANY-11884095,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20160824.0,,OT,US,SN,EFAVIRENZ,Pregnancy;Tuberculosis,126793291.0,OT,,,126793291.0,1.0,20000118.0,20010507.0,,,126793291.0,1.0,HIV infection
12679716,126797161,1,I,20150913.0,20160804.0,20160824,20160824,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069195,BRISTOL MYERS SQUIBB,,56.0,YR,,F,Y,,,20160824.0,,OT,ZA,ZA,EFAVIRENZ,Diabetes mellitus inadequate control;Haematemesis,126797161.0,HO,,,126797161.0,1.0,20150217.0,20150913.0,,,126797161.0,1.0,HIV infection
12682077,126820772,2,F,20150413.0,20160804.0,20160824,20160831,EXP,,ZA-GILEAD-2016-0230242,GILEAD,,47.0,YR,A,F,Y,,,20160831.0,,OT,ZA,ZA,EFAVIRENZ,Anaemia,126820772.0,LT,,,126820772.0,1.0,20140611.0,,,,126820772.0,1.0,HIV infection
12682573,126825731,1,I,200906.0,20160810.0,20160825,20160825,EXP,,TH-CIPLA LTD.-2016TH17435,CIPLA,,,,,,Y,,,20160825.0,,OT,TH,TH,Efavirenz,Anaemia;Death;Leishmaniasis;Meningitis cryptococcal;Rash;Seizure;Weight increased,126825731.0,DE,,,,,,,,,126825731.0,1.0,HIV infection
12682848,126828481,1,I,,20160812.0,20160825,20160825,EXP,,JP-CIPLA LTD.-2016JP17498,CIPLA,,,,,,Y,,,20160825.0,,OT,JP,JP,Efavirenz,Hyperlipidaemia,126828481.0,OT,,,,,,,,,126828481.0,1.0,HIV infection
12682853,126828531,1,I,,20160812.0,20160825,20160825,EXP,,JP-CIPLA LTD.-2016JP17499,CIPLA,,,,,,Y,,,20160825.0,,OT,JP,JP,Efavirenz,Hyperlipidaemia,126828531.0,OT,,,,,,,,,126828531.0,1.0,HIV infection
12685353,126853533,3,F,20140810.0,20160901.0,20160825,20160908,EXP,,IT-GILEAD-2016-0230054,GILEAD,,51.0,YR,A,F,Y,48.0,KG,20160908.0,,MD,IT,IT,EFAVIRENZ,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,126853533.0,OT,,,126853533.0,1.0,20120627.0,20141110.0,,,126853533.0,1.0,HIV infection
12688243,126882431,1,I,,20160812.0,20160826,20160826,EXP,,IT-CIPLA LTD.-2016IT17540,CIPLA,,,,,,Y,,,20160826.0,,OT,IT,IT,Efavirenz,Diarrhoea;Hepatitis B;Interstitial lung disease;Mycobacterium avium complex infection;Oesophageal candidiasis;Rash;Treatment noncompliance;Virologic failure,126882431.0,OT,,,126882431.0,1.0,200205.0,200304.0,,,126882431.0,1.0,Antiretroviral therapy
12689480,126894803,3,F,20140810.0,20170419.0,20160826,20170421,EXP,,IT-GLAXOSMITHKLINE-IT2016123953,GLAXOSMITHKLINE,,51.0,YR,,F,Y,48.0,KG,20170421.0,,OT,IT,IT,EFAVIRENZ,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,126894803.0,OT,,,126894803.0,1.0,20120627.0,20141110.0,,,126894803.0,1.0,HIV infection
12689614,126896144,4,F,20140810.0,20170419.0,20160826,20170421,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016123953,VIIV,,51.0,YR,,F,Y,48.0,KG,20170421.0,,OT,IT,IT,EFAVIRENZ,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,126896144.0,OT,,,126896144.0,1.0,20120627.0,20141110.0,,,126896144.0,1.0,HIV infection
12689615,1268961515,15,F,20160812.0,20170923.0,20160826,20170928,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2016GSK123261,VIIV,,37.0,YR,,F,Y,43.0,KG,20170928.0,,MD,BR,BR,EFAVIRENZ,Acute kidney injury;Immune reconstitution inflammatory syndrome,1268961515.0,LT,,,1268961515.0,1.0,20160805.0,,,,1268961515.0,1.0,HIV infection
12692464,126924642,2,F,201006.0,20180314.0,20160829,20180329,EXP,,CA-CIPLA LTD.-2016CA17600,CIPLA,"AWORTWE C, MAKIWANE M, REUTER H, MULLER C, LOUW J, ROSENKRANZ. CRITICAL EVALUATION OF CAUSALITY ASSESSMENT OF HERB-DRUG INTERACTIONS IN PATIENTS",,,,,Y,,,20180329.0,,OT,ZA,CA,EFAVIRENZ.,Drug interaction;Virologic failure,126924642.0,OT,,,,,,,,,126924642.0,1.0,HIV infection
12692497,126924971,1,I,,20160815.0,20160829,20160829,EXP,,IT-CIPLA LTD.-2016IT17591,CIPLA,,,,,,Y,,,20160829.0,,OT,IT,IT,Efavirenz,Treatment noncompliance,126924971.0,OT,,,,,,,,,126924971.0,1.0,Antiretroviral therapy
12692700,126927001,1,I,,20130416.0,20160829,20160829,EXP,,ZA-CIPLA LTD.-2013US00458,CIPLA,"STEFAN DC, DIPPENAAR A, DE BRUIN G, UYS R, VAN TOORN R. CHALLENGES TO TREATMENT OF LEUKEMIA IN HIV-POSITIVE CHILDREN. JOURNAL OF TROPICAL PEDIATRICS. 2012;58 (6):521 TO 522",,,,,Y,,,20160829.0,,OT,ZA,ZA,Efavirenz,Anal incontinence;Hypersensitivity;Leukaemic infiltration;Paraplegia;Systemic infection;Urinary incontinence,126927001.0,OT,,,,,,,,,126927001.0,1.0,HIV infection
12692726,126927261,1,I,,20160817.0,20160829,20160829,EXP,,TH-CIPLA LTD.-2016TH17685,CIPLA,,,,,,Y,,,20160829.0,,OT,TH,TH,Efavirenz,Rash maculo-papular,126927261.0,OT,,,,,,,,,126927261.0,1.0,HIV infection
12692732,126927321,1,I,,20160817.0,20160829,20160829,EXP,,IT-CIPLA LTD.-2016IT17679,CIPLA,"MANFREDI R, PIERGENTILI B, MARINACCI G, CALZA L. ATYPICAL PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN HIV WITH A HIGH CD4 COUNT: THE USE OF MAGNETIC RESONANCE IMAGING PLUS SPECTROMETRY STUDIES. INTERNATIONAL JOURNAL OF STD + AIDS. 2012;23:E35 TO E38",,,,,Y,,,20160829.0,,OT,IT,IT,Efavirenz,Condition aggravated;Respiratory failure,126927321.0,DE,,,,,,,,,126927321.0,1.0,HIV infection
12696616,126966162,2,F,20160313.0,20160822.0,20160830,20160909,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-070753,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,66.0,KG,20160909.0,,CN,CN,CN,EFAVIRENZ,Rash,126966162.0,HO,,,126966162.0,1.0,20160308.0,20160331.0,,,126966162.0,1.0,Acquired immunodeficiency syndrome
12697012,126970121,1,I,20160223.0,20160822.0,20160830,20160830,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-070749,BRISTOL MYERS SQUIBB,,77.0,YR,,F,Y,,,20160830.0,,CN,CN,CN,EFAVIRENZ,Abdominal discomfort;Diarrhoea;Nausea,126970121.0,HO,,,126970121.0,1.0,20160203.0,,,,126970121.0,1.0,HIV infection
12702855,127028551,1,I,20130503.0,20160804.0,20160831,20160831,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016122522,VIIV,,31.0,YR,,F,Y,,,20160831.0,,MD,ZA,ZA,Efavirenz,Caesarean section;Exposure during pregnancy;Normal newborn,127028551.0,OT,,,127028551.0,2.0,20110317.0,20130826.0,,,127028551.0,1.0,HIV infection
12702858,127028581,1,I,,20160823.0,20160831,20160831,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2016GSK126089,VIIV,"WINGI O, CAPPELLESSO R, AREGO R, CUPPINI E, MUHELO A, PUTOTO G ET AL. FAILED CONSERVATIVE MANAGEMENT OF A CASE OF APLASIA CUTIS CONGENITA IN A LOW-INCOME COUNTRY. CLINICAL CASE REPORTS. 2016;4 (8):756-758",,,N,F,Y,,,20160831.0,,OT,MZ,MZ,Efavirenz,Abdominal distension;Aplasia cutis congenita;Condition aggravated;Contraindication to medical treatment;Fistula;Foetal exposure during pregnancy;Irritability;Laceration;Necrosis;Pain;Selective eating disorder;Skin disorder;Skin exfoliation;Skin lesion;Skin necrosis;Treatment failure;Weight decreased,127028581.0,OT,,,,,,,,,127028581.0,1.0,Antiretroviral therapy
12702962,127029621,1,I,,20160823.0,20160831,20160831,EXP,,MZ-GLAXOSMITHKLINE-MZ2016GSK126089,GLAXOSMITHKLINE,"WINGI O, CAPPELLESSO R, AREGO R, CUPPINI E, MUHELO A, PUTOTO G ET AL. FAILED CONSERVATIVE MANAGEMENT OF A CASE OF APLASIA CUTIS CONGENITA IN A LOW-INCOME COUNTRY. CLINICAL CASE REPORTS. 2016;4 (8):756-758",,,N,F,Y,,,20160831.0,,OT,MZ,MZ,Efavirenz,Abdominal distension;Aplasia cutis congenita;Condition aggravated;Contraindication to medical treatment;Fistula;Foetal exposure during pregnancy;Irritability;Laceration;Necrosis;Pain;Selective eating disorder;Skin disorder;Skin exfoliation;Skin lesion;Skin necrosis;Treatment failure;Weight decreased,127029621.0,OT,,,,,,,,,127029621.0,1.0,Antiretroviral therapy
12703039,127030391,1,I,20130503.0,20160804.0,20160831,20160831,EXP,,ZA-GLAXOSMITHKLINE-ZA2016122522,GLAXOSMITHKLINE,,31.0,YR,,F,Y,,,20160831.0,,MD,ZA,ZA,Efavirenz,Caesarean section;Exposure during pregnancy;Normal newborn,127030391.0,OT,,,127030391.0,2.0,20110317.0,20130826.0,,,127030391.0,1.0,HIV infection
12708298,127082981,1,I,,20160826.0,20160901,20160901,EXP,,NL-MYLANLABS-2016M1037070,MYLAN,"SCHERPBIER HJ, TERPSTRA V, PAJKRT D, PUTHAKANIT T, ANANWORANICH J, FOSTER C, ET AL. NONCIRRHOTIC PORTAL HYPERTENSION IN PERINATALLY HIV-INFECTED ADOLESCENTS TREATED WITH DIDANOSINE-CONTAINING ANTIRETROVIRAL REGIMENS IN CHILDHOOD. PEDIATR-INFECT-DIS-J 2016;35(8):E248-E252.",,,,,Y,,,20160901.0,,MD,NL,NL,EFAVIRENZ,Gastric varices haemorrhage;Non-cirrhotic portal hypertension,127082981.0,OT,,,,,,,,,127082981.0,1.0,Perinatal HIV infection
12713243,127132431,1,I,20160824.0,20160824.0,20160902,20160902,EXP,,CN-GILEAD-2016-0231761,GILEAD,,54.0,YR,A,F,Y,,,20160902.0,,OT,CN,CN,EFAVIRENZ,Lung infection;Renal disorder,127132431.0,OT,,,127132431.0,1.0,20160223.0,,,,127132431.0,1.0,HIV infection
12716231,127162311,1,I,200208.0,20021028.0,20160906,20160906,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12095063,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20160906.0,,CN,FR,FR,SUSTIVA,Abortion induced;Abortion spontaneous;Maternal exposure during pregnancy;Twin pregnancy;Vanishing twin syndrome,127162311.0,OT,,,127162311.0,1.0,,20020831.0,,,127162311.0,1.0,HIV infection
12717225,127172252,2,F,201408.0,20160830.0,20160906,20160908,EXP,,IT-GLAXOSMITHKLINE-IT2016GSK124581,GLAXOSMITHKLINE,,53.0,YR,,F,Y,50.0,KG,20160908.0,,MD,IT,IT,EFAVIRENZ,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,127172252.0,OT,,,127172252.0,6.0,20001122.0,,,,127172252.0,1.0,HIV infection
12718236,127182362,2,F,201408.0,20160830.0,20160906,20160908,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016GSK124581,VIIV,,53.0,YR,,F,Y,50.0,KG,20160908.0,,MD,IT,IT,EFAVIRENZ,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,127182362.0,OT,,,127182362.0,6.0,20001122.0,,,,127182362.0,1.0,HIV infection
12723364,127233641,1,I,,20160830.0,20160908,20160908,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-073617,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,,,20160908.0,,OT,CO,CO,EFAVIRENZ,Hepatic cirrhosis,127233641.0,DE,,,,,,,,,127233641.0,1.0,HIV infection
12727841,127278412,2,F,20160314.0,20161122.0,20160909,20161130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-073055,BRISTOL MYERS SQUIBB,,52.0,YR,,F,Y,66.0,KG,20161130.0,,CN,US,GB,EFAVIRENZ,Extradural abscess,127278412.0,LT,,,127278412.0,1.0,20100617.0,,,,127278412.0,1.0,HIV infection
12729803,127298031,1,I,,20160830.0,20160909,20160909,EXP,,CO-009507513-1609COL004786,MERCK,,60.0,YR,,M,Y,,,20160909.0,,CN,US,CO,EFAVIRENZ,Hepatic cirrhosis,127298031.0,DE,,,,,,,,,127298031.0,1.0,HIV infection
12741850,127418501,1,I,,20160830.0,20160914,20160914,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-072133,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160914.0,,CN,US,US,SUSTIVA,Feeling abnormal,,,,,,,,,,,127418501.0,1.0,HIV infection
12742894,127428941,1,I,,20160907.0,20160914,20160914,EXP,,MZ-MYLANLABS-2016M1039032,MYLAN,"WINGI O, CAPPELLESSO R, AREGO R, CUPPINI E, MUHELO A, PUTOTO G, ET AL. FAILED CONSERVATIVE MANAGEMENT OF A CASE OF APLASIA CUTIS CONGENITA IN A LOW-INCOME COUNTRY. CLIN-CASE-REP 2016;4(8):756-758.",,,,,Y,,,20160914.0,,OT,MZ,MZ,EFAVIRENZ,Aplasia cutis congenita;Foetal exposure during pregnancy,127428941.0,DE,,,,,,,,,127428941.0,1.0,Antiretroviral therapy
12744704,127447042,2,F,,20160916.0,20160915,20160927,EXP,,ES-CIPLA LTD.-2016ES18271,CIPLA,"ESCOBAR-VILLALBA A, SAINZ DE LA MAZA S, PEREZ TORRE P, GALAN JC, RODRIGUEZ-DOMINGUEZ M, MONREAL LAGUILLO E, ET AL. ACUTE MYELITIS BY HUMAN HERPES VIRUS 7 IN AN HIV-INFECTED PATIENT. JOURNAL OF CLINICAL VIROLOGY. 2016;77:63 TO 65",,,,,Y,,,20160927.0,,OT,ES,ES,Efavirenz,Myelitis transverse,127447042.0,HO,,,,,,,,,127447042.0,1.0,HIV infection
12749672,127496721,1,I,20160720.0,20160912.0,20160916,20160916,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076201,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,37.0,KG,20160916.0,,OT,CI,CI,EFAVIRENZ,Hypersomnia;Ulcer,127496721.0,HO,,,,,,,,,127496721.0,1.0,HIV infection
12755110,127551101,1,I,,20160830.0,20160916,20160916,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-072085,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160916.0,,CN,US,US,SUSTIVA,Adverse event,,,,,,,,,,,127551101.0,1.0,HIV infection
12755111,127551112,2,F,20160503.0,20161213.0,20160916,20161216,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-040754,BRISTOL MYERS SQUIBB,,18.0,YR,,F,Y,36.0,KG,20161216.0,,OT,MZ,MZ,EFAVIRENZ,Acute kidney injury;Anaemia,127551112.0,HO,,,127551112.0,1.0,20160406.0,20160912.0,,,127551112.0,1.0,HIV infection
12755348,127553482,2,F,,20170126.0,20160916,20170206,EXP,,PHHY2016US127187,SANDOZ,"LAZENBY GB, MMEJE O, FISHER BM, WEINBERG A, AARON EK, KEATING M, ET AL.. ANTIRETROVIRAL RESISTANCE AND PREGNANCY CHARACTERISTICS OF WOMEN WITH PERINATAL AND NONPERINATAL HIV INFECTION.. INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY. 2016",,,,F,Y,,,20170206.0,,OT,US,US,EFAVIRENZ,Drug resistance;Maternal exposure during pregnancy,127553482.0,OT,,,,,,,,,127553482.0,1.0,Perinatal HIV infection
12756064,127560642,2,F,,20170215.0,20160916,20170228,EXP,,GB-MYLANLABS-2016M1039688,MYLAN,"GRIMES R, APPLEBY T, STOCKWELL S, SANDER NP, SAHABANDU T, GILLEECE Y, BRADSHAW D, STEIN P. A CASE OF HEREDITARY COPROPORPHYRIA TRIGGERED BY EFAVIRENZ. HIV MEDICINE 17 (SUPPL. 1): 53 ABSTR. P119, APR 2016.",,,,,Y,,,20170228.0,,OT,GB,GB,EFAVIRENZ,Porphyria acute,127560642.0,OT,,,,,,,,,127560642.0,1.0,Antiretroviral therapy
12761074,127610742,2,F,20160706.0,20160921.0,20160920,20161005,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076083,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,40.0,KG,20161005.0,,CN,CN,CN,EFAVIRENZ,Delirium,,,,,127610742.0,1.0,20160622.0,20160706.0,,,127610742.0,1.0,Acquired immunodeficiency syndrome
12763410,127634102,2,F,20151207.0,20160922.0,20160920,20160928,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076105,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,56.0,KG,20160928.0,,CN,CN,CN,EFAVIRENZ,Hepatic failure;Jaundice,127634102.0,OT,,,127634102.0,1.0,20150301.0,20151207.0,,,127634102.0,1.0,Acquired immunodeficiency syndrome
12764791,127647912,2,F,20160415.0,20160922.0,20160921,20160928,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076118,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,64.0,KG,20160928.0,,CN,CN,CN,EFAVIRENZ,Hepatic failure;Jaundice,127647912.0,HO,,,127647912.0,1.0,20150901.0,,,,127647912.0,1.0,Acquired immunodeficiency syndrome
12764792,127647923,3,F,,20201008.0,20160921,20201022,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076797,BRISTOL MYERS SQUIBB,"GRIMES R, GILLEECE Y, APPLEBY T, STOCKWELL S, PINTO-SANDER N, SAHABANDU T, ET AL. A CASE OF HEREDITARY COPROPORPHYRIA PRECIPITATED BY EFAVIRENZ. AIDS. 2016;30(13):2142-3",25.0,YR,,M,Y,,,20201022.0,,MD,GB,GB,EFAVIRENZ.,Acquired porphyria,127647923.0,OT,,,,,,,,,127647923.0,1.0,HIV infection
12770858,127708582,2,F,20160605.0,20161011.0,20160922,20161013,PER,,US-VIIV HEALTHCARE LIMITED-US2016137901,VIIV,,72.0,YR,,M,Y,85.26,KG,20161013.0,,CN,US,US,SUSTIVA,Chills;Drug hypersensitivity;Headache;Hyperhidrosis;Myalgia;Nausea;Pyrexia,,,,,127708582.0,1.0,20160516.0,20160613.0,,,127708582.0,1.0,HIV infection
12781130,127811301,1,I,2010.0,20160810.0,20160926,20160926,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-077942,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160926.0,,OT,CA,US,EFAVIRENZ,Drug resistance;Live birth;Maternal exposure during delivery;Product use issue,127811301.0,OT,,,,,,,,,127811301.0,1.0,Perinatal HIV infection
12781495,127814951,1,I,,20160915.0,20160926,20160926,EXP,,GR-GLAXOSMITHKLINE-GR2016GSK136367,GLAXOSMITHKLINE,"ROMANOU B, XILOMENOS G, BLIOZIOTIS I, GARGALIANOS-KAKOLIRIS P.. CHRONIC LYMPHOCYTIC LEUKEMIA IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME AND A HISTORY OF HODGKIN LYMPHOMA. HELLENIC ARCHIVES OF AIDS. 2015;1",53.0,YR,,M,Y,,,20160926.0,,MD,GR,GR,Efavirenz,Chronic lymphocytic leukaemia;Leukocytosis,127814951.0,OT,,,,,,,,,127814951.0,1.0,HIV infection
12783821,127838211,1,I,,20160915.0,20160927,20160927,EXP,,GR-VIIV HEALTHCARE LIMITED-GR2016GSK136367,VIIV,"ROMANOU B, XILOMENOS G, BLIOZIOTIS I, GARGALIANOS-KAKOLIRIS P.. CHRONIC LYMPHOCYTIC LEUKEMIA IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME AND A HISTORY OF HODGKIN LYMPHOMA. HELLENIC ARCHIVES OF AIDS. 2015;1",53.0,YR,,M,Y,,,20160927.0,,MD,GR,GR,Efavirenz,Chronic lymphocytic leukaemia;Leukocytosis,127838211.0,OT,,,,,,,,,127838211.0,1.0,HIV infection
12786177,127861772,2,F,20160828.0,20161019.0,20160927,20161028,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-078232,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,66.0,KG,20161028.0,,OT,UG,UG,EFAVIRENZ,Abortion incomplete;Anaemia;Maternal exposure during pregnancy;Pyrexia;Transfusion,127861772.0,HO,,,127861772.0,1.0,20130603.0,,,,127861772.0,1.0,HIV infection
12789452,127894521,1,I,201606.0,20160920.0,20160928,20160928,EXP,,UG-GILEAD-2016-0234781,GILEAD,,37.0,YR,A,F,Y,66.0,KG,20160928.0,,MD,UG,UG,EFAVIRENZ,Abortion incomplete;Anaemia;Maternal exposure during pregnancy,127894521.0,HO,,,127894521.0,1.0,20130603.0,,,,127894521.0,1.0,HIV infection
12796591,127965911,1,I,,20160922.0,20160929,20160929,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-079766,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160929.0,,CN,US,US,SUSTIVA,Dialysis,127965911.0,OT,,,,,,,,,127965911.0,1.0,HIV infection
12800684,128006841,1,I,,20160919.0,20161001,20161001,EXP,,GB-HETERO LABS LTD-1057897,HETERO,,25.0,YR,,M,Y,,,20161001.0,,MD,GB,GB,Efavirenz,Porphyria acute,128006841.0,HO,,,,,,,,,128006841.0,1.0,HIV infection
12801125,128011251,1,I,,20160919.0,20161003,20161003,EXP,,GR-CIPLA LTD.-2016GR18982,CIPLA,,,,,,Y,,,20161003.0,,OT,FR,GR,Efavirenz,Acute kidney injury;Lactic acidosis,128011251.0,HO,,,,,,,,,128011251.0,1.0,HIV infection
12801144,128011441,1,I,,20160919.0,20161003,20161003,EXP,,US-CIPLA LTD.-2016US18986,CIPLA,,,,,,Y,,,20161003.0,,OT,FR,US,Efavirenz,Post infection glomerulonephritis;Renal tubular necrosis,128011441.0,OT,,,,,,,,,128011441.0,1.0,HIV infection
12801169,128011691,1,I,,20160919.0,20161003,20161003,EXP,,US-CIPLA LTD.-2016US18989,CIPLA,,,,,,Y,,,20161003.0,,OT,FR,US,Efavirenz,Intercapillary glomerulosclerosis;Tubulointerstitial nephritis,128011691.0,OT,,,,,,,,,128011691.0,1.0,HIV infection
12801175,128011751,1,I,,20160919.0,20161003,20161003,EXP,,US-CIPLA LTD.-2016US18996,CIPLA,,,,,,Y,,,20161003.0,,OT,FR,US,Efavirenz,Renal tubular necrosis,128011751.0,OT,,,,,,,,,128011751.0,1.0,HIV infection
12812571,128125712,2,F,20160809.0,20161017.0,20161005,20161019,EXP,,AR-ABBVIE-16P-007-1744542-00,ABBOTT,,51.0,YR,,M,Y,85.0,KG,20161019.0,,MD,AR,AR,EFAVIRENZ,Overdose,128125712.0,OT,,,128125712.0,1.0,20160216.0,,,,128125712.0,1.0,HIV infection
12825387,128253871,1,I,,20160929.0,20161006,20161006,EXP,,IT-GILEAD-2016-0236046,GILEAD,,67.0,YR,E,M,Y,87.0,KG,20161006.0,,MD,IT,IT,EFAVIRENZ,Chronic kidney disease;Toxicity to various agents,128253871.0,OT,,,128253871.0,1.0,20151022.0,,,,128253871.0,1.0,Antiretroviral therapy
12830781,128307811,1,I,20150413.0,20160920.0,20161007,20161007,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK146704,VIIV,,47.0,YR,,F,Y,,,20161007.0,,MD,ZA,ZA,Efavirenz,Anaemia,128307811.0,OT,,,128307811.0,1.0,20140611.0,,,,128307811.0,1.0,HIV infection
12830782,128307821,1,I,201504.0,20160920.0,20161007,20161007,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK146744,VIIV,,,,,M,Y,,,20161007.0,,MD,ZA,ZA,Efavirenz,Death,128307821.0,DE,,,128307821.0,1.0,20141125.0,20141125.0,,,128307821.0,1.0,HIV infection
12830783,128307831,1,I,20150913.0,20160920.0,20161007,20161007,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK146755,VIIV,,56.0,YR,,F,Y,,,20161007.0,,MD,ZA,ZA,Efavirenz,Diabetes mellitus inadequate control;Haematemesis,128307831.0,OT,,,128307831.0,1.0,20150217.0,20150913.0,,,128307831.0,1.0,HIV infection
12830784,128307841,1,I,201504.0,20160920.0,20161007,20161007,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK146744,GLAXOSMITHKLINE,,,,,M,Y,,,20161007.0,,MD,ZA,ZA,Efavirenz,Death,128307841.0,DE,,,128307841.0,1.0,20141125.0,20141125.0,,,128307841.0,1.0,HIV infection
12830785,128307851,1,I,20150413.0,20160920.0,20161007,20161007,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK146704,GLAXOSMITHKLINE,,47.0,YR,,F,Y,,,20161007.0,,MD,ZA,ZA,Efavirenz,Anaemia,128307851.0,OT,,,128307851.0,1.0,20140611.0,,,,128307851.0,1.0,HIV infection
12830786,128307861,1,I,20150913.0,20160920.0,20161007,20161007,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK146755,GLAXOSMITHKLINE,,56.0,YR,,F,Y,,,20161007.0,,MD,ZA,ZA,Efavirenz,Diabetes mellitus inadequate control;Haematemesis,128307861.0,OT,,,128307861.0,1.0,20150217.0,20150913.0,,,128307861.0,1.0,HIV infection
12845892,128458923,3,F,,20190617.0,20161013,20190624,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-083271,BRISTOL MYERS SQUIBB,,55.0,YR,,F,Y,,,20190624.0,,OT,IT,IT,EFAVIRENZ.,Lipodystrophy acquired,128458923.0,OT,,,128458923.0,1.0,200412.0,200605.0,,,128458923.0,1.0,Antiretroviral therapy
12847189,128471891,1,I,2013.0,20151026.0,20161014,20161014,PER,,US-ABBVIE-15P-163-1493615-00,ABBOTT,,,,,M,Y,77.18,KG,20161014.0,,CN,US,US,Sustiva (NON-ABBVIE),Blood triglycerides increased;Nasopharyngitis;Oropharyngeal pain,,,,,128471891.0,1.0,2005.0,,,,128471891.0,1.0,HIV infection
12851865,128518653,3,F,,20171102.0,20161017,20171103,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-084929,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,,,20171103.0,,CN,GB,IT,EFAVIRENZ.,Lipodystrophy acquired,128518653.0,OT,,,,,,,,,128518653.0,1.0,HIV infection
12852628,128526281,1,I,,20161007.0,20161017,20161017,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-086102,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161017.0,,MD,IT,IT,SUSTIVA,Neurotoxicity,128526281.0,OT,,,128526281.0,1.0,20110420.0,,,,128526281.0,1.0,HIV infection
12854418,128544181,1,I,,20161011.0,20161017,20161017,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-086083,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161017.0,,CN,US,US,SUSTIVA,Fatigue,,,,,,,,,,,128544181.0,1.0,HIV infection
12855851,128558511,1,I,,20161005.0,20161018,20161018,EXP,,US-CIPLA LTD.-2016US19338,CIPLA,,,,,,Y,,,20161018.0,,OT,US,US,Efavirenz,Adrenal suppression;Drug interaction,128558511.0,OT,,,,,,,,,128558511.0,1.0,HIV infection
12860709,128607095,5,F,20161004.0,20161117.0,20161019,20161123,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-084891,BRISTOL MYERS SQUIBB,,24.0,YR,,F,Y,77.0,KG,20161123.0,,OT,BR,BR,EFAVIRENZ,Caesarean section;Gestational hypertension;Maternal exposure during pregnancy;Normal newborn;Suicidal ideation,128607095.0,OT,,,128607095.0,1.0,20160923.0,20161004.0,,,128607095.0,1.0,HIV infection
12865163,128651631,1,I,,20161017.0,20161020,20161020,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016GSK153318,VIIV,,,,,M,Y,50.0,KG,20161020.0,,OT,CN,CN,Efavirenz,Anaemia;Asthenia;Dizziness;Granulocytopenia;Headache;Liver injury;Syncope,128651631.0,HO,,,128651631.0,1.0,20160401.0,20160808.0,,,128651631.0,1.0,HIV infection
12866060,128660601,1,I,,20161017.0,20161020,20161020,EXP,,CN-GLAXOSMITHKLINE-CN2016GSK153318,GLAXOSMITHKLINE,,,,,M,Y,50.0,KG,20161020.0,,OT,CN,CN,Efavirenz,Anaemia;Asthenia;Dizziness;Granulocytopenia;Headache;Liver injury;Syncope,128660601.0,HO,,,128660601.0,1.0,20160401.0,20160808.0,,,128660601.0,1.0,HIV infection
12869205,128692051,1,I,200502.0,20161012.0,20161021,20161021,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016154817,VIIV,,50.0,YR,,M,Y,,,20161021.0,,MD,GB,GB,Efavirenz,Treatment failure,128692051.0,OT,,,128692051.0,1.0,,200502.0,,,128692051.0,1.0,HIV infection
12870291,128702911,1,I,200502.0,20161012.0,20161021,20161021,EXP,,GB-GLAXOSMITHKLINE-GB2016154817,GLAXOSMITHKLINE,,50.0,YR,,M,Y,,,20161021.0,,MD,GB,GB,Efavirenz,Treatment failure,128702911.0,OT,,,128702911.0,1.0,,200502.0,,,128702911.0,1.0,HIV infection
12876845,128768454,4,F,201004.0,20170601.0,20161024,20170605,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2016JPN152007,VIIV,,49.0,YR,,F,Y,,,20170605.0,,CN,JP,JP,EFAVIRENZ,Chronic kidney disease;Diabetes mellitus;Hypertension;Lipids abnormal,128768454.0,OT,,,128768454.0,1.0,2009.0,20150202.0,,,128768454.0,1.0,HIV infection
12876846,128768462,2,F,,20161108.0,20161024,20161114,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2016JPN152009,VIIV,,65.0,YR,,F,Y,,,20161114.0,,MD,JP,JP,EFAVIRENZ,No adverse event,,,,,128768462.0,1.0,201212.0,201402.0,,,128768462.0,1.0,HIV infection
12876972,128769724,4,F,201004.0,20170601.0,20161024,20170605,EXP,,JP-GLAXOSMITHKLINE-JP2016JPN152007,GLAXOSMITHKLINE,,49.0,YR,,F,Y,,,20170605.0,,CN,JP,JP,EFAVIRENZ,Chronic kidney disease;Diabetes mellitus;Hypertension;Lipids abnormal,128769724.0,OT,,,128769724.0,1.0,2009.0,20150202.0,,,128769724.0,1.0,HIV infection
12878917,128789172,2,F,20160809.0,20161019.0,20161024,20161027,EXP,,CN-GILEAD-2016-0238925,GILEAD,,40.0,YR,A,M,Y,50.0,KG,20161027.0,,OT,CN,CN,EFAVIRENZ,Anaemia;Granulocytopenia;Liver injury,128789172.0,OT,,,128789172.0,1.0,20160401.0,20160808.0,,,128789172.0,1.0,HIV infection
12879418,128794182,2,F,20160809.0,20161108.0,20161025,20161116,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-089581,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,50.0,KG,20161116.0,,CN,CN,CN,EFAVIRENZ,Anaemia;Granulocytopenia;Liver injury,128794182.0,HO,,,128794182.0,1.0,20160401.0,20160808.0,,,128794182.0,1.0,HIV infection
12887669,128876691,1,I,,20161017.0,20161026,20161026,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-088494,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20161026.0,,OT,US,US,EFAVIRENZ,Retinal toxicity,128876691.0,OT,,,,,,,,,128876691.0,1.0,HIV infection
12891076,128910761,1,I,20051011.0,20161021.0,20161027,20161027,EXP,,GB-GILEAD-2016-0240193,GILEAD,,51.0,YR,A,M,Y,,,20161027.0,,MD,GB,GB,EFAVIRENZ,Herpes zoster;Secondary syphilis,128910761.0,OT,,,128910761.0,1.0,20030912.0,20051223.0,,,128910761.0,1.0,HIV infection
12891989,128919891,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20027,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Virologic failure,128919891.0,OT,,,,,,,,,128919891.0,1.0,HIV infection
12892001,128920011,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20031,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Virologic failure,128920011.0,OT,,,,,,,,,128920011.0,1.0,HIV infection
12892054,128920541,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20032,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Virologic failure,128920541.0,OT,,,,,,,,,128920541.0,1.0,HIV infection
12892070,128920701,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20033,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Virologic failure,128920701.0,OT,,,,,,,,,128920701.0,1.0,HIV infection
12892447,128924471,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20044,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128924471.0,OT,,,,,,,,,128924471.0,1.0,HIV infection
12892490,128924901,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20034,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128924901.0,OT,,,,,,,,,128924901.0,1.0,HIV infection
12892569,128925691,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20035,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128925691.0,OT,,,,,,,,,128925691.0,1.0,HIV infection
12892591,128925911,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20043,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Disease progression,128925911.0,OT,,,,,,,,,128925911.0,1.0,HIV infection
12892660,128926601,1,I,,20161018.0,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20063,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,GB,Efavirenz,Virologic failure,128926601.0,OT,,,,,,,,,128926601.0,1.0,HIV infection
12892681,128926812,2,F,,20200820.0,20161028,20200902,EXP,,GB-CIPLA LTD.-2016US20054,CIPLA,,,,,,Y,,,20200902.0,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,128926812.0,OT,,,,,,,,,128926812.0,1.0,HIV infection
12892723,128927231,1,I,,20161018.0,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20052,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,GB,Efavirenz,Cardiac disorder,128927231.0,OT,,,,,,,,,128927231.0,1.0,HIV infection
12892738,128927381,1,I,,20161018.0,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20051,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,GB,Efavirenz,Cardiac disorder,128927381.0,OT,,,,,,,,,128927381.0,1.0,HIV infection
12892744,128927441,1,I,,20161018.0,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20050,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,GB,Efavirenz,Cardiac disorder,128927441.0,OT,,,,,,,,,128927441.0,1.0,HIV infection
12892747,128927472,2,F,,20200820.0,20161028,20200903,EXP,,GB-CIPLA LTD.-2016US20049,CIPLA,,,,,,Y,,,20200903.0,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,128927472.0,OT,,,,,,,,,128927472.0,1.0,HIV infection
12892805,128928051,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20047,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128928051.0,OT,,,,,,,,,128928051.0,1.0,HIV infection
12892831,128928311,1,I,,20161018.0,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20046,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128928311.0,OT,,,,,,,,,128928311.0,1.0,HIV infection
12892896,128928961,1,I,,20161018.0,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20064,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,GB,Efavirenz,Virologic failure,128928961.0,OT,,,,,,,,,128928961.0,1.0,HIV infection
12892903,128929031,1,I,,20161018.0,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20065,CIPLA,,,,,,Y,,,20161028.0,,OT,ES,GB,Efavirenz,Virologic failure,128929031.0,OT,,,,,,,,,128929031.0,1.0,HIV infection
12901850,129018501,1,I,,20161018.0,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20056,CIPLA,,,,,,Y,,,20161102.0,,OT,ES,GB,Efavirenz,Cardiac disorder,129018501.0,OT,,,,,,,,,129018501.0,1.0,HIV infection
12901876,129018762,2,F,,20200820.0,20161102,20200903,EXP,,GB-CIPLA LTD.-2016US20057,CIPLA,,,,,,Y,,,20200903.0,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,129018762.0,OT,,,,,,,,,129018762.0,1.0,HIV infection
12901926,129019262,2,F,,20200820.0,20161102,20200902,EXP,,GB-CIPLA LTD.-2016US20058,CIPLA,,,,,,Y,,,20200902.0,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,129019262.0,OT,,,,,,,,,129019262.0,2.0,HIV infection
12901928,129019281,1,I,,20161018.0,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20062,CIPLA,,,,,,Y,,,20161102.0,,OT,ES,GB,Efavirenz,Virologic failure,129019281.0,OT,,,,,,,,,129019281.0,1.0,HIV infection
12901936,129019361,1,I,,20161018.0,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20061,CIPLA,,,,,,Y,,,20161102.0,,OT,ES,GB,Efavirenz,Virologic failure,129019361.0,OT,,,,,,,,,129019361.0,1.0,HIV infection
12901944,129019441,1,I,,20161018.0,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20060,CIPLA,,,,,,Y,,,20161102.0,,OT,ES,GB,Efavirenz,Virologic failure,129019441.0,OT,,,,,,,,,129019441.0,1.0,HIV infection
12901945,129019451,1,I,,20161018.0,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20059,CIPLA,,,,,,Y,,,20161102.0,,OT,ES,GB,Efavirenz,Virologic failure,129019451.0,OT,,,,,,,,,129019451.0,1.0,HIV infection
12901977,129019771,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20438,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129019771.0,OT,,,,,,,,,129019771.0,1.0,Prophylaxis against HIV infection
12901991,129019911,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20440,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Foetal exposure during pregnancy;Virologic failure,129019911.0,OT,,,,,,,,,129019911.0,1.0,Prophylaxis against HIV infection
12901994,129019941,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20437,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129019941.0,OT,,,,,,,,,129019941.0,1.0,Prophylaxis against HIV infection
12901998,129019981,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20439,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129019981.0,OT,,,,,,,,,129019981.0,1.0,Prophylaxis against HIV infection
12902048,129020481,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20447,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020481.0,OT,,,,,,,,,129020481.0,1.0,HIV infection
12902055,129020551,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20448,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020551.0,OT,,,,,,,,,129020551.0,1.0,HIV infection
12902058,129020581,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20451,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020581.0,OT,,,,,,,,,129020581.0,1.0,HIV infection
12902061,129020611,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20443,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,LB,Efavirenz,Drug resistance;Virologic failure,129020611.0,OT,,,,,,,,,129020611.0,1.0,Prophylaxis against HIV infection
12902066,129020661,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20449,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020661.0,OT,,,,,,,,,129020661.0,1.0,HIV infection
12902070,129020701,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20446,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020701.0,OT,,,,,,,,,129020701.0,1.0,HIV infection
12902072,129020721,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20452,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63(8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020721.0,OT,,,,,,,,,129020721.0,1.0,Prophylaxis against HIV infection
12902081,129020811,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20450,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020811.0,OT,,,,,,,,,129020811.0,1.0,HIV infection
12902089,129020891,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20441,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020891.0,OT,,,,,,,,,129020891.0,1.0,Prophylaxis against HIV infection
12902091,129020911,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20444,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020911.0,OT,,,,,,,,,129020911.0,1.0,HIV infection
12902097,129020971,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20445,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020971.0,OT,,,,,,,,,129020971.0,1.0,HIV infection
12902100,129021001,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20442,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,LB,Efavirenz,Drug resistance;Virologic failure,129021001.0,OT,,,,,,,,,129021001.0,1.0,Prophylaxis against HIV infection
12902308,129023081,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20456,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129023081.0,OT,,,,,,,,,129023081.0,1.0,Prophylaxis against HIV infection
12902339,129023391,1,I,,20161019.0,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20455,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63(8):1113 TO 1121",,,,,Y,,,20161102.0,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129023391.0,OT,,,,,,,,,129023391.0,1.0,Prophylaxis against HIV infection
12909513,129095131,1,I,,20140719.0,20161104,20161104,EXP,,TH-CIPLA LTD.-2016TH10034,CIPLA,"CRESSEY TR, STEK A, CAPPARELLI E, BOWONWATANUWONG C, PROMMAS S, SIRIVATANAPA AND ET AL.,. EFAVIRENZ PHARMACOKINETICS DURING THE THIRD TRIMESTER OF PREGNANCY AND POSTPARTUM. J ACQUIR IMMUNE DEFIC SYNDR. 2012;59(3):245 TO 252",,,,,Y,,,20161104.0,,OT,TH,TH,Efavirenz,Exposure during pregnancy;Premature labour;Premature rupture of membranes,129095131.0,OT,,,,,,,,,129095131.0,1.0,HIV infection
12909520,129095201,1,I,,20140719.0,20161104,20161104,EXP,,TH-CIPLA LTD.-2016TH10035,CIPLA,"CRESSEY TR, STEK A, CAPPARELLI E, BOWONWATANUWONG C, PROMMAS S, SIRIVATANAPA ET AL.. EFAVIRENZ PHARMACOKINETICS DURING THE THIRD TRIMESTER OF PREGNANCY AND POSTPARTUM. J ACQUIR IMMUNE DEFIC SYNDR. 2012;59(3):245 TO 252",,,,,Y,,,20161104.0,,OT,TH,TH,Efavirenz,Exposure during pregnancy;Gestational diabetes;Premature rupture of membranes,129095201.0,OT,,,,,,,,,129095201.0,1.0,HIV infection
12911257,129112571,1,I,,20140719.0,20161104,20161104,EXP,,TH-CIPLA LTD.-2016TH10032,CIPLA,"CRESSEY TR, STEK A, CAPPARELLI E, BOWONWATANUWONG C, PROMMAS S, SIRIVATANAPA P ET AL. EFAVIRENZ PHARMACOKINETICS DURING THE THIRD TRIMESTER OF PREGNANCY AND POSTPARTUM. J ACQUIR IMMUNE DEFIC SYNDR. 2012;59 (3):245 TO 252",,,,,Y,,,20161104.0,,OT,TH,TH,Efavirenz,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,129112571.0,OT,,,,,,,,,129112571.0,5.0,Prophylaxis against HIV infection
12913682,129136822,2,F,,20171102.0,20161104,20171103,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-093597,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20171103.0,,OT,RO,RO,EFAVIRENZ.,Blood cholesterol increased;Blood triglycerides increased;Irritability;Lipodystrophy acquired;Sleep disorder,129136822.0,OT,,,,,,,,,129136822.0,1.0,Antiretroviral therapy
12913922,129139222,2,F,,20171102.0,20161104,20171103,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-093988,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20171103.0,,OT,RO,RO,EFAVIRENZ.,Lipodystrophy acquired;Neuropathy peripheral;Nightmare;Sleep disorder,129139222.0,OT,,,,,,,,,129139222.0,1.0,Antiretroviral therapy
12922790,129227901,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20816,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Adverse event,129227901.0,OT,,,,,,,,,129227901.0,1.0,HIV infection
12922809,129228091,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20820,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Death,129228091.0,DE,,,,,,,,,129228091.0,1.0,HIV infection
12922817,129228171,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20818,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Adverse event,129228171.0,OT,,,,,,,,,129228171.0,1.0,HIV infection
12922821,129228211,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20819,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Death,129228211.0,DE,,,,,,,,,129228211.0,1.0,HIV infection
12922838,129228381,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20829,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Treatment failure,129228381.0,OT,,,,,,,,,129228381.0,1.0,HIV infection
12922852,129228521,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20832,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Treatment failure,129228521.0,OT,,,,,,,,,129228521.0,1.0,HIV infection
12922858,129228581,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20830,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Treatment failure,129228581.0,OT,,,,,,,,,129228581.0,1.0,HIV infection
12922863,129228631,1,I,,20161028.0,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20828,CIPLA,,,,,,Y,,,20161109.0,,OT,US,GH,Efavirenz,Treatment failure,129228631.0,OT,,,,,,,,,129228631.0,1.0,HIV infection
12922870,129228701,1,I,,20161028.0,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20750,CIPLA,,,,,,Y,,,20161109.0,,OT,SE,TZ,Efavirenz,Death,129228701.0,DE,,,,,,,,,129228701.0,1.0,HIV infection
12922874,129228741,1,I,,20161028.0,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20745,CIPLA,,,,,,Y,,,20161109.0,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129228741.0,DE,,,,,,,,,129228741.0,1.0,HIV infection
12922885,129228851,1,I,,20161028.0,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20757,CIPLA,,,,,,Y,,,20161109.0,,OT,SE,TZ,Efavirenz,Death,129228851.0,DE,,,,,,,,,129228851.0,1.0,HIV infection
12922892,129228921,1,I,,20161028.0,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20752,CIPLA,,,,,,Y,,,20161109.0,,OT,SE,TZ,Efavirenz,Death,129228921.0,DE,,,,,,,,,129228921.0,1.0,HIV infection
12922896,129228961,1,I,,20161028.0,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20746,CIPLA,,,,,,Y,,,20161109.0,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129228961.0,DE,,,,,,,,,129228961.0,1.0,HIV infection
12922906,129229061,1,I,,20161028.0,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20747,CIPLA,,,,,,Y,,,20161109.0,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129229061.0,DE,,,,,,,,,129229061.0,1.0,HIV infection
12922914,129229141,1,I,,20161028.0,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20748,CIPLA,,,,,,Y,,,20161109.0,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129229141.0,DE,,,,,,,,,129229141.0,1.0,HIV infection
12922931,129229311,1,I,,20161027.0,20161109,20161109,EXP,,RO-MYLANLABS-2016M1047678,MYLAN,"NEGUT AC, STREINU-CERCEL O, LAZER M, STREINU-CERCEL A. LONG SURVIVOR FAMILY WITH HIV INFECTION. CASE PRESENTATION. BMC-INFECT-DIS 2013;13 (SUPPL. 1): ABSTR. P56.",,,,,Y,,,20161109.0,,OT,RO,RO,EFAVIRENZ,Lipodystrophy acquired;Neuropathy peripheral;Nightmare;Sleep disorder,129229311.0,OT,,,,,,,,,129229311.0,1.0,Antiretroviral therapy
12923773,129237731,1,I,20161108.0,,20161108,20161108,DIR,,,FDA-CTU,,56.0,YR,,F,N,,,20161108.0,N,OT,US,US,SUSTIVA,"Accident at work;Anxiety;Arthralgia;Hallucination, auditory;Limb injury;Platelet count decreased;Sciatica",,,129237731.0,HP,,,,,,,129237731.0,1.0,HIV infection
12927432,129274322,2,F,20160922.0,20161110.0,20161109,20161116,EXP,ES-AGEMED-326706347,ES-GILEAD-2016-0242095,GILEAD,,47.0,YR,A,F,Y,,,20161116.0,,MD,ES,ES,EFAVIRENZ,Rib fracture,129274322.0,OT,,,129274322.0,1.0,2003.0,,,,129274322.0,1.0,HIV infection
12927583,129275831,1,I,,20161027.0,20161109,20161109,EXP,,RO-MYLANLABS-2016M1047680,MYLAN,"NEGUT AC, STREINU-CERCEL O, LAZER M, STREINU-CERCEL A. LONG SURVIVOR FAMILY WITH HIV INFECTION. CASE PRESENTATION. BMC-INFECT-DIS 2013;13 (SUPPL. 1): ABSTR. P56.",,,,,Y,,,20161109.0,,OT,RO,RO,EFAVIRENZ,Blood cholesterol increased;Blood triglycerides increased;Irritability;Lipodystrophy acquired;Sleep disorder,129275831.0,OT,,,,,,,,,129275831.0,1.0,Antiretroviral therapy
12928117,129281171,1,I,,20161027.0,20161110,20161110,EXP,,GB-CIPLA LTD.-2016GB20864,CIPLA,,,,,,Y,,,20161110.0,,OT,GB,GB,Efavirenz,Acute hepatic failure;Hepatic encephalopathy;Hyperlipidaemia;Myopathy;Rash;Renal impairment;Transplant dysfunction;Transplant rejection;Viral load increased,129281171.0,HO,,,,,,,,,129281171.0,1.0,HIV infection
12928286,129282861,1,I,,20161028.0,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20824,CIPLA,,,,,,Y,,,20161110.0,,OT,US,GH,Efavirenz,Disease progression,129282861.0,OT,,,,,,,,,129282861.0,1.0,HIV infection
12928300,129283001,1,I,,20161028.0,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20815,CIPLA,,,,,,Y,,,20161110.0,,OT,US,GH,Efavirenz,Mental disorder,129283001.0,OT,,,,,,,,,129283001.0,1.0,HIV infection
12928302,129283021,1,I,,20161028.0,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20813,CIPLA,,,,,,Y,,,20161110.0,,OT,US,GH,Efavirenz,Mental disorder,129283021.0,OT,,,,,,,,,129283021.0,1.0,HIV infection
12928320,129283201,1,I,,20161028.0,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20822,CIPLA,,,,,,Y,,,20161110.0,,OT,US,GH,Efavirenz,Disease progression,129283201.0,OT,,,,,,,,,129283201.0,1.0,HIV infection
12928336,129283361,1,I,,20161028.0,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20789,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110.0,,OT,JP,JP,Efavirenz,Drug level increased,129283361.0,OT,,,,,,,,,129283361.0,1.0,HIV infection
12928339,129283391,1,I,,20161028.0,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20786,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H ET AL.,. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26.. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110.0,,OT,JP,JP,Efavirenz,Thrombocytopenia,129283391.0,OT,,,,,,,,,129283391.0,1.0,HIV infection
12928353,129283531,1,I,,20161028.0,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20783,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H ET AL.,. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1 INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110.0,,OT,JP,JP,Efavirenz,Dizziness;Drug level increased,129283531.0,OT,,,,,,,,,129283531.0,1.0,HIV infection
12928357,129283571,1,I,,20161028.0,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20826,CIPLA,,,,,,Y,,,20161110.0,,OT,US,GH,Efavirenz,Disease progression,129283571.0,OT,,,,,,,,,129283571.0,1.0,HIV infection
12928370,129283701,1,I,,20161028.0,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20825,CIPLA,,,,,,Y,,,20161110.0,,OT,US,GH,Efavirenz,Disease progression,129283701.0,OT,,,,,,,,,129283701.0,1.0,HIV infection
12928388,129283881,1,I,,20161028.0,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20751,CIPLA,,,,,,Y,,,20161110.0,,OT,SE,TZ,Efavirenz,Death,129283881.0,DE,,,,,,,,,129283881.0,1.0,HIV infection
12928396,129283961,1,I,,20161028.0,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20795,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110.0,,OT,JP,JP,Efavirenz,Drug level increased,129283961.0,OT,,,,,,,,,129283961.0,1.0,HIV infection
12928401,129284011,1,I,,20161028.0,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20790,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110.0,,OT,JP,JP,Efavirenz,Drug level increased,129284011.0,OT,,,,,,,,,129284011.0,1.0,HIV infection
12928402,129284021,1,I,,20161028.0,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20794,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110.0,,OT,JP,JP,Efavirenz,Drug level increased,129284021.0,OT,,,,,,,,,129284021.0,1.0,HIV infection
12928475,129284751,1,I,,20161028.0,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20754,CIPLA,,,,,,Y,,,20161110.0,,OT,SE,TZ,Efavirenz,Death,129284751.0,DE,,,,,,,,,129284751.0,1.0,HIV infection
12928479,129284791,1,I,,20161028.0,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20753,CIPLA,,,,,,Y,,,20161110.0,,OT,SE,TZ,Efavirenz,Death,129284791.0,DE,,,,,,,,,129284791.0,1.0,HIV infection
12928519,129285191,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21029,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285191.0,OT,,,,,,,,,129285191.0,1.0,Antiretroviral therapy
12928529,129285291,1,I,,20161028.0,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20756,CIPLA,,,,,,Y,,,20161110.0,,OT,SE,TZ,Efavirenz,Death,129285291.0,DE,,,,,,,,,129285291.0,1.0,HIV infection
12928538,129285381,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW20766,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285381.0,OT,,,,,,,,,129285381.0,1.0,Antiretroviral therapy
12928544,129285441,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21030,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285441.0,OT,,,,,,,,,129285441.0,1.0,Antiretroviral therapy
12928555,129285551,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21031,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285551.0,OT,,,,,,,,,129285551.0,1.0,Antiretroviral therapy
12928575,129285751,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21032,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285751.0,OT,,,,,,,,,129285751.0,1.0,Antiretroviral therapy
12928600,129286001,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21034,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129286001.0,OT,,,,,,,,,129286001.0,1.0,Antiretroviral therapy
12928603,129286031,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21033,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129286031.0,OT,,,,,,,,,129286031.0,1.0,Antiretroviral therapy
12928618,129286181,1,I,,20161028.0,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21035,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110.0,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129286181.0,OT,,,,,,,,,129286181.0,1.0,Antiretroviral therapy
12930223,129302231,1,I,20160630.0,20161104.0,20161110,20161110,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-095298,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,104.0,KG,20161110.0,,OT,CH,CH,EFAVIRENZ,Appendicitis,129302231.0,HO,,,129302231.0,2.0,20151222.0,,,,129302231.0,1.0,HIV infection
12931785,129317851,1,I,,20161031.0,20161111,20161111,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-095784,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,,,20161111.0,,OT,US,US,EFAVIRENZ,Blood HIV RNA increased;Viraemia,129317851.0,OT,,,,,,,,,129317851.0,1.0,Antiretroviral therapy
12931799,129317991,1,I,,20161031.0,20161111,20161111,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-095756,BRISTOL MYERS SQUIBB,,23.0,YR,,M,Y,,,20161111.0,,OT,US,US,EFAVIRENZ,Blood HIV RNA increased;Viral mutation identified,129317991.0,OT,,,,,,,,,129317991.0,1.0,Antiretroviral therapy
12931923,129319231,1,I,,20161028.0,20161111,20161111,EXP,,TH-CIPLA LTD.-2016TH20848,CIPLA,,,,,,Y,,,20161111.0,,OT,US,TH,Efavirenz,Delusion,129319231.0,OT,,,,,,,,,129319231.0,1.0,HIV infection
12939475,129394751,1,I,,20161102.0,20161115,20161115,EXP,,ES-CIPLA LTD.-2016ES21009,CIPLA,"GANTNER P, BANI-SADR F, GARRAFFO R, ROGER PM, TREGER M, JOVELIN T ET AL.,. SWITCH TO RITONAVIR-BOOSTED VERSUS UNBOOSTED ATAZANAVIR PLUS RALTEGRAVIR DUAL-DRUG THERAPY LEADS TO SIMILAR EFFICACY AND SAFETY OUTCOMES IN CLINICAL PRACTICE. PLOS ONE. 2016;1 TO 13",,,,,Y,,,20161115.0,,OT,FR,ES,Efavirenz,Diabetes mellitus;Diarrhoea;Drug resistance;Dyslipidaemia;Lipodystrophy acquired;Osteoporosis;Virologic failure,129394751.0,OT,,,,,,,,,129394751.0,1.0,HIV infection
12942708,129427081,1,I,,20161104.0,20161114,20161114,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-094642,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161114.0,,CN,US,US,SUSTIVA,Depression;Drug abuse;Hallucination;Insomnia;Mood swings;Suicidal ideation,129427081.0,OT,,,129427081.0,1.0,2002.0,,,,129427081.0,1.0,HIV infection
12945570,129455702,2,F,20160906.0,20161107.0,20161116,20161121,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096060,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20161121.0,,CN,CN,CN,EFAVIRENZ,Drug eruption,129455702.0,HO,,,129455702.0,1.0,20160902.0,20160906.0,,,129455702.0,1.0,HIV infection
12946469,129464691,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21146,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Hearing disability;Vestibular disorder,129464691.0,OT,,,,,,,,,129464691.0,1.0,HIV infection
12946470,129464701,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21141,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129464701.0,OT,,,,,,,,,129464701.0,1.0,HIV infection
12946475,129464751,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21145,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Nervous system disorder,129464751.0,OT,,,,,,,,,129464751.0,1.0,HIV infection
12946488,129464881,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21140,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129464881.0,OT,,,,,,,,,129464881.0,1.0,HIV infection
12946494,129464941,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21143,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Mental disorder,129464941.0,OT,,,,,,,,,129464941.0,1.0,HIV infection
12946497,129464971,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21142,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129464971.0,OT,,,,,,,,,129464971.0,1.0,HIV infection
12946521,129465211,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21150,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129465211.0,OT,,,,,,,,,129465211.0,1.0,HIV infection
12946522,129465221,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21156,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Musculoskeletal disorder,129465221.0,OT,,,,,,,,,129465221.0,1.0,HIV infection
12946541,129465411,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21153,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129465411.0,OT,,,,,,,,,129465411.0,1.0,HIV infection
12946566,129465661,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21171,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Mental disorder,129465661.0,OT,,,,,,,,,129465661.0,1.0,HIV infection
12946584,129465841,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21147,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129465841.0,OT,,,,,,,,,129465841.0,1.0,HIV infection
12946590,129465901,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21158,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Musculoskeletal disorder,129465901.0,OT,,,,,,,,,129465901.0,1.0,HIV infection
12946610,129466101,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21173,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129466101.0,OT,,,,,,,,,129466101.0,1.0,HIV infection
12946612,129466121,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21179,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129466121.0,OT,,,,,,,,,129466121.0,1.0,HIV infection
12946619,129466191,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21178,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129466191.0,OT,,,,,,,,,129466191.0,1.0,HIV infection
12946635,129466351,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21181,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129466351.0,OT,,,,,,,,,129466351.0,1.0,HIV infection
12946637,129466371,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21182,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129466371.0,OT,,,,,,,,,129466371.0,1.0,HIV infection
12946650,129466501,1,I,,20161104.0,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21186,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116.0,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129466501.0,OT,,,,,,,,,129466501.0,1.0,HIV infection
12947636,129476362,2,F,,20161027.0,20161116,20161205,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-092524,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161205.0,,PH,US,US,SUSTIVA,Cyst removal;Dysphagia;Gastrointestinal tube insertion;Tonsillar cyst,129476362.0,OT,,,,,,,,,129476362.0,1.0,HIV infection
12948028,129480281,1,I,20160630.0,20161109.0,20161116,20161116,EXP,,CH-GILEAD-2016-0242742,GILEAD,,42.0,YR,A,M,Y,104.0,KG,20161116.0,,OT,CH,CH,EFAVIRENZ,Appendicitis,129480281.0,HO,,,129480281.0,1.0,20160608.0,20160607.0,,,129480281.0,1.0,HIV infection
12948678,129486781,1,I,,20161104.0,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21133,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,GH,GH,Efavirenz,Mental disorder,129486781.0,OT,,,,,,,,,129486781.0,1.0,HIV infection
12948679,129486791,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21139,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129486791.0,OT,,,,,,,,,129486791.0,1.0,HIV infection
12948680,129486801,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21138,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129486801.0,OT,,,,,,,,,129486801.0,1.0,HIV infection
12948681,129486811,1,I,,20161104.0,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21135,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,GH,GH,Efavirenz,Nervous system disorder;Neuropathy peripheral,129486811.0,OT,,,,,,,,,129486811.0,1.0,HIV infection
12948682,129486821,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21136,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129486821.0,OT,,,,,,,,,129486821.0,1.0,HIV infection
12948683,129486831,1,I,,20161104.0,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21134,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,GH,GH,Efavirenz,Mental disorder,129486831.0,OT,,,,,,,,,129486831.0,1.0,HIV infection
12948684,129486841,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21131,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Mental disorder,129486841.0,OT,,,,,,,,,129486841.0,1.0,HIV infection
12948686,129486861,1,I,,20161104.0,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21132,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,GH,GH,Efavirenz,Mental disorder,129486861.0,OT,,,,,,,,,129486861.0,1.0,HIV infection
12948705,129487051,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21144,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Musculoskeletal disorder,129487051.0,OT,,,,,,,,,129487051.0,1.0,HIV infection
12948728,129487281,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21151,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Mental disorder,129487281.0,OT,,,,,,,,,129487281.0,1.0,HIV infection
12948730,129487301,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21160,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Hepatobiliary disease,129487301.0,OT,,,,,,,,,129487301.0,1.0,HIV infection
12948742,129487421,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21149,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129487421.0,OT,,,,,,,,,129487421.0,1.0,HIV infection
12948801,129488011,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21164,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129488011.0,OT,,,,,,,,,129488011.0,1.0,HIV infection
12948857,129488571,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21168,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Mental disorder,129488571.0,OT,,,,,,,,,129488571.0,1.0,HIV infection
12948875,129488751,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21176,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129488751.0,OT,,,,,,,,,129488751.0,1.0,HIV infection
12948890,129488901,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21175,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129488901.0,OT,,,,,,,,,129488901.0,1.0,HIV infection
12948930,129489301,1,I,,20161104.0,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21174,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117.0,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129489301.0,OT,,,,,,,,,129489301.0,1.0,HIV infection
12953145,129531454,4,F,20160510.0,20170620.0,20161117,20170628,EXP,,BR-ABBVIE-16P-020-1783211-00,ABBVIE,,33.0,YR,,M,Y,70.0,KG,20170628.0,,CN,BR,BR,EFAVIRENZ,Abasia;Asthenia;CD4 lymphocytes decreased;Crying;Decreased appetite;Eating disorder;Fatigue;Immunodeficiency;Memory impairment;Nodule;Somnolence;Viral load increased;Visual impairment,129531454.0,OT,,,129531454.0,1.0,2012.0,2014.0,,,129531454.0,1.0,Acquired immunodeficiency syndrome
12953222,129532222,2,F,20151106.0,20161130.0,20161117,20161130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096103,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,148.8,KG,20161130.0,,OT,US,US,EFAVIRENZ,Asthma,129532222.0,HO,,,129532222.0,1.0,20151030.0,,,,129532222.0,1.0,HIV infection
12953344,129533441,1,I,,20161109.0,20161117,20161117,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096332,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161117.0,,MD,IT,IT,EFAVIRENZ,Cytomegalovirus infection;Hepatocellular carcinoma;Nervous system disorder;Transaminases increased,129533441.0,OT,,,129533441.0,1.0,20081016.0,,,,129533441.0,1.0,HIV infection
12953708,129537081,1,I,,20161104.0,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21126,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118.0,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537081.0,OT,,,,,,,,,129537081.0,1.0,HIV infection
12953747,129537471,1,I,,20161104.0,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21129,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118.0,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537471.0,OT,,,,,,,,,129537471.0,1.0,HIV infection
12953755,129537551,1,I,,20161104.0,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21128,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118.0,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537551.0,OT,,,,,,,,,129537551.0,1.0,HIV infection
12953758,129537581,1,I,,20161104.0,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21127,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118.0,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537581.0,OT,,,,,,,,,129537581.0,1.0,HIV infection
12953780,129537801,1,I,,20161104.0,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21130,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118.0,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129537801.0,OT,,,,,,,,,129537801.0,1.0,HIV infection
12953837,129538371,1,I,,20161104.0,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21193,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118.0,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129538371.0,OT,,,,,,,,,129538371.0,1.0,HIV infection
12957690,129576901,1,I,,20161107.0,20161119,20161119,EXP,,RO-HETERO LABS LTD-1059796,HETERO,,,,,F,Y,,,20161119.0,,,COUNTRY NOT SPECIFIED,RO,Efavirenz,Lipodystrophy acquired;Neuropathy peripheral;Nightmare;Sleep disorder,129576901.0,OT,,,,,,,,,129576901.0,1.0,HIV infection
12962925,129629251,1,I,,20161107.0,20161122,20161122,EXP,,RO-HETERO LABS LTD-1059902,HETERO,ALINA CRISTINA NEGUT. LONG SURVIVOR FAMILY WITH HIV INFECTION. CASE PRESENTATION. BMC-INFECT-DIS 2013;13(SUPPL 1):P56.,,,,M,Y,,,20161122.0,,OT,RO,RO,Efavirenz,Bladder irritation;Blood cholesterol increased;Blood triglycerides increased;Lipodystrophy acquired;Sleep disorder,129629251.0,OT,,,,,,,,,129629251.0,1.0,HIV infection
12963459,129634591,1,I,,20161110.0,20161122,20161122,EXP,,TH-CIPLA LTD.-2016TH21437,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161122.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129634591.0,OT,,,,,,,,,129634591.0,1.0,HIV infection
12963601,129636011,1,I,,20161110.0,20161122,20161122,EXP,,TH-CIPLA LTD.-2016TH21438,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S.. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161122.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129636011.0,OT,,,,,,,,,129636011.0,1.0,HIV infection
12965347,129653471,1,I,2003.0,20150127.0,20161122,20161122,PER,,US-GILEAD-2016-0244335,GILEAD,,69.0,YR,E,M,Y,,,20161122.0,,CN,US,US,SUSTIVA,Drug interaction,,,,,129653471.0,1.0,2003.0,201412.0,,,129653471.0,1.0,HIV infection
12966008,129660081,1,I,20151106.0,20161118.0,20161122,20161122,EXP,,US-GILEAD-2016-0244405,GILEAD,,38.0,YR,A,F,Y,148.8,KG,20161122.0,,MD,US,US,EFAVIRENZ,Asthma,129660081.0,HO,,,129660081.0,1.0,20151030.0,,,,129660081.0,1.0,HIV infection
12966250,129662501,1,I,20161116.0,20161117.0,20161122,20161122,EXP,,IT-GILEAD-2016-0244288,GILEAD,,61.0,YR,A,M,Y,,,20161122.0,,MD,IT,IT,EFAVIRENZ,Pancytopenia,129662501.0,OT,,,129662501.0,1.0,200611.0,201611.0,,,129662501.0,1.0,HIV infection
12966370,129663701,1,I,,,20161121,20161121,DIR,US-FDA-356251,,FDA-CTU,,50.0,YR,,M,N,72.0,KG,20161121.0,N,CN,US,US,SUSTIVA,Abdominal distension;Asthenia;Hepatic enzyme increased;Hepatic lesion;Internal haemorrhage;Pancreatic disorder;Product formulation issue;Renal disorder,129663701.0,OT,129663701.0,CSM,,,,,,,129663701.0,1.0,HIV infection
12966901,129669011,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21439,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669011.0,OT,,,,,,,,,129669011.0,1.0,HIV infection
12966918,129669181,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21441,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669181.0,OT,,,,,,,,,129669181.0,1.0,HIV infection
12966922,129669221,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21440,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669221.0,OT,,,,,,,,,129669221.0,1.0,HIV infection
12966938,129669381,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21443,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669381.0,OT,,,,,,,,,129669381.0,1.0,HIV infection
12966944,129669441,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21442,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CYP2B6 18492T T-}C POLYMORPHISM COMPROMISES EFAVIRENZ CONCENTRATION IN COINFECTED HIV AND TUBERCULOSIS PATIENTS CARRYING CYP2B6 HAPLOTYPE *1/*1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669441.0,OT,,,,,,,,,129669441.0,1.0,HIV infection
12966949,129669491,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21448,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Death,129669491.0,DE,,,,,,,,,129669491.0,1.0,HIV infection
12966975,129669751,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21445,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669751.0,OT,,,,,,,,,129669751.0,1.0,HIV infection
12966997,129669971,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21446,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Death,129669971.0,DE,,,,,,,,,129669971.0,1.0,HIV infection
12967000,129670001,1,I,,20161110.0,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21447,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123.0,,OT,TH,TH,Efavirenz,Death,129670001.0,DE,,,,,,,,,129670001.0,1.0,HIV infection
12967019,129670191,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21405,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G-} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Virologic failure,129670191.0,OT,,,,,,,,,129670191.0,1.0,HIV infection
12967030,129670301,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21367,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Virologic failure,129670301.0,OT,,,,,,,,,129670301.0,1.0,HIV infection
12967313,129673131,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21406,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Virologic failure,129673131.0,OT,,,,,,,,,129673131.0,1.0,HIV infection
12967328,129673281,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21407,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Virologic failure,129673281.0,OT,,,,,,,,,129673281.0,1.0,HIV infection
12967340,129673401,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21409,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673401.0,OT,,,,,,,,,129673401.0,1.0,HIV infection
12967345,129673451,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21408,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Drug level below therapeutic;Virologic failure,129673451.0,OT,,,,,,,,,129673451.0,1.0,HIV infection
12967347,129673471,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21410,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673471.0,OT,,,,,,,,,129673471.0,1.0,HIV infection
12967353,129673531,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21411,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673531.0,OT,,,,,,,,,129673531.0,1.0,HIV infection
12967355,129673551,1,I,,20161110.0,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21412,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G-}T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123.0,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673551.0,OT,,,,,,,,,129673551.0,1.0,HIV infection
12970056,129700561,1,I,20161010.0,20161117.0,20161123,20161123,EXP,,IT-GILEAD-2016-0244629,GILEAD,,61.0,YR,A,M,Y,,,20161123.0,,MD,IT,IT,EFAVIRENZ,Pancytopenia,129700561.0,OT,,,,,,,,,129700561.0,1.0,HIV infection
12973734,129737341,1,I,20161116.0,20161117.0,20161124,20161124,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-098830,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,,,20161124.0,,CN,IT,IT,EFAVIRENZ,Pancytopenia;Transfusion,129737341.0,OT,,,,,,,,,129737341.0,1.0,HIV infection
12975593,129755932,2,F,,20161117.0,20161125,20190722,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-100018,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722.0,,OT,US,US,EFAVIRENZ.,Drug interaction,129755932.0,OT,,,,,,,,,129755932.0,1.0,HIV infection
12978924,129789241,1,I,20161022.0,,20161125,20161125,DIR,,,FDA-CTU,,72.0,YR,,M,N,,,20161125.0,N,PH,US,US,SUSTIVA,Blood cholesterol increased,,,129789241.0,HP,,,,,,,129789241.0,1.0,HIV infection
12979018,129790181,1,I,20161116.0,20161118.0,20161128,20161128,EXP,IT-MINISAL02-383838,IT-MYLANLABS-2016M1051019,MYLAN,,,,,,Y,,,20161127.0,,MD,IT,IT,EFAVIRENZ,Pancytopenia,129790181.0,OT,,,,,,,,,129790181.0,1.0,HIV infection
12984152,129841521,1,I,,20161122.0,20161129,20161129,EXP,IT-MINISAL02-384097,IT-MYLANLABS-2016M1051531,MYLAN,"MICHELINI Z., GALLUZZO C., PIRILLO M., FRANCISCI D., ANTONI A., VIVARELLI A., ET AL,. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR- BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY. 2016;88:12:2115-2124",,,,,Y,,,20161129.0,,OT,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,129841521.0,OT,,,,,,,,,129841521.0,1.0,HIV infection
12984157,129841571,1,I,,20161119.0,20161129,20161129,EXP,,FR-MYLANLABS-2016M1051559,MYLAN,"ZUCMAN D, SENE T, HILLAIRE S, KAHN J-E, FARFOUR E, PEYTAVIN G. ANTIHEPATITIS C VIRUS TREATMENTS FOR HIV-HEPATITIS C VIRUS COINFECTED CIRRHOTIC PATIENTS: A NEED TO LOOK BEYOND THE SUSTAINED VIRAL RESPONSE. AIDS 2015;29(14):1903-1904.",,,,,Y,,,20161129.0,,OT,FR,FR,EFAVIRENZ,Chronic hepatic failure;Drug interaction;Gastrointestinal haemorrhage;Hepatic encephalopathy;Portal venous system anomaly;Renal failure;Renal impairment,129841571.0,HO,,,,,,,,,129841571.0,1.0,HIV infection
12985056,1298505611,11,F,,20240916.0,20161129,20240927,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52.0,YR,,M,Y,,,20240927.0,,MD,CA,CA,EFAVIRENZ,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,1298505611.0,OT,,,1298505611.0,1.0,,,9668.0,DAY,1298505611.0,1.0,HIV infection
12987764,129877641,1,I,2013.0,20161118.0,20161130,20161130,EXP,,ZA-BAYER-2016-224904,BAYER,MOUTON J P; MEHTA U; PARRISH A G; WILSON D P K; STEWART A; NJUGUNA C W; ET.AL.. MORTALITY FROM ADVERSE DRUG REACTIONS IN ADULT MEDICAL INPATIENTS AT FOUR HOSPITALS IN SOUTH AFRICA: A CROSS-SECTIONAL SURVEY.. BR.J.CLIN.PHARMACOL. 2016;80 (4):818-26,39.0,YR,A,M,Y,,,20161130.0,,MD,ZA,ZA,EFAVIRENZ,Hypovolaemic shock,129877641.0,DE,,,129877641.0,1.0,2013.0,2013.0,,,129877641.0,2.0,Antiretroviral therapy
12988143,129881432,2,F,,20161130.0,20161130,20161207,EXP,,IT-ABBVIE-16P-083-1793685-00,ABBVIE,,,,,M,Y,,,20161207.0,,MD,IT,IT,EFAVIRENZ,Cytomegalovirus infection;Hepatitis C;Hepatocellular carcinoma;Herpes zoster;Hypertension;Neuropsychiatric symptoms;Ophthalmic herpes simplex;Renal failure;Transaminases increased,129881432.0,OT,,,129881432.0,1.0,20081016.0,,,,129881432.0,1.0,HIV infection
12989435,129894351,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22260,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Liver disorder,129894351.0,OT,,,,,,,,,129894351.0,1.0,HIV infection
12989454,129894541,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22261,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Pneumonia,129894541.0,OT,,,,,,,,,129894541.0,1.0,HIV infection
12989455,129894551,1,I,,20161121.0,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22263,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,TH,TH,Efavirenz,Death,129894551.0,DE,,,,,,,,,129894551.0,1.0,HIV infection
12989538,129895381,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22303,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Liver disorder,129895381.0,OT,,,,,,,,,129895381.0,1.0,HIV infection
12989542,129895421,1,I,,20161121.0,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22322,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,TH,TH,Efavirenz,Death,129895421.0,DE,,,,,,,,,129895421.0,1.0,HIV infection
12989546,129895461,1,I,,20161121.0,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22321,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,TH,TH,Efavirenz,Death,129895461.0,DE,,,,,,,,,129895461.0,1.0,HIV infection
12989559,129895591,1,I,,20161121.0,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22320,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,TH,TH,Efavirenz,Death,129895591.0,DE,,,,,,,,,129895591.0,1.0,HIV infection
12989594,129895941,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22308,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Pneumonia,129895941.0,OT,,,,,,,,,129895941.0,1.0,HIV infection
12989602,129896021,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22307,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Pneumonia,129896021.0,OT,,,,,,,,,129896021.0,1.0,HIV infection
12989612,129896121,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22306,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Pneumonia,129896121.0,OT,,,,,,,,,129896121.0,1.0,HIV infection
12989620,129896201,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22305,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Liver disorder,129896201.0,OT,,,,,,,,,129896201.0,1.0,HIV infection
12989636,129896361,1,I,,20161121.0,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22304,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201.0,,OT,US,TH,Efavirenz,Liver disorder,129896361.0,OT,,,,,,,,,129896361.0,1.0,HIV infection
12991318,129913181,1,I,,20161124.0,20161201,20161201,EXP,IT-MINISAL02-384623,IT-MYLANLABS-2016M1051904,MYLAN,,,,,,Y,,,20161201.0,,MD,IT,IT,EFAVIRENZ,Cytomegalovirus infection;Hepatocellular carcinoma;Herpes zoster;Hypertension;Neuropsychiatric symptoms;Ophthalmic herpes simplex;Renal failure;Transaminases increased,129913181.0,OT,,,129913181.0,1.0,20081016.0,,,,129913181.0,1.0,Acute HIV infection
12991976,129919762,2,F,,20170103.0,20161201,20170111,EXP,,TR-GILEAD-2016-0245947,GILEAD,,44.0,YR,A,M,Y,,,20170111.0,,MD,TR,TR,EFAVIRENZ,Anogenital dysplasia,129919762.0,OT,,,,,,,,,129919762.0,1.0,HIV infection
12997222,129972221,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22268,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,Efavirenz,Virologic failure,129972221.0,OT,,,,,,,,,129972221.0,1.0,HIV infection
12997245,129972451,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22280,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129972451.0,OT,,,,,,,,,129972451.0,1.0,HIV infection
12997320,129973201,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22402,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129973201.0,OT,,,,,,,,,129973201.0,1.0,HIV infection
12997334,129973341,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22401,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129973341.0,OT,,,,,,,,,129973341.0,1.0,HIV infection
12997341,129973411,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22392,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,Efavirenz,Virologic failure,129973411.0,OT,,,,,,,,,129973411.0,1.0,HIV infection
12997345,129973451,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22390,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,Efavirenz,Virologic failure,129973451.0,OT,,,,,,,,,129973451.0,1.0,HIV infection
12997346,129973461,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22391,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,Efavirenz,Virologic failure,129973461.0,OT,,,,,,,,,129973461.0,1.0,HIV infection
12997350,129973501,1,I,,20161122.0,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22400,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205.0,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129973501.0,OT,,,,,,,,,129973501.0,1.0,HIV infection
12997382,129973821,1,I,,20161122.0,20161205,20161205,EXP,,IT-CIPLA LTD.-2016IT22342,CIPLA,"MOFENSON LM, BAGGALEY RC AND MAMELETZIS I.. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. AIDS. 2016",,,,,Y,,,20161205.0,,MD,US,IT,Efavirenz,Foetal exposure during pregnancy;Talipes,129973821.0,CA,,,,,,,,,129973821.0,1.0,HIV infection
12997393,129973931,1,I,,20161122.0,20161205,20161205,EXP,,IT-CIPLA LTD.-2016IT22345,CIPLA,"MOFENSON LM, BAGGALEY RC, MAMELETZIS I. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. AIDS. 2016",,,,,Y,,,20161205.0,,MD,US,IT,Efavirenz,Cryptorchism;Foetal exposure during pregnancy,129973931.0,CA,,,,,,,,,129973931.0,1.0,HIV infection
13000317,130003171,1,I,,20151118.0,20161206,20161206,EXP,,GB-HETERO LABS LTD-1060445,HETERO,,33.0,YR,,F,Y,,,20161206.0,,CN,GB,GB,Efavirenz,Maternal exposure during pregnancy;Normal newborn;Pregnancy with implant contraceptive,130003171.0,OT,,,,,,,,,130003171.0,1.0,HIV infection
13003261,130032611,1,I,20161104.0,20161201.0,20161206,20161206,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-103863,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,68.0,KG,20161206.0,,OT,IT,IT,EFAVIRENZ,Nephrolithiasis,130032611.0,OT,,,130032611.0,3.0,20161012.0,,,,130032611.0,1.0,HIV infection
13004665,130046651,1,I,,20161124.0,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22472,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207.0,,OT,UG,UG,Efavirenz,Virologic failure,130046651.0,OT,,,,,,,,,130046651.0,1.0,HIV infection
13004679,130046791,1,I,,20161124.0,20161207,20161207,EXP,,US-CIPLA LTD.-2016US22403,CIPLA,"LOWENHAUPT EA, MATSON K, QUREISHI B, SAITOH A, PUGATCH D. PSYCHOSIS IN A 12-YEAR-OLD HIV-POSITIVE GIRL WITH AN INCREASED SERUM CONCENTRATION OF EFAVIRENZ. CLINICAL INFECTIOUS DISEASES. 2007;45:E128 TO E130",,,,,Y,,,20161207.0,,OT,US,US,Efavirenz,Drug level increased;Psychotic disorder;Weight increased,130046791.0,HO,,,130046791.0,2.0,200304.0,,,,130046791.0,1.0,HIV infection
13004683,130046831,1,I,,20161124.0,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22477,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET.AL,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207.0,,OT,UG,UG,Efavirenz,Virologic failure,130046831.0,OT,,,,,,,,,130046831.0,1.0,HIV infection
13004688,130046881,1,I,,20161124.0,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22475,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET.AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207.0,,OT,UG,UG,Efavirenz,Virologic failure,130046881.0,OT,,,,,,,,,130046881.0,1.0,HIV infection
13004691,130046911,1,I,,20161124.0,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22476,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET.AL,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207.0,,OT,UG,UG,Efavirenz,Virologic failure,130046911.0,OT,,,,,,,,,130046911.0,1.0,HIV infection
13004696,130046961,1,I,,20161124.0,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22474,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207.0,,OT,UG,UG,Efavirenz,Virologic failure,130046961.0,OT,,,,,,,,,130046961.0,1.0,HIV infection
13004700,130047001,1,I,,20161124.0,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22473,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N ET AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9(1):1 TO 8",,,,,Y,,,20161207.0,,OT,UG,UG,Efavirenz,Virologic failure,130047001.0,OT,,,,,,,,,130047001.0,1.0,HIV infection
13008521,130085211,1,I,,20161124.0,20161208,20161208,EXP,,US-AUROBINDO-AUR-APL-2016-15208,AUROBINDO,,66.0,YR,,M,Y,,,20161208.0,,MD,US,US,EFAVIRENZ,Retinal degeneration;Retinal toxicity,130085211.0,OT,,,,,,,,,130085211.0,1.0,HIV infection
13010853,130108531,1,I,,20161130.0,20161208,20161208,EXP,,ZA-MYLANLABS-2016M1053403,MYLAN,"VARIAVA E, SIGAUKE FR, MUCHICHWA P, MAARTENS G, MARTINSON N. EFAVIRENZ TOXICITY MANIFESTING AS CEREBELLAR ATAXIA: CASE SERIES FROM SOUTH AFRICA. TOP-ANTIVIR-MED 2016;24(1):412.",,,,,Y,,,20161208.0,,OT,ZA,ZA,EFAVIRENZ,Anticonvulsant drug level increased;Cerebellar ataxia;Toxicity to various agents,130108531.0,HO,,,,,,,,,130108531.0,1.0,HIV infection
13014250,130142501,1,I,,20161128.0,20161209,20161209,EXP,,FR-TEVA-718046ISR,TEVA,"ZUCMAN D, SENE T, HILLAIRE S, KAHN J-E, FARFOUR E, PEYTAVIN G. ANTIHEPATITIS C VIRUS TREATMENTS FOR HIV-HEPATITIS C VIRUS COINFECTED CIRRHOTIC PATIENTS: A NEED TO LOOK BEYOND THE SUSTAINED VIRAL RESPONSE. AIDS 2015;29(14):1903-1904.",,,A,M,Y,,,20161209.0,,OT,FR,FR,efavirenz,Chronic hepatic failure;Drug interaction;Gastrointestinal haemorrhage;Hepatic encephalopathy;Renal failure;Renal impairment;Venous injury,130142501.0,OT,,,,,,,,,130142501.0,1.0,HIV infection
13037962,130379622,2,F,20160422.0,20170113.0,20161218,20170117,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-107358,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,41.0,KG,20170117.0,,OT,MZ,MZ,EFAVIRENZ,Anaemia;Pneumonia bacterial,130379622.0,OT,,,130379622.0,1.0,20160415.0,,,,130379622.0,1.0,HIV infection
13038747,130387471,1,I,,20161205.0,20161219,20161219,EXP,,ZA-HETERO LABS LTD-1060959,HETERO,"VARIAVA E, SIGAUKE FR, MUCHICHWA P, MAARTENS G, MARTINSON N. EFAVIRENZ TOXICITY MANIFESTING AS CEREBELLAR ATAXIA: CASE SERIES FROM SOUTH AFRICA.",,,,F,Y,,,20161219.0,,OT,ZA,ZA,Efavirenz,Cerebellar ataxia,130387471.0,OT,,,,,,,,,130387471.0,1.0,HIV infection
13054613,130546132,2,F,,20161222.0,20161222,20161223,EXP,,IT-009507513-1612ITA011075,MERCK,,,,,,Y,,,20161223.0,,OT,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130546132.0,OT,,,,,,,,,130546132.0,1.0,HIV infection
13059080,130590803,3,F,20160111.0,20170130.0,20161223,20170202,EXP,,UG-GILEAD-2016-0250168,GILEAD,,28.0,YR,A,F,Y,53.0,KG,20170202.0,,MD,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,130590803.0,OT,,,130590803.0,1.0,20140113.0,,,,130590803.0,1.0,HIV infection
13059393,130593931,1,I,20160921.0,20161215.0,20161223,20161223,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-108225,BRISTOL MYERS SQUIBB,,52.0,YR,,F,Y,50.0,KG,20161223.0,,CN,CN,CN,EFAVIRENZ,Hepatic function abnormal,130593931.0,OT,,,130593931.0,1.0,20160722.0,20161014.0,,,130593931.0,1.0,HIV test
13059406,130594061,1,I,20160914.0,20161220.0,20161223,20161223,EXP,,UG-GLAXOSMITHKLINE-UG2016GSK189477,GLAXOSMITHKLINE,,23.0,YR,,F,Y,39.5,KG,20161223.0,,MD,UG,UG,EFAVIRENZ,Weight decreased,130594061.0,OT,,,130594061.0,1.0,20150104.0,20160913.0,,,130594061.0,1.0,HIV infection
13059435,130594351,1,I,20160914.0,20161220.0,20161223,20161223,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2016GSK189477,VIIV,,23.0,YR,,F,Y,39.5,KG,20161223.0,,MD,UG,UG,EFAVIRENZ,Weight decreased,130594351.0,OT,,,130594351.0,1.0,20150104.0,20160913.0,,,130594351.0,1.0,HIV infection
13059609,130596091,1,I,,20161121.0,20161223,20161223,EXP,,IT-009507513-1612ITA011364,MERCK,,,,A,,Y,,,20161223.0,,CN,US,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130596091.0,OT,,,,,,,,,130596091.0,1.0,HIV infection
13061396,130613961,1,I,,20161214.0,20161226,20161226,EXP,,DE-CIPLA LTD.-2016DE23747,CIPLA,"KROIDL A, ELLO F, MGAYA J, LENNEMANN T, MOH R, MAGANGA L ET AL.,. VIROLOGICAL EFFICACY OF 24-WEEKS FOZIVUDINE BASED REGIMEN IN ART-NAIVE PATIENTS FROM TANZANIA AND COTE D^IVOIRE. AIDS. 2016",,,,,Y,,,20161226.0,,OT,DE,DE,Efavirenz,Anaemia,130613961.0,OT,,,,,,,,,130613961.0,1.0,HIV infection
13065755,130657551,1,I,,20161220.0,20161227,20161227,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016190886,VIIV,,,,A,M,Y,,,20161227.0,,MD,IT,IT,Efavirenz,Virologic failure,130657551.0,OT,,,,,,,,,130657551.0,1.0,HIV infection
13065833,130658331,1,I,,20161220.0,20161227,20161227,EXP,,IT-GLAXOSMITHKLINE-IT2016190886,GLAXOSMITHKLINE,,,,A,M,Y,,,20161227.0,,MD,IT,IT,Efavirenz,Virologic failure,130658331.0,OT,,,,,,,,,130658331.0,1.0,HIV infection
13066539,130665391,1,I,200606.0,20161018.0,20161227,20161227,EXP,,GB-JNJFOC-20161100084,JANSSEN,,44.0,YR,A,M,Y,88.0,KG,20161227.0,,MD,GB,GB,EFAVIRENZ,Glomerular filtration rate decreased;Transient ischaemic attack,130665391.0,OT,,,130665391.0,1.0,201209.0,201401.0,,,130665391.0,1.0,HIV infection
13067439,130674392,2,F,20160729.0,20170120.0,20161228,20170202,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-109185,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20170202.0,,CN,BR,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Product use issue,130674392.0,OT,,,130674392.0,1.0,20160610.0,,,,130674392.0,1.0,HIV infection
13067654,130676542,2,F,,20161216.0,20161228,20161228,EXP,,US-CIPLA LTD.-2016US23768,CIPLA,,,,,,Y,,,20161228.0,,OT,BR,US,Efavirenz,Concomitant disease aggravated;Drug-induced liver injury;Hypersensitivity,130676542.0,OT,,,,,,,,,130676542.0,1.0,HIV infection
13068147,130681472,2,F,20160701.0,20161221.0,20161228,20161229,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-109319,BRISTOL MYERS SQUIBB,,,,,,Y,,,20161229.0,,CN,GB,GB,EFAVIRENZ;EFAVIRENZ AUROBINDO,Macular oedema,130681472.0,OT,,,130681472.0,1.0,201006.0,201606.0,,,130681472.0,1.0,HIV infection
13069028,130690281,1,I,,20161220.0,20161228,20161228,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-110512,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161228.0,,OT,BE,BE,EFAVIRENZ,Drug resistance;Viral mutation identified,130690281.0,OT,,,,,,,,,130690281.0,1.0,Antiretroviral therapy
13069029,130690291,1,I,,20161220.0,20161228,20161228,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-110539,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161228.0,,OT,BE,BE,EFAVIRENZ,Drug resistance;Viral mutation identified,130690291.0,OT,,,,,,,,,130690291.0,1.0,Antiretroviral therapy
13083246,130832463,3,F,,20170118.0,20170104,20170118,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-112415,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20170118.0,,OT,NG,NG,EFAVIRENZ,Maternal exposure during pregnancy;Premature delivery;Product use issue;Pyrexia,130832463.0,OT,,,,,,,,,130832463.0,1.0,HIV infection
13083427,130834271,1,I,,20161202.0,20170104,20170104,PER,,JP-LUPIN PHARMACEUTICALS INC.-2016-05494,LUPIN,"UEHARA Y, SUZUKI A, SAITA M, INUI A, ISONUMA H, NAITO T. RALTEGRAVIR AND ABACAVIR/LAMIVUDINE IN JAPANESE TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HIV INFECTION: A 48-WEEK RETROSPECTIVE PILOT ANALYSIS.. JAPANESE JOURNAL OF INFECTIOUS DISEASES. 2016;69(1):33-38.",40.0,YR,,M,Y,,,20170104.0,,OT,JP,JP,Efavirenz,Insomnia,,,,,,,,,,,130834271.0,1.0,HIV infection
13085644,130856441,1,I,,20161228.0,20170104,20170104,EXP,,IT-ABBVIE-17P-083-1827452-00,ABBVIE,"BARONCELLI Z, MICHELINI Z, GALLUZZO C, ET AL. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY.. JOURNAL OF MEDICAL VIROLOGY. 2016;2115-2124.",45.0,YR,,,Y,,,20170104.0,,MD,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130856441.0,OT,,,,,,,,,130856441.0,1.0,HIV infection
13085666,130856661,1,I,,20161228.0,20170104,20170104,EXP,,IT-ABBVIE-17P-083-1827457-00,ABBVIE,"BARONCELLI S, MICHELINI Z, GALLUZZO C, ET AL. HIV-1 DNA DYNAMIC AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY. 2016;2115-2124.",45.0,YR,,,Y,,,20170104.0,,MD,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130856661.0,OT,,,,,,,,,130856661.0,1.0,HIV infection
13090025,130900251,1,I,,20161226.0,20170105,20170105,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2016GSK195552,VIIV,"KROIDL A, MGAYA J, LENEMANN T, MOH R, MAGANGA L, EHOLIE S ET AL.. VIROLOGICAL EFFICACY OF 24-WEEKS FOZIVUDINE BASED REGIMEN IN ART-NAIVE PATIENTS FROM TANZANIA AND COTE D^IVOIRE. 2016",,,,,Y,,,20170105.0,,MD,DE,DE,Efavirenz,Virologic failure,130900251.0,OT,,,,,,,,,130900251.0,1.0,HIV infection
13090070,130900701,1,I,,20161226.0,20170105,20170105,EXP,,DE-GLAXOSMITHKLINE-DE2016GSK195552,GLAXOSMITHKLINE,"KROIDL A, MGAYA J, LENEMANN T, MOH R, MAGANGA L, EHOLIE S ET AL.. VIROLOGICAL EFFICACY OF 24-WEEKS FOZIVUDINE BASED REGIMEN IN ART-NAIVE PATIENTS FROM TANZANIA AND COTE D^IVOIRE. 2016",,,,,Y,,,20170105.0,,MD,DE,DE,Efavirenz,Virologic failure,130900701.0,OT,,,,,,,,,130900701.0,1.0,HIV infection
13090102,130901021,1,I,,20161228.0,20170105,20170105,EXP,,IT-GILEAD-2017-0251961,GILEAD,,,,A,,Y,,,20170105.0,,MD,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130901021.0,OT,,,,,,,,,130901021.0,1.0,HIV infection
13090798,130907983,3,F,20160629.0,20170207.0,20170106,20170213,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-056226,BRISTOL MYERS SQUIBB,,26.0,YR,,M,Y,51.0,KG,20170213.0,,MD,CI,CI,EFAVIRENZ,Encephalopathy;General physical condition abnormal;Hepatic enzyme increased;Hepatocellular injury,130907983.0,DE,,,130907983.0,1.0,20160511.0,20161228.0,,,130907983.0,1.0,HIV infection
13093353,130933531,1,I,,20161228.0,20170106,20170106,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016195662,VIIV,"MICHELINI Z., ET AL. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY.. JOURNAL OF MEDICAL VIROLOGY. 2016;88:12:2115-2124",,,A,,Y,,,20170106.0,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933531.0,OT,,,,,,,,,130933531.0,1.0,HIV infection
13093355,130933551,1,I,,20161228.0,20170106,20170106,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016195654,VIIV,,,,A,,Y,,,20170106.0,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933551.0,OT,,,,,,,,,130933551.0,1.0,HIV infection
13093366,130933661,1,I,,20161228.0,20170106,20170106,EXP,,IT-GLAXOSMITHKLINE-IT2016195654,GLAXOSMITHKLINE,,,,A,,Y,,,20170106.0,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933661.0,OT,,,,,,,,,130933661.0,1.0,HIV infection
13093372,130933721,1,I,,20161228.0,20170106,20170106,EXP,,IT-GLAXOSMITHKLINE-IT2016195662,GLAXOSMITHKLINE,"MICHELINI Z., ET AL. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY.. JOURNAL OF MEDICAL VIROLOGY. 2016;88:12:2115-2124",,,A,,Y,,,20170106.0,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933721.0,OT,,,,,,,,,130933721.0,1.0,HIV infection
13094456,130944561,1,I,,20161228.0,20170106,20170106,EXP,IT-MINISAL02-389982,IT-MYLANLABS-2017M1000023,MYLAN,MICHELINI Z.. HIV-1 DNA DYNAMIC AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY,,,,,Y,,,20170106.0,,OT,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130944561.0,OT,,,,,,,,,130944561.0,1.0,HIV infection
13094483,130944832,2,F,,20180105.0,20170106,20180116,EXP,IT-MINISAL02-390000,IT-MYLANLABS-2017M1000021,MYLAN,"MICHELINI Z, GALLUZZO CM, PIRILLO MF, FRANCISCI D, ANTONI AD, VIVARELLI A ET AL.. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY. 2016;88:2115-2124",45.0,YR,,,Y,,,20180116.0,,OT,IT,IT,EFAVIRENZ.,Multiple-drug resistance;Viral mutation identified,130944832.0,OT,,,,,,,,,130944832.0,1.0,HIV infection
13095809,130958091,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00084,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130958091.0,DE,,,130958091.0,1.0,2009.0,,,,130958091.0,1.0,HIV infection
13095900,130959001,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00091,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959001.0,DE,,,130959001.0,1.0,2010.0,,,,130959001.0,1.0,HIV infection
13095907,130959071,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00093,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959071.0,DE,,,130959071.0,1.0,2011.0,,,,130959071.0,1.0,HIV infection
13095923,130959231,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00092,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959231.0,DE,,,130959231.0,1.0,2010.0,,,,130959231.0,1.0,HIV infection
13095928,130959281,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00090,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959281.0,DE,,,130959281.0,1.0,2009.0,,,,130959281.0,1.0,HIV infection
13095936,130959361,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00089,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959361.0,DE,,,130959361.0,1.0,2009.0,,,,130959361.0,1.0,HIV infection
13095944,130959441,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00088,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959441.0,DE,,,130959441.0,1.0,2010.0,,,,130959441.0,1.0,HIV infection
13095957,130959571,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00087,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959571.0,DE,,,130959571.0,1.0,2009.0,,,,130959571.0,1.0,HIV infection
13095992,130959921,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00086,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130959921.0,DE,,,130959921.0,1.0,2009.0,,,,130959921.0,1.0,HIV infection
13096030,130960301,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00085,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960301.0,DE,,,130960301.0,1.0,2010.0,,,,130960301.0,1.0,HIV infection
13096043,130960431,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00104,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960431.0,DE,,,130960431.0,1.0,2011.0,,,,130960431.0,1.0,HIV infection
13096061,130960611,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00103,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960611.0,DE,,,130960611.0,1.0,2011.0,,,,130960611.0,1.0,HIV infection
13096075,130960751,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00101,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960751.0,DE,,,130960751.0,1.0,2010.0,,,,130960751.0,1.0,HIV infection
13096078,130960781,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00102,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960781.0,DE,,,130960781.0,1.0,2010.0,,,,130960781.0,1.0,HIV infection
13096084,130960841,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00100,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960841.0,DE,,,130960841.0,1.0,2009.0,,,,130960841.0,1.0,HIV infection
13096090,130960901,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00099,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960901.0,DE,,,130960901.0,1.0,2010.0,,,,130960901.0,1.0,HIV infection
13096097,130960971,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00098,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130960971.0,DE,,,130960971.0,1.0,2012.0,,,,130960971.0,1.0,HIV infection
13096100,130961001,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00097,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961001.0,DE,,,130961001.0,1.0,2010.0,,,,130961001.0,1.0,HIV infection
13096103,130961031,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00096,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961031.0,DE,,,130961031.0,1.0,2009.0,,,,130961031.0,1.0,HIV infection
13096111,130961111,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00095,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961111.0,DE,,,130961111.0,1.0,2009.0,,,,130961111.0,1.0,HIV infection
13096114,130961141,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00094,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961141.0,DE,,,130961141.0,1.0,2009.0,,,,130961141.0,1.0,HIV infection
13096136,130961361,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00145,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130961361.0,OT,,,130961361.0,1.0,2011.0,,,,130961361.0,1.0,HIV infection
13096155,130961551,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00112,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961551.0,DE,,,130961551.0,1.0,2011.0,,,,130961551.0,1.0,HIV infection
13096157,130961571,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00110,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961571.0,DE,,,130961571.0,1.0,2009.0,,,,130961571.0,1.0,HIV infection
13096161,130961611,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00111,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961611.0,DE,,,130961611.0,1.0,2011.0,,,,130961611.0,1.0,HIV infection
13096183,130961831,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00109,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130961831.0,DE,,,130961831.0,1.0,2010.0,,,,130961831.0,1.0,HIV infection
13096200,130962001,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00108,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130962001.0,DE,,,130962001.0,1.0,2009.0,,,,130962001.0,1.0,HIV infection
13096201,130962011,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00107,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130962011.0,DE,,,130962011.0,1.0,2009.0,,,,130962011.0,1.0,HIV infection
13096208,130962081,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00106,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130962081.0,DE,,,130962081.0,1.0,2009.0,,,,130962081.0,1.0,HIV infection
13096212,130962121,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00146,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130962121.0,OT,,,130962121.0,1.0,2011.0,,,,130962121.0,1.0,HIV infection
13096214,130962141,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00147,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130962141.0,OT,,,130962141.0,1.0,2012.0,,,,130962141.0,1.0,HIV infection
13096222,130962221,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00149,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130962221.0,DE,,,130962221.0,1.0,2009.0,,,,130962221.0,1.0,HIV infection
13096319,130963191,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00150,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963191.0,DE,,,130963191.0,1.0,2009.0,,,,130963191.0,1.0,HIV infection
13096326,130963261,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00151,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963261.0,DE,,,130963261.0,1.0,2009.0,,,,130963261.0,1.0,HIV infection
13096343,130963431,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00152,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963431.0,DE,,,130963431.0,1.0,2010.0,,,,130963431.0,1.0,HIV infection
13096347,130963471,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00153,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963471.0,DE,,,130963471.0,1.0,2011.0,,,,130963471.0,1.0,HIV infection
13096352,130963521,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00154,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963521.0,DE,,,130963521.0,1.0,2009.0,,,,130963521.0,1.0,HIV infection
13096366,130963661,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00155,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963661.0,DE,,,130963661.0,1.0,2010.0,,,,130963661.0,1.0,HIV infection
13096380,130963801,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00156,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963801.0,DE,,,130963801.0,1.0,2011.0,,,,130963801.0,1.0,HIV infection
13096392,130963921,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00157,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130963921.0,DE,,,130963921.0,1.0,2012.0,,,,130963921.0,1.0,HIV infection
13096410,130964101,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00124,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964101.0,DE,,,130964101.0,1.0,2011.0,,,,130964101.0,1.0,HIV infection
13096411,130964111,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00118,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964111.0,DE,,,130964111.0,1.0,2011.0,,,,130964111.0,1.0,HIV infection
13096412,130964121,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00127,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964121.0,DE,,,130964121.0,1.0,2009.0,,,,130964121.0,1.0,HIV infection
13096413,130964131,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00116,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964131.0,DE,,,130964131.0,1.0,2010.0,,,,130964131.0,1.0,HIV infection
13096414,130964141,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00117,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964141.0,DE,,,130964141.0,1.0,2010.0,,,,130964141.0,1.0,HIV infection
13096415,130964151,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00113,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964151.0,DE,,,130964151.0,1.0,2011.0,,,,130964151.0,1.0,HIV infection
13096416,130964161,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00122,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964161.0,DE,,,130964161.0,1.0,2012.0,,,,130964161.0,1.0,HIV infection
13096417,130964171,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00114,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964171.0,DE,,,130964171.0,1.0,2009.0,,,,130964171.0,1.0,HIV infection
13096418,130964181,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00128,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964181.0,DE,,,130964181.0,1.0,2009.0,,,,130964181.0,1.0,HIV infection
13096419,130964191,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00105,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964191.0,DE,,,130964191.0,1.0,2009.0,,,,130964191.0,1.0,HIV infection
13096420,130964201,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00129,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964201.0,DE,,,130964201.0,1.0,2010.0,,,,130964201.0,1.0,HIV infection
13096421,130964211,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00126,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964211.0,DE,,,130964211.0,1.0,2013.0,,,,130964211.0,1.0,HIV infection
13096422,130964221,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00125,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964221.0,DE,,,130964221.0,1.0,2012.0,,,,130964221.0,1.0,HIV infection
13096423,130964231,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00130,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964231.0,DE,,,130964231.0,1.0,2012.0,,,,130964231.0,1.0,HIV infection
13096424,130964241,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00120,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964241.0,DE,,,130964241.0,1.0,2009.0,,,,130964241.0,1.0,HIV infection
13096425,130964251,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00123,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964251.0,DE,,,130964251.0,1.0,2013.0,,,,130964251.0,1.0,HIV infection
13096426,130964261,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00121,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964261.0,DE,,,130964261.0,1.0,2011.0,,,,130964261.0,1.0,HIV infection
13096429,130964291,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00115,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964291.0,DE,,,130964291.0,1.0,2009.0,,,,130964291.0,1.0,HIV infection
13096430,130964301,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00119,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964301.0,DE,,,130964301.0,1.0,2010.0,,,,130964301.0,1.0,HIV infection
13096436,130964361,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00158,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964361.0,DE,,,130964361.0,1.0,2012.0,,,,130964361.0,1.0,HIV infection
13096437,130964371,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00142,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130964371.0,OT,,,130964371.0,1.0,2009.0,,,,130964371.0,1.0,HIV infection
13096438,130964381,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00139,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964381.0,DE,,,130964381.0,1.0,2012.0,,,,130964381.0,1.0,HIV infection
13096440,130964401,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00135,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964401.0,DE,,,130964401.0,1.0,2012.0,,,,130964401.0,1.0,HIV infection
13096442,130964421,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00131,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964421.0,DE,,,130964421.0,1.0,2012.0,,,,130964421.0,1.0,HIV infection
13096447,130964471,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00140,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130964471.0,OT,,,130964471.0,1.0,2010.0,,,,130964471.0,1.0,HIV infection
13096448,130964481,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00161,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964481.0,DE,,,130964481.0,1.0,2010.0,,,,130964481.0,1.0,HIV infection
13096449,130964491,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00138,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964491.0,DE,,,130964491.0,1.0,2012.0,,,,130964491.0,1.0,HIV infection
13096451,130964511,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00137,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964511.0,DE,,,130964511.0,1.0,2010.0,,,,130964511.0,1.0,HIV infection
13096452,130964521,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00136,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964521.0,DE,,,130964521.0,1.0,2010.0,,,,130964521.0,1.0,HIV infection
13096453,130964531,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00159,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964531.0,DE,,,130964531.0,1.0,2011.0,,,,130964531.0,1.0,HIV infection
13096454,130964541,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00134,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964541.0,DE,,,130964541.0,1.0,2010.0,,,,130964541.0,1.0,HIV infection
13096456,130964561,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00162,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964561.0,DE,,,130964561.0,1.0,2010.0,,,,130964561.0,1.0,HIV infection
13096457,130964571,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00141,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130964571.0,OT,,,130964571.0,1.0,2009.0,,,,130964571.0,1.0,HIV infection
13096458,130964581,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00132,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964581.0,DE,,,130964581.0,1.0,2009.0,,,,130964581.0,1.0,HIV infection
13096459,130964591,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00133,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964591.0,DE,,,130964591.0,1.0,2009.0,,,,130964591.0,1.0,HIV infection
13096461,130964611,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00143,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130964611.0,OT,,,130964611.0,1.0,2009.0,,,,130964611.0,1.0,HIV infection
13096462,130964621,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00160,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Death,130964621.0,DE,,,130964621.0,1.0,2011.0,,,,130964621.0,1.0,HIV infection
13096463,130964631,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00144,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130964631.0,OT,,,130964631.0,1.0,2013.0,,,,130964631.0,1.0,HIV infection
13096599,130965991,1,I,,20170103.0,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-000893,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20170109.0,,OT,NL,UG,EFAVIRENZ,Death,130965991.0,OT,,,,,,,,,130965991.0,1.0,Antiretroviral therapy
13096758,130967581,1,I,,20161226.0,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00163,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109.0,,OT,ET,ET,Efavirenz,Virologic failure,130967581.0,OT,,,130967581.0,1.0,2009.0,,,,130967581.0,1.0,HIV infection
13097222,130972221,1,I,,20170103.0,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001082,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170109.0,,OT,NL,UG,EFAVIRENZ,Bedridden;Death;Decreased appetite;Dehydration;Diarrhoea;Fatigue;Lethargy,130972221.0,OT,,,,,,,,,130972221.0,1.0,Antiretroviral therapy
13097918,130979181,1,I,,20170103.0,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001083,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,,,20170109.0,,OT,NL,UG,EFAVIRENZ,Anaemia;Asthenia;Disseminated tuberculosis;Leukopenia;Thrombocytopenia,130979181.0,DE,,,,,,,,,130979181.0,1.0,Antiretroviral therapy
13098560,130985601,1,I,,20170103.0,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001084,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,,,20170109.0,,OT,NL,UG,EFAVIRENZ,Diarrhoea;Drug-induced liver injury;Pancytopenia,130985601.0,OT,,,,,,,,,130985601.0,1.0,Antiretroviral therapy
13098568,130985681,1,I,,20170103.0,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001086,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20170109.0,,OT,NL,UG,EFAVIRENZ,Cough;Diarrhoea;Leukopenia,130985681.0,OT,,,,,,,,,130985681.0,1.0,Antiretroviral therapy
13099374,130993741,1,I,,20170104.0,20170109,20170109,EXP,,US-GILEAD-2017-0252246,GILEAD,"GUPTA S-K, MCCOMSEY G-A, LOMBAARD J, ECHEVARRIA J, ORRELL C, AVIHINGSANON, OSIYEMI O, SANTOSCOY M, RAY N, STOCK D-A, JOSHI S-R, HANNA G-J, LATAILLADE M. EFFICACY, SAFETY, BONE AND METABOLIC EFFECTS OF HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR BMS-986001 (AI467003): A PHASE 2B RANDOMISED, CONTROLLED, PARTLY BLINDED TRIAL. THE LANCET. 2016;3 (1):E13-22",,,A,,Y,,,20170109.0,,MD,US,US,EFAVIRENZ,Depression;Drug-induced liver injury,130993741.0,OT,,,,,,,,,130993741.0,1.0,HIV infection
13099776,130997761,1,I,,20161226.0,20170110,20170110,EXP,,ET-CIPLA LTD.-2017ET00001,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170110.0,,OT,ET,ET,Efavirenz,Death,130997761.0,DE,,,130997761.0,1.0,2010.0,,,,130997761.0,1.0,HIV infection
13100995,131009951,1,I,20140715.0,20170105.0,20170110,20170110,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017GSK002037,VIIV,,28.0,YR,,F,Y,,,20170110.0,,CN,US,UG,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,131009951.0,OT,,,131009951.0,1.0,20131010.0,20140619.0,,,131009951.0,1.0,HIV infection
13102725,131027251,1,I,,20170103.0,20170110,20170110,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001085,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20170110.0,,OT,NL,UG,EFAVIRENZ,Acute kidney injury;Diarrhoea;Drug-induced liver injury;Lung consolidation;Pancytopenia,131027251.0,DE,,,,,,,,,131027251.0,1.0,Antiretroviral therapy
13103037,131030371,1,I,,20170103.0,20170110,20170110,EXP,,MX-GILEAD-2017-0252129,GILEAD,"GUTIERREZ-DELGADO E-M, VILLANEUVA-LOZANO H, GARCIA ROJAS-ACOSTA M-J, MIRANDA-MALDONADO I-C, RAMOS-JIMENEZ J. A CASE REPORT OF SMALL BOWEL PERFORATION SECONDARY TO CYTOMEGALOVIRUS RELATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN AIDS PATIENT. ANNALS OF MEDICINE AND SURGERY. 2017;13:20-23",40.0,YR,A,M,Y,,,20170110.0,,OT,MX,MX,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Intestinal perforation;Large intestine perforation,131030371.0,OT,,,131030371.0,1.0,201506.0,,,,131030371.0,1.0,HIV infection
13105691,131056913,3,F,,20190213.0,20170111,20190225,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK195660,VIIV,"MAHLAB-GURI K, ASHER I, ROSENBERG-BEZALEL S, ELBIRT D, BURKE M, STHOEGER ZM. TWO CASE REPORTS OF SEVERE MYOCARDITIS ASSOCIATED WITH THE INITIATION OF DOLUTEGRAVIR TREATMENT IN HIV PATIENTS. MEDICINE (UNITED STATES). 2016;95(47)",51.0,YR,,M,Y,,,20190225.0,,MD,IL,IL,EFAVIRENZ.,Cardiac failure;Dyspnoea;Dyspnoea exertional;Myocardial infarction;Myocarditis;Oedema peripheral;Sleep disorder;Ventricular dysfunction,131056913.0,OT,,,,,,,,,131056913.0,1.0,HIV infection
13106197,131061971,1,I,20131016.0,20170105.0,20170111,20170111,EXP,,UG-GILEAD-2017-0252414,GILEAD,,27.0,YR,A,F,Y,,,20170111.0,,MD,UG,UG,EFAVIRENZ,Abortion spontaneous;Death;Fall;Maternal exposure during pregnancy;Metrorrhagia,131061971.0,OT,,,131061971.0,1.0,20130723.0,20131121.0,,,131061971.0,1.0,HIV infection
13106609,131066092,2,F,20140715.0,20170105.0,20170111,20170623,EXP,,UG-GILEAD-2017-0252401,GILEAD,,28.0,YR,A,F,Y,,,20170623.0,,OT,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,131066092.0,OT,,,131066092.0,1.0,20140620.0,20140619.0,,,131066092.0,1.0,HIV infection
13109304,131093041,1,I,20161018.0,20170106.0,20170112,20170112,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001793,BRISTOL MYERS SQUIBB,,47.0,YR,,M,Y,,,20170112.0,,CN,CN,CN,EFAVIRENZ,Bone marrow failure,131093041.0,OT,,,131093041.0,1.0,20160719.0,,,,131093041.0,1.0,Acquired immunodeficiency syndrome
13109551,131095514,4,F,20160922.0,20170816.0,20170112,20170825,EXP,,BR-GILEAD-2017-0252446,GILEAD,,36.0,YR,A,M,Y,113.3,KG,20170825.0,,MD,BR,BR,EFAVIRENZ,Anal abscess;Rectal haemorrhage,131095514.0,HO,,,131095514.0,1.0,20150505.0,,,,131095514.0,1.0,HIV infection
13111604,131116041,1,I,20160927.0,20170106.0,20170112,20170112,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001799,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,42.0,KG,20170112.0,,CN,CN,CN,EFAVIRENZ,Anaemia,131116041.0,HO,,,131116041.0,1.0,20160628.0,20160927.0,,,131116041.0,1.0,Acquired immunodeficiency syndrome
13113118,131131181,1,I,,20170102.0,20170113,20170113,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2017GSK003722,VIIV,"BURNS K, LAM T, CHIPPS DR.. ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE. ENDOCRINE REVIEW. 2015",51.0,YR,,M,Y,,,20170113.0,,OT,AU,AU,EFAVIRENZ,Blood phosphorus decreased;Fanconi syndrome;Femur fracture;Osteomalacia;Pathogen resistance,131131181.0,OT,,,,,,,,,131131181.0,2.0,Acquired immunodeficiency syndrome
13113259,131132591,1,I,,20170102.0,20170113,20170113,EXP,,AU-GLAXOSMITHKLINE-AU2017GSK003722,GLAXOSMITHKLINE,"BURNS K, LAM T, CHIPPS DR.. ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE. ENDOCRINE REVIEW. 2015",51.0,YR,,M,Y,,,20170113.0,,OT,AU,AU,EFAVIRENZ,Blood phosphorus decreased;Fanconi syndrome;Femur fracture;Osteomalacia;Pathogen resistance,131132591.0,OT,,,,,,,,,131132591.0,2.0,Acquired immunodeficiency syndrome
13113690,131136901,1,I,,20170105.0,20170113,20170113,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001020,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20170113.0,,CN,UG,UG,EFAVIRENZ,Death;Maternal exposure during pregnancy,131136901.0,OT,,,131136901.0,1.0,20130723.0,20131121.0,,,131136901.0,1.0,HIV infection
13115921,131159211,1,I,20160125.0,20170105.0,20170115,20170115,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001235,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170115.0,,CN,UG,UG,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,131159211.0,OT,,,131159211.0,1.0,20150401.0,,,,131159211.0,1.0,HIV infection
13115922,131159221,1,I,20150607.0,20170105.0,20170115,20170115,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001021,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20170115.0,,CN,ZW,ZW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,131159221.0,OT,,,131159221.0,1.0,20140619.0,20150520.0,,,131159221.0,1.0,HIV infection
13116418,131164181,1,I,,20170106.0,20170116,20170116,EXP,,ZW-HETERO LABS LTD-1062034,HETERO,,30.0,YR,,F,Y,,,20170116.0,,OT,ZW,ZW,Efavirenz,Exposure during pregnancy;Stillbirth,131164181.0,DE,,,,,,,,,131164181.0,1.0,HIV infection
13120836,131208362,2,F,20140715.0,20170123.0,20170117,20170202,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001237,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20170202.0,,OT,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,131208362.0,OT,,,131208362.0,1.0,20131010.0,20140619.0,,,131208362.0,1.0,HIV infection
13121296,131212961,1,I,,20170110.0,20170117,20170117,EXP,,PK-VIIV HEALTHCARE LIMITED-PK2017GSK005895,VIIV,KHAN EA. LESSONS FROM A SEVEN-YEAR EXPERIENCE OF PAEDIATRIC HIV IN PAKISTAN: A SINGLE CENTRE EXPERIENCE. J PAK MED ASSOC. 2017;67 (1):105 - 110,5.0,YR,,F,Y,,,20170117.0,,OT,PK,PK,Efavirenz,Drug resistance;Pathogen resistance;Treatment noncompliance,131212961.0,OT,,,,,,,,,131212961.0,1.0,HIV infection
13121453,131214531,1,I,,20170110.0,20170117,20170117,EXP,,PK-GLAXOSMITHKLINE-PK2017GSK005895,GLAXOSMITHKLINE,KHAN EA. LESSONS FROM A SEVEN-YEAR EXPERIENCE OF PAEDIATRIC HIV IN PAKISTAN: A SINGLE CENTRE EXPERIENCE. J PAK MED ASSOC. 2017;67 (1):105 - 110,5.0,YR,,F,Y,,,20170117.0,,OT,PK,PK,Efavirenz,Drug resistance;Pathogen resistance;Treatment noncompliance,131214531.0,OT,,,,,,,,,131214531.0,1.0,HIV infection
13122342,131223421,1,I,,20170106.0,20170117,20170117,EXP,,MX-MYLANLABS-2017M1001923,MYLAN,"GUTIERREZ-DELGADO EM, VILLANUEVA-LOZANO H, GARCIA ROJAS-ACOSTA MJ, MIRANDA-MALDONADO IC, RAMOS-JIMENEZ J. A CASE REPORT OF SMALL BOWEL PERFORATION SECONDARY TO CYTOMEGALOVIRUS RELATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN AIDS PATIENT. ANN-MED-SURGERY 2017;13:20-23.",,,,,Y,,,20170117.0,,OT,MX,MX,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Jejunal perforation;Large intestine perforation,131223421.0,OT,,,,,,,,,131223421.0,1.0,Antiretroviral therapy
13123353,131233531,1,I,,20170112.0,20170117,20170117,EXP,,CA-GILEAD-2017-0253464,GILEAD,,69.0,YR,E,M,Y,,,20170117.0,,PH,CA,CA,EFAVIRENZ,Bone density decreased;Fracture;Osteopenia;Osteoporosis,131233531.0,HO,,,,,,,,,131233531.0,1.0,Antiretroviral therapy
13143518,131435181,1,I,,20170109.0,20170123,20170123,EXP,,AU-HETERO LABS LTD-1062320,HETERO,"JOURNAL: ENDOCR-REV 2015?AUTHOR: BURNS K, LAM T, CHIPPS DR.?TITLE: ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE?YEAR: 2015",51.0,YR,,M,Y,,,20170123.0,,MD,AU,AU,Efavirenz,Fanconi syndrome;Osteomalacia,131435181.0,OT,,,,,,,,,131435181.0,1.0,HIV infection
13144218,1314421810,10,F,20170116.0,20170823.0,20170124,20170828,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004480,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170828.0,,CN,BR,BR,EFAVIRENZ,Atrial septal defect;Cardiomegaly;Cerebral calcification;Cerebral cyst;Cerebral ventricle dilatation;Congenital central nervous system anomaly;Congenital cytomegalovirus infection;Dandy-Walker syndrome;Foetal cardiac disorder;Foetal exposure during pregnancy;Foetal growth restriction;HIV infection;Haemoglobin decreased;Microcephaly;Platelet count decreased;Platelet transfusion;Pneumonia cytomegaloviral;Premature baby;Skull malformation;Transfusion,1314421810.0,HO,,,1314421810.0,1.0,20161223.0,20170201.0,,,1314421810.0,1.0,Prophylaxis against HIV infection
13148975,131489757,7,F,20170116.0,20170309.0,20170125,20170316,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK007932,VIIV,,0.0,YR,,F,Y,62.0,KG,20170316.0,,MD,BR,BR,Efavirenz,Foetal malformation,131489757.0,HO,,,131489757.0,1.0,20161223.0,20161230.0,,,131489757.0,1.0,HIV infection
13148984,131489842,2,F,20170117.0,20170301.0,20170125,20170306,EXP,,CL-VIIV HEALTHCARE LIMITED-CL2017GSK007358,VIIV,,35.0,YR,,M,Y,,,20170306.0,,MD,CL,CL,EFAVIRENZ,Acute myocardial infarction;Coronary artery disease,131489842.0,HO,,,131489842.0,1.0,201104.0,,,,131489842.0,1.0,HIV infection
13150769,131507692,2,F,20170117.0,20170301.0,20170125,20170306,EXP,,CL-GLAXOSMITHKLINE-CL2017GSK007358,GLAXOSMITHKLINE,,35.0,YR,,M,Y,,,20170306.0,,MD,CL,CL,EFAVIRENZ,Acute myocardial infarction;Coronary artery disease,131507692.0,OT,,,131507692.0,1.0,201104.0,,,,131507692.0,1.0,HIV infection
13159629,131596291,1,I,,20170119.0,20170127,20170127,EXP,,CN-MYLANLABS-2017M1004454,MYLAN,"XIAO H, XUE Y, GU S, WANG J, SUN H, LU H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCI-TRENDS 2016;10(1):42-46.",,,,,Y,,,20170127.0,,OT,CN,CN,EFAVIRENZ,Osteoporosis,131596291.0,OT,,,,,,,,,131596291.0,1.0,HIV infection
13159639,131596391,1,I,,20170119.0,20170127,20170127,EXP,,CN-MYLANLABS-2017M1004418,MYLAN,"XIAO H, XUE Y, GU S, WANG J, SUN H, LU H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCI-TRENDS 2016;10(1):42-46.",,,,,Y,,,20170127.0,,OT,CN,CN,EFAVIRENZ,Anaemia;Nightmare,131596391.0,OT,,,,,,,,,131596391.0,1.0,HIV infection
13159668,131596681,1,I,,20170123.0,20170127,20170127,EXP,,US-GILEAD-2017-0255004,GILEAD,"MAYER, K.H., ET AL.. EXCELLENT HIV POST-EXPOSURE PROPHYLAXIS REGIMEN COMPLETION WITH SINGLE TABLET DAILY ELVITEGRAVIR/COBICISTAT/TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE COMPARED TO MORE FREQUENT DOSING REGIMENS. NOT AVAILABLE. NA;NA:NA",,,A,M,Y,,,20170127.0,,MD,US,US,EFAVIRENZ,Accidental overdose;Dizziness;Syncope;Vomiting,131596681.0,OT,,,,,,,,,131596681.0,1.0,Prophylaxis against HIV infection
13179255,131792551,1,I,,20170127.0,20170202,20170202,EXP,,ZA-SCIEGEN PHARMACEUTICALS INC-2017SCILIT00024,SCIEGEN,,,,A,F,Y,,,20170202.0,,OT,ZA,ZA,Efavirenz,Stevens-Johnson syndrome,131792551.0,LT,,,,,,,,,131792551.0,1.0,Antiretroviral therapy
13188201,131882011,1,I,,20170131.0,20170206,20170206,EXP,,AR-VIIV HEALTHCARE LIMITED-AR2017GSK016403,VIIV,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",49.0,YR,,F,Y,,,20170206.0,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131882011.0,OT,,,,,,,,,131882011.0,1.0,HIV infection
13188203,131882031,1,I,,20170131.0,20170206,20170206,EXP,,AR-VIIV HEALTHCARE LIMITED-AR2017GSK016430,VIIV,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",75.0,YR,,M,Y,,,20170206.0,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131882031.0,OT,,,,,,,,,131882031.0,1.0,HIV infection
13188679,131886791,1,I,,20170131.0,20170206,20170206,EXP,,AR-GLAXOSMITHKLINE-AR2017GSK016403,GLAXOSMITHKLINE,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",49.0,YR,,F,Y,,,20170206.0,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131886791.0,OT,,,,,,,,,131886791.0,1.0,HIV infection
13188688,131886881,1,I,,20170131.0,20170206,20170206,EXP,,AR-GLAXOSMITHKLINE-AR2017GSK016430,GLAXOSMITHKLINE,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",75.0,YR,,M,Y,,,20170206.0,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131886881.0,OT,,,,,,,,,131886881.0,1.0,HIV infection
13195465,131954656,6,F,20170201.0,20170823.0,20170208,20170828,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010413,BRISTOL MYERS SQUIBB,,15.0,YR,,F,Y,62.0,KG,20170828.0,,CN,BR,BR,EFAVIRENZ,Caesarean section;Folliculitis;Maternal exposure during pregnancy;Premature delivery,131954656.0,OT,,,131954656.0,1.0,20161223.0,20170201.0,,,131954656.0,1.0,HIV infection
13196502,131965029,9,F,20170201.0,20170529.0,20170208,20170602,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK015761,VIIV,,0.0,DY,,F,Y,1.89,KG,20170602.0,,MD,BR,BR,Efavirenz,Atrial septal defect;Congenital cytomegalovirus infection,131965029.0,LT,,,131965029.0,1.0,20161223.0,20170201.0,,,131965029.0,1.0,HIV infection
13203543,132035431,1,I,,20170201.0,20170209,20170209,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2017GSK015282,VIIV,"GAVRILIU LC, BENEA OE,. HIV ASSOCIATED LYMPHOMA -TWO CASE REPORT SERIES. ROMANIAN JOURNAL OF INFECTIOUS DISEASES. 2016;XIX(3):157-165",27.0,YR,,M,Y,,,20170209.0,,MD,RO,RO,EFAVIRENZ,Asthenia;CD4 lymphocytes abnormal;Cough;Hepatic enzyme increased;Hepatomegaly;Hodgkin's disease;Hyperhidrosis;Leukopenia;Lymphadenopathy;Lymphopenia;Microcytic anaemia;Splenomegaly;Thrombocytopenia,132035431.0,HO,,,,,,,,,132035431.0,2.0,Antiretroviral therapy
13204147,132041471,1,I,,20170201.0,20170209,20170209,EXP,,RO-GLAXOSMITHKLINE-RO2017GSK015282,GLAXOSMITHKLINE,"GAVRILIU LC, BENEA OE,. HIV ASSOCIATED LYMPHOMA -TWO CASE REPORT SERIES. ROMANIAN JOURNAL OF INFECTIOUS DISEASES. 2016;XIX(3):157-165",27.0,YR,,M,Y,,,20170209.0,,MD,RO,RO,EFAVIRENZ,Asthenia;CD4 lymphocytes abnormal;Cough;Hepatic enzyme increased;Hepatomegaly;Hodgkin's disease;Hyperhidrosis;Leukopenia;Lymphadenopathy;Lymphopenia;Microcytic anaemia;Splenomegaly;Thrombocytopenia,132041471.0,OT,,,,,,,,,132041471.0,2.0,Antiretroviral therapy
13216665,132166651,1,I,19980223.0,20030226.0,20170210,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12197463,BRISTOL MYERS SQUIBB,,23.0,YR,,M,Y,54.0,KG,20170210.0,,OT,JP,JP,EFAVIRENZ,Cachexia;Hyperlactacidaemia;Osteonecrosis;Platelet count decreased,132166651.0,DS,,,132166651.0,1.0,19980114.0,20040527.0,,,132166651.0,1.0,HIV infection
13220170,132201705,5,F,20170201.0,20170705.0,20170210,20170719,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010253,BRISTOL MYERS SQUIBB,,0.0,DY,,F,Y,1.89,KG,20170719.0,,OT,BR,BR,EFAVIRENZ,Atrial septal defect;Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,132201705.0,CA,,,132201705.0,1.0,20161223.0,20170201.0,,,132201705.0,1.0,Prophylaxis against HIV infection
13220172,132201723,3,F,20170201.0,20170609.0,20170210,20170615,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-011279,BRISTOL MYERS SQUIBB,,15.0,YR,,F,Y,,,20170615.0,,OT,BR,BR,EFAVIRENZ,Maternal exposure during pregnancy;Premature delivery,132201723.0,OT,,,132201723.0,1.0,20161223.0,20170201.0,,,132201723.0,1.0,HIV infection
13229601,132296011,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01842,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296011.0,OT,,,,,,,,,132296011.0,1.0,HIV infection
13229628,132296281,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01843,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296281.0,OT,,,,,,,,,132296281.0,1.0,HIV infection
13229635,132296351,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01847,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296351.0,OT,,,,,,,,,132296351.0,1.0,HIV infection
13229645,132296451,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01845,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296451.0,OT,,,,,,,,,132296451.0,1.0,HIV infection
13229655,132296551,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01844,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296551.0,OT,,,,,,,,,132296551.0,1.0,HIV infection
13229666,132296661,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01850,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296661.0,OT,,,,,,,,,132296661.0,1.0,HIV infection
13229673,132296731,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01848,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296731.0,OT,,,,,,,,,132296731.0,1.0,HIV infection
13229681,132296811,1,I,,20170201.0,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01851,CIPLA,,,,,,Y,,,20170214.0,,OT,SG,UG,Efavirenz,Virologic failure,132296811.0,OT,,,,,,,,,132296811.0,1.0,HIV infection
13233537,132335371,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01857,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132335371.0,OT,,,,,,,,,132335371.0,1.0,HIV infection
13233548,132335481,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01860,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132335481.0,OT,,,,,,,,,132335481.0,1.0,HIV infection
13233550,132335501,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01854,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132335501.0,OT,,,,,,,,,132335501.0,1.0,HIV infection
13233557,132335571,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01862,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132335571.0,OT,,,,,,,,,132335571.0,1.0,HIV infection
13233562,132335621,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01864,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132335621.0,OT,,,,,,,,,132335621.0,1.0,HIV infection
13233581,132335811,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01865,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132335811.0,OT,,,,,,,,,132335811.0,1.0,HIV infection
13233659,132336591,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01868,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132336591.0,OT,,,,,,,,,132336591.0,1.0,HIV infection
13233665,132336651,1,I,,20170201.0,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01870,CIPLA,,,,,,Y,,,20170215.0,,OT,SG,UG,Efavirenz,Virologic failure,132336651.0,OT,,,,,,,,,132336651.0,1.0,HIV infection
13245399,132453991,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01968,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132453991.0,OT,,,,,,,,,132453991.0,1.0,HIV infection
13245401,132454011,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01981,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J, ET.AL,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132454011.0,OT,,,,,,,,,132454011.0,1.0,HIV infection
13245403,132454031,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01982,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J, ET.AL;. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132454031.0,OT,,,,,,,,,132454031.0,1.0,HIV infection
13245405,132454051,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01967,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS: A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Depression;Suicidal ideation;Suicide attempt,132454051.0,OT,,,,,,,,,132454051.0,1.0,HIV infection
13245407,132454071,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01969,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132454071.0,OT,,,,,,,,,132454071.0,1.0,HIV infection
13245409,132454091,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01980,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132454091.0,OT,,,,,,,,,132454091.0,1.0,HIV infection
13245414,132454141,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01971,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIA. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132454141.0,OT,,,,,,,,,132454141.0,1.0,HIV infection
13246639,132466391,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01983,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J, ET.AL;. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132466391.0,OT,,,,,,,,,132466391.0,1.0,HIV infection
13246688,132466881,1,I,,20170206.0,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01970,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217.0,,OT,FR,FR,Efavirenz,Nervous system disorder,132466881.0,OT,,,,,,,,,132466881.0,1.0,HIV infection
13252033,132520333,3,F,,20170227.0,20170220,20170307,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2017022671,VIIV,UNK. LAMIVUDINE PLUS DARNAVIR POTENTIATED AS DUAL THERAPY IN HIV PATIENTS WITH NUCLEOSIDE ANALOGUE TOXICITY OR IN THE PRESENCE OF COMMORBIDITIES (LAMDA STUDY). MEDED INFECTIOUS DISEASES 2017. 2017;UNK:UNK,,,A,,Y,,,20170307.0,,MD,ES,ES,EFAVIRENZ,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132520333.0,DE,,,,,,,,,132520333.0,1.0,HIV infection
13252162,132521623,3,F,,20170227.0,20170220,20170307,EXP,,ES-GLAXOSMITHKLINE-ES2017022671,GLAXOSMITHKLINE,UNK. LAMIVUDINE PLUS DARNAVIR POTENTIATED AS DUAL THERAPY IN HIV PATIENTS WITH NUCLEOSIDE ANALOGUE TOXICITY OR IN THE PRESENCE OF COMMORBIDITIES (LAMDA STUDY). MEDED INFECTIOUS DISEASES 2017. 2017;UNK:UNK,,,A,,Y,,,20170307.0,,MD,ES,ES,EFAVIRENZ,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132521623.0,DE,,,,,,,,,132521623.0,1.0,HIV infection
13257832,132578321,1,I,,20170207.0,20170221,20170221,EXP,,GB-GLAXOSMITHKLINE-GB2017GSK018157,GLAXOSMITHKLINE,,50.0,YR,,,Y,,,20170221.0,,CN,GB,GB,SUSTIVA,Anxiety;Memory impairment;Nightmare;Paraesthesia;Renal impairment,132578321.0,OT,,,,,,,,,132578321.0,1.0,HIV infection
13257842,132578421,1,I,,20170207.0,20170221,20170221,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017GSK018157,VIIV,,50.0,YR,,,Y,,,20170221.0,,CN,GB,GB,SUSTIVA,Anxiety;Memory impairment;Nightmare;Paraesthesia;Renal impairment,132578421.0,OT,,,,,,,,,132578421.0,1.0,HIV infection
13265550,132655502,2,F,,20170404.0,20170223,20170407,EXP,,ES-JNJFOC-20170209920,JANSSEN,,,,,,Y,,,20170407.0,,MD,ES,ES,EFAVIRENZ,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132655502.0,OT,,,,,,,,,132655502.0,1.0,HIV infection
13274205,1327420512,12,F,,20191106.0,20170227,20191117,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016053,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,,,20191117.0,,CN,FR,FR,EFAVIRENZ.,Abortion induced;Intentional product use issue;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,1327420512.0,OT,,,1327420512.0,1.0,201110.0,,,,1327420512.0,1.0,HIV infection
13274215,132742158,8,F,,20191022.0,20170227,20191025,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015407,BRISTOL MYERS SQUIBB,,32.0,YR,,F,Y,,,20191025.0,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Intentional product use issue;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,132742158.0,OT,,,132742158.0,1.0,200909.0,,,,132742158.0,1.0,HIV infection
13274309,132743092,2,F,,20170310.0,20170227,20170315,EXP,,TR-GILEAD-2017-0259775,GILEAD,,44.0,YR,A,M,Y,82.0,KG,20170315.0,,MD,TR,TR,EFAVIRENZ,Coronary artery disease,132743092.0,OT,,,,,,,,,132743092.0,1.0,HIV infection
13274317,132743172,2,F,,20170310.0,20170227,20170315,EXP,,TR-GILEAD-2017-0259777,GILEAD,,31.0,YR,A,M,Y,,,20170315.0,,MD,TR,TR,EFAVIRENZ,Non-Hodgkin's lymphoma,132743172.0,OT,,,,,,,,,132743172.0,1.0,HIV infection
13274653,132746531,1,I,,20170220.0,20170227,20170227,EXP,,US-TEVA-743148USA,TEVA,"HAUG SJ, WONG RW, DAY S, CHOUDHRY N, SNEED S, PRASAD P, ET AL. DIDANOSINE RETINAL TOXICITY. RETINA 2016;36 (SUPPL. 1):S159-S167.",66.0,YR,,M,Y,,,20170227.0,,MD,US,US,efavirenz,Retinal toxicity,132746531.0,OT,,,,,,,,,132746531.0,1.0,Antiretroviral therapy
13275773,132757731,1,I,201603.0,20170206.0,20170228,20170228,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010596,BRISTOL MYERS SQUIBB,,10.0,YR,,F,Y,,,20170228.0,,PH,US,US,SUSTIVA,Off label use,,,,,132757731.0,1.0,201603.0,,,,132757731.0,1.0,HIV infection
13278413,132784133,3,F,20170201.0,20170323.0,20170228,20170329,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015623,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170329.0,,OT,BR,BR,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Premature delivery,132784133.0,OT,,,132784133.0,1.0,20161223.0,20170201.0,,,132784133.0,1.0,HIV infection
13278414,132784145,5,F,20170116.0,20170321.0,20170228,20170324,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-009368,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170324.0,,OT,BR,BR,EFAVIRENZ,Atrial septal defect;Cardiomegaly;Cerebral calcification;Cerebral cyst;Cerebral ventricle dilatation;Congenital central nervous system anomaly;Congenital cytomegalovirus infection;Dandy-Walker syndrome;Foetal cardiac disorder;Foetal exposure during pregnancy;Foetal growth restriction;HIV infection;Haemoglobin decreased;Microcephaly;Platelet count decreased;Platelet transfusion;Pneumonia cytomegaloviral;Premature baby;Skull malformation;Transfusion,132784145.0,HO,,,132784145.0,1.0,20161223.0,20170201.0,,,132784145.0,1.0,Prophylaxis against HIV infection
13288466,132884661,1,I,,20161128.0,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020093,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302.0,,OT,US,US,EFAVIRENZ,Pancreatitis chronic,132884661.0,OT,,,,,,,,,132884661.0,1.0,HIV infection
13288475,132884751,1,I,,20161128.0,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020094,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302.0,,OT,US,US,EFAVIRENZ,Pancreatitis acute,132884751.0,OT,,,,,,,,,132884751.0,1.0,HIV infection
13288483,132884831,1,I,,20161128.0,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020096,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302.0,,OT,US,US,EFAVIRENZ,Lactic acidosis,132884831.0,OT,,,,,,,,,132884831.0,1.0,HIV infection
13288508,132885081,1,I,,20161128.0,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020417,STRIDES,"CAMPBELL TB, SMEATON LM, KUMARASAMY N, FLANIGAN T, KLINGMAN KL, ET AL. EFFICACY AND SAFETY OF THREE ANTIRETROVIRAL REGIMENS FOR INITIAL TREATMENT OF HIV-1: A RANDOMIZED CLINICAL TRIAL IN DIVERSE MULTINATIONAL SETTINGS. PLOS MED. 2012;9(8):E1001290",,,,,Y,,,20170302.0,,OT,US,US,EFAVIRENZ,Virologic failure,132885081.0,OT,,,,,,,,,132885081.0,1.0,HIV infection
13288512,132885121,1,I,,20161128.0,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020098,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS.. 2014;15(6):246-60",,,,,Y,,,20170302.0,,OT,US,US,EFAVIRENZ,Body fat disorder,132885121.0,OT,,,,,,,,,132885121.0,1.0,HIV infection
13288522,132885221,1,I,,20161128.0,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020099,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302.0,,OT,US,US,EFAVIRENZ,Body fat disorder,132885221.0,OT,,,,,,,,,132885221.0,1.0,HIV infection
13288545,132885451,1,I,,20161128.0,20170302,20170302,PER,,US-STRIDES ARCOLAB LIMITED-2016SP020418,STRIDES,"CAMPBELL TB, SMEATON LM, KUMARASAMY N, FLANIGAN T, KLINGMAN KL, ET AL. EFFICACY AND SAFETY OF THREE ANTIRETROVIRAL REGIMENS FOR INITIAL TREATMENT OF HIV-1: A RANDOMIZED CLINICAL TRIAL IN DIVERSE MULTINATIONAL SETTINGS. PLOS MED. 2012;9(8):E1001290",,,,,Y,,,20170302.0,,OT,US,US,EFAVIRENZ,Exposure during pregnancy,,,,,,,,,,,132885451.0,1.0,HIV infection
13291602,132916021,1,I,,20170222.0,20170303,20170303,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017029870,VIIV,"KIGGUNDU, R., NABETA, H.W., OKIA, R., RHEIN, J., LUKUNDE R. UNMASKING HISTOPLASMOSIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PATIENT RECENTLY STARTED ON ANTIRETROVIRAL THERAPY.. AUTOPSY + CASE REPORTS. 2016;(4):27-33",43.0,YR,,M,Y,,,20170303.0,,OT,UG,UG,EFAVIRENZ,Immune reconstitution inflammatory syndrome,132916021.0,HO,,,,,,,,,132916021.0,1.0,HIV infection
13291885,132918851,1,I,,20170222.0,20170303,20170303,EXP,,UG-GLAXOSMITHKLINE-UG2017029870,GLAXOSMITHKLINE,"KIGGUNDU, R., NABETA, H.W., OKIA, R., RHEIN, J., LUKUNDE R. UNMASKING HISTOPLASMOSIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PATIENT RECENTLY STARTED ON ANTIRETROVIRAL THERAPY.. AUTOPSY + CASE REPORTS. 2016;(4):27-33",43.0,YR,,M,Y,,,20170303.0,,OT,UG,UG,EFAVIRENZ,Immune reconstitution inflammatory syndrome,132918851.0,HO,,,,,,,,,132918851.0,1.0,HIV infection
13297351,132973511,1,I,20160501.0,20170228.0,20170306,20170306,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK030103,GLAXOSMITHKLINE,,55.0,YR,,M,Y,52.0,KG,20170306.0,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Flushing;Product use issue;Pruritus;Pyrexia;Rash;Rash maculo-papular,132973511.0,OT,,,,,,,,,132973511.0,1.0,Acquired immunodeficiency syndrome
13301143,133011431,1,I,,20170223.0,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03310,CIPLA,,,,,,Y,,,20170307.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011431.0,OT,,,,,,,,,133011431.0,1.0,HIV infection
13301145,133011451,1,I,,20170223.0,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03304,CIPLA,,,,,,Y,,,20170307.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011451.0,OT,,,,,,,,,133011451.0,1.0,HIV infection
13301155,133011551,1,I,,20170223.0,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03274,CIPLA,,,,,,Y,,,20170307.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011551.0,OT,,,,,,,,,133011551.0,1.0,HIV infection
13301186,133011861,1,I,,20170223.0,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03368,CIPLA,,,,,,Y,,,20170307.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011861.0,OT,,,,,,,,,133011861.0,1.0,HIV infection
13301255,133012551,1,I,,20170223.0,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03370,CIPLA,,,,,,Y,,,20170307.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133012551.0,OT,,,,,,,,,133012551.0,1.0,HIV infection
13301593,133015931,1,I,20160501.0,20170228.0,20170307,20170307,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK030103,VIIV,,55.0,YR,,M,Y,52.0,KG,20170307.0,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Flushing;Product use issue;Pruritus;Pyrexia;Rash;Rash maculo-papular,133015931.0,HO,,,,,,,,,133015931.0,1.0,Acquired immunodeficiency syndrome
13304072,133040721,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03338,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040721.0,OT,,,,,,,,,133040721.0,1.0,HIV infection
13304076,133040761,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03704,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040761.0,OT,,,,,,,,,133040761.0,1.0,HIV infection
13304079,133040791,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03703,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040791.0,OT,,,,,,,,,133040791.0,1.0,HIV infection
13304080,133040801,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03279,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040801.0,OT,,,,,,,,,133040801.0,1.0,HIV infection
13304081,133040811,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03677,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040811.0,OT,,,,,,,,,133040811.0,1.0,HIV infection
13304184,133041841,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03743,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Adverse event,133041841.0,OT,,,,,,,,,133041841.0,1.0,HIV infection
13304195,133041951,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03808,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Neuropsychiatric symptoms;Rash,133041951.0,OT,,,,,,,,,133041951.0,1.0,HIV infection
13304258,133042581,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03696,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133042581.0,OT,,,,,,,,,133042581.0,1.0,HIV infection
13304259,133042591,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03369,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133042591.0,OT,,,,,,,,,133042591.0,1.0,HIV infection
13304265,133042651,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03308,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Alanine aminotransferase increased;Drug resistance;Virologic failure,133042651.0,OT,,,,,,,,,133042651.0,1.0,HIV infection
13304325,133043251,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03711,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133043251.0,OT,,,,,,,,,133043251.0,1.0,HIV infection
13304338,133043381,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03819,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133043381.0,OT,,,,,,,,,133043381.0,1.0,HIV infection
13304340,133043401,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03834,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133043401.0,OT,,,,,,,,,133043401.0,1.0,HIV infection
13304403,133044031,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03315,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133044031.0,OT,,,,,,,,,133044031.0,1.0,HIV infection
13304405,133044051,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03689,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133044051.0,OT,,,,,,,,,133044051.0,1.0,HIV infection
13304813,133048131,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW02725,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Hyperlipidaemia;Lipodystrophy acquired,133048131.0,OT,,,,,,,,,133048131.0,1.0,HIV infection
13304890,133048901,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03828,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133048901.0,OT,,,,,,,,,133048901.0,1.0,HIV infection
13304896,133048961,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03804,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Delirium;Nervous system disorder;Psychotic disorder,133048961.0,OT,,,,,,,,,133048961.0,1.0,HIV infection
13306007,133060071,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW02981,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Alanine aminotransferase increased;Drug resistance;Pyrexia;Rash;Virologic failure,133060071.0,OT,,,,,,,,,133060071.0,1.0,HIV infection
13306008,133060081,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03034,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133060081.0,OT,,,,,,,,,133060081.0,1.0,HIV infection
13306326,133063261,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03672,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Nervous system disorder;Virologic failure,133063261.0,OT,,,,,,,,,133063261.0,1.0,HIV infection
13306345,133063451,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03673,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Alanine aminotransferase increased;Aspartate aminotransferase increased;Nephropathy toxic,133063451.0,OT,,,,,,,,,133063451.0,1.0,HIV infection
13306364,133063641,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03675,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133063641.0,OT,,,,,,,,,133063641.0,1.0,HIV infection
13306410,133064101,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03679,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Rash;Virologic failure,133064101.0,OT,,,,,,,,,133064101.0,1.0,HIV infection
13306421,133064211,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03676,CIPLA,,,,,,Y,,,20170308.0,,OT,TW,TW,Efavirenz,Drug resistance;Nervous system disorder;Virologic failure,133064211.0,OT,,,,,,,,,133064211.0,1.0,HIV infection
13306443,133064431,1,I,,20170227.0,20170308,20170308,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-020346,BRISTOL MYERS SQUIBB,,75.0,YR,,M,Y,,,20170308.0,,OT,AR,AR,EFAVIRENZ,Herbal interaction;Viral load increased,133064431.0,OT,,,133064431.0,1.0,2007.0,,,,133064431.0,1.0,HIV infection
13306444,133064442,2,F,201303.0,20170315.0,20170308,20170323,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-019946,BRISTOL MYERS SQUIBB,,47.0,YR,,F,Y,67.0,KG,20170323.0,,OT,AR,AR,EFAVIRENZ,Herbal interaction;Viral load increased,133064442.0,OT,,,133064442.0,1.0,2007.0,,,,133064442.0,1.0,HIV infection
13312734,133127341,1,I,20160519.0,20170307.0,20170308,20170308,EXP,,BR-GILEAD-2017-0261525,GILEAD,,52.0,YR,A,M,Y,79.0,KG,20170308.0,,MD,BR,BR,EFAVIRENZ,Acute myocardial infarction,133127341.0,HO,,,133127341.0,1.0,20131114.0,,,,133127341.0,1.0,HIV infection
13314596,133145961,1,I,20170302.0,20170302.0,20170309,20170309,EXP,,BR-ABBVIE-17P-020-1899514-00,ABBVIE,,,,,M,Y,70.0,KG,20170309.0,,CN,BR,BR,EFAVIRENZ,CD4 lymphocytes decreased;Incorrect dose administered;Intracranial mass;Mental disorder;Schizophrenia;Suicidal ideation,133145961.0,OT,,,,,,,,,133145961.0,1.0,HIV infection
13319496,133194961,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03714,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133194961.0,OT,,,,,,,,,133194961.0,1.0,HIV infection
13319534,133195341,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03682,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133195341.0,OT,,,,,,,,,133195341.0,1.0,HIV infection
13319579,133195791,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03721,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133195791.0,OT,,,,,,,,,133195791.0,1.0,HIV infection
13319615,133196151,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03710,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133196151.0,OT,,,,,,,,,133196151.0,1.0,HIV infection
13319695,133196951,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03906,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133196951.0,OT,,,,,,,,,133196951.0,1.0,HIV infection
13319736,133197361,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03429,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Adverse event,133197361.0,OT,,,,,,,,,133197361.0,1.0,HIV infection
13319748,133197481,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03782,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Dizziness;Drug resistance;Insomnia;Nervous system disorder;Virologic failure,133197481.0,OT,,,,,,,,,133197481.0,1.0,HIV infection
13319753,133197531,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03850,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Completed suicide;Rash,133197531.0,DE,,,,,,,,,133197531.0,1.0,HIV infection
13319758,133197581,1,I,,20170223.0,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03795,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133197581.0,OT,,,,,,,,,133197581.0,1.0,HIV infection
13325639,133256391,1,I,,20170223.0,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03829,CIPLA,,,,,,Y,,,20170309.0,,OT,TW,TW,Efavirenz,Renal impairment,133256391.0,OT,,,,,,,,,133256391.0,1.0,HIV infection
13335985,133359853,3,F,20150430.0,20180711.0,20170314,20180724,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-021688,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20180724.0,,CN,FR,FR,SUSTIVA,Gestational hypertension;Headache;Live birth;Maternal exposure during pregnancy;Metrorrhagia;Placental disorder;Premature labour;Product use issue;Streptococcus test positive,133359853.0,OT,,,,,,,,,133359853.0,1.0,HIV infection
13339761,133397618,8,F,,20191028.0,20170315,20191103,EXP,,FR-009507513-1702FRA008692,MERCK,"RUELLAN AL, VEYRAC G, BRUNET-CARTLER C, JARNET L, JOLLIET P. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016;30 SUPPL (1):50",28.0,YR,,F,Y,,,20191103.0,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,133397618.0,OT,,,133397618.0,2.0,201206.0,,,,133397618.0,1.0,HIV infection
13343354,133433541,1,I,,20170307.0,20170316,20170316,EXP,,ZA-MYLANLABS-2017M1016192,MYLAN,"PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L, PATEL F, ET AL. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC-INFECT-DIS 2016;16:56.",,,,,Y,,,20170316.0,,OT,ZA,ZA,EFAVIRENZ,Nervous system disorder,133433541.0,HO,,,,,,,,,133433541.0,1.0,Perinatal HIV infection
13343835,133438351,1,I,,20170307.0,20170316,20170316,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-023107,BRISTOL MYERS SQUIBB,,7.0,YR,,F,Y,,,20170316.0,,OT,US,ZA,EFAVIRENZ,Generalised tonic-clonic seizure,133438351.0,OT,,,,,,,,,133438351.0,1.0,Antiretroviral therapy
13343839,133438392,2,F,,20170307.0,20170316,20190524,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-023108,BRISTOL MYERS SQUIBB,,4.0,YR,,F,Y,,,20190524.0,,OT,US,ZA,EFAVIRENZ.,Petit mal epilepsy,133438392.0,OT,,,,,,,,,133438392.0,1.0,Antiretroviral therapy
13350010,133500101,1,I,,20170308.0,20170320,20170320,EXP,,CN-MYLANLABS-2017M1017020,MYLAN,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI 2016;32(6):1574-1579.",,,,,Y,,,20170320.0,,MD,CN,CN,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,133500101.0,OT,,,,,,,,,133500101.0,1.0,Acquired immunodeficiency syndrome
13350473,133504731,1,I,,20170308.0,20170320,20170320,EXP,,CN-MYLANLABS-2017M1017177,MYLAN,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI 2016;32(6):1574-1579.",,,,,Y,,,20170320.0,,MD,CN,CN,EFAVIRENZ,Acinetobacter infection;Bone marrow failure;Gastrointestinal disorder;Respiratory failure;Sepsis,133504731.0,DE,,,,,,,,,133504731.0,1.0,Acquired immunodeficiency syndrome
13350474,133504741,1,I,,20170308.0,20170320,20170320,EXP,,CN-MYLANLABS-2017M1017180,MYLAN,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI 2016;32(6):1574-1579.",,,,,Y,,,20170320.0,,MD,CN,CN,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,133504741.0,OT,,,,,,,,,133504741.0,1.0,Acquired immunodeficiency syndrome
13368899,133688991,1,I,2014.0,20170316.0,20170324,20170324,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-024639,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,75.0,KG,20170324.0,,OT,CO,CO,EFAVIRENZ,Dyspnoea;Post procedural sepsis;Sleep disorder;Somnolence;Turbinectomy,133688991.0,HO,,,133688991.0,1.0,20120101.0,,,,133688991.0,1.0,HIV infection
13382748,133827482,2,F,19990929.0,20170329.0,20170329,20170405,EXP,,AU-ABBVIE-17P-008-1919042-00,ABBVIE,,43.0,YR,,M,Y,71.0,KG,20170405.0,,CN,AU,AU,EFAVIRENZ,Acute kidney injury;Hydroureter;Nephrolithiasis;Ureterolithiasis,133827482.0,OT,,,133827482.0,1.0,19990429.0,19990929.0,,,133827482.0,1.0,HIV infection
13388567,133885671,1,I,,20170321.0,20170330,20170330,EXP,,BR-ABBVIE-17K-020-1920058-00,ABBVIE,,,,,M,Y,73.0,KG,20170330.0,,CN,BR,BR,EFAVIRENZ,Blindness unilateral;Cerebrovascular accident;Crying;Dysphonia;Eye contusion;Eye disorder;Gait disturbance;HIV infection;Immunodeficiency;Liver disorder;Malaise;Meningitis;Panic reaction;Retinopathy;Schizophrenia;Syphilis;Ulcer;Unevaluable event;Urinary tract infection;Visual acuity reduced;Visual impairment,133885671.0,OT,,,133885671.0,1.0,201604.0,,,,133885671.0,1.0,HIV infection
13395440,133954401,1,I,,20170327.0,20170403,20170403,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-026458,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170403.0,,CN,US,US,SUSTIVA,Gastric disorder,,,,,,,,,,,133954401.0,1.0,HIV infection
13399265,133992651,1,I,,20170321.0,20170404,20170404,EXP,,BR-HETERO LABS LTD-1064955,HETERO,,,,,M,Y,,,20170404.0,,OT,BR,BR,Efavirenz,Congenital syphilis;Foetal exposure during pregnancy,133992651.0,CA,,,,,,,,,133992651.0,1.0,HIV infection
13401350,134013501,1,I,,20170328.0,20170404,20170404,EXP,,ET-GILEAD-2017-0265558,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170404.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134013501.0,OT,,,,,,,,,134013501.0,1.0,HIV infection
13401353,134013531,1,I,20150610.0,20170313.0,20170404,20170404,EXP,,IN-GILEAD-2017-0262826,GILEAD,"KUMAR A, MAJHEE L, GARI M. CAUSALITY, SEVERITY AND PREVENTABILITY ASSESSMENT OF ADVERSE DRUG REACTIONS IN PATIENTS RECEIVED ANTI-RETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL: A RETROSPECTIVE STUDY.. NATIONAL JOURNAL OF PHYSIOLOGY, PHARMACY AND PHARMACOLOGY.. 2017;7(2):PP 178-182",32.0,YR,A,F,Y,24.0,KG,20170404.0,,MD,IN,IN,EFAVIRENZ,Renal failure,134013531.0,HO,,,134013531.0,1.0,201411.0,,,,134013531.0,1.0,HIV infection
13402471,134024711,1,I,,20170328.0,20170404,20170404,EXP,,ET-GILEAD-2017-0265777,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170404.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134024711.0,OT,,,,,,,,,134024711.0,1.0,HIV infection
13404987,134049871,1,I,,20170328.0,20170405,20170405,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017047999,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134049871.0,OT,,,,,,,,,134049871.0,1.0,HIV infection
13404994,134049941,1,I,20170323.0,20170404.0,20170405,20170405,EXP,GB-MHRA-EYC 00156013,GB-VIIV HEALTHCARE LIMITED-GB2017047846,VIIV,,45.0,YR,,F,Y,,,20170405.0,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134049941.0,OT,,,134049941.0,1.0,20170313.0,20170323.0,,,134049941.0,1.0,HIV infection
13404997,134049971,1,I,,20170328.0,20170405,20170405,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017047944,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134049971.0,OT,,,,,,,,,134049971.0,1.0,HIV infection
13405115,134051151,1,I,,20170328.0,20170405,20170405,EXP,,ET-GLAXOSMITHKLINE-ET2017047999,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134051151.0,OT,,,,,,,,,134051151.0,1.0,HIV infection
13405121,134051211,1,I,,20170328.0,20170405,20170405,EXP,,ET-GLAXOSMITHKLINE-ET2017047944,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134051211.0,OT,,,,,,,,,134051211.0,1.0,HIV infection
13405315,134053151,1,I,20170323.0,20170404.0,20170405,20170405,EXP,GB-MHRA-EYC 00156013,GB-GLAXOSMITHKLINE-GB2017047846,GLAXOSMITHKLINE,,45.0,YR,,F,Y,,,20170405.0,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134053151.0,OT,,,134053151.0,1.0,20170313.0,20170323.0,,,134053151.0,1.0,HIV infection
13407143,134071431,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265778,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134071431.0,OT,,,,,,,,,134071431.0,1.0,HIV infection
13407151,134071511,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265779,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134071511.0,OT,,,,,,,,,134071511.0,1.0,HIV infection
13407354,134073541,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265780,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073541.0,OT,,,,,,,,,134073541.0,1.0,HIV infection
13407355,134073551,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265781,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073551.0,OT,,,,,,,,,134073551.0,1.0,HIV infection
13407356,134073561,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265782,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073561.0,OT,,,,,,,,,134073561.0,1.0,HIV infection
13407357,134073571,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265783,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073571.0,OT,,,,,,,,,134073571.0,1.0,HIV infection
13407358,134073581,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265784,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073581.0,OT,,,,,,,,,134073581.0,1.0,HIV infection
13407362,134073621,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265785,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073621.0,OT,,,,,,,,,134073621.0,1.0,HIV infection
13407365,134073651,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265787,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073651.0,OT,,,,,,,,,134073651.0,1.0,HIV infection
13407367,134073671,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265786,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073671.0,OT,,,,,,,,,134073671.0,1.0,HIV infection
13407374,134073741,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265788,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073741.0,OT,,,,,,,,,134073741.0,1.0,HIV infection
13407375,134073751,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265789,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073751.0,OT,,,,,,,,,134073751.0,1.0,HIV infection
13407395,134073951,1,I,,20170328.0,20170405,20170405,EXP,,ET-GILEAD-2017-0265790,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073951.0,OT,,,,,,,,,134073951.0,1.0,HIV infection
13413107,134131072,2,F,,20170328.0,20170406,20170406,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048814,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170406.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134131072.0,OT,,,,,,,,,134131072.0,1.0,HIV infection
13414642,134146422,2,F,,20170328.0,20170406,20170406,EXP,,ET-GLAXOSMITHKLINE-ET2017048814,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170406.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134146422.0,OT,,,,,,,,,134146422.0,1.0,HIV infection
13415974,134159742,2,F,,20170406.0,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048863,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159742.0,OT,,,,,,,,,134159742.0,1.0,HIV infection
13415976,134159762,2,F,,20170406.0,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048857,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159762.0,OT,,,,,,,,,134159762.0,1.0,HIV infection
13415978,134159782,2,F,,20170406.0,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048862,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159782.0,OT,,,,,,,,,134159782.0,1.0,HIV infection
13415979,134159792,2,F,,20170406.0,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048868,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159792.0,OT,,,,,,,,,134159792.0,1.0,HIV infection
13415980,134159802,2,F,,20170406.0,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048865,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159802.0,OT,,,,,,,,,134159802.0,1.0,HIV infection
13415987,134159872,2,F,,20170406.0,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048864,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159872.0,OT,,,,,,,,,134159872.0,1.0,HIV infection
13415992,134159922,2,F,,20170406.0,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048858,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159922.0,OT,,,,,,,,,134159922.0,1.0,HIV infection
13415997,134159972,2,F,,20170406.0,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048870,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159972.0,OT,,,,,,,,,134159972.0,1.0,HIV infection
13416000,134160002,2,F,,20170406.0,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048816,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160002.0,OT,,,,,,,,,134160002.0,1.0,HIV infection
13416005,134160052,2,F,,20170406.0,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048867,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160052.0,OT,,,,,,,,,134160052.0,1.0,HIV infection
13416008,134160082,2,F,,20170406.0,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048860,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160082.0,OT,,,,,,,,,134160082.0,1.0,HIV infection
13416010,134160102,2,F,,20170406.0,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048861,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160102.0,OT,,,,,,,,,134160102.0,1.0,HIV infection
13417093,134170932,2,F,,20170406.0,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048863,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134170932.0,OT,,,,,,,,,134170932.0,1.0,HIV infection
13417095,134170952,2,F,,20170406.0,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048857,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134170952.0,OT,,,,,,,,,134170952.0,1.0,HIV infection
13417097,134170972,2,F,,20170406.0,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048862,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134170972.0,OT,,,,,,,,,134170972.0,1.0,HIV infection
13417100,134171002,2,F,,20170406.0,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048868,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171002.0,OT,,,,,,,,,134171002.0,1.0,HIV infection
13417103,134171032,2,F,,20170406.0,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048865,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171032.0,OT,,,,,,,,,134171032.0,1.0,HIV infection
13417116,134171162,2,F,,20170406.0,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048864,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171162.0,OT,,,,,,,,,134171162.0,1.0,HIV infection
13417126,134171262,2,F,,20170406.0,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048858,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171262.0,OT,,,,,,,,,134171262.0,1.0,HIV infection
13417136,134171362,2,F,,20170406.0,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048870,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171362.0,OT,,,,,,,,,134171362.0,1.0,HIV infection
13417139,134171392,2,F,,20170406.0,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048816,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171392.0,OT,,,,,,,,,134171392.0,1.0,HIV infection
13417142,134171422,2,F,,20170406.0,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048867,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171422.0,OT,,,,,,,,,134171422.0,1.0,HIV infection
13417145,134171452,2,F,,20170406.0,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048860,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171452.0,OT,,,,,,,,,134171452.0,1.0,HIV infection
13417148,134171482,2,F,,20170406.0,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048861,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410.0,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171482.0,OT,,,,,,,,,134171482.0,1.0,HIV infection
13417539,134175391,1,I,,20170316.0,20170406,20170406,EXP,,GB-GLAXOSMITHKLINE-GB2017GSK038125,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20170406.0,,CN,GB,GB,EFAVIRENZ,CD4 lymphocytes decreased;Condition aggravated;Depression;Diarrhoea;Feeling abnormal;Haemochromatosis trait;Hepatic function abnormal;Lipodystrophy acquired;Nausea;Rash;Renal impairment;Vomiting;Weight decreased,134175391.0,OT,,,,,,,,,134175391.0,1.0,HIV infection
13417590,134175901,1,I,,20170316.0,20170406,20170406,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017GSK038125,VIIV,,63.0,YR,,M,Y,,,20170406.0,,CN,GB,GB,EFAVIRENZ,CD4 lymphocytes decreased;Condition aggravated;Depression;Diarrhoea;Feeling abnormal;Haemochromatosis trait;Hepatic function abnormal;Lipodystrophy acquired;Nausea;Rash;Renal impairment;Vomiting;Weight decreased,134175901.0,OT,,,,,,,,,134175901.0,1.0,HIV infection
13417675,134176753,3,F,,20170329.0,20170407,20170618,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-030315,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20170618.0,,OT,GB,GB,EFAVIRENZ,Blood HIV RNA increased;Drug resistance;Viral mutation identified,134176753.0,OT,,,,,,,,,134176753.0,1.0,HIV infection
13419456,134194561,1,I,,20170329.0,20170407,20170407,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-028573,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170407.0,,OT,US,US,EFAVIRENZ,Drug level below therapeutic;Labelled drug-drug interaction medication error;Transplant failure,134194561.0,OT,,,,,,,,,134194561.0,1.0,HIV infection
13419458,134194581,1,I,,20170329.0,20170407,20170407,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-030281,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170407.0,,OT,US,US,EFAVIRENZ,Drug level below therapeutic;Labelled drug-drug interaction medication error;Transplant failure,134194581.0,OT,,,,,,,,,134194581.0,1.0,HIV infection
13423892,134238921,1,I,20170323.0,20170404.0,20170410,20170410,EXP,GB-MHRA-EYC 00156013,GB-MYLANLABS-2017M1021644,MYLAN,,,,,,Y,,,20170408.0,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134238921.0,OT,,,134238921.0,1.0,20170313.0,20170323.0,,,134238921.0,1.0,HIV infection
13425309,134253091,1,I,20060110.0,20061221.0,20170411,20170411,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13623434,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20170411.0,,CN,US,JP,EFAVIRENZ,Depression;Disseminated intravascular coagulation;Disseminated tuberculosis;Kaposi's sarcoma,134253091.0,DE,,,134253091.0,1.0,20060111.0,20060130.0,,,134253091.0,1.0,HIV infection
13426660,134266601,1,I,,20170221.0,20170411,20170411,PER,,AR-LUPIN PHARMACEUTICALS INC.-2017-00903,LUPIN,,49.0,YR,,F,Y,,,20170411.0,,MD,AR,AR,EFAVIRENZ,Drug interaction;Viral load increased,,,,,134266601.0,1.0,2001.0,2007.0,,,134266601.0,1.0,HIV infection
13443187,134431871,1,I,,20170330.0,20170414,20170414,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-031493,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20170414.0,,OT,US,US,EFAVIRENZ,Alanine aminotransferase increased,134431871.0,OT,,,,,,,,,134431871.0,1.0,Acquired immunodeficiency syndrome
13443499,134434991,1,I,,20170330.0,20170414,20170414,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-032496,BRISTOL MYERS SQUIBB,,51.0,YR,,M,Y,,,20170414.0,,OT,US,US,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Neutropenia;Renal failure,134434991.0,OT,,,,,,,,,134434991.0,1.0,Acquired immunodeficiency syndrome
13443501,134435011,1,I,,20170330.0,20170414,20170414,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-032495,BRISTOL MYERS SQUIBB,,65.0,YR,,M,Y,,,20170414.0,,OT,US,US,EFAVIRENZ,Herpes zoster;Neutropenia,134435011.0,OT,,,,,,,,,134435011.0,1.0,Acquired immunodeficiency syndrome
13446778,134467781,1,I,20170323.0,20170404.0,20170417,20170417,EXP,GB-MHRA-EYC 00156013,GB-TEVA-758083ACC,TEVA,,45.0,YR,,F,Y,,,20170417.0,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134467781.0,OT,,,134467781.0,1.0,20170313.0,20170323.0,,,134467781.0,1.0,HIV infection
13450558,134505581,1,I,20170323.0,20170404.0,20170418,20170418,EXP,GB-MHRA-ADR 23922700,GB-LUPIN PHARMACEUTICALS INC.-2017-01766,LUPIN,,45.0,YR,,F,Y,,,20170418.0,,CN,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134505581.0,OT,,,134505581.0,1.0,20170313.0,20170323.0,,,134505581.0,1.0,HIV infection
13457787,134577871,1,I,19990929.0,20170411.0,20170419,20170419,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-032516,BRISTOL MYERS SQUIBB,,43.0,YR,,M,Y,71.0,KG,20170419.0,,CN,AU,AU,EFAVIRENZ,Acute kidney injury;Hydroureter;Nephrolithiasis,134577871.0,OT,,,134577871.0,1.0,19990429.0,19990927.0,,,134577871.0,1.0,HIV infection
13458871,134588711,1,I,,20170407.0,20170419,20170419,EXP,,"CN-LANNETT COMPANY, INC.-PK-2017LAN000724",LANNETT,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI. 2016;32(6):1574-1579",27.0,YR,,M,Y,,,20170419.0,,MD,CN,PK,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,134588711.0,OT,,,,,,,,,134588711.0,1.0,Acquired immunodeficiency syndrome
13461442,134614421,1,I,,20170411.0,20170420,20170420,EXP,,US-VIIV HEALTHCARE LIMITED-US2017GSK055892,VIIV,"JOHNSTON C, HARRINGTON R, JAIN R, SCHIFFER J, KIEM H-P, WOOLFREY A. SAFETY AND EFFICACY OF COMBINATION ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUSEINFECTED ADULTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016;22:149-156",43.0,YR,,M,Y,,,20170420.0,,OT,US,US,EFAVIRENZ,Acute kidney injury;Pneumonia influenzal;Skin toxicity;Toxicity to various agents,134614421.0,OT,,,,,,,,,134614421.0,1.0,HIV infection
13462364,134623641,1,I,,20170407.0,20170420,20170420,EXP,,"CN-LANNETT COMPANY, INC.-PK-2017LAN000721",LANNETT,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI. 2016;32(6):1574-1579",28.0,YR,,M,Y,,,20170420.0,,MD,CN,PK,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,134623641.0,LT,,,,,,,,,134623641.0,1.0,Acquired immunodeficiency syndrome
13462367,134623671,1,I,,20170407.0,20170420,20170420,EXP,,"CN-LANNETT COMPANY, INC.-PK-2017LAN000720",LANNETT,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI. 2016;32(6):1574-1579",28.0,YR,,M,Y,,,20170420.0,,MD,CN,PK,EFAVIRENZ,Acinetobacter infection;Bone marrow failure;Gastrointestinal disorder;Respiratory failure,134623671.0,LT,,,,,,,,,134623671.0,1.0,Acquired immunodeficiency syndrome
13466716,134667163,3,F,20170326.0,20170502.0,20170421,20170505,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK057369,VIIV,,0.0,DY,,M,Y,3.29,KG,20170505.0,,MD,BR,BR,Efavirenz,Tricuspid valve incompetence,134667163.0,CA,,,134667163.0,1.0,20161118.0,20170325.0,,,134667163.0,1.0,HIV infection
13469134,134691341,1,I,19990929.0,20170411.0,20170421,20170421,EXP,,AU-009507513-1704AUS008412,MERCK,,43.0,YR,,M,Y,71.0,KG,20170421.0,,OT,AU,AU,EFAVIRENZ,Acute kidney injury;Hydroureter;Nephrolithiasis,134691341.0,OT,,,134691341.0,1.0,19990429.0,19990929.0,,,134691341.0,1.0,HIV infection
13484464,134844646,6,F,201701.0,20170609.0,20170425,20170615,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-034926,BRISTOL MYERS SQUIBB,,22.0,YR,,F,Y,,,20170615.0,,MD,BR,BR,EFAVIRENZ,Bacterial vaginosis;Caesarean section;Genital herpes;Live birth;Maternal exposure during pregnancy;Urinary tract infection,134844646.0,OT,,,134844646.0,1.0,20161118.0,20170325.0,,,134844646.0,1.0,HIV infection
13484467,134844679,9,F,20161215.0,20170920.0,20170425,20170925,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-033775,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170925.0,,MD,BR,BR,EFAVIRENZ,Congenital tricuspid valve incompetence;Foetal exposure during pregnancy,134844679.0,CA,,,134844679.0,1.0,20161118.0,20170325.0,,,134844679.0,1.0,Prophylaxis against HIV infection
13490238,134902382,2,F,2017.0,20170627.0,20170426,20170630,EXP,,BR-ASTRAZENECA-2017SE42683,ASTRAZENECA,,,,,M,Y,,,20170630.0,,CN,BR,BR,EFAVIRENZ,Dehydration;Ischaemic stroke,134902382.0,OT,,,134902382.0,1.0,2017.0,2017.0,,,134902382.0,2.0,Acquired immunodeficiency syndrome
13490580,134905801,1,I,,20170417.0,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025314,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427.0,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134905801.0,OT,,,,,,,,,134905801.0,1.0,HIV infection
13491974,134919741,1,I,,20170417.0,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025354,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427.0,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134919741.0,OT,,,,,,,,,134919741.0,1.0,HIV infection
13491975,134919751,1,I,,20170417.0,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025355,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427.0,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134919751.0,OT,,,,,,,,,134919751.0,1.0,HIV infection
13492393,134923931,1,I,,20170417.0,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025392,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427.0,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134923931.0,OT,,,,,,,,,134923931.0,1.0,HIV infection
13495628,134956281,1,I,20131009.0,20170425.0,20170428,20170428,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK060424,VIIV,,42.0,YR,,M,Y,,,20170428.0,,OT,BR,BR,EFAVIRENZ,Stevens-Johnson syndrome,134956281.0,LT,,,134956281.0,1.0,20131009.0,,,,134956281.0,1.0,HIV infection
13497919,134979191,1,I,,20170417.0,20170428,20170428,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-036581,BRISTOL MYERS SQUIBB,,15.0,YR,,M,Y,,,20170428.0,,OT,GB,GB,EFAVIRENZ,Gynaecomastia;Mammoplasty,134979191.0,OT,,,,,,,,,134979191.0,1.0,HIV infection
13497930,134979301,1,I,,20170417.0,20170428,20170428,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-036579,BRISTOL MYERS SQUIBB,,14.0,YR,,M,Y,,,20170428.0,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134979301.0,OT,,,,,,,,,134979301.0,1.0,HIV infection
13510629,135106291,1,I,,20170420.0,20170503,20170503,EXP,,US-MYLANLABS-2017M1026353,MYLAN,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT. OPEN-FORUM-INFECT-DIS 2017;4(1):1-4.",,,,,Y,,,20170503.0,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis,135106291.0,OT,,,,,,,,,135106291.0,1.0,HIV infection
13510925,135109251,1,I,,20170420.0,20170503,20170503,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038065,BRISTOL MYERS SQUIBB,,24.0,YR,,M,Y,,,20170503.0,,OT,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis coronary artery,135109251.0,OT,,,,,,,,,135109251.0,1.0,HIV infection
13512754,135127543,3,F,20100624.0,20171017.0,20170504,20171018,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-15986243,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,,,20171018.0,,CN,JP,JP,EFAVIRENZ.,Death;Hypertriglyceridaemia,135127543.0,OT,,,135127543.0,1.0,20051226.0,20150901.0,,,135127543.0,1.0,HIV infection
13513827,135138271,1,I,,20170424.0,20170504,20170504,EXP,,US-MYLANLABS-2017M1026998,MYLAN,"KIA L, BEATTIE A, GREEN RM. AUTOIMMUNE HEPATITIS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): CASE REPORTS OF A RARE, BUT IMPORTANT DIAGNOSIS WITH THERAPEUTIC IMPLICATIONS. MEDICINE 2017;96(7):E6011.",,,,,Y,,,20170504.0,,MD,US,US,EFAVIRENZ,Acute hepatic failure;Autoimmune hepatitis;Sepsis;Toxicity to various agents,135138271.0,HO,,,,,,,,,135138271.0,1.0,HIV infection
13514585,135145851,1,I,,20170314.0,20170504,20170504,PER,,US-STRIDES ARCOLAB LIMITED-2017SP004844,STRIDES,"WALENSKY RP, GOLDBERG JH, DAILY JP. ANAPHYLAXIS AFTER RECHALLENGE WITH ABACAVIR. AIDS. 1999;13(8):999-1000",,,,,Y,,,20170504.0,,OT,US,US,EFAVIRENZ,Anaphylactic reaction;Chest discomfort;Chills;Dermatitis exfoliative;Diarrhoea;Dyspnoea;Hypotension;Ischaemia;Pyrexia;Rash erythematous;Rash macular;Stomatitis,135145851.0,HO,,,,,,,,,135145851.0,1.0,Acquired immunodeficiency syndrome
13514904,135149041,1,I,,20170424.0,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038108,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170504.0,,OT,US,US,EFAVIRENZ,Acute hepatic failure;Autoimmune hepatitis;Liver transplant;Toxicity to various agents,135149041.0,OT,,,,,,,,,135149041.0,1.0,HIV test
13515208,135152081,1,I,,20170428.0,20170504,20170504,EXP,,CA-GILEAD-2017-0270615,GILEAD,,52.0,YR,A,M,Y,,,20170504.0,,OT,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135152081.0,OT,,,,,,,,,135152081.0,1.0,HIV infection
13515529,135155291,1,I,,20170424.0,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038930,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170504.0,,OT,US,US,EFAVIRENZ,Autoimmune hepatitis;Toxicity to various agents,135155291.0,OT,,,,,,,,,135155291.0,1.0,HIV test
13515530,135155301,1,I,,20170424.0,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038931,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170504.0,,OT,US,US,EFAVIRENZ,Autoimmune hepatitis;Toxicity to various agents,135155301.0,OT,,,,,,,,,135155301.0,1.0,HIV test
13515535,135155351,1,I,,20170424.0,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038932,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170504.0,,OT,US,US,EFAVIRENZ,Autoimmune hepatitis;Toxicity to various agents,135155351.0,OT,,,,,,,,,135155351.0,1.0,HIV test
13515593,135155931,1,I,,20170421.0,20170504,20170504,EXP,,CA-GILEAD-2017-0269568,GILEAD,,35.0,YR,A,M,Y,,,20170504.0,,OT,CA,CA,EFAVIRENZ,HIV viraemia;Nephropathy toxic;Therapeutic response decreased,135155931.0,OT,,,,,,,,,135155931.0,1.0,HIV infection
13518041,135180411,1,I,,20170427.0,20170505,20170505,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-037419,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170505.0,,CN,US,US,SUSTIVA,Dialysis;Visual impairment,135180411.0,OT,,,,,,,,,135180411.0,1.0,HIV infection
13520796,135207961,1,I,,20170426.0,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07939,CIPLA,,,,,,Y,,,20170508.0,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135207961.0,OT,,,,,,,,,135207961.0,1.0,HIV infection
13520802,135208021,1,I,,20170426.0,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07936,CIPLA,,,,,,Y,,,20170508.0,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135208021.0,OT,,,,,,,,,135208021.0,1.0,HIV infection
13520804,135208041,1,I,,20170426.0,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07938,CIPLA,,,,,,Y,,,20170508.0,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135208041.0,OT,,,,,,,,,135208041.0,1.0,HIV infection
13520813,135208131,1,I,,20170426.0,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07935,CIPLA,,,,,,Y,,,20170508.0,,OT,FR,BF,Efavirenz,Virologic failure,135208131.0,OT,,,,,,,,,135208131.0,1.0,HIV infection
13520815,135208151,1,I,,20170426.0,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07937,CIPLA,,,,,,Y,,,20170508.0,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135208151.0,OT,,,,,,,,,135208151.0,1.0,HIV infection
13521928,135219282,2,F,,20180824.0,20170508,20180907,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2017065893,VIIV,UNK. UNK. UNK. UNK?UNK:UNK,52.0,YR,,M,Y,,,20180907.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135219282.0,OT,,,,,,,,,135219282.0,1.0,HIV infection
13522021,135220211,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027030,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220211.0,OT,,,,,,,,,135220211.0,1.0,HIV infection
13522023,135220231,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027029,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220231.0,OT,,,,,,,,,135220231.0,1.0,HIV infection
13522025,135220251,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027031,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220251.0,OT,,,,,,,,,135220251.0,1.0,HIV infection
13522026,135220261,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027032,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220261.0,OT,,,,,,,,,135220261.0,1.0,HIV infection
13522034,135220341,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027033,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220341.0,OT,,,,,,,,,135220341.0,1.0,HIV infection
13522216,135222162,2,F,,20180824.0,20170508,20180907,EXP,,CA-GLAXOSMITHKLINE-CA2017065893,GLAXOSMITHKLINE,UNK. UNK. UNK. UNK?UNK:UNK,52.0,YR,,M,Y,,,20180907.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135222162.0,OT,,,,,,,,,135222162.0,1.0,HIV infection
13522269,135222691,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027049,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222691.0,OT,,,,,,,,,135222691.0,1.0,HIV infection
13522270,135222701,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027047,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222701.0,OT,,,,,,,,,135222701.0,1.0,HIV infection
13522271,135222711,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027050,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222711.0,OT,,,,,,,,,135222711.0,1.0,HIV infection
13522272,135222721,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027054,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222721.0,OT,,,,,,,,,135222721.0,1.0,HIV infection
13522274,135222741,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027053,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222741.0,OT,,,,,,,,,135222741.0,1.0,HIV infection
13522276,135222761,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027051,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222761.0,OT,,,,,,,,,135222761.0,1.0,HIV infection
13522277,135222771,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027055,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222771.0,OT,,,,,,,,,135222771.0,1.0,HIV infection
13522365,135223651,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027061,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223651.0,OT,,,,,,,,,135223651.0,1.0,HIV infection
13522366,135223661,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027060,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223661.0,OT,,,,,,,,,135223661.0,1.0,HIV infection
13522368,135223681,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027057,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223681.0,OT,,,,,,,,,135223681.0,1.0,HIV infection
13522369,135223691,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027056,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223691.0,OT,,,,,,,,,135223691.0,1.0,HIV infection
13522371,135223711,1,I,,20170425.0,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027065,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508.0,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223711.0,OT,,,,,,,,,135223711.0,1.0,HIV infection
13526370,135263701,1,I,,20170501.0,20170509,20170509,EXP,,US-HETERO LABS LTD-2020436,HETERO,,24.0,YR,,M,Y,,,20170509.0,,OT,US,US,Efavirenz,Acute myocardial infarction;Arteriosclerosis,135263701.0,OT,,,,,,,,,135263701.0,1.0,HIV infection
13526383,135263831,1,I,,20170501.0,20170509,20170509,EXP,,IN-HETERO LABS LTD-2020438,HETERO,,,,,,Y,,,20170509.0,,OT,IN,IN,Efavirenz,Stevens-Johnson syndrome,135263831.0,OT,,,,,,,,,135263831.0,1.0,HIV infection
13528637,135286371,1,I,,20170501.0,20170509,20170509,EXP,,US-TEVA-766033USA,TEVA,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT. OPEN-FORUM-INFECT-DIS 2017;4(1):1-4.",24.0,YR,,M,Y,,,20170509.0,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis,135286371.0,HO,,,,,,,,,135286371.0,1.0,HIV infection
13531770,135317701,1,I,20170411.0,20170503.0,20170510,20170510,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK067339,VIIV,,19.0,YR,,F,Y,47.2,KG,20170510.0,,MD,BR,BR,Efavirenz,Overdose,135317701.0,OT,,,135317701.0,1.0,20170309.0,20170417.0,,,135317701.0,1.0,HIV infection
13537406,135374063,3,F,20170411.0,20170516.0,20170511,20170522,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-040783,BRISTOL MYERS SQUIBB,,19.0,YR,,F,Y,50.0,KG,20170522.0,,OT,BR,BR,EFAVIRENZ,Drug dose omission;Insomnia;Maternal exposure during pregnancy;Overdose,135374063.0,OT,,,135374063.0,1.0,20170309.0,20170417.0,,,135374063.0,1.0,HIV infection
13540243,135402431,1,I,,20170428.0,20170512,20170512,EXP,,US-MYLANLABS-2017M1028043,MYLAN,"AZAR MM, MALINIS MF, MOSS J, FORMICA RN, VILLANUEVA MS. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT-J-STD-AIDS 2017;28(5):447-458.",,,,,Y,,,20170512.0,,OT,US,US,EFAVIRENZ,Chronic allograft nephropathy;Drug interaction;Transplant failure,135402431.0,OT,,,,,,,,,135402431.0,1.0,HIV infection
13540293,135402931,1,I,,20170428.0,20170512,20170512,EXP,,US-MYLANLABS-2017M1028103,MYLAN,"AZAR MM, MALINIS MF, MOSS J, FORMICA RN, VILLANUEVA MS. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT-J-STD-AIDS 2017;28(5):447-458.",,,,,Y,,,20170512.0,,OT,US,US,EFAVIRENZ,Chronic allograft nephropathy;Drug interaction;Toxicity to various agents;Transplant failure;Transplant rejection,135402931.0,OT,,,,,,,,,135402931.0,1.0,HIV infection
13541292,135412921,1,I,,20170504.0,20170512,20170512,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-039217,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170512.0,,MD,US,US,EFAVIRENZ,Lip and/or oral cavity cancer,135412921.0,OT,,,,,,,,,135412921.0,1.0,HIV infection
13549769,135497691,1,I,,20170505.0,20170516,20170516,EXP,,US-STRIDES ARCOLAB LIMITED-2017SP007467,STRIDES,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL.. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT.. OPEN-FORUM-INFECT-DIS. 2017;4(1):1-4",,,,,Y,,,20170516.0,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis;Chest pain;Discomfort;Hyperhidrosis,135497691.0,HO,,,,,,,,,135497691.0,1.0,Perinatal HIV infection
13551832,135518321,1,I,,20170501.0,20170516,20170516,EXP,,US-GLAXOSMITHKLINE-US2017GSK072067,GLAXOSMITHKLINE,"SCOTT GB, BROGLY SB, MUENZ D, STEK AM, READ JS.. MISSED OPPORTUNITIES FOR PREVENTION OF MOTHER -TO-CHILD TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS. OBSTETRICS + GYNECOLOGY. 2017;129 (4):621-628",,,,M,Y,,,20170516.0,,MD,US,US,EFAVIRENZ,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,135518321.0,OT,,,,,,,,,135518321.0,1.0,HIV infection
13551837,135518371,1,I,,20170501.0,20170516,20170516,EXP,,US-VIIV HEALTHCARE LIMITED-US2017GSK072067,VIIV,"SCOTT GB, BROGLY SB, MUENZ D, STEK AM, READ JS.. MISSED OPPORTUNITIES FOR PREVENTION OF MOTHER -TO-CHILD TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS. OBSTETRICS + GYNECOLOGY. 2017;129 (4):621-628",,,,M,Y,,,20170516.0,,MD,US,US,EFAVIRENZ,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,135518371.0,OT,,,,,,,,,135518371.0,1.0,HIV infection
13559360,135593602,2,F,20141121.0,20220415.0,20170518,20220419,EXP,,JP-GILEAD-2017-0273052,GILEAD,,43.0,YR,A,M,Y,,,20220419.0,,PH,JP,JP,EFAVIRENZ,Beta 2 microglobulin urine increased,135593602.0,OT,,,135593602.0,1.0,20100305.0,,,,135593602.0,1.0,HIV infection
13561491,135614911,1,I,201702.0,20170509.0,20170518,20170518,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-042597,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,70.0,KG,20170518.0,,OT,CN,CN,EFAVIRENZ,Abdominal distension;Asthenia;Decreased appetite;Food aversion;Hepatic function abnormal,135614911.0,HO,,,135614911.0,1.0,20160423.0,,,,135614911.0,1.0,Acquired immunodeficiency syndrome
13569652,135696522,2,F,20170419.0,20170525.0,20170522,20170605,EXP,GB-MHRA-EYC 00158567,GB-GILEAD-2017-0273109,GILEAD,,55.0,YR,A,F,Y,64.6,KG,20170605.0,,PH,GB,GB,EFAVIRENZ,Headache;Papule;Product physical issue;Product taste abnormal;Rash erythematous;Rash pruritic,135696522.0,OT,,,135696522.0,1.0,20170418.0,20170503.0,,,135696522.0,1.0,Asymptomatic HIV infection
13584642,135846421,1,I,,20170515.0,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09253,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526.0,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846421.0,OT,,,,,,,,,135846421.0,1.0,Prophylaxis against HIV infection
13584663,135846631,1,I,,20170515.0,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09252,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526.0,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846631.0,OT,,,,,,,,,135846631.0,1.0,Prophylaxis against HIV infection
13584664,135846641,1,I,,20170515.0,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09251,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526.0,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846641.0,OT,,,,,,,,,135846641.0,1.0,Prophylaxis against HIV infection
13584671,135846711,1,I,,20170515.0,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09249,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526.0,,OT,US,US,Efavirenz,Exposure during pregnancy;Virologic failure,135846711.0,OT,,,,,,,,,135846711.0,1.0,Prophylaxis against HIV infection
13584679,135846791,1,I,,20170515.0,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09250,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526.0,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846791.0,OT,,,,,,,,,135846791.0,1.0,Prophylaxis against HIV infection
13597527,135975271,1,I,,20161123.0,20170531,20170531,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019454,STRIDES,"COHAN D, MWESIGWA J, NATUREEBA P, ALIBA LUWEDDE F, ADES V, PLENTY A ET AL. WHO OPTION B+: EARLY EXPERIENCE OF ANTIRETROVIRAL THERAPY SEQUENCING AFTER CESSATION OF BREASTFEEDING  AND RISK OF DERMATOLOGIC TOXICITY. J ACQUIR IMMUNE DEFIC SYNDR. 2013;62(3):E101-3",,,,,Y,,,20170531.0,,OT,US,US,EFAVIRENZ,Erythema;Rash macular;Skin toxicity,135975271.0,HO,,,,,,,,,135975271.0,1.0,HIV infection
13597530,135975301,1,I,,20161123.0,20170531,20170531,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019324,STRIDES,"VALLABHANENI S, CHANDY S, HEYLEN E, EKSTRAND ML. EVALUATION OF WHO IMMUNOLOGIC CRITERIA FOR TREATMENT FAILURE: IMPLICATIONS FOR DETECTION OF VIROLOGIC FAILURE, EVOLUTION OF DRUG RESISTANCE AND CHOICE OF SECOND-LINE THERAPY IN INDIA. J INT AIDS SOC. 2013;16:18449",,,,,Y,,,20170531.0,,OT,US,US,EFAVIRENZ,Drug resistance;Virologic failure,135975301.0,OT,,,,,,,,,135975301.0,1.0,HIV infection
13600474,136004741,1,I,,20161123.0,20170601,20170601,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019458,STRIDES,"COHAN D, MWESIGWA J, NATUREEBA P, ALIBA LUWEDDE F, ADES V, PLENTY A ET AL. WHO OPTION B+: EARLY EXPERIENCE OF ANTIRETROVIRAL THERAPY SEQUENCING AFTER CESSATION OF BREASTFEEDING  AND RISK OF DERMATOLOGIC TOXICITY. J ACQUIR IMMUNE DEFIC SYNDR. 2013;62(3):E101-3",,,,,Y,,,20170601.0,,OT,US,US,EFAVIRENZ,Pruritus generalised;Rash maculo-papular;Skin toxicity,,,,,,,,,,,136004741.0,1.0,HIV infection
13600532,136005321,1,I,,20161123.0,20170601,20170601,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019456,STRIDES,"COHAN D, MWESIGWA J, NATUREEBA P, ALIBA LUWEDDE F, ADES V, PLENTY A ET AL. WHO OPTION B+: EARLY EXPERIENCE OF ANTIRETROVIRAL THERAPY SEQUENCING AFTER CESSATION OF BREASTFEEDING  AND RISK OF DERMATOLOGIC TOXICITY. J ACQUIR IMMUNE DEFIC SYNDR. 2013;62(3):E101-3",,,,,Y,,,20170601.0,,OT,US,US,EFAVIRENZ,Conjunctival hyperaemia;Rash maculo-papular;Skin toxicity,,,,,,,,,,,136005321.0,1.0,HIV infection
13607637,136076371,1,I,,20170518.0,20170602,20170602,EXP,,MY-MYLANLABS-2017M1032624,MYLAN,"KHAN KU, KHAN AH, SULAIMAN SA, SOO CT, AHMAD SI. UNUSUAL CASE OF LAMIVUDINE-ASSOCIATED SKIN RASHES IN AN HIV/AIDS PATIENT: A CASE PRESENTATION. ARCH-PHARMACY-PRACTICE 2017;8(2):82-83.",,,,,Y,,,20170602.0,,OT,MY,MY,EFAVIRENZ,Myalgia;Pyrexia;Rash,136076371.0,HO,,,,,,,,,136076371.0,1.0,HIV infection
13608714,136087148,8,F,20170513.0,20170722.0,20170602,20170726,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-048141,BRISTOL MYERS SQUIBB,,0.0,DY,,M,Y,2.49,KG,20170726.0,,OT,BR,BR,EFAVIRENZ,Foetal exposure during pregnancy;Poor sucking reflex;Premature baby;Transient tachypnoea of the newborn,136087148.0,LT,,,136087148.0,1.0,20170329.0,,,,136087148.0,1.0,Prophylaxis against HIV infection
13610106,136101061,1,I,,20170522.0,20170604,20170604,EXP,,US-HETERO LABS LTD-2021533,HETERO,"FONG PS, FLYNN DM, EVANS CD, KORTHUIS PT. INTEGRASE STRAND TRANSFER INHIBITOR-ASSOCIATED DIABETES MELLITUS: A CASE REPORT. INT-J-STD-AIDS 2017; 28(6):626-628.",44.0,YR,,M,Y,,,20170604.0,,OT,US,US,Efavirenz,Blood triglycerides increased;Diabetes mellitus;Hyperglycaemia;Insomnia,136101061.0,OT,,,,,,,,,136101061.0,1.0,HIV infection
13610646,136106466,6,F,20170513.0,20170704.0,20170605,20170707,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK082929,VIIV,,0.0,DY,,M,Y,2.94,KG,20170707.0,,MD,BR,BR,Efavirenz,Premature baby,136106466.0,HO,,,136106466.0,1.0,20170329.0,20170512.0,,,136106466.0,1.0,HIV infection
13612571,136125712,2,F,,20170606.0,20170605,20170612,EXP,,TR-GILEAD-2017-0275386,GILEAD,,34.0,YR,A,M,Y,,,20170612.0,,MD,TR,TR,EFAVIRENZ,Osteopenia;Osteoporosis,136125712.0,OT,,,,,,,,,136125712.0,1.0,HIV infection
13614049,136140491,1,I,,20170529.0,20170606,20170606,EXP,,MY-HETERO LABS LTD-2021582,HETERO,,43.0,YR,,F,Y,,,20170606.0,,OT,MY,MY,Efavirenz,Myalgia;Pyrexia;Rash maculo-papular;Rash pruritic,136140491.0,HO,,,,,,,,,136140491.0,1.0,HIV infection
13614423,136144232,2,F,2015.0,20180411.0,20170606,20180426,EXP,,RO-AUROBINDO-AUR-APL-2017-35002,AUROBINDO,,28.0,YR,,F,Y,,,20180426.0,,OT,RO,RO,EFAVIRENZ.,Ballismus;Brain oedema;Central nervous system lesion;Cerebral toxoplasmosis;Intracranial mass;Loss of consciousness;Motor dysfunction;Product use issue;Treatment noncompliance,136144232.0,HO,,,136144232.0,1.0,2006.0,,,,136144232.0,1.0,HIV infection
13619822,136198221,1,I,,20170529.0,20170606,20170606,EXP,,DK-ROCHE-1942164,ROCHE,"BORGES A, HOY J, FLORENCE E, FLORENCE D, STELLBRINK H, UZDAVINIENE V, TOMAZIC J, GARGALIANOS-KAKOLYRIS P, SCHMID P, ORKIN C, PEDERSEN C, LEEN C, PRADIER C, MULCAHY F, RIDOLFO A, STAUB T, MALTEZ F, WEBER R, FLAMHOLC L, KYSELYOVA G, LUNDGREN J AND MOCROFT A.    ANTIRETROVIRALS, FRACTURES, AND OSTEONECROSIS IN A LARGE INTERNATIONAL HIV COHORT. CLINICAL INFECTIOUS DISEASES 2017 MAY 15;64 (10):1413-1421.",,,,,Y,,,20170607.0,,MD,DK,DK,EFAVIRENZ,Osteonecrosis;Osteoporotic fracture,136198221.0,OT,,,,,,,,,136198221.0,1.0,HIV infection
13622213,136222131,1,I,200802.0,20070531.0,20170607,20170607,PER,,US-ROCHE-500022,ROCHE,,56.0,YR,,M,Y,155.0,KG,20170608.0,,CN,US,US,SUSTIVA,Accidental exposure to product;Complication associated with device;No adverse event,,,,,,,,,,,136222131.0,1.0,HIV infection
13634024,136340241,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10195,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340241.0,OT,,,,,,,,,136340241.0,1.0,HIV infection
13634065,136340651,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10201,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340651.0,OT,,,,,,,,,136340651.0,1.0,HIV infection
13634085,136340851,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10199,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340851.0,OT,,,,,,,,,136340851.0,1.0,HIV infection
13634099,136340991,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10200,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340991.0,OT,,,,,,,,,136340991.0,1.0,HIV infection
13634114,136341141,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10198,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341141.0,OT,,,,,,,,,136341141.0,1.0,HIV infection
13634128,136341281,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10197,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341281.0,OT,,,,,,,,,136341281.0,1.0,HIV infection
13634141,136341411,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10196,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341411.0,OT,,,,,,,,,136341411.0,1.0,HIV infection
13634190,136341901,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10120,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341901.0,OT,,,,,,,,,136341901.0,1.0,HIV infection
13634201,136342011,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10225,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Virologic failure,136342011.0,OT,,,,,,,,,136342011.0,1.0,HIV infection
13634365,136343651,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10202,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136343651.0,OT,,,,,,,,,136343651.0,1.0,HIV infection
13634381,136343811,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10203,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Adverse event,136343811.0,OT,,,,,,,,,136343811.0,1.0,HIV infection
13634426,136344261,1,I,,20170526.0,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09921,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL.,. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609.0,,OT,US,US,Efavirenz,Death,136344261.0,DE,,,,,,,,,136344261.0,1.0,HIV infection
13634432,136344321,1,I,,20170526.0,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09922,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL.,. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609.0,,OT,US,US,Efavirenz,Death,136344321.0,DE,,,,,,,,,136344321.0,1.0,HIV infection
13634476,136344761,1,I,,20170526.0,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09923,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL;. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609.0,,OT,US,US,Efavirenz,Death,136344761.0,DE,,,,,,,,,136344761.0,1.0,HIV infection
13634479,136344791,1,I,,20170526.0,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09924,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL;. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609.0,,OT,US,US,Efavirenz,Death,136344791.0,DE,,,,,,,,,136344791.0,1.0,HIV infection
13634565,136345651,1,I,,20170526.0,20170609,20170609,EXP,,ZM-CIPLA LTD.-2017ZM10147,CIPLA,"MOORE CB, CAPPARELLI EV, SAMSON P, BWAKURA-DANGAREMBIZI M, JEAN-PHILIPPE P, WORRELL C ET AL.,. CYP2B6 GENOTYPE-DIRECTED DOSING IS REQUIRED FOR OPTIMAL EFAVIRENZ EXPOSURE IN CHILDREN 3-36 MONTHS WITH HIV INFECTION. AIDS. 2017;31(8):1129 TO 1136",,,,,Y,,,20170609.0,,OT,ZM,ZM,Efavirenz,Tuberculosis,136345651.0,OT,,,,,,,,,136345651.0,1.0,HIV infection
13634615,136346152,2,F,,20170620.0,20170609,20170630,EXP,,ZM-CIPLA LTD.-2017ZM10131,CIPLA,"MOORE CB, CAPPARELLI EV, SAMSON P, BWAKURA-DANGAREMBIZI M, JEAN-PHILIPPE P, WORRELL C ET AL.,. CYP2B6 GENOTYPE-DIRECTED DOSING IS REQUIRED FOR OPTIMAL EFAVIRENZ EXPOSURE IN CHILDREN 3-36 MONTHS WITH HIV INFECTION. AIDS. 2017;31 (8):1129 TO 1136",,,,,Y,,,20170630.0,,OT,ZM,ZM,Efavirenz,Lipase increased,136346152.0,OT,,,,,,,,,136346152.0,1.0,HIV infection
13634673,136346731,1,I,,20170526.0,20170609,20170609,EXP,,ZM-CIPLA LTD.-2017ZM10115,CIPLA,"MOORE CB, CAPPARELLI EV, SAMSON P, BWAKURA-DANGAREMBIZI M, JEAN-PHILIPPE P, WORRELL C ET AL.,. CYP2B6 GENOTYPE-DIRECTED DOSING IS REQUIRED FOR OPTIMAL EFAVIRENZ EXPOSURE IN CHILDREN 3-36 MONTHS WITH HIV INFECTION. AIDS. 2017;31(8):1129 TO 1136",,,,,Y,,,20170609.0,,OT,ZM,ZM,Efavirenz,Tuberculosis,136346731.0,OT,,,,,,,,,136346731.0,1.0,HIV infection
13635053,136350531,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10204,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Adverse event,136350531.0,OT,,,,,,,,,136350531.0,1.0,HIV infection
13635939,136359391,1,I,,20170526.0,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10205,CIPLA,,,,,,Y,,,20170609.0,,OT,ZM,MX,Efavirenz,Epilepsy,136359391.0,OT,,,,,,,,,136359391.0,1.0,HIV infection
13636714,136367141,1,I,,20170605.0,20170609,20170609,EXP,,BF-STRIDES ARCOLAB LIMITED-2017SP009182,STRIDES,,,,,,Y,,,20170609.0,,OT,FR,BF,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,136367141.0,OT,,,,,,,,,136367141.0,1.0,HIV infection
13636901,136369011,1,I,,20170605.0,20170609,20170609,EXP,,GB-STRIDES ARCOLAB LIMITED-2017SP009286,STRIDES,,,,,,Y,,,20170609.0,,OT,GB,GB,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,136369011.0,OT,,,,,,,,,136369011.0,1.0,HIV infection
13637003,136370031,1,I,,20170605.0,20170609,20170609,EXP,,GB-STRIDES ARCOLAB LIMITED-2017SP009287,STRIDES,,,,,,Y,,,20170609.0,,OT,GB,GB,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,136370031.0,OT,,,,,,,,,136370031.0,1.0,HIV infection
13640921,136409213,3,F,20170530.0,20170714.0,20170612,20170719,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-050474,BRISTOL MYERS SQUIBB,,20.0,YR,,F,Y,62.0,KG,20170719.0,,OT,BR,BR,EFAVIRENZ,Caesarean section;Cephalo-pelvic disproportion;Genital herpes;Iron deficiency anaemia;Live birth;Maternal exposure during pregnancy;Meconium in amniotic fluid,136409213.0,OT,,,136409213.0,1.0,20170223.0,,,,136409213.0,1.0,HIV infection
13658831,136588312,2,F,20170317.0,20170619.0,20170616,20170623,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-051773,BRISTOL MYERS SQUIBB,,29.0,YR,,M,Y,80.0,KG,20170623.0,,OT,CN,CN,EFAVIRENZ,Macule,136588312.0,HO,,,136588312.0,1.0,20170310.0,20170320.0,,,136588312.0,1.0,HIV infection
13667984,136679849,9,F,20170602.0,20171208.0,20170620,20171222,EXP,,TZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-052405,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,85.0,KG,20171222.0,,OT,TZ,TZ,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,136679849.0,HO,,,136679849.0,1.0,20170313.0,,,,136679849.0,1.0,HIV infection
13670578,136705781,1,I,,20170605.0,20170620,20170620,EXP,,"US-LANNETT COMPANY, INC.-US-2017LAN000844",LANNETT,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT. OPEN-FORUM-INFECT-DIS. 2017;4(1):1-4",24.0,YR,,M,Y,,,20170620.0,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis,136705781.0,HO,,,,,,,,,136705781.0,1.0,Antiretroviral therapy
13674491,136744911,1,I,201704.0,20170612.0,20170621,20170621,EXP,,CN-GILEAD-2017-0278700,GILEAD,,46.0,YR,A,M,Y,68.0,KG,20170621.0,,OT,CN,CN,EFAVIRENZ,Liver injury;Pruritus,136744911.0,HO,,,136744911.0,1.0,20170402.0,20170418.0,,,136744911.0,1.0,HIV carrier
13674712,136747121,1,I,,20170608.0,20170621,20170621,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-054682,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170621.0,,OT,IN,IN,EFAVIRENZ,Hypersensitivity vasculitis,136747121.0,OT,,,,,,,,,136747121.0,1.0,HIV test positive
13675272,136752721,1,I,,20170612.0,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009653,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136752721.0,OT,,,,,,,,,136752721.0,1.0,HIV infection
13675301,136753011,1,I,,20170612.0,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009670,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753011.0,OT,,,,,,,,,136753011.0,1.0,HIV infection
13675316,136753161,1,I,,20170612.0,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009646,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753161.0,OT,,,,,,,,,136753161.0,1.0,HIV infection
13675322,136753221,1,I,,20170612.0,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009628,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753221.0,OT,,,,,,,,,136753221.0,1.0,HIV infection
13675341,136753411,1,I,,20170612.0,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009654,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753411.0,OT,,,,,,,,,136753411.0,1.0,HIV infection
13675354,136753541,1,I,,20170612.0,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009639,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753541.0,OT,,,,,,,,,136753541.0,1.0,HIV infection
13676619,136766191,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10920,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136766191.0,OT,,,,,,,,,136766191.0,1.0,HIV infection WHO clinical stage IV
13676787,136767871,1,I,,20170612.0,20170622,20170622,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009632,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170622.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136767871.0,OT,,,,,,,,,136767871.0,1.0,HIV infection
13676800,136768001,1,I,,20170612.0,20170622,20170622,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009676,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170622.0,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136768001.0,OT,,,,,,,,,136768001.0,1.0,HIV infection
13676834,136768341,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10931,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136768341.0,OT,,,,,,,,,136768341.0,1.0,HIV infection WHO clinical stage III
13676911,136769111,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10936,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136769111.0,OT,,,,,,,,,136769111.0,1.0,HIV infection WHO clinical stage II
13676989,136769891,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10932,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136769891.0,OT,,,,,,,,,136769891.0,1.0,HIV infection WHO clinical stage III
13677049,136770491,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10953,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136770491.0,OT,,,,,,,,,136770491.0,1.0,HIV infection WHO clinical stage IV
13677094,136770941,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10933,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136770941.0,OT,,,,,,,,,136770941.0,1.0,HIV infection WHO clinical stage II
13677134,136771341,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10935,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136771341.0,OT,,,,,,,,,136771341.0,1.0,HIV infection WHO clinical stage III
13677150,136771501,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10934,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136771501.0,OT,,,,,,,,,136771501.0,1.0,HIV infection WHO clinical stage III
13677151,136771511,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10954,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136771511.0,OT,,,,,,,,,136771511.0,1.0,HIV infection WHO clinical stage IV
13677347,136773471,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10922,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773471.0,OT,,,,,,,,,136773471.0,1.0,HIV infection WHO clinical stage IV
13677350,136773501,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10925,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773501.0,OT,,,,,,,,,136773501.0,1.0,HIV infection WHO clinical stage II
13677351,136773511,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10924,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773511.0,OT,,,,,,,,,136773511.0,1.0,HIV infection WHO clinical stage II
13677353,136773531,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10923,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773531.0,OT,,,,,,,,,136773531.0,1.0,HIV infection WHO clinical stage IV
13677356,136773561,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10956,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773561.0,OT,,,,,,,,,136773561.0,1.0,HIV infection WHO clinical stage IV
13677359,136773591,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10921,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773591.0,OT,,,,,,,,,136773591.0,1.0,HIV infection WHO clinical stage III
13677371,136773711,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10926,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773711.0,OT,,,,,,,,,136773711.0,1.0,HIV infection WHO clinical stage IV
13677379,136773791,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10927,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773791.0,OT,,,,,,,,,136773791.0,1.0,HIV infection WHO clinical stage III
13677380,136773801,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10928,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773801.0,OT,,,,,,,,,136773801.0,1.0,HIV infection WHO clinical stage II
13677386,136773861,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10929,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773861.0,OT,,,,,,,,,136773861.0,1.0,HIV infection WHO clinical stage III
13677389,136773891,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10930,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773891.0,OT,,,,,,,,,136773891.0,1.0,HIV infection WHO clinical stage III
13677393,136773931,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10955,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Treatment failure,136773931.0,OT,,,,,,,,,136773931.0,1.0,HIV infection WHO clinical stage IV
13677402,136774021,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10958,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136774021.0,OT,,,,,,,,,136774021.0,1.0,HIV infection WHO clinical stage IV
13677515,136775151,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10940,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775151.0,OT,,,,,,,,,136775151.0,1.0,HIV infection WHO clinical stage III
13677516,136775161,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10939,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775161.0,OT,,,,,,,,,136775161.0,1.0,HIV infection WHO clinical stage II
13677517,136775171,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10941,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775171.0,OT,,,,,,,,,136775171.0,1.0,HIV infection WHO clinical stage IV
13677519,136775191,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10975,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775191.0,OT,,,,,,,,,136775191.0,1.0,HIV infection WHO clinical stage III
13677520,136775201,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10945,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775201.0,OT,,,,,,,,,136775201.0,1.0,HIV infection WHO clinical stage III
13677527,136775271,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10976,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775271.0,OT,,,,,,,,,136775271.0,1.0,HIV infection WHO clinical stage III
13677552,136775521,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10978,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775521.0,OT,,,,,,,,,136775521.0,1.0,HIV infection WHO clinical stage III
13677564,136775641,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10981,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775641.0,OT,,,,,,,,,136775641.0,1.0,HIV infection WHO clinical stage II
13677565,136775651,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10980,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775651.0,OT,,,,,,,,,136775651.0,1.0,HIV infection WHO clinical stage II
13677568,136775681,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10979,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775681.0,OT,,,,,,,,,136775681.0,1.0,HIV infection WHO clinical stage II
13677591,136775911,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10937,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775911.0,OT,,,,,,,,,136775911.0,1.0,HIV infection WHO clinical stage III
13677592,136775921,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10938,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775921.0,OT,,,,,,,,,136775921.0,1.0,HIV infection WHO clinical stage IV
13677600,136776001,1,I,,20170608.0,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10982,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136776001.0,OT,,,,,,,,,136776001.0,1.0,HIV infection WHO clinical stage III
13680466,136804661,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10942,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136804661.0,OT,,,,,,,,,136804661.0,1.0,HIV infection WHO clinical stage IV
13680542,136805421,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10943,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136805421.0,OT,,,,,,,,,136805421.0,1.0,HIV infection WHO clinical stage IV
13680573,136805731,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10944,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136805731.0,OT,,,,,,,,,136805731.0,1.0,HIV infection WHO clinical stage IV
13680586,136805861,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10946,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136805861.0,OT,,,,,,,,,136805861.0,1.0,HIV infection WHO clinical stage III
13680665,136806651,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10948,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136806651.0,OT,,,,,,,,,136806651.0,1.0,HIV infection WHO clinical stage II
13680709,136807091,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10950,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807091.0,OT,,,,,,,,,136807091.0,1.0,HIV infection WHO clinical stage III
13680713,136807131,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10951,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807131.0,OT,,,,,,,,,136807131.0,1.0,HIV infection WHO clinical stage II
13680733,136807333,3,F,20170513.0,20170722.0,20170623,20170726,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-053522,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170726.0,,OT,BR,BR,EFAVIRENZ,Anaemia;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,136807333.0,OT,,,136807333.0,1.0,20170329.0,,,,136807333.0,1.0,HIV infection
13680742,136807421,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10952,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807421.0,OT,,,,,,,,,136807421.0,1.0,HIV infection WHO clinical stage IV
13680743,136807431,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10957,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807431.0,OT,,,,,,,,,136807431.0,1.0,HIV infection
13680762,136807621,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10964,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807621.0,OT,,,,,,,,,136807621.0,1.0,HIV infection WHO clinical stage III
13680763,136807631,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10963,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807631.0,OT,,,,,,,,,136807631.0,1.0,HIV infection WHO clinical stage II
13680767,136807671,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10962,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807671.0,OT,,,,,,,,,136807671.0,1.0,HIV infection WHO clinical stage IV
13680773,136807731,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10961,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807731.0,OT,,,,,,,,,136807731.0,1.0,HIV infection WHO clinical stage III
13680775,136807751,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10960,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807751.0,OT,,,,,,,,,136807751.0,1.0,HIV infection WHO clinical stage IV
13680786,136807861,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10968,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807861.0,OT,,,,,,,,,136807861.0,1.0,HIV infection WHO clinical stage III
13680788,136807881,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10967,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807881.0,OT,,,,,,,,,136807881.0,1.0,HIV infection WHO clinical stage III
13680792,136807921,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10971,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Treatment failure,136807921.0,OT,,,,,,,,,136807921.0,1.0,HIV infection WHO clinical stage II
13680793,136807931,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10970,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807931.0,OT,,,,,,,,,136807931.0,1.0,HIV infection WHO clinical stage I
13680795,136807951,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10974,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807951.0,OT,,,,,,,,,136807951.0,1.0,HIV infection WHO clinical stage II
13680796,136807961,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10973,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807961.0,OT,,,,,,,,,136807961.0,1.0,HIV infection WHO clinical stage II
13680797,136807971,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10984,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807971.0,OT,,,,,,,,,136807971.0,1.0,HIV infection WHO clinical stage IV
13681219,136812191,1,I,,20170608.0,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10983,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622.0,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136812191.0,OT,,,,,,,,,136812191.0,1.0,HIV infection WHO clinical stage III
13685470,136854702,2,F,,20170720.0,20170623,20170728,EXP,,ES-GILEAD-2017-0278162,GILEAD,,64.0,YR,A,F,Y,,,20170728.0,,MD,ES,ES,EFAVIRENZ,Osteopenia;Osteoporosis,136854702.0,OT,,,136854702.0,1.0,201010.0,,,,136854702.0,1.0,HIV infection
13686825,136868257,7,F,20170604.0,20170817.0,20170623,20170821,EXP,,TZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-052094,BRISTOL MYERS SQUIBB,,0.0,DY,,F,Y,2.2,KG,20170821.0,,OT,TZ,TZ,EFAVIRENZ,Anaemia;Exposure during breast feeding;Foetal exposure during pregnancy;Necrotising colitis;Platelet count decreased;Premature baby;Sepsis neonatal;White blood cell count decreased,136868257.0,DE,,,136868257.0,1.0,20170313.0,20170604.0,,,136868257.0,1.0,Prophylaxis against HIV infection
13687034,136870341,1,I,,20170609.0,20170623,20170623,EXP,,UG-MYLANLABS-2017M1037702,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623.0,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136870341.0,OT,,,,,,,,,136870341.0,1.0,HIV infection
13687035,136870351,1,I,,20170609.0,20170623,20170623,EXP,,UG-MYLANLABS-2017M1037717,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623.0,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136870351.0,OT,,,,,,,,,136870351.0,1.0,HIV infection
13687580,136875801,1,I,,20170609.0,20170624,20170624,EXP,,UG-MYLANLABS-2017M1037773,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623.0,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136875801.0,OT,,,,,,,,,136875801.0,1.0,HIV infection
13687581,136875811,1,I,,20170609.0,20170624,20170624,EXP,,UG-MYLANLABS-2017M1037751,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623.0,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136875811.0,OT,,,,,,,,,136875811.0,1.0,HIV infection
13697384,136973842,2,F,,20170623.0,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099689,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",48.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Oral disorder;Rash;Rash maculo-papular;Vomiting,136973842.0,HO,,,,,,,,,136973842.0,1.0,Antiretroviral therapy
13697385,136973852,2,F,,20170623.0,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099692,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",32.0,YR,,M,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Rash maculo-papular,136973852.0,OT,,,,,,,,,136973852.0,1.0,Antiretroviral therapy
13697386,136973862,2,F,,20170623.0,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099687,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",35.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Oral disorder;Rash maculo-papular,136973862.0,OT,,,,,,,,,136973862.0,1.0,Antiretroviral therapy
13697389,136973892,2,F,,20170623.0,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099688,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",36.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Asthma;Condition aggravated;Dermatitis atopic;Rash maculo-papular,136973892.0,OT,,,,,,,,,136973892.0,1.0,Antiretroviral therapy
13697391,136973912,2,F,,20170623.0,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099685,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",39.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Hepatic enzyme increased;Rash maculo-papular,136973912.0,OT,,,,,,,,,136973912.0,1.0,Antiretroviral therapy
13697503,136975032,2,F,,20170623.0,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099689,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",48.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Oral disorder;Rash;Rash maculo-papular;Vomiting,136975032.0,HO,,,,,,,,,136975032.0,1.0,Antiretroviral therapy
13697505,136975052,2,F,,20170623.0,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099687,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",35.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Oral disorder;Rash maculo-papular,136975052.0,OT,,,,,,,,,136975052.0,1.0,Antiretroviral therapy
13697510,136975102,2,F,,20170623.0,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099688,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",36.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Asthma;Condition aggravated;Dermatitis atopic;Rash maculo-papular,136975102.0,OT,,,,,,,,,136975102.0,1.0,Antiretroviral therapy
13697512,136975122,2,F,,20170623.0,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099685,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",39.0,YR,,F,Y,,,20170705.0,,MD,IN,IN,EFAVIRENZ,Hepatic enzyme increased;Rash maculo-papular,136975122.0,OT,,,,,,,,,136975122.0,1.0,Antiretroviral therapy
13713354,137133541,1,I,,20161202.0,20170704,20170704,PER,,JP-LUPIN PHARMACEUTICALS INC.-2016-05492,LUPIN,,44.0,YR,,M,Y,,,20170704.0,,OT,JP,JP,EFAVIRENZ,Nightmare,,,,,,,,,,,137133541.0,1.0,HIV infection
13713654,137136542,2,F,,20170619.0,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059185,BRISTOL MYERS SQUIBB,,25.0,YR,,M,Y,,,20170804.0,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137136542.0,OT,,,,,,,,,137136542.0,1.0,HIV infection
13713693,137136932,2,F,,20170719.0,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-058794,BRISTOL MYERS SQUIBB,,51.0,YR,,M,Y,,,20170804.0,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137136932.0,OT,,,,,,,,,137136932.0,1.0,HIV infection
13713694,137136942,2,F,,20170619.0,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059182,BRISTOL MYERS SQUIBB,,28.0,YR,,M,Y,,,20170804.0,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137136942.0,OT,,,,,,,,,137136942.0,1.0,HIV infection
13713829,137138292,2,F,,20170619.0,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059183,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20170804.0,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137138292.0,OT,,,,,,,,,137138292.0,1.0,HIV infection
13713839,137138392,2,F,,20170619.0,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059186,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20170804.0,,OT,DE,ET,EFAVIRENZ,Viral mutation identified;Virologic failure,137138392.0,OT,,,,,,,,,137138392.0,1.0,HIV infection
13718110,137181103,3,F,2014.0,20170817.0,20170705,20170823,PER,,US-GILEAD-2017-0281053,GILEAD,,54.0,YR,A,M,Y,96.6,KG,20170823.0,,PH,US,US,SUSTIVA,Amnesia;Drug dose omission;Insurance issue;Memory impairment,,,,,137181103.0,1.0,20160408.0,20160609.0,,,137181103.0,1.0,HIV infection
13725012,137250121,1,I,,20031204.0,20170706,20170706,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12454591,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170706.0,,CN,FR,SN,EFAVIRENZ,Cervix carcinoma stage 0,137250121.0,HO,,,,,,,,,137250121.0,1.0,HIV infection
13736498,137364981,1,I,20170621.0,20170621.0,20170710,20170710,EXP,,MX-VIIV HEALTHCARE LIMITED-MX2017GSK098190,VIIV,,31.0,YR,,M,Y,68.0,KG,20170710.0,,MD,MX,MX,EFAVIRENZ,Pancreatitis,137364981.0,DE,,,137364981.0,1.0,20170619.0,20170621.0,,,137364981.0,1.0,HIV infection
13739571,137395711,1,I,,20170705.0,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106243,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711.0,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137395711.0,OT,,,,,,,,,137395711.0,1.0,Prophylaxis against HIV infection
13739573,137395731,1,I,,20170705.0,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106240,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANSEGUIN-DEVAUX DOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711.0,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137395731.0,OT,,,,,,,,,137395731.0,1.0,Prophylaxis against HIV infection
13739816,137398161,1,I,,20170705.0,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106244,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711.0,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137398161.0,OT,,,,,,,,,137398161.0,1.0,Prophylaxis against HIV infection
13739841,137398411,1,I,,20170705.0,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106246,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711.0,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137398411.0,OT,,,,,,,,,137398411.0,1.0,Prophylaxis against HIV infection
13740546,137405461,1,I,,20170515.0,20170711,20170711,PER,,MY-LUPIN PHARMACEUTICALS INC.-2017-02631,LUPIN,,43.0,YR,,F,Y,,,20170710.0,,OT,MY,MY,EFAVIRENZ,Myalgia;Pyrexia;Rash maculo-papular;Rash pruritic,137405461.0,HO,,,,,,,,,137405461.0,1.0,Antiretroviral therapy
13747003,137470031,1,I,,20170705.0,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106240,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANSEGUIN-DEVAUX DOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712.0,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137470031.0,OT,,,,,,,,,137470031.0,1.0,Prophylaxis against HIV infection
13747085,137470851,1,I,,20170705.0,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106243,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712.0,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137470851.0,OT,,,,,,,,,137470851.0,1.0,Prophylaxis against HIV infection
13747127,137471271,1,I,,20170705.0,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106244,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712.0,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137471271.0,OT,,,,,,,,,137471271.0,1.0,Prophylaxis against HIV infection
13747503,137475031,1,I,,20170705.0,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106247,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712.0,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Viral mutation identified;Virologic failure,137475031.0,OT,,,,,,,,,137475031.0,1.0,Prophylaxis against HIV infection
13747504,137475041,1,I,,20170705.0,20170712,20170712,EXP,,BF-GLAXOSMITHKLINE-BF2017106247,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712.0,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Viral mutation identified;Virologic failure,137475041.0,OT,,,,,,,,,137475041.0,1.0,Prophylaxis against HIV infection
13752828,137528281,1,I,20170111.0,,20170713,20170713,DIR,US-FDA-377832,,FDA-CTU,,61.0,YR,,M,N,70.8,KG,20170713.0,N,OT,US,US,EFAVIRENZ,Abnormal dreams,137528281.0,OT,137528281.0,HP,137528281.0,1.0,,,6.0,MON,137528281.0,1.0,HIV infection
13754304,137543041,1,I,,20170703.0,20170714,20170714,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017105237,VIIV,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",50.0,YR,,F,Y,85.0,KG,20170714.0,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543041.0,OT,,,,,,,,,137543041.0,1.0,Antiretroviral therapy
13754306,137543061,1,I,,20170703.0,20170714,20170714,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017105236,VIIV,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",42.0,YR,,F,Y,67.0,KG,20170714.0,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543061.0,OT,,,,,,,,,137543061.0,1.0,Antiretroviral therapy
13754395,137543951,1,I,,20170703.0,20170714,20170714,EXP,,GB-GLAXOSMITHKLINE-GB2017105237,GLAXOSMITHKLINE,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",50.0,YR,,F,Y,85.0,KG,20170714.0,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543951.0,OT,,,,,,,,,137543951.0,1.0,Antiretroviral therapy
13754396,137543961,1,I,,20170703.0,20170714,20170714,EXP,,GB-GLAXOSMITHKLINE-GB2017105236,GLAXOSMITHKLINE,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",42.0,YR,,F,Y,67.0,KG,20170714.0,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543961.0,OT,,,,,,,,,137543961.0,1.0,Antiretroviral therapy
13755735,137557351,1,I,,20170706.0,20170714,20170714,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-061871,BRISTOL MYERS SQUIBB,,67.0,YR,,M,Y,,,20170714.0,,OT,PT,PT,EFAVIRENZ,Progressive multifocal leukoencephalopathy,137557351.0,HO,,,,,,,,,137557351.0,1.0,HIV infection
13756645,137566451,1,I,,20170705.0,20170714,20170714,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106246,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170714.0,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137566451.0,OT,,,,,,,,,137566451.0,1.0,Prophylaxis against HIV infection
13760045,137600451,1,I,20170515.0,20170710.0,20170717,20170717,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-063543,BRISTOL MYERS SQUIBB,,63.0,YR,,F,Y,,,20170717.0,,OT,CN,CN,EFAVIRENZ,Oral herpes;Rash,137600451.0,HO,,,137600451.0,1.0,20170410.0,,,,137600451.0,1.0,HIV infection
13769936,137699361,1,I,,20170711.0,20170719,20170719,EXP,,TH-GLAXOSMITHKLINE-TH2017109349,GLAXOSMITHKLINE,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719.0,,OT,TH,TH,EFAVIRENZ,Cervical dysplasia,137699361.0,HO,,,,,,,,,137699361.0,1.0,HIV infection
13769939,137699391,1,I,,20170711.0,20170719,20170719,EXP,,TH-GLAXOSMITHKLINE-TH2017109352,GLAXOSMITHKLINE,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719.0,,OT,TH,TH,EFAVIRENZ,Endocarditis enterococcal,137699391.0,OT,,,,,,,,,137699391.0,1.0,HIV infection
13769942,137699421,1,I,,20170711.0,20170719,20170719,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2017109349,VIIV,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719.0,,OT,TH,TH,EFAVIRENZ,Cervical dysplasia,137699421.0,OT,,,,,,,,,137699421.0,1.0,HIV infection
13769946,137699461,1,I,,20170711.0,20170719,20170719,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2017109352,VIIV,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719.0,,OT,TH,TH,EFAVIRENZ,Endocarditis enterococcal,137699461.0,HO,,,,,,,,,137699461.0,1.0,HIV infection
13776722,137767221,1,I,,20170714.0,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111893,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Virologic failure,137767221.0,OT,,,,,,,,,137767221.0,1.0,HIV infection
13776726,137767261,1,I,,20170714.0,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111888,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767261.0,OT,,,,,,,,,137767261.0,1.0,HIV infection
13776729,137767291,1,I,,20170714.0,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111890,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767291.0,OT,,,,,,,,,137767291.0,1.0,HIV infection
13776734,137767341,1,I,,20170714.0,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111892,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767341.0,OT,,,,,,,,,137767341.0,1.0,HIV infection
13776737,137767371,1,I,,20170714.0,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111889,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767371.0,OT,,,,,,,,,137767371.0,1.0,HIV infection
13776748,137767481,1,I,,20170714.0,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111889,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767481.0,OT,,,,,,,,,137767481.0,1.0,HIV infection
13776750,137767501,1,I,,20170714.0,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111893,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Virologic failure,137767501.0,OT,,,,,,,,,137767501.0,1.0,HIV infection
13776752,137767521,1,I,,20170714.0,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111888,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767521.0,OT,,,,,,,,,137767521.0,1.0,HIV infection
13776757,137767571,1,I,,20170714.0,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111890,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767571.0,OT,,,,,,,,,137767571.0,1.0,HIV infection
13776759,137767591,1,I,,20170714.0,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111892,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720.0,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767591.0,OT,,,,,,,,,137767591.0,1.0,HIV infection
13778006,137780065,5,F,20170417.0,20170809.0,20170721,20170814,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-064616,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,76.0,KG,20170814.0,,OT,BR,BR,EFAVIRENZ,Blood pressure increased;Live birth;Maternal exposure during pregnancy;Polyhydramnios;Proteinuria,137780065.0,HO,,,137780065.0,1.0,20170417.0,,,,137780065.0,1.0,HIV infection
13778580,137785801,1,I,20170201.0,20170713.0,20170721,20170721,EXP,GB-MHRA-EYC 00161661,GB-GILEAD-2017-0283467,GILEAD,,63.0,YR,A,M,Y,111.0,KG,20170721.0,,PH,GB,GB,EFAVIRENZ,Myalgia,137785801.0,OT,,,137785801.0,1.0,20170110.0,20170412.0,,,137785801.0,1.0,HIV infection
13797035,137970351,1,I,20170706.0,20170720.0,20170727,20170727,EXP,,BR-HETERO LABS LTD-2023830,HETERO,,1.0,DY,,F,Y,3.73,KG,20170727.0,,OT,BR,BR,Efavirenz,Congenital pyelocaliectasis;Foetal exposure during pregnancy;Macrosomia,137970351.0,OT,,,137970351.0,1.0,20170417.0,,,,137970351.0,1.0,HIV infection
13825128,138251281,1,I,201005.0,20170719.0,20170802,20170802,EXP,,MW-MYLANLABS-2017M1046886,MYLAN,"BARNETT BS, CHAWEZA T, TWEYA H, NGAMBI W, PHIRI S, HOSSEINIPOUR MC. ASSESSMENT OF NON-STANDARD HIV ANTIRETROVIRAL THERAPY REGIMENS AT LIGHTHOUSE TRUST IN LILONGWE, MALAWI. MALAWI-MED-J 2016;28(1):6-9.",,,,,Y,,,20170802.0,,OT,MW,MW,EFAVIRENZ,Abdominal discomfort;Confusional state;Depression;Hepatitis;Insomnia;Neuropathy peripheral,138251281.0,OT,,,138251281.0,1.0,201001.0,,,,138251281.0,1.0,HIV infection
13829320,138293201,1,I,201707.0,20170726.0,20170803,20170803,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-067153,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20170803.0,,PH,US,US,SUSTIVA,Cerebrovascular accident,138293201.0,LT,,,,,,,,,138293201.0,1.0,HIV infection
13834780,138347801,1,I,20170727.0,20170727.0,20170804,20170804,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-068553,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20170804.0,,PH,US,US,SUSTIVA,Crohn's disease;Macular degeneration;Product storage error,138347801.0,OT,,,,,,,,,138347801.0,1.0,HIV infection
13847395,138473951,1,I,20131022.0,20170731.0,20170808,20170808,EXP,,PT-009507513-1708PRT001228,MERCK,,36.0,YR,,F,Y,,,20170808.0,,MD,PT,PT,EFAVIRENZ,Anaemia of pregnancy;Caesarean section;Maternal exposure during pregnancy,138473951.0,OT,,,138473951.0,1.0,20131022.0,20131022.0,,,138473951.0,1.0,HIV infection
13849167,138491671,1,I,201005.0,20170727.0,20170809,20170809,EXP,,MW-CIPLA LTD.-2017MW13641,CIPLA,"BARNETT BS, CHAWEZA T, TWEYA H, NGAMBI W, PHIRI S, HOSSEINIPOUR MC. ASSESSMENT OF NON-STANDARD HIV ANTIRETROVIRAL THERAPY REGIMENS AT LIGHTHOUSE TRUST IN LILONGWE, MALAWI. MALAWI-MED-J. 2016;28 (1):6 TO 9",,,,,Y,,,20170809.0,,OT,MW,MW,Efavirenz,Abdominal discomfort;Confusional state;Depression;Hepatitis;Insomnia;Neuropathy peripheral,138491671.0,OT,,,138491671.0,2.0,201001.0,201009.0,,,138491671.0,1.0,HIV infection
13850768,138507681,1,I,,20170725.0,20170809,20170809,EXP,,GR-VIIV HEALTHCARE LIMITED-GR2017GSK123085,VIIV,"KOTSAFTI O, PAPARIZOS V, KOURKOUNTI S, CHATZIIOANNOU A, NICOLAIDOU E, KAPSIMALI V, ANTONIOU C. EARLY SYPHILIS AFFECTS MARKERS OF HIV. INTERNATIONAL JOURNAL OF STD + AIDS. 2016;27(9):739-745",,,,M,Y,,,20170809.0,,OT,GR,GR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,138507681.0,OT,,,,,,,,,138507681.0,1.0,HIV infection
13850786,138507861,1,I,,20170725.0,20170809,20170809,EXP,,GR-GLAXOSMITHKLINE-GR2017GSK123085,GLAXOSMITHKLINE,"KOTSAFTI O, PAPARIZOS V, KOURKOUNTI S, CHATZIIOANNOU A, NICOLAIDOU E, KAPSIMALI V, ANTONIOU C. EARLY SYPHILIS AFFECTS MARKERS OF HIV. INTERNATIONAL JOURNAL OF STD + AIDS. 2016;27(9):739-745",,,,M,Y,,,20170809.0,,OT,GR,GR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,138507861.0,OT,,,,,,,,,138507861.0,1.0,HIV infection
13851390,138513904,4,F,,20210907.0,20170809,20210909,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-069840,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210909.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,138513904.0,DE,,,,,,,,,138513904.0,1.0,HIV infection
13869531,138695312,2,F,2016.0,20170831.0,20170815,20170905,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK124729,GLAXOSMITHKLINE,,34.0,YR,,M,Y,80.0,KG,20170905.0,,CN,CN,CN,EFAVIRENZ TABLET,Blood cholesterol abnormal;Blood creatinine increased;Blood triglycerides abnormal;Concomitant disease aggravated;Insomnia;Liver injury,138695312.0,OT,,,138695312.0,1.0,201508.0,201706.0,,,138695312.0,1.0,HIV infection
13869707,138697072,2,F,2016.0,20170831.0,20170815,20170905,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK124729,VIIV,,34.0,YR,,M,Y,80.0,KG,20170905.0,,CN,CN,CN,EFAVIRENZ TABLET,Blood cholesterol abnormal;Blood creatinine increased;Blood triglycerides abnormal;Concomitant disease aggravated;Insomnia;Liver injury,138697072.0,OT,,,138697072.0,1.0,201508.0,201706.0,,,138697072.0,1.0,HIV infection
13874864,138748641,1,I,,20170808.0,20170816,20170816,EXP,,CN-GILEAD-2017-0288119,GILEAD,,34.0,YR,A,M,Y,80.0,KG,20170816.0,,CN,CN,CN,EFAVIRENZ,Liver injury,138748641.0,OT,,,138748641.0,1.0,2014.0,201508.0,,,138748641.0,1.0,HIV infection
13881052,138810521,1,I,20170430.0,20170809.0,20170818,20170818,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-072999,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,78.5,KG,20170818.0,,OT,CN,CN,EFAVIRENZ,Hepatocellular injury,138810521.0,OT,,,138810521.0,1.0,20150411.0,20170609.0,,,138810521.0,1.0,HIV infection
13884510,138845101,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14200,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138845101.0,OT,,,,,,,,,138845101.0,1.0,HIV infection
13884653,138846531,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14198,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138846531.0,OT,,,,,,,,,138846531.0,1.0,HIV infection
13884681,138846811,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14197,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138846811.0,OT,,,,,,,,,138846811.0,1.0,HIV infection
13884708,138847081,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14211,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138847081.0,OT,,,,,,,,,138847081.0,1.0,HIV infection
13884728,138847281,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14202,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138847281.0,OT,,,,,,,,,138847281.0,1.0,HIV infection
13884762,138847621,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14199,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138847621.0,OT,,,,,,,,,138847621.0,1.0,HIV infection
13884771,138847711,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14196,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138847711.0,OT,,,,,,,,,138847711.0,1.0,HIV infection
13884834,138848341,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14102,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138848341.0,OT,,,,,,,,,138848341.0,1.0,HIV infection
13884875,138848751,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14212,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138848751.0,OT,,,,,,,,,138848751.0,1.0,HIV infection
13884879,138848791,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14201,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138848791.0,OT,,,,,,,,,138848791.0,1.0,HIV infection
13885001,138850011,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14213,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138850011.0,OT,,,,,,,,,138850011.0,1.0,HIV infection
13885020,138850201,1,I,,20170809.0,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14214,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821.0,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138850201.0,OT,,,,,,,,,138850201.0,1.0,HIV infection
13897383,138973831,1,I,,20170817.0,20170823,20170823,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017129197,VIIV,"VALVIESSE VRGA, DE PINHO LI, FREITAS RF, VARON AG, LEMOS AS. LAMIVUDINE^S HYPERSENSITIVITY IN AN HIV INFECTED PATIENT: CASE REPORT. MEDICINA (BRAZIL). 2017;50(2):139-142",50.0,YR,,F,Y,,,20170823.0,,OT,BR,BR,EFAVIRENZ,Erythema multiforme;Hypersensitivity;Stevens-Johnson syndrome,138973831.0,HO,,,,,,,,,138973831.0,1.0,Antiretroviral therapy
13897385,138973851,1,I,,20170817.0,20170823,20170823,EXP,,BR-GLAXOSMITHKLINE-BR2017129197,GLAXOSMITHKLINE,"VALVIESSE VRGA, DE PINHO LI, FREITAS RF, VARON AG, LEMOS AS. LAMIVUDINE^S HYPERSENSITIVITY IN AN HIV INFECTED PATIENT: CASE REPORT. MEDICINA (BRAZIL). 2017;50(2):139-142",50.0,YR,,F,Y,,,20170823.0,,OT,BR,BR,EFAVIRENZ,Erythema multiforme;Hypersensitivity;Stevens-Johnson syndrome,138973851.0,OT,,,,,,,,,138973851.0,1.0,Antiretroviral therapy
13900025,139000251,1,I,,20161130.0,20170823,20170823,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-104574,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20170823.0,,OT,ZA,ZA,EFAVIRENZ,Cerebellar ataxia,139000251.0,HO,,,,,,,,,139000251.0,1.0,HIV infection
13905753,139057531,1,I,,20170818.0,20170825,20170825,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130750,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139057531.0,OT,,,139057531.0,1.0,20151010.0,,,,139057531.0,1.0,HIV infection
13906408,1390640862,62,F,,20241029.0,20170825,20241104,EXP,,CA-009507513-0809CAN00001,MERCK,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases.. AIDS. 2008;22(14):1890-2",54.0,YR,,M,Y,,,20241104.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Diplopia;Drug interaction;Eyelid ptosis;Incorrect route of product administration;Intentional product use issue;Lipodystrophy acquired;Loss of personal independence in daily activities;Mitochondrial toxicity;Off label use;Paranoia;Prescribed overdose;Product use in unapproved indication;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1390640862.0,HO,,,1390640862.0,1.0,20070620.0,,,,1390640862.0,1.0,HIV infection
13906966,139069661,1,I,,20170818.0,20170825,20170825,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130749,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139069661.0,OT,,,139069661.0,1.0,20151008.0,,,,139069661.0,1.0,HIV infection
13906967,139069671,1,I,,20170818.0,20170825,20170825,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130750,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139069671.0,OT,,,139069671.0,1.0,20151010.0,,,,139069671.0,1.0,HIV infection
13906968,139069681,1,I,,20170818.0,20170825,20170825,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130749,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139069681.0,OT,,,139069681.0,1.0,20151008.0,,,,139069681.0,1.0,HIV infection
13907006,139070061,1,I,,20170818.0,20170825,20170825,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130752,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139070061.0,OT,,,139070061.0,1.0,20150909.0,,,,139070061.0,1.0,HIV infection
13907007,139070071,1,I,,20170818.0,20170825,20170825,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130752,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139070071.0,OT,,,139070071.0,1.0,20150909.0,,,,139070071.0,1.0,HIV infection
13908647,139086471,1,I,,20170818.0,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130755,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086471.0,OT,,,139086471.0,1.0,20150930.0,,,,139086471.0,1.0,HIV infection
13908648,139086481,1,I,,20170818.0,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130753,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086481.0,OT,,,139086481.0,1.0,20151109.0,,,,139086481.0,1.0,HIV infection
13908649,139086491,1,I,,20170818.0,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130758,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086491.0,OT,,,139086491.0,1.0,20150701.0,,,,139086491.0,1.0,HIV infection
13908650,139086501,1,I,,20170818.0,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130757,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086501.0,OT,,,139086501.0,1.0,20150819.0,,,,139086501.0,1.0,HIV infection
13908651,139086511,1,I,,20170818.0,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130756,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086511.0,OT,,,139086511.0,1.0,20141028.0,,,,139086511.0,1.0,HIV infection
13908652,139086521,1,I,,20170818.0,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130754,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086521.0,OT,,,139086521.0,1.0,20150209.0,,,,139086521.0,1.0,HIV infection
13908653,139086531,1,I,,20170818.0,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130755,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086531.0,OT,,,139086531.0,1.0,20150930.0,,,,139086531.0,1.0,HIV infection
13908654,139086541,1,I,,20170818.0,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130753,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086541.0,OT,,,139086541.0,1.0,20151109.0,,,,139086541.0,1.0,HIV infection
13908655,139086551,1,I,,20170818.0,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130758,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086551.0,OT,,,139086551.0,1.0,20150701.0,,,,139086551.0,1.0,HIV infection
13908656,139086561,1,I,,20170818.0,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130757,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086561.0,OT,,,139086561.0,1.0,20150819.0,,,,139086561.0,1.0,HIV infection
13908657,139086571,1,I,,20170818.0,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130756,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086571.0,OT,,,139086571.0,1.0,20141028.0,,,,139086571.0,1.0,HIV infection
13908658,139086581,1,I,,20170818.0,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130754,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827.0,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086581.0,OT,,,139086581.0,1.0,20150209.0,,,,139086581.0,1.0,HIV infection
13909830,139098301,1,I,,20170821.0,20170828,20170828,EXP,,ZA-HETERO-HET2017ZA00116,HETERO,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL.. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES.. J-ACQUIR-IMMUNE-DEFIC-SYNDR. 2017;75(5):577-579",,,,F,Y,,,20170828.0,,OT,ZA,ZA,Efavirenz,Ataxia,139098301.0,HO,,,,,,,,,139098301.0,1.0,HIV infection
13909831,139098312,2,F,,20170821.0,20170828,20170904,EXP,,ZA-HETERO CORPORATE-HET2017ZA00115,HETERO,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL.. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES.. J-ACQUIR-IMMUNE-DEFIC-SYNDR. 2017;75(5):577-579",,,,F,Y,,,20170904.0,,OT,ZA,ZA,Efavirenz,Ataxia,139098312.0,HO,,,,,,,,,139098312.0,1.0,HIV infection
13910385,139103851,1,I,,20170814.0,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052768,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828.0,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139103851.0,HO,,,,,,,,,139103851.0,1.0,HIV infection
13910386,139103861,1,I,,20170814.0,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052745,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828.0,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139103861.0,HO,,,,,,,,,139103861.0,1.0,HIV infection
13910411,139104111,1,I,,20170814.0,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052744,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828.0,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139104111.0,HO,,,,,,,,,139104111.0,1.0,HIV infection
13910633,139106331,1,I,,20170814.0,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052825,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828.0,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139106331.0,HO,,,,,,,,,139106331.0,1.0,HIV infection
13910636,139106361,1,I,,20170814.0,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052778,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828.0,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139106361.0,HO,,,,,,,,,139106361.0,1.0,HIV infection
13910637,139106371,1,I,,20170814.0,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052842,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828.0,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139106371.0,HO,,,,,,,,,139106371.0,1.0,HIV infection
13910838,139108381,1,I,,20170814.0,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052863,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828.0,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139108381.0,HO,,,,,,,,,139108381.0,1.0,HIV infection
13911432,139114321,1,I,2014.0,20170823.0,20170828,20170828,PER,,US-GLAXOSMITHKLINE-US2017GSK131689,GLAXOSMITHKLINE,,54.0,YR,,M,Y,96.6,KG,20170828.0,,CN,US,US,SUSTIVA,Amnesia;Drug dose omission;Memory impairment,,,,,139114321.0,1.0,1999.0,20141118.0,,,139114321.0,1.0,HIV infection
13911778,139117781,1,I,2014.0,20170823.0,20170828,20170828,PER,,US-VIIV HEALTHCARE LIMITED-US2017GSK131689,VIIV,,54.0,YR,,M,Y,96.6,KG,20170828.0,,CN,US,US,SUSTIVA,Amnesia;Drug dose omission;Memory impairment,,,,,139117781.0,1.0,1999.0,20141118.0,,,139117781.0,1.0,HIV infection
13914640,139146404,4,F,20170813.0,20170915.0,20170829,20170920,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-076816,BRISTOL MYERS SQUIBB,,3.0,MON,,M,Y,3.65,KG,20170920.0,,OT,BR,BR,EFAVIRENZ,Bronchiolitis;Foetal exposure during pregnancy;Pneumonia bacterial,139146404.0,OT,,,139146404.0,1.0,20170309.0,20170319.0,,,139146404.0,1.0,Prophylaxis against HIV infection
13924142,139241421,1,I,,20170816.0,20170831,20170831,EXP,,BR-LUPIN PHARMACEUTICALS INC.-2017-05106,LUPIN,,50.0,YR,,F,Y,,,20170831.0,,OT,BR,BR,EFAVIRENZ,Hypersensitivity;Stevens-Johnson syndrome,139241421.0,HO,,,,,,,,,139241421.0,1.0,Acquired immunodeficiency syndrome
13924232,139242321,1,I,,20170822.0,20170831,20170831,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-078162,BRISTOL MYERS SQUIBB,,49.0,YR,,F,Y,,,20170831.0,,OT,MW,MW,EFAVIRENZ,Labelled drug-drug interaction medication error;Plasmodium malariae infection,139242321.0,OT,,,,,,,,,139242321.0,1.0,HIV infection
13924235,139242351,1,I,,20170822.0,20170831,20170831,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-078356,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20170831.0,,OT,MW,MW,EFAVIRENZ,Labelled drug-drug interaction medication error;Plasmodium malariae infection,139242351.0,OT,,,,,,,,,139242351.0,1.0,HIV infection
13925619,139256193,3,F,,20190227.0,20170831,20190304,EXP,,UG-SA-2017SA157037,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20190304.0,,OT,UG,UG,EFAVIRENZ.,Anticoagulation drug level above therapeutic;Drug interaction;Epistaxis,139256193.0,OT,,,,,,,,,139256193.0,2.0,HIV infection
13928968,139289682,2,F,,20170825.0,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14996,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,Efavirenz,Ataxia;Cerebellar syndrome;Drug level increased;Dysarthria;Hepatic enzyme increased,139289682.0,HO,,,,,,,,,139289682.0,1.0,HIV infection
13930783,139307831,1,I,,20170828.0,20170901,20170901,EXP,,KE-GILEAD-2017-0291241,GILEAD,"SOME F, KOECH M, CHESIRE E, KIGEN G.. REVERSAL OF TENOFOVIR INDUCED NEPHROTOXICITY: CASE REPORTS OF TWO PATIENTS.. PAN AFRICAN MEDICAL JOURNAL. 2017;27:UNK",54.0,YR,A,M,Y,,,20170901.0,,OT,KE,KE,EFAVIRENZ,Acute kidney injury;Nephropathy toxic,139307831.0,HO,,,,,,,,,139307831.0,1.0,HIV infection
13931860,139318601,1,I,,20170822.0,20170904,20170904,EXP,,MY-APPCO PHARMA LLC-2025511,APPCO PHARMA,,43.0,YR,,F,Y,,,20170904.0,,OT,MY,MY,efavirenz,Rash maculo-papular;Rash pruritic,139318601.0,HO,,,,,,,,,139318601.0,1.0,Antiretroviral therapy
13936025,139360251,1,I,,20170822.0,20170905,20170905,EXP,,US-VIIV HEALTHCARE LIMITED-MW2017GSK134860,VIIV,,,,,F,Y,,,20170905.0,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139360251.0,OT,,,,,,,,,139360251.0,1.0,HIV infection
13936026,139360261,1,I,,20170822.0,20170905,20170905,EXP,,US-VIIV HEALTHCARE LIMITED-MW2017GSK134859,VIIV,,,,,F,Y,,,20170905.0,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139360261.0,OT,,,,,,,,,139360261.0,1.0,HIV infection
13936027,139360271,1,I,,20170822.0,20170905,20170905,EXP,,US-VIIV HEALTHCARE LIMITED-MW2017GSK134825,VIIV,,,,,F,Y,,,20170905.0,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139360271.0,OT,,,,,,,,,139360271.0,1.0,HIV infection
13936247,139362471,1,I,,20170822.0,20170905,20170905,EXP,,US-GLAXOSMITHKLINE-MW2017GSK134860,GLAXOSMITHKLINE,,,,,F,Y,,,20170905.0,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139362471.0,OT,,,,,,,,,139362471.0,1.0,HIV infection
13936253,139362531,1,I,,20170822.0,20170905,20170905,EXP,,US-GLAXOSMITHKLINE-MW2017GSK134859,GLAXOSMITHKLINE,,,,,F,Y,,,20170905.0,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139362531.0,OT,,,,,,,,,139362531.0,1.0,HIV infection
13936254,139362541,1,I,,20170822.0,20170905,20170905,EXP,,US-GLAXOSMITHKLINE-MW2017GSK134825,GLAXOSMITHKLINE,,,,,F,Y,,,20170905.0,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139362541.0,OT,,,,,,,,,139362541.0,1.0,HIV infection
13940444,139404442,2,F,,20170830.0,20170906,20170914,EXP,,BR-MYLANLABS-2017M1054536,MYLAN,"VALVIESSE VRGA, DE PINHO LI, FREITAS RF, VARON AG, LEMOS AS. LAMIVUDINE^S HYPERSENSITIVITY IN AN HIV INFECTED PATIENT: CASE REPORT. MEDICINA-BRAZIL 2017;50(2):139-142.",50.0,YR,,F,Y,,,20170914.0,,OT,BR,BR,EFAVIRENZ,Hypersensitivity;Stevens-Johnson syndrome,139404442.0,OT,,,,,,,,,139404442.0,1.0,HIV infection
13955320,139553201,1,I,,20170905.0,20170911,20170911,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2017GSK140190,VIIV,,,,,M,Y,,,20170911.0,,MD,CO,CO,EFAVIRENZ,Drug ineffective;Treatment noncompliance,139553201.0,LT,,,,,,,,,139553201.0,1.0,HIV infection
13964540,139645401,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140679,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645401.0,OT,,,,,,,,,139645401.0,1.0,HIV infection
13964541,139645411,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140676,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645411.0,OT,,,,,,,,,139645411.0,1.0,HIV infection
13964543,139645431,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140681,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645431.0,OT,,,,,,,,,139645431.0,1.0,HIV infection
13964544,139645441,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140674,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016.",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645441.0,OT,,,,,,,,,139645441.0,1.0,HIV infection
13964547,139645471,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140679,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645471.0,OT,,,,,,,,,139645471.0,1.0,HIV infection
13964548,139645481,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140676,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645481.0,OT,,,,,,,,,139645481.0,1.0,HIV infection
13964550,139645501,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140681,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645501.0,OT,,,,,,,,,139645501.0,1.0,HIV infection
13964551,139645511,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140674,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016.",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645511.0,OT,,,,,,,,,139645511.0,1.0,HIV infection
13965858,139658581,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140684,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139658581.0,OT,,,,,,,,,139658581.0,1.0,HIV infection
13965860,139658601,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140684,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139658601.0,OT,,,,,,,,,139658601.0,1.0,HIV infection
13966087,139660871,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140689,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660871.0,OT,,,,,,,,,139660871.0,1.0,HIV infection
13966088,139660881,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140693,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660881.0,OT,,,,,,,,,139660881.0,1.0,HIV infection
13966091,139660911,1,I,,20170907.0,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140691,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660911.0,OT,,,,,,,,,139660911.0,1.0,HIV infection
13966094,139660941,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140693,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660941.0,OT,,,,,,,,,139660941.0,1.0,HIV infection
13966095,139660951,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140689,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660951.0,OT,,,,,,,,,139660951.0,1.0,HIV infection
13966098,139660981,1,I,,20170907.0,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140691,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913.0,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660981.0,OT,,,,,,,,,139660981.0,1.0,HIV infection
13977826,139778261,1,I,199804.0,20011121.0,20170915,20170915,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-11598133,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20170915.0,,MD,JP,JP,EFAVIRENZ,Acute kidney injury;Amylase increased;Death;Diarrhoea;Hyperlactacidaemia;Hyperlipidaemia;Lactic acidosis;Neuropathy peripheral;Pancreatitis acute,139778261.0,OT,,,139778261.0,1.0,19950801.0,20001208.0,,,139778261.0,1.0,Acquired immunodeficiency syndrome
13980436,139804362,2,F,,20180126.0,20170918,20180203,EXP,,UG-HETERO CORPORATE-HET2017UG00185,HETERO,,28.0,YR,,F,Y,,,20180203.0,,OT,UG,UG,EFAVIRENZ.,Drug-induced liver injury;Exposure during pregnancy;Foetal death,139804362.0,OT,,,139804362.0,1.0,20170309.0,20170313.0,,,139804362.0,1.0,HIV infection
13984466,139844667,7,F,20170901.0,20171009.0,20170918,20180706,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-083133,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180706.0,,OT,BR,BR,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery;Urinary tract infection,139844667.0,OT,,,139844667.0,1.0,20170629.0,20170907.0,,,139844667.0,1.0,HIV infection
13990215,139902151,1,I,,20170913.0,20170920,20170920,EXP,,FR-GLAXOSMITHKLINE-FR2017GSK145845,GLAXOSMITHKLINE,,67.0,YR,,F,Y,,,20170920.0,,MD,FR,FR,EFAVIRENZ,Drug ineffective;Renal failure;Virologic failure,139902151.0,OT,,,,,,,,,139902151.0,1.0,HIV infection
13990283,139902831,1,I,20170509.0,20170913.0,20170920,20170920,EXP,,UG-GLAXOSMITHKLINE-UG2017GSK145019,GLAXOSMITHKLINE,,28.0,YR,,F,Y,,,20170920.0,,CN,US,UG,EFAVIRENZ,Exposure during pregnancy;Hepatotoxicity;Stillbirth,139902831.0,OT,,,139902831.0,1.0,20170314.0,20170313.0,,,139902831.0,1.0,HIV infection
13990685,139906851,1,I,,20170913.0,20170920,20170920,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK145845,VIIV,,67.0,YR,,F,Y,,,20170920.0,,MD,FR,FR,EFAVIRENZ,Drug ineffective;Renal failure;Virologic failure,139906851.0,OT,,,,,,,,,139906851.0,1.0,HIV infection
13990715,139907151,1,I,20170509.0,20170913.0,20170920,20170920,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017GSK145019,VIIV,,28.0,YR,,F,Y,,,20170920.0,,CN,US,UG,EFAVIRENZ,Exposure during pregnancy;Hepatotoxicity;Stillbirth,139907151.0,OT,,,139907151.0,1.0,20170314.0,20170313.0,,,139907151.0,1.0,HIV infection
13994608,139946084,4,F,,20171003.0,20170921,20171012,EXP,,UG-HETERO CORPORATE-HET2017UG00184,HETERO,,,,,M,Y,3.0,KG,20171012.0,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly;Syndactyly,139946084.0,CA,,,139946084.0,1.0,20170530.0,,,,139946084.0,1.0,HIV infection
14012510,140125101,1,I,2014.0,20170823.0,20170926,20170926,PER,,US-ABBVIE-17P-163-2082230-00,ABBVIE,,54.0,YR,,M,Y,96.6,KG,20170926.0,,MD,US,US,SUSTIVA,Amnesia;Drug dose omission;Memory impairment,,,,,140125101.0,1.0,1999.0,20141118.0,,,140125101.0,1.0,HIV infection
14012522,140125224,4,F,20170914.0,20171003.0,20170926,20171005,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-085358,BRISTOL MYERS SQUIBB,,0.0,DY,,F,Y,2.7,KG,20171005.0,,OT,BR,BR,EFAVIRENZ.,Congenital syphilis;Foetal exposure during pregnancy,140125224.0,OT,,,140125224.0,1.0,20170503.0,20170517.0,,,140125224.0,1.0,Prophylaxis against HIV infection
14015494,140154941,1,I,20170827.0,20170918.0,20170927,20170927,EXP,PT-INFARMED-J201709-4,PT-TEVA-808793ISR,TEVA,,62.0,YR,,M,Y,60.0,KG,20170927.0,,PH,PT,PT,EFAVIRENZ TEVA,Abdominal distension;Abnormal dreams;Diarrhoea;Fatigue;Nightmare;Product substitution issue,140154941.0,OT,,,140154941.0,1.0,20170622.0,,,,140154941.0,1.0,HIV infection
14017096,140170963,3,F,20170509.0,20181129.0,20170927,20181206,EXP,,UG-MYLANLABS-2017M1058627,MYLAN,,,,,M,Y,3.0,KG,20181206.0,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Stillbirth,140170963.0,OT,,,140170963.0,1.0,20170309.0,20170313.0,,,140170963.0,1.0,HIV infection
14017101,140171012,2,F,,20181129.0,20170927,20181210,EXP,,UG-MYLANLABS-2017M1058622,MYLAN,,,,,M,Y,3.0,KG,20181210.0,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly;Syndactyly,140171012.0,CA,,,140171012.0,1.0,20170530.0,,,,140171012.0,1.0,HIV infection
14017893,140178932,2,F,2017.0,20171002.0,20170928,20171011,EXP,,UG-AUROBINDO-AUR-APL-2017-40567,AUROBINDO,,,,,M,Y,,,20171011.0,,MD,UG,UG,Efavirenz 600mg,Foetal exposure during pregnancy;Polydactyly;Syndactyly,140178932.0,OT,,,140178932.0,1.0,20170530.0,,,,140178932.0,1.0,HIV infection
14018138,140181382,2,F,,20180126.0,20170928,20180208,EXP,,UG-CIPLA LTD.-2017UG17389,CIPLA,,,,,,Y,,,20180208.0,,CN,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,140181382.0,OT,,,140181382.0,1.0,20170309.0,20170313.0,,,140181382.0,1.0,HIV infection
14024343,140243431,1,I,20170801.0,20170928.0,20170929,20170929,EXP,GB-MHRA-EYC 00163243,GB-VIIV HEALTHCARE LIMITED-GB2017150413,VIIV,,26.0,YR,,F,Y,68.0,KG,20170929.0,,MD,GB,GB,EFAVIRENZ,Acute kidney injury;Feeling hot;Flushing;Hypersensitivity;Hypotension;Liver function test increased;Ocular hyperaemia;Oral discomfort;Vomiting,140243431.0,HO,,,140243431.0,1.0,20170801.0,20170802.0,,,140243431.0,1.0,Asymptomatic HIV infection
14025378,140253781,1,I,20170801.0,20170928.0,20170929,20170929,EXP,GB-MHRA-EYC 00163243,GB-GLAXOSMITHKLINE-GB2017150413,GLAXOSMITHKLINE,,26.0,YR,,F,Y,68.0,KG,20170929.0,,MD,GB,GB,EFAVIRENZ,Acute kidney injury;Feeling hot;Flushing;Hypersensitivity;Hypotension;Liver function test increased;Ocular hyperaemia;Oral discomfort;Vomiting,140253781.0,HO,,,140253781.0,1.0,20170801.0,20170802.0,,,140253781.0,1.0,Asymptomatic HIV infection
14026571,140265712,2,F,,20190422.0,20170929,20190507,EXP,,US-CIPLA LTD.-2017US17668,CIPLA,"ALI MS, KOORAGAYALU S, MBA BI, OLSEN FC. ISOLATED MYOPATHY: AN UNUSUAL MANIFESTATION OF INHALED FLUTICASONE PROPIONATE AND RITONAVIR INTERACTION.. ARCHIVOS DE BRONCONEUMOLOGIA. 2019;55 (4):223 TO 225",,,,,Y,,,20190507.0,,,COUNTRY NOT SPECIFIED,US,EFAVIRENZ.,Drug interaction;Fall;Myopathy;Toxicity to various agents,140265712.0,HO,,,,,,,,,140265712.0,1.0,Antiretroviral therapy
14028106,140281061,1,I,,,20170929,20170929,DIR,US-FDA-385008,,FDA-CTU,,,,,M,N,67.5,KG,20170929.0,N,PH,US,US,efavirenz,Diarrhoea;Fatigue;Pyrexia;Weight decreased,,,140281061.0,HP,140281061.0,1.0,20170213.0,20170406.0,,,140281061.0,1.0,HIV infection
14030173,140301731,1,I,,20170923.0,20171002,20171002,EXP,,TR-GILEAD-2017-0295675,GILEAD,,53.0,YR,A,M,Y,,,20171002.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,140301731.0,OT,,,140301731.0,1.0,200906.0,,,,140301731.0,1.0,HIV infection
14032879,140328791,1,I,20170222.0,20170928.0,20171002,20171002,EXP,GB-MHRA-EYC 00165806,GB-GILEAD-2017-0296004,GILEAD,,51.0,YR,A,M,Y,,,20171002.0,,MD,GB,GB,EFAVIRENZ.,Gynaecomastia;Pain;Product substitution issue,140328791.0,OT,,,140328791.0,1.0,201702.0,20170510.0,,,140328791.0,1.0,HIV infection
14035414,140354141,1,I,,20170925.0,20171003,20171003,EXP,,CN-GILEAD-2017-0295887,GILEAD,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J, WANG H, ZHU Y, WANG Y, LI X, GU S, TAN Z, CHEN H, LUO X, ZHU W, LU W, XU P, LI M, CHEN Y, GAO Y, YANG R, ZHU C, SUN B. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NAIVE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;32:271-279",,,,,Y,,,20171003.0,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,140354141.0,OT,,,140354141.0,1.0,20150819.0,,,,140354141.0,1.0,HIV infection
14035415,140354151,1,I,,20170925.0,20171003,20171003,EXP,,CN-GILEAD-2017-0295885,GILEAD,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J, WANG H, ZHU Y, WANG Y, LI X, GU S, TAN Z, CHEN H, LUO X, ZHU W, LU W, XU P, LI M, CHEN Y, GAO Y, YANG R, ZHU C, SUN B. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NAIVE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;32:271-279",,,,,Y,,,20171003.0,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,140354151.0,OT,,,140354151.0,1.0,20150930.0,,,,140354151.0,1.0,HIV infection
14035416,140354161,1,I,,20170925.0,20171003,20171003,EXP,,CN-GILEAD-2017-0295886,GILEAD,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J, WANG H, ZHU Y, WANG Y, LI X, GU S, TAN Z, CHEN H, LUO X, ZHU W, LU W, XU P, LI M, CHEN Y, GAO Y, YANG R, ZHU C, SUN B. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NAIVE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;32:271-279",,,,,Y,,,20171003.0,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,140354161.0,OT,,,,,,,,,140354161.0,1.0,HIV infection
14035417,140354171,1,I,,20170925.0,20171003,20171003,EXP,,CN-GILEAD-2017-0295884,GILEAD,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J, WANG H, ZHU Y, WANG Y, LI X, GU S, TAN Z, CHEN H, LUO X, ZHU W, LU W, XU P, LI M, CHEN Y, GAO Y, YANG R, ZHU C, SUN B. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NAIVE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;32:271-279",,,,,Y,,,20171003.0,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,140354171.0,OT,,,140354171.0,1.0,20150209.0,,,,140354171.0,1.0,HIV infection
14035438,140354381,1,I,,20170925.0,20171003,20171003,EXP,,CN-GILEAD-2017-0295888,GILEAD,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J, WANG H, ZHU Y, WANG Y, LI X, GU S, TAN Z, CHEN H, LUO X, ZHU W, LU W, XU P, LI M, CHEN Y, GAO Y, YANG R, ZHU C, SUN B. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NAIVE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;32:271-279",,,,,Y,,,20171003.0,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,140354381.0,OT,,,140354381.0,1.0,20150701.0,,,,140354381.0,1.0,HIV infection
14038998,140389982,2,F,,20171002.0,20171004,20171005,EXP,,BR-GLAXOSMITHKLINE-BR2017152693,GLAXOSMITHKLINE,"ABALEM MF, CARRICONDO PC, RAO RC. BULLSEYE RETINOPATHY FROM ANTIRETROVIRAL THERAPY. OPHTHALMOLOGY. 2017;124(10):1539.",58.0,YR,,M,Y,,,20171005.0,,MD,BR,BR,EFAVIRENZ.,Maculopathy;Toxicity to various agents,140389982.0,OT,,,,,,,,,140389982.0,1.0,Antiretroviral therapy
14039074,140390742,2,F,,20171002.0,20171004,20171005,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017152693,VIIV,"ABALEM MF, CARRICONDO PC, RAO RC. BULLSEYE RETINOPATHY FROM ANTIRETROVIRAL THERAPY. OPHTHALMOLOGY. 2017;124(10):1539.",58.0,YR,,M,Y,,,20171005.0,,MD,BR,BR,EFAVIRENZ.,Maculopathy;Toxicity to various agents,140390742.0,OT,,,,,,,,,140390742.0,1.0,Antiretroviral therapy
14041635,140416351,1,I,20170918.0,20170921.0,20171004,20171004,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-088435,BRISTOL MYERS SQUIBB,,6.0,YR,,F,Y,16.3,KG,20171004.0,,OT,ZA,ZA,EFAVIRENZ.,Neutropenia,140416351.0,OT,,,140416351.0,1.0,20170802.0,,,,140416351.0,1.0,HIV infection
14045054,140450543,3,F,201709.0,20171201.0,20171005,20171205,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-088505,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20171205.0,,OT,US,US,EFAVIRENZ.,Fall;Gestational hypertension;Live birth;Maternal exposure during pregnancy,140450543.0,OT,,,140450543.0,1.0,20170620.0,20170921.0,,,140450543.0,1.0,HIV infection
14046358,140463581,1,I,20170906.0,20170923.0,20171005,20171005,EXP,,GB-AUROBINDO-AUR-APL-2017-41440,AUROBINDO,,,,,,Y,,,20171005.0,,PH,GB,GB,EFAVIRENZ FILM-COATED TABLET,Death neonatal;Maternal drugs affecting foetus;Premature baby,140463581.0,DE,,,140463581.0,1.0,20170901.0,,,,140463581.0,1.0,Acute HIV infection
14046877,140468772,2,F,,20171002.0,20171005,20171015,EXP,,UG-MYLANLABS-2017M1061195,MYLAN,,,,,M,Y,3.0,KG,20171010.0,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly;Syndactyly,140468772.0,OT,,,140468772.0,1.0,20170530.0,,,,140468772.0,1.0,HIV infection
14056407,140564074,4,F,20170924.0,20171201.0,20171006,20171205,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-088344,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20171205.0,,OT,US,US,EFAVIRENZ.,Acidosis;Bradycardia foetal;Feeding intolerance;Floppy infant;Foetal exposure during pregnancy;Generalised oedema;Hypoxic-ischaemic encephalopathy;Neonatal respiratory distress syndrome;Partial seizures;Patent ductus arteriosus;Pulmonary arterial hypertension;Umbilical cord around neck,140564074.0,LT,,,140564074.0,1.0,20170620.0,20170921.0,,,140564074.0,1.0,Prophylaxis against HIV infection
14060939,140609391,1,I,20170801.0,20170928.0,20171007,20171007,EXP,,GB-AUROBINDO-AUR-APL-2017-41480,AUROBINDO,,26.0,YR,,F,Y,68.0,KG,20171007.0,,MD,GB,GB,EFAVIRENZ.,Acute kidney injury;Feeling hot;Flushing;Hypersensitivity;Hypotension;Liver function test increased;Ocular hyperaemia;Oral discomfort;Vomiting,140609391.0,LT,,,140609391.0,1.0,20170801.0,20170802.0,,,140609391.0,1.0,Asymptomatic HIV infection
14070062,140700621,1,I,20170801.0,20170928.0,20171010,20171010,EXP,GB-MHRA-EYC 00163243,GB-TEVA-812023ACC,TEVA,,26.0,YR,,F,Y,68.0,KG,20171010.0,,MD,GB,GB,EFAVIRENZ.,Acute kidney injury;Feeling hot;Flushing;Hypersensitivity;Hypotension;Liver function test increased;Ocular hyperaemia;Oral discomfort;Vomiting,140700621.0,HO,,,140700621.0,1.0,20170801.0,20170802.0,,,140700621.0,1.0,Asymptomatic HIV infection
14074500,140745002,2,F,201512.0,20171030.0,20171011,20171101,EXP,,SE-VIIV HEALTHCARE LIMITED-SE2017GSK144183,VIIV,,50.0,YR,,F,Y,,,20171101.0,,MD,SE,SE,EFAVIRENZ.,Headache;Insomnia;Progressive multifocal leukoencephalopathy,140745002.0,DE,,,140745002.0,1.0,20150723.0,20160210.0,,,140745002.0,1.0,HIV infection
14075128,140751281,1,I,20170801.0,20170928.0,20171011,20171011,EXP,GB-MHRA-EYC 00163243,GB-MYLANLABS-2017M1062491,MYLAN,,26.0,YR,,F,Y,68.0,KG,20171006.0,,MD,GB,GB,EFAVIRENZ.,Acute kidney injury;Feeling hot;Flushing;Hypersensitivity;Hypotension;Liver function test increased;Ocular hyperaemia;Oral discomfort;Vomiting,140751281.0,OT,,,140751281.0,1.0,20170801.0,20170802.0,,,140751281.0,1.0,Asymptomatic HIV infection
14075248,140752481,1,I,20170402.0,20170928.0,20171011,20171011,EXP,GB-MHRA-EYC 00165806,GB-MYLANLABS-2017M1062501,MYLAN,,51.0,YR,,M,Y,,,20171005.0,,MD,GB,GB,EFAVIRENZ.,Gynaecomastia;Pain;Product substitution issue,140752481.0,OT,,,140752481.0,1.0,20170222.0,20170510.0,,,140752481.0,1.0,HIV infection
14080633,140806331,1,I,20020909.0,20030131.0,20171012,20171012,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12181145,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20171012.0,,CN,JP,JP,EFAVIRENZ.,Dysgeusia;Pancytopenia,140806331.0,LT,,,140806331.0,1.0,20020906.0,20020918.0,,,140806331.0,1.0,HIV infection
14080637,140806371,1,I,200802.0,20100810.0,20171012,20171012,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-15237464,BRISTOL MYERS SQUIBB,,36.0,YR,,M,Y,,,20171012.0,,CN,JP,JP,EFAVIRENZ.,Depression;Suicide attempt,140806371.0,OT,,,140806371.0,1.0,20060615.0,20080204.0,,,140806371.0,1.0,HIV infection
14092647,140926471,1,I,,20171011.0,20171016,20171016,EXP,,UY-VIIV HEALTHCARE LIMITED-UY2017GSK158330,VIIV,"SANTOS GD, ET AL.. S?NDROME HEMOFAGOC?TICO: UNA RARA COMPLICACI?N EN EL PACIENTE CON INFECCI?N POR EL VIRUS DE INMUNODEFICIENCIA HUMANA (VIH). REV. URUG. MED. INTERNA. 2017;2 (1):25-31",24.0,YR,,F,Y,36.0,KG,20171016.0,,MD,UY,UY,EFAVIRENZ.,Histiocytosis haematophagic;Treatment noncompliance,140926471.0,OT,,,,,,,,,140926471.0,1.0,HIV infection
14096861,140968612,2,F,,20171031.0,20171017,20171103,EXP,,FR-HETERO-HET2017FR00263,HETERO,,,,,,Y,,,20171103.0,,OT,FR,FR,SUSTIVA,Exposure during pregnancy;Small for dates baby,140968612.0,OT,,,140968612.0,4.0,20150608.0,20150608.0,,,140968612.0,1.0,HIV infection
14098128,140981281,1,I,,20171010.0,20171017,20171017,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-092783,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,,,20171017.0,,OT,ZA,ZA,EFAVIRENZ.,Lipodystrophy acquired,140981281.0,OT,,,,,,,,,140981281.0,1.0,HIV infection
14099580,140995801,1,I,,20171009.0,20171017,20171017,EXP,,IN-GILEAD-2017-0299069,GILEAD,"MUKHERJEE S, ERA N, SAHA B, TRIPATHI SK. ADVERSE DRUG REACTION MONITORING IN PATIENTS ON ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL IN EASTERN INDIA. INDIAN JOURNAL OF PHARMACOLOGY. 2017;49 (3):223-228",,,A,,Y,,,20171017.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,140995801.0,HO,,,,,,,,,140995801.0,1.0,HIV infection
14099659,140996591,1,I,,20171009.0,20171017,20171017,EXP,,IN-GILEAD-2017-0299501,GILEAD,"MUKHERJEE S, ERA N, SAHA B, TRIPATHI SK. ADVERSE DRUG REACTION MONITORING IN PATIENTS ON ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL IN EASTERN INDIA. INDIAN JOURNAL OF PHARMACOLOGY. 2017;49 (3):223-228",,,A,,Y,,,20171017.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,140996591.0,HO,,,,,,,,,140996591.0,1.0,HIV infection
14102609,141026091,1,I,,20171010.0,20171018,20171018,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-092772,BRISTOL MYERS SQUIBB,SACOOR MF. DISSEMINATED CUTANEOUS HISTOPLASMOSIS WITH LARYNGEAL INVOLVEMENT IN A SETTING OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2017;18(1):A693,39.0,YR,,M,Y,,,20171018.0,,OT,ZA,ZA,EFAVIRENZ.,Histoplasmosis disseminated;Immune reconstitution inflammatory syndrome,141026091.0,HO,,,,,,,,,141026091.0,1.0,HIV infection
14102752,141027521,1,I,,20171013.0,20171018,20171018,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2017159869,VIIV,"AMPONSAH-DACOSTA E, RAKGOLE JN, GEDEDZHA MP, LUKHWARENI A, BLACKARD JT, SELABE SG, ET AL. EVIDENCE OF SUSCEPTIBILITY TO LAMIVUDINE-BASED HAART AND GENETIC STABILITY OF HEPATITIS B VIRUS (HBV) IN HIV CO-INFECTED PATIENTS: A SOUTH AFRICAN LONGITUDINAL HBV WHOLE GENOME STUDY. INFECTION, GENETICS AND EVOLUTION. 2016;43:232-238",44.0,YR,,M,Y,,,20171018.0,,OT,ZA,ZA,EFAVIRENZ.,Liver injury,141027521.0,OT,,,,,,,,,141027521.0,1.0,Antiretroviral therapy
14102786,141027861,1,I,,20171009.0,20171018,20171018,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017159510,VIIV,"MUKHERJEE S, ERA N, SAHA B, TRIPATHI SK.. ADVERSE DRUG REACTION MONITORING IN PATIENTS ON ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL IN EASTERN INDIA.. INDIAN JOURNAL OF PHARMACOLOGY.. 2017;49 (3):223-228",,,A,,Y,,,20171018.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,141027861.0,OT,,,,,,,,,141027861.0,1.0,HIV infection
14102787,141027871,1,I,,20171009.0,20171018,20171018,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017159504,VIIV,"MUKHERJEE S, ERA N, SAHA B, TRIPATHI SK. ADVERSE DRUG REACTION MONITORING IN PATIENTS ON ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL IN EASTERN INDIA. INDIAN JOURNAL OF PHARMACOLOGY. 2017;49 (3):223-228",,,A,,Y,,,20171018.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,141027871.0,HO,,,,,,,,,141027871.0,1.0,HIV infection
14102832,141028321,1,I,,20171009.0,20171018,20171018,EXP,,IN-GLAXOSMITHKLINE-IN2017159510,GLAXOSMITHKLINE,"MUKHERJEE S, ERA N, SAHA B, TRIPATHI SK.. ADVERSE DRUG REACTION MONITORING IN PATIENTS ON ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL IN EASTERN INDIA.. INDIAN JOURNAL OF PHARMACOLOGY.. 2017;49 (3):223-228",,,A,,Y,,,20171018.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,141028321.0,OT,,,,,,,,,141028321.0,1.0,HIV infection
14102848,141028481,1,I,,20171009.0,20171018,20171018,EXP,,IN-GLAXOSMITHKLINE-IN2017159504,GLAXOSMITHKLINE,"MUKHERJEE S, ERA N, SAHA B, TRIPATHI SK. ADVERSE DRUG REACTION MONITORING IN PATIENTS ON ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL IN EASTERN INDIA. INDIAN JOURNAL OF PHARMACOLOGY. 2017;49 (3):223-228",,,A,,Y,,,20171018.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,141028481.0,HO,,,,,,,,,141028481.0,1.0,HIV infection
14102851,141028511,1,I,,20171013.0,20171018,20171018,EXP,,ZA-GLAXOSMITHKLINE-ZA2017159869,GLAXOSMITHKLINE,"AMPONSAH-DACOSTA E, RAKGOLE JN, GEDEDZHA MP, LUKHWARENI A, BLACKARD JT, SELABE SG, ET AL. EVIDENCE OF SUSCEPTIBILITY TO LAMIVUDINE-BASED HAART AND GENETIC STABILITY OF HEPATITIS B VIRUS (HBV) IN HIV CO-INFECTED PATIENTS: A SOUTH AFRICAN LONGITUDINAL HBV WHOLE GENOME STUDY. INFECTION, GENETICS AND EVOLUTION. 2016;43:232-238",44.0,YR,,M,Y,,,20171018.0,,OT,ZA,ZA,EFAVIRENZ.,Liver injury,141028511.0,OT,,,,,,,,,141028511.0,1.0,Antiretroviral therapy
14107276,141072762,2,F,,20171005.0,20171018,20180530,EXP,,US-MYLANLABS-2017M1064617,MYLAN,BHOGAL S. TENOFOVIR-INDUCED FANCONI SYNDROME PRESENTING AS HYPOKALEMIC PERIODIC PARALYSIS. AM-J-THER 2017;24(5):E617-E618.,54.0,YR,,F,Y,,,20180530.0,,MD,US,US,EFAVIRENZ.,Fall;Fanconi syndrome acquired,141072762.0,OT,,,,,,,,,141072762.0,1.0,HIV infection
14107673,141076733,3,F,20171013.0,20180221.0,20171019,20180226,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-094025,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180226.0,,OT,BR,BR,EFAVIRENZ.,Foetal distress syndrome;Foetal exposure during pregnancy;Premature baby,141076733.0,OT,,,141076733.0,1.0,20170810.0,20171013.0,,,141076733.0,1.0,Prophylaxis against HIV infection
14107707,141077073,3,F,20170824.0,20180221.0,20171019,20180226,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-088415,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,56.0,KG,20180226.0,,OT,BR,BR,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery;Premature labour;Vulvovaginal candidiasis,141077073.0,OT,,,141077073.0,1.0,20170810.0,20170922.0,,,141077073.0,1.0,HIV infection
14111103,141111033,3,F,,20180112.0,20171020,20180119,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK161427,VIIV,,37.0,YR,,F,Y,,,20180119.0,,CN,US,FR,SUSTIVA,Beta haemolytic streptococcal infection;Cytomegalovirus enterocolitis;Headache;Hepatitis B;Live birth;Maternal exposure during pregnancy;Metrorrhagia;Placental disorder;Pulmonary arterial hypertension;Threatened labour;Uterine contractions during pregnancy,141111033.0,OT,,,141111033.0,3.0,20150608.0,20150608.0,,,141111033.0,1.0,HIV infection
14111106,141111064,4,F,20150608.0,20180713.0,20171020,20180726,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK161303,VIIV,,0.0,DY,,M,Y,3.0,KG,20180726.0,,CN,US,FR,SUSTIVA,Atrophy;Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,141111064.0,CA,,,141111064.0,3.0,20150608.0,20150608.0,,,141111064.0,1.0,HIV infection
14111220,141112203,3,F,,20180112.0,20171020,20180119,EXP,,FR-GLAXOSMITHKLINE-FR2017GSK161427,GLAXOSMITHKLINE,,37.0,YR,,F,Y,,,20180119.0,,CN,US,FR,SUSTIVA,Beta haemolytic streptococcal infection;Cytomegalovirus enterocolitis;Headache;Hepatitis B;Live birth;Maternal exposure during pregnancy;Metrorrhagia;Placental disorder;Pulmonary arterial hypertension;Threatened labour;Uterine contractions during pregnancy,141112203.0,HO,,,141112203.0,3.0,20150608.0,20150608.0,,,141112203.0,1.0,HIV infection
14111227,141112274,4,F,20150608.0,20180713.0,20171020,20180726,EXP,,FR-GLAXOSMITHKLINE-FR2017GSK161303,GLAXOSMITHKLINE,,0.0,DY,,M,Y,3.0,KG,20180726.0,,CN,US,FR,SUSTIVA,Atrophy;Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,141112274.0,CA,,,141112274.0,3.0,20150608.0,20150608.0,,,141112274.0,1.0,HIV infection
14111910,141119101,1,I,,20171010.0,20171020,20171020,EXP,,ZA-MYLANLABS-2017M1065701,MYLAN,SACOOR MF. DISSEMINATED CUTANEOUS HISTOPLASMOSIS WITH LARYNGEAL INVOLVEMENT IN A SETTING OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. SOUTH-AFR-J-HIV-MED 2017;18(1):A693.,39.0,YR,,M,Y,,,20171019.0,,OT,ZA,ZA,EFAVIRENZ.,Histoplasmosis disseminated;Immune reconstitution inflammatory syndrome,141119101.0,OT,,,,,,,,,141119101.0,1.0,HIV infection
14111911,141119111,1,I,,20171010.0,20171020,20171020,EXP,,ZA-MYLANLABS-2017M1065734,MYLAN,"MITHA M, CUPIDO G, TALJAARD J. A RARE PHENOMENON OF ATYPICAL LIPODYSTROPHY IN A PATIENT ON HAART IN THE ABSENCE OF A PROTEASE INHIBITOR REGIMEN. SOUTH-AFR-J-HIV-MED 2010;11(2):37-38.",45.0,YR,,M,Y,,,20171019.0,,OT,ZA,ZA,EFAVIRENZ.,Lipodystrophy acquired,141119111.0,OT,,,,,,,,,141119111.0,1.0,HIV infection
14117376,141173764,4,F,201404.0,20180117.0,20171023,20180119,EXP,,IT-GILEAD-2017-0300028,GILEAD,,27.0,YR,A,F,Y,,,20180119.0,,CN,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,141173764.0,OT,,,141173764.0,1.0,201505.0,201404.0,,,141173764.0,1.0,HIV infection
14117624,141176243,3,F,20170913.0,20171111.0,20171023,20171115,EXP,,TZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-094278,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20171115.0,,OT,TZ,TZ,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,141176243.0,OT,,,141176243.0,1.0,20170831.0,,,,141176243.0,1.0,HIV infection
14119209,141192091,1,I,,20171016.0,20171024,20171024,EXP,,ZA-HETERO-HET2017ZA00288,HETERO,"MOHAMMED MITHA, GORDON CUPIDO, JANTJIE TALJAARD.. A RARE PHENOMENON OF ATYPICAL LIPODYSTROPHY IN A PATIENT ON HAART IN THE ABSENCE OF A PROTEASE INHIBITOR REGIMEN.. SOUTH-AFR-J-HIV-MED. 2010;11(2):37-38",,,,,Y,,,20171024.0,,MD,ZA,ZA,EFAVIRENZ.,Lipodystrophy acquired;Tuberculosis,141192091.0,OT,,,,,,,,,141192091.0,1.0,HIV infection
14119498,141194981,1,I,,20171016.0,20171024,20171024,EXP,,ZA-HETERO-HET2017ZA00286,HETERO,MOHAMED F. SACOOR. DISSEMINATED CUTANEOUS HISTOPLASMOSIS WITH LARYNGEAL INVOLVEMENT IN A SETTING OF IMMUNE RECONSTITUTION  INFLAMMATORY SYNDROME. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2017;18(1):A693,39.0,YR,,M,Y,,,20171024.0,,OT,ZA,ZA,EFAVIRENZ.,Histoplasmosis disseminated;Immune reconstitution inflammatory syndrome,141194981.0,OT,,,,,,,,,141194981.0,1.0,HIV infection
14121935,141219351,1,I,,20171012.0,20171024,20171024,EXP,,FR-MYLANLABS-2017M1066017,MYLAN,,,,I,M,Y,,,20171022.0,,OT,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby,141219351.0,CA,,,141219351.0,4.0,20150608.0,20150608.0,,,141219351.0,1.0,HIV infection
14121936,141219364,4,F,20150430.0,20190711.0,20171024,20190924,EXP,,UG-MYLANLABS-2017M1066016,MYLAN,,37.0,YR,,F,Y,,,20190924.0,,MD,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Headache;Hypertension;Metrorrhagia;Pre-eclampsia;Uterine hypotonus,141219364.0,HO,,,141219364.0,4.0,20150608.0,20150608.0,,,141219364.0,1.0,HIV infection
14122591,141225911,1,I,,20171016.0,20171024,20171024,EXP,,MW-GILEAD-2017-0300071,GILEAD,"DADABHAI S, GADAMA L, CHAMANGA R, KAWALAZIRA R, KATUMBI C, DULA D, SINGINI I, DEGNAN L, KAMANGA M, LAU B, TAHA TE. PREGNANCY OUTCOMES AND INFANT SURVIVAL IN THE ERA OF UNIVERSAL HAART IN AFRICA: THE POISE STUDY. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2017;20:74",,,I,,Y,,,20171024.0,,OT,MW,MW,EFAVIRENZ.,Death,141225911.0,DE,,,,,,,,,141225911.0,1.0,HIV infection
14122867,141228672,2,F,20171013.0,20171108.0,20171024,20171110,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-095169,BRISTOL MYERS SQUIBB,,0.0,DY,,F,Y,2.91,KG,20171110.0,,OT,BR,BR,EFAVIRENZ.,Congenital syphilis;Foetal exposure during pregnancy;Premature baby,141228672.0,OT,,,141228672.0,1.0,20170810.0,20170816.0,,,141228672.0,1.0,Prophylaxis against HIV infection
14123977,141239773,3,F,,20190125.0,20171025,20190208,EXP,,FR-AUROBINDO-AUR-APL-2017-42195,AUROBINDO,,37.0,YR,,F,Y,,,20190208.0,,MD,FR,FR,SUSTIVA,Headache;Hypertension;Metrorrhagia;Pre-eclampsia,141239773.0,HO,,,141239773.0,5.0,20150608.0,20150608.0,,,141239773.0,1.0,HIV infection
14124663,141246631,1,I,,20171024.0,20171025,20171025,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-095932,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20171025.0,,CN,US,US,SUSTIVA,Chapped lips;Lip pain,,,,,,,,,,,141246631.0,1.0,HIV infection
14124826,141248261,1,I,,20171012.0,20171025,20171025,EXP,,CA-MYLANLABS-2017M1066508,MYLAN,"HAJEK J, OUMA S, HEMMETT J, STARKO R, APIYO P. CHEST DEFORMITY AND DISABILITY DUE TO TENOFOVIR-INDUCED HYPOPHOSPHATEMIC OSTEOMALACIA: CASE REPORT AND CALL FOR IMPROVED GLOBAL ACCESS TO LABORATORY TESTING. J-INT-ASSOC-PROVID-AIDS-CARE 2017;16(5):430-432.",45.0,YR,,M,Y,,,20171025.0,,OT,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,141248261.0,HO,,,141248261.0,1.0,2007.0,,,,141248261.0,1.0,HIV infection
14125221,141252211,1,I,20010224.0,20171017.0,20171025,20171025,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-095241,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20171025.0,,OT,US,US,EFAVIRENZ.,Guillain-Barre syndrome;Pneumonia aspiration;Respiratory failure,141252211.0,LT,,,141252211.0,1.0,20010129.0,20010226.0,,,141252211.0,1.0,HIV infection
14125380,141253801,1,I,,20171016.0,20171025,20171025,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2017163275,VIIV,"DADABHAI S, GADAMA L, CHAMANGA R, KAWALAZIRA R, KATUMBI C, DULA D, SINGINI I, DEGNAN L, KAMANGA M, LAU B, TAHA TE. PREGNANCY OUTCOMES AND INFANT SURVIVAL IN THE ERA OF UNIVERSAL HAART IN AFRICA: THE POISE STUDY. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2017;20:74",,,I,,Y,,,20171025.0,,OT,MW,MW,EFAVIRENZ.,Death,141253801.0,DE,,,,,,,,,141253801.0,1.0,HIV infection
14125532,141255321,1,I,,20171016.0,20171025,20171025,EXP,,MW-GLAXOSMITHKLINE-MW2017163275,GLAXOSMITHKLINE,"DADABHAI S, GADAMA L, CHAMANGA R, KAWALAZIRA R, KATUMBI C, DULA D, SINGINI I, DEGNAN L, KAMANGA M, LAU B, TAHA TE. PREGNANCY OUTCOMES AND INFANT SURVIVAL IN THE ERA OF UNIVERSAL HAART IN AFRICA: THE POISE STUDY. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2017;20:74",,,I,,Y,,,20171025.0,,OT,MW,MW,EFAVIRENZ.,Death,141255321.0,DE,,,,,,,,,141255321.0,1.0,HIV infection
14125839,141258392,2,F,201503.0,20171031.0,20171025,20171102,EXP,,JP-GILEAD-2017-0300551,GILEAD,HAYAKAWA Y. A CASE OF CHEMORADIOTHERAPY FOR ADVANCED ESOPHAGEAL CANCER ASSOCIATED WITH HIV-1 INFECTION.. UNK. 2017;UNK:UNK,77.0,YR,E,F,Y,,,20171102.0,,MD,JP,JP,EFAVIRENZ.,Dysphagia;Oesophageal carcinoma,141258392.0,DE,,,,,,,,,141258392.0,1.0,HIV infection
14132073,141320734,4,F,20150608.0,20180711.0,20171027,20180726,EXP,,FR-AUROBINDO-AUR-APL-2017-42194,AUROBINDO,,0.0,DY,,M,Y,2.64,KG,20180726.0,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,141320734.0,CA,,,141320734.0,5.0,20150608.0,20150608.0,,,141320734.0,1.0,HIV infection
14132606,141326063,3,F,,20171031.0,20171027,20181224,EXP,,FR-CIPLA LTD.-2017FR18490,CIPLA,,,,,,Y,,,20181224.0,,CN,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Headache;Hypertension;Metrorrhagia,141326063.0,HO,,,141326063.0,2.0,20150608.0,20150608.0,,,141326063.0,1.0,HIV infection
14145931,141459311,1,I,,20171026.0,20171031,20171031,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017166253,VIIV,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",38.0,YR,,F,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141459311.0,OT,,,,,,,,,141459311.0,1.0,HIV infection
14145932,141459321,1,I,,20171026.0,20171031,20171031,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017166255,VIIV,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",51.0,YR,,M,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141459321.0,OT,,,,,,,,,141459321.0,1.0,HIV infection
14145935,141459352,2,F,,20180420.0,20171031,20180430,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017166264,VIIV,,44.0,YR,,F,Y,,,20180430.0,,OT,DE,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,141459352.0,OT,,,,,,,,,141459352.0,1.0,HIV infection
14145936,141459361,1,I,,20171026.0,20171031,20171031,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017166251,VIIV,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",25.0,YR,,F,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141459361.0,OT,,,,,,,,,141459361.0,1.0,HIV infection
14145939,141459391,1,I,,20171026.0,20171031,20171031,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017166265,VIIV,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",35.0,YR,,F,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141459391.0,OT,,,,,,,,,141459391.0,1.0,HIV infection
14146006,141460062,2,F,,20180420.0,20171031,20180430,EXP,,ET-GLAXOSMITHKLINE-ET2017166264,GLAXOSMITHKLINE,,44.0,YR,,F,Y,,,20180430.0,,OT,DE,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,141460062.0,OT,,,,,,,,,141460062.0,1.0,HIV infection
14146007,141460071,1,I,,20171026.0,20171031,20171031,EXP,,ET-GLAXOSMITHKLINE-ET2017166265,GLAXOSMITHKLINE,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",35.0,YR,,F,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141460071.0,OT,,,,,,,,,141460071.0,1.0,HIV infection
14146025,141460251,1,I,,20171026.0,20171031,20171031,EXP,,ET-GLAXOSMITHKLINE-ET2017166255,GLAXOSMITHKLINE,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",51.0,YR,,M,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141460251.0,OT,,,,,,,,,141460251.0,1.0,HIV infection
14146026,141460261,1,I,,20171026.0,20171031,20171031,EXP,,ET-GLAXOSMITHKLINE-ET2017166253,GLAXOSMITHKLINE,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",38.0,YR,,F,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141460261.0,OT,,,,,,,,,141460261.0,1.0,HIV infection
14146028,141460281,1,I,,20171026.0,20171031,20171031,EXP,,ET-GLAXOSMITHKLINE-ET2017166251,GLAXOSMITHKLINE,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12(10):E0186619.",25.0,YR,,F,Y,,,20171031.0,,OT,ET,ET,EFAVIRENZ.,Acquired gene mutation;Drug resistance;Virologic failure,141460281.0,OT,,,,,,,,,141460281.0,1.0,HIV infection
14152750,141527501,1,I,,20171024.0,20171102,20171102,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK165666,VIIV,"MEI X, ZHANG R, LU H. ONE CASE OF HBV-RELATED LIVER FAILURE CAUSED BY HAART OF LAMIVUDINE ALONE. CHINESE HEPATOLOGY. 2017;22:565-566",53.0,YR,,M,Y,,,20171102.0,,OT,CN,CN,EFAVIRENZ.,Ascites;Asthenia;Chromaturia;Decreased appetite;Drug resistance;Hepatic cirrhosis;Hepatic failure;Hepatic function abnormal;Pathogen resistance,141527501.0,HO,,,,,,,,,141527501.0,1.0,Acquired immunodeficiency syndrome
14152772,141527721,1,I,,20171024.0,20171102,20171102,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK165666,GLAXOSMITHKLINE,"MEI X, ZHANG R, LU H. ONE CASE OF HBV-RELATED LIVER FAILURE CAUSED BY HAART OF LAMIVUDINE ALONE. CHINESE HEPATOLOGY. 2017;22:565-566",53.0,YR,,M,Y,,,20171102.0,,OT,CN,CN,EFAVIRENZ.,Ascites;Asthenia;Chromaturia;Decreased appetite;Drug resistance;Hepatic cirrhosis;Hepatic failure;Hepatic function abnormal;Pathogen resistance,141527721.0,HO,,,,,,,,,141527721.0,1.0,Acquired immunodeficiency syndrome
14155361,141553611,1,I,,20171023.0,20171103,20171103,EXP,,ZA-AUROBINDO-AUR-APL-2017-42719,AUROBINDO,SACOOR MF.. ABACAVIR/EFAVIRENZ/LAMIVUDINE DISSEMINATED CUTANEOUS HISTOPLASMOSIS WITHLARYNGEAL INVOLVEMENT ASSOCIATED AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: CASE REPORT. REACTIONS WEEKLY. 2017;1674:12,39.0,YR,,M,Y,,,20171102.0,,OT,ZA,ZA,Efavirenz 600mg,Dysphonia;Histoplasmosis disseminated;Immune reconstitution inflammatory syndrome;Oropharyngeal pain;Papule;Skin lesion;Skin mass;Skin plaque,141553611.0,OT,,,,,,,,,141553611.0,1.0,HIV infection
14155881,141558811,1,I,,20171023.0,20171103,20171103,EXP,,ZA-AUROBINDO-AUR-APL-2017-42729,AUROBINDO,,45.0,YR,,M,Y,,,20171103.0,,OT,ZA,ZA,Efavirenz 600mg,Lipodystrophy acquired;Tuberculosis,141558811.0,OT,,,,,,,,,141558811.0,1.0,HIV infection
14156503,141565031,1,I,,20171027.0,20171103,20171103,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-098704,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20171103.0,,MD,US,BR,EFAVIRENZ.,Maculopathy,141565031.0,OT,,,,,,,,,141565031.0,1.0,HIV infection
14157199,141571991,1,I,,20171023.0,20171103,20171103,EXP,,TR-MYLANLABS-2017M1068764,MYLAN,"DEMIRASLAN H, DENIZ K, DOGANAY M. MULTIPLE PAPULAR LESIONS IN A PATIENT WITH HIV AND/OR AIDS AND CO-INFECTED WITH HEPATITIS B VIRUS: AMYLOIDOSIS. SOUTH-AFR-J-HIV-MED 2017;18:NO. 1.",43.0,YR,,M,Y,,,20171103.0,,OT,TR,TR,EFAVIRENZ.,Amyloidosis,141571991.0,HO,,,,,,,,,141571991.0,1.0,Antiretroviral therapy
14165463,1416546310,10,F,201404.0,20181128.0,20171107,20181211,EXP,,IT-AUROBINDO-AUR-APL-2017-43260,AUROBINDO,,27.0,YR,,F,Y,,,20181212.0,,OT,IT,IT,Efavirenz Film Coated Tablets,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,1416546310.0,OT,,,1416546310.0,7.0,201505.0,,,,1416546310.0,1.0,Antiretroviral therapy
14165912,1416591211,11,F,,20230101.0,20171107,20230103,EXP,,GB-GILEAD-2017-0303084,GILEAD,,85.0,YR,E,M,Y,,,20230103.0,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,1416591211.0,OT,,,1416591211.0,1.0,,,152.0,DAY,1416591211.0,1.0,HIV infection
14169692,141696921,1,I,,20171030.0,20171108,20171108,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017169820,VIIV,"MATHUKUMALLI N, ALI N, KANIKANNAN M, YAREEDA S. WORSENING GUILLAIN-BARRE SYNDROME: HARBINGER OF IRIS IN HIV?. 2017. BMJ CASE REPORTS. 2017;221874:UNK",38.0,YR,,M,Y,,,20171108.0,,MD,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,141696921.0,OT,,,,,,,,,141696921.0,1.0,HIV infection
14170491,141704911,1,I,20170907.0,20171102.0,20171108,20171108,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-099727,BRISTOL MYERS SQUIBB,,32.0,YR,,M,Y,56.0,KG,20171108.0,,OT,CN,CN,EFAVIRENZ.,Anaemia;White blood cell count decreased,141704911.0,DS,,,141704911.0,1.0,20170725.0,20170918.0,,,141704911.0,1.0,Acquired immunodeficiency syndrome
14170664,141706641,1,I,,20171030.0,20171108,20171108,EXP,,IN-GLAXOSMITHKLINE-IN2017169820,GLAXOSMITHKLINE,"MATHUKUMALLI N, ALI N, KANIKANNAN M, YAREEDA S. WORSENING GUILLAIN-BARRE SYNDROME: HARBINGER OF IRIS IN HIV?. 2017. BMJ CASE REPORTS. 2017;221874:UNK",38.0,YR,,M,Y,,,20171108.0,,MD,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,141706641.0,OT,,,,,,,,,141706641.0,1.0,HIV infection
14171609,141716093,3,F,201404.0,20180112.0,20171108,20180130,EXP,,IT-MYLANLABS-2017M1069639,MYLAN,,27.0,YR,,F,Y,,,20180130.0,,CN,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,141716093.0,OT,,,141716093.0,1.0,201505.0,201505.0,,,141716093.0,1.0,Antiretroviral therapy
14174515,141745151,1,I,20170813.0,20171102.0,20171109,20171109,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-099771,BRISTOL MYERS SQUIBB,,48.0,YR,,M,Y,56.0,KG,20171109.0,,OT,CN,CN,EFAVIRENZ.,Dermatitis exfoliative;Hallucination;Hyperpyrexia;Nausea;Vomiting,141745151.0,OT,,,141745151.0,1.0,20170808.0,20170818.0,,,141745151.0,1.0,HIV antibody positive
14175204,141752041,1,I,,20171027.0,20171109,20171109,EXP,,BR-MYLANLABS-2017M1069636,MYLAN,"ABALEM MF, CARRICONDO PC, RAO RC. BULLSEYE RETINOPATHY FROM ANTIRETROVIRAL THERAPY. OPHTHALMOLOGY 2017;124(10):1539.",6.0,DEC,,M,Y,,,20171107.0,,MD,BR,BR,EFAVIRENZ.,Maculopathy,141752041.0,OT,,,,,,,,,141752041.0,1.0,HIV infection
14175791,141757913,3,F,,20190408.0,20171109,20190410,EXP,,BG-GILEAD-2017-0303513,GILEAD,"YANCHEVA N, TEMELKOVA N, STRASHIMIROV D, GABARSKA I, TCHERVENYAKOVA T. ANTIRETROVIRAL THERAPY AND BONE HEALTH. ACTA MEDICA BULGARICA. 2019;46:5-10",45.0,YR,A,M,Y,,,20190410.0,,MD,BG,BG,EFAVIRENZ.,Osteoporosis,141757913.0,OT,,,,,,,,,141757913.0,1.0,HIV infection
14181160,141811601,1,I,,20171106.0,20171112,20171112,EXP,,IT-TEVA-824233ROM,TEVA,"TARTAGLIA A, FERRARA SM, SICA S, SANTANTONIO T. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS. AIDS 2017;31(16):2314-2315.",27.0,YR,,F,Y,,,20171112.0,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Haemodialysis;Nephropathy toxic;Pathogen resistance;Virologic failure,141811601.0,OT,,,141811601.0,1.0,201505.0,201505.0,,,141811601.0,1.0,Antiretroviral therapy
14184694,141846944,4,F,20171103.0,20171116.0,20171114,20171122,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-101508,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20171122.0,,OT,ZA,ZA,EFAVIRENZ.,Exposure during breast feeding;Foetal exposure during pregnancy;Foetal growth restriction;Hypoglycaemia neonatal;Neonatal respiratory distress syndrome;Premature baby,141846944.0,OT,,,141846944.0,1.0,20170908.0,20171106.0,,,141846944.0,1.0,Prophylaxis against HIV infection
14184696,141846964,4,F,20171103.0,20171117.0,20171114,20171120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-100945,BRISTOL MYERS SQUIBB,,18.0,YR,,F,Y,53.0,KG,20171120.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Oligohydramnios;Placental insufficiency;Pre-eclampsia;Premature delivery,141846964.0,HO,,,141846964.0,1.0,20170908.0,20171104.0,,,141846964.0,1.0,HIV infection
14186638,141866385,5,F,2014.0,20180117.0,20171114,20180208,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2017GSK173670,VIIV,,27.0,YR,,F,Y,,,20180208.0,,CN,IT,IT,EFAVIRENZ.,Drug ineffective;Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Renal failure;Renal impairment;Secondary hypertension;Treatment noncompliance;Viral mutation identified;Virologic failure,141866385.0,OT,,,141866385.0,4.0,201505.0,,,,141866385.0,1.0,HIV infection
14207139,142071393,3,F,,20171213.0,20171121,20180315,EXP,,BR-HETERO CORPORATE-HET2017BR00352,HETERO,,,,,M,Y,,,20180315.0,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Talipes,142071393.0,CA,,,142071393.0,1.0,20170705.0,20171108.0,,,142071393.0,1.0,HIV infection
14210539,142105394,4,F,,20180103.0,20171121,20180112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-103450,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180112.0,,CN,GB,GB,EFAVIRENZ.,Lip and/or oral cavity cancer,142105394.0,OT,,,,,,,,,142105394.0,1.0,Antiretroviral therapy
14221025,142210252,2,F,,20180108.0,20171124,20180110,EXP,,TR-GILEAD-2017-0306400,GILEAD,,41.0,YR,A,M,Y,,,20180110.0,,MD,TR,TR,EFAVIRENZ.,Mesangioproliferative glomerulonephritis,142210252.0,DE,,,,,,,,,142210252.0,1.0,HIV infection
14226568,142265681,1,I,,20171117.0,20171127,20171127,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2017GSK179674,VIIV,,35.0,YR,,M,Y,,,20171127.0,,MD,RO,RO,EFAVIRENZ.,Drug dependence;Drug ineffective,142265681.0,OT,,,,,,,,,142265681.0,1.0,HIV infection
14228736,142287361,1,I,,20171113.0,20171128,20171128,EXP,,TD-CIPLA LTD.-2017TD20732,CIPLA,"ADAWAYE C, FOKAM J, KAMANGU E, ALIO HM, CHAHAD AM, SUSIN F ET AL .,. VIROLOGICAL RESPONSE, HIV-1 DRUG RESISTANCE MUTATIONS AND GENETIC DIVERSITY AMONG PATIENTS ON FIRST-LINE ANTIRETROVIRAL THERAPY IN N^DJAMENA, CHAD: FINDINGS FROM A CROSS-SECTIONAL STUDY. BMC RESEARCH NOTES. 2017;1 TO 10",,,,,Y,,,20171128.0,,OT,TD,TD,EFAVIRENZ.,Virologic failure,142287361.0,OT,,,,,,,,,142287361.0,1.0,HIV infection
14228737,142287371,1,I,,20171113.0,20171128,20171128,EXP,,TD-CIPLA LTD.-2017TD20735,CIPLA,"ADAWAYE C, FOKAM J, KAMANGU E, ALIO HM, CHAHAD AM, SUSIN F ET AL.,. VIROLOGICAL RESPONSE, HIV-1 DRUG RESISTANCE MUTATIONS AND GENETIC DIVERSITY AMONG PATIENTS ON FIRST-LINE ANTIRETROVIRAL THERAPY IN N^DJAMENA, CHAD: FINDINGS FROM A CROSS-SECTIONAL STUDY. BMC RESEARCH NOTES. 2017;1 TO 10",,,,,Y,,,20171128.0,,OT,TD,TD,EFAVIRENZ.,Virologic failure,142287371.0,OT,,,,,,,,,142287371.0,1.0,HIV infection
14228738,142287381,1,I,,20171113.0,20171128,20171128,EXP,,TD-CIPLA LTD.-2017TD20730,CIPLA,"ADAWAYE C, FOKAM J, KAMANGU E, ALIO HM, CHAHAD AM, SUSIN F ET AL .,. VIROLOGICAL RESPONSE, HIV-1 DRUG RESISTANCE MUTATIONS AND GENETIC DIVERSITY AMONG PATIENTS ON FIRST-LINE ANTIRETROVIRAL THERAPY IN N^DJAMENA, CHAD: FINDINGS FROM A CROSS-SECTIONAL STUDY. BMC RESEARCH NOTES. 2017;1 TO 10",,,,,Y,,,20171128.0,,OT,TD,TD,EFAVIRENZ.,Virologic failure,142287381.0,OT,,,,,,,,,142287381.0,1.0,Antiretroviral therapy
14228748,142287481,1,I,,20171113.0,20171128,20171128,EXP,,TD-CIPLA LTD.-2017TD20738,CIPLA,"ADAWAYE C, FOKAM J, KAMANGU E, ALIO HM, CHAHAD AM, SUSIN F ET AL.,. VIROLOGICAL RESPONSE, HIV-1 DRUG RESISTANCE MUTATIONS AND GENETIC DIVERSITY AMONG PATIENTS ON FIRST-LINE ANTIRETROVIRAL THERAPY IN N^DJAMENA, CHAD: FINDINGS FROM A CROSS-SECTIONAL STUDY. BMC RESEARCH NOTES. 2017;10 (589):1 TO 10",,,,,Y,,,20171128.0,,OT,TD,TD,EFAVIRENZ.,Virologic failure,142287481.0,OT,,,,,,,,,142287481.0,1.0,HIV infection
14228755,142287551,1,I,,20171113.0,20171128,20171128,EXP,,TD-CIPLA LTD.-2017TD20739,CIPLA,"ADAWAYE C, FOKAM J, KAMANGU E, ALIO HM, CHAHAD AM, SUSIN F ET AL .,. VIROLOGICAL RESPONSE, HIV-1 DRUG RESISTANCE MUTATIONS AND GENETIC DIVERSITY AMONG PATIENTS ON FIRST-LINE ANTIRETROVIRAL THERAPY IN N^DJAMENA, CHAD: FINDINGS FROM A CROSS-SECTIONAL STUDY. BMC RESEARCH NOTES. 2017;1 TO 10",,,,,Y,,,20171128.0,,OT,TD,TD,EFAVIRENZ.,Virologic failure,142287551.0,OT,,,,,,,,,142287551.0,1.0,Antiretroviral therapy
14228925,142289251,1,I,,20171113.0,20171128,20171128,EXP,,TD-CIPLA LTD.-2017TD20734,CIPLA,"ADAWAYE C, FOKAM J, KAMANGU E, ALIO HM, CHAHAD AM, SUSIN F ET AL .,. VIROLOGICAL RESPONSE, HIV-1 DRUG RESISTANCE MUTATIONS AND GENETIC DIVERSITY AMONG PATIENTS ON FIRST-LINE ANTIRETROVIRAL THERAPY IN N^DJAMENA, CHAD: FINDINGS FROM A CROSS-SECTIONAL STUDY. BMC RESEARCH NOTES. 2017;1 TO 10",,,,,Y,,,20171128.0,,OT,TD,TD,EFAVIRENZ.,Virologic failure,142289251.0,OT,,,,,,,,,142289251.0,1.0,HIV infection
14235560,142355603,3,F,,20200310.0,20171129,20200320,EXP,,IN-AUROBINDO-AUR-APL-2017-43833,AUROBINDO,,38.0,YR,,M,Y,,,20200320.0,,HP,IN,IN,EFAVIRENZ.,Acarodermatitis;Bulbar palsy;Condition aggravated;Guillain-Barre syndrome;Immune reconstitution inflammatory syndrome;Muscular weakness;Rash;Rash papular,142355603.0,OT,,,,,,,,,142355603.0,1.0,HIV infection
14244884,142448843,3,F,201404.0,20171227.0,20171201,20180105,EXP,IT-MINISAL02-436103,IT-009507513-1711ITA010779,MERCK,"TARTAGLIA A, ET AL.. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS.. AIDS. 2017;31(16):2314-5",27.0,YR,,F,Y,,,20180105.0,,CN,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance;Treatment noncompliance;Virologic failure,142448843.0,OT,,,142448843.0,9.0,201505.0,201404.0,,,142448843.0,1.0,HIV infection
14248970,142489702,2,F,,20191210.0,20171204,20191224,EXP,IT-MINISAL02-436750,IT-MYLANLABS-2017M1075186,MYLAN,"TARTAGLIA A, FERRARA SM, SICA S, SANTANTONIO T.. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS.. AIDS. 2017;31(16):2314-2315",27.0,YR,,F,Y,,,20191224.0,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance,142489702.0,OT,,,,,,,,,142489702.0,1.0,Antiretroviral therapy
14248971,142489712,2,F,,20190906.0,20171204,20190910,EXP,,BG-MYLANLABS-2017M1075485,MYLAN,"YANCHEVA N, TEMELKOVA N, STRASHIMIROV D, GABARSKA I, TCHERVENYAKOVA T. ANTIRETROVIRAL THERAPY AND BONE HEALTH. ACTA MEDICA BULGARICA.. 2019;46:5-10",45.0,YR,,M,Y,,,20190910.0,,MD,BG,BG,EFAVIRENZ.,Osteoporosis,142489712.0,OT,,,,,,,,,142489712.0,1.0,HIV infection
14254321,142543211,1,I,,20171201.0,20171206,20171206,EXP,,ET-STRIDES ARCOLAB LIMITED-2017SP014456,STRIDES,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS-ONE. 2017;12(10):E0186619",38.0,YR,,F,Y,,,20171206.0,,OT,ET,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,142543211.0,OT,,,142543211.0,1.0,2008.0,,,,142543211.0,1.0,HIV infection CDC category C
14254333,142543331,1,I,,20171201.0,20171206,20171206,EXP,,ET-STRIDES ARCOLAB LIMITED-2017SP014455,STRIDES,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY.. PLOS-ONE. 2017;12(10):E0186619",25.0,YR,,F,Y,,,20171206.0,,OT,ET,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,142543331.0,OT,,,142543331.0,1.0,2008.0,,,,142543331.0,1.0,HIV infection CDC category C
14254413,142544131,1,I,,20171201.0,20171206,20171206,EXP,,ET-STRIDES ARCOLAB LIMITED-2017SP014438,STRIDES,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS-ONE. 2017;12(10):E0186619",35.0,YR,,F,Y,,,20171206.0,,OT,ET,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,142544131.0,OT,,,142544131.0,2.0,2008.0,,,,142544131.0,1.0,HIV infection CDC category C
14257826,142578261,1,I,,20171201.0,20171207,20171207,EXP,,ET-STRIDES ARCOLAB LIMITED-2017SP014465,STRIDES,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS-ONE. 2017;12(10):E0186619",45.0,YR,,F,Y,,,20171207.0,,OT,ET,ET,EFAVIRENZ.,Virologic failure,142578261.0,OT,,,142578261.0,1.0,2008.0,,,,142578261.0,1.0,HIV infection CDC category C
14262018,142620181,1,I,,20171201.0,20171208,20171208,EXP,,ET-STRIDES ARCOLAB LIMITED-2017SP014437,STRIDES,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS-ONE. 2017;12(10):E0186619",44.0,YR,,F,Y,,,20171208.0,,OT,ET,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,142620181.0,OT,,,142620181.0,1.0,2008.0,,,,142620181.0,1.0,HIV infection CDC category C
14265127,142651272,2,F,2015.0,20180817.0,20171208,20180827,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK177731,VIIV,,56.0,YR,,M,Y,57.0,KG,20180827.0,,MD,FR,FR,SUSTIVA,General physical health deterioration;Hypermetabolism;Pulmonary mass;Virologic failure,142651272.0,HO,,,142651272.0,1.0,,20151117.0,,,142651272.0,1.0,HIV infection
14266076,142660765,5,F,201404.0,20180213.0,20171209,20180226,EXP,IT-MINISAL02-437307,PHHY2017IT167635,NOVARTIS,,27.0,YR,,F,Y,,,20180226.0,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance;Prescribed overdose;Virologic failure,142660765.0,OT,,,,,,,,,142660765.0,1.0,HIV infection
14268387,142683871,1,I,2015.0,20171117.0,20171211,20171211,EXP,,FR-GLAXOSMITHKLINE-FR2017GSK177731,GLAXOSMITHKLINE,,56.0,YR,,M,Y,57.0,KG,20171211.0,,MD,FR,FR,SUSTIVA,General physical health deterioration;Hypermetabolism;Pulmonary mass;Virologic failure,142683871.0,HO,,,142683871.0,1.0,20151117.0,20151117.0,,,142683871.0,1.0,HIV infection
14269504,142695041,1,I,,20171129.0,20171211,20171211,EXP,,"BR-LANNETT COMPANY, INC.-BR-2017LAN001232",LANNETT,"ABALEM MF, CARRICONDO PC, RAO RC. BULLSEYE RETINOPATHY FROM ANTIRETROVIRAL THERAPY. OPHTHALMOLOGY. 2017;124(10):1539",,,A,M,Y,,,20171211.0,,MD,BR,BR,EFAVIRENZ.,Retinopathy,142695041.0,OT,,,,,,,,,142695041.0,1.0,Antiretroviral therapy
14269557,142695571,1,I,,20171129.0,20171211,20171211,EXP,,"TR-LANNETT COMPANY, INC.-TR-2017LAN001233",LANNETT,"DEMIRASLAN H, DENIZ K, DOGANAY M. MULTIPLE PAPULAR LESIONS IN A PATIENT WITH HIV AND/OR AIDS AND CO-INFECTED WITH HEPATITIS B VIRUS: AMYLOIDOSIS. SOUTH-AFR-J-HIV-MED. 2017;18(1):A735",43.0,YR,,M,Y,,,20171211.0,,OT,TR,TR,EFAVIRENZ.,Amyloidosis,142695571.0,HO,,,,,,,,,142695571.0,1.0,Antiretroviral therapy
14273399,142733991,1,I,,20171127.0,20171212,20171212,EXP,,RO-AUROBINDO-AUR-APL-2017-44905,AUROBINDO,,35.0,YR,,M,Y,,,20171212.0,,MD,RO,RO,EFAVIRENZ.,Drug dependence;Drug ineffective,142733991.0,OT,,,,,,,,,142733991.0,1.0,HIV infection
14283035,142830353,3,F,20071025.0,20181031.0,20171213,20181109,EXP,,FR-GILEAD-2017-0310074,GILEAD,,,,,F,Y,,,20181109.0,,CN,GB,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,142830353.0,OT,,,142830353.0,1.0,20071025.0,20071211.0,,,142830353.0,1.0,Antiretroviral therapy
14288112,142881121,1,I,,20171130.0,20171215,20171215,EXP,,GB-CIPLA LTD.-2017GB22670,CIPLA,"WYNBERG E, WILLIAMS E, TUDOR-WILLIAMS G, LYALL H, FOSTER C. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLINICAL DRUG INVESTIGATION. 2017;1 TO 12",,,,,Y,,,20171215.0,,OT,GB,GB,EFAVIRENZ.,Adverse event;Virologic failure,142881121.0,OT,,,,,,,,,142881121.0,1.0,Perinatal HIV infection
14288581,142885811,1,I,,20171130.0,20171215,20171215,EXP,,GB-CIPLA LTD.-2017GB25923,CIPLA,"WYNBERG E, WILLIAMS E, TUDOR-WILLIAMS G, LYALL H, FOSTER C. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLINICAL DRUG INVESTIGATION. 2017;1 TO 12",,,,,Y,,,20171215.0,,OT,GB,GB,EFAVIRENZ.,Drug resistance;Virologic failure,142885811.0,OT,,,,,,,,,142885811.0,1.0,Perinatal HIV infection
14288583,142885831,1,I,,20171130.0,20171215,20171215,EXP,,GB-CIPLA LTD.-2017GB25922,CIPLA,"WYNBERG E, WILLIAMS E, TUDOR-WILLIAMS G, LYALL H, FOSTER C. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLINICAL DRUG INVESTIGATION. 2017;1 TO 12",,,,,Y,,,20171215.0,,OT,GB,GB,EFAVIRENZ.,Drug resistance;Virologic failure,142885831.0,OT,,,,,,,,,142885831.0,1.0,Perinatal HIV infection
14288585,142885851,1,I,,20171130.0,20171215,20171215,EXP,,GB-CIPLA LTD.-2017GB25921,CIPLA,"WYNBERG E, WILLIAMS E, TUDOR-WILLIAMS G, LYALL H, FOSTER C. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLINICAL DRUG INVESTIGATION. 2017;1 TO 12",,,,,Y,,,20171215.0,,OT,GB,GB,EFAVIRENZ.,Drug resistance;Virologic failure,142885851.0,OT,,,,,,,,,142885851.0,1.0,Perinatal HIV infection
14289400,142894001,1,I,,20171130.0,20171215,20171215,EXP,,GB-CIPLA LTD.-2017GB25920,CIPLA,"WYNBERG E, WILLIAMS E, TUDOR-WILLIAMS G, LYALL H, FOSTER C. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLINICAL DRUG INVESTIGATION. 2017;1 TO 12",,,,,Y,,,20171215.0,,OT,GB,GB,EFAVIRENZ.,Drug resistance;Virologic failure,142894001.0,OT,,,,,,,,,142894001.0,1.0,Perinatal HIV infection
14293714,142937141,1,I,,20171201.0,20171216,20171216,EXP,,GB-CIPLA LTD.-2017CM23329,CIPLA,,,,,,Y,,,20171216.0,,OT,CM,CM,EFAVIRENZ.,Anaemia,142937141.0,OT,,,,,,,,,142937141.0,1.0,HIV infection
14297931,142979312,2,F,20171116.0,20180203.0,20171218,20180215,EXP,,PL-MYLANLABS-2017M1079437,MYLAN,KRANKOWSKA D.. MAOPYTKOWO HISTORIA PACJENTA Z HIV.,45.0,YR,,M,Y,,,20180214.0,,MD,PL,PL,EFAVIRENZ.,Death;Immune reconstitution inflammatory syndrome,142979312.0,HO,,,142979312.0,1.0,20171113.0,20171116.0,,,142979312.0,1.0,HIV infection
14300343,143003432,2,F,,20171204.0,20171219,20171219,EXP,,ET-AUROBINDO-AUR-APL-2017-46008,AUROBINDO,,48.0,YR,,F,Y,,,20171219.0,,OT,DE,ET,EFAVIRENZ.,Acquired gene mutation;Multiple-drug resistance;Virologic failure,,,,,,,,,,,143003432.0,1.0,Antiretroviral therapy
14301744,143017442,2,F,20171116.0,20180122.0,20171219,20180205,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-112135,BRISTOL MYERS SQUIBB,KRANKOWSKA D. THROMBOCYTOPENIA- PATIENT HISTORY,45.0,YR,,M,Y,,,20180205.0,,MD,PL,PL,EFAVIRENZ.,Death;Immune reconstitution inflammatory syndrome;Thrombocytopenia,143017442.0,OT,,,143017442.0,1.0,20171113.0,20171116.0,,,143017442.0,1.0,HIV infection
14306018,143060181,1,I,,20171211.0,20171219,20171219,EXP,,AT-GILEAD-2017-0311148,GILEAD,,64.0,YR,A,F,Y,,,20171219.0,,MD,AT,AT,EFAVIRENZ.,Osteoporosis;Stress fracture,143060181.0,OT,,,143060181.0,1.0,2003.0,201506.0,,,143060181.0,1.0,HIV infection
14307343,143073431,1,I,,20171205.0,20171220,20171220,EXP,,CA-CIPLA LTD.-2017UG29153,CIPLA,,,,,,Y,,,20171220.0,,OT,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,143073431.0,OT,,,,,,,,,143073431.0,1.0,HIV infection
14307472,143074721,1,I,,20171205.0,20171220,20171220,EXP,,CA-CIPLA LTD.-2017UG29274,CIPLA,,,,,,Y,,,20171220.0,,MD,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,143074721.0,OT,,,,,,,,,143074721.0,1.0,HIV infection
14307547,143075471,1,I,,20171205.0,20171220,20171220,EXP,,CA-CIPLA LTD.-2017UG29275,CIPLA,,,,,,Y,,,20171220.0,,MD,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,143075471.0,OT,,,,,,,,,143075471.0,1.0,HIV infection
14307819,143078191,1,I,,20171205.0,20171220,20171220,EXP,,US-CIPLA LTD.-2017UG29280,CIPLA,,,,,,Y,,,20171220.0,,OT,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143078191.0,OT,,,,,,,,,143078191.0,1.0,HIV infection
14307824,143078241,1,I,,20171205.0,20171220,20171220,EXP,,US-CIPLA LTD.-2017UG29281,CIPLA,,,,,,Y,,,20171220.0,,OT,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143078241.0,OT,,,,,,,,,143078241.0,1.0,HIV infection
14307844,143078441,1,I,,20171205.0,20171220,20171220,EXP,,US-CIPLA LTD.-2017UG29282,CIPLA,,,,,,Y,,,20171220.0,,OT,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143078441.0,OT,,,,,,,,,143078441.0,1.0,HIV infection
14308057,143080571,1,I,,20171205.0,20171220,20171220,EXP,,US-CIPLA LTD.-2017UG29283,CIPLA,,,,,,Y,,,20171220.0,,OT,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143080571.0,OT,,,,,,,,,143080571.0,1.0,HIV infection
14308387,143083871,1,I,,20171205.0,20171220,20171220,EXP,,CA-CIPLA LTD.-2017UG29273,CIPLA,,,,,,Y,,,20171220.0,,MD,CA,UG,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,143083871.0,OT,,,,,,,,,143083871.0,1.0,HIV infection
14309684,143096841,1,I,,20171205.0,20171220,20171220,EXP,,RO-TEVA-2017-RO-834595,TEVA,,35.0,YR,,M,Y,,,20171220.0,,MD,RO,RO,EFAVIRENZ.,Drug dependence;Drug ineffective,143096841.0,OT,,,,,,,,,143096841.0,1.0,HIV infection
14312130,143121301,1,I,,20171211.0,20171221,20171221,EXP,,US-HETERO-HET2017US00401,HETERO,"BELCHER R, MARCANGELO M. EFAVIRENZ PRECIPITATING HALLUCINATIONS IN A PATIENT WITH AN UNDETECTED PSYCHOTIC PRODROME: A CALL FOR BETTER SCREENING AT THE POINT OF CARE. AIDS. 2017;31(18):2561-2562",25.0,YR,,M,Y,,,20171221.0,,OT,US,US,EFAVIRENZ.,Schizoaffective disorder bipolar type,143121301.0,HO,,,,,,,,,143121301.0,1.0,HIV infection
14313510,143135101,1,I,20171110.0,,20171220,20171220,DIR,FDA-CDER-CTU-2017-82442,,FDA-CTU,,70.0,YR,,M,N,,,20171220.0,N,PH,US,US,EFAVIRENZ.,Arthritis infective;Device related infection;Diarrhoea;Dizziness;Hypotension,143135101.0,HO,143135101.0,HP,143135101.0,1.0,20020624.0,20171113.0,,,143135101.0,1.0,HIV infection
14323370,143233703,3,F,,20171214.0,20171226,20181224,EXP,,IN-CIPLA LTD.-2017IN29074,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143233703.0,OT,,,,,,,,,143233703.0,1.0,Antiretroviral therapy
14323371,143233712,2,F,,20171214.0,20171226,20181224,EXP,,IN-CIPLA LTD.-2017IN29072,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Death,143233712.0,DE,,,,,,,,,143233712.0,1.0,Antiretroviral therapy
14330897,143308972,2,F,,20171229.0,20171228,20171229,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-114025,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20171229.0,,OT,MW,GB,EFAVIRENZ.,Haemoglobin decreased;Maternal exposure during pregnancy;Meningitis cryptococcal;Premature delivery,143308972.0,OT,,,,,,,,,143308972.0,1.0,HIV infection
14331921,143319211,1,I,20111007.0,20171215.0,20171228,20171228,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-114845,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,,,20171228.0,,PH,GB,GB,EFAVIRENZ.,Lethargy,143319211.0,OT,,,143319211.0,1.0,20111007.0,20171114.0,,,143319211.0,1.0,HIV infection
14334853,143348532,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29080,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143348532.0,DE,,,,,,,,,143348532.0,1.0,HIV infection
14334866,143348662,2,F,,20171214.0,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29071,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220.0,,OT,IN,IN,EFAVIRENZ.,Death,143348662.0,DE,,,,,,,,,143348662.0,1.0,Antiretroviral therapy
14335012,143350122,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN28885,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Death,143350122.0,DE,,,,,,,,,143350122.0,1.0,Antiretroviral therapy
14335017,143350172,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29078,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143350172.0,OT,,,,,,,,,143350172.0,1.0,HIV infection
14335018,143350182,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29084,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350182.0,OT,,,,,,,,,143350182.0,1.0,Antiretroviral therapy
14335021,143350212,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29081,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Death,143350212.0,DE,,,,,,,,,143350212.0,1.0,HIV infection
14335022,143350222,2,F,,20171214.0,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29075,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350222.0,OT,,,,,,,,,143350222.0,1.0,Antiretroviral therapy
14335023,143350231,1,I,,20171214.0,20171229,20171229,EXP,,IN-CIPLA LTD.-2017IN29086,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20171229.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350231.0,OT,,,,,,,,,143350231.0,1.0,Antiretroviral therapy
14335024,143350242,2,F,,20171214.0,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29089,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220.0,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143350242.0,OT,,,,,,,,,143350242.0,1.0,HIV infection
14335025,143350252,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29083,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350252.0,OT,,,,,,,,,143350252.0,1.0,Antiretroviral therapy
14335026,143350261,1,I,,20171214.0,20171229,20171229,EXP,,IN-CIPLA LTD.-2017IN29077,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20171229.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350261.0,OT,,,,,,,,,143350261.0,1.0,Antiretroviral therapy
14335053,143350531,1,I,,20171214.0,20171229,20171229,EXP,,IN-CIPLA LTD.-2017IN29090,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20171229.0,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143350531.0,DE,,,,,,,,,143350531.0,1.0,HIV infection
14335057,143350572,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29087,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143350572.0,OT,,,,,,,,,143350572.0,1.0,Antiretroviral therapy
14335518,143355182,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29088,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143355182.0,DE,,,,,,,,,143355182.0,1.0,Antiretroviral therapy
14335522,143355222,2,F,,20171214.0,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29076,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143355222.0,OT,,,,,,,,,143355222.0,1.0,Antiretroviral therapy
14335523,143355232,2,F,,20171214.0,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29085,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220.0,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143355232.0,OT,,,,,,,,,143355232.0,1.0,Antiretroviral therapy
14335524,143355241,1,I,,20171214.0,20171229,20171229,EXP,,IN-CIPLA LTD.-2017IN29073,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20171229.0,,OT,IN,IN,EFAVIRENZ.,Death,143355241.0,DE,,,,,,,,,143355241.0,1.0,Antiretroviral therapy
14335525,143355252,2,F,,20171214.0,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29082,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181220.0,,OT,IN,IN,EFAVIRENZ.,Death,143355252.0,DE,,,,,,,,,143355252.0,1.0,Antiretroviral therapy
14335535,143355352,2,F,,20171214.0,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29079,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181220.0,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143355352.0,OT,,,,,,,,,143355352.0,1.0,HIV infection
14336540,143365401,1,I,,20171214.0,20171229,20171229,EXP,IT-MINISAL02-436103,IT-AUROBINDO-AUR-APL-2017-48134,AUROBINDO,"TARTAGLIA A, ET AL.. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS. AIDS. 2017;31(16):2314-5",27.0,YR,,F,Y,,,20171229.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Treatment noncompliance;Virologic failure,143365401.0,OT,,,,,,,,,143365401.0,1.0,HIV infection
14336554,143365542,2,F,,20180329.0,20171229,20180331,EXP,,IT-AUROBINDO-AUR-APL-2017-48135,AUROBINDO,,27.0,YR,,F,Y,,,20180331.0,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance,143365542.0,OT,,,,,,,,,143365542.0,1.0,Antiretroviral therapy
14339370,143393701,1,I,20111007.0,20171215.0,20171230,20171230,EXP,,GB-AUROBINDO-AUR-APL-2017-47830,AUROBINDO,,41.0,YR,,M,Y,,,20171230.0,,PH,GB,GB,EFAVIRENZ.,Lethargy,143393701.0,OT,,,143393701.0,1.0,20111007.0,20171114.0,,,143393701.0,1.0,HIV infection
14339631,143396315,5,F,,20181013.0,20171230,20181026,EXP,,GB-AUROBINDO-AUR-APL-2017-48435,AUROBINDO,,,,C,,Y,,,20181026.0,,OT,GB,GB,Efavirenz Film-coated Tablet,Cognitive disorder;Diplegia;Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;HIV-associated neurocognitive disorder;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,143396315.0,OT,,,,,,,,,143396315.0,1.0,Perinatal HIV infection
14339869,143398691,1,I,20111007.0,20171215.0,20171230,20171230,EXP,GB-MHRA-EYC 00170653,GB-MYLANLABS-2017M1083126,MYLAN,,41.0,YR,,M,Y,,,20171230.0,,PH,GB,GB,EFAVIRENZ.,Lethargy,143398691.0,OT,,,143398691.0,1.0,20111007.0,20171114.0,,,143398691.0,1.0,HIV infection
14341582,143415821,1,I,,20171218.0,20180102,20180102,EXP,,MY-CIPLA LTD.-2017MY30224,CIPLA,,,,,,Y,,,20180102.0,,OT,MY,MY,EFAVIRENZ.,Face oedema;Photosensitivity reaction,143415821.0,OT,,,,,,,,,143415821.0,1.0,Antiretroviral therapy
14341617,143416171,1,I,,20171218.0,20180102,20180102,EXP,,MY-CIPLA LTD.-2017MY30209,CIPLA,,,,,,Y,,,20180102.0,,PH,MY,MY,EFAVIRENZ.,Chapped lips;Ocular hyperaemia;Pruritus;Rash maculo-papular;Urinary incontinence,143416171.0,OT,,,,,,,,,143416171.0,1.0,HIV infection
14352961,143529613,3,F,20150608.0,20190118.0,20180104,20190128,EXP,,FR-MYLANLABS-2018M1000485,MYLAN,,,,,M,Y,2.64,KG,20190128.0,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,143529613.0,OT,,,143529613.0,5.0,20150608.0,20150608.0,,,143529613.0,1.0,HIV infection
14361836,143618362,2,F,,20171226.0,20180108,20181220,EXP,,US-CIPLA LTD.-2017US30878,CIPLA,,,,,,Y,,,20181220.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143618362.0,OT,,,,,,,,,143618362.0,1.0,HIV infection
14361837,143618372,2,F,,20171226.0,20180108,20181224,EXP,,US-CIPLA LTD.-2017US30879,CIPLA,,,,,,Y,,,20181224.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143618372.0,OT,,,,,,,,,143618372.0,1.0,HIV infection
14363782,143637825,5,F,201404.0,20181129.0,20180108,20181212,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-098391,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20181212.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,143637825.0,OT,,,,,,,,,143637825.0,1.0,HIV infection
14364072,143640721,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001286,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640721.0,OT,,,,,,,,,143640721.0,1.0,Antiretroviral therapy
14364074,143640741,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001284,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640741.0,OT,,,,,,,,,143640741.0,1.0,Antiretroviral therapy
14364076,143640761,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001286,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640761.0,OT,,,,,,,,,143640761.0,1.0,Antiretroviral therapy
14364079,143640791,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001284,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640791.0,OT,,,,,,,,,143640791.0,1.0,Antiretroviral therapy
14364280,143642801,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001287,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143642801.0,OT,,,,,,,,,143642801.0,1.0,Antiretroviral therapy
14364282,143642821,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001287,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143642821.0,OT,,,,,,,,,143642821.0,1.0,Antiretroviral therapy
14364385,143643851,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001289,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643851.0,OT,,,,,,,,,143643851.0,1.0,Antiretroviral therapy
14364386,143643861,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001290,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643861.0,OT,,,,,,,,,143643861.0,1.0,Antiretroviral therapy
14364387,143643871,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001288,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,143643871.0,OT,,,,,,,,,143643871.0,1.0,Antiretroviral therapy
14364388,143643881,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001289,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643881.0,OT,,,,,,,,,143643881.0,1.0,Antiretroviral therapy
14364389,143643891,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001290,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643891.0,OT,,,,,,,,,143643891.0,1.0,Antiretroviral therapy
14364390,143643901,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001288,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,143643901.0,OT,,,,,,,,,143643901.0,1.0,Antiretroviral therapy
14364413,143644131,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001291,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644131.0,OT,,,,,,,,,143644131.0,1.0,Antiretroviral therapy
14364414,143644141,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001294,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644141.0,OT,,,,,,,,,143644141.0,1.0,Antiretroviral therapy
14364415,143644151,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001292,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644151.0,OT,,,,,,,,,143644151.0,1.0,Antiretroviral therapy
14364416,143644161,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001291,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644161.0,OT,,,,,,,,,143644161.0,1.0,Antiretroviral therapy
14364417,143644171,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001294,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644171.0,OT,,,,,,,,,143644171.0,1.0,Antiretroviral therapy
14364419,143644191,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001292,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644191.0,OT,,,,,,,,,143644191.0,1.0,Antiretroviral therapy
14364453,143644531,1,I,,20180103.0,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001295,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644531.0,OT,,,,,,,,,143644531.0,1.0,Antiretroviral therapy
14364454,143644541,1,I,,20180103.0,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001295,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108.0,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644541.0,OT,,,,,,,,,143644541.0,1.0,Antiretroviral therapy
14366099,143660991,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30750,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143660991.0,OT,,,,,,,,,143660991.0,1.0,HIV infection
14366162,143661624,4,F,,20220318.0,20180109,20220329,EXP,,CA-009507513-1801CAN001991,MERCK,Unknown. Unknown. Unknown,,,,,Y,,,20220329.0,,HP,CA,CA,EFAVIRENZ,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,143661624.0,OT,,,,,,,,,143661624.0,1.0,HIV infection
14366163,143661631,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30820,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143661631.0,OT,,,,,,,,,143661631.0,1.0,HIV infection
14366190,143661901,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30822,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143661901.0,OT,,,,,,,,,143661901.0,1.0,HIV infection
14366194,143661941,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30821,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143661941.0,OT,,,,,,,,,143661941.0,1.0,HIV infection
14366655,143666551,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30827,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666551.0,OT,,,,,,,,,143666551.0,1.0,HIV infection
14366656,143666561,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30823,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666561.0,OT,,,,,,,,,143666561.0,1.0,HIV infection
14366657,143666571,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30831,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143666571.0,OT,,,,,,,,,143666571.0,1.0,HIV infection
14366658,143666581,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30833,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143666581.0,OT,,,,,,,,,143666581.0,1.0,HIV infection
14366659,143666591,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30824,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666591.0,OT,,,,,,,,,143666591.0,1.0,HIV infection
14366660,143666601,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30825,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666601.0,OT,,,,,,,,,143666601.0,1.0,HIV infection
14366661,143666611,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30826,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666611.0,OT,,,,,,,,,143666611.0,1.0,HIV infection
14366662,143666621,1,I,,20171226.0,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30832,CIPLA,,,,,,Y,,,20180109.0,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143666621.0,OT,,,,,,,,,143666621.0,1.0,HIV infection
14367906,143679064,4,F,2015.0,20181019.0,20180109,20181026,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-118541,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,57.0,KG,20181026.0,,MD,FR,FR,SUSTIVA,General physical health deterioration;Hypermetabolism;Pulmonary mass;Virologic failure,143679064.0,HO,,,143679064.0,3.0,20151117.0,,,,143679064.0,1.0,HIV infection
14371508,143715082,2,F,20171107.0,20180503.0,20180110,20180508,EXP,GB-MHRA-EYC 00171403,GB-VIIV HEALTHCARE LIMITED-GB2018001376,VIIV,,47.0,YR,,F,Y,,,20180508.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143715082.0,HO,,,143715082.0,1.0,20170501.0,20171216.0,,,143715082.0,1.0,HIV infection
14371647,143716472,2,F,20171107.0,20180503.0,20180110,20180508,EXP,GB-MHRA-EYC 00171403,GB-GLAXOSMITHKLINE-GB2018001376,GLAXOSMITHKLINE,,47.0,YR,,F,Y,,,20180508.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143716472.0,LT,,,143716472.0,1.0,20170501.0,20171216.0,,,143716472.0,1.0,HIV infection
14379460,143794601,1,I,,20180108.0,20180112,20180112,EXP,,US-HETERO CORPORATE-HET2018US00019,HETERO,"ONYEMA OGBUAGU, RITCHE HAO, MICHAEL VIRATA, MERCEDITAS S. VILLANUEVA MARICAR MALINIS. EFFICACY OF AN 8-WEEK COURSE OF SOFOSBUVIR AND LEDIPASVIR FOR THE TREATMENT OF HCV INFECTION IN SELECTED HIV-INFECTED PATIENTS.. F1000RESEARCH. 2017;6:620:1-8",,,,M,Y,,,20180112.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury,143794601.0,OT,,,,,,,,,143794601.0,1.0,HIV infection
14379754,143797542,2,F,20171107.0,20190504.0,20180112,20190513,EXP,,GB-AUROBINDO-AUR-APL-2018-001814,AUROBINDO,,47.0,YR,,F,Y,,,20190513.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143797542.0,OT,,,143797542.0,1.0,20170501.0,20171216.0,,,143797542.0,1.0,HIV infection
14380117,143801171,1,I,,20180102.0,20180112,20180112,EXP,,CA-AUROBINDO-AUR-APL-2018-001060,AUROBINDO,,32.0,YR,,M,Y,,,20180112.0,,PH,CA,CA,AURO-EFAVIRENZ TABLETS,Depression;Mood altered;Neurotoxicity;Suicide attempt,143801171.0,LT,,,,,,,,,143801171.0,1.0,Antiretroviral therapy
14393108,143931081,1,I,,20171229.0,20180116,20180116,EXP,,FR-GLAXOSMITHKLINE-FR2017202986,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20180116.0,,MD,FR,FR,SUSTIVA,Virologic failure,143931081.0,OT,,,143931081.0,1.0,20021113.0,20140402.0,,,143931081.0,1.0,HIV infection
14393109,143931091,1,I,,20171229.0,20180116,20180116,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017202986,VIIV,,54.0,YR,,M,Y,,,20180116.0,,MD,FR,FR,SUSTIVA,Virologic failure,143931091.0,OT,,,143931091.0,1.0,20021113.0,20140402.0,,,143931091.0,1.0,HIV infection
14395520,143955201,1,I,,20180108.0,20180116,20180116,EXP,,BR-GILEAD-2018-0315135,GILEAD,"ALVES B,SIQUEIRA J, GARRIDO M, BOTELHO O, PRELLWITZ I, RIBEIRO S, SOARES E, SOARES M. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9 (12):UNK",,,A,,Y,,,20180116.0,,MD,BR,BR,EFAVIRENZ.,Drug ineffective;Drug resistance;Gene mutation identification test positive;Viral load increased,143955201.0,OT,,,,,,,,,143955201.0,1.0,HIV infection
14398198,143981981,1,I,,20180110.0,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007224,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Anal atresia;Foetal exposure during pregnancy,143981981.0,OT,,,,,,,,,143981981.0,1.0,HIV infection
14398199,143981991,1,I,,20180110.0,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007225,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Heart disease congenital,143981991.0,CA,,,,,,,,,143981991.0,1.0,HIV infection
14398200,143982001,1,I,,20180110.0,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007221,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Anaemia;Foetal exposure during pregnancy,143982001.0,DE,,,,,,,,,143982001.0,1.0,HIV infection
14398201,143982011,1,I,,20180110.0,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007222,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Pyrexia,143982011.0,DE,,,,,,,,,143982011.0,1.0,HIV infection
14398202,143982021,1,I,,20180110.0,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007198,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Diarrhoea;Foetal exposure during pregnancy,143982021.0,DE,,,,,,,,,143982021.0,1.0,HIV infection
14398203,143982031,1,I,,20180110.0,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007220,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Tuberculosis,143982031.0,DE,,,,,,,,,143982031.0,1.0,HIV infection
14398204,143982041,1,I,,20180110.0,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007223,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Malnutrition,143982041.0,DE,,,,,,,,,143982041.0,1.0,HIV infection
14398205,143982051,1,I,,20180110.0,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007225,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Heart disease congenital,143982051.0,OT,,,,,,,,,143982051.0,1.0,HIV infection
14398206,143982061,1,I,,20180110.0,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007224,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Anal atresia;Foetal exposure during pregnancy,143982061.0,OT,,,,,,,,,143982061.0,1.0,HIV infection
14398207,143982071,1,I,,20180110.0,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007221,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Anaemia;Foetal exposure during pregnancy,143982071.0,DE,,,,,,,,,143982071.0,1.0,HIV infection
14398208,143982081,1,I,,20180110.0,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007222,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Pyrexia,143982081.0,DE,,,,,,,,,143982081.0,1.0,HIV infection
14398209,143982091,1,I,,20180110.0,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007220,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Tuberculosis,143982091.0,DE,,,,,,,,,143982091.0,1.0,HIV infection
14398210,143982101,1,I,,20180110.0,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007198,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Diarrhoea;Foetal exposure during pregnancy,143982101.0,DE,,,,,,,,,143982101.0,1.0,HIV infection
14398211,143982111,1,I,,20180110.0,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007223,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116.0,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Malnutrition,143982111.0,DE,,,,,,,,,143982111.0,1.0,HIV infection
14398398,143983981,1,I,,20180104.0,20180116,20180116,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-001661,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180116.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury,143983981.0,OT,,,,,,,,,143983981.0,1.0,HIV infection
14398660,143986607,7,F,20171107.0,20180508.0,20180117,20180522,EXP,GB-MHRA-EYC 00171403,GB-LUPIN PHARMACEUTICALS INC.-2018-00076,LUPIN,,47.0,YR,,F,Y,,,20180522.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143986607.0,LT,,,143986607.0,1.0,20170501.0,20171216.0,,,143986607.0,1.0,HIV infection
14402110,144021101,1,I,,20180104.0,20180117,20180117,EXP,,US-MYLANLABS-2018M1002223,MYLAN,"OGBUAGU O, HAO R, VIRATA M, VILLANUEVA MS, MALINIS M. EFFICACY OF AN 8-WEEK COURSE OF SOFOSBUVIR AND LEDIPASVIR FOR THE TREATMENT OF HCV INFECTION IN SELECTED HIV-INFECTED PATIENTS. F1000RES 2017;6:620.",,,A,M,Y,,,20180117.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury,144021101.0,OT,,,,,,,,,144021101.0,1.0,HIV infection
14404464,144044641,1,I,,20171211.0,20180117,20180117,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-120521,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20180117.0,,MD,FR,FR,SUSTIVA,Maternal exposure during pregnancy;Product use issue;Tuberculosis,144044641.0,OT,,,144044641.0,1.0,20051201.0,,,,144044641.0,1.0,Antiretroviral therapy
14408319,144083191,1,I,,20180104.0,20180118,20180118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-003535,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180118.0,,OT,US,US,EFAVIRENZ.,Fatigue;Influenza,,,,,,,,,,,144083191.0,1.0,HIV infection
14408320,144083201,1,I,,20180104.0,20180118,20180118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-003534,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180118.0,,OT,US,US,EFAVIRENZ.,Abdominal pain;Diarrhoea,,,,,,,,,,,144083201.0,1.0,HIV infection
14408321,144083211,1,I,,20180104.0,20180118,20180118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-003536,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180118.0,,OT,US,US,EFAVIRENZ.,Chronic obstructive pulmonary disease,,,,,,,,,,,144083211.0,1.0,HIV infection
14409362,144093621,1,I,,20180108.0,20180119,20180119,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018007433,VIIV,"ALVES B,SIQUEIRA J, GARRIDO M, BOTELHO O, PRELLWITZ I, RIBEIRO S, SOARES E, SOARES M. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9 (12):UNK",,,A,,Y,,,20180118.0,,MD,BR,BR,EFAVIRENZ.,Drug ineffective;Drug resistance;Gene mutation identification test positive;Viral load increased,144093621.0,OT,,,,,,,,,144093621.0,1.0,HIV infection
14409365,144093651,1,I,,20180115.0,20180119,20180119,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018GSK008901,VIIV,"COLUMPSI P, BHAGANI S. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS)  :  ():. 2017",56.0,YR,,M,Y,,,20180118.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,144093651.0,OT,,,,,,,,,144093651.0,1.0,HIV infection
14409370,144093701,1,I,,20180108.0,20180119,20180119,EXP,,BR-GLAXOSMITHKLINE-BR2018007433,GLAXOSMITHKLINE,"ALVES B,SIQUEIRA J, GARRIDO M, BOTELHO O, PRELLWITZ I, RIBEIRO S, SOARES E, SOARES M. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9 (12):UNK",,,A,,Y,,,20180118.0,,MD,BR,BR,EFAVIRENZ.,Drug ineffective;Drug resistance;Gene mutation identification test positive;Viral load increased,144093701.0,OT,,,,,,,,,144093701.0,1.0,HIV infection
14409378,144093781,1,I,,20180115.0,20180119,20180119,EXP,,GB-GLAXOSMITHKLINE-GB2018GSK008901,GLAXOSMITHKLINE,"COLUMPSI P, BHAGANI S. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS)  :  ():. 2017",56.0,YR,,M,Y,,,20180118.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,144093781.0,OT,,,,,,,,,144093781.0,1.0,HIV infection
14413250,144132501,1,I,,20180117.0,20180119,20180119,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018008936,VIIV,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",53.0,YR,,M,Y,,,20180119.0,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132501.0,OT,,,,,,,,,144132501.0,1.0,HIV infection
14413251,144132511,1,I,,20180117.0,20180119,20180119,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018008935,VIIV,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",49.0,YR,,M,Y,,,20180119.0,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132511.0,OT,,,,,,,,,144132511.0,1.0,HIV infection
14413271,144132711,1,I,,20180117.0,20180119,20180119,EXP,,GA-GLAXOSMITHKLINE-GA2018008936,GLAXOSMITHKLINE,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",53.0,YR,,M,Y,,,20180119.0,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132711.0,OT,,,,,,,,,144132711.0,1.0,HIV infection
14413272,144132721,1,I,,20180117.0,20180119,20180119,EXP,,GA-GLAXOSMITHKLINE-GA2018008935,GLAXOSMITHKLINE,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",49.0,YR,,M,Y,,,20180119.0,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132721.0,OT,,,,,,,,,144132721.0,1.0,HIV infection
14415884,144158843,3,F,20171107.0,20180227.0,20180122,20180313,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-001016,BRISTOL MYERS SQUIBB,,47.0,YR,,F,Y,,,20180313.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,144158843.0,HO,,,144158843.0,1.0,20170501.0,20170516.0,,,144158843.0,1.0,HIV infection
14418134,144181342,2,F,,20180117.0,20180122,20180129,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018008940,VIIV,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",46.0,YR,,F,Y,,,20180129.0,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144181342.0,OT,,,,,,,,,144181342.0,1.0,HIV infection
14447342,144473421,1,I,,20180122.0,20180126,20180126,EXP,,VN-GLAXOSMITHKLINE-VN2018012671,GLAXOSMITHKLINE,"THANH NT, VINH LD, LIEM NT, SHIKUMA C, DAY JN, THWAITES G ET AL. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19():33-37. DOI: 10.1016/J.MMCR.2016.12.005.",31.0,YR,,F,Y,,,20180126.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144473421.0,HO,,,,,,,,,144473421.0,1.0,Antiretroviral therapy
14447344,144473441,1,I,,20180122.0,20180126,20180126,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018012671,VIIV,"THANH NT, VINH LD, LIEM NT, SHIKUMA C, DAY JN, THWAITES G ET AL. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19():33-37. DOI: 10.1016/J.MMCR.2016.12.005.",31.0,YR,,F,Y,,,20180126.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144473441.0,HO,,,,,,,,,144473441.0,1.0,Antiretroviral therapy
14453674,144536741,1,I,,20180117.0,20180129,20180129,EXP,,GA-GLAXOSMITHKLINE-GA2018008940,GLAXOSMITHKLINE,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",46.0,YR,,F,Y,,,20180129.0,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144536741.0,OT,,,,,,,,,144536741.0,1.0,HIV infection
14454904,144549041,1,I,20170309.0,20170912.0,20180129,20180129,EXP,,UG-GILEAD-2017-0293742,GILEAD,,28.0,YR,A,F,Y,,,20180129.0,,OT,UG,UG,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,144549041.0,OT,,,144549041.0,1.0,20170309.0,20170313.0,,,144549041.0,1.0,HIV infection
14457122,144571222,2,F,,20180301.0,20180130,20180316,EXP,,US-AUROBINDO-AUR-APL-2018-003659,AUROBINDO,,,,,,Y,,,20180316.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury,144571222.0,OT,,,,,,,,,144571222.0,1.0,HIV infection
14457277,144572772,2,F,,20190205.0,20180130,20190215,EXP,,GB-AUROBINDO-AUR-APL-2018-004041,AUROBINDO,,,,,,Y,,,20190215.0,,CN,GB,GB,EFAVIRENZ.,Lip and/or oral cavity cancer,144572772.0,OT,,,,,,,,,144572772.0,1.0,Antiretroviral therapy
14460481,144604812,2,F,20170309.0,20180302.0,20180130,20180305,EXP,,UG-GLAXOSMITHKLINE-UG2017203170,GLAXOSMITHKLINE,,28.0,YR,,F,Y,,,20180305.0,,OT,UG,UG,EFAVIRENZ.,Drug-induced liver injury;Maternal exposure during pregnancy;Stillbirth,144604812.0,OT,,,144604812.0,1.0,20170309.0,20170313.0,,,144604812.0,2.0,HIV infection
14460922,144609222,2,F,20170309.0,20180302.0,20180130,20180305,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017203170,VIIV,,28.0,YR,,F,Y,,,20180305.0,,OT,UG,UG,EFAVIRENZ.,Drug-induced liver injury;Maternal exposure during pregnancy;Stillbirth,144609222.0,OT,,,144609222.0,1.0,20170309.0,20170313.0,,,144609222.0,2.0,HIV infection
14463771,144637713,3,F,,20180201.0,20180130,20180212,EXP,,UG-HETERO-HET2018UG00056,HETERO,,,,,M,Y,2.5,KG,20180212.0,,OT,UG,UG,EFAVIRENZ.,Congenital knee dislocation;Congenital limb hyperextension;Congenital syphilis;Cushingoid;Developmental hip dysplasia;Foetal exposure during pregnancy;Hair texture abnormal;Micrognathia;Skull malformation;Talipes;Wrist deformity,144637713.0,CA,,,144637713.0,1.0,20171206.0,20180112.0,,,144637713.0,1.0,HIV infection
14474087,144740872,2,F,,20180117.0,20180201,20180422,EXP,,US-APOTEX-2018AP006304,APOTEX,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE DOI: 10.1177/2325957417729751. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (6):540-545",43.0,YR,,M,Y,,,20180201.0,,MD,US,US,EFAVIRENZ.,Coccidioidomycosis;Condition aggravated;Immune reconstitution inflammatory syndrome,144740872.0,OT,,,,,,,,,144740872.0,1.0,Antiretroviral therapy
14474245,144742452,2,F,,20180209.0,20180201,20180219,EXP,,GB-009507513-1801GBR008170,MERCK,"COLUMPSI P, BHAGANI S. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION.. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS). 2017",56.0,YR,,M,Y,,,20180219.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,144742452.0,OT,,,,,,,,,144742452.0,1.0,HIV infection
14474585,144745854,4,F,20171107.0,20180920.0,20180201,20180925,EXP,GB-MHRA-EYC 00171403,GB-MYLANLABS-2018M1006020,MYLAN,,47.0,YR,,F,Y,,,20180925.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,144745854.0,OT,,,144745854.0,1.0,20170501.0,20171216.0,,,144745854.0,1.0,HIV infection
14475832,144758321,1,I,,20180126.0,20180201,20180201,EXP,,SG-ABBVIE-18S-141-2239299-00,ABBVIE,"YOUNG B, YEO T, LIM H, ET AL. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (PML-IRIS): TWO CASE REPORTS OF SUCCESSFUL TREATMENT WITH MEFLOQUINE AND A REVIEW OF THE LITERATURE. ANNALS ACADEMY OF MEDICINE SG. ANNALS ACADEMY OF MEDICINE. 2012 DEC;VOLUME 41 ISSUE 12:620-624.",39.0,YR,,M,Y,,,20180201.0,,OT,COUNTRY NOT SPECIFIED,SG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Progressive multifocal leukoencephalopathy,144758321.0,OT,,,,,,,,,144758321.0,1.0,HIV infection
14479122,144791221,1,I,,20180119.0,20180202,20180202,EXP,,ET-CIPLA LTD.-2018ET03089,CIPLA,"BIRLIE B, BRAEKERS R, AWOKE T, KASIM A, SHKEDY Z. MULTI-STATE MODELS FOR THE ANALYSIS OF TIME-TO-TREATMENT MODIFICATION AMONG HIV PATIENTS UNDER HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN SOUTHWEST ETHIOPIA. BMC INFECTIOUS DISEASES. 2017;17 (453):1 TO 13",,,,,Y,,,20180202.0,,OT,ET,ET,EFAVIRENZ.,Treatment failure,144791221.0,OT,,,,,,,,,144791221.0,1.0,HIV infection
14481960,144819602,2,F,,20180301.0,20180202,20180302,EXP,,ZA-GILEAD-2018-0317596,GILEAD,"SPRINGER PE, SLOGROVE AL, LAUGHTON B, BETTINGER JA, SAUNDERS HH, MOLTENO CD, KRUGER M. NEURODEVELOPMENTAL OUTCOME OF HIV-EXPOSED BUT UNINFECTED INFANTS IN THE MOTHER AND INFANTS HEALTH STUDY, CAPE TOWN, SOUTH AFRICA. TROPICAL MEDICINE AND INTERNATIONAL HEALTH. 2018;23:69-78 DOI:10.1111/TMI.13006",,,I,,Y,,,20180302.0,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Macrocephaly,144819602.0,OT,,,,,,,,,144819602.0,1.0,HIV infection
14482018,144820182,2,F,,20180301.0,20180202,20180302,EXP,,ZA-GILEAD-2018-0318424,GILEAD,"SPRINGER PE, SLOGROVE AL, LAUGHTON B, BETTINGER JA, SAUNDERS HH, MOLTENO CD, KRUGER M. NEURODEVELOPMENTAL OUTCOME OF HIV-EXPOSED BUT UNINFECTED INFANTS IN THE MOTHER AND INFANTS HEALTH STUDY, CAPE TOWN, SOUTH AFRICA. TROPICAL MEDICINE AND INTERNATIONAL HEALTH. 2018;23:69-78 DOI:10.1111/TMI.13006",,,I,,Y,,,20180302.0,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Macrocephaly,144820182.0,OT,,,,,,,,,144820182.0,1.0,HIV infection
14485393,144853934,4,F,20180112.0,20180201.0,20180205,20200806,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-010659,BRISTOL MYERS SQUIBB,,21.0,YR,,F,Y,,,20200806.0,,HP,UG,UG,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Premature delivery,144853934.0,OT,,,144853934.0,1.0,20171206.0,,,,144853934.0,1.0,HIV infection
14489861,144898612,2,F,,20180127.0,20180206,20180209,EXP,,UG-CIPLA LTD.-2018UG02611,CIPLA,,,,,,Y,,,20180209.0,,OT,UG,UG,EFAVIRENZ.,Congenital knee deformity;Congenital limb hyperextension;Developmental hip dysplasia;Foetal exposure during pregnancy;Premature baby;Skull malformation;Talipes;Wrist deformity,144898612.0,OT,,,,,,,,,144898612.0,1.0,HIV infection
14489887,144898872,2,F,20180112.0,20180127.0,20180206,20180209,EXP,,UG-CIPLA LTD.-2018UG02610,CIPLA,,,,,,Y,,,20180209.0,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,144898872.0,OT,,,144898872.0,1.0,20171206.0,,,,144898872.0,1.0,HIV infection
14491697,144916971,1,I,201801.0,20180122.0,20180206,20180206,EXP,,UG-AUROBINDO-AUR-APL-2018-003995,AUROBINDO,,,,,M,Y,2.5,KG,20180206.0,,OT,UG,UG,EFAVIRENZ.,Developmental hip dysplasia;Foetal exposure during pregnancy;Limb deformity;Skull malformation;Talipes,144916971.0,CA,,,144916971.0,1.0,20171206.0,,,,144916971.0,1.0,HIV infection
14494652,144946527,7,F,,20190904.0,20180206,20191021,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006996,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,,,20191021.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,144946527.0,OT,,,,,,,,,144946527.0,1.0,HIV infection
14495031,144950312,2,F,,20180209.0,20180206,20180215,EXP,,VN-GLAXOSMITHKLINE-VN2018019506,GLAXOSMITHKLINE,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",31.0,YR,,F,Y,,,20180215.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144950312.0,OT,,,144950312.0,1.0,2013.0,,,,144950312.0,1.0,HIV infection
14495042,144950422,2,F,,20180209.0,20180206,20180215,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018019506,VIIV,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",31.0,YR,,F,Y,,,20180215.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144950422.0,OT,,,144950422.0,1.0,2013.0,,,,144950422.0,1.0,HIV infection
14495878,144958783,3,F,,20180124.0,20180207,20181224,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA02656,CIPLA,"SCRIVEN JE, BOTHA FCJ, SCHUTZ C, LALLOO DG, WAINWRIGHT H, MEINTJES G. PARADOXICAL RESPIRATORY FAILURE DUE TO CRYPTOCOCCAL PNEUMONIA AFTER AMPHOTERICIN B TREATMENT FOR HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:38 TO 40",,,,,Y,,,20181224.0,,OT,ZA,ZA,EFAVIRENZ.,Anaemia macrocytic;Meningitis cryptococcal;Pneumonia cryptococcal;Respiratory failure,144958783.0,HO,,,,,,,,,144958783.0,1.0,HIV infection
14497708,144977081,1,I,2015.0,20180129.0,20180207,20180207,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018020373,VIIV,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T.. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION.. MEDICAL MYCOLOGY CASE REPORTS.. 2018;19:33-37",25.0,YR,,F,Y,,,20180207.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Immune reconstitution inflammatory syndrome associated tuberculosis,144977081.0,HO,,,144977081.0,1.0,2015.0,,,,144977081.0,1.0,HIV infection
14497710,144977102,2,F,,20180213.0,20180207,20180222,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018020377,VIIV,"LE T, THANH N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",35.0,YR,,M,Y,,,20180222.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144977102.0,HO,,,,,,,,,144977102.0,1.0,HIV infection
14497847,144978471,1,I,2015.0,20180129.0,20180207,20180207,EXP,,VN-GLAXOSMITHKLINE-VN2018020373,GLAXOSMITHKLINE,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T.. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION.. MEDICAL MYCOLOGY CASE REPORTS.. 2018;19:33-37",25.0,YR,,F,Y,,,20180207.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Immune reconstitution inflammatory syndrome associated tuberculosis,144978471.0,HO,,,144978471.0,1.0,2015.0,,,,144978471.0,1.0,HIV infection
14497849,144978492,2,F,,20180213.0,20180207,20180222,EXP,,VN-GLAXOSMITHKLINE-VN2018020377,GLAXOSMITHKLINE,"LE T, THANH N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",35.0,YR,,M,Y,,,20180222.0,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144978492.0,HO,,,,,,,,,144978492.0,1.0,HIV infection
14509357,145093571,1,I,,20180201.0,20180209,20180209,EXP,,UG-GLAXOSMITHKLINE-UG2018GSK021773,GLAXOSMITHKLINE,,21.0,YR,,F,Y,,,20180209.0,,CN,US,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery;Syphilis,145093571.0,OT,,,145093571.0,1.0,20171206.0,,,,145093571.0,1.0,HIV infection
14509359,145093591,1,I,20180112.0,20180203.0,20180209,20180209,EXP,,UG-GLAXOSMITHKLINE-UG2018GSK021911,GLAXOSMITHKLINE,,0.0,DY,,M,Y,,,20180209.0,,CN,US,UG,EFAVIRENZ.,Congenital hair disorder;Cushingoid;Foetal exposure during pregnancy;Low birth weight baby;Micrognathia,145093591.0,CA,,,145093591.0,1.0,20171206.0,,,,145093591.0,1.0,HIV infection
14510208,145102081,1,I,,20180201.0,20180209,20180209,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK021773,VIIV,,21.0,YR,,F,Y,,,20180209.0,,CN,US,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery;Syphilis,145102081.0,OT,,,145102081.0,1.0,20171206.0,,,,145102081.0,1.0,HIV infection
14510210,145102101,1,I,20180112.0,20180203.0,20180209,20180209,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK021911,VIIV,,0.0,DY,,M,Y,,,20180209.0,,CN,US,UG,EFAVIRENZ.,Congenital hair disorder;Cushingoid;Foetal exposure during pregnancy;Low birth weight baby;Micrognathia,145102101.0,CA,,,145102101.0,1.0,20171206.0,,,,145102101.0,1.0,HIV infection
14511631,145116311,1,I,20171206.0,20180122.0,20180209,20180209,EXP,,UG-GILEAD-2018-0317952,GILEAD,,0.0,YR,N,M,Y,,,20180209.0,,OT,UG,UG,EFAVIRENZ.,Autosomal chromosome anomaly;Congenital knee deformity;Developmental hip dysplasia;Dysmorphism;Foetal exposure during pregnancy;Hair texture abnormal;Limb malformation;Micrognathia;Skull malformation;Talipes,145116311.0,CA,,,145116311.0,1.0,20171206.0,,,,145116311.0,1.0,HIV infection
14519136,145191361,1,I,,20180130.0,20180212,20180212,EXP,,GB-MYLANLABS-2018M1008448,MYLAN,"COLUMPSI P, BHAGANI S.. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION.. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS). 2017",56.0,YR,,M,Y,,,20180212.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,145191361.0,OT,,,,,,,,,145191361.0,1.0,HIV infection
14525159,145251591,1,I,20171206.0,20180122.0,20180213,20180213,EXP,,UG-GLAXOSMITHKLINE-UG2018022996,GLAXOSMITHKLINE,,0.0,YR,,M,Y,,,20180213.0,,OT,UG,UG,EFAVIRENZ.,Autosomal chromosome anomaly;Congenital knee deformity;Developmental hip dysplasia;Dysmorphism;Foetal exposure during pregnancy;Hair texture abnormal;Limb malformation;Micrognathia;Skull malformation;Talipes,145251591.0,CA,,,145251591.0,1.0,20171206.0,,,,145251591.0,1.0,HIV infection
14525236,145252361,1,I,20171206.0,20180122.0,20180213,20180213,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018022996,VIIV,,0.0,YR,,M,Y,,,20180213.0,,OT,UG,UG,EFAVIRENZ.,Autosomal chromosome anomaly;Congenital knee deformity;Developmental hip dysplasia;Dysmorphism;Foetal exposure during pregnancy;Hair texture abnormal;Limb malformation;Micrognathia;Skull malformation;Talipes,145252361.0,OT,,,145252361.0,1.0,20171206.0,,,,145252361.0,1.0,HIV infection
14529571,145295711,1,I,,20180206.0,20180214,20180214,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018024872,VIIV,"NDJOYI-MBIGUINO A, KOMBE A, BIVIGOU-MBOUMBA B, ZOA-ASSOUMOU S, AKOMBI F, NZENGUI F, KAMDEM H, FRANCOIS-SOUQUIERE S.. LOW PREVALENCE OF HCV INFECTION WITH PREDOMINANCE OF GENOTYPE 4 AMONG HIV PATIENTS LIVING IN LIBREVILLE, GABON.. PLOS ONE.. 2018;13:1-12",44.0,YR,,F,Y,,,20180214.0,,OT,GA,GA,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective,145295711.0,OT,,,,,,,,,145295711.0,1.0,HIV infection
14530383,145303831,1,I,20171011.0,20180130.0,20180214,20180214,EXP,FR-AFSSAPS-LY20180391,FR-MYLANLABS-2018M1008481,MYLAN,,54.0,YR,,M,Y,98.0,KG,20180214.0,,PH,FR,FR,EFAVIRENZ.,Drug ineffective;No adverse event,145303831.0,HO,,,145303831.0,2.0,201509.0,,,,145303831.0,1.0,HIV infection
14530509,145305091,1,I,,20180206.0,20180214,20180214,EXP,,GA-GLAXOSMITHKLINE-GA2018024872,GLAXOSMITHKLINE,"NDJOYI-MBIGUINO A, KOMBE A, BIVIGOU-MBOUMBA B, ZOA-ASSOUMOU S, AKOMBI F, NZENGUI F, KAMDEM H, FRANCOIS-SOUQUIERE S.. LOW PREVALENCE OF HCV INFECTION WITH PREDOMINANCE OF GENOTYPE 4 AMONG HIV PATIENTS LIVING IN LIBREVILLE, GABON.. PLOS ONE.. 2018;13:1-12",44.0,YR,,F,Y,,,20180214.0,,OT,GA,GA,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective,145305091.0,OT,,,,,,,,,145305091.0,1.0,HIV infection
14548035,145480351,1,I,20180101.0,20180205.0,20180219,20180219,EXP,,LS-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-011495,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,45.0,KG,20180219.0,,MD,LS,LS,EFAVIRENZ.,Asthenia;Burning sensation;Dyspnoea;Left ventricular failure;Respiratory failure;Vomiting,145480351.0,HO,,,145480351.0,2.0,20170812.0,,,,145480351.0,1.0,HIV infection
14552465,145524651,1,I,2015.0,20180205.0,20180220,20180220,EXP,,US-AUROBINDO-AUR-APL-2018-005890,AUROBINDO,,43.0,YR,,M,Y,,,20180220.0,,OT,US,US,EFAVIRENZ.,Cardio-respiratory arrest;Coccidioidomycosis;Hypotension;Immune reconstitution inflammatory syndrome;Night sweats;Pneumonia;Productive cough;Pyrexia,145524651.0,DE,,,,,,,,,145524651.0,1.0,Antiretroviral therapy
14553441,145534416,6,F,20171107.0,20180805.0,20180220,20180813,EXP,GB-MHRA-EYC 00171403,GB-TEVA-2018-GB-857839,TEVA,,47.0,YR,,F,Y,,,20180813.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,145534416.0,HO,,,145534416.0,1.0,20170501.0,20171216.0,,,145534416.0,1.0,HIV infection
14562137,145621371,1,I,20171115.0,,20180222,20180222,DIR,,,FDA-CTU,,51.0,YR,,F,N,97.52,KG,,Y,CN,US,US,SUSTIVA,Asthenia;Blood glucose increased;Cough;Disorientation;Feeling abnormal;Gingival bleeding;Gingival recession;Heart rate increased;Pruritus;Thirst;Vision blurred,145621371.0,DS,145621371.0,CSM,145621371.0,1.0,20170710.0,20171115.0,,,145621371.0,1.0,HIV infection
14564233,145642331,1,I,,20180219.0,20180222,20180222,EXP,,IE-VIIV HEALTHCARE LIMITED-IE2018028715,VIIV,"BUTLER K, INSHAW J, FORD D, BERNAYS S, SCOTT K, KENNY J.ET.AL BREATHER (PENTA 16) SHORT-CYCLE THERAPY (SCT)(5 DAYS ON/2 DAYS OFF) IN YOUNG PEOPLE WITH CHRONIC HUMAN IMMUNODEFICIENCY VIRUS INFECTION: AN OPEN, RANDOMISED, PARALLEL-GROUP PHASE II/III TRIAL. HEALTH TECHNOLOGY ASSESSMENT. 2016 JUN;20(49):1-107. DOI: 10.3310/HTA20490",,,C,,Y,,,20180222.0,,MD,IE,IE,EFAVIRENZ.,Virologic failure,145642331.0,OT,,,,,,,,,145642331.0,1.0,HIV infection
14564238,145642381,1,I,,20180219.0,20180222,20180222,EXP,,IE-GLAXOSMITHKLINE-IE2018028715,GLAXOSMITHKLINE,"BUTLER K, INSHAW J, FORD D, BERNAYS S, SCOTT K, KENNY J.ET.AL BREATHER (PENTA 16) SHORT-CYCLE THERAPY (SCT)(5 DAYS ON/2 DAYS OFF) IN YOUNG PEOPLE WITH CHRONIC HUMAN IMMUNODEFICIENCY VIRUS INFECTION: AN OPEN, RANDOMISED, PARALLEL-GROUP PHASE II/III TRIAL. HEALTH TECHNOLOGY ASSESSMENT. 2016 JUN;20(49):1-107. DOI: 10.3310/HTA20490",,,C,,Y,,,20180222.0,,MD,IE,IE,EFAVIRENZ.,Virologic failure,145642381.0,OT,,,,,,,,,145642381.0,1.0,HIV infection
14564417,145644171,1,I,,20180219.0,20180222,20180222,EXP,,GB-GILEAD-2018-0322420,GILEAD,,54.0,YR,A,M,Y,,,20180222.0,,CN,GB,GB,EFAVIRENZ.,Anal fistula infection,145644171.0,HO,,,,,,,,,145644171.0,1.0,HIV infection
14565194,145651941,1,I,20171107.0,20180208.0,20180223,20180223,EXP,,GB-AUROBINDO-AUR-APL-2018-009154,AUROBINDO,,47.0,YR,,F,Y,,,20180222.0,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,145651941.0,HO,,,145651941.0,1.0,20170501.0,20170516.0,,,145651941.0,1.0,HIV infection
14565353,145653531,1,I,,20180208.0,20180223,20180223,EXP,,GB-AUROBINDO-AUR-APL-2018-009313,AUROBINDO,,56.0,YR,,M,Y,,,20180223.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,145653531.0,OT,,,,,,,,,145653531.0,1.0,HIV infection
14571070,145710701,1,I,20000405.0,20020729.0,20180226,20180226,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-11970746,BRISTOL MYERS SQUIBB,,35.0,YR,,M,Y,,,20180226.0,,OT,US,JP,EFAVIRENZ.,Gastrointestinal haemorrhage;Haematochezia;Hepatic function abnormal;Hyperlipidaemia;Shock haemorrhagic,145710701.0,DE,,,145710701.0,1.0,19970930.0,20010928.0,,,145710701.0,1.0,Acquired immunodeficiency syndrome
14576417,145764171,1,I,20001114.0,20010403.0,20180227,20180227,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-10784924,BRISTOL MYERS SQUIBB,,65.0,YR,,M,Y,48.0,KG,20180227.0,,OT,JP,JP,EFAVIRENZ.,AIDS related complex,145764171.0,OT,,,145764171.0,1.0,20000615.0,20000914.0,,,145764171.0,1.0,Acquired immunodeficiency syndrome
14589604,145896041,1,I,,20180217.0,20180302,20180302,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-015867,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,67.0,KG,20180302.0,,MD,GB,GB,SUSTIVA,Nightmare;Sleep disorder;Suicidal ideation,145896041.0,OT,,,,,,,,,145896041.0,1.0,HIV test positive
14592833,145928332,2,F,201707.0,20180306.0,20180302,20180313,EXP,,TR-GILEAD-2018-0322917,GILEAD,,45.0,YR,A,M,Y,,,20180313.0,,MD,TR,TR,EFAVIRENZ.,Herpes zoster;Treatment noncompliance,145928332.0,HO,,,145928332.0,1.0,2013.0,,,,145928332.0,1.0,HIV infection
14593102,145931022,2,F,2016.0,20180406.0,20180302,20180411,EXP,,TR-GILEAD-2018-0322921,GILEAD,,58.0,YR,A,M,Y,108.0,KG,20180411.0,,MD,TR,TR,EFAVIRENZ.,Bone density decreased;Nephrolithiasis;Renal impairment,145931022.0,OT,,,145931022.0,1.0,2013.0,2015.0,,,145931022.0,1.0,HIV infection
14593834,145938341,1,I,,20180220.0,20180302,20180302,EXP,,TR-GILEAD-2018-0322713,GILEAD,,44.0,YR,A,M,Y,,,20180302.0,,MD,TR,TR,EFAVIRENZ.,Drug resistance;Gene mutation identification test positive;Treatment noncompliance;Virologic failure,145938341.0,OT,,,,,,,,,145938341.0,1.0,HIV infection
14595944,145959441,1,I,,20180216.0,20180303,20180303,EXP,,GB-AUROBINDO-AUR-APL-2018-010500,AUROBINDO,,54.0,YR,,M,Y,67.0,KG,20180303.0,,MD,GB,GB,EFAVIRENZ.,Nightmare;Sleep disorder;Suicidal ideation,145959441.0,DS,,,,,,,,,145959441.0,1.0,HIV test positive
14595957,145959576,6,F,,20180524.0,20180303,20180531,EXP,,FR-AUROBINDO-AUR-APL-2018-010835,AUROBINDO,,,,,,Y,,,20180601.0,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Drug interaction;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue;Unwanted pregnancy,145959576.0,OT,,,145959576.0,1.0,20111001.0,,,,145959576.0,1.0,HIV infection
14596055,145960551,1,I,20001221.0,20180226.0,20180303,20180303,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018031833,VIIV,,37.0,YR,,F,Y,,,20180303.0,,CN,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn,145960551.0,OT,,,145960551.0,2.0,19960814.0,,,,145960551.0,1.0,Antiretroviral therapy
14596130,145961301,1,I,20001221.0,20180226.0,20180303,20180303,EXP,,FR-GLAXOSMITHKLINE-FR2018031833,GLAXOSMITHKLINE,,37.0,YR,,F,Y,,,20180303.0,,CN,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn,145961301.0,OT,,,145961301.0,2.0,19960814.0,,,,145961301.0,1.0,Antiretroviral therapy
14596238,145962387,7,F,,20191022.0,20180303,20191102,EXP,,FR-AUROBINDO-AUR-APL-2018-010672,AUROBINDO,,32.0,YR,,F,Y,,,20191102.0,,OT,US,FR,Efavirenz Film Coated Tablets,Abortion induced;Drug interaction;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue;Unwanted pregnancy,145962387.0,OT,,,145962387.0,1.0,20090901.0,,,,145962387.0,1.0,HIV infection
14599811,145998112,2,F,,20180719.0,20180305,20180726,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018031666,VIIV,ESTEVES T.. MATERNAL DRUG USE DURING PREGNANCY AND INFANCY ?THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH.. REVISTA PORTUGUESA DE CLINICA GERAL.. 2011?27::458?64,27.0,YR,,F,Y,,,20180726.0,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,145998112.0,OT,,,145998112.0,3.0,2007.0,,,,145998112.0,1.0,HIV infection
14599813,145998132,2,F,,20180719.0,20180305,20180726,EXP,,PT-GLAXOSMITHKLINE-PT2018031666,GLAXOSMITHKLINE,ESTEVES T.. MATERNAL DRUG USE DURING PREGNANCY AND INFANCY ?THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH.. REVISTA PORTUGUESA DE CLINICA GERAL.. 2011?27::458?64,27.0,YR,,F,Y,,,20180726.0,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,145998132.0,OT,,,145998132.0,3.0,2007.0,,,,145998132.0,1.0,HIV infection
14604248,146042481,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0323708,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146042481.0,OT,,,,,,,,,146042481.0,1.0,HIV infection
14604272,146042721,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324575,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146042721.0,OT,,,,,,,,,146042721.0,1.0,HIV infection
14604417,146044171,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324581,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044171.0,OT,,,,,,,,,146044171.0,1.0,HIV infection
14604418,146044181,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324579,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044181.0,OT,,,,,,,,,146044181.0,1.0,HIV infection
14604419,146044191,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324577,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044191.0,OT,,,,,,,,,146044191.0,1.0,HIV infection
14604420,146044201,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324578,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044201.0,OT,,,,,,,,,146044201.0,1.0,HIV infection
14604432,146044321,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324576,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044321.0,OT,,,,,,,,,146044321.0,1.0,HIV infection
14604433,146044331,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324582,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044331.0,OT,,,,,,,,,146044331.0,1.0,HIV infection
14604434,146044341,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324580,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044341.0,OT,,,,,,,,,146044341.0,1.0,HIV infection
14604439,146044391,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324583,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044391.0,OT,,,,,,,,,146044391.0,1.0,HIV infection
14604440,146044401,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324584,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044401.0,OT,,,,,,,,,146044401.0,1.0,HIV infection
14604441,146044411,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324585,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044411.0,OT,,,,,,,,,146044411.0,1.0,HIV infection
14604442,146044421,1,I,,20180226.0,20180306,20180306,EXP,,ZA-GILEAD-2018-0324586,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044421.0,OT,,,,,,,,,146044421.0,1.0,HIV infection
14605422,146054221,1,I,,20180301.0,20180306,20180306,EXP,,GB-GILEAD-2018-0324072,GILEAD,,,,,M,Y,,,20180306.0,,PH,GB,GB,EFAVIRENZ.,Death,146054221.0,OT,,,,,,,,,146054221.0,1.0,HIV infection
14607636,146076361,1,I,,20180222.0,20180307,20180307,EXP,,AU-MYLANLABS-2018M1014320,MYLAN,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STD-AIDS 2018;29(3):227-236.",,,A,M,Y,,,20180307.0,,OT,AU,AU,EFAVIRENZ.,Anaemia;Fanconi syndrome acquired,146076361.0,OT,,,,,,,,,146076361.0,1.0,HIV infection
14607848,146078481,1,I,,20180222.0,20180307,20180307,EXP,,AU-MYLANLABS-2018M1014345,MYLAN,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STD-AIDS 2018;29(3):227-236.",,,A,M,Y,,,20180307.0,,OT,AU,AU,EFAVIRENZ.,Drug interaction;Fanconi syndrome acquired,146078481.0,OT,,,,,,,,,146078481.0,1.0,HIV infection
14608010,146080104,4,F,,20240429.0,20180307,20240507,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK038183,GLAXOSMITHKLINE,,,,,,Y,,,20240507.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,146080104.0,OT,,,146080104.0,1.0,,,549.0,DAY,146080104.0,1.0,HIV infection
14612446,146124464,4,F,,20240429.0,20180308,20240507,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK038183,VIIV,,,,,,Y,,,20240507.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,146124464.0,OT,,,146124464.0,1.0,,,549.0,DAY,146124464.0,1.0,HIV infection
14619562,146195624,4,F,20001221.0,20180322.0,20180309,20180403,EXP,,FR-AUROBINDO-AUR-APL-2018-011998,AUROBINDO,,37.0,YR,,F,Y,,,20180403.0,,CN,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn;Pregnancy,146195624.0,OT,,,146195624.0,1.0,19960814.0,,,,146195624.0,1.0,Antiretroviral therapy
14620011,146200111,1,I,20170823.0,20180224.0,20180309,20180309,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-018331,BRISTOL MYERS SQUIBB,,34.0,YR,,M,Y,84.0,KG,20180309.0,,PH,GB,GB,SUSTIVA,Nightmare,146200111.0,OT,,,146200111.0,1.0,20170823.0,20171123.0,,,146200111.0,1.0,Acute HIV infection
14621083,146210831,1,I,20170823.0,20180223.0,20180310,20180310,EXP,GB-MHRA-EYC 00171579,GB-AUROBINDO-AUR-APL-2018-012110,AUROBINDO,,34.0,YR,,M,Y,84.0,KG,20180310.0,,PH,GB,GB,EFAVIRENZ.,Nightmare,146210831.0,OT,,,146210831.0,1.0,20170823.0,20171123.0,,,146210831.0,1.0,Acute HIV infection
14623366,146233662,2,F,,20180312.0,20180312,20180316,EXP,,AU-STRIDES ARCOLAB LIMITED-2018SP001663,STRIDES,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STDAIDS. 2017;29(3):227-236",,,,,Y,,,20180316.0,,OT,AU,AU,EFAVIRENZ.,Acute kidney injury;Anaemia;Fanconi syndrome;Glycosuria;Proteinuria,146233662.0,OT,,,,,,,,,146233662.0,1.0,HIV infection
14626923,146269231,1,I,,20180226.0,20180312,20180312,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-018763,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,,,20180312.0,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,146269231.0,HO,,,146269231.0,1.0,199902.0,,,,146269231.0,1.0,HIV infection
14631761,146317613,3,F,,20180320.0,20180313,20180327,EXP,,ES-GILEAD-2018-0325136,GILEAD,,46.0,YR,A,,Y,,,20180327.0,,MD,ES,ES,EFAVIRENZ.,Drug withdrawal maintenance therapy;Nervous system disorder;Neurodermatitis;Treatment noncompliance;Weight decreased,146317613.0,OT,,,146317613.0,1.0,200805.0,,,,146317613.0,1.0,HIV infection
14631821,146318211,1,I,,20180228.0,20180313,20180313,EXP,,"US-LANNETT COMPANY, INC.-US-2018LAN000518",LANNETT,"OGBUAGU O, HAO R, VIRATA M, VILLANUEVA MS, MALINIS M. EFFICACY OF AN 8-WEEK COURSE OF SOFOSBUVIR AND LEDIPASVIR FOR THE TREATMENT OF HCV INFECTION IN SELECTED HIV-INFECTED PATIENTS. F1000RES. 2017;6620",,,A,M,Y,,,20180313.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury,146318211.0,OT,,,,,,,,,146318211.0,1.0,Antiretroviral therapy
14633105,146331051,1,I,,20180227.0,20180313,20180313,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-018769,BRISTOL MYERS SQUIBB,,6.0,YR,,F,Y,,,20180313.0,,MD,US,US,EFAVIRENZ.,Hypersensitivity,146331051.0,OT,,,,,,,,,146331051.0,1.0,HIV infection
14633200,146332002,2,F,,20180316.0,20180313,20180323,EXP,,PT-ABBVIE-18P-130-2283024-00,ABBVIE,"NUNES C, ROCHA S, ESTEVES T. DRUG ADDICTION DURING PREGNANCY AND MOTHERHOOD  THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH. REVISTA PORTUGUESA DE CLINICA GERAL. 2011;27:458-564.",27.0,YR,,F,Y,,,20180323.0,,OT,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ.,Exposure during pregnancy,,,,,146332002.0,4.0,2007.0,,,,146332002.0,1.0,HIV infection
14641442,146414421,1,I,20170101.0,20180228.0,20180315,20180315,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-020295,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20180315.0,,MD,FR,FR,SUSTIVA,Renal colic,146414421.0,OT,,,,,,,,,146414421.0,1.0,Antiretroviral therapy
14645809,146458091,1,I,,20180301.0,20180316,20180316,EXP,,FR-CIPLA LTD.-2018FR11841,CIPLA,"PRESSIAT C, AMORISSANI-FOLQUET M, YONABA C, TRELUYER JM, DAHOUROU DL, EBOUA F ET.AL.,. PHARMACOKINETICS OF EFAVIRENZ IN 2-3 YEARS OLD CHILDREN: A HIGH DOSE OF 25 MG/KG PER DAY. ANTIMICROBIAL AGENTS AND CHEMOTHEMOTHERAPY. 2017;1 TO 25",,,,,Y,,,20180316.0,,OT,FR,FR,EFAVIRENZ.,Sleep disorder,146458091.0,OT,,,,,,,,,146458091.0,1.0,HIV infection
14649319,146493193,3,F,,20200528.0,20180316,20200603,EXP,,CA-APOTEX-2018AP006359,APOTEX,,45.0,YR,,M,Y,,,20200603.0,,CN,CA,CA,EFAVIRENZ.,Multiple-drug resistance,146493193.0,OT,,,,,,,,,146493193.0,1.0,HIV infection
14651092,146510926,6,F,,20190219.0,20180316,20190228,EXP,FR-EMA-20170316-SROYP-090824780,FR-GILEAD-2016-0216060,GILEAD,"RUELLAN AL, VEYRAC G, BRUNET-CARTIER C, JARNET L, JOLLIET P. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016;30 (1):50",32.0,YR,A,F,Y,,,20190228.0,,OT,FR,FR,EFAVIRENZ.,Maternal exposure during pregnancy,,,,,146510926.0,1.0,2009.0,,,,146510926.0,1.0,HIV infection
14662859,146628593,3,F,,20180306.0,20180321,20201229,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000005,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL..DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",57.0,YR,A,F,Y,,,20180321.0,,HP,TH,TH,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms;Hepatitis;Leukocytosis;Product use in unapproved indication;Purpura;Pyrexia;Rash maculo-papular;Skin exfoliation,146628593.0,LT,,,,,,,,,146628593.0,1.0,Prophylaxis against HIV infection
14662921,146629212,2,F,,20180306.0,20180321,20181011,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000014,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL.DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",41.0,YR,A,M,Y,,,20181011.0,,,TH,TH,EFAVIRENZ.,Hepatitis;Product use in unapproved indication;Purpura;Pyrexia;Rash maculo-papular;Skin exfoliation;Stevens-Johnson syndrome,146629212.0,LT,,,,,,,,,146629212.0,1.0,Prophylaxis against HIV infection
14663072,146630721,1,I,,20180308.0,20180321,20180321,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-023073,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20180321.0,,PH,GB,GB,EFAVIRENZ.,Death,146630721.0,OT,,,,,,,,,146630721.0,1.0,HIV infection
14666305,146663054,4,F,,20180403.0,20180321,20181109,EXP,FR-EMA-20170404-RENITAROYP-155219665,FR-GILEAD-2016-0216062,GILEAD,,28.0,YR,A,F,Y,,,20181109.0,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,146663054.0,OT,,,146663054.0,1.0,201110.0,,,,146663054.0,1.0,HIV infection
14668853,146688531,1,I,,20180308.0,20180322,20180322,EXP,,GB-AUROBINDO-AUR-APL-2018-016210,AUROBINDO,,66.0,YR,,M,Y,,,20180322.0,,PH,GB,GB,EFAVIRENZ.,Death,146688531.0,DE,,,,,,,,,146688531.0,1.0,HIV infection
14669548,146695481,1,I,,20180315.0,20180322,20180322,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018044235,VIIV,COLIN D. HYPERSENSITIVITY SYNDROME ASSOCIATED WITH EFAVIRENZ THERAPY.. CLINICAL INFECTIOUS DISEASES. 2000;30:227-8,44.0,YR,,F,Y,,,20180322.0,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,146695481.0,OT,,,146695481.0,1.0,199902.0,,,,146695481.0,1.0,HIV infection
14670449,146704491,1,I,,20180315.0,20180322,20180322,EXP,,FR-GLAXOSMITHKLINE-FR2018044235,GLAXOSMITHKLINE,COLIN D. HYPERSENSITIVITY SYNDROME ASSOCIATED WITH EFAVIRENZ THERAPY.. CLINICAL INFECTIOUS DISEASES. 2000;30:227-8,44.0,YR,,F,Y,,,20180322.0,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,146704491.0,HO,,,146704491.0,1.0,199902.0,,,,146704491.0,1.0,HIV infection
14673095,146730951,1,I,,20180314.0,20180323,20180323,EXP,,ZA-HETERO CORPORATE-HET2018ZA00216,HETERO,,35.0,YR,,F,Y,,,20180323.0,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Foetal death;Haemoglobin decreased;Platelet count decreased;Vitamin B12 deficiency,146730951.0,OT,,,146730951.0,1.0,20180214.0,,,,146730951.0,1.0,HIV infection
14674924,146749244,4,F,20180304.0,20190319.0,20180323,20190322,EXP,,CO-AUROBINDO-AUR-APL-2018-016866,AUROBINDO,,26.0,YR,,M,Y,105.0,KG,20190322.0,,PH,CO,CO,Efavirenz 600mg,Arthralgia;Diarrhoea;Headache;Pyrexia;Treatment noncompliance;Vomiting,146749244.0,HO,,,146749244.0,1.0,20180226.0,,,,146749244.0,1.0,HIV infection
14676686,146766862,2,F,,20190619.0,20180324,20190701,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-025144,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20190701.0,,OT,ZA,ZA,EFAVIRENZ.,Haemoglobin decreased;Maternal exposure during pregnancy;Platelet count decreased;Ventricular extrasystoles;Vitamin B12 deficiency,146766862.0,HO,,,146766862.0,1.0,20180214.0,,,,146766862.0,1.0,HIV infection
14679807,146798071,1,I,,20180319.0,20180326,20180326,EXP,,BR-ABBVIE-18P-020-2295403-00,ABBVIE,"DA FONSECA M, MESQUITA L, DA SILVA R, MORIZOT E. PANRETINAL RITONAVIR-INDUCED RETINOPATHY: A REPORT OF LONG-TERM USEPANRETINAL RITONAVIR-INDUCED RETINOPATHY: A REPORT OF LONG-TERM USE. RETINAL CASES + BRIEF REPORTS. 2018 MAR 15;1-3.",52.0,YR,,M,Y,,,20180326.0,,MD,COUNTRY NOT SPECIFIED,BR,EFAVIRENZ.,Retinal toxicity;Retinopathy,146798071.0,OT,,,,,,,,,146798071.0,1.0,HIV infection
14680403,146804031,1,I,,20180312.0,20180326,20180326,EXP,,FR-TEVA-2018-FR-872166,TEVA,"CEZ A, BROCHERIOU I, LESCURE F-X, ADAM C, GIRARD P-M, PIALOUX G, ET AL. DECREASED EXPRESSION OF MEGALIN AND CUBILIN AND ALTERED MITOCHONDRIAL ACTIVITY IN TENOFOVIR NEPHROTOXICITY. HUM-PATHOL 2018;73:89-101.",54.0,YR,,M,Y,,,20180326.0,,MD,FR,FR,EFAVIRENZ.,Fanconi syndrome acquired;Renal tubular dysfunction,146804031.0,OT,,,,,,,,,146804031.0,1.0,Antiretroviral therapy
14682508,146825081,1,I,,20180313.0,20180327,20180327,EXP,,FR-AUROBINDO-AUR-APL-2018-016242,AUROBINDO,,44.0,YR,,F,Y,,,20180327.0,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,,,,,146825081.0,1.0,199902.0,,,,146825081.0,1.0,HIV infection
14682623,146826235,5,F,20180313.0,20200514.0,20180327,20200521,EXP,,ZA-AUROBINDO-AUR-APL-2018-015610,AUROBINDO,,35.0,YR,,F,Y,,,20200521.0,,HP,ZA,ZA,EFAVIRENZ.,Cardiac murmur;Maternal exposure during pregnancy,146826235.0,OT,,,146826235.0,1.0,20180214.0,,,,146826235.0,1.0,HIV infection
14683821,146838212,2,F,2017.0,20180326.0,20180327,20180411,PER,,"US-THERATECHNOLOGIES, INC.-TH-2018-00226",THERATECHNOLOGIES,,,,,,Y,,,20180411.0,,CN,US,US,SUSTIVA,HIV test positive,,,,,146838212.0,1.0,201105.0,,,,146838212.0,1.0,HIV infection
14685358,146853581,1,I,,20180314.0,20180327,20180327,EXP,,"AU-LANNETT COMPANY, INC.-AU-2018LAN000566",LANNETT,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STD-AIDS. 2018;29(3):227-236",43.0,YR,,M,Y,,,20180327.0,,OT,AU,AU,EFAVIRENZ.,Fanconi syndrome,146853581.0,OT,,,,,,,,,146853581.0,1.0,Antiretroviral therapy
14703627,147036271,1,I,19991102.0,20010702.0,20180402,20180402,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-10902104,BRISTOL MYERS SQUIBB,,24.0,YR,,M,Y,,,20180402.0,,OT,US,JP,EFAVIRENZ.,Anaemia;Hypokalaemia,147036271.0,LT,,,147036271.0,1.0,19991020.0,19991102.0,,,147036271.0,1.0,Acquired immunodeficiency syndrome
14703977,147039772,2,F,,20180504.0,20180402,20180511,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018GSK054286,VIIV,,20.0,YR,,F,Y,,,20180511.0,,CN,US,BR,ESTOCRIN (EFAVIRENZ),Bacterial vaginosis;Blepharospasm;Blood pressure increased;Exposure during pregnancy;Gait disturbance;Headache;Live birth;Paraesthesia;Syphilis;Vision blurred,147039772.0,OT,,,147039772.0,1.0,20171208.0,,,,147039772.0,1.0,HIV infection
14705040,147050401,1,I,,20180327.0,20180402,20180402,EXP,,US-JNJFOC-20180341027,JANSSEN,"DEAN R, SUBEDI R, KARKEE A. CHYLOUS ASCITES IN INTRA-ABDOMINAL MYCOBACTERIUM AVIUM COMPLEX IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME.. JOURNAL OF INVESTIGATIVE MEDICINE 2018;66(2):457.",51.0,YR,A,M,Y,,,20180402.0,,OT,US,US,EFAVIRENZ.,Ascites;Mycobacterium avium complex immune restoration disease,147050401.0,OT,,,,,,,,,147050401.0,1.0,Acquired immunodeficiency syndrome
14711202,147112022,2,F,,20180416.0,20180403,20180424,EXP,,FR-GILEAD-2018-0323412,GILEAD,,54.0,YR,A,M,Y,,,20180424.0,,OT,FR,FR,EFAVIRENZ.,Fanconi syndrome acquired;Nephropathy toxic;Renal tubular dysfunction,147112022.0,OT,,,,,,,,,147112022.0,1.0,HIV infection
14715497,147154972,2,F,,20181008.0,20180404,20181118,EXP,,FR-MYLANLABS-2018M1020400,MYLAN,,28.0,YR,,F,Y,,,20181118.0,,CN,US,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,147154972.0,OT,,,,,,,,,147154972.0,1.0,HIV infection
14715558,147155582,2,F,,20180402.0,20180404,20180410,EXP,,TR-GILEAD-2018-0329488,GILEAD,,45.0,YR,A,F,Y,,,20180410.0,,MD,TR,TR,EFAVIRENZ.,Anxiety disorder;Blood HIV RNA increased;Drug ineffective;Multiple-drug resistance;Off label use,147155582.0,OT,,,147155582.0,1.0,2011.0,,,,147155582.0,1.0,HIV infection
14719430,147194301,1,I,,20180321.0,20180405,20180405,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-027036,BRISTOL MYERS SQUIBB,,,,,F,Y,63.5,KG,20180405.0,,CN,US,US,SUSTIVA,Adverse event;Drug screen positive,,,,,147194301.0,1.0,2010.0,201712.0,,,147194301.0,1.0,HIV infection
14726637,147266371,1,I,,20180323.0,20180406,20180406,EXP,,IT-CIPLA LTD.-2018IT14717,CIPLA,,,,,,Y,,,20180406.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Gastrointestinal disorder;Treatment noncompliance;Virologic failure,147266371.0,OT,,,,,,,,,147266371.0,1.0,HIV infection
14727479,147274791,1,I,,20180330.0,20180406,20180406,EXP,,FR-JNJFOC-20180402054,JANSSEN,,,,A,F,Y,57.0,KG,20180406.0,,MD,FR,FR,EFAVIRENZ.,Hospitalisation;Treatment noncompliance,147274791.0,HO,,,,,,,,,147274791.0,1.0,HIV infection
14728431,147284311,1,I,201603.0,20180328.0,20180406,20180406,EXP,,CO-009507513-1803COL013075,MERCK,,26.0,YR,,M,Y,,,20180406.0,,MD,CO,CO,EFAVIRENZ.,Autoimmune hepatitis;Autoimmune thyroiditis;Thrombocytopenia,147284311.0,HO,,,147284311.0,1.0,201603.0,201603.0,,,147284311.0,1.0,HIV infection
14732971,147329711,1,I,,20180405.0,20180409,20180409,EXP,,US-STRIDES ARCOLAB LIMITED-2018SP002641,STRIDES,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD-CASE-REP. 2018;4(3):256-258",,,,,Y,,,20180409.0,,MD,US,US,EFAVIRENZ.,Drug hypersensitivity;Lichenoid keratosis;Pruritus;Rash erythematous;Skin hyperpigmentation;Skin plaque,147329711.0,OT,,,,,,,,,147329711.0,1.0,HIV infection
14735340,147353401,1,I,,20180327.0,20180409,20180409,EXP,,US-MYLANLABS-2018M1022043,MYLAN,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD-CASE-REP 2018;4(3):256-258.",4.0,DEC,,M,Y,,,20180409.0,,MD,US,US,EFAVIRENZ.,Lichenoid keratosis,147353401.0,OT,,,,,,,,,147353401.0,1.0,HIV infection
14737618,147376181,1,I,,20180327.0,20180409,20180409,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-029837,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,,,20180409.0,,OT,US,ZA,EFAVIRENZ.,Drug eruption,147376181.0,OT,,,,,,,,,147376181.0,1.0,HIV infection
14738191,147381912,2,F,20171215.0,20180411.0,20180409,20180417,EXP,,FR-GILEAD-2018-0324258,GILEAD,,33.0,YR,A,M,Y,62.5,KG,20180417.0,,MD,FR,FR,EFAVIRENZ.,Hepatitis A,147381912.0,HO,,,147381912.0,1.0,20150616.0,201711.0,,,147381912.0,1.0,HIV infection
14740218,147402181,1,I,,20180402.0,20180410,20180410,EXP,,US-HETERO CORPORATE-HET2018US00298,HETERO,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD-CASE-REP. 2018;4(3):256-258",40.0,YR,,M,Y,,,20180410.0,,MD,US,US,EFAVIRENZ.,Lichenoid keratosis,147402181.0,OT,,,,,,,,,147402181.0,1.0,HIV infection
14756319,147563191,1,I,,20180409.0,20180413,20180413,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018GSK063417,VIIV,,46.0,YR,,M,Y,,,20180413.0,,MD,GB,GB,EFAVIRENZ.,Renal failure,147563191.0,OT,,,,,,,,,147563191.0,1.0,HIV infection
14756367,147563671,1,I,,20180409.0,20180413,20180413,EXP,,GB-GLAXOSMITHKLINE-GB2018GSK063417,GLAXOSMITHKLINE,,46.0,YR,,M,Y,,,20180413.0,,MD,GB,GB,EFAVIRENZ.,Renal failure,147563671.0,OT,,,,,,,,,147563671.0,1.0,HIV infection
14758880,147588802,2,F,,20181017.0,20180413,20181023,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018058111,VIIV,LYALL H. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG. 2018;38(3):231-8,,,C,,Y,,,20181023.0,,OT,GB,GB,EFAVIRENZ.,Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,147588802.0,OT,,,,,,,,,147588802.0,1.0,Perinatal HIV infection
14758881,147588812,2,F,,20181017.0,20180413,20181023,EXP,,GB-GLAXOSMITHKLINE-GB2018058111,GLAXOSMITHKLINE,LYALL H. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG. 2018;38(3):231-8,,,C,,Y,,,20181023.0,,OT,GB,GB,EFAVIRENZ.,Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,147588812.0,OT,,,,,,,,,147588812.0,1.0,Perinatal HIV infection
14759637,147596371,1,I,20140810.0,20180406.0,20180413,20180413,EXP,,IT-ABBVIE-18S-083-2316572-00,ABBVIE,,51.0,YR,,F,Y,48.0,KG,20180413.0,,OT,IT,IT,EFAVIRENZ.,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,147596371.0,OT,,,147596371.0,3.0,20120627.0,20141110.0,,,147596371.0,1.0,HIV infection
14772020,147720201,1,I,,20180410.0,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK066160,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Renal injury,147720201.0,OT,,,,,,,,,147720201.0,1.0,HIV infection
14772021,147720211,1,I,,20180410.0,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK063154,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720211.0,OT,,,,,,,,,147720211.0,1.0,HIV infection
14772025,147720251,1,I,,20180410.0,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK066151,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Liver injury,147720251.0,OT,,,,,,,,,147720251.0,1.0,HIV infection
14772031,147720311,1,I,,20180410.0,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK066150,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720311.0,OT,,,,,,,,,147720311.0,1.0,HIV infection
14772032,147720321,1,I,,20180410.0,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK066160,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Renal injury,147720321.0,OT,,,,,,,,,147720321.0,1.0,HIV infection
14772033,147720331,1,I,,20180410.0,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK063154,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720331.0,OT,,,,,,,,,147720331.0,1.0,HIV infection
14772034,147720341,1,I,,20180410.0,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK066151,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Liver injury,147720341.0,OT,,,,,,,,,147720341.0,1.0,HIV infection
14772040,147720401,1,I,,20180410.0,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK066150,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720401.0,OT,,,,,,,,,147720401.0,1.0,HIV infection
14772166,147721661,1,I,,20180403.0,20180418,20180418,EXP,,GB-AUROBINDO-AUR-APL-2018-020351,AUROBINDO,,,,C,,Y,,,20180418.0,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,147721661.0,OT,,,,,,,,,147721661.0,1.0,Perinatal HIV infection
14776657,147766571,1,I,20160329.0,20160405.0,20180419,20180419,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026039,BRISTOL MYERS SQUIBB,,53.0,YR,,F,Y,54.0,KG,20180419.0,,MD,UG,UG,EFAVIRENZ.,Cardiac arrest;Electrolyte imbalance;Gastritis;Helicobacter test positive;Malnutrition;Oesophageal carcinoma;Oral candidiasis,147766571.0,OT,,,147766571.0,1.0,20120705.0,20160329.0,,,147766571.0,1.0,HIV infection
14781533,147815332,2,F,,20180522.0,20180420,20180601,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035189,BRISTOL MYERS SQUIBB,,47.0,YR,,F,Y,109.0,KG,20180601.0,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,147815332.0,HO,,,147815332.0,1.0,20161004.0,20171215.0,,,147815332.0,1.0,HIV infection
14782075,147820752,2,F,,20180406.0,20180420,20190722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035829,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722.0,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myasthenia gravis,147820752.0,OT,,,,,,,,,147820752.0,1.0,HIV infection
14782122,147821222,2,F,,20180406.0,20180420,20190722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035832,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722.0,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Sarcoidosis,147821222.0,OT,,,,,,,,,147821222.0,1.0,HIV infection
14782138,147821382,2,F,,20180406.0,20180420,20190722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035835,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722.0,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Immune thrombocytopenic purpura,147821382.0,OT,,,,,,,,,147821382.0,1.0,HIV infection
14784717,147847171,1,I,,20180409.0,20180420,20180420,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035345,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20180420.0,,OT,BR,PT,EFAVIRENZ.,Pemphigoid,147847171.0,HO,,,,,,,,,147847171.0,1.0,HIV infection
14788887,147888871,1,I,,20180408.0,20180423,20180423,EXP,,ES-AUROBINDO-AUR-APL-2018-021230,AUROBINDO,BARRUFET P.. EXPERIENCIA CON GENVOYA VIDA REAL PACIENTE PRETRATO. PRESENTATION.,46.0,YR,,,Y,,,20180423.0,,MD,ES,ES,EFAVIRENZ.,Drug withdrawal maintenance therapy;Nervous system disorder;Neurodermatitis;Treatment noncompliance;Weight decreased,147888871.0,OT,,,147888871.0,2.0,200805.0,,,,147888871.0,1.0,HIV infection
14790646,147906464,4,F,,20190205.0,20180423,20190211,EXP,,PT-MYLANLABS-2018M1025394,MYLAN,,27.0,YR,,F,Y,,,20190211.0,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,147906464.0,OT,,,147906464.0,1.0,2007.0,,,,147906464.0,1.0,HIV infection
14793964,147939641,1,I,,20180418.0,20180423,20180423,EXP,GB-MHRA-EYC 00171779,GB-GLAXOSMITHKLINE-GB2018067264,GLAXOSMITHKLINE,,47.0,YR,,F,Y,109.0,KG,20180423.0,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,147939641.0,OT,,,147939641.0,1.0,20170418.0,20171215.0,,,147939641.0,1.0,HIV infection
14794086,147940861,1,I,,20180418.0,20180423,20180423,EXP,GB-MHRA-EYC 00171779,GB-VIIV HEALTHCARE LIMITED-GB2018067264,VIIV,,47.0,YR,,F,Y,109.0,KG,20180423.0,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,147940861.0,HO,,,147940861.0,1.0,20170418.0,20171215.0,,,147940861.0,1.0,HIV infection
14797476,147974761,1,I,20170610.0,20180213.0,20180424,20180424,PER,GB-MHRA-EYC 00173678,GB-LUPIN PHARMACEUTICALS INC.-2018-01261,LUPIN,,55.0,YR,,F,Y,,,20180424.0,,CN,GB,GB,SUSTIVA,Headache;Product substitution issue,,,,,147974761.0,1.0,20170601.0,20180131.0,,,147974761.0,1.0,HIV infection
14797478,147974782,2,F,,20191230.0,20180424,20200110,EXP,,US-LUPIN PHARMACEUTICALS INC.-2018-00403,LUPIN,,,,A,M,Y,,,20200110.0,,HP,US,US,EFAVIRENZ.,Acute kidney injury,147974782.0,OT,,,147974782.0,3.0,20141101.0,,,,147974782.0,1.0,HIV infection
14800764,148007644,4,F,20001221.0,20190523.0,20180424,20190531,EXP,,FR-MYLANLABS-2018M1025782,MYLAN,,37.0,YR,,F,Y,,,20190531.0,,OT,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn,148007644.0,OT,,,148007644.0,1.0,19960814.0,,,,148007644.0,1.0,Antiretroviral therapy
14804156,148041562,2,F,,20180525.0,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16566,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525.0,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148041562.0,OT,,,,,,,,,148041562.0,1.0,HIV infection
14804157,148041572,2,F,,20180525.0,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16560,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525.0,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148041572.0,OT,,,,,,,,,148041572.0,1.0,HIV infection
14804170,148041702,2,F,,20180525.0,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16562,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525.0,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148041702.0,OT,,,,,,,,,148041702.0,1.0,HIV infection
14804712,148047122,2,F,,20180525.0,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16559,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525.0,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148047122.0,OT,,,,,,,,,148047122.0,1.0,HIV infection
14804725,148047252,2,F,,20180525.0,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16565,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525.0,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148047252.0,OT,,,,,,,,,148047252.0,1.0,HIV infection
14812901,148129011,1,I,,20180412.0,20180426,20180426,EXP,,US-CIPLA (EU) LIMITED-2018US16683,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180426.0,,OT,US,US,EFAVIRENZ.,Blood creatinine increased,148129011.0,OT,,,,,,,,,148129011.0,1.0,HIV infection
14813041,148130412,2,F,,20180622.0,20180426,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16704,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016?1?21",,,,,Y,,,20180706.0,,OT,US,US,EFAVIRENZ.,Renal failure,148130412.0,OT,,,,,,,,,148130412.0,1.0,HIV infection
14813174,148131741,1,I,,20180411.0,20180426,20180426,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16563,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180426.0,,OT,ZA,ZA,EFAVIRENZ.,Treatment failure,148131741.0,OT,,,,,,,,,148131741.0,1.0,HIV infection
14813198,148131981,1,I,,20180411.0,20180426,20180426,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16557,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180426.0,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148131981.0,OT,,,,,,,,,148131981.0,1.0,HIV infection
14814084,148140842,2,F,,20180525.0,20180426,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16561,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525.0,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148140842.0,OT,,,,,,,,,148140842.0,1.0,HIV infection
14814946,148149462,2,F,,20180426.0,20180426,20180509,EXP,,PE-MYLANLABS-2018M1026294,MYLAN,"GAMERO MT, GALLARDO MS, AGUILAR V, BRAVO E, GUEVARA J, MEJIA F. [NON-CIRRHOTIC PORTAL HYPERTENSION DUE TO DIDANOSINA. A RARE CASE]. REV-GASTROENTEROL-PERU 2017;37(1):87-90.",39.0,YR,,F,Y,,,20180509.0,,OT,PE,PE,EFAVIRENZ.,Ascites;Non-cirrhotic portal hypertension;Normocytic anaemia;Upper gastrointestinal haemorrhage,148149462.0,DE,,,,,,,,,148149462.0,1.0,HIV infection
14816449,148164492,2,F,201606.0,20180424.0,20180426,20180504,EXP,,TR-GILEAD-2018-0334419,GILEAD,,37.0,YR,A,M,Y,,,20180504.0,,MD,TR,TR,EFAVIRENZ.,Cardiac arrest;Low density lipoprotein increased;Myocardial infarction,148164492.0,HO,,,148164492.0,1.0,2010.0,2011.0,,,148164492.0,1.0,HIV infection
14818099,148180992,2,F,,20180622.0,20180427,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16705,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016?1?21",,,,,Y,,,20180706.0,,OT,US,US,EFAVIRENZ.,Glomerulonephritis acute,148180992.0,OT,,,,,,,,,148180992.0,1.0,HIV infection
14818100,148181001,1,I,,20180412.0,20180427,20180427,EXP,,US-CIPLA (EU) LIMITED-2018US16684,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180427.0,,OT,US,US,EFAVIRENZ.,Blood creatinine abnormal,148181001.0,OT,,,,,,,,,148181001.0,1.0,HIV infection
14818477,148184771,1,I,,20180412.0,20180427,20180427,EXP,,US-CIPLA (EU) LIMITED-2018US16680,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180427.0,,OT,US,US,EFAVIRENZ.,Renal failure,148184771.0,OT,,,,,,,,,148184771.0,1.0,HIV infection
14819154,148191542,2,F,,20180622.0,20180427,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16702,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016?1?21",,,,,Y,,,20180706.0,,OT,US,US,EFAVIRENZ.,Nephrolithiasis,148191542.0,OT,,,,,,,,,148191542.0,1.0,HIV infection
14820568,148205681,1,I,,20180417.0,20180427,20180427,EXP,,ZA-MYLANLABS-2018M1026732,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",37.0,YR,,F,Y,,,20180427.0,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148205681.0,OT,,,,,,,,,148205681.0,1.0,HIV infection
14821037,148210371,1,I,,20180414.0,20180427,20180427,EXP,,GB-AUROBINDO-AUR-APL-2018-022611,AUROBINDO,,46.0,YR,,M,Y,,,20180427.0,,MD,GB,GB,EFAVIRENZ.,Renal failure,148210371.0,OT,,,,,,,,,148210371.0,1.0,HIV infection
14821380,148213801,1,I,,20180402.0,20180427,20180427,EXP,,TR-GILEAD-2018-0331331,GILEAD,,57.0,YR,A,M,Y,,,20180427.0,,MD,TR,TR,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,148213801.0,OT,,,148213801.0,2.0,2016.0,,,,148213801.0,1.0,HIV infection
14821421,148214211,1,I,,20180413.0,20180427,20180427,EXP,,GB-AUROBINDO-AUR-APL-2018-023059,AUROBINDO,,,,,,Y,,,20180427.0,,OT,GB,GB,EFAVIRENZ.,Learning disorder;Psychotic symptom,148214211.0,OT,,,,,,,,,148214211.0,1.0,Perinatal HIV infection
14822044,148220442,2,F,,20190416.0,20180427,20190429,EXP,,GB-AUROBINDO-AUR-APL-2018-022247,AUROBINDO,,,,,,Y,,,20190429.0,,PH,GB,GB,EFAVIRENZ MILPHARM FILM-COATED TABLET,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,148220442.0,HO,,,148220442.0,1.0,20161004.0,20171215.0,,,148220442.0,1.0,HIV infection
14826910,148269101,1,I,,20180416.0,20180430,20180430,EXP,,US-AUROBINDO-AUR-APL-2018-021805,AUROBINDO,,55.0,YR,,M,Y,,,20180430.0,,MD,US,US,EFAVIRENZ.,Cough;Erythema;Fatigue;Haematuria;Hepatosplenomegaly;Hypercalcaemia;Hyperphosphataemia;Immune reconstitution inflammatory syndrome;Inflammation;Lymphadenopathy;Mycobacterium kansasii infection;Nephropathy toxic;Nodule;Pancytopenia;Papule;Pollakiuria;Pruritus;Skin lesion;Toxicity to various agents;Tubulointerstitial nephritis;Weight decreased,148269101.0,OT,,,148269101.0,1.0,2015.0,,,,148269101.0,1.0,HIV infection
14834074,148340741,1,I,20170823.0,20180419.0,20180501,20180501,EXP,GB-MHRA-EYC 00171579,GB-MYLANLABS-2018M1027953,MYLAN,,34.0,YR,,M,Y,84.0,KG,20180430.0,,PH,GB,GB,EFAVIRENZ.,Nightmare,148340741.0,OT,,,148340741.0,1.0,20170823.0,20171123.0,,,148340741.0,1.0,Acute HIV infection
14844449,148444491,1,I,201801.0,20180424.0,20180503,20180503,EXP,,CL-VIIV HEALTHCARE LIMITED-CL2018GSK072426,VIIV,,47.0,YR,,M,Y,,,20180503.0,,MD,CL,CL,EFAVIRENZ.,Neutropenia;Primary syphilis;Pyrexia;Rash maculo-papular;Thrombocytopenia,148444491.0,OT,,,148444491.0,1.0,201801.0,201802.0,,,148444491.0,1.0,HIV test positive
14849889,148498893,3,F,2002.0,20180621.0,20180504,20180625,EXP,,PT-ABBVIE-18P-130-2343262-00,ABBVIE,"MARTINS S, QUINAZ C, XARA S, ET AL. AIDS  RELATED PRIMARY PULMONARY LYMPHOMA. REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS. 2017;13 (3):142-145.",55.0,YR,,M,Y,,,20180625.0,,OT,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148498893.0,DE,,,148498893.0,4.0,1997.0,,,,148498893.0,1.0,HIV infection
14850446,148504463,3,F,,20190520.0,20180505,20190522,EXP,,FR-AUROBINDO-AUR-APL-2018-024204,AUROBINDO,,,,,,Y,,,20190522.0,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myositis,148504463.0,OT,,,,,,,,,148504463.0,1.0,HIV infection
14850621,148506211,1,I,2009.0,20180420.0,20180506,20180506,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-037345,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20180506.0,,OT,FR,FR,EFAVIRENZ.,Inclusion body myositis,148506211.0,OT,,,148506211.0,1.0,1992.0,1995.0,,,148506211.0,1.0,HIV test positive
14853855,148538551,1,I,,20180424.0,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041530,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180507.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148538551.0,OT,,,,,,,,,148538551.0,1.0,HIV infection
14853856,148538561,1,I,,20180424.0,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041531,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20180507.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148538561.0,HO,,,,,,,,,148538561.0,1.0,HIV infection
14853857,148538571,1,I,,20180424.0,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041528,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180507.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148538571.0,OT,,,,,,,,,148538571.0,1.0,HIV infection
14854194,148541943,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-039831,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148541943.0,OT,,,,,,,,,148541943.0,1.0,HIV infection
14854269,148542693,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041218,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542693.0,OT,,,,,,,,,148542693.0,1.0,HIV infection
14854271,148542713,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041223,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148542713.0,OT,,,,,,,,,148542713.0,1.0,HIV infection
14854272,148542723,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041222,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148542723.0,OT,,,,,,,,,148542723.0,1.0,HIV infection
14854273,148542733,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041221,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542733.0,OT,,,,,,,,,148542733.0,1.0,HIV infection
14854274,148542743,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041219,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542743.0,OT,,,,,,,,,148542743.0,1.0,HIV infection
14854276,148542763,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041220,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542763.0,OT,,,,,,,,,148542763.0,1.0,HIV infection
14854352,148543523,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041224,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148543523.0,OT,,,,,,,,,148543523.0,1.0,HIV infection
14854415,148544153,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041225,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148544153.0,OT,,,,,,,,,148544153.0,1.0,HIV infection
14854423,148544233,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041226,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148544233.0,OT,,,,,,,,,148544233.0,1.0,HIV infection
14854441,148544413,3,F,,20180509.0,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041227,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806.0,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148544413.0,OT,,,,,,,,,148544413.0,1.0,HIV infection
14854677,148546771,1,I,,20180424.0,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041529,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180507.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148546771.0,OT,,,,,,,,,148546771.0,1.0,HIV infection
14858601,148586011,1,I,,20180424.0,20180508,20180508,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041526,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180508.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148586011.0,OT,,,,,,,,,148586011.0,1.0,HIV infection
14858605,148586051,1,I,,20180424.0,20180508,20180508,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041555,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180508.0,,OT,US,ZA,EFAVIRENZ.,Treatment failure,148586051.0,OT,,,,,,,,,148586051.0,1.0,HIV infection
14858764,148587641,1,I,,20180424.0,20180508,20180508,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-039845,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180508.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148587641.0,OT,,,,,,,,,148587641.0,1.0,HIV infection
14858765,148587651,1,I,,20180424.0,20180508,20180508,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041527,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180508.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148587651.0,OT,,,,,,,,,148587651.0,1.0,HIV infection
14862937,148629371,1,I,,20180424.0,20180508,20180508,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-039909,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180508.0,,OT,TH,TH,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,148629371.0,OT,,,,,,,,,148629371.0,1.0,Prophylaxis against HIV infection
14862938,148629381,1,I,,20180424.0,20180508,20180508,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041533,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180508.0,,OT,TH,TH,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,148629381.0,OT,,,,,,,,,148629381.0,1.0,Prophylaxis against HIV infection
14862940,148629401,1,I,,20180424.0,20180508,20180508,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041532,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180508.0,,OT,TH,TH,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,148629401.0,OT,,,,,,,,,148629401.0,1.0,Prophylaxis against HIV infection
14869524,148695244,4,F,2002.0,20180820.0,20180509,20180827,EXP,,PT-JNJFOC-20180508029,JANSSEN,"MARTINS S, QUINAZ C, XARA S, VASCONCELOS O, VICENTE P, SARMENTO?CASTRO R. AIDS ?RELATED PRIMARY PULMONARY LYMPHOMA. REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS. 2017?13 (3):142?5.",55.0,YR,A,M,Y,,,20180827.0,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148695244.0,DE,,,148695244.0,3.0,1997.0,,,,148695244.0,1.0,HIV infection
14874964,148749641,1,I,,20180426.0,20180510,20180510,EXP,,FR-AUROBINDO-AUR-APL-2018-025008,AUROBINDO,,54.0,YR,,M,Y,,,20180510.0,,OT,FR,FR,EFAVIRENZ.,Fanconi syndrome acquired;Nephropathy toxic;Renal tubular dysfunction,148749641.0,OT,,,,,,,,,148749641.0,1.0,Antiretroviral therapy
14884665,148846652,2,F,,20180511.0,20180511,20180522,EXP,,BR-MYLANLABS-2018M1030976,MYLAN,,,,,F,Y,,,20180519.0,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Genitalia external ambiguous,148846652.0,CA,,,148846652.0,1.0,20171030.0,20180301.0,,,148846652.0,1.0,HIV infection
14894776,148947766,6,F,2002.0,20181205.0,20180515,20181218,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041488,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20181218.0,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148947766.0,HO,,,148947766.0,5.0,1997.0,,,,148947766.0,1.0,HIV infection
14900459,149004591,1,I,,20180502.0,20180516,20180516,EXP,,ZA-AUROBINDO-AUR-APL-2018-025512,AUROBINDO,,37.0,YR,,F,Y,,,20180516.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Confusional state;Encephalopathy;Gait disturbance,149004591.0,OT,,,,,,,,,149004591.0,1.0,HIV infection
14900505,149005053,3,F,2002.0,20180816.0,20180516,20180830,EXP,,PT-AUROBINDO-AUR-APL-2018-025856,AUROBINDO,,55.0,YR,,M,Y,,,20180830.0,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Drug ineffective;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,149005053.0,OT,,,149005053.0,1.0,1997.0,2010.0,,,149005053.0,1.0,HIV infection
14905487,149054871,1,I,,20170608.0,20180517,20180517,EXP,,UG-CIPLA LTD.-2017UG10688,CIPLA,,,,,,Y,,,20180517.0,,OT,GB,UG,EFAVIRENZ.,Death,149054871.0,OT,,,,,,,,,149054871.0,1.0,HIV infection
14906424,149064241,1,I,,20170608.0,20180517,20180517,EXP,,UG-CIPLA (EU) LIMITED-2017UG10619,CIPLA,,,,,,Y,,,20180517.0,,OT,GB,UG,EFAVIRENZ.,Pneumonia,149064241.0,DE,,,,,,,,,149064241.0,1.0,HIV infection
14907478,149074781,1,I,,20180502.0,20180517,20180517,EXP,,ZA-AUROBINDO-AUR-APL-2018-026564,AUROBINDO,,,,,F,Y,,,20180517.0,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Gait disturbance,149074781.0,OT,,,,,,,,,149074781.0,1.0,HIV infection
14907874,149078742,2,F,,20180518.0,20180517,20180601,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17898,CIPLA,,,,,,Y,,,20180601.0,,OT,US,ZA,EFAVIRENZ.,Abnormal behaviour;Antiviral drug level above therapeutic;Petit mal epilepsy,149078742.0,OT,,,,,,,,,149078742.0,1.0,HIV infection
14909965,149099653,3,F,,20180528.0,20180517,20180529,EXP,,TR-GILEAD-2018-0338363,GILEAD,,,,A,,Y,,,20180529.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149099653.0,OT,,,,,,,,,149099653.0,1.0,HIV infection
14910087,149100873,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338916,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100873.0,OT,,,,,,,,,149100873.0,1.0,HIV infection
14910088,149100883,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338914,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100883.0,OT,,,,,,,,,149100883.0,1.0,HIV infection
14910089,149100893,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338915,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100893.0,OT,,,,,,,,,149100893.0,1.0,HIV infection
14910090,149100903,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338912,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100903.0,OT,,,,,,,,,149100903.0,1.0,HIV infection
14910091,149100913,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338913,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100913.0,OT,,,,,,,,,149100913.0,1.0,HIV infection
14910092,149100923,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338911,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100923.0,OT,,,,,,,,,149100923.0,1.0,HIV infection
14910103,149101033,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338920,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101033.0,OT,,,,,,,,,149101033.0,1.0,HIV infection
14910104,149101043,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338919,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101043.0,OT,,,,,,,,,149101043.0,1.0,HIV infection
14910105,149101053,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338922,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101053.0,OT,,,,,,,,,149101053.0,1.0,HIV infection
14910106,149101063,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338921,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101063.0,OT,,,,,,,,,149101063.0,1.0,HIV infection
14910107,149101073,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338917,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101073.0,OT,,,,,,,,,149101073.0,1.0,HIV infection
14910108,149101083,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338918,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101083.0,OT,,,,,,,,,149101083.0,1.0,HIV infection
14910118,149101183,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338926,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101183.0,OT,,,,,,,,,149101183.0,1.0,HIV infection
14910120,149101203,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338925,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101203.0,OT,,,,,,,,,149101203.0,1.0,HIV infection
14910122,149101223,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338923,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101223.0,OT,,,,,,,,,149101223.0,1.0,HIV infection
14910123,149101233,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338924,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101233.0,OT,,,,,,,,,149101233.0,1.0,HIV infection
14910124,149101243,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338928,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101243.0,OT,,,,,,,,,149101243.0,1.0,HIV infection
14910125,149101253,3,F,,20180528.0,20180517,20180530,EXP,,TR-GILEAD-2018-0338927,GILEAD,,,,A,,Y,,,20180530.0,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101253.0,OT,,,,,,,,,149101253.0,1.0,HIV infection
14911120,149111201,1,I,,20180504.0,20180518,20180518,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17892,CIPLA,,,,,,Y,,,20180518.0,,OT,US,ZA,EFAVIRENZ.,Abdominal pain upper;Antisocial behaviour;Nervous system disorder;Toxicity to various agents;Vomiting,149111201.0,OT,,,,,,,,,149111201.0,1.0,Perinatal HIV infection
14911344,149113443,3,F,,20180810.0,20180518,20180822,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17895,CIPLA,,,,,,Y,,,20180822.0,,OT,US,ZA,EFAVIRENZ.,Antiviral drug level above therapeutic;Generalised tonic-clonic seizure;Postictal state;Urinary incontinence,149113443.0,OT,,,,,,,,,149113443.0,1.0,Perinatal HIV infection
14911468,149114682,2,F,,20180518.0,20180518,20180601,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17889,CIPLA,,,,,,Y,,,20180601.0,,OT,US,ZA,EFAVIRENZ.,Aggression;Antiviral drug level above therapeutic;Generalised tonic-clonic seizure;Pyrexia,149114682.0,HO,,,,,,,,,149114682.0,1.0,Perinatal HIV infection
14917168,149171681,1,I,,20180508.0,20180521,20180521,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-043137,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20180521.0,,OT,PT,PT,SUSTIVA,Drug ineffective;Multiple organ dysfunction syndrome;Septic shock,149171681.0,DE,,,,,,,,,149171681.0,1.0,HIV infection
14921347,149213473,3,F,20180413.0,20180615.0,20180522,20180626,EXP,,BR-HETERO CORPORATE-HET2018BR00424,HETERO,,1.0,MON,,F,Y,,,20180626.0,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Genitalia external ambiguous,149213473.0,CA,,,149213473.0,1.0,20171030.0,20180301.0,,,149213473.0,1.0,HIV infection
14927739,149277391,1,I,2009.0,20170403.0,20180523,20180523,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-028877,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,,,20180523.0,,CN,GB,GB,SUSTIVA,Gynaecomastia,149277391.0,OT,,,149277391.0,1.0,2007.0,2010.0,,,149277391.0,1.0,HIV infection
14931261,149312617,7,F,,20200612.0,20180524,20200817,EXP,,CA-ROCHE-2126762,ROCHE,,52.0,YR,,M,Y,,,20200817.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,149312617.0,OT,,,,,,,,,149312617.0,1.0,HIV infection
14931694,149316942,2,F,,20180529.0,20180524,20180611,EXP,,GB-AUROBINDO-AUR-APL-2018-027240,AUROBINDO,,,,,F,Y,,,20180611.0,,OT,GB,GB,Efavirenz Film-coated Tablet,Breast feeding;Hypertension;Liver function test increased;Maternal exposure during pregnancy;Product use issue;Stillbirth,149316942.0,OT,,,,,,,,,149316942.0,1.0,HIV infection
14936059,149360592,2,F,20170908.0,20181126.0,20180524,20181203,EXP,,ZA-GILEAD-2018-0339854,GILEAD,,,,,F,Y,,,20181203.0,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Pre-eclampsia;Premature delivery,149360592.0,OT,,,149360592.0,1.0,20170908.0,20171105.0,,,149360592.0,1.0,HIV infection
14936127,149361272,2,F,20170908.0,20181126.0,20180524,20181203,EXP,,ZA-GILEAD-2018-0339857,GILEAD,,,,N,F,Y,,,20181203.0,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Neonatal respiratory distress,149361272.0,OT,,,149361272.0,1.0,20170908.0,20171105.0,,,149361272.0,1.0,HIV infection
14937462,149374622,2,F,,20181005.0,20180525,20181018,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-043920,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20181018.0,,OT,GB,GB,EFAVIRENZ.,Gestational hypertension;Live birth;Maternal exposure during pregnancy;Product use issue,149374622.0,OT,,,,,,,,,149374622.0,1.0,HIV infection
14940410,149404101,1,I,,20180514.0,20180525,20180525,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-045054,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,,,20180525.0,,OT,TN,TN,EFAVIRENZ.,Cytomegalovirus infection;Histoplasmosis disseminated;Hypoxia;Labelled drug-drug interaction medication error;Pneumonia cytomegaloviral;Treatment failure,149404101.0,LT,,,,,,,,,149404101.0,1.0,HIV infection
14942766,149427661,1,I,,20180515.0,20180528,20180528,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-048195,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180528.0,,OT,ZA,GB,EFAVIRENZ.,Liver function test increased;Maternal exposure during pregnancy;Product use issue;Stillbirth,149427661.0,OT,,,,,,,,,149427661.0,1.0,HIV infection
14950570,149505701,1,I,2015.0,20180528.0,20180530,20180530,EXP,FR-AFSSAPS-LM20180416,FR-ABBVIE-18S-056-2369897-00,ABBVIE,,,,,M,Y,105.0,KG,20180530.0,,MD,FR,FR,SUSTIVA,Condition aggravated;Hepatitis,149505701.0,HO,,,149505701.0,1.0,2005.0,,,,149505701.0,1.0,HIV infection
14953354,149533542,2,F,,20180523.0,20180530,20180531,EXP,,MX-VIIV HEALTHCARE LIMITED-MX2018GSK094520,VIIV,"PORTILLA-JIMENEZ A, ARIAS-DELGADILLO C, PARRA-AVILA I, MARINO-VAZQUEZ L, ROSADO-CANTO R, MORALES-BUENROSTRO L.. LONG-TERM EVOLUTION OF TRANSPLANT RECIPIENTS^ KIDNEY WITH HIV INFECTION.. REVISTA MEXICANA DE TRASPLANTES. 2017;6 (1):66",53.0,YR,,M,Y,,,20180531.0,,MD,MX,MX,EFAVIRENZ.,Diabetes mellitus;Transplant rejection,149533542.0,OT,,,,,,,,,149533542.0,1.0,HIV infection
14953361,149533612,2,F,,20180523.0,20180530,20180531,EXP,,MX-GLAXOSMITHKLINE-MX2018GSK094520,GLAXOSMITHKLINE,"PORTILLA-JIMENEZ A, ARIAS-DELGADILLO C, PARRA-AVILA I, MARINO-VAZQUEZ L, ROSADO-CANTO R, MORALES-BUENROSTRO L.. LONG-TERM EVOLUTION OF TRANSPLANT RECIPIENTS^ KIDNEY WITH HIV INFECTION.. REVISTA MEXICANA DE TRASPLANTES. 2017;6 (1):66",53.0,YR,,M,Y,,,20180531.0,,MD,MX,MX,EFAVIRENZ.,Diabetes mellitus;Transplant rejection,149533612.0,OT,,,,,,,,,149533612.0,1.0,HIV infection
14959465,149594651,1,I,,20180522.0,20180531,20180531,EXP,,GB-MYLANLABS-2018M1034971,MYLAN,,66.0,YR,,M,Y,,,20180524.0,,PH,GB,GB,EFAVIRENZ.,Death,149594651.0,DE,,,,,,,,,149594651.0,1.0,HIV infection
14959722,149597222,2,F,,20180519.0,20180531,20180601,EXP,,ZA-AUROBINDO-AUR-APL-2014-04025,AUROBINDO,,34.0,YR,,M,Y,,,20180602.0,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Virologic failure,149597222.0,OT,,,,,,,,,149597222.0,1.0,Antiretroviral therapy
14961417,149614172,2,F,,20180823.0,20180601,20180823,EXP,,FR-MACLEODS PHARMACEUTICALS US LTD-MAC2018013928,MACLEODS,,,,,,Y,,,20180823.0,,CN,FR,FR,EFAVIRENZ.,Fanconi syndrome;Nephropathy toxic;Renal tubular dysfunction,149614172.0,OT,,,,,,,,,149614172.0,1.0,Antiretroviral therapy
14962390,149623901,1,I,,20171204.0,20180601,20180601,EXP,,ET-AUROBINDO-AUR-APL-2017-46000,AUROBINDO,,30.0,YR,,M,Y,,,20180601.0,,OT,DE,ET,EFAVIRENZ.,Gene mutation;Pathogen resistance;Virologic failure,149623901.0,OT,,,,,,,,,149623901.0,1.0,Antiretroviral therapy
14963407,149634071,1,I,,20180521.0,20180601,20180601,EXP,,TW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-049478,BRISTOL MYERS SQUIBB,,47.0,YR,,M,Y,,,20180601.0,,OT,TW,TW,EFAVIRENZ.,Non-cirrhotic portal hypertension,149634071.0,OT,,,,,,,,,149634071.0,1.0,HIV infection
14964933,149649331,1,I,,20180523.0,20180601,20180601,EXP,,TW-MYLANLABS-2018M1036498,MYLAN,"HO Y-H, YI LW, HSU Y-H, WANG L-S. NON-CIRRHOTIC PORTAL HYPERTENSION IN HIV PATIENTS. INT-J-ANTIMICROB-AGENTS 2017;50 (SUPPL. 2):S199.",47.0,YR,,M,Y,,,20180601.0,,OT,TW,TW,EFAVIRENZ.,Gastric ulcer;Non-cirrhotic portal hypertension;Portal hypertensive gastropathy;Splenomegaly;Varices oesophageal,149649331.0,HO,,,,,,,,,149649331.0,1.0,HIV infection
14968323,149683231,1,I,,20180522.0,20180604,20180604,EXP,GB-MHRA-EYC 00171779,GB-LUPIN PHARMACEUTICALS INC.-2018-04098,LUPIN,,47.0,YR,,F,Y,109.0,KG,20180604.0,,CN,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,149683231.0,HO,,,149683231.0,1.0,20170418.0,20171215.0,,,149683231.0,1.0,HIV infection
14968758,149687581,1,I,,,20180511,20180511,DIR,,,FDA-CTU,,53.0,YR,,F,N,,,20180511.0,N,OT,US,US,EFAVIRENZ.,Nausea;Weight decreased,149687581.0,OT,149687581.0,HP,149687581.0,1.0,,,8.0,YR,149687581.0,1.0,HIV infection
14976004,149760042,2,F,,20180528.0,20180605,20180625,EXP,,FR-MYLANLABS-2018M1037134,MYLAN,,44.0,YR,,F,Y,,,20180625.0,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,149760042.0,OT,,,149760042.0,1.0,199902.0,,,,149760042.0,1.0,HIV infection
14983919,149839193,3,F,,20180907.0,20180607,20180913,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018GSK100503,VIIV,,48.0,YR,,F,Y,,,20180913.0,,MD,FR,FR,SUSTIVA,Drug interaction;Tuberculosis,149839193.0,OT,,,149839193.0,1.0,20160528.0,20160704.0,,,149839193.0,1.0,HIV infection
14984254,149842541,1,I,,20180531.0,20180607,20180607,EXP,,ZA-VIIV HEALTHCARE LIMITED-GB2018097202,VIIV,,,,,F,Y,,,20180607.0,,OT,ZA,GB,EFAVIRENZ.,Exposure during pregnancy;Liver function test increased;Product use issue;Stillbirth,149842541.0,OT,,,,,,,,,149842541.0,1.0,HIV infection
14986565,149865652,2,F,2015.0,20181101.0,20180608,20181112,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-049452,BRISTOL MYERS SQUIBB,,,,,M,Y,105.0,KG,20181112.0,,MD,FR,FR,SUSTIVA,Condition aggravated;Hepatitis,149865652.0,OT,,,149865652.0,1.0,2005.0,,,,149865652.0,1.0,HIV infection
14991292,149912923,3,F,20180601.0,20201030.0,20180608,20201103,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2018GSK101917,VIIV,,,,,F,Y,66.5,KG,20201103.0,,MD,ZA,ZA,EFAVIRENZ.,Transaminases increased,149912923.0,OT,,,149912923.0,1.0,20180314.0,20180605.0,,,149912923.0,1.0,HIV infection
14992184,149921842,2,F,,20180625.0,20180608,20180629,EXP,,GH-GILEAD-2018-0343047,GILEAD,"BADII VS, BUABENG KO, POKU TA, FORKUO AD, BOAMAH BB, ARHIN SM, KPEWOU DE.. TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IS ASSOCIATED WITH SUPERIOR CD4 T CELLS REPOPULATION COMPARED TO ZIDOVUDINE-BASED HAART IN HIV 1 INFECTED ADULTS. INTERNATIONAL JOURNAL OF CHRONIC DISEASE PRINT. 2018;UNK:8 DOI.ORG/10.1155/2018/3702740",,,A,F,Y,38.0,KG,20180629.0,,MD,GH,GH,EFAVIRENZ.,Nephropathy,149921842.0,DE,,,149921842.0,2.0,20160705.0,,,,149921842.0,1.0,HIV infection
14992195,149921952,2,F,20160228.0,20180625.0,20180608,20180703,EXP,,GH-GILEAD-2018-0343050,GILEAD,,,,A,F,Y,,,20180703.0,,OT,GH,GH,EFAVIRENZ.,Psychotic disorder,149921952.0,OT,,,149921952.0,3.0,20160226.0,20160309.0,,,149921952.0,1.0,HIV infection
14998093,149980931,1,I,,20180529.0,20180611,20180611,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-053800,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20180611.0,,MD,GB,GB,EFAVIRENZ.,Burkitt's lymphoma;Pancytopenia,149980931.0,HO,,,,,,,,,149980931.0,1.0,HIV infection
15000172,150001723,3,F,2017.0,20190319.0,20180612,20190322,EXP,,CO-AUROBINDO-AUR-APL-2018-031555,AUROBINDO,,39.0,YR,,M,Y,68.3,KG,20190322.0,,PH,CO,CO,EFAVIRENZ.,Treatment failure;Viral load increased,150001723.0,OT,,,150001723.0,1.0,201607.0,,,,150001723.0,1.0,HIV infection
15003212,150032121,1,I,,20180606.0,20180613,20180613,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001947",BOEHRINGER INGELHEIM,"BRUZZESE E, VECCHIO A, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44:37:.",17.0,YR,,F,Y,,,20180613.0,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150032121.0,OT,,,,,,,,,150032121.0,1.0,HIV infection
15003485,150034851,1,I,,20180606.0,20180613,20180613,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001948",BOEHRINGER INGELHEIM,"BRUZZESE E, VECCHIO A, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37):.",16.0,YR,,M,Y,,,20180613.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150034851.0,OT,,,,,,,,,150034851.0,1.0,HIV infection
15003986,150039861,1,I,,20180606.0,20180613,20180613,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001944",BOEHRINGER INGELHEIM,"BRUZZESE E, VECCHIO, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL.. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37:.",18.0,YR,,F,Y,,,20180613.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150039861.0,OT,,,,,,,,,150039861.0,1.0,HIV infection
15007684,150076841,1,I,20170618.0,20180601.0,20180613,20180613,EXP,SE-MPA-2018-001593,SE-MYLANLABS-2018M1038820,MYLAN,,32.0,YR,,F,Y,,,20180608.0,,MD,SE,SE,EFAVIRENZ.,Dizziness,150076841.0,OT,,,,,,,,,150076841.0,1.0,HIV infection
15009609,150096093,3,F,,20190227.0,20180614,20190312,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-050860,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,,,20190312.0,,OT,GB,GB,EFAVIRENZ.,Toxicity to various agents,150096093.0,OT,,,,,,,,,150096093.0,1.0,HIV infection
15011880,150118801,1,I,,20180608.0,20180614,20180614,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2018102598,VIIV,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44:37,16.0,YR,,M,Y,,,20180614.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150118801.0,OT,,,,,,,,,150118801.0,1.0,HIV infection
15011882,150118821,1,I,,20180608.0,20180614,20180614,EXP,,IT-GLAXOSMITHKLINE-IT2018102598,GLAXOSMITHKLINE,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44:37,16.0,YR,,M,Y,,,20180614.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150118821.0,OT,,,,,,,,,150118821.0,1.0,HIV infection
15012916,150129161,1,I,,20180604.0,20180614,20180614,PER,,US-TEVA-2018-US-905535,TEVA,SHARMA AV. DRUG-DRUG INTERACTION LEADING TO FANCONI^S SYNDROME IN A GERIATRIC PATIENT. J-AM-GERIATR-SOC 2018;66 (SUPPL. 2):S17.,73.0,YR,,M,Y,,,20180614.0,,OT,US,US,EFAVIRENZ.,Drug interaction;Fanconi syndrome,150129161.0,OT,,,,,,,,,150129161.0,1.0,HIV infection
15014930,150149301,1,I,,20180604.0,20180615,20180615,EXP,,US-AUROBINDO-AUR-APL-2018-031267,AUROBINDO,"SHARMA AV.. LEDIPASVIR/SOFOSBUVIR/TENOFOVIR DISOPROXIL-FUMARATE INTERACTION, FANCONI SYNDROME: CASE REPORT. REACTIONS WEEKLY. 2018;1704:P219",73.0,YR,,M,Y,,,20180615.0,,OT,US,US,EFAVIRENZ.,Chest pain;Drug interaction;Fanconi syndrome;Nausea;Vomiting,150149301.0,HO,,,,,,,,,150149301.0,1.0,HIV infection
15017665,150176652,2,F,20110914.0,20181115.0,20180615,20181122,EXP,,GB-JNJFOC-20111001501,JANSSEN,,15.0,YR,T,M,Y,35.0,KG,20181122.0,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,150176652.0,OT,,,150176652.0,1.0,20110819.0,20110920.0,,,150176652.0,1.0,HIV infection
15020285,150202851,1,I,,20180605.0,20180618,20180618,EXP,,GB-AUROBINDO-AUR-APL-2018-031365,AUROBINDO,,,,A,,Y,,,20180618.0,,OT,GB,GB,EFAVIRENZ.,Psychotic disorder,150202851.0,OT,,,,,,,,,150202851.0,1.0,Perinatal HIV infection
15022546,150225461,1,I,,20180608.0,20180618,20180618,EXP,,IT-GLAXOSMITHKLINE-IT2018102596,GLAXOSMITHKLINE,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),18.0,YR,,F,Y,,,20180618.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225461.0,OT,,,,,,,,,150225461.0,1.0,HIV infection
15022547,150225471,1,I,,20180608.0,20180618,20180618,EXP,,IT-GLAXOSMITHKLINE-NG2018102597,GLAXOSMITHKLINE,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),17.0,YR,,F,Y,,,20180618.0,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225471.0,OT,,,,,,,,,150225471.0,1.0,HIV infection
15022569,150225691,1,I,,20180608.0,20180618,20180618,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2018102596,VIIV,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),18.0,YR,,F,Y,,,20180618.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225691.0,OT,,,,,,,,,150225691.0,1.0,HIV infection
15022571,150225711,1,I,,20180608.0,20180618,20180618,EXP,,IT-VIIV HEALTHCARE LIMITED-NG2018102597,VIIV,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),17.0,YR,,F,Y,,,20180618.0,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225711.0,OT,,,,,,,,,150225711.0,1.0,HIV infection
15027468,150274682,2,F,,20200102.0,20180619,20200110,EXP,,IT-AUROBINDO-AUR-APL-2018-031662,AUROBINDO,,16.0,YR,,M,Y,,,20200111.0,,HP,IT,IT,EFAVIRENZ.,Drug resistance;Toxicity to various agents;Viral mutation identified,150274682.0,OT,,,,,,,,,150274682.0,1.0,HIV infection
15027477,150274772,2,F,,20200102.0,20180619,20200110,EXP,,IT-AUROBINDO-AUR-APL-2018-031687,AUROBINDO,,17.0,YR,,F,Y,,,20200111.0,,HP,IT,NG,EFAVIRENZ.,Drug resistance;Toxicity to various agents;Viral mutation identified,150274772.0,OT,,,,,,,,,150274772.0,1.0,HIV infection
15027629,150276292,2,F,,20200102.0,20180619,20200110,EXP,,IT-AUROBINDO-AUR-APL-2018-031684,AUROBINDO,,18.0,YR,,F,Y,,,20200111.0,,HP,IT,IT,EFAVIRENZ.,Drug resistance;Toxicity to various agents;Viral mutation identified,150276292.0,OT,,,,,,,,,150276292.0,1.0,HIV infection
15037386,150373861,1,I,,20170522.0,20180620,20180620,EXP,,US-GILEAD-2017-0274853,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373861.0,OT,,,,,,,,,150373861.0,1.0,HIV infection
15037387,150373871,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345022,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373871.0,OT,,,,,,,,,150373871.0,1.0,HIV infection
15037391,150373911,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345431,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373911.0,OT,,,,,,,,,150373911.0,1.0,HIV infection
15037394,150373941,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345433,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373941.0,OT,,,,,,,,,150373941.0,1.0,HIV infection
15037400,150374001,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345434,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374001.0,OT,,,,,,,,,150374001.0,1.0,HIV infection
15037401,150374011,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345432,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374011.0,OT,,,,,,,,,150374011.0,1.0,HIV infection
15037419,150374191,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345435,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374191.0,OT,,,,,,,,,150374191.0,1.0,HIV infection
15037422,150374221,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345436,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374221.0,OT,,,,,,,,,150374221.0,1.0,HIV infection
15037427,150374271,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345437,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374271.0,OT,,,,,,,,,150374271.0,1.0,HIV infection
15037428,150374281,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345438,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374281.0,OT,,,,,,,,,150374281.0,1.0,HIV infection
15037447,150374471,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345445,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374471.0,OT,,,,,,,,,150374471.0,1.0,HIV infection
15037451,150374511,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345444,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374511.0,OT,,,,,,,,,150374511.0,1.0,HIV infection
15037452,150374521,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345443,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374521.0,OT,,,,,,,,,150374521.0,1.0,HIV infection
15037473,150374731,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345439,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374731.0,OT,,,,,,,,,150374731.0,1.0,HIV infection
15037474,150374741,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345440,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374741.0,OT,,,,,,,,,150374741.0,1.0,HIV infection
15037487,150374871,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345441,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374871.0,OT,,,,,,,,,150374871.0,1.0,HIV infection
15037488,150374881,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345442,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374881.0,OT,,,,,,,,,150374881.0,1.0,HIV infection
15037495,150374951,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345446,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374951.0,OT,,,,,,,,,150374951.0,1.0,HIV infection
15037496,150374961,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345447,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374961.0,OT,,,,,,,,,150374961.0,1.0,HIV infection
15037508,150375081,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345448,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375081.0,OT,,,,,,,,,150375081.0,1.0,HIV infection
15037554,150375541,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345449,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375541.0,OT,,,,,,,,,150375541.0,1.0,HIV infection
15037560,150375601,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345450,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375601.0,OT,,,,,,,,,150375601.0,1.0,HIV infection
15037589,150375891,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345451,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375891.0,OT,,,,,,,,,150375891.0,1.0,HIV infection
15037599,150375991,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345452,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375991.0,OT,,,,,,,,,150375991.0,1.0,HIV infection
15037632,150376321,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345454,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376321.0,OT,,,,,,,,,150376321.0,1.0,HIV infection
15037653,150376531,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345453,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376531.0,OT,,,,,,,,,150376531.0,1.0,HIV infection
15037665,150376651,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345455,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376651.0,OT,,,,,,,,,150376651.0,1.0,HIV infection
15037667,150376671,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345456,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376671.0,OT,,,,,,,,,150376671.0,1.0,HIV infection
15037675,150376751,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345457,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376751.0,OT,,,,,,,,,150376751.0,1.0,HIV infection
15037676,150376761,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345458,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376761.0,OT,,,,,,,,,150376761.0,1.0,HIV infection
15037692,150376921,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345461,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376921.0,OT,,,,,,,,,150376921.0,1.0,HIV infection
15037695,150376951,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345460,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376951.0,OT,,,,,,,,,150376951.0,1.0,HIV infection
15037699,150376991,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345459,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376991.0,OT,,,,,,,,,150376991.0,1.0,HIV infection
15037794,150377941,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345462,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150377941.0,OT,,,,,,,,,150377941.0,1.0,HIV infection
15037841,150378411,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345465,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378411.0,OT,,,,,,,,,150378411.0,1.0,HIV infection
15037845,150378451,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345463,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378451.0,OT,,,,,,,,,150378451.0,1.0,HIV infection
15037846,150378461,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345464,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378461.0,OT,,,,,,,,,150378461.0,1.0,HIV infection
15037860,150378601,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345466,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378601.0,OT,,,,,,,,,150378601.0,1.0,HIV infection
15037862,150378621,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345468,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378621.0,OT,,,,,,,,,150378621.0,1.0,HIV infection
15037863,150378631,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345469,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378631.0,OT,,,,,,,,,150378631.0,1.0,HIV infection
15037866,150378661,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345467,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378661.0,OT,,,,,,,,,150378661.0,1.0,HIV infection
15037869,150378691,1,I,,20180611.0,20180620,20180620,EXP,,US-GILEAD-2018-0345470,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378691.0,OT,,,,,,,,,150378691.0,1.0,HIV infection
15043791,150437911,1,I,,20170522.0,20180621,20180621,EXP,,US-GILEAD-2017-0274374,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180621.0,,OT,US,US,EFAVIRENZ.,Osteoporosis,150437911.0,OT,,,,,,,,,150437911.0,1.0,HIV infection
15048350,150483501,1,I,,20180613.0,20180622,20180622,EXP,,IT-ROCHE-2141539,ROCHE,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37):-.",17.0,YR,,F,Y,,,20180622.0,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150483501.0,OT,,,,,,,,,150483501.0,1.0,HIV infection
15048355,150483551,1,I,,20180613.0,20180622,20180622,EXP,,IT-ROCHE-2141544,ROCHE,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37):-.",16.0,YR,,M,Y,,,20180622.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150483551.0,OT,,,,,,,,,150483551.0,1.0,HIV infection
15057866,150578661,1,I,20180530.0,20180604.0,20180625,20180625,EXP,,GP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-052113,BRISTOL MYERS SQUIBB,,49.0,YR,,F,Y,,,20180625.0,,OT,GP,FR,SUSTIVA,Attention deficit/hyperactivity disorder;Headache;Hypertension;Intracranial pressure increased;Vertigo,150578661.0,OT,,,150578661.0,1.0,19990820.0,,,,150578661.0,1.0,HIV infection
15059175,150591751,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058319,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591751.0,OT,,,,,,,,,150591751.0,1.0,HIV infection
15059176,150591761,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058322,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591761.0,OT,,,,,,,,,150591761.0,1.0,HIV infection
15059177,150591771,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058321,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591771.0,OT,,,,,,,,,150591771.0,1.0,HIV infection
15059181,150591811,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058324,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591811.0,OT,,,,,,,,,150591811.0,1.0,HIV infection
15059182,150591821,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058326,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591821.0,OT,,,,,,,,,150591821.0,1.0,HIV infection
15059183,150591831,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058320,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591831.0,OT,,,,,,,,,150591831.0,1.0,HIV infection
15059186,150591861,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058325,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591861.0,OT,,,,,,,,,150591861.0,1.0,HIV infection
15059187,150591871,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058323,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591871.0,OT,,,,,,,,,150591871.0,1.0,HIV infection
15059190,150591901,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-055471,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591901.0,OT,,,,,,,,,150591901.0,1.0,HIV infection
15060777,150607771,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058327,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607771.0,OT,,,,,,,,,150607771.0,1.0,HIV infection
15060778,150607781,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058329,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607781.0,OT,,,,,,,,,150607781.0,1.0,HIV infection
15060779,150607791,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058328,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607791.0,OT,,,,,,,,,150607791.0,1.0,HIV infection
15060780,150607801,1,I,,20180612.0,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058330,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625.0,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607801.0,OT,,,,,,,,,150607801.0,1.0,HIV infection
15065451,150654511,1,I,,20180613.0,20180626,20180626,EXP,,IT-ROCHE-2141542,ROCHE,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44 (37):-.",18.0,YR,,F,Y,,,20180626.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150654511.0,OT,,,,,,,,,150654511.0,1.0,HIV infection
15066142,150661421,1,I,,20171127.0,20180626,20180626,EXP,,IT-AUROBINDO-AUR-APL-2017-45042,AUROBINDO,,27.0,YR,,F,Y,,,20180626.0,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance,150661421.0,OT,,,,,,,,,150661421.0,1.0,Antiretroviral therapy
15095440,1509544011,11,F,20100629.0,20230119.0,20180702,20230124,EXP,,GB-GILEAD-2018-0347475,GILEAD,,43.0,YR,A,F,Y,43.0,KG,20230124.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,1509544011.0,OT,,,1509544011.0,1.0,20180205.0,20180205.0,4.0,MON,1509544011.0,1.0,HIV infection
15101395,151013951,1,I,,20180629.0,20180703,20180703,EXP,GB-MHRA-EYC 00181171,GB-VIIV HEALTHCARE LIMITED-GB2018116277,VIIV,,44.0,YR,,,Y,,,20180703.0,,CN,GB,GB,EFAVIRENZ.,Death,151013951.0,OT,,,,,,,,,151013951.0,1.0,HIV infection
15101516,151015161,1,I,,20180629.0,20180703,20180703,EXP,GB-MHRA-EYC 00181171,GB-GLAXOSMITHKLINE-GB2018116277,GLAXOSMITHKLINE,,44.0,YR,,,Y,,,20180703.0,,CN,GB,GB,EFAVIRENZ.,Death,151015161.0,DE,,,,,,,,,151015161.0,1.0,HIV infection
15109396,151093963,3,F,,20180710.0,20180705,20180720,EXP,,GB-HETERO CORPORATE-HET2018GB00592,HETERO,,,,,M,Y,,,20180720.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Maternal drugs affecting foetus;Trisomy 18,151093963.0,DE,,,151093963.0,1.0,,20180205.0,,,151093963.0,1.0,HIV infection
15112110,1511211011,11,F,20171006.0,20230113.0,20180705,20230118,EXP,,GB-GILEAD-2018-0347708,GILEAD,,3.0,MON,I,M,Y,,,20230118.0,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Off label use;Trisomy 18;Ultrasound antenatal screen,1511211011.0,CA,,,1511211011.0,1.0,20171006.0,20180205.0,122.0,DAY,1511211011.0,1.0,HIV infection
15114149,1511414949,49,F,20100629.0,20230524.0,20180706,20230601,EXP,,GB-AUROBINDO-AUR-APL-2018-033634,AUROBINDO,,3.0,MON,,M,Y,,,20230601.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Alopecia;Anaemia;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Device related infection;Diarrhoea;Ejection fraction decreased;Epistaxis;Exposure during pregnancy;Fatigue;Foetal exposure during pregnancy;Gastrooesophageal reflux disease;Gingival swelling;Hepatic cytolysis;Hot flush;Hydrops foetalis;Influenza like illness;Intentional product use issue;Lymphoedema;Maternal exposure during pregnancy;Mucosal inflammation;Off label use;Osteonecrosis of jaw;Rash;Sepsis;Trisomy 18;Ultrasound antenatal screen;Vascular device infection,1511414949.0,CA,,,1511414949.0,1.0,20171006.0,20180205.0,4.0,MON,1511414949.0,1.0,HIV infection
15115814,1511581454,54,F,20100629.0,20230919.0,20180706,20231003,EXP,,GB-MYLANLABS-2018M1048354,MYLAN,,3.0,MON,,M,Y,,,20231003.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Drug abuse;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen;Volvulus,1511581454.0,CA,,,1511581454.0,9.0,20090101.0,20180205.0,241.0,DAY,1511581454.0,1.0,HIV infection
15118575,151185753,3,F,,20180625.0,20180709,20190815,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-059819,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190815.0,,OT,IT,IT,EFAVIRENZ.,Neurotoxicity;Toxicity to various agents,151185753.0,OT,,,,,,,,,151185753.0,1.0,HIV infection
15119112,151191121,1,I,,20180624.0,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034732,AUROBINDO,,,,A,,Y,,,20180709.0,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Cardiotoxicity;Toxicity to various agents,151191121.0,OT,,,,,,,,,151191121.0,1.0,HIV infection
15120220,151202201,1,I,,20180624.0,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034733,AUROBINDO,,,,A,,Y,,,20180709.0,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Drug intolerance;Lipodystrophy acquired,151202201.0,OT,,,,,,,,,151202201.0,1.0,HIV infection
15120221,151202211,1,I,,20180624.0,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034730,AUROBINDO,,,,A,,Y,,,20180709.0,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Neurotoxicity;Toxicity to various agents,151202211.0,OT,,,,,,,,,151202211.0,1.0,HIV infection
15120227,151202271,1,I,,20180624.0,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034731,AUROBINDO,,,,A,,Y,,,20180709.0,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Hepatotoxicity;Toxicity to various agents,151202271.0,OT,,,,,,,,,151202271.0,1.0,HIV infection
15123441,151234411,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064192,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234411.0,OT,,,,,,,,,151234411.0,1.0,HIV infection
15123442,151234421,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064194,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234421.0,OT,,,,,,,,,151234421.0,1.0,HIV infection
15123443,151234431,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064195,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234431.0,OT,,,,,,,,,151234431.0,1.0,HIV infection
15123453,151234531,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064220,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Cardiotoxicity,151234531.0,OT,,,,,,,,,151234531.0,1.0,HIV infection
15123455,151234551,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064221,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234551.0,OT,,,,,,,,,151234551.0,1.0,HIV infection
15123467,151234671,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064225,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234671.0,OT,,,,,,,,,151234671.0,1.0,HIV infection
15123468,151234681,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064244,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234681.0,OT,,,,,,,,,151234681.0,1.0,HIV infection
15123469,151234691,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064224,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234691.0,OT,,,,,,,,,151234691.0,1.0,HIV infection
15123470,151234701,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064228,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234701.0,OT,,,,,,,,,151234701.0,1.0,HIV infection
15123471,151234711,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064226,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234711.0,OT,,,,,,,,,151234711.0,1.0,HIV infection
15123475,151234751,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064240,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234751.0,OT,,,,,,,,,151234751.0,1.0,HIV infection
15123476,151234761,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064223,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234761.0,OT,,,,,,,,,151234761.0,1.0,HIV infection
15123479,151234791,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064222,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234791.0,OT,,,,,,,,,151234791.0,1.0,HIV infection
15123480,151234801,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064227,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234801.0,OT,,,,,,,,,151234801.0,1.0,HIV infection
15123481,151234811,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064239,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234811.0,OT,,,,,,,,,151234811.0,1.0,HIV infection
15123482,151234821,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064243,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234821.0,OT,,,,,,,,,151234821.0,1.0,HIV infection
15123483,151234831,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064242,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234831.0,OT,,,,,,,,,151234831.0,1.0,HIV infection
15123484,151234841,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064238,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234841.0,OT,,,,,,,,,151234841.0,1.0,HIV infection
15123485,151234851,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064241,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234851.0,OT,,,,,,,,,151234851.0,1.0,HIV infection
15123491,151234911,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064233,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234911.0,OT,,,,,,,,,151234911.0,1.0,HIV infection
15123492,151234921,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064237,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234921.0,OT,,,,,,,,,151234921.0,1.0,HIV infection
15123493,151234931,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064245,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234931.0,OT,,,,,,,,,151234931.0,1.0,HIV infection
15123494,151234941,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064230,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234941.0,OT,,,,,,,,,151234941.0,1.0,HIV infection
15123496,151234961,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064231,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234961.0,OT,,,,,,,,,151234961.0,1.0,HIV infection
15123497,151234971,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064236,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234971.0,OT,,,,,,,,,151234971.0,1.0,HIV infection
15123498,151234981,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064201,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234981.0,OT,,,,,,,,,151234981.0,1.0,HIV infection
15123499,151234991,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064234,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234991.0,OT,,,,,,,,,151234991.0,1.0,HIV infection
15123501,151235011,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064229,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151235011.0,OT,,,,,,,,,151235011.0,1.0,HIV infection
15123503,151235031,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064232,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151235031.0,OT,,,,,,,,,151235031.0,1.0,HIV infection
15123505,151235051,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064246,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151235051.0,OT,,,,,,,,,151235051.0,1.0,HIV infection
15123506,151235061,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064198,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235061.0,OT,,,,,,,,,151235061.0,1.0,HIV infection
15123507,151235071,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064199,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235071.0,OT,,,,,,,,,151235071.0,1.0,HIV infection
15123508,151235081,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064196,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235081.0,OT,,,,,,,,,151235081.0,1.0,HIV infection
15123509,151235091,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064235,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151235091.0,OT,,,,,,,,,151235091.0,1.0,HIV infection
15123510,151235102,2,F,,20180625.0,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064249,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710.0,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235102.0,OT,,,,,,,,,151235102.0,1.0,HIV infection
15123511,151235111,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064197,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235111.0,OT,,,,,,,,,151235111.0,1.0,HIV infection
15123512,151235121,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064200,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235121.0,OT,,,,,,,,,151235121.0,1.0,HIV infection
15123517,151235171,1,I,,20180625.0,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064202,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235171.0,OT,,,,,,,,,151235171.0,1.0,HIV infection
15123524,151235242,2,F,,20180625.0,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064255,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710.0,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235242.0,OT,,,,,,,,,151235242.0,1.0,HIV infection
15123525,151235252,2,F,,20180625.0,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064253,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710.0,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235252.0,OT,,,,,,,,,151235252.0,1.0,HIV infection
15123526,151235262,2,F,,20180625.0,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064254,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710.0,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235262.0,OT,,,,,,,,,151235262.0,1.0,HIV infection
15123527,151235272,2,F,,20180625.0,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064256,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710.0,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235272.0,OT,,,,,,,,,151235272.0,1.0,HIV infection
15123625,1512362528,28,F,20180205.0,20220601.0,20180710,20221110,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43.0,YR,A,F,Y,,,20221110.0,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362528.0,OT,,,1512362528.0,1.0,20171006.0,20180205.0,123.0,DAY,1512362528.0,1.0,HIV infection
15123914,151239141,1,I,,20180625.0,20180710,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064193,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710.0,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151239141.0,OT,,,,,,,,,151239141.0,1.0,HIV infection
15124065,151240652,2,F,,20180625.0,20180710,20190523,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064218,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190523.0,,OT,GB,IT,EFAVIRENZ.,Lipodystrophy acquired,151240652.0,OT,,,,,,,,,151240652.0,1.0,HIV infection
15124276,151242761,1,I,,20180628.0,20180710,20180710,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-061059,BRISTOL MYERS SQUIBB,,44.0,YR,,,Y,,,20180710.0,,CN,GB,GB,EFAVIRENZ.,Death,151242761.0,DE,,,,,,,,,151242761.0,1.0,HIV infection
15124395,151243951,1,I,,20180627.0,20180710,20180710,EXP,GB-MHRA-EYC 00181171,GB-LUPIN PHARMACEUTICALS INC.-2018-04870,LUPIN,,44.0,YR,,,Y,,,20180710.0,,CN,GB,GB,EFAVIRENZ.,Death,151243951.0,OT,,,,,,,,,151243951.0,1.0,HIV infection
15124577,151245772,2,F,,20180625.0,20180710,20190523,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064219,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190523.0,,OT,GB,IT,EFAVIRENZ.,Lipodystrophy acquired,151245772.0,OT,,,,,,,,,151245772.0,1.0,HIV infection
15131489,151314891,1,I,,20180629.0,20180711,20180711,EXP,,GB-MYLANLABS-2018M1048847,MYLAN,"WYNBERG E, WILLIAMS E, TUDOR?WILLIAMS G, LYALL H, LYALL C.. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG.. 2018?38(3):231?8",,,C,,Y,,,20180708.0,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,151314891.0,OT,,,,,,,,,151314891.0,1.0,Perinatal HIV infection
15133729,151337292,2,F,20180205.0,20180710.0,20180712,20180720,EXP,,GB-HETERO CORPORATE-HET2018GB00593,HETERO,,,,,F,Y,,,20180720.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Maternal exposure during pregnancy,151337292.0,OT,,,,,,,,,151337292.0,1.0,HIV infection
15135037,151350371,1,I,,20180627.0,20180712,20180712,EXP,,GB-AUROBINDO-AUR-APL-2018-034945,AUROBINDO,,44.0,YR,,,Y,,,20180712.0,,CN,GB,GB,EFAVIRENZ.,Death,151350371.0,DE,,,,,,,,,151350371.0,1.0,HIV infection
15139436,151394361,1,I,20121128.0,20130214.0,20180713,20180713,EXP,,BR-HETERO CORPORATE-2013HINSPO0158,HETERO,,0.0,DY,,F,Y,2.88,KG,20180713.0,,OT,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,151394361.0,OT,,,151394361.0,3.0,20120521.0,20120803.0,,,151394361.0,1.0,Acquired immunodeficiency syndrome
15144880,151448801,1,I,200812.0,20180704.0,20180713,20180713,EXP,,JP-MYLANLABS-2018M1051655,MYLAN,,7.0,DEC,,M,Y,,,20180713.0,,OT,JP,JP,EFAVIRENZ.,Basedow's disease;Endocrine ophthalmopathy;Epistaxis;Immune reconstitution inflammatory syndrome;Immune thrombocytopenic purpura,151448801.0,OT,,,151448801.0,1.0,200606.0,,,,151448801.0,1.0,HIV infection
15150763,151507631,1,I,,20180705.0,20180716,20180716,EXP,,ES-MYLANLABS-2018M1050661,MYLAN,,46.0,YR,,,Y,,,20180716.0,,MD,ES,ES,EFAVIRENZ.,Drug withdrawal maintenance therapy;Nervous system disorder;Neurodermatitis;Treatment noncompliance;Weight decreased,151507631.0,OT,,,,,,,,,151507631.0,1.0,HIV infection
15157399,151573991,1,I,,20180713.0,20180718,20180718,EXP,GB-MHRA-EYC 00181171,GB-TEVA-2018-GB-926820,TEVA,,44.0,YR,,,Y,,,20180718.0,,CN,GB,GB,EFAVIRENZ.,Death,151573991.0,DE,,,,,,,,,151573991.0,1.0,HIV infection
15158092,151580921,1,I,,20180703.0,20180718,20180718,EXP,,PT-AUROBINDO-AUR-APL-2018-036024,AUROBINDO,,27.0,YR,,F,Y,,,20180718.0,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,151580921.0,OT,,,151580921.0,2.0,2007.0,,,,151580921.0,1.0,HIV infection
15158285,151582851,1,I,2015.0,20180706.0,20180718,20180718,EXP,,RO-MYLANLABS-2018M1051210,MYLAN,"CAMBREA SC, PASCU C, RUGINA S.. HEMIBALLISMUS IN A PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME AND TOXOPLASMA INFECTION.. ROMANIAN JOURNAL OF INFECTIOUS DISEASES. 2017?20(1):20?5, 47?52",28.0,YR,,F,Y,,,20180713.0,,OT,RO,RO,EFAVIRENZ.,Ballismus;Brain oedema;Central nervous system lesion;Cerebral toxoplasmosis;Intracranial mass;Loss of consciousness;Motor dysfunction;Product use issue,151582851.0,HO,,,151582851.0,4.0,2015.0,,,,151582851.0,1.0,HIV infection
15169075,151690751,1,I,,20180705.0,20180720,20180720,EXP,,GB-AUROBINDO-AUR-APL-2018-036152,AUROBINDO,,,,N,F,Y,,,20180720.0,,MD,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,151690751.0,CA,,,151690751.0,1.0,201103.0,201806.0,,,151690751.0,1.0,HIV infection
15171605,151716051,1,I,,20180710.0,20180720,20180720,EXP,,GB-MYLANLABS-2018M1052844,MYLAN,"WYNBERG E, WILLIAMS E, TUDOR?WILLIAMS G, LYALL H, FOSTER C.. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?.. CLINICAL DRUG INVESTIGATION.. 2018?38:231?8",,,,,Y,,,20180716.0,,OT,GB,GB,EFAVIRENZ.,Learning disorder;Psychotic symptom,151716051.0,OT,,,,,,,,,151716051.0,1.0,Perinatal HIV infection
15180832,1518083223,23,F,20100629.0,20221215.0,20180723,20221228,EXP,,GB-AUROBINDO-AUR-APL-2018-036898,AUROBINDO,,3.0,MON,,M,Y,,,20221228.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,1518083223.0,CA,,,1518083223.0,1.0,20090101.0,20100610.0,526.0,DAY,1518083223.0,1.0,HIV infection
15183751,151837511,1,I,,20180711.0,20180723,20180723,EXP,GB-MHRA-EYC 00171779,GB-MYLANLABS-2018M1053986,MYLAN,,47.0,YR,,F,Y,109.0,KG,20180716.0,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,151837511.0,DE,,,151837511.0,1.0,20161004.0,20171215.0,,,151837511.0,1.0,HIV infection
15184038,151840381,1,I,20180305.0,20180711.0,20180723,20180723,EXP,ES-AEMPS-345940,ES-MYLANLABS-2018M1053697,MYLAN,,48.0,YR,,M,Y,,,20180723.0,,MD,ES,ES,EFAVIRENZ SANDOZ,Abnormal dreams;Feeling hot;Insomnia,151840381.0,OT,,,151840381.0,1.0,20180302.0,20180322.0,,,151840381.0,1.0,HIV infection
15188355,151883551,1,I,,20180712.0,20180724,20180724,EXP,,IN-CIPLA LTD.-2018IN20050,CIPLA,,,,,,Y,,,20180724.0,,OT,IN,IN,EFAVIRENZ.,Central nervous system immune reconstitution inflammatory response;Death;Meningitis cryptococcal,151883551.0,HO,,,,,,,,,151883551.0,1.0,HIV infection
15190280,151902801,1,I,,20180711.0,20180724,20180724,EXP,,GB-MYLANLABS-2018M1053758,MYLAN,,46.0,YR,,M,Y,,,20180724.0,,MD,GB,GB,EFAVIRENZ.,Renal failure,151902801.0,OT,,,,,,,,,151902801.0,1.0,HIV infection
15195615,151956151,1,I,20150608.0,20180112.0,20180725,20180725,EXP,,FR-AUROBINDO-AUR-APL-2018-002734,AUROBINDO,,37.0,YR,,F,Y,,,20180725.0,,CN,US,FR,SUSTIVA,Foetal growth restriction;Live birth;Maternal exposure during pregnancy,151956151.0,OT,,,151956151.0,7.0,20150608.0,20150608.0,,,151956151.0,1.0,HIV infection
15205851,152058511,1,I,,20180723.0,20180727,20180727,EXP,,US-STRIDES ARCOLAB LIMITED-2018SP006194,STRIDES,"APONTE J, SALONIA J, STOEVER J, SHUJAAT A.. WHEN NOT TO CHOOSE APIXABAN: A CASE OF APIXABAN FAILURE.. AM?J?RESPIR?CRIT?CARE?MED. 2018?197",,,,,Y,,,20180727.0,,OT,US,US,EFAVIRENZ.,Drug interaction;Pulmonary embolism;Thrombosis,152058511.0,OT,,,,,,,,,152058511.0,1.0,HIV infection
15207054,152070541,1,I,20051226.0,20100629.0,20180727,20180727,EXP,,US-VIIV HEALTHCARE LIMITED-US2010000242,VIIV,,0.0,DY,,,Y,,,20180727.0,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,152070541.0,CA,,,,,,,,,152070541.0,1.0,HIV infection
15207059,152070591,1,I,20051226.0,20100629.0,20180727,20180727,EXP,,US-GLAXOSMITHKLINE-US2010000242,GLAXOSMITHKLINE,,0.0,DY,,,Y,,,20180727.0,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,152070591.0,CA,,,,,,,,,152070591.0,1.0,HIV infection
15209935,152099351,1,I,,20180717.0,20180727,20180727,EXP,,PT-MYLANLABS-2018M1056119,MYLAN,"SOEIRO C, TAVARES AP, E CASTRO RS. HEPATITIS B REACTIVATION AFTER HCV TREATMENT WITH SOFOSBUVIR/LEDIPASVIR IN A HIV?COINFECTED PATIENT WITH PREVIOUS POSITIVE ANTI?HBS ANTIBODY: A CASE REPORT AND A REVIEW OF LITERATURE. HIV?AIDS?REV 2018?17(2):146?151.",54.0,YR,,M,Y,,,20180726.0,,MD,PT,PT,EFAVIRENZ.,Hepatitis B reactivation;Neuropsychiatric symptoms,152099351.0,OT,,,152099351.0,1.0,2014.0,,,,152099351.0,1.0,HIV infection
15214568,152145684,4,F,2005.0,20200910.0,20180730,20200917,EXP,,FR-VIIV HEALTHCARE LIMITED-B0561595A,VIIV,,25.0,YR,,F,Y,,,20200917.0,,HP,FR,FR,EFAVIRENZ.,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,152145684.0,OT,,,152145684.0,1.0,20050908.0,20050908.0,,,152145684.0,1.0,HIV infection
15214571,152145712,2,F,,20190510.0,20180730,20190523,EXP,,FR-VIIV HEALTHCARE LIMITED-B0561595B,VIIV,,,,N,,Y,,,20190523.0,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,152145712.0,DE,,,152145712.0,1.0,20050908.0,20050908.0,,,152145712.0,1.0,HIV infection
15228449,152284491,1,I,,20180718.0,20180801,20180801,EXP,,US-MYLANLABS-2018M1056860,MYLAN,"APONTE J, SALONIA J, STOEVER J, SHUJAAT A. WHEN NOT TO CHOOSE APIXABAN: A CASE OF APIXABAN FAILURE. AM?J?RESPIR?CRIT?CARE?MED 2018?197: ABSTR. A3451.",64.0,YR,,M,Y,,,20180801.0,,OT,US,US,EFAVIRENZ.,Drug interaction;Pulmonary embolism,152284491.0,OT,,,,,,,,,152284491.0,1.0,HIV infection
15229518,152295181,1,I,,20180606.0,20180802,20180802,PER,,US-STRIDES ARCOLAB LIMITED-2018SP004642,STRIDES,SHARMA AV. DRUG?DRUG INTERACTION LEADING TO FANCONI^S SYNDROME IN A GERIATRIC PATIENT. J?AM?GERIATR?SOC. 2018?66 (SUPPL. 2):S17,,,,,Y,,,20180802.0,,OT,US,US,EFAVIRENZ.,Chest pain;Drug interaction;Fanconi syndrome acquired;Nausea;Vomiting,152295181.0,OT,,,,,,,,,152295181.0,1.0,HIV infection
15229519,152295191,1,I,,20180723.0,20180802,20180802,PER,,US-STRIDES ARCOLAB LIMITED-2018SP006173,STRIDES,"HASSAN S?A, SIDDIQUI A, BURKS J, KAWJI M.. A RARE CAUSE OF GRAVES DISEASE IN HIV INFECTION. ENDOCR? PRACT. 2018?24 (SUPPL.1):264?265",,,,,Y,,,20180802.0,,MD,US,US,EFAVIRENZ.,Anxiety;Basedow's disease;Endocrine ophthalmopathy;Exophthalmos;Goitre;Hyperthyroidism;Immune reconstitution inflammatory syndrome;Insomnia;Lid lag;Palpitations;Temperature intolerance;Tremor;Weight decreased,152295191.0,OT,,,,,,,,,152295191.0,1.0,HIV infection
15229875,152298751,1,I,,20180327.0,20180802,20180802,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2018US-169287,RANBAXY,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD CASE REP. 2018?APR? 4(3):256?258",40.0,YR,,M,Y,,,20180802.0,,MD,US,US,EFAVIRENZ.,Lichenoid keratosis,152298751.0,OT,,,,,,,,,152298751.0,1.0,Antiretroviral therapy
15230085,152300852,2,F,,20180725.0,20180802,20181220,EXP,,IN-CIPLA LTD.-2018IN20418,CIPLA,"SEHGAL VN, VERMA P, SHARMA S. HIV/AIDS KAPOSI SARCOMA: THE INDIAN PERSPECTIVE. SKINMED. 2013;11 (6):375 TO 377",,,,,Y,,,20181220.0,,OT,IN,IN,EFAVIRENZ.,Drug ineffective;Pulmonary tuberculosis,152300852.0,OT,,,,,,,,,152300852.0,1.0,Antiretroviral therapy
15234354,152343541,1,I,,20180723.0,20180803,20180803,EXP,,US-HETERO CORPORATE-HET2018US00719,HETERO,"APONTE J, SALONIA J, STOEVER J, SHUJAAT A. WHEN NOT TO CHOOSE APIXABAN: A CASE OF APIXABAN FAILURE. AM?J?RESPIR?CRIT?CARE?MED. 2018?197:A3451",64.0,YR,,M,Y,,,20180803.0,,OT,US,US,EFAVIRENZ.,Drug interaction;Pulmonary embolism,152343541.0,OT,,,,,,,,,152343541.0,1.0,HIV infection
15236145,152361451,1,I,20180706.0,,20180709,20180709,DIR,,,FDA-CTU,,20.0,YR,,M,N,,,20180709.0,N,OT,US,US,EFAVIRENZ.;SUSTIVA,Pneumonia,152361451.0,HO,152361451.0,HP,152361451.0,1.0,20160420.0,,,,152361451.0,1.0,HIV infection
15238000,152380001,1,I,,20180720.0,20180803,20180803,EXP,,FR-MYLANLABS-2018M1057026,MYLAN,,,,,,Y,,,20180727.0,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myositis,152380001.0,OT,,,,,,,,,152380001.0,1.0,HIV infection
15239133,152391332,2,F,,20180810.0,20180803,20180817,EXP,,GB-GILEAD-2018-0353190,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS. SCAND J GASTROENTEROL. 2016?51(7):814?8",42.0,YR,A,F,Y,,,20180817.0,,OT,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis,152391332.0,OT,,,,,,,,,152391332.0,1.0,HIV infection
15239979,152399792,2,F,,20180810.0,20180803,20180817,EXP,,ZA-GILEAD-2018-0353191,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV.. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND J GASTROENTEROL.. 2016?51(7):814?8",45.0,YR,A,F,Y,,,20180817.0,,MD,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis,152399792.0,OT,,,,,,,,,152399792.0,1.0,HIV infection
15239997,152399972,2,F,,20180810.0,20180803,20180817,EXP,,ZA-GILEAD-2018-0353194,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND J GASTROENTEROL. 2016?51(7):814?8",39.0,YR,A,F,Y,,,20180817.0,,OT,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis,152399972.0,OT,,,,,,,,,152399972.0,1.0,HIV infection
15240014,152400141,1,I,,20180727.0,20180803,20180803,EXP,,US-GILEAD-2018-0353206,GILEAD,,45.0,YR,A,F,Y,,,20180803.0,,MD,US,US,EFAVIRENZ.,Autoimmune hepatitis,152400141.0,OT,,,152400141.0,1.0,200405.0,200502.0,,,152400141.0,1.0,HIV infection
15240105,152401052,2,F,,20180810.0,20180803,20180817,EXP,,GB-GILEAD-2018-0353197,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV.. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND J GASTROENTEROL.. 2016?51(7):814?8",43.0,YR,A,F,Y,,,20180817.0,,MD,GB,GB,EFAVIRENZ.,Autoimmune hepatitis,152401052.0,OT,,,,,,,,,152401052.0,1.0,HIV infection
15242740,152427401,1,I,,20180723.0,20180806,20180806,EXP,,US-AUROBINDO-AUR-APL-2018-039256,AUROBINDO,SWINDELLS.. EFAVIRENZ IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: CASE REPORT. REACTIONS WEEKLY. 2018?1711:P113,54.0,YR,,F,Y,,,20180806.0,,OT,US,US,EFAVIRENZ.,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung infiltration;Pyrexia;Weight decreased,152427401.0,HO,,,,,,,,,152427401.0,1.0,HIV infection
15243637,152436372,2,F,20060216.0,20191105.0,20180806,20191108,EXP,,FR-ABBVIE-18S-056-2442144-00,ABBVIE,,25.0,YR,,F,Y,,,20191108.0,,MD,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy,152436372.0,CA,,,152436372.0,1.0,20050908.0,20050908.0,,,152436372.0,1.0,HIV infection
15245128,152451283,3,F,20180209.0,20180731.0,20180806,20220713,EXP,,LS-GLAXOSMITHKLINE-LS2018GSK140125,GLAXOSMITHKLINE,,,,,,Y,,,20220713.0,,MD,LS,LS,EFAVIRENZ,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152451283.0,HO,,,152451283.0,1.0,20180216.0,20180715.0,153.0,DAY,152451283.0,1.0,HIV infection
15245584,152455841,1,I,,20180724.0,20180806,20180806,EXP,,PHHY2018IT059299,SANDOZ,,,,,,Y,,,20180806.0,,OT,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,152455841.0,OT,,,,,,,,,152455841.0,1.0,HIV infection
15246169,152461693,3,F,20180209.0,20180731.0,20180806,20220624,EXP,,LS-VIIV HEALTHCARE LIMITED-LS2018GSK140125,VIIV,,,,,,Y,,,20220624.0,,MD,LS,LS,EFAVIRENZ,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152461693.0,HO,,,152461693.0,1.0,20180216.0,20180715.0,153.0,DAY,152461693.0,1.0,HIV infection
15248149,152481499,9,F,20050813.0,20200918.0,20180807,20200929,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002639",BOEHRINGER INGELHEIM,,25.0,YR,A,F,Y,56.0,KG,20200929.0,,HP,FR,FR,EFAVIRENZ.;SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,152481499.0,OT,,,152481499.0,1.0,20050908.0,20050908.0,,,152481499.0,1.0,HIV infection
15249825,152498251,1,I,,20180725.0,20180807,20180807,EXP,,"MZ-LANNETT COMPANY, INC.-MZ-2018LAN000892",LANNETT,"ANTUNES M, SCHIAVONE M, PIZZOL D, DI GENNARO F, LUDOVICO R, DE PALMA A. BILATERAL MASTECTOMY AS RADICAL TREATMENT OF GYNECOMASTIA SECONDARY TO ANTIRETROVIRAL THERAPY IN A LOW?INCOME SETTING: A CASE REPORT. DRUG?SAF?CASE?REP. 2018?5(1):21",46.0,YR,,M,Y,,,20180807.0,,OT,MZ,MZ,EFAVIRENZ.,Gynaecomastia,152498251.0,HO,,,,,,,,,152498251.0,1.0,HIV infection
15249829,152498296,6,F,20060216.0,20220513.0,20180807,20220514,EXP,,FR-ABBVIE-18S-056-2444229-00,ABBVIE,,25.0,YR,,F,Y,56.0,KG,20220513.0,,MD,COUNTRY NOT SPECIFIED,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,152498296.0,HO,,,152498296.0,1.0,20050908.0,20050908.0,,,152498296.0,1.0,HIV infection
15249898,152498981,1,I,,20171009.0,20180807,20180807,EXP,,GB-GILEAD-2018-0353613,GILEAD,,,,A,,Y,,,20180807.0,,MD,GB,GB,SUSTIVA,Hepatitis B,152498981.0,OT,,,,,,,,,152498981.0,1.0,HIV infection
15250314,152503141,1,I,,20180725.0,20180807,20180807,EXP,,ES-MYLANLABS-2018M1059149,MYLAN,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J. RECURRENT CORONARY DISEASE IN HIV?INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BR?J?CLIN?PHARMACOL 2018?84(7):1617?1619.",39.0,YR,,M,Y,,,20180807.0,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Drug interaction;Vascular stent thrombosis,152503141.0,HO,,,,,,,,,152503141.0,1.0,HIV infection
15253366,152533661,1,I,,20180730.0,20180808,20180808,EXP,,US-TEVA-2018-US-937952,TEVA,"HASSAN S?A, SIDDIQUI A, BURKS J, KAWJI M. A RARE CAUSE OF GRAVES DISEASE IN HIV INFECTION. ENDOCR?PRACT 2018?24 (SUPPL. 1):264?265 ABSTR. #1086.",5.0,DEC,,M,Y,,,20180808.0,,MD,US,US,EFAVIRENZ.,Basedow's disease;Endocrine ophthalmopathy;Immune reconstitution inflammatory syndrome,152533661.0,OT,,,,,,,,,152533661.0,1.0,HIV infection
15258044,152580441,1,I,,20180730.0,20180809,20180809,EXP,,ES-HETERO CORPORATE-HET2018ES00749,HETERO,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J. RECURRENT CORONARY DISEASE IN HIV?INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BR?J?CLIN?PHARMACOL. 2018?84(7):1617?1619",39.0,YR,,M,Y,,,20180809.0,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Drug interaction;Myocardial infarction;Vascular stent thrombosis,152580441.0,OT,,,,,,,,,152580441.0,1.0,HIV infection
15258048,152580481,1,I,,20180730.0,20180809,20180809,EXP,,US-AUROBINDO-AUR-APL-2018-040451,AUROBINDO,,64.0,YR,,M,Y,,,20180809.0,,OT,US,US,EFAVIRENZ.,Atrial fibrillation;Deep vein thrombosis;Dyspnoea;Pulmonary embolism,152580481.0,OT,,,,,,,,,152580481.0,1.0,HIV infection
15273708,152737081,1,I,,20180805.0,20180813,20180813,EXP,,US-GILEAD-2018-0354858,GILEAD,"TSO FY, KANG G, KWON EH, JULIUS P, LI Q, WEST JT, WOOD C. BRAIN IS A POTENTIAL SANCTUARY FOR SUBTYPE C HIV?1 IRRESPECTIVE OF ART TREATMENT OUTCOME. PLOS ONE. 13 (7) (NO PAGINATION), 2018. ARTICLE NUMBER: E0201325.. 2018?UNK:1?12",40.0,YR,A,M,Y,,,20180813.0,,OT,US,ZM,EFAVIRENZ.,Treatment failure,152737081.0,DE,,,,,,,,,152737081.0,1.0,HIV infection
15273723,152737231,1,I,,20180805.0,20180813,20180813,EXP,,US-GILEAD-2018-0355932,GILEAD,"TSO FY, KANG G, KWON EH, JULIUS P, LI Q, WEST JT, WOOD C. BRAIN IS A POTENTIAL SANCTUARY FOR SUBTYPE C HIV?1 IRRESPECTIVE OF ART TREATMENT OUTCOME. PLOS ONE. 13 (7) (NO PAGINATION), 2018. ARTICLE NUMBER: E0201325.. 2018?UNK:1?12 DOI:10.1371",34.0,YR,A,F,Y,,,20180813.0,,OT,US,ZM,EFAVIRENZ.,Treatment failure,152737231.0,DE,,,,,,,,,152737231.0,1.0,HIV infection
15276721,152767211,1,I,200805.0,20180808.0,20180814,20180814,EXP,GB-MHRA-ADR 20276241,GB-009507513-1808GBR003583,MERCK,,32.0,YR,,F,Y,,,20180814.0,,MD,GB,GB,EFAVIRENZ.,Drug ineffective;Drug interaction;Pregnancy with implant contraceptive,152767211.0,OT,,,152767211.0,2.0,2006.0,,,,152767211.0,1.0,HIV test
15277256,152772561,1,I,,20110607.0,20180814,20180814,EXP,,GB-GILEAD-2011-0040557,GILEAD,,31.0,YR,A,F,Y,,,20180814.0,,CN,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,152772561.0,OT,,,,,,,,,152772561.0,1.0,HIV infection
15281164,152811641,1,I,,20180806.0,20180815,20180815,EXP,,GB-TEVA-2018-GB-940058,TEVA,,54.0,YR,,M,Y,,,20180815.0,,CN,GB,GB,EFAVIRENZ.,Anal fistula infection,152811641.0,OT,,,,,,,,,152811641.0,1.0,HIV infection
15283073,152830731,1,I,20180730.0,,20180731,20180731,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20180730.0,N,PH,US,US,EFAVIRENZ.,Fall;Laceration,,,152830731.0,HP,152830731.0,1.0,20030110.0,,,,152830731.0,1.0,HIV test positive
15287323,152873233,3,F,,20181018.0,20180817,20181101,EXP,,PT-AUROBINDO-AUR-APL-2018-041849,AUROBINDO,,54.0,YR,,M,Y,,,20181101.0,,OT,PT,PT,EFAVIRENZ.,Hepatitis B reactivation;Neuropsychiatric symptoms,152873233.0,OT,,,152873233.0,1.0,2014.0,,,,152873233.0,1.0,Antiretroviral therapy
15291772,152917721,1,I,20180619.0,20180813.0,20180817,20180817,EXP,GB-MHRA-EYC 00183472,GB-GILEAD-2018-0356331,GILEAD,,62.0,YR,A,M,Y,75.0,KG,20180817.0,,MD,GB,GB,EFAVIRENZ.,Breast swelling;Breast tenderness;Gynaecomastia,152917721.0,OT,,,152917721.0,1.0,20180614.0,,,,152917721.0,1.0,HIV infection
15296122,152961221,1,I,,20180806.0,20180820,20180820,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-073457,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180820.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,152961221.0,OT,,,152961221.0,1.0,201611.0,,,,152961221.0,1.0,HIV infection
15296312,152963122,2,F,,20180814.0,20180820,20180921,EXP,,US-VIIV HEALTHCARE LIMITED-US2018149371,VIIV,"MICHAL JL, RAB S, PATEL M, KYLE AW, MILLER LS, EASLEY KA ET.ALL. INCIDENCE OF ACUTE KIDNEY INJURY IN PATIENTS COINFECTED WITH HIV AND HEPATITIS C VIRUS RECEIVING TENOFOVIR DISOPROXIL FUMARATE AND LEDIPASVIR/SOFOSBUVIR IN A REAL?WORLD, URBAN, RYAN WHITE CLINIC. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2018?34(8):690?698.DOI:10.1089/AID.2017.0271",47.0,YR,,M,Y,,,20180921.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury,152963122.0,OT,,,,,,,,,152963122.0,1.0,Antiretroviral therapy
15307026,153070261,1,I,20180720.0,20180814.0,20180822,20180822,EXP,,ZA-MYLANLABS-2018M1062941,MYLAN,,27.0,YR,,M,Y,,,20180822.0,,OT,ZA,ZA,EFAVIRENZ.,Acute kidney injury;Coma scale abnormal;Dyspnoea;General physical health deterioration,153070261.0,OT,,,153070261.0,1.0,20180604.0,20180721.0,,,153070261.0,1.0,Antiretroviral therapy
15308899,153088993,3,F,2014.0,20200608.0,20180823,20200616,EXP,,ES-MACLEODS PHARMACEUTICALS US LTD-MAC2018015707,MACLEODS,,,,,,Y,,,20200616.0,,CN,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,153088993.0,OT,,,153088993.0,1.0,2012.0,,,,153088993.0,1.0,HIV infection
15309218,153092181,1,I,20180810.0,20180810.0,20180823,20180823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-075558,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,,,20180823.0,,PH,CA,CA,SUSTIVA,Constipation,153092181.0,HO,,,,,,,,,153092181.0,1.0,HIV infection
15312442,153124421,1,I,1999.0,20010710.0,20180823,20180823,EXP,,US-VIIV HEALTHCARE LIMITED-A0153857A,VIIV,,,,,M,Y,,,20180823.0,,OT,NG,US,EFAVIRENZ.,Condition aggravated;Deafness bilateral;Ototoxicity;Tinnitus,153124421.0,OT,,,153124421.0,1.0,199810.0,1999.0,,,153124421.0,1.0,HIV infection
15312447,153124471,1,I,1999.0,20010710.0,20180823,20180823,EXP,,US-GLAXOSMITHKLINE-A0153857A,GLAXOSMITHKLINE,,,,,M,Y,,,20180823.0,,OT,NG,US,EFAVIRENZ.,Condition aggravated;Deafness bilateral;Ototoxicity;Tinnitus,153124471.0,OT,,,153124471.0,1.0,199810.0,1999.0,,,153124471.0,1.0,HIV infection
15321890,153218901,1,I,,20180816.0,20180827,20180827,EXP,,RO-MYLANLABS-2018M1063114,MYLAN,"BLAGA I?C, STOICA NL, DADALAU AT, POPESCU G, ABAGIU A. TUBERCULOUS MENINGITIS IN HIV PATIENT, DEVELOPED DURING APPARENTLY EFFCIENT TREATMENT FOR PULMONARY TUBERCULOSIS. CLUJUL?MED 2016?89 (SUPPL. 3):S75.",27.0,YR,,,Y,,,20180827.0,,OT,RO,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,153218901.0,OT,,,,,,,,,153218901.0,1.0,Acquired immunodeficiency syndrome
15324302,153243021,1,I,,20180813.0,20180828,20180828,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-078376,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180828.0,,OT,AU,GB,EFAVIRENZ.,Completed suicide,153243021.0,OT,,,,,,,,,153243021.0,1.0,Antiretroviral therapy
15337817,153378171,1,I,,20151028.0,20180831,20180831,EXP,,ZA-009507513-1510ZAF015311,MERCK,,,,,F,Y,,,20180831.0,,CN,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Off label use;Pregnancy with implant contraceptive,153378171.0,OT,,,153378171.0,2.0,201403.0,,,,153378171.0,1.0,Antiretroviral therapy
15341650,153416502,2,F,,20180827.0,20180901,20180910,EXP,,US-AUROBINDO-AUR-APL-2018-043353,AUROBINDO,,50.0,YR,,M,Y,,,20180910.0,,OT,US,US,EFAVIRENZ.,Bradycardia;Cardiac arrest;Electrocardiogram QT prolonged;Hypothermia;Myxoedema coma;Unresponsive to stimuli;Ventricular arrhythmia,153416502.0,HO,,,,,,,,,153416502.0,1.0,Antiretroviral therapy
15343799,153437991,1,I,,20160809.0,20180903,20180903,EXP,,ZA-AUROBINDO-AUR-APL-2016-10805,AUROBINDO,,43.0,YR,,F,Y,,,20180903.0,,OT,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis;Hepatic enzyme abnormal;Immune reconstitution inflammatory syndrome,153437991.0,OT,,,,,,,,,153437991.0,1.0,HIV infection
15346868,153468681,1,I,,20180821.0,20180904,20180904,EXP,,GB-AUROBINDO-AUR-APL-2018-043972,AUROBINDO,,,,A,,Y,,,20180904.0,,MD,GB,GB,SUSTIVA,Virologic failure,153468681.0,OT,,,,,,,,,153468681.0,1.0,HIV infection
15348259,153482592,2,F,,20180830.0,20180904,20211118,EXP,FR-AFSSAPS-ST20181160,FR-GLAXOSMITHKLINE-FR2018158242,GLAXOSMITHKLINE,,40.0,YR,,M,Y,,,20211118.0,,MD,FR,FR,SUSTIVA,Lipodystrophy acquired,153482592.0,OT,,,153482592.0,1.0,19990412.0,20050512.0,2222.0,DAY,153482592.0,1.0,HIV infection
15348740,153487402,2,F,,20180830.0,20180904,20211118,EXP,FR-AFSSAPS-ST20181160,FR-VIIV HEALTHCARE LIMITED-FR2018158242,VIIV,,40.0,YR,,M,Y,,,20211118.0,,MD,FR,FR,SUSTIVA,Lipodystrophy acquired,153487402.0,OT,,,153487402.0,1.0,19990412.0,20050512.0,2222.0,DAY,153487402.0,1.0,HIV infection
15350485,153504852,2,F,,20180914.0,20180905,20180917,EXP,,UG-HETERO CORPORATE-HET2018UG00862,HETERO,,,,,,Y,,,20180917.0,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,153504852.0,CA,,,153504852.0,1.0,20180510.0,,,,153504852.0,1.0,HIV infection
15357253,153572533,3,F,20060216.0,20191105.0,20180906,20191108,EXP,,FR-ABBVIE-18S-056-2474150-00,ABBVIE,,25.0,YR,,F,Y,,,20191108.0,,OT,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,153572533.0,OT,,,153572533.0,1.0,20050908.0,20050908.0,,,153572533.0,1.0,HIV infection
15357967,153579671,1,I,,20180831.0,20180906,20180906,EXP,,UG-MYLANLABS-2018M1065596,MYLAN,,,,I,F,Y,3.6,KG,20180906.0,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,153579671.0,OT,,,153579671.0,1.0,20180510.0,,,,153579671.0,1.0,HIV infection
15362806,153628061,1,I,,20180827.0,20180907,20180907,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081824,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20180907.0,,OT,US,US,EFAVIRENZ.,Basedow's disease;Immune reconstitution inflammatory syndrome,153628061.0,OT,,,,,,,,,153628061.0,1.0,HIV infection
15362898,153628983,3,F,,20210202.0,20180907,20210208,PER,,ID-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081902,BRISTOL MYERS SQUIBB,"MOKOAGOW I, YUWAAFII M. GRAVES DISEASE AS MANIFESTATION OF IMMUNE RECONSTITUTION SYNDROME IN A PREGNANT PATIENT WITH HIV/AIDS RECEIVING ANTIRETROVIRAL THERAPY. ENDOCRINE PRACTICE. 2018?24(SUPPL 1):270?1",36.0,YR,,F,Y,,,20210208.0,,MD,ID,ID,EFAVIRENZ.,Basedow's disease;Immune reconstitution inflammatory syndrome;Intentional product use issue;Maternal exposure during pregnancy;Normal newborn,153628983.0,OT,,,,,,,,,153628983.0,1.0,HIV infection
15363025,1536302522,22,F,20171006.0,20220927.0,20180907,20230626,EXP,GB-EMA-DD-20180827-KSEVHUMANWT-125137,GB-NOVOPROD-619421,NOVO NORDISK,,3.0,MON,,M,Y,,,20230626.0,,HP,GB,GB,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,1536302522.0,DE,,,1536302522.0,1.0,20180205.0,20180205.0,122.0,DAY,1536302522.0,1.0,HIV infection
15367987,153679874,4,F,20180630.0,20181018.0,20180910,20181023,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK156040,VIIV,,39.0,YR,,F,Y,49.0,KG,20181023.0,,MD,CN,CN,EFAVIRENZ.,Hypersensitivity;Liver injury,153679874.0,HO,,,153679874.0,1.0,20180621.0,20180712.0,,,153679874.0,1.0,HIV infection
15370793,153707933,3,F,20171006.0,20220802.0,20180911,20220812,EXP,,GB-TEVA-2018-GB-953327,TEVA,,,,,M,Y,,,20220812.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Off label use;Trisomy 18;Ultrasound antenatal screen,153707933.0,DE,,,153707933.0,1.0,20171006.0,20180205.0,4.0,MON,153707933.0,1.0,HIV infection
15372370,153723703,3,F,20090930.0,20190125.0,20180911,20190205,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-GILEAD-2018-0362320,GILEAD,,19.0,YR,A,F,Y,,,20190205.0,,CN,FR,FR,SUSTIVA,Caesarean section;Drug ineffective;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,153723703.0,OT,,,153723703.0,6.0,20080918.0,,,,153723703.0,1.0,HIV infection
15375863,153758631,1,I,20171006.0,20180910.0,20180912,20180912,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-TEVA-2018-GB-954133,TEVA,,43.0,YR,,F,Y,,,20180912.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,153758631.0,OT,,,,,,,,,153758631.0,1.0,HIV infection
15383786,153837861,1,I,,20180705.0,20180913,20180913,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063019,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180913.0,,OT,IE,IE,EFAVIRENZ.,No adverse event,153837861.0,OT,,,153837861.0,1.0,20180620.0,20180814.0,,,153837861.0,1.0,HIV infection
15386725,153867252,2,F,2014.0,20181213.0,20180914,20181221,EXP,,PHHY2018ES049784,SANDOZ,,39.0,YR,,M,Y,,,20181221.0,,OT,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,153867252.0,HO,,,,,,,,,153867252.0,1.0,HIV infection
15387938,153879381,1,I,,20180831.0,20180915,20180915,EXP,,GB-AUROBINDO-AUR-APL-2018-045413,AUROBINDO,,,,A,,Y,,,20180915.0,,MD,GB,GB,SUSTIVA,Virologic failure,153879381.0,OT,,,,,,,,,153879381.0,1.0,HIV infection
15388140,153881402,2,F,,20180911.0,20180915,20180924,EXP,,UG-AUROBINDO-AUR-APL-2018-045363,AUROBINDO,,,,,F,Y,3.6,KG,20180924.0,,OT,UG,UG,EFAVIRENZ.,Polydactyly,153881402.0,CA,,,153881402.0,1.0,20180510.0,,,,153881402.0,1.0,HIV infection
15389945,153899451,1,I,,20180911.0,20180917,20180917,EXP,,IN-STRIDES ARCOLAB LIMITED-2018SP007787,STRIDES,,,,,,Y,,,20180917.0,,OT,IN,IN,EFAVIRENZ.,Nephropathy toxic,153899451.0,OT,,,,,,,,,153899451.0,1.0,HIV infection
15397944,153979441,1,I,,20180907.0,20180918,20180918,EXP,,ES-GILEAD-2018-0362550,GILEAD,"ALVAREZ H, MARINO A, VALCARCE N, GARCIA?GONZALEZ J, DIAZ?CAMBRE H, LLIBRE JM. OVERDOSE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN AN HIV?1?INFECTED SUBJECT WITH ATTEMPTED SUICIDE. INFECTION. 2018?UNK:UNK",51.0,YR,A,M,Y,,,20180918.0,,OT,ES,ES,EFAVIRENZ.,Hypophosphataemia;Osteopenia;Vitamin D deficiency,153979441.0,OT,,,153979441.0,1.0,2012.0,,,,153979441.0,1.0,HIV infection
15398444,153984447,7,F,2002.0,20190215.0,20180918,20190225,EXP,,PT-MYLANLABS-2018M1068194,MYLAN,"MARTINS S, QUINAZ C, XARA S, VASCONCELOS O, VICENTE P, SARMENTO-CASTRO R.. AIDS ? RELATED PRIMARY PULMONARY LYMPHOMA.. REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS.. 2017;13 (3):142-5",55.0,YR,,M,Y,,,20190225.0,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,153984447.0,OT,,,153984447.0,4.0,1997.0,,,,153984447.0,1.0,HIV infection
15405189,154051891,1,I,,20180605.0,20180920,20180920,PER,,US-LAURUS LABS LIMITED-201800046,LAURUS LABS LIMITED,SHARMA AV. DRUG?DRUG INTERACTION LEADING TO FANCONI^S SYNDROME IN A GERIATRIC PATIENT. J?AM?GERIATR?SOC . 2018?66 (SUPPL 2)S17:,73.0,YR,,M,Y,,,20180911.0,,OT,US,US,EFAVIRENZ.,Chest pain;Drug interaction;Fanconi syndrome acquired;Nausea;Vomiting,154051891.0,OT,,,,,,,,,154051891.0,1.0,HIV infection
15405233,154052331,1,I,,20180709.0,20180920,20180920,PER,,US-LAURUS LABS LIMITED-201800105,LAURUS LABS LIMITED,BHOGAL S. TENOFOVIR?INDUCED FANCONI SYNDROME PRESENTING AS HYPOKALEMIC PERIODIC PARALYSIS. AMJ?THER 2017?24(5):E617?E618.,54.0,YR,,F,Y,,,20180911.0,,OT,US,US,EFAVIRENZ.,Fall;Fanconi syndrome acquired;Muscular weakness,154052331.0,OT,,,,,,,,,154052331.0,1.0,HIV infection
15418970,154189701,1,I,,20180919.0,20180924,20180924,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-087430,BRISTOL MYERS SQUIBB,,,,,M,Y,74.83,KG,20180924.0,,CN,US,US,SUSTIVA,Drug screen positive,,,,,154189701.0,1.0,1998.0,,,,154189701.0,1.0,HIV infection
15419057,154190571,1,I,,20180828.0,20180924,20180924,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2018155512,VIIV,"BLAGA I?C, STOICA NL, DADALAU AT, POPESCU G, ABAGIU A. TUBERCULOUS MENINGITIS IN HIV PATIENT, DEVELOPED DURING APPARENTLY EFFCIENT TREATMENT FOR PULMONARY TUBERCULOSIS. CLUJUL MEDICAL. 2016?89:75",27.0,YR,,,Y,,,20180924.0,,,COUNTRY NOT SPECIFIED,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,154190571.0,OT,,,,,,,,,154190571.0,1.0,Acquired immunodeficiency syndrome
15419067,154190671,1,I,,20180828.0,20180924,20180924,EXP,,RO-GLAXOSMITHKLINE-RO2018155512,GLAXOSMITHKLINE,"BLAGA I?C, STOICA NL, DADALAU AT, POPESCU G, ABAGIU A. TUBERCULOUS MENINGITIS IN HIV PATIENT, DEVELOPED DURING APPARENTLY EFFCIENT TREATMENT FOR PULMONARY TUBERCULOSIS. CLUJUL MEDICAL. 2016?89:75",27.0,YR,,,Y,,,20180924.0,,,COUNTRY NOT SPECIFIED,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,154190671.0,OT,,,,,,,,,154190671.0,1.0,Acquired immunodeficiency syndrome
15419136,154191361,1,I,200109.0,20180919.0,20180924,20180924,EXP,,FR-GLAXOSMITHKLINE-FR2018172212,GLAXOSMITHKLINE,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI?GRADT E, GUILLOU?GUILLEMETTE HL, CHENNEBAULT JM ET AL. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV?1 GROUP O. AIDS. 2016?30(16):2565?2568. DOI: 10.1097/QAD.0000000000001253.",,,,F,Y,,,20180924.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,154191361.0,OT,,,,,,,,,154191361.0,1.0,HIV infection
15419142,154191421,1,I,200109.0,20180919.0,20180924,20180924,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018172212,VIIV,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI?GRADT E, GUILLOU?GUILLEMETTE HL, CHENNEBAULT JM ET AL. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV?1 GROUP O. AIDS. 2016?30(16):2565?2568. DOI: 10.1097/QAD.0000000000001253.",,,,F,Y,,,20180924.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,154191421.0,OT,,,,,,,,,154191421.0,1.0,HIV infection
15420891,154208911,1,I,20171209.0,20180919.0,20180924,20180924,EXP,,ZW-GILEAD-2018-0364724,GILEAD,,33.0,YR,A,F,Y,,,20180924.0,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,154208911.0,OT,,,154208911.0,1.0,20151015.0,,,,154208911.0,1.0,HIV infection
15423369,154233691,1,I,,20180919.0,20180925,20180925,PER,,US-GILEAD-2018-0364520,GILEAD,,65.0,YR,E,M,Y,,,20180925.0,,CN,US,US,EFAVIRENZ.,Vomiting,,,,,,,,,,,154233691.0,1.0,HIV infection
15424004,154240041,1,I,20171209.0,20180919.0,20180925,20180925,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2018173230,VIIV,,33.0,YR,,F,Y,,,20180925.0,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,154240041.0,OT,,,154240041.0,1.0,20151015.0,,,,154240041.0,1.0,HIV infection
15424034,154240341,1,I,20171209.0,20180919.0,20180925,20180925,EXP,,ZW-GLAXOSMITHKLINE-ZW2018173230,GLAXOSMITHKLINE,,33.0,YR,,F,Y,,,20180925.0,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,154240341.0,OT,,,154240341.0,1.0,20151015.0,,,,154240341.0,1.0,HIV infection
15427917,154279171,1,I,,20180715.0,20180926,20180926,PER,,US-STRIDES ARCOLAB LIMITED-2018SP005984,STRIDES,SWINDELLS S. NEW AND NOTEWORTHY IN TUBERCULOSIS DIAGNOSTICS AND TREATMENT. TOP ANTIVIR MED. 2018?26(2):58?61,,,,,Y,,,20180926.0,,OT,US,US,EFAVIRENZ.,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Pyrexia,154279171.0,OT,,,,,,,,,154279171.0,1.0,HIV infection
15433271,154332711,1,I,,20180917.0,20180927,20180927,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-122007,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180927.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,154332711.0,OT,,,,,,,,,154332711.0,1.0,HIV infection
15435632,154356322,2,F,,20181023.0,20180927,20181025,EXP,,PHHY2018PT105702,SANDOZ,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;1-8",32.0,YR,,M,Y,,,20181025.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154356322.0,OT,,,,,,,,,154356322.0,1.0,HIV infection
15438011,154380111,1,I,201610.0,20180630.0,20180928,20180928,EXP,,GB-AUROBINDO-AUR-APL-2018-035836,AUROBINDO,,38.0,YR,,F,Y,,,20180928.0,,OT,GB,GB,Efavirenz Film?coated Tablet,Abortion induced;Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,154380111.0,OT,,,154380111.0,3.0,201106.0,,,,154380111.0,1.0,HIV infection
15438733,154387333,3,F,,20190129.0,20180928,20190205,EXP,,UG-AUROBINDO-AUR-APL-2018-048507,AUROBINDO,,36.0,WK,,,Y,2.2,KG,20190205.0,,MD,UG,UG,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy;Premature baby,154387333.0,OT,,,154387333.0,1.0,20171030.0,20180302.0,,,154387333.0,1.0,HIV infection
15439575,154395752,2,F,20171030.0,20181009.0,20180928,20181012,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP008415,STRIDES,,,,,F,Y,,,20181012.0,,OT,UG,BR,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,154395752.0,OT,,,154395752.0,1.0,20171030.0,20180302.0,,,154395752.0,1.0,HIV infection
15440108,154401081,1,I,20180917.0,,20180925,20180925,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20180924.0,N,PH,US,US,EFAVIRENZ TAB 600MG,Pruritus,,,154401081.0,HP,154401081.0,1.0,201801.0,,,,154401081.0,1.0,HIV infection
15440348,154403481,1,I,,20180924.0,20180928,20180928,EXP,,PHHY2018PT108602,SANDOZ,,29.0,YR,,M,Y,,,20180928.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154403481.0,LT,,,,,,,,,154403481.0,1.0,HIV infection
15441050,154410502,2,F,20180907.0,20181001.0,20180928,20181012,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088186,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20181012.0,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,154410502.0,OT,,,154410502.0,1.0,20151015.0,,,,154410502.0,1.0,HIV infection
15456648,154566485,5,F,,20190510.0,20181002,20190618,EXP,,GB-MYLANLABS-2018M1071213,MYLAN,,,,,F,Y,,,20190618.0,,PH,GB,GB,EFAVIRENZ.,Hypertension;Liver function test increased;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Product use issue,154566485.0,OT,,,,,,,,,154566485.0,1.0,HIV infection
15456922,154569221,1,I,,20180925.0,20181002,20181002,EXP,,IN-MYLANLABS-2018M1072052,MYLAN,"GOYAL A, BISWAS A. SEVERE LIPODYSTROPHY AND GYNECOMASTIA IN A MALE PATIENT ON LOPINAVIR-BASED SECOND-LINE ANTIRETROVIRAL THERAPY. TURK-J-ENDOCRIN-METAB 2018;22(3):208-212.",,,A,M,Y,100.5,KG,20181002.0,,OT,IN,IN,EFAVIRENZ.,Acanthosis nigricans;Diabetes mellitus;Dyslipidaemia;Gynaecomastia;Lipodystrophy acquired,154569221.0,OT,,,154569221.0,1.0,2004.0,200703.0,,,154569221.0,1.0,HIV infection
15457218,154572181,1,I,201808.0,20180924.0,20181002,20181002,EXP,,BW-GILEAD-2018-0365714,GILEAD,,41.0,YR,A,M,Y,,,20181002.0,,MD,BW,BW,EFAVIRENZ.,Meningitis cryptococcal,154572181.0,OT,,,154572181.0,1.0,201807.0,,,,154572181.0,1.0,HIV infection
15463001,154630011,1,I,2014.0,20180928.0,20181004,20181004,PER,,IN-LAURUS LABS LIMITED-201800200,LAURUS LABS LIMITED,,,,A,M,Y,,,20181004.0,,OT,IN,IN,EFAVIRENZ.,Central obesity;Dyslipidaemia;Gynaecomastia;Lipodystrophy acquired;Lipohypertrophy;Weight increased,154630011.0,OT,,,154630011.0,4.0,200401.0,200703.0,,,154630011.0,1.0,HIV infection
15463860,154638607,7,F,2018.0,20210913.0,20181004,20210920,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2018GSK177825,VIIV,,,,,,Y,,,20210920.0,,MD,ZA,ZA,EFAVIRENZ.,Congenital umbilical hernia,154638607.0,CA,,,154638607.0,1.0,20180628.0,20200326.0,,,154638607.0,1.0,HIV infection
15466091,1546609110,10,F,,20181217.0,20181004,20181221,EXP,,PT-PFIZER INC-2018394465,PFIZER,"SOARES, J.. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;61 (2):64-71",32.0,YR,,M,Y,,,20181221.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,1546609110.0,LT,,,,,,,,,1546609110.0,2.0,HIV infection
15480033,154800333,3,F,,20231121.0,20181009,20231127,EXP,,PT-GILEAD-2018-0367224,GILEAD,"Santos JV, Soares J, Sarmento A, Costa-Pereira A. Spontaneous Viral Clearance in Sixteen HIV Infected Patients with Chronic Hepatitis C. Intervirology. 2018;unk:1-8. doi:10.1159/000490056",29.0,YR,A,M,Y,,,20231127.0,,HP,PT,PT,EFAVIRENZ,Drug-induced liver injury,154800333.0,OT,,,,,,,,,154800333.0,1.0,HIV infection
15480679,154806796,6,F,20050813.0,20220516.0,20181010,20220524,EXP,,PHHY2009FR075290,NOVARTIS,,25.0,YR,,F,Y,56.0,KG,20220524.0,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Exposure during pregnancy;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,154806796.0,HO,,,154806796.0,1.0,20050513.0,20050908.0,119.0,DAY,154806796.0,1.0,HIV infection
15488801,154888016,6,F,,20231117.0,20181011,20231130,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-090269,BRISTOL MYERS SQUIBB,"Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, et al. Raltegravir in pregnancy: A case series presentation. International Journal of STD and AIDS 2011;22(6):358-60.",39.0,YR,A,F,Y,,,20231130.0,,MD,AT,AT,EFAVIRENZ,Acute stress disorder;Live birth;Maternal exposure during pregnancy;Off label use;Premature rupture of membranes,154888016.0,HO,,,154888016.0,9.0,,,17.0,DAY,154888016.0,1.0,Antiretroviral therapy
15510768,155107681,1,I,,20181008.0,20181016,20181016,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018186257,VIIV,"CORBIN V, FRANGE P, VEBER F, BLANCHE S, RUNEL-BELLIARD C, LALANDE M, ET AL. CLINICAL, VIROLOGICAL AND IMMUNOLOGICAL FEATURES OF HIV-POSITIVE CHILDREN INTERNATIONALLY ADOPTED IN FRANCE FROM 2005-2015. PLOS ONE. 2018;13(9):E0203438. DOI: 10.1371/JOURNAL.PONE.0203438.",3.0,YR,,,Y,,,20181016.0,,OT,FR,FR,EFAVIRENZ.,Virologic failure,155107681.0,OT,,,,,,,,,155107681.0,1.0,HIV infection
15510776,155107761,1,I,,20181008.0,20181016,20181016,EXP,,FR-GLAXOSMITHKLINE-FR2018186257,GLAXOSMITHKLINE,"CORBIN V, FRANGE P, VEBER F, BLANCHE S, RUNEL-BELLIARD C, LALANDE M, ET AL. CLINICAL, VIROLOGICAL AND IMMUNOLOGICAL FEATURES OF HIV-POSITIVE CHILDREN INTERNATIONALLY ADOPTED IN FRANCE FROM 2005-2015. PLOS ONE. 2018;13(9):E0203438. DOI: 10.1371/JOURNAL.PONE.0203438.",3.0,YR,,,Y,,,20181016.0,,OT,FR,FR,EFAVIRENZ.,Virologic failure,155107761.0,OT,,,,,,,,,155107761.0,1.0,HIV infection
15515872,155158724,4,F,200101.0,20190130.0,20181017,20190213,EXP,,FR-AUROBINDO-AUR-APL-2018-050974,AUROBINDO,,,,,,Y,,,20190213.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,155158724.0,OT,,,,,,,,,155158724.0,1.0,HIV infection
15517352,155173521,1,I,,20181005.0,20181017,20181017,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-093898,BRISTOL MYERS SQUIBB,,96.0,YR,,M,Y,,,20181017.0,,PH,CA,CA,SUSTIVA,Dementia;Dysphagia,155173521.0,OT,,,,,,,,,155173521.0,1.0,HIV infection
15524974,155249741,1,I,,20181009.0,20181018,20181018,EXP,,BR-HETERO CORPORATE-HET2018BR01048,HETERO,,,,,,Y,2.2,KG,20181018.0,,OT,BR,BR,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy;Low birth weight baby;Premature baby,155249741.0,OT,,,155249741.0,1.0,20171030.0,20180302.0,,,155249741.0,1.0,HIV infection
15525391,155253911,1,I,,20181008.0,20181018,20181018,EXP,,PH-GLAXOSMITHKLINE-PH2018188199,GLAXOSMITHKLINE,"FRANCISCO CN., ALEJANDRIA M, SALVANA E.M, DE VERA ANDAL VM.. PRIMARY INTRACRANIAL LEIOMYOSARCOMA AMONG PATIENTS WITH AIDS IN THE ERA OF NEW CHEMOTHERAPEUTIC AND BIOLOGICAL AGENTS.. BMJ CASE REPORTS. 2018 (NO PAGINATION), 2018. ARTICLE NUMBER: BCR-2018-225714. D. 2018;UNK:1-6",36.0,YR,,M,Y,,,20181018.0,,MD,PH,PH,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155253911.0,OT,,,,,,,,,155253911.0,1.0,HIV infection
15525501,155255011,1,I,,20181008.0,20181018,20181018,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2018188199,VIIV,"FRANCISCO CN., ALEJANDRIA M, SALVANA E.M, DE VERA ANDAL VM.. PRIMARY INTRACRANIAL LEIOMYOSARCOMA AMONG PATIENTS WITH AIDS IN THE ERA OF NEW CHEMOTHERAPEUTIC AND BIOLOGICAL AGENTS.. BMJ CASE REPORTS. 2018 (NO PAGINATION), 2018. ARTICLE NUMBER: BCR-2018-225714. D. 2018;UNK:1-6",36.0,YR,,M,Y,,,20181018.0,,MD,PH,PH,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155255011.0,OT,,,,,,,,,155255011.0,1.0,HIV infection
15535398,155353981,1,I,20180303.0,20181009.0,20181022,20181022,EXP,,BR-HETERO CORPORATE-HET2018BR01049,HETERO,,,,,F,Y,,,20181022.0,,OT,BR,BR,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,155353981.0,OT,,,155353981.0,1.0,20171030.0,20180302.0,,,155353981.0,1.0,HIV infection
15542106,155421061,1,I,,20181009.0,20181023,20181023,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018017499,MACLEODS,,,,,,Y,,,20181023.0,,OT,US,US,EFAVIRENZ.,Congenital tongue anomaly;Foetal exposure during pregnancy,155421061.0,CA,,,155421061.0,1.0,20171030.0,20180302.0,,,155421061.0,1.0,HIV infection
15550540,155505402,2,F,,20181016.0,20181025,20181029,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018193747,VIIV,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35.0,YR,,M,Y,,,20181029.0,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155505402.0,OT,,,,,,,,,155505402.0,1.0,HIV infection
15550548,155505482,2,F,,20181016.0,20181025,20181029,EXP,,UG-GLAXOSMITHKLINE-UG2018193747,GLAXOSMITHKLINE,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35.0,YR,,M,Y,,,20181029.0,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155505482.0,HO,,,,,,,,,155505482.0,1.0,HIV infection
15559787,155597877,7,F,,20200617.0,20181029,20200619,EXP,,PHHY2018PT113969,NOVARTIS,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;1-8",32.0,YR,,M,Y,,,20200619.0,,HP,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,155597877.0,OT,,,,,,,,,155597877.0,1.0,HIV infection
15565558,155655581,1,I,,20181016.0,20181030,20181030,EXP,,FR-AUROBINDO-AUR-APL-2018-052499,AUROBINDO,,3.0,YR,,,Y,,,20181030.0,,OT,FR,FR,EFAVIRENZ.,Virologic failure,155655581.0,OT,,,,,,,,,155655581.0,1.0,HIV infection
15567325,155673251,1,I,,20181022.0,20181030,20181030,EXP,,UG-GILEAD-2018-0370962,GILEAD,"MAHSA ABASSI, JOSHUA RHEIN, DAVID B MEYA,  DAVID R BOULWARE. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. FORUM INFECTIOUS DISEASES. 2018;UNK:UNK. DOI:10.1093/OFID/OFX274",35.0,YR,A,M,Y,,,20181030.0,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155673251.0,DE,,,,,,,,,155673251.0,1.0,HIV test positive
15567332,155673321,1,I,,20181022.0,20181030,20181030,EXP,,UG-GILEAD-2018-0370961,GILEAD,"MAHSA ABASSI, JOSHUA RHEIN, DAVID B MEYA,  DAVID R BOULWARE. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. FORUM INFECTIOUS DISEASES. 2018;UNK:UNK. DOI:10.1093/OFID/OFX274",35.0,YR,A,M,Y,,,20181030.0,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155673321.0,DE,,,,,,,,,155673321.0,1.0,HIV test positive
15567504,155675041,1,I,,20181022.0,20181030,20181030,EXP,,UG-GILEAD-2018-0370960,GILEAD,"ABASSI M, RHEIN J, MEYA D B, BOULWARE D R. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. FORUM INFECTIOUS DISEASES. 2018;5:1. DOI:DOI.ORG/10.1093/OFID/OFX274",45.0,YR,A,M,Y,,,20181030.0,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155675041.0,DE,,,,,,,,,155675041.0,1.0,HIV infection
15569050,155690501,1,I,,20181023.0,20181031,20181031,EXP,UG-MLMSERVICE-20181017-1429060-2,UG-CIPLA LTD.-2018UG22190,CIPLA,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2017;1 TO 4",,,,,Y,,,20181031.0,,OT,UG,UG,EFAVIRENZ.,Meningitis cryptococcal,155690501.0,DE,,,,,,,,,155690501.0,1.0,HIV infection
15573380,155733801,1,I,,20181023.0,20181101,20181101,EXP,UG-MLMSERVICE-20181017-1429060-1,UG-CIPLA LTD.-2018UG22189,CIPLA,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2017;1 TO 4",,,,,Y,,,20181101.0,,OT,UG,UG,EFAVIRENZ.,Meningitis cryptococcal,155733801.0,DE,,,,,,,,,155733801.0,1.0,HIV infection
15573679,1557367911,11,F,,20230914.0,20181101,20230922,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54.0,YR,A,M,Y,,,20230922.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1557367911.0,OT,,,,,,,,,1557367911.0,1.0,HIV infection
15573949,155739492,2,F,,20181022.0,20181101,20181224,EXP,,IN-CIPLA LTD.-2018IN22202,CIPLA,"RAMRAKHIANI N, MISHRA V. NEUROLOGIC IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A SEROPOSITIVE PATIENT: AN INTERESTING CASE. NEUROLOGY INDIA. 2016;64 (1):155 TO 157",,,,,Y,,,20181224.0,,OT,IN,IN,EFAVIRENZ.,Anal incontinence;Condition aggravated;Depressed level of consciousness;Immune reconstitution inflammatory syndrome;Urinary incontinence,155739492.0,OT,,,155739492.0,1.0,201309.0,201311.0,,,155739492.0,1.0,HIV infection
15575661,155756611,1,I,,20181026.0,20181101,20181101,EXP,,IT-MYLANLABS-2018M1081591,MYLAN,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL.. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITAL. J. PEDIATR.. 2018;44(37)",17.0,YR,,F,Y,,,20181031.0,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,155756611.0,OT,,,,,,,,,155756611.0,1.0,HIV infection
15575720,155757201,1,I,,20181026.0,20181101,20181101,EXP,,IT-MYLANLABS-2018M1081600,MYLAN,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G,. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITAL. J. PEDIATR.. 2018;44(37)",16.0,YR,,M,Y,,,20181101.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,155757201.0,OT,,,,,,,,,155757201.0,1.0,HIV infection
15575733,155757331,1,I,,20181026.0,20181101,20181101,EXP,,IT-MYLANLABS-2018M1081593,MYLAN,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL.. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITAL. J. PEDIATR.. 2018;44(37)",18.0,YR,,F,Y,,,20181031.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,155757331.0,OT,,,,,,,,,155757331.0,1.0,HIV infection
15578283,155782831,1,I,,20181023.0,20181102,20181102,EXP,,UG-CIPLA LTD.-2018UG22174,CIPLA,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2017;1 TO 4",,,,,Y,,,20181102.0,,OT,UG,UG,EFAVIRENZ.,Meningitis cryptococcal,155782831.0,DE,,,,,,,,,155782831.0,1.0,HIV infection
15578546,155785461,1,I,,20181023.0,20181102,20181102,EXP,,UG-ZYDUS-029415,ZYDUS PHARM,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF TEST AND TREAT: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35.0,YR,,M,Y,,,20181102.0,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155785461.0,LT,,,,,,,,,155785461.0,1.0,HIV infection
15578554,155785541,1,I,,20181023.0,20181102,20181102,EXP,,UG-ZYDUS-029502,ZYDUS PHARM,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF TEST AND TREAT: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35.0,YR,,M,Y,,,20181102.0,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155785541.0,HO,,,,,,,,,155785541.0,1.0,HIV infection
15580903,155809032,2,F,,20181023.0,20181105,20190717,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100299,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,,,20190717.0,,OT,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155809032.0,HO,,,,,,,,,155809032.0,1.0,HIV infection
15580993,155809932,2,F,,20181023.0,20181105,20190717,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100312,BRISTOL MYERS SQUIBB,,35.0,YR,,M,Y,,,20190717.0,,OT,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155809932.0,OT,,,,,,,,,155809932.0,1.0,HIV infection
15582640,155826401,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103249,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826401.0,OT,,,,,,,,,155826401.0,1.0,HIV infection
15582652,155826521,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103247,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826521.0,OT,,,,,,,,,155826521.0,1.0,HIV infection
15582653,155826531,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-101808,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826531.0,OT,,,,,,,,,155826531.0,1.0,HIV infection
15582654,155826541,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103248,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826541.0,OT,,,,,,,,,155826541.0,1.0,HIV infection
15582779,155827791,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103252,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155827791.0,OT,,,,,,,,,155827791.0,1.0,HIV infection
15582780,155827801,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103254,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155827801.0,OT,,,,,,,,,155827801.0,1.0,HIV infection
15582803,155828031,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103251,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828031.0,OT,,,,,,,,,155828031.0,1.0,HIV infection
15582805,155828051,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103253,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828051.0,OT,,,,,,,,,155828051.0,1.0,HIV infection
15582808,155828081,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103250,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828081.0,OT,,,,,,,,,155828081.0,1.0,HIV infection
15582810,155828101,1,I,,20181022.0,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103255,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105.0,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828101.0,OT,,,,,,,,,155828101.0,1.0,HIV infection
15583294,155832941,1,I,,20181023.0,20181103,20181103,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018452,MACLEODS,,,,,,Y,,,20181103.0,,CN,IN,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155832941.0,DE,,,,,,,,,155832941.0,1.0,HIV infection
15583302,155833021,1,I,,20181023.0,20181103,20181103,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018451,MACLEODS,,,,,,Y,,,20181103.0,,CN,IN,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155833021.0,LT,,,,,,,,,155833021.0,1.0,HIV infection
15583305,155833051,1,I,,20181023.0,20181103,20181103,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018453,MACLEODS,,,,,,Y,,,20181103.0,,CN,IN,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155833051.0,HO,,,,,,,,,155833051.0,1.0,HIV infection
15583421,155834211,1,I,,20181023.0,20181105,20181105,EXP,,UG-AUROBINDO-AUR-APL-2018-053001,AUROBINDO,,35.0,YR,,M,Y,,,20181105.0,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155834211.0,DE,,,,,,,,,155834211.0,1.0,HIV infection
15583549,155835492,2,F,,20181105.0,20181105,20181118,EXP,,UG-AUROBINDO-AUR-APL-2018-053002,AUROBINDO,,35.0,YR,,M,Y,,,20181118.0,,MD,UG,UG,EFAVIRENZ.,Confusional state;Cough;General physical health deterioration;Headache;Immune reconstitution inflammatory syndrome;Intracranial pressure increased;Respiratory failure;Unresponsive to stimuli;Vomiting,155835492.0,OT,,,,,,,,,155835492.0,1.0,HIV infection
15585586,155855861,1,I,,20181023.0,20181104,20181104,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100462,BRISTOL MYERS SQUIBB,,35.0,YR,,M,Y,,,20181104.0,,OT,US,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155855861.0,LT,,,,,,,,,155855861.0,1.0,HIV infection
15586886,155868862,2,F,200507.0,20190206.0,20181105,20190213,EXP,,FR-GILEAD-2018-0371637,GILEAD,,42.0,YR,A,F,Y,,,20190213.0,,MD,FR,FR,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective;Therapy cessation,155868862.0,OT,,,155868862.0,1.0,200308.0,200507.0,,,155868862.0,1.0,HIV infection
15588896,155888961,1,I,,20181023.0,20181106,20181106,EXP,,UG-AUROBINDO-AUR-APL-2018-053000,AUROBINDO,,45.0,YR,,M,Y,,,20181106.0,,MD,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155888961.0,OT,,,,,,,,,155888961.0,1.0,HIV infection
15589909,155899091,1,I,,20181024.0,20181106,20181106,EXP,,UG-MYLANLABS-2018M1082075,MYLAN,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN-FORUM-INFECT-DIS 2018;5(1):NO PAGINATION.",45.0,YR,,M,Y,,,20181106.0,,OT,UG,UG,EFAVIRENZ.,Condition aggravated;Cryptococcosis;Generalised tonic-clonic seizure;Hypotension;Hypoxia;Immune reconstitution inflammatory syndrome;Loss of consciousness;Unmasking of previously unidentified disease,155899091.0,DE,,,,,,,,,155899091.0,1.0,HIV infection
15591956,155919561,1,I,,20181029.0,20181106,20181106,EXP,,GH-GILEAD-2018-0372669,GILEAD,,,,A,,Y,,,20181106.0,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155919561.0,OT,,,,,,,,,155919561.0,1.0,HIV infection
15591972,155919721,1,I,,20181029.0,20181106,20181106,EXP,,GH-GILEAD-2018-0372670,GILEAD,,,,A,,Y,,,20181106.0,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155919721.0,OT,,,,,,,,,155919721.0,1.0,HIV infection
15591973,155919731,1,I,,20181029.0,20181106,20181106,EXP,,GH-GILEAD-2018-0372675,GILEAD,,,,A,,Y,,,20181106.0,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155919731.0,OT,,,,,,,,,155919731.0,1.0,HIV infection
15592041,155920411,1,I,,20181029.0,20181106,20181106,EXP,,GH-GILEAD-2018-0372676,GILEAD,,,,A,,Y,,,20181106.0,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155920411.0,OT,,,,,,,,,155920411.0,1.0,HIV infection
15592042,155920421,1,I,,20181029.0,20181106,20181106,EXP,,GH-GILEAD-2018-0372678,GILEAD,,,,A,,Y,,,20181106.0,,MD,GB,GH,EFAVIRENZ.,Gene mutation identification test positive;Virologic failure,155920421.0,OT,,,,,,,,,155920421.0,1.0,HIV infection
15592067,155920671,1,I,,20181029.0,20181106,20181106,EXP,,GH-GILEAD-2018-0372677,GILEAD,,,,A,,Y,,,20181106.0,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155920671.0,OT,,,,,,,,,155920671.0,1.0,HIV infection
15594088,155940881,1,I,,20181029.0,20181106,20181106,EXP,,GH-GILEAD-2018-0372681,GILEAD,,,,A,,Y,,,20181106.0,,MD,GB,GH,EFAVIRENZ.,Gene mutation identification test positive;Virologic failure,155940881.0,OT,,,,,,,,,155940881.0,1.0,HIV infection
15594255,155942551,1,I,,20181029.0,20181106,20181106,EXP,,IN-GILEAD-2018-0372053,GILEAD,"BALASWAMY REDDY, GURUPRASAD SRINIVAS. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV AND AIDS REVIEW. 17 (3) (PP 224-226), 2018. DATE OF PUBLICATION: 2018. 2018;17, 3::224-226. DOI:DOI.ORG/10.5114/HIVAR.2018.78496",39.0,YR,A,M,Y,,,20181106.0,,MD,IN,IN,EFAVIRENZ.,Drug interaction;HIV-associated neurocognitive disorder;Psychotic disorder,155942551.0,OT,,,,,,,,,155942551.0,1.0,HIV infection
15597754,155977541,1,I,,20181024.0,20181108,20181108,EXP,,UG-MYLANLABS-2018M1082135,MYLAN,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS 2018;5(1):NO PAGINATION.",35.0,YR,,M,Y,,,20181108.0,,OT,UG,UG,EFAVIRENZ.,Condition aggravated;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Unmasking of previously unidentified disease,155977541.0,HO,,,,,,,,,155977541.0,1.0,HIV infection
15597755,155977551,1,I,,20181024.0,20181108,20181108,EXP,,UG-MYLANLABS-2018M1082136,MYLAN,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS 2018;5(1):NO PAGINATION.",35.0,YR,,M,Y,,,20181108.0,,OT,UG,UG,EFAVIRENZ.,Condition aggravated;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Respiratory failure;Unmasking of previously unidentified disease;Unresponsive to stimuli,155977551.0,DE,,,,,,,,,155977551.0,1.0,HIV infection
15601246,156012461,1,I,,20181026.0,20181109,20181109,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2018GSK201803,VIIV,"BALASWAMY R G,  SRINIVAS G. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV AND AIDS REVIEW. 2018;17(3):224-226",39.0,YR,,M,Y,,,20181109.0,,MD,IN,IN,EFAVIRENZ.,Altered state of consciousness;Daydreaming;Disturbance in attention;Illusion;Irritability;Memory impairment;Psychomotor retardation;Psychotic disorder;Sensory disturbance;Slow response to stimuli;Sluggishness;Thinking abnormal;Treatment noncompliance,156012461.0,OT,,,,,,,,,156012461.0,1.0,HIV infection
15602096,156020961,1,I,,20181026.0,20181109,20181109,EXP,,IN-GLAXOSMITHKLINE-IN2018GSK201803,GLAXOSMITHKLINE,"BALASWAMY R G,  SRINIVAS G. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV AND AIDS REVIEW. 2018;17(3):224-226",39.0,YR,,M,Y,,,20181109.0,,MD,IN,IN,EFAVIRENZ.,Altered state of consciousness;Daydreaming;Disturbance in attention;Illusion;Irritability;Memory impairment;Psychomotor retardation;Psychotic disorder;Sensory disturbance;Slow response to stimuli;Sluggishness;Thinking abnormal;Treatment noncompliance,156020961.0,OT,,,,,,,,,156020961.0,1.0,HIV infection
15613650,156136503,3,F,2018.0,20190206.0,20181113,20190213,EXP,,UG-MYLANLABS-2018M1085392,MYLAN,,,,,M,Y,3.48,KG,20190213.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156136503.0,OT,,,156136503.0,1.0,20180220.0,,,,156136503.0,1.0,HIV infection
15615161,156151612,2,F,,20181215.0,20181114,20190122,EXP,,UG-HETERO CORPORATE-HET2018UG01328,HETERO,,,,,M,Y,3.5,KG,20190122.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156151612.0,OT,,,156151612.0,1.0,20180220.0,20180412.0,,,156151612.0,1.0,HIV infection
15615163,156151631,1,I,,20181103.0,20181114,20181114,EXP,,UG-HETERO CORPORATE-HET2018UG01326,HETERO,,,,,M,Y,2.9,KG,20181114.0,,OT,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156151631.0,OT,,,156151631.0,1.0,20180213.0,20180322.0,,,156151631.0,1.0,HIV infection
15615270,156152707,7,F,,20210118.0,20181114,20210129,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103626,BRISTOL MYERS SQUIBB,"RAPOSO AF, ANTUNES AP, STRECHT T, ALVES SC, OLIVEIRA C, GUIMARAES M ET AL. PHARMACOLOGICAL COMPLEXITY IN HIV?INFECTED PATIENTS. MEDICINA INTERNA. 2017?23:1",49.0,YR,,M,Y,,,20210129.0,,HP,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156152707.0,OT,,,,,,,,,156152707.0,1.0,HIV infection
15619814,156198144,4,F,,20190131.0,20181115,20190213,EXP,,UG-AUROBINDO-AUR-APL-2018-054474,AUROBINDO,,,,,,Y,,,20190214.0,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156198144.0,CA,,,156198144.0,1.0,20180322.0,,,,156198144.0,1.0,HIV infection
15619938,156199386,6,F,20180101.0,20231222.0,20181115,20240104,EXP,,UG-AUROBINDO-AUR-APL-2018-054472,AUROBINDO,,,,I,M,Y,3.4,KG,20240105.0,,MD,UG,UG,EFAVIRENZ,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156199386.0,CA,,,156199386.0,1.0,20180220.0,,,,156199386.0,1.0,HIV infection
15620323,156203233,3,F,,20181215.0,20181115,20181229,EXP,,UG-HETERO-HET2018UG01334,HETERO,,,,,F,Y,3.6,KG,20181229.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156203233.0,CA,,,156203233.0,1.0,20180312.0,20180419.0,,,156203233.0,1.0,HIV infection
15620325,156203251,1,I,,20181103.0,20181115,20181115,EXP,,UG-HETERO CORPORATE-HET2018UG01336,HETERO,,,,N,F,Y,3.12,KG,20181115.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156203251.0,OT,,,156203251.0,1.0,20180301.0,20180614.0,,,156203251.0,1.0,HIV infection
15620327,156203271,1,I,,20181103.0,20181115,20181115,EXP,,UG-HETERO CORPORATE-HET2018UG01338,HETERO,,,,,F,Y,3.5,KG,20181115.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156203271.0,OT,,,156203271.0,1.0,20180322.0,20180615.0,,,156203271.0,1.0,HIV infection
15620483,156204835,5,F,20180101.0,20231222.0,20181115,20240103,EXP,,UG-AUROBINDO-AUR-APL-2018-054477,AUROBINDO,,,,N,M,Y,2.9,KG,20240103.0,,MD,UG,UG,EFAVIRENZ,Congenital umbilical hernia;Foetal exposure during pregnancy,156204835.0,CA,,,156204835.0,1.0,20180213.0,,,,156204835.0,1.0,HIV infection
15620493,156204935,5,F,20180101.0,20231221.0,20181115,20240103,EXP,,UG-AUROBINDO-AUR-APL-2018-054478,AUROBINDO,,,,N,F,Y,3.6,KG,20240103.0,,MD,UG,UG,EFAVIRENZ,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156204935.0,CA,,,156204935.0,1.0,20180312.0,,,,156204935.0,1.0,HIV infection
15620496,156204963,3,F,,20190131.0,20181115,20190214,EXP,,UG-AUROBINDO-AUR-APL-2018-054491,AUROBINDO,,,,,,Y,,,20190214.0,,MD,UG,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156204963.0,OT,,,156204963.0,1.0,20180301.0,,,,156204963.0,1.0,HIV infection
15621321,156213211,1,I,,20181108.0,20181115,20181115,EXP,,CA-ABBVIE-18S-028-2554261-00,ABBVIE,,54.0,YR,,M,Y,,,20181115.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,156213211.0,OT,,,,,,,,,156213211.0,1.0,HIV infection
15624537,156245375,5,F,,20201228.0,20181116,20210103,EXP,,PT-AUROBINDO-AUR-APL-2018-055802,AUROBINDO,,49.0,YR,,M,Y,,,20210104.0,,HP,PT,PT,Efavirenz Film Coated Tablets,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156245375.0,OT,,,,,,,,,156245375.0,1.0,HIV infection
15624884,156248841,1,I,,20181105.0,20181116,20181116,EXP,,UG-CIPLA (EU) LIMITED-2018UG22542,CIPLA,,,,,,Y,,,20181116.0,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;No adverse event,156248841.0,OT,,,156248841.0,2.0,20180301.0,,,,156248841.0,1.0,HIV infection
15624935,156249351,1,I,,20181105.0,20181116,20181116,EXP,,UG-CIPLA (EU) LIMITED-2018UG22538,CIPLA,,,,,,Y,,,20181116.0,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;No adverse event,156249351.0,OT,,,156249351.0,1.0,20180322.0,,,,156249351.0,1.0,HIV infection
15626057,156260572,2,F,,20181214.0,20181116,20181226,EXP,,UG-MYLANLABS-2018M1086712,MYLAN,,,,,F,Y,3.6,KG,20181226.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156260572.0,CA,,,156260572.0,1.0,20180312.0,,,,156260572.0,1.0,HIV infection
15626058,156260582,2,F,2018.0,20190131.0,20181116,20190208,EXP,,UG-MYLANLABS-2018M1086715,MYLAN,,,,N,F,Y,,,20190208.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156260582.0,CA,,,156260582.0,1.0,20180322.0,,,,156260582.0,1.0,HIV infection
15626564,156265642,2,F,20040806.0,20160713.0,20181116,20211118,EXP,,JP-GLAXOSMITHKLINE-JP2016GSK200647,GLAXOSMITHKLINE,,46.0,YR,,M,Y,,,20211118.0,,MD,JP,JP,EFAVIRENZ,Diabetes mellitus;Hepatic function abnormal;Hypercholesterolaemia;Hypertriglyceridaemia;Lipoatrophy,156265642.0,OT,,,156265642.0,1.0,20050716.0,20090828.0,1460.0,DAY,156265642.0,1.0,HIV infection
15626573,156265732,2,F,20040806.0,20160713.0,20181116,20211118,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2016GSK200647,VIIV,,46.0,YR,,M,Y,,,20211118.0,,MD,JP,JP,EFAVIRENZ,Diabetes mellitus;Hepatic function abnormal;Hypercholesterolaemia;Hypertriglyceridaemia;Lipoatrophy,156265732.0,OT,,,156265732.0,1.0,20050716.0,20090828.0,1460.0,DAY,156265732.0,1.0,HIV infection
15626574,156265741,1,I,201202.0,20140715.0,20181116,20181116,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2014GSK055696,VIIV,,51.0,YR,,M,Y,,,20181116.0,,CN,FR,FR,SUSTIVA,Axonal neuropathy;Hypokinesia;Muscular weakness;Pain;Spinal muscular atrophy,156265741.0,OT,,,156265741.0,1.0,2005.0,20111102.0,,,156265741.0,1.0,HIV infection
15627873,156278732,2,F,2018.0,20190114.0,20181116,20190121,EXP,,UG-MYLANLABS-2018M1086713,MYLAN,,,,,M,Y,2.99,KG,20190121.0,,OT,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156278732.0,OT,,,156278732.0,1.0,20180213.0,,,,156278732.0,1.0,HIV infection
15630483,156304833,3,F,,20200113.0,20181119,20200123,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-104504,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,,,20200123.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,156304833.0,OT,,,,,,,,,156304833.0,1.0,HIV infection
15630832,156308321,1,I,,20181105.0,20181119,20181119,EXP,,MW-CIPLA LTD.-2018MW22677,CIPLA,,,,,,Y,,,20181119.0,,OT,MW,MW,EFAVIRENZ.,Neutropenia,156308321.0,OT,,,,,,,,,156308321.0,1.0,HIV infection
15635369,156353691,1,I,20180213.0,20181105.0,20181120,20181120,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018671,MACLEODS,,,,,,Y,,,20181120.0,,OT,US,UG,EFAVIRENZ 600 MG,Foetal exposure during pregnancy;Umbilical hernia,156353691.0,CA,,,156353691.0,1.0,20180213.0,,,,156353691.0,1.0,HIV infection
15635371,156353711,1,I,20180312.0,20181105.0,20181120,20181120,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018666,MACLEODS,,,,,,Y,,,20181120.0,,OT,US,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156353711.0,OT,,,156353711.0,1.0,20180312.0,,,,156353711.0,1.0,HIV infection
15635372,156353722,2,F,20180301.0,20181205.0,20181120,20181220,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018676,MACLEODS,,,,,,Y,,,20181220.0,,OT,US,UG,EFAVIRENZ 600 MG,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156353722.0,OT,,,156353722.0,1.0,20180301.0,,,,156353722.0,1.0,HIV infection
15635377,156353771,1,I,20180220.0,20181105.0,20181120,20181120,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018685,MACLEODS,,,,,,Y,,,20181120.0,,OT,UG,UG,EFAVIRENZ 600 MG,Foetal exposure during pregnancy;Umbilical hernia,156353771.0,OT,,,156353771.0,1.0,20180220.0,,,,156353771.0,1.0,HIV infection
15635454,156354542,2,F,20180322.0,20190109.0,20181120,20190123,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018678,MACLEODS,,,,,,Y,,,20190123.0,,OT,US,UG,Efavirenz 600 mg,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156354542.0,OT,,,156354542.0,1.0,20180322.0,,,,156354542.0,1.0,HIV infection
15640518,156405181,1,I,,20181115.0,20181120,20181120,EXP,,GB-GILEAD-2018-0375288,GILEAD,,,,A,M,Y,,,20181120.0,,MD,GB,GB,EFAVIRENZ.,Diabetes mellitus;Disease risk factor;Hypertension;Renal impairment,156405181.0,OT,,,,,,,,,156405181.0,1.0,HIV infection
15645707,156457074,4,F,20110101.0,20240207.0,20181121,20240209,EXP,,US-GILEAD-2018-0375755,GILEAD,,60.0,YR,A,F,Y,65.76,KG,20240209.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Cystitis;Dysstasia;Economic problem;Emotional distress;Mobility decreased;Nephropathy;Osteoporosis;Pain;Renal failure;Renal impairment,156457074.0,OT,,,156457074.0,1.0,201108.0,201407.0,3.0,MON,156457074.0,1.0,HIV infection
15645742,156457422,2,F,,20190610.0,20181121,20190615,EXP,,PHHY2018GB161759,SANDOZ,,,,,,Y,,,20190615.0,,OT,GB,GB,EFAVIRENZ.,Congenital toxoplasmosis;Foetal exposure during pregnancy,156457422.0,DE,,,,,,,,,156457422.0,1.0,HIV infection
15645863,156458632,2,F,2011.0,20200713.0,20181121,20200904,PER,,US-GILEAD-2018-0375758,GILEAD,,,,A,M,Y,75.74,KG,20200904.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Osteopenia;Pain,156458632.0,OT,,,156458632.0,1.0,201102.0,20120519.0,,,156458632.0,1.0,HIV infection
15650108,156501081,1,I,,20181112.0,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22897,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123.0,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,156501081.0,OT,,,,,,,,,156501081.0,1.0,Prophylaxis against HIV infection
15650118,156501181,1,I,,20181112.0,20181123,20181123,EXP,,US-CIPLA LTD.-2018ZA22899,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123.0,,OT,US,ZA,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,156501181.0,OT,,,,,,,,,156501181.0,1.0,HIV infection
15650133,156501331,1,I,,20181112.0,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22901,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123.0,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,156501331.0,OT,,,,,,,,,156501331.0,1.0,Prophylaxis against HIV infection
15650510,156505101,1,I,,20181112.0,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22900,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66:921 TO 929",,,,,Y,,,20181123.0,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,156505101.0,OT,,,,,,,,,156505101.0,2.0,Prophylaxis against HIV infection
15650512,156505121,1,I,,20181112.0,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22902,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123.0,,OT,ZA,ZA,EFAVIRENZ.,Dehydration;Foetal exposure during pregnancy;Gastroenteritis;Human immunodeficiency virus transmission,156505121.0,DE,,,,,,,,,156505121.0,1.0,Prophylaxis against HIV infection
15650517,156505171,1,I,,20181112.0,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22898,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. HIV AND TUBERCULOSIS DISEASE IN PREGNANCY. 2018;66:921 TO 929",,,,,Y,,,20181123.0,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,156505171.0,OT,,,,,,,,,156505171.0,2.0,Prophylaxis against HIV infection
15651977,156519774,4,F,20130801.0,20230429.0,20181123,20230504,EXP,,US-GILEAD-2018-0375835,GILEAD,,43.0,YR,A,M,Y,117.01,KG,20230504.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Foot fracture;Osteoporosis;Pain;Spinal compression fracture,156519774.0,OT,,,156519774.0,1.0,2001.0,2012.0,2.0,YR,156519774.0,1.0,HIV infection
15651984,156519842,2,F,20110114.0,20200716.0,20181123,20200828,EXP,,US-GILEAD-2018-0375837,GILEAD,,50.0,YR,A,F,Y,81.63,KG,20200828.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Foot fracture;Glomerular filtration rate abnormal;Osteopenia;Osteoporosis;Pain,156519842.0,OT,,,156519842.0,1.0,2003.0,2017.0,,,156519842.0,1.0,HIV infection
15652074,156520742,2,F,,20181215.0,20181123,20181219,EXP,,UG-GILEAD-2018-0373362,GILEAD,,,,N,M,Y,3.48,KG,20181219.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156520742.0,OT,,,156520742.0,1.0,20180220.0,20180412.0,,,156520742.0,1.0,HIV infection
15652130,156521304,4,F,20130513.0,20231125.0,20181123,20231127,EXP,,US-GILEAD-2018-0376062,GILEAD,,45.0,YR,A,F,Y,47.619,KG,20231127.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Economic problem;Emotional distress;Gait disturbance;Osteopenia;Osteoporosis;Pain,156521304.0,OT,,,156521304.0,1.0,2011.0,2013.0,3125.0,DAY,156521304.0,1.0,HIV infection
15652146,156521463,3,F,20161005.0,20201228.0,20181123,20210105,EXP,,US-GILEAD-2018-0376080,GILEAD,,47.0,YR,A,M,Y,94.33,KG,20210105.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,156521463.0,HO,,,156521463.0,1.0,2006.0,2016.0,,,156521463.0,1.0,HIV infection
15652214,156522143,3,F,20160401.0,20230429.0,20181123,20230503,PER,,US-GILEAD-2018-0376074,GILEAD,,54.0,YR,A,F,Y,107.48,KG,20230503.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Loss of personal independence in daily activities;Osteopenia;Pain,,,,,156522143.0,1.0,2001.0,2004.0,,,156522143.0,1.0,HIV infection
15655884,156558842,2,F,,20181215.0,20181126,20181220,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018213126,VIIV,,,,,M,Y,3.0,KG,20181220.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156558842.0,CA,,,156558842.0,1.0,20180220.0,20180412.0,,,156558842.0,1.0,HIV infection
15655906,156559062,2,F,,20181215.0,20181126,20181220,EXP,,UG-GLAXOSMITHKLINE-UG2018213126,GLAXOSMITHKLINE,,,,,M,Y,3.0,KG,20181220.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156559062.0,OT,,,156559062.0,1.0,20180220.0,20180412.0,,,156559062.0,1.0,HIV infection
15656583,156565834,4,F,20150101.0,20231215.0,20181126,20231218,EXP,,US-GILEAD-2018-0376057,GILEAD,,67.0,YR,E,F,Y,91.61,KG,20231218.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Dysstasia;Economic problem;Emotional distress;Fall;Lower limb fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Wrist fracture,156565834.0,OT,,,156565834.0,1.0,200601.0,20171008.0,88.0,DAY,156565834.0,1.0,HIV infection
15656869,156568693,3,F,20141201.0,20230401.0,20181126,20230407,PER,,US-GILEAD-2018-0376047,GILEAD,,61.0,YR,A,F,Y,120.64,KG,20230407.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal pain,156568693.0,OT,,,156568693.0,1.0,2004.0,201302.0,,,156568693.0,1.0,HIV infection
15658877,156588773,3,F,2018.0,20190129.0,20181126,20190205,EXP,,UG-MYLANLABS-2018M1087630,MYLAN,,,,N,F,Y,3.6,KG,20190205.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156588773.0,OT,,,156588773.0,1.0,20180312.0,,,,156588773.0,1.0,HIV infection
15660800,156608001,1,I,,20181119.0,20181127,20181127,EXP,,PT-TEVA-2018-PT-980117,TEVA,SANTOS J. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;61(2):64-71.,32.0,YR,,M,Y,,,20181127.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156608001.0,OT,,,,,,,,,156608001.0,2.0,HIV infection CDC category C
15660824,156608242,2,F,,20181123.0,20181127,20181205,EXP,,PT-TEVA-2018-PT-980142,TEVA,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",32.0,YR,,M,Y,,,20181205.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156608242.0,OT,,,,,,,,,156608242.0,2.0,HIV infection CDC category C
15660861,156608612,2,F,,20181123.0,20181127,20181205,EXP,,PT-TEVA-2018-PT-980116,TEVA,SANTOS J. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;61(2):64-71.,29.0,YR,,M,Y,,,20181205.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156608612.0,OT,,,,,,,,,156608612.0,2.0,HIV infection CDC category C
15661445,156614454,4,F,2018.0,20201118.0,20181127,20201126,EXP,,US-GILEAD-2018-0376064,GILEAD,,38.0,YR,A,M,Y,,,20201126.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Pain,156614454.0,OT,,,156614454.0,1.0,20111221.0,20120120.0,,,156614454.0,1.0,HIV infection
15661710,156617106,6,F,20100101.0,20230413.0,20181127,20230418,EXP,,US-GILEAD-2018-0376139,GILEAD,,38.0,YR,A,M,Y,89.796,KG,20230418.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Off label use;Pain,156617106.0,OT,,,156617106.0,1.0,2010.0,2013.0,,,156617106.0,1.0,HIV infection
15662443,156624431,1,I,,20181119.0,20181127,20181127,EXP,,ZA-GILEAD-2018-0376550,GILEAD,"VENTER WDF, KAMBUGU A, CHERSICH MF, BECKER S, HILL A, ARULAPPAN N, MOORHOUSE M, MAJAM M, AKPOMIEMIE G, SOKHELA S, POONGULALI S, FELDMAN C, DUNCOMBE C, BROWN RIPIN DH, KUMARASAMY N. EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS LOW-DOSE STAVUDINE OVER 96 WEEKS: A MULTI-COUNTRY RANDOMISED, NON-INFERIORITY TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018;UNK:UNK. DOI:DOI: 10.1097/QAI.0000000000001908",,,A,,Y,,,20181127.0,,MD,ZA,ZA,EFAVIRENZ.,Fracture,156624431.0,OT,,,,,,,,,156624431.0,1.0,HIV infection
15662449,156624491,1,I,,20181119.0,20181127,20181127,EXP,,ZA-GILEAD-2018-0376551,GILEAD,"VENTER WDF, KAMBUGU A, CHERSICH MF, BECKER S, HILL A, ARULAPPAN N, MOORHOUSE M, MAJAM M, AKPOMIEMIE G, SOKHELA S, POONGULALI S, FELDMAN C, DUNCOMBE C, BROWN RIPIN DH, KUMARASAMY N. EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS LOW-DOSE STAVUDINE OVER 96 WEEKS: A MULTI-COUNTRY RANDOMISED, NON-INFERIORITY TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018;UNK:UNK. DOI:DOI: 10.1097/QAI.0000000000001908",,,A,,Y,,,20181127.0,,MD,ZA,ZA,EFAVIRENZ.,Fracture,156624491.0,OT,,,,,,,,,156624491.0,1.0,HIV infection
15662450,156624501,1,I,,20181119.0,20181127,20181127,EXP,,ZA-GILEAD-2018-0376552,GILEAD,"VENTER WDF, KAMBUGU A, CHERSICH MF, BECKER S, HILL A, ARULAPPAN N, MOORHOUSE M, MAJAM M, AKPOMIEMIE G, SOKHELA S, POONGULALI S, FELDMAN C, DUNCOMBE C, BROWN RIPIN DH, KUMARASAMY N. EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS LOW-DOSE STAVUDINE OVER 96 WEEKS: A MULTI-COUNTRY RANDOMISED, NON-INFERIORITY TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018;UNK:UNK. DOI:DOI: 10.1097/QAI.0000000000001908",,,A,,Y,,,20181127.0,,MD,ZA,ZA,EFAVIRENZ.,Fracture,156624501.0,OT,,,,,,,,,156624501.0,1.0,HIV infection
15665943,156659431,1,I,,20181119.0,20181128,20181128,EXP,,PK-GILEAD-2018-0375884,GILEAD,"TARIQ U, PARVEEN A, AKHTAR F, MAHMOOD F, ALI S, ABIDI S. EMERGENCE OF CIRCULATING RECOMBINANT FORM 56-CPX IN PAKISTAN. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2018;34 (11):1002-1004. DOI:10.1089/AID.2018.0128",29.0,YR,A,M,Y,,,20181128.0,,OT,PK,PK,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,156659431.0,OT,,,,,,,,,156659431.0,1.0,HIV infection
15674687,156746871,1,I,,20181119.0,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112917,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130.0,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156746871.0,OT,,,,,,,,,156746871.0,1.0,HIV infection
15674688,156746883,3,F,,20181119.0,20181130,20190205,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-111091,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190205.0,,OT,IN,ZA,EFAVIRENZ.,Pancreatitis;Prescribed underdose,156746883.0,OT,,,,,,,,,156746883.0,1.0,HIV infection
15674696,156746961,1,I,,20181119.0,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112918,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130.0,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156746961.0,OT,,,,,,,,,156746961.0,1.0,HIV infection
15674709,156747091,1,I,,20181119.0,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112919,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130.0,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156747091.0,OT,,,,,,,,,156747091.0,1.0,HIV infection
15674772,156747721,1,I,,20181119.0,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112920,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130.0,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156747721.0,OT,,,,,,,,,156747721.0,1.0,HIV infection
15681433,156814331,1,I,,20181112.0,20181203,20181203,EXP,,UG-MYLANLABS-2018M1089620,MYLAN,,,,I,F,Y,3.12,KG,20181203.0,,OT,UG,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156814331.0,CA,,,156814331.0,1.0,20180301.0,,,,156814331.0,1.0,HIV infection
15681520,156815201,1,I,20070426.0,20181121.0,20181203,20181203,EXP,,JP-GILEAD-2018-0376861,GILEAD,,41.0,YR,A,M,Y,,,20181203.0,,OT,JP,JP,EFAVIRENZ.,Autoimmune hepatitis;Hyperlipidaemia,156815201.0,HO,,,156815201.0,1.0,20060526.0,20060429.0,,,156815201.0,1.0,HIV infection
15684612,156846121,1,I,,20181121.0,20181204,20181204,EXP,,"UG-LANNETT COMPANY, INC.-UG-2018LAN001362",LANNETT,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS. 2018;5(1):NO PAGINATION",45.0,YR,,M,Y,,,20181204.0,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,156846121.0,DE,,,,,,,,,156846121.0,1.0,Antiretroviral therapy
15684666,156846661,1,I,,20181121.0,20181204,20181204,EXP,,"UG-LANNETT COMPANY, INC.-UG-2018LAN001363",LANNETT,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS. 2018;5(1):NO PAGINATION",35.0,YR,,M,Y,,,20181204.0,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,156846661.0,DE,,,,,,,,,156846661.0,1.0,Antiretroviral therapy
15684861,156848611,1,I,,20181121.0,20181204,20181204,EXP,,"UG-LANNETT COMPANY, INC.-UG-2018LAN001364",LANNETT,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS. 2018;5(1):NO PAGINATION",,,,,Y,,,20181204.0,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,156848611.0,DE,,,,,,,,,156848611.0,1.0,Antiretroviral therapy
15685736,156857361,1,I,201610.0,20180711.0,20181204,20181204,EXP,,GB-GILEAD-2018-0349731,GILEAD,"SUTTON N, GUPTA N. HIV-POSITIVE WOMEN AND CONTRACEPTION; EFFICACY VERSUS ACCEPTABILITY. HIV MEDICINE. 2018;19(19):S122",38.0,YR,A,F,Y,,,20181204.0,,MD,GB,GB,EFAVIRENZ.,Abortion induced;Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,156857361.0,OT,,,,,,,,,156857361.0,1.0,Antiretroviral therapy
15692336,156923362,2,F,,20181215.0,20181205,20181226,EXP,,UG-MYLANLABS-2018M1090123,MYLAN,,,,,M,Y,2.99,KG,20181226.0,,OT,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156923362.0,CA,,,156923362.0,1.0,20180213.0,,,,156923362.0,1.0,HIV infection
15694155,156941551,1,I,,20181112.0,20181206,20181206,EXP,,PT-MYLANLABS-2018M1089146,MYLAN,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",32.0,YR,,M,Y,,,20181206.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156941551.0,OT,,,,,,,,,156941551.0,1.0,HIV infection CDC category C
15694342,156943421,1,I,,20181112.0,20181206,20181206,EXP,,PT-MYLANLABS-2018M1089147,MYLAN,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",29.0,YR,,M,Y,,,20181206.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156943421.0,OT,,,,,,,,,156943421.0,1.0,HIV infection CDC category C
15695364,156953641,1,I,,20181112.0,20181206,20181206,EXP,,PT-MYLANLABS-2018M1089143,MYLAN,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",32.0,YR,,M,Y,,,20181206.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156953641.0,OT,,,,,,,,,156953641.0,1.0,HIV infection CDC category C
15696681,156966811,1,I,20150411.0,20181129.0,20181206,20181206,EXP,,TH-MYLANLABS-2018M1090876,MYLAN,,30.0,YR,,F,Y,,,20181206.0,,OT,TH,TH,EFAVIRENZ MYLAN,Abortion spontaneous;Maternal exposure during pregnancy,156966811.0,OT,,,156966811.0,1.0,20140604.0,,,,156966811.0,1.0,HIV infection
15699652,156996521,1,I,,20181108.0,20181207,20181207,PER,,US-009507513-1811USA003665,MERCK,"MORGELLO S, JACOBS M, MURRAY J, BYRD D, NEIBART E, MINTZ L, ET AL. ALZHEIMER?S DISEASE NEUROPATHOLOGY MAY NOT PREDICT FUNCTIONAL IMPAIRMENT IN HIV: A REPORT OF TWO INDIVIDUALS. JOURNAL OF NEUROVIROLOGY. 2018;24(5):629-37",81.0,YR,,F,Y,,,20181207.0,,OT,US,US,SUSTIVA,Drug ineffective,,,,,,,,,,,156996521.0,1.0,Antiretroviral therapy
15708417,157084173,3,F,,20190110.0,20181211,20190222,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112504,BRISTOL MYERS SQUIBB,,29.0,YR,,M,Y,,,20190222.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,157084173.0,OT,,,,,,,,,157084173.0,1.0,HIV infection CDC category C
15721173,157211732,2,F,,20181203.0,20181214,20181219,EXP,,IN-HETERO LABS LIMITED-HET2018IN01520,HETERO,"BALASWAMY REDDY G, SRINIVAS G.. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER.. HIV-AIDS-REV.. 2018;17(3):224-226.",39.0,YR,,M,Y,,,20181219.0,,OT,IN,IN,EFAVIRENZ.,HIV-associated neurocognitive disorder;Psychotic disorder,157211732.0,OT,,,,,,,,,157211732.0,1.0,HIV infection
15734371,1573437110,10,F,20011001.0,20210810.0,20181218,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-A200601823,VIIV,,,,,,Y,,,20220624.0,,MD,JP,JP,EFAVIRENZ,Arterial stenosis;Hepatic steatosis;Hyperlipidaemia,1573437110.0,OT,,,1573437110.0,1.0,20000706.0,20030331.0,998.0,DAY,1573437110.0,1.0,Acquired immunodeficiency syndrome
15734587,1573458710,10,F,20011001.0,20210810.0,20181218,20220628,EXP,,JP-GLAXOSMITHKLINE-A200601823,GLAXOSMITHKLINE,,,,,,Y,,,20220628.0,,MD,JP,JP,EFAVIRENZ,Arterial stenosis;Hepatic steatosis;Hyperlipidaemia,1573458710.0,OT,,,1573458710.0,1.0,20000706.0,20030331.0,998.0,DAY,1573458710.0,1.0,Acquired immunodeficiency syndrome
15743463,157434631,1,I,2013.0,20181210.0,20181220,20181220,EXP,,UG-CIPLA LTD.-2018UG23687,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181220.0,,OT,UG,UG,EFAVIRENZ.,Osteomalacia,157434631.0,OT,,,,,,,,,157434631.0,1.0,Antiretroviral therapy
15743464,157434641,1,I,2013.0,20181210.0,20181220,20181220,EXP,,UG-CIPLA LTD.-2018UG23685,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE(?): DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181220.0,,OT,UG,UG,EFAVIRENZ.,Parkinsonism,157434641.0,OT,,,,,,,,,157434641.0,1.0,Antiretroviral therapy
15749989,157499891,1,I,,20181210.0,20181221,20181221,EXP,,UG-CIPLA LTD.-2018UG23732,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181221.0,,OT,UG,UG,EFAVIRENZ.,Eyelid disorder,157499891.0,OT,,,,,,,,,157499891.0,1.0,Antiretroviral therapy
15749992,157499923,3,F,201312.0,20181210.0,20181221,20181224,EXP,,UG-CIPLA LTD.-2018UG23709,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181224.0,,OT,UG,UG,EFAVIRENZ.,Gynaecomastia,157499923.0,OT,,,,,,,,,157499923.0,1.0,Antiretroviral therapy
15749995,157499951,1,I,201804.0,20181210.0,20181221,20181221,EXP,,UG-CIPLA LTD.-2018UG23710,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181221.0,,OT,UG,UG,EFAVIRENZ.,Gynaecomastia,157499951.0,OT,,,,,,,,,157499951.0,1.0,Antiretroviral therapy
15749997,157499971,1,I,,20181210.0,20181221,20181221,EXP,,UG-CIPLA LTD.-2018UG23734,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE(?): DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181221.0,,OT,UG,UG,EFAVIRENZ.,Aphthous ulcer,157499971.0,OT,,,,,,,,,157499971.0,1.0,Antiretroviral therapy
15752109,157521091,1,I,,20181211.0,20181221,20181221,EXP,,TG-MYLANLABS-2018M1093926,MYLAN,"SAKA B, AKAKPO AS, BASSOWA A, DAPAM AN, MAHAMADOU G, TECLESSOU JN, ET AL. NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)-INDUCED STEVENS-JOHNSON SYNDROME AND GYNECOMASTIA IN AN HIV-INFECTED CHILD: A CASE REPORT. ANN-DERMATOL-VENEREOL 2018;145(12):773-776.",,,T,M,Y,,,20181221.0,,OT,TG,TG,EFAVIRENZ.,Gynaecomastia;Stevens-Johnson syndrome,157521091.0,OT,,,157521091.0,1.0,201508.0,201707.0,,,157521091.0,1.0,HIV infection
15752741,157527411,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381546,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527411.0,OT,,,,,,,,,157527411.0,1.0,HIV infection
15752742,157527421,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381549,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527421.0,OT,,,,,,,,,157527421.0,1.0,HIV infection
15752743,157527431,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381547,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527431.0,OT,,,,,,,,,157527431.0,1.0,HIV infection
15752744,157527441,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381548,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527441.0,OT,,,,,,,,,157527441.0,1.0,HIV infection
15752748,157527481,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381544,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527481.0,OT,,,,,,,,,157527481.0,1.0,HIV infection
15752749,157527491,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381545,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,F,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527491.0,OT,,,,,,,,,157527491.0,1.0,HIV infection
15752755,157527551,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381554,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527551.0,OT,,,,,,,,,157527551.0,1.0,HIV infection
15752756,157527561,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381560,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527561.0,OT,,,,,,,,,157527561.0,1.0,HIV infection
15752757,157527571,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381557,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527571.0,OT,,,,,,,,,157527571.0,1.0,HIV infection
15752758,157527581,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381565,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527581.0,OT,,,,,,,,,157527581.0,1.0,HIV infection
15752765,157527651,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381556,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527651.0,OT,,,,,,,,,157527651.0,1.0,HIV infection
15752766,157527661,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381563,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527661.0,OT,,,,,,,,,157527661.0,1.0,HIV infection
15752767,157527671,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381564,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527671.0,OT,,,,,,,,,157527671.0,1.0,HIV infection
15752768,157527681,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381553,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527681.0,OT,,,,,,,,,157527681.0,1.0,HIV infection
15752769,157527691,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381566,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527691.0,OT,,,,,,,,,157527691.0,1.0,HIV infection
15752770,157527701,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381550,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527701.0,OT,,,,,,,,,157527701.0,1.0,HIV infection
15752772,157527721,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381562,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527721.0,OT,,,,,,,,,157527721.0,1.0,HIV infection
15752773,157527731,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381561,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527731.0,OT,,,,,,,,,157527731.0,1.0,HIV infection
15752774,157527741,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381559,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527741.0,OT,,,,,,,,,157527741.0,1.0,HIV infection
15752775,157527751,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381551,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527751.0,OT,,,,,,,,,157527751.0,1.0,HIV infection
15752778,157527781,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381555,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527781.0,OT,,,,,,,,,157527781.0,1.0,HIV infection
15752779,157527791,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381552,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527791.0,OT,,,,,,,,,157527791.0,1.0,HIV infection
15752780,157527801,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381567,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527801.0,OT,,,,,,,,,157527801.0,1.0,HIV infection
15752781,157527811,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381558,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527811.0,OT,,,,,,,,,157527811.0,1.0,HIV infection
15752783,157527831,1,I,,20181217.0,20181221,20181221,EXP,,MW-GILEAD-2018-0381507,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527831.0,OT,,,,,,,,,157527831.0,1.0,HIV infection
15752900,157529001,1,I,,20180430.0,20181221,20181221,EXP,,MW-GILEAD-2018-0336633,GILEAD,,,,I,,Y,,,20181221.0,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157529001.0,OT,,,,,,,,,157529001.0,1.0,HIV infection
15754515,157545151,1,I,2013.0,20181210.0,20181224,20181224,EXP,,UG-CIPLA LTD.-2018UG23692,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181224.0,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Foetal death,157545151.0,OT,,,,,,,,,157545151.0,1.0,Antiretroviral therapy
15754626,157546261,1,I,2014.0,20181210.0,20181224,20181224,EXP,,UG-CIPLA LTD.-2018UG23691,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE(?): DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181224.0,,OT,UG,UG,EFAVIRENZ.,Hepatorenal syndrome,157546261.0,OT,,,,,,,,,157546261.0,1.0,Antiretroviral therapy
15757567,157575672,2,F,20090618.0,20190103.0,20181224,20190110,EXP,,FR-GILEAD-2018-0381472,GILEAD,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL.. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T).. CHEMICAL BIOLOGY + DRUG DESIGN.. 2018;N/A:N/A. DOI:DOI: 10.1111/CBDD.13378",47.0,YR,A,M,Y,,,20190110.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,157575672.0,OT,,,,,,,,,157575672.0,1.0,HIV infection
15758249,157582491,1,I,20070426.0,20181210.0,20181225,20181225,EXP,,GB-AUROBINDO-AUR-APL-2018-061061,AUROBINDO,,41.0,YR,,M,Y,,,20181225.0,,OT,JP,GB,EFAVIRENZ.,Autoimmune hepatitis;Hyperlipidaemia,157582491.0,HO,,,157582491.0,1.0,20060421.0,,,,157582491.0,1.0,HIV infection
15758812,157588122,2,F,,20190214.0,20181225,20190226,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-117137,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190226.0,,OT,GB,GB,EFAVIRENZ.,No adverse event,,,,,,,,,,,157588122.0,1.0,HIV infection
15763185,157631851,1,I,,20181217.0,20181226,20181226,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-119901,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20181226.0,,MD,PT,PT,EFAVIRENZ.,Lipodystrophy acquired,157631851.0,OT,,,,,,,,,157631851.0,1.0,HIV infection
15763654,157636541,1,I,,20181217.0,20181227,20181227,EXP,,IN-CIPLA LTD.-2018IN24004,CIPLA,,,,,,Y,,,20181227.0,,OT,IN,IN,EFAVIRENZ.,Generalised oedema;Periorbital oedema;Proteinuria;Virologic failure,157636541.0,OT,,,,,,,,,157636541.0,1.0,HIV infection
15766916,157669162,2,F,,20181218.0,20181227,20181228,EXP,,IT-MYLANLABS-2018M1095305,MYLAN,,,,A,,Y,,,20181228.0,,MD,IT,IT,EFAVIRENZ.,Hepatotoxicity;Toxicity to various agents,157669162.0,OT,,,,,,,,,157669162.0,1.0,HIV infection
15766921,157669212,2,F,,20181218.0,20181227,20181228,EXP,,IT-MYLANLABS-2018M1095307,MYLAN,,,,A,,Y,,,20181228.0,,MD,IT,IT,EFAVIRENZ.,Neurotoxicity;Toxicity to various agents,157669212.0,OT,,,,,,,,,157669212.0,1.0,HIV infection
15767908,157679081,1,I,,20181220.0,20181227,20181227,EXP,GB-MHRA-EYC 00181171,GB-MYLANLABS-2018M1096185,MYLAN,,44.0,YR,,,Y,,,20181227.0,,CN,GB,GB,EFAVIRENZ.,Death,157679081.0,DE,,,,,,,,,157679081.0,1.0,HIV infection
15773855,157738552,2,F,,20200928.0,20181229,20201006,EXP,,DE-AUROBINDO-AUR-APL-2018-063436,AUROBINDO,,52.0,YR,,F,Y,,,20201006.0,,HP,DE,DE,EFAVIRENZ.,"Abnormal behaviour;Acute psychosis;Cognitive disorder;Delusion;Depressed mood;Disturbance in attention;Hallucinations, mixed;Impulse-control disorder;Irritability;Memory impairment;Personality change;Psychomotor hyperactivity;Tension",157738552.0,HO,,,,,,,,,157738552.0,1.0,HIV infection
15775420,157754201,1,I,20060629.0,20181217.0,20181231,20181231,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-119832,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,50.0,KG,20181231.0,,OT,GB,GB,SUSTIVA,Body temperature increased;Hypotension;Hypoxia;Liver function test abnormal;Malaise;Oxygen saturation decreased;Tachycardia;Tachypnoea;Traumatic lung injury,157754201.0,HO,,,157754201.0,1.0,20060628.0,20060629.0,,,157754201.0,1.0,HIV infection
15775439,157754391,1,I,,20181217.0,20181231,20181231,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-122012,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181231.0,,OT,IN,IN,EFAVIRENZ.,CD4 lymphocytes decreased,157754391.0,OT,,,,,,,,,157754391.0,1.0,HIV infection
15776367,157763671,1,I,20180920.0,20181229.0,20181231,20181231,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK233646,VIIV,,23.0,YR,,M,Y,65.0,KG,20181231.0,,OT,CN,CN,STOCRIN (EFAVIRENZ),Hepatic function abnormal;Liver injury;Product use in unapproved indication,157763671.0,OT,,,157763671.0,1.0,20180920.0,,,,157763671.0,1.0,Acquired immunodeficiency syndrome
15776474,157764741,1,I,20180920.0,20181229.0,20181231,20181231,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK233646,GLAXOSMITHKLINE,,23.0,YR,,M,Y,65.0,KG,20181231.0,,OT,CN,CN,STOCRIN (EFAVIRENZ),Hepatic function abnormal;Liver injury;Product use in unapproved indication,157764741.0,OT,,,157764741.0,1.0,20180920.0,,,,157764741.0,1.0,Acquired immunodeficiency syndrome
15784943,157849431,1,I,20131007.0,20131023.0,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08317,CIPLA,,,,,,Y,,,20190103.0,,OT,KE,KE,EFAVIRENZ.,Death;Malnutrition,157849431.0,DE,,,157849431.0,1.0,20130924.0,20131007.0,,,157849431.0,1.0,HIV infection
15784956,157849561,1,I,20130822.0,20130823.0,20190103,20190103,EXP,,KE-CIPLA (EU) LIMITED-2016KE08314,CIPLA,,,,,,Y,,,20190103.0,,OT,KE,KE,EFAVIRENZ.,Acute kidney injury;Acute respiratory distress syndrome;Alanine aminotransferase increased;Hyperkalaemia;Immune reconstitution inflammatory syndrome;Intestinal obstruction;Pulmonary embolism;Pulmonary tuberculosis;Pyrexia;Sepsis,157849561.0,DE,,,157849561.0,1.0,20130815.0,20130824.0,,,157849561.0,1.0,HIV infection
15784965,157849651,1,I,,20140227.0,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08319,CIPLA,,,,,,Y,,,20190103.0,,OT,KE,KE,EFAVIRENZ.,Death,157849651.0,DE,,,157849651.0,1.0,20140128.0,20140224.0,,,157849651.0,1.0,HIV infection
15785010,157850101,1,I,20140129.0,20140204.0,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08333,CIPLA,,,,,,Y,,,20190103.0,,OT,KE,KE,EFAVIRENZ.,Acute kidney injury;Meningitis bacterial;Meningitis tuberculous;Myelitis transverse;Neuropathy peripheral;Oral candidiasis;Urinary retention,157850101.0,OT,,,157850101.0,1.0,20140114.0,20140227.0,,,157850101.0,1.0,HIV infection
15785022,157850221,1,I,,20140129.0,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08318,CIPLA,,,,,,Y,,,20190103.0,,OT,KE,KE,EFAVIRENZ.,Death,157850221.0,DE,,,157850221.0,1.0,20131205.0,20140127.0,,,157850221.0,1.0,HIV infection
15785036,157850361,1,I,20130827.0,20130830.0,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08316,CIPLA,,,,,,Y,,,20190103.0,,OT,KE,KE,EFAVIRENZ.,Acute kidney injury;Anaemia;Death;Lymphopenia;Pulmonary tuberculosis,157850361.0,HO,,,157850361.0,1.0,20130822.0,20130830.0,,,157850361.0,1.0,HIV infection
15795852,157958521,1,I,,20190103.0,20190107,20190107,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-122302,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190107.0,,MD,GB,GB,EFAVIRENZ.,Hepatitis B,157958521.0,OT,,,,,,,,,157958521.0,1.0,HIV infection
15798355,157983551,1,I,,20181226.0,20190108,20190108,EXP,,"IN-LANNETT COMPANY, INC.-IN-2018LAN004652",LANNETT,"BALASWAMY REDDY G, SRINIVAS G. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV-AIDS-REV. 2018;17(3):224-226",,,A,M,Y,,,20190108.0,,MD,IN,IN,EFAVIRENZ.,HIV-associated neurocognitive disorder;Psychotic disorder,157983551.0,OT,,,,,,,,,157983551.0,1.0,HIV infection
15800297,158002972,2,F,,20190619.0,20190108,20190624,EXP,,CA-GILEAD-2019-0383284,GILEAD,,45.0,YR,A,M,Y,,,20190624.0,,OT,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,158002972.0,DS,,,158002972.0,1.0,2007.0,,,,158002972.0,1.0,HIV infection
15824722,158247221,1,I,,20190108.0,20190115,20190115,EXP,,CA-ABBVIE-19S-028-2618488-00,ABBVIE,,54.0,YR,,M,Y,,,20190115.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,158247221.0,OT,,,,,,,,,158247221.0,1.0,HIV infection
15828303,158283032,2,F,20180322.0,20190131.0,20190115,20190207,EXP,,UG-GILEAD-2018-0373403,GILEAD,,0.0,YR,N,F,Y,3.5,KG,20190207.0,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158283032.0,OT,,,158283032.0,1.0,20180322.0,,,,158283032.0,1.0,HIV infection
15830514,158305141,1,I,,20190109.0,20190115,20190115,EXP,GB-MHRA-EYC 00181639,GB-MYLANLABS-2019M1003224,MYLAN,,,,N,F,Y,,,20190115.0,,MD,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,158305141.0,CA,,,158305141.0,1.0,201103.0,201806.0,,,158305141.0,1.0,HIV infection
15832748,158327481,1,I,,20190108.0,20190116,20190116,EXP,,ZA-MYLANLABS-2019M1003076,MYLAN,"MEINTJES G, STEK C, BLUMENTHAL L, THIENEMANN F, SCHUTZ C, BUYZE J, ET AL. PREDNISONE FOR THE PREVENTION OF PARADOXICAL TUBERCULOSIS-ASSOCIATED IRIS. N-ENGL-J-MED 2018;379(20):1915-1925.",,,A,,Y,,,20190116.0,,MD,ZA,ZA,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis;Paradoxical drug reaction;Protein-losing gastroenteropathy;Sepsis;Tuberculosis gastrointestinal,158327481.0,DE,,,,,,,,,158327481.0,1.0,HIV infection
15832758,158327582,2,F,20180322.0,20190131.0,20190116,20190208,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018236801,VIIV,,0.0,YR,,F,Y,3.5,KG,20190208.0,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158327582.0,CA,,,158327582.0,1.0,20180322.0,,,,158327582.0,1.0,HIV infection
15834946,158349462,2,F,,20190225.0,20190116,20190304,EXP,,FR-GILEAD-2019-0384132,GILEAD,,37.0,YR,A,M,Y,,,20190304.0,,OT,IT,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,158349462.0,OT,,,,,,,,,158349462.0,1.0,HIV infection
15837621,158376211,1,I,,20190108.0,20190117,20190117,EXP,,ZA-MYLANLABS-2019M1003075,MYLAN,"MEINTJES G, STEK C, BLUMENTHAL L, THIENEMANN F, SCHUTZ C, BUYZE J, ET AL. PREDNISONE FOR THE PREVENTION OF PARADOXICAL TUBERCULOSIS-ASSOCIATED IRIS. N-ENGL-J-MED 2018;379(20):1915-1925.",,,A,,Y,,,20190117.0,,MD,ZA,ZA,EFAVIRENZ.,Cardiac tamponade;Immune reconstitution inflammatory syndrome associated tuberculosis;Paradoxical drug reaction,158376211.0,DE,,,,,,,,,158376211.0,1.0,HIV infection
15838467,158384676,6,F,20171006.0,20200601.0,20190117,20200602,EXP,,GB-MYLANLABS-2019M1001573,MYLAN,,43.0,YR,,F,Y,,,20200602.0,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,158384676.0,OT,,,158384676.0,1.0,20171006.0,20180205.0,,,158384676.0,1.0,HIV infection
15839144,158391442,2,F,20110825.0,20190109.0,20190117,20190117,EXP,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-123520,IT-JNJFOC-20190115342,JANSSEN,"POUGA  L, SANTORO  MM, CHARPENTIER  C, CARLO  DD, ROMEO  I, ARTESE  A. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY AND DRUG DESIGN 2018:1-10.",37.0,YR,A,M,Y,,,20190117.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,158391442.0,OT,,,,,,,,,158391442.0,1.0,HIV infection
15839390,158393902,2,F,20180322.0,20190131.0,20190117,20190208,EXP,,UG-GLAXOSMITHKLINE-UG2018236801,GLAXOSMITHKLINE,,0.0,YR,,F,Y,3.5,KG,20190208.0,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158393902.0,OT,,,158393902.0,1.0,20180322.0,,,,158393902.0,1.0,HIV infection
15839428,158394282,2,F,201610.0,20190201.0,20190117,20190207,EXP,,GB-MYLANLABS-2019M1003653,MYLAN,"SUTTON N, GUPTA N.. HIV-POSITIVE WOMEN AND CONTRACEPTION; EFFICACY VERSUS ACCEPTABILITY. HIV MEDICINE. 2018;19 (SUPPL. 2):S21?S152",38.0,YR,,F,Y,,,20190207.0,,,COUNTRY NOT SPECIFIED,GB,EFAVIRENZ.,Abortion induced;Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,158394282.0,OT,,,158394282.0,1.0,201106.0,,,,158394282.0,1.0,HIV infection
15839587,158395871,1,I,,20190108.0,20190117,20190117,EXP,,ZA-MYLANLABS-2019M1003211,MYLAN,"MEINTJES G, STEK C, BLUMENTHAL L, THIENEMANN F, SCHUTZ C, BUYZE J, ET AL. PREDNISONE FOR THE PREVENTION OF PARADOXICAL TUBERCULOSIS-ASSOCIATED IRIS. N-ENGL-J-MED 2018;379(20):1915-1925.",,,A,,Y,,,20190117.0,,MD,ZA,ZA,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis;Paradoxical drug reaction,158395871.0,DE,,,,,,,,,158395871.0,1.0,HIV infection
15845850,158458501,1,I,201808.0,20190107.0,20190120,20190120,EXP,,PT-AUROBINDO-AUR-APL-2019-001642,AUROBINDO,,45.0,YR,,M,Y,,,20190120.0,,PH,PT,PT,EFAVIRENZ.,Insomnia;Nightmare,158458501.0,OT,,,158458501.0,1.0,20130702.0,20181217.0,,,158458501.0,1.0,HIV infection
15852189,158521891,1,I,,20190109.0,20190122,20190122,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-003208,BRISTOL MYERS SQUIBB,,29.0,YR,,M,Y,,,20190122.0,,MD,IN,IN,EFAVIRENZ.,Angioedema;Pruritus;Therapeutic product cross-reactivity,158521891.0,OT,,,,,,,,,158521891.0,1.0,Antiretroviral therapy
15852229,158522291,1,I,,20190109.0,20190122,20190122,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-005406,BRISTOL MYERS SQUIBB,,45.0,YR,,F,Y,,,20190122.0,,MD,IN,IN,EFAVIRENZ.,Rash macular;Therapeutic product cross-reactivity,158522291.0,OT,,,,,,,,,158522291.0,1.0,Antiretroviral therapy
15852544,158525441,1,I,,20190109.0,20190122,20190122,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-005407,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20190122.0,,MD,IN,IN,EFAVIRENZ.,Rash maculo-papular;Therapeutic product cross-reactivity,158525441.0,OT,,,,,,,,,158525441.0,1.0,Antiretroviral therapy
15854101,158541013,3,F,20181127.0,20190903.0,20190122,20190904,EXP,FR-AFSSAPS-NC20190054,FR-ABBVIE-19S-056-2634604-00,ABBVIE,,52.0,YR,,M,Y,46.0,KG,20190904.0,,MD,FR,FR,EFAVIRENZ.,Muscular weakness;Paresis;Renal tubular disorder,158541013.0,LT,,,158541013.0,2.0,20180815.0,20181015.0,,,158541013.0,1.0,HIV infection
15861434,158614341,1,I,,20171120.0,20190124,20190124,EXP,,CN-ROCHE-2241092,ROCHE,,21.0,YR,,M,Y,,,20190124.0,,MD,CN,CN,EFAVIRENZ.,Flatulence;Hypermetabolism;Pelvic cyst;Pelvic fluid collection;Positron emission tomogram abnormal,158614341.0,OT,,,,,,,,,158614341.0,1.0,Lymphoma AIDS related
15865337,158653372,2,F,20110825.0,20210614.0,20190124,20210624,EXP,,FR-AUROBINDO-AUR-APL-2019-002782,AUROBINDO,,37.0,YR,,M,Y,,,20210624.0,,HP,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,158653372.0,OT,,,,,,,,,158653372.0,1.0,HIV infection
15868666,158686662,2,F,20180806.0,20190205.0,20190125,20190212,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK143246,VIIV,,12.0,WK,,,Y,,,20190212.0,,MD,UG,UG,EFAVIRENZ.,Sudden infant death syndrome,158686662.0,DE,,,158686662.0,1.0,20180328.0,,,,158686662.0,1.0,HIV infection
15874853,158748531,1,I,20041201.0,20060718.0,20190126,20190126,EXP,,FR-ABBVIE-06P-056-0338441-00,ABBVIE,,57.0,YR,,M,Y,49.0,KG,20190126.0,,OT,FR,FR,SUSTIVA,Aminoaciduria;Blood creatine increased;Fanconi syndrome;Hypophosphataemia;Proteinuria;Renal failure,158748531.0,HO,,,158748531.0,1.0,20030901.0,20060408.0,,,158748531.0,1.0,HIV infection
15880301,158803011,1,I,20181225.0,,20190104,20190104,DIR,,,FDA-CTU,,29.0,YR,,M,N,,,20190103.0,N,OT,US,US,EFAVIRENZ.,Bipolar I disorder,,,158803011.0,HP,158803011.0,1.0,20181005.0,,,,158803011.0,1.0,HIV infection
15886086,158860865,5,F,20090618.0,20220404.0,20190129,20220406,EXP,,PHHY2018FR195297,NOVARTIS,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). CHEMICAL BIOLOGY AND DRUG DESIGN. 2018;93:13378",47.0,YR,,M,Y,,,20220407.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,158860865.0,OT,,,,,,,,,158860865.0,1.0,HIV infection
15893560,158935601,1,I,,20190123.0,20190131,20190131,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-007790,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,,,20190131.0,,MD,PT,PT,EFAVIRENZ.,Nephropathy toxic,158935601.0,OT,,,,,,,,,158935601.0,1.0,HIV infection
15897393,158973933,3,F,20090119.0,20230913.0,20190131,20230918,EXP,,US-GILEAD-2019-0387829,GILEAD,,58.0,YR,A,M,Y,72.562,KG,20230918.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Fear;Osteopenia;Osteoporosis;Pain;Stress,158973933.0,OT,,,158973933.0,1.0,2001.0,200705.0,,,158973933.0,1.0,HIV infection
15897679,158976791,1,I,,20180718.0,20190131,20190131,EXP,,ID-SUN PHARMACEUTICAL INDUSTRIES LTD-2018R1-180145,RANBAXY,"MOKOAGOW I, YUWAAFII M. GRAVES DISEASE AS MANIFESTATION OF IMMUNE RECONSTITUTION SYNDROME IN A PREGNANT PATIENT WITH HIV/AIDS RECEIVING ANTIRETROVIRAL THERAPY. ENDOCR PRACT. 2018;24 (SUPPL.1):270-271(ABSTRACT #1096)",36.0,YR,,F,Y,,,20190201.0,,OT,ID,ID,EFAVIRENZ.,Basedow's disease;Exposure during pregnancy,158976791.0,OT,,,,,,,,,158976791.0,1.0,HIV infection
15897762,158977621,1,I,20060413.0,20060516.0,20190201,20190201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13380423,BRISTOL MYERS SQUIBB,,28.0,YR,,F,Y,65.0,KG,20190201.0,,CN,FR,FR,SUSTIVA,Pruritus;Rash maculo-papular;Toxic skin eruption,158977621.0,OT,,,158977621.0,1.0,20060403.0,20060413.0,,,158977621.0,1.0,HIV infection
15900709,159007091,1,I,201711.0,20190122.0,20190201,20190201,EXP,,PL-GILEAD-2019-0386699,GILEAD,,45.0,YR,A,M,Y,,,20190201.0,,MD,PL,PL,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Thrombocytopenia,159007091.0,DE,,,159007091.0,1.0,20171113.0,20171116.0,,,159007091.0,1.0,HIV infection
15900940,159009404,4,F,20120101.0,20240207.0,20190201,20240209,EXP,,US-GILEAD-2019-0387824,GILEAD,,60.0,YR,A,M,Y,82.086,KG,20240209.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Bone disorder;Cervical vertebral fracture;Diabetes mellitus;Economic problem;Emotional distress;Humerus fracture;Insomnia;Loss of personal independence in daily activities;Multiple fractures;Nephrolithiasis;Osteoporosis;Pain;Renal impairment;Tendon rupture;Upper limb fracture,159009404.0,OT,,,159009404.0,1.0,2004.0,2006.0,,,159009404.0,1.0,HIV infection
15900993,159009931,1,I,,20190118.0,20190201,20190201,EXP,,GB-GLAXOSMITHKLINE-GB2019GSK017750,GLAXOSMITHKLINE,"AHMED N, FLAVELL S, FERNS B, FRAMPTON D, EDWARDS SG, MILLER RF ET AL.. DEVELOPMENT OF THE R263K MUTATION TO DOLUTEGRAVIR IN AN HIV-1 SUBTYPE D VIRUS HARBORING 3 CLASS- DRUG RESISTANCE. OFID. 2018;6 (1):329",22.0,YR,,F,Y,,,20190201.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,159009931.0,OT,,,,,,,,,159009931.0,1.0,HIV infection
15900994,159009941,1,I,,20190118.0,20190201,20190201,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2019GSK017750,VIIV,"AHMED N, FLAVELL S, FERNS B, FRAMPTON D, EDWARDS SG, MILLER RF ET AL.. DEVELOPMENT OF THE R263K MUTATION TO DOLUTEGRAVIR IN AN HIV-1 SUBTYPE D VIRUS HARBORING 3 CLASS- DRUG RESISTANCE. OFID. 2018;6 (1):329",22.0,YR,,F,Y,,,20190201.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,159009941.0,OT,,,,,,,,,159009941.0,1.0,HIV infection
15901024,159010243,3,F,20150914.0,20231110.0,20190201,20231113,EXP,,US-GILEAD-2019-0387831,GILEAD,,57.0,YR,A,F,Y,121.11,KG,20231113.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Osteoporosis;Pain;Renal impairment,159010243.0,OT,,,159010243.0,1.0,2005.0,20150328.0,1760.0,DAY,159010243.0,1.0,HIV infection
15902280,159022804,4,F,20160101.0,20211014.0,20190201,20211028,EXP,,US-GILEAD-2019-0387827,GILEAD,,47.0,YR,A,M,Y,72.56,KG,20211028.0,,LW,US,US,SUSTIVA,Abnormal dreams;Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;Fatigue;Pain;Protein urine present;Quality of life decreased;Renal failure;Renal impairment;Renal injury,159022804.0,OT,,,159022804.0,1.0,200805.0,2015.0,464.0,DAY,159022804.0,1.0,HIV infection
15902352,159023521,1,I,20060413.0,20060516.0,20190201,20190201,EXP,,FR-GILEAD-2006-0009601,GILEAD,,28.0,YR,A,F,Y,65.0,KG,20190201.0,,MD,FR,FR,SUSTIVA,Pruritus;Rash maculo-papular;Toxic skin eruption,159023521.0,OT,,,159023521.0,1.0,20060403.0,20060413.0,,,159023521.0,1.0,HIV infection
15903040,159030401,1,I,,20190121.0,20190202,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-004927,AUROBINDO,,,,,,Y,,,20190202.0,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Tuberculosis,159030401.0,OT,,,159030401.0,4.0,,200905.0,,,159030401.0,1.0,HIV infection
15903044,159030441,1,I,201102.0,20190121.0,20190202,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-004928,AUROBINDO,,,,,,Y,,,20190202.0,,OT,ZA,ZA,EFAVIRENZ.,Disease recurrence;Drug resistance;Tuberculosis,159030441.0,OT,,,,,,,,,159030441.0,1.0,HIV infection
15903045,159030451,1,I,,20190121.0,20190202,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-004929,AUROBINDO,,,,,,Y,,,20190202.0,,OT,ZA,ZA,EFAVIRENZ.,Disease recurrence;Drug resistance;Tuberculosis,159030451.0,DE,,,,,,,,,159030451.0,1.0,HIV infection
15903765,159037651,1,I,201011.0,20190121.0,20190203,20190203,EXP,,ZA-AUROBINDO-AUR-APL-2019-004930,AUROBINDO,,,,,,Y,,,20190204.0,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Tuberculosis,159037651.0,OT,,,,,,,,,159037651.0,1.0,HIV infection
15903768,159037681,1,I,,20190121.0,20190203,20190203,EXP,,ZA-AUROBINDO-AUR-APL-2019-004931,AUROBINDO,,,,,,Y,,,20190204.0,,OT,ZA,ZA,EFAVIRENZ.,Disease recurrence;Drug resistance;Tuberculosis,159037681.0,OT,,,,,,,,,159037681.0,1.0,HIV infection
15905632,159056321,1,I,20060318.0,20060613.0,20190204,20190204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13412275,BRISTOL MYERS SQUIBB,,38.0,YR,,M,Y,,,20190204.0,,CN,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,159056321.0,OT,,,159056321.0,1.0,20060225.0,20060329.0,,,159056321.0,1.0,Acquired immunodeficiency syndrome
15907000,159070002,2,F,,20190214.0,20190204,20190221,EXP,,ZA-GILEAD-2019-0387924,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G.. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS. 2019;NI:NI. DOI:DOI: 10.1097/QAD.0000000000002136",35.0,YR,A,F,Y,,,20190221.0,,OT,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159070002.0,HO,,,,,,,,,159070002.0,1.0,HIV infection
15907173,159071732,2,F,,20190214.0,20190204,20190221,EXP,,ZA-GILEAD-2019-0387922,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G.. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS.. 2019;NI:NI. DOI:DOI: 10.1097/QAD.0000000000002136",28.0,YR,A,F,Y,,,20190221.0,,OT,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159071732.0,OT,,,,,,,,,159071732.0,1.0,HIV infection
15907184,159071842,2,F,,20190214.0,20190204,20190221,EXP,,ZA-GILEAD-2019-0387923,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G.. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS.. 2019;NI:NI. DOI:DOI: 10.1097/QAD.0000000000002136",39.0,YR,A,F,Y,,,20190221.0,,OT,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159071842.0,OT,,,,,,,,,159071842.0,1.0,HIV infection
15914632,159146321,1,I,20190111.0,,20190111,20190111,DIR,,,FDA-CTU,,25.0,YR,,M,N,,,20190111.0,N,PH,US,US,EFAVIRENZ.,Blood HIV RNA;Drug ineffective,,,159146321.0,HP,159146321.0,1.0,201804.0,201812.0,,,159146321.0,1.0,HIV infection
15916332,159163321,1,I,20040206.0,20060313.0,20190204,20190204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13313473,BRISTOL MYERS SQUIBB,,35.0,YR,,M,Y,63.0,KG,20190204.0,,OT,FR,FR,SUSTIVA,Abdominal pain upper;Amylase increased;Cholelithiasis;Hyperbilirubinaemia;Jaundice;Lipase increased;Pancreatitis acute;Pancreatitis chronic;Vomiting,159163321.0,OT,,,159163321.0,1.0,20030514.0,20050629.0,,,159163321.0,1.0,HIV infection
15920383,159203834,4,F,,20211004.0,20190205,20211014,EXP,,CA-TEVA-2019-CA-1007031,TEVA,,52.0,YR,A,M,Y,,,20211014.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,159203834.0,OT,,,,,,,,,159203834.0,1.0,HIV infection
15920730,159207303,3,F,20140801.0,20230921.0,20190205,20230927,EXP,,US-GILEAD-2019-0387816,GILEAD,,61.0,YR,A,M,Y,,,20230927.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Depression;Economic problem;Emotional distress;Loss of libido;Loss of personal independence in daily activities;Osteopenia;Pain;Renal impairment,159207303.0,OT,,,159207303.0,1.0,201310.0,201510.0,,,159207303.0,1.0,HIV infection
15923308,159233081,1,I,,20190128.0,20190206,20190206,EXP,,IN-HETERO CORPORATE-HET2019IN00110,HETERO,"SHAMANNA SURYANARAYANA BETTADPURA, MATTA KIRAN KUMAR AND HAMIDE ABDOUL. TRENDS IN CLINICAL CHARACTERISTICS AND SHORT-TERM OUTCOME OF HIV-INFECTED PATIENTS AT A TERTIARY CARE HOSPITAL IN SOUTH INDIA. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2018;17",,,A,,Y,,,20190206.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,159233081.0,OT,,,,,,,,,159233081.0,1.0,HIV infection
15923322,159233221,1,I,,20190128.0,20190206,20190206,EXP,,IN-HETERO CORPORATE-HET2019IN00132,HETERO,"SHAMANNA SURYANARAYANA BETTADPURA , MATTA KIRAN KUMAR AND HAMIDE ABDOUL. TRENDS IN CLINICAL CHARACTERISTICS AND SHORT-TERM OUTCOME OF HIV-INFECTED PATIENTS AT A TERTIARY CARE HOSPITAL IN SOUTH INDIA. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2018;17",,,A,,Y,,,20190206.0,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,159233221.0,OT,,,,,,,,,159233221.0,1.0,HIV infection
15927122,159271221,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020678,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159271221.0,OT,,,,,,,,,159271221.0,1.0,HIV infection
15927124,159271241,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020678,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159271241.0,OT,,,,,,,,,159271241.0,1.0,HIV infection
15927250,159272501,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020733,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272501.0,OT,,,,,,,,,159272501.0,1.0,HIV infection
15927253,159272531,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020740,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272531.0,OT,,,,,,,,,159272531.0,1.0,HIV infection
15927265,159272651,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020733,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272651.0,OT,,,,,,,,,159272651.0,1.0,HIV infection
15927267,159272671,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020740,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272671.0,OT,,,,,,,,,159272671.0,1.0,HIV infection
15927372,159273721,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020735,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273721.0,OT,,,,,,,,,159273721.0,1.0,HIV infection
15927374,159273741,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020741,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273741.0,OT,,,,,,,,,159273741.0,1.0,HIV infection
15927378,159273781,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020735,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273781.0,OT,,,,,,,,,159273781.0,1.0,HIV infection
15927380,159273801,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020741,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273801.0,OT,,,,,,,,,159273801.0,1.0,HIV infection
15927382,159273821,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020734,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273821.0,OT,,,,,,,,,159273821.0,1.0,HIV infection
15927384,159273841,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020751,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273841.0,OT,,,,,,,,,159273841.0,1.0,HIV infection
15927387,159273871,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020749,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273871.0,OT,,,,,,,,,159273871.0,1.0,HIV infection
15927389,159273891,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020750,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273891.0,OT,,,,,,,,,159273891.0,1.0,HIV infection
15927391,159273911,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020748,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273911.0,OT,,,,,,,,,159273911.0,1.0,HIV infection
15927393,159273931,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020734,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273931.0,OT,,,,,,,,,159273931.0,1.0,HIV infection
15927395,159273951,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020751,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273951.0,OT,,,,,,,,,159273951.0,1.0,HIV infection
15927397,159273971,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020750,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273971.0,OT,,,,,,,,,159273971.0,1.0,HIV infection
15927399,159273991,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020749,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273991.0,OT,,,,,,,,,159273991.0,1.0,HIV infection
15927401,159274011,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020748,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159274011.0,OT,,,,,,,,,159274011.0,1.0,HIV infection
15927501,159275011,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020747,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275011.0,OT,,,,,,,,,159275011.0,1.0,HIV infection
15927503,159275031,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020746,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275031.0,OT,,,,,,,,,159275031.0,1.0,HIV infection
15927505,159275051,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020745,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275051.0,OT,,,,,,,,,159275051.0,1.0,HIV infection
15927507,159275071,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020744,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275071.0,OT,,,,,,,,,159275071.0,1.0,HIV infection
15927510,159275101,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020747,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275101.0,OT,,,,,,,,,159275101.0,1.0,HIV infection
15927512,159275121,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020746,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275121.0,OT,,,,,,,,,159275121.0,1.0,HIV infection
15927514,159275141,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020745,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275141.0,OT,,,,,,,,,159275141.0,1.0,HIV infection
15927516,159275161,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020744,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275161.0,OT,,,,,,,,,159275161.0,1.0,HIV infection
15927521,159275211,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020736,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275211.0,OT,,,,,,,,,159275211.0,1.0,HIV infection
15927523,159275231,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020739,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275231.0,OT,,,,,,,,,159275231.0,1.0,HIV infection
15927525,159275251,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020738,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275251.0,OT,,,,,,,,,159275251.0,1.0,HIV infection
15927527,159275271,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020737,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275271.0,OT,,,,,,,,,159275271.0,1.0,HIV infection
15927530,159275301,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020742,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275301.0,OT,,,,,,,,,159275301.0,1.0,HIV infection
15927532,159275321,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020736,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275321.0,OT,,,,,,,,,159275321.0,1.0,HIV infection
15927534,159275341,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020739,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275341.0,OT,,,,,,,,,159275341.0,1.0,HIV infection
15927537,159275371,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020737,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275371.0,OT,,,,,,,,,159275371.0,1.0,HIV infection
15927539,159275391,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020738,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275391.0,OT,,,,,,,,,159275391.0,1.0,HIV infection
15927541,159275411,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020742,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275411.0,OT,,,,,,,,,159275411.0,1.0,HIV infection
15927675,159276751,1,I,,20190125.0,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020743,VIIV,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159276751.0,OT,,,,,,,,,159276751.0,1.0,HIV infection
15927677,159276771,1,I,,20190125.0,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020743,GLAXOSMITHKLINE,,,,A,,Y,,,20190206.0,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159276771.0,OT,,,,,,,,,159276771.0,1.0,HIV infection
15929817,159298173,3,F,,20190214.0,20190206,20190221,EXP,,ZA-GILEAD-2019-0387921,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS. 2019;UNK:UNK. DOI:10.1097/QAD.0000000000002136",28.0,YR,A,F,Y,,,20190221.0,,MD,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159298173.0,OT,,,,,,,,,159298173.0,1.0,HIV infection
15934516,159345167,7,F,20050813.0,20220519.0,20190207,20220525,EXP,,FR-MYLANLABS-2019M1011150,MYLAN,,25.0,YR,,F,Y,56.0,KG,20220525.0,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,159345167.0,HO,,,159345167.0,1.0,20050523.0,20050908.0,109.0,DAY,159345167.0,1.0,HIV infection
15934528,159345286,6,F,,20220512.0,20190207,20220517,EXP,,FR-MYLANLABS-2019M1011151,MYLAN,,26.0,WK,,F,Y,,,20220517.0,,MD,FR,FR,EFAVIRENZ,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,159345286.0,OT,,,159345286.0,1.0,20050523.0,20050908.0,109.0,DAY,159345286.0,1.0,HIV infection
15935686,159356861,1,I,,20190129.0,20190208,20190208,EXP,,ZA-GILEAD-2019-0389520,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190207.0,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous,159356861.0,OT,,,,,,,,,159356861.0,1.0,HIV infection
15935691,159356912,2,F,,20190129.0,20190208,20190321,EXP,,ZA-GILEAD-2019-0389519,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190321.0,,OT,ZA,ZA,EFAVIRENZ.,Stillbirth,159356912.0,OT,,,,,,,,,159356912.0,1.0,HIV infection
15935699,159356991,1,I,,20190129.0,20190208,20190208,EXP,,ZA-GILEAD-2019-0389522,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190207.0,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous,159356991.0,OT,,,,,,,,,159356991.0,1.0,HIV infection
15935700,159357001,1,I,,20190129.0,20190208,20190208,EXP,,ZA-GILEAD-2019-0389521,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190207.0,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous,159357001.0,OT,,,,,,,,,159357001.0,1.0,HIV infection
15950518,159505185,5,F,2014.0,20190930.0,20190211,20191003,EXP,ES-EMA-20180731-AUTODUP-27044000,ES-MYLANLABS-2019M1011377,MYLAN,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J.. RECURRENT CORONARY DISEASE IN HIV-INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2018;84 (7):1617-9",39.0,YR,,M,Y,,,20191003.0,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,159505185.0,HO,,,159505185.0,1.0,2012.0,,,,159505185.0,1.0,HIV infection
15954199,159541991,1,I,20060719.0,20190207.0,20190212,20190212,EXP,FR-EMA-20130709-MMEVHUMANWT-104720368,FR-GILEAD-2019-0390071,GILEAD,,41.0,YR,A,F,Y,,,20190212.0,,MD,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159541991.0,HO,,,159541991.0,1.0,20060713.0,20060721.0,,,159541991.0,1.0,HIV infection
15954282,159542821,1,I,,20190205.0,20190212,20190212,EXP,,GB-MYLANLABS-2019M1011884,MYLAN,"WOODCOCK H, NELSON M.. BURKITT^S NON-HODGKINS LYMPHOMA PRESENTING AS FACIAL NERVE PALSY IN HIVPOSITIVE PATIENTS.. INTERNATIONAL.. 2011;22 (2):112-114",55.0,YR,,M,Y,,,20190212.0,,OT,GB,GB,EFAVIRENZ.,Pancytopenia;Toxicity to various agents,159542821.0,OT,,,,,,,,,159542821.0,1.0,HIV infection
15962439,159624397,7,F,20181001.0,20200130.0,20190214,20200207,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2018GSK236781,VIIV,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G ET AL.. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;DOI: 10.1056/NEJMOA1905230",,,,,Y,,,20200207.0,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159624397.0,OT,,,159624397.0,1.0,20170330.0,,,,159624397.0,1.0,HIV infection
15962440,159624407,7,F,20181001.0,20200130.0,20190214,20200207,EXP,,BW-GLAXOSMITHKLINE-BW2018GSK236781,GLAXOSMITHKLINE,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G ET AL.. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;DOI: 10.1056/NEJMOA1905230",,,,,Y,,,20200207.0,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159624407.0,DE,,,159624407.0,1.0,20170330.0,,,,159624407.0,1.0,HIV infection
15965660,159656601,1,I,,20190204.0,20190215,20190215,EXP,,GB-AUROBINDO-AUR-APL-2019-007759,AUROBINDO,,,,,,Y,,,20190215.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,159656601.0,OT,,,,,,,,,159656601.0,1.0,HIV infection
15973979,159739791,1,I,20060717.0,20060818.0,20190217,20190217,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13482070,BRISTOL MYERS SQUIBB,,41.0,YR,,F,Y,,,20190217.0,,CN,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159739791.0,HO,,,159739791.0,1.0,20060713.0,20060721.0,,,159739791.0,1.0,HIV infection
15978748,159787481,1,I,,20190213.0,20190219,20190219,EXP,,IN-GLAXOSMITHKLINE-IN2019GSK028835,GLAXOSMITHKLINE,,72.0,YR,,M,Y,,,20190219.0,,MD,IN,IN,EFAVIRENZ.,Arthralgia;Femoral neck fracture;Hypokinesia;Insomnia;Movement disorder,159787481.0,OT,,,,,,,,,159787481.0,1.0,HIV infection
15978751,159787511,1,I,,20190213.0,20190219,20190219,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019GSK028835,VIIV,,72.0,YR,,M,Y,,,20190219.0,,MD,IN,IN,EFAVIRENZ.,Arthralgia;Femoral neck fracture;Hypokinesia;Insomnia;Movement disorder,159787511.0,OT,,,,,,,,,159787511.0,1.0,HIV infection
15982257,159822572,2,F,20030725.0,20190305.0,20190219,20190306,EXP,,FR-GILEAD-2003-06494,GILEAD,,43.0,YR,A,F,Y,74.0,KG,20190306.0,,OT,FR,FR,SUSTIVA,Aggression;Ascites;Hepatic necrosis;Hepatitis A;Jaundice;Peritoneal haematoma;Somnolence;Vomiting,159822572.0,HO,,,159822572.0,1.0,20030412.0,20030728.0,,,159822572.0,1.0,HIV infection
15982566,159825661,1,I,20060602.0,20190212.0,20190219,20190219,EXP,,CA-ABBVIE-19P-028-2666991-00,ABBVIE,"HARRIS M, LARSEN G, MONTANER J. EXACERBATION OF DEPRESSION ASSOCIATED WITH STARTING RALTEGRAVIR: A REPORT OF FOUR CASES. AIDS. 2008;22 (14):1890-1892.",44.0,YR,,M,Y,,,20190219.0,,OT,COUNTRY NOT SPECIFIED,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,159825661.0,HO,,,159825661.0,2.0,20060602.0,20070522.0,,,159825661.0,1.0,HIV infection
15983366,159833663,3,F,,20220604.0,20190220,20220618,EXP,,IT-AUROBINDO-AUR-APL-2019-008587,AUROBINDO,"Cattaneo D, Giacomelli A, Gervasoni C.. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?.. Obesity.. 2018;26 (8):1251-1252",40.0,YR,,F,Y,,,20220618.0,,MD,IT,IT,EFAVIRENZ,Drug interaction;Virologic failure,159833663.0,OT,,,,,,,,,159833663.0,1.0,HIV infection
15985004,159850042,2,F,20181001.0,20200423.0,20190220,20200430,EXP,,BW-STRIDES ARCOLAB LIMITED-2019SP001576,STRIDES,,42.0,YR,,F,Y,,,20200430.0,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,159850042.0,OT,,,,,,,,,159850042.0,1.0,HIV infection
15990442,159904422,2,F,,20220329.0,20190221,20220331,EXP,,FR-MYLANLABS-2019M1016125,MYLAN,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem-Biol-Drug-Des 2019;93(1):50-59.",35.0,YR,,F,Y,,,20220331.0,,HP,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment failure,159904422.0,OT,,,,,,,,,159904422.0,1.0,HIV infection
15990444,159904441,1,I,,20190213.0,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016207,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",60.0,YR,,M,Y,,,20190221.0,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159904441.0,OT,,,,,,,,,159904441.0,1.0,HIV infection
15990529,159905291,1,I,,20190213.0,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016255,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",51.0,YR,,F,Y,,,20190221.0,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159905291.0,OT,,,,,,,,,159905291.0,1.0,HIV infection
15991009,159910091,1,I,,20190213.0,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016134,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",37.0,YR,,M,Y,,,20190221.0,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159910091.0,OT,,,,,,,,,159910091.0,1.0,HIV infection
15992613,159926131,1,I,,20190213.0,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016265,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",47.0,YR,,M,Y,,,20190221.0,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159926131.0,OT,,,,,,,,,159926131.0,1.0,HIV infection
15992639,159926391,1,I,,20190213.0,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016272,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",51.0,YR,,M,Y,,,20190221.0,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159926391.0,OT,,,,,,,,,159926391.0,1.0,HIV infection
15992731,159927311,1,I,,20190213.0,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016122,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",45.0,YR,,M,Y,,,20190221.0,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159927311.0,OT,,,,,,,,,159927311.0,1.0,HIV infection
15994788,159947882,2,F,20181001.0,20200423.0,20190222,20200429,EXP,,BW-HETERO CORPORATE-HET2019BW00182,HETERO,,0.0,DY,,,Y,,,20200429.0,,HP,BW,BW,EFAVIRENZ.,Death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159947882.0,CA,,,159947882.0,1.0,,20181001.0,,,159947882.0,1.0,HIV infection
15998256,159982563,3,F,,20200420.0,20190223,20200425,EXP,,CA-009507513-1902CAN006457,MERCK,,54.0,YR,,M,Y,,,20200425.0,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,159982563.0,DE,,,,,,,,,159982563.0,1.0,HIV infection
15998853,159988538,8,F,,20220106.0,20190223,20220115,EXP,,CA-009507513-1902CAN006364,MERCK,unknown. unknown. unknown,52.0,YR,,M,Y,,,20220115.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,159988538.0,CA,,,159988538.0,1.0,,,91.0,DAY,159988538.0,1.0,HIV infection
15998972,159989721,1,I,,20190219.0,20190223,20190223,EXP,,PHHY2019PT042426,SANDOZ,,42.0,YR,,M,Y,,,20190224.0,,OT,PT,PT,EFAVIRENZ.,Death,159989721.0,DE,,,,,,,,,159989721.0,1.0,HIV test positive
16001877,160018771,1,I,,20190219.0,20190225,20190225,EXP,,PHHY2019PT042241,SANDOZ,,59.0,YR,,M,Y,,,20190225.0,,OT,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,160018771.0,DE,,,,,,,,,160018771.0,1.0,HIV test positive
16004905,160049052,2,F,20181001.0,20200423.0,20190226,20200429,EXP,,BW-HETERO CORPORATE-HET2019BW00183,HETERO,,42.0,YR,,F,Y,,,20200429.0,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,160049052.0,OT,,,,,,,,,160049052.0,1.0,HIV infection
16009753,160097539,9,F,20181001.0,20200903.0,20190225,20200911,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-017261,BRISTOL MYERS SQUIBB,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G, ET AL. NEURAL?TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019",42.0,YR,,F,Y,,,20200911.0,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,160097539.0,OT,,,,,,,,,160097539.0,1.0,HIV infection
16010009,160100091,1,I,,20190213.0,20190227,20190227,EXP,,CA-AUROBINDO-AUR-APL-2019-010050,AUROBINDO,,,,,,Y,,,20190227.0,,CN,CA,CA,EFAVIRENZ.,Aphonia;Dysphonia;Eczema;Hepatitis B;Intervertebral disc protrusion;Lumbar spinal stenosis;Nasopharyngitis;Nausea;Pulmonary pain;Sleep disorder;Syphilis,160100091.0,OT,,,,,,,,,160100091.0,1.0,HIV infection
16013410,160134101,1,I,,20190225.0,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018191,MYLAN,,,,A,,Y,,,20190227.0,,MD,GB,GB,SUSTIVA,Treatment noncompliance;Virologic failure,160134101.0,OT,,,,,,,,,160134101.0,1.0,HIV infection
16014594,160145941,1,I,,20190225.0,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018245,MYLAN,,,,A,F,Y,,,20190227.0,,MD,GB,GB,SUSTIVA,Maternal exposure during pregnancy;Treatment noncompliance;Virologic failure,160145941.0,OT,,,,,,,,,160145941.0,1.0,HIV infection
16019605,160196051,1,I,,20190225.0,20190228,20190228,EXP,,GB-MYLANLABS-2019M1018255,MYLAN,,,,A,,Y,,,20190228.0,,MD,GB,GB,SUSTIVA,Treatment noncompliance;Virologic failure,160196051.0,OT,,,,,,,,,160196051.0,1.0,HIV infection
16020890,1602089027,27,F,,20240801.0,20190301,20240814,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,"Harris M, Larsen G, Montaner JSG.. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):1890-2",54.0,YR,,M,Y,,,20240814.0,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Paranoia;Prescribed overdose;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1602089027.0,HO,,,,,,,,,1602089027.0,1.0,HIV infection
16020953,160209531,1,I,,20190214.0,20190301,20190301,EXP,,CA-AUROBINDO-AUR-APL-2019-010724,AUROBINDO,,,,,,Y,,,20190301.0,,OT,CA,CA,EFAVIRENZ.,HIV viraemia;Nephropathy toxic;Therapeutic response decreased,160209531.0,OT,,,,,,,,,160209531.0,1.0,HIV infection
16021279,160212794,4,F,,20200423.0,20190301,20200506,EXP,,BW-CIPLA LTD.-2019BW01099,CIPLA,,,,,,Y,,,20200506.0,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,160212794.0,OT,,,,,,,,,160212794.0,1.0,HIV infection
16022512,1602251211,11,F,,20240829.0,20190301,20240909,EXP,,CA-AUROBINDO-AUR-APL-2019-010641,AUROBINDO,"Pfeffer G, Mezei MM, Montaner JS, Li CC, Jitratkosol M, Cote HC. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. NEUROLOGY. 2009;73 (1):71-2",52.0,YR,,M,Y,,,20240909.0,,HP,CA,CA,EFAVIRENZ,Aphasia;Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,1602251211.0,CA,,,1602251211.0,1.0,,,91.0,DAY,1602251211.0,1.0,HIV infection
16025359,160253592,2,F,,20231107.0,20190301,20231205,EXP,,BR-GILEAD-2019-0393897,GILEAD,"Nunes de Almeida B, Campello Vieira M, Ramos Dal Piaz M, Silva Cunha M, Compart Hemerly M, Ara?jo de Freitas P etal. FANCONI SYNDROME AND BONE FRACTURES RELATED TO TENOFOVIR USE. 29th Brazilian Congress of Nephrology held jointly with the 17th Brazilian Congr. 2019;unk:unk",62.0,YR,A,F,Y,,,20231205.0,,HP,BR,BR,EFAVIRENZ,Acute kidney injury;Bone disorder;Bone lesion;Chronic kidney disease;Fanconi syndrome acquired;Hyperparathyroidism secondary;Multiple fractures;Nephropathy toxic;Vitamin D deficiency,160253592.0,HO,,,160253592.0,1.0,2014.0,,,,160253592.0,1.0,HIV infection
16025998,160259984,4,F,,20210519.0,20190302,20210601,EXP,,PT-AUROBINDO-AUR-APL-2019-011083,AUROBINDO,"MENDEZ,J. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS. PRESENTED AT CO?INFECTION PORTUGUESE STUDY GROUP. 2019?UNK:UNK",43.0,YR,,M,Y,,,20210601.0,,MD,PT,PT,Efavirenz Film Coated Tablets,Hepatitis C;Treatment failure,160259984.0,OT,,,,,,,,,160259984.0,1.0,HIV test positive
16032364,160323641,1,I,20110825.0,20181217.0,20190304,20190304,EXP,,PHHY2018FR195300,SANDOZ,,51.0,YR,,M,Y,,,20190305.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160323641.0,OT,,,,,,,,,160323641.0,1.0,HIV infection
16032510,160325101,1,I,,20190220.0,20190304,20190304,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019030,BRISTOL MYERS SQUIBB,,48.0,YR,,M,Y,,,20190304.0,,MD,PT,PT,EFAVIRENZ.,Acute myocardial infarction,160325101.0,DE,,,,,,,,,160325101.0,1.0,HIV infection
16032534,160325341,1,I,,20190220.0,20190304,20190304,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019017,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20190304.0,,MD,PT,PT,EFAVIRENZ.,Death,160325341.0,OT,,,,,,,,,160325341.0,1.0,HIV test positive
16032571,160325715,5,F,,20210405.0,20190304,20210415,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019003,BRISTOL MYERS SQUIBB,MENDEZ J. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS. PRESENTED AT CO?INFECTION PORTUGUESE STUDY GROUP. 2019,43.0,YR,,M,Y,,,20210415.0,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160325715.0,OT,,,,,,,,,160325715.0,1.0,HIV test positive
16032574,160325741,1,I,,20190220.0,20190304,20190304,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019013,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,,,20190304.0,,MD,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,160325741.0,DE,,,,,,,,,160325741.0,1.0,HIV test positive
16032642,160326423,3,F,20180116.0,20190401.0,20190305,20190414,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-018776,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,41.0,KG,20190414.0,,OT,MZ,MZ,EFAVIRENZ.,Encephalitis;Pathological fracture;Spinal cord injury,160326423.0,OT,,,160326423.0,1.0,20170411.0,20170411.0,,,160326423.0,1.0,HIV infection
16038219,160382191,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019057,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,SUSTIVA,Virologic failure,160382191.0,OT,,,,,,,,,160382191.0,1.0,HIV infection
16038861,160388611,1,I,20110825.0,20181217.0,20190306,20190306,EXP,,PHHY2018FR195309,SANDOZ,,45.0,YR,,M,Y,,,20190306.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160388611.0,OT,,,,,,,,,160388611.0,1.0,HIV infection
16040861,160408611,1,I,,20190222.0,20190306,20190306,PER,,US-GILEAD-2019-0392959,GILEAD,,60.0,YR,A,M,Y,,,20190306.0,,OT,US,US,SUSTIVA,Drug resistance,160408611.0,OT,,,,,,,,,160408611.0,1.0,HIV infection
16043054,160430543,3,F,20180806.0,20200304.0,20190306,20200311,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2019GSK039654,VIIV,,29.0,YR,,F,Y,,,20200311.0,,MD,UG,UG,EFAVIRENZ.,Suicidal ideation,160430543.0,LT,,,160430543.0,1.0,20180328.0,20180403.0,,,160430543.0,1.0,HIV infection
16043710,160437101,1,I,,20190301.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020547,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,SUSTIVA,Virologic failure,160437101.0,OT,,,,,,,,,160437101.0,1.0,HIV infection
16044093,160440931,1,I,,20190301.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020518,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,SUSTIVA,Virologic failure,160440931.0,OT,,,,,,,,,160440931.0,1.0,HIV infection
16051353,160513537,7,F,20110825.0,20220401.0,20190308,20220415,EXP,,FR-AUROBINDO-AUR-APL-2018-062564,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). Chemical biology + drug design. 2019;93(1):50-59",35.0,YR,,F,Y,,,20220415.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160513537.0,OT,,,,,,,,,160513537.0,1.0,HIV infection
16052306,160523063,3,F,,20190514.0,20190308,20211118,EXP,,US-GLAXOSMITHKLINE-US2019040980,GLAXOSMITHKLINE,,,,,M,Y,,,20211118.0,,HP,US,US,SUSTIVA,Drug resistance,160523063.0,OT,,,,,,,,,160523063.0,1.0,HIV infection
16052308,160523083,3,F,,20190514.0,20190308,20211118,EXP,,US-VIIV HEALTHCARE LIMITED-US2019040980,VIIV,,,,,M,Y,,,20211118.0,,HP,US,US,SUSTIVA,Drug resistance,160523083.0,OT,,,,,,,,,160523083.0,1.0,HIV infection
16054130,160541301,1,I,20180503.0,20190227.0,20190308,20190308,EXP,,CN-GILEAD-2019-0393740,GILEAD,,59.0,YR,A,M,Y,,,20190308.0,,MD,CN,CN,EFAVIRENZ.,Dermatitis exfoliative,160541301.0,HO,,,160541301.0,1.0,20180410.0,,,,160541301.0,1.0,HIV infection
16062068,160620681,1,I,20190212.0,,20190212,20190212,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20190212.0,N,PH,US,US,EFAVIRENZ TAB,Anal cancer,,,160620681.0,HP,160620681.0,1.0,20160422.0,,,,160620681.0,1.0,HIV infection
16064184,160641842,2,F,,20190325.0,20190312,20190330,EXP,,PHHY2018IT041063,SANDOZ,,17.0,YR,,F,Y,,,20190330.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Gastrointestinal disorder;Inappropriate schedule of product administration;Pathogen resistance;Product use issue;Viral mutation identified,160641842.0,OT,,,,,,,,,160641842.0,1.0,HIV infection
16064290,160642901,1,I,,20190307.0,20190312,20190312,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2019044390,VIIV,GERHARDY B. AN ATYPICAL PNEUMONIA. RESPIROLOGY CASE REPORTS. 2019;7(3):ARTICLE NUMBER E00407. DOI: 10.1002/RCR2.407.,70.0,YR,,F,Y,,,20190312.0,,OT,AU,AU,EFAVIRENZ.,Acute kidney injury;Haemoglobin decreased;Microscopic polyangiitis;Respiratory failure,160642901.0,HO,,,,,,,,,160642901.0,1.0,HIV infection
16064291,160642911,1,I,,20190307.0,20190312,20190312,EXP,,AU-GLAXOSMITHKLINE-AU2019044390,GLAXOSMITHKLINE,GERHARDY B. AN ATYPICAL PNEUMONIA. RESPIROLOGY CASE REPORTS. 2019;7(3):ARTICLE NUMBER E00407. DOI: 10.1002/RCR2.407.,70.0,YR,,F,Y,,,20190312.0,,OT,AU,AU,EFAVIRENZ.,Acute kidney injury;Haemoglobin decreased;Microscopic polyangiitis;Respiratory failure,160642911.0,OT,,,,,,,,,160642911.0,1.0,HIV infection
16064422,160644221,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022497,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,SUSTIVA,Nervous system disorder;Treatment noncompliance;Virologic failure,160644221.0,OT,,,,,,,,,160644221.0,1.0,HIV infection
16066602,160666021,1,I,20180503.0,20190227.0,20190313,20190313,EXP,,CN-GLAXOSMITHKLINE-CN2019038950,GLAXOSMITHKLINE,,59.0,YR,,M,Y,,,20190313.0,,MD,CN,CN,EFAVIRENZ.,Dermatitis exfoliative,160666021.0,OT,,,160666021.0,1.0,20180410.0,,,,160666021.0,1.0,HIV infection
16066624,160666241,1,I,20180503.0,20190227.0,20190313,20190313,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019038950,VIIV,,59.0,YR,,M,Y,,,20190313.0,,MD,CN,CN,EFAVIRENZ.,Dermatitis exfoliative,160666241.0,HO,,,160666241.0,1.0,20180410.0,,,,160666241.0,1.0,HIV infection
16066682,160666821,1,I,,20190311.0,20190313,20190313,EXP,,PT-GLAXOSMITHKLINE-PT2019043879,GLAXOSMITHKLINE,,43.0,YR,,M,Y,,,20190313.0,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160666821.0,OT,,,,,,,,,160666821.0,1.0,HIV test positive
16066684,160666841,1,I,,20190311.0,20190313,20190313,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2019043879,VIIV,,43.0,YR,,M,Y,,,20190313.0,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160666841.0,OT,,,,,,,,,160666841.0,1.0,HIV test positive
16066946,160669461,1,I,,20190307.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022809,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,SUSTIVA,Nervous system disorder;Virologic failure,160669461.0,OT,,,,,,,,,160669461.0,1.0,HIV infection
16066993,160669931,1,I,,20190307.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022909,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,SUSTIVA,Treatment noncompliance;Virologic failure,160669931.0,OT,,,,,,,,,160669931.0,1.0,HIV infection
16070460,160704603,3,F,20110825.0,20190916.0,20190314,20190926,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018223044,VIIV,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY + DRUG DESIGN. 2018. DOI: 10.1111/CBDD.13378.",35.0,YR,,F,Y,,,20190926.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160704603.0,OT,,,,,,,,,160704603.0,1.0,HIV infection
16070467,160704673,3,F,20110825.0,20190916.0,20190314,20190926,EXP,,FR-GLAXOSMITHKLINE-FR2018223044,GLAXOSMITHKLINE,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY + DRUG DESIGN. 2018. DOI: 10.1111/CBDD.13378.",35.0,YR,,F,Y,,,20190926.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160704673.0,OT,,,,,,,,,160704673.0,1.0,HIV infection
16075222,160752223,3,F,20090618.0,20240117.0,20190315,20240123,EXP,,FR-AUROBINDO-AUR-APL-2019-012832,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T).. Chem-Biol-Drug-Des. 2019;93(1):50-59",47.0,YR,,M,Y,,,20240123.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160752223.0,OT,,,,,,,,,160752223.0,1.0,HIV infection
16081150,1608115010,10,F,,20210325.0,20190316,20210405,EXP,,CA-AUROBINDO-AUR-APL-2019-013361,AUROBINDO,,54.0,YR,,M,Y,,,20210405.0,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1608115010.0,DE,,,,,,,,,1608115010.0,1.0,HIV infection
16081155,1608115510,10,F,,20230417.0,20190316,20230428,EXP,,CA-AUROBINDO-AUR-APL-2019-013363,AUROBINDO,,54.0,YR,,M,Y,,,20230428.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1608115510.0,HO,,,,,,,,,1608115510.0,1.0,HIV infection
16089254,160892541,1,I,,20190307.0,20190319,20190319,EXP,,GB-MYLANLABS-2019M1022798,MYLAN,,,,A,,Y,,,20190319.0,,MD,GB,GB,SUSTIVA,Virologic failure,160892541.0,OT,,,,,,,,,160892541.0,1.0,HIV infection
16096424,160964241,1,I,,20190314.0,20190320,20190320,EXP,,CA-GILEAD-2019-0397265,GILEAD,,52.0,YR,A,M,Y,,,20190320.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,160964241.0,OT,,,,,,,,,160964241.0,1.0,HIV infection
16104926,161049261,1,I,,20190314.0,20190322,20190322,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019051107,VIIV,,52.0,YR,,M,Y,,,20190322.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,161049261.0,OT,,,,,,,,,161049261.0,1.0,HIV infection
16104931,161049311,1,I,,20190314.0,20190322,20190322,EXP,,CA-GLAXOSMITHKLINE-CA2019051107,GLAXOSMITHKLINE,,52.0,YR,,M,Y,,,20190322.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,161049311.0,OT,,,,,,,,,161049311.0,1.0,HIV infection
16106969,161069692,2,F,20180116.0,20190325.0,20190322,20190330,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK028179,GLAXOSMITHKLINE,,44.0,YR,,F,Y,41.0,KG,20190330.0,,MD,MZ,MZ,EFAVIRENZ.,Cervical vertebral fracture;Encephalitis;Spinal cord injury,161069692.0,HO,,,161069692.0,1.0,20170411.0,,,,161069692.0,1.0,HIV infection
16107024,161070242,2,F,20180116.0,20190325.0,20190322,20190330,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK028179,VIIV,,44.0,YR,,F,Y,41.0,KG,20190330.0,,MD,MZ,MZ,EFAVIRENZ.,Cervical vertebral fracture;Encephalitis;Spinal cord injury,161070242.0,OT,,,161070242.0,1.0,20170411.0,,,,161070242.0,1.0,HIV infection
16110301,161103012,2,F,20180122.0,20190318.0,20190325,20190328,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK048950,GLAXOSMITHKLINE,,31.0,YR,,M,Y,40.0,KG,20190328.0,,MD,MZ,MZ,EFAVIRENZ.,Anaemia;Malnutrition,161103012.0,DE,,,161103012.0,1.0,20171124.0,20180228.0,,,161103012.0,1.0,HIV infection
16110356,161103562,2,F,20180122.0,20190318.0,20190325,20190328,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK048950,VIIV,,31.0,YR,,M,Y,40.0,KG,20190328.0,,MD,MZ,MZ,EFAVIRENZ.,Anaemia;Malnutrition,161103562.0,DE,,,161103562.0,1.0,20171124.0,20180228.0,,,161103562.0,1.0,HIV infection
16112768,161127684,4,F,20181128.0,20200106.0,20190325,20200110,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK218858,VIIV,,4.0,MON,,M,Y,,,20200110.0,,MD,UG,UG,EFAVIRENZ.,Sickle cell disease,161127684.0,LT,,,161127684.0,1.0,20180522.0,201810.0,,,161127684.0,1.0,HIV infection
16115166,161151661,1,I,20190312.0,20190322.0,20190325,20190325,EXP,,US-VIIV HEALTHCARE LIMITED-US2019052604,VIIV,,56.0,YR,,M,Y,,,20190325.0,,CN,US,US,SUSTIVA,"Hallucination, auditory;Hallucination, visual;Insomnia;Nausea;Seizure;Vomiting",161151661.0,HO,,,161151661.0,1.0,20190311.0,20190318.0,,,161151661.0,1.0,HIV infection
16127371,161273711,1,I,,20190315.0,20190328,20190328,EXP,,ML-CIPLA LTD.-2019ML01623,CIPLA,,,,,,Y,,,20190328.0,,OT,ML,ML,EFAVIRENZ.,Virologic failure,161273711.0,OT,,,,,,,,,161273711.0,1.0,HIV infection
16127383,161273831,1,I,,20190315.0,20190328,20190328,EXP,,ML-CIPLA LTD.-2019ML01621,CIPLA,,,,,,Y,,,20190328.0,,OT,ML,ML,EFAVIRENZ.,Virologic failure,161273831.0,OT,,,,,,,,,161273831.0,1.0,HIV infection
16134747,161347471,1,I,,20190315.0,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01616,CIPLA,,,,,,Y,,,20190329.0,,OT,ML,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161347471.0,OT,,,,,,,,,161347471.0,1.0,HIV infection
16134897,161348972,2,F,,20190506.0,20190329,20190510,EXP,,PT-MYLANLABS-2019M1027766,MYLAN,"SUZUKI F, HOSAKA T, SUZUKI Y, SEZAKI H, AKUTA N, FUJIYAMA S, ET AL.. LONG-TERM OUTCOME OF ENTECAVIR TREATMENT OF NUCLEOS (T) IDE ANALOGUE-NA?VE CHRONIC HEPATITIS B PATIENTS IN JAPAN.. JOURNAL OF GASTROENTEROLOGY. 2018;1-2",32.0,YR,,M,Y,,,20190510.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,161348972.0,OT,,,,,,,,,161348972.0,1.0,HIV infection
16135471,161354711,1,I,,20190315.0,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01617,CIPLA,,,,,,Y,,,20190329.0,,OT,FR,ML,EFAVIRENZ.,Virologic failure,161354711.0,OT,,,,,,,,,161354711.0,1.0,HIV infection
16135486,161354861,1,I,,20190315.0,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01618,CIPLA,,,,,,Y,,,20190329.0,,OT,FR,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161354861.0,OT,,,,,,,,,161354861.0,1.0,HIV infection WHO clinical stage II
16135514,161355141,1,I,,20190315.0,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01619,CIPLA,,,,,,Y,,,20190329.0,,OT,FR,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161355141.0,OT,,,,,,,,,161355141.0,1.0,HIV infection
16135544,161355441,1,I,,20190315.0,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01620,CIPLA,,,,,,Y,,,20190329.0,,OT,FR,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161355441.0,OT,,,,,,,,,161355441.0,1.0,HIV infection
16141046,161410461,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028492,MYLAN,"SUZUKI F, HOSAKA T, SUZUKI Y, SEZAKI H, AKUTA N, FUJIYAMA S, ET AL.. LONG-TERM OUTCOME OF ENTECAVIR TREATMENT OF NUCLEOS (T) IDE ANALOGUE-NAVE CHRONIC HEPATITIS B PATIENTS IN JAPAN.. JOURNAL OF GASTROENTEROLOGY. 2018;1-2",29.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,161410461.0,LT,,,,,,,,,161410461.0,1.0,HIV infection
16158910,161589102,2,F,20110825.0,20190831.0,20190404,20190912,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-118425,BRISTOL MYERS SQUIBB,,35.0,YR,,F,Y,,,20190912.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,161589102.0,OT,,,,,,,,,161589102.0,1.0,HIV infection
16170457,161704573,3,F,,20190429.0,20190408,20190506,EXP,,JP-SA-2019SA094965,SANOFI AVENTIS,"SAKURAI H., SASAO K., SUGAWARA Y., IRINO S., TAKEBE M., TSUCHIYA Y. ET.AL.. CONSCIOUSNESS DISTURBANCE WITH A FALSE POSITIVE OF TETRAHYDROCANNABINOL BY A DRUG URINE SCREENING IMMUNOASSAY: A CASE REPORT. KANTO JOURNAL OF JAPANESE ASSOCIATION FOR ACUTE MEDICINE (E-JOURNAL). 2018;39(2):307-10",67.0,YR,E,M,Y,,,20190506.0,,MD,JP,JP,EFAVIRENZ.,Altered state of consciousness;Atrophy;Hypercapnia;Loss of personal independence in daily activities;Respiratory acidosis;Respiratory depression;Respiratory failure;Respiratory muscle weakness,161704573.0,OT,,,,,,,,,161704573.0,2.0,HIV infection
16170692,161706925,5,F,,20231127.0,20190408,20231130,EXP,,AT-MYLANLABS-2019M1031449,MYLAN,"Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, et al... Raltegravir in Pregnancy: A Case Series Presentation.. International Journal of STD + AIDS.. 2011;22(6):358 -60",39.0,YR,,F,Y,,,20231130.0,,HP,AT,AT,EFAVIRENZ,Acute stress disorder;Drug abuse;Maternal exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,161706925.0,HO,,,161706925.0,22.0,,,17.0,DAY,161706925.0,1.0,Antiretroviral therapy
16172857,161728571,1,I,,20181204.0,20190409,20190409,PER,,UG-LUPIN PHARMACEUTICALS INC.-2018-08624,LUPIN,,,,,,Y,,,20190409.0,,OT,UG,UG,EFAVIRENZ.,Hypersensitivity,161728571.0,OT,,,,,,,,,161728571.0,1.0,Antiretroviral therapy
16172860,161728602,2,F,,20190429.0,20190409,20190514,PER,,UG-LUPIN PHARMACEUTICALS INC.-2018-08632,LUPIN,,,,,,Y,,,20190514.0,,OT,UG,UG,EFAVIRENZ.,Aphthous ulcer,,,,,,,,,,,161728602.0,1.0,Antiretroviral therapy
16181512,161815121,1,I,,20190404.0,20190410,20190410,EXP,,BW-GLAXOSMITHKLINE-BW2019GSK060518,GLAXOSMITHKLINE,"RWEGERERA GM, RAMOLEFHE TT, NGOY NA, LESIAMANG M, RI VERA YP. SALMONELLA SEPSIS AND URINARY TRACT INFECTION COMPLICATING WITH ACUTE KIDNEY INJURY IN A HIV POSITIVE FEMALE PATIENT. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2019;13 (3):OD11-OD12 DOI: 10.7860/JCDR/20",44.0,YR,,F,Y,67.0,KG,20190410.0,,MD,BW,BW,EFAVIRENZ.,Treatment noncompliance;Virologic failure,161815121.0,OT,,,,,,,,,161815121.0,1.0,HIV infection
16181632,161816321,1,I,,20190404.0,20190410,20190410,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2019GSK060518,VIIV,"RWEGERERA GM, RAMOLEFHE TT, NGOY NA, LESIAMANG M, RI VERA YP. SALMONELLA SEPSIS AND URINARY TRACT INFECTION COMPLICATING WITH ACUTE KIDNEY INJURY IN A HIV POSITIVE FEMALE PATIENT. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2019;13 (3):OD11-OD12 DOI: 10.7860/JCDR/20",44.0,YR,,F,Y,67.0,KG,20190410.0,,MD,BW,BW,EFAVIRENZ.,Treatment noncompliance;Virologic failure,161816321.0,OT,,,,,,,,,161816321.0,1.0,HIV infection
16182683,161826831,1,I,,20190403.0,20190411,20190411,EXP,,IN-CIPLA LTD.-2019IN01856,CIPLA,,,,,,Y,,,20190411.0,,OT,IN,IN,EFAVIRENZ.,Jaundice,161826831.0,OT,,,,,,,,,161826831.0,1.0,HIV infection
16182869,161828692,2,F,,20190401.0,20190411,20190412,EXP,,UG-CIPLA LTD.-2019UG01819,CIPLA,"SSEBAMBULIDDE K, SEGAWA I, LAKER E, LAMORDE M, CASTELNOUVO B, NAKASUJJA N ET AL.. SYMPTOMATIC CEREBROSPINAL FLUID HIV-1 ESCAPE IN TWO PATIENTS ON SECOND-LINE ANTIRETROVIRAL THERAPY IN UGANDA. OXFORD MEDICAL CASE REPORTS. 2019;2:79 TO 82",,,,,Y,,,20190412.0,,OT,UG,UG,EFAVIRENZ.,Treatment noncompliance;Virologic failure,161828692.0,OT,,,,,,,,,161828692.0,1.0,HIV infection
16183901,161839012,2,F,,20191021.0,20190411,20191028,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-015928",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20191028.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,161839012.0,OT,,,,,,,,,161839012.0,1.0,HIV infection
16196049,161960491,1,I,20110523.0,20190401.0,20190415,20190415,EXP,,IT-AUROBINDO-AUR-APL-2019-019629,AUROBINDO,,,,,,Y,,,20190415.0,,MD,IT,IT,EFAVIRENZ.,Nervous system disorder;Renal impairment,161960491.0,OT,,,161960491.0,1.0,20150730.0,20110523.0,,,161960491.0,1.0,HIV infection
16198926,161989262,2,F,,20190718.0,20190415,20190725,EXP,,FR-MYLANLABS-2019M1034886,MYLAN,,,,A,F,Y,,,20190725.0,,MD,FR,FR,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective,161989262.0,OT,,,161989262.0,1.0,200308.0,200507.0,,,161989262.0,1.0,HIV infection
16201453,162014531,1,I,20110523.0,20190402.0,20190416,20190416,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-033631,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,80.0,KG,20190416.0,,MD,IT,IT,EFAVIRENZ.,Nervous system disorder;Neurotoxicity;Renal impairment,162014531.0,OT,,,162014531.0,1.0,20110420.0,20110523.0,,,162014531.0,1.0,HIV infection
16209032,162090321,1,I,,20190408.0,20190417,20190417,EXP,,US-VIIV HEALTHCARE LIMITED-KE2019GSK066516,VIIV,,,,A,F,Y,,,20190417.0,,OT,US,KE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,162090321.0,OT,,,,,,,,,162090321.0,1.0,HIV infection
16209033,162090331,1,I,,20190408.0,20190417,20190417,EXP,,US-GLAXOSMITHKLINE-KE2019GSK066516,GLAXOSMITHKLINE,,,,A,F,Y,,,20190417.0,,OT,US,KE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,162090331.0,OT,,,,,,,,,162090331.0,1.0,HIV infection
16213144,162131445,5,F,20080619.0,20210623.0,20190418,20210701,EXP,,US-GILEAD-2019-0402581,GILEAD,,36.0,YR,A,M,Y,78.46,KG,20210701.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fracture;Hip fracture;Osteopenia;Pain;Renal failure;Tooth loss,162131445.0,OT,,,162131445.0,1.0,2008.0,2009.0,,,162131445.0,1.0,Acquired immunodeficiency syndrome
16213513,162135134,4,F,2010.0,20200505.0,20190418,20200819,PER,,US-GILEAD-2019-0402870,GILEAD,,,,A,M,Y,64.4,KG,20200819.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Osteoporosis;Pain;Renal failure;Tooth loss,162135134.0,OT,,,162135134.0,1.0,200901.0,201901.0,,,162135134.0,1.0,HIV infection
16213545,162135456,6,F,2009.0,20201103.0,20190418,20201112,EXP,,US-GILEAD-2019-0402572,GILEAD,,59.0,YR,A,F,Y,81.63,KG,20201112.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Exostosis;Osteoarthritis;Pain;Renal failure;Renal impairment;Spinal compression fracture,162135456.0,OT,,,162135456.0,1.0,20090207.0,20160812.0,,,162135456.0,1.0,HIV infection
16214079,162140794,4,F,2004.0,20210111.0,20190418,20210125,PER,,US-GILEAD-2019-0402864,GILEAD,,47.0,YR,A,M,Y,86.62,KG,20210125.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Inflammation;Insomnia;Pain,162140794.0,OT,,,162140794.0,1.0,200401.0,200612.0,,,162140794.0,1.0,HIV infection
16217278,162172781,1,I,,20190415.0,20190419,20190419,EXP,,UG-STRIDES ARCOLAB LIMITED-2019SP003294,STRIDES,"SSEBAMBULIDDE K, SEGAWA I, LAKER E, LAMORDE M, CASTELNOUVO B, NAKASUJJA N, ET AL. SYMPTOMATIC CEREBROSPINAL FLUID HIV-1 ESCAPE IN TWO PATIENTS ON SECOND-LINE ANTIRETROVIRAL THERAPY IN UGANDA. OXF- MED-CASE-REPORTS. 2019;2019(2):79-82",62.0,YR,,M,Y,,,20190419.0,,OT,UG,UG,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,162172781.0,OT,,,,,,,,,162172781.0,1.0,HIV infection
16229747,162297476,6,F,20071207.0,20201103.0,20190423,20201112,EXP,,US-GILEAD-2019-0402590,GILEAD,,36.0,YR,A,M,Y,68.03,KG,20201112.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood calcium decreased;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;HIV infection;Haematuria;Joint dislocation;Neuropathy peripheral;Pain;Proteinuria;Renal failure;Renal impairment;Vitamin D deficiency,162297476.0,OT,,,162297476.0,1.0,20050323.0,20161121.0,,,162297476.0,1.0,Acquired immunodeficiency syndrome
16229775,162297751,1,I,200401.0,20190417.0,20190423,20190423,EXP,,ES-GILEAD-2019-0403238,GILEAD,,68.0,YR,E,M,Y,69.5,KG,20190423.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction;Diabetes mellitus;Hepatomegaly;Hypertension,162297751.0,OT,,,162297751.0,1.0,200311.0,200805.0,,,162297751.0,1.0,HIV infection
16231775,162317753,3,F,,20190820.0,20190424,20190824,EXP,,CA-ABBVIE-19S-028-2752397-00,ABBVIE,,52.0,YR,,M,Y,,,20190824.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,162317753.0,OT,,,,,,,,,162317753.0,1.0,HIV infection
16236751,162367512,2,F,,20190422.0,20190425,20190506,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-02577,HIKMA,"ALI M, KOORAGAYALU S, MBA B, OLSEN F. ISOLATED MYOPATHY: AN UNUSUAL MANIFESTATION OF INHALED FLUTICASONE PROPIONATE AND RITONAVIR INTERACTION. ARCHIVOS DE BRONCONEUMOLOGIA. 2019;55(4):223-225.",58.0,YR,,M,Y,,,20190506.0,,MD,US,US,EFAVIRENZ.,Drug interaction;Fall;Myopathy;Toxicity to various agents,162367512.0,HO,,,,,,,,,162367512.0,1.0,HIV infection
16246275,162462752,2,F,200809.0,20190428.0,20190426,20190509,EXP,,ES-GILEAD-2019-0403239,GILEAD,,68.0,YR,E,M,Y,69.5,KG,20190509.0,,MD,ES,ES,EFAVIRENZ.,Pulmonary tuberculosis,162462752.0,OT,,,162462752.0,1.0,200805.0,200905.0,,,162462752.0,1.0,HIV infection
16249617,162496178,8,F,,20190716.0,20190429,20190719,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-019405",BOEHRINGER INGELHEIM,,,,N,,Y,,,20190719.0,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162496178.0,DE,,,162496178.0,1.0,20050704.0,20050908.0,,,162496178.0,1.0,HIV infection
16251297,162512975,5,F,20050813.0,20191112.0,20190429,20191118,EXP,,FR-GILEAD-2019-0404516,GILEAD,,,,N,,Y,,,20191118.0,,CN,FR,FR,EFAVIRENZ.,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,162512975.0,OT,,,162512975.0,1.0,20050813.0,20050908.0,,,162512975.0,1.0,HIV infection
16252625,162526251,1,I,,20190419.0,20190429,20190429,EXP,,GB-MYLANLABS-2019M1040011,MYLAN,,,,A,M,Y,,,20190429.0,,MD,GB,GB,EFAVIRENZ.,Diabetes mellitus;Disease risk factor;Hypertension;Renal impairment,162526251.0,OT,,,,,,,,,162526251.0,1.0,HIV infection
16256776,162567761,1,I,,20190422.0,20190430,20190430,EXP,,CN-GLAXOSMITHKLINE-CN2019075869,GLAXOSMITHKLINE,PAN X. SHORT COMMUNICATION: DISCORDANCE OF HIV-1 VIRAL LOAD FROM PAIRED BLOOD AND SEMINAL PLASMA SAMPLES IN A CHINESE MEN WHO HAVE SEX WITH MEN POPULATION.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019;35 (4):393-395,49.0,YR,,M,Y,,,20190430.0,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Viral load increased,162567761.0,OT,,,,,,,,,162567761.0,1.0,HIV infection
16256778,162567781,1,I,,20190422.0,20190430,20190430,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019075869,VIIV,PAN X. SHORT COMMUNICATION: DISCORDANCE OF HIV-1 VIRAL LOAD FROM PAIRED BLOOD AND SEMINAL PLASMA SAMPLES IN A CHINESE MEN WHO HAVE SEX WITH MEN POPULATION.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019;35 (4):393-395,49.0,YR,,M,Y,,,20190430.0,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Viral load increased,162567781.0,OT,,,,,,,,,162567781.0,1.0,HIV infection
16256971,162569711,1,I,,20190417.0,20190430,20190430,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-039675,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190430.0,,PH,DE,DE,SUSTIVA,Adverse event;Off label use,162569711.0,HO,,,,,,,,,162569711.0,1.0,HIV infection
16263806,162638061,1,I,,20190417.0,20190502,20190502,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-039739,BRISTOL MYERS SQUIBB,,,,,M,Y,88.44,KG,20190502.0,,CN,US,US,SUSTIVA,Adverse event,,,,,162638061.0,1.0,2000.0,,,,162638061.0,1.0,HIV infection
16264201,162642011,1,I,201404.0,20181219.0,20190502,20190502,EXP,IT-EMA-DD-20180724-TANEJAEVHP-112149,IT-MYLANLABS-2018M1095832,MYLAN,"TARTAGLIA A, FERRARA SM, SICA S, SANTANTONIO T.. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS.. AIDS. 2017;31(16):2314-2315",27.0,YR,,F,Y,,,20190502.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,162642011.0,OT,,,162642011.0,5.0,201505.0,201404.0,,,162642011.0,1.0,HIV infection
16266155,162661555,5,F,201204.0,20201019.0,20190502,20201118,EXP,,US-GILEAD-2019-0405401,GILEAD,,29.0,YR,A,M,Y,68.0,KG,20201118.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Multiple fractures;Osteonecrosis;Osteoporosis;Pain,162661555.0,OT,,,162661555.0,1.0,200602.0,201601.0,,,162661555.0,1.0,HIV infection
16266182,162661825,5,F,2006.0,20201002.0,20190502,20210222,EXP,,US-GILEAD-2019-0405370,GILEAD,,55.0,YR,A,M,Y,90.7,KG,20210222.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Lipohypertrophy;Loss of personal independence in daily activities;Osteonecrosis;Pain in extremity;Renal failure,162661825.0,OT,,,162661825.0,1.0,200602.0,200802.0,,,162661825.0,1.0,HIV infection
16272000,162720002,2,F,,20190801.0,20190506,20190806,EXP,,FR-STRIDES ARCOLAB LIMITED-2019SP003754,STRIDES,,43.0,YR,,F,Y,,,20190806.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Hydrops foetalis,162720002.0,OT,,,162720002.0,2.0,20171006.0,,,,162720002.0,1.0,HIV infection
16272580,162725803,3,F,2016.0,20200519.0,20190503,20200824,EXP,,US-GILEAD-2019-0405402,GILEAD,,52.0,YR,A,M,Y,100.23,KG,20200823.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Osteopenia;Pain,162725803.0,OT,,,162725803.0,1.0,201109.0,201812.0,,,162725803.0,1.0,HIV infection
16277931,162779318,8,F,20160329.0,20231006.0,20190506,20231009,EXP,,US-GILEAD-2019-0405253,GILEAD,,32.0,YR,A,F,Y,81.646,KG,20231009.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Gait disturbance;Oedema peripheral;Pain;Renal failure;Tooth loss;Tubulointerstitial nephritis,162779318.0,HO,,,162779318.0,1.0,2011.0,201603.0,1703.0,DAY,162779318.0,1.0,HIV infection
16279346,162793461,1,I,,20190422.0,20190507,20190507,EXP,,US-AUROBINDO-AUR-APL-2019-023749,AUROBINDO,,,,,,Y,,,20190507.0,,OT,US,US,EFAVIRENZ.,Drug interaction;Fall;Myopathy;Toxicity to various agents,162793461.0,HO,,,,,,,,,162793461.0,1.0,HIV infection
16280615,162806152,2,F,,20190424.0,20190507,20190508,EXP,,FR-HETERO CORPORATE-HET2019FR00584,HETERO,,,,N,,Y,,,20190508.0,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162806152.0,CA,,,162806152.0,1.0,20050513.0,20050908.0,,,162806152.0,1.0,HIV infection
16287246,162872462,2,F,,20190529.0,20190508,20190603,EXP,,PE-GILEAD-2019-0406159,GILEAD,,21.0,YR,A,M,Y,,,20190603.0,,OT,PE,PE,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,162872462.0,HO,,,,,,,,,162872462.0,1.0,HIV infection
16288958,162889586,6,F,20050813.0,20200916.0,20190509,20200923,EXP,,FR-AUROBINDO-AUR-APL-2019-026163,AUROBINDO,,25.0,YR,,F,Y,56.0,KG,20200923.0,,CN,US,FR,SUSTIVA,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,162889586.0,HO,,,162889586.0,1.0,20050620.0,20050908.0,,,162889586.0,1.0,HIV infection
16289880,162898801,1,I,,20190425.0,20190509,20190509,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019021164,MACLEODS,,,,,,Y,,,20190509.0,,OT,GB,FR,EFAVIRENZ.,Maternal exposure during pregnancy,162898801.0,OT,,,162898801.0,1.0,20050704.0,20050908.0,,,162898801.0,1.0,HIV infection
16299594,162995942,2,F,,20190606.0,20190510,20190607,EXP,,PE-VIIV HEALTHCARE LIMITED-PE2019GSK080906,VIIV,,21.0,YR,,M,Y,,,20190607.0,,OT,PE,PE,EFAVIRENZ.,Alopecia areata;CSF glucose decreased;CSF test abnormal;Capillary disorder;Disease recurrence;Eczema;Epidermal necrosis;Headache;Immune reconstitution inflammatory syndrome;Lacrimation increased;Lichenoid keratosis;Lymphocytic infiltration;Madarosis;Melanoderma;Neurosyphilis;Parakeratosis;Penile exfoliation;Penile ulceration;Periorbital oedema;Rash papular;Scrotal ulcer;Secondary syphilis;Skin discolouration;Skin exfoliation;Skin hyperpigmentation;Skin plaque;Uveitis;Vision blurred;Visual acuity reduced;Visual field defect;Visual impairment,162995942.0,HO,,,,,,,,,162995942.0,1.0,HIV infection
16299595,162995952,2,F,,20190606.0,20190510,20190607,EXP,,PE-GLAXOSMITHKLINE-PE2019GSK080906,GLAXOSMITHKLINE,,21.0,YR,,M,Y,,,20190607.0,,OT,PE,PE,EFAVIRENZ.,Alopecia areata;CSF glucose decreased;CSF test abnormal;Capillary disorder;Disease recurrence;Eczema;Epidermal necrosis;Headache;Immune reconstitution inflammatory syndrome;Lacrimation increased;Lichenoid keratosis;Lymphocytic infiltration;Madarosis;Melanoderma;Neurosyphilis;Parakeratosis;Penile exfoliation;Penile ulceration;Periorbital oedema;Rash papular;Scrotal ulcer;Secondary syphilis;Skin discolouration;Skin exfoliation;Skin hyperpigmentation;Skin plaque;Uveitis;Vision blurred;Visual acuity reduced;Visual field defect;Visual impairment,162995952.0,OT,,,,,,,,,162995952.0,1.0,HIV infection
16302622,163026223,3,F,,20200120.0,20190513,20200203,EXP,,GB-CIPLA LTD.-2019GB02975,CIPLA,,,,,,Y,,,20200203.0,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Hydrops foetalis,163026223.0,OT,,,163026223.0,2.0,20171006.0,,,,163026223.0,1.0,HIV infection
16303467,163034674,4,F,,20191113.0,20190513,20191118,EXP,,GB-HETERO-HET2019GB00641,HETERO,,43.0,YR,,F,Y,,,20191119.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163034674.0,OT,,,163034674.0,1.0,20171006.0,,,,163034674.0,1.0,HIV infection
16308301,163083012,2,F,20060216.0,20191105.0,20190514,20191108,EXP,,FR-ABBVIE-19S-056-2772098-00,ABBVIE,,25.0,YR,,F,Y,,,20191108.0,,MD,FR,FR,EFAVIRENZ.,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,163083012.0,OT,,,163083012.0,1.0,20050908.0,20050908.0,,,163083012.0,1.0,HIV infection
16309398,163093982,2,F,20181030.0,20190527.0,20190514,20190529,EXP,,BW-VIIV HEALTHCARE LIMITED-ZA2019GSK082902,VIIV,,72.0,YR,,F,Y,,,20190529.0,,MD,BW,BW,EFAVIRENZ.,Abdominal distension;Death;Hepatic cancer,163093982.0,OT,,,163093982.0,1.0,20170614.0,,,,163093982.0,1.0,HIV infection
16309927,163099274,4,F,200101.0,20190703.0,20190514,20190710,EXP,,FR-MYLANLABS-2019M1044768,MYLAN,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI-GRADT E, GUILLOU-GUILLEMETTE HL, CHENNEBAULT JM.. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV-1 GROUP O.. AIDS. 2016;30 (16):2565-8",,,,F,Y,,,20190710.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,163099274.0,OT,,,,,,,,,163099274.0,1.0,HIV infection
16311357,163113571,1,I,,20190509.0,20190514,20190514,EXP,,GB-GILEAD-2019-0407153,GILEAD,,53.0,YR,A,M,Y,,,20190514.0,,CN,GB,GB,EFAVIRENZ.,Abnormal dreams;Hallucination,163113571.0,OT,,,163113571.0,1.0,2006.0,,,,163113571.0,1.0,HIV infection
16318287,163182871,1,I,,20190509.0,20190516,20190516,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK083462,VIIV,,2.0,MON,,M,Y,4.2,KG,20190516.0,,MD,US,MZ,EFAVIRENZ.,Abdominal distension;Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Exposure via breast milk;Foetal exposure during pregnancy;Fontanelle depressed;Generalised tonic-clonic seizure;Hepatosplenomegaly;Irritability;Mass;Meningitis tuberculous;Osteopenia;Pallor;Pyrexia;Tuberculosis gastrointestinal,163182871.0,OT,,,,,,,,,163182871.0,1.0,Antiretroviral therapy
16318288,163182881,1,I,,20190509.0,20190516,20190516,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK083462,GLAXOSMITHKLINE,,2.0,MON,,M,Y,4.2,KG,20190516.0,,MD,US,MZ,EFAVIRENZ.,Abdominal distension;Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Exposure via breast milk;Foetal exposure during pregnancy;Fontanelle depressed;Generalised tonic-clonic seizure;Hepatosplenomegaly;Irritability;Mass;Meningitis tuberculous;Osteopenia;Pallor;Pyrexia;Tuberculosis gastrointestinal,163182881.0,HO,,,,,,,,,163182881.0,1.0,Antiretroviral therapy
16321056,163210564,4,F,20130301.0,20231124.0,20190516,20231127,EXP,,US-GILEAD-2019-0407712,GILEAD,,44.0,YR,A,F,Y,62.585,KG,20231126.0,,LW,US,US,SUSTIVA,Acidosis hyperchloraemic;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Fatigue;Hypokalaemia;Pain;Renal failure;Renal tubular acidosis,163210564.0,HO,,,163210564.0,1.0,20140224.0,2016.0,,,163210564.0,1.0,HIV infection
16321127,163211276,6,F,20040608.0,20240124.0,20190516,20240129,EXP,,US-GILEAD-2019-0407768,GILEAD,,57.0,YR,A,M,Y,65.76,KG,20240128.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Foot fracture;Hyperparathyroidism secondary;Hyperphosphataemia;Nephropathy;Osteopenia;Pain;Proteinuria;Radius fracture;Wrist fracture,163211276.0,HO,,,163211276.0,1.0,200404.0,2005.0,,,163211276.0,1.0,HIV infection
16321491,163214915,5,F,20090501.0,20231204.0,20190516,20231206,PER,,US-GILEAD-2019-0407756,GILEAD,,40.0,YR,A,M,Y,98.413,KG,20231206.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Chronic kidney disease;Drug resistance;Economic problem;Emotional distress;Fanconi syndrome acquired;Gait disturbance;Pain;Renal impairment,163214915.0,HO,,,163214915.0,1.0,200110.0,200609.0,1142.0,DAY,163214915.0,1.0,HIV infection
16322153,163221531,1,I,,20190509.0,20190516,20190516,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK083468,GLAXOSMITHKLINE,,3.0,MON,,M,Y,4.3,KG,20190516.0,,MD,US,MZ,EFAVIRENZ.,Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Crepitations;Exposure via breast milk;Foetal exposure during pregnancy;Hypoxia;Irritability;Lung infiltration;Mass;Osteopenia;Pallor;Pneumonia bacterial;Pulmonary tuberculosis;Pyrexia;Rales;Respiratory distress;Tachypnoea;Use of accessory respiratory muscles,163221531.0,OT,,,,,,,,,163221531.0,1.0,Antiretroviral therapy
16322154,163221541,1,I,,20190509.0,20190516,20190516,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK083468,VIIV,,3.0,MON,,M,Y,4.3,KG,20190516.0,,MD,US,MZ,EFAVIRENZ.,Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Crepitations;Exposure via breast milk;Foetal exposure during pregnancy;Hypoxia;Irritability;Lung infiltration;Mass;Osteopenia;Pallor;Pneumonia bacterial;Pulmonary tuberculosis;Pyrexia;Rales;Respiratory distress;Tachypnoea;Use of accessory respiratory muscles,163221541.0,OT,,,,,,,,,163221541.0,1.0,Antiretroviral therapy
16325122,163251223,3,F,20120922.0,20231220.0,20190517,20231222,EXP,,US-GILEAD-2019-0407763,GILEAD,,42.0,YR,A,M,Y,142.86,KG,20231222.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Dyspnoea;Economic problem;Emotional distress;End stage renal disease;Gait disturbance;Glomerular filtration rate decreased;Pain,163251223.0,OT,,,163251223.0,1.0,2005.0,,,,163251223.0,1.0,HIV infection
16325325,163253256,6,F,20030101.0,20240205.0,20190517,20240207,EXP,,US-GILEAD-2019-0407769,GILEAD,,,,A,M,Y,70.295,KG,20240207.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone density decreased;Bone pain;Chronic kidney disease;Depression;Economic problem;Emotional distress;Hypercreatininaemia;Osteoarthritis;Osteonecrosis;Pain;Pain in extremity;Renal failure;Renal pain,163253256.0,OT,,,163253256.0,1.0,200305.0,200409.0,,,163253256.0,1.0,HIV infection
16326345,163263452,2,F,200211.0,20200814.0,20190517,20200904,EXP,,US-GILEAD-2019-0407770,GILEAD,,39.0,YR,A,F,Y,62.59,KG,20200904.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Osteoporosis;Pain,163263452.0,OT,,,163263452.0,1.0,2003.0,20130104.0,,,163263452.0,1.0,HIV infection
16326384,163263843,3,F,201010.0,20210128.0,20190517,20210210,EXP,,US-GILEAD-2019-0407830,GILEAD,,53.0,YR,A,M,Y,82.99,KG,20210210.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fall;Fibula fracture;Hand fracture;Lower limb fracture;Muscular weakness;Osteopenia;Pain;Proteinuria;Tibia fracture,163263843.0,OT,,,163263843.0,1.0,20100419.0,20150713.0,,,163263843.0,1.0,HIV infection
16327418,163274185,5,F,19980101.0,20231016.0,20190517,20231017,PER,,US-GILEAD-2019-0407762,GILEAD,,53.0,YR,A,F,Y,86.621,KG,20231016.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood pressure abnormal;Bone demineralisation;Bone density decreased;Bone loss;CD4 lymphocytes abnormal;Depression;Economic problem;Emotional distress;Osteoporosis;Pain;Pain in extremity;Renal impairment;Wrist fracture,163274185.0,OT,,,163274185.0,1.0,2008.0,2010.0,2748.0,DAY,163274185.0,1.0,HIV infection
16333019,163330192,2,F,2009.0,20200815.0,20190520,20200908,EXP,,US-GILEAD-2019-0407859,GILEAD,,44.0,YR,A,M,Y,56.69,KG,20200908.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Degenerative bone disease;Economic problem;Emotional distress;Osteoporosis;Pain,163330192.0,OT,,,163330192.0,1.0,20071214.0,20120913.0,,,163330192.0,1.0,HIV infection
16333090,163330903,3,F,20120412.0,20200714.0,20190520,20210514,PER,,US-GILEAD-2019-0407953,GILEAD,,42.0,YR,A,M,Y,111.11,KG,20210514.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Pain;Proteinuria;Renal disorder;Renal impairment,163330903.0,OT,,,163330903.0,1.0,2007.0,20160407.0,,,163330903.0,1.0,HIV infection
16333099,163330992,2,F,200705.0,20200815.0,20190520,20201030,EXP,,US-GILEAD-2019-0407826,GILEAD,,49.0,YR,A,M,Y,99.0,KG,20201030.0,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Fear;Foot fracture;General physical health deterioration;Loose tooth;Muscle spasms;Myalgia;Neck pain;Osteoporosis;Pain;Periodontitis;Quality of life decreased;Spinal pain;Tooth fracture;Tooth loss,163330992.0,OT,,,163330992.0,1.0,2006.0,2016.0,,,163330992.0,1.0,HIV infection
16333242,163332422,2,F,2015.0,20200811.0,20190520,20200831,PER,,US-GILEAD-2019-0407824,GILEAD,,39.0,YR,A,F,Y,65.76,KG,20200831.0,,CN,US,US,EFAVIRENZ.;SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Exercise tolerance decreased;Fatigue;General physical health deterioration;Pain;Quality of life decreased;Renal failure,163332422.0,OT,,,163332422.0,1.0,2010.0,20120202.0,,,163332422.0,1.0,HIV infection
16334713,163347136,6,F,2008.0,20210414.0,20190520,20210419,EXP,,US-GILEAD-2019-0408522,GILEAD,,59.0,YR,A,M,Y,75.7,KG,20210419.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Fall;Femoral neck fracture;Gait disturbance;Osteomalacia;Osteopenia;Osteoporosis;Osteoporotic fracture;Pain;Scar;Tooth loss,163347136.0,DS,,,163347136.0,1.0,200402.0,201303.0,,,163347136.0,1.0,HIV infection
16335806,163358062,2,F,2010.0,20200815.0,20190521,20201017,EXP,,US-GILEAD-2019-0408027,GILEAD,,55.0,YR,A,M,Y,,,20201017.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fatigue;Osteoporosis;Pain;Renal failure,163358062.0,OT,,,163358062.0,1.0,2011.0,20190826.0,,,163358062.0,1.0,HIV infection
16337744,163377441,1,I,,20190506.0,20190521,20190521,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-044731,BRISTOL MYERS SQUIBB,,25.0,YR,,F,Y,,,20190521.0,,OT,FR,FR,EFAVIRENZ.,Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,163377441.0,OT,,,163377441.0,1.0,20050513.0,20050908.0,,,163377441.0,1.0,HIV infection
16337993,163379931,1,I,,20190508.0,20190521,20190521,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047432,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,,,20190521.0,,OT,NG,NG,EFAVIRENZ.,Cryptococcosis;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,163379931.0,HO,,,,,,,,,163379931.0,1.0,HIV infection
16338249,163382493,3,F,20120213.0,20210604.0,20190521,20210607,EXP,,US-GILEAD-2019-0408272,GILEAD,,50.0,YR,A,M,Y,62.59,KG,20210607.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Pain,163382493.0,OT,,,163382493.0,1.0,20090705.0,20120214.0,,,163382493.0,1.0,HIV infection
16338266,163382661,1,I,,20190507.0,20190521,20190521,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-049395,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190521.0,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,163382661.0,OT,,,,,,,,,163382661.0,1.0,HIV infection
16338358,163383584,4,F,20131001.0,20220714.0,20190521,20220719,PER,,US-GILEAD-2019-0408525,GILEAD,,45.0,YR,A,M,Y,,,20220719.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Drug ineffective;Economic problem;Emotional distress;Pain,163383584.0,OT,,,163383584.0,1.0,201208.0,201807.0,,,163383584.0,1.0,HIV infection
16340372,163403721,1,I,,20190509.0,20190522,20190522,EXP,,CO-CIPLA LTD.-2019CO03642,CIPLA,,,,,,Y,,,20190522.0,,OT,CO,CO,EFAVIRENZ.,Toxic skin eruption,163403721.0,OT,,,,,,,,,163403721.0,1.0,Antiretroviral therapy
16340534,163405346,6,F,,20230418.0,20190522,20230430,EXP,,CA-AUROBINDO-AUR-APL-2019-027585,AUROBINDO,,54.0,YR,,M,Y,,,20230429.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,163405346.0,OT,,,,,,,,,163405346.0,1.0,HIV infection
16340936,163409362,2,F,2016.0,20200729.0,20190522,20200831,EXP,,US-GILEAD-2019-0407997,GILEAD,,,,A,F,Y,69.84,KG,20200831.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Fear;Femur fracture;General physical health deterioration;Hand fracture;Hip fracture;Osteoporosis;Pain;Post-traumatic stress disorder;Quality of life decreased;Radius fracture;Tibia fracture;Wheelchair user,163409362.0,OT,,,163409362.0,1.0,2009.0,2015.0,,,163409362.0,1.0,HIV infection
16340986,163409863,3,F,20171007.0,20231121.0,20190522,20231123,EXP,,US-GILEAD-2019-0408031,GILEAD,,48.0,YR,A,F,Y,95.238,KG,20231123.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Cough;Economic problem;Emotional distress;Femur fracture;Foot fracture;General physical health deterioration;Impaired work ability;Loss of personal independence in daily activities;Lower limb fracture;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Rib fracture;Walking aid user,163409863.0,OT,,,163409863.0,1.0,2004.0,2012.0,,,163409863.0,1.0,HIV infection
16341719,163417192,2,F,20101201.0,20220602.0,20190522,20220603,EXP,,PT-ABBVIE-19S-130-2780428-00,ABBVIE,,,,A,F,Y,,,20220603.0,,MD,PT,PT,EFAVIRENZ,Drug ineffective;Exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163417192.0,OT,,,163417192.0,1.0,201006.0,201012.0,,,163417192.0,1.0,HIV infection
16342541,163425413,3,F,20110101.0,20230411.0,20190522,20230413,EXP,,US-GILEAD-2019-0407993,GILEAD,,59.0,YR,A,F,Y,78.912,KG,20230413.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone loss;Depression;Economic problem;Emotional distress;General physical health deterioration;Hip arthroplasty;Osteopenia;Osteoporosis;Pain;Quality of life decreased,163425413.0,OT,,,163425413.0,1.0,2004.0,20161012.0,,,163425413.0,1.0,HIV infection
16345806,163458063,3,F,20130601.0,20200319.0,20190523,20200326,PER,,US-GILEAD-2019-0409080,GILEAD,,50.0,YR,A,M,Y,89.21,KG,20200326.0,,CN,US,US,SUSTIVA,Chronic kidney disease;Hepatic enzyme increased;Hydronephrosis;Renal failure,163458063.0,HO,,,163458063.0,1.0,20110629.0,201709.0,,,163458063.0,1.0,HIV infection
16346211,163462111,1,I,,20190508.0,20190523,20190523,EXP,,CA-AUROBINDO-AUR-APL-2019-028403,AUROBINDO,,,,,,Y,,,20190523.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,163462111.0,OT,,,,,,,,,163462111.0,1.0,HIV infection
16346235,163462355,5,F,,20221129.0,20190523,20221214,EXP,,CA-AUROBINDO-AUR-APL-2019-027597,AUROBINDO,,54.0,YR,,M,Y,,,20221214.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Incorrect route of product administration,163462355.0,OT,,,,,,,,,163462355.0,1.0,HIV infection
16347125,163471252,2,F,,20190527.0,20190523,20190603,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-049516,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20190603.0,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,163471252.0,OT,,,163471252.0,2.0,20171006.0,,,,163471252.0,1.0,HIV infection
16349775,163497753,3,F,20140701.0,20230412.0,20190523,20230413,PER,,US-GILEAD-2019-0408303,GILEAD,,55.0,YR,A,F,Y,78.005,KG,20230413.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Pain,,,,,163497753.0,1.0,2005.0,2010.0,,,163497753.0,1.0,HIV infection
16350708,163507085,5,F,20150301.0,20241112.0,20190524,20241114,EXP,,US-GILEAD-2019-0409332,GILEAD,,44.0,YR,A,M,Y,,,20241114.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Multiple fractures;Osteonecrosis;Osteoporosis;Pain;Renal failure;Renal injury;Spinal fracture,163507085.0,HO,,,163507085.0,1.0,2009.0,2011.0,,,163507085.0,1.0,HIV infection
16354407,163544071,1,I,200809.0,20190513.0,20190524,20190524,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047790,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,69.5,KG,20190524.0,,MD,ES,ES,EFAVIRENZ.,Pulmonary tuberculosis,163544071.0,OT,,,163544071.0,1.0,200311.0,200809.0,,,163544071.0,1.0,HIV infection
16356995,163569951,1,I,,20190515.0,20190527,20190527,EXP,,UG-CIPLA LTD.-2019UG03919,CIPLA,,,,,,Y,,,20190527.0,,OT,US,UG,EFAVIRENZ.,Death;Exposure during pregnancy,163569951.0,DE,,,163569951.0,1.0,20130723.0,20131121.0,,,163569951.0,1.0,HIV infection
16357029,163570295,5,F,20130311.0,20200904.0,20190527,20201005,EXP,,US-GILEAD-2019-0409401,GILEAD,,45.0,YR,A,M,Y,79.37,KG,20201005.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,163570295.0,OT,,,163570295.0,1.0,20040106.0,20080514.0,,,163570295.0,1.0,HIV infection
16358435,163584351,1,I,20110407.0,20181206.0,20190527,20190527,EXP,,FR-GLAXOSMITHKLINE-FR2018223061,GLAXOSMITHKLINE,,51.0,YR,,F,Y,,,20190527.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Treatment failure;Viral mutation identified,163584351.0,OT,,,,,,,,,163584351.0,1.0,HIV infection
16358437,163584371,1,I,20110407.0,20181206.0,20190527,20190527,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018223061,VIIV,,51.0,YR,,F,Y,,,20190527.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Treatment failure;Viral mutation identified,163584371.0,OT,,,,,,,,,163584371.0,1.0,HIV infection
16359867,163598676,6,F,200901.0,20201019.0,20190528,20201102,EXP,,US-GILEAD-2019-0409397,GILEAD,,48.0,YR,A,M,Y,83.9,KG,20201102.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Nightmare;Pain;Suicidal ideation,163598676.0,OT,,,163598676.0,1.0,200901.0,201001.0,,,163598676.0,1.0,HIV infection
16360074,163600742,2,F,201103.0,20200320.0,20190528,20200408,PER,,US-GILEAD-2019-0409404,GILEAD,,52.0,YR,A,M,Y,,,20200408.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Foot fracture;Pain,163600742.0,OT,,,163600742.0,1.0,200410.0,201907.0,,,163600742.0,1.0,HIV infection
16360719,163607193,3,F,20100601.0,20220604.0,20190528,20220618,EXP,,PT-AUROBINDO-AUR-APL-2019-029299,AUROBINDO,,,,A,F,Y,,,20220618.0,,MD,PT,PT,EFAVIRENZ,Drug ineffective;Maternal exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163607193.0,OT,,,163607193.0,1.0,201006.0,201012.0,,,163607193.0,1.0,HIV infection
16361013,163610131,1,I,,20190513.0,20190528,20190528,EXP,,NL-AUROBINDO-AUR-APL-2019-028955,AUROBINDO,,,,,,Y,,,20190528.0,,OT,NL,NL,EFAVIRENZ.,Neuropsychiatric symptoms,163610131.0,OT,,,,,,,,,163610131.0,1.0,HIV infection
16363321,163633211,1,I,,20190517.0,20190528,20190528,EXP,,FR-MYLANLABS-2019M1048515,MYLAN,"CORBIN V, FRANGE P, VEBER F, BLANCHE S, RUNEL-BELLIARD C, LALANDE M, ET AL.. CLINICAL, VIROLOGICAL AND IMMUNOLOGICAL FEATURES OF HIV-POSITIVE CHILDREN INTERNATIONALLY ADOPTED IN FRANCE FROM 2005-2015. PLOS ONE.. 2018;13(9):E0203438",3.0,YR,,,Y,,,20190528.0,,OT,FR,FR,EFAVIRENZ.,Virologic failure,163633211.0,OT,,,,,,,,,163633211.0,1.0,HIV infection
16365955,163659551,1,I,201012.0,20190514.0,20190529,20190529,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-048083,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20190529.0,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Maternal exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163659551.0,OT,,,163659551.0,1.0,200905.0,201012.0,,,163659551.0,1.0,HIV infection
16370095,163700952,2,F,,20190524.0,20190530,20190612,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-048913,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20190612.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,163700952.0,OT,,,163700952.0,1.0,20171006.0,,,,163700952.0,1.0,HIV infection
16372667,163726671,1,I,,20190518.0,20190530,20190530,EXP,,CA-APOTEX-2019AP014810,APOTEX,,45.0,YR,,M,Y,,,20190530.0,,CN,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,163726671.0,DS,,,,,,,,,163726671.0,1.0,HIV infection
16375402,163754021,1,I,,20190522.0,20190531,20190531,EXP,,NG-APPCO PHARMA LLC-2067630,APPCO PHARMA,,52.0,YR,,M,Y,,,20190531.0,,OT,NG,NG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,163754021.0,LT,,,,,,,,,163754021.0,1.0,HIV antibody positive
16376493,163764932,2,F,20110407.0,20220322.0,20190531,20220406,EXP,,FR-AUROBINDO-AUR-APL-2019-031186,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Carlo DD, Romeo I, Artese A, et al.. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem-Biol-Drug-Des. 2019;93 (1):50-59",51.0,YR,,F,Y,,,20220406.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,163764932.0,OT,,,,,,,,,163764932.0,1.0,HIV infection
16385324,163853241,1,I,,20190524.0,20190603,20190603,EXP,,UG-MYLANLABS-2019M1051575,MYLAN,,,,A,,Y,,,20190603.0,,MD,DE,UG,EFAVIRENZ.,Treatment failure,163853241.0,OT,,,,,,,,,163853241.0,1.0,HIV infection
16390637,163906371,1,I,,20190522.0,20190604,20190604,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-051187,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,,,20190604.0,,MD,GB,GB,EFAVIRENZ.,Cardiovascular disorder,163906371.0,OT,,,,,,,,,163906371.0,1.0,HIV infection
16392710,163927102,2,F,20051226.0,20190529.0,20190605,20190614,EXP,,US-VIIV HEALTHCARE LIMITED-A0868257A,VIIV,,,,N,,Y,,,20190614.0,,OT,COUNTRY NOT SPECIFIED,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,163927102.0,CA,,,,,,,,,163927102.0,1.0,HIV infection
16392728,163927282,2,F,20051226.0,20190529.0,20190605,20190614,EXP,,US-GLAXOSMITHKLINE-A0868257A,GLAXOSMITHKLINE,,,,N,,Y,,,20190614.0,,OT,COUNTRY NOT SPECIFIED,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,163927282.0,CA,,,,,,,,,163927282.0,1.0,HIV infection
16392757,163927571,1,I,,20190528.0,20190605,20190605,EXP,,GB-TEVA-2019-GB-1057581,TEVA,,43.0,YR,,F,Y,,,20190605.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163927571.0,OT,,,163927571.0,2.0,20171006.0,,,,163927571.0,1.0,HIV infection
16400657,164006571,1,I,,20190522.0,20190606,20190606,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-051889,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20190606.0,,OT,GB,GB,EFAVIRENZ.,Alanine aminotransferase increased;C-reactive protein increased;Maternal exposure during pregnancy;Pyrexia,164006571.0,OT,,,,,,,,,164006571.0,1.0,Antiretroviral therapy
16401859,164018591,1,I,,20190522.0,20190607,20190607,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-055537,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20190607.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164018591.0,OT,,,,,,,,,164018591.0,1.0,HIV infection
16403552,164035521,1,I,,20190523.0,20190607,20190607,EXP,,IT-AUROBINDO-AUR-APL-2019-031588,AUROBINDO,,,,,,Y,,,20190607.0,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,164035521.0,OT,,,,,,,,,164035521.0,1.0,HIV infection
16410957,164109572,2,F,,20190529.0,20190610,20190823,EXP,,US-VIIV HEALTHCARE LIMITED-US2019AMR103087,VIIV,,,,,M,Y,,,20190823.0,,CN,US,US,EFAVIRENZ.,Blood creatinine increased;Proteinuria;Renal failure;Viraemia;Viral mutation identified,164109572.0,OT,,,,,,,,,164109572.0,1.0,HIV infection
16410974,164109742,2,F,,20190529.0,20190610,20190823,EXP,,US-GLAXOSMITHKLINE-US2019AMR103087,GLAXOSMITHKLINE,,,,,M,Y,,,20190823.0,,CN,US,US,EFAVIRENZ.,Blood creatinine increased;Proteinuria;Renal failure;Viraemia;Viral mutation identified,164109742.0,OT,,,,,,,,,164109742.0,1.0,HIV infection
16425185,164251853,3,F,20140214.0,20200506.0,20190613,20200603,PER,,US-GILEAD-2019-0413099,GILEAD,,47.0,YR,A,M,Y,,,20200603.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Pain;Tooth loss,,,,,164251853.0,1.0,20040213.0,20100708.0,,,164251853.0,1.0,HIV infection
16426280,164262801,1,I,,20190610.0,20190613,20190613,PER,,US-GILEAD-2019-0413042,GILEAD,,64.0,YR,A,M,Y,,,20190613.0,,CN,US,US,SUSTIVA,Nightmare,,,,,164262801.0,1.0,2004.0,,,,164262801.0,1.0,HIV infection
16428713,164287133,3,F,,20200630.0,20190613,20200707,EXP,,MY-GILEAD-2019-0413166,GILEAD,"KOH K, IBRAHIM N, ONG S. PARADOXICAL WORSENING OF CHEST RADIOGRAPHS SECONDARY TO IMMUNE RECONSTITUTION SYNDROME (IRIS) IN A PATIENT WITH ADVANCED HIV INFECTION AND RHODOCOCCUS PNEUMONIA. MED J MALAYSIA. 2020?75:164?166",38.0,YR,A,M,Y,,,20200707.0,,MD,MY,MY,EFAVIRENZ.,Chest X-ray abnormal;Immune reconstitution inflammatory syndrome;Pneumonia bacterial,164287133.0,OT,,,,,,,,,164287133.0,1.0,HIV infection
16430786,164307866,6,F,20050101.0,20220718.0,20190614,20220719,EXP,,US-GILEAD-2019-0413028,GILEAD,,,,A,M,Y,74.83,KG,20220719.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Pain;Post-traumatic stress disorder;Renal cyst;Tooth loss,164307866.0,OT,,,164307866.0,1.0,2010.0,201701.0,,,164307866.0,1.0,HIV infection
16434575,164345751,1,I,,20190611.0,20190614,20190614,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105248,VIIV,,54.0,YR,,M,Y,,,20190614.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164345751.0,OT,,,,,,,,,164345751.0,1.0,HIV infection
16434585,164345851,1,I,,20190611.0,20190614,20190614,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105248,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20190614.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164345851.0,OT,,,,,,,,,164345851.0,1.0,HIV infection
16437282,164372821,1,I,,20190613.0,20190615,20190615,EXP,,CA-009507513-1906CAN005474,MERCK,,54.0,YR,,M,Y,,,20190615.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164372821.0,OT,,,,,,,,,164372821.0,1.0,HIV infection
16439329,164393292,2,F,,20190905.0,20190617,20190912,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106102,VIIV,,52.0,YR,,M,Y,,,20190912.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,164393292.0,OT,,,,,,,,,164393292.0,1.0,HIV infection
16439340,164393402,2,F,,20190905.0,20190617,20190912,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106102,GLAXOSMITHKLINE,,52.0,YR,,M,Y,,,20190912.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,164393402.0,CA,,,,,,,,,164393402.0,1.0,HIV infection
16444785,164447851,1,I,201805.0,20190611.0,20190618,20190618,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-058554,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,111.13,KG,20190618.0,,CN,US,US,EFAVIRENZ.,Depression;Mental disorder;Substance abuse,164447851.0,HO,,,164447851.0,1.0,1999.0,,,,164447851.0,1.0,HIV infection
16446146,164461461,1,I,,20190611.0,20190618,20190618,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105235,VIIV,,54.0,YR,,M,Y,,,20190618.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461461.0,OT,,,,,,,,,164461461.0,1.0,HIV infection
16446149,164461491,1,I,,20190611.0,20190618,20190618,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106131,VIIV,,54.0,YR,,M,Y,,,20190618.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461491.0,OT,,,,,,,,,164461491.0,1.0,HIV infection
16446153,164461531,1,I,,20190611.0,20190618,20190618,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105235,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20190618.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461531.0,OT,,,,,,,,,164461531.0,1.0,HIV infection
16446177,164461771,1,I,,20190611.0,20190618,20190618,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106131,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20190618.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461771.0,OT,,,,,,,,,164461771.0,1.0,HIV infection
16447375,164473751,1,I,,20190605.0,20190619,20190619,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-056308,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190619.0,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164473751.0,OT,,,164473751.0,1.0,20171006.0,,,,164473751.0,1.0,HIV infection
16454218,164542181,1,I,201808.0,20190610.0,20190619,20190619,EXP,PT-INFARMED-J201812-1031,PT-MYLANLABS-2019M1057186,MYLAN,,45.0,YR,,M,Y,,,20190619.0,,PH,PT,PT,EFAVIRENZ.,Insomnia;Nightmare,164542181.0,OT,,,164542181.0,1.0,20130702.0,20181217.0,,,164542181.0,1.0,HIV infection
16457895,164578954,4,F,20190530.0,20200129.0,20190620,20200205,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2018GSK214194,VIIV,,19.0,YR,,F,Y,44.4,KG,20200205.0,,MD,ZW,ZW,EFAVIRENZ.,Back pain;Exposure during pregnancy;Headache;Live birth;Pneumonia,164578954.0,OT,,,164578954.0,1.0,20170321.0,20181123.0,,,164578954.0,1.0,HIV infection
16457897,164578974,4,F,20190530.0,20200129.0,20190620,20200205,EXP,,ZW-GLAXOSMITHKLINE-ZW2018GSK214194,GLAXOSMITHKLINE,,19.0,YR,,F,Y,44.4,KG,20200205.0,,MD,ZW,ZW,EFAVIRENZ.,Back pain;Exposure during pregnancy;Headache;Live birth;Pneumonia,164578974.0,OT,,,164578974.0,1.0,20170321.0,20181123.0,,,164578974.0,1.0,HIV infection
16461189,164611892,2,F,,20190624.0,20190621,20190626,EXP,,CO-AUROBINDO-AUR-APL-2019-036353,AUROBINDO,"RODRIGUEZ-HERRERA D, ET AL. CISPLATIN/EFAVIRENZ/FLUOROURACIL: TOXICODERMA AND HERPES SIMPLEX VIRUS TYPE 1 INFECTION: CASE REPORT. REACTIONS WEEKLY. 2019;1757:P87",,,,,Y,,,20190626.0,,OT,CO,CO,EFAVIRENZ.,Toxic skin eruption,164611892.0,OT,,,164611892.0,3.0,201609.0,,,,164611892.0,1.0,HIV infection
16464279,164642791,1,I,,20190617.0,20190621,20190621,EXP,,IN-GILEAD-2019-0414307,GILEAD,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79. DOI:10.4103/JGID.JGID_160_18",,,A,,Y,,,20190621.0,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164642791.0,OT,,,,,,,,,164642791.0,1.0,HIV infection
16464348,164643481,1,I,,20190617.0,20190621,20190621,EXP,,IN-GILEAD-2019-0414308,GILEAD,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79. DOI:10.4103/JGID.JGID_160_18",,,A,,Y,,,20190621.0,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164643481.0,OT,,,,,,,,,164643481.0,1.0,HIV infection
16466893,164668931,1,I,,20190610.0,20190624,20190624,EXP,,GB-AUROBINDO-AUR-APL-2019-034451,AUROBINDO,,,,,,Y,,,20190624.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164668931.0,OT,,,,,,,,,164668931.0,1.0,HIV infection
16467469,164674692,2,F,,20190907.0,20190624,20190921,EXP,,GB-AUROBINDO-AUR-APL-2019-034453,AUROBINDO,,,,A,F,Y,,,20190921.0,,OT,GB,GB,EFAVIRENZ.,Alanine aminotransferase increased;C-reactive protein increased;Exposure during pregnancy;Medication error;Pyrexia,164674692.0,OT,,,,,,,,,164674692.0,1.0,Antiretroviral therapy
16470765,164707651,1,I,,20190617.0,20190624,20190624,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112936,VIIV,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79",,,A,,Y,,,20190624.0,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164707651.0,OT,,,,,,,,,164707651.0,1.0,HIV infection
16470766,164707661,1,I,,20190617.0,20190624,20190624,EXP,,IN-GLAXOSMITHKLINE-IN2019112936,GLAXOSMITHKLINE,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79",,,A,,Y,,,20190624.0,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164707661.0,OT,,,,,,,,,164707661.0,1.0,HIV infection
16473304,164733041,1,I,,20190617.0,20190625,20190625,EXP,,IN-GLAXOSMITHKLINE-IN2019112951,GLAXOSMITHKLINE,"KUMAR V,. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625.0,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164733041.0,OT,,,,,,,,,164733041.0,1.0,HIV infection
16473307,164733071,1,I,,20190617.0,20190625,20190625,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112935,VIIV,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625.0,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164733071.0,OT,,,,,,,,,164733071.0,1.0,HIV infection
16473419,164734191,1,I,,20190617.0,20190625,20190625,EXP,,IN-GLAXOSMITHKLINE-IN2019112935,GLAXOSMITHKLINE,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625.0,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164734191.0,OT,,,,,,,,,164734191.0,1.0,HIV infection
16473421,164734211,1,I,,20190617.0,20190625,20190625,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112951,VIIV,"KUMAR V,. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625.0,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164734211.0,OT,,,,,,,,,164734211.0,1.0,HIV infection
16474440,164744404,4,F,20151123.0,20191001.0,20190625,20191009,EXP,,BR-GILEAD-2019-0414876,GILEAD,,26.0,YR,A,F,Y,,,20191009.0,,MD,BR,BR,EFAVIRENZ.,Hepatitis fulminant,164744404.0,OT,,,164744404.0,1.0,20150831.0,20160107.0,,,164744404.0,1.0,HIV infection
16475912,164759124,4,F,1996.0,20200901.0,20190625,20200909,EXP,,IT-MYLANLABS-2019M1058328,MYLAN,"LANZAFAME M, LATTUADA E, RIZZARDO S, PIACENTINI D, CHIESI S, MAZZI R.. DOLUTEGRAVIR MONOTHERAPY^S VIROLOGICAL EFFICACY IN A HIGHLY TREATMENT?EXPERIENCED PATIENT.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019",74.0,YR,,F,Y,,,20200909.0,,HP,IT,IT,EFAVIRENZ.,Drug resistance;Genotype drug resistance test negative;Treatment failure;Treatment noncompliance;Virologic failure,164759124.0,OT,,,164759124.0,1.0,2005.0,2009.0,,,164759124.0,1.0,HIV infection
16476887,164768871,1,I,,20190617.0,20190626,20190626,EXP,,IN-GLAXOSMITHKLINE-IN2019112949,GLAXOSMITHKLINE,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190626.0,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164768871.0,OT,,,,,,,,,164768871.0,1.0,HIV infection
16476893,164768931,1,I,,20190617.0,20190626,20190626,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112949,VIIV,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190626.0,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164768931.0,OT,,,,,,,,,164768931.0,1.0,HIV infection
16477356,164773561,1,I,,20190617.0,20190626,20190626,EXP,,DK-HETERO-HET2019DK00859,HETERO,"LETH S, JENSEN-FANGEL S. INFRAPATELLAR BURSITIS WITH MYCOBACTERIUM MALMOENSE RELATED TO IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV-POSITIVE PATIENT. BMJ-CASE-REP. 2012",39.0,YR,,M,Y,,,20190626.0,,OT,DK,DK,EFAVIRENZ.,Bursitis;Immune reconstitution inflammatory syndrome,164773561.0,HO,,,,,,,,,164773561.0,1.0,HIV infection
16479805,164798051,1,I,200109.0,20190617.0,20190626,20190626,EXP,,FR-MYLANLABS-2019M1057619,MYLAN,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI-GRADT E, GUILLOU-GUILLEMETTE HL, CHENNEBAULT JM ET AL. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV-1 GROUP O. AIDS. 2016;30(16):2565-2568. DOI: 10.1097/QAD.0000000000001253.",,,,F,Y,,,20190626.0,,,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,164798051.0,OT,,,,,,,,,164798051.0,1.0,HIV infection
16482251,164822513,3,F,20190122.0,20190919.0,20190627,20190923,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-060326,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20190923.0,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164822513.0,OT,,,164822513.0,1.0,20140501.0,,,,164822513.0,1.0,HIV infection
16487549,164875491,1,I,2017.0,20190616.0,20190627,20190627,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-059258,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190627.0,,CN,US,US,SUSTIVA,Depression;Neoplasm malignant;Suicidal ideation,164875491.0,OT,,,,,,,,,164875491.0,1.0,HIV infection
16489848,164898481,1,I,,20190619.0,20190628,20190628,EXP,,ZA-CIPLA LTD.-2019ZA04670,CIPLA,,,,,,Y,,,20190628.0,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Haemoglobin decreased;Platelet count decreased;Ventricular extrasystoles;Vitamin B12 deficiency,164898481.0,OT,,,164898481.0,1.0,20180214.0,,,,164898481.0,1.0,HIV infection
16494843,164948439,9,F,2014.0,20200402.0,20190628,20200424,EXP,,US-GILEAD-2019-0415427,GILEAD,,64.0,YR,A,M,Y,81.25,KG,20200424.0,,CN,US,US,SUSTIVA,Amnesia;Anal cancer;Anxiety;Arthralgia;Cardiac failure;Colorectal cancer;Diarrhoea;Disturbance in attention;Gait disturbance;Gastrointestinal disorder;HIV-associated neurocognitive disorder;Insomnia;Laboratory test abnormal;Lipids abnormal;Nausea;Neuropathy peripheral;Nightmare;Osteopenia;Pain in extremity;Stevens-Johnson syndrome;T-lymphocyte count decreased;Tinnitus,164948439.0,OT,,,164948439.0,3.0,2004.0,,,,164948439.0,1.0,HIV infection
16499608,164996081,1,I,,20190625.0,20190701,20190701,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2019GSK116833,VIIV,,,,,M,Y,62.0,KG,20190701.0,,MD,DE,DE,EFAVIRENZ.,Anaemia;Anal cancer;Sleep disorder,164996081.0,OT,,,164996081.0,2.0,201411.0,,,,164996081.0,1.0,HIV infection
16507810,165078103,3,F,20020101.0,20190624.0,20190701,20220624,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2019GSK116835,VIIV,,,,,,Y,,,20220624.0,,MD,DE,DE,EFAVIRENZ;SUSTIVA,Aortic stenosis;Arthralgia;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078103.0,OT,,,165078103.0,1.0,199702.0,201510.0,,,165078103.0,1.0,HIV infection
16507857,165078573,3,F,20020101.0,20190624.0,20190701,20220713,EXP,,DE-GLAXOSMITHKLINE-DE2019GSK116835,GLAXOSMITHKLINE,,,,,,Y,,,20220713.0,,MD,DE,DE,EFAVIRENZ;SUSTIVA,Aortic stenosis;Arthralgia;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078573.0,HO,,,165078573.0,1.0,199702.0,201510.0,,,165078573.0,1.0,HIV infection
16514432,165144324,4,F,,20190720.0,20190702,20190803,EXP,,DK-AUROBINDO-AUR-APL-2019-037048,AUROBINDO,,,,,,Y,,,20190803.0,,MD,DK,DK,EFAVIRENZ.,Arthralgia;Atypical mycobacterial infection;Bursitis;Bursitis infective;Depression;Immune reconstitution inflammatory syndrome;Post-traumatic stress disorder;Scar,165144324.0,OT,,,,,,,,,165144324.0,1.0,HIV infection
16519280,165192801,1,I,,20190621.0,20190702,20190702,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-061353,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190702.0,,CN,US,US,SUSTIVA,Depression;Suicidal ideation,165192801.0,OT,,,165192801.0,1.0,1999.0,2010.0,,,165192801.0,1.0,HIV infection
16524746,165247461,1,I,20180219.0,20190619.0,20190703,20190703,EXP,,ZA-MYLANLABS-2019M1061790,MYLAN,,35.0,YR,,F,Y,,,20190703.0,,OT,ZA,ZA,EFAVIRENZ.,Haemoglobin decreased;Maternal exposure during pregnancy;Platelet count decreased;Ventricular extrasystoles;Vitamin B12 deficiency,165247461.0,HO,,,165247461.0,1.0,20180214.0,,,,165247461.0,1.0,HIV infection
16528627,165286273,3,F,,20191003.0,20190703,20191014,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019AMR119230,VIIV,,35.0,YR,,M,Y,,,20191014.0,,MD,BR,BR,EFAVIRENZ.,Blood creatine phosphokinase increased;Cardiovascular disorder;Chest pain;Electrocardiogram ST segment elevation;Myocarditis;Troponin I increased,165286273.0,OT,,,,,,,,,165286273.0,1.0,HIV infection
16528645,165286453,3,F,,20191003.0,20190703,20191014,EXP,,BR-GLAXOSMITHKLINE-BR2019AMR119230,GLAXOSMITHKLINE,,35.0,YR,,M,Y,,,20191014.0,,MD,BR,BR,EFAVIRENZ.,Blood creatine phosphokinase increased;Cardiovascular disorder;Chest pain;Electrocardiogram ST segment elevation;Myocarditis;Troponin I increased,165286453.0,OT,,,,,,,,,165286453.0,1.0,HIV infection
16531183,165311831,1,I,,20190701.0,20190704,20190704,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019119847,VIIV,,38.0,YR,,F,Y,,,20190704.0,,OT,IN,IN,EFAVIRENZ.,Virologic failure,165311831.0,OT,,,,,,,,,165311831.0,1.0,HIV infection
16531187,165311871,1,I,,20190701.0,20190704,20190704,EXP,,IN-GLAXOSMITHKLINE-IN2019119847,GLAXOSMITHKLINE,,38.0,YR,,F,Y,,,20190704.0,,OT,IN,IN,EFAVIRENZ.,Virologic failure,165311871.0,OT,,,,,,,,,165311871.0,1.0,HIV infection
16536330,165363301,1,I,,20190625.0,20190705,20190705,EXP,,US-CIPLA LTD.-2019US04767,CIPLA,"KARASINSKI A, RAZA A, AGGARWAL S. AN AILING KIDNEY WITH A CHANGE OF HAART AN INTERESTING CASE OF RAPIDLY PROGRESSIVE HIV ASSOCIATED IMMUNE COMPLEX KIDNEY DISEASE (HIVICK) AFTER A CHANGE IN HIV THERAPY. AMERICAN JOURNAL OF KIDNEY DISEASES. 2018;71(4):552 TO 553",,,,,Y,,,20190705.0,,OT,US,US,EFAVIRENZ.,Renal failure,165363301.0,OT,,,,,,,,,165363301.0,1.0,HIV infection
16536587,165365877,7,F,20050813.0,20220518.0,20190706,20220601,EXP,,FR-AUROBINDO-AUR-APL-2019-038824,AUROBINDO,,26.0,WK,,F,Y,1.96,KG,20220601.0,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Anencephaly;Arnold-Chiari malformation;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Foetal malformation;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,165365877.0,CA,,,165365877.0,1.0,20050704.0,20050908.0,109.0,DAY,165365877.0,1.0,HIV infection
16537810,165378101,1,I,,20190627.0,20190708,20190708,EXP,,IN-CIPLA LTD.-2019IN04816,CIPLA,"FAZAL F, GUPTA N, RAMU SK, NAYAN N, VIKRAM NK, RAY A.. HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION: TO TREAT OR NOT TO TREAT. PAN AFRICAN MEDICAL JOURNAL. 2019;32:105",,,,,Y,,,20190708.0,,OT,IN,IN,EFAVIRENZ.,Virologic failure,165378101.0,OT,,,,,,,,,165378101.0,1.0,HIV infection
16542961,165429616,6,F,,20230417.0,20190709,20230430,EXP,,CA-AUROBINDO-AUR-APL-2019-037761,AUROBINDO,,54.0,YR,,M,Y,,,20230429.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,165429616.0,HO,,,,,,,,,165429616.0,1.0,HIV infection
16543299,165432991,1,I,,20190626.0,20190709,20190709,EXP,,IT-MACLEODS PHARMACEUTICALS US LTD-MAC2019021963,MACLEODS,,,,,,Y,,,20190709.0,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Retroviral infection,165432991.0,OT,,,,,,,,,165432991.0,1.0,HIV infection
16549483,165494836,6,F,,20230417.0,20190710,20230430,EXP,,CA-AUROBINDO-AUR-APL-2019-037892,AUROBINDO,,54.0,YR,,M,Y,,,20230429.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,165494836.0,DE,,,,,,,,,165494836.0,1.0,HIV infection
16557080,165570801,1,I,,20190702.0,20190711,20190711,EXP,,CH-GLAXOSMITHKLINE-ZW2019GSK121329,GLAXOSMITHKLINE,"CHIMBETETE C, CHIRIMUTA L, PASCOE M, KEISER O.. A CASE REPORT OF UNTREATABLE HIV INFECTION IN HARARE, ZIMBABWE. S AFR J HIV MED. 2019;20(1):A885, DOI: HTTPS://DOI.ORG/ 10",17.0,YR,,F,Y,,,20190711.0,,MD,CH,ZW,EFAVIRENZ.,Drug resistance;Pathogen resistance;Pulmonary tuberculosis;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight decreased,165570801.0,OT,,,,,,,,,165570801.0,1.0,HIV infection
16557082,165570821,1,I,,20190703.0,20190711,20190711,EXP,,IN-GLAXOSMITHKLINE-IN2019GSK121369,GLAXOSMITHKLINE,,51.0,YR,,F,Y,,,20190711.0,,OT,BR,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood HIV RNA increased;Blood bilirubin increased;Central nervous system immune reconstitution inflammatory response;Central nervous system lesion;Cough;Disseminated tuberculosis;Drug-induced liver injury;Focal dyscognitive seizures;General physical health deterioration;Immune reconstitution inflammatory syndrome associated tuberculosis;Jaundice;Lymphadenopathy;Muscle abscess;Night sweats;Partial seizures;Portal vein occlusion;Pruritus generalised;Pulmonary tuberculosis;Pyrexia;Swelling;Tuberculoma of central nervous system;Weight decreased,165570821.0,OT,,,165570821.0,3.0,20180508.0,20180508.0,,,165570821.0,1.0,Antiretroviral therapy
16557088,165570881,1,I,,20190702.0,20190711,20190711,EXP,,CH-VIIV HEALTHCARE LIMITED-ZW2019GSK121329,VIIV,"CHIMBETETE C, CHIRIMUTA L, PASCOE M, KEISER O.. A CASE REPORT OF UNTREATABLE HIV INFECTION IN HARARE, ZIMBABWE. S AFR J HIV MED. 2019;20(1):A885, DOI: HTTPS://DOI.ORG/ 10",17.0,YR,,F,Y,,,20190711.0,,MD,CH,ZW,EFAVIRENZ.,Drug resistance;Pathogen resistance;Pulmonary tuberculosis;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight decreased,165570881.0,OT,,,,,,,,,165570881.0,1.0,HIV infection
16557089,165570891,1,I,,20190703.0,20190711,20190711,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019GSK121369,VIIV,,51.0,YR,,F,Y,,,20190711.0,,OT,BR,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood HIV RNA increased;Blood bilirubin increased;Central nervous system immune reconstitution inflammatory response;Central nervous system lesion;Cough;Disseminated tuberculosis;Drug-induced liver injury;Focal dyscognitive seizures;General physical health deterioration;Immune reconstitution inflammatory syndrome associated tuberculosis;Jaundice;Lymphadenopathy;Muscle abscess;Night sweats;Partial seizures;Portal vein occlusion;Pruritus generalised;Pulmonary tuberculosis;Pyrexia;Swelling;Tuberculoma of central nervous system;Weight decreased,165570891.0,OT,,,165570891.0,3.0,20180508.0,20180508.0,,,165570891.0,1.0,Antiretroviral therapy
16559676,165596761,1,I,200808.0,20190704.0,20190711,20190711,EXP,,DE-SA-2019SA182823,SANOFI AVENTIS,,44.0,YR,A,M,Y,,,20190711.0,,OT,DE,DE,EFAVIRENZ.,Acute hepatic failure;Drug resistance;Hepatic function abnormal;Hepatitis B,165596761.0,OT,,,165596761.0,1.0,200209.0,2008.0,,,165596761.0,1.0,Antiretroviral therapy
16567899,165678991,1,I,,20190709.0,20190712,20190712,EXP,,GB-MYLANLABS-2019M1064898,MYLAN,"AHMED N, FLAVELL S, FERNS B, FRAMPTON D, EDWARDS SG, MILLER RF ET AL.. DEVELOPMENT OF THE R263K MUTATION TO DOLUTEGRAVIR IN AN HIV-1 SUBTYPE D VIRUS HARBORING 3 CLASS- DRUG RESISTANCE. OFID. 2018;6 (1):329",22.0,YR,,F,Y,,,20190712.0,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,165678991.0,OT,,,,,,,,,165678991.0,1.0,HIV infection
16568054,165680541,1,I,2012.0,20190705.0,20190712,20190712,EXP,,AT-GLAXOSMITHKLINE-AT2019GSK123941,GLAXOSMITHKLINE,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,,,,M,Y,,,20190712.0,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,165680541.0,OT,,,165680541.0,1.0,20031107.0,20040423.0,,,165680541.0,1.0,Antiretroviral therapy
16568056,165680561,1,I,2012.0,20190705.0,20190712,20190712,EXP,,AT-VIIV HEALTHCARE LIMITED-AT2019GSK123941,VIIV,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,,,,M,Y,,,20190712.0,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,165680561.0,OT,,,165680561.0,1.0,20031107.0,20040423.0,,,165680561.0,1.0,Antiretroviral therapy
16572757,165727571,1,I,,20190703.0,20190715,20190715,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-066000,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,62.0,KG,20190715.0,,MD,DE,DE,EFAVIRENZ.,Anaemia;Anal cancer;Sleep disorder,165727571.0,OT,,,165727571.0,2.0,201411.0,,,,165727571.0,1.0,HIV infection
16576425,165764252,2,F,,20240103.0,20190716,20240111,EXP,,CA-AUROBINDO-AUR-APL-2019-010654,AUROBINDO,,46.0,YR,,M,Y,72.0,KG,20240111.0,,HP,CA,CA,EFAVIRENZ,Drug interaction;Drug level decreased;Transaminases increased,165764252.0,OT,,,,,,,,,165764252.0,1.0,HIV infection
16580930,165809307,7,F,,20200821.0,20190716,20220624,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019AMR117290,VIIV,,,,,,Y,,,20220624.0,,MD,BR,BR,EFAVIRENZ,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint effusion;Joint swelling;Malaise;Neuritis;Neurosyphilis;Oedema peripheral;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal deformity;White blood cell disorder;Wound secretion,165809307.0,HO,,,165809307.0,1.0,201902.0,,,,165809307.0,1.0,HIV infection
16580959,165809597,7,F,,20200821.0,20190716,20220628,EXP,,BR-GLAXOSMITHKLINE-BR2019AMR117290,GLAXOSMITHKLINE,,,,,,Y,,,20220628.0,,MD,BR,BR,EFAVIRENZ,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint effusion;Joint swelling;Malaise;Neuritis;Neurosyphilis;Oedema peripheral;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal deformity;White blood cell disorder;Wound secretion,165809597.0,OT,,,165809597.0,1.0,201902.0,,,,165809597.0,1.0,HIV infection
16583290,165832901,1,I,,20190702.0,20190717,20190717,EXP,,CA-AUROBINDO-AUR-APL-2019-039499,AUROBINDO,,,,,,Y,,,20190717.0,,OT,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,165832901.0,OT,,,,,,,,,165832901.0,1.0,HIV infection
16588924,165889241,1,I,,20190703.0,20190718,20190718,EXP,,DE-AUROBINDO-AUR-APL-2019-040974,AUROBINDO,,,,,,Y,,,20190718.0,,MD,DE,DE,EFAVIRENZ.,Anaemia;Anal cancer;Sleep disorder,165889241.0,OT,,,165889241.0,2.0,201411.0,,,,165889241.0,1.0,HIV infection
16589111,165891115,5,F,200801.0,20210623.0,20190718,20210630,EXP,,US-GILEAD-2019-0418470,GILEAD,,49.0,YR,A,M,Y,78.91,KG,20210630.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone density decreased;Bone loss;Economic problem;Emotional distress;Hydronephrosis;Nephrolithiasis;Osteoarthritis;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure,165891115.0,OT,,,165891115.0,1.0,2001.0,2011.0,,,165891115.0,1.0,HIV infection
16589219,165892191,1,I,,20190710.0,20190718,20190718,EXP,,IR-GLAXOSMITHKLINE-IR2019GSK126579,GLAXOSMITHKLINE,,,,A,M,Y,,,20190718.0,,OT,IR,IR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,165892191.0,OT,,,,,,,,,165892191.0,1.0,HIV infection
16589222,165892221,1,I,,20190710.0,20190718,20190718,EXP,,IR-VIIV HEALTHCARE LIMITED-IR2019GSK126579,VIIV,,,,A,M,Y,,,20190718.0,,OT,IR,IR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,165892221.0,OT,,,,,,,,,165892221.0,1.0,HIV infection
16590194,165901947,7,F,,20230123.0,20190718,20230203,EXP,,CA-TEVA-2018-CA-968075,TEVA,,44.0,YR,A,M,Y,,,20230202.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,165901947.0,HO,,,,,,,,,165901947.0,1.0,HIV infection
16593072,165930723,3,F,,20190912.0,20190718,20190916,EXP,,CA-TEVA-2019-CA-1079149,TEVA,,,,,M,Y,,,20190916.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165930723.0,OT,,,,,,,,,165930723.0,1.0,HIV infection
16594484,165944841,1,I,,20190711.0,20190718,20190718,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK130506,GLAXOSMITHKLINE,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",36.0,YR,,F,Y,,,20190718.0,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165944841.0,HO,,,,,,,,,165944841.0,1.0,HIV infection
16594488,165944881,1,I,,20190711.0,20190718,20190718,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK130506,VIIV,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",36.0,YR,,F,Y,,,20190718.0,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165944881.0,OT,,,,,,,,,165944881.0,1.0,HIV infection
16596270,165962703,3,F,20120805.0,20200918.0,20190719,20200928,EXP,,US-GILEAD-2019-0418471,GILEAD,,42.0,YR,A,M,Y,79.37,KG,20200928.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Nephrolithiasis;Pain;Proteinuria;Renal failure,165962703.0,OT,,,165962703.0,1.0,2010.0,2019.0,,,165962703.0,1.0,HIV infection
16596947,165969471,1,I,,20190711.0,20190719,20190719,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK130512,GLAXOSMITHKLINE,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",37.0,YR,,F,Y,,,20190719.0,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165969471.0,OT,,,,,,,,,165969471.0,1.0,HIV infection
16596948,165969481,1,I,,20190711.0,20190719,20190719,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK130512,VIIV,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",37.0,YR,,F,Y,,,20190719.0,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165969481.0,OT,,,,,,,,,165969481.0,1.0,HIV infection
16597483,165974838,8,F,20080101.0,20230621.0,20190719,20230626,PER,,US-GILEAD-2019-0418455,GILEAD,,52.0,YR,A,M,Y,,,20230626.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Back pain;Bone density decreased;Bone loss;Cervical radiculopathy;Cervical spinal stenosis;Depression;Drug ineffective;Economic problem;Emotional distress;Hip fracture;Intervertebral disc degeneration;Intervertebral disc operation;Mobility decreased;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporotic fracture;Pain;Pathological fracture;Sacroiliac joint dysfunction;Spinal column injury;Spinal osteoarthritis;Spinal stenosis;Tooth fracture,165974838.0,OT,,,165974838.0,1.0,2004.0,2013.0,1706.0,DAY,165974838.0,1.0,HIV infection
16598661,165986611,1,I,,20190709.0,20190719,20190719,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-068791,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20190719.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165986611.0,OT,,,,,,,,,165986611.0,1.0,HIV infection
16599716,165997161,1,I,,20190711.0,20190719,20190719,EXP,,CA-TEVA-2019-CA-1078848,TEVA,,44.0,YR,,M,Y,,,20190719.0,,OT,CA,CA,SUSTIVA,Anxiety,165997161.0,HO,,,,,,,,,165997161.0,1.0,HIV infection
16608959,166089596,6,F,2009.0,20200904.0,20190722,20200925,EXP,,US-GILEAD-2019-0419331,GILEAD,,,,A,M,Y,97.51,KG,20200925.0,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Bone density decreased;Bone loss;Coma;Dental caries;Depression;Emotional distress;Fracture;Gastric disorder;Glomerular filtration rate abnormal;Illness;Oesophageal disorder;Osteonecrosis;Osteoporosis;Pain;Protein total abnormal;Renal disorder;Tooth loss,166089596.0,OT,,,166089596.0,1.0,2009.0,2019.0,,,166089596.0,1.0,HIV infection
16618592,166185921,1,I,,20190718.0,20190723,20190723,EXP,,PT-MYLANLABS-2019M1069126,MYLAN,,59.0,YR,,M,Y,,,20190723.0,,MD,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,166185921.0,DE,,,,,,,,,166185921.0,1.0,HIV test positive
16622566,166225664,4,F,,20210105.0,20190723,20210118,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-069006,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210118.0,,CN,CA,CA,SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,166225664.0,OT,,,,,,,,,166225664.0,1.0,HIV infection
16623707,166237078,8,F,20120615.0,20240930.0,20190724,20241003,EXP,,US-GILEAD-2019-0419555,GILEAD,,56.0,YR,A,M,Y,57.2,KG,20241003.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Condition aggravated;Economic problem;Emotional distress;Glomerulonephritis;Haematuria;Intervertebral disc degeneration;Neck pain;Nephropathy;Orthostatic hypotension;Osteoarthritis;Osteopenia;Pain;Pain in extremity;Proteinuria;Renal cyst;Renal failure;Scoliosis;Spinal disorder;Spinal pain,166237078.0,OT,,,166237078.0,1.0,2006.0,2018.0,2188.0,DAY,166237078.0,1.0,HIV infection
16633800,166338001,1,I,,20130212.0,20190725,20190725,EXP,,DK-GILEAD-2013-0069943,GILEAD,"LETH S, JENSEN-FANGEL S.. INFRAPATELLAR BURSITIS WITH MYCOBACTERIUM MALMOENSE RELATED TO IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV-POSITIVE PATIENT. BMJ CASE REPORTS. 2012;10.1136:1-4. DOI:10.1136/BCR-2012-007459",39.0,YR,A,M,Y,,,20190725.0,,MD,DK,DK,EFAVIRENZ.,Arthralgia;Atypical mycobacterial infection;Bursitis;Bursitis infective;Immune reconstitution inflammatory syndrome;Scar,166338001.0,OT,,,,,,,,,166338001.0,1.0,HIV infection
16634649,166346493,3,F,20181001.0,20200903.0,20190726,20200914,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022219,MACLEODS,,,,,,Y,,,20200914.0,,HP,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,166346493.0,OT,,,,,,,,,166346493.0,1.0,HIV infection
16636329,166363291,1,I,20050813.0,20190715.0,20190726,20190726,EXP,,FR-PRINSTON PHARMACEUTICAL INC.-2019PRN00704,PRINSTON PHARMACEUTICAL,,25.0,YR,,F,Y,,,20190725.0,,CN,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ.,Brain herniation;Exposure during pregnancy;Spina bifida,166363291.0,CA,,,166363291.0,1.0,20050704.0,20050908.0,,,166363291.0,1.0,HIV infection
16647369,166473695,5,F,20160425.0,20220224.0,20190730,20220301,EXP,,US-GILEAD-2019-0420236,GILEAD,,51.0,YR,A,M,Y,95.238,KG,20220301.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Dysuria;Economic problem;Emotional distress;End stage renal disease;Fatigue;Nephrolithiasis;Osteonecrosis;Pain;Renal failure;Tooth loss,166473695.0,OT,,,166473695.0,1.0,200608.0,201608.0,,,166473695.0,1.0,HIV infection
16649549,166495492,2,F,2012.0,20200212.0,20190730,20200219,EXP,,"AT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-002333",BOEHRINGER INGELHEIM,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,69.0,YR,,M,Y,90.0,KG,20200219.0,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166495492.0,OT,,,166495492.0,1.0,20120419.0,20121203.0,,,166495492.0,1.0,Antiretroviral therapy
16652764,166527641,1,I,,20190716.0,20190731,20190731,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-04388,HIKMA,"MANION M, ULDRICK T, POLIZZOTTO M, SHEIKH V, ROBY G, LURAIN K, METZGER D, MICAN J, PAU A, LISCO A, LAIDLAW E, HAMMOUD D, WHITBY D, YARCHOAN R, SERETI I. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN FORUM INFECTED DISEASE; DI: 10.1093/OFID/OFY217. 2018;5(10):.",30.0,YR,,F,Y,,,20190731.0,,MD,US,US,EFAVIRENZ.,Castleman's disease;Kaposi's sarcoma,166527641.0,OT,,,,,,,,,166527641.0,1.0,Immune reconstitution inflammatory syndrome associated tuberculosis
16653423,166534237,7,F,20130101.0,20240206.0,20190731,20240207,EXP,,US-GILEAD-2019-0420315,GILEAD,,,,A,M,Y,89.796,KG,20240207.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Depression;Economic problem;Emotional distress;Mobility decreased;Multiple fractures;Osteonecrosis;Osteoporosis;Pain;Patella fracture;Tooth loss,166534237.0,OT,,,166534237.0,1.0,20080715.0,20190215.0,127.0,MON,166534237.0,1.0,HIV infection
16653524,166535244,4,F,201611.0,20210622.0,20190731,20210625,EXP,,US-GILEAD-2019-0420287,GILEAD,,60.0,YR,A,M,Y,72.56,KG,20210625.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Diabetic nephropathy;Economic problem;Emotional distress;End stage renal disease;Focal segmental glomerulosclerosis;Glomerulosclerosis;Intercapillary glomerulosclerosis;Kidney fibrosis;Pain;Renal arteriosclerosis;Renal failure,166535244.0,OT,,,166535244.0,1.0,200812.0,201511.0,,,166535244.0,1.0,HIV infection
16654245,166542455,5,F,2010.0,20201019.0,20190731,20201028,EXP,,US-GILEAD-2019-0420395,GILEAD,,38.0,YR,A,M,Y,70.3,KG,20201028.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Osteopenia;Osteoporotic fracture;Pain;Renal failure,166542455.0,OT,,,166542455.0,1.0,200205.0,201206.0,,,166542455.0,1.0,HIV infection
16662141,166621418,8,F,2012.0,20200818.0,20190802,20200821,EXP,,PHHY2019AT170861,NOVARTIS,SCHALK H. DUALE ART IM NEBENWIRKUNGSMANAGEMENT. JATROS INFEKTIOLOGIE AND GASTROENTEROLOGIE?HEPATOLOGIE. 2019?2:22,69.0,YR,,M,Y,90.0,KG,20200821.0,,HP,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166621418.0,OT,,,166621418.0,1.0,20031107.0,20040423.0,,,166621418.0,1.0,Antiretroviral therapy
16663985,166639852,2,F,,20220614.0,20190802,20220623,EXP,,IT-MYLANLABS-2019M1032806,MYLAN,"Cattaneo D, Giacomelli A, Gervasoni C.. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution. Obesity. 2018;26(8):1251-2",39.0,YR,,F,Y,,,20220623.0,,MD,IT,IT,EFAVIRENZ,Drug interaction;Virologic failure,166639852.0,OT,,,,,,,,,166639852.0,1.0,HIV infection
16666980,166669804,4,F,200501.0,20210129.0,20190805,20210517,EXP,,US-GILEAD-2019-0421690,GILEAD,,40.0,YR,A,M,Y,83.9,KG,20210517.0,,LW,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Appetite disorder;Asthenia;Back pain;Chronic kidney disease;Depression;Diarrhoea;Economic problem;Emotional distress;Night sweats;Pain;Pollakiuria;Rhinorrhoea;Weight decreased,166669804.0,OT,,,166669804.0,1.0,200601.0,201001.0,,,166669804.0,1.0,HIV infection
16669370,166693701,1,I,20150806.0,20190801.0,20190805,20190805,EXP,,ZA-GILEAD-2019-0421790,GILEAD,"ROSSOUW TM, VAN DYK G, VAN ZYL G. RAPID EMERGENCE OF RESISTANCE TO ANTIRETROVIRAL TREATMENT AFTER UNDISCLOSED PRIOR EXPOSURE: A CASE REPORT. S AFR J HIV MED. 2019;20(1):A965. DOI:10.4102/SAJHIVMED.V20I1.965",43.0,YR,A,F,Y,,,20190805.0,,OT,ZA,ZA,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,166693701.0,OT,,,166693701.0,1.0,20140806.0,,,,166693701.0,1.0,HIV infection
16671350,166713504,4,F,2012.0,20200224.0,20190806,20200304,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-073480,BRISTOL MYERS SQUIBB,SCHALK WH. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019;2:22,69.0,YR,,M,Y,90.0,KG,20200304.0,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166713504.0,OT,,,166713504.0,1.0,20040423.0,20140606.0,,,166713504.0,1.0,Antiretroviral therapy
16672048,166720485,5,F,20120420.0,20200924.0,20190806,20200928,EXP,,US-GILEAD-2019-0421735,GILEAD,,53.0,YR,A,M,Y,70.3,KG,20200928.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Osteoporosis;Pain;Tooth loss,166720485.0,OT,,,166720485.0,1.0,20080826.0,20080831.0,,,166720485.0,1.0,HIV infection
16674551,166745514,4,F,,20200115.0,20190806,20200211,EXP,,AT-VIIV HEALTHCARE LIMITED-AT2019139261,VIIV,,39.0,YR,,F,Y,,,20200211.0,,HP,AT,AT,EFAVIRENZ.,Acute stress disorder;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,166745514.0,HO,,,,,,,,,166745514.0,1.0,Antiretroviral therapy
16674552,166745524,4,F,,20200115.0,20190806,20200211,EXP,,AT-GLAXOSMITHKLINE-AT2019139261,GLAXOSMITHKLINE,,39.0,YR,,F,Y,,,20200211.0,,HP,AT,AT,EFAVIRENZ.,Acute stress disorder;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,166745524.0,HO,,,,,,,,,166745524.0,1.0,Antiretroviral therapy
16676274,166762742,2,F,201701.0,20200401.0,20190807,20200416,EXP,,US-GILEAD-2019-0421714,GILEAD,,55.0,YR,A,M,Y,,,20200416.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Pain;Tooth loss,166762742.0,OT,,,166762742.0,1.0,20090622.0,20180103.0,,,166762742.0,1.0,HIV infection
16676304,166763044,4,F,20080101.0,20220225.0,20190807,20220302,EXP,,US-GILEAD-2019-0421721,GILEAD,,46.0,YR,A,M,Y,81.633,KG,20220302.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Depression;Economic problem;Emotional distress;Loss of personal independence in daily activities;Osteonecrosis;Osteoporosis;Pain;Renal failure;Sleep terror;Tooth loss;Upper limb fracture,166763044.0,OT,,,166763044.0,1.0,200912.0,201907.0,,,166763044.0,1.0,HIV infection
16677491,166774911,1,I,,20190724.0,20190807,20190807,EXP,,IT-AUROBINDO-AUR-APL-2019-046191,AUROBINDO,,,,,,Y,,,20190807.0,,OT,IT,IT,Efavirenz Film Coated Tablets,Blood HIV RNA increased,166774911.0,OT,,,,,,,,,166774911.0,1.0,HIV infection
16678638,166786386,6,F,20150101.0,20211130.0,20190807,20211209,EXP,,US-GILEAD-2019-0421720,GILEAD,,59.0,YR,A,F,Y,63.5,KG,20211209.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,166786386.0,HO,,,166786386.0,1.0,20100506.0,20160606.0,73.0,MON,166786386.0,1.0,HIV infection
16700440,167004401,1,I,,20190805.0,20190814,20190814,EXP,,ZA-CIPLA LTD.-2019ZA05705,CIPLA,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM.. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA - A RETROSPECTIVE CASE SERIES. FRONTIERS IN NEUROLOGY. 2019;10 (742):1 TO 10",,,,,Y,,,20190814.0,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Disturbance in attention,167004401.0,OT,,,,,,,,,167004401.0,1.0,HIV infection
16702813,167028131,1,I,,20190808.0,20190814,20190814,EXP,,TH-MYLANLABS-2019M1076139,MYLAN,,27.0,YR,,M,Y,,,20190814.0,,OT,TH,TH,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Penicillium infection;Unmasking of previously unidentified disease,167028131.0,HO,,,,,,,,,167028131.0,1.0,Acquired immunodeficiency syndrome
16704866,167048661,1,I,,20190812.0,20190814,20190814,EXP,,US-GILEAD-2019-0423564,GILEAD,N. MAOUELAININ; J. ILUSTRE; R. PROMISLOFF. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PCP PNEUMONIA + ACUTE RESPIRATORY FAILURE. AM J RESPIR CRIT CARE MED. 2019;UNK:UNK,41.0,YR,A,M,Y,,,20190814.0,,MD,US,US,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,167048661.0,OT,,,,,,,,,167048661.0,1.0,HIV infection
16705848,167058481,1,I,2009.0,20190802.0,20190815,20190815,EXP,,MX-GILEAD-2019-0423594,GILEAD,,56.0,YR,A,F,Y,,,20190815.0,,OT,MX,MX,EFAVIRENZ.,Chronic kidney disease;Fanconi syndrome acquired;Renal failure,167058481.0,OT,,,167058481.0,1.0,2009.0,2013.0,,,167058481.0,1.0,HIV infection
16705908,167059082,2,F,2003.0,20190807.0,20190815,20190918,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019GSK146156,VIIV,,12.0,YR,,F,Y,,,20190918.0,,OT,BR,BR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Papilloma viral infection,167059082.0,OT,,,,,,,,,167059082.0,1.0,HIV infection CDC category A
16705911,167059112,2,F,2003.0,20190807.0,20190815,20190918,EXP,,BR-GLAXOSMITHKLINE-BR2019GSK146156,GLAXOSMITHKLINE,,12.0,YR,,F,Y,,,20190918.0,,OT,BR,BR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Papilloma viral infection,167059112.0,OT,,,,,,,,,167059112.0,1.0,HIV infection CDC category A
16707501,167075011,1,I,,20190802.0,20190815,20190815,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-077618,BRISTOL MYERS SQUIBB,,64.0,YR,,M,Y,,,20190815.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,167075011.0,OT,,,167075011.0,1.0,201906.0,,,,167075011.0,1.0,HIV infection
16708256,167082561,1,I,,20190802.0,20190816,20190816,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-077453,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,,,20190816.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,167082561.0,OT,,,167082561.0,1.0,201809.0,,,,167082561.0,1.0,HIV infection
16708486,167084861,1,I,2008.0,20190805.0,20190816,20190816,EXP,,ZA-CIPLA LTD.-2019ZA05699,CIPLA,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA- A RETROSPECTIVE CASE SERIES. FRONTIERS IN NEUROLOGY. 2019;10 (742):1 TO 10",,,,,Y,,,20190816.0,,OT,ZA,ZA,EFAVIRENZ.,Disturbance in attention;Generalised tonic-clonic seizure;Insomnia,167084861.0,OT,,,,,,,,,167084861.0,1.0,HIV infection
16708732,167087321,1,I,,20190805.0,20190816,20190816,EXP,,ZA-CIPLA LTD.-2019ZA05700,CIPLA,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA- A RETROSPECTIVE CASE SERIES. FRONTIERS IN NEUROLOGY. 2019;10 (742):1 TO 10",,,,,Y,,,20190816.0,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Disturbance in attention;Fine motor delay;Generalised tonic-clonic seizure;Speech disorder,167087321.0,OT,,,,,,,,,167087321.0,1.0,HIV infection
16709578,167095781,1,I,201707.0,20190808.0,20190816,20190816,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK146309,VIIV,"ZHU K, ZHU Z, ZHU X, WANG Y.. ANALYSIS OF RELATED FACTORS OF SEVERE MYELOSUPPRESSION IN 3 PATIENTS WITH AIDS RELATED LYMPHOMA AFTER CHEMOTHERAPY. CLINICAL MEDICINE PRACTICE. 2019;28 (2):91-96, DOI:10.16047/J.CNKI.CN1",34.0,YR,,M,Y,,,20190816.0,,OT,CN,CN,EFAVIRENZ.,Anaemia;Bone marrow failure;Drug interaction;Granulocytosis;Haemoglobin decreased;Neutropenia;Pulmonary mycosis;Pyrexia,167095781.0,OT,,,167095781.0,2.0,20170615.0,,,,167095781.0,1.0,Acquired immunodeficiency syndrome
16711062,167110621,1,I,,20190808.0,20190816,20190816,EXP,,CA-TEVA-2019-CA-1091619,TEVA,,52.0,YR,,M,Y,,,20190816.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,167110621.0,OT,,,,,,,,,167110621.0,1.0,HIV infection
16713049,167130491,1,I,,20190803.0,20190817,20190817,EXP,,GB-AUROBINDO-AUR-APL-2019-054693,AUROBINDO,,,,,,Y,,,20190817.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,167130491.0,OT,,,167130491.0,1.0,201906.0,,,,167130491.0,1.0,HIV infection
16724673,167246731,1,I,,20190813.0,20190821,20190821,EXP,,CA-MYLANLABS-2019M1077398,MYLAN,"TSENG AL, WONG AYJ, MCLELLAND CJ, WALMSLEY SL. DRUG INTERACTIONS ARE NOT ALWAYS PREDICTABLE: THE CURIOUS CASE OF VALPROIC ACID AND DOLUTEGRAVIR AND A POSSIBLE EXPLANATION. AIDS 2019;33(10):1677-1679.",43.0,YR,,F,Y,,,20190821.0,,PH,CA,CA,EFAVIRENZ.,Anticonvulsant drug level below therapeutic;Antiviral drug level below therapeutic;Drug interaction,167246731.0,OT,,,167246731.0,1.0,2016.0,2018.0,,,167246731.0,1.0,HIV infection
16728652,167286521,1,I,,20190808.0,20190822,20190822,EXP,,CA-AUROBINDO-AUR-APL-2019-054273,AUROBINDO,,,,,,Y,,,20190822.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,167286521.0,OT,,,,,,,,,167286521.0,1.0,HIV infection
16734522,167345221,1,I,,20190809.0,20190823,20190823,EXP,,CA-AUROBINDO-AUR-APL-2019-055314,AUROBINDO,,,,,,Y,,,20190823.0,,PH,CA,CA,EFAVIRENZ.,Hip fracture;Osteopenia;Osteoporosis;Spinal compression fracture,167345221.0,OT,,,,,,,,,167345221.0,1.0,HIV infection
16736725,167367251,1,I,,20190812.0,20190823,20190823,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-082814,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190823.0,,OT,ZA,ZA,EFAVIRENZ.,Neurotoxicity,167367251.0,OT,,,,,,,,,167367251.0,1.0,HIV infection
16736844,167368441,1,I,,20190812.0,20190823,20190823,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-081257,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190823.0,,OT,ZA,ZA,EFAVIRENZ.,Accidental overdose;Neurotoxicity,167368441.0,OT,,,,,,,,,167368441.0,1.0,HIV infection
16737441,167374412,2,F,,20191002.0,20190823,20191004,EXP,,TH-GILEAD-2019-0424899,GILEAD,"LIEGEON G, HARRISON L, NECHBA A, HALUE G, BANCHONGKIT S, NILMANAT A, YUTTHAKASEMSUNT N, PATHIPVANICH P, THONGPAEN S, LERTKOONALAK R, ALTHAUS T, LALLEMANT M, MARY JY, JOURDAIN G. LONG TERM RENAL FUNCTION IN ASIAN HIV-1 INFECTED ADULTS RECEIVING TENOFOVIR DISOPROXIL FUMARATE WITHOUT PROTEASE INHIBITORS. J. INFECT.. 2019;UNK:UNK. DOI:10.1016/J.JINF.2019.08.006",36.0,YR,A,M,Y,53.0,KG,20191004.0,,MD,TH,TH,EFAVIRENZ.,Death,167374412.0,DE,,,,,,,,,167374412.0,1.0,HIV infection
16737448,167374482,2,F,,20191002.0,20190823,20191004,EXP,,TH-GILEAD-2019-0424305,GILEAD,"LIEGEON G, HARRISON L, NECHBA A, HALUE G, BANCHONGKIT S, NILMANAT A, YUTTHAKASEMSUNT N, PATHIPVANICH P, THONGPAEN S, LERTKOONALAK R, ALTHAUS T, LALLEMANT M, MARY JY, JOURDAIN G. LONG TERM RENAL FUNCTION IN ASIAN HIV-1 INFECTED ADULTS RECEIVING TENOFOVIR DISOPROXIL FUMARATE WITHOUT PROTEASE INHIBITORS. J. INFECT.. 2019;UNK:UNK. DOI:10.1016/J.JINF.2019.08.006",44.0,YR,A,M,Y,52.0,KG,20191004.0,,MD,TH,TH,EFAVIRENZ.,Death,167374482.0,DE,,,,,,,,,167374482.0,1.0,HIV infection
16737882,167378823,3,F,,20191002.0,20190824,20191017,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004747,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20191017.0,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,167378823.0,OT,,,,,,,,,167378823.0,1.0,HIV infection
16741532,167415325,5,F,,20221011.0,20190826,20221014,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080379,BRISTOL MYERS SQUIBB,,52.0,YR,A,M,Y,,,20221014.0,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,167415325.0,CA,,,,,,,,,167415325.0,1.0,HIV infection
16745875,167458753,3,F,,20210517.0,20190827,20210524,EXP,PT-EMA-DD-20181218-KUMARVN_P-173122,PT-MYLANLABS-2019M1079394,MYLAN,"RAPOSO AF, ANTUNES AP, STRECHT T, ALVES SC, OLIVEIRA C, GUIMARAES M, ET AL... PHARMACOLOGICAL COMPLEXITY IN HIV?INFECTED PATIENTS. 23RD NATIONAL INTERNAL MEDICINE CONGRESS. 2017?23:1",49.0,YR,,M,Y,,,20210524.0,,HP,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,167458753.0,OT,,,,,,,,,167458753.0,1.0,HIV infection
16748110,167481101,1,I,2016.0,20190826.0,20190827,20190827,EXP,FR-AFSSAPS-RN20191169,FR-GILEAD-2019-0425401,GILEAD,,68.0,YR,E,M,Y,82.0,KG,20190827.0,,CN,FR,FR,SUSTIVA,Ageusia;Anosmia;Renal failure,167481101.0,OT,,,167481101.0,1.0,20160201.0,,,,167481101.0,1.0,HIV test positive
16749585,167495851,1,I,,20190826.0,20190828,20190828,EXP,,IN-GILEAD-2019-0425464,GILEAD,"CHHABRA M, DAVER RG. MULTIDRUG REGIMEN FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE MOTHERS IN INDIA FROM PREVENTION TOWARD ELIMINATION. UNK. 2019;11:50-57",,,,F,Y,,,20190828.0,,MD,IN,IN,EFAVIRENZ.,Nephritis,167495851.0,OT,,,,,,,,,167495851.0,1.0,HIV infection
16754843,167548431,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081032,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,M,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Accidental overdose;Ataxia;Cognitive disorder;Dysarthria;Generalised tonic-clonic seizure;Incorrect dose administered;Neuropsychiatric symptoms;Somnolence;Toxicity to various agents,167548431.0,OT,,,,,,,,,167548431.0,1.0,HIV infection
16754990,167549901,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081042,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167549901.0,OT,,,,,,,,,167549901.0,1.0,HIV infection
16754992,167549921,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081033,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167549921.0,OT,,,,,,,,,167549921.0,1.0,HIV infection
16754994,167549941,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081037,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167549941.0,OT,,,,,,,,,167549941.0,1.0,HIV infection
16754995,167549951,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081046,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Condition aggravated;Growth retardation;HIV-associated neurocognitive disorder,167549951.0,OT,,,,,,,,,167549951.0,1.0,HIV infection
16754998,167549981,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081040,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Condition aggravated;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder,167549981.0,OT,,,,,,,,,167549981.0,1.0,HIV infection
16755095,167550951,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081048,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder;Microcephaly,167550951.0,OT,,,,,,,,,167550951.0,1.0,HIV infection
16755096,167550961,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081050,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder,167550961.0,OT,,,,,,,,,167550961.0,1.0,HIV infection
16755097,167550971,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081047,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167550971.0,OT,,,,,,,,,167550971.0,1.0,HIV infection
16755098,167550981,1,I,,20190822.0,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081052,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829.0,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;Growth retardation;HIV-associated neurocognitive disorder,167550981.0,OT,,,,,,,,,167550981.0,1.0,HIV infection
16758574,167585744,4,F,20130101.0,20230506.0,20190830,20230516,EXP,,US-GILEAD-2019-0425696,GILEAD,,55.0,YR,A,M,Y,,,20230516.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Blood creatinine increased;Bone loss;Chronic kidney disease;Dental caries;Economic problem;Emotional distress;Oral disorder;Osteoporotic fracture;Pain,167585744.0,OT,,,167585744.0,1.0,20060615.0,2019.0,3294.0,DAY,167585744.0,1.0,HIV infection
16761858,167618584,4,F,20121001.0,20230929.0,20190830,20231003,EXP,,US-GILEAD-2019-0425666,GILEAD,,48.0,YR,A,M,Y,121.09,KG,20231003.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Multiple injuries;Pain;Pain in extremity;Renal failure;Tooth fracture;Tooth loss,167618584.0,OT,,,167618584.0,1.0,2002.0,201202.0,,,167618584.0,1.0,HIV infection
16762184,167621841,1,I,,20190819.0,20190831,20190831,EXP,,TH-HETERO-HET2019TH01170,HETERO,"PONGPECH N, ROTJANAPAN P. ABSENCE OF CUTANEOUS INVOLVEMENT IN DISSEMINATED TALAROMYCES MARNEFFEI INFECTION IN AN AIDS PATIENT: A CASE REPORT AND LITERATURE REVIEW. INFECT-DRUG-RESIST. 2019;12:1493-1499",27.0,YR,,M,Y,,,20190831.0,,OT,TH,TH,EFAVIRENZ.,Fungal infection;Immune reconstitution inflammatory syndrome,167621841.0,OT,,,,,,,,,167621841.0,1.0,Acquired immunodeficiency syndrome
16764331,167643311,1,I,,20190823.0,20190902,20190902,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019GSK157091,VIIV,"STEEGEN K, VAN ZYL G, LETSOALO E, CLAASSEN M, HANS L, CARMONA S.. RESISTANCE IN PATIENTS FAILING INTEGRASE STRAND TRANSFER INHIBITORS: A CALL TO REPLACE RALTEGRAVIR WITH DOLUTEGRAVIR IN THIRD-LINE TREATMENT IN SOUTH AFRICA. OPEN FORUM INFECTIOUS DISEASES. 2019;DOI: HTTPS://DOI.ORG/10.1093/O",57.0,YR,,,Y,,,20190902.0,,MD,ZA,ZA,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Viral mutation identified;Virologic failure,167643311.0,OT,,,,,,,,,167643311.0,1.0,HIV infection
16765373,167653735,5,F,20150829.0,20210924.0,20190903,20210929,EXP,,US-GILEAD-2019-0425747,GILEAD,,41.0,YR,A,M,Y,99.79,KG,20210929.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chest pain;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Headache;Loss of personal independence in daily activities;Pain,167653735.0,OT,,,167653735.0,1.0,2012.0,2017.0,,,167653735.0,1.0,HIV infection
16765537,167655377,7,F,20131026.0,20210608.0,20190903,20210611,EXP,,US-GILEAD-2019-0425749,GILEAD,,51.0,YR,A,M,Y,74.39,KG,20210611.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Hand fracture;Osteopenia;Pain;Tooth loss,167655377.0,OT,,,167655377.0,1.0,2014.0,2019.0,,,167655377.0,1.0,HIV infection
16770969,167709691,1,I,2016.0,20190823.0,20190904,20190904,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-083948,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,82.0,KG,20190904.0,,CN,FR,FR,SUSTIVA,Ageusia;Anosmia;Renal failure,167709691.0,OT,,,167709691.0,1.0,2016.0,,,,167709691.0,1.0,HIV test positive
16773759,167737591,1,I,,20190828.0,20190904,20190904,EXP,,PHHY2019IN200997,SANDOZ,,51.0,YR,,F,Y,,,20190905.0,,OT,BR,IN,EFAVIRENZ.,Abdominal pain;Central nervous system immune reconstitution inflammatory response;Hepatic congestion;Hepatotoxicity;Jaundice;Lymphadenopathy;Pruritus generalised;Pyrexia;Seizure;Tuberculoma of central nervous system,167737591.0,OT,,,167737591.0,2.0,20100508.0,20101206.0,,,167737591.0,1.0,HIV infection
16774553,167745535,5,F,2018.0,20210601.0,20190905,20210603,EXP,,US-GILEAD-2019-0425688,GILEAD,,53.0,YR,A,M,Y,73.47,KG,20210603.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Multiple injuries;Pain;Panic attack,167745535.0,OT,,,167745535.0,1.0,2011.0,201803.0,,,167745535.0,1.0,HIV infection
16774600,167746004,4,F,20180209.0,20210528.0,20190905,20210601,EXP,,US-GILEAD-2019-0425686,GILEAD,,54.0,YR,A,M,Y,72.56,KG,20210601.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Hip fracture;Multiple injuries;Osteoporosis;Pain;Upper limb fracture,167746004.0,OT,,,167746004.0,1.0,201807.0,201901.0,,,167746004.0,1.0,HIV infection
16778673,167786731,1,I,,20190822.0,20190906,20190906,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086418,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20190906.0,,MD,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,167786731.0,OT,,,,,,,,,167786731.0,1.0,HIV infection
16779164,167791646,6,F,201404.0,20210319.0,20190906,20210323,EXP,,US-GILEAD-2019-0426574,GILEAD,,47.0,YR,A,M,Y,108.0,KG,20210323.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Multiple fractures;Osteonecrosis;Pain;Renal failure,167791646.0,OT,,,167791646.0,1.0,200301.0,201404.0,,,167791646.0,1.0,HIV infection
16779436,167794363,3,F,20151012.0,20200520.0,20190906,20200814,EXP,,US-GILEAD-2019-0426527,GILEAD,,53.0,YR,A,F,Y,,,20200814.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Osteonecrosis;Pain;Tooth loss,167794363.0,OT,,,167794363.0,1.0,201505.0,201805.0,,,167794363.0,1.0,HIV infection
16785413,167854135,5,F,,20231122.0,20190909,20231129,EXP,,AT-ROCHE-2394721,ROCHE,"Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R et al. Raltegravir in Pregnancy: A Case Series Presentation.. International Journal Of Std And Aids. 2011;22 (6):350-60.",39.0,YR,,F,Y,,,20231129.0,,HP,AT,AT,EFAVIRENZ,Acute stress disorder;Maternal exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,167854135.0,HO,,,,,,,,,167854135.0,1.0,HIV infection
16785564,167855643,3,F,2013.0,20200615.0,20190909,20200831,EXP,,US-GILEAD-2019-0426593,GILEAD,,44.0,YR,A,F,Y,108.84,KG,20200831.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Osteoporosis;Pain,167855643.0,OT,,,167855643.0,1.0,2005.0,2006.0,,,167855643.0,1.0,HIV infection
16789078,1678907810,10,F,20150518.0,20210323.0,20190910,20210329,EXP,,US-GILEAD-2019-0426612,GILEAD,,48.0,YR,A,M,Y,123.36,KG,20210329.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Osteopenia;Osteoporosis;Pain;Renal failure,1678907810.0,OT,,,1678907810.0,1.0,2012.0,2019.0,,,1678907810.0,1.0,HIV infection
16795810,167958102,2,F,201510.0,20190910.0,20190911,20190917,EXP,,CH-GILEAD-2019-0427660,GILEAD,,53.0,YR,A,M,Y,,,20190917.0,,OT,CH,CH,EFAVIRENZ.,Hepatic cirrhosis;Hepatitis B;Hepatitis D;Hepatocellular injury;Liver transplant,167958102.0,OT,,,,,,,,,167958102.0,1.0,HIV infection
16795975,167959753,3,F,1996.0,20200327.0,20190911,20200401,EXP,,"ES-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-100655",BOEHRINGER INGELHEIM,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT. CLINICAL DRUG INVESTIGATION. 2019;39:1125-31. DOI:L 0.1007/S40261 -019-00829-X",38.0,YR,,M,Y,,,20200402.0,,HP,ES,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,167959753.0,OT,,,167959753.0,1.0,2001.0,2002.0,,,167959753.0,1.0,Antiretroviral therapy
16800956,168009564,4,F,1996.0,20200529.0,20190912,20200602,EXP,,PHHY2019ES207545,NOVARTIS,,38.0,YR,,M,Y,,,20200602.0,,HP,ES,ES,EFAVIRENZ.,Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,168009564.0,OT,,,168009564.0,11.0,2001.0,2001.0,,,168009564.0,1.0,Antiretroviral therapy
16802468,168024682,2,F,,20230421.0,20190912,20230424,EXP,,ES-ABBVIE-19P-144-2915335-00,ABBVIE,"Kwon M, Bailen R, Balsalobre P, Jurado M, Bermudez A, Badiola J, et al.. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders.. AIDS. 2019;33(9):1441-1447.",,,A,,Y,,,20230424.0,,MD,ES,ES,EFAVIRENZ,Blood HIV RNA;Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,168024682.0,OT,,,168024682.0,1.0,2008.0,,,,168024682.0,1.0,HIV infection
16806887,168068873,3,F,,20191002.0,20190913,20191015,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-088376,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20191015.0,,OT,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,168068873.0,OT,,,,,,,,,168068873.0,1.0,HIV infection
16806891,1680689110,10,F,2001.0,20201103.0,20190913,20201110,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086812,BRISTOL MYERS SQUIBB,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT. CLINICAL DRUG INVESTIGATION. 2019;39 (11):1125-31",38.0,YR,,M,Y,,,20201110.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,1680689110.0,OT,,,1680689110.0,1.0,2001.0,2001.0,,,1680689110.0,1.0,HIV infection
16810112,168101123,3,F,20050822.0,20200428.0,20190916,20200601,EXP,,US-GILEAD-2019-0428023,GILEAD,,48.0,YR,A,M,Y,136.51,KG,20200601.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,168101123.0,OT,,,168101123.0,1.0,200904.0,201606.0,,,168101123.0,1.0,HIV infection
16810270,168102705,5,F,20030814.0,20210621.0,20190916,20210624,EXP,,US-GILEAD-2019-0428371,GILEAD,,43.0,YR,A,M,Y,58.96,KG,20210624.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Bone loss;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Nephropathy;Osteonecrosis;Osteopenia;Pain;Proteinuria;Renal cell carcinoma;Renal cyst;Renal failure;Renal mass;Vitamin D deficiency,168102705.0,OT,,,168102705.0,1.0,20020801.0,20031110.0,,,168102705.0,1.0,HIV infection
16814645,168146451,1,I,,20190903.0,20190917,20190917,EXP,,ZA-AUROBINDO-AUR-APL-2019-060073,AUROBINDO,,,,C,,Y,,,20190917.0,,OT,ZA,ZA,EFAVIRENZ.,Disturbance in attention;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder;Insomnia,168146451.0,OT,,,,,,,,,168146451.0,1.0,HIV infection WHO clinical stage II
16820606,168206061,1,I,,20190912.0,20190918,20190918,EXP,,CA-TEVA-2019-CA-1109439,TEVA,,54.0,YR,,M,Y,,,20190918.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,168206061.0,OT,,,,,,,,,168206061.0,1.0,HIV infection
16820699,168206991,1,I,,20190903.0,20190918,20190918,EXP,,ZA-AUROBINDO-AUR-APL-2019-060077,AUROBINDO,,,,C,,Y,,,20190918.0,,OT,ZA,ZA,EFAVIRENZ.,Disturbance in attention;HIV-associated neurocognitive disorder;Motor dysfunction;Toxicity to various agents,168206991.0,OT,,,,,,,,,168206991.0,1.0,HIV infection
16820781,168207811,1,I,,20190903.0,20190918,20190918,EXP,,ZA-AUROBINDO-AUR-APL-2019-060075,AUROBINDO,,,,C,,Y,,,20190918.0,,OT,ZA,ZA,EFAVIRENZ.,Ataxia;Developmental regression;Dysarthria;Generalised tonic-clonic seizure;Neurotoxicity;Overdose;Somnolence;Toxicity to various agents,168207811.0,OT,,,,,,,,,168207811.0,1.0,HIV infection WHO clinical stage III
16820800,168208001,1,I,,20190903.0,20190918,20190918,EXP,,ZA-AUROBINDO-AUR-APL-2019-060076,AUROBINDO,,,,,,Y,,,20190918.0,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Disturbance in attention;Fine motor delay;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder;Microcephaly;Speech disorder developmental;Toxicity to various agents,168208001.0,OT,,,,,,,,,168208001.0,1.0,HIV infection
16823466,168234661,1,I,,20190910.0,20190918,20190918,EXP,,PK-GILEAD-2019-0427843,GILEAD,"JAFRY NH, MUBARAK M, ANIS S, AHMED E, AKHTAR F. MYELOMA-LIKE CAST NEPHROPATHY IN A HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT: A CASE REPORT. PORT J NEPHROL HYPERT. 2019;33 (2):118-121. DOI:DOI.ORG/10.32932/PJNH.2019.07.024",27.0,YR,A,M,Y,,,20190918.0,,MD,PK,PK,EFAVIRENZ.,Acute kidney injury;Myeloma cast nephropathy,168234661.0,HO,,,,,,,,,168234661.0,1.0,HIV infection
16823614,168236141,1,I,200311.0,20060103.0,20190918,20190918,EXP,DJ0500887,FR-VIIV HEALTHCARE LIMITED-B0405145A,VIIV,,36.0,YR,,F,Y,82.0,KG,20190918.0,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,168236141.0,OT,,,168236141.0,1.0,20051010.0,20051021.0,,,168236141.0,1.0,HIV infection
16824234,168242341,1,I,20070124.0,20190424.0,20190918,20190918,EXP,,US-GILEAD-2019-0427889,GILEAD,,26.0,YR,A,M,Y,,,20190918.0,,OT,US,US,SUSTIVA,Bilevel positive airway pressure;Blood creatinine increased;Drug-induced liver injury;Fluid imbalance;Hypoalbuminaemia;Hypotension;Intestinal obstruction;Kaposi's sarcoma;Malnutrition;Muscle fatigue;Pleural effusion;Respiratory arrest,168242341.0,DE,,,,,,,,,168242341.0,1.0,Acquired immunodeficiency syndrome
16824274,168242746,6,F,20060216.0,20200820.0,20190918,20200831,EXP,,FR-MYLANLABS-2019M1087495,MYLAN,,,,N,,Y,,,20200831.0,,CN,US,FR,EFAVIRENZ.,Brain herniation;Encephalocele;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,168242746.0,CA,,,168242746.0,1.0,20050704.0,20050908.0,,,168242746.0,1.0,HIV infection
16824384,168243846,6,F,20070403.0,20200911.0,20190918,20200917,EXP,,FR-GILEAD-2019-0427918,GILEAD,,0.0,YR,N,M,Y,3.23,KG,20200917.0,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168243846.0,CA,,,168243846.0,1.0,20070403.0,20070521.0,,,168243846.0,1.0,HIV infection
16826328,168263287,7,F,20070215.0,20200928.0,20190919,20210407,EXP,,US-GILEAD-2019-0428473,GILEAD,,35.0,YR,A,M,Y,79.37,KG,20210407.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Depression;Economic problem;Emotional distress;Fanconi syndrome acquired;Femur fracture;Flank pain;Hip arthroplasty;Insomnia;Leukocyturia;Multiple fractures;Nephrolithiasis;Osteoarthritis;Osteomalacia;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Post-traumatic stress disorder;Renal cyst;Renal failure;Rib fracture;Scapula fracture;Sternal fracture;Vitamin D deficiency,168263287.0,OT,,,168263287.0,1.0,20060725.0,20121203.0,,,168263287.0,1.0,HIV infection
16829774,168297742,2,F,,20200703.0,20190919,20200713,EXP,,CA-TEVA-2019-CA-1109359,TEVA,,44.0,YR,,M,Y,,,20200713.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,168297742.0,HO,,,,,,,,,168297742.0,1.0,HIV infection
16830668,168306684,4,F,,20210715.0,20190920,20210728,EXP,,AT-ROCHE-1061841,ROCHE,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R ET AL. RALTEGRAVIR IN PREGNANCY A CASE SERIES PRESENTATION. INTERNATIONAL JOURNAL OF STD ANSD AIDS. DOI:10.1258/IJSA.2011.010469 2011?22 (6):358?360.",39.0,YR,,F,Y,,,20210728.0,,MD,AT,AT,EFAVIRENZ.,Acute stress disorder;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes;Rebound effect;Viral load increased,168306684.0,HO,,,,,,,,,168306684.0,1.0,HIV infection
16831229,168312295,5,F,20151126.0,20210623.0,20190920,20210628,EXP,,US-GILEAD-2019-0428481,GILEAD,,49.0,YR,A,M,Y,79.38,KG,20210628.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Bone loss;Cervical vertebral fracture;Chronic kidney disease;Clavicle fracture;Economic problem;Emotional distress;Glomerular filtration rate decreased;Intervertebral disc protrusion;Osteoarthritis;Osteonecrosis;Pain;Renal failure;Rib fracture;Spinal osteoarthritis;Spinal stenosis,168312295.0,OT,,,168312295.0,1.0,2006.0,2016.0,,,168312295.0,1.0,HIV infection
16832947,168329474,4,F,20150625.0,20200831.0,20190920,20210407,EXP,,US-GILEAD-2019-0428480,GILEAD,,38.0,YR,A,F,Y,63.49,KG,20210407.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,168329474.0,OT,,,168329474.0,1.0,200610.0,201705.0,,,168329474.0,1.0,HIV infection
16834054,168340547,7,F,20080403.0,20231106.0,20190920,20231108,EXP,,US-GILEAD-2019-0428527,GILEAD,,69.0,YR,E,M,Y,86.183,KG,20231107.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Bone loss;Chronic kidney disease;Decreased appetite;Depression;Economic problem;Emotional distress;Facet joint syndrome;Fibula fracture;Hip arthroplasty;Intervertebral disc protrusion;Mobility decreased;Multiple fractures;Nephrosclerosis;Osteoarthritis;Osteonecrosis;Pain;Proteinuria;Radiculopathy;Renal failure;Renal tubular injury;Spinal osteoarthritis,168340547.0,OT,,,168340547.0,1.0,20040626.0,20190710.0,5492.0,DAY,168340547.0,1.0,HIV infection
16835292,168352929,9,F,,20201030.0,20190920,20201106,EXP,,FR-GLAXOSMITHKLINE-FR2019169921,GLAXOSMITHKLINE,,,,,M,Y,3.23,KG,20201106.0,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168352929.0,CA,,,168352929.0,1.0,20070403.0,20070521.0,,,168352929.0,1.0,HIV infection
16835297,168352979,9,F,,20201030.0,20190920,20201106,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2019169921,VIIV,,,,,M,Y,3.23,KG,20201106.0,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168352979.0,CA,,,168352979.0,1.0,20070403.0,20070521.0,,,168352979.0,1.0,HIV infection
16837681,168376813,3,F,20110901.0,20230914.0,20190923,20230921,EXP,,US-GILEAD-2019-0429593,GILEAD,,67.0,YR,E,M,Y,,,20230921.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Economic problem;Emotional distress;Insomnia;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Quality of life decreased,168376813.0,OT,,,168376813.0,1.0,2001.0,20080110.0,56.0,DAY,168376813.0,1.0,HIV infection
16837827,168378275,5,F,20050301.0,20240120.0,20190923,20240122,EXP,,US-GILEAD-2019-0429625,GILEAD,,64.0,YR,A,M,Y,,,20240122.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Death;Economic problem;Emotional distress;Injury;Pain;Renal failure,168378275.0,DE,,,168378275.0,1.0,20130416.0,201507.0,2.0,MON,168378275.0,1.0,HIV infection
16837989,168379895,5,F,20040701.0,20231222.0,20190923,20231225,EXP,,US-GILEAD-2019-0429311,GILEAD,,37.0,YR,A,M,Y,104.76,KG,20231224.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure;Renal neoplasm;Upper limb fracture,168379895.0,HO,,,168379895.0,1.0,200111.0,20060830.0,,,168379895.0,1.0,HIV infection
16838529,168385295,5,F,20130422.0,20231213.0,20190923,20231222,EXP,,US-GILEAD-2019-0429261,GILEAD,,54.0,YR,A,F,Y,142.86,KG,20231221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Immobile;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal cyst;Renal failure;Renal pain,168385295.0,HO,,,168385295.0,1.0,2010.0,20150321.0,2066.0,DAY,168385295.0,1.0,HIV infection
16839622,168396226,6,F,20120101.0,20240105.0,20190923,20240207,PER,,US-GILEAD-2019-0429613,GILEAD,,30.0,YR,A,M,Y,82.086,KG,20240207.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Decreased activity;Drug hypersensitivity;Drug resistance;Economic problem;Emotional distress;Insomnia;Jaundice;Loss of personal independence in daily activities;Pain;Pollakiuria;Quality of life decreased;Renal failure;T-lymphocyte count abnormal,168396226.0,OT,,,168396226.0,1.0,2003.0,2009.0,,,168396226.0,1.0,HIV infection
16839623,168396234,4,F,20060101.0,20240213.0,20190923,20240214,EXP,,US-GILEAD-2019-0429680,GILEAD,,59.0,YR,A,M,Y,106.12,KG,20240214.0,,LW,US,US,SUSTIVA,Abdominal pain upper;Anhedonia;Anxiety;Cachexia;Diarrhoea;Economic problem;Emotional distress;Femur fracture;Flatulence;Joint injury;Limb injury;Osteopenia;Osteoporosis;Pain,168396234.0,OT,,,168396234.0,1.0,2012.0,201707.0,,,168396234.0,1.0,HIV infection
16840694,168406945,5,F,20120628.0,20220112.0,20190923,20220120,EXP,,US-GILEAD-2019-0429308,GILEAD,,53.0,YR,A,M,Y,,,20220120.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Nephrogenic anaemia;Pain;Renal failure,168406945.0,OT,,,168406945.0,1.0,2004.0,201209.0,1615.0,DAY,168406945.0,1.0,HIV infection
16840765,168407653,3,F,201805.0,20200715.0,20190923,20200805,PER,,US-GILEAD-2019-0429232,GILEAD,,47.0,YR,A,M,Y,81.63,KG,20200805.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood creatinine increased;Decreased activity;Drug ineffective;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Pollakiuria;Quality of life decreased;Renal impairment,168407653.0,OT,,,168407653.0,1.0,2001.0,2011.0,,,168407653.0,1.0,HIV infection
16843309,168433094,4,F,20070801.0,20240304.0,20190924,20240306,EXP,,US-GILEAD-2019-0429345,GILEAD,,45.0,YR,A,M,Y,68.481,KG,20240305.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Illness;Loss of personal independence in daily activities;Nephrogenic anaemia;Nephropathy;Pain;Quality of life decreased;Renal failure,168433094.0,HO,,,168433094.0,1.0,2005.0,2018.0,,,168433094.0,1.0,HIV infection
16843451,168434514,4,F,20100513.0,20231220.0,20190924,20231221,EXP,,US-GILEAD-2019-0429705,GILEAD,,62.0,YR,A,M,Y,133.79,KG,20231221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Emotional distress;Fracture;Kyphosis;Loss of personal independence in daily activities;Mobility decreased;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Spinal compression fracture;Weight increased,168434514.0,OT,,,168434514.0,1.0,2002.0,2005.0,,,168434514.0,1.0,HIV infection
16843822,168438222,2,F,20161101.0,20230429.0,20190924,20230505,EXP,,US-GILEAD-2019-0429585,GILEAD,,61.0,YR,A,M,Y,,,20230505.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Death;Decreased activity;Depression;Economic problem;Emotional distress;Loss of personal independence in daily activities;Multiple injuries;Quality of life decreased,168438222.0,OT,,,168438222.0,1.0,20090822.0,20141017.0,1882.0,DAY,168438222.0,1.0,HIV infection
16844259,168442593,3,F,20190822.0,20230421.0,20190924,20230424,PER,,US-GILEAD-2019-0429219,GILEAD,,54.0,YR,A,F,Y,58.957,KG,20230424.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Osteopenia;Pain,,,,,168442593.0,1.0,2001.0,2018.0,,,168442593.0,1.0,HIV infection
16844386,168443863,3,F,20160122.0,20201113.0,20190924,20201119,EXP,,US-GILEAD-2019-0429662,GILEAD,,60.0,YR,A,M,Y,72.56,KG,20201119.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Emotional distress;Loss of personal independence in daily activities;Pain;Quality of life decreased,168443863.0,OT,,,168443863.0,1.0,2001.0,201901.0,,,168443863.0,1.0,HIV infection
16844478,168444783,3,F,20080101.0,20230421.0,20190924,20230425,EXP,,US-GILEAD-2019-0429687,GILEAD,,29.0,YR,A,M,Y,65.76,KG,20230425.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Hyperlipidaemia;Insomnia;Loss of personal independence in daily activities;Osteoporosis;Pain;Quality of life decreased;Renal disorder;Renal failure;Renal impairment,168444783.0,OT,,,168444783.0,1.0,2001.0,2008.0,,,168444783.0,1.0,HIV infection
16844534,168445343,3,F,2017.0,20200708.0,20190924,20200915,EXP,,US-GILEAD-2019-0429756,GILEAD,,43.0,YR,A,M,Y,,,20200915.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anaemia of chronic disease;Anhedonia;Anxiety;Asthenia;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Impaired work ability;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Sluggishness,168445343.0,OT,,,168445343.0,1.0,2009.0,20140912.0,,,168445343.0,1.0,HIV infection
16845064,168450643,3,F,2013.0,20201214.0,20190924,20201223,EXP,,US-GILEAD-2019-0429307,GILEAD,,,,A,F,Y,45.35,KG,20201223.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure,168450643.0,OT,,,168450643.0,1.0,2008.0,2013.0,,,168450643.0,1.0,HIV infection
16845382,168453823,3,F,20150301.0,20230411.0,20190924,20230413,EXP,,US-GILEAD-2019-0429703,GILEAD,,51.0,YR,A,M,Y,84.807,KG,20230413.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Depression;Emotional distress;Fatigue;Mobility decreased;Osteoporosis;Pain;Quality of life decreased;Renal impairment,168453823.0,OT,,,168453823.0,1.0,2002.0,20181002.0,,,168453823.0,1.0,HIV infection
16845626,168456264,4,F,20040401.0,20240207.0,20190924,20240209,EXP,,US-GILEAD-2019-0429615,GILEAD,,41.0,YR,A,M,Y,68.027,KG,20240208.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Gait disturbance;Pain;Quality of life decreased;Renal failure;Renal transplant,168456264.0,OT,,,168456264.0,1.0,2001.0,2017.0,,,168456264.0,1.0,HIV infection
16846009,168460093,3,F,2008.0,20200814.0,20190924,20201022,PER,,US-GILEAD-2019-0429346,GILEAD,,30.0,YR,A,M,Y,105.22,KG,20201022.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal transplant,168460093.0,HO,,,168460093.0,1.0,2012.0,2013.0,,,168460093.0,1.0,HIV infection
16846100,168461004,4,F,200601.0,20210407.0,20190924,20210412,EXP,,US-GILEAD-2019-0429620,GILEAD,,42.0,YR,A,M,Y,94.79,KG,20210412.0,,CN,US,US,SUSTIVA,Amnesia;Anhedonia;Ankle fracture;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Foot fracture;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Rib fracture,168461004.0,HO,,,168461004.0,1.0,200111.0,2005.0,,,168461004.0,1.0,HIV infection
16846522,168465221,1,I,,20190920.0,20190924,20190924,EXP,FR-EMA-DD-20190507-SAHU_K-170342,FR-MYLANLABS-2019M1088784,MYLAN,,,,N,,Y,,,20190924.0,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,168465221.0,CA,,,168465221.0,4.0,20050908.0,,,,168465221.0,1.0,HIV infection
16846793,168467931,1,I,20171006.0,20190920.0,20190924,20190924,EXP,,GB-MYLANLABS-2019M1088802,MYLAN,,,,,,Y,,,20190924.0,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrops foetalis,168467931.0,CA,,,168467931.0,1.0,20171006.0,,,,168467931.0,1.0,HIV infection
16847030,168470304,4,F,20150409.0,20240205.0,20190924,20240207,EXP,,US-GILEAD-2019-0429491,GILEAD,,64.0,YR,A,F,Y,49.887,KG,20240207.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia of chronic disease;Anhedonia;Anxiety;Carpal tunnel syndrome;Decreased activity;Emotional distress;End stage renal disease;Fatigue;Fistula;Loss of personal independence in daily activities;Mobility decreased;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal failure;Renal tubular necrosis,168470304.0,HO,,,168470304.0,1.0,20170601.0,201810.0,,,168470304.0,1.0,HIV infection
16848787,168487873,3,F,20050101.0,20240210.0,20190925,20240212,EXP,,US-GILEAD-2019-0429707,GILEAD,,,,A,M,Y,92.971,KG,20240212.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Cardiac failure congestive;Congenital cystic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Renal failure,168487873.0,HO,,,168487873.0,1.0,2001.0,200602.0,,,168487873.0,1.0,HIV infection
16849240,168492402,2,F,20130510.0,20200613.0,20190925,20200820,EXP,,US-GILEAD-2019-0429708,GILEAD,,38.0,YR,A,F,Y,44.54,KG,20200820.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Arthritis;Decreased activity;Depression;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Multiple fractures;Osteonecrosis;Osteoporosis;Pain;Proteinuria;Quality of life decreased;Renal transplant;Spinal osteoarthritis,168492402.0,OT,,,168492402.0,1.0,20111013.0,20130131.0,,,168492402.0,1.0,HIV infection
16850098,168500985,5,F,20050101.0,20231215.0,20190925,20231218,EXP,,US-GILEAD-2019-0429508,GILEAD,,41.0,YR,A,M,Y,77.098,KG,20231218.0,,LW,US,US,SUSTIVA,Abdominal distension;Anhedonia;Anxiety;Arthritis;Bone density decreased;Bone loss;Bone pain;Carpal tunnel syndrome;Decreased activity;Depression;Economic problem;Emotional distress;Fat tissue increased;Gastrointestinal disorder;Grip strength decreased;Hypoaesthesia;Loss of personal independence in daily activities;Nephropathy;Osteopenia;Osteoporosis;Pain;Plantar fasciitis;Quality of life decreased;Tendonitis,168500985.0,OT,,,168500985.0,1.0,2001.0,2008.0,,,168500985.0,1.0,HIV infection
16850183,168501834,4,F,20151128.0,20240120.0,20190925,20240122,EXP,,US-GILEAD-2019-0429207,GILEAD,,34.0,YR,A,F,Y,,,20240122.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Chronic kidney disease;Economic problem;Emotional distress;Hepatic enzyme increased;Multiple injuries;Pain;Renal failure,168501834.0,HO,,,168501834.0,1.0,20150817.0,20161102.0,443.0,DAY,168501834.0,1.0,HIV infection
16850210,168502101,1,I,,20190916.0,20190925,20190925,EXP,,ZW-MYLANLABS-2019M1088651,MYLAN,"BWAKURA DANGAREMBIZI M, SAMSON P, CAPPARELLI EV, MOORE CB, JEAN-PHILIPPE P, SPECTOR SA, ET AL. ESTABLISHING DOSING RECOMMENDATIONS FOR EFAVIRENZ IN HIV/TB-COINFECTED CHILDREN YOUNGER THAN 3 YEARS. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2019;81(4):473-480.",,,C,,Y,,,20190925.0,,MD,ZW,ZW,EFAVIRENZ.,Labelled drug-drug interaction medication error;Neutropenia,168502101.0,OT,,,,,,,,,168502101.0,1.0,HIV infection
16850211,168502111,1,I,,20190916.0,20190925,20190925,EXP,,ZW-MYLANLABS-2019M1088650,MYLAN,"BWAKURA DANGAREMBIZI M, SAMSON P, CAPPARELLI EV, MOORE CB, JEAN-PHILIPPE P, SPECTOR SA, ET AL. ESTABLISHING DOSING RECOMMENDATIONS FOR EFAVIRENZ IN HIV/TB-COINFECTED CHILDREN YOUNGER THAN 3 YEARS. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2019;81(4):473-480.",,,C,,Y,,,20190925.0,,MD,ZW,ZW,EFAVIRENZ.,Labelled drug-drug interaction medication error;Neutropenia,168502111.0,OT,,,,,,,,,168502111.0,1.0,HIV infection
16850212,168502122,2,F,2017.0,20200814.0,20190925,20200904,EXP,,US-GILEAD-2019-0429610,GILEAD,,49.0,YR,A,M,Y,103.4,KG,20200904.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Decreased activity;Depression;Dysstasia;Economic problem;Emotional distress;Fibula fracture;Gait disturbance;Impaired work ability;Loss of personal independence in daily activities;Musculoskeletal chest pain;Osteoporosis;Pain;Pain in extremity;Quality of life decreased;Rib fracture;Spinal fracture;Spinal pain,168502122.0,OT,,,168502122.0,1.0,2015.0,2016.0,,,168502122.0,1.0,HIV infection
16851521,168515214,4,F,20150101.0,20230914.0,20190925,20230921,EXP,,US-GILEAD-2019-0429645,GILEAD,,25.0,YR,A,M,Y,135.0,KG,20230921.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Cardiac failure congestive;Chronic kidney disease;Decreased activity;Depressed mood;Emotional distress;End stage renal disease;Fatigue;Gait disturbance;Impaired work ability;Loss of personal independence in daily activities;Nephropathy;Pain;Panic attack;Peripheral swelling;Pneumonia;Quality of life decreased;Renal failure;Sepsis,168515214.0,HO,,,168515214.0,1.0,2005.0,2011.0,,,168515214.0,1.0,HIV infection
16851762,168517626,6,F,20150101.0,20240213.0,20190925,20240215,PER,,US-GILEAD-2019-0429561,GILEAD,,,,A,M,Y,94.331,KG,20240214.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Cardiac disorder;Chronic kidney disease;Decreased activity;Depression;Emotional distress;Fear;Gait disturbance;Gout;Pain;Quality of life decreased;Renal failure,168517626.0,OT,,,168517626.0,1.0,2005.0,20140707.0,,,168517626.0,1.0,HIV infection
16851962,168519623,3,F,200712.0,20201106.0,20190925,20201119,EXP,,US-GILEAD-2019-0429428,GILEAD,,45.0,YR,A,F,Y,54.42,KG,20201119.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Clavicle fracture;Decreased activity;Disturbance in attention;Economic problem;Emotional distress;Fatigue;Femoral neck fracture;Fine motor skill dysfunction;Foot fracture;Forearm fracture;Hip fracture;Loss of employment;Loss of personal independence in daily activities;Mobility decreased;Osteopenia;Osteoporosis;Pain;Personal relationship issue;Quality of life decreased;Renal failure;Rib fracture;Social problem;Upper limb fracture,168519623.0,OT,,,168519623.0,1.0,2003.0,2015.0,,,168519623.0,1.0,HIV infection
16852615,168526153,3,F,2006.0,20200715.0,20190925,20200902,EXP,,US-GILEAD-2019-0429663,GILEAD,,49.0,YR,A,F,Y,102.04,KG,20200902.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Dysstasia;Economic problem;Emotional distress;Fear;Gait disturbance;Insomnia;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain;Quality of life decreased,168526153.0,OT,,,168526153.0,1.0,2004.0,201304.0,,,168526153.0,1.0,HIV infection
16852656,168526561,1,I,,20190920.0,20190925,20190925,EXP,,FR-MYLANLABS-2019M1088733,MYLAN,,25.0,YR,,F,Y,,,20190925.0,,OT,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Insomnia;Vertigo,168526561.0,OT,,,168526561.0,1.0,20050704.0,20050908.0,,,168526561.0,1.0,HIV infection
16852781,168527815,5,F,20150115.0,20231116.0,20190925,20231120,EXP,,US-GILEAD-2019-0429286,GILEAD,,55.0,YR,A,M,Y,112.93,KG,20231119.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone disorder;Chronic kidney disease-mineral and bone disorder;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Mobility decreased;Pain;Proteinuria;Quality of life decreased,168527815.0,OT,,,168527815.0,1.0,200908.0,201403.0,2083.0,DAY,168527815.0,1.0,HIV infection
16853159,168531596,6,F,20040801.0,20210509.0,20190925,20211020,EXP,,US-GILEAD-2019-0429655,GILEAD,,66.0,YR,E,M,Y,58.96,KG,20211020.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood cholesterol increased;Blood creatinine increased;Bone density decreased;Economic problem;Emotional distress;Fall;Fear;Foot fracture;Lipids increased;Loss of personal independence in daily activities;Lower limb fracture;Multiple fractures;Muscle spasms;Muscular weakness;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal impairment;Rib fracture;Spinal cord compression;Upper limb fracture,168531596.0,OT,,,168531596.0,1.0,20041115.0,20080926.0,1411.0,DAY,168531596.0,1.0,HIV infection
16854016,168540163,3,F,2011.0,20210305.0,20190926,20210311,EXP,,US-GILEAD-2019-0429760,GILEAD,,,,A,M,Y,,,20210311.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Pain;Renal failure,168540163.0,HO,,,168540163.0,1.0,2007.0,20150916.0,,,168540163.0,1.0,HIV infection
16854037,168540375,5,F,20141201.0,20231006.0,20190926,20231009,EXP,,US-GILEAD-2019-0429745,GILEAD,,63.0,YR,E,M,Y,214.0,KG,20231008.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of libido;Loss of personal independence in daily activities;Mobility decreased;Pain;Renal failure;Vitamin D deficiency,168540375.0,OT,,,168540375.0,1.0,2012.0,2018.0,,,168540375.0,1.0,HIV infection
16854308,168543083,3,F,20140201.0,20231009.0,20190926,20231011,EXP,,US-GILEAD-2019-0429572,GILEAD,,67.0,YR,E,F,Y,,,20231011.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Cardio-respiratory arrest;Chronic kidney disease;Death;Economic problem;Emotional distress;End stage renal disease;Oedema;Pain,168543083.0,DE,,,168543083.0,1.0,20080702.0,2019.0,18.0,DAY,168543083.0,1.0,HIV infection
16854370,168543703,3,F,2008.0,20201028.0,20190926,20201106,EXP,,US-GILEAD-2019-0429592,GILEAD,,63.0,YR,A,F,Y,52.15,KG,20201106.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fanconi syndrome acquired;Fatigue;Fear;Foot fracture;Glomerular filtration rate abnormal;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain;Protein urine present;Quality of life decreased;Rib fracture;Wrist fracture,168543703.0,OT,,,168543703.0,1.0,200405.0,200907.0,,,168543703.0,1.0,HIV infection
16854746,168547464,4,F,20110101.0,20221220.0,20190926,20221227,EXP,,US-GILEAD-2019-0429522,GILEAD,,51.0,YR,A,F,Y,69.841,KG,20221227.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Nephrogenic anaemia;Pain;Quality of life decreased;Renal failure,168547464.0,OT,,,168547464.0,1.0,201107.0,20130812.0,2190.0,DAY,168547464.0,1.0,HIV infection
16854788,168547882,2,F,2018.0,20200716.0,20190926,20200831,EXP,,US-GILEAD-2019-0429794,GILEAD,,43.0,YR,A,M,Y,,,20200831.0,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased,168547882.0,OT,,,168547882.0,1.0,2004.0,2009.0,,,168547882.0,1.0,HIV infection
16855068,168550684,4,F,20150902.0,20210602.0,20190926,20210603,EXP,,US-GILEAD-2019-0429433,GILEAD,,66.0,YR,E,M,Y,108.84,KG,20210603.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Fear;Osteopenia;Pain;Quality of life decreased;Renal failure,168550684.0,OT,,,168550684.0,1.0,20081218.0,20170823.0,,,168550684.0,1.0,HIV infection
16855474,168554743,3,F,20091001.0,20240122.0,20190926,20240124,EXP,,US-GILEAD-2019-0429375,GILEAD,,45.0,YR,A,F,Y,61.224,KG,20240124.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Bedridden;Bone density decreased;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Fanconi syndrome acquired;Fatigue;Fractured sacrum;Hip fracture;Hyperparathyroidism;Hypoaesthesia;Ilium fracture;Loss of personal independence in daily activities;Muscle atrophy;Nephritis;Osteopenia;Osteoporosis;Pain;Pain in extremity;Quality of life decreased;Wrist fracture,168554743.0,OT,,,168554743.0,1.0,200508.0,201407.0,,,168554743.0,1.0,HIV infection
16855625,168556254,4,F,2010.0,20210426.0,20190926,20210429,EXP,,US-GILEAD-2019-0429788,GILEAD,,47.0,YR,A,M,Y,90.7,KG,20210429.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone disorder;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Insomnia;Loss of personal independence in daily activities;Pain;Panic attack;Quality of life decreased;Renal failure;Wheelchair user,168556254.0,OT,,,168556254.0,1.0,2006.0,2010.0,,,168556254.0,1.0,HIV infection
16855931,168559313,3,F,20140601.0,20230406.0,20190926,20230411,EXP,,US-GILEAD-2019-0429827,GILEAD,,28.0,YR,A,M,Y,97.959,KG,20230411.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Emotional distress;End stage renal disease;Fatigue;Illness;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased;Vomiting,168559313.0,HO,,,168559313.0,1.0,2006.0,2014.0,,,168559313.0,1.0,HIV infection
16855977,168559771,1,I,,20190916.0,20190926,20190926,EXP,,ZW-MYLANLABS-2019M1088638,MYLAN,"BWAKURA DANGAREMBIZI M, SAMSON P, CAPPARELLI EV, MOORE CB, JEAN-PHILIPPE P, SPECTOR SA, ET AL. ESTABLISHING DOSING RECOMMENDATIONS FOR EFAVIRENZ IN HIV/TB-COINFECTED CHILDREN YOUNGER THAN 3 YEARS. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2019;81(4):473-480.",,,C,,Y,,,20190926.0,,MD,ZW,ZW,EFAVIRENZ.,Drug interaction;Drug level increased;Transaminases increased,168559771.0,OT,,,,,,,,,168559771.0,1.0,HIV infection
16856140,168561403,3,F,,20200113.0,20190926,20200115,PER,,US-PFIZER INC-2019411166,PFIZER,,49.0,YR,,M,Y,94.8,KG,20200115.0,,MD,US,US,SUSTIVA,Drug interaction;White blood cell count decreased,,,,,,,,,,,168561403.0,2.0,HIV infection
16856415,168564153,3,F,2009.0,20200715.0,20190926,20200826,EXP,,US-GILEAD-2019-0429606,GILEAD,,56.0,YR,A,M,Y,70.3,KG,20200826.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Fear;Impaired work ability;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased;Renal failure;Spinal compression fracture,168564153.0,OT,,,168564153.0,1.0,2006.0,200906.0,,,168564153.0,1.0,HIV infection
16856450,168564504,4,F,201106.0,20200708.0,20190926,20210209,PER,,US-GILEAD-2019-0429605,GILEAD,,26.0,YR,A,M,Y,79.37,KG,20210209.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Depression;Drug ineffective;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism;Hyperthyroidism;Hyperuricaemia;Impaired work ability;Nephropathy;Pain;Proteinuria;Renal disorder;Renal failure,168564504.0,HO,,,168564504.0,1.0,2010.0,2017.0,,,168564504.0,1.0,HIV infection
16856453,168564532,2,F,201308.0,20200722.0,20190926,20200729,EXP,,US-GILEAD-2019-0429244,GILEAD,,71.0,YR,E,F,Y,85.26,KG,20200729.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Fracture;Gait disturbance;Loss of personal independence in daily activities;Lower limb fracture;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal failure;Tibia fracture,168564532.0,OT,,,168564532.0,1.0,2009.0,20141107.0,,,168564532.0,1.0,HIV infection
16856454,168564544,4,F,20120101.0,20230404.0,20190926,20230407,EXP,,US-GILEAD-2019-0429624,GILEAD,,23.0,YR,A,M,Y,72.562,KG,20230407.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Death;Decreased activity;Emotional distress;Fear;Impaired work ability;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal injury;Skeletal injury,168564544.0,HO,,,168564544.0,1.0,2008.0,2013.0,1080.0,DAY,168564544.0,1.0,HIV infection
16856482,168564823,3,F,20181201.0,20230403.0,20190926,20230407,EXP,,US-GILEAD-2019-0429730,GILEAD,,60.0,YR,A,M,Y,,,20230407.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal impairment;Urinary tract infection,168564823.0,HO,,,168564823.0,1.0,2014.0,201903.0,,,168564823.0,1.0,HIV infection
16856671,168566713,3,F,2018.0,20210517.0,20190926,20210518,EXP,,US-GILEAD-2019-0429735,GILEAD,,42.0,YR,A,M,Y,93.88,KG,20210518.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased,168566713.0,HO,,,168566713.0,1.0,200411.0,2009.0,,,168566713.0,1.0,HIV infection
16856872,168568724,4,F,20170101.0,20231129.0,20190926,20231201,EXP,,US-GILEAD-2019-0429524,GILEAD,,51.0,YR,A,M,Y,65.3,KG,20231201.0,,LW,US,US,SUSTIVA,"Anhedonia;Anxiety;Arthralgia;Back pain;Depression;Dysstasia;Economic problem;Emotional distress;Fear-related avoidance of activities;Gait disturbance;Osteoporosis;Pain;Quality of life decreased;Sleep disorder due to general medical condition, insomnia type;Suicidal ideation",168568724.0,HO,,,168568724.0,1.0,20100907.0,20130514.0,980.0,DAY,168568724.0,1.0,HIV infection
16857423,168574233,3,F,20100101.0,20230331.0,20190926,20230406,EXP,,US-GILEAD-2019-0429293,GILEAD,,42.0,YR,A,F,Y,176.87,KG,20230406.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Arthropathy;Bone density decreased;Economic problem;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain,168574233.0,OT,,,168574233.0,1.0,2009.0,2016.0,,,168574233.0,1.0,HIV infection
16858117,168581172,2,F,201309.0,20200715.0,20190926,20200825,EXP,,US-GILEAD-2019-0429577,GILEAD,,70.0,YR,E,F,Y,,,20200825.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure,168581172.0,OT,,,168581172.0,1.0,2006.0,201309.0,,,168581172.0,1.0,HIV infection
16858174,168581744,4,F,20090901.0,20231114.0,20190926,20231116,EXP,,US-GILEAD-2019-0429386,GILEAD,,20.0,YR,A,F,Y,58.957,KG,20231116.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Decreased activity;Dysstasia;Economic problem;Emotional distress;End stage renal disease;Fatigue;Gait disturbance;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure;Renal impairment,168581744.0,HO,,,168581744.0,1.0,2004.0,20140522.0,650.0,DAY,168581744.0,1.0,HIV infection
16858241,168582412,2,F,2017.0,20200810.0,20190926,20200827,EXP,,US-GILEAD-2019-0429239,GILEAD,,,,A,M,Y,72.56,KG,20200827.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Decreased appetite;Economic problem;Emotional distress;Fear-related avoidance of activities;Gait disturbance;Loss of personal independence in daily activities;Osteoporosis;Pain;Pain in extremity;Quality of life decreased;Weight decreased,168582412.0,OT,,,168582412.0,1.0,2004.0,2018.0,,,168582412.0,1.0,HIV infection
16858242,168582423,3,F,20150906.0,20201229.0,20190926,20210108,EXP,,US-GILEAD-2019-0429395,GILEAD,,54.0,YR,A,M,Y,54.42,KG,20210108.0,,CN,US,US,SUSTIVA,Acute kidney injury;Amnesia;Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Death;Decreased activity;Discomfort;Disturbance in attention;Economic problem;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Nephropathy;Pain;Quality of life decreased,168582423.0,OT,,,168582423.0,1.0,2006.0,20151103.0,,,168582423.0,1.0,HIV infection
16858570,168585703,3,F,2018.0,20200814.0,20190926,20200904,PER,,US-GILEAD-2019-0429731,GILEAD,,,,A,M,Y,94.79,KG,20200904.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Economic problem;Emotional distress;Fear-related avoidance of activities;Gait disturbance;Hepatic enzyme increased;Loss of personal independence in daily activities;Pain;Quality of life decreased,168585703.0,OT,,,168585703.0,1.0,2005.0,2007.0,,,168585703.0,1.0,HIV infection
16858956,168589564,4,F,20080901.0,20231130.0,20190926,20231204,EXP,,US-GILEAD-2019-0429204,GILEAD,,45.0,YR,A,F,Y,47.619,KG,20231204.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal pain,168589564.0,DE,,,168589564.0,1.0,2004.0,2015.0,,,168589564.0,1.0,HIV infection
16858997,168589974,4,F,20070501.0,20230511.0,20190926,20230516,EXP,,US-GILEAD-2019-0429671,GILEAD,,43.0,YR,A,M,Y,,,20230515.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Decreased activity;Emotional distress;End stage renal disease;Fatigue;Nephrogenic anaemia;Pain;Quality of life decreased;Renal failure;Renal tubular necrosis,168589974.0,HO,,,168589974.0,1.0,20070409.0,200806.0,96.0,DAY,168589974.0,1.0,HIV infection
16859196,168591962,2,F,2009.0,20200727.0,20190926,20200806,EXP,,US-GILEAD-2019-0429411,GILEAD,,,,A,M,Y,69.39,KG,20200806.0,,CN,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Decreased activity;Economic problem;Emotional distress;Fear;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal impairment;Upper limb fracture;Wrist fracture,168591962.0,OT,,,168591962.0,1.0,20051024.0,2018.0,,,168591962.0,1.0,HIV infection
16860051,168600514,4,F,20140301.0,20211115.0,20190927,20211130,EXP,,US-GILEAD-2019-0429732,GILEAD,,59.0,YR,A,M,Y,77.0,KG,20211130.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Decreased activity;Economic problem;Emotional distress;Osteoporosis;Quality of life decreased,168600514.0,OT,,,168600514.0,1.0,20100826.0,20140605.0,1379.0,DAY,168600514.0,1.0,HIV infection
16860358,168603582,2,F,2014.0,20200715.0,20190927,20200818,EXP,,US-GILEAD-2019-0429584,GILEAD,,,,,M,Y,90.7,KG,20200818.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Multiple injuries;Pain;Renal failure;Suicidal ideation,168603582.0,OT,,,168603582.0,1.0,2015.0,2017.0,,,168603582.0,1.0,HIV infection
16860421,168604213,3,F,20110101.0,20231010.0,20190927,20231011,PER,,US-GILEAD-2019-0429722,GILEAD,,37.0,YR,A,M,Y,86.168,KG,20231011.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood urine present;Bone density decreased;Decreased activity;Depression;Economic problem;Emotional distress;Fear;Joint noise;Loss of personal independence in daily activities;Osteopenia;Pain;Quality of life decreased,,,,,168604213.0,1.0,20090819.0,20120919.0,37.0,MON,168604213.0,1.0,HIV infection
16860533,168605333,3,F,20131001.0,20231006.0,20190927,20231010,EXP,,US-GILEAD-2019-0429643,GILEAD,,29.0,YR,A,F,Y,72.562,KG,20231009.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Hypersomnia;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal impairment;Selective eating disorder,168605333.0,HO,,,168605333.0,1.0,200907.0,201102.0,169.0,DAY,168605333.0,1.0,HIV infection
16860704,168607044,4,F,20100101.0,20240207.0,20190927,20240209,EXP,,US-GILEAD-2019-0429650,GILEAD,,,,A,M,Y,78.005,KG,20240209.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Chronic kidney disease;Decreased activity;Decreased appetite;Economic problem;Emotional distress;Fatigue;Gait disturbance;Osteoporosis;Pain;Quality of life decreased;Renal failure,168607044.0,HO,,,168607044.0,1.0,2004.0,,,,168607044.0,1.0,HIV infection
16860718,168607182,2,F,201006.0,20200922.0,20190927,20200928,EXP,,US-GILEAD-2019-0429656,GILEAD,,22.0,YR,A,M,Y,106.58,KG,20200928.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal transplant,168607182.0,OT,,,168607182.0,1.0,2007.0,2010.0,,,168607182.0,1.0,HIV infection
16861386,168613863,3,F,2005.0,20210601.0,20190927,20210603,EXP,,US-GILEAD-2019-0429649,GILEAD,,45.0,YR,A,F,Y,,,20210603.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Bone pain;Economic problem;Emotional distress;Gait disturbance;Hyperkalaemia;Loss of personal independence in daily activities;Lower limb fracture;Osteoporosis;Pain;Quality of life decreased;Renal failure;Renal pain;Suicidal ideation;Suicide attempt,168613863.0,OT,,,168613863.0,1.0,200408.0,2017.0,,,168613863.0,1.0,HIV infection
16861811,168618114,4,F,201011.0,20210915.0,20190927,20210923,EXP,,US-GILEAD-2019-0429413,GILEAD,,55.0,YR,A,M,Y,45.35,KG,20210923.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased,168618114.0,OT,,,168618114.0,1.0,200910.0,201011.0,,,168618114.0,1.0,HIV infection
16861997,168619971,1,I,,20190923.0,20190927,20190927,EXP,GB-EMA-DD-20190508-SAHU_K-153427,GB-MYLANLABS-2019M1089322,MYLAN,,43.0,YR,,F,Y,,,20190927.0,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,168619971.0,OT,,,,,,,,,168619971.0,1.0,HIV infection
16862172,168621723,3,F,20160301.0,20231103.0,20190927,20231106,EXP,,US-GILEAD-2019-0429742,GILEAD,,51.0,YR,A,F,Y,,,20231106.0,,LW,US,US,SUSTIVA,Abnormal dreams;Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Depression;Economic problem;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Metabolic acidosis;Multiple injuries;Osteoporosis;Pain;Renal failure;Somnambulism,168621723.0,DE,,,168621723.0,1.0,201304.0,201603.0,318.0,DAY,168621723.0,1.0,HIV infection
16862241,168622414,4,F,20120801.0,20231124.0,20190927,20231127,EXP,,US-GILEAD-2019-0429714,GILEAD,,39.0,YR,A,M,Y,71.202,KG,20231127.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Economic problem;Emotional distress;End stage renal disease;Fatigue;Fear-related avoidance of activities;Impaired work ability;Loss of personal independence in daily activities;Mobility decreased;Myocardial infarction;Nephrolithiasis;Osteopenia;Pain;Quality of life decreased;Renal cyst;Renal failure,168622414.0,HO,,,168622414.0,1.0,2011.0,2018.0,,,168622414.0,1.0,HIV infection
16862483,168624831,1,I,,20190923.0,20190927,20190927,EXP,,FR-MYLANLABS-2019M1089460,MYLAN,,,,,,Y,,,20190927.0,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,168624831.0,CA,,,168624831.0,1.0,20050513.0,20050908.0,,,168624831.0,1.0,HIV infection
16863042,168630424,4,F,20070101.0,20231221.0,20190927,20231225,EXP,,US-GILEAD-2019-0429241,GILEAD,,53.0,YR,A,M,Y,84.807,KG,20231225.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Economic problem;Emotional distress;Pain,168630424.0,DE,,,168630424.0,1.0,200607.0,201606.0,,,168630424.0,1.0,HIV infection
16863190,168631904,4,F,20130101.0,20231218.0,20190927,20231220,EXP,,US-GILEAD-2019-0429518,GILEAD,,57.0,YR,A,M,Y,,,20231220.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Fatigue;Fear;Hypercalcaemia;Hyperparathyroidism;Leg amputation;Loss of personal independence in daily activities;Mobility decreased;Pain;Pollakiuria;Quality of life decreased,168631904.0,HO,,,168631904.0,1.0,20131118.0,20160510.0,904.0,DAY,168631904.0,1.0,HIV infection
16863363,168633632,2,F,2005.0,20200713.0,20190927,20200723,EXP,,US-GILEAD-2019-0429499,GILEAD,,51.0,YR,A,M,Y,81.63,KG,20200723.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Decreased activity;Depression;Economic problem;Emotional distress;Fear;Loss of personal independence in daily activities;Nephropathy;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal failure,168633632.0,OT,,,168633632.0,1.0,2004.0,2016.0,,,168633632.0,1.0,HIV infection
16867869,168678691,1,I,,20190916.0,20190930,20190930,EXP,,IT-ROCHE-2419096,ROCHE,"BINI T, TESTA L, CHIESA E, ADORNI F, ABELI C, CASTELNUOVO B, MELZI S, SOLLIMA S, BONGIOVANNI M AND D^ARMINIO MONFORTE A OUTCOME OF A SECOND-LINE PROTEASE INHIBITOR-CONTAINING REGIMEN IN PATIENTS FAILING OR INTOLERANT OF A FIRST HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2000 JUN 01;24 (2):115-22.",,,,,Y,,,20190930.0,,OT,IT,IT,EFAVIRENZ.,Hepatotoxicity,168678691.0,OT,,,,,,,,,168678691.0,1.0,HIV infection
16867931,168679314,4,F,1996.0,20200904.0,20190930,20200908,EXP,,ES-ROCHE-2412643,ROCHE,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV?INFECTED PATIENT. CLINICAL DRUG INVESTIGATION 2019?39:1125?1131.",38.0,YR,,M,Y,,,20200908.0,,HP,ES,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome;Fatigue;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal glycosuria;Renal impairment;Virologic failure,168679314.0,OT,,,168679314.0,1.0,1996.0,1997.0,,,168679314.0,1.0,Antiretroviral therapy
16869360,168693601,1,I,,20190924.0,20190930,20190930,EXP,,GB-MYLANLABS-2019M1090004,MYLAN,,43.0,YR,,F,Y,,,20190930.0,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,168693601.0,OT,,,168693601.0,2.0,20171006.0,,,,168693601.0,1.0,HIV infection
16870109,168701091,1,I,,20190926.0,20190930,20190930,EXP,,GB-MYLANLABS-2019M1091043,MYLAN,,43.0,YR,,F,Y,,,20190930.0,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,168701091.0,OT,,,168701091.0,1.0,20171006.0,,,,168701091.0,1.0,HIV infection
16874037,168740371,1,I,,20190919.0,20191001,20191001,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092106,BRISTOL MYERS SQUIBB,,43.0,YR,,,Y,,,20191001.0,,OT,CH,CH,EFAVIRENZ.,Drug dependence;Weight decreased,168740371.0,OT,,,168740371.0,1.0,201405.0,201412.0,,,168740371.0,1.0,Antiretroviral therapy
16889040,168890402,2,F,,20190927.0,20191007,20191011,EXP,,IN-CIPLA LTD.-2019IN06677,CIPLA,,,,,,Y,,,20191011.0,,OT,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,168890402.0,OT,,,,,,,,,168890402.0,1.0,Prophylaxis against HIV infection
16889041,168890412,2,F,,20190927.0,20191007,20191011,EXP,,IN-CIPLA LTD.-2019IN06678,CIPLA,,,,,,Y,,,20191011.0,,OT,IN,IN,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,168890412.0,OT,,,,,,,,,168890412.0,1.0,HIV infection
16889107,168891072,2,F,,20190927.0,20191007,20191011,EXP,,IN-CIPLA (EU) LIMITED-2019IN06675,CIPLA,,,,,,Y,,,20191011.0,,OT,IN,IN,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,168891072.0,OT,,,,,,,,,168891072.0,1.0,HIV test positive
16889463,168894631,1,I,,20190923.0,20191007,20191007,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-096878,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191007.0,,OT,IN,IN,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,168894631.0,OT,,,,,,,,,168894631.0,1.0,HIV infection
16889473,168894731,1,I,,20190923.0,20191007,20191007,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-094422,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191007.0,,OT,IN,IN,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,168894731.0,OT,,,,,,,,,168894731.0,1.0,HIV infection
16889486,168894861,1,I,,20190923.0,20191007,20191007,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-096879,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191007.0,,OT,IN,IN,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,168894861.0,OT,,,,,,,,,168894861.0,1.0,HIV infection
16891046,168910461,1,I,201012.0,20190930.0,20191007,20191007,EXP,,PT-MYLANLABS-2019M1091846,MYLAN,,,,A,F,Y,,,20191007.0,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Maternal exposure during pregnancy;Treatment noncompliance;Viral load increased,168910461.0,OT,,,168910461.0,1.0,201006.0,201006.0,,,168910461.0,1.0,HIV infection
16895391,168953911,1,I,2012.0,20191001.0,20191008,20191008,EXP,,"AT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-105155",BOEHRINGER INGELHEIM,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,69.0,YR,,M,Y,90.0,KG,20191008.0,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,168953911.0,OT,,,168953911.0,1.0,20120419.0,20121203.0,,,168953911.0,1.0,Antiretroviral therapy
16897772,168977723,3,F,,20190927.0,20191009,20191011,EXP,,IN-CIPLA LTD.-2019IN06679,CIPLA,,,,,,Y,,,20191011.0,,OT,IN,IN,EFAVIRENZ.,Exposure via breast milk;Foetal exposure during pregnancy;Human immunodeficiency virus transmission,168977723.0,OT,,,,,,,,,168977723.0,1.0,Prophylaxis against HIV infection
16898099,168980996,6,F,,20191130.0,20191009,20191211,EXP,,PT-AUROBINDO-AUR-APL-2019-064780,AUROBINDO,,45.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,Efavirenz Film Coated Tablets,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,168980996.0,OT,,,168980996.0,1.0,2010.0,,,,168980996.0,1.0,HIV infection
16906076,169060761,1,I,,20190610.0,20191010,20191010,EXP,,CA-AUROBINDO-AUR-APL-2019-034286,AUROBINDO,,54.0,YR,,M,Y,,,20191011.0,,OT,CA,CA,EFAVIRENZ.,Drug ineffective;Hypertriglyceridaemia,169060761.0,OT,,,,,,,,,169060761.0,1.0,HIV infection
16906252,169062522,2,F,,20191011.0,20191011,20191024,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-095044,BRISTOL MYERS SQUIBB,,52.0,YR,,F,Y,,,20191024.0,,OT,US,US,SUSTIVA,No adverse event,,,,,,,,,,,169062522.0,1.0,Antiretroviral therapy
16907243,169072431,1,I,,20191002.0,20191011,20191011,EXP,,DE-VIIV HEALTHCARE LIMITED-NG2019GSK183006,VIIV,,7.0,YR,,M,Y,,,20191011.0,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072431.0,OT,,,,,,,,,169072431.0,1.0,HIV infection
16907244,169072441,1,I,,20191002.0,20191011,20191011,EXP,,DE-VIIV HEALTHCARE LIMITED-NG2019GSK183008,VIIV,,42.0,YR,,M,Y,,,20191011.0,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072441.0,OT,,,,,,,,,169072441.0,1.0,HIV infection
16907247,169072471,1,I,,20191002.0,20191011,20191011,EXP,,DE-GLAXOSMITHKLINE-NG2019GSK183006,GLAXOSMITHKLINE,,7.0,YR,,M,Y,,,20191011.0,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072471.0,OT,,,,,,,,,169072471.0,1.0,HIV infection
16907249,169072491,1,I,,20191002.0,20191011,20191011,EXP,,DE-GLAXOSMITHKLINE-NG2019GSK183008,GLAXOSMITHKLINE,,42.0,YR,,M,Y,,,20191011.0,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072491.0,OT,,,,,,,,,169072491.0,1.0,HIV infection
16908146,169081462,2,F,20190929.0,20200721.0,20191011,20200727,EXP,,US-GILEAD-2019-0432211,GILEAD,,60.0,YR,A,M,Y,99.7,KG,20200727.0,,CN,US,US,SUSTIVA,Abnormal dreams;Atrial fibrillation;Burn oral cavity;Burning sensation;Emotional disorder;Feeling hot;Flushing;Genital burning sensation;Genital rash;Gingival bleeding;Hypertension;Mental disorder;Myocardial infarction;Nervous system disorder;Nightmare;Oral disorder;Poisoning;Poor dental condition;Skin burning sensation,169081462.0,OT,,,169081462.0,2.0,201901.0,,,,169081462.0,1.0,HIV test positive
16914788,169147883,3,F,,20191115.0,20191014,20191128,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-095326,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,,,20191128.0,,MD,PT,PT,EFAVIRENZ.,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,169147883.0,HO,,,169147883.0,1.0,2010.0,,,,169147883.0,1.0,HIV infection
16928470,169284701,1,I,,20191007.0,20191017,20191017,EXP,,ZA-CIPLA LTD.-2019ZA06872,CIPLA,"ROSSOUW TM, VAN DYK G, VAN ZYL G. RAPID EMERGENCE OF RESISTANCE TO ANTIRETROVIRAL TREATMENT AFTER UNDISCLOSED PRIOR EXPOSURE: A CASE REPORT. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2019;20 (1):1 TO 3",,,,,Y,,,20191017.0,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Gene mutation,169284701.0,OT,,,169284701.0,1.0,20140806.0,,,,169284701.0,1.0,HIV infection
16928945,169289453,3,F,20070403.0,20201004.0,20191017,20201012,EXP,,FR-TEVA-2019-FR-1122063,TEVA,,,,N,M,Y,3.23,KG,20201012.0,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,169289453.0,CA,,,169289453.0,1.0,20070403.0,20070521.0,,,169289453.0,1.0,HIV infection
16929724,169297241,1,I,,20191003.0,20191017,20191017,EXP,,BR-MACLEODS PHARMACEUTICALS US LTD-MAC2019023376,MACLEODS,,,,,,Y,,,20191017.0,,OT,BR,BR,EFAVIRENZ.,Toxic epidermal necrolysis;Treatment failure,169297241.0,OT,,,169297241.0,1.0,2012.0,,,,169297241.0,1.0,Acquired immunodeficiency syndrome
16934617,169346171,1,I,,20191004.0,20191018,20191018,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019023328,MACLEODS,,,,,,Y,,,20191018.0,,OT,US,US,EFAVIRENZ.,Acute kidney injury,169346171.0,OT,,,,,,,,,169346171.0,1.0,HIV infection
16937381,169373812,2,F,,20200116.0,20191018,20200122,EXP,,CA-TEVA-2019-CA-1124072,TEVA,,52.0,YR,,M,Y,,,20200122.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,169373812.0,OT,,,,,,,,,169373812.0,1.0,HIV infection
16938068,169380682,2,F,,20200306.0,20191018,20200310,EXP,,CA-TEVA-2019-CA-1123923,TEVA,,45.0,YR,,M,Y,,,20200310.0,,HP,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,169380682.0,DS,,,,,,,,,169380682.0,1.0,HIV infection
16939274,169392743,3,F,,20200710.0,20191021,20200718,EXP,,NG-AUROBINDO-AUR-APL-2019-067617,AUROBINDO,,7.0,YR,,M,Y,,,20200718.0,,HP,DE,DE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,169392743.0,OT,,,,,,,,,169392743.0,1.0,HIV infection
16939571,169395711,1,I,,20191015.0,20191021,20191021,EXP,,CA-TEVA-2019-CA-1123890,TEVA,,61.0,YR,,M,Y,,,20191021.0,,PH,CA,CA,EFAVIRENZ.,Hip fracture;Osteopenia;Osteoporosis;Spinal compression fracture,169395711.0,HO,,,,,,,,,169395711.0,1.0,HIV infection
16939572,169395722,2,F,,20200116.0,20191021,20200121,EXP,,CA-TEVA-2019-CA-1123997,TEVA,,52.0,YR,,M,Y,,,20200121.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,169395722.0,CA,,,,,,,,,169395722.0,1.0,HIV infection
16939753,169397532,2,F,,20200706.0,20191021,20200716,EXP,,DE-AUROBINDO-AUR-APL-2019-067618,AUROBINDO,,42.0,YR,,M,Y,,,20200717.0,,HP,NG,DE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,169397532.0,OT,,,,,,,,,169397532.0,1.0,HIV infection
16941938,169419381,1,I,2005.0,20191009.0,20191021,20191021,EXP,,US-VIIV HEALTHCARE LIMITED-US2019GSK184821,VIIV,,,,A,M,Y,,,20191021.0,,OT,US,US,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169419381.0,OT,,,,,,,,,169419381.0,1.0,HIV infection
16941939,169419391,1,I,2005.0,20191009.0,20191021,20191021,EXP,,US-GLAXOSMITHKLINE-US2019GSK184821,GLAXOSMITHKLINE,,,,A,M,Y,,,20191021.0,,OT,US,US,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169419391.0,OT,,,,,,,,,169419391.0,1.0,HIV infection
16944576,169445762,2,F,,20200116.0,20191022,20200123,EXP,,CA-TEVA-2019-CA-1123953,TEVA,,52.0,YR,,M,Y,,,20200123.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,169445762.0,OT,,,,,,,,,169445762.0,1.0,HIV infection
16958349,169583492,2,F,,20191030.0,20191024,20191107,EXP,,ZA-GLAXOSMITHKLINE-ZA2019GSK191886,GLAXOSMITHKLINE,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR ET AL.. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2019;20 (1):A971, DOI:10.4102/SAJHIVMED.V2",,,,,Y,,,20191107.0,,MD,ZA,ZA,SUSTIVA,Brachydactyly;Foetal exposure during pregnancy,169583492.0,OT,,,,,,,,,169583492.0,1.0,HIV infection
16958483,169584832,2,F,,20191030.0,20191024,20191107,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019GSK191886,VIIV,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR ET AL.. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2019;20 (1):A971, DOI:10.4102/SAJHIVMED.V2",,,,,Y,,,20191107.0,,MD,ZA,ZA,SUSTIVA,Brachydactyly;Foetal exposure during pregnancy,169584832.0,CA,,,,,,,,,169584832.0,1.0,HIV infection
16962914,169629141,1,I,,20191013.0,20191025,20191025,EXP,,US-CMP PHARMA-2019CMP00028,CMP PHARMA,"GUPTA A, MONTEPIEDRA G, AARON L, ET AL.. ISONIAZID PREVENTIVE THERAPY IN HIV-INFECTED PREGNANT AND POSTPARTUM WOMEN.. N ENGL J MED.. 2019;381(14):1333-1346",,,A,F,Y,,,20191025.0,,MD,US,US,EFAVIRENZ.,Drug interaction;Exposure during pregnancy;Hepatic failure,169629141.0,OT,,,,,,,,,169629141.0,1.0,HIV infection
16962915,169629151,1,I,,20191013.0,20191025,20191025,EXP,,US-CMP PHARMA-2019CMP00029,CMP PHARMA,"GUPTA A, MONTEPIEDRA G, AARON L, ET AL. ISONIAZID PREVENTIVE THERAPY IN HIV-INFECTED PREGNANT AND POSTPARTUM WOMEN. N ENGL J MED. 2019;381(14):1333-1346",,,A,F,Y,,,20191025.0,,OT,US,US,EFAVIRENZ.,Drug interaction;Hepatic failure,169629151.0,DE,,,,,,,,,169629151.0,1.0,HIV infection
16966245,169662455,5,F,20100224.0,20210623.0,20191028,20210630,EXP,,US-GILEAD-2019-0434722,GILEAD,,37.0,YR,A,F,Y,59.86,KG,20210629.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Arthralgia;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Haematuria;Nephrolithiasis;Pain;Proteinuria;Pyuria;Red blood cell count increased;Renal failure;Tooth disorder,169662455.0,OT,,,169662455.0,1.0,2001.0,2006.0,,,169662455.0,1.0,HIV infection
16967344,169673441,1,I,,20191021.0,20191028,20191028,EXP,,IT-MYLANLABS-2019M1101321,MYLAN,,,,,F,Y,,,20191028.0,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,169673441.0,OT,,,,,,,,,169673441.0,1.0,HIV infection
16969122,169691225,5,F,20160101.0,20201202.0,20191029,20201207,EXP,,US-GILEAD-2019-0434689,GILEAD,,57.0,YR,A,M,Y,113.38,KG,20201207.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone loss;Depression;Economic problem;Emotional distress;Intervertebral disc degeneration;Liver disorder;Nerve compression;Osteonecrosis;Osteoporosis;Osteoporotic fracture;Pain;Renal disorder,169691225.0,OT,,,169691225.0,1.0,200101.0,201601.0,,,169691225.0,1.0,HIV infection
16970346,169703468,8,F,20080101.0,20230626.0,20191029,20230629,EXP,,US-GILEAD-2019-0434731,GILEAD,,41.0,YR,A,F,Y,57.143,KG,20230629.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Fanconi syndrome acquired;Fatigue;Glycosuria;Osteopenia;Osteoporosis;Pain;Pathological fracture;Proteinuria;Renal failure;Vitamin D decreased;Weight decreased,169703468.0,OT,,,169703468.0,1.0,2001.0,2010.0,3261.0,DAY,169703468.0,1.0,HIV infection
16972969,169729696,6,F,201706.0,20210923.0,20191030,20210929,EXP,,US-GILEAD-2019-0434698,GILEAD,,44.0,YR,A,M,Y,79.37,KG,20210929.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Multiple fractures;Osteomalacia;Osteopenia;Pain;Rib fracture;Vitamin D deficiency,169729696.0,OT,,,169729696.0,1.0,200601.0,200701.0,,,169729696.0,1.0,HIV infection
16973386,169733866,6,F,20050101.0,20231107.0,20191030,20231109,EXP,,US-GILEAD-2019-0434777,GILEAD,,52.0,YR,A,F,Y,97.506,KG,20231109.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Bone loss;Chronic sinusitis;Clavicle fracture;Economic problem;Emotional distress;Femur fracture;Foot fracture;Glomerular filtration rate decreased;Hip arthroplasty;Intervertebral disc disorder;Knee arthroplasty;Multiple fractures;Neuropathy peripheral;Osteoarthritis;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal disorder;Renal failure;Shoulder arthroplasty;Vitamin D deficiency,169733866.0,OT,,,169733866.0,1.0,20021016.0,20080307.0,1969.0,DAY,169733866.0,1.0,HIV infection
16974611,169746117,7,F,20060101.0,20240122.0,20191030,20240124,EXP,,US-GILEAD-2019-0434773,GILEAD,,56.0,YR,A,M,Y,,,20240123.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Facet joint syndrome;Feeling abnormal;Gait disturbance;General physical health deterioration;Intervertebral disc degeneration;Intervertebral disc space narrowing;Lumbar vertebral fracture;Mobility decreased;Multiple fractures;Osteopenia;Osteoporosis;Pain;Partner stress;Sacroiliitis;Shoulder operation;Spinal compression fracture;Spinal osteoarthritis;Vertebral foraminal stenosis;Vertebroplasty,169746117.0,OT,,,169746117.0,1.0,2002.0,2015.0,,,169746117.0,1.0,HIV infection
16978043,169780436,6,F,20060101.0,20230503.0,20191031,20230505,EXP,,US-GILEAD-2019-0434706,GILEAD,,42.0,YR,A,M,Y,,,20230505.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Bone loss;Economic problem;Emotional distress;Foot fracture;Fracture;Osteoporosis;Osteoporotic fracture;Pain,169780436.0,OT,,,169780436.0,1.0,2002.0,2005.0,,,169780436.0,1.0,HIV infection
16979900,169799001,1,I,,20191022.0,20191031,20191031,EXP,,NVSC2019MW019751,NOVARTIS,,,,A,,Y,,,20191031.0,,OT,MW,MW,EFAVIRENZ.,Electrocardiogram QT prolonged;Product use in unapproved indication,169799001.0,OT,,,,,,,,,169799001.0,1.0,HIV infection
16991019,169910193,3,F,,20191104.0,20191104,20191113,EXP,,ZA-GILEAD-2019-0435933,GILEAD,,,,N,,Y,,,20191113.0,,OT,ZA,ZA,EFAVIRENZ.,Brachydactyly;Foetal exposure during pregnancy,169910193.0,CA,,,,,,,,,169910193.0,1.0,HIV infection
16992764,169927641,1,I,,,20190923,20190923,DIR,,,FDA-CTU,,,,,M,N,,,20190907.0,N,OT,US,US,EFAVIRENZ 600MG,Coordination abnormal,,,169927641.0,HP,169927641.0,1.0,20030711.0,,,,169927641.0,1.0,HIV infection
16998200,169982003,3,F,,20191111.0,20191106,20191114,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019200075,VIIV,,,,N,,Y,,,20191114.0,,OT,ZA,ZA,EFAVIRENZ.,Brachydactyly;Foetal exposure during pregnancy,169982003.0,CA,,,,,,,,,169982003.0,1.0,HIV infection
16998253,169982533,3,F,,20191111.0,20191106,20191114,EXP,,ZA-GLAXOSMITHKLINE-ZA2019200075,GLAXOSMITHKLINE,,,,N,,Y,,,20191114.0,,OT,ZA,ZA,EFAVIRENZ.,Brachydactyly;Foetal exposure during pregnancy,169982533.0,CA,,,,,,,,,169982533.0,1.0,HIV infection
17004531,170045311,1,I,20190827.0,20191105.0,20191107,20191107,EXP,GB-MHRA-EYC 00210716,GB-VIIV HEALTHCARE LIMITED-GB2019200750,VIIV,,55.0,YR,,M,Y,76.0,KG,20191107.0,,MD,GB,GB,EFAVIRENZ.,Myocardial infarction,170045311.0,HO,,,170045311.0,1.0,20080201.0,20191014.0,,,170045311.0,1.0,HIV infection
17005802,170058021,1,I,,20191106.0,20191107,20191107,EXP,,IT-GILEAD-2019-0436557,GILEAD,,51.0,YR,A,M,Y,,,20191107.0,,CN,IT,IT,SUSTIVA,Osteoporosis,170058021.0,OT,,,,,,,,,170058021.0,1.0,HIV infection
17017670,170176707,7,F,,20230425.0,20191111,20230508,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-081449,BRISTOL MYERS SQUIBB,"Kwon M, Bailen R, Balsalobre P, Jurado M, Bermudez A, Badiola J, et al. Allogenic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. AIDS. 2019;33(9):1441-7. doi:10.1097/QAD.0000000000002209.",,,A,,Y,,,20230508.0,,MD,ES,ES,EFAVIRENZ,Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,170176707.0,OT,,,170176707.0,1.0,2008.0,,,,170176707.0,1.0,Antiretroviral therapy
17034605,170346056,6,F,,20210309.0,20191115,20210319,EXP,,CA-009507513-1911CAN004586,MERCK,,52.0,YR,,M,Y,,,20210319.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,170346056.0,OT,,,,,,,,,170346056.0,1.0,HIV infection
17040024,170400241,1,I,,20191113.0,20191116,20191116,EXP,,GB-GILEAD-2019-0437798,GILEAD,,,,A,M,Y,,,20191116.0,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,170400241.0,OT,,,,,,,,,170400241.0,1.0,HIV infection
17042336,170423362,2,F,,20200722.0,20191118,20200731,EXP,,CA-009507513-1911CAN004576,MERCK,,44.0,YR,,M,Y,,,20200731.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,170423362.0,HO,,,,,,,,,170423362.0,1.0,HIV infection
17046127,170461272,2,F,,20200529.0,20191119,20200606,EXP,,CA-AUROBINDO-AUR-APL-2019-010734,AUROBINDO,,45.0,YR,,M,Y,,,20200606.0,,CN,CA,CA,EFAVIRENZ.,Multiple-drug resistance,170461272.0,OT,,,,,,,,,170461272.0,1.0,HIV infection
17048421,170484211,1,I,20070313.0,20191112.0,20191119,20191119,EXP,US-EMA-20170412-KUMARNVEVHP-112118607,US-GILEAD-2019-0437138,GILEAD,,45.0,YR,A,M,Y,100.0,KG,20191119.0,,MD,US,US,EFAVIRENZ.,Aplasia pure red cell;Axillary vein thrombosis;Febrile neutropenia;Squamous cell carcinoma;Subclavian vein thrombosis;Venous thrombosis,170484211.0,OT,,,170484211.0,1.0,20060628.0,20070412.0,,,170484211.0,1.0,HIV infection
17051507,170515071,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073468,AUROBINDO,,54.0,YR,,M,Y,,,20191120.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,170515071.0,OT,,,,,,,,,170515071.0,1.0,HIV infection
17052970,170529701,1,I,20191022.0,,20191022,20191022,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20191022.0,N,,US,US,SUSTIVA,Product use issue;Viral load abnormal,,,,,170529701.0,1.0,201910.0,201910.0,,,170529701.0,1.0,HIV infection
17055866,170558661,1,I,,20191111.0,20191120,20191120,EXP,,GB-AUROBINDO-AUR-APL-2019-073748,AUROBINDO,,70.0,YR,,M,Y,,,20191121.0,,MD,GB,GB,Efavirenz Film-coated Tablet,Neurotoxicity,170558661.0,OT,,,,,,,,,170558661.0,1.0,HIV infection
17056191,170561911,1,I,,20191112.0,20191121,20191121,EXP,,CA-009507513-1911CAN004547,MERCK,,54.0,YR,,M,Y,,,20191121.0,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,170561911.0,DE,,,,,,,,,170561911.0,1.0,HIV infection
17069235,170692352,2,F,,20191111.0,20191125,20191126,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-108547,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,,,20191126.0,,MD,GB,GB,EFAVIRENZ.,Neurotoxicity,170692352.0,OT,,,,,,,,,170692352.0,1.0,HIV infection
17075949,170759496,6,F,20081203.0,20231102.0,20191126,20231107,EXP,,US-GILEAD-2019-0439508,GILEAD,,49.0,YR,A,M,Y,86.168,KG,20231107.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Back pain;Bone density decreased;Cervical vertebral fracture;Economic problem;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal compression fracture;Spinal fusion surgery;Spinal operation;Therapeutic product effect decreased,170759496.0,OT,,,170759496.0,1.0,20070131.0,20170502.0,3744.0,DAY,170759496.0,1.0,HIV infection
17075955,170759556,6,F,2013.0,20200904.0,20191126,20201119,EXP,,US-GILEAD-2019-0439498,GILEAD,,55.0,YR,A,M,Y,70.3,KG,20201119.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Antisocial behaviour;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Foot fracture;Osteoporosis;Pain;Renal failure;Renal tubular necrosis,170759556.0,HO,,,170759556.0,1.0,20130612.0,20130719.0,,,170759556.0,1.0,HIV infection
17075959,1707595910,10,F,20160530.0,20210504.0,20191126,20210506,EXP,,US-GILEAD-2019-0439481,GILEAD,,59.0,YR,A,M,Y,64.85,KG,20210506.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back injury;Chest injury;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Foot fracture;Joint injury;Limb injury;Osteoarthritis;Osteoporosis;Pain;Pancreatitis;Renal failure;Renal tubular disorder;Renal tubular necrosis;Tooth loss,1707595910.0,OT,,,1707595910.0,1.0,200709.0,20111028.0,,,1707595910.0,1.0,HIV infection
17075964,170759646,6,F,201009.0,20201210.0,20191126,20201215,EXP,,US-GILEAD-2019-0439491,GILEAD,,53.0,YR,A,M,Y,52.15,KG,20201215.0,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain;Renal failure,170759646.0,OT,,,170759646.0,1.0,20020823.0,20101201.0,,,170759646.0,1.0,HIV infection
17079970,170799701,1,I,,20191112.0,20191127,20191127,EXP,,CH-VIIV HEALTHCARE LIMITED-CH2019GSK212262,VIIV,"WAGNER N, WYLER-LAZAREVIC CA, YERLY S, SAMER C, PEYTAVIN G, POSFAY-BARBE KM ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY IN A SEVERELY OVERWEIGHT CHILD WITH A MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION. A CASE REPORT AND REVIEW.. NEW MICROBES NEW INFECT. 2015;6:DOI.10.1016/J.NMNI.2015.02.003",,,C,M,Y,,,20191127.0,,OT,CH,CH,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,170799701.0,OT,,,,,,,,,170799701.0,1.0,HIV infection
17079974,170799741,1,I,,20191112.0,20191127,20191127,EXP,,CH-GLAXOSMITHKLINE-CH2019GSK212262,GLAXOSMITHKLINE,"WAGNER N, WYLER-LAZAREVIC CA, YERLY S, SAMER C, PEYTAVIN G, POSFAY-BARBE KM ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY IN A SEVERELY OVERWEIGHT CHILD WITH A MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION. A CASE REPORT AND REVIEW.. NEW MICROBES NEW INFECT. 2015;6:DOI.10.1016/J.NMNI.2015.02.003",,,C,M,Y,,,20191127.0,,OT,CH,CH,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,170799741.0,OT,,,,,,,,,170799741.0,1.0,HIV infection
17084668,170846683,3,F,20181001.0,20200810.0,20191127,20200820,EXP,,"BW-LANNETT COMPANY, INC.-BW-2019LAN001043",LANNETT,,0.0,DY,,,Y,,,20200820.0,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,170846683.0,OT,,,,,,,,,170846683.0,1.0,HIV infection
17087202,170872021,1,I,,20191118.0,20191128,20191128,EXP,,GB-AUROBINDO-AUR-APL-2019-075486,AUROBINDO,,,,A,M,Y,,,20191128.0,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,170872021.0,OT,,,,,,,,,170872021.0,1.0,HIV infection
17093344,170933441,1,I,,20191125.0,20191129,20191129,EXP,,ZA-GILEAD-2019-0439767,GILEAD,"MORARE NMT, ROSE DM, APPELS O. OESOPHAGEAL TUBERCULOSIS WITH CONCOMITANT CANDIDIASIS: A RARE CAUSE OF DYSPHAGIA.. BMJ CASE REPORTS. 2019;12:UNK. DOI:10.1136/BCR-2019-231435",23.0,YR,A,F,Y,,,20191129.0,,OT,ZA,ZA,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis,170933441.0,OT,,,,,,,,,170933441.0,1.0,HIV infection
17094109,170941091,1,I,,20191115.0,20191129,20191129,EXP,,US-GLAXOSMITHKLINE-UG2019GSK213564,GLAXOSMITHKLINE,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",23.0,YR,,F,Y,,,20191129.0,,OT,US,UG,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,170941091.0,OT,,,,,,,,,170941091.0,1.0,HIV infection
17094110,170941101,1,I,,20191115.0,20191129,20191129,EXP,,US-VIIV HEALTHCARE LIMITED-UG2019GSK213564,VIIV,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",23.0,YR,,F,Y,,,20191129.0,,OT,US,UG,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,170941101.0,OT,,,,,,,,,170941101.0,1.0,HIV infection
17094111,170941111,1,I,,20191115.0,20191129,20191129,EXP,,US-VIIV HEALTHCARE LIMITED-UG2019GSK216637,VIIV,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",,,,,Y,,,20191129.0,,OT,US,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Stillbirth,170941111.0,DE,,,,,,,,,170941111.0,1.0,HIV infection
17094112,170941121,1,I,,20191115.0,20191129,20191129,EXP,,US-GLAXOSMITHKLINE-UG2019GSK216637,GLAXOSMITHKLINE,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",,,,,Y,,,20191129.0,,OT,US,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Stillbirth,170941121.0,OT,,,,,,,,,170941121.0,1.0,HIV infection
17096196,170961961,1,I,,20191118.0,20191202,20191202,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-111396,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20191202.0,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,170961961.0,OT,,,,,,,,,170961961.0,1.0,HIV infection
17097939,170979395,5,F,20120101.0,20211109.0,20191202,20211124,EXP,,US-GILEAD-2019-0440104,GILEAD,,,,A,M,Y,,,20211124.0,,LW,US,US,SUSTIVA,Arthralgia;Bone density abnormal;Bone density decreased;Bone loss;Hip arthroplasty;Joint arthroplasty;Multiple fractures;Osteonecrosis;Osteoporosis;Tooth fracture;Tooth loss,170979395.0,OT,,,170979395.0,1.0,2008.0,2008.0,,,170979395.0,1.0,HIV infection
17110907,171109074,4,F,20150101.0,20211017.0,20191204,20211028,EXP,,US-GILEAD-2019-0440237,GILEAD,,,,A,F,Y,,,20211028.0,,LW,US,US,SUSTIVA,Back disorder;Bone density decreased;Bone loss;Intervertebral disc degeneration;Multiple fractures;Osteonecrosis;Osteoporosis;Tooth loss;Upper limb fracture,171109074.0,OT,,,171109074.0,1.0,2005.0,200612.0,,,171109074.0,1.0,HIV infection
17113099,171130991,1,I,20191114.0,20191203.0,20191204,20191204,EXP,ES-AEMPS-568082,ES-GILEAD-2019-0440732,GILEAD,,43.0,YR,A,M,Y,,,20191204.0,,PH,ES,ES,EFAVIRENZ SANDOZ,Erythema;Rash,171130991.0,OT,,,171130991.0,1.0,20170801.0,20191114.0,,,171130991.0,1.0,HIV test positive
17120780,171207806,6,F,2010.0,20201023.0,20191206,20201102,EXP,,US-GILEAD-2019-0440919,GILEAD,,57.0,YR,A,M,Y,72.56,KG,20201102.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Dysstasia;Economic problem;Emotional distress;Forearm fracture;Gait disturbance;Genotype drug resistance test positive;Loss of personal independence in daily activities;Osteonecrosis;Osteopenia;Pain;Tooth fracture;Tooth loss;Viral load abnormal;Wrist fracture,171207806.0,OT,,,171207806.0,1.0,20100316.0,20110510.0,,,171207806.0,1.0,HIV infection
17124376,171243761,1,I,,20191202.0,20191206,20191206,EXP,,IT-MYLANLABS-2019M1119580,MYLAN,"CASTAGNA A, MUCCINI C, GALLI L, BIGOLONI A, POLI A, SPAGNUOLO V, ET AL.. ANALYTICAL TREATMENT INTERRUPTION IN CHRONIC HIV-1 INFECTION: TIME AND MAGNITUDE OF VIRAL REBOUND IN ADULTS WITH 10 YEARS OF UNDETECTABLE VIRAL LOAD AND LOW HIV-DNA (APACHE STUDY). J. ANTIMICROB. CHEMOTHER.. 2019;74(7):2039-46",,,A,,Y,,,20191206.0,,OT,IT,IT,EFAVIRENZ.,Blood HIV RNA increased,171243761.0,OT,,,,,,,,,171243761.0,1.0,HIV infection
17129467,171294673,3,F,2012.0,20200414.0,20191209,20200417,EXP,,AT-MYLANLABS-2019M1119555,MYLAN,SCHALK H.. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,69.0,YR,,M,Y,90.0,KG,20200417.0,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Cough;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,171294673.0,OT,,,171294673.0,1.0,20040423.0,201708.0,,,171294673.0,1.0,Antiretroviral therapy
17135027,171350271,1,I,,20191128.0,20191210,20191210,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK223524,GLAXOSMITHKLINE,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,2.4,KG,20191210.0,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Low birth weight baby,171350271.0,OT,,,,,,,,,171350271.0,1.0,HIV infection
17135031,171350311,1,I,,20191128.0,20191210,20191210,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK224172,GLAXOSMITHKLINE,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,,,20191210.0,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,171350311.0,OT,,,,,,,,,171350311.0,1.0,HIV infection
17135041,171350411,1,I,,20191128.0,20191210,20191210,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK223524,VIIV,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,2.4,KG,20191210.0,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Low birth weight baby,171350411.0,OT,,,,,,,,,171350411.0,1.0,HIV infection
17135044,171350441,1,I,,20191128.0,20191210,20191210,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK224172,VIIV,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,,,20191210.0,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,171350441.0,OT,,,,,,,,,171350441.0,1.0,HIV infection
17140455,171404551,1,I,,20191129.0,20191211,20191211,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-115856,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,,,20191211.0,,MD,LV,LV,EFAVIRENZ.,Acute myocardial infarction;Cardiac disorder;Coronary artery disease,171404551.0,OT,,,171404551.0,1.0,201501.0,,,,171404551.0,1.0,HIV infection
17149728,171497283,3,F,,20210426.0,20191213,20210429,EXP,,US-GILEAD-2019-0442009,GILEAD,,,,A,F,Y,52.15,KG,20210429.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Quality of life decreased;Renal failure;Skeletal injury;Tooth injury,171497283.0,OT,,,171497283.0,1.0,2009.0,2017.0,,,171497283.0,1.0,HIV infection
17150292,171502923,3,F,20141202.0,20231125.0,20191213,20231127,EXP,,US-GILEAD-2019-0442021,GILEAD,,47.0,YR,A,M,Y,102.04,KG,20231126.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Glomerular filtration rate decreased;Pain,171502923.0,OT,,,171502923.0,1.0,2001.0,2018.0,,,171502923.0,1.0,HIV infection
17150366,171503661,1,I,20190216.0,20191014.0,20191213,20191213,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019APC185465,VIIV,,,,,,Y,,,20191213.0,,MD,CN,CN,EFAVIRENZ TABLET,Pulmonary tuberculosis,171503661.0,DE,,,171503661.0,1.0,20180821.0,20190105.0,,,171503661.0,1.0,HIV test positive
17150391,171503911,1,I,20190216.0,20191014.0,20191213,20191213,EXP,,CN-GLAXOSMITHKLINE-CN2019APC185465,GLAXOSMITHKLINE,,,,,,Y,,,20191213.0,,MD,CN,CN,EFAVIRENZ TABLET,Pulmonary tuberculosis,171503911.0,DE,,,171503911.0,1.0,20180821.0,20190105.0,,,171503911.0,1.0,HIV test positive
17156913,171569137,7,F,20150101.0,20211223.0,20191216,20220105,EXP,,US-GILEAD-2019-0441951,GILEAD,,,,A,M,Y,104.31,KG,20220105.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Drug ineffective;Dysstasia;Economic problem;Emotional distress;Osteoporosis;Pain;Renal disorder;Renal failure,171569137.0,OT,,,171569137.0,1.0,2009.0,2017.0,,,171569137.0,1.0,HIV infection
17162493,171624934,4,F,2008.0,20200429.0,20191217,20200514,EXP,,US-GILEAD-2019-0442861,GILEAD,,,,A,M,Y,107.03,KG,20200514.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Osteopenia;Pain;Renal failure,171624934.0,OT,,,171624934.0,1.0,200411.0,20170113.0,,,171624934.0,1.0,HIV infection
17168394,171683941,1,I,20191101.0,,20191125,20191125,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20191125.0,N,,US,US,SUSTIVA,Insomnia;Nightmare;Therapy cessation,,,,,171683941.0,1.0,201901.0,201911.0,,,171683941.0,1.0,HIV infection
17178834,171788341,1,I,,20191212.0,20191219,20191219,EXP,,CA-ROCHE-2499425,ROCHE,,54.0,YR,,M,Y,,,20191219.0,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,171788341.0,OT,,,,,,,,,171788341.0,1.0,HIV infection
17187134,171871342,2,F,,20200210.0,20191220,20200214,EXP,,JP-GILEAD-2019-0443510,GILEAD,,37.0,YR,A,M,Y,,,20200214.0,,MD,JP,JP,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis,171871342.0,HO,,,,,,,,,171871342.0,1.0,HIV test positive
17187844,171878441,1,I,201310.0,20191207.0,20191221,20191221,EXP,,GB-AUROBINDO-AUR-APL-2019-105955,AUROBINDO,,39.0,YR,,M,Y,,,20191221.0,,OT,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia;Product use in unapproved indication,171878441.0,HO,,,171878441.0,4.0,200308.0,200311.0,,,171878441.0,1.0,HIV infection CDC category C
17200843,172008431,1,I,,20191212.0,20191226,20191226,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2019-08531,LUPIN,,42.0,YR,,M,Y,,,20191226.0,,OT,DE,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,172008431.0,OT,,,,,,,,,172008431.0,1.0,HIV infection
17200846,172008461,1,I,,20191212.0,20191226,20191226,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2019-08529,LUPIN,,7.0,YR,,M,Y,,,20191226.0,,OT,DE,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,172008461.0,OT,,,,,,,,,172008461.0,1.0,HIV infection
17202563,172025631,1,I,20110825.0,20191217.0,20191226,20191226,EXP,,FR-MYLANLABS-2019M1126225,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL.. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM. BIOL. DRUG DES.. 2018",35.0,YR,,F,Y,,,20191226.0,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,172025631.0,OT,,,,,,,,,172025631.0,1.0,HIV infection
17214260,172142606,6,F,19960101.0,20231127.0,20191230,20231130,EXP,,ES-MYLANLABS-2019M1127115,MYLAN,"Lopez Aspiroz E, Cabrera Figueroa SE, Valverde Merino MP, Carracedo Alvarez AC. Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient.. Clin. Drug Invest.. 2019",38.0,YR,,M,Y,,,20231130.0,,HP,ES,ES,EFAVIRENZ,Asthenia;Bone metabolism disorder;Bone pain;Chronic kidney disease;Drug abuse;Dyslipidaemia;Fanconi syndrome;Fatigue;Glycosuria;Hypophosphataemia;Intentional product misuse;Lipodystrophy acquired;Medication error;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Nephropathy toxic;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,172142606.0,OT,,,172142606.0,1.0,1997.0,2001.0,,,172142606.0,1.0,Antiretroviral therapy
17217518,172175182,2,F,201807.0,20200529.0,20191231,20200609,EXP,,CA-AUROBINDO-AUR-APL-2019-058844,AUROBINDO,"TSENG AL, ET,AL. DOLUTEGRAVIR/EFAVIRENZ/VALPROIC ACID INTERACTION SUBTHERAPEUTIC DRUG CONCENTRATION: CASE REPORT. REACTIONS WEEKLY. 2019;1767:P124",43.0,YR,,F,Y,,,20200609.0,,HP,CA,CA,EFAVIRENZ.,Anticonvulsant drug level below therapeutic;Antiviral drug level below therapeutic;Drug interaction;Drug level below therapeutic;Seizure,172175182.0,OT,,,172175182.0,1.0,2016.0,,,,172175182.0,1.0,HIV infection
17220278,172202786,6,F,20160101.0,20211011.0,20191231,20211019,EXP,,US-GILEAD-2019-0444912,GILEAD,,39.0,YR,A,M,Y,108.84,KG,20211019.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fatigue;Pain;Renal disorder;Renal failure;Spinal osteoarthritis,172202786.0,OT,,,172202786.0,1.0,2001.0,202007.0,,,172202786.0,1.0,HIV infection
17222298,172222981,1,I,20191221.0,,20191231,20191231,DIR,,,FDA-CTU,,64.0,YR,,M,N,,,20191231.0,N,PH,US,US,EFAVIRENZ.,Gastric perforation;Impaired healing,172222981.0,HO,172222981.0,HP,172222981.0,1.0,20190131.0,,,,172222981.0,1.0,HIV infection
17222306,172223061,1,I,20191221.0,,20191231,20191231,DIR,,,FDA-CTU,,64.0,YR,,M,N,,,20191231.0,N,PH,US,US,EFAVIRENZ.,Gastric perforation;Impaired healing,172223061.0,HO,172223061.0,HP,172223061.0,1.0,20190131.0,,,,172223061.0,1.0,HIV infection
17225079,1722507918,18,F,20070403.0,20201204.0,20200102,20201218,EXP,,FR-MYLANLABS-2019M1131600,MYLAN,,,,N,M,Y,3.23,KG,20201218.0,,HP,FR,FR,EFAVIRENZ.;SUSTIVA,Foetal exposure during pregnancy;Hydrocele,1722507918.0,OT,,,1722507918.0,1.0,20070403.0,20070521.0,,,1722507918.0,1.0,HIV infection
17228741,172287411,1,I,,20191224.0,20200103,20200103,EXP,,TH-GLAXOSMITHKLINE-TH2019GSK235930,GLAXOSMITHKLINE,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS ONE. 2019;14 (12):DOI.ORG/10.1371/JOURNAL.PONE.0",23.0,YR,,M,Y,101.0,KG,20200103.0,,HP,TH,TH,EFAVIRENZ.,Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic fibrosis;Hepatic function abnormal;Hepatic steatosis;Nonalcoholic fatty liver disease,172287411.0,OT,,,,,,,,,172287411.0,1.0,Perinatal HIV infection
17228745,172287451,1,I,,20191224.0,20200103,20200103,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2019GSK235930,VIIV,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS ONE. 2019;14 (12):DOI.ORG/10.1371/JOURNAL.PONE.0",23.0,YR,,M,Y,101.0,KG,20200103.0,,HP,TH,TH,EFAVIRENZ.,Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic fibrosis;Hepatic function abnormal;Hepatic steatosis;Nonalcoholic fatty liver disease,172287451.0,OT,,,,,,,,,172287451.0,1.0,Perinatal HIV infection
17237436,172374361,1,I,,20191223.0,20200106,20200106,EXP,,CA-JNJFOC-20191243323,JOHNSON AND JOHNSON,,52.0,YR,,M,Y,,,20200106.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,172374361.0,OT,,,,,,,,,172374361.0,1.0,HIV infection
17240641,172406411,1,I,20191007.0,,20191212,20191212,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20191129.0,N,OT,US,US,EFAVIRENZ 600MG MYLAN,Diarrhoea;Manufacturing issue,,,172406411.0,HP,172406411.0,1.0,20191003.0,,,,172406411.0,1.0,HIV infection
17243257,172432571,1,I,,,20191212,20191212,DIR,,,FDA-CTU,,,,,M,N,,,20191204.0,N,OT,US,US,EFAVIRENZ.,Acute kidney injury,172432571.0,HO,172432571.0,HP,172432571.0,1.0,201201.0,,,,172432571.0,1.0,HIV infection
17244297,172442977,7,F,2006.0,20210105.0,20200107,20210115,EXP,,US-GILEAD-2019-0444758,GILEAD,,54.0,YR,A,M,Y,81.63,KG,20210115.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Depression;Economic problem;Emotional distress;Fracture;Hypersensitivity;Osteopenia;Osteoporosis;Pain;Renal failure;Tooth loss;Upper limb fracture,172442977.0,OT,,,172442977.0,1.0,200604.0,201701.0,,,172442977.0,1.0,HIV infection
17244308,172443084,4,F,2014.0,20210323.0,20200107,20210329,EXP,,US-GILEAD-2019-0444842,GILEAD,,52.0,YR,A,F,Y,70.31,KG,20210329.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain,172443084.0,OT,,,172443084.0,1.0,20121011.0,20150409.0,,,172443084.0,1.0,HIV infection
17244332,172443329,9,F,20070101.0,20230215.0,20200107,20230221,PER,,US-GILEAD-2019-0444850,GILEAD,,,,A,M,Y,86.168,KG,20230221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Drug resistance;Emotional distress;Pain;Renal failure;Skeletal injury,172443329.0,OT,,,172443329.0,1.0,201302.0,201604.0,,,172443329.0,1.0,HIV infection
17244336,172443363,3,F,20161103.0,20201112.0,20200107,20201119,PER,,US-GILEAD-2019-0444847,GILEAD,,49.0,YR,A,M,Y,68.93,KG,20201119.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Osteopenia;Pain,,,,,172443363.0,1.0,20030819.0,20060826.0,,,172443363.0,1.0,HIV infection
17244339,172443392,2,F,20190222.0,20200417.0,20200107,20200811,EXP,,US-GILEAD-2019-0444878,GILEAD,,57.0,YR,A,M,Y,85.26,KG,20200811.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain,172443392.0,OT,,,172443392.0,1.0,2003.0,201407.0,,,172443392.0,1.0,HIV infection
17244347,172443474,4,F,2012.0,20210514.0,20200107,20210520,EXP,,US-GILEAD-2019-0444865,GILEAD,,,,A,M,Y,81.63,KG,20210520.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Fatigue;Gait disturbance;Pain;Pollakiuria,172443474.0,OT,,,172443474.0,1.0,2003.0,201510.0,,,172443474.0,1.0,HIV infection
17244361,172443613,3,F,2016.0,20200910.0,20200107,20200924,EXP,,US-GILEAD-2019-0444939,GILEAD,,57.0,YR,A,F,Y,86.17,KG,20200924.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Hand fracture;Pain;Tooth loss,172443613.0,OT,,,172443613.0,1.0,2005.0,201908.0,,,172443613.0,1.0,HIV infection
17244373,172443737,7,F,20151109.0,20230502.0,20200107,20230504,EXP,,US-GILEAD-2020-0445052,GILEAD,,50.0,YR,A,M,Y,64.863,KG,20230504.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Hip fracture;Multiple fractures;Nephrolithiasis;Osteoporosis;Pain,172443737.0,OT,,,172443737.0,1.0,201208.0,201610.0,1225.0,DAY,172443737.0,1.0,HIV infection
17244379,172443794,4,F,20070101.0,20221209.0,20200107,20221214,EXP,,US-GILEAD-2020-0445051,GILEAD,,59.0,YR,A,M,Y,140.59,KG,20221214.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Depression;Economic problem;Emotional distress;Foot fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Tooth loss,172443794.0,OT,,,172443794.0,1.0,2004.0,2009.0,913.0,DAY,172443794.0,1.0,HIV infection
17244437,172444374,4,F,2017.0,20200902.0,20200107,20201022,EXP,,US-GILEAD-2019-0444942,GILEAD,,,,A,M,Y,58.5,KG,20201022.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Fracture;Pain;Tooth loss;Wrist fracture,172444374.0,OT,,,172444374.0,1.0,2006.0,20170731.0,,,172444374.0,1.0,HIV infection
17244440,172444404,4,F,2017.0,20200911.0,20200107,20200925,EXP,,US-GILEAD-2020-0445067,GILEAD,,40.0,YR,A,M,Y,77.1,KG,20200925.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fracture;Hand fracture;Pain;Renal failure;Rib fracture;Spinal fracture;Tooth loss,172444404.0,OT,,,172444404.0,1.0,2008.0,201803.0,,,172444404.0,1.0,HIV infection
17244469,172444696,6,F,20150612.0,20211022.0,20200107,20211105,EXP,,US-GILEAD-2020-0445093,GILEAD,,69.0,YR,E,M,Y,117.93,KG,20211105.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Mobility decreased;Pain;Proteinuria,172444696.0,OT,,,172444696.0,1.0,200808.0,20170714.0,3217.0,DAY,172444696.0,1.0,HIV infection
17244479,172444795,5,F,20100201.0,20211115.0,20200107,20211130,EXP,,US-GILEAD-2020-0445100,GILEAD,,41.0,YR,A,F,Y,,,20211130.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Death;Drooling;Economic problem;Emotional distress;End stage renal disease;Headache;Hypoaesthesia;Multiple fractures;Nausea;Pain;Pyelonephritis;Rash;Renal failure;Renal impairment;Sinusitis;Somnolence;Urinary tract infection;Vision blurred,172444795.0,HO,,,172444795.0,1.0,2004.0,2008.0,1106.0,DAY,172444795.0,1.0,HIV infection
17244551,172445512,2,F,,20200106.0,20200107,20200110,EXP,,CA-GILEAD-2020-0445490,GILEAD,,52.0,YR,A,M,Y,,,20200110.0,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,172445512.0,OT,,,,,,,,,172445512.0,1.0,HIV infection
17245635,172456356,6,F,20081203.0,20211019.0,20200108,20211028,PER,,US-GILEAD-2020-0445081,GILEAD,,49.0,YR,A,M,Y,86.17,KG,20211028.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Back pain;Bone density decreased;Economic problem;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal compression fracture;Spinal fracture;Spinal operation;Therapeutic product effect decreased,172456356.0,OT,,,172456356.0,1.0,20130104.0,20130106.0,2.0,DAY,172456356.0,1.0,HIV infection
17249734,172497341,1,I,20190425.0,20200102.0,20200109,20200109,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-000815,BRISTOL MYERS SQUIBB,,37.0,YR,,F,Y,,,20200109.0,,HP,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Normal newborn;Twin pregnancy;Vanishing twin syndrome,172497341.0,OT,,,,,,,,,172497341.0,1.0,HIV infection
17250665,172506654,4,F,,20220601.0,20200109,20220608,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020003324,VIIV,,,,,,Y,,,20220608.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,172506654.0,OT,,,,,,,,,172506654.0,1.0,HIV infection
17250675,172506754,4,F,,20220601.0,20200109,20220608,EXP,,CA-GLAXOSMITHKLINE-CA2020003324,GLAXOSMITHKLINE,,,,,,Y,,,20220608.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,172506754.0,OT,,,,,,,,,172506754.0,1.0,HIV infection
17250797,172507971,1,I,,20180305.0,20200109,20200109,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK038176,VIIV,,45.0,YR,,M,Y,,,20200109.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,172507971.0,OT,,,,,,,,,172507971.0,1.0,HIV infection
17250798,172507981,1,I,,20180305.0,20200109,20200109,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK038176,GLAXOSMITHKLINE,,45.0,YR,,M,Y,,,20200109.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,172507981.0,OT,,,,,,,,,172507981.0,1.0,HIV infection
17256109,172561091,1,I,,20200103.0,20200110,20200110,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020GSK004894,VIIV,,37.0,YR,,F,Y,,,20200110.0,,CN,US,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Foetal death,172561091.0,OT,,,,,,,,,172561091.0,1.0,HIV infection
17256115,172561151,1,I,,20200103.0,20200110,20200110,EXP,,GB-GLAXOSMITHKLINE-GB2020GSK004894,GLAXOSMITHKLINE,,37.0,YR,,F,Y,,,20200110.0,,CN,US,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Foetal death,172561151.0,OT,,,,,,,,,172561151.0,1.0,HIV infection
17257415,172574151,1,I,,20200106.0,20200110,20200110,EXP,,IN-MYLANLABS-2020M1003974,MYLAN,"DAVE M, SR L, PATIDAR M, BAPAT P, JITERWAL M, YADAV K, ET AL. HAART INDUCED GYNAECOMASTIA. J-ASSOC-PHYSICIANS-INDIA 2019;67(12):82-83.",42.0,YR,,M,Y,65.0,KG,20200110.0,,MD,IN,IN,EFAVIRENZ.,Gynaecomastia,172574151.0,HO,,,,,,,,,172574151.0,1.0,HIV infection
17257723,172577234,4,F,,20201124.0,20200110,20201202,EXP,,PT-MYLANLABS-2020M1002389,MYLAN,"CERTAL M, CUNHA RG, MOUTINHO A, TAVARES S, GUIMARAES F, MARQUES PV.. HIPOPITUITARISMO EM DOENTE COM CO-INFECCAO PELO VIRUS DA IMUNODEFICIENCIA HUMANA (VIH) TIPO 1 E HEPATITE C (VHC) CRONICA.EPOSTER:DOEN?AS ENDOCRINAS E METABOLICAS.. CONGRESSO NACIONAL DE MEDICINA INTERNA. 2019;23-26",45.0,YR,,M,Y,,,20201202.0,,MD,PT,PT,EFAVIRENZ.,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,172577234.0,HO,,,172577234.0,2.0,2010.0,,,,172577234.0,1.0,HIV infection
17257731,172577311,1,I,,20200106.0,20200110,20200110,EXP,,PT-MYLANLABS-2020M1002400,MYLAN,"CERTAL M, CUNHA RG, MOUTINHO A, TAVARES S, GUIMARAES  F, MARQUES  PV ET AL.. HIPOPITUITARISM IN CO-INFECTED SICKNESS BY IMMUNODEFICIENCY VIRUS HUMAN (HIV) TYPE 1 AND CHRONIC HEPATITIS C (HCV).. 25 CONGRESSO NACIONAL DE MEDICINA INTERNA:ENDOCRINE AND METABOLIC DISEASES-E-POS. 2019",,,A,M,Y,,,20200110.0,,HP,PT,PT,EFAVIRENZ.,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,172577311.0,OT,,,,,,,,,172577311.0,1.0,HIV infection
17261017,172610173,3,F,1989.0,20200819.0,20200113,20200825,EXP,,US-GILEAD-2020-0445884,GILEAD,,53.0,YR,A,M,Y,63.49,KG,20200825.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back injury;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Hip arthroplasty;Hyperparathyroidism;Intervertebral disc degeneration;Nephrolithiasis;Osteoarthritis;Osteopenia;Pain;Renal arteriosclerosis;Renal failure;Renal transplant;Vitamin D decreased,172610173.0,OT,,,172610173.0,1.0,2010.0,2018.0,,,172610173.0,1.0,HIV infection
17261505,172615054,4,F,201202.0,20200429.0,20200113,20200515,PER,,US-GILEAD-2020-0446114,GILEAD,,43.0,YR,A,M,Y,81.18,KG,20200515.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Dehydration;Diarrhoea;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain;Pancreatitis;Renal failure;Vomiting,172615054.0,HO,,,172615054.0,1.0,20111010.0,20120309.0,,,172615054.0,1.0,HIV infection
17261513,172615134,4,F,20100713.0,20200903.0,20200113,20200923,EXP,,US-GILEAD-2020-0446117,GILEAD,,47.0,YR,A,M,Y,76.64,KG,20200923.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;New onset diabetes after transplantation;Osteonecrosis;Osteopenia;Pain;Renal transplant;Renal tubular disorder;Tooth loss,172615134.0,OT,,,172615134.0,1.0,200712.0,201411.0,,,172615134.0,1.0,HIV infection
17262061,172620613,3,F,20150115.0,20220215.0,20200113,20220221,EXP,,US-GILEAD-2020-0446121,GILEAD,,51.0,YR,A,M,Y,,,20220221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Haematuria;Pain,172620613.0,OT,,,172620613.0,1.0,20070427.0,20170424.0,3650.0,DAY,172620613.0,1.0,HIV infection
17262217,172622171,1,I,,20190623.0,20200113,20200113,PER,,US-APOTEX-2019AP017663,APOTEX,"HARZKE AJ, DIAZ M, TONG E, BAILLARGEON G, ZEPEDA S, KORANEK A, SANDMANN R.. SUBSTITUTING GENERIC LAMIVUDINE FOR EMTRICITABINE IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS. DOI: 10.1177/1078345818792834. JOURNAL OF CORRECTIONAL HEALTH CARE. 2018",,,A,,Y,,,20200113.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,172622171.0,1.0,HIV infection
17265362,172653622,2,F,,20231228.0,20200114,20240108,EXP,,US-AUROBINDO-AUR-APL-2020-002236,AUROBINDO,"Griffith DC, Aronis KN, Orozco AM, Traill TA, Manabe YC, Agwu AL.. Premature coronary artery disease and ST-elevation myocardial infarction in a 24-year-old man with perinatally acquired human immunodeficiency virus: A case report. Open Forum Infectious Disease. 2017;4(1):1-4",24.0,YR,,M,Y,,,20240108.0,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis;Coronary artery disease;Electrocardiogram ST segment elevation,172653622.0,HO,,,,,,,,,172653622.0,1.0,Perinatal HIV infection
17267230,172672304,4,F,20130907.0,20210622.0,20200114,20210624,EXP,,US-GILEAD-2020-0445907,GILEAD,,44.0,YR,A,M,Y,79.37,KG,20210624.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Body height decreased;Bone density decreased;Depression;Economic problem;Emotional distress;Femoral neck fracture;Foot fracture;Mobility decreased;Osteonecrosis;Osteoporosis;Pain;Spinal osteoarthritis,172672304.0,OT,,,172672304.0,1.0,200608.0,20200108.0,,,172672304.0,1.0,HIV infection
17269385,172693851,1,I,,20190717.0,20200114,20200114,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK129219,VIIV,"TSENG AL, WONG AYJ, MCLELLAND CJ, WALMSLEY SL.. DRUG INTERACTIONS ARE NOT ALWAYS PREDICTABLE: THE CURIOUS CASE OF VALPROIC ACID AND DOLUTEGRAVIR AND A POSSIBLE EXPLANATION. AIDS. 2019;33(10):1677-1679 DOI: 10.1097/QAD.000",43.0,YR,,F,Y,,,20200114.0,,PH,CA,CA,EFAVIRENZ.,Anticonvulsant drug level below therapeutic;Antiviral drug level below therapeutic;Drug interaction;Drug level below therapeutic;Seizure,172693851.0,OT,,,172693851.0,1.0,201810.0,,,,172693851.0,1.0,HIV infection
17269614,172696141,1,I,20191224.0,,20191224,20191224,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20191224.0,N,,US,US,EFAVIRENZ TAB 600MG,Intentional product use issue,,,,,172696141.0,1.0,201801.0,,,,172696141.0,1.0,HIV infection
17274781,172747811,1,I,,20200109.0,20200115,20200115,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP000318,STRIDES,"DAVE M, SR L, PATIDAR M, BAPAT P, JITERWAL M, YADAV K, ET AL.. HAART INDUCED GYNAECOMASTIA.. JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA. 2019;67(12):82-83",42.0,YR,,M,Y,,,20200116.0,,HP,IN,IN,EFAVIRENZ.,Gynaecomastia,172747811.0,HO,,,,,,,,,172747811.0,1.0,HIV infection
17274987,172749871,1,I,20050602.0,20200103.0,20200116,20200116,EXP,,ZA-MACLEODS PHARMACEUTICALS US LTD-MAC2020024763,MACLEODS,,,,,,Y,,,20200116.0,,HP,ZA,ZA,EFAVIRENZ.,Autoimmune haemolytic anaemia;Hypersensitivity,172749871.0,OT,,,172749871.0,1.0,20050510.0,20050602.0,,,172749871.0,1.0,HIV infection WHO clinical stage III
17281855,172818551,1,I,,20200114.0,20200117,20200117,EXP,GB-MHRA-EYC 00215719,GB-LUPIN PHARMACEUTICALS INC.-2020-00197,LUPIN,,49.0,YR,,M,Y,,,20200117.0,,CN,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172818551.0,OT,,,,,,,,,172818551.0,1.0,HIV infection
17283524,172835243,3,F,20051025.0,20200822.0,20200117,20200916,EXP,,US-GILEAD-2020-0447082,GILEAD,,52.0,YR,A,M,Y,89.8,KG,20200916.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure;Renal transplant;Tooth loss,172835243.0,OT,,,172835243.0,1.0,2005.0,20140407.0,,,172835243.0,1.0,HIV infection
17286891,172868911,1,I,,20200114.0,20200120,20200120,EXP,,GB-AUROBINDO-AUR-APL-2020-003203,AUROBINDO,,49.0,YR,,M,Y,,,20200120.0,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172868911.0,OT,,,,,,,,,172868911.0,1.0,HIV infection
17287878,172878784,4,F,2013.0,20210617.0,20200120,20210624,EXP,,US-GILEAD-2020-0447078,GILEAD,,,,A,M,Y,98.9,KG,20210624.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Bone density abnormal;Chronic kidney disease;Depression;Diabetes mellitus inadequate control;Economic problem;Emotional distress;End stage renal disease;Neuropathy peripheral;Pain;Renal failure;Tooth loss,172878784.0,HO,,,172878784.0,1.0,2005.0,2016.0,,,172878784.0,1.0,HIV infection
17288035,172880353,3,F,20191211.0,20200220.0,20200120,20200228,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019GSK212578,VIIV,,,,,F,Y,,,20200228.0,,MD,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,172880353.0,OT,,,172880353.0,1.0,20170508.0,20191125.0,,,172880353.0,1.0,HIV infection
17288036,172880361,1,I,,20200116.0,20200120,20200120,EXP,GB-MHRA-EYC 00215719,GB-VIIV HEALTHCARE LIMITED-GB2020008852,VIIV,,49.0,YR,,M,Y,,,20200120.0,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172880361.0,LT,,,,,,,,,172880361.0,1.0,HIV infection
17288043,172880431,1,I,,20200116.0,20200120,20200120,EXP,GB-MHRA-EYC 00215719,GB-GLAXOSMITHKLINE-GB2020008852,GLAXOSMITHKLINE,,49.0,YR,,M,Y,,,20200120.0,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172880431.0,OT,,,,,,,,,172880431.0,1.0,HIV infection
17290120,172901201,1,I,,20200115.0,20200120,20200120,PER,,NVSC2020US011372,NOVARTIS,KELLY SL. TIMELY FORMULARY MANAGEMENT FOR PREVENTING ERRORS RELATED TO ANTIRETROVIRAL DRUGS. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY. 2013;70(12):1014-15,48.0,YR,,M,Y,,,20200121.0,,HP,US,US,EFAVIRENZ.,Drug resistance;Product name confusion,,,,,,,,,,,172901201.0,1.0,Antiretroviral therapy
17291227,172912276,6,F,20070101.0,20230522.0,20200121,20230524,EXP,,US-GILEAD-2020-0447101,GILEAD,,54.0,YR,A,M,Y,74.376,KG,20230524.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Economic problem;Emotional distress;Fanconi syndrome acquired;Hip fracture;Multiple fractures;Nephrolithiasis;Osteomalacia;Osteopenia;Osteoporotic fracture;Pain;Renal cyst;Tooth loss;Wrist fracture,172912276.0,OT,,,172912276.0,1.0,200510.0,20060203.0,732.0,DAY,172912276.0,1.0,HIV infection
17291318,172913186,6,F,20120209.0,20220831.0,20200121,20220907,EXP,,US-GILEAD-2020-0447102,GILEAD,,40.0,YR,A,M,Y,104.31,KG,20220907.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Dental caries;Economic problem;Emotional distress;Exercise tolerance decreased;Fatigue;Fracture;Multiple fractures;Osteonecrosis;Pain;Quality of life decreased;Renal cyst;Renal failure;Renal impairment;Tooth loss,172913186.0,OT,,,172913186.0,1.0,201111.0,2013.0,2.0,DAY,172913186.0,1.0,HIV infection
17295433,172954331,1,I,,20200115.0,20200121,20200121,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-003557,BRISTOL MYERS SQUIBB,,49.0,YR,,M,Y,,,20200121.0,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172954331.0,OT,,,,,,,,,172954331.0,1.0,HIV infection
17296315,172963151,1,I,,20191215.0,20200121,20200121,EXP,,CA-TEVA-2019-CA-1154879,TEVA,,54.0,YR,,M,Y,,,20200121.0,,HP,CA,CA,EFAVIRENZ.,Hypertriglyceridaemia,172963151.0,OT,,,,,,,,,172963151.0,1.0,HIV infection
17297535,172975351,1,I,,20050711.0,20200122,20200122,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-13031737,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,,,20200122.0,,CN,ES,ES,EFAVIRENZ.,Acute kidney injury;Hepatitis;Hypersensitivity;Leukocyturia;Pneumonitis;Tuberculosis;Tubulointerstitial nephritis,172975351.0,OT,,,,,,,,,172975351.0,1.0,HIV infection
17303704,173037042,2,F,20170508.0,20200608.0,20200122,20200609,EXP,,ZA-GILEAD-2020-0447684,GILEAD,,,,,F,Y,,,20200609.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173037042.0,OT,,,173037042.0,1.0,20170508.0,,,,173037042.0,1.0,HIV infection
17305733,173057333,3,F,20191218.0,20200203.0,20200123,20200210,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2020GSK008904,VIIV,,29.0,YR,,F,Y,,,20200210.0,,MD,UG,UG,EFAVIRENZ.,Abortion spontaneous,173057333.0,OT,,,173057333.0,1.0,20180606.0,20191105.0,,,173057333.0,1.0,HIV infection
17309113,173091131,1,I,201007.0,20100921.0,20200123,20200123,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15321177,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,60.0,KG,20200123.0,,CN,US,US,EFAVIRENZ.,Blood HIV RNA increased;Drug interaction;Drug level below therapeutic,173091131.0,OT,,,173091131.0,2.0,,20100808.0,,,173091131.0,1.0,Acquired immunodeficiency syndrome
17313822,173138225,5,F,20140101.0,20230926.0,20200124,20230928,EXP,,US-GILEAD-2020-0448025,GILEAD,,,,A,M,Y,104.3,KG,20230928.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Disturbance in attention;Eating disorder;Economic problem;Emotional distress;End stage renal disease;Fatigue;Pain;Renal disorder;Renal failure;Sexual dysfunction;Sleep apnoea syndrome;Sleep disorder,173138225.0,OT,,,173138225.0,1.0,20120209.0,201601.0,26.0,DAY,173138225.0,1.0,HIV infection
17314568,173145681,1,I,,20200116.0,20200124,20200124,EXP,,MM-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-004940,BRISTOL MYERS SQUIBB,"LIN KS, WIN S, NYEIN PP. DRUG-INDUCED IMMUNE HEMOLYTIC ANEMIA BECAUSE OF EFAVIRENZ: A CASE REPORT. AIDS. 2020;34(2):326-8",50.0,YR,,F,Y,,,20200124.0,,HP,MM,MM,EFAVIRENZ.,Haemolytic anaemia,173145681.0,OT,,,173145681.0,1.0,2015.0,,,,173145681.0,1.0,HIV infection
17314757,173147573,3,F,20171213.0,20200206.0,20200124,20200211,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020GSK011990,VIIV,,18.0,YR,,M,Y,,,20200211.0,,MD,GB,GB,EFAVIRENZ.,Pneumonia,173147573.0,HO,,,173147573.0,1.0,20170406.0,20170109.0,,,173147573.0,1.0,HIV infection
17315252,173152521,1,I,20191211.0,20200120.0,20200124,20200124,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-005583,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200124.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173152521.0,OT,,,173152521.0,1.0,20191125.0,,,,173152521.0,1.0,HIV infection
17324001,173240013,3,F,20191211.0,20200514.0,20200127,20200529,EXP,,ZA-AUROBINDO-AUR-APL-2020-004158,AUROBINDO,,,,,F,Y,,,20200529.0,,MD,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173240013.0,OT,,,173240013.0,1.0,20191125.0,,,,173240013.0,1.0,HIV infection
17324065,173240657,7,F,20090909.0,20230913.0,20200127,20230918,EXP,,US-GILEAD-2020-0448201,GILEAD,,30.0,YR,A,F,Y,64.853,KG,20230918.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;End stage renal disease;Renal injury,173240657.0,HO,,,173240657.0,1.0,200605.0,201912.0,1759.0,DAY,173240657.0,1.0,HIV infection
17325096,173250961,1,I,,20200118.0,20200127,20200127,EXP,,IT-MYLANLABS-2020M1007860,MYLAN,,51.0,YR,,M,Y,,,20200127.0,,CN,IT,IT,SUSTIVA,Osteoporosis,173250961.0,OT,,,,,,,,,173250961.0,1.0,HIV infection
17325998,173259982,2,F,20191211.0,20200217.0,20200127,20200224,EXP,,ZA-MYLANLABS-2020M1007885,MYLAN,,,,,F,Y,,,20200224.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173259982.0,OT,,,173259982.0,1.0,20191125.0,,,,173259982.0,1.0,HIV infection
17330571,173305711,1,I,,20200121.0,20200128,20200128,EXP,,GB-MYLANLABS-2020M1008905,MYLAN,,,,A,M,Y,,,20200128.0,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,173305711.0,OT,,,,,,,,,173305711.0,1.0,HIV infection
17335073,173350733,3,F,,20200319.0,20200128,20200325,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2020AMR014738,VIIV,,,,,F,Y,72.0,KG,20200325.0,,MD,BR,BR,EFAVIRENZ.,Dizziness;Gastrointestinal disorder;Hepatotoxicity;Transaminases abnormal,173350733.0,OT,,,173350733.0,5.0,20190326.0,20190826.0,,,173350733.0,1.0,HIV infection
17335755,173357551,1,I,,20200121.0,20200128,20200128,EXP,,ZA-STRIDES ARCOLAB LIMITED-2020SP000630,STRIDES,,,,,F,Y,,,20200128.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173357551.0,OT,,,173357551.0,1.0,20191125.0,,,,173357551.0,1.0,HIV infection
17345583,173455831,1,I,,20200122.0,20200129,20200129,EXP,GB-MHRA-EYC 00215719,GB-TEVA-2020-GB-1175512,TEVA,,49.0,YR,,M,Y,,,20200129.0,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,173455831.0,LT,,,,,,,,,173455831.0,1.0,HIV infection
17346788,173467881,1,I,20191211.0,20200120.0,20200130,20200130,EXP,,ZA-HETERO-HET2020ZA00068,HETERO,,,,,F,Y,,,20200130.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,173467881.0,OT,,,173467881.0,1.0,20191125.0,,,,173467881.0,1.0,HIV infection
17346840,173468402,2,F,200705.0,20200825.0,20200130,20200909,EXP,,US-GILEAD-2020-0448756,GILEAD,,40.0,YR,A,F,Y,87.53,KG,20200909.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;End stage renal disease;Pain,173468402.0,OT,,,173468402.0,1.0,2003.0,20100601.0,,,173468402.0,1.0,HIV infection
17347351,173473514,4,F,2009.0,20210208.0,20200130,20210222,EXP,,US-GILEAD-2020-0448787,GILEAD,,34.0,YR,A,M,Y,65.76,KG,20210222.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain,173473514.0,OT,,,173473514.0,1.0,201407.0,2016.0,,,173473514.0,1.0,HIV infection
17348937,173489372,2,F,201505.0,20200830.0,20200130,20200922,EXP,,US-GILEAD-2020-0448801,GILEAD,,45.0,YR,A,M,Y,50.8,KG,20200922.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Body height decreased;Bone density decreased;Decreased activity;Depression;Economic problem;Emotional distress;Muscular weakness;Musculoskeletal stiffness;Osteopenia;Osteoporosis;Pain;Pain in extremity;Spinal compression fracture;Spinal pain,173489372.0,OT,,,173489372.0,1.0,201309.0,201605.0,,,173489372.0,1.0,HIV infection
17349167,173491675,5,F,201009.0,20210831.0,20200130,20210902,EXP,,US-GILEAD-2020-0448797,GILEAD,,36.0,YR,A,M,Y,79.37,KG,20210901.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,173491675.0,OT,,,173491675.0,1.0,2001.0,20170802.0,,,173491675.0,1.0,HIV infection
17349384,173493841,1,I,,20200125.0,20200130,20200130,EXP,,GB-MYLANLABS-2020M1010503,MYLAN,,43.0,YR,,F,Y,,,20200130.0,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173493841.0,OT,,,173493841.0,1.0,20171006.0,,,,173493841.0,1.0,HIV infection
17350590,173505903,3,F,20111227.0,20231010.0,20200130,20231011,EXP,,US-GILEAD-2020-0448729,GILEAD,,39.0,YR,A,M,Y,,,20231011.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Osteopenia;Pain,173505903.0,OT,,,173505903.0,1.0,2010.0,2015.0,2380.0,DAY,173505903.0,1.0,HIV infection
17350813,173508133,3,F,20070101.0,20230411.0,20200130,20230414,EXP,,US-GILEAD-2020-0448710,GILEAD,,,,A,M,Y,99.773,KG,20230414.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Comminuted fracture;Depression;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain,173508133.0,OT,,,173508133.0,1.0,2006.0,2009.0,,,173508133.0,1.0,HIV infection
17353136,173531363,3,F,20131001.0,20230911.0,20200131,20230914,EXP,,US-GILEAD-2020-0448717,GILEAD,,48.0,YR,A,M,Y,68.027,KG,20230914.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,173531363.0,HO,,,173531363.0,1.0,2011.0,20130321.0,1099.0,DAY,173531363.0,1.0,HIV infection
17353480,173534805,5,F,20110101.0,20230911.0,20200131,20230918,EXP,,US-GILEAD-2020-0448802,GILEAD,,,,A,F,Y,,,20230918.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,173534805.0,OT,,,173534805.0,1.0,2004.0,,,,173534805.0,1.0,HIV infection
17353538,173535382,2,F,20170515.0,20200803.0,20200131,20200827,EXP,,US-GILEAD-2020-0448725,GILEAD,,,,,F,Y,,,20200827.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteoporosis;Pain,173535382.0,OT,,,173535382.0,1.0,2006.0,201801.0,,,173535382.0,1.0,HIV infection
17353625,173536255,5,F,20120601.0,20231216.0,20200131,20231218,EXP,,US-GILEAD-2020-0448749,GILEAD,,46.0,YR,A,M,Y,52.154,KG,20231218.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine decreased;Bone demineralisation;Chronic kidney disease;Clavicle fracture;Economic problem;Emotional distress;Osteoporosis;Pain,173536255.0,OT,,,173536255.0,2.0,2010.0,201005.0,,,173536255.0,1.0,HIV infection
17354354,173543545,5,F,20130601.0,20240103.0,20200131,20240105,EXP,,US-GILEAD-2020-0448785,GILEAD,,62.0,YR,A,M,Y,67.0,KG,20240105.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;End stage renal disease;Osteopenia;Pain;Renal disorder;Renal failure,173543545.0,OT,,,173543545.0,1.0,2013.0,20100323.0,55.0,DAY,173543545.0,1.0,HIV infection
17355530,173555303,3,F,20131005.0,20201203.0,20200131,20201210,EXP,,US-GILEAD-2020-0448761,GILEAD,,44.0,YR,A,M,Y,77.1,KG,20201210.0,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Apathy;Asthenia;Chronic kidney disease;Depression;Economic problem;Emotional distress;Fatigue;Insomnia;Pain;Social avoidant behaviour,173555303.0,OT,,,173555303.0,1.0,20111213.0,20140812.0,,,173555303.0,1.0,HIV infection
17356069,173560691,1,I,,20190905.0,20200131,20200131,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK161485,GLAXOSMITHKLINE,,,,,,Y,,,20200131.0,,HP,CN,CN,EFAVIRENZ.,Renal impairment,173560691.0,OT,,,,,,,,,173560691.0,1.0,HIV infection
17358293,173582931,1,I,,20200117.0,20200201,20200201,EXP,,US-CIPLA (EU) LIMITED-2020US00558,CIPLA,"HSU O, HILL CJ, KIM M, TAN B, O^BRIEN JG.. DECREASED PLASMA EFAVIRENZ CONCENTRATIONS IN A PATIENT RECEIVING RIFABUTIN. AM J HEALTH-SYST PHARM. 2010;67:1611 TO 1614",,,,,Y,,,20200201.0,,HP,US,US,EFAVIRENZ.,Drug interaction;Drug level below therapeutic;Mycobacterium avium complex infection,173582931.0,OT,,,,,,,,,173582931.0,1.0,HIV infection
17359915,173599153,3,F,20141007.0,20230509.0,20200203,20230513,EXP,,US-GILEAD-2020-0448758,GILEAD,,53.0,YR,A,F,Y,71.655,KG,20230513.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone loss;Economic problem;Emotional distress;Gait inability;Osteopenia;Osteoporosis;Pain,173599153.0,OT,,,173599153.0,1.0,2009.0,20170221.0,,,173599153.0,1.0,HIV infection
17359956,173599565,5,F,20090428.0,20240910.0,20200203,20240916,PER,,US-GILEAD-2020-0448795,GILEAD,,54.0,YR,A,M,Y,99.773,KG,20240916.0,,LW,US,US,EFAVIRENZ,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,173599565.0,HO,,,173599565.0,1.0,2004.0,20090312.0,717.0,DAY,173599565.0,1.0,HIV infection
17360065,173600652,2,F,201410.0,20200831.0,20200203,20200916,PER,,US-GILEAD-2020-0448747,GILEAD,,64.0,YR,A,M,Y,94.33,KG,20200916.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Pain;Renal failure,173600652.0,OT,,,173600652.0,1.0,2004.0,2019.0,,,173600652.0,1.0,HIV infection
17360333,173603333,3,F,20190201.0,20231010.0,20200203,20231012,PER,,US-GILEAD-2020-0448768,GILEAD,,57.0,YR,A,M,Y,63.492,KG,20231012.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Pain;Renal failure,173603333.0,OT,,,173603333.0,1.0,2015.0,201905.0,,,173603333.0,1.0,HIV infection
17360688,173606882,2,F,2016.0,20200831.0,20200203,20200915,EXP,,US-GILEAD-2020-0448770,GILEAD,,,,A,F,Y,81.63,KG,20200915.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Fall;Multiple fractures;Osteoporosis;Pain,173606882.0,OT,,,173606882.0,1.0,2008.0,201612.0,,,173606882.0,1.0,HIV infection
17360997,173609973,3,F,20130101.0,20240116.0,20200203,20240118,EXP,,US-GILEAD-2020-0448773,GILEAD,,27.0,YR,A,F,Y,68.039,KG,20240118.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Crying;Death;Depression;Economic problem;Emotional distress;End stage renal disease;Gait disturbance;Helplessness;Pain;Renal atrophy;Renal impairment;Restlessness;Suicidal ideation;Thrombosis,173609973.0,DE,,,173609973.0,1.0,2009.0,20110210.0,125.0,DAY,173609973.0,1.0,HIV infection
17362144,173621443,3,F,20170101.0,20230414.0,20200203,20230419,EXP,,US-GILEAD-2020-0448814,GILEAD,,,,A,F,Y,98.0,KG,20230419.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Death;Economic problem;Emotional distress;Foot fracture;Gait disturbance;Osteoporosis;Pain;Pelvic fracture;Upper limb fracture,173621443.0,DE,,,173621443.0,1.0,2004.0,201605.0,,,173621443.0,1.0,HIV infection
17362297,173622971,1,I,,20200129.0,20200203,20200203,EXP,,BW-MYLANLABS-2020M1011271,MYLAN,,,,,,Y,,,20200203.0,,HP,BW,BW,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,173622971.0,CA,,,,,,,,,173622971.0,1.0,HIV infection
17363179,173631792,2,F,,20200127.0,20200203,20200211,EXP,,UG-GLAXOSMITHKLINE-UG2020GSK014383,GLAXOSMITHKLINE,"KWIZERA R, KATENDE A, TEU A, APOLOT D, WORODRIA W, KIRENGA BJ ET AL.. ALGORITHM-AIDED DIAGNOSIS OF CHRONIC PULMONARY ASPERGILLOSIS IN LOW- AND MIDDLE-INCOME COUNTRIES BY USE OF A LATERAL FLOW DEVICE. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES. 2020;39 (1):DOI.ORG/10.1007/S10096-019-037",40.0,YR,,F,Y,,,20200211.0,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic;Bronchopleural fistula;Bronchopulmonary aspergillosis;HIV infection;Oral candidiasis;Pneumothorax;Virologic failure,173631792.0,HO,,,,,,,,,173631792.0,1.0,HIV infection
17363180,173631802,2,F,,20200127.0,20200203,20200211,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2020GSK014383,VIIV,"KWIZERA R, KATENDE A, TEU A, APOLOT D, WORODRIA W, KIRENGA BJ ET AL.. ALGORITHM-AIDED DIAGNOSIS OF CHRONIC PULMONARY ASPERGILLOSIS IN LOW- AND MIDDLE-INCOME COUNTRIES BY USE OF A LATERAL FLOW DEVICE. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES. 2020;39 (1):DOI.ORG/10.1007/S10096-019-037",40.0,YR,,F,Y,,,20200211.0,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic;Bronchopleural fistula;Bronchopulmonary aspergillosis;HIV infection;Oral candidiasis;Pneumothorax;Virologic failure,173631802.0,HO,,,,,,,,,173631802.0,1.0,HIV infection
17364204,1736420420,20,F,20070403.0,20210525.0,20200204,20210607,EXP,,FR-AUROBINDO-AUR-APL-2020-004851,AUROBINDO,,7.0,WK,,M,Y,3.23,KG,20210607.0,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Hydrocele,1736420420.0,OT,,,1736420420.0,1.0,20070512.0,20070521.0,,,1736420420.0,1.0,HIV infection
17364627,173646271,1,I,,20200121.0,20200204,20200204,EXP,,ZA-CIPLA LTD.-2020ZA00600,CIPLA,,,,,,Y,,,20200204.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,173646271.0,OT,,,173646271.0,1.0,20191125.0,,,,173646271.0,1.0,HIV infection
17365379,173653791,1,I,,20200128.0,20200204,20200204,EXP,,BW-HETERO-HET2020BW00114,HETERO,,,,,,Y,,,20200204.0,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Foetal exposure during pregnancy,173653791.0,DE,,,,,,,,,173653791.0,1.0,HIV infection
17365422,173654221,1,I,20181001.0,20200128.0,20200204,20200204,EXP,,BW-HETERO-HET2020BW00113,HETERO,,42.0,YR,,F,Y,,,20200204.0,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,173654221.0,OT,,,,,,,,,173654221.0,1.0,HIV infection
17366054,173660541,1,I,,20200128.0,20200204,20200204,EXP,,LV-MYLANLABS-2020M1011758,MYLAN,,70.0,YR,,M,Y,,,20200204.0,,MD,LV,LV,EFAVIRENZ.,Acute myocardial infarction;Coronary artery disease,173660541.0,OT,,,173660541.0,1.0,201501.0,,,,173660541.0,1.0,HIV infection
17366090,173660901,1,I,,20200128.0,20200204,20200204,EXP,,UG-MYLANLABS-2020M1011876,MYLAN,,40.0,YR,,F,Y,,,20200204.0,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic,173660901.0,HO,,,,,,,,,173660901.0,1.0,HIV infection
17366674,173666743,3,F,,20201123.0,20200204,20220624,EXP,,BW-MYLANLABS-2020M1013049,MYLAN,,42.0,YR,,F,Y,,,20220624.0,,HP,BW,BW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,173666743.0,OT,,,,,,,,,173666743.0,1.0,HIV infection
17371123,173711231,1,I,,20200123.0,20200205,20200205,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2020025069,MACLEODS,,,,,,Y,,,20200205.0,,HP,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Treatment failure;Treatment noncompliance;VIth nerve disorder,173711231.0,OT,,,,,,,,,173711231.0,1.0,Antiretroviral therapy
17371923,173719231,1,I,,20200126.0,20200205,20200205,EXP,,UG-HETERO-HET2020UG00098,HETERO,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT.. BMC INFECT DIS. 2020;20(1):68",10.0,YR,,F,Y,,,20200205.0,,HP,UG,UG,EFAVIRENZ.,Virologic failure,173719231.0,OT,,,,,,,,,173719231.0,1.0,HIV infection
17375212,173752121,1,I,20181001.0,20200129.0,20200205,20200205,EXP,,BW-STRIDES ARCOLAB LIMITED-2020SP000985,STRIDES,,42.0,YR,,F,Y,,,20200205.0,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,173752121.0,OT,,,,,,,,,173752121.0,1.0,HIV infection
17375564,173755641,1,I,,20200203.0,20200206,20200206,EXP,,IN-GILEAD-2020-0449580,GILEAD,"SALIMI R, BEGUM I, VARMA DM, NANDAKRISHNA B, RAJESH R, VIDYASAGAR S. TENOFOVIR DISOPROXIL FUMARATE-INDUCED DISTAL RENAL TUBULAR ACIDOSIS: A CASE REPORT.. INTERNATIONAL JOURNAL OF STD + AIDS. 2020;0():1-4. DOI:10.1177/0956462419887877",58.0,YR,A,F,Y,,,20200206.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,173755641.0,OT,,,,,,,,,173755641.0,1.0,HIV infection
17375986,173759861,1,I,,20200203.0,20200206,20200206,EXP,,UG-AUROBINDO-AUR-APL-2020-006516,AUROBINDO,,40.0,YR,,F,Y,,,20200206.0,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic,173759861.0,HO,,,,,,,,,173759861.0,1.0,HIV infection
17376247,173762471,1,I,,20200130.0,20200206,20200206,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK016891,VIIV,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",22.0,YR,,M,Y,,,20200206.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762471.0,OT,,,,,,,,,173762471.0,1.0,HIV infection
17376248,173762481,1,I,,20200130.0,20200206,20200206,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK019673,VIIV,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",42.0,YR,,M,Y,,,20200206.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762481.0,OT,,,,,,,,,173762481.0,1.0,HIV infection
17376294,173762941,1,I,,20200130.0,20200206,20200206,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK016891,GLAXOSMITHKLINE,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",22.0,YR,,M,Y,,,20200206.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762941.0,OT,,,,,,,,,173762941.0,1.0,HIV infection
17376298,173762981,1,I,,20200130.0,20200206,20200206,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK019673,GLAXOSMITHKLINE,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",42.0,YR,,M,Y,,,20200206.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762981.0,OT,,,,,,,,,173762981.0,1.0,HIV infection
17376416,173764161,1,I,,20200130.0,20200206,20200206,EXP,,TH-MYLANLABS-2020M1014071,MYLAN,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS-ONE 2019;14:NO. 12.",21.0,YR,,M,Y,,,20200206.0,,HP,TH,TH,EFAVIRENZ.,Nonalcoholic fatty liver disease,173764161.0,OT,,,,,,,,,173764161.0,1.0,HIV infection
17386952,173869521,1,I,,20200127.0,20200206,20200206,EXP,,UG-GLAXOSMITHKLINE-UG2020GSK014347,GLAXOSMITHKLINE,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N.. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT. BMC INFECTIOUS DISEASES. 2020;20 (1):68, DOI: HTTPS://DOI.ORG/10.11",10.0,YR,,F,Y,,,20200206.0,,HP,UG,UG,EFAVIRENZ.,Brain oedema;Generalised tonic-clonic seizure;Headache;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Pyrexia;Treatment noncompliance;VIth nerve paralysis;Virologic failure;Vomiting,173869521.0,OT,,,,,,,,,173869521.0,1.0,HIV infection
17386953,173869531,1,I,,20200127.0,20200206,20200206,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2020GSK014347,VIIV,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N.. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT. BMC INFECTIOUS DISEASES. 2020;20 (1):68, DOI: HTTPS://DOI.ORG/10.11",10.0,YR,,F,Y,,,20200206.0,,HP,UG,UG,EFAVIRENZ.,Brain oedema;Generalised tonic-clonic seizure;Headache;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Pyrexia;Treatment noncompliance;VIth nerve paralysis;Virologic failure;Vomiting,173869531.0,OT,,,,,,,,,173869531.0,1.0,HIV infection
17387072,173870721,1,I,,20200204.0,20200206,20200206,PER,,US-GILEAD-2020-0450006,GILEAD,,53.0,YR,A,M,Y,,,20200206.0,,CN,US,US,SUSTIVA,Blood creatinine increased;Blood triglycerides increased;Viral load increased,,,,,,,,,,,173870721.0,1.0,HIV infection
17388422,173884221,1,I,,20200130.0,20200207,20200207,EXP,,TH-MYLANLABS-2020M1014072,MYLAN,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS-ONE 2019;14:NO. 12.",23.0,YR,,M,Y,,,20200207.0,,HP,TH,TH,EFAVIRENZ.,Hepatic fibrosis;Nonalcoholic fatty liver disease,173884221.0,OT,,,,,,,,,173884221.0,1.0,HIV infection
17389306,173893061,1,I,,20200127.0,20200207,20200207,EXP,,ES-AUROBINDO-AUR-APL-2020-005572,AUROBINDO,,,,A,M,Y,,,20200207.0,,HP,ES,ES,EFAVIRENZ.,Acute kidney injury;Hepatitis;Hypersensitivity;Leukocyturia;Pneumonitis;Tuberculosis;Tubulointerstitial nephritis,173893061.0,OT,,,,,,,,,173893061.0,1.0,HIV infection
17392205,173922051,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010090,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922051.0,OT,,,,,,,,,173922051.0,1.0,HIV infection
17392207,173922071,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-008788,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922071.0,OT,,,,,,,,,173922071.0,1.0,HIV infection
17392215,173922151,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010102,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922151.0,OT,,,,,,,,,173922151.0,1.0,HIV infection
17392217,173922171,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010103,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922171.0,OT,,,,,,,,,173922171.0,1.0,HIV infection
17392227,173922271,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010100,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922271.0,OT,,,,,,,,,173922271.0,1.0,HIV infection
17392229,173922291,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010101,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922291.0,OT,,,,,,,,,173922291.0,1.0,HIV infection
17392236,173922361,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010097,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922361.0,OT,,,,,,,,,173922361.0,1.0,HIV infection
17392237,173922371,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010098,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922371.0,OT,,,,,,,,,173922371.0,1.0,HIV infection
17392239,173922391,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010099,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922391.0,OT,,,,,,,,,173922391.0,1.0,HIV infection
17392244,173922441,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010094,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922441.0,OT,,,,,,,,,173922441.0,1.0,HIV infection
17392246,173922461,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010096,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922461.0,OT,,,,,,,,,173922461.0,1.0,HIV infection
17392250,173922501,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010095,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922501.0,OT,,,,,,,,,173922501.0,1.0,HIV infection
17392258,173922581,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010093,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922581.0,OT,,,,,,,,,173922581.0,1.0,HIV infection
17392260,173922601,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010092,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922601.0,OT,,,,,,,,,173922601.0,1.0,HIV infection
17392271,173922711,1,I,,20200127.0,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010091,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207.0,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922711.0,OT,,,,,,,,,173922711.0,1.0,HIV infection
17394728,173947281,1,I,20181001.0,20200128.0,20200210,20200210,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-008044,BRISTOL MYERS SQUIBB,,42.0,YR,,F,Y,,,20200210.0,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,173947281.0,OT,,,,,,,,,173947281.0,1.0,HIV infection
17399860,173998602,2,F,,20200226.0,20200211,20200305,EXP,,UG-CIPLA LTD.-2020UG01099,CIPLA,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT. BMC INFECTIOUS DISEASES. 2020;20 (68):1 TO 5",,,,,Y,,,20200305.0,,HP,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Treatment noncompliance;Virologic failure,173998602.0,OT,,,,,,,,,173998602.0,1.0,HIV infection
17402682,174026821,1,I,,20200128.0,20200211,20200211,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2020GSK022110,VIIV,"AJIBOLA G, ROWLEY C, MARUAPULA D, LEIDNER J, BENNETT K, POWIS K ET AL.. DRUG RESISTANCE AFTER CESSATION OF EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT STARTED IN PREGNANCY. AFR J HIV MED. 2020;21(1):A1023, DOI.ORG/10.4102/SAJHIVM",,,,,Y,,,20200211.0,,MD,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Live birth;Pathogen resistance;Viral mutation identified,174026821.0,OT,,,,,,,,,174026821.0,1.0,HIV infection
17402737,174027371,1,I,,20200205.0,20200211,20200211,EXP,,DE-MYLANLABS-2020M1014542,MYLAN,,42.0,YR,,M,Y,,,20200211.0,,HP,NG,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174027371.0,OT,,,,,,,,,174027371.0,1.0,HIV infection
17408367,174083674,4,F,20140604.0,20200520.0,20200212,20200821,EXP,,US-GILEAD-2020-0450628,GILEAD,,60.0,YR,A,M,Y,90.7,KG,20200821.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Upper limb fracture;Wrist fracture,174083674.0,HO,,,174083674.0,1.0,20130102.0,20160316.0,,,174083674.0,1.0,HIV infection
17410311,174103111,1,I,,20190905.0,20200212,20200212,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK161485,VIIV,,,,,,Y,,,20200212.0,,HP,CN,CN,EFAVIRENZ.,Renal impairment,174103111.0,OT,,,,,,,,,174103111.0,1.0,HIV infection
17411552,174115521,1,I,,20200129.0,20200213,20200213,EXP,,BW-MACLEODS PHARMACEUTICALS US LTD-MAC2020025068,MACLEODS,,,,,,Y,,,20200213.0,,HP,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,174115521.0,OT,,,,,,,,,174115521.0,1.0,HIV infection
17412129,174121296,6,F,20140101.0,20230616.0,20200213,20230621,EXP,,US-GILEAD-2020-0450637,GILEAD,,51.0,YR,A,M,Y,86.2,KG,20230621.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Economic problem;Emotional distress;Joint destruction;Mobility decreased;Osteopenia;Pain;Spinal osteoarthritis,174121296.0,OT,,,174121296.0,1.0,201312.0,20170412.0,,,174121296.0,1.0,HIV infection
17412233,174122338,8,F,20150101.0,20211008.0,20200213,20211015,PER,,US-GILEAD-2020-0450638,GILEAD,,57.0,YR,A,M,Y,81.6,KG,20211015.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Multiple fractures;Off label use;Osteopenia;Osteoporosis;Pain;Renal failure;Suicidal ideation,174122338.0,OT,,,174122338.0,1.0,201505.0,201508.0,,,174122338.0,1.0,HIV infection
17413756,174137562,2,F,,20200204.0,20200213,20200311,EXP,,JP-GILEAD-2017-0300705,GILEAD,,77.0,YR,E,F,Y,,,20200311.0,,MD,JP,JP,EFAVIRENZ.,Cachexia;Metastases to liver;Metastases to lung;Metastases to lymph nodes;Oesophageal carcinoma;Oesophageal squamous cell carcinoma metastatic;Off label use;Pneumonia aspiration;Renal impairment,174137562.0,OT,,,,,,,,,174137562.0,1.0,HIV infection
17415569,174155692,2,F,,20200206.0,20200213,20200220,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK022741,VIIV,,10.0,YR,,M,Y,,,20200220.0,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury;Cough;Febrile neutropenia;General physical health deterioration;Haemophagocytic lymphohistiocytosis;Hepatic enzyme increased;Hypertriglyceridaemia;Pancytopenia;Pleural effusion;Pneumonia;Pulmonary tuberculosis;Pyrexia;Tachypnoea,174155692.0,OT,,,174155692.0,1.0,201706.0,,,,174155692.0,1.0,HIV infection
17415570,174155702,2,F,,20200206.0,20200213,20200220,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK022741,GLAXOSMITHKLINE,,10.0,YR,,M,Y,,,20200220.0,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury;Cough;Febrile neutropenia;General physical health deterioration;Haemophagocytic lymphohistiocytosis;Hepatic enzyme increased;Hypertriglyceridaemia;Pancytopenia;Pleural effusion;Pneumonia;Pulmonary tuberculosis;Pyrexia;Tachypnoea,174155702.0,OT,,,174155702.0,1.0,201706.0,,,,174155702.0,1.0,HIV infection
17418310,174183102,2,F,201801.0,20200306.0,20200213,20200318,EXP,,MM-AUROBINDO-AUR-APL-2020-007342,AUROBINDO,,39.0,YR,,F,Y,,,20200318.0,,HP,MM,MM,EFAVIRENZ.,Asthenia;Autoimmune haemolytic anaemia;Dyspnoea exertional;Pallor;Tachycardia,174183102.0,HO,,,174183102.0,1.0,2015.0,,,,174183102.0,1.0,HIV infection
17422452,174224522,2,F,,20200201.0,20200215,20200215,EXP,,IN-HETERO-HET2020IN00088,HETERO,"RAJESH R, SALIMI R, BEGUM I1 VARMA DM, NANDAKRISHNA B, VIDYASAGAR S.. TENOFOVIR DISOPROXIL FUMARATE-INDUCED DISTAL RENAL TUBULAR ACIDOSIS: A CASE REPORT. INTERNATIONAL JOURNAL OF STD + AIDS. 2020;1-4",58.0,YR,,F,Y,,,20200215.0,,HP,IN,IN,EFAVIRENZ.,Oropharyngeal candidiasis;Renal tubular acidosis,174224522.0,OT,,,,,,,,,174224522.0,1.0,HIV infection
17423538,174235382,2,F,,20200610.0,20200217,20200622,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-009805,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200622.0,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,174235382.0,OT,,,,,,,,,174235382.0,1.0,HIV infection
17423840,174238401,1,I,,20200206.0,20200217,20200217,EXP,,CA-AUROBINDO-AUR-APL-2020-007477,AUROBINDO,,,,,,Y,,,20200217.0,,HP,CA,CA,EFAVIRENZ.,Hypertriglyceridaemia,174238401.0,OT,,,,,,,,,174238401.0,1.0,HIV infection
17424136,174241365,5,F,20100506.0,20211115.0,20200217,20211129,EXP,,US-GILEAD-2020-0450654,GILEAD,,48.0,YR,A,M,Y,83.9,KG,20211129.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Hip arthroplasty;Loss of personal independence in daily activities;Osteopenia;Pain;Renal failure,174241365.0,HO,,,174241365.0,1.0,20070109.0,200704.0,2115.0,DAY,174241365.0,1.0,HIV infection
17425042,174250421,1,I,,20200203.0,20200218,20200218,EXP,,UG-HETERO-HET2020UG00146,HETERO,"KWIZERA R, KATENDE A, TEU A, APOLOT D, WORODRIA W, KIRENGA BJ, ET AL.. ALGORITHM-AIDED DIAGNOSIS OF CHRONIC PULMONARY ASPERGILLOSIS IN LOW- AND MIDDLE-INCOME COUNTRIES BY USE OF A LATERAL FLOW DEVICE. EUR-J-CLIN-MICROBIOL-INFECT-DIS. 2020;39(1):1-3",40.0,YR,,F,Y,,,20200218.0,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic;Treatment failure,174250421.0,HO,,,,,,,,,174250421.0,1.0,HIV infection
17428104,174281041,1,I,,20200210.0,20200217,20200217,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK027685,VIIV,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217.0,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174281041.0,OT,,,,,,,,,174281041.0,1.0,HIV infection
17428105,174281051,1,I,,20200210.0,20200217,20200217,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK027685,GLAXOSMITHKLINE,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217.0,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174281051.0,OT,,,,,,,,,174281051.0,1.0,HIV infection
17428229,174282291,1,I,,20200210.0,20200217,20200217,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK027686,VIIV,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217.0,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174282291.0,OT,,,,,,,,,174282291.0,1.0,HIV infection
17428233,174282331,1,I,,20200210.0,20200217,20200217,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK027686,GLAXOSMITHKLINE,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217.0,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174282331.0,OT,,,,,,,,,174282331.0,1.0,HIV infection
17435761,174357614,4,F,201509.0,20210614.0,20200219,20210616,EXP,,US-GILEAD-2020-0451434,GILEAD,,58.0,YR,A,M,Y,,,20210616.0,,CN,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Nephrolithiasis;Pain;Renal failure,174357614.0,OT,,,174357614.0,1.0,2010.0,20190729.0,,,174357614.0,1.0,HIV infection
17438180,174381801,1,I,,20200205.0,20200220,20200220,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2020025190,MACLEODS,,,,,,Y,,,20200220.0,,HP,IN,IN,Efavirenz (EFV),Drug hypersensitivity;Oropharyngeal candidiasis;Renal tubular acidosis,174381801.0,HO,,,,,,,,,174381801.0,1.0,HIV infection
17439483,174394831,1,I,,20200214.0,20200220,20200220,EXP,,CN-STRIDES ARCOLAB LIMITED-2020SP001561,STRIDES,,,,,,Y,,,20200220.0,,HP,CN,CN,EFAVIRENZ.,Blood cholesterol abnormal,174394831.0,OT,,,,,,,,,174394831.0,1.0,HIV infection
17440556,174405561,1,I,2012.0,20130214.0,20200220,20200220,EXP,,BR-GLAXOSMITHKLINE-A1012284A,GLAXOSMITHKLINE,,0.0,YR,,F,Y,2.9,KG,20200220.0,,CN,US,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,174405561.0,CA,,,174405561.0,1.0,20121128.0,20121128.0,,,174405561.0,1.0,HIV infection
17441006,174410061,1,I,,20200213.0,20200220,20200220,EXP,,IN-MYLANLABS-2020M1019576,MYLAN,,10.0,YR,,M,Y,,,20200220.0,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury,174410061.0,HO,,,174410061.0,2.0,201706.0,,,,174410061.0,1.0,HIV infection
17441515,174415154,4,F,20110601.0,20210315.0,20200220,20210316,EXP,,US-GILEAD-2020-0451447,GILEAD,,43.0,YR,A,M,Y,126.08,KG,20210316.0,,LW,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fracture;Osteoporosis;Pain;Renal failure;Tooth loss,174415154.0,OT,,,174415154.0,1.0,2006.0,201912.0,,,174415154.0,1.0,HIV infection
17442817,174428171,1,I,,20200210.0,20200221,20200221,EXP,,IN-CIPLA LTD.-2020IN01149,CIPLA,,,,,,Y,,,20200221.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,174428171.0,OT,,,,,,,,,174428171.0,1.0,HIV infection
17443664,174436641,1,I,,20200210.0,20200221,20200221,EXP,,TH-HETERO-HET2020TH00184,HETERO,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY.. PLOS-ONE. 2019;14 (12):1-16",23.0,YR,,M,Y,36.0,KG,20200221.0,,HP,TH,TH,EFAVIRENZ.,Hepatic fibrosis;Nonalcoholic fatty liver disease,174436641.0,OT,,,,,,,,,174436641.0,1.0,HIV infection
17443992,174439921,1,I,,20200210.0,20200221,20200221,EXP,,TH-HETERO-HET2020TH00186,HETERO,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY.. PLOS-ONE. 2019;14(12):1-16",21.0,YR,,M,Y,31.0,KG,20200221.0,,HP,TH,TH,EFAVIRENZ.,Nonalcoholic fatty liver disease,174439921.0,OT,,,,,,,,,174439921.0,1.0,HIV infection
17445442,174454421,1,I,,20200211.0,20200221,20200221,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-012332,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200221.0,,PH,GB,GB,SUSTIVA,Neoplasm malignant,174454421.0,OT,,,,,,,,,174454421.0,1.0,HIV infection
17452307,174523072,2,F,2001.0,20200319.0,20200224,20200325,EXP,,ES-MYLANLABS-2020M1018675,MYLAN,,,,A,M,Y,,,20200325.0,,HP,CL,ES,EFAVIRENZ.,Neurotoxicity,174523072.0,OT,,,174523072.0,1.0,2001.0,2001.0,,,174523072.0,1.0,HIV infection
17457587,174575871,1,I,,20200218.0,20200225,20200225,EXP,,ES-MYLANLABS-2020M1019289,MYLAN,"ANGEL-MORENO-MAROTO A, SUAREZ-CASTELLANO L, HERNANDEZ-CABRERA M, PEREZ-ARELLANO J-L.. SEVERE EFAVIRENZ-INDUCED HYPERSENSITIVITY SYNDROME (NOT-DRESS) WITH ACUTE RENAL FAILURE.. J INFECT.. 2006;52(2):E39-40",,,A,,Y,,,20200225.0,,HP,ES,ES,EFAVIRENZ.,Acute kidney injury;Drug reaction with eosinophilia and systemic symptoms,174575871.0,OT,,,,,,,,,174575871.0,1.0,HIV infection
17465175,174651751,1,I,,20200220.0,20200226,20200226,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-010577",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200227.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,174651751.0,OT,,,,,,,,,174651751.0,1.0,HIV infection
17467168,174671681,1,I,,20200220.0,20200227,20200227,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020AMR031068,VIIV,,,,,,Y,,,20200227.0,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,174671681.0,OT,,,,,,,,,174671681.0,1.0,HIV infection
17469838,174698381,1,I,,20200220.0,20200227,20200227,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-010587",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200227.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,174698381.0,OT,,,,,,,,,174698381.0,1.0,HIV infection
17484391,174843919,9,F,20090901.0,20230519.0,20200302,20230523,EXP,,US-GILEAD-2020-0452915,GILEAD,,51.0,YR,A,M,Y,88.435,KG,20230523.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Cerebral haemorrhage;Condition aggravated;Economic problem;Emotional distress;Fear of falling;Loss of personal independence in daily activities;Nephrolithiasis;Osteopenia;Osteoporosis;Pain;Physical disability;Renal impairment;Tooth fracture;Tooth loss,174843919.0,OT,,,174843919.0,1.0,20090225.0,20100809.0,530.0,DAY,174843919.0,1.0,HIV infection
17484740,174847401,1,I,,20200225.0,20200302,20200302,EXP,GB-MHRA-EYC 00215719,GB-MYLANLABS-2020M1021957,MYLAN,,49.0,YR,,M,Y,,,20200302.0,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,174847401.0,LT,,,,,,,,,174847401.0,1.0,HIV infection
17497526,174975268,8,F,20060101.0,20240501.0,20200304,20240503,EXP,,US-GILEAD-2020-0452918,GILEAD,,42.0,YR,A,M,Y,70.748,KG,20240503.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Glomerulonephritis chronic;Pain;Renal failure;Renal tubular necrosis,174975268.0,HO,,,174975268.0,1.0,2006.0,201808.0,86.0,DAY,174975268.0,1.0,HIV infection
17504474,175044741,1,I,,20200228.0,20200305,20200305,EXP,,ES-MYLANLABS-2020M1023391,MYLAN,,,,A,M,Y,,,20200305.0,,CN,ES,ES,EFAVIRENZ.,Acute kidney injury;Hepatitis;Hypersensitivity;Leukocyturia;Pneumonitis;Tuberculosis;Tubulointerstitial nephritis,175044741.0,OT,,,,,,,,,175044741.0,1.0,HIV infection
17505377,175053771,1,I,,20200224.0,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01523,CIPLA,,,,,,Y,,,20200306.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175053771.0,OT,,,,,,,,,175053771.0,1.0,HIV infection
17505379,175053791,1,I,,20200224.0,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01521,CIPLA,,,,,,Y,,,20200306.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175053791.0,OT,,,,,,,,,175053791.0,1.0,HIV infection
17505657,175056571,1,I,,20200224.0,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01522,CIPLA,,,,,,Y,,,20200306.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175056571.0,OT,,,,,,,,,175056571.0,1.0,HIV infection
17505659,175056591,1,I,,20200224.0,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01525,CIPLA,,,,,,Y,,,20200306.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175056591.0,OT,,,,,,,,,175056591.0,1.0,HIV infection
17510274,175102741,1,I,201701.0,20200304.0,20200306,20200306,EXP,,PT-ABBVIE-20K-130-3308139-00,ABBVIE,UNKNOWN. SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE.. FARMACEUTICO NEWS. 2020;.,45.0,YR,,M,Y,,,20200306.0,,HP,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,175102741.0,OT,,,175102741.0,1.0,2009.0,,,,175102741.0,1.0,HIV infection
17510565,175105657,7,F,20190114.0,20220202.0,20200306,20220210,EXP,,US-GILEAD-2020-0453649,GILEAD,,44.0,YR,A,M,Y,75.737,KG,20220210.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Economic problem;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Pain;Renal failure,175105657.0,HO,,,175105657.0,1.0,20130920.0,20150501.0,588.0,DAY,175105657.0,1.0,HIV infection
17511755,175117551,1,I,,20200224.0,20200307,20200307,EXP,,IN-AUROBINDO-AUR-APL-2020-012429,AUROBINDO,,10.0,YR,,M,Y,,,20200307.0,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury;Febrile neutropenia;Haemophagocytic lymphohistiocytosis;Hepatic enzyme increased;Pancytopenia;Pyrexia,175117551.0,OT,,,175117551.0,3.0,201706.0,,,,175117551.0,1.0,HIV infection
17514117,175141171,1,I,,20200224.0,20200306,20200306,EXP,,IN-HETERO-HET2020IN00251,HETERO,"BAJRACHARYA P, KALRA S, JAIN G, SOOD A. UNUSUALLY COMPLICATED COURSE OF A COMMON DISEASE: CHALLENGES IN MANAGING PEDIATRIC HIV. MED-J-ARMED-FORCES-INDIA. 2020;76(1):118-119",10.0,YR,,M,Y,,,20200307.0,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury,175141171.0,HO,,,,,,,,,175141171.0,1.0,Antiretroviral therapy
17518009,175180091,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041139,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180091.0,OT,,,,,,,,,175180091.0,1.0,HIV infection
17518056,175180561,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041307,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180561.0,OT,,,,,,,,,175180561.0,1.0,HIV infection
17518060,175180601,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041307,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180601.0,OT,,,,,,,,,175180601.0,1.0,HIV infection
17518098,175180981,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041306,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180981.0,OT,,,,,,,,,175180981.0,1.0,HIV infection
17518099,175180991,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041306,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180991.0,OT,,,,,,,,,175180991.0,1.0,HIV infection
17518157,175181571,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041267,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175181571.0,OT,,,,,,,,,175181571.0,1.0,HIV infection
17518159,175181591,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041267,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175181591.0,OT,,,,,,,,,175181591.0,1.0,HIV infection
17518213,175182131,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041268,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182131.0,OT,,,,,,,,,175182131.0,1.0,HIV infection
17518218,175182181,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041303,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182181.0,OT,,,,,,,,,175182181.0,1.0,HIV infection
17518219,175182191,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041303,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182191.0,OT,,,,,,,,,175182191.0,1.0,HIV infection
17518220,175182201,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041268,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182201.0,OT,,,,,,,,,175182201.0,1.0,HIV infection
17518262,175182621,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041269,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182621.0,OT,,,,,,,,,175182621.0,1.0,HIV infection
17518263,175182631,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041302,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182631.0,OT,,,,,,,,,175182631.0,1.0,HIV infection
17518264,175182641,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041269,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182641.0,OT,,,,,,,,,175182641.0,1.0,HIV infection
17518265,175182651,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041302,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182651.0,OT,,,,,,,,,175182651.0,1.0,HIV infection
17518305,175183051,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041300,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175183051.0,OT,,,,,,,,,175183051.0,1.0,HIV infection
17518306,175183061,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041300,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175183061.0,OT,,,,,,,,,175183061.0,1.0,HIV infection
17518466,175184661,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041270,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175184661.0,OT,,,,,,,,,175184661.0,1.0,HIV infection
17518475,175184751,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041270,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175184751.0,OT,,,,,,,,,175184751.0,1.0,HIV infection
17518834,175188341,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041289,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175188341.0,OT,,,,,,,,,175188341.0,1.0,HIV infection
17518836,175188361,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041289,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175188361.0,OT,,,,,,,,,175188361.0,1.0,HIV infection
17519661,175196611,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041271,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175196611.0,OT,,,,,,,,,175196611.0,1.0,HIV infection
17519666,175196661,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041271,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175196661.0,OT,,,,,,,,,175196661.0,1.0,HIV infection
17519703,175197031,1,I,,20200225.0,20200310,20200310,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041281,VIIV,,,,A,M,Y,,,20200310.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197031.0,OT,,,,,,,,,175197031.0,1.0,HIV infection
17519715,175197151,1,I,,20200225.0,20200310,20200310,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041281,GLAXOSMITHKLINE,,,,A,M,Y,,,20200310.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197151.0,OT,,,,,,,,,175197151.0,1.0,HIV infection
17519716,175197161,1,I,,20200225.0,20200310,20200310,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041282,GLAXOSMITHKLINE,,,,A,M,Y,,,20200310.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197161.0,OT,,,,,,,,,175197161.0,1.0,HIV infection
17519720,175197201,1,I,,20200225.0,20200310,20200310,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041282,VIIV,,,,A,M,Y,,,20200310.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197201.0,OT,,,,,,,,,175197201.0,1.0,HIV infection
17519744,175197441,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041284,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197441.0,OT,,,,,,,,,175197441.0,1.0,HIV infection
17519746,175197461,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041284,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197461.0,OT,,,,,,,,,175197461.0,1.0,HIV infection
17519976,175199761,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041272,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175199761.0,OT,,,,,,,,,175199761.0,1.0,HIV infection
17519977,175199771,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041272,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175199771.0,OT,,,,,,,,,175199771.0,1.0,HIV infection
17520023,175200231,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041273,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200231.0,OT,,,,,,,,,175200231.0,1.0,HIV infection
17520024,175200241,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041283,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200241.0,OT,,,,,,,,,175200241.0,1.0,HIV infection
17520025,175200251,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041273,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200251.0,OT,,,,,,,,,175200251.0,1.0,HIV infection
17520026,175200261,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041283,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200261.0,OT,,,,,,,,,175200261.0,1.0,HIV infection
17520174,175201741,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041274,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175201741.0,OT,,,,,,,,,175201741.0,1.0,HIV infection
17520176,175201761,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041274,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175201761.0,OT,,,,,,,,,175201761.0,1.0,HIV infection
17520226,175202261,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041275,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175202261.0,OT,,,,,,,,,175202261.0,1.0,HIV infection
17520229,175202291,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041275,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175202291.0,OT,,,,,,,,,175202291.0,1.0,HIV infection
17520344,175203441,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041276,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203441.0,OT,,,,,,,,,175203441.0,1.0,HIV infection
17520346,175203461,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041276,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203461.0,OT,,,,,,,,,175203461.0,1.0,HIV infection
17520359,175203591,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041277,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203591.0,OT,,,,,,,,,175203591.0,1.0,HIV infection
17520361,175203611,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041277,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203611.0,OT,,,,,,,,,175203611.0,1.0,HIV infection
17520401,175204011,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041278,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175204011.0,OT,,,,,,,,,175204011.0,1.0,HIV infection
17520420,175204201,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041278,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175204201.0,OT,,,,,,,,,175204201.0,1.0,HIV infection
17520444,175204441,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041139,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175204441.0,OT,,,,,,,,,175204441.0,1.0,HIV infection
17520472,175204721,1,I,,20200225.0,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041279,VIIV,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175204721.0,OT,,,,,,,,,175204721.0,1.0,HIV infection
17520473,175204731,1,I,,20200225.0,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041279,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175204731.0,OT,,,,,,,,,175204731.0,1.0,HIV infection
17521893,175218931,1,I,,20200302.0,20200310,20200310,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-018412,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,,,20200310.0,,MD,RO,RO,EFAVIRENZ.,Lipodystrophy acquired,175218931.0,OT,,,,,,,,,175218931.0,1.0,HIV infection
17523420,175234205,5,F,20161220.0,20230104.0,20200310,20230109,EXP,,US-GILEAD-2020-0454098,GILEAD,,55.0,YR,A,M,Y,72.562,KG,20230109.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175234205.0,OT,,,175234205.0,1.0,20090824.0,20141119.0,1913.0,DAY,175234205.0,1.0,HIV infection
17523857,175238571,1,I,,20200302.0,20200310,20200310,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-018430,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20200310.0,,MD,RO,RO,EFAVIRENZ.,Lipodystrophy acquired,175238571.0,OT,,,,,,,,,175238571.0,1.0,HIV infection
17525586,175255861,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041296,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175255861.0,OT,,,,,,,,,175255861.0,1.0,HIV infection
17525592,175255921,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041309,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175255921.0,OT,,,,,,,,,175255921.0,1.0,HIV infection
17525594,175255941,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041297,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175255941.0,OT,,,,,,,,,175255941.0,1.0,HIV infection
17525595,175255951,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041294,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175255951.0,OT,,,,,,,,,175255951.0,1.0,HIV infection
17525600,175256001,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041296,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256001.0,OT,,,,,,,,,175256001.0,1.0,HIV infection
17525605,175256051,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041309,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256051.0,OT,,,,,,,,,175256051.0,1.0,HIV infection
17525607,175256071,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041297,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175256071.0,OT,,,,,,,,,175256071.0,1.0,HIV infection
17525609,175256091,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041294,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256091.0,OT,,,,,,,,,175256091.0,1.0,HIV infection
17525679,175256791,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041317,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256791.0,OT,,,,,,,,,175256791.0,1.0,HIV infection
17525681,175256811,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041315,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256811.0,OT,,,,,,,,,175256811.0,1.0,HIV infection
17525684,175256841,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041311,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256841.0,OT,,,,,,,,,175256841.0,1.0,HIV infection
17525687,175256871,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041313,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256871.0,OT,,,,,,,,,175256871.0,1.0,HIV infection
17525689,175256891,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041295,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256891.0,OT,,,,,,,,,175256891.0,1.0,HIV infection
17525692,175256921,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041316,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256921.0,OT,,,,,,,,,175256921.0,1.0,HIV infection
17525693,175256931,1,I,,20200225.0,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041314,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256931.0,OT,,,,,,,,,175256931.0,1.0,HIV infection
17525698,175256981,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041313,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256981.0,OT,,,,,,,,,175256981.0,1.0,HIV infection
17525699,175256991,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041317,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256991.0,OT,,,,,,,,,175256991.0,1.0,HIV infection
17525706,175257061,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041314,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257061.0,OT,,,,,,,,,175257061.0,1.0,HIV infection
17525707,175257071,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041311,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257071.0,OT,,,,,,,,,175257071.0,1.0,HIV infection
17525709,175257091,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041315,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257091.0,OT,,,,,,,,,175257091.0,1.0,HIV infection
17525711,175257111,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041295,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257111.0,OT,,,,,,,,,175257111.0,1.0,HIV infection
17525714,175257141,1,I,,20200225.0,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041316,VIIV,,,,A,M,Y,,,20200311.0,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257141.0,OT,,,,,,,,,175257141.0,1.0,HIV infection
17527872,175278725,5,F,,20211007.0,20200311,20211013,EXP,,US-GILEAD-2020-0454096,GILEAD,,,,A,M,Y,83.9,KG,20211013.0,,LW,US,US,SUSTIVA,Bone density decreased;Dysstasia;Economic problem;Emotional distress;Gait disturbance;Osteomalacia;Pain;Renal failure;Renal tubular injury;Vitamin D deficiency,175278725.0,OT,,,175278725.0,1.0,2002.0,2013.0,1198.0,DAY,175278725.0,1.0,HIV infection
17533091,175330916,6,F,200908.0,20201008.0,20200312,20210407,EXP,,US-GILEAD-2020-0454085,GILEAD,,47.0,YR,A,M,Y,101.13,KG,20210407.0,,LW,US,US,SUSTIVA,Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Nephrotic syndrome;Pain;Renal failure,175330916.0,OT,,,175330916.0,1.0,20090402.0,201001.0,,,175330916.0,1.0,HIV infection
17534513,175345131,1,I,2002.0,20200228.0,20200312,20200312,EXP,,PT-MYLANLABS-2020M1024443,MYLAN,ABREU R.. A COMBINA??O DTG+3TC NO MUNDO REAL; FARMAC?UTICO NEWS;. JANEIRO-FEVEREIRO. 2020,45.0,YR,,M,Y,,,20200312.0,,HP,PT,PT,EFAVIRENZ.,Myalgia;Treatment noncompliance,175345131.0,HO,,,175345131.0,2.0,2002.0,,,,175345131.0,1.0,Antiretroviral therapy
17536264,175362643,3,F,20110620.0,20210623.0,20200313,20210630,EXP,,US-GILEAD-2020-0454512,GILEAD,,43.0,YR,A,M,Y,77.1,KG,20210630.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Dysstasia;Economic problem;Emotional distress;Gait disturbance;Hip arthroplasty;Osteoarthritis;Osteonecrosis;Pain;Pneumonia;Renal failure,175362643.0,OT,,,175362643.0,1.0,20060629.0,20150314.0,,,175362643.0,1.0,HIV infection
17539807,175398073,3,F,201210.0,20210617.0,20200313,20210618,EXP,,US-GILEAD-2020-0454520,GILEAD,,50.0,YR,A,M,Y,63.49,KG,20210618.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Cervical spinal stenosis;Emotional distress;Intervertebral disc degeneration;Multiple fractures;Neuropathy peripheral;Osteopenia;Osteoporosis;Pain;Spinal cord compression;Spinal fracture;Upper limb fracture;Wrist fracture,175398073.0,OT,,,175398073.0,1.0,20040217.0,20040318.0,,,175398073.0,1.0,HIV infection
17547388,175473881,1,I,,20200303.0,20200317,20200317,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-240147,RANBAXY,"GUPTA N, MITTAL A, NISCHAL N. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)-A DIAGNOSTIC DILEMMA. QJM. 2019;112(12):925-926",38.0,YR,,M,Y,,,20200317.0,,HP,IN,IN,EFAVIRENZ.,Acarodermatitis;Immune reconstitution inflammatory syndrome,175473881.0,OT,,,,,,,,,175473881.0,1.0,Antiretroviral therapy
17548253,175482531,1,I,201701.0,20200304.0,20200317,20200317,EXP,,PT-AUROBINDO-AUR-APL-2020-012434,AUROBINDO,SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE. FARMACEUTICO NEWS. 2020,45.0,YR,,M,Y,,,20200317.0,,HP,PT,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,175482531.0,HO,,,175482531.0,1.0,2011.0,,,,175482531.0,1.0,HIV infection
17548280,175482804,4,F,1996.0,20200829.0,20200317,20200905,EXP,,ES-AUROBINDO-AUR-APL-2020-012619,AUROBINDO,,38.0,YR,,M,Y,,,20200905.0,,HP,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,175482804.0,OT,,,175482804.0,1.0,2001.0,2001.0,,,175482804.0,1.0,HIV infection
17549058,175490581,1,I,201701.0,20200304.0,20200317,20200317,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-019479,BRISTOL MYERS SQUIBB,SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE. FARMACEUTICO NEWS. 2020,45.0,YR,,M,Y,,,20200317.0,,HP,PT,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,175490581.0,HO,,,175490581.0,1.0,2011.0,,,,175490581.0,1.0,HIV infection
17549433,175494335,5,F,,20200801.0,20200317,20220624,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK046275,VIIV,,,,,,Y,,,20220624.0,,HP,NG,NG,EFAVIRENZ,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494335.0,OT,,,,,,,,,175494335.0,1.0,HIV infection
17549495,175494955,5,F,,20200801.0,20200317,20220713,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK046275,GLAXOSMITHKLINE,,,,,,Y,,,20220713.0,,HP,NG,NG,EFAVIRENZ,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494955.0,CA,,,,,,,,,175494955.0,1.0,HIV infection
17551291,175512912,2,F,20090619.0,20220329.0,20200317,20220823,EXP,,FR-MYLANLABS-2019M1038547,MYLAN,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design. 2018",42.0,YR,,F,Y,,,20220823.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,175512912.0,OT,,,,,,,,,175512912.0,1.0,HIV infection
17564646,175646462,2,F,20180701.0,20200731.0,20200320,20200806,EXP,,NG-HETERO-HET2020NG00332,HETERO,,,,,,Y,,,20200806.0,,HP,NG,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175646462.0,CA,,,,,,,,,175646462.0,1.0,HIV infection
17568636,175686362,2,F,20180715.0,20200801.0,20200321,20200813,EXP,,NG-MACLEODS PHARMACEUTICALS US LTD-MAC2020025774,MACLEODS,,,,,,Y,,,20200813.0,,HP,US,NG,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,175686362.0,OT,,,,,,,,,175686362.0,1.0,HIV infection
17570438,175704384,4,F,20110101.0,20220708.0,20200323,20220714,EXP,,US-GILEAD-2020-0455808,GILEAD,,69.0,YR,E,M,Y,74.0,KG,20220714.0,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Economic problem;Emotional distress;Fracture;Hip fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Tooth loss,175704384.0,OT,,,175704384.0,1.0,200701.0,201907.0,1360.0,DAY,175704384.0,1.0,HIV infection
17571419,175714192,2,F,2010.0,20200831.0,20200323,20201017,EXP,,US-GILEAD-2020-0455859,GILEAD,,,,A,M,Y,55.33,KG,20201017.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Tooth loss,175714192.0,OT,,,175714192.0,1.0,20080107.0,201712.0,,,175714192.0,1.0,HIV infection
17571617,175716172,2,F,,20210817.0,20200323,20210826,EXP,,CA-TEVA-2020-CA-1207783,TEVA,,52.0,YR,A,M,Y,,,20210826.0,,HP,CA,CA,SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,175716172.0,OT,,,,,,,,,175716172.0,1.0,HIV infection
17572197,175721973,3,F,201301.0,20200818.0,20200323,20200904,EXP,,US-GILEAD-2020-0455841,GILEAD,,47.0,YR,A,M,Y,,,20200904.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175721973.0,OT,,,175721973.0,1.0,2013.0,201301.0,,,175721973.0,1.0,HIV infection
17572240,175722402,2,F,2004.0,20201209.0,20200323,20201222,EXP,,US-GILEAD-2020-0455887,GILEAD,,,,A,M,Y,79.37,KG,20201222.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Foot fracture;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Sciatica,175722402.0,OT,,,175722402.0,1.0,200206.0,20021125.0,,,175722402.0,1.0,HIV infection
17574109,175741096,6,F,20170101.0,20230515.0,20200323,20230518,EXP,,US-GILEAD-2020-0456091,GILEAD,,,,A,M,Y,90.703,KG,20230518.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175741096.0,HO,,,175741096.0,1.0,2006.0,20180109.0,26.0,DAY,175741096.0,1.0,HIV infection
17574124,175741242,2,F,20101027.0,20200911.0,20200323,20200917,EXP,,US-GILEAD-2020-0456084,GILEAD,,,,,F,Y,95.24,KG,20200917.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Disability;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Vitamin D deficiency,175741242.0,OT,,,175741242.0,1.0,2010.0,201603.0,,,175741242.0,1.0,HIV infection
17574821,175748212,2,F,2006.0,20210119.0,20200324,20210201,EXP,,US-GILEAD-2020-0455937,GILEAD,,,,A,M,Y,63.5,KG,20210201.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;End stage renal disease;Pain;Pneumonia;Renal failure,175748212.0,HO,,,175748212.0,1.0,2001.0,2004.0,,,175748212.0,1.0,HIV infection
17574846,175748462,2,F,2010.0,20200831.0,20200324,20200910,PER,,US-GILEAD-2020-0455882,GILEAD,,,,A,F,Y,126.53,KG,20200910.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Nephropathy;Pain;Renal failure,175748462.0,OT,,,175748462.0,1.0,2010.0,2010.0,,,175748462.0,1.0,HIV infection
17574921,175749214,4,F,20180101.0,20230426.0,20200324,20230503,PER,,US-GILEAD-2020-0455870,GILEAD,,57.0,YR,A,M,Y,,,20230503.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Drug ineffective;Economic problem;Emotional distress;Foot fracture;Osteopenia;Osteoporosis;Pain,175749214.0,OT,,,175749214.0,1.0,2006.0,2017.0,,,175749214.0,1.0,HIV infection
17575000,175750003,3,F,20171201.0,20230507.0,20200324,20230511,EXP,,US-GILEAD-2020-0455867,GILEAD,,69.0,YR,E,M,Y,70.295,KG,20230511.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Economic problem;Emotional distress;Hepatic cirrhosis;Osteoporosis;Pain;Spinal fracture,175750003.0,OT,,,175750003.0,1.0,2006.0,201608.0,279.0,DAY,175750003.0,1.0,HIV infection
17575487,175754873,3,F,2015.0,20210406.0,20200324,20210412,EXP,,US-GILEAD-2020-0455884,GILEAD,,61.0,YR,A,M,Y,94.79,KG,20210412.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteopenia;Pain,175754873.0,OT,,,175754873.0,1.0,2006.0,2018.0,,,175754873.0,1.0,HIV infection
17575701,175757013,3,F,20090101.0,20230406.0,20200324,20230411,EXP,,US-GILEAD-2020-0456183,GILEAD,,,,A,M,Y,88.4,KG,20230411.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,175757013.0,OT,,,175757013.0,1.0,2013.0,2015.0,,,175757013.0,1.0,HIV infection
17576667,175766672,2,F,2012.0,20200827.0,20200324,20200917,EXP,,US-GILEAD-2020-0455896,GILEAD,,,,A,F,Y,111.11,KG,20200917.0,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteoporosis;Pain,175766672.0,OT,,,175766672.0,1.0,2010.0,2018.0,,,175766672.0,1.0,HIV infection
17576959,175769593,3,F,20090604.0,20230417.0,20200324,20230420,EXP,,US-GILEAD-2020-0455949,GILEAD,,62.0,YR,A,M,Y,74.83,KG,20230420.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Fall;Hip fracture;Osteoporosis;Pain,175769593.0,HO,,,175769593.0,1.0,2001.0,20120423.0,,,175769593.0,1.0,HIV infection
17577037,175770373,3,F,20100401.0,20230405.0,20200324,20230411,EXP,,US-GILEAD-2020-0456126,GILEAD,,44.0,YR,A,M,Y,77.0,KG,20230411.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone density decreased;Economic problem;Emotional distress;Osteonecrosis;Osteoporosis;Pain;Renal failure;Renal impairment;Spinal osteoarthritis;Tibia fracture,175770373.0,OT,,,175770373.0,1.0,2004.0,201412.0,,,175770373.0,1.0,HIV infection
17577194,175771945,5,F,20140101.0,20240206.0,20200324,20240208,EXP,,US-GILEAD-2020-0455942,GILEAD,,57.0,YR,A,M,Y,90.703,KG,20240208.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Loss of personal independence in daily activities;Nephrolithiasis;Osteopenia;Pain,175771945.0,OT,,,175771945.0,1.0,20070427.0,2014.0,,,175771945.0,1.0,HIV infection
17577668,175776684,4,F,19980101.0,20240201.0,20200324,20240205,EXP,,US-GILEAD-2020-0456010,GILEAD,,,,A,M,Y,83.9,KG,20240204.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Cardiac disorder;Chronic kidney disease;Depression;Emotional distress;Hand fracture;Hypertension;Osteopenia;Osteoporosis;Pain;Tooth fracture,175776684.0,OT,,,175776684.0,1.0,2001.0,2001.0,2358.0,DAY,175776684.0,1.0,HIV infection
17577715,175777155,5,F,20170101.0,20211208.0,20200324,20211224,EXP,,US-GILEAD-2020-0456092,GILEAD,,61.0,YR,A,M,Y,60.771,KG,20211223.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Dysstasia;Economic problem;Emotional distress;Fanconi syndrome acquired;Mobility decreased;Nephrogenic anaemia;Osteopenia;Osteoporosis;Pain;Renal impairment;Rib fracture,175777155.0,HO,,,175777155.0,1.0,2006.0,201709.0,,,175777155.0,1.0,HIV infection
17578302,175783023,3,F,20170817.0,20240122.0,20200324,20240124,EXP,,US-GILEAD-2020-0456004,GILEAD,,56.0,YR,A,M,Y,70.295,KG,20240124.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Economic problem;Emotional distress;Hand fracture;Osteoporosis;Pain,175783023.0,OT,,,175783023.0,1.0,200711.0,201712.0,,,175783023.0,1.0,HIV infection
17579166,175791663,3,F,2008.0,20201113.0,20200325,20201125,PER,,US-GILEAD-2020-0456141,GILEAD,,46.0,YR,A,M,Y,81.63,KG,20201125.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Clavicle fracture;Depression;Economic problem;Emotional distress;Gout;Pain;Rib fracture;Wrist fracture,175791663.0,OT,,,175791663.0,1.0,2004.0,2018.0,,,175791663.0,1.0,HIV infection
17579345,175793451,1,I,,20200126.0,20200325,20200325,EXP,,BR-GLAXOSMITHKLINE-BR2020AMR014738,GLAXOSMITHKLINE,,,,,F,Y,72.0,KG,20200325.0,,MD,BR,BR,EFAVIRENZ.,Dizziness;Gastrointestinal disorder;Hepatotoxicity;Transaminases abnormal,175793451.0,OT,,,175793451.0,5.0,20190326.0,20190826.0,,,175793451.0,1.0,HIV infection
17579467,175794675,5,F,20150101.0,20230407.0,20200325,20230413,EXP,,US-GILEAD-2020-0456157,GILEAD,,,,A,M,Y,68.027,KG,20230413.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone demineralisation;Decreased activity;Depression;Diarrhoea;Economic problem;Emotional distress;Fatigue;Headache;Hip arthroplasty;Left ventricular failure;Osteonecrosis;Osteoporosis;Pain,175794675.0,OT,,,175794675.0,1.0,20100802.0,20170729.0,2553.0,DAY,175794675.0,1.0,HIV infection
17579634,175796344,4,F,20171101.0,20230911.0,20200325,20230914,EXP,,US-GILEAD-2020-0455880,GILEAD,,46.0,YR,A,F,Y,162.36,KG,20230914.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,175796344.0,OT,,,175796344.0,1.0,201205.0,201711.0,,,175796344.0,1.0,HIV infection
17579753,175797533,3,F,20060101.0,20230512.0,20200325,20230517,EXP,,US-GILEAD-2020-0456111,GILEAD,,,,A,F,Y,140.59,KG,20230517.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Dyspnoea;Economic problem;Emotional distress;Gait disturbance;Pain,175797533.0,OT,,,175797533.0,2.0,2004.0,2017.0,,,175797533.0,1.0,HIV infection
17579788,175797883,3,F,20140201.0,20230505.0,20200325,20230509,EXP,,US-GILEAD-2020-0455851,GILEAD,,71.0,YR,E,M,Y,69.0,KG,20230509.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Hyperparathyroidism;Hypokalaemia;Osteopenia;Pain;Proteinuria;Renal impairment,175797883.0,OT,,,175797883.0,1.0,2006.0,2013.0,,,175797883.0,1.0,HIV infection
17580644,175806443,3,F,20110101.0,20230424.0,20200325,20230426,EXP,,US-GILEAD-2020-0456171,GILEAD,,,,A,M,Y,81.633,KG,20230426.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure;Skin lesion,175806443.0,OT,,,175806443.0,1.0,201208.0,201209.0,1.0,MON,175806443.0,1.0,HIV infection
17581216,175812163,3,F,201201.0,20200819.0,20200325,20200826,EXP,,US-GILEAD-2020-0455861,GILEAD,,42.0,YR,A,M,Y,86.17,KG,20200826.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Fanconi syndrome acquired;Gait disturbance;Pain,175812163.0,OT,,,175812163.0,1.0,201001.0,201304.0,,,175812163.0,1.0,HIV infection
17583328,175833281,1,I,2002.0,20200316.0,20200326,20200326,EXP,,PT-AUROBINDO-AUR-APL-2020-015125,AUROBINDO,ABREU R. A COMBINACAO DTG+3TC NO MUNDO REAL; FARMAC?UTICO NEWS. JANEIRO-FEVEREIRO. 2020,45.0,YR,,M,Y,,,20200326.0,,HP,PT,PT,EFAVIRENZ.,Myalgia;Treatment noncompliance,175833281.0,HO,,,175833281.0,2.0,2002.0,,,,175833281.0,1.0,Antiretroviral therapy
17583391,175833912,2,F,,20200604.0,20200326,20200606,EXP,,PE-AUROBINDO-AUR-APL-2020-015876,AUROBINDO,,32.0,YR,,F,Y,,,20200606.0,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis,175833912.0,HO,,,,,,,,,175833912.0,1.0,HIV infection
17584138,175841382,2,F,,20200604.0,20200326,20200606,EXP,,PE-AUROBINDO-AUR-APL-2020-015875,AUROBINDO,,33.0,YR,,F,Y,,,20200606.0,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis disseminated,175841382.0,HO,,,,,,,,,175841382.0,1.0,HIV infection
17584141,175841413,3,F,,20210729.0,20200326,20210810,EXP,,NG-CIPLA LTD.-2020NG02102,CIPLA,,,,,,Y,,,20210810.0,,HP,NG,NG,EFAVIRENZ.,Exposure during pregnancy,,,,,,,,,,,175841413.0,1.0,HIV infection
17584163,175841631,1,I,,20200316.0,20200326,20200326,EXP,,PE-MYLANLABS-2020M1032531,MYLAN,"MONTENEGRO-IDROGO JJ, CHIAPPE-GONZALEZ A, VARGAS-GONZALES R, AREVALO J, NAVINCOPA M, TICONA E. DISSEMINATED HISTOPLASMOSIS AND HAEMOPHAGOCYTIC SYNDROME IN HIV PATIENTS: A CASE SERIES IN A PERUVIAN HOSPITAL. REV-IBEROAM-MICOL 2020;37(1):28-33.",33.0,YR,,F,Y,,,20200326.0,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis,175841631.0,HO,,,,,,,,,175841631.0,1.0,HIV infection
17584738,175847383,3,F,20120701.0,20231102.0,20200326,20231106,EXP,,US-GILEAD-2020-0456102,GILEAD,,58.0,YR,A,M,Y,95.0,KG,20231106.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Economic problem;Emotional distress;Hyperkalaemia;Joint injury;Osteopenia;Osteoporosis;Pain;Renal impairment;Rib fracture,175847383.0,HO,,,175847383.0,1.0,2004.0,20050729.0,106.0,DAY,175847383.0,1.0,HIV infection
17587182,175871821,1,I,,20200319.0,20200326,20200326,EXP,,FR-MYLANLABS-2020M1031822,MYLAN,,,,A,M,Y,60.0,KG,20200326.0,,MD,FR,FR,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,175871821.0,OT,,,175871821.0,1.0,2006.0,2007.0,,,175871821.0,1.0,HIV infection
17587478,175874781,1,I,,20200311.0,20200326,20200326,EXP,,UG-APPCO PHARMA LLC-2082015,APPCO PHARMA,,10.0,YR,,F,Y,,,20200326.0,,HP,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Therapy change;Treatment noncompliance;Virologic failure,175874781.0,HO,,,,,,,,,175874781.0,1.0,HIV infection
17590225,175902251,1,I,,20200316.0,20200327,20200327,EXP,,PE-MYLANLABS-2020M1032530,MYLAN,"MONTENEGRO-IDROGO JJ, CHIAPPE-GONZALEZ A, VARGAS-GONZALES R, AREVALO J, NAVINCOPA M, TICONA E. DISSEMINATED HISTOPLASMOSIS AND HAEMOPHAGOCYTIC SYNDROME IN HIV PATIENTS: A CASE SERIES IN A PERUVIAN HOSPITAL. REV-IBEROAM-MICOL 2020;37(1):28-33.",32.0,YR,,F,Y,,,20200327.0,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis,175902251.0,HO,,,,,,,,,175902251.0,1.0,HIV infection
17591915,175919152,2,F,20161221.0,20200506.0,20200327,20200527,EXP,,US-GILEAD-2020-0456524,GILEAD,,61.0,YR,A,M,Y,60.7,KG,20200527.0,,CN,US,US,SUSTIVA,Bone density decreased;Economic problem;Osteoporosis,175919152.0,OT,,,175919152.0,1.0,20020808.0,20050321.0,,,175919152.0,1.0,HIV infection
17598401,175984011,1,I,2009.0,20200318.0,20200330,20200330,EXP,,GB-MYLANLABS-2020M1032930,MYLAN,"PANOU E, WATCHORN R, BAKKOUR W, RATYNSKA M, BUNKER CB. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE. J-EUR-ACAD-DERMATOL-VENEREOL 2020;34(2):E100-E101.",35.0,YR,,M,Y,,,20200330.0,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,175984011.0,OT,,,175984011.0,1.0,2009.0,,,,175984011.0,1.0,HIV infection
17599240,175992401,1,I,,20200323.0,20200330,20200330,EXP,,GB-STRIDES ARCOLAB LIMITED-2020SP004091,STRIDES,"PANOU E, WATCHORN R, BAKKOUR W, RATYNSKA M, BUNKER CB. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE?. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2020;34(2):E100-E101",35.0,YR,,M,Y,,,20200330.0,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome;Pigmentation disorder;Skin lesion,175992401.0,OT,,,175992401.0,1.0,2009.0,,,,175992401.0,1.0,HIV infection
17600360,1760036011,11,F,,20211223.0,20200330,20211229,EXP,,FR-MYLANLABS-2020M1032592,MYLAN,"Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, et al... Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects. An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11). PLoS Medicine. 2014;11(11):1-22",,,,F,Y,,,20211229.0,,MD,FR,FR,EFAVIRENZ,Cerebral ventricle dilatation;Foetal exposure during pregnancy;Pachygyria;White matter lesion,1760036011.0,CA,,,,,,,,,1760036011.0,1.0,HIV infection
17604948,176049481,1,I,201701.0,20200319.0,20200331,20200331,EXP,,PT-MYLANLABS-2020M1031681,MYLAN,SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE.. FARMACEUTICO NEWS. 2020,45.0,YR,,M,Y,,,20200331.0,,HP,PT,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,176049481.0,HO,,,176049481.0,1.0,2011.0,,,,176049481.0,1.0,HIV infection
17614197,176141975,5,F,2009.0,20200416.0,20200402,20200420,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-027483,BRISTOL MYERS SQUIBB,"PANOU E, WATCHORN R, BAKKOUR W, RATYNSKA M, BUNKER CB. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY(JEADV). 2020;34(2):E100-E101",35.0,YR,,M,Y,,,20200420.0,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,176141975.0,OT,,,176141975.0,1.0,2009.0,,,,176141975.0,1.0,HIV infection
17618617,176186171,1,I,,20200326.0,20200402,20200402,EXP,,IN-MYLANLABS-2020M1034516,MYLAN,,58.0,YR,,F,Y,,,20200402.0,,HP,IN,IN,EFAVIRENZ.,Hyperchloraemia;Hypokalaemia;Metabolic acidosis;Renal tubular acidosis,176186171.0,HO,,,,,,,,,176186171.0,1.0,HIV infection
17620198,176201982,2,F,20191115.0,20200720.0,20200403,20200722,EXP,,CN-GLAXOSMITHKLINE-CN2020APC055904,GLAXOSMITHKLINE,,28.0,YR,,M,Y,66.0,KG,20200722.0,,HP,CN,CN,EFAVIRENZ TABLETS,Drug eruption;Drug-induced liver injury;Hepatic failure;Liver injury;Pyrexia;Rash,176201982.0,HO,,,176201982.0,1.0,20191031.0,20191225.0,,,176201982.0,1.0,Acquired immunodeficiency syndrome
17620215,176202152,2,F,20191115.0,20200720.0,20200403,20200722,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020APC055904,VIIV,,28.0,YR,,M,Y,66.0,KG,20200722.0,,HP,CN,CN,EFAVIRENZ TABLETS,Drug eruption;Drug-induced liver injury;Hepatic failure;Liver injury;Pyrexia;Rash,176202152.0,OT,,,176202152.0,1.0,20191031.0,20191225.0,,,176202152.0,1.0,Acquired immunodeficiency syndrome
17621214,176212141,1,I,20130601.0,20200401.0,20200403,20200403,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-028000,BRISTOL MYERS SQUIBB,,50.0,YR,,M,Y,89.21,KG,20200403.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Hepatic enzyme increased;Hydronephrosis;Nephritis allergic;Renal failure;Urinary tract obstruction;Urosepsis,176212141.0,HO,,,176212141.0,1.0,20110729.0,201709.0,,,176212141.0,1.0,HIV infection
17629307,176293071,1,I,2009.0,20200330.0,20200406,20200406,EXP,,GB-TEVA-2020-GB-1218717,TEVA,PANOU E. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE?. J-EUR-ACAD-DERMATOL-VENEREOL.,35.0,YR,,M,Y,,,20200406.0,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,176293071.0,OT,,,176293071.0,1.0,2009.0,,,,176293071.0,1.0,HIV infection
17643674,176436742,2,F,2009.0,20200407.0,20200408,20200420,EXP,,GB-AUROBINDO-AUR-APL-2020-016531,AUROBINDO,,35.0,YR,,M,Y,,,20200420.0,,HP,GB,GB,EFAVIRENZ.,Drug resistance;Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,176436742.0,OT,,,176436742.0,1.0,2009.0,,,,176436742.0,1.0,HIV infection
17646796,176467961,1,I,,20200406.0,20200408,20200408,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029010,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20200408.0,,HP,CA,CA,SUSTIVA,Anxiety,176467961.0,HO,,,,,,,,,176467961.0,1.0,HIV infection
17650432,176504321,1,I,20091201.0,20200408.0,20200409,20200409,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029565,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20200409.0,,MD,DE,DE,SUSTIVA,Superficial spreading melanoma stage unspecified,176504321.0,LT,,,,,,,,,176504321.0,1.0,HIV infection
17653758,176537581,1,I,,20200406.0,20200410,20200410,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029047,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20200410.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176537581.0,OT,,,,,,,,,176537581.0,1.0,HIV infection
17653762,176537621,1,I,,20200406.0,20200410,20200410,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029009,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20200410.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176537621.0,OT,,,,,,,,,176537621.0,1.0,HIV infection
17661614,176616141,1,I,,20200406.0,20200413,20200413,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029069,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20200413.0,,HP,CA,CA,SUSTIVA,Anxiety,176616141.0,HO,,,,,,,,,176616141.0,1.0,HIV infection
17664037,176640371,1,I,,20200408.0,20200414,20200414,EXP,,CA-009507513-2004CAN002935,MERCK,,,,,,Y,,,20200414.0,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,176640371.0,OT,,,,,,,,,176640371.0,1.0,HIV infection
17665268,176652681,1,I,,20200406.0,20200414,20200414,EXP,,GB-MYLANLABS-2020M1037153,MYLAN,,,,A,F,Y,,,20200414.0,,HP,GB,GB,EFAVIRENZ.,Hypertension;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Pre-eclampsia,176652681.0,OT,,,,,,,,,176652681.0,1.0,HIV infection
17668145,176681451,1,I,,20200406.0,20200415,20200415,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029032,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20200415.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176681451.0,OT,,,,,,,,,176681451.0,1.0,HIV infection
17670190,176701903,3,F,201805.0,20200817.0,20200415,20200914,PER,,US-GILEAD-2020-0458892,GILEAD,,59.0,YR,A,M,Y,,,20200914.0,,LW,US,US,EFAVIRENZ.,Bone density decreased;Economic problem;Emotional distress;Pain,,,,,176701903.0,1.0,200511.0,201805.0,,,176701903.0,1.0,HIV infection
17672027,176720271,1,I,2014.0,20200407.0,20200415,20200415,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2020GSK060636,VIIV,"LAITON-DONATO K, AVILA-ROBAYO P, PAEZ-MARTINEZ A, BENJUMEA-NIETO P, USME-CIRO JA, PINZON-NARINO N ET AL.. PROGRESSIVE VACCINIA ACQUIRED THROUGH ZOONOTIC TRANSMISSION IN A PATIENT WITH HIV/AIDS, COLOMBIA. EMERGING INFECTIOUS DISEASES. 2020;26 (3):601-605 DOI.ORG/10.3201/EID260",30.0,YR,,M,Y,,,20200415.0,,MD,CO,CO,EFAVIRENZ.,Anaemia;Condition aggravated;General physical health deterioration;Hypoacusis;Leukopenia;Pathogen resistance;Progressive vaccinia;Pyrexia;Skin lesion;Skin ulcer;Tachycardia;Treatment noncompliance;Virologic failure;Visual impairment,176720271.0,OT,,,176720271.0,1.0,,20150330.0,,,176720271.0,1.0,HIV infection
17673683,176736831,1,I,,20080116.0,20200415,20200415,EXP,,IT-009507513-0801ITA00021,MERCK,,50.0,YR,,M,Y,,,20200415.0,,CN,IT,IT,EFAVIRENZ.,Atrial hypertrophy;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Hypertension;Hypertensive crisis;Left ventricular hypertrophy;Lipoatrophy;Posterior reversible encephalopathy syndrome,176736831.0,HO,,,,,,,,,176736831.0,1.0,HIV infection
17674968,176749682,2,F,,20200420.0,20200416,20200423,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029068,BRISTOL MYERS SQUIBB,"RIDOLFO AL, RESTA F, MILAZZO L, CARAMMA I, MATACENA G, ANTINORI S, ET AL.. REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME IN 2 HIV INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY. CLINICAL INFECTIOUS DISEASES. 2008;46:E19-22",50.0,YR,,M,Y,,,20200423.0,,HP,IT,IT,EFAVIRENZ.,Posterior reversible encephalopathy syndrome,176749682.0,HO,,,,,,,,,176749682.0,1.0,Antiretroviral therapy
17677484,176774845,5,F,20060501.0,20240119.0,20200416,20240122,PER,,US-GILEAD-2020-0459254,GILEAD,,47.0,YR,A,M,Y,87.9,KG,20240122.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Drug ineffective;Dysstasia;Economic problem;Emotional distress;Gait disturbance;Osteoporosis;Pain;Renal pain,176774845.0,OT,,,176774845.0,1.0,201906.0,201911.0,,,176774845.0,1.0,HIV infection
17677809,176778091,1,I,,20200410.0,20200416,20200416,EXP,,CA-ROCHE-2583351,ROCHE,,54.0,YR,,M,Y,,,20200417.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176778091.0,OT,,,,,,,,,176778091.0,1.0,HIV infection
17678730,176787303,3,F,201205.0,20200828.0,20200417,20200904,PER,,US-GILEAD-2020-0459240,GILEAD,,41.0,YR,A,M,Y,72.11,KG,20200904.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Dysuria;Economic problem;Emotional distress;Mobility decreased;Nephrolithiasis;Pain;Unevaluable event,176787303.0,OT,,,176787303.0,1.0,201209.0,201604.0,,,176787303.0,1.0,HIV infection
17678746,176787463,3,F,2003.0,20210517.0,20200417,20210520,PER,,US-GILEAD-2020-0459248,GILEAD,,28.0,YR,A,M,Y,74.83,KG,20210520.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone density decreased;Depression;Disturbance in attention;Economic problem;Emotional distress;Fear;Loss of personal independence in daily activities;Osteopenia;Pain;Renal disorder;Sexual dysfunction;Tooth loss,,,,,176787463.0,1.0,200105.0,20100929.0,,,176787463.0,1.0,HIV infection
17679010,176790102,2,F,20091201.0,20200412.0,20200417,20200421,EXP,DE-DCGMA-20184716,DE-TEVA-2020-DE-1224251,TEVA,,44.0,YR,,M,Y,,,20200421.0,,MD,DE,DE,EFAVIRENZ.,Superficial spreading melanoma stage unspecified,176790102.0,LT,,,,,,,,,176790102.0,1.0,HIV infection
17679133,176791333,3,F,2011.0,20210129.0,20200417,20210211,PER,,US-GILEAD-2020-0459235,GILEAD,,48.0,YR,A,M,Y,81.63,KG,20210211.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Osteopenia;Pain;Proteinuria;Renal failure,176791333.0,OT,,,176791333.0,1.0,200601.0,201003.0,,,176791333.0,1.0,HIV infection
17679533,176795334,4,F,20120531.0,20210212.0,20200417,20210225,EXP,,US-GILEAD-2020-0459258,GILEAD,,56.0,YR,A,M,Y,84.35,KG,20210225.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone pain;Carpal tunnel syndrome;Depression;Dyspnoea;Economic problem;Emotional distress;Gastrointestinal disorder;Impaired work ability;Injury;Insomnia;Myalgia;Osteopenia;Pain;Panic attack;Sitting disability;Sleep apnoea syndrome,176795334.0,OT,,,176795334.0,1.0,20030811.0,2005.0,,,176795334.0,1.0,HIV infection
17679923,176799232,2,F,2012.0,20200828.0,20200417,20200924,EXP,,US-GILEAD-2020-0459255,GILEAD,,46.0,YR,A,M,Y,77.1,KG,20200924.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Spinal compression fracture;Tibia fracture;Tooth disorder;Tooth loss;Wrist fracture,176799232.0,OT,,,176799232.0,1.0,201203.0,201812.0,,,176799232.0,1.0,HIV infection
17680173,176801734,4,F,20150723.0,20210617.0,20200417,20210622,EXP,,US-GILEAD-2020-0459562,GILEAD,,38.0,YR,A,M,Y,,,20210622.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure,176801734.0,OT,,,176801734.0,1.0,20060831.0,20180106.0,,,176801734.0,1.0,HIV infection
17680666,176806661,1,I,,20200413.0,20200417,20200417,EXP,,GF-GLAXOSMITHKLINE-GF2020GSK064965,GLAXOSMITHKLINE,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200417.0,,HP,GF,GF,EFAVIRENZ.,Abdominal pain;Diarrhoea;Dyspnoea;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia;Virologic failure,176806661.0,OT,,,,,,,,,176806661.0,1.0,HIV infection
17680667,176806671,1,I,,20200413.0,20200417,20200417,EXP,,GF-VIIV HEALTHCARE LIMITED-GF2020GSK064965,VIIV,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200417.0,,HP,GF,GF,EFAVIRENZ.,Abdominal pain;Diarrhoea;Dyspnoea;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia;Virologic failure,176806671.0,OT,,,,,,,,,176806671.0,1.0,HIV infection
17681702,176817023,3,F,2013.0,20210224.0,20200417,20210305,EXP,,US-GILEAD-2020-0459245,GILEAD,,,,A,M,Y,68.03,KG,20210305.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Proteinuria,176817023.0,OT,,,176817023.0,1.0,201008.0,201602.0,,,176817023.0,1.0,HIV infection
17684290,176842901,1,I,,20200413.0,20200420,20200420,EXP,,GF-GLAXOSMITHKLINE-GF2020GSK065897,GLAXOSMITHKLINE,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420.0,,HP,GF,GF,EFAVIRENZ.,Anaemia;Arthralgia;Condition aggravated;Diarrhoea;Encephalitis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia,176842901.0,OT,,,,,,,,,176842901.0,1.0,HIV infection
17684293,176842931,1,I,,20200413.0,20200420,20200420,EXP,,GF-VIIV HEALTHCARE LIMITED-GF2020GSK065897,VIIV,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420.0,,HP,GF,GF,EFAVIRENZ.,Anaemia;Arthralgia;Condition aggravated;Diarrhoea;Encephalitis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia,176842931.0,OT,,,,,,,,,176842931.0,1.0,HIV infection
17684348,176843481,1,I,,20200413.0,20200420,20200420,EXP,,GF-VIIV HEALTHCARE LIMITED-GF2020GSK065908,VIIV,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420.0,,HP,GF,GF,EFAVIRENZ.,Acute kidney injury;Anaemia;Diarrhoea;Hepatomegaly;Histoplasmosis;Immune reconstitution inflammatory syndrome;Pyrexia;Weight decreased,176843481.0,HO,,,,,,,,,176843481.0,1.0,HIV infection
17684351,176843511,1,I,,20200413.0,20200420,20200420,EXP,,GF-GLAXOSMITHKLINE-GF2020GSK065908,GLAXOSMITHKLINE,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420.0,,HP,GF,GF,EFAVIRENZ.,Acute kidney injury;Anaemia;Diarrhoea;Hepatomegaly;Histoplasmosis;Immune reconstitution inflammatory syndrome;Pyrexia;Weight decreased,176843511.0,OT,,,,,,,,,176843511.0,1.0,HIV infection
17684543,176845432,2,F,,20200824.0,20200420,20200831,EXP,,CA-ROCHE-2583703,ROCHE,,52.0,YR,,M,Y,,,20200901.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,176845432.0,OT,,,,,,,,,176845432.0,1.0,HIV infection
17685877,176858771,1,I,20171006.0,20200214.0,20200420,20200420,EXP,,NVSC2020GB043058,NOVARTIS,,43.0,YR,,F,Y,,,20200420.0,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,176858771.0,OT,,,176858771.0,1.0,20171006.0,20180205.0,,,176858771.0,1.0,HIV infection
17685920,176859201,1,I,,20200407.0,20200420,20200420,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067790,VIIV,,36.0,YR,,M,Y,,,20200420.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176859201.0,OT,,,,,,,,,176859201.0,1.0,HIV infection
17685921,176859211,1,I,,20200407.0,20200420,20200420,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK067790,GLAXOSMITHKLINE,,36.0,YR,,M,Y,,,20200420.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176859211.0,OT,,,,,,,,,176859211.0,1.0,HIV infection
17686173,176861731,1,I,,20200407.0,20200420,20200420,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067727,VIIV,,28.0,YR,,M,Y,,,20200420.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176861731.0,OT,,,,,,,,,176861731.0,1.0,HIV infection
17686174,176861741,1,I,,20200407.0,20200420,20200420,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK067727,GLAXOSMITHKLINE,,28.0,YR,,M,Y,,,20200420.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176861741.0,OT,,,,,,,,,176861741.0,1.0,HIV infection
17687492,176874922,2,F,,20200407.0,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK067791,GLAXOSMITHKLINE,,32.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176874922.0,OT,,,,,,,,,176874922.0,1.0,HIV infection
17687523,176875232,2,F,,20200407.0,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067791,VIIV,,32.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176875232.0,OT,,,,,,,,,176875232.0,1.0,HIV infection
17688040,176880401,1,I,,20200407.0,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067793,VIIV,,36.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176880401.0,OT,,,,,,,,,176880401.0,1.0,HIV infection
17688148,176881481,1,I,,20200407.0,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068224,VIIV,,42.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176881481.0,OT,,,,,,,,,176881481.0,1.0,HIV infection
17688151,176881511,1,I,,20200407.0,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068224,GLAXOSMITHKLINE,,42.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176881511.0,OT,,,,,,,,,176881511.0,1.0,HIV infection
17689207,176892071,1,I,,20200407.0,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068410,GLAXOSMITHKLINE,,50.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176892071.0,OT,,,,,,,,,176892071.0,1.0,HIV infection
17689225,176892251,1,I,,20200407.0,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068410,VIIV,,50.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176892251.0,OT,,,,,,,,,176892251.0,1.0,HIV infection
17692547,176925471,1,I,,20200415.0,20200422,20200422,EXP,,US-MYLANLABS-2020M1040591,MYLAN,"DOOLEY KE, KAPLAN R, MWELASE N, GRINSZTEJN B, TICONA E, LACERDA M, ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY FOR PATIENTS COINFECTED WITH TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS: A MULTICENTER, NONCOMPARATIVE, OPEN-LABEL, RANDOMIZED TRIAL. CLIN-INFECT-DIS 2020;70(4):549-556.",,,A,F,Y,,,20200422.0,,HP,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,176925471.0,OT,,,,,,,,,176925471.0,1.0,HIV infection
17692553,176925531,1,I,,20200415.0,20200422,20200422,EXP,,US-MYLANLABS-2020M1040596,MYLAN,"DOOLEY KE, KAPLAN R, MWELASE N, GRINSZTEJN B, TICONA E, LACERDA M, ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY FOR PATIENTS COINFECTED WITH TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS: A MULTICENTER, NONCOMPARATIVE, OPEN-LABEL, RANDOMIZED TRIAL. CLIN-INFECT-DIS 2020;70(4):549-556.",,,A,,Y,,,20200422.0,,HP,US,US,EFAVIRENZ.,Acute kidney injury;Immune reconstitution inflammatory syndrome,176925531.0,OT,,,,,,,,,176925531.0,1.0,HIV infection
17696743,176967431,1,I,,20200411.0,20200423,20200423,EXP,,IN-HETERO-HET2020IN00414,HETERO,"SEN P, SUDHARSHAN S, BANERJEE A, DHAMI A.. CLINICAL AND ELECTROPHYSIOLOGICAL CHARACTERISTICS OF EFAVIRENZ-INDUCED MACULAR TOXICITY. GMS OPHTHALMOL CASES. 2020;10 (8):1-5",54.0,YR,,F,Y,,,20200423.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,176967431.0,OT,,,,,,,,,176967431.0,1.0,HIV infection
17704872,177048721,1,I,,20200415.0,20200424,20200424,EXP,,US-MYLANLABS-2020M1040599,MYLAN,"DOOLEY KE, KAPLAN R, MWELASE N, GRINSZTEJN B, TICONA E, LACERDA M, ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY FOR PATIENTS COINFECTED WITH TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS: A MULTICENTER, NONCOMPARATIVE, OPEN-LABEL, RANDOMIZED TRIAL. CLIN-INFECT-DIS 2020;70(4):549-556.",,,A,,Y,,,20200424.0,,HP,US,US,EFAVIRENZ.,Drug resistance;Virologic failure,177048721.0,OT,,,,,,,,,177048721.0,1.0,HIV infection
17705396,177053965,5,F,20080115.0,20210723.0,20200424,20210730,EXP,,US-GILEAD-2020-0460253,GILEAD,,47.0,YR,A,M,Y,49.89,KG,20210730.0,,CN,US,US,SUSTIVA,Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Femoral neck fracture;Haematuria;Hip arthroplasty;Illness;Nausea;Osteoarthritis;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal failure;Rib fracture;Tooth loss,177053965.0,OT,,,177053965.0,1.0,2007.0,20090202.0,,,177053965.0,1.0,HIV infection
17705704,177057043,3,F,20141026.0,20211018.0,20200424,20211021,EXP,,US-GILEAD-2020-0460888,GILEAD,,52.0,YR,A,M,Y,,,20211021.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Nephrolithiasis;Renal failure;Skeletal injury,177057043.0,OT,,,177057043.0,1.0,2015.0,20160830.0,,,177057043.0,1.0,HIV infection
17707929,177079291,1,I,,20200420.0,20200425,20200425,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020607",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200425.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,177079291.0,OT,,,,,,,,,177079291.0,1.0,HIV infection
17709804,177098041,1,I,,20200415.0,20200427,20200427,EXP,,GB-AUROBINDO-AUR-APL-2020-020175,AUROBINDO,,,,A,F,Y,,,20200427.0,,HP,GB,GB,EFAVIRENZ.,Hypertension;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Pre-eclampsia,177098041.0,OT,,,,,,,,,177098041.0,1.0,HIV infection
17709831,177098311,1,I,,20200420.0,20200427,20200427,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020619",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200427.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,177098311.0,CA,,,,,,,,,177098311.0,1.0,HIV infection
17709935,177099353,3,F,20130301.0,20230222.0,20200427,20230227,EXP,,US-GILEAD-2020-0460866,GILEAD,,34.0,YR,A,M,Y,,,20230227.0,,LW,US,US,SUSTIVA,Arthralgia;Back pain;Bone density decreased;Bone loss;Multiple fractures;Osteonecrosis;Renal injury,177099353.0,OT,,,177099353.0,1.0,201304.0,2019.0,,,177099353.0,1.0,HIV infection
17710102,177101021,1,I,,20200420.0,20200427,20200427,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200427.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,177101021.0,OT,,,,,,,,,177101021.0,1.0,HIV infection
17714453,177144537,7,F,20040617.0,20230919.0,20200427,20230922,EXP,,US-GILEAD-2020-0460865,GILEAD,,33.0,YR,A,M,Y,73.016,KG,20230922.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Mobility decreased;Pain;Renal cyst;Renal failure;Renal tubular necrosis,177144537.0,OT,,,177144537.0,1.0,20040112.0,20171023.0,5033.0,DAY,177144537.0,1.0,HIV infection
17715956,177159561,1,I,,20200418.0,20200428,20200428,EXP,,IT-AUROBINDO-AUR-APL-2020-020537,AUROBINDO,,50.0,YR,,M,Y,,,20200428.0,,MD,IT,IT,EFAVIRENZ.,Atrial hypertrophy;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Hypertension;Hypertensive crisis;Left ventricular hypertrophy;Lipoatrophy;Posterior reversible encephalopathy syndrome,177159561.0,HO,,,,,,,,,177159561.0,1.0,HIV infection
17716104,177161041,1,I,,20200421.0,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020959",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200428.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,177161041.0,OT,,,,,,,,,177161041.0,1.0,HIV infection
17716181,177161811,1,I,,20200421.0,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-021213",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200428.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,177161811.0,OT,,,,,,,,,177161811.0,1.0,HIV infection
17717701,177177011,1,I,,20200420.0,20200428,20200428,EXP,,FR-MYLANLABS-2020M1042155,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200428.0,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177177011.0,HO,,,,,,,,,177177011.0,1.0,HIV infection
17717704,177177041,1,I,,20200420.0,20200428,20200428,EXP,,FR-MYLANLABS-2020M1042160,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200428.0,,HP,FR,FR,EFAVIRENZ.,Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177177041.0,HO,,,,,,,,,177177041.0,1.0,HIV infection
17717710,177177101,1,I,,20200420.0,20200428,20200428,EXP,,FR-MYLANLABS-2020M1042132,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200428.0,,HP,FR,FR,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177177101.0,HO,,,,,,,,,177177101.0,1.0,HIV infection
17718876,177188766,6,F,20180101.0,20230609.0,20200428,20230613,EXP,,US-GILEAD-2020-0461588,GILEAD,,,,A,F,Y,35.374,KG,20230613.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Bone pain;Emotional distress;Foot fracture;Hand fracture;Liver disorder;Loss of personal independence in daily activities;Multiple fractures;Osteonecrosis;Osteoporosis;Pain;Renal disorder;Renal injury;Skeletal injury;Spinal fracture,177188766.0,HO,,,177188766.0,1.0,201001.0,201908.0,,,177188766.0,1.0,HIV infection
17719478,177194784,4,F,2012.0,20210316.0,20200428,20210701,EXP,,US-GILEAD-2020-0460476,GILEAD,,46.0,YR,A,M,Y,77.1,KG,20210701.0,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Cataract;Depression;Emotional distress;Insomnia;Intervertebral disc degeneration;Osteonecrosis;Osteopenia;Pain;Radiculopathy;Renal failure;Social anxiety disorder;Spinal osteoarthritis;Spinal stenosis,177194784.0,OT,,,177194784.0,1.0,20130730.0,20151022.0,,,177194784.0,1.0,HIV infection
17721939,177219395,5,F,20050101.0,20230808.0,20200429,20230814,EXP,,US-GILEAD-2020-0462221,GILEAD,,,,A,M,Y,81.63,KG,20230814.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Bone pain;Emotional distress;Exercise tolerance decreased;Gait disturbance;Multiple fractures;Muscular weakness;Osteonecrosis;Osteoporosis;Pain;Renal impairment;Renal injury;Skeletal injury,177219395.0,OT,,,177219395.0,1.0,2001.0,2002.0,,,177219395.0,1.0,HIV infection
17722739,177227391,1,I,,20200420.0,20200429,20200429,EXP,,FR-MYLANLABS-2020M1042126,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200429.0,,HP,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177227391.0,HO,,,,,,,,,177227391.0,1.0,HIV infection
17722779,177227791,1,I,,20200420.0,20200429,20200429,EXP,,FR-MYLANLABS-2020M1042129,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200429.0,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177227791.0,HO,,,,,,,,,177227791.0,1.0,HIV infection
17723099,177230991,1,I,,20200420.0,20200429,20200429,EXP,,FR-MYLANLABS-2020M1042142,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200429.0,,HP,FR,FR,EFAVIRENZ.,Acute kidney injury;Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177230991.0,HO,,,,,,,,,177230991.0,1.0,HIV infection
17723323,177233231,1,I,,20200415.0,20200429,20200429,EXP,,CH-GLAXOSMITHKLINE-MM2020GSK071237,GLAXOSMITHKLINE,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429.0,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177233231.0,OT,,,,,,,,,177233231.0,1.0,HIV infection
17723325,177233251,1,I,,20200415.0,20200429,20200429,EXP,,CH-VIIV HEALTHCARE LIMITED-MM2020GSK071237,VIIV,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429.0,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177233251.0,OT,,,,,,,,,177233251.0,1.0,HIV infection
17723508,177235081,1,I,,20200415.0,20200429,20200429,EXP,,CH-GLAXOSMITHKLINE-MM2020GSK071240,GLAXOSMITHKLINE,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429.0,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177235081.0,OT,,,,,,,,,177235081.0,1.0,HIV infection
17723511,177235111,1,I,,20200415.0,20200429,20200429,EXP,,CH-VIIV HEALTHCARE LIMITED-MM2020GSK071240,VIIV,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429.0,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177235111.0,OT,,,,,,,,,177235111.0,1.0,HIV infection
17723970,177239703,3,F,20151001.0,20230214.0,20200429,20230221,EXP,,US-GILEAD-2020-0462309,GILEAD,,59.0,YR,A,M,Y,72.562,KG,20230221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone loss;Cervical vertebral fracture;Chronic kidney disease;Emotional distress;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure,177239703.0,OT,,,177239703.0,1.0,200706.0,201706.0,,,177239703.0,1.0,HIV infection
17725483,177254831,1,I,,20200415.0,20200429,20200429,EXP,,CH-GLAXOSMITHKLINE-MM2020GSK071242,GLAXOSMITHKLINE,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429.0,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177254831.0,OT,,,,,,,,,177254831.0,1.0,HIV infection
17725484,177254841,1,I,,20200415.0,20200429,20200429,EXP,,CH-VIIV HEALTHCARE LIMITED-MM2020GSK071242,VIIV,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429.0,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177254841.0,OT,,,,,,,,,177254841.0,1.0,HIV infection
17726107,177261074,4,F,20150401.0,20211229.0,20200429,20220105,EXP,,US-GILEAD-2020-0462425,GILEAD,,56.0,YR,A,M,Y,77.098,KG,20220105.0,,LW,US,US,SUSTIVA,Anxiety;Arthralgia;Bone density abnormal;Bone density decreased;Depression;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Procedural pain;Road traffic accident;Tooth loss;Ulna fracture,177261074.0,OT,,,177261074.0,1.0,201108.0,201601.0,,,177261074.0,1.0,HIV infection
17727228,177272287,7,F,20150102.0,20230519.0,20200430,20230524,EXP,,US-GILEAD-2020-0460881,GILEAD,,65.0,YR,E,F,Y,61.224,KG,20230524.0,,LW,US,US,SUSTIVA,Acute kidney injury;Azotaemia;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Insomnia;Malaise;Pain;Pollakiuria;Renal disorder;Renal failure;Renal impairment;Renal tubular disorder,177272287.0,OT,,,177272287.0,1.0,20150904.0,20151021.0,47.0,DAY,177272287.0,1.0,HIV infection
17728731,177287313,3,F,201010.0,20210623.0,20200430,20210702,EXP,,US-GILEAD-2020-0462651,GILEAD,,36.0,YR,A,F,Y,83.45,KG,20210702.0,,CN,US,US,SUSTIVA,Chronic kidney disease;Depression;Dyspnoea;Emotional distress;End stage renal disease;Fatigue;Pain;Renal failure,177287313.0,OT,,,177287313.0,1.0,20141002.0,20141226.0,,,177287313.0,1.0,HIV infection
17729780,177297801,1,I,,20200421.0,20200430,20200430,EXP,,CH-JNJFOC-20200430981,JOHNSON AND JOHNSON,"KOVARI H, CALMY A, DOCO-LECOMPTE T, NKOULOU R, MARZEL A, WEBER R, PHILIPP A. K, RONNY R. B, LEDERGERBER B, PHILIP E. T. ANTIRETROVIRAL DRUGS ASSOCIATED WITH SUBCLINICAL CORONARY ARTERY DISEASE IN THE SWISS HUMAN IMMUNODEFICIENCY VIRUS COHORT STUDY. CLIN INFECT DIS. 70(5):884-889.",,,,,Y,,,20200430.0,,HP,CH,CH,EFAVIRENZ.,Coronary artery disease,177297801.0,OT,,,,,,,,,177297801.0,1.0,HIV infection
17730133,177301336,6,F,20130501.0,20231211.0,20200430,20231213,EXP,,US-GILEAD-2020-0462718,GILEAD,,58.0,YR,A,M,Y,75.7,KG,20231213.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Chronic kidney disease;Emotional distress;Pain;Renal failure;Renal impairment;Tooth loss,177301336.0,OT,,,177301336.0,1.0,2004.0,2010.0,,,177301336.0,1.0,HIV infection
17734092,177340923,3,F,200812.0,20210617.0,20200501,20210624,EXP,,US-GILEAD-2020-0462970,GILEAD,,57.0,YR,A,M,Y,94.4,KG,20210623.0,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Multiple fractures;Osteonecrosis;Pain;Tooth loss,177340923.0,OT,,,177340923.0,1.0,200110.0,200408.0,,,177340923.0,1.0,HIV infection
17735313,177353133,3,F,20111005.0,20210617.0,20200501,20210624,EXP,,US-GILEAD-2020-0462743,GILEAD,,63.0,YR,A,M,Y,96.15,KG,20210623.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Loss of personal independence in daily activities;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure;Rib fracture;Vitamin D deficiency,177353133.0,OT,,,177353133.0,1.0,200511.0,201410.0,,,177353133.0,1.0,HIV infection
17736679,177366795,5,F,20170101.0,20230403.0,20200501,20230407,PER,,US-GILEAD-2020-0463103,GILEAD,,,,A,M,Y,72.562,KG,20230407.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Chronic kidney disease;End stage renal disease;Hepatitis C;Hyperkalaemia;Hypertension;Renal failure,177366795.0,HO,,,177366795.0,1.0,2004.0,2016.0,,,177366795.0,1.0,HIV infection
17741422,177414221,1,I,,20200428.0,20200504,20200504,EXP,,IT-MYLANLABS-2020M1042727,MYLAN,,50.0,YR,,M,Y,,,20200504.0,,MD,IT,IT,EFAVIRENZ.,Agitation;Asthenia;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Coma;Confusional state;Extensor plantar response;Facial paralysis;Hydrocephalus;Hyperreflexia;Hypertension;Hypertensive crisis;Left atrial hypertrophy;Left ventricular hypertrophy;Lipodystrophy acquired;Loss of consciousness;Papilloedema;Posterior reversible encephalopathy syndrome;Pyrexia;Tachycardia;Vasogenic cerebral oedema;Waist circumference increased,177414221.0,HO,,,,,,,,,177414221.0,1.0,Antiretroviral therapy
17742314,177423144,4,F,,20211001.0,20200505,20211008,EXP,,CA-ROCHE-2592280,ROCHE,,54.0,YR,,M,Y,,,20211008.0,,CN,CA,CA,SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,177423144.0,OT,,,,,,,,,177423144.0,1.0,HIV infection
17743771,177437716,6,F,,20241204.0,20200505,20241211,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK075602,VIIV,,,,,,Y,,,20241211.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,177437716.0,OT,,,,,,,,,177437716.0,1.0,HIV infection
17743782,177437826,6,F,,20241204.0,20200505,20241211,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK075602,GLAXOSMITHKLINE,,,,,,Y,,,20241211.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,177437826.0,DE,,,,,,,,,177437826.0,1.0,HIV infection
17747940,177479406,6,F,20100101.0,20211013.0,20200505,20211208,EXP,,US-GILEAD-2020-0462872,GILEAD,,59.0,YR,A,F,Y,93.9,KG,20211208.0,,LW,US,US,SUSTIVA,Abdominal pain upper;Ankle fracture;Ankle impingement;Back pain;Bone density decreased;Bone marrow oedema;Chronic kidney disease;Emotional distress;Fall;Fibula fracture;Gait disturbance;Hypertension;Lower limb fracture;Mobility decreased;Multiple fractures;Osteoporosis;Pain;Posterior tibial tendon dysfunction;Tendonitis,177479406.0,HO,,,177479406.0,1.0,200601.0,201804.0,1823.0,DAY,177479406.0,1.0,HIV infection
17751316,177513168,8,F,20130930.0,20210830.0,20200506,20210906,EXP,,US-GILEAD-2020-0464283,GILEAD,,63.0,YR,A,M,Y,86.18,KG,20210906.0,,CN,US,US,SUSTIVA,Acute kidney injury;Azotaemia;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Clostridium difficile infection;Device related bacteraemia;Disorientation;Emotional distress;End stage renal disease;Feeling drunk;Hyperkalaemia;Hyperparathyroidism secondary;Intervertebral discitis;Lower limb fracture;Nephrogenic anaemia;Nightmare;Osteomyelitis;Osteopenia;Pain;Paranoia;Poor quality sleep;Renal failure;Renal tubular necrosis;Somnolence;Staphylococcal bacteraemia;Tibia fracture;Toxic encephalopathy,177513168.0,OT,,,177513168.0,1.0,20120512.0,20131013.0,,,177513168.0,1.0,HIV infection
17753739,177537391,1,I,,20200427.0,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-021832,AUROBINDO,,,,,,Y,,,20200507.0,,HP,FR,FR,EFAVIRENZ.,Abdominal pain;Cough;Diarrhoea;Dyspnoea;Haemophagocytic lymphohistiocytosis;Hepatomegaly;Histoplasmosis;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Pyrexia,177537391.0,HO,,,,,,,,,177537391.0,1.0,HIV infection
17754134,177541341,1,I,,20200429.0,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-022131,AUROBINDO,,,,,,Y,,,20200507.0,,HP,FR,FR,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177541341.0,HO,,,,,,,,,177541341.0,1.0,HIV infection
17754160,177541601,1,I,,20200429.0,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-022134,AUROBINDO,,,,,,Y,,,20200507.0,,HP,FR,FR,EFAVIRENZ.,Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177541601.0,HO,,,,,,,,,177541601.0,1.0,HIV infection
17754175,177541751,1,I,,20200429.0,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-022136,AUROBINDO,,,,,,Y,,,20200507.0,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177541751.0,OT,,,,,,,,,177541751.0,1.0,HIV infection
17754258,177542581,1,I,,20200427.0,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-021830,AUROBINDO,,,,,,Y,,,20200507.0,,HP,FR,FR,EFAVIRENZ.,Anaemia;Dyspnoea;Hepatocellular injury;Histoplasmosis;Immune reconstitution inflammatory syndrome;Neurological symptom;Pyrexia;Weight decreased,177542581.0,HO,,,,,,,,,177542581.0,1.0,HIV infection
17754797,177547971,1,I,,20200427.0,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-021826,AUROBINDO,,,,,,Y,,,20200507.0,,HP,FR,FR,EFAVIRENZ.,Anaemia;Arthralgia;Diarrhoea;Encephalitis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia,177547971.0,HO,,,,,,,,,177547971.0,1.0,HIV infection
17758801,177588011,1,I,,20200427.0,20200508,20200508,EXP,,FR-AUROBINDO-AUR-APL-2020-021821,AUROBINDO,,,,,,Y,,,20200508.0,,HP,FR,FR,EFAVIRENZ.,Anaemia;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Pulmonary interstitial emphysema syndrome;Weight decreased,177588011.0,OT,,,,,,,,,177588011.0,1.0,HIV infection
17759277,177592773,3,F,,20210706.0,20200508,20210712,EXP,,CA-ROCHE-2485311,ROCHE,,45.0,YR,,M,Y,,,20210712.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,177592773.0,OT,,,,,,,,,177592773.0,1.0,HIV infection
17759420,177594202,2,F,,20200603.0,20200508,20200612,EXP,,FR-AUROBINDO-AUR-APL-2020-022351,AUROBINDO,,,,,,Y,,,20200612.0,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction;Unmasking of previously unidentified disease,177594202.0,OT,,,,,,,,,177594202.0,1.0,HIV infection
17759425,177594251,1,I,,20200430.0,20200508,20200508,EXP,,FR-AUROBINDO-AUR-APL-2020-022349,AUROBINDO,,,,,,Y,,,20200508.0,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177594251.0,HO,,,,,,,,,177594251.0,1.0,HIV infection
17764040,177640401,1,I,,20200430.0,20200511,20200511,EXP,,FR-AUROBINDO-AUR-APL-2020-022263,AUROBINDO,,,,,,Y,,,20200511.0,,HP,FR,FR,EFAVIRENZ.,Acute kidney injury;Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177640401.0,HO,,,,,,,,,177640401.0,1.0,HIV infection
17771701,177717015,5,F,20090410.0,20220215.0,20200512,20220223,EXP,,US-GILEAD-2020-0465958,GILEAD,,32.0,YR,A,M,Y,,,20220222.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Dental caries;Renal failure;Renal impairment;Renal injury;Skeletal injury;Tooth loss,177717015.0,OT,,,177717015.0,1.0,20090121.0,20160101.0,2536.0,DAY,177717015.0,1.0,HIV infection
17772651,177726514,4,F,20181001.0,20220324.0,20200512,20220330,EXP,,US-GILEAD-2020-0466109,GILEAD,,56.0,YR,A,F,Y,,,20220330.0,,LW,US,US,SUSTIVA,Ankle fracture;Bone density decreased;Bone loss;Multiple fractures;Osteonecrosis;Osteoporosis;Renal injury;Skeletal injury,177726514.0,OT,,,177726514.0,1.0,2004.0,2017.0,140.0,DAY,177726514.0,1.0,HIV infection
17778522,177785221,1,I,,20200511.0,20200513,20200513,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020GSK080340,VIIV,,76.0,YR,,M,Y,,,20200513.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,177785221.0,OT,,,,,,,,,177785221.0,1.0,HIV infection
17779212,177792121,1,I,,20200506.0,20200513,20200513,EXP,,IT-MYLANLABS-2020M1045913,MYLAN,,50.0,YR,,M,Y,,,20200513.0,,CN,IT,IT,EFAVIRENZ.,Atrial hypertrophy;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Hypertension;Hypertensive crisis;Left ventricular hypertrophy;Lipoatrophy;Posterior reversible encephalopathy syndrome,177792121.0,OT,,,,,,,,,177792121.0,1.0,HIV infection
17786904,177869041,1,I,,20200507.0,20200514,20200514,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081421,VIIV,,,,,,Y,,,20200514.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177869041.0,OT,,,,,,,,,177869041.0,1.0,HIV infection
17786905,177869051,1,I,,20200507.0,20200514,20200514,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081421,GLAXOSMITHKLINE,,,,,,Y,,,20200514.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177869051.0,OT,,,,,,,,,177869051.0,1.0,HIV infection
17789964,177899645,5,F,20160528.0,20210623.0,20200515,20210625,EXP,,US-GILEAD-2020-0467099,GILEAD,,72.0,YR,E,F,Y,60.77,KG,20210625.0,,CN,US,US,SUSTIVA,Ankle fracture;Anxiety;Bone density decreased;Depression;Emotional distress;Oedema;Osteoarthritis;Osteopenia;Osteoporosis;Pain;Sciatica;Tooth loss;Wrist fracture,177899645.0,OT,,,177899645.0,1.0,20070409.0,20160922.0,,,177899645.0,1.0,HIV infection
17790761,177907611,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081451,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907611.0,OT,,,,,,,,,177907611.0,1.0,HIV infection
17790763,177907631,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081450,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907631.0,OT,,,,,,,,,177907631.0,1.0,HIV infection
17790786,177907861,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081451,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907861.0,OT,,,,,,,,,177907861.0,1.0,HIV infection
17790789,177907891,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081450,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907891.0,OT,,,,,,,,,177907891.0,1.0,HIV infection
17790865,177908651,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081452,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908651.0,OT,,,,,,,,,177908651.0,1.0,HIV infection
17790867,177908671,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081453,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908671.0,OT,,,,,,,,,177908671.0,1.0,HIV infection
17790893,177908931,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081453,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908931.0,OT,,,,,,,,,177908931.0,1.0,HIV infection
17790895,177908951,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081456,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908951.0,OT,,,,,,,,,177908951.0,1.0,HIV infection
17790897,177908971,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081455,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177908971.0,OT,,,,,,,,,177908971.0,1.0,HIV infection
17790900,177909001,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081454,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177909001.0,OT,,,,,,,,,177909001.0,1.0,HIV infection
17790905,177909051,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081452,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177909051.0,OT,,,,,,,,,177909051.0,1.0,HIV infection
17790911,177909111,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081455,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177909111.0,OT,,,,,,,,,177909111.0,1.0,HIV infection
17790913,177909131,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081456,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177909131.0,OT,,,,,,,,,177909131.0,1.0,HIV infection
17790916,177909161,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081454,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177909161.0,OT,,,,,,,,,177909161.0,1.0,HIV infection
17791019,177910191,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081457,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910191.0,OT,,,,,,,,,177910191.0,1.0,HIV infection
17791021,177910211,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081459,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177910211.0,OT,,,,,,,,,177910211.0,1.0,HIV infection
17791024,177910241,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081458,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910241.0,OT,,,,,,,,,177910241.0,1.0,HIV infection
17791027,177910271,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081457,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910271.0,OT,,,,,,,,,177910271.0,1.0,HIV infection
17791029,177910291,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081459,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177910291.0,OT,,,,,,,,,177910291.0,1.0,HIV infection
17791031,177910311,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081458,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910311.0,OT,,,,,,,,,177910311.0,1.0,HIV infection
17791156,177911561,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081461,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911561.0,OT,,,,,,,,,177911561.0,1.0,HIV infection
17791157,177911571,1,I,,20200507.0,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081460,GLAXOSMITHKLINE,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911571.0,OT,,,,,,,,,177911571.0,1.0,HIV infection
17791160,177911601,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081460,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911601.0,OT,,,,,,,,,177911601.0,1.0,HIV infection
17791161,177911611,1,I,,20200507.0,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081461,VIIV,,,,,,Y,,,20200515.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911611.0,OT,,,,,,,,,177911611.0,1.0,HIV infection
17793320,177933202,2,F,20200507.0,20200513.0,20200515,20200526,EXP,,IE-GILEAD-2020-0467150,GILEAD,,,,,M,Y,70.6,KG,20200526.0,,HP,IE,IE,EFAVIRENZ.,Anaemia;Bladder neoplasm,177933202.0,HO,,,177933202.0,1.0,20200507.0,,,,177933202.0,1.0,HIV infection
17799295,177992955,5,F,20120130.0,20220201.0,20200518,20220207,EXP,,US-GILEAD-2020-0467051,GILEAD,,44.0,YR,A,M,Y,90.703,KG,20220207.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Arthralgia;Back pain;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Hip arthroplasty;Intervertebral disc protrusion;Osteoarthritis;Pain;Renal cyst;Renal failure;Spinal deformity;Spinal osteoarthritis;Tendon disorder,177992955.0,OT,,,177992955.0,1.0,2009.0,2017.0,,,177992955.0,1.0,HIV infection
17799574,177995741,1,I,,20200512.0,20200518,20200518,EXP,,IN-MYLANLABS-2020M1049684,MYLAN,"VASA SUSRUTHA, SHUAIB M.A, SOMA SANTOSH KUMAR. EFAVIRENZ INDUCED HAEMOLYTIC ANAEMIA : A RARE CASE REPORT. INDIAN JOURNAL OF BASIC AND APPLIED MEDICAL RESEARCH. 2018;8(1):530-532",38.0,YR,,F,Y,,,20200518.0,,HP,IN,IN,EFAVIRENZ.,Haemolytic anaemia,177995741.0,OT,,,,,,,,,177995741.0,1.0,Antiretroviral therapy
17810183,178101831,1,I,,20200509.0,20200521,20200521,EXP,,CN-GLAXOSMITHKLINE-CN2020APC078974,GLAXOSMITHKLINE,"XIAO Q, XIAO H. STUDY ON IMMUNE RECONSTRUCTION AFTER ANTIRETROVIRAL THERAPY IN HIV / HCV CO-INFECTED PATIENTS. 2020;26(09):1864-1868 DOI:10. 3969 /J.IS",,,,,Y,,,20200521.0,,MD,CN,CN,EFAVIRENZ.,Nephrolithiasis,178101831.0,OT,,,,,,,,,178101831.0,1.0,HIV infection
17810184,178101841,1,I,,20200509.0,20200521,20200521,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020APC078974,VIIV,"XIAO Q, XIAO H. STUDY ON IMMUNE RECONSTRUCTION AFTER ANTIRETROVIRAL THERAPY IN HIV / HCV CO-INFECTED PATIENTS. 2020;26(09):1864-1868 DOI:10. 3969 /J.IS",,,,,Y,,,20200521.0,,MD,CN,CN,EFAVIRENZ.,Nephrolithiasis,178101841.0,OT,,,,,,,,,178101841.0,1.0,HIV infection
17820050,178200501,1,I,,20200511.0,20200525,20200525,EXP,,IN-AUROBINDO-AUR-APL-2020-026172,AUROBINDO,EFAVIRENZ/RETINOL/WARFARIN ACUTE LIVER FAILURE: 4 CASE REPORTS. 2020,35.0,YR,,F,Y,,,20200525.0,,HP,IN,IN,EFAVIRENZ.,Acute hepatic failure;Ascites;Hepatomegaly;Jaundice,178200501.0,HO,,,,,,,,,178200501.0,1.0,HIV infection
17827031,178270311,1,I,,20200514.0,20200527,20200527,EXP,,MY-CIPLA LTD.-2020MY03520,CIPLA,,,,,,Y,,,20200527.0,,HP,MY,MY,EFAVIR (EFAVIRENZ),Toxic epidermal necrolysis,178270311.0,OT,,,,,,,,,178270311.0,1.0,Antiretroviral therapy
17831133,178311331,1,I,,20200525.0,20200527,20200527,EXP,,IN-GILEAD-2020-0468883,GILEAD,"JOHN K.J., GUNASEKARAN K., SULTAN N., IYYADURAI R.. CYTOMEGALOVIRUS VENTRICULOENCEPHALITIS PRESENTING WITH HYDROCEPHALUS IN A PATIENT WITH ADVANCED HIV INFECTION. OXFORD MEDICAL CASE REPORTS. 2019;10:443-446. DOI:10.1093/OMCR/OMZ104",38.0,YR,A,F,Y,,,20200527.0,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,178311331.0,OT,,,,,,,,,178311331.0,1.0,HIV infection
17834941,178349411,1,I,,20200514.0,20200528,20200528,EXP,,MY-CIPLA LTD.-2020MY03512,CIPLA,,,,,,Y,,,20200528.0,,HP,MY,MY,EFAVIR (EFAVIRENZ),Skin hyperpigmentation,178349411.0,OT,,,,,,,,,178349411.0,1.0,Antiretroviral therapy
17839091,178390911,1,I,,20200520.0,20200529,20200529,EXP,,GB-AUROBINDO-AUR-APL-2020-026312,AUROBINDO,,76.0,YR,,M,Y,,,20200529.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,178390911.0,OT,,,,,,,,,178390911.0,1.0,HIV infection
17841668,178416681,1,I,,20200525.0,20200529,20200529,EXP,,GB-MYLANLABS-2020M1051991,MYLAN,,76.0,YR,,M,Y,,,20200529.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,178416681.0,OT,,,,,,,,,178416681.0,1.0,HIV infection
17845184,178451841,1,I,,20200520.0,20200601,20200601,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-040119,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,,,20200601.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,178451841.0,OT,,,,,,,,,178451841.0,1.0,HIV infection
17864160,178641601,1,I,,20200601.0,20200605,20200605,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-027653",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200605.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178641601.0,OT,,,,,,,,,178641601.0,1.0,HIV infection
17868370,178683701,1,I,,20200601.0,20200606,20200606,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-027696",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,,,20200606.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,178683701.0,OT,,,,,,,,,178683701.0,1.0,HIV infection
17868459,1786845915,15,F,20100629.0,20221005.0,20200606,20221018,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2020026669,MACLEODS,,,,,,Y,,,20221017.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Drug abuse;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,1786845915.0,HO,,,1786845915.0,1.0,20171006.0,20180205.0,122.0,DAY,1786845915.0,1.0,HIV infection
17869480,178694803,3,F,201106.0,20210617.0,20200608,20210622,EXP,,US-GILEAD-2020-0470360,GILEAD,,58.0,YR,A,M,Y,61.68,KG,20210622.0,,CN,US,US,SUSTIVA,Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Foot fracture;Glomerular filtration rate decreased;Osteopenia;Pain;Renal failure;Rib fracture,178694803.0,OT,,,178694803.0,1.0,2007.0,2018.0,,,178694803.0,1.0,HIV infection
17870637,178706375,5,F,2018.0,20210617.0,20200608,20210624,EXP,,US-GILEAD-2020-0469433,GILEAD,,50.0,YR,A,M,Y,74.83,KG,20210624.0,,CN,US,US,SUSTIVA,Bone density decreased;Emotional distress;Osteoporosis;Pain;Tooth loss,178706375.0,OT,,,178706375.0,1.0,201201.0,2018.0,,,178706375.0,1.0,HIV infection
17872735,178727351,1,I,,20200604.0,20200608,20200608,EXP,,CA-GILEAD-2020-0470560,GILEAD,,52.0,YR,A,M,Y,,,20200608.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178727351.0,OT,,,,,,,,,178727351.0,1.0,HIV infection
17875422,178754221,1,I,201912.0,20200608.0,20200609,20200609,EXP,FR-AFSSAPS-AN20200672,FR-ABBVIE-20K-056-3435792-00,ABBVIE,,45.0,YR,,M,Y,,,20200609.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,178754221.0,HO,,,178754221.0,1.0,20030615.0,20190228.0,,,178754221.0,1.0,HIV infection
17877650,178776501,1,I,,20200605.0,20200609,20200609,EXP,,NL-GILEAD-2020-0470893,GILEAD,,40.0,YR,A,M,Y,,,20200609.0,,MD,NL,NL,EFAVIRENZ.,Migraine,178776501.0,OT,,,178776501.0,1.0,2005.0,,,,178776501.0,1.0,HIV infection
17878630,178786301,1,I,,20200528.0,20200610,20200610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042255,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20200610.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,178786301.0,HO,,,,,,,,,178786301.0,1.0,HIV infection
17879578,178795781,1,I,,20200528.0,20200610,20200610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042196,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200610.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,178795781.0,OT,,,,,,,,,178795781.0,1.0,HIV infection
17883746,178837461,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-044933,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837461.0,OT,,,,,,,,,178837461.0,1.0,HIV infection
17883747,178837471,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046213,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837471.0,OT,,,,,,,,,178837471.0,1.0,HIV infection
17883749,178837491,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046197,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837491.0,OT,,,,,,,,,178837491.0,1.0,HIV infection
17883751,178837511,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046198,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837511.0,OT,,,,,,,,,178837511.0,1.0,HIV infection
17883752,178837521,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046196,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837521.0,OT,,,,,,,,,178837521.0,1.0,HIV infection
17884248,178842481,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046204,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842481.0,OT,,,,,,,,,178842481.0,1.0,HIV infection
17884249,178842491,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046199,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842491.0,OT,,,,,,,,,178842491.0,1.0,HIV infection
17884250,178842501,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046210,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842501.0,OT,,,,,,,,,178842501.0,1.0,HIV infection
17884266,178842661,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046207,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842661.0,OT,,,,,,,,,178842661.0,1.0,HIV infection
17884267,178842671,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046205,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842671.0,OT,,,,,,,,,178842671.0,1.0,HIV infection
17884268,178842681,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046206,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842681.0,OT,,,,,,,,,178842681.0,1.0,HIV infection
17884280,178842801,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046202,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842801.0,OT,,,,,,,,,178842801.0,1.0,HIV infection
17884281,178842811,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046208,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842811.0,OT,,,,,,,,,178842811.0,1.0,HIV infection
17884282,178842821,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046211,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842821.0,OT,,,,,,,,,178842821.0,1.0,HIV infection
17884286,178842861,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046212,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842861.0,OT,,,,,,,,,178842861.0,1.0,HIV infection
17884287,178842871,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046203,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842871.0,OT,,,,,,,,,178842871.0,1.0,HIV infection
17884288,178842881,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046209,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842881.0,OT,,,,,,,,,178842881.0,1.0,HIV infection
17884289,178842891,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046201,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842891.0,OT,,,,,,,,,178842891.0,1.0,HIV infection
17884290,178842901,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046200,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842901.0,OT,,,,,,,,,178842901.0,1.0,HIV infection
17884526,178845261,1,I,,20200604.0,20200611,20200611,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020096443,VIIV,,52.0,YR,,M,Y,,,20200611.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178845261.0,OT,,,,,,,,,178845261.0,1.0,HIV infection
17884550,178845501,1,I,,20200604.0,20200611,20200611,EXP,,CA-GLAXOSMITHKLINE-CA2020096443,GLAXOSMITHKLINE,,52.0,YR,,M,Y,,,20200611.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178845501.0,OT,,,,,,,,,178845501.0,1.0,HIV infection
17885011,178850111,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046233,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850111.0,OT,,,,,,,,,178850111.0,1.0,HIV infection
17885012,178850121,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046259,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850121.0,OT,,,,,,,,,178850121.0,1.0,HIV infection
17885016,178850161,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046238,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850161.0,OT,,,,,,,,,178850161.0,1.0,HIV infection
17885017,178850171,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046260,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850171.0,OT,,,,,,,,,178850171.0,1.0,HIV infection
17885034,178850341,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046232,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850341.0,OT,,,,,,,,,178850341.0,1.0,HIV infection
17885035,178850351,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046261,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850351.0,OT,,,,,,,,,178850351.0,1.0,HIV infection
17885068,178850681,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046236,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850681.0,OT,,,,,,,,,178850681.0,1.0,HIV infection
17885069,178850691,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046237,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850691.0,OT,,,,,,,,,178850691.0,1.0,HIV infection
17885152,178851521,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046217,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851521.0,OT,,,,,,,,,178851521.0,1.0,HIV infection
17885153,178851531,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046263,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851531.0,OT,,,,,,,,,178851531.0,1.0,HIV infection
17885156,178851561,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046254,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851561.0,OT,,,,,,,,,178851561.0,1.0,HIV infection
17885157,178851571,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046264,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851571.0,OT,,,,,,,,,178851571.0,1.0,HIV infection
17885158,178851581,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046255,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851581.0,OT,,,,,,,,,178851581.0,1.0,HIV infection
17885159,178851591,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046265,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851591.0,OT,,,,,,,,,178851591.0,1.0,HIV infection
17885160,178851601,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046230,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851601.0,OT,,,,,,,,,178851601.0,1.0,HIV infection
17885161,178851611,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046262,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851611.0,OT,,,,,,,,,178851611.0,1.0,HIV infection
17885213,178852131,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046229,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852131.0,OT,,,,,,,,,178852131.0,1.0,HIV infection
17885214,178852141,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046258,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852141.0,OT,,,,,,,,,178852141.0,1.0,HIV infection
17885215,178852151,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046270,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852151.0,OT,,,,,,,,,178852151.0,1.0,HIV infection
17885222,178852221,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046266,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852221.0,OT,,,,,,,,,178852221.0,1.0,HIV infection
17885223,178852231,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046231,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852231.0,OT,,,,,,,,,178852231.0,1.0,HIV infection
17885224,178852241,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046256,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852241.0,OT,,,,,,,,,178852241.0,1.0,HIV infection
17885225,178852251,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046223,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852251.0,OT,,,,,,,,,178852251.0,1.0,HIV infection
17885226,178852261,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046219,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852261.0,OT,,,,,,,,,178852261.0,1.0,HIV infection
17885227,178852271,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046272,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852271.0,OT,,,,,,,,,178852271.0,1.0,HIV infection
17885228,178852281,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046228,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852281.0,OT,,,,,,,,,178852281.0,1.0,HIV infection
17885229,178852291,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046273,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852291.0,OT,,,,,,,,,178852291.0,1.0,HIV infection
17885230,178852301,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046214,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852301.0,OT,,,,,,,,,178852301.0,1.0,HIV infection
17885231,178852311,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046216,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852311.0,OT,,,,,,,,,178852311.0,1.0,HIV infection
17885232,178852321,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046218,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852321.0,OT,,,,,,,,,178852321.0,1.0,HIV infection
17885233,178852331,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046268,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852331.0,OT,,,,,,,,,178852331.0,1.0,HIV infection
17885234,178852341,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046227,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852341.0,OT,,,,,,,,,178852341.0,1.0,HIV infection
17885235,178852351,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046267,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852351.0,OT,,,,,,,,,178852351.0,1.0,HIV infection
17885236,178852361,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046271,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852361.0,OT,,,,,,,,,178852361.0,1.0,HIV infection
17885237,178852371,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046220,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852371.0,OT,,,,,,,,,178852371.0,1.0,HIV infection
17885240,178852401,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046225,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852401.0,OT,,,,,,,,,178852401.0,1.0,HIV infection
17885241,178852411,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046222,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852411.0,OT,,,,,,,,,178852411.0,1.0,HIV infection
17885242,178852421,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046226,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852421.0,OT,,,,,,,,,178852421.0,1.0,HIV infection
17885244,178852441,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046235,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852441.0,OT,,,,,,,,,178852441.0,1.0,HIV infection
17885245,178852451,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046269,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852451.0,OT,,,,,,,,,178852451.0,1.0,HIV infection
17885246,178852461,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046257,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852461.0,OT,,,,,,,,,178852461.0,1.0,HIV infection
17885247,178852471,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046221,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852471.0,OT,,,,,,,,,178852471.0,1.0,HIV infection
17885248,178852481,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046224,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852481.0,OT,,,,,,,,,178852481.0,1.0,HIV infection
17885249,178852491,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046215,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852491.0,OT,,,,,,,,,178852491.0,1.0,HIV infection
17885251,178852511,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046234,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852511.0,OT,,,,,,,,,178852511.0,1.0,HIV infection
17885648,178856481,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046249,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856481.0,OT,,,,,,,,,178856481.0,1.0,HIV infection
17885650,178856501,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046244,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856501.0,OT,,,,,,,,,178856501.0,1.0,HIV infection
17885651,178856511,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046245,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856511.0,OT,,,,,,,,,178856511.0,1.0,HIV infection
17885652,178856521,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046243,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856521.0,OT,,,,,,,,,178856521.0,1.0,HIV infection
17885656,178856561,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046246,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856561.0,OT,,,,,,,,,178856561.0,1.0,HIV infection
17885671,178856711,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046247,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856711.0,OT,,,,,,,,,178856711.0,1.0,HIV infection
17885672,178856721,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046248,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856721.0,OT,,,,,,,,,178856721.0,1.0,HIV infection
17885673,178856731,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046241,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856731.0,OT,,,,,,,,,178856731.0,1.0,HIV infection
17885674,178856741,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046240,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856741.0,OT,,,,,,,,,178856741.0,1.0,HIV infection
17885675,178856751,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046253,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856751.0,OT,,,,,,,,,178856751.0,1.0,HIV infection
17885676,178856761,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046251,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856761.0,OT,,,,,,,,,178856761.0,1.0,HIV infection
17885678,178856781,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046252,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856781.0,OT,,,,,,,,,178856781.0,1.0,HIV infection
17885679,178856791,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046242,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856791.0,OT,,,,,,,,,178856791.0,1.0,HIV infection
17885681,178856811,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046239,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856811.0,OT,,,,,,,,,178856811.0,1.0,HIV infection
17885685,178856851,1,I,,20200601.0,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046250,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611.0,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856851.0,OT,,,,,,,,,178856851.0,1.0,HIV infection
17894021,178940213,3,F,200805.0,20210617.0,20200615,20210622,EXP,,US-GILEAD-2020-0470809,GILEAD,,48.0,YR,A,M,Y,85.71,KG,20210622.0,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Emotional distress;Multiple fractures;Osteonecrosis;Osteoporosis;Pain;Tooth loss,178940213.0,OT,,,178940213.0,1.0,200607.0,201609.0,,,178940213.0,1.0,HIV infection
17895204,178952041,1,I,,20200601.0,20200615,20200615,EXP,,MY-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-044929,BRISTOL MYERS SQUIBB,"KOH KC, IBRAHIM NM, ONG SCL. PARADOXICAL WORSENING OF CHEST RADIOGRAPHS SECONDARY TO IMMUNE RECONSTITUTION SYNDROME (IRIS) IN A PATIENT WITH ADVANCED HIV INFECTION AND RHODOCOCCUS PNEUMONIA. MEDICAL JOURNAL OF MALAYSIA. 2020;75(2):164-6",36.0,YR,,M,Y,,,20200615.0,,MD,MY,MY,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Pneumonia bacterial,178952041.0,OT,,,,,,,,,178952041.0,1.0,HIV infection
17902632,179026321,1,I,201912.0,20200608.0,20200617,20200617,EXP,,FR-AUROBINDO-AUR-APL-2020-029010,AUROBINDO,,45.0,YR,,M,Y,,,20200617.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179026321.0,HO,,,179026321.0,1.0,20070115.0,20160420.0,,,179026321.0,1.0,HIV infection
17902750,179027501,1,I,201912.0,20200610.0,20200616,20200616,EXP,FR-AFSSAPS-AN20200672,FR-JNJFOC-20200617185,JOHNSON AND JOHNSON,,45.0,YR,,M,Y,,,20200616.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179027501.0,HO,,,179027501.0,1.0,20181018.0,20190228.0,,,179027501.0,1.0,HIV infection
17904368,179043684,4,F,20110301.0,20210707.0,20200617,20210713,EXP,,US-GILEAD-2020-0470173,GILEAD,,34.0,YR,A,F,Y,65.77,KG,20210713.0,,CN,US,US,SUSTIVA,Chronic kidney disease,179043684.0,OT,,,179043684.0,1.0,2004.0,,,,179043684.0,1.0,HIV infection
17904644,179046449,9,F,20020111.0,20210727.0,20200617,20210803,PER,,US-GILEAD-2020-0471554,GILEAD,,65.0,YR,E,M,Y,88.44,KG,20210803.0,,LW,US,US,SUSTIVA,Acute kidney injury;Blood creatinine increased;Chronic kidney disease;Drug ineffective;Fanconi syndrome acquired;Lumbar vertebral fracture;Multiple fractures;Nephropathy;Radiculopathy;Renal failure;Viral load increased,179046449.0,OT,,,179046449.0,1.0,20020111.0,20050525.0,,,179046449.0,1.0,HIV infection
17909424,179094241,1,I,,20200609.0,20200617,20200617,EXP,,MY-MYLANLABS-2020M1057062,MYLAN,"KOH KC, IBRAHIM NM, ONG SCL. PARADOXICAL WORSENING OF CHEST RADIOGRAPHS SECONDARY TO IMMUNE RECONSTITUTION SYNDROME (IRIS) IN A PATIENT WITH ADVANCED HIV INFECTION AND RHODOCOCCUS PNEUMONIA. MED-J-MALAYSIA 2020;75(2):164-166.",38.0,YR,,M,Y,,,20200617.0,,MD,MY,MY,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,179094241.0,OT,,,,,,,,,179094241.0,1.0,HIV infection
17910386,179103864,4,F,20110311.0,20220324.0,20200618,20220401,EXP,,US-GILEAD-2020-0473224,GILEAD,,47.0,YR,A,M,Y,53.07,KG,20220401.0,,LW,US,US,SUSTIVA,Acute kidney injury;Ankle fracture;Chronic kidney disease;Emotional distress;End stage renal disease;Fatigue;Fibula fracture;Foot fracture;Mobility decreased;Multiple fractures;Musculoskeletal disorder;Pain;Renal failure;Tibia fracture,179103864.0,HO,,,179103864.0,1.0,2004.0,201906.0,1650.0,DAY,179103864.0,1.0,HIV infection
17910829,179108292,2,F,,20200617.0,20200618,20200622,EXP,,MY-AUROBINDO-AUR-APL-2020-030085,AUROBINDO,,38.0,YR,,M,Y,,,20200622.0,,HP,MY,MY,EFAVIRENZ.,Atelectasis;Condition aggravated;Immune reconstitution inflammatory syndrome,179108292.0,OT,,,,,,,,,179108292.0,1.0,HIV infection
17911115,179111154,4,F,20190401.0,20220324.0,20200618,20220401,EXP,,US-GILEAD-2020-0473488,GILEAD,,55.0,YR,A,F,Y,106.58,KG,20220401.0,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Cardiac failure congestive;Chronic kidney disease;Depression;End stage renal disease;Osteoporosis;Renal failure,179111154.0,DE,,,179111154.0,1.0,2007.0,201801.0,967.0,DAY,179111154.0,1.0,HIV infection
17912636,179126365,5,F,20080101.0,20220325.0,20200618,20220401,EXP,,US-GILEAD-2020-0473465,GILEAD,,47.0,YR,A,F,Y,72.562,KG,20220401.0,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Depression;Exostosis;Foot fracture;Gingival swelling;Haematuria;Hand fracture;Intervertebral disc degeneration;Loose tooth;Multiple fractures;Nephrolithiasis;Oropharyngeal plaque;Osteoarthritis;Osteopenia;Osteoporosis;Periodontitis;Renal cyst;Renal failure;Scoliosis;Spinal osteoarthritis;Tooth fracture;Tooth loss;Upper limb fracture;Ureterolithiasis;Vertebral foraminal stenosis,179126365.0,HO,,,179126365.0,1.0,2004.0,20150924.0,1554.0,DAY,179126365.0,1.0,HIV infection
17914713,179147131,1,I,201912.0,20200611.0,20200618,20200618,EXP,FR-AFSSAPS-AN20200672,FR-GILEAD-2020-0473012,GILEAD,,45.0,YR,A,M,Y,,,20200618.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179147131.0,HO,,,179147131.0,1.0,20070115.0,20181018.0,,,179147131.0,1.0,HIV infection
17915157,179151575,5,F,20131129.0,20220420.0,20200619,20220425,EXP,,US-GILEAD-2020-0473732,GILEAD,,59.0,YR,A,F,Y,102.04,KG,20220425.0,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Fracture;Loss of personal independence in daily activities;Osteonecrosis;Osteopenia;Osteoporosis;Pain,179151575.0,OT,,,179151575.0,1.0,20100204.0,20151207.0,2132.0,DAY,179151575.0,1.0,HIV infection
17916100,179161004,4,F,201412.0,20201005.0,20200619,20201015,EXP,,US-GILEAD-2020-0473594,GILEAD,,67.0,YR,E,F,Y,58.96,KG,20201015.0,,CN,US,US,SUSTIVA,Anhedonia;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Fracture;Hip arthroplasty;Hip fracture;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Pathological fracture;Proteinuria;Stress fracture,179161004.0,OT,,,179161004.0,1.0,2009.0,2019.0,,,179161004.0,1.0,HIV infection
17916419,179164191,1,I,201912.0,20200608.0,20200619,20200619,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-045454,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,,,20200619.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179164191.0,OT,,,179164191.0,1.0,20070115.0,20160420.0,,,179164191.0,1.0,HIV infection
17917426,179174261,1,I,201912.0,20200612.0,20200619,20200619,EXP,FR-AFSSAPS-AN20200672,FR-009507513-2006FRA004674,MERCK,,45.0,YR,,M,Y,,,20200619.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179174261.0,HO,,,179174261.0,1.0,20070911.0,20160210.0,,,179174261.0,1.0,HIV infection
17917665,179176657,7,F,20100920.0,20240422.0,20200619,20240424,EXP,,US-GILEAD-2020-0473759,GILEAD,,59.0,YR,A,M,Y,76.19,KG,20240424.0,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Chronic kidney disease;End stage renal disease;Fatigue;General physical health deterioration;Hip fracture;Libido decreased;Medical diet;Nephrogenic anaemia;Nephropathy;Osteoporosis;Renal failure,179176657.0,HO,,,179176657.0,1.0,20031206.0,20040407.0,123.0,DAY,179176657.0,1.0,HIV infection
17917928,179179281,1,I,2005.0,20200615.0,20200619,20200619,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-VIIV HEALTHCARE LIMITED-PT2020101740,VIIV,,41.0,YR,,F,Y,,,20200619.0,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179179281.0,OT,,,179179281.0,1.0,2003.0,2005.0,,,179179281.0,1.0,Antiretroviral therapy
17917940,179179401,1,I,2005.0,20200615.0,20200619,20200619,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-GLAXOSMITHKLINE-PT2020101740,GLAXOSMITHKLINE,,41.0,YR,,F,Y,,,20200619.0,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179179401.0,OT,,,179179401.0,1.0,2003.0,2005.0,,,179179401.0,1.0,Antiretroviral therapy
17919994,179199943,3,F,2005.0,20210604.0,20200620,20210608,EXP,,PT-AUROBINDO-AUR-APL-2020-029718,AUROBINDO,,41.0,YR,,F,Y,,,20210608.0,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179199943.0,OT,,,179199943.0,1.0,2005.0,2008.0,,,179199943.0,1.0,Antiretroviral therapy
17923272,179232721,1,I,201912.0,20200614.0,20200622,20200622,EXP,FR-AFSSAPS-AN20200672,FR-TEVA-2020-FR-1788963,TEVA,,45.0,YR,,M,Y,,,20200622.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179232721.0,HO,,,179232721.0,1.0,20020615.0,20181018.0,,,179232721.0,1.0,HIV infection
17924422,179244225,5,F,20060101.0,20211115.0,20200622,20211130,EXP,,US-GILEAD-2020-0474191,GILEAD,,57.0,YR,A,M,Y,104.31,KG,20211130.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia of chronic disease;Anhedonia;Anxiety;Bone density decreased;Bone metabolism disorder;Chronic kidney disease;Dyspnoea;Emotional distress;End stage renal disease;Erectile dysfunction;Focal segmental glomerulosclerosis;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Pain;Proteinuria;Renal failure;Tooth loss,179244225.0,OT,,,179244225.0,1.0,2006.0,20120816.0,145.0,DAY,179244225.0,1.0,HIV infection
17924500,179245003,3,F,,20221115.0,20200622,20221121,EXP,,CA-ROCHE-2621283,ROCHE,,52.0,YR,,M,Y,,,20221121.0,,HP,CA,,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,179245003.0,OT,,,,,,,,,179245003.0,1.0,HIV infection
17924752,179247521,1,I,,20200615.0,20200622,20200622,EXP,,CA-ROCHE-2622430,ROCHE,,45.0,YR,,M,Y,,,20200622.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,179247521.0,OT,,,,,,,,,179247521.0,1.0,HIV infection
17925970,179259701,1,I,201912.0,20200612.0,20200622,20200622,EXP,FR-AFSSAPS-AN20200672,FR-MYLANLABS-2020M1056848,MYLAN,,45.0,YR,,M,Y,,,20200622.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179259701.0,HO,,,179259701.0,1.0,20020615.0,20181018.0,,,179259701.0,1.0,HIV infection
17930251,179302514,4,F,20150101.0,20211201.0,20200623,20211217,EXP,,US-GILEAD-2020-0474566,GILEAD,,61.0,YR,A,F,Y,47.166,KG,20211217.0,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;Foot fracture;Hip fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Tooth loss,179302514.0,OT,,,179302514.0,1.0,20040101.0,20171231.0,5113.0,DAY,179302514.0,1.0,HIV infection
17930307,179303076,6,F,20100826.0,20220316.0,20200623,20220330,EXP,,US-GILEAD-2020-0474953,GILEAD,,49.0,YR,A,M,Y,97.5,KG,20220330.0,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Tooth fracture;Tooth loss;Upper limb fracture;Weight decreased,179303076.0,OT,,,179303076.0,1.0,2007.0,20110817.0,141.0,DAY,179303076.0,1.0,HIV infection
17930673,179306732,2,F,,20200612.0,20200623,20200827,EXP,,CA-ROCHE-2621256,ROCHE,,52.0,YR,,M,Y,,,20200827.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,179306732.0,OT,,,,,,,,,179306732.0,1.0,HIV infection
17933676,179336761,1,I,2005.0,20200616.0,20200624,20200624,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-TEVA-2020-PT-1790166,TEVA,,41.0,YR,,F,Y,,,20200624.0,,MD,PT,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179336761.0,OT,,,179336761.0,1.0,2005.0,2006.0,,,179336761.0,1.0,Antiretroviral therapy
17936980,179369807,7,F,20121212.0,20211207.0,20200624,20211213,EXP,,US-GILEAD-2020-0475000,GILEAD,,52.0,YR,A,M,Y,93.424,KG,20211213.0,,LW,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;End stage renal disease;Nephropathy;Pain;Renal failure;Somnolence,179369807.0,OT,,,179369807.0,1.0,2005.0,200903.0,5273.0,DAY,179369807.0,1.0,HIV infection
17938178,179381782,2,F,2005.0,20200629.0,20200624,20200709,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-MYLANLABS-2020M1057301,MYLAN,,41.0,YR,,F,Y,,,20200709.0,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179381782.0,OT,,,179381782.0,1.0,20050710.0,2008.0,,,179381782.0,1.0,Antiretroviral therapy
17943142,179431425,5,F,20111229.0,20241015.0,20200625,20241022,EXP,,US-GILEAD-2020-0474690,GILEAD,,51.0,YR,A,M,Y,64.41,KG,20241022.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone loss;Emotional distress;Multiple fractures;Osteonecrosis;Osteopenia;Pain;Renal injury;Skeletal injury;Spinal compression fracture,179431425.0,OT,,,179431425.0,1.0,2007.0,2019.0,,,179431425.0,1.0,HIV infection
17945212,179452124,4,F,20100101.0,20211208.0,20200626,20211223,EXP,,US-GILEAD-2020-0475190,GILEAD,,,,A,M,Y,79.365,KG,20211223.0,,LW,US,US,EFAVIRENZ,Chronic kidney disease;Depression;Nephropathy;Renal failure;Renal injury;Renal mass;Skeletal injury;Tooth loss,179452124.0,OT,,,179452124.0,1.0,2001.0,200506.0,,,179452124.0,1.0,HIV infection
17952409,179524094,4,F,20160101.0,20211203.0,20200626,20211221,EXP,,US-GILEAD-2020-0474171,GILEAD,,43.0,YR,A,F,Y,,,20211221.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Gastrointestinal disorder;Pain;Renal failure;Renal injury;Skeletal injury,179524094.0,OT,,,179524094.0,1.0,201410.0,,,,179524094.0,1.0,HIV infection
17954859,179548593,3,F,,20211013.0,20200629,20211028,EXP,,CA-AUROBINDO-AUR-APL-2020-030609,AUROBINDO,,54.0,YR,,M,Y,,,20211028.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,179548593.0,OT,,,,,,,,,179548593.0,1.0,HIV infection
17960294,1796029410,10,F,20180301.0,20231129.0,20200630,20231201,EXP,,US-GILEAD-2020-0476825,GILEAD,,49.0,YR,A,M,Y,68.027,KG,20231201.0,,LW,US,US,SUSTIVA,Bone density decreased;Emotional distress;Gait disturbance;Multiple fractures;Osteopenia;Osteoporosis;Pain;Pulpless tooth;Radius fracture;Spinal compression fracture;Spinal fracture;Tooth fracture;Tooth loss;Ulna fracture,1796029410.0,OT,,,1796029410.0,1.0,2006.0,20190819.0,152.0,DAY,1796029410.0,1.0,HIV infection
17963016,179630164,4,F,20090829.0,20220121.0,20200630,20220127,EXP,,US-GILEAD-2020-0477066,GILEAD,,50.0,YR,A,M,Y,68.027,KG,20220127.0,,LW,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Renal failure;Renal impairment,179630164.0,OT,,,179630164.0,1.0,20050308.0,20090322.0,1475.0,DAY,179630164.0,1.0,HIV infection
17969704,179697041,1,I,201912.0,20200610.0,20200701,20200701,EXP,FR-AFSSAPS-AN20200672,FR-VIIV HEALTHCARE LIMITED-FR2020098065,VIIV,,45.0,YR,,M,Y,,,20200701.0,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179697041.0,HO,,,179697041.0,1.0,20181018.0,20160210.0,,,179697041.0,1.0,HIV infection
17973430,179734304,4,F,20140603.0,20211110.0,20200702,20211125,EXP,,US-GILEAD-2020-0478106,GILEAD,,52.0,YR,A,F,Y,,,20211125.0,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Fanconi syndrome acquired;Osteoporosis;Pain,179734304.0,OT,,,179734304.0,1.0,2003.0,2006.0,970.0,DAY,179734304.0,1.0,HIV infection
17977642,179776422,2,F,2005.0,20210604.0,20200703,20210608,EXP,,PT-AUROBINDO-AUR-APL-2020-031581,AUROBINDO,,41.0,YR,,F,Y,,,20210608.0,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179776422.0,OT,,,179776422.0,1.0,2005.0,2008.0,,,179776422.0,1.0,Antiretroviral therapy
17981932,179819325,5,F,20070809.0,20220502.0,20200706,20220506,EXP,,US-GILEAD-2020-0475831,GILEAD,,53.0,YR,A,F,Y,81.633,KG,20220506.0,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;End stage renal disease;Loss of personal independence in daily activities;Nausea;Osteopenia;Pain;Renal failure;Vomiting,179819325.0,HO,,,179819325.0,1.0,2001.0,2013.0,3773.0,DAY,179819325.0,1.0,HIV infection
17982071,179820711,1,I,,20200629.0,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032148,AUROBINDO,,25.0,YR,,F,Y,,,20200706.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820711.0,OT,,,,,,,,,179820711.0,1.0,HIV infection
17982074,179820741,1,I,,20200629.0,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032147,AUROBINDO,,23.0,YR,,F,Y,,,20200706.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179820741.0,OT,,,,,,,,,179820741.0,1.0,HIV infection
17982077,179820771,1,I,,20200629.0,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032150,AUROBINDO,,40.0,YR,,F,Y,,,20200706.0,,HP,US,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820771.0,OT,,,,,,,,,179820771.0,1.0,HIV infection
17982088,179820881,1,I,,20200629.0,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032160,AUROBINDO,,40.0,YR,,F,Y,,,20200706.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820881.0,OT,,,,,,,,,179820881.0,1.0,HIV infection
17982091,179820911,1,I,,20200629.0,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032170,AUROBINDO,,29.0,YR,,F,Y,,,20200706.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820911.0,OT,,,,,,,,,179820911.0,1.0,HIV infection
17982291,179822916,6,F,,20211204.0,20200706,20211217,EXP,,FR-AUROBINDO-AUR-APL-2020-032078,AUROBINDO,"Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, et al.. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the french perinatal cohort study (ANRS CO1/CO11).. PLOS Medicine. 2014;11(4)::1-22",,,,F,Y,,,20211217.0,,MD,FR,FR,EFAVIRENZ,Cerebral ventricle dilatation;Foetal exposure during pregnancy;Pachygyria;White matter lesion,179822916.0,OT,,,,,,,,,179822916.0,1.0,HIV infection
17986460,179864601,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032152,AUROBINDO,,25.0,YR,,F,Y,,,20200707.0,,HP,US,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179864601.0,OT,,,,,,,,,179864601.0,1.0,HIV infection
17986465,179864651,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032154,AUROBINDO,,25.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179864651.0,OT,,,,,,,,,179864651.0,1.0,HIV infection
17986481,179864811,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032158,AUROBINDO,,29.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179864811.0,OT,,,,,,,,,179864811.0,1.0,HIV infection
17986484,179864841,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032171,AUROBINDO,,26.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179864841.0,OT,,,,,,,,,179864841.0,1.0,HIV infection
17986504,179865041,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032174,AUROBINDO,,40.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179865041.0,OT,,,,,,,,,179865041.0,1.0,HIV infection
17987253,179872531,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032157,AUROBINDO,,27.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179872531.0,OT,,,,,,,,,179872531.0,1.0,HIV infection
17987258,179872581,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032146,AUROBINDO,,27.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179872581.0,OT,,,,,,,,,179872581.0,1.0,HIV infection
17987332,179873321,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032149,AUROBINDO,,35.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179873321.0,OT,,,,,,,,,179873321.0,1.0,HIV infection
17987710,179877101,1,I,,20200629.0,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032161,AUROBINDO,,33.0,YR,,F,Y,,,20200707.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179877101.0,OT,,,,,,,,,179877101.0,1.0,HIV infection
17989419,179894194,4,F,20050101.0,20231013.0,20200707,20231016,EXP,,US-GILEAD-2020-0478431,GILEAD,,,,A,M,Y,92.986,KG,20231016.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Chronic kidney disease;Depression;Dysstasia;Emotional distress;Fracture;Gait disturbance;Lower limb fracture;Osteopenia;Pain;Renal failure;Renal impairment;Tooth loss,179894194.0,OT,,,179894194.0,1.0,200401.0,201001.0,,,179894194.0,1.0,HIV infection
17989504,179895041,1,I,,20200625.0,20200707,20200707,EXP,,DE-MYLANLABS-2020M1061156,MYLAN,,7.0,YR,,M,Y,,,20200707.0,,HP,DE,NG,EFAVIRENZ.,Pathogen resistance,179895041.0,OT,,,,,,,,,179895041.0,1.0,HIV infection
17989513,179895131,1,I,,20200625.0,20200707,20200707,EXP,,DE-MYLANLABS-2020M1061150,MYLAN,,42.0,YR,,M,Y,,,20200707.0,,HP,DE,NG,EFAVIRENZ.,Pathogen resistance,179895131.0,OT,,,,,,,,,179895131.0,1.0,HIV infection
17991249,179912496,6,F,201203.0,20210617.0,20200707,20210702,PER,,US-GILEAD-2020-0478868,GILEAD,,54.0,YR,A,M,Y,99.77,KG,20210702.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Drug ineffective;Emotional distress;End stage renal disease;Glomerulonephritis membranous;Malaise;Pain,179912496.0,HO,,,179912496.0,1.0,2006.0,2014.0,,,179912496.0,1.0,HIV infection
17992095,179920951,1,I,,20200629.0,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032153,AUROBINDO,,35.0,YR,,F,Y,,,20200708.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179920951.0,OT,,,,,,,,,179920951.0,1.0,HIV infection
17992102,179921021,1,I,,20200629.0,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032167,AUROBINDO,,24.0,YR,,F,Y,,,20200708.0,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179921021.0,OT,,,,,,,,,179921021.0,1.0,HIV infection
17992107,179921071,1,I,,20200629.0,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032175,AUROBINDO,,28.0,YR,,F,Y,,,20200708.0,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179921071.0,OT,,,,,,,,,179921071.0,1.0,HIV infection
17993740,179937401,1,I,,20200629.0,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032163,AUROBINDO,,26.0,YR,,F,Y,,,20200708.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179937401.0,OT,,,,,,,,,179937401.0,1.0,HIV infection
17994113,179941134,4,F,20130708.0,20210617.0,20200708,20210624,EXP,,US-GILEAD-2020-0479635,GILEAD,,48.0,YR,A,M,Y,111.11,KG,20210624.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Impaired self-care;Intervertebral disc operation;Osteopenia;Osteoporosis;Pain;Tooth loss,179941134.0,OT,,,179941134.0,1.0,20121202.0,20190109.0,,,179941134.0,1.0,HIV infection
17994819,179948193,3,F,20050607.0,20210615.0,20200708,20210621,EXP,,US-GILEAD-2020-0479212,GILEAD,,58.0,YR,A,M,Y,83.9,KG,20210620.0,,CN,US,US,SUSTIVA,Anxiety;Bone density decreased;Bone loss;Depression;Dizziness;Emotional distress;Gait disturbance;Lower limb fracture;Osteonecrosis;Pain;Spinal fracture;Tooth loss,179948193.0,OT,,,179948193.0,1.0,200110.0,201401.0,,,179948193.0,1.0,HIV infection
17996590,179965901,1,I,,20200629.0,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032178,AUROBINDO,,20.0,YR,,F,Y,,,20200709.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Gene mutation,179965901.0,OT,,,,,,,,,179965901.0,1.0,HIV infection
17998484,179984841,1,I,,20200629.0,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032145,AUROBINDO,,27.0,YR,,F,Y,,,20200709.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984841.0,OT,,,,,,,,,179984841.0,1.0,HIV infection
17998486,179984861,1,I,,20200629.0,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032165,AUROBINDO,,40.0,YR,,F,Y,,,20200709.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984861.0,OT,,,,,,,,,179984861.0,1.0,HIV infection
17998489,179984891,1,I,,20200629.0,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032164,AUROBINDO,,27.0,YR,,F,Y,,,20200709.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984891.0,OT,,,,,,,,,179984891.0,1.0,HIV infection
17998495,179984951,1,I,,20200629.0,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032162,AUROBINDO,,30.0,YR,,F,Y,,,20200709.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984951.0,OT,,,,,,,,,179984951.0,1.0,HIV infection
17998503,179985031,1,I,,20200629.0,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032172,AUROBINDO,,41.0,YR,,F,Y,,,20200709.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179985031.0,OT,,,,,,,,,179985031.0,1.0,HIV infection
17998519,179985191,1,I,,20200629.0,20200709,20200709,EXP,,FR-HETERO-HET2020FR00755,HETERO,,,,I,,Y,,,20200709.0,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,179985191.0,CA,,,,,,,,,179985191.0,1.0,HIV infection
18002066,180020661,1,I,,20200629.0,20200710,20200710,EXP,,BW-AUROBINDO-AUR-APL-2020-032156,AUROBINDO,,26.0,YR,,F,Y,,,20200710.0,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,180020661.0,OT,,,,,,,,,180020661.0,1.0,HIV infection
18007417,180074179,9,F,20120101.0,20230524.0,20200710,20230528,EXP,,US-GILEAD-2020-0481205,GILEAD,,,,A,F,Y,54.422,KG,20230528.0,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Chronic kidney disease;Depression;Drug dependence;Dysstasia;Emotional distress;Fanconi syndrome acquired;Femur fracture;Gait disturbance;Metabolic acidosis;Osteoporosis;Pain;Pancreatitis;Renal failure,180074179.0,OT,,,180074179.0,1.0,20080101.0,20080601.0,5.0,MON,180074179.0,1.0,HIV infection
18007582,180075821,1,I,,20200706.0,20200710,20200710,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-034172",BOEHRINGER INGELHEIM,,,,,,Y,,,20200710.0,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,180075821.0,OT,,,,,,,,,180075821.0,1.0,HIV infection
18009569,180095693,3,F,20130505.0,20210618.0,20200710,20210622,EXP,,US-GILEAD-2020-0480309,GILEAD,,48.0,YR,A,M,Y,99.77,KG,20210622.0,,CN,US,US,SUSTIVA,Agoraphobia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Fanconi syndrome acquired;Pain;Renal failure;Skeletal injury,180095693.0,OT,,,180095693.0,1.0,2007.0,2015.0,,,180095693.0,1.0,HIV infection
18012492,180124924,4,F,20161119.0,20210617.0,20200713,20210624,EXP,,US-GILEAD-2020-0477129,GILEAD,,59.0,YR,A,F,Y,81.63,KG,20210624.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;End stage renal disease;Multiple fractures;Osteonecrosis;Pain;Renal failure;Tooth loss,180124924.0,OT,,,180124924.0,1.0,2001.0,20140821.0,,,180124924.0,1.0,HIV infection
18013641,180136418,8,F,20150717.0,20211222.0,20200713,20220215,PER,,US-GILEAD-2020-0481303,GILEAD,,53.0,YR,A,M,Y,90.703,KG,20220215.0,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Emotional distress;Exercise tolerance decreased;Foot fracture;Lumbar vertebral fracture;Mobility decreased;Multiple fractures;Myelitis;Osteoarthritis;Osteoporosis;Pain;Rib fracture;Spinal osteoarthritis;Virologic failure,180136418.0,OT,,,180136418.0,1.0,20180108.0,20181012.0,277.0,DAY,180136418.0,1.0,HIV infection
18016136,180161364,4,F,,20210830.0,20200713,20210909,EXP,,CA-TEVA-2020-CA-1798833,TEVA,,54.0,YR,A,M,Y,,,20210909.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,180161364.0,DE,,,,,,,,,180161364.0,1.0,HIV infection
18018055,180180551,1,I,,20200703.0,20200713,20200713,EXP,,DE-AUROBINDO-AUR-APL-2020-034154,AUROBINDO,,42.0,YR,,M,Y,,,20200714.0,,HP,DE,DE,EFAVIRENZ.,Pathogen resistance,180180551.0,OT,,,,,,,,,180180551.0,1.0,HIV infection
18019221,180192211,1,I,200909.0,20200706.0,20200714,20200714,EXP,,ZA-GLAXOSMITHKLINE-ZA2020EME123755,GLAXOSMITHKLINE,,,,A,F,Y,,,20200714.0,,HP,ZA,ZA,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180192211.0,OT,,,180192211.0,1.0,2007.0,,,,180192211.0,1.0,HIV infection
18020729,180207294,4,F,20100101.0,20220131.0,20200714,20220207,EXP,,US-GILEAD-2020-0482670,GILEAD,,60.0,YR,A,M,Y,79.365,KG,20220207.0,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;Emotional distress;Gait disturbance;General physical health deterioration;Mobility decreased;Osteoporosis;Pain;Renal failure;Renal injury;Skeletal injury,180207294.0,OT,,,180207294.0,1.0,200503.0,201812.0,,,180207294.0,1.0,HIV infection
18020882,180208821,1,I,2001.0,20200702.0,20200714,20200714,EXP,,DE-GLAXOSMITHKLINE-DE2020GSK120069,GLAXOSMITHKLINE,HAFNER J AND BOGNER J. 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS. MMW FORTSCHRITTE DER MEDIZIN. 2020?162 (SUPPL 2):16?19,,,,M,Y,,,20200714.0,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180208821.0,OT,,,180208821.0,1.0,198909.0,2015.0,,,180208821.0,1.0,HIV infection
18020905,180209051,1,I,2001.0,20200702.0,20200714,20200714,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2020GSK120069,VIIV,HAFNER J AND BOGNER J. 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS. MMW FORTSCHRITTE DER MEDIZIN. 2020?162 (SUPPL 2):16?19,,,,M,Y,,,20200714.0,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180209051.0,OT,,,180209051.0,1.0,198909.0,2015.0,,,180209051.0,1.0,HIV infection
18021000,180210001,1,I,,20200703.0,20200714,20200714,EXP,,DE-AUROBINDO-AUR-APL-2020-034155,AUROBINDO,,7.0,YR,,M,Y,,,20200714.0,,HP,DE,NG,EFAVIRENZ.,Pathogen resistance,180210001.0,OT,,,,,,,,,180210001.0,1.0,HIV infection
18021469,180214696,6,F,20110818.0,20231019.0,20200714,20231023,EXP,,US-GILEAD-2020-0481614,GILEAD,,55.0,YR,A,M,Y,60.317,KG,20231023.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Nephropathy;Pain;Renal failure,180214696.0,OT,,,180214696.0,1.0,2008.0,2011.0,20.0,DAY,180214696.0,1.0,HIV infection
18021486,180214864,4,F,20050101.0,20230511.0,20200714,20230516,EXP,,US-GILEAD-2020-0482560,GILEAD,,59.0,YR,A,M,Y,,,20230516.0,,LW,US,US,SUSTIVA,Blood creatinine increased;Bone density decreased;Chronic kidney disease;Multiple fractures;Osteonecrosis of jaw;Osteoporosis;Pain;Renal failure;Tooth fracture;Tooth loss,180214864.0,OT,,,180214864.0,1.0,20080602.0,20091102.0,17.0,MON,180214864.0,1.0,HIV infection
18022832,180228323,3,F,2020.0,20200824.0,20200715,20210101,PER,,DE-HORMOSAN PHARMA GMBH-2020-02278,LUPIN,,44.0,YR,,M,Y,,,20210101.0,,CN,DE,DE,EFAVIRENZ.,Arthralgia;Back pain;Faeces soft;Fatigue;Muscle disorder;Myalgia;Pain in extremity;Rash,,,,,,,,,,,180228323.0,1.0,HIV infection
18023506,180235065,5,F,20121001.0,20220114.0,20200715,20220119,EXP,,US-GILEAD-2020-0477191,GILEAD,,39.0,YR,A,M,Y,76.644,KG,20220119.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;General physical health deterioration;Pain;Renal injury;Tooth loss,180235065.0,OT,,,180235065.0,1.0,200801.0,201401.0,,,180235065.0,1.0,HIV infection
18026883,180268835,5,F,20150101.0,20211106.0,20200715,20211117,EXP,,US-GILEAD-2020-0479893,GILEAD,,,,E,F,Y,,,20211117.0,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure;Tooth loss,180268835.0,OT,,,180268835.0,1.0,2011.0,2015.0,,,180268835.0,1.0,HIV infection
18029816,180298161,1,I,200909.0,20200706.0,20200715,20200715,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2020EME123755,VIIV,,,,A,F,Y,,,20200715.0,,HP,ZA,ZA,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180298161.0,OT,,,180298161.0,1.0,2007.0,,,,180298161.0,1.0,HIV infection
18033126,180331261,1,I,,20200708.0,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130228,GLAXOSMITHKLINE,,24.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331261.0,OT,,,,,,,,,180331261.0,1.0,HIV infection
18033133,180331331,1,I,,20200708.0,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130228,VIIV,,24.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331331.0,OT,,,,,,,,,180331331.0,1.0,HIV infection
18033166,180331661,1,I,,20200708.0,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130229,VIIV,,52.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331661.0,OT,,,,,,,,,180331661.0,1.0,HIV infection
18033167,180331671,1,I,,20200708.0,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130229,GLAXOSMITHKLINE,,52.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331671.0,OT,,,,,,,,,180331671.0,1.0,HIV infection
18033841,180338415,5,F,20150224.0,20210617.0,20200716,20210624,PER,,US-GILEAD-2020-0483577,GILEAD,,47.0,YR,A,M,Y,68.03,KG,20210623.0,,LW,US,US,SUSTIVA,Acute kidney injury;Bone loss;Chronic kidney disease;Drug ineffective;Emotional distress;End stage renal disease;Pain;Renal failure;Tooth extraction;Tooth fracture,180338415.0,OT,,,180338415.0,1.0,2006.0,2015.0,,,180338415.0,1.0,HIV infection
18033949,180339491,1,I,,20200708.0,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130232,GLAXOSMITHKLINE,,26.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180339491.0,OT,,,,,,,,,180339491.0,1.0,HIV infection
18033950,180339501,1,I,,20200708.0,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130232,VIIV,,26.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180339501.0,OT,,,,,,,,,180339501.0,1.0,HIV infection
18034001,180340011,1,I,,20200708.0,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130234,VIIV,,25.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180340011.0,OT,,,,,,,,,180340011.0,1.0,HIV infection
18034002,180340021,1,I,,20200708.0,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130234,GLAXOSMITHKLINE,,25.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180340021.0,OT,,,,,,,,,180340021.0,1.0,HIV infection
18034167,180341671,1,I,,20200708.0,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130239,VIIV,,41.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180341671.0,OT,,,,,,,,,180341671.0,1.0,HIV infection
18034168,180341681,1,I,,20200708.0,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130239,GLAXOSMITHKLINE,,41.0,YR,,M,Y,,,20200716.0,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180341681.0,OT,,,,,,,,,180341681.0,1.0,HIV infection
18035690,180356902,2,F,,20200831.0,20200717,20200911,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-03391,LUPIN,,,,A,F,Y,,,20200911.0,,HP,KE,US,EFAVIRENZ.,Drug resistance;Exposure during pregnancy,180356902.0,OT,,,,,,,,,180356902.0,1.0,Prophylaxis against HIV infection
18037850,180378502,2,F,,20200831.0,20200717,20200911,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-03387,LUPIN,,,,A,F,Y,,,20200911.0,,HP,KE,US,EFAVIRENZ.,Drug resistance;Exposure during pregnancy,180378502.0,OT,,,,,,,,,180378502.0,1.0,Prophylaxis against HIV infection
18038721,180387212,2,F,,20210519.0,20200717,20210531,EXP,,SG-LUPIN PHARMACEUTICALS INC.-2020-03425,LUPIN,,,,A,M,Y,,,20210601.0,,HP,SG,SG,EFAVIRENZ.,Retroviral rebound syndrome,180387212.0,OT,,,,,,,,,180387212.0,1.0,HIV infection
18038722,180387223,3,F,,20210519.0,20200717,20210603,EXP,,SG-LUPIN PHARMACEUTICALS INC.-2020-03426,LUPIN,,,,A,M,Y,,,20210603.0,,HP,SG,SG,EFAVIRENZ.,Drug resistance;Retroviral rebound syndrome,180387223.0,OT,,,,,,,,,180387223.0,1.0,HIV infection
18040288,180402883,3,F,20121101.0,20211208.0,20200717,20211223,EXP,,US-GILEAD-2020-0483314,GILEAD,,36.0,YR,A,M,Y,92.971,KG,20211223.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Decreased activity;Emotional distress;Fear;Insomnia;Loss of personal independence in daily activities;Pain;Quality of life decreased,180402883.0,OT,,,180402883.0,1.0,200604.0,20181126.0,,,180402883.0,1.0,HIV infection
18040753,180407534,4,F,200912.0,20210616.0,20200717,20210622,EXP,,US-GILEAD-2020-0481716,GILEAD,,73.0,YR,E,M,Y,68.93,KG,20210622.0,,CN,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;Osteoporosis;Pain;Renal failure;Renal tubular necrosis;Tooth loss,180407534.0,OT,,,180407534.0,1.0,200606.0,2009.0,,,180407534.0,1.0,HIV infection
18043574,180435747,7,F,20100801.0,20230818.0,20200720,20230822,EXP,,US-GILEAD-2020-0483861,GILEAD,,59.0,YR,A,M,Y,175.0,KG,20230822.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone pain;Dysstasia;Emotional distress;Gait disturbance;Osteoporosis;Pain;Pollakiuria;Renal failure;Renal impairment;Tooth loss,180435747.0,OT,,,180435747.0,1.0,200708.0,2018.0,,,180435747.0,1.0,HIV infection
18045190,180451903,3,F,20110101.0,20221214.0,20200720,20221219,EXP,,US-GILEAD-2020-0480222,GILEAD,,42.0,YR,A,M,Y,83.914,KG,20221219.0,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Bone loss;Brain neoplasm;Depression;Femur fracture;Hip fracture;Osteonecrosis;Osteoporosis;Pain;Pain in extremity;Renal injury;Rib fracture;Upper limb fracture,180451903.0,OT,,,180451903.0,1.0,2004.0,2012.0,,,180451903.0,1.0,HIV infection
18045782,180457822,2,F,,20200713.0,20200720,20210628,EXP,,CA-TEVA-2020-CA-1801616,TEVA,,52.0,YR,A,M,Y,,,20210628.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,180457822.0,CA,,,,,,,,,180457822.0,1.0,HIV infection
18051609,180516092,2,F,,20200708.0,20200721,20201007,EXP,,LV-GLAXOSMITHKLINE-LV2020EME125104,GLAXOSMITHKLINE,,45.0,YR,,F,Y,,,20201007.0,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,180516092.0,OT,,,180516092.0,1.0,2015.0,,,,180516092.0,1.0,HIV infection
18051610,180516102,2,F,,20200708.0,20200721,20201007,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2020EME125104,VIIV,,45.0,YR,,F,Y,,,20201007.0,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,180516102.0,OT,,,180516102.0,1.0,2015.0,,,,180516102.0,1.0,HIV infection
18052384,180523841,1,I,2001.0,20200714.0,20200722,20200722,EXP,,DE-AUROBINDO-AUR-APL-2020-035645,AUROBINDO,,,,,M,Y,,,20200722.0,,HP,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180523841.0,OT,,,180523841.0,2.0,2002.0,2015.0,,,180523841.0,1.0,HIV infection
18052548,180525481,1,I,2012.0,20200713.0,20200722,20200722,EXP,,US-AUROBINDO-AUR-APL-2020-035573,AUROBINDO,,24.0,YR,,M,Y,,,20200722.0,,HP,US,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180525481.0,LT,,,180525481.0,1.0,2010.0,2013.0,,,180525481.0,1.0,HIV infection
18053271,180532711,1,I,2001.0,20200717.0,20200722,20200722,EXP,,DE-ROCHE-2644768,ROCHE,"HAFNER J, AND BOGNER J 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS. MMW FORTSCHRITTE DER MEDIZIN 2020?162 (SUPPL 2):16?19.",,,,M,Y,,,20200722.0,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180532711.0,OT,,,180532711.0,2.0,198909.0,2015.0,,,180532711.0,1.0,HIV infection
18055939,1805593912,12,F,20130801.0,20240220.0,20200722,20240222,EXP,,US-GILEAD-2020-0484456,GILEAD,,58.0,YR,A,M,Y,84.807,KG,20240221.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Back pain;Bone demineralisation;Bone density decreased;Depression;Drug ineffective;Emotional distress;Fatigue;Genotype drug resistance test positive;Humerus fracture;Mood altered;Multiple fractures;Osteoporosis;Pain;Rash pruritic;Rib fracture;Sinus headache,1805593912.0,OT,,,1805593912.0,1.0,2001.0,2010.0,504.0,DAY,1805593912.0,1.0,HIV infection
18057020,180570203,3,F,20090212.0,20220127.0,20200722,20220202,EXP,,US-GILEAD-2020-0484454,GILEAD,,33.0,YR,A,M,Y,88.435,KG,20220202.0,,LW,US,US,SUSTIVA,Abnormal dreams;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Decreased activity;Emotional distress;Fatigue;Glomerular filtration rate decreased;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure;Renal impairment,180570203.0,OT,,,180570203.0,1.0,20040120.0,20050519.0,485.0,DAY,180570203.0,1.0,HIV infection
18058168,180581685,5,F,,20201222.0,20200723,20201231,EXP,,FR-AUROBINDO-AUR-APL-2020-036053,AUROBINDO,,1.0,DY,,,Y,,,20201231.0,,HP,FR,FR,Efavirenz Film Coated Tablets,Cerebral ventricle dilatation;Foetal exposure during pregnancy;Pachygyria;White matter lesion,180581685.0,CA,,,,,,,,,180581685.0,1.0,HIV infection
18061821,180618211,1,I,20120923.0,20200715.0,20200723,20200723,EXP,,US-GILEAD-2020-0484958,GILEAD,,23.0,YR,A,M,Y,72.56,KG,20200723.0,,CN,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Haematoma;Pain;Renal failure,180618211.0,HO,,,180618211.0,1.0,20100324.0,20130308.0,,,180618211.0,1.0,HIV infection
18063886,180638861,1,I,2012.0,20200713.0,20200724,20200724,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2020027417,MACLEODS,,,,,,Y,,,20200724.0,,CN,IN,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180638861.0,OT,,,180638861.0,1.0,2010.0,2013.0,,,180638861.0,1.0,HIV infection
18065634,180656341,1,I,2012.0,20200713.0,20200724,20200724,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-056332,BRISTOL MYERS SQUIBB,"MODI AR, KOVAL CE, TAEGE AJ, MODARESI ESFEH J, EGHTESAD B, NARAYANAN MENON KV, ET AL. CORONAVIRUS DISEASE 2019 IN AN ORTHOTOPIC LIVER TRANSPLANT RECIPIENT LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS. TRANSPLANT INFECTIOUS DISEASE. 2020",24.0,YR,,M,Y,,,20200724.0,,MD,US,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180656341.0,LT,,,180656341.0,1.0,2010.0,2013.0,,,180656341.0,1.0,HIV infection
18065982,180659824,4,F,20160101.0,20230407.0,20200724,20230412,EXP,,LV-ABBVIE-20K-287-3495672-00,ABBVIE,,45.0,YR,,F,Y,,,20230412.0,,MD,LV,LV,EFAVIRENZ,Blood HIV RNA increased;Drug resistance;Hyperhidrosis;Live birth;Maternal exposure during pregnancy;Therapy change,180659824.0,OT,,,180659824.0,1.0,2015.0,,,,180659824.0,1.0,HIV infection
18067088,180670883,3,F,20071001.0,20230411.0,20200724,20230413,EXP,,US-GILEAD-2020-0485091,GILEAD,,46.0,YR,A,M,Y,95.238,KG,20230413.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal impairment,180670883.0,OT,,,180670883.0,1.0,200708.0,2014.0,,,180670883.0,1.0,HIV infection
18067893,180678931,1,I,2001.0,20200718.0,20200724,20200724,EXP,,DE-MYLANLABS-2020M1066161,MYLAN,HAFNER J AND BOGNER J.. 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS.. MMW FORTSCHRITTE DER MEDIZIN.. 2020?162 (SUPPL 2):16?19,,,,M,Y,,,20200724.0,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180678931.0,OT,,,180678931.0,1.0,2002.0,2015.0,,,180678931.0,1.0,HIV infection
18068131,180681313,3,F,20090101.0,20230501.0,20200724,20230504,EXP,,US-GILEAD-2020-0485178,GILEAD,,,,A,F,Y,142.86,KG,20230504.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Depression;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Osteoporosis;Pain,180681313.0,OT,,,180681313.0,1.0,2001.0,201605.0,,,180681313.0,1.0,HIV infection
18068866,180688663,3,F,20130101.0,20230427.0,20200724,20230503,PER,,US-GILEAD-2020-0485048,GILEAD,,,,A,M,Y,86.18,KG,20230503.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Renal impairment,180688663.0,OT,,,180688663.0,1.0,2008.0,201506.0,,,180688663.0,1.0,HIV infection
18072196,180721961,1,I,,20200713.0,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04960,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200727.0,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180721961.0,OT,,,,,,,,,180721961.0,1.0,HIV infection WHO clinical stage I
18072198,180721981,1,I,,20200713.0,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04955,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200727.0,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia;Hyperphosphataemia;Hypocalcaemia,180721981.0,OT,,,,,,,,,180721981.0,1.0,HIV infection WHO clinical stage II
18072199,180721991,1,I,,20200713.0,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04952,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727.0,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180721991.0,OT,,,,,,,,,180721991.0,1.0,HIV infection WHO clinical stage I
18072200,180722001,1,I,,20200713.0,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04963,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727.0,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180722001.0,OT,,,,,,,,,180722001.0,1.0,HIV infection WHO clinical stage I
18072207,180722071,1,I,,20200713.0,20200727,20200727,EXP,US-MLMSERVICE-20200707-2366000-1,US-CIPLA LTD.-2020US04931,CIPLA,"MODI AR, KOVAL CE, TAEGE AJ, MODARESI EJ, EGHTESAD B,NARAYANAN MKV ET AL.. CORONAVIRUS DISEASE 2019 IN AN ORTHOTOPIC LIVER TRANSPLANT RECIPIENT LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS. TRANSPLANT INFECTIOUS DISEASE. 2020",,,,,Y,,,20200727.0,,MD,US,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180722071.0,LT,,,180722071.0,1.0,2010.0,2013.0,,,180722071.0,1.0,HIV infection
18072208,180722081,1,I,,20200713.0,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04958,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727.0,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia;Renal impairment,180722081.0,OT,,,,,,,,,180722081.0,1.0,HIV infection WHO clinical stage II
18072209,180722091,1,I,,20200713.0,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04956,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200727.0,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180722091.0,OT,,,,,,,,,180722091.0,1.0,HIV infection WHO clinical stage III
18072215,180722151,1,I,,20200713.0,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04990,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727.0,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180722151.0,OT,,,,,,,,,180722151.0,1.0,HIV infection WHO clinical stage I
18074119,180741191,1,I,2016.0,20200720.0,20200727,20200727,EXP,,TZ-GLAXOSMITHKLINE-US2020GSK137403,GLAXOSMITHKLINE,"BACHA JM, EL?MALLAWANY NK, SLONE JS, WILKINSON JP, MEHTA PS, CAMPBELL LR. RECOMMENDATIONS FOR TREATING LIFE?THREATENING KAPOSI SARCOMA DURING PREGNANCY IN HIV?POSITIVE WOMEN IN LOW INCOME COUNTRIES. INTERNATIONAL JOURNAL OF STD AND AIDS. 2020?31 (8):724?734",31.0,YR,,F,Y,,,20200727.0,,HP,TZ,TZ,EFAVIRENZ.,Abdominal pain;Condition aggravated;Dysphagia;Dyspnoea;Exposure during pregnancy;Exposure via breast milk;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Live birth;Lymphadenopathy;Obstructive airways disorder;Oral candidiasis;Skin lesion,180741191.0,LT,,,180741191.0,1.0,2016.0,,,,180741191.0,1.0,HIV infection
18074133,180741331,1,I,2016.0,20200720.0,20200727,20200727,EXP,,TZ-VIIV HEALTHCARE LIMITED-US2020GSK137403,VIIV,"BACHA JM, EL?MALLAWANY NK, SLONE JS, WILKINSON JP, MEHTA PS, CAMPBELL LR. RECOMMENDATIONS FOR TREATING LIFE?THREATENING KAPOSI SARCOMA DURING PREGNANCY IN HIV?POSITIVE WOMEN IN LOW INCOME COUNTRIES. INTERNATIONAL JOURNAL OF STD AND AIDS. 2020?31 (8):724?734",31.0,YR,,F,Y,,,20200727.0,,HP,TZ,TZ,EFAVIRENZ.,Abdominal pain;Condition aggravated;Dysphagia;Dyspnoea;Exposure during pregnancy;Exposure via breast milk;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Live birth;Lymphadenopathy;Obstructive airways disorder;Oral candidiasis;Skin lesion,180741331.0,OT,,,180741331.0,1.0,2016.0,,,,180741331.0,1.0,HIV infection
18074485,180744853,3,F,,20230907.0,20200727,20230912,EXP,,US-GILEAD-2020-0485549,GILEAD,,,,A,M,Y,86.168,KG,20230912.0,,LW,US,US,SUSTIVA,Acute kidney injury;Acute respiratory failure;Anaemia;Chronic kidney disease;Craniocerebral injury;Emotional distress;End stage renal disease;Metabolic acidosis;Pain;Renal failure;Status epilepticus,180744853.0,HO,,,180744853.0,1.0,2010.0,2017.0,,,180744853.0,1.0,HIV infection
18077162,180771622,2,F,,20201123.0,20200728,20201130,EXP,,FR-HETERO-HET2020FR00834,HETERO,,,,I,,Y,,,20201130.0,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,180771622.0,CA,,,,,,,,,180771622.0,1.0,HIV infection
18077288,180772882,2,F,2014.0,20201116.0,20200727,20201120,EXP,,US-GILEAD-2020-0485109,GILEAD,,,,A,M,Y,63.49,KG,20201120.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteonecrosis;Osteoporosis;Pain;Renal failure;Renal impairment,180772882.0,OT,,,180772882.0,1.0,2005.0,2018.0,,,180772882.0,1.0,HIV infection
18077791,180777912,2,F,20080201.0,20230429.0,20200727,20230504,EXP,,US-GILEAD-2020-0484975,GILEAD,,60.0,YR,E,F,Y,104.31,KG,20230504.0,,LW,US,US,SUSTIVA,Emotional distress;Osteoporosis;Pain,180777912.0,OT,,,180777912.0,1.0,2004.0,20130629.0,1985.0,DAY,180777912.0,1.0,HIV infection
18078179,180781792,2,F,,20221006.0,20200728,20221018,EXP,,UG-CIPLA LTD.-2020UG04969,CIPLA,"Nyende L, Kalyesubula R, Sekasanvu E, Byakika-Kibwika P. Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study. BMC Nephrology. 2020;21 (232):1 to 6",,,A,M,Y,,,20221018.0,,HP,UG,UG,EFAVIRENZ,Hyperkalaemia;Hypophosphataemia,180781792.0,OT,,,180781792.0,1.0,,,24.0,MON,180781792.0,1.0,HIV infection WHO clinical stage I
18080758,180807584,4,F,20130901.0,20231023.0,20200728,20231025,EXP,,US-GILEAD-2020-0485140,GILEAD,,50.0,YR,A,F,Y,81.633,KG,20231025.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Economic problem;Emotional distress;Loss of personal independence in daily activities;Osteoporosis;Pain;Ulna fracture,180807584.0,OT,,,180807584.0,1.0,2007.0,201501.0,,,180807584.0,1.0,HIV infection
18096248,180962485,5,F,20140101.0,20230515.0,20200730,20230519,PER,,US-GILEAD-2020-0487166,GILEAD,,56.0,YR,A,M,Y,113.39,KG,20230519.0,,LW,US,US,SUSTIVA,Acute kidney injury;Emotional distress;Fanconi syndrome acquired;Pain;Proteinuria;Renal impairment,180962485.0,HO,,,180962485.0,1.0,20070227.0,20170919.0,3857.0,DAY,180962485.0,1.0,HIV infection
18102678,181026783,3,F,20120101.0,20230602.0,20200803,20230606,EXP,,US-GILEAD-2020-0486585,GILEAD,,39.0,YR,A,M,Y,73.469,KG,20230606.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal failure,181026783.0,OT,,,181026783.0,1.0,2011.0,2016.0,520.0,DAY,181026783.0,1.0,HIV infection
18102908,181029083,3,F,2017.0,20210119.0,20200803,20210201,PER,,US-GILEAD-2020-0486603,GILEAD,,,,A,M,Y,108.0,KG,20210201.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;Nephrolithiasis;Pain;Proteinuria;Renal impairment;Stress,181029083.0,OT,,,181029083.0,1.0,2004.0,2018.0,,,181029083.0,1.0,HIV infection
18103245,181032454,4,F,20180110.0,20210618.0,20200803,20210701,EXP,,US-GILEAD-2020-0487229,GILEAD,,67.0,YR,E,M,Y,56.24,KG,20210701.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal failure;Skeletal injury,181032454.0,OT,,,181032454.0,1.0,2001.0,2018.0,,,181032454.0,1.0,HIV infection
18105559,181055595,5,F,20080101.0,20230421.0,20200804,20230425,EXP,,US-GILEAD-2020-0486479,GILEAD,,42.0,YR,A,M,Y,81.633,KG,20230425.0,,LW,US,US,SUSTIVA,Abdominal discomfort;Abnormal dreams;Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Decreased appetite;Emotional distress;Femur fracture;Hand fracture;Lower limb fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal injury;Skeletal injury;Weight decreased,181055595.0,HO,,,181055595.0,1.0,2004.0,2017.0,1363.0,DAY,181055595.0,1.0,HIV infection
18105627,181056274,4,F,2015.0,20201019.0,20200803,20201023,EXP,,LV-MYLANLABS-2020M1068298,MYLAN,,45.0,YR,,F,Y,,,20201023.0,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,181056274.0,OT,,,181056274.0,1.0,2019.0,,,,181056274.0,1.0,HIV infection
18105661,181056614,4,F,20120101.0,20240117.0,20200804,20240118,EXP,,US-GILEAD-2020-0486474,GILEAD,,47.0,YR,A,M,Y,131.07,KG,20240118.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Dysstasia;Emotional distress;Osteoarthritis;Pain,181056614.0,OT,,,181056614.0,1.0,2004.0,201703.0,,,181056614.0,1.0,HIV infection
18106071,181060713,3,F,2015.0,20210119.0,20200804,20210204,PER,,US-GILEAD-2020-0486758,GILEAD,,,,A,M,Y,94.33,KG,20210204.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Bone pain;Emotional distress;Fracture;Gait disturbance;Pain;Renal failure;Rib fracture,181060713.0,OT,,,181060713.0,1.0,200912.0,201309.0,,,181060713.0,1.0,HIV infection
18107079,181070793,3,F,20090101.0,20231013.0,20200804,20231019,EXP,,US-GILEAD-2020-0486915,GILEAD,,40.0,YR,A,M,Y,142.0,KG,20231018.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Foot fracture;Insomnia;Loss of personal independence in daily activities;Pain,181070793.0,OT,,,181070793.0,1.0,20080506.0,20190609.0,4051.0,DAY,181070793.0,1.0,HIV infection
18109437,181094374,4,F,20101014.0,20231006.0,20200804,20231010,EXP,,US-GILEAD-2020-0486792,GILEAD,,59.0,YR,A,F,Y,49.0,KG,20231010.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Depression;Emotional distress;Glomerular filtration rate decreased;Hand fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal failure;Renal impairment,181094374.0,HO,,,181094374.0,1.0,20050401.0,20160914.0,4184.0,DAY,181094374.0,1.0,HIV infection
18109928,181099283,3,F,20100201.0,20230429.0,20200804,20230503,PER,,US-GILEAD-2020-0486821,GILEAD,,56.0,YR,A,M,Y,72.562,KG,20230503.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteopenia;Pain,,,,,181099283.0,1.0,2006.0,201902.0,,,181099283.0,1.0,HIV infection
18110465,181104653,3,F,20130508.0,20230405.0,20200804,20230411,EXP,,US-GILEAD-2020-0486802,GILEAD,,41.0,YR,A,M,Y,85.0,KG,20230411.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Abdominal pain;Anhedonia;Ankle fracture;Anxiety;Chronic kidney disease;Dizziness;Emotional distress;Loss of consciousness;Pain;Pyrexia;Syncope,181104653.0,HO,,,181104653.0,1.0,2001.0,2007.0,328.0,DAY,181104653.0,1.0,HIV infection
18110954,181109543,3,F,20140701.0,20230501.0,20200804,20230504,EXP,,US-GILEAD-2020-0488466,GILEAD,,22.0,YR,A,F,Y,55.782,KG,20230504.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure,181109543.0,HO,,,181109543.0,1.0,201011.0,201212.0,1022.0,DAY,181109543.0,1.0,HIV infection
18111305,181113054,4,F,20160101.0,20230414.0,20200804,20230418,EXP,,LV-009507513-2007LVA010997,MERCK,,45.0,YR,,F,Y,,,20230418.0,,MD,LV,LV,EFAVIRENZ,Blood HIV RNA increased;Drug resistance;Hyperhidrosis;Therapy change,181113054.0,OT,,,181113054.0,1.0,2015.0,,,,181113054.0,1.0,HIV infection
18112870,181128703,3,F,20130912.0,20210617.0,20200805,20210624,EXP,,US-GILEAD-2020-0486808,GILEAD,,75.0,YR,E,F,Y,118.0,KG,20210624.0,,LW,US,US,SUSTIVA,Acute kidney injury;Ankle fracture;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;End stage renal disease;Foot fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Radius fracture;Tooth loss;Wrist fracture,181128703.0,OT,,,181128703.0,1.0,20111130.0,20120824.0,,,181128703.0,1.0,HIV infection
18113202,181132024,4,F,20110101.0,20240119.0,20200805,20240122,EXP,,US-GILEAD-2020-0486855,GILEAD,,57.0,YR,A,M,Y,108.84,KG,20240122.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Gait disturbance;Hip fracture;Multiple fractures;Nephrolithiasis;Osteonecrosis;Osteopenia;Pain,181132024.0,OT,,,181132024.0,1.0,200910.0,2014.0,,,181132024.0,1.0,HIV infection
18114349,181143496,6,F,20120101.0,20220310.0,20200805,20220315,EXP,,US-GILEAD-2020-0488911,GILEAD,,,,A,M,Y,83.447,KG,20220314.0,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Osteoarthritis;Osteonecrosis;Pain;Polyneuropathy;Renal cyst;Renal failure;Tooth loss;Vitamin D deficiency,181143496.0,OT,,,181143496.0,1.0,20000101.0,201803.0,7304.0,DAY,181143496.0,1.0,HIV infection
18116263,181162632,2,F,20100101.0,20211025.0,20200805,20211108,EXP,,US-GILEAD-2020-0488774,GILEAD,,45.0,YR,A,M,Y,80.726,KG,20211108.0,,LW,US,US,SUSTIVA,Angina pectoris;Anxiety;Arterial disorder;Asthenia;Bone density decreased;Chronic kidney disease;Depression;Dysstasia;Emotional distress;End stage renal disease;Gait disturbance;Jaw fracture;Nephrectomy;Pain;Periodontal disease;Renal failure;Renal injury,181162632.0,OT,,,181162632.0,1.0,20110224.0,20131007.0,956.0,DAY,181162632.0,1.0,HIV infection
18117892,181178926,6,F,20111201.0,20240125.0,20200806,20240129,EXP,,US-GILEAD-2020-0486848,GILEAD,,29.0,YR,A,M,Y,,,20240129.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Death;Economic problem;Emotional distress;Pain;Renal failure;Tooth loss,181178926.0,OT,,,181178926.0,1.0,2007.0,2015.0,1383.0,DAY,181178926.0,1.0,HIV infection
18117927,181179274,4,F,20171018.0,20210623.0,20200806,20210628,EXP,,US-GILEAD-2020-0488914,GILEAD,,52.0,YR,A,M,Y,74.83,KG,20210628.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone disorder;Depression;Dysstasia;Emotional distress;Gait disturbance;Mobility decreased;Nephropathy;Osteonecrosis;Pain;Renal injury;Skeletal injury;Tooth disorder;Tooth loss,181179274.0,OT,,,181179274.0,1.0,2001.0,2003.0,,,181179274.0,1.0,HIV infection
18119698,181196984,4,F,20170101.0,20220929.0,20200806,20221003,EXP,,US-GILEAD-2020-0487217,GILEAD,,56.0,YR,A,M,Y,180.0,KG,20221003.0,,LW,US,US,SUSTIVA,Anxiety;Asthenia;Bone density decreased;Bone loss;Chronic kidney disease;Creatinine urine increased;Emotional distress;Fatigue;Osteonecrosis;Osteopenia;Pain;Renal failure;Tooth disorder;Tooth loss,181196984.0,OT,,,181196984.0,1.0,20050107.0,201512.0,,,181196984.0,1.0,HIV infection
18120238,181202384,4,F,20090401.0,20220303.0,20200806,20220309,EXP,,US-GILEAD-2020-0484417,GILEAD,,74.0,YR,E,M,Y,90.718,KG,20220309.0,,LW,US,US,SUSTIVA,Abdominal pain;Back pain;Bone density decreased;Chronic kidney disease;Emotional distress;Gait disturbance;Nausea;Nephropathy;Osteopenia;Pain;Renal cyst;Renal failure;Renal impairment,181202384.0,OT,,,181202384.0,1.0,2001.0,2001.0,72.0,DAY,181202384.0,1.0,HIV infection
18121742,181217421,1,I,2014.0,20200503.0,20200806,20200806,EXP,,US-GILEAD-2020-0487715,GILEAD,,45.0,YR,A,M,Y,106.12,KG,20200806.0,,LW,US,US,SUSTIVA,Anxiety;Arthralgia;Back pain;Blood creatinine increased;Bone density decreased;Bone loss;Chronic kidney disease;Crying;Depressed mood;Depression;Disturbance in attention;Dysstasia;Emotional distress;Emotional poverty;HIV infection;Loss of personal independence in daily activities;Mood swings;Musculoskeletal pain;Pain;Tooth disorder;Tooth loss;Vitamin D deficiency,181217421.0,OT,,,181217421.0,1.0,2009.0,20151116.0,,,181217421.0,1.0,HIV infection
18129721,181297215,5,F,20160101.0,20240131.0,20200810,20240202,EXP,,US-GILEAD-2020-0488477,GILEAD,,44.0,YR,A,M,Y,122.45,KG,20240202.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bronchitis;Chronic kidney disease;Depression;Emotional distress;Hepatic function abnormal;Nephropathy;Pain;Renal impairment;Spinal fracture;Wrist fracture,181297215.0,OT,,,181297215.0,1.0,2001.0,2016.0,223.0,DAY,181297215.0,1.0,HIV infection
18130200,181302001,1,I,,20200806.0,20200810,20200810,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063532,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20200810.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,181302001.0,OT,,,,,,,,,181302001.0,1.0,HIV infection
18130563,181305631,1,I,,20200804.0,20200810,20200810,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040221",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,,,20200810.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,181305631.0,OT,,,,,,,,,181305631.0,1.0,HIV infection
18130712,181307123,3,F,20150527.0,20200912.0,20200810,20200917,PER,,US-GILEAD-2020-0489352,GILEAD,,61.0,YR,A,M,Y,86.0,KG,20200917.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteopenia;Osteoporosis;Pain,181307123.0,OT,,,181307123.0,1.0,2006.0,20141105.0,,,181307123.0,1.0,HIV infection
18131515,181315151,1,I,,20200804.0,20200810,20200810,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040147",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200810.0,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,181315151.0,OT,,,,,,,,,181315151.0,1.0,HIV infection
18132499,181324991,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040473",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,,,20200811.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,181324991.0,OT,,,,,,,,,181324991.0,1.0,HIV infection
18133299,181332993,3,F,,20210924.0,20200811,20210929,EXP,,FR-MYLANLABS-2020M1070646,MYLAN,,,,I,,Y,,,20210929.0,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,181332993.0,CA,,,,,,,,,181332993.0,1.0,HIV infection
18133418,181334182,2,F,20010322.0,20200805.0,20200811,20201028,EXP,,US-VIIV HEALTHCARE LIMITED-A0147188A,VIIV,,0.0,DY,,M,Y,3.2,KG,20201028.0,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,181334182.0,OT,,,181334182.0,2.0,20001109.0,20000926.0,,,181334182.0,1.0,HIV infection
18133525,181335252,2,F,20010322.0,20200805.0,20200811,20201028,EXP,,US-GLAXOSMITHKLINE-A0147188A,GLAXOSMITHKLINE,,0.0,DY,,M,Y,3.2,KG,20201028.0,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,181335252.0,OT,,,181335252.0,2.0,20001109.0,20000926.0,,,181335252.0,1.0,HIV infection
18139381,181393811,1,I,,20200804.0,20200812,20200812,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040199",BOEHRINGER INGELHEIM,,,,,,Y,,,20200812.0,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,181393811.0,OT,,,,,,,,,181393811.0,1.0,HIV infection
18141192,181411923,3,F,20110901.0,20230424.0,20200812,20230427,EXP,,US-GILEAD-2020-0489338,GILEAD,,63.0,YR,A,M,Y,76.19,KG,20230427.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Mobility decreased;Osteopenia;Pain,181411923.0,OT,,,181411923.0,1.0,2008.0,201109.0,56.0,DAY,181411923.0,1.0,HIV infection
18142329,181423292,2,F,2011.0,20201006.0,20200812,20201017,EXP,,US-GILEAD-2020-0489724,GILEAD,,50.0,YR,A,M,Y,68.03,KG,20201017.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Osteopenia;Osteoporosis;Pain;Spinal fracture,181423292.0,OT,,,181423292.0,1.0,200712.0,201612.0,,,181423292.0,1.0,HIV infection
18142985,181429851,1,I,20100801.0,20200806.0,20200812,20200812,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-064355,BRISTOL MYERS SQUIBB,,48.0,YR,,F,Y,,,20200812.0,,CN,US,US,SUSTIVA,Arthritis;Bone density decreased,,,,,,,,,,,181429851.0,1.0,HIV infection
18147294,181472941,1,I,,20190918.0,20200814,20200814,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2019023105,MACLEODS,,,,,,Y,,,20200814.0,,MD,IN,IN,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms;Rash erythematous,181472941.0,OT,,,,,,,,,181472941.0,1.0,HIV infection
18148567,181485672,2,F,,20200914.0,20200813,20200921,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063642,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20200921.0,,HP,CA,CA,SUSTIVA,Anxiety,181485672.0,HO,,,,,,,,,181485672.0,1.0,HIV infection
18148773,181487735,5,F,20140729.0,20240110.0,20200813,20240112,EXP,,US-GILEAD-2020-0489270,GILEAD,,60.0,YR,A,M,Y,88.435,KG,20240112.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Spinal compression fracture,181487735.0,OT,,,181487735.0,1.0,200908.0,20160914.0,,,181487735.0,1.0,HIV infection
18150978,181509784,4,F,20070403.0,20200817.0,20200814,20211122,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2020160069,VIIV,,,,N,M,Y,3.2,KG,20211122.0,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Foetal exposure during pregnancy;Hydrocele,181509784.0,OT,,,181509784.0,1.0,20070512.0,20070521.0,49.0,DAY,181509784.0,1.0,HIV infection
18150985,181509854,4,F,20070403.0,20200817.0,20200814,20211122,EXP,,FR-GLAXOSMITHKLINE-FR2020160069,GLAXOSMITHKLINE,,,,N,M,Y,3.2,KG,20211122.0,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Foetal exposure during pregnancy;Hydrocele,181509854.0,OT,,,181509854.0,1.0,20070512.0,20070521.0,49.0,DAY,181509854.0,1.0,HIV infection
18152088,181520884,4,F,2017.0,20210527.0,20200814,20210601,PER,,US-GILEAD-2020-0489879,GILEAD,,,,A,M,Y,81.63,KG,20210601.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Osteopenia;Pain,,,,,181520884.0,1.0,2008.0,201710.0,,,181520884.0,1.0,HIV infection
18154052,181540523,3,F,20160912.0,20210119.0,20200816,20210312,PER,,US-GILEAD-2020-0489413,GILEAD,,59.0,YR,A,F,Y,80.3,KG,20210312.0,,CN,US,US,SUSTIVA,Anxiety;Bone density decreased;Emotional distress;Osteopenia;Renal impairment,,,,,181540523.0,1.0,20140415.0,,,,181540523.0,1.0,HIV infection
18154249,181542491,1,I,,20200619.0,20200816,20200816,EXP,,CA-ROCHE-2627259,ROCHE,,52.0,YR,,M,Y,,,20200817.0,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,181542491.0,OT,,,,,,,,,181542491.0,1.0,HIV infection
18154572,181545721,1,I,,20200625.0,20200817,20200817,PER,,US-STRIDES ARCOLAB LIMITED-2020SP007554,STRIDES,,61.0,YR,,F,Y,,,20200817.0,,MD,US,US,EFAVIRENZ.,Alopecia,,,,,,,,,,,181545721.0,1.0,HIV infection
18155717,181557171,1,I,,20200806.0,20200817,20200817,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063936,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20200817.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181557171.0,OT,,,,,,,,,181557171.0,1.0,HIV infection
18156798,181567983,3,F,20050101.0,20230922.0,20200817,20230928,EXP,,US-GILEAD-2020-0490398,GILEAD,,51.0,YR,A,F,Y,246.0,KG,20230928.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Depression;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal impairment,181567983.0,OT,,,181567983.0,1.0,2005.0,200908.0,,,181567983.0,1.0,HIV infection
18157575,181575754,4,F,20180101.0,20230825.0,20200817,20230830,EXP,,US-GILEAD-2020-0490404,GILEAD,,,,A,F,Y,113.38,KG,20230830.0,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Depression;Emotional distress;Osteoporosis;Pain,181575754.0,OT,,,181575754.0,1.0,2008.0,2016.0,,,181575754.0,1.0,HIV infection
18157901,181579013,3,F,20090101.0,20230414.0,20200817,20230418,EXP,,US-GILEAD-2020-0489192,GILEAD,,59.0,YR,A,M,Y,141.95,KG,20230418.0,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Depression;Emotional distress;Femur fracture;Insomnia;Osteoporosis;Pain,181579013.0,OT,,,181579013.0,1.0,2004.0,2009.0,,,181579013.0,1.0,HIV infection
18158157,181581573,3,F,20141126.0,20230419.0,20200817,20230424,EXP,,US-GILEAD-2020-0489417,GILEAD,,51.0,YR,A,M,Y,123.36,KG,20230424.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Osteoporosis;Pain,181581573.0,OT,,,181581573.0,1.0,2001.0,2020.0,,,181581573.0,1.0,HIV infection
18158162,181581624,4,F,20070605.0,20230925.0,20200817,20230929,EXP,,US-GILEAD-2020-0489414,GILEAD,,43.0,YR,A,M,Y,,,20230929.0,,LW,US,US,EFAVIRENZ,Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal impairment,181581624.0,OT,,,181581624.0,1.0,2009.0,201001.0,,,181581624.0,1.0,HIV infection
18158198,181581983,3,F,2012.0,20210505.0,20200817,20210510,EXP,,US-GILEAD-2020-0489363,GILEAD,,55.0,YR,A,F,Y,75.28,KG,20210510.0,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Chronic kidney disease;Emotional distress;Femur fracture;Gait disturbance;Hip fracture;Lower limb fracture;Mental impairment;Osteoporosis;Pain,181581983.0,OT,,,181581983.0,1.0,2003.0,20131115.0,,,181581983.0,1.0,HIV infection
18158284,181582843,3,F,20150511.0,20231013.0,20200817,20231017,EXP,,US-GILEAD-2020-0489757,GILEAD,,56.0,YR,A,M,Y,81.633,KG,20231017.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Coronary artery disease;Emotional distress;Gait disturbance;Pain,181582843.0,OT,,,181582843.0,1.0,2014.0,201505.0,,,181582843.0,1.0,HIV infection
18158290,181582903,3,F,20150501.0,20230403.0,20200817,20230407,EXP,,US-GILEAD-2020-0489759,GILEAD,,49.0,YR,A,F,Y,68.027,KG,20230407.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal tubular acidosis,181582903.0,OT,,,181582903.0,1.0,2006.0,2018.0,,,181582903.0,1.0,HIV infection
18158478,181584784,4,F,20160101.0,20230404.0,20200817,20230407,EXP,,US-GILEAD-2020-0490412,GILEAD,,,,A,M,Y,104.31,KG,20230407.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Proteinuria,181584784.0,OT,,,181584784.0,1.0,2012.0,2018.0,2353.0,DAY,181584784.0,1.0,HIV infection
18158546,181585464,4,F,20140301.0,20240213.0,20200817,20240215,EXP,,US-GILEAD-2020-0489318,GILEAD,,40.0,YR,A,M,Y,74.83,KG,20240214.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Loss of personal independence in daily activities;Pain;Renal failure;Vitamin D deficiency,181585464.0,OT,,,181585464.0,1.0,2010.0,2013.0,,,181585464.0,1.0,HIV infection
18158634,181586344,4,F,20050425.0,20240119.0,20200817,20240122,EXP,,US-GILEAD-2020-0489335,GILEAD,,59.0,YR,A,F,Y,45.351,KG,20240122.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Death;Emotional distress;Gait disturbance;General physical health deterioration;Multiple fractures;Osteoporosis;Pain,181586344.0,DE,,,181586344.0,1.0,200609.0,20161107.0,,,181586344.0,1.0,HIV infection
18159203,181592031,1,I,,20200806.0,20200818,20200818,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-064977,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20200818.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181592031.0,OT,,,,,,,,,181592031.0,1.0,HIV infection
18160188,181601882,2,F,20051201.0,20230412.0,20200817,20230418,EXP,,US-GILEAD-2020-0489476,GILEAD,,48.0,YR,A,M,Y,185.0,KG,20230418.0,,LW,US,US,SUSTIVA,Anxiety;Back pain;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Erectile dysfunction;Fatigue;Incontinence;Pain;Pollakiuria;Post-traumatic stress disorder;Proteinuria;Restlessness,181601882.0,OT,,,181601882.0,1.0,2001.0,2017.0,,,181601882.0,1.0,HIV infection
18160753,181607533,3,F,2013.0,20201217.0,20200817,20201230,PER,,US-GILEAD-2020-0489852,GILEAD,,,,A,M,Y,97.51,KG,20201230.0,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Multiple fractures;Pain;Renal impairment,181607533.0,OT,,,181607533.0,1.0,20120828.0,20120919.0,,,181607533.0,1.0,HIV infection
18160971,181609711,1,I,2019.0,20200814.0,20200817,20200817,EXP,,LV-GILEAD-2020-0490338,GILEAD,,45.0,YR,A,F,Y,,,20200817.0,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,181609711.0,OT,,,181609711.0,1.0,2019.0,,,,181609711.0,1.0,HIV infection
18161065,181610652,2,F,2009.0,20200912.0,20200817,20200925,EXP,,US-GILEAD-2020-0489853,GILEAD,,,,A,F,Y,69.39,KG,20200925.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Osteoporosis;Pain,181610652.0,OT,,,181610652.0,1.0,200905.0,201603.0,,,181610652.0,1.0,HIV infection
18163421,181634213,3,F,2005.0,20200914.0,20200818,20200924,EXP,,US-GILEAD-2020-0490118,GILEAD,,54.0,YR,A,F,Y,88.44,KG,20200924.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,181634213.0,OT,,,181634213.0,1.0,2003.0,2005.0,,,181634213.0,1.0,HIV infection
18163556,181635563,3,F,20150101.0,20230414.0,20200818,20230419,PER,,US-GILEAD-2020-0490410,GILEAD,,52.0,YR,A,M,Y,72.562,KG,20230419.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Drug ineffective;Emotional distress;Myalgia;Pain;Pain in extremity,181635563.0,OT,,,181635563.0,1.0,2004.0,20181016.0,,,181635563.0,1.0,HIV infection
18163710,181637104,4,F,2008.0,20200918.0,20200818,20201016,EXP,,US-GILEAD-2020-0490419,GILEAD,,,,A,M,Y,81.63,KG,20201016.0,,LW,US,US,SUSTIVA,Bone density decreased;Emotional distress;Foot fracture;Osteoporosis;Pain,181637104.0,OT,,,181637104.0,1.0,2004.0,2008.0,,,181637104.0,1.0,HIV infection
18164183,181641833,3,F,20140101.0,20230414.0,20200818,20230418,EXP,,US-GILEAD-2020-0490397,GILEAD,,59.0,YR,A,M,Y,95.238,KG,20230418.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Decreased activity;Emotional distress;Pain;Renal tubular acidosis,181641833.0,OT,,,181641833.0,1.0,2006.0,201408.0,,,181641833.0,1.0,HIV infection
18164238,181642383,3,F,20050101.0,20230501.0,20200818,20230504,EXP,,US-GILEAD-2020-0490115,GILEAD,,,,A,M,Y,61.224,KG,20230504.0,,LW,US,US,SUSTIVA,Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal impairment,181642383.0,OT,,,181642383.0,1.0,2004.0,20111214.0,,,181642383.0,1.0,HIV infection
18165528,181655285,5,F,20130601.0,20211011.0,20200818,20211019,EXP,,US-GILEAD-2020-0489964,GILEAD,,51.0,YR,A,M,Y,91.16,KG,20211019.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blindness;Blood creatinine increased;Bone disorder;Bone pain;Chronic kidney disease;Dry skin;Emotional distress;Hypokinesia;Pain;Pruritus;Rash;Renal impairment;Skin disorder,181655285.0,OT,,,181655285.0,1.0,200303.0,2012.0,1060.0,DAY,181655285.0,1.0,HIV infection
18165600,181656003,3,F,20060701.0,20231013.0,20200818,20231017,EXP,,US-GILEAD-2020-0490476,GILEAD,,46.0,YR,A,M,Y,94.785,KG,20231017.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;End stage renal disease;Gout;Pain,181656003.0,OT,,,181656003.0,1.0,200304.0,200603.0,,,181656003.0,1.0,HIV infection
18166711,181667113,3,F,201207.0,20210325.0,20200819,20210330,EXP,,US-GILEAD-2020-0490497,GILEAD,,71.0,YR,A,M,Y,125.0,KG,20210330.0,,LW,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal impairment,181667113.0,OT,,,181667113.0,1.0,201009.0,20180108.0,,,181667113.0,1.0,HIV infection
18167628,181676281,1,I,,20181105.0,20200819,20200819,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-104537,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20200819.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,181676281.0,HO,,,,,,,,,181676281.0,1.0,HIV infection
18168279,181682793,3,F,20191111.0,20200827.0,20200819,20200831,EXP,,ZA-AUROBINDO-AUR-APL-2020-040561,AUROBINDO,,17.0,YR,,F,Y,,,20200831.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,181682793.0,OT,,,181682793.0,1.0,20070906.0,,,,181682793.0,1.0,HIV infection
18168897,181688973,3,F,2005.0,20210217.0,20200818,20210301,EXP,,US-GILEAD-2020-0490418,GILEAD,,,,A,M,Y,112.47,KG,20210301.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Cervical vertebral fracture;Emotional distress;Lumbar vertebral fracture;Osteoporosis;Pain;Renal impairment,181688973.0,OT,,,181688973.0,1.0,2004.0,20190827.0,,,181688973.0,1.0,HIV infection
18168922,181689224,4,F,20170310.0,20230606.0,20200818,20230612,EXP,,US-GILEAD-2020-0489977,GILEAD,,38.0,YR,A,F,Y,63.492,KG,20230612.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Emotional distress;Nephropathy;Pain;Renal failure;Renal injury,181689224.0,HO,,,181689224.0,1.0,2009.0,201202.0,,,181689224.0,1.0,HIV infection
18168943,181689436,6,F,20090101.0,20230509.0,20200818,20230516,EXP,,US-GILEAD-2020-0489652,GILEAD,,,,A,M,Y,58.957,KG,20230516.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone demineralisation;Bone density decreased;Emotional distress;Hip fracture;Osteoporosis;Pain;Protein urine present;Renal impairment;Rotator cuff syndrome;Tendon rupture;Wrist fracture,181689436.0,OT,,,181689436.0,1.0,2006.0,201612.0,,,181689436.0,1.0,HIV infection
18170718,181707183,3,F,20160729.0,20201202.0,20200819,20201209,EXP,,US-GILEAD-2020-0489845,GILEAD,,50.0,YR,A,M,Y,98.87,KG,20201209.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal failure,181707183.0,OT,,,181707183.0,1.0,201504.0,201607.0,,,181707183.0,1.0,HIV infection
18170885,181708852,2,F,20170116.0,20201007.0,20200819,20201018,EXP,,US-GILEAD-2020-0490137,GILEAD,,63.0,YR,A,M,Y,53.52,KG,20201018.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Osteoporosis;Pain;Renal impairment,181708852.0,OT,,,181708852.0,1.0,2006.0,20150527.0,,,181708852.0,1.0,HIV infection
18171201,181712013,3,F,20060101.0,20230502.0,20200819,20230508,EXP,,US-GILEAD-2020-0489986,GILEAD,,,,A,M,Y,70.3,KG,20230508.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,181712013.0,OT,,,181712013.0,1.0,2003.0,2006.0,,,181712013.0,1.0,HIV infection
18171264,181712645,5,F,20160101.0,20230331.0,20200819,20230405,EXP,,US-GILEAD-2020-0490139,GILEAD,,54.0,YR,A,M,Y,114.29,KG,20230405.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Depression;Emotional distress;Multiple fractures;Osteonecrosis;Osteoporosis;Pain;Renal injury;Skeletal injury;Tooth loss,181712645.0,OT,,,181712645.0,1.0,2004.0,2008.0,,,181712645.0,1.0,HIV infection
18171947,181719474,4,F,20070501.0,20240213.0,20200819,20240215,EXP,,US-GILEAD-2020-0490066,GILEAD,,32.0,YR,A,M,Y,78.9,KG,20240215.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Fracture;Gait disturbance;Osteoporosis;Pain,181719474.0,OT,,,181719474.0,1.0,20070118.0,200809.0,,,181719474.0,1.0,HIV infection
18172099,181720994,4,F,20080101.0,20240116.0,20200819,20240118,EXP,,US-GILEAD-2020-0490269,GILEAD,,,,A,F,Y,104.32,KG,20240118.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Gout;Hypertension;Joint swelling;Pain;Renal injury,181720994.0,OT,,,181720994.0,1.0,2007.0,2018.0,,,181720994.0,1.0,HIV infection
18172100,181721003,3,F,20180901.0,20230502.0,20200819,20230505,EXP,,US-GILEAD-2020-0490070,GILEAD,,47.0,YR,A,M,Y,63.492,KG,20230505.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Lower limb fracture;Multiple fractures;Osteoporosis;Pain,181721003.0,OT,,,181721003.0,1.0,2006.0,201809.0,,,181721003.0,1.0,HIV infection
18172232,181722322,2,F,,20200912.0,20200819,20200928,PER,,US-GILEAD-2020-0490163,GILEAD,,,,A,M,Y,89.34,KG,20200928.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Emotional distress;Pain,,,,,181722322.0,1.0,2001.0,1996.0,,,181722322.0,1.0,HIV infection
18172426,181724263,3,F,20080801.0,20230331.0,20200820,20230404,PER,,US-GILEAD-2020-0490168,GILEAD,,48.0,YR,A,F,Y,99.773,KG,20230404.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Injury;Osteopenia;Pain,,,,,181724263.0,1.0,2001.0,201705.0,,,181724263.0,1.0,HIV infection
18172920,181729205,5,F,20110901.0,20240206.0,20200820,20240208,EXP,,US-GILEAD-2020-0490188,GILEAD,,63.0,YR,A,M,Y,81.633,KG,20240208.0,,LW,US,US,SUSTIVA,Abdominal distension;Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Chronic kidney disease;Dysstasia;Emotional distress;Exercise tolerance decreased;Foot fracture;Gait disturbance;Multiple fractures;Pain,181729205.0,OT,,,181729205.0,1.0,2001.0,2004.0,,,181729205.0,1.0,HIV infection
18172968,181729682,2,F,200812.0,20201016.0,20200819,20201028,EXP,,US-GILEAD-2020-0490120,GILEAD,,31.0,YR,A,M,Y,145.0,KG,20201028.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteoporosis;Pain,181729682.0,OT,,,181729682.0,1.0,200608.0,201710.0,,,181729682.0,1.0,HIV infection
18172978,181729784,4,F,2005.0,20210409.0,20200819,20210414,EXP,,US-GILEAD-2020-0490072,GILEAD,,56.0,YR,A,M,Y,78.46,KG,20210414.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Nightmare;Pain,181729784.0,OT,,,181729784.0,1.0,200211.0,201706.0,,,181729784.0,1.0,HIV infection
18173013,181730133,3,F,2015.0,20210106.0,20200819,20210121,PER,,US-GILEAD-2020-0489954,GILEAD,,36.0,YR,A,M,Y,,,20210121.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Intervertebral disc protrusion;Osteopenia;Osteoporosis;Pain;Renal injury,181730133.0,OT,,,181730133.0,1.0,2010.0,20121016.0,,,181730133.0,1.0,HIV infection
18173335,181733353,3,F,20110712.0,20200918.0,20200819,20210408,EXP,,US-GILEAD-2020-0489972,GILEAD,,63.0,YR,A,M,Y,62.59,KG,20210408.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Emotional distress;Femur fracture;Hip fracture;Osteoporosis,181733353.0,OT,,,181733353.0,1.0,2002.0,20160908.0,,,181733353.0,1.0,HIV infection
18173426,181734262,2,F,2010.0,20200913.0,20200819,20200925,EXP,,US-GILEAD-2020-0489699,GILEAD,,60.0,YR,A,M,Y,74.84,KG,20200925.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Fracture;Osteoporosis;Pain;Prostate cancer,181734262.0,OT,,,181734262.0,1.0,20061219.0,20131008.0,,,181734262.0,1.0,HIV infection
18176884,181768844,4,F,20080625.0,20231124.0,20200820,20231127,EXP,,US-GILEAD-2020-0491025,GILEAD,,58.0,YR,A,M,Y,111.57,KG,20231127.0,,LW,US,US,SUSTIVA,Depression;Diarrhoea;Emotional distress;Exercise tolerance decreased;Muscle spasms;Muscular weakness;Osteopenia;Osteoporosis;Pain;Protein urine present,181768844.0,OT,,,181768844.0,1.0,20060711.0,20190528.0,4704.0,DAY,181768844.0,1.0,HIV infection
18176940,181769403,3,F,201411.0,20201016.0,20200820,20201022,EXP,,US-GILEAD-2020-0489895,GILEAD,,50.0,YR,A,F,Y,70.75,KG,20201022.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density abnormal;Chronic kidney disease;Emotional distress;Osteopenia;Pain;Product use complaint;Wrist fracture,181769403.0,HO,,,181769403.0,1.0,201008.0,201410.0,,,181769403.0,1.0,HIV infection
18178260,181782603,3,F,2019.0,20210824.0,20200821,20210831,PER,,US-GILEAD-2020-0491252,GILEAD,,64.0,YR,A,M,Y,73.92,KG,20210831.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone pain;Depression;Emotional distress;Fear of falling;Hepatic function abnormal;Injury;Loss of personal independence in daily activities;Osteopenia;Pain,,,,,181782603.0,1.0,2004.0,201901.0,,,181782603.0,1.0,HIV infection
18178893,181788933,3,F,20171213.0,20201202.0,20200820,20201209,EXP,,US-GILEAD-2020-0489901,GILEAD,,56.0,YR,A,F,Y,88.44,KG,20201209.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Depression;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Peripheral swelling;Pollakiuria;Renal tubular necrosis,181788933.0,OT,,,181788933.0,1.0,201510.0,201807.0,,,181788933.0,1.0,HIV infection
18179064,181790645,5,F,20080301.0,20230503.0,20200821,20230508,EXP,,US-GILEAD-2020-0490483,GILEAD,,60.0,YR,A,M,Y,77.1,KG,20230508.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Drug ineffective;Emotional distress;Pain,181790645.0,HO,,,181790645.0,1.0,2001.0,200508.0,,,181790645.0,1.0,HIV infection
18179409,1817940910,10,F,,20241022.0,20200821,20241028,EXP,,CA-ROCHE-2583896,ROCHE,,52.0,YR,A,M,Y,,,20241028.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,1817940910.0,OT,,,,,,,,,1817940910.0,1.0,HIV infection
18179440,181794404,4,F,20091216.0,20201016.0,20200820,20201119,EXP,,US-GILEAD-2020-0489859,GILEAD,,44.0,YR,A,M,Y,115.0,KG,20201119.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Drug resistance;Economic problem;Emotional distress;Osteopenia;Pain,181794404.0,OT,,,181794404.0,1.0,200403.0,200409.0,,,181794404.0,1.0,HIV infection
18181094,181810945,5,F,2002.0,20210922.0,20200821,20210928,PER,,US-GILEAD-2020-0491031,GILEAD,,,,A,F,Y,90.7,KG,20210928.0,,CN,US,US,SUSTIVA,Anxiety;Back pain;Blood creatinine increased;Bone pain;Chromaturia;Depression;Emotional distress;Groin pain;Hypertension;Nephropathy;Pain,,,,,181810945.0,1.0,20090612.0,20100217.0,,,181810945.0,1.0,HIV infection
18182871,181828713,3,F,20070918.0,20200916.0,20200821,20201007,PER,,US-GILEAD-2020-0489938,GILEAD,,33.0,YR,A,M,Y,98.87,KG,20201007.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Pain;Renal impairment;Renal injury,181828713.0,OT,,,181828713.0,1.0,2004.0,2007.0,,,181828713.0,1.0,HIV infection
18183207,181832074,4,F,20180701.0,20230413.0,20200821,20230420,EXP,,US-GILEAD-2020-0489941,GILEAD,,47.0,YR,A,M,Y,79.365,KG,20230420.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Emotional distress;Fracture;Pain,181832074.0,OT,,,181832074.0,1.0,2004.0,2010.0,,,181832074.0,1.0,HIV infection
18184143,181841433,3,F,20080101.0,20230501.0,20200823,20230505,EXP,,US-GILEAD-2020-0491100,GILEAD,,,,A,M,Y,96.145,KG,20230505.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Emotional distress;Fracture;Osteoporosis;Pain;Renal impairment,181841433.0,OT,,,181841433.0,1.0,2004.0,2018.0,,,181841433.0,1.0,HIV infection
18184148,181841483,3,F,20070101.0,20230422.0,20200824,20230425,EXP,,US-GILEAD-2020-0491250,GILEAD,,51.0,YR,A,M,Y,77.098,KG,20230425.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Chronic kidney disease;Depression;Emotional distress;Foot fracture;Nightmare;Osteoporosis;Pain;Renal impairment;Stress fracture,181841483.0,OT,,,181841483.0,1.0,2006.0,2012.0,,,181841483.0,1.0,HIV infection
18193939,181939392,2,F,201406.0,20201125.0,20200825,20201207,EXP,,US-GILEAD-2020-0491422,GILEAD,,66.0,YR,E,M,Y,73.47,KG,20201207.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Chronic kidney disease;Emotional distress;Loss of personal independence in daily activities;Pain,181939392.0,OT,,,181939392.0,1.0,200406.0,201710.0,,,181939392.0,1.0,HIV infection
18195137,181951371,1,I,,20200817.0,20200825,20200825,EXP,,CA-ASTRAZENECA-2020SF06627,ASTRAZENECA,,44.0,YR,,M,Y,,,20200825.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,181951371.0,OT,,,,,,,,,181951371.0,2.0,HIV infection
18195354,181953545,5,F,2008.0,20210909.0,20200825,20210917,EXP,,US-GILEAD-2020-0490990,GILEAD,,47.0,YR,A,F,Y,53.06,KG,20210917.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Dysstasia;Emotional distress;Fanconi syndrome acquired;Foot fracture;Gait disturbance;Hip fracture;Metabolic acidosis;Multiple fractures;Nephrogenic anaemia;Osteoporosis;Pain;Renal impairment,181953545.0,HO,,,181953545.0,1.0,2006.0,2016.0,,,181953545.0,1.0,HIV infection
18196776,181967764,4,F,20060101.0,20230404.0,20200826,20230407,EXP,,US-GILEAD-2020-0491925,GILEAD,,,,A,M,Y,120.64,KG,20230407.0,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Emotional distress;Fatigue;Feeling drunk;Headache;Migraine;Mood swings;Nephrolithiasis;Pain;Renal impairment,181967764.0,HO,,,181967764.0,1.0,2006.0,2012.0,,,181967764.0,1.0,HIV infection
18198021,181980213,3,F,20150101.0,20230421.0,20200826,20230425,EXP,,US-GILEAD-2020-0491862,GILEAD,,44.0,YR,A,M,Y,81.633,KG,20230425.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone loss;Dysstasia;Emotional distress;Loose tooth;Multiple fractures;Osteopenia;Osteoporosis;Pain;Stress fracture,181980213.0,OT,,,181980213.0,1.0,200403.0,201801.0,,,181980213.0,1.0,HIV infection
18199815,181998154,4,F,20130501.0,20240103.0,20200826,20240104,EXP,,US-GILEAD-2020-0491171,GILEAD,,50.0,YR,A,F,Y,79.365,KG,20240104.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Depression;Emotional distress;Fanconi syndrome acquired;Haematuria;Hand fracture;Osteopenia;Pain;Renal disorder;Renal impairment;Renal tubular dysfunction,181998154.0,OT,,,181998154.0,1.0,201304.0,201409.0,2793.0,DAY,181998154.0,1.0,HIV infection
18205129,182051295,5,F,20140101.0,20230512.0,20200828,20230517,PER,,US-GILEAD-2020-0491856,GILEAD,,,,A,M,Y,87.528,KG,20230517.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Eating disorder;Emotional distress;Pain;Renal failure;Urinary incontinence,182051295.0,OT,,,182051295.0,1.0,2010.0,2012.0,,,182051295.0,1.0,HIV infection
18206163,182061632,2,F,20150501.0,20230426.0,20200827,20230428,EXP,,US-GILEAD-2020-0491423,GILEAD,,41.0,YR,A,M,Y,88.889,KG,20230428.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Mobility decreased;Pain;Renal failure,182061632.0,HO,,,182061632.0,1.0,2012.0,2015.0,,,182061632.0,1.0,HIV infection
18209319,182093191,1,I,,20200824.0,20200828,20200828,EXP,,GB-GILEAD-2020-0492282,GILEAD,KEELEY A ET AL. ANAKINRA IN THE TREATMENT OF PROTRACTED PARADOXICAL INFLAMMATORY REACTIONS IN HIV?ASSOCIATED TUBERCULOSIS IN THE UNITED KINGDOM: A REPORT OF TWO CASES.. INTERNATIONAL JOURNAL OF STD AND AIDS.. 2020?31(8):808?82,33.0,YR,A,F,Y,,,20200828.0,,HP,GB,GB,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,182093191.0,LT,,,,,,,,,182093191.0,1.0,Antiretroviral therapy
18209399,182093991,1,I,,20200824.0,20200828,20200828,EXP,,GB-GILEAD-2020-0492283,GILEAD,KEELEY A ET AL. ANAKINRA IN THE TREATMENT OF PROTRACTED PARADOXICAL INFLAMMATORY REACTIONS IN HIV?ASSOCIATED TUBERCULOSIS IN THE UNITED KINGDOM: A REPORT OF TWO CASES.. INTERNATIONAL JOURNAL OF STD AND AIDS.. 2020?31 (8):808?812. DOI:10.1177/0956462420915394,41.0,YR,A,M,Y,,,20200828.0,,HP,GB,GB,EFAVIRENZ.,Inflammation,182093991.0,DS,,,,,,,,,182093991.0,1.0,Antiretroviral therapy
18211805,182118052,2,F,2019.0,20200824.0,20200831,20200831,EXP,,ZA-CIPLA LTD.-2020ZA06030,CIPLA,,,,,,Y,,,20200831.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion induced;Exposure during pregnancy,182118052.0,OT,,,182118052.0,1.0,20070906.0,,,,182118052.0,1.0,HIV infection
18213241,182132413,3,F,20150101.0,20230418.0,20200831,20230428,EXP,,LV-TEVA-2020-LV-1820060,TEVA,,45.0,YR,A,F,Y,,,20230428.0,,CN,LV,LV,EFAVIRENZ,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,182132413.0,OT,,,182132413.0,1.0,2015.0,,,,182132413.0,1.0,HIV infection
18214639,182146392,2,F,,20200828.0,20200831,20200904,EXP,,CM-VIIV HEALTHCARE LIMITED-CM2020GSK174678,VIIV,"FOKAM J, TAKOU D, SEMENGUE ENJ, TETO G, BELOUMOU G, DAMBAYA B ET AL.. FIRST CASE OF DOLUTEGRAVIR AND DARUNAVIR/R MULTI DRUG?RESISTANT HIV?1 IN CAMEROON FOLLOWING EXPOSURE TO RALTEGRAVIR: LESSONS AND IMPLICATIONS IN THE ERA OF TRANSITION TO DOLUTEGRAVIR?BASED REGIMENS. ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL. 2020?9 (1):143",,,A,M,Y,,,20200904.0,,HP,CM,CM,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,182146392.0,OT,,,182146392.0,1.0,200608.0,200908.0,,,182146392.0,1.0,HIV infection
18214646,182146462,2,F,,20200828.0,20200831,20200904,EXP,,CM-GLAXOSMITHKLINE-CM2020GSK174678,GLAXOSMITHKLINE,"FOKAM J, TAKOU D, SEMENGUE ENJ, TETO G, BELOUMOU G, DAMBAYA B ET AL.. FIRST CASE OF DOLUTEGRAVIR AND DARUNAVIR/R MULTI DRUG?RESISTANT HIV?1 IN CAMEROON FOLLOWING EXPOSURE TO RALTEGRAVIR: LESSONS AND IMPLICATIONS IN THE ERA OF TRANSITION TO DOLUTEGRAVIR?BASED REGIMENS. ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL. 2020?9 (1):143",,,A,M,Y,,,20200904.0,,HP,CM,CM,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,182146462.0,OT,,,182146462.0,1.0,200608.0,200908.0,,,182146462.0,1.0,HIV infection
18215147,182151475,5,F,20100901.0,20240125.0,20200831,20240129,EXP,,US-GILEAD-2020-0491163,GILEAD,,60.0,YR,A,M,Y,95.238,KG,20240129.0,,LW,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Coronary artery disease;Depression;Fatigue;Hypoaesthesia;Myocardial infarction;Osteopenia,182151475.0,OT,,,182151475.0,1.0,200506.0,201506.0,149.0,DAY,182151475.0,1.0,HIV infection
18217383,182173833,3,F,,20201009.0,20200901,20201015,EXP,,GB-ADVANZ PHARMA-202008008318,ADVANZ PHARMA,,,,,,Y,,,20201015.0,,HP,GB,GB,EFAVIRENZ.,Cataract;Osteoporotic fracture;Steroid diabetes;Urinary tract infection,182173833.0,OT,,,182173833.0,2.0,2009.0,,,,182173833.0,1.0,Immune reconstitution inflammatory syndrome associated tuberculosis
18223483,182234835,5,F,20131101.0,20210623.0,20200902,20210701,EXP,,US-GILEAD-2020-0492514,GILEAD,,50.0,YR,A,F,Y,99.79,KG,20210701.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure,182234835.0,OT,,,182234835.0,1.0,20120118.0,20170122.0,,,182234835.0,1.0,HIV infection
18224609,182246096,6,F,20060101.0,20220124.0,20200902,20220204,EXP,,US-GILEAD-2020-0492507,GILEAD,,56.0,YR,A,M,Y,77.098,KG,20220204.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Asthenia;Back pain;Chronic kidney disease;Depression;Dysstasia;Emotional distress;End stage renal disease;Gait disturbance;Hyperkalaemia;Osteonecrosis;Pain;Renal failure;Tooth loss,182246096.0,HO,,,182246096.0,1.0,20051007.0,20060913.0,341.0,DAY,182246096.0,1.0,HIV infection
18228239,182282391,1,I,,20200901.0,20200903,20200903,EXP,,US-PFIZER INC-2020340114,PFIZER,,19.0,YR,,M,Y,,,20200903.0,,HP,US,US,SUSTIVA,Cystic fibrosis gastrointestinal disease;Maternal exposure during pregnancy;Meconium ileus,182282391.0,OT,,,182282391.0,2.0,20001109.0,,,,182282391.0,1.0,HIV infection
18228493,182284933,3,F,20060629.0,20210313.0,20200903,20210316,EXP,,US-GILEAD-2020-0492171,GILEAD,,44.0,YR,A,M,Y,83.9,KG,20210316.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fatigue;Insomnia;Liver disorder;Pain;Proteinuria;Renal impairment,182284933.0,OT,,,182284933.0,1.0,201109.0,201703.0,,,182284933.0,1.0,HIV infection
18229944,182299441,1,I,20191111.0,20200817.0,20200904,20200904,EXP,,ZA-HETERO-HET2020ZA00930,HETERO,,17.0,YR,,F,Y,,,20200831.0,,HP,ZA,ZA,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,182299441.0,OT,,,182299441.0,1.0,20070906.0,,,,182299441.0,1.0,HIV infection
18238479,182384791,1,I,200909.0,20200826.0,20200907,20200907,EXP,,ZA-MACLEODS PHARMACEUTICALS US LTD-MAC2020027909,MACLEODS,,,,,,Y,,,20200907.0,,HP,ZA,ZA,EFAVIRENZ.,Diarrhoea;Drug interaction;Drug resistance;Insomnia;Treatment noncompliance;Virologic failure,182384791.0,OT,,,182384791.0,1.0,2007.0,,,,182384791.0,1.0,Antiretroviral therapy
18242103,182421034,4,F,20170501.0,20231221.0,20200908,20231225,EXP,,US-GILEAD-2020-0494027,GILEAD,,51.0,YR,A,M,Y,81.633,KG,20231225.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,182421034.0,OT,,,182421034.0,1.0,2009.0,2012.0,,,182421034.0,1.0,HIV infection
18245660,182456602,2,F,2015.0,20210402.0,20200909,20210406,EXP,,US-GILEAD-2020-0494046,GILEAD,,,,A,M,Y,106.6,KG,20210406.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,182456602.0,OT,,,182456602.0,1.0,2004.0,201205.0,,,182456602.0,1.0,HIV infection
18251324,182513243,3,F,20110520.0,20210331.0,20200910,20210408,PER,,US-GILEAD-2020-0494275,GILEAD,,50.0,YR,A,F,Y,111.11,KG,20210408.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arteriovenous fistula thrombosis;Bone density decreased;Emotional distress;End stage renal disease;Gait inability;Multiple fractures;Pain;Renal failure,182513243.0,OT,,,182513243.0,1.0,2006.0,20080225.0,,,182513243.0,1.0,HIV infection
18251715,182517153,3,F,20110511.0,20210317.0,20200910,20210319,PER,,US-GILEAD-2020-0494290,GILEAD,,48.0,YR,A,M,Y,,,20210319.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia of chronic disease;Anhedonia;Anxiety;Dyspnoea;Emotional distress;End stage renal disease;Erectile dysfunction;Focal segmental glomerulosclerosis;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Pain;Proteinuria,182517153.0,OT,,,182517153.0,1.0,2006.0,20110712.0,,,182517153.0,1.0,HIV infection
18252769,182527693,3,F,2016.0,20210301.0,20200910,20210517,EXP,,US-GILEAD-2020-0494492,GILEAD,,67.0,YR,E,M,Y,63.49,KG,20210517.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Dysstasia;Emotional distress;Femur fracture;Gait disturbance;Multiple fractures;Osteoporosis;Pain;Pelvic fracture;Upper limb fracture;Wrist fracture,182527693.0,OT,,,182527693.0,1.0,2010.0,201612.0,,,182527693.0,1.0,HIV infection
18254327,182543272,2,F,2020.0,20200925.0,20200910,20201008,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-073154,BRISTOL MYERS SQUIBB,,64.0,YR,,M,Y,,,20201008.0,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome acquired,182543272.0,OT,,,182543272.0,1.0,20110323.0,20200823.0,,,182543272.0,1.0,HIV infection
18256570,182565703,3,F,20140101.0,20230418.0,20200911,20230421,EXP,,US-GILEAD-2020-0494621,GILEAD,,,,A,M,Y,68.027,KG,20230421.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;Foot fracture;Fractured coccyx;Osteoporosis;Pain;Rib fracture;Spinal compression fracture,182565703.0,OT,,,182565703.0,1.0,2004.0,201210.0,,,182565703.0,1.0,HIV infection
18257450,182574503,3,F,20130101.0,20230428.0,20200911,20230504,EXP,,US-GILEAD-2020-0494599,GILEAD,,,,A,F,Y,147.39,KG,20230504.0,,LW,US,US,SUSTIVA,Emotional distress;End stage renal disease;Pain,182574503.0,OT,,,182574503.0,1.0,2006.0,2018.0,,,182574503.0,1.0,HIV infection
18261156,182611562,2,F,2020.0,20200925.0,20200914,20201003,EXP,,FR-AUROBINDO-AUR-APL-2020-047348,AUROBINDO,,64.0,YR,,M,Y,,,20201003.0,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome,182611562.0,OT,,,182611562.0,1.0,20110323.0,20200823.0,,,182611562.0,1.0,HIV infection
18261233,182612331,1,I,,20200831.0,20200914,20200914,EXP,,UG-CIPLA LTD.-2020UG06362,CIPLA,"KIGGUNDU R, RHEIN J, MEYA DB, BOULWARE DR, BAHR NC.. UNMASKING CRYPTOCOCCAL MENINGITIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PREGNANCY INDUCED BY HIV ANTIRETROVIRAL THERAPY WITH POSTPARTUM. MEDICAL MYCOLOGY CASE REPORTS. 2014?1 TO 9",,,,,Y,,,20200914.0,,HP,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,182612331.0,OT,,,,,,,,,182612331.0,1.0,HIV infection
18269411,182694113,3,F,20100118.0,20231020.0,20200915,20231023,EXP,,US-GILEAD-2020-0494051,GILEAD,,39.0,YR,A,F,Y,80.272,KG,20231023.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Depression;Emotional distress;End stage renal disease;Hyperkalaemia;Hypertension;Pain;Pneumonia;Renal failure;Renal impairment;Renal injury;Seizure,182694113.0,OT,,,182694113.0,1.0,200911.0,20180430.0,,,182694113.0,1.0,HIV infection
18269468,182694684,4,F,20050101.0,20231207.0,20200915,20231211,EXP,,US-GILEAD-2020-0494476,GILEAD,,,,A,M,Y,92.517,KG,20231211.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Hyperkalaemia;Hypertension;Loss of personal independence in daily activities;Pain,182694684.0,OT,,,182694684.0,1.0,2001.0,2006.0,,,182694684.0,1.0,HIV infection
18269696,182696963,3,F,2010.0,20210315.0,20200915,20210318,EXP,,US-GILEAD-2020-0494607,GILEAD,,,,A,M,Y,70.3,KG,20210318.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal failure,182696963.0,OT,,,182696963.0,1.0,2001.0,2006.0,,,182696963.0,1.0,HIV infection
18270425,182704252,2,F,,20200921.0,20200915,20200928,EXP,,GB-TEVA-2020-GB-1827332,TEVA,"KEELEY AJ, PARKASH V, TUNBRIDGE A, GREIG J, COLLINI P, MCKANE W, ET AL. ANAKINRA IN THE TREATMENT OF PROTRACTED PARADOXICAL INFLAMMATORY REACTIONS IN HIV?ASSOCIATED TUBERCULOSIS IN THE UNITED KINGDOM: A REPORT OF TWO CASES. INT?J?STD?AIDS 2020?31(8):808?812.",4.0,DEC,A,F,Y,,,20200928.0,,HP,GB,GB,EFAVIRENZ.,Cataract;Inflammation;Osteoporotic fracture;Paradoxical drug reaction;Steroid diabetes;Urinary tract infection,182704252.0,OT,,,,,,,,,182704252.0,1.0,Immune reconstitution inflammatory syndrome associated tuberculosis
18270668,182706682,2,F,2020.0,20200928.0,20200915,20200928,EXP,FR-AFSSAPS-NT20201194,FR-GILEAD-2020-0494882,GILEAD,,64.0,YR,A,M,Y,,,20200928.0,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome,182706682.0,OT,,,182706682.0,1.0,20110323.0,20200823.0,,,182706682.0,1.0,HIV infection
18275338,182753381,1,I,,20200902.0,20200916,20200916,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK181494,GLAXOSMITHKLINE,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916.0,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753381.0,OT,,,,,,,,,182753381.0,1.0,HIV infection
18275339,182753391,1,I,,20200902.0,20200916,20200916,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK181570,GLAXOSMITHKLINE,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916.0,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753391.0,OT,,,,,,,,,182753391.0,1.0,HIV infection
18275340,182753401,1,I,,20200902.0,20200916,20200916,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK181494,VIIV,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916.0,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753401.0,OT,,,,,,,,,182753401.0,1.0,HIV infection
18275341,182753411,1,I,,20200902.0,20200916,20200916,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK181570,VIIV,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916.0,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753411.0,OT,,,,,,,,,182753411.0,1.0,HIV infection
18279239,182792394,4,F,2013.0,20210414.0,20200917,20210416,EXP,,US-GILEAD-2020-0494039,GILEAD,,,,A,M,Y,83.9,KG,20210416.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Pain;Renal failure,182792394.0,OT,,,182792394.0,1.0,2013.0,2019.0,,,182792394.0,1.0,HIV infection
18284305,182843052,2,F,,20200929.0,20200918,20201001,EXP,,ID-GILEAD-2020-0495222,GILEAD,"SUFIAWATI I., MASKOEN A, SOEMANTRI E.. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL DISEASES. 2020;26 (1):165-168. DOI:10.1111/ODI.13403",,,N,F,Y,,,20201001.0,,MD,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Gene mutation,182843052.0,OT,,,,,,,,,182843052.0,1.0,HIV infection
18286631,182866311,1,I,,20200911.0,20200921,20200921,EXP,,FR-HETERO-HET2020FR01042,HETERO,,,,,M,Y,3.2,KG,20200921.0,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,182866311.0,CA,,,182866311.0,1.0,20070403.0,20070521.0,,,182866311.0,1.0,HIV infection
18286798,182867983,3,F,2018.0,20210210.0,20200921,20210224,EXP,,US-GILEAD-2020-0494043,GILEAD,,,,A,M,Y,84.3,KG,20210224.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone disorder;Emotional distress;Osteopenia;Osteoporosis;Pain,182867983.0,OT,,,182867983.0,1.0,2003.0,2007.0,,,182867983.0,1.0,HIV infection
18290835,182908351,1,I,,20200914.0,20200922,20200922,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-048232",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20200922.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,182908351.0,OT,,,,,,,,,182908351.0,1.0,HIV infection
18291577,182915772,2,F,20081201.0,20230321.0,20200921,20230327,EXP,,US-GILEAD-2020-0495218,GILEAD,,52.0,YR,A,M,Y,77.098,KG,20230327.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Gout;Osteoporosis;Pain;Renal disorder,182915772.0,OT,,,182915772.0,1.0,2008.0,201811.0,,,182915772.0,1.0,HIV infection
18296443,182964435,5,F,20070808.0,20210623.0,20200922,20210625,EXP,,US-GILEAD-2020-0495296,GILEAD,,51.0,YR,A,M,Y,63.49,KG,20210625.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Depression;Diarrhoea;Emotional distress;End stage renal disease;Haematuria;Hyperlipidaemia;Hypertension;Hypophosphataemia;Intervertebral disc degeneration;Nephrolithiasis;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal cyst;Renal failure;Renal injury;Skeletal injury;Spinal osteoarthritis;Vertebral foraminal stenosis;Vitamin D deficiency,182964435.0,OT,,,182964435.0,1.0,2001.0,20080508.0,,,182964435.0,1.0,HIV infection
18299725,182997252,2,F,200909.0,20200915.0,20200923,20210112,EXP,,ZA-CIPLA LTD.-2020ZA06612,CIPLA,,,,,,Y,,,20210112.0,,PH,ZA,ZA,EFAVIRENZ.,Diarrhoea;Drug interaction;Drug resistance;Insomnia;Treatment noncompliance;Virologic failure,182997252.0,OT,,,182997252.0,1.0,2007.0,2018.0,,,182997252.0,1.0,HIV infection
18301827,183018272,2,F,,20200929.0,20200923,20201005,EXP,,ID-VIIV HEALTHCARE LIMITED-ID2020GSK184896,VIIV,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL DISEASES. 2020;26(S1):165-168",,,,F,Y,,,20201005.0,,HP,ID,ID,SUSTIVA,Cleft lip and palate;Foetal exposure during pregnancy;Gene mutation;HIV infection;Vertical infection transmission,183018272.0,CA,,,,,,,,,183018272.0,1.0,HIV infection
18301831,183018312,2,F,,20200929.0,20200923,20201005,EXP,,ID-GLAXOSMITHKLINE-ID2020GSK184896,GLAXOSMITHKLINE,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL DISEASES. 2020;26(S1):165-168",,,,F,Y,,,20201005.0,,HP,ID,ID,SUSTIVA,Cleft lip and palate;Foetal exposure during pregnancy;Gene mutation;HIV infection;Vertical infection transmission,183018312.0,CA,,,,,,,,,183018312.0,1.0,HIV infection
18305146,183051462,2,F,2012.0,20200914.0,20200923,20200928,EXP,,AU-VIIV HEALTHCARE LIMITED-US2020GSK186145,VIIV,"RAJAKARUNA GK, ITALIANO CM, JOHN M, NOLAN D. CHOREA ASSOCIATED WITH PERSISTENT LOW?LEVEL VIREMIA IN A PATIENT LIVING WITH HIV: A CASE REPORT. JOURNAL OF VIRUS ERADICATION. 2020?6(1):27?29",,,A,F,Y,,,20200928.0,,HP,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging brain abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,183051462.0,HO,,,183051462.0,2.0,2012.0,,,,183051462.0,1.0,HIV infection
18306235,183062352,2,F,,20230409.0,20200924,20230419,EXP,,CA-TEVA-2020-CA-1830303,TEVA,,54.0,YR,A,M,Y,,,20230419.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Psychiatric decompensation,183062352.0,HO,,,,,,,,,183062352.0,1.0,HIV infection
18306813,183068132,2,F,,20210308.0,20200924,20210316,EXP,,CA-TEVA-2020-CA-1830320,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,183068132.0,OT,,,,,,,,,183068132.0,1.0,HIV infection
18313071,183130711,1,I,200909.0,20200917.0,20200925,20200925,EXP,,ZA-MYLANLABS-2020M1081656,MYLAN,,40.0,YR,,F,Y,,,20200925.0,,HP,ZA,ZA,EFAVIRENZ.,Diarrhoea;Drug resistance;Insomnia;Intentional dose omission;Labelled drug-drug interaction medication error;Pathogen resistance;Virologic failure,183130711.0,OT,,,183130711.0,1.0,2007.0,20091224.0,,,183130711.0,1.0,HIV infection
18314835,183148352,2,F,2020.0,20201006.0,20200926,20201014,EXP,FR-AFSSAPS-NT20201194,FR-TEVA-2020-FR-1830959,TEVA,,64.0,YR,A,M,Y,,,20201014.0,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome,183148352.0,HO,,,183148352.0,1.0,20110323.0,20200823.0,,,183148352.0,1.0,HIV infection
18320424,183204242,2,F,,20200915.0,20200929,20210112,EXP,,IN-CIPLA LTD.-2020IN06604,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20210112.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183204242.0,OT,,,,,,,,,183204242.0,1.0,HIV infection
18320586,183205862,2,F,,20200915.0,20200929,20210112,EXP,,IN-CIPLA LTD.-2020IN06851,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20210112.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183205862.0,OT,,,,,,,,,183205862.0,1.0,HIV infection
18320592,183205922,2,F,,20200915.0,20200929,20210112,EXP,,IN-CIPLA LTD.-2020IN06850,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20210112.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183205922.0,OT,,,,,,,,,183205922.0,1.0,HIV infection
18320599,183205992,2,F,,20200915.0,20200929,20210112,EXP,,IN-CIPLA LTD.-2020IN06844,CIPLA,"SUDHARSHAN S, KUMAR KP, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 10",,,,,Y,,,20210112.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183205992.0,OT,,,,,,,,,183205992.0,1.0,HIV infection
18320601,183206012,2,F,,20200915.0,20200929,20210112,EXP,,IN-CIPLA LTD.-2020IN06847,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20210112.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183206012.0,OT,,,,,,,,,183206012.0,1.0,HIV infection
18321184,183211841,1,I,,20200921.0,20200928,20200928,EXP,,IN-GILEAD-2020-0495952,GILEAD,"RAJNISH R.K., RATHOD P.M., AGGARWAL S., AGARWAL S., KUMAR P.. BILATERAL SUB?TROCHANTERIC FEMUR FRAGILITY FRACTURES IN A PATIENT ON ANTIRETROVIRAL THERAPY: A CASE BASED DISCUSSION AND REVIEW OF LITERATURE. INTERNATIONAL JOURNAL OF BURNS + TRAUMA. 2020?10(4):121?126. DOI:2160?2026/IJBT0116707",45.0,YR,A,F,Y,,,20200928.0,,MD,IN,IN,EFAVIRENZ.,Fanconi syndrome acquired;Femur fracture;Renal disorder;Renal failure;Sepsis,183211841.0,HO,,,183211841.0,1.0,201408.0,,,,183211841.0,1.0,HIV infection
18322389,183223891,1,I,2012.0,20200914.0,20200928,20200928,EXP,,AU-GLAXOSMITHKLINE-US2020GSK186145,GLAXOSMITHKLINE,"RAJAKARUNA GK, ITALIANO CM, JOHN M, NOLAN D. CHOREA ASSOCIATED WITH PERSISTENT LOW?LEVEL VIREMIA IN A PATIENT LIVING WITH HIV: A CASE REPORT. JOURNAL OF VIRUS ERADICATION. 2020?6(1):27?29",,,A,F,Y,,,20200928.0,,HP,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging brain abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,183223891.0,OT,,,183223891.0,2.0,2012.0,,,,183223891.0,1.0,HIV infection
18322908,183229081,1,I,,20200914.0,20200928,20200928,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-075452,BRISTOL MYERS SQUIBB,,45.0,YR,,M,Y,,,20200928.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,183229081.0,OT,,,,,,,,,183229081.0,1.0,HIV infection
18322942,183229422,2,F,,20210309.0,20200928,20210311,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-075279,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210311.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Off label use;Prescribed overdose,183229422.0,OT,,,,,,,,,183229422.0,1.0,HIV infection
18323227,183232271,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079912,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232271.0,1.0,HIV infection
18323229,183232291,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079940,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183232291.0,1.0,HIV infection
18323235,183232351,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079925,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232351.0,1.0,HIV infection
18323238,183232381,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079922,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232381.0,1.0,HIV infection
18323239,183232391,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079924,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232391.0,1.0,HIV infection
18323302,183233021,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079921,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233021.0,1.0,HIV infection
18323305,183233051,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079918,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233051.0,1.0,HIV infection
18323307,183233071,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079919,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233071.0,1.0,HIV infection
18323309,183233091,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079923,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233091.0,1.0,HIV infection
18323311,183233111,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079915,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233111.0,1.0,HIV infection
18323313,183233131,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079913,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233131.0,1.0,HIV infection
18323323,183233231,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079920,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233231.0,1.0,HIV infection
18323338,183233381,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079916,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233381.0,1.0,HIV infection
18323340,183233401,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079917,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233401.0,1.0,HIV infection
18323343,183233431,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079914,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233431.0,1.0,HIV infection
18324197,183241971,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079958,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183241971.0,1.0,HIV infection
18324198,183241981,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079959,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183241981.0,1.0,HIV infection
18324199,183241991,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079957,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183241991.0,1.0,HIV infection
18324200,183242001,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079943,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242001.0,1.0,HIV infection
18324204,183242041,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079935,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242041.0,1.0,HIV infection
18324206,183242061,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079948,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242061.0,1.0,HIV infection
18324208,183242081,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079953,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242081.0,1.0,HIV infection
18324209,183242091,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079947,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242091.0,1.0,HIV infection
18324211,183242111,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079946,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242111.0,1.0,HIV infection
18324212,183242121,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079934,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242121.0,1.0,HIV infection
18324214,183242141,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079933,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242141.0,1.0,HIV infection
18324216,183242161,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079950,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242161.0,1.0,HIV infection
18324222,183242221,1,I,,20200914.0,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-077120,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",39.0,YR,,M,Y,,,20200928.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183242221.0,OT,,,,,,,,,183242221.0,1.0,HIV infection
18324224,183242241,1,I,,20200914.0,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079529,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",51.0,YR,,M,Y,,,20200928.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183242241.0,OT,,,,,,,,,183242241.0,1.0,HIV infection
18324227,183242271,1,I,,20200914.0,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079530,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",46.0,YR,,M,Y,,,20200928.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183242271.0,OT,,,,,,,,,183242271.0,1.0,HIV infection
18324244,183242441,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079930,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242441.0,1.0,HIV infection
18324245,183242451,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079952,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242451.0,1.0,HIV infection
18324250,183242501,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079926,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242501.0,1.0,HIV infection
18324253,183242531,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079951,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242531.0,1.0,HIV infection
18324255,183242551,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079956,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242551.0,1.0,HIV infection
18324258,183242581,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079941,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242581.0,1.0,HIV infection
18324278,183242781,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079955,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242781.0,1.0,HIV infection
18324280,183242801,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079938,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242801.0,1.0,HIV infection
18324282,183242821,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079932,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242821.0,1.0,HIV infection
18324283,183242831,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079961,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242831.0,1.0,HIV infection
18324284,183242841,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079954,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242841.0,1.0,HIV infection
18324286,183242861,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079960,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242861.0,1.0,HIV infection
18324288,183242881,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-076976,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242881.0,1.0,HIV infection
18324293,183242931,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079937,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242931.0,1.0,HIV infection
18324294,183242941,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079962,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242941.0,1.0,HIV infection
18324296,183242961,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079942,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242961.0,1.0,HIV infection
18324297,183242971,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079944,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242971.0,1.0,HIV infection
18324298,183242981,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079927,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242981.0,1.0,HIV infection
18324300,183243001,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079931,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243001.0,1.0,HIV infection
18324304,183243041,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079929,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243041.0,1.0,HIV infection
18324308,183243081,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079945,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183243081.0,1.0,HIV infection
18324317,183243171,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079949,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183243171.0,1.0,HIV infection
18324318,183243181,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079928,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243181.0,1.0,HIV infection
18324320,183243201,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079936,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243201.0,1.0,HIV infection
18324356,183243561,1,I,,20200914.0,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079939,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929.0,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243561.0,1.0,HIV infection
18326533,183265331,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079971,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265331.0,1.0,HIV infection
18326536,183265361,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079963,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Hypercholesterolaemia,,,,,,,,,,,183265361.0,1.0,HIV infection
18326538,183265381,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079970,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265381.0,1.0,HIV infection
18326548,183265481,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079972,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265481.0,1.0,HIV infection
18326550,183265501,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079969,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265501.0,1.0,HIV infection
18326552,183265521,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079968,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265521.0,1.0,HIV infection
18326557,183265571,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079964,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Hypercholesterolaemia,,,,,,,,,,,183265571.0,1.0,HIV infection
18326558,183265581,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079967,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265581.0,1.0,HIV infection
18327790,183277901,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079965,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Drug interaction,,,,,,,,,,,183277901.0,1.0,HIV infection
18327791,183277911,1,I,,20200914.0,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079966,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930.0,,HP,US,US,EFAVIRENZ.,Drug interaction,,,,,,,,,,,183277911.0,1.0,HIV infection
18332754,183327541,1,I,200909.0,20200917.0,20201001,20201001,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2020-06616,LUPIN,,40.0,YR,,F,Y,,,20201001.0,,HP,ZA,ZA,EFAVIRENZ.,Drug interaction;Drug resistance;Pathogen resistance;Virologic failure,183327541.0,OT,,,183327541.0,1.0,2007.0,20091224.0,,,183327541.0,1.0,Antiretroviral therapy
18336818,183368185,5,F,,20210325.0,20201001,20210330,EXP,,CA-009507513-1902CAN006433,MERCK,,44.0,YR,,M,Y,,,20210330.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,183368185.0,OT,,,,,,,,,183368185.0,1.0,HIV infection
18339119,183391191,1,I,,20200925.0,20201002,20201002,EXP,,ID-MYLANLABS-2020M1083731,MYLAN,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL-DIS 2020;26(1):165-168.",,,,F,Y,,,20201002.0,,HP,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy,183391191.0,CA,,,,,,,,,183391191.0,1.0,HIV infection
18343370,183433701,1,I,,20200922.0,20201005,20201005,EXP,,ZA-CIPLA LTD.-2020ZA07004,CIPLA,,,,,,Y,,,20201005.0,,HP,ZA,ZA,EFAVIRENZ.,Nephropathy,183433701.0,HO,,,,,,,,,183433701.0,1.0,HIV infection
18346421,183464211,1,I,,20160903.0,20201006,20201006,EXP,,GB-AUROBINDO-AUR-APL-2016-11730,AUROBINDO,,25.0,YR,,M,Y,,,20201006.0,,HP,GB,GB,EFAVIRENZ.,"Abdominal pain lower;Abdominal tenderness;Chromaturia;Constipation;Hallucinations, mixed;Pain;Porphyria acute;Vomiting",183464211.0,OT,,,,,,,,,183464211.0,1.0,HIV infection
18347003,183470031,1,I,,20200928.0,20201006,20201006,EXP,,US-AUROBINDO-AUR-APL-2020-050001,AUROBINDO,,25.0,YR,,M,Y,,,20201006.0,,HP,US,US,EFAVIRENZ.,"Hallucination, visual;Psychotic disorder",183470031.0,OT,,,,,,,,,183470031.0,1.0,HIV infection
18348022,183480222,2,F,,20201016.0,20201006,20201029,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2020028268,MACLEODS,,,,,,Y,,,20201029.0,,CN,IN,IN,EFAVIRENZ.,Anaemia;Fanconi syndrome acquired;Femur fracture;General physical health deterioration;Renal failure;Sepsis,183480222.0,OT,,,183480222.0,1.0,201408.0,2019.0,,,183480222.0,1.0,Antiretroviral therapy
18349036,183490366,6,F,,20220601.0,20201006,20220608,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK189276,GLAXOSMITHKLINE,,,,,,Y,,,20220608.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490366.0,OT,,,,,,,,,183490366.0,1.0,HIV infection
18349038,183490385,5,F,,20220323.0,20201006,20220330,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK189276,VIIV,,54.0,YR,,M,Y,,,20220330.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490385.0,OT,,,,,,,,,183490385.0,1.0,HIV infection
18352863,183528631,1,I,,20200928.0,20201007,20201007,EXP,,US-AUROBINDO-AUR-APL-2020-050201,AUROBINDO,,,,,F,Y,,,20201007.0,,MD,US,US,EFAVIRENZ.,Autoimmune hepatitis;Toxicity to various agents,183528631.0,OT,,,,,,,,,183528631.0,1.0,HIV infection
18357718,183577184,4,F,,20210825.0,20201008,20210904,EXP,,ES-AUROBINDO-AUR-APL-2020-051068,AUROBINDO,,47.0,YR,,M,Y,,,20210904.0,,HP,ES,ES,EFAVIRENZ.,"Bipolar disorder;Cyclothymic disorder;Delirium;Hallucination, auditory;Insomnia;Mania;Persecutory delusion;Psychiatric decompensation;Psychotic disorder;Psychotic symptom;Substance-induced psychotic disorder;Suicidal ideation",183577184.0,OT,,,,,,,,,183577184.0,1.0,HIV infection
18358719,183587191,1,I,,20200925.0,20201008,20201008,EXP,,ID-LUPIN PHARMACEUTICALS INC.-2020-06920,LUPIN,,,,,F,Y,,,20201008.0,,HP,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy,183587191.0,OT,,,,,,,,,183587191.0,1.0,HIV infection
18376368,183763682,2,F,201707.0,20200930.0,20201013,20210112,EXP,,IN-CIPLA LTD.-2020IN07156,CIPLA,"PRABHU V, COELHO S, ACHAPPA B, BALIGA S, SHARON L, SHAH J.. ROLE OF FLUORESCENCE IN SITU HYBRIDIZATION IN DETECTING MYCOBACTERIUM AVIUM COMPLEX PRESENTING AS FEVER IN TREATMENT FAILURE HIV. J CLIN TUBERC OTHER MYCOBACT DIS. 2020?21 (100188):1 TO 3",,,,,Y,,,20210112.0,,HP,IN,IN,EFAVIRENZ.,Fatigue;Mycobacterium avium complex infection;Somnolence;Treatment failure;Treatment noncompliance,183763682.0,HO,,,,,,,,,183763682.0,1.0,HIV infection
18385419,183854192,2,F,,20230516.0,20201015,20230518,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-076820,BRISTOL MYERS SQUIBB,,55.0,YR,A,M,Y,,,20230518.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain,,,,,183854192.0,1.0,20040315.0,2008.0,1388.0,DAY,183854192.0,1.0,HIV infection
18387262,183872625,5,F,20160401.0,20230613.0,20201015,20230616,EXP,,US-GILEAD-2020-0498473,GILEAD,,47.0,YR,A,M,Y,,,20230616.0,,LW,US,US,SUSTIVA,Bone density decreased;Osteopenia;Osteoporosis;Spinal disorder;Spinal stenosis;Tooth loss,183872625.0,OT,,,183872625.0,1.0,2006.0,2016.0,,,183872625.0,1.0,HIV infection
18388864,183888643,3,F,201412.0,20210617.0,20201015,20210625,EXP,,US-GILEAD-2020-0498938,GILEAD,,49.0,YR,A,F,Y,58.97,KG,20210625.0,,LW,US,US,SUSTIVA,Asthenia;Emotional distress;End stage renal disease;Nausea;Pain;Renal failure,183888643.0,OT,,,183888643.0,1.0,201611.0,202001.0,,,183888643.0,1.0,HIV infection
18401629,184016294,4,F,201905.0,20210623.0,20201019,20210628,EXP,,US-GILEAD-2020-0499532,GILEAD,,57.0,YR,A,M,Y,93.88,KG,20210628.0,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Mobility decreased;Osteonecrosis;Renal injury;Skeletal injury;Tooth injury,184016294.0,HO,,,184016294.0,2.0,20040101.0,20060801.0,,,184016294.0,1.0,HIV infection
18405930,184059304,4,F,,20211108.0,20201020,20211115,EXP,,ES-MYLANLABS-2020M1087834,MYLAN,"Basterreche N, Arrue A, Arnaiz A, Olivas O, Zumarraga M.. Repeat episode of late-onset psychosis associated with efavirenz.. Actas espanolas de psiquiatria.. 2020;48(4):181-183",47.0,YR,,M,Y,,,20211115.0,,HP,ES,ES,EFAVIRENZ,"Atrophy;Bipolar disorder;Central nervous system lesion;Delirium;Delusional perception;Hallucination, auditory;Insomnia;Mania;Psychiatric decompensation;Psychotic behaviour;Psychotic disorder;Psychotic symptom;Substance-induced psychotic disorder;Suicidal ideation",184059304.0,HO,,,184059304.0,1.0,,,4.0,YR,184059304.0,1.0,HIV infection
18412888,184128881,1,I,201408.0,20201012.0,20201022,20201022,EXP,,IN-CIPLA LTD.-2020IN07585,CIPLA,,,,,,Y,,,20201022.0,,HP,IN,IN,EFAVIRENZ.,Anaemia;Fanconi syndrome;Femur fracture;Pathological fracture,184128881.0,HO,,,184128881.0,1.0,201408.0,201408.0,,,184128881.0,1.0,HIV infection
18420531,184205314,4,F,2007.0,20210509.0,20201023,20210517,EXP,,US-GILEAD-2020-0499315,GILEAD,,64.0,YR,A,M,Y,113.38,KG,20210517.0,,LW,US,US,SUSTIVA,Acute kidney injury;Back pain;Bone density decreased;Chronic kidney disease;Condition aggravated;Decreased activity;Depression;Emotional distress;Obesity;Pain;Post-traumatic stress disorder;Renal failure;Renal impairment;Sleep apnoea syndrome;Weight increased,184205314.0,OT,,,184205314.0,1.0,2003.0,201205.0,,,184205314.0,1.0,HIV infection
18422750,184227501,1,I,,20201013.0,20201023,20201023,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK205570,VIIV,"WEN Y, WANG MC, ZHOU Y, LIN XY, HOU G, YIN Y. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH PNEUMOCYSTIS PNEUMONIA IN A PATIENT WITH AIDS. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 2020;48(8)",21.0,YR,,M,Y,,,20201023.0,,HP,CN,CN,EFAVIRENZ.,Chills;Condition aggravated;Disease recurrence;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Lung consolidation;Nausea;Pneumocystis jirovecii pneumonia;Pneumonitis;Pyrexia;Respiratory failure;White blood cell count increased,184227501.0,OT,,,,,,,,,184227501.0,1.0,HIV infection
18422751,184227511,1,I,,20201013.0,20201023,20201023,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK205570,GLAXOSMITHKLINE,"WEN Y, WANG MC, ZHOU Y, LIN XY, HOU G, YIN Y. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH PNEUMOCYSTIS PNEUMONIA IN A PATIENT WITH AIDS. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 2020;48(8)",21.0,YR,,M,Y,,,20201023.0,,HP,CN,CN,EFAVIRENZ.,Chills;Condition aggravated;Disease recurrence;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Lung consolidation;Nausea;Pneumocystis jirovecii pneumonia;Pneumonitis;Pyrexia;Respiratory failure;White blood cell count increased,184227511.0,OT,,,,,,,,,184227511.0,1.0,HIV infection
18428002,184280021,1,I,,20201019.0,20201026,20201026,EXP,,CN-GILEAD-2020-0500441,GILEAD,"WEN Y, WANG MC, ZHOU Y, LIN XY, HOU G, YIN Y. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH PNEUMOCYSTIS PNEUMONIA IN A PATIENT WITH AIDS. J INT MED RES.. 2020;48(8):1-6. DOI:10.1177/0300060520946544",21.0,YR,A,M,Y,,,20201026.0,,MD,CN,CN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,184280021.0,OT,,,,,,,,,184280021.0,1.0,HIV infection
18428121,184281212,2,F,,20201020.0,20201026,20201124,EXP,,IN-MYLANLABS-2020M1089993,MYLAN,,45.0,YR,,F,Y,,,20201124.0,,HP,IN,IN,EFAVIRENZ.,Anaemia;Fanconi syndrome acquired;Femur fracture;Renal disorder;Renal failure,184281212.0,OT,,,184281212.0,1.0,201404.0,201408.0,,,184281212.0,1.0,HIV infection
18428348,184283481,1,I,,20201019.0,20201026,20201026,EXP,,IN-GILEAD-2020-0500543,GILEAD,"DALAL P, ANOT K, MONICA G, D?CRUZ S. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. J NEUROVIROL.. 2020;26(5):793-796. DOI:10.1007/S13365-020-00879-4",35.0,YR,A,M,Y,,,20201026.0,,MD,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,184283481.0,HO,,,,,,,,,184283481.0,1.0,HIV infection
18429140,184291401,1,I,,20201016.0,20201027,20201027,EXP,,IN-HETERO-HET2020IN01158,HETERO,,45.0,YR,,F,Y,,,20201027.0,,HP,IN,IN,EFAVIRENZ.,Fanconi syndrome acquired;Femur fracture;Renal failure,184291401.0,DE,,,184291401.0,1.0,201408.0,2019.0,,,184291401.0,1.0,Antiretroviral therapy
18429327,184293271,1,I,,20201017.0,20201027,20201027,EXP,,ES-AUROBINDO-AUR-APL-2020-053584,AUROBINDO,,52.0,YR,,M,Y,,,20201027.0,,HP,ES,ES,EFAVIRENZ.,"Atrophy;Central nervous system lesion;Delusional perception;Hallucination, auditory;Insomnia;Mania;Psychotic behaviour;Suicidal ideation",184293271.0,HO,,,,,,,,,184293271.0,1.0,HIV infection
18430490,184304903,3,F,2012.0,20210617.0,20201027,20210624,EXP,,US-GILEAD-2020-0501280,GILEAD,,,,A,M,Y,80.73,KG,20210622.0,,CN,US,US,SUSTIVA,Anxiety;Bone loss;Depression;Osteonecrosis,184304903.0,OT,,,184304903.0,1.0,200408.0,201904.0,,,184304903.0,1.0,HIV infection
18433520,184335201,1,I,2017.0,20201014.0,20201027,20201027,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK208216,GLAXOSMITHKLINE,"PRABHU V, COELHO S, ACHAPPA B, BALIGA S, SHARON L, SHAH J. ROLE OF FLUORESCENCE IN SITU HYBRIDIZATION IN DETECTING MYCOBACTERIUM AVIUM COMPLEX PRESENTING AS FEVER IN TREATMENT FAILURE HIV. JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES. 2020;21",49.0,YR,,M,Y,,,20201027.0,,HP,IN,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;CD4 lymphocytes decreased;Candida infection;Chills;Dysphagia;Erosive duodenitis;Gastrooesophageal reflux disease;Granulomatous liver disease;Granulomatous lymphadenitis;HIV infection;Hepatomegaly;Hypochromic anaemia;Lymphadenitis bacterial;Lymphadenopathy;Lymphocytosis;Mycobacterium avium complex infection;Oesophageal ulcer;Oesophagitis;Oropharyngeal pain;Pharyngeal ulceration;Pyrexia;Splenomegaly;Thrombocytopenia;Treatment noncompliance;Vomiting,184335201.0,HO,,,184335201.0,1.0,,2017.0,,,184335201.0,1.0,HIV infection
18433646,184336461,1,I,2017.0,20201014.0,20201027,20201027,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK208216,VIIV,"PRABHU V, COELHO S, ACHAPPA B, BALIGA S, SHARON L, SHAH J. ROLE OF FLUORESCENCE IN SITU HYBRIDIZATION IN DETECTING MYCOBACTERIUM AVIUM COMPLEX PRESENTING AS FEVER IN TREATMENT FAILURE HIV. JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES. 2020;21",49.0,YR,,M,Y,,,20201027.0,,HP,IN,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;CD4 lymphocytes decreased;Candida infection;Chills;Dysphagia;Erosive duodenitis;Gastrooesophageal reflux disease;Granulomatous liver disease;Granulomatous lymphadenitis;HIV infection;Hepatomegaly;Hypochromic anaemia;Lymphadenitis bacterial;Lymphadenopathy;Lymphocytosis;Mycobacterium avium complex infection;Oesophageal ulcer;Oesophagitis;Oropharyngeal pain;Pharyngeal ulceration;Pyrexia;Splenomegaly;Thrombocytopenia;Treatment noncompliance;Vomiting,184336461.0,HO,,,184336461.0,1.0,,2017.0,,,184336461.0,1.0,HIV infection
18435228,184352281,1,I,199809.0,20201022.0,20201028,20201028,EXP,,IT-ROCHE-2701861,ROCHE,"ORTU F, WEIMER LE, FLORIDIA M, MANCONI PE. RALTEGAVIR, TENOFOVIR, AND EMTRICITABINE IN AN HIV INFECTED PATIENT WITH HCV CHRONIC HEPATITIS, NNRTI INTOLERANCE AND PROTEASE INHIBITORS INDUCED SEVERE LIVER TOXICITY. EUROPEAN JOURNAL OF MEDICAL RESEARCH. 2010;15:81-83.",,,A,F,Y,,,20201028.0,,HP,IT,IT,EFAVIRENZ.,Hepatotoxicity;Nausea;Nephrolithiasis;Neurological symptom;Rash;Vomiting,184352281.0,OT,,,184352281.0,5.0,200210.0,,,,184352281.0,1.0,Antiretroviral therapy
18435451,184354511,1,I,,20201019.0,20201028,20201028,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP012702,STRIDES,"SEN P, SUDHARSHAN S, BANERJEE A, DHAMI A.. CLINICAL AND ELECTROPHYSIOLOGICAL CHARACTERISTICS OF EFAVIRENZ-INDUCED MACULAR TOXICITY.. GMS OPHTHAMOL CASES.. 2020;10:2193-1496",54.0,YR,,F,Y,,,20201028.0,,MD,IN,IN,EFAVIRENZ.,Vision blurred;Visual field defect,184354511.0,OT,,,,,,,,,184354511.0,1.0,HIV infection
18441452,184414523,3,F,20171006.0,20211112.0,20201029,20211201,EXP,,US-GILEAD-2020-0501284,GILEAD,,61.0,YR,A,F,Y,,,20211201.0,,LW,US,US,SUSTIVA,Ankle fracture;Chronic kidney disease;Multiple fractures;Osteopenia,184414523.0,OT,,,184414523.0,1.0,20061231.0,20180101.0,4019.0,DAY,184414523.0,1.0,HIV infection
18442863,184428634,4,F,20150623.0,20211108.0,20201030,20211122,EXP,,US-GILEAD-2020-0501285,GILEAD,,67.0,YR,E,F,Y,,,20211121.0,,LW,US,US,SUSTIVA,Acute kidney injury;Bone loss;Chronic kidney disease;Osteoarthritis;Tooth loss,184428634.0,OT,,,184428634.0,1.0,20150206.0,20161018.0,620.0,DAY,184428634.0,1.0,HIV infection
18444919,184449191,1,I,,20201016.0,20201030,20201030,EXP,,CL-GLAXOSMITHKLINE-CL2020GSK215217,GLAXOSMITHKLINE,,,,,,Y,,,20201030.0,,HP,CL,CL,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,184449191.0,OT,,,,,,,,,184449191.0,1.0,HIV infection
18444965,184449651,1,I,,20201016.0,20201030,20201030,EXP,,CL-VIIV HEALTHCARE LIMITED-CL2020GSK215217,VIIV,,,,,,Y,,,20201030.0,,HP,CL,CL,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,184449651.0,OT,,,,,,,,,184449651.0,1.0,HIV infection
18445873,184458731,1,I,,20201022.0,20201030,20201030,EXP,,IN-MYLANLABS-2020M1090972,MYLAN,,35.0,YR,,M,Y,,,20201030.0,,MD,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse;Paraparesis,184458731.0,HO,,,,,,,,,184458731.0,1.0,HIV infection
18449904,184499042,2,F,,20201125.0,20201102,20201208,EXP,,IN-LUPIN PHARMACEUTICALS INC.-2020-08008,LUPIN,,45.0,YR,,F,Y,,,20201208.0,,HP,IN,IN,EFAVIRENZ.,Fanconi syndrome acquired;Femur fracture;General physical health deterioration;Renal disorder;Renal failure,184499042.0,DE,,,184499042.0,1.0,201404.0,201408.0,,,184499042.0,1.0,HIV infection
18452184,184521841,1,I,,20201019.0,20201102,20201102,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK209280,GLAXOSMITHKLINE,"DALAL P, ANOT K, MONICA G, D^CRUZ S. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. JOURNAL OF NEUROVIROLOGY. 2020;26 (5):793-796",35.0,YR,,M,Y,,,20201102.0,,MD,IN,IN,EFAVIRENZ.,Abdominal discomfort;Areflexia;Central nervous system immune reconstitution inflammatory response;Hyperintensity in brain deep nuclei;Hypoaesthesia;Hypotonia;Muscular weakness;Myelitis transverse;Paraparesis;Sensory disturbance;Spinal pain;Urinary retention,184521841.0,HO,,,,,,,,,184521841.0,1.0,HIV infection
18452546,184525461,1,I,,20201019.0,20201102,20201102,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK209280,VIIV,"DALAL P, ANOT K, MONICA G, D^CRUZ S. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. JOURNAL OF NEUROVIROLOGY. 2020;26 (5):793-796",35.0,YR,,M,Y,,,20201102.0,,MD,IN,IN,EFAVIRENZ.,Abdominal discomfort;Areflexia;Central nervous system immune reconstitution inflammatory response;Hyperintensity in brain deep nuclei;Hypoaesthesia;Hypotonia;Muscular weakness;Myelitis transverse;Paraparesis;Sensory disturbance;Spinal pain;Urinary retention,184525461.0,HO,,,,,,,,,184525461.0,1.0,HIV infection
18452791,184527914,4,F,,20201120.0,20201102,20201202,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-089390,BRISTOL MYERS SQUIBB,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV: DATA FROM A LONDON COHORT. JOURNAL OF VIRUS ERADICATION. 2019;5(1):44-6",28.0,YR,,F,Y,,,20201202.0,,HP,GB,GB,EFAVIRENZ.,Off label use;Ovarian failure,184527914.0,OT,,,184527914.0,1.0,1997.0,,,,184527914.0,1.0,Antiretroviral therapy
18456605,184566052,2,F,,20201023.0,20201103,20201106,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP013136,STRIDES,"RAJNISH RK, RATHOD PM, AGGARWAL S, AGARWAL S, KUMAR P.. BILATERAL SUB-TROCHANTERIC FEMUR FRAGILITY FRACTURES IN A PATIENT ON ANTIRETROVIRAL THERAPY: A CASE BASED DISCUSSION AND REVIEW OF LITERATURE. INTERNATIONAL JOURNAL OF BURNS AND TRAUMA. 2020;10(4):121-126",,,A,M,Y,,,20201106.0,,HP,IN,IN,EFAVIRENZ.,Arthralgia;Fall;Fanconi syndrome;Femur fracture;Osteoporosis;Renal failure;Tenderness;Weight bearing difficulty,184566052.0,HO,,,184566052.0,1.0,201404.0,201408.0,,,184566052.0,1.0,HIV infection
18457282,184572821,1,I,,20201029.0,20201103,20201103,EXP,,CA-009507513-2010CAN012011,MERCK,,54.0,YR,,M,Y,,,20201103.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,184572821.0,OT,,,,,,,,,184572821.0,1.0,HIV infection
18459805,184598051,1,I,,20201029.0,20201103,20201103,EXP,,CA-009507513-2010CAN012169,MERCK,,54.0,YR,,M,Y,,,20201103.0,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,184598051.0,OT,,,,,,,,,184598051.0,1.0,HIV infection
18462253,184622531,1,I,,20201022.0,20201104,20201104,EXP,,IN-LUPIN PHARMACEUTICALS INC.-2020-08139,LUPIN,,35.0,YR,,M,Y,,,20201104.0,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse;Paraparesis,184622531.0,OT,,,,,,,,,184622531.0,1.0,HIV infection
18462532,184625321,1,I,,20201027.0,20201104,20201104,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP013171,STRIDES,"DALAL P, ANOT K, MONICA G, D^CRUZ S.. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY.. JOURNAL OF NEUROVIROLOGY.. 2020;26 (5):793-796",35.0,YR,,M,Y,,,20201104.0,,HP,IN,IN,EFAVIRENZ.,Areflexia;Hypoaesthesia;Hypotonia;Immune reconstitution inflammatory syndrome;Muscle tightness;Muscular weakness;Myelitis transverse;Paraesthesia;Paraparesis;Urinary retention,184625321.0,HO,,,,,,,,,184625321.0,1.0,HIV infection
18467979,184679791,1,I,,20201028.0,20201105,20201105,EXP,,CM-MYLANLABS-2020M1092284,MYLAN,"FOKAM J, TAKOU D, SEMENGUE ENJ, TETO G, BELOUMOU G, DAMBAYA B, ET AL. FIRST CASE OF DOLUTEGRAVIR AND DARUNAVIR/R MULTI DRUG-RESISTANT HIV-1 IN CAMEROON FOLLOWING EXPOSURE TO RALTEGRAVIR: LESSONS AND IMPLICATIONS IN THE ERA OF TRANSITION TO DOLUTEGRAVIR-BASED REGIMENS. ANTIMICROB-RESIST-INFECT-CONTROL 2020;9(1):143.",,,A,M,Y,,,20201105.0,,HP,CM,CM,EFAVIRENZ.,Drug resistance,184679791.0,OT,,,184679791.0,1.0,201711.0,201905.0,,,184679791.0,1.0,HIV infection
18468672,184686722,2,F,20180822.0,20201101.0,20201105,20210302,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2020GSK216742,VIIV,,41.0,YR,,F,Y,,,20210302.0,,MD,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,,,,,184686722.0,1.0,20171204.0,20180814.0,,,184686722.0,1.0,HIV infection
18473058,184730581,1,I,,20201030.0,20201106,20201106,EXP,,GB-MYLANLABS-2020M1092865,MYLAN,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV: DATA FROM A LONDON COHORT. J-VIRUS-ERAD 2019;5(1):44-46.",,,,F,Y,,,20201106.0,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Infertility;Ovarian failure,184730581.0,OT,,,184730581.0,1.0,1997.0,,,,184730581.0,1.0,Perinatal HIV infection
18474173,184741731,1,I,199809.0,20201102.0,20201106,20201106,EXP,,IT-MYLANLABS-2020M1093096,MYLAN,"ORTU F, WEIMER LE, FLORIDIA M, MANCONI PE.. RALTEGAVIR, TENOFOVIR, AND EMTRICITABINE IN AN HIV INFECTED PATIENT WITH HCV CHRONIC HEPATITIS, NNRTI INTOLERANCE AND PROTEASE INHIBITORS INDUCED SEVERE LIVER TOXICITY.. EUR. J. MED. RES.. 2010;15:81-3",,,A,F,Y,,,20201106.0,,HP,IT,IT,EFAVIRENZ.,Hepatotoxicity;Nausea;Nephrolithiasis;Neurological symptom;Rash;Vomiting,184741731.0,OT,,,184741731.0,1.0,199806.0,,,,184741731.0,1.0,Antiretroviral therapy
18486507,184865071,1,I,2019.0,20201101.0,20201110,20201110,EXP,,PT-GILEAD-2020-0503472,GILEAD,,29.0,YR,A,M,Y,,,20201110.0,,MD,PT,PT,EFAVIRENZ.,Acne;Aggression;Anaemia;Anxiety;Dizziness;Dyslipidaemia;Gynaecomastia;Helicobacter gastritis;Hepatocellular injury;Hypersomnia;Hypertension;Insomnia;Polydipsia;Polyuria;Sleep disorder;Treatment noncompliance;Upper gastrointestinal haemorrhage,184865071.0,OT,,,184865071.0,1.0,202006.0,202006.0,,,184865071.0,1.0,HIV infection
18487660,184876601,1,I,,20201028.0,20201111,20201111,EXP,,CM-LUPIN PHARMACEUTICALS INC.-2020-08527,LUPIN,,65.0,YR,,M,Y,,,20201111.0,,HP,CM,CM,EFAVIRENZ.,Drug resistance,184876601.0,OT,,,184876601.0,1.0,200608.0,200708.0,,,184876601.0,1.0,HIV infection
18489274,184892741,1,I,,20201103.0,20201111,20201111,EXP,,IN-AUROBINDO-AUR-APL-2020-055875,AUROBINDO,,35.0,YR,,M,Y,,,20201111.0,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse;Paraparesis,184892741.0,OT,,,,,,,,,184892741.0,1.0,HIV infection
18498108,184981081,1,I,,20201102.0,20201112,20201112,EXP,,IN-HETERO-HET2020IN01233,HETERO,"DALAL P, ANOT K, MONICA G, D^CRUZ S.. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY.. J-NEUROVIROL. 2020;26(5):793-796",35.0,YR,,M,Y,,,20201113.0,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse,184981081.0,OT,,,,,,,,,184981081.0,1.0,HIV infection
18503485,185034852,2,F,,20201130.0,20201114,20201211,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-08818,LUPIN,,27.0,YR,,F,Y,,,20201211.0,,HP,US,US,EFAVIRENZ.,Ectopic pregnancy;Exposure during pregnancy,185034852.0,OT,,,,,,,,,185034852.0,1.0,HIV infection
18503545,185035451,1,I,,20201103.0,20201114,20201114,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-08816,LUPIN,,25.0,YR,,F,Y,,,20201114.0,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,185035451.0,OT,,,,,,,,,185035451.0,1.0,HIV infection
18503570,185035701,1,I,,20201103.0,20201114,20201114,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-08823,LUPIN,,23.0,YR,,F,Y,,,20201114.0,,HP,US,US,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,185035701.0,OT,,,,,,,,,185035701.0,1.0,HIV infection
18504764,185047641,1,I,,20201103.0,20201115,20201115,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-09033,LUPIN,,,,N,,Y,2.1,KG,20201115.0,,HP,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby;Premature baby,185047641.0,OT,,,,,,,,,185047641.0,1.0,HIV infection
18504886,185048863,3,F,,20201203.0,20201115,20201214,EXP,,GB-AUROBINDO-AUR-APL-2020-056000,AUROBINDO,,28.0,YR,,F,Y,,,20201214.0,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Off label use;Ovarian disorder;Ovarian failure;Portal hypertension;Treatment noncompliance,185048863.0,OT,,,185048863.0,1.0,1997.0,,,,185048863.0,1.0,Antiretroviral therapy
18509237,185092371,1,I,201909.0,20201104.0,20201117,20201117,EXP,,CN-CIPLA LTD.-2020CN08704,CIPLA,,,,,,Y,,,20201117.0,,HP,CN,CN,EFAVIRENZ.,Dermatitis allergic,185092371.0,OT,,,185092371.0,1.0,20190915.0,201909.0,,,185092371.0,1.0,HIV infection
18517808,185178084,4,F,20120120.0,20230720.0,20201118,20230726,PER,,US-GILEAD-2020-0503385,GILEAD,,38.0,YR,A,M,Y,77.098,KG,20230726.0,,LW,US,US,SUSTIVA,Blood creatinine increased;Nephropathy;Renal cyst;Renal failure,185178084.0,OT,,,185178084.0,1.0,2004.0,2016.0,1945.0,DAY,185178084.0,1.0,HIV infection
18523637,185236371,1,I,,20201113.0,20201119,20201119,EXP,,CN-GILEAD-2020-0504783,GILEAD,,49.0,YR,A,F,Y,50.0,KG,20201119.0,,MD,CN,CN,EFAVIRENZ.,Hepatic function abnormal,185236371.0,HO,,,185236371.0,1.0,20200623.0,20200628.0,,,185236371.0,1.0,HIV infection
18531891,185318911,1,I,20200527.0,20201113.0,20201123,20201123,EXP,,CN-009507513-2011CHN009941,MERCK,,49.0,YR,,F,Y,50.0,KG,20201123.0,,HP,CN,CN,EFAVIRENZ.,Hepatic function abnormal,185318911.0,HO,,,185318911.0,1.0,20200602.0,20200623.0,,,185318911.0,1.0,HIV-associated neurocognitive disorder
18534358,185343582,2,F,,20201124.0,20201123,20201201,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020226365,VIIV,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV. DATA FROM A LONDON COHORT. J-VIRUS-ERAD. 2019;5(1):44-46",,,C,F,Y,,,20201201.0,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Ovarian failure;Portal hypertension;Treatment noncompliance,185343582.0,OT,,,185343582.0,1.0,1997.0,,,,185343582.0,1.0,HIV infection
18534361,185343612,2,F,,20201124.0,20201123,20201201,EXP,,GB-GLAXOSMITHKLINE-GB2020226365,GLAXOSMITHKLINE,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV. DATA FROM A LONDON COHORT. J-VIRUS-ERAD. 2019;5(1):44-46",,,C,F,Y,,,20201201.0,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Ovarian failure;Portal hypertension;Treatment noncompliance,185343612.0,OT,,,185343612.0,1.0,1997.0,,,,185343612.0,1.0,HIV infection
18537338,185373382,2,F,,20201120.0,20201124,20201130,EXP,,GB-AUROBINDO-AUR-APL-2020-057584,AUROBINDO,,,,C,F,Y,,,20201130.0,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Ovarian failure;Portal hypertension;Treatment noncompliance,185373382.0,OT,,,185373382.0,1.0,1997.0,,,,185373382.0,1.0,HIV infection
18552722,185527221,1,I,,20201116.0,20201127,20201127,EXP,,CA-JNJFOC-20201134794,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20201127.0,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,185527221.0,OT,,,,,,,,,185527221.0,1.0,HIV infection
18553691,185536914,4,F,20130725.0,20220406.0,20201127,20220408,EXP,,US-GILEAD-2020-0505720,GILEAD,,54.0,YR,A,F,Y,,,20220408.0,,LW,US,US,SUSTIVA,Anaemia;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;End stage renal disease;Glomerular filtration rate increased;Loss of personal independence in daily activities;Muscular weakness;Pain;Protein total abnormal;Protein total increased;Renal failure;Tooth loss,185536914.0,OT,,,185536914.0,1.0,20090701.0,20111106.0,858.0,DAY,185536914.0,1.0,HIV infection
18559950,185599501,1,I,,20201116.0,20201130,20201130,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-101487,BRISTOL MYERS SQUIBB,"NDERITU P, RIGA P, MANN S, GARNAVOU-XIROU C, ELEFTHERIADIS H. DIDANOSINE-ASSOCIATED RETINAL TOXICITY (DART) AMONGST HIV-POSITIVE PATIENTS: A CASE SERIES AND LITERATURE REVIEW. COMPREHENSIVE CLINICAL MEDICINE. 2020",73.0,YR,,F,Y,,,20201130.0,,HP,GB,GB,EFAVIRENZ.,Retinal toxicity,185599501.0,OT,,,185599501.0,1.0,2003.0,2007.0,,,185599501.0,1.0,HIV infection
18564882,185648822,2,F,20110101.0,20230605.0,20201201,20230608,EXP,,US-GILEAD-2020-0503846,GILEAD,,,,A,M,Y,54.422,KG,20230608.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;Hyperkalaemia;Hypertension;Pain;Renal tubular acidosis,185648822.0,OT,,,185648822.0,1.0,2004.0,2017.0,,,185648822.0,1.0,HIV infection
18569619,185696192,2,F,,20201130.0,20201202,20210104,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-08814,LUPIN,,29.0,YR,,F,Y,,,20210104.0,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy,,,,,,,,,,,185696192.0,1.0,HIV infection
18586990,185869901,1,I,,20201130.0,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100353,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",48.0,YR,,F,Y,,,20201207.0,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity;Visual field defect,185869901.0,OT,,,,,,,,,185869901.0,1.0,HIV infection
18586991,185869911,1,I,,20201130.0,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100352,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",33.0,YR,,M,Y,,,20201207.0,,MD,IN,IN,EFAVIRENZ.,Colour vision tests abnormal;Night blindness;Retinal toxicity,185869911.0,OT,,,,,,,,,185869911.0,1.0,HIV infection
18587001,185870011,1,I,,20201130.0,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100355,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",46.0,YR,,M,Y,,,20201207.0,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,185870011.0,OT,,,,,,,,,185870011.0,1.0,HIV infection
18587006,185870061,1,I,,20201130.0,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100354,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",51.0,YR,,,Y,,,20201207.0,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,185870061.0,OT,,,,,,,,,185870061.0,1.0,HIV infection
18587128,185871281,1,I,,20201130.0,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100351,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",39.0,YR,,M,Y,,,20201207.0,,MD,IN,IN,EFAVIRENZ.,Colour vision tests abnormal;Night blindness;Retinal toxicity;Visual field defect,185871281.0,OT,,,,,,,,,185871281.0,1.0,HIV infection
18588008,185880081,1,I,,20201127.0,20201207,20201207,EXP,,US-GLAXOSMITHKLINE-US2020GSK241890,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20201207.0,,HP,US,US,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,185880081.0,OT,,,,,,,,,185880081.0,1.0,HIV infection CDC category B
18588009,185880091,1,I,,20201127.0,20201207,20201207,EXP,,US-VIIV HEALTHCARE LIMITED-US2020GSK241890,VIIV,,63.0,YR,,M,Y,,,20201207.0,,HP,US,US,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,185880091.0,OT,,,,,,,,,185880091.0,1.0,HIV infection CDC category B
18588984,185889841,1,I,,20151210.0,20201208,20201208,PER,,US-009507513-1512USA010646,MERCK,,25.0,YR,,F,Y,,,20201208.0,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,185889841.0,1.0,20001109.0,20000810.0,,,185889841.0,1.0,HIV infection
18601761,186017612,2,F,,20201209.0,20201210,20201221,EXP,,GB-MYLANLABS-2020M1100529,MYLAN,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S.. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV. DATA FROM A LONDON COHORT. J VIRUS ERAD.. 2019;5(1):44-46",28.0,YR,,F,Y,,,20201221.0,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Depression;Lipodystrophy acquired;Off label use;Ovarian disorder;Ovarian failure;Portal hypertension,186017612.0,OT,,,,,,,,,186017612.0,1.0,Antiretroviral therapy
18604399,186043992,2,F,,20201210.0,20201211,20201217,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015243,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",48.0,YR,,F,Y,,,20201217.0,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186043992.0,OT,,,,,,,,,186043992.0,1.0,HIV infection
18604401,186044011,1,I,,20201203.0,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015244,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",51.0,YR,,M,Y,,,20201211.0,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044011.0,OT,,,,,,,,,186044011.0,1.0,HIV infection
18604406,186044061,1,I,,20201203.0,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015241,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",39.0,YR,,M,Y,,,20201211.0,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044061.0,OT,,,,,,,,,186044061.0,1.0,HIV infection
18604407,186044071,1,I,,20201203.0,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015245,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",46.0,YR,,M,Y,,,20201211.0,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044071.0,OT,,,,,,,,,186044071.0,1.0,HIV infection
18604408,186044081,1,I,,20201203.0,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015242,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",33.0,YR,,M,Y,,,20201211.0,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044081.0,OT,,,,,,,,,186044081.0,1.0,HIV infection
18605497,186054972,2,F,20050913.0,20201207.0,20201211,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-A200603214,VIIV,,,,,,Y,,,20220624.0,,MD,JP,JP,EFAVIRENZ,Asthma;Death;Suicide attempt,186054972.0,DE,,,186054972.0,1.0,20050113.0,,,,186054972.0,1.0,HIV infection
18605554,186055542,2,F,20050913.0,20201207.0,20201211,20220628,EXP,,JP-GlaxoSmithKline-B0434971A,GLAXOSMITHKLINE,,,,,,Y,,,20220628.0,,MD,JP,JP,EFAVIRENZ,Asthma;Death;Suicide attempt,186055542.0,HO,,,186055542.0,1.0,20050113.0,,,,186055542.0,1.0,HIV infection
18616933,186169331,1,I,,20201207.0,20201215,20201215,EXP,,IN-AUROBINDO-AUR-APL-2020-061297,AUROBINDO,,48.0,YR,,F,Y,,,20201215.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186169331.0,OT,,,,,,,,,186169331.0,1.0,HIV infection
18617530,186175301,1,I,,20201207.0,20201215,20201215,EXP,,IN-AUROBINDO-AUR-APL-2020-061299,AUROBINDO,,46.0,YR,,M,Y,,,20201215.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186175301.0,OT,,,,,,,,,186175301.0,1.0,HIV infection
18617553,186175531,1,I,,20201207.0,20201215,20201215,EXP,,IN-AUROBINDO-AUR-APL-2020-061298,AUROBINDO,,51.0,YR,,M,Y,,,20201215.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186175531.0,OT,,,,,,,,,186175531.0,1.0,HIV infection
18620585,186205851,1,I,,20201207.0,20201216,20201216,EXP,,IN-HETERO-HET2020IN01327,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",39.0,YR,,M,Y,,,20201216.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186205851.0,OT,,,,,,,,,186205851.0,1.0,HIV infection
18620755,186207551,1,I,,20201207.0,20201216,20201216,EXP,,IN-HETERO-HET2020IN01357,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",33.0,YR,,M,Y,,,20201216.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186207551.0,OT,,,,,,,,,186207551.0,1.0,HIV infection
18620816,186208161,1,I,,20201207.0,20201216,20201216,EXP,,IN-HETERO-HET2020IN01358,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",48.0,YR,,F,Y,,,20201216.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186208161.0,OT,,,,,,,,,186208161.0,1.0,HIV infection
18620885,186208851,1,I,,20201207.0,20201216,20201216,EXP,,IN-HETERO-HET2020IN01359,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",51.0,YR,,M,Y,,,20201216.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186208851.0,OT,,,,,,,,,186208851.0,1.0,HIV infection
18621009,186210091,1,I,,20201207.0,20201216,20201216,EXP,,IN-AUROBINDO-AUR-APL-2020-061295,AUROBINDO,,39.0,YR,,M,Y,,,20201216.0,,HP,IN,IN,EFAVIRENZ.,Colour vision tests abnormal;Night blindness;Retinal toxicity;Visual field defect,186210091.0,OT,,,,,,,,,186210091.0,1.0,HIV infection
18621048,186210481,1,I,,20201207.0,20201216,20201216,EXP,,IN-HETERO-HET2020IN01360,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",46.0,YR,,M,Y,,,20201216.0,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186210481.0,OT,,,,,,,,,186210481.0,1.0,HIV infection
18622037,186220371,1,I,,20201207.0,20201216,20201216,EXP,,IN-AUROBINDO-AUR-APL-2020-061296,AUROBINDO,,33.0,YR,,M,Y,,,20201216.0,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186220371.0,OT,,,,,,,,,186220371.0,1.0,HIV infection
18632989,186329893,3,F,201411.0,20210407.0,20201218,20210414,PER,,US-GILEAD-2020-0509294,GILEAD,,61.0,YR,A,M,Y,41.73,KG,20210414.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Enuresis;Feeling hot;Feeling jittery;Glomerular filtration rate abnormal;Nightmare;Pain;Renal impairment,186329893.0,OT,,,186329893.0,1.0,2010.0,201307.0,,,186329893.0,1.0,HIV infection
18636808,186368081,1,I,,20201207.0,20201218,20201218,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-107851,BRISTOL MYERS SQUIBB,"CHEN J, CHEN R, SHEN Y, WEI H, WANG X, ZHANG R, ET AL. EFFICACY AND SAFETY OF LOWER DOSE TENOFOVIR DISOPROXIL FUMNARATE AND EFAVIRENZ VERSUS STANDARD DOSE IN HIV-INFECTED, ANTIRETROVIRAL-NAIVE ADULTS: A MULTICENTRE, RANDOMIZED, NONINFERIORITY TRIAL. EMERGING MICROBES + INFECTIONS. 2020;9 (1):843-50",,,A,M,Y,,,20201218.0,,HP,CN,CN,EFAVIRENZ.,Renal impairment,186368081.0,OT,,,,,,,,,186368081.0,1.0,HIV infection
18641058,186410583,3,F,20130901.0,20230403.0,20201221,20230407,EXP,,US-GILEAD-2020-0509278,GILEAD,,49.0,YR,A,F,Y,147.39,KG,20230406.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Cardiac failure congestive;Depression;Emotional distress;End stage renal disease;Fatigue;Lethargy;Negative thoughts;Pain;Renal failure;Renal impairment,186410583.0,OT,,,186410583.0,1.0,2001.0,201812.0,,,186410583.0,1.0,HIV infection
18646310,186463104,4,F,20110101.0,20230412.0,20201222,20230418,EXP,,US-GILEAD-2020-0509313,GILEAD,,,,A,M,Y,77.098,KG,20230418.0,,LW,US,US,EFAVIRENZ,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Gait disturbance;Hypertension;Pain;Renal failure;Renal impairment;Sleep disorder,186463104.0,OT,,,186463104.0,1.0,2004.0,2015.0,,,186463104.0,1.0,HIV infection
18649235,186492353,3,F,20090101.0,20231002.0,20201222,20231004,EXP,,US-GILEAD-2020-0509311,GILEAD,,50.0,YR,A,M,Y,81.0,KG,20231004.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Fatigue;Hyperkalaemia;Hyperparathyroidism secondary;Hypertension;Oxygen saturation abnormal;Pain;Renal failure;Renal impairment;Vitamin D deficiency;Weight increased,186492353.0,HO,,,186492353.0,1.0,2009.0,20140520.0,1876.0,DAY,186492353.0,1.0,HIV infection
18654621,186546212,2,F,2010.0,20210407.0,20201223,20210414,EXP,,US-GILEAD-2020-0509300,GILEAD,,,,A,M,Y,68.04,KG,20210414.0,,LW,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Hypertension;Pain;Tooth loss,186546212.0,OT,,,186546212.0,1.0,2004.0,2006.0,,,186546212.0,1.0,HIV infection
18655742,186557423,3,F,20090801.0,20231004.0,20201223,20231005,EXP,,US-GILEAD-2020-0509331,GILEAD,,53.0,YR,A,M,Y,,,20231005.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Foot fracture;Fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain,186557423.0,OT,,,186557423.0,1.0,2007.0,20110902.0,1698.0,DAY,186557423.0,1.0,HIV infection
18658223,186582232,2,F,2010.0,20210525.0,20201224,20210527,EXP,,US-GILEAD-2020-0509266,GILEAD,,,,A,M,Y,77.1,KG,20210527.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Multiple fractures;Osteoporosis;Pain;Wrist fracture,186582232.0,OT,,,186582232.0,1.0,2001.0,2010.0,,,186582232.0,1.0,HIV infection
18658805,186588054,4,F,20160415.0,20220521.0,20201224,20220526,EXP,,US-GILEAD-2020-0509256,GILEAD,,40.0,YR,A,M,Y,72.575,KG,20220526.0,,LW,US,US,SUSTIVA,Bone loss;Emotional distress;Loss of personal independence in daily activities;Osteonecrosis;Pain;Skeletal injury,186588054.0,OT,,,186588054.0,1.0,20101201.0,20130831.0,1004.0,DAY,186588054.0,1.0,HIV infection
18661112,186611123,3,F,20170101.0,20230426.0,20201224,20230501,PER,,US-GILEAD-2020-0509320,GILEAD,,,,A,F,Y,109.75,KG,20230501.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Renal failure,186611123.0,HO,,,186611123.0,1.0,2001.0,2006.0,,,186611123.0,1.0,HIV infection
18661131,186611312,2,F,2014.0,20210430.0,20201224,20210505,EXP,,US-GILEAD-2020-0509306,GILEAD,,65.0,YR,E,M,Y,,,20210505.0,,LW,US,US,EFAVIRENZ.,Acute kidney injury;Anhedonia;Anxiety;Diarrhoea;Discomfort;Emotional distress;End stage renal disease;Nausea;Pain;Renal failure;Renal impairment,186611312.0,DE,,,186611312.0,1.0,2010.0,20150320.0,,,186611312.0,1.0,HIV infection
18663452,186634523,3,F,20181001.0,20220324.0,20201224,20220401,EXP,,US-009507513-2012USA011140,MERCK,,,,,F,Y,,,20220401.0,,LW,US,US,SUSTIVA,Ankle fracture;Bone density decreased;Bone loss;Multiple fractures;Osteonecrosis;Osteoporosis;Renal injury;Skeletal injury,186634523.0,OT,,,186634523.0,1.0,20101231.0,20110520.0,141.0,DAY,186634523.0,1.0,HIV infection
18664314,186643141,1,I,,20201103.0,20201225,20201225,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-08812,LUPIN,,25.0,YR,,F,Y,,,20201225.0,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy,,,,,,,,,,,186643141.0,1.0,HIV infection
18666181,186661811,1,I,,20201103.0,20201226,20201226,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-08822,LUPIN,,35.0,YR,,F,Y,,,20201226.0,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;Normal newborn,,,,,,,,,,,186661811.0,1.0,HIV infection
18674615,186746151,1,I,,20201216.0,20201229,20201229,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2020029578,MACLEODS,"SPIEGEL LR, SCHRIER PB, SHAH HH. SEVERE RECURRENT RHABDOMYOLYSIS-INDUCED ACUTE KIDNEY INJURY IN A HIV-INFECTED PATIENT ON ANTIRETROVIRAL THERAPY. RENAL FAILURE. 2013;35(8):1186-90",,,,,Y,,,20201229.0,,HP,US,US,EFAVIRENZ.,Alanine aminotransferase increased;Aspartate aminotransferase increased;Back pain;Blood creatine phosphokinase increased;Drug interaction;Swelling;Tenderness,186746151.0,HO,,,,,,,,,186746151.0,1.0,Antiretroviral therapy
18687555,186875551,1,I,,20200925.0,20201231,20201231,PER,,ID-LUPIN PHARMACEUTICALS INC.-2020-07095,LUPIN,,29.0,YR,,F,Y,,,20201231.0,,HP,ID,ID,EFAVIRENZ.,Exposure during pregnancy,186875551.0,OT,,,,,,,,,186875551.0,1.0,HIV infection
18690228,186902281,1,I,20181215.0,20201216.0,20201231,20201231,EXP,,CN-GLAXOSMITHKLINE-CN2020APC251054,GLAXOSMITHKLINE,,36.0,YR,,M,Y,,,20201231.0,,HP,CN,CN,EFAVIRENZ.,Abdominal distension;Abdominal pain;Breath sounds abnormal;Bronchial wall thickening;Bronchogenic cyst;Central nervous system lesion;Condition aggravated;Cough;Decreased appetite;Disseminated tuberculosis;Drug interaction;Haemoglobin decreased;Hilar lymphadenopathy;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Lung opacity;Lymph node abscess;Lymph node pain;Lymph node tuberculosis;Lymph node ulcer;Lymphadenopathy;Malaise;Myelosuppression;Necrosis;Nodule;Pneumocystis jirovecii pneumonia;Pneumothorax;Productive cough;Psoas abscess;Pulmonary tuberculosis;Pyrexia;Retroperitoneal lymphadenopathy;Therapeutic product effect incomplete,186902281.0,OT,,,186902281.0,1.0,20181115.0,,,,186902281.0,1.0,HIV infection
18690230,186902301,1,I,20181215.0,20201216.0,20201231,20201231,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020APC251054,VIIV,,36.0,YR,,M,Y,,,20201231.0,,HP,CN,CN,EFAVIRENZ.,Abdominal distension;Abdominal pain;Breath sounds abnormal;Bronchial wall thickening;Bronchogenic cyst;Central nervous system lesion;Condition aggravated;Cough;Decreased appetite;Disseminated tuberculosis;Drug interaction;Haemoglobin decreased;Hilar lymphadenopathy;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Lung opacity;Lymph node abscess;Lymph node pain;Lymph node tuberculosis;Lymph node ulcer;Lymphadenopathy;Malaise;Myelosuppression;Necrosis;Nodule;Pneumocystis jirovecii pneumonia;Pneumothorax;Productive cough;Psoas abscess;Pulmonary tuberculosis;Pyrexia;Retroperitoneal lymphadenopathy;Therapeutic product effect incomplete,186902301.0,HO,,,186902301.0,1.0,20181115.0,,,,186902301.0,1.0,HIV infection
18690324,186903241,1,I,,20201103.0,20210101,20210101,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-08819,LUPIN,,29.0,YR,,F,Y,,,20210101.0,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,,,,,,,,,,,186903241.0,1.0,HIV infection
18690345,186903451,1,I,,20201103.0,20210101,20210101,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-08824,LUPIN,,34.0,YR,,F,Y,,,20210101.0,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;Normal newborn,,,,,,,,,,,186903451.0,1.0,HIV infection
18696971,186969714,4,F,20130823.0,20211011.0,20210104,20211024,EXP,,US-GILEAD-2020-0510869,GILEAD,,60.0,YR,A,M,Y,74.83,KG,20211023.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Chronic obstructive pulmonary disease;Depression;Dyspnoea;Emotional distress;End stage renal disease;Fatigue;Impaired work ability;Pain;Renal failure;Walking disability,186969714.0,HO,,,186969714.0,1.0,2004.0,2010.0,,,186969714.0,1.0,HIV infection
18703266,187032661,1,I,,20200320.0,20210105,20210105,PER,,IN-LUPIN LIMITED-2020-01682,LUPIN,,58.0,YR,,F,Y,,,20210106.0,,HP,IN,IN,EFAVIRENZ.,Drug eruption;Drug hypersensitivity;Renal tubular acidosis,187032661.0,OT,,,,,,,,,187032661.0,1.0,HIV infection
18703934,187039343,3,F,20181001.0,20220331.0,20210106,20220413,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-111175,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20220413.0,,LW,US,US,SUSTIVA,Ankle fracture;Bone density decreased;Bone loss;Multiple fractures;Osteoporosis;Renal injury;Skeletal injury,187039343.0,OT,,,187039343.0,2.0,2004.0,2017.0,15.0,YR,187039343.0,1.0,HIV infection
18705278,187052784,4,F,20090326.0,20220824.0,20210106,20220826,EXP,,US-GILEAD-2021-0511357,GILEAD,,34.0,YR,A,M,Y,78.93,KG,20220826.0,,LW,US,US,SUSTIVA,"Acute kidney injury;Anxiety;Asthenia;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Clavicle fracture;Decreased appetite;Delusional disorder, unspecified type;Depression;Dysstasia;End stage renal disease;Fatigue;Fracture;Micturition disorder;Mobility decreased;Multiple fractures;Muscle spasms;Nausea;Night sweats;Renal failure;Tooth loss",187052784.0,HO,,,187052784.0,1.0,2004.0,2013.0,1855.0,DAY,187052784.0,1.0,HIV infection
18716418,187164181,1,I,20180115.0,20201230.0,20210108,20210108,EXP,,ES-STRIDES ARCOLAB LIMITED-2021SP000073,STRIDES,,50.0,YR,,F,Y,,,20210108.0,,HP,ES,ES,EFAVIRENZ.,Haemolytic anaemia,187164181.0,HO,,,187164181.0,1.0,2015.0,20180123.0,,,187164181.0,1.0,HIV infection
18733265,187332653,3,F,200908.0,20210617.0,20210113,20210622,EXP,,US-GILEAD-2021-0512540,GILEAD,,51.0,YR,A,F,Y,93.42,KG,20210622.0,,CN,US,US,SUSTIVA,Anxiety;Chronic kidney disease;Depression;End stage renal disease,187332653.0,OT,,,187332653.0,1.0,2017.0,2019.0,,,187332653.0,1.0,HIV infection
18739723,187397233,3,F,20050401.0,20230418.0,20210114,20230425,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN003775,VIIV,Tomohiro Hosoda. The current situation of 3TC+DTG in our hospital. E2 HIV Expert Forum in Tokyo. 2023,,,,,Y,,,20230425.0,,MD,JP,JP,EFAVIRENZ,Blood lactate dehydrogenase increased;Diabetes mellitus;Dyslipidaemia;Glomerular filtration rate decreased;Proteinuria;Renal impairment,187397233.0,OT,,,187397233.0,1.0,201302.0,,,,187397233.0,1.0,HIV infection
18739841,187398413,3,F,20050401.0,20230418.0,20210114,20230425,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN003775,GLAXOSMITHKLINE,Tomohiro Hosoda. The current situation of 3TC+DTG in our hospital. E2 HIV Expert Forum in Tokyo. 2023,,,,,Y,,,20230425.0,,MD,JP,JP,EFAVIRENZ,Blood lactate dehydrogenase increased;Diabetes mellitus;Dyslipidaemia;Glomerular filtration rate decreased;Proteinuria;Renal impairment,187398413.0,OT,,,187398413.0,1.0,201302.0,,,,187398413.0,1.0,HIV infection
18751634,187516341,1,I,,20210112.0,20210118,20210118,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-076311",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20210117.0,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,187516341.0,OT,,,,,,,,,187516341.0,1.0,HIV infection
18761468,187614681,1,I,,20210105.0,20210119,20210119,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-000686,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20210119.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,187614681.0,OT,,,,,,,,,187614681.0,1.0,HIV infection
18763728,187637281,1,I,,20210112.0,20210120,20210120,EXP,,CA-JNJFOC-20210120667,JOHNSON AND JOHNSON,,,,,,Y,,,20210120.0,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,187637281.0,OT,,,,,,,,,187637281.0,1.0,HIV infection
18768161,187681611,1,I,,20201210.0,20210121,20210121,EXP,,MY-CIPLA LTD.-2021MY00375,CIPLA,,,,,,Y,,,20210121.0,,HP,MY,MY,EFAVIR (EFAVIRENZ),Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood bilirubin increased;Coagulation factor increased;Lactic acidosis;Rash,187681611.0,OT,,,,,,,,,187681611.0,1.0,Antiretroviral therapy
18768162,187681621,1,I,,20201210.0,20210121,20210121,EXP,,MY-CIPLA LTD.-2021MY00407,CIPLA,,,,,,Y,,,20210121.0,,HP,MY,MY,EFAVIR (EFAVIRENZ),Productive cough;Pyrexia;Rash;Rash maculo-papular;Rhinorrhoea,187681621.0,OT,,,,,,,,,187681621.0,1.0,Antiretroviral therapy
18768168,187681681,1,I,,20201210.0,20210121,20210121,EXP,,MY-CIPLA LTD.-2021MY00408,CIPLA,,,,,,Y,,,20210121.0,,HP,MY,MY,EFAVIR (EFAVIRENZ),Eye pruritus;Rash maculo-papular;Rash pruritic;Swelling;Swelling face,187681681.0,OT,,,,,,,,,187681681.0,1.0,Antiretroviral therapy
18770483,187704833,3,F,20050801.0,20231030.0,20210122,20231031,EXP,,US-GILEAD-2021-0512294,GILEAD,,46.0,YR,A,M,Y,81.633,KG,20231031.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Emotional distress;Osteopenia;Osteoporosis;Pain,187704833.0,OT,,,187704833.0,1.0,200507.0,200508.0,,,187704833.0,1.0,HIV infection
18776215,187762153,3,F,201912.0,20210209.0,20210123,20210224,PER,,GB-LUPIN PHARMACEUTICALS INC.-2021-00424,LUPIN,,28.0,YR,,F,Y,,,20210224.0,,CN,GB,GB,EFAVIRENZ.,Breast mass;Breast pain;Breast swelling;Insomnia,,,,,187762153.0,1.0,201709.0,,,,187762153.0,1.0,HIV infection
18779815,187798152,2,F,201812.0,20210122.0,20210125,20210201,EXP,,GB-GILEAD-2021-0513018,GILEAD,,38.0,YR,A,F,Y,,,20210201.0,,PH,GB,GB,EFAVIRENZ.,Oesophageal ulcer,187798152.0,OT,,,187798152.0,1.0,201609.0,201810.0,,,187798152.0,1.0,HIV infection
18786658,187866583,3,F,20120101.0,20230403.0,20210126,20230407,EXP,,US-GILEAD-2021-0513366,GILEAD,,,,A,M,Y,54.431,KG,20230406.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood urine present;Chronic kidney disease;Discomfort;Emotional distress;Grip strength decreased;Joint contracture;Nephrolithiasis;Osteoporosis;Pain;Upper limb fracture,187866583.0,OT,,,187866583.0,1.0,200609.0,201404.0,,,187866583.0,1.0,HIV infection
18787463,187874631,1,I,201812.0,20210122.0,20210126,20210126,EXP,GB-MHRA-MIDB-25B82B98-3A93-4248-A2A0-FC7337FC2E0F,GB-MYLANLABS-2021M1004747,MYLAN,,38.0,YR,,F,Y,,,20210126.0,,PH,GB,GB,EFAVIRENZ.,Oesophageal ulcer,187874631.0,HO,,,187874631.0,1.0,201810.0,,,,187874631.0,1.0,HIV test
18796595,187965953,3,F,20050101.0,20230329.0,20210128,20230403,EXP,,US-GILEAD-2021-0513358,GILEAD,,64.0,YR,A,M,Y,65.3,KG,20230403.0,,LW,US,US,EFAVIRENZ,Anhedonia;Anxiety;Clavicle fracture;Depression;Emotional distress;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Shoulder fracture;Wrist fracture,187965953.0,OT,,,187965953.0,1.0,2005.0,2015.0,,,187965953.0,1.0,HIV infection
18796763,187967633,3,F,20070101.0,20230612.0,20210128,20230615,EXP,,US-GILEAD-2021-0513451,GILEAD,,,,A,M,Y,70.295,KG,20230615.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Osteoporosis;Pain;Renal injury;Vitamin D deficiency,187967633.0,OT,,,187967633.0,1.0,2005.0,2010.0,,,187967633.0,1.0,HIV infection
18796772,187967723,3,F,20101001.0,20230422.0,20210128,20230424,PER,,US-GILEAD-2021-0513381,GILEAD,,43.0,YR,A,M,Y,79.365,KG,20230424.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;Osteopenia;Pain;Wrist fracture,,,,,187967723.0,1.0,2011.0,2019.0,,,187967723.0,1.0,HIV infection
18798418,187984181,1,I,2006.0,20210118.0,20210128,20210128,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-004665,BRISTOL MYERS SQUIBB,,57.0,YR,,M,Y,,,20210128.0,,MD,DE,DE,SUSTIVA,Abdominal mass;Coronary artery disease;Glomerular filtration rate decreased;Hypercholesterolaemia;Hypertension;Lipoatrophy;Proteinuria;Viraemia,187984181.0,OT,,,187984181.0,1.0,1997.0,,,,187984181.0,1.0,HIV infection
18799271,187992714,4,F,20100101.0,20230509.0,20210128,20230512,EXP,,US-GILEAD-2021-0513354,GILEAD,,,,A,M,Y,119.73,KG,20230512.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Depression;Emotional distress;Foot fracture;Jaw fracture;Nephropathy;Osteonecrosis;Osteopenia;Osteoporosis;Pain,187992714.0,OT,,,187992714.0,1.0,2005.0,2012.0,,,187992714.0,1.0,HIV infection
18801757,188017573,3,F,20090101.0,20230404.0,20210128,20230408,EXP,,US-GILEAD-2021-0513415,GILEAD,,,,A,F,Y,58.957,KG,20230408.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Lower limb fracture;Nephrolithiasis;Osteoporosis;Pain;Renal tubular injury,188017573.0,HO,,,188017573.0,1.0,2006.0,2004.0,,,188017573.0,1.0,HIV infection
18802325,188023251,1,I,,20210118.0,20210128,20210128,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020417,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210128.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188023251.0,OT,,,,,,,,,188023251.0,1.0,HIV infection
18802328,188023281,1,I,,20210118.0,20210128,20210128,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020417,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210128.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188023281.0,OT,,,,,,,,,188023281.0,1.0,HIV infection
18802373,188023731,1,I,,20210118.0,20210128,20210128,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020418,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210128.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188023731.0,OT,,,,,,,,,188023731.0,1.0,HIV infection
18802374,188023741,1,I,,20210118.0,20210128,20210128,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020418,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210128.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188023741.0,OT,,,,,,,,,188023741.0,1.0,HIV infection
18802498,188024981,1,I,,20210118.0,20210128,20210128,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020419,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210128.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188024981.0,OT,,,,,,,,,188024981.0,1.0,HIV infection
18802500,188025001,1,I,,20210118.0,20210128,20210128,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020419,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210128.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188025001.0,OT,,,,,,,,,188025001.0,1.0,HIV infection
18806515,188065151,1,I,,20210125.0,20210129,20210129,EXP,,MX-GILEAD-2021-0514771,GILEAD,,30.0,YR,A,M,Y,,,20210129.0,,CN,MX,MX,EFAVIRENZ.,Hallucination;Poor quality sleep;Product use issue;Somnolence,188065151.0,OT,,,188065151.0,1.0,201706.0,201901.0,,,188065151.0,1.0,HIV infection
18806899,188068994,4,F,20070101.0,20230403.0,20210129,20230408,EXP,,US-GILEAD-2021-0513418,GILEAD,,,,A,M,Y,77.098,KG,20230408.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Lower limb fracture;Osteopenia;Osteoporosis;Pain;Tibia fracture,188068994.0,OT,,,188068994.0,1.0,2003.0,2004.0,,,188068994.0,1.0,HIV infection
18807345,188073452,2,F,20190101.0,20210929.0,20210128,20211001,PER,,US-GILEAD-2021-0513434,GILEAD,,,,A,M,Y,67.12,KG,20211001.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Mobility decreased;Pain,,,,,188073452.0,1.0,2001.0,2004.0,,,188073452.0,1.0,HIV infection
18808889,188088891,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-DO2021GSK020449,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188088891.0,OT,,,,,,,,,188088891.0,1.0,HIV infection
18808891,188088911,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-DO2021GSK020449,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188088911.0,OT,,,,,,,,,188088911.0,1.0,HIV infection
18809081,188090811,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-DO2021GSK020451,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188090811.0,OT,,,,,,,,,188090811.0,1.0,HIV infection
18809082,188090821,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-DO2021GSK020451,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188090821.0,OT,,,,,,,,,188090821.0,1.0,HIV infection
18809321,188093211,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-DO2021GSK020452,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188093211.0,OT,,,,,,,,,188093211.0,1.0,HIV infection
18809325,188093251,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-DO2021GSK020452,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188093251.0,OT,,,,,,,,,188093251.0,1.0,HIV infection
18809622,188096221,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-DO2021GSK020448,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188096221.0,OT,,,,,,,,,188096221.0,1.0,HIV infection
18809623,188096231,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-DO2021GSK020448,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,DO,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188096231.0,OT,,,,,,,,,188096231.0,1.0,HIV infection
18810411,188104111,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020420,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188104111.0,OT,,,,,,,,,188104111.0,1.0,HIV infection
18810413,188104131,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020420,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188104131.0,OT,,,,,,,,,188104131.0,1.0,HIV infection
18810712,188107121,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020421,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188107121.0,OT,,,,,,,,,188107121.0,1.0,HIV infection
18810716,188107161,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020421,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188107161.0,OT,,,,,,,,,188107161.0,1.0,HIV infection
18810764,188107642,2,F,,20210125.0,20210129,20210218,EXP,,MX-GILEAD-2021-0515071,GILEAD,,30.0,YR,A,M,Y,,,20210218.0,,CN,MX,MX,EFAVIRENZ.,Hallucination;Poor quality sleep;Product dose omission in error;Somnolence,188107642.0,OT,,,188107642.0,1.0,201706.0,201901.0,,,188107642.0,1.0,HIV infection
18810877,188108771,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020422,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188108771.0,OT,,,,,,,,,188108771.0,1.0,HIV infection
18810880,188108801,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020422,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188108801.0,OT,,,,,,,,,188108801.0,1.0,HIV infection
18810978,188109781,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020424,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188109781.0,OT,,,,,,,,,188109781.0,1.0,HIV infection
18810979,188109791,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020423,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188109791.0,OT,,,,,,,,,188109791.0,1.0,HIV infection
18810981,188109811,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020423,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188109811.0,OT,,,,,,,,,188109811.0,1.0,HIV infection
18810992,188109921,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020424,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188109921.0,OT,,,,,,,,,188109921.0,1.0,HIV infection
18811115,188111151,1,I,,20210118.0,20210129,20210129,EXP,,US-VIIV HEALTHCARE LIMITED-TZ2021GSK020425,VIIV,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188111151.0,OT,,,,,,,,,188111151.0,1.0,HIV infection
18811117,188111171,1,I,,20210118.0,20210129,20210129,EXP,,US-GLAXOSMITHKLINE-TZ2021GSK020425,GLAXOSMITHKLINE,"GRANT?MCAULEY W, FOGEL JM, GALAI N, CLARKE W, BREAUD A, MARZINKE MA ET AL. ANTIRETROVIRAL DRUG USE AND HIV DRUG RESISTANCE IN FEMALE SEX WORKERS IN TANZANIA AND THE DOMINICAN REPUBLIC. PLOS ONE. 2020?15 (10)",,,,F,Y,,,20210129.0,,HP,US,TZ,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,188111171.0,OT,,,,,,,,,188111171.0,1.0,HIV infection
18818695,188186951,1,I,,20210122.0,20210201,20210201,EXP,GB-MHRA-MIDB-25B82B98-3A93-4248-A2A0-FC7337FC2E0F,GB-009507513-2101GBR011304,MERCK,,38.0,YR,,F,Y,,,20210201.0,,PH,GB,GB,EFAVIRENZ.,Oesophageal ulcer,188186951.0,HO,,,,,,,,,188186951.0,1.0,HIV test
18832051,188320512,2,F,20171006.0,20211203.0,20210203,20211215,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-009871,BRISTOL MYERS SQUIBB,,61.0,YR,,F,Y,,,20211215.0,,LW,US,US,SUSTIVA,Ankle fracture;Chronic kidney disease;Multiple fractures;Osteopenia,188320512.0,OT,,,188320512.0,1.0,199812.0,20060801.0,3861.0,DAY,188320512.0,1.0,HIV infection
18833406,188334061,1,I,,20210122.0,20210203,20210203,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2021029952,MACLEODS,,,,,,Y,,,20210203.0,,CN,GB,GB,EFAVIRENZ.,Oesophageal ulcer,188334061.0,HO,,,188334061.0,3.0,201810.0,,,,188334061.0,1.0,HIV test
18843044,188430441,1,I,,20210127.0,20210204,20210204,EXP,,GB-MYLANLABS-2021M1006850,MYLAN,"NDERITU P, RIGA P, MANN S, GARNAVOU?XIROU C, ELEFTHERIADIS H. DIDANOSINE?ASSOCIATED RETINAL TOXICITY (DART) AMONGST HIV?POSITIVE PATIENTS: A CASE SERIES AND LITERATURE REVIEW. SN?COMPR?CLIN?MED 2020?2:2939?2952.",73.0,YR,,F,Y,,,20210204.0,,MD,GB,GB,EFAVIRENZ.,Disease progression;Retinal toxicity,188430441.0,OT,,,188430441.0,1.0,2013.0,2007.0,,,188430441.0,1.0,HIV infection
18849877,188498772,2,F,2018.0,20210130.0,20210205,20210205,EXP,,VN-CIPLA LTD.-2021VN00764,CIPLA,,,,,,Y,,,20210205.0,,HP,VN,VN,EFAVIRENZ.,Abdominal distension;Abdominal pain;Immune reconstitution inflammatory syndrome;Penicillium infection;Septic shock,188498772.0,HO,,,188498772.0,1.0,20180107.0,,,,188498772.0,1.0,HIV infection
18851168,188511682,2,F,201706.0,20210130.0,20210205,20210208,EXP,,VN-CIPLA LTD.-2021VN00763,CIPLA,,,,,,Y,,,20210208.0,,MD,VN,VN,EFAVIRENZ.,Treatment failure,188511682.0,OT,,,188511682.0,1.0,,201706.0,,,188511682.0,1.0,HIV infection
18851252,188512521,1,I,,20210128.0,20210205,20210205,EXP,,CN-GILEAD-2021-0515348,GILEAD,"SHUWEN J, CANYE M, FAN Y, RUIXIANG H, JIANXUE W, BAOJIN L, CUNCHUAN W. 1 CASE REPORT OF LAPAROSCOPIC SLEEVE GASTRECTOMY IN A PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND OBESITY. CHIN J OBES METAB DIS.. 2020?6:259?261. DOI:10.3877/CMA.J.ISSN.2095?9605.2020.04.011",29.0,YR,A,M,Y,,,20210205.0,,MD,CN,CN,EFAVIRENZ.,Blood calcium decreased;Osteoporosis,188512521.0,OT,,,,,,,,,188512521.0,1.0,HIV infection
18855116,188551161,1,I,,20210122.0,20210205,20210205,EXP,GB-MHRA-MIDB-25B82B98-3A93-4248-A2A0-FC7337FC2E0F,GB-TEVA-2021-GB-1874864,TEVA,,38.0,YR,A,F,Y,,,20210205.0,,PH,GB,GB,EFAVIRENZ.,Oesophageal ulcer,188551161.0,HO,,,,,,,,,188551161.0,1.0,HIV test
18855729,188557294,4,F,,20210805.0,20210205,20210810,EXP,,AU-GILEAD-2021-0516233,GILEAD,,52.0,YR,A,F,Y,,,20210810.0,,HP,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Past-pointing;Pathogen resistance;Rhinitis;Treatment noncompliance;Viraemia;Viral mutation identified,188557294.0,HO,,,,,,,,,188557294.0,1.0,HIV infection
18860935,188609351,1,I,,20210127.0,20210208,20210208,EXP,,GB-LUPIN PHARMACEUTICALS INC.-2021-01350,LUPIN,,73.0,YR,,F,Y,,,20210208.0,,HP,GB,GB,EFAVIRENZ.,Disease progression;Retinal toxicity,188609351.0,OT,,,188609351.0,1.0,2003.0,2008.0,,,188609351.0,1.0,HIV infection
18863391,188633912,2,F,20150623.0,20211124.0,20210209,20211207,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-008411,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,,,20211207.0,,LW,US,US,SUSTIVA,Acute kidney injury;Bone loss;Chronic kidney disease;Osteoarthritis;Tooth loss,188633912.0,OT,,,188633912.0,1.0,201502.0,20150206.0,621.0,DAY,188633912.0,1.0,HIV infection
18863497,188634971,1,I,,20210127.0,20210209,20210209,EXP,,ZA-CIPLA LTD.-2021ZA00840,CIPLA,,,,,,Y,,,20210209.0,,HP,ZA,ZA,EFAVIRENZ.,Drug-induced liver injury;Hepatocellular injury,188634971.0,OT,,,,,,,,,188634971.0,1.0,HIV infection
18863820,188638201,1,I,,20210127.0,20210209,20210209,EXP,,ZA-CIPLA LTD.-2021ZA00841,CIPLA,,,,,,Y,,,20210209.0,,HP,ZA,ZA,EFAVIRENZ.,Drug-induced liver injury;Hepatocellular injury,188638201.0,HO,,,,,,,,,188638201.0,1.0,HIV infection
18866523,188665231,1,I,20210105.0,20210126.0,20210208,20210208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-012569,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,,,20210208.0,,LW,US,US,SUSTIVA,Death,188665231.0,DE,,,188665231.0,1.0,201502.0,20161018.0,,,188665231.0,1.0,HIV infection
18867761,188677613,3,F,,20210211.0,20210209,20220624,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2021GSK033741,VIIV,,,,,,Y,,,20220624.0,,HP,FR,FR,EFAVIRENZ,Foetal exposure during pregnancy;Polycystic liver disease;Sickle cell disease;Spleen malformation,188677613.0,CA,,,188677613.0,1.0,20060426.0,20061018.0,130.0,DAY,188677613.0,1.0,HIV infection
18867829,188678293,3,F,,20210211.0,20210209,20220713,EXP,,FR-GLAXOSMITHKLINE-FR2021GSK033741,GLAXOSMITHKLINE,,,,,,Y,,,20220713.0,,HP,FR,FR,EFAVIRENZ,Foetal exposure during pregnancy;Polycystic liver disease;Sickle cell disease;Spleen malformation,188678293.0,CA,,,188678293.0,1.0,20060426.0,20061018.0,130.0,DAY,188678293.0,1.0,HIV infection
18869554,188695541,1,I,,20210127.0,20210210,20210210,EXP,,ZA-CIPLA LTD.-2021ZA00843,CIPLA,,,,,,Y,,,20210210.0,,HP,ZA,ZA,EFAVIRENZ.,Drug-induced liver injury;Mixed liver injury,188695541.0,HO,,,,,,,,,188695541.0,1.0,HIV infection
18869891,188698913,3,F,20150101.0,20230414.0,20210209,20230419,EXP,,US-GILEAD-2021-0515572,GILEAD,,,,A,F,Y,73.93,KG,20230419.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,188698913.0,OT,,,188698913.0,1.0,2011.0,2011.0,,,188698913.0,1.0,HIV infection
18870238,188702381,1,I,,20210127.0,20210210,20210210,EXP,,CN-LUPIN PHARMACEUTICALS INC.-2021-01317,LUPIN,,27.0,YR,,F,Y,,,20210210.0,,HP,CN,CN,EFAVIRENZ.,Dermatitis allergic,188702381.0,OT,,,,,,,,,188702381.0,1.0,HIV infection CDC category B
18870412,188704121,1,I,,20210127.0,20210210,20210210,EXP,,ZA-CIPLA LTD.-2021ZA00842,CIPLA,,,,,,Y,,,20210210.0,,HP,ZA,ZA,EFAVIRENZ.,Cholestatic liver injury,188704121.0,OT,,,,,,,,,188704121.0,1.0,HIV infection
18871837,188718373,3,F,20140301.0,20230410.0,20210210,20230414,EXP,,US-GILEAD-2021-0515563,GILEAD,,47.0,YR,A,M,Y,79.819,KG,20230414.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Depression;Emotional distress;Exostosis;Foot fracture;Osteoarthritis;Osteoporosis;Pain;Proteinuria;Renal failure;Renal injury,188718373.0,OT,,,188718373.0,1.0,2004.0,2006.0,,,188718373.0,1.0,HIV infection
18871840,188718403,3,F,20080101.0,20230403.0,20210210,20230407,EXP,,US-GILEAD-2021-0515565,GILEAD,,,,A,F,Y,45.359,KG,20230407.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Pain,188718403.0,OT,,,188718403.0,1.0,2008.0,201402.0,,,188718403.0,1.0,HIV infection
18874084,188740844,4,F,20090101.0,20230416.0,20210210,20230419,PER,,US-GILEAD-2021-0515558,GILEAD,,,,A,F,Y,66.667,KG,20230419.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal impairment,188740844.0,OT,,,188740844.0,1.0,2004.0,2017.0,,,188740844.0,1.0,HIV infection
18874963,188749633,3,F,20060601.0,20240227.0,20210211,20240229,EXP,,US-GILEAD-2021-0515547,GILEAD,,51.0,YR,E,F,Y,68.039,KG,20240229.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Gait disturbance;Osteopenia;Osteoporosis;Pain;Renal impairment,188749633.0,HO,,,188749633.0,1.0,2004.0,2006.0,,,188749633.0,1.0,HIV infection
18875824,188758242,2,F,200604.0,20210803.0,20210211,20210818,EXP,,US-GILEAD-2021-0515554,GILEAD,,45.0,YR,A,M,Y,66.67,KG,20210818.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine abnormal;Emotional distress;Multiple fractures;Osteoporosis;Pain;Proteinuria;Rib fracture;Road traffic accident,188758242.0,HO,,,188758242.0,1.0,2009.0,2016.0,,,188758242.0,1.0,HIV infection
18881838,188818383,3,F,20120701.0,20230428.0,20210212,20230504,EXP,,US-GILEAD-2021-0515536,GILEAD,,53.0,YR,A,M,Y,175.0,KG,20230504.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Fracture pain;Hand fracture;Osteoarthritis;Osteoporosis;Pain,188818383.0,OT,,,188818383.0,2.0,201106.0,2017.0,,,188818383.0,1.0,HIV infection
18883984,188839844,4,F,20120701.0,20230928.0,20210211,20231002,EXP,,US-GILEAD-2021-0515564,GILEAD,,53.0,YR,A,F,Y,72.12,KG,20231002.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Osteopenia;Pain;Renal impairment,188839844.0,OT,,,188839844.0,1.0,200701.0,201109.0,,,188839844.0,1.0,HIV infection
18888480,188884803,3,F,,20240927.0,20210212,20241007,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013018,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20241007.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,188884803.0,DE,,,,,,,,,188884803.0,1.0,HIV infection
18888983,188889833,3,F,20120101.0,20230508.0,20210213,20230512,EXP,,US-GILEAD-2021-0515568,GILEAD,,,,A,F,Y,74.83,KG,20230512.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Dysstasia;Emotional distress;Fanconi syndrome acquired;Femur fracture;Foot fracture;Gait disturbance;Hip fracture;Multiple fractures;Osteomalacia;Pain,188889833.0,OT,,,188889833.0,1.0,2006.0,201408.0,,,188889833.0,1.0,HIV infection
18891109,188911091,1,I,,20210209.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013612,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210215.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Off label use,188911091.0,DE,,,,,,,,,188911091.0,1.0,HIV infection
18891586,188915861,1,I,,20210209.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013598,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20210215.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,188915861.0,HO,,,,,,,,,188915861.0,1.0,HIV infection
18893076,188930767,7,F,,20230605.0,20210215,20230608,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013005,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20230608.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Hospitalisation;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,188930767.0,DE,,,,,,,,,188930767.0,1.0,HIV infection
18893253,188932531,1,I,,20210209.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013458,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210215.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue,188932531.0,OT,,,,,,,,,188932531.0,1.0,HIV infection
18896932,188969321,1,I,,20210205.0,20210216,20210216,EXP,,ZA-GLAXOSMITHKLINE-US2021GSK035398,GLAXOSMITHKLINE,,,,,,Y,,,20210216.0,,HP,US,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,188969321.0,OT,,,,,,,,,188969321.0,1.0,HIV infection
18898598,188985983,3,F,20170509.0,20231030.0,20210216,20231031,EXP,,US-GILEAD-2021-0515747,GILEAD,,56.0,YR,A,M,Y,89.796,KG,20231031.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Musculoskeletal disorder;Osteoporosis;Pain;Rib fracture,188985983.0,OT,,,188985983.0,1.0,2001.0,201708.0,,,188985983.0,1.0,HIV infection
18899256,188992561,1,I,,20210205.0,20210216,20210216,EXP,,ZA-VIIV HEALTHCARE LIMITED-US2021GSK035398,VIIV,,,,,,Y,,,20210216.0,,HP,US,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,188992561.0,OT,,,,,,,,,188992561.0,1.0,HIV infection
18900413,189004131,1,I,,20210205.0,20210216,20210216,EXP,,ZA-GLAXOSMITHKLINE-ZA2021GSK040946,GLAXOSMITHKLINE,,,,,,Y,,,20210216.0,,HP,US,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,189004131.0,OT,,,,,,,,,189004131.0,1.0,HIV infection
18900421,189004211,1,I,,20210205.0,20210216,20210216,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2021GSK040946,VIIV,,,,,,Y,,,20210216.0,,HP,US,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,189004211.0,OT,,,,,,,,,189004211.0,1.0,HIV infection
18902538,189025381,1,I,,20210212.0,20210217,20210217,EXP,,CA-GILEAD-2021-0517517,GILEAD,,52.0,YR,A,M,Y,,,20210217.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,189025381.0,OT,,,,,,,,,189025381.0,1.0,HIV infection
18910938,189109382,2,F,,20210315.0,20210218,20210330,PER,,ID-LUPIN PHARMACEUTICALS INC.-2021-02011,LUPIN,,,,A,,Y,,,20210330.0,,HP,ID,ID,EFAVIRENZ.,Rash,,,,,,,,,,,189109382.0,1.0,HIV infection
18916042,189160423,3,F,,20240428.0,20210218,20240506,EXP,,AU-JNJFOC-20210220797,JOHNSON AND JOHNSON,,,,,,Y,,,20240506.0,,HP,AU,AU,EFAVIRENZ,Dyslipidaemia;Hypertension,189160423.0,OT,,,,,,,,,189160423.0,1.0,HIV infection
18917986,189179861,1,I,,20210208.0,20210220,20210220,EXP,,GB-AUROBINDO-AUR-APL-2021-006373,AUROBINDO,,73.0,YR,,F,Y,,,20210220.0,,HP,GB,GB,EFAVIRENZ.,Disease progression;Retinal toxicity,189179861.0,OT,,,189179861.0,1.0,2013.0,2015.0,,,189179861.0,1.0,HIV infection
18921190,189211903,3,F,,20211115.0,20210222,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013147,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20211124.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189211903.0,OT,,,,,,,,,189211903.0,1.0,HIV infection
18921209,189212091,1,I,,20210208.0,20210222,20210222,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013010,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189212091.0,OT,,,,,,,,,189212091.0,1.0,HIV infection
18921445,189214451,1,I,,20210212.0,20210222,20210222,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021044991,VIIV,,52.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,189214451.0,OT,,,,,,,,,189214451.0,1.0,HIV infection
18921783,189217831,1,I,,20210212.0,20210222,20210222,EXP,,CA-GLAXOSMITHKLINE-CA2021044991,GLAXOSMITHKLINE,,52.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,189217831.0,OT,,,,,,,,,189217831.0,1.0,HIV infection
18923115,189231153,3,F,,20210607.0,20210222,20210616,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013419,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,,,20210616.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,189231153.0,OT,,,,,,,,,189231153.0,1.0,HIV infection
18923726,189237261,1,I,,20210209.0,20210222,20210222,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013581,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,SUSTIVA,Anxiety,189237261.0,OT,,,,,,,,,189237261.0,1.0,HIV infection
18924449,189244495,5,F,,20220404.0,20210222,20220606,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013816,BRISTOL MYERS SQUIBB,,44.0,YR,A,M,Y,,,20220606.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,189244495.0,HO,,,189244495.0,2.0,,,355.0,DAY,189244495.0,1.0,HIV infection
18924853,189248531,1,I,,20210209.0,20210222,20210222,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013583,BRISTOL MYERS SQUIBB,,44.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,189248531.0,OT,,,,,,,,,189248531.0,1.0,HIV infection
18925865,189258651,1,I,,20210215.0,20210223,20210223,EXP,,PK-GILEAD-2021-0517535,GILEAD,"AZMI M, BABER ZU, BADLANI S, DODANI SK, NASIM A, SHEERANI M. MOVEMENT DISORDER IN A PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS ON AN ANTI?RETROVIRAL THERAPY: A CASE REPORT. J PAK MED ASSOC.. 2020?70(4):734?737. DOI:10.5455/JPMA.298947",49.0,YR,A,F,Y,,,20210223.0,,HP,PK,PK,EFAVIRENZ.,CSF HIV escape syndrome;HIV-associated neurocognitive disorder,189258651.0,OT,,,,,,,,,189258651.0,1.0,HIV infection
18925910,189259104,4,F,,20220120.0,20210222,20220203,EXP,,CA-AUROBINDO-AUR-APL-2021-006678,AUROBINDO,,54.0,YR,,M,Y,,,20220204.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189259104.0,DE,,,,,,,,,189259104.0,1.0,HIV infection
18928015,189280155,5,F,20150101.0,20230424.0,20210223,20230427,PER,,US-GILEAD-2021-0517985,GILEAD,,,,A,F,Y,83.92,KG,20230427.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Cough;Drug resistance;Emotional distress;Osteopenia;Pain;Rib fracture;Wrist fracture,189280155.0,OT,,,189280155.0,1.0,2006.0,2010.0,,,189280155.0,1.0,HIV infection
18929654,189296541,1,I,,20210209.0,20210223,20210223,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013750,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210223.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue,189296541.0,OT,,,,,,,,,189296541.0,1.0,HIV infection
18930155,189301551,1,I,,20210209.0,20210223,20210223,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013645,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210223.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities,189301551.0,OT,,,,,,,,,189301551.0,1.0,HIV infection
18932084,189320842,2,F,,20210614.0,20210224,20210623,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-084598",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20210623.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,189320842.0,OT,,,,,,,,,189320842.0,1.0,HIV infection
18932495,189324952,2,F,200906.0,20210924.0,20210224,20210930,EXP,,US-GILEAD-2021-0517968,GILEAD,,42.0,YR,A,M,Y,81.65,KG,20210930.0,,LW,US,US,SUSTIVA,Abdominal discomfort;Abnormal dreams;Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Decreased appetite;Emotional distress;Femur fracture;Hand fracture;Lower limb fracture;Osteopenia;Pain;Road traffic accident;Weight decreased,189324952.0,OT,,,189324952.0,1.0,2001.0,2005.0,,,189324952.0,1.0,HIV infection
18934893,189348933,3,F,20110401.0,20230407.0,20210224,20230412,EXP,,US-GILEAD-2021-0517983,GILEAD,,53.0,YR,A,F,Y,74.83,KG,20230412.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bacterial infection;Depression;Diarrhoea;Emotional distress;Fungal infection;Intervertebral disc degeneration;Neck pain;Osteoarthritis;Osteopenia;Pain;Upper limb fracture;Wrist fracture,189348933.0,OT,,,189348933.0,1.0,2008.0,201811.0,,,189348933.0,1.0,HIV infection
18936387,189363873,3,F,20151017.0,20231002.0,20210224,20231004,EXP,,US-GILEAD-2021-0517963,GILEAD,,56.0,YR,A,M,Y,83.9,KG,20231003.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Emotional distress;Gait disturbance;Osteoporosis;Pain;Renal impairment;Weight bearing difficulty,189363873.0,OT,,,189363873.0,1.0,2007.0,201908.0,,,189363873.0,1.0,HIV infection
18954100,189541005,5,F,,20230320.0,20210301,20230327,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053499,VIIV,,,,,,Y,,,20230327.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189541005.0,OT,,,,,,,,,189541005.0,1.0,HIV infection
18954111,189541115,5,F,,20230320.0,20210301,20230327,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053499,GLAXOSMITHKLINE,,,,,,Y,,,20230327.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189541115.0,OT,,,,,,,,,189541115.0,1.0,HIV infection
18957139,189571396,6,F,20201101.0,20210617.0,20210302,20210626,EXP,,PT-AUROBINDO-AUR-APL-2021-008814,AUROBINDO,,28.0,YR,,M,Y,92.0,KG,20210626.0,,PH,PT,PT,Efavirenz Aurovitas Film Coated Tablets,Anxiety;Headache;Hyperhidrosis,189571396.0,OT,,,189571396.0,1.0,20201101.0,,,,189571396.0,1.0,HIV infection
18958371,189583712,2,F,20210101.0,20211115.0,20210302,20211125,EXP,,CZ-VIIV HEALTHCARE LIMITED-CZ2021EME053964,VIIV,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending. Acta medicinae. 2021;10(14):50-52",53.0,YR,,M,Y,,,20211125.0,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,189583712.0,HO,,,189583712.0,1.0,199502.0,19990322.0,434.0,DAY,189583712.0,1.0,HIV infection
18958395,189583952,2,F,20210101.0,20211115.0,20210302,20211125,EXP,,CZ-GLAXOSMITHKLINE-CZ2021EME053964,GLAXOSMITHKLINE,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending. Acta medicinae. 2021;10(14):50-52",53.0,YR,,M,Y,,,20211125.0,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,189583952.0,OT,,,189583952.0,1.0,199502.0,19990322.0,434.0,DAY,189583952.0,1.0,HIV infection
18963107,189631071,1,I,,20210225.0,20210303,20210303,EXP,,ZA-MYLANLABS-2021M1013354,MYLAN,,45.0,YR,,F,Y,,,20210303.0,,HP,ZA,ZA,EFAVIRENZ.,Acute kidney injury;Drug-induced liver injury;Mixed liver injury,189631071.0,OT,,,,,,,,,189631071.0,1.0,HIV infection
18968421,189684211,1,I,,20210225.0,20210304,20210304,EXP,,ZA-MYLANLABS-2021M1013396,MYLAN,,32.0,YR,,F,Y,,,20210304.0,,HP,ZA,ZA,EFAVIRENZ.,Cholestatic liver injury;Drug-induced liver injury,189684211.0,OT,,,,,,,,,189684211.0,1.0,HIV infection
18971386,189713861,1,I,,20210222.0,20210304,20210304,EXP,,DE-AUROBINDO-AUR-APL-2021-008585,AUROBINDO,,57.0,YR,,M,Y,,,20210305.0,,CN,DE,DE,EFAVIRENZ.,Drug resistance,189713861.0,OT,,,,,,,,,189713861.0,1.0,HIV infection
18972408,189724081,1,I,,20210302.0,20210305,20210305,EXP,,CA-ROCHE-2782290,ROCHE,,54.0,YR,,M,Y,,,20210305.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189724081.0,OT,,,,,,,,,189724081.0,1.0,HIV infection
18975810,189758102,2,F,2004.0,20210927.0,20210305,20210930,EXP,,US-GILEAD-2021-0519262,GILEAD,,,,E,M,Y,86.17,KG,20210930.0,,LW,US,US,SUSTIVA,Anger;Anhedonia;Anxiety;Chronic kidney disease;Decreased appetite;Depression;Emotional distress;Fatigue;Pain;Peripheral swelling;Renal failure;Suicidal ideation,189758102.0,OT,,,189758102.0,1.0,2001.0,20080201.0,,,189758102.0,1.0,HIV infection
18980075,189800753,3,F,20101001.0,20231024.0,20210308,20231026,EXP,,US-GILEAD-2021-0519282,GILEAD,,52.0,YR,A,M,Y,74.83,KG,20231026.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arteriosclerosis coronary artery;Bone density decreased;Chronic kidney disease;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal disorder;Renal impairment,189800753.0,OT,,,189800753.0,1.0,20090210.0,20130209.0,1460.0,DAY,189800753.0,1.0,HIV infection
18980892,189808922,2,F,20181214.0,20211126.0,20210308,20211204,EXP,,CZ-ABBVIE-21K-217-3801302-00,ABBVIE,,53.0,YR,,M,Y,,,20211204.0,,HP,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,189808922.0,OT,,,189808922.0,1.0,20000912.0,20161016.0,434.0,DAY,189808922.0,1.0,HIV infection
18986747,189867473,3,F,20150301.0,20230403.0,20210309,20230408,EXP,,US-GILEAD-2021-0519942,GILEAD,,55.0,YR,A,F,Y,86.168,KG,20230408.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Fatigue;Fibula fracture;Hip fracture;Multiple fractures;Osteoporosis;Pain;Spinal compression fracture,189867473.0,OT,,,189867473.0,1.0,2010.0,201902.0,,,189867473.0,1.0,HIV infection
18987681,189876813,3,F,20201101.0,20210621.0,20210309,20210624,EXP,PT-INFARMED-F202102-1682,PT-GILEAD-2021-0519736,GILEAD,,28.0,YR,A,M,Y,92.0,KG,20210624.0,,PH,PT,PT,EFAVIRENZ AUROBINDO,Anxiety;Headache;Hyperhidrosis,189876813.0,OT,,,189876813.0,1.0,20201101.0,,,,189876813.0,1.0,HIV infection
18989016,189890161,1,I,,20210224.0,20210309,20210309,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-085635",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20210309.0,,MD,DE,DE,EFAVIRENZ.,Drug resistance,189890161.0,OT,,,,,,,,,189890161.0,1.0,HIV infection
19000469,190004692,2,F,20181214.0,20211130.0,20210312,20211205,EXP,,CZ-JNJFOC-20210312901,JOHNSON AND JOHNSON,,53.0,YR,A,M,Y,,,20211206.0,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dysuria;HIV infection;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Toxicity to various agents;Urinary tract infection;Virologic failure,190004692.0,OT,,,190004692.0,1.0,20170214.0,19990322.0,434.0,DAY,190004692.0,1.0,HIV infection
19002827,190028271,1,I,,20210224.0,20210312,20210312,EXP,,NVSC2021DE043726,NOVARTIS,,57.0,YR,,M,Y,,,20210312.0,,HP,DE,DE,EFAVIRENZ.,Drug resistance,190028271.0,OT,,,,,,,,,190028271.0,1.0,HIV infection
19004847,190048471,1,I,,20210308.0,20210312,20210312,EXP,,PH-GILEAD-2021-0520575,GILEAD,"DITAN I, ANDAL VM, PAGALING G, IGNACIO KH, DIMAL NP, ROXAS AJ. CRYPTOCOCCAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (C?IRIS) PRESENTING AS ACUTE CEREBELLITIS: A CASE REPORT AND REVIEW OF LITERATURE. UNK. 2020?101:UNK. DOI:10.1016/J.IJID.2020.09.462",30.0,YR,A,M,Y,,,20210312.0,,HP,PH,PH,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,190048471.0,HO,,,,,,,,,190048471.0,1.0,HIV infection
19013794,190137941,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889833,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190137941.0,OT,,,,,,,,,190137941.0,1.0,HIV infection
19013877,190138772,2,F,,20210519.0,20210316,20210528,EXP,,CA-TEVA-2021-CA-1889881,TEVA,,54.0,YR,A,M,Y,,,20210528.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190138772.0,OT,,,,,,,,,190138772.0,1.0,HIV infection
19014954,190149542,2,F,20181214.0,20211129.0,20210316,20211207,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-088636",BOEHRINGER INGELHEIM,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending. Acta medicinae. 2021;10(14):50-52",53.0,YR,A,M,Y,,,20211208.0,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,190149542.0,HO,,,190149542.0,5.0,20050808.0,20061016.0,434.0,DAY,190149542.0,1.0,HIV infection
19016203,190162031,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889879,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190162031.0,OT,,,,,,,,,190162031.0,1.0,HIV infection
19017605,190176051,1,I,,20210311.0,20210317,20210317,EXP,,CA-ROCHE-2789247,ROCHE,,54.0,YR,,M,Y,,,20210317.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190176051.0,OT,,,,,,,,,190176051.0,1.0,HIV infection
19019101,190191011,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889860,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190191011.0,OT,,,,,,,,,190191011.0,1.0,HIV infection
19019103,190191031,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1890017,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190191031.0,OT,,,,,,,,,190191031.0,1.0,HIV infection
19019104,190191041,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889535,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190191041.0,OT,,,,,,,,,190191041.0,1.0,HIV infection
19019106,190191061,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1890025,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190191061.0,OT,,,,,,,,,190191061.0,1.0,HIV infection
19019108,190191083,3,F,,20210830.0,20210316,20210909,EXP,,CA-TEVA-2021-CA-1889831,TEVA,,54.0,YR,A,M,Y,,,20210909.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190191083.0,OT,,,,,,,,,190191083.0,1.0,HIV infection
19019110,190191103,3,F,,20210830.0,20210316,20210908,EXP,,CA-TEVA-2021-CA-1890032,TEVA,,54.0,YR,A,M,Y,,,20210908.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190191103.0,OT,,,,,,,,,190191103.0,1.0,HIV infection
19019120,190191201,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889840,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190191201.0,OT,,,,,,,,,190191201.0,1.0,HIV infection
19019122,190191221,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889900,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190191221.0,OT,,,,,,,,,190191221.0,1.0,HIV infection
19019136,190191361,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889901,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190191361.0,OT,,,,,,,,,190191361.0,1.0,HIV infection
19019137,190191371,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1890035,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190191371.0,OT,,,,,,,,,190191371.0,1.0,HIV infection
19019139,190191391,1,I,,20210308.0,20210316,20210316,EXP,,CA-TEVA-2021-CA-1889814,TEVA,,54.0,YR,A,M,Y,,,20210316.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190191391.0,OT,,,,,,,,,190191391.0,1.0,HIV infection
19019479,190194792,2,F,20120402.0,20210818.0,20210316,20210823,EXP,,US-GILEAD-2021-0520123,GILEAD,,51.0,YR,A,M,Y,82.55,KG,20210823.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Decreased interest;Emotional distress;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal impairment;Rib fracture;Sleep disorder;Upper limb fracture,190194792.0,OT,,,190194792.0,1.0,2006.0,20120611.0,,,190194792.0,1.0,HIV infection
19022359,190223594,4,F,,20220712.0,20210318,20220714,EXP,,DE-009507513-2103DEU001244,MERCK,,57.0,YR,,M,Y,,,20220714.0,,MD,DE,DE,EFAVIRENZ,Drug resistance,190223594.0,OT,,,,,,,,,190223594.0,1.0,HIV infection
19022399,190223991,1,I,,20210311.0,20210317,20210317,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2021APC060859,VIIV,,41.0,YR,,M,Y,,,20210317.0,,MD,CN,CN,EFAVIRENZ.,Abdominal pain;Abdominal pain lower;Acute kidney injury;Anuria;CD4 lymphocytes decreased;Death;Gastrointestinal oedema;Pancreatitis acute,190223991.0,HO,,,,,,,,,190223991.0,1.0,HIV infection
19022401,190224011,1,I,,20210311.0,20210317,20210317,EXP,,CN-GLAXOSMITHKLINE-CN2021APC060859,GLAXOSMITHKLINE,,41.0,YR,,M,Y,,,20210317.0,,MD,CN,CN,EFAVIRENZ.,Abdominal pain;Abdominal pain lower;Acute kidney injury;Anuria;CD4 lymphocytes decreased;Death;Gastrointestinal oedema;Pancreatitis acute,190224011.0,HO,,,,,,,,,190224011.0,1.0,HIV infection
19024102,190241021,1,I,,20210304.0,20210318,20210318,EXP,,DE-35507-2021-03271,LUPIN,,57.0,YR,,M,Y,,,20210318.0,,CN,NL,DE,EFAVIRENZ.,Drug resistance,190241021.0,OT,,,,,,,,,190241021.0,1.0,HIV infection
19031184,190311841,1,I,,20210315.0,20210319,20210319,EXP,,FR-GILEAD-2021-0521755,GILEAD,"DE CASTRO N, MARCY O, CHAZALLON C, MESSOU E, EHOLIE S, N^TAKPE JB, BHATT N, KHOSA C, TIMANA MI, LAUREILLARD, CHAU GD, DOMERGUE A, VELOSO V, ESCADA R, WAGNER CS, DELAUGERRE C, ANGLARET, MOLINA JM. STANDARD DOSE RALTEGRAVIR OR EFAVIRENZ?BASED ANTIRETROVIRAL TREATMENT FOR PATIENTS CO?INFECTED WITH HIV AND TUBERCULOSIS (ANRS 12 300 REFLATE TB 2): AN OPEN?LABEL, NON?INFERIORITY, RANDOMISED, PHASE 3 TRIAL. LANCET INFECT DIS.. 2021?UNK:1?23. DOI:10.1016/S1473?3099(20)30869?0",,,A,,Y,,,20210319.0,,MD,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis,190311841.0,OT,,,,,,,,,190311841.0,1.0,HIV infection
19032425,190324251,1,I,,20210308.0,20210319,20210319,PER,,PK-LUPIN PHARMACEUTICALS INC.-2021-03297,LUPIN,,49.0,YR,,F,Y,,,20210319.0,,HP,PK,PK,EFAVIRENZ.,Drug ineffective,190324251.0,OT,,,190324251.0,2.0,2017.0,,,,190324251.0,1.0,HIV-associated neurocognitive disorder
19033823,190338232,2,F,20181214.0,20211201.0,20210319,20211208,EXP,,CZ-ROCHE-2786120,ROCHE,"Reporter known to authority, Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending.. Acta medicinae 2021;10(14):50-52.",53.0,YR,,M,Y,,,20211208.0,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,190338232.0,HO,,,190338232.0,4.0,20050808.0,20061016.0,435.0,DAY,190338232.0,1.0,HIV infection
19034484,190344841,1,I,,20210310.0,20210319,20210319,EXP,,CA-TEVA-2021-CA-1890105,TEVA,,54.0,YR,A,M,Y,,,20210319.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,190344841.0,OT,,,,,,,,,190344841.0,1.0,HIV infection
19034557,190345573,3,F,,20211222.0,20210319,20220101,EXP,,CZ-009507513-2103CZE003413,MERCK,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending.. Acta medicinae. 2021;10(14):50-2",53.0,YR,,M,Y,,,20220101.0,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Glucose tolerance impaired;Hypertension,,,,,190345573.0,1.0,20090507.0,20061016.0,434.0,DAY,190345573.0,4.0,HIV infection
19039334,190393341,1,I,,20210309.0,20210322,20210322,EXP,,IN-GLAXOSMITHKLINE-IN2021GSK061250,GLAXOSMITHKLINE,,45.0,YR,,M,Y,,,20210322.0,,HP,IN,IN,EFAVIRENZ.,B-cell lymphoma;Drug ineffective;Mouth ulceration;Non-Hodgkin's lymphoma;Oral discomfort;Oral disorder;Oral pain;Pyrexia;Virologic failure;Weight decreased,190393341.0,OT,,,,,,,,,190393341.0,1.0,Antiretroviral therapy
19039343,190393431,1,I,,20210309.0,20210322,20210322,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2021GSK061250,VIIV,,45.0,YR,,M,Y,,,20210322.0,,HP,IN,IN,EFAVIRENZ.,B-cell lymphoma;Drug ineffective;Mouth ulceration;Non-Hodgkin's lymphoma;Oral discomfort;Oral disorder;Oral pain;Pyrexia;Virologic failure;Weight decreased,190393431.0,OT,,,,,,,,,190393431.0,1.0,Antiretroviral therapy
19040818,190408182,2,F,,20211115.0,20210322,20211118,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-023401,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20211118.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,190408182.0,OT,,,,,,,,,190408182.0,1.0,HIV infection
19047220,190472202,2,F,2007.0,20210909.0,20210323,20210921,EXP,,US-GILEAD-2021-0522286,GILEAD,,,,A,M,Y,86.17,KG,20210921.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Cyst;Depression;Dysstasia;Emotional distress;Femoral neck fracture;Foot fracture;Gait disturbance;Hand fracture;Hip fracture;Osteoporosis;Pain,190472202.0,OT,,,190472202.0,1.0,20041201.0,201908.0,,,190472202.0,1.0,HIV infection
19048139,190481392,2,F,200208.0,20210921.0,20210324,20210927,EXP,,US-GILEAD-2021-0522309,GILEAD,,48.0,YR,A,M,Y,68.93,KG,20210927.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Depression;Emotional distress;Foot fracture;Gait disturbance;Hand fracture;Mobility decreased;Osteoporosis;Pain;Physical deconditioning;Spinal compression fracture;Tibia fracture,190481392.0,OT,,,190481392.0,1.0,2004.0,201801.0,,,190481392.0,1.0,HIV infection
19053681,190536811,1,I,,20210310.0,20210325,20210325,EXP,,DE-TEVA-2021-DE-1891494,TEVA,,57.0,YR,A,M,Y,,,20210325.0,,CN,DE,DE,EFAVIRENZ.,Drug resistance,190536811.0,OT,,,,,,,,,190536811.0,1.0,HIV infection
19059090,190590902,2,F,20210101.0,20211127.0,20210325,20211210,EXP,,CZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-022037,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20211210.0,,CN,CZ,CZ,EFAVIRENZ,Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Malignant neoplasm progression;Multiple-drug resistance;Pancytopenia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,190590902.0,OT,,,190590902.0,2.0,20000403.0,19990322.0,434.0,DAY,190590902.0,1.0,HIV infection
19061485,190614852,2,F,20120320.0,20210809.0,20210325,20210815,EXP,,US-GILEAD-2021-0522288,GILEAD,,,,,M,Y,97.07,KG,20210815.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteoarthritis;Osteoporosis;Pain;Patella fracture;Protein urine present,190614852.0,OT,,,190614852.0,1.0,20081031.0,2006.0,,,190614852.0,1.0,HIV infection
19069125,190691251,1,I,,20210316.0,20210329,20210329,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-026456,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,,,20210329.0,,MD,RO,RO,EFAVIRENZ.,Dyslipidaemia;Lipodystrophy acquired,190691251.0,OT,,,,,,,,,190691251.0,1.0,HIV infection
19074794,190747943,3,F,20110201.0,20230408.0,20210330,20230412,EXP,,US-GILEAD-2021-0523126,GILEAD,,45.0,YR,A,M,Y,113.38,KG,20230412.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Fatigue;Hypokinesia;Pain;Pollakiuria,190747943.0,OT,,,190747943.0,1.0,20090609.0,20101114.0,523.0,DAY,190747943.0,1.0,HIV infection
19074827,190748272,2,F,20100101.0,20210924.0,20210331,20211001,EXP,,US-GILEAD-2021-0523128,GILEAD,,,,A,M,Y,86.17,KG,20211001.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Emotional distress;Gait disturbance;Infection;Osteoporosis;Pain,190748272.0,OT,,,190748272.0,1.0,2006.0,2010.0,,,190748272.0,1.0,HIV infection
19075820,190758203,3,F,20151201.0,20230426.0,20210330,20230501,PER,,US-GILEAD-2021-0523103,GILEAD,,55.0,YR,A,M,Y,100.68,KG,20230501.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Dysstasia;Emotional distress;Gait disturbance;Pain;Renal failure,190758203.0,HO,,,190758203.0,1.0,2009.0,2006.0,,,190758203.0,1.0,HIV infection
19075869,190758693,3,F,20070801.0,20230407.0,20210330,20230412,EXP,,US-GILEAD-2021-0523102,GILEAD,,57.0,YR,E,F,Y,68.04,KG,20230412.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Emotional distress;Gait disturbance;Joint range of motion decreased;Joint swelling;Multiple fractures;Osteopenia;Osteoporosis;Pain;Skeletal injury,190758693.0,HO,,,190758693.0,1.0,2001.0,201201.0,269.0,DAY,190758693.0,1.0,HIV infection
19075896,190758963,3,F,20161001.0,20230404.0,20210330,20230411,EXP,,US-GILEAD-2021-0523094,GILEAD,,52.0,YR,A,F,Y,83.447,KG,20230411.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Dyspnoea;Emotional distress;End stage renal disease;Gout;Pain;Quality of life decreased;Renal failure;Renal injury,190758963.0,HO,,,190758963.0,1.0,2015.0,201909.0,,,190758963.0,1.0,HIV infection
19080220,190802202,2,F,,20210326.0,20210401,20210403,EXP,,SE-AUROBINDO-AUR-APL-2021-013260,AUROBINDO,,36.0,YR,,M,Y,79.0,KG,20210403.0,,HP,SE,SE,Efavirenz Film?coated Tablet,Abnormal dreams;Coma;Erectile dysfunction,190802202.0,OT,,,,,,,,,190802202.0,1.0,HIV infection
19080655,190806553,3,F,20090101.0,20231021.0,20210331,20231023,EXP,,US-GILEAD-2021-0523123,GILEAD,,,,A,M,Y,110.0,KG,20231023.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Dysstasia;Emotional distress;Gait disturbance;Hip arthroplasty;Joint range of motion decreased;Osteopenia;Osteoporosis;Pain;Shoulder arthroplasty;Skeletal injury;Spinal fracture,190806553.0,OT,,,190806553.0,1.0,2003.0,201504.0,,,190806553.0,1.0,HIV infection
19095903,190959031,1,I,,20210331.0,20210406,20210406,EXP,,US-AUROBINDO-AUR-APL-2021-013621,AUROBINDO,,60.0,YR,,M,Y,,,20210406.0,,HP,US,US,EFAVIRENZ.,Cytomegalovirus infection;Cytomegalovirus infection reactivation;Malabsorption;Off label use,190959031.0,OT,,,,,,,,,190959031.0,1.0,HIV infection
19117314,191173143,3,F,20201014.0,20220807.0,20210409,20220809,EXP,,CN-GILEAD-2021-0521065,GILEAD,,,,A,M,Y,50.0,KG,20220809.0,,HP,CN,CN,EFAVIRENZ,Insomnia,191173143.0,DS,,,191173143.0,1.0,20200919.0,20201214.0,86.0,DAY,191173143.0,1.0,HIV infection
19118304,191183041,1,I,,20210329.0,20210409,20210409,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2021APC071715,VIIV,,33.0,YR,,M,Y,,,20210409.0,,MD,CN,CN,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Virologic failure,191183041.0,OT,,,,,,,,,191183041.0,1.0,HIV infection
19118317,191183171,1,I,,20210329.0,20210409,20210409,EXP,,CN-GLAXOSMITHKLINE-CN2021APC071715,GLAXOSMITHKLINE,,33.0,YR,,M,Y,,,20210409.0,,MD,CN,CN,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Virologic failure,191183171.0,OT,,,,,,,,,191183171.0,1.0,HIV infection
19118364,191183641,1,I,,20210408.0,20210409,20210409,EXP,GB-MHRA-EYC 00246831,GB-GILEAD-2021-0524732,GILEAD,,64.0,YR,A,M,Y,106.0,KG,20210409.0,,CN,GB,GB,EFAVIRENZ.,Weight increased,191183641.0,OT,,,191183641.0,1.0,20190101.0,,,,191183641.0,1.0,HIV infection
19132855,191328554,4,F,20110101.0,20230508.0,20210413,20230512,PER,,US-GILEAD-2021-0524831,GILEAD,,,,E,F,Y,90.703,KG,20230512.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Drug ineffective;Emotional distress;Fatigue;Hypertension;Nephropathy;Pain;Renal failure;Renal impairment,191328554.0,OT,,,191328554.0,1.0,2001.0,2018.0,,,191328554.0,1.0,HIV infection
19132976,191329763,3,F,20090101.0,20230427.0,20210413,20230502,EXP,,US-GILEAD-2021-0524855,GILEAD,,52.0,YR,A,M,Y,80.726,KG,20230502.0,,LW,US,US,SUSTIVA,Amnesia;Anhedonia;Anxiety;Asthenia;Brain fog;Chronic kidney disease;Depression;Emotional distress;Exercise tolerance decreased;Fatigue;Flatulence;Insomnia;Memory impairment;Nephropathy;Pain;Pollakiuria;Renal impairment;Suicide attempt;Urinary retention,191329763.0,OT,,,191329763.0,1.0,2004.0,2006.0,22344.0,HR,191329763.0,1.0,HIV infection
19137612,191376122,2,F,2009.0,20210730.0,20210414,20210806,EXP,,US-GILEAD-2021-0524852,GILEAD,,40.0,YR,A,M,Y,142.0,KG,20210806.0,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Foot fracture;Pain,191376122.0,OT,,,191376122.0,1.0,200805.0,,,,191376122.0,1.0,HIV infection
19139724,191397241,1,I,,20210402.0,20210415,20210415,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2021030774,MACLEODS,"NWAESEI AS, MOYE?DICKERSON PM, DRETLER RH. EFAVIRENZ?INDUCED VANISHING BILE DUCT SYNDROME: A CASE REPORT.. JOURNAL OF PHARMACY PRACTICE. 2021?34(2):319?324",,,,,Y,,,20210415.0,,HP,GB,GB,EFAVIRENZ.,Sepsis;Vanishing bile duct syndrome,191397241.0,HO,,,,,,,,,191397241.0,1.0,Antiretroviral therapy
19140898,191408981,1,I,,20210412.0,20210415,20210415,EXP,,CN-GILEAD-2021-0525100,GILEAD,,,,A,,Y,,,20210415.0,,MD,CN,CN,EFAVIRENZ.,Liver injury,191408981.0,OT,,,,,,,,,191408981.0,1.0,Acquired immunodeficiency syndrome
19142655,191426551,1,I,,20210407.0,20210416,20210416,EXP,,GB-AUROBINDO-AUR-APL-2021-015173,AUROBINDO,,58.0,YR,,F,Y,,,20210416.0,,CN,GB,GB,Efavirenz Film?coated Tablet,Suicidal ideation,191426551.0,OT,,,,,,,,,191426551.0,1.0,HIV infection
19149483,191494831,1,I,,20210407.0,20210417,20210417,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2021030802,MACLEODS,,,,,,Y,,,20210417.0,,CN,GB,GB,EFAVIRENZ.,Suicidal ideation,191494831.0,OT,,,,,,,,,191494831.0,1.0,HIV infection
19153691,191536911,1,I,,20210412.0,20210419,20210419,EXP,,ID-GILEAD-2021-0525429,GILEAD,"PUDJIATI S, RADIONO S, SOEBONO H, SISWATI A, WIROHADIDJOJO Y, KURNIAWATI C. SUCCESSFUL TREATMENT OF AIDS?ASSOCIATED TALAROMYCOSIS WITH LOW?DOSE ITRACONAZOLE. JAAD CASE REP.. 2020?6(12):1278?1280. DOI:10.1016/J.JDCR.2020.09.015",41.0,YR,A,M,Y,,,20210419.0,,MD,ID,ID,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,191536911.0,OT,,,,,,,,,191536911.0,1.0,HIV infection
19158544,191585441,1,I,2013.0,20200828.0,20210420,20210420,EXP,,US-VIIV HEALTHCARE LIMITED-US2020186935,VIIV,,,,,M,Y,83.9,KG,20210420.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Pain;Renal failure,191585441.0,OT,,,191585441.0,1.0,2013.0,2019.0,,,191585441.0,1.0,HIV infection
19158634,191586341,1,I,2013.0,20200828.0,20210420,20210420,EXP,,US-GLAXOSMITHKLINE-US2020186935,GLAXOSMITHKLINE,,,,,M,Y,83.9,KG,20210420.0,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Pain;Renal failure,191586341.0,OT,,,191586341.0,1.0,2013.0,2019.0,,,191586341.0,1.0,HIV infection
19169020,191690203,3,F,,20230123.0,20210422,20230202,EXP,,CA-TEVA-2021-CA-1901914,TEVA,,44.0,YR,A,M,Y,,,20230202.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,191690203.0,HO,,,,,,,,,191690203.0,1.0,HIV infection
19175835,191758351,1,I,,20210412.0,20210424,20210424,EXP,,IR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-037619,BRISTOL MYERS SQUIBB,"HAJSADEGHI S, IRANPOUR A, KALANTARI S, DASHTI F. A RARE MANIFESTATION OF EXTRAPULMONARY TUBERCULOSIS: LEFT VENTRICULAR CARDIAC TUBERCULOMA IN AN HIV INFECTED MALE ^CASE REPORT^. CARDIOVASCULAR DIAGNOSIS AND THERAPY. 2020?10(5):1341?4",37.0,YR,,M,Y,,,20210424.0,,HP,IR,IR,EFAVIRENZ.,Cardiac disorder;Pericardial effusion;Pleural effusion;Tuberculosis,191758351.0,OT,,,,,,,,,191758351.0,1.0,HIV infection
19182539,191825392,2,F,,20220304.0,20210427,20220318,EXP,,RO-AUROBINDO-AUR-APL-2020-012807,AUROBINDO,,31.0,YR,,M,Y,,,20220318.0,,MD,RO,RO,EFAVIRENZ,Drug ineffective;Virologic failure,191825392.0,OT,,,,,,,,,191825392.0,1.0,HIV infection
19192355,191923554,4,F,,20230417.0,20210429,20230430,EXP,,CA-AUROBINDO-AUR-APL-2021-016522,AUROBINDO,,54.0,YR,,M,Y,,,20230429.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,191923554.0,OT,,,,,,,,,191923554.0,1.0,HIV infection
19198418,191984182,2,F,,20210425.0,20210430,20210519,EXP,,CN-GILEAD-2021-0527089,GILEAD,LI LL. ANALYSIS AND RESEARCH ON THE CLINICAL EFFECTS AND ADVERSE REACTIONS OF AIDS PATIENTS TREATED WITH DIFFERENT ANTIVIRAL REGIMENS. WORLD JOURNAL OF COMPLEX MEDICINE. 2021?272:192?194. DOI:10.11966/J.ISSN.2095?994X. 2021.07.02.63,,,A,,Y,,,20210519.0,,MD,CN,CN,EFAVIRENZ.,Liver injury,191984182.0,OT,,,,,,,,,191984182.0,1.0,Acquired immunodeficiency syndrome
19198419,191984192,2,F,,20210425.0,20210430,20210519,EXP,,CN-GILEAD-2021-0527090,GILEAD,LI LL. ANALYSIS AND RESEARCH ON THE CLINICAL EFFECTS AND ADVERSE REACTIONS OF AIDS PATIENTS TREATED WITH DIFFERENT ANTIVIRAL REGIMENS. WORLD JOURNAL OF COMPLEX MEDICINE. 2021?272:192?194. DOI:10.11966/J.ISSN.2095?994X. 2021.07.02.63,,,A,,Y,,,20210519.0,,MD,CN,CN,EFAVIRENZ.,Renal injury,191984192.0,OT,,,,,,,,,191984192.0,1.0,Acquired immunodeficiency syndrome
19204406,192044061,1,I,,20210419.0,20210503,20210503,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-039048,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,79.38,KG,20210503.0,,HP,US,US,SUSTIVA,Anaphylactic reaction,192044061.0,OT,,,,,,,,,192044061.0,1.0,Acquired immunodeficiency syndrome
19208184,192081842,2,F,,20210920.0,20210503,20210927,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK093641,VIIV,,54.0,YR,,M,Y,,,20210927.0,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,192081842.0,OT,,,,,,,,,192081842.0,1.0,HIV infection
19208192,192081922,2,F,,20210920.0,20210503,20210927,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK093641,GLAXOSMITHKLINE,,54.0,YR,,M,Y,,,20210927.0,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,192081922.0,OT,,,,,,,,,192081922.0,1.0,HIV infection
19212064,192120641,1,I,,20210427.0,20210504,20210504,EXP,,US-VIIV HEALTHCARE LIMITED-US2021AMR093228,VIIV,,,,,F,Y,79.38,KG,20210504.0,,CN,US,US,SUSTIVA,Anaphylactic reaction;Throat tightness;Thyroiditis;Urticaria,192120641.0,OT,,,192120641.0,3.0,2003.0,,,,192120641.0,1.0,Acquired immunodeficiency syndrome
19212598,192125981,1,I,20210408.0,20210422.0,20210504,20210504,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-039386,BRISTOL MYERS SQUIBB,,27.0,YR,,M,Y,75.0,KG,20210504.0,,CN,FR,FR,EFAVIRENZ.,Confusional state;Loss of consciousness;Nausea;Pruritus;Pyrexia;Vertigo,192125981.0,OT,,,192125981.0,1.0,20210401.0,,,,192125981.0,1.0,Prophylaxis against HIV infection
19214814,192148143,3,F,20160101.0,20230512.0,20210504,20230516,PER,,US-GILEAD-2021-0527867,GILEAD,,,,A,M,Y,63.0,KG,20230516.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteopenia;Pain,,,,,192148143.0,1.0,2004.0,200903.0,,,192148143.0,1.0,HIV infection
19215171,192151715,5,F,20190614.0,20230420.0,20210504,20230425,EXP,,US-GILEAD-2021-0527872,GILEAD,,63.0,YR,A,M,Y,113.38,KG,20230425.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Dyspareunia;Emotional distress;Gait disturbance;Insomnia;Multiple fractures;Osteopenia;Osteoporosis;Pain;Pathological fracture;Physical disability;Renal failure;Spinal fracture,192151715.0,OT,,,192151715.0,1.0,2004.0,202009.0,4602.0,DAY,192151715.0,1.0,HIV infection
19215421,192154213,3,F,20180114.0,20231031.0,20210504,20231102,EXP,,US-GILEAD-2021-0527871,GILEAD,,69.0,YR,E,F,Y,86.18,KG,20231102.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,192154213.0,OT,,,192154213.0,1.0,2008.0,20180212.0,,,192154213.0,1.0,HIV infection
19220333,192203334,4,F,20190225.0,20230318.0,20210506,20230321,EXP,,US-GILEAD-2021-0527870,GILEAD,,53.0,YR,A,M,Y,140.59,KG,20230321.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Bone loss;Bone pain;Emotional distress;Fatigue;Osteopenia;Osteoporosis;Pain;Renal injury,192203334.0,OT,,,192203334.0,1.0,2002.0,201902.0,,,192203334.0,1.0,HIV infection
19221587,192215873,3,F,20080901.0,20230511.0,20210505,20230515,EXP,,US-GILEAD-2021-0527899,GILEAD,,70.0,YR,E,M,Y,72.562,KG,20230515.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Fall;Foot fracture;Gait disturbance;Hip fracture;Mobility decreased;Nephrolithiasis;Osteopenia;Osteoporosis;Pain,192215873.0,OT,,,192215873.0,1.0,200304.0,201108.0,,,192215873.0,1.0,HIV infection
19224072,192240723,3,F,20070101.0,20230914.0,20210505,20230918,PER,,US-GILEAD-2021-0527891,GILEAD,,50.0,YR,A,M,Y,95.238,KG,20230918.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteopenia;Pain;Post-traumatic stress disorder,,,,,192240723.0,1.0,200709.0,201203.0,1728.0,DAY,192240723.0,1.0,HIV infection
19224918,192249181,1,I,20210408.0,20210427.0,20210506,20210506,EXP,FR-AFSSAPS-PB20212147,FR-TEVA-2021-FR-1907478,TEVA,,27.0,YR,A,M,Y,75.0,KG,20210506.0,,CN,FR,FR,EFAVIRENZ.,Confusional state;Loss of consciousness;Nausea;Pruritus;Pyrexia;Vertigo,192249181.0,OT,,,192249181.0,1.0,20210401.0,20210410.0,,,192249181.0,1.0,Prophylaxis against HIV infection
19229151,192291514,4,F,20150527.0,20240411.0,20210506,20240415,PER,,US-GILEAD-2021-0528659,GILEAD,,46.0,YR,A,M,Y,85.27,KG,20240415.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone density decreased;Emotional distress;Fatigue;Foot fracture;Gait disturbance;Myalgia;Osteopenia;Pain,,,,,192291514.0,1.0,200601.0,201403.0,,,192291514.0,1.0,HIV infection
19243372,192433721,1,I,,20210505.0,20210511,20210511,EXP,,TH-MYLANLABS-2021M1027841,MYLAN,,27.0,YR,,F,Y,,,20210511.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192433721.0,OT,,,192433721.0,5.0,2000.0,,,,192433721.0,1.0,HIV infection
19243388,192433881,1,I,,20210505.0,20210511,20210511,EXP,,TH-MYLANLABS-2021M1027843,MYLAN,,35.0,YR,,M,Y,,,20210511.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192433881.0,OT,,,192433881.0,1.0,2009.0,,,,192433881.0,1.0,HIV infection
19248500,192485001,1,I,,20210505.0,20210512,20210512,EXP,,TH-MYLANLABS-2021M1027839,MYLAN,,24.0,YR,,M,Y,,,20210512.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192485001.0,OT,,,192485001.0,1.0,2015.0,,,,192485001.0,1.0,HIV infection
19250133,192501331,1,I,,20210505.0,20210512,20210512,EXP,,TH-MYLANLABS-2021M1027840,MYLAN,,35.0,YR,,F,Y,,,20210512.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192501331.0,OT,,,192501331.0,1.0,2000.0,,,,192501331.0,1.0,HIV infection
19250147,192501471,1,I,,20210505.0,20210512,20210512,EXP,,TH-MYLANLABS-2021M1027844,MYLAN,,57.0,YR,,M,Y,,,20210512.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192501471.0,OT,,,192501471.0,1.0,2013.0,,,,192501471.0,1.0,Acquired immunodeficiency syndrome
19250157,192501571,1,I,,20210505.0,20210512,20210512,EXP,,TH-MYLANLABS-2021M1027845,MYLAN,,35.0,YR,,F,Y,,,20210512.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192501571.0,OT,,,192501571.0,1.0,2007.0,,,,192501571.0,1.0,HIV infection
19258363,192583631,1,I,,20210505.0,20210514,20210514,EXP,,JP-VIIV HEALTHCARE LIMITED-VN2021GSK102373,VIIV,"KINAI E, NGUYEN HDT, DO HQ, MATSUMOTO S, NAGAI M, TANUMA J ET AL. INFLUENCE OF MATERNAL USE OF TENOFOVIR DISOPROXIL FUMARATE OR ZIDOVUDINE IN VIETNAMESE PREGNANT WOMEN WITH HIV ON INFANT GROWTH, RENAL FUNCTION, AND BONE HEALTH. PLOS ONE. 2021?16(4)",12.0,MON,,F,Y,9.0,KG,20210514.0,,HP,JP,VN,EFAVIRENZ.,Bone disorder;Foetal exposure during pregnancy;Live birth;Rickets,192583631.0,OT,,,192583631.0,1.0,20161227.0,,,,192583631.0,1.0,HIV infection
19258369,192583691,1,I,,20210505.0,20210514,20210514,EXP,,JP-GLAXOSMITHKLINE-VN2021GSK102373,GLAXOSMITHKLINE,"KINAI E, NGUYEN HDT, DO HQ, MATSUMOTO S, NAGAI M, TANUMA J ET AL. INFLUENCE OF MATERNAL USE OF TENOFOVIR DISOPROXIL FUMARATE OR ZIDOVUDINE IN VIETNAMESE PREGNANT WOMEN WITH HIV ON INFANT GROWTH, RENAL FUNCTION, AND BONE HEALTH. PLOS ONE. 2021?16(4)",12.0,MON,,F,Y,9.0,KG,20210514.0,,HP,JP,VN,EFAVIRENZ.,Bone disorder;Foetal exposure during pregnancy;Live birth;Rickets,192583691.0,OT,,,192583691.0,1.0,20161227.0,,,,192583691.0,1.0,HIV infection
19264810,192648101,1,I,2004.0,20210504.0,20210517,20210517,EXP,,ES-AUROBINDO-AUR-APL-2021-019110,AUROBINDO,"JOVER, F ET AL. SIMPLIFICACI?N DEL TRATAMIENTO ANTIRRETROVIRAL. N/A. N/A?N/A:N/A",66.0,YR,,M,Y,,,20210517.0,,MD,ES,ES,EFAVIRENZ.,Drug ineffective;Treatment failure,192648101.0,OT,,,,,,,,,192648101.0,1.0,HIV infection
19266013,192660131,1,I,,20210505.0,20210518,20210518,EXP,,TH-LUPIN PHARMACEUTICALS INC.-2021-07051,LUPIN,,27.0,YR,,F,Y,,,20210518.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192660131.0,OT,,,192660131.0,3.0,2000.0,,,,192660131.0,1.0,HIV infection
19266019,192660191,1,I,,20210505.0,20210518,20210518,EXP,,TH-LUPIN PHARMACEUTICALS INC.-2021-07052,LUPIN,,35.0,YR,,F,Y,,,20210518.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192660191.0,OT,,,192660191.0,1.0,2007.0,,,,192660191.0,1.0,HIV infection
19266022,192660221,1,I,,20210505.0,20210518,20210518,EXP,,TH-LUPIN PHARMACEUTICALS INC.-2021-07057,LUPIN,,24.0,YR,,M,Y,,,20210518.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192660221.0,OT,,,192660221.0,1.0,2015.0,,,,192660221.0,1.0,HIV infection
19267062,192670621,1,I,,20210505.0,20210517,20210517,EXP,,CA-GLAXOSMITHKLINE-TZ2021GSK097454,GLAXOSMITHKLINE,,10.0,YR,,F,Y,,,20210517.0,,HP,TZ,TZ,EFAVIRENZ.,Anaemia;Cytopenia;Histoplasmosis;Immunosuppression;Malnutrition;Pyrexia;Skin induration;Skin mass;Skin plaque;Skin ulcer;Treatment noncompliance;Virologic failure;Weight decreased,192670621.0,HO,,,192670621.0,1.0,,2016.0,,,192670621.0,1.0,Antiretroviral therapy
19267064,192670641,1,I,,20210505.0,20210517,20210517,EXP,,CA-VIIV HEALTHCARE LIMITED-TZ2021GSK097454,VIIV,,10.0,YR,,F,Y,,,20210517.0,,HP,TZ,TZ,EFAVIRENZ.,Anaemia;Cytopenia;Histoplasmosis;Immunosuppression;Malnutrition;Pyrexia;Skin induration;Skin mass;Skin plaque;Skin ulcer;Treatment noncompliance;Virologic failure;Weight decreased,192670641.0,OT,,,192670641.0,1.0,,2016.0,,,192670641.0,1.0,Antiretroviral therapy
19275538,192755381,1,I,,20210505.0,20210519,20210519,EXP,,TH-LUPIN PHARMACEUTICALS INC.-2021-07056,LUPIN,,57.0,YR,,M,Y,,,20210519.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192755381.0,OT,,,192755381.0,1.0,2013.0,,,,192755381.0,1.0,HIV infection
19275788,192757881,1,I,,20210505.0,20210519,20210519,EXP,,TH-LUPIN PHARMACEUTICALS INC.-2021-07050,LUPIN,,35.0,YR,,F,Y,,,20210519.0,,HP,TH,TH,EFAVIRENZ.,Drug resistance,192757881.0,OT,,,192757881.0,1.0,2000.0,,,,192757881.0,1.0,HIV infection
19280502,192805021,1,I,2004.0,20210512.0,20210521,20210521,EXP,,PT-AUROBINDO-AUR-APL-2021-020213,AUROBINDO,,55.0,YR,,F,Y,,,20210521.0,,MD,PT,PT,Efavirenz Film?coated Tablet,Major depression;Neuropathy peripheral,192805021.0,OT,,,192805021.0,1.0,2011.0,2014.0,,,192805021.0,1.0,HIV infection
19301800,193018001,1,I,,20210510.0,20210525,20210525,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-047350,BRISTOL MYERS SQUIBB,"BHATTACHARYA D, GUPTA A, TIERNEY C, HUANG S, PETERS MG, CHIPATO T, ET AL. HEPATOTOXICITY AND LIVER?RELATED MORTALITY IN WOMEN OF CHILDBEARING POTENTIAL LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS AND HIGH CD4 CELL COUNTS INITIATING EFAVIRENZ?CONTAINING REGIMENS. CLINICAL INFECTIOUS DISEASES. 2021?72(8):1342?9",,,A,F,Y,,,20210525.0,,HP,US,US,EFAVIRENZ.,Hepatitis,193018001.0,DE,,,,,,,,,193018001.0,1.0,HIV infection
19301842,193018421,1,I,,20210510.0,20210525,20210525,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-050670,BRISTOL MYERS SQUIBB,"BHATTACHARYA D, GUPTA A, TIERNEY C, HUANG S, PETERS MG, CHIPATO T, ET AL. HEPATOTOXICITY AND LIVER?RELATED MORTALITY IN WOMEN OF CHILDBEARING POTENTIAL LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS AND HIGH CD4 CELL COUNTS INITIATING EFAVIRENZ?CONTAINING REGIMENS. CLINICAL INFECTIOUS DISEASES. 2021?72(8):1342?9",,,A,F,Y,,,20210525.0,,HP,US,US,EFAVIRENZ.,Hepatitis,193018421.0,OT,,,,,,,,,193018421.0,1.0,HIV infection
19305993,193059931,1,I,,20210514.0,20210526,20210526,EXP,,CN-CIPLA LTD.-2021CN03687,CIPLA,,,,,,Y,,,20210526.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance,193059931.0,OT,,,,,,,,,193059931.0,1.0,Acquired immunodeficiency syndrome
19309038,193090381,1,I,,20210518.0,20210525,20210525,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021GSK110708,VIIV,,23.0,YR,,F,Y,,,20210525.0,,MD,GB,GB,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,193090381.0,OT,,,193090381.0,1.0,20180111.0,,,,193090381.0,1.0,HIV infection
19310362,193103621,1,I,,20210518.0,20210526,20210526,EXP,,CN-GLAXOSMITHKLINE-CN2021APC104723,GLAXOSMITHKLINE,,,,,,Y,,,20210526.0,,HP,CN,CN,EFAVIRENZ.,Chronic kidney disease,193103621.0,OT,,,,,,,,,193103621.0,1.0,HIV infection
19311081,193110811,1,I,,20210518.0,20210527,20210527,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2021APC104723,VIIV,,,,,,Y,,,20210526.0,,HP,CN,CN,EFAVIRENZ.,Chronic kidney disease,193110811.0,OT,,,,,,,,,193110811.0,1.0,HIV infection
19314076,193140761,1,I,,20210518.0,20210527,20210527,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2021GSK112037,VIIV,,,,,,Y,,,20210527.0,,HP,CN,CN,EFAVIRENZ.,Chronic kidney disease,193140761.0,OT,,,,,,,,,193140761.0,1.0,HIV infection
19314084,193140841,1,I,,20210518.0,20210527,20210527,EXP,,CN-GLAXOSMITHKLINE-CN2021GSK112037,GLAXOSMITHKLINE,,,,,,Y,,,20210527.0,,HP,CN,CN,EFAVIRENZ.,Chronic kidney disease,193140841.0,OT,,,,,,,,,193140841.0,1.0,HIV infection
19330723,193307231,1,I,,20210521.0,20210528,20210528,PER,,NG-LUPIN PHARMACEUTICALS INC.-2021-08419,LUPIN,,10.0,YR,,M,Y,,,20210529.0,,HP,NG,NG,EFAVIRENZ.,Impaired fasting glucose,,,,,,,,,,,193307231.0,1.0,HIV infection
19352075,193520751,1,I,,20210517.0,20210531,20210531,EXP,,CN-GLAXOSMITHKLINE-CN2021111926,GLAXOSMITHKLINE,,38.0,YR,,,Y,,,20210531.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,193520751.0,OT,,,193520751.0,1.0,201410.0,201411.0,,,193520751.0,1.0,HIV infection
19352099,193520991,1,I,,20210517.0,20210531,20210531,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2021111926,VIIV,,38.0,YR,,,Y,,,20210531.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,193520991.0,OT,,,193520991.0,1.0,201410.0,201411.0,,,193520991.0,1.0,HIV infection
19359425,193594251,1,I,,20210528.0,20210602,20210602,EXP,,GB-MYLANLABS-2021M1031866,MYLAN,,23.0,YR,,F,Y,,,20210602.0,,MD,GB,GB,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,193594251.0,OT,,,193594251.0,1.0,20180111.0,,,,193594251.0,1.0,HIV infection
19364447,193644471,1,I,,20210521.0,20210602,20210602,PER,,NG-LUPIN PHARMACEUTICALS INC.-2021-08420,LUPIN,,13.0,YR,,F,Y,,,20210602.0,,HP,CI,NG,EFAVIRENZ.,Impaired fasting glucose,,,,,,,,,,,193644471.0,1.0,HIV infection
19364448,193644481,1,I,,20210521.0,20210602,20210602,PER,,NG-LUPIN PHARMACEUTICALS INC.-2021-08421,LUPIN,,14.0,YR,,F,Y,,,20210602.0,,HP,CI,NG,EFAVIRENZ.,Impaired fasting glucose,,,,,,,,,,,193644481.0,1.0,HIV infection
19370072,193700723,3,F,20100601.0,20231027.0,20210603,20231030,EXP,,US-GILEAD-2021-0534078,GILEAD,,46.0,YR,A,M,Y,123.36,KG,20231030.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Cardiac failure congestive;Chronic kidney disease;Depression;Emotional distress;Hyperkalaemia;Pain;Renal failure,193700723.0,OT,,,193700723.0,1.0,2009.0,2016.0,,,193700723.0,1.0,HIV infection
19374072,193740722,2,F,20040101.0,20220216.0,20210603,20220221,EXP,,US-GILEAD-2021-0534101,GILEAD,,,,A,M,Y,79.365,KG,20220221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asocial behaviour;Asthenia;Chronic kidney disease;Decreased activity;Depression;Emotional distress;Mood swings;Musculoskeletal disorder;Pain;Pollakiuria,193740722.0,OT,,,193740722.0,1.0,2004.0,2015.0,,,193740722.0,1.0,HIV infection
19375558,193755581,1,I,,20210528.0,20210604,20210604,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME116426,VIIV,,62.0,YR,,M,Y,,,20210604.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,193755581.0,OT,,,193755581.0,1.0,20150301.0,,,,193755581.0,1.0,HIV infection
19380179,193801791,1,I,,20210528.0,20210607,20210607,EXP,,GB-AUROBINDO-AUR-APL-2021-022937,AUROBINDO,,23.0,YR,,F,Y,,,20210607.0,,MD,GB,GB,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,193801791.0,OT,,,193801791.0,1.0,20180111.0,,,,193801791.0,1.0,HIV infection
19381264,193812641,1,I,,20210601.0,20210607,20210607,EXP,,US-GLAXOSMITHKLINE-US2021GSK121574,GLAXOSMITHKLINE,,,,,,Y,,,20210607.0,,HP,US,US,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,193812641.0,OT,,,,,,,,,193812641.0,1.0,HIV infection
19381265,193812651,1,I,,20210601.0,20210607,20210607,EXP,,US-VIIV HEALTHCARE LIMITED-US2021GSK121574,VIIV,,,,,,Y,,,20210607.0,,HP,US,US,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,193812651.0,OT,,,,,,,,,193812651.0,1.0,HIV infection
19391015,193910151,1,I,,20210606.0,20210609,20210609,EXP,,GB-ABBVIE-21K-167-3938458-00,ABBVIE,,62.0,YR,,M,Y,,,20210608.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,193910151.0,OT,,,193910151.0,1.0,20150301.0,,,,193910151.0,1.0,HIV infection
19392273,193922734,4,F,20111201.0,20231024.0,20210608,20231026,EXP,,US-GILEAD-2021-0534892,GILEAD,,55.0,YR,A,M,Y,108.84,KG,20231026.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Fatigue;Gait disturbance;Nightmare;Pain,193922734.0,OT,,,193922734.0,1.0,2005.0,201512.0,,,193922734.0,1.0,HIV infection
19394148,193941482,2,F,20200401.0,20220119.0,20210609,20220125,EXP,,US-GILEAD-2021-0534824,GILEAD,,57.0,YR,A,M,Y,,,20220125.0,,LW,US,US,SUSTIVA,Adverse event;Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Dysstasia;Emotional distress;Gait disturbance;Osteoarthritis;Osteoporosis;Pain,193941482.0,OT,,,193941482.0,1.0,2001.0,2018.0,,,193941482.0,1.0,HIV infection
19394276,193942762,2,F,20070101.0,20220119.0,20210609,20220125,EXP,,US-GILEAD-2021-0534828,GILEAD,,,,A,M,Y,88.435,KG,20220125.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood urine present;Bone density decreased;Bone disorder;Chronic kidney disease;Dysstasia;Dysuria;Emotional distress;Gait disturbance;General physical health deterioration;Hand fracture;Hip fracture;Nephrolithiasis;Osteopenia;Osteoporosis;Pain;Post-traumatic stress disorder;Renal injury,193942762.0,OT,,,193942762.0,1.0,2004.0,2004.0,,,193942762.0,1.0,HIV infection
19394934,193949341,1,I,,20210528.0,20210609,20210609,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-052814,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,,,20210609.0,,MD,GB,GB,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,193949341.0,OT,,,193949341.0,1.0,20180111.0,,,,193949341.0,1.0,HIV infection
19397632,193976323,3,F,20110501.0,20220209.0,20210610,20220324,EXP,,US-GILEAD-2021-0534867,GILEAD,,59.0,YR,A,M,Y,78.005,KG,20220324.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Emotional distress;Fall;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal compression fracture,193976323.0,OT,,,193976323.0,1.0,200802.0,201801.0,,,193976323.0,1.0,HIV infection
19397700,193977001,1,I,,20210607.0,20210609,20210609,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-056021,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210609.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,193977001.0,OT,,,,,,,,,193977001.0,1.0,HIV infection
19397735,193977351,1,I,,20210606.0,20210610,20210610,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055188,BRISTOL MYERS SQUIBB,,62.0,YR,,M,Y,,,20210610.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,193977351.0,OT,,,193977351.0,1.0,20150301.0,,,,193977351.0,1.0,HIV infection
19398179,193981793,3,F,20171201.0,20231024.0,20210610,20231026,EXP,,US-GILEAD-2021-0534890,GILEAD,,54.0,YR,A,M,Y,63.492,KG,20231026.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Hip fracture;Mobility decreased;Osteoporosis;Pain;Vitamin D deficiency,193981793.0,OT,,,193981793.0,1.0,2010.0,2004.0,,,193981793.0,1.0,HIV infection
19399611,193996111,1,I,,20210606.0,20210610,20210610,EXP,,GB-MYLANLABS-2021M1033517,MYLAN,,62.0,YR,,M,Y,,,20210610.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,193996111.0,OT,,,193996111.0,1.0,20150301.0,,,,193996111.0,1.0,HIV infection
19401235,194012351,1,I,,20210531.0,20210611,20210611,EXP,,ET-AUROBINDO-AUR-APL-2021-023203,AUROBINDO,,25.0,YR,,F,Y,,,20210611.0,,HP,SE,ET,EFAVIRENZ.,Drug-induced liver injury,194012351.0,OT,,,,,,,,,194012351.0,1.0,HIV infection
19401260,194012601,1,I,,20210531.0,20210611,20210611,EXP,,ET-AUROBINDO-AUR-APL-2021-023205,AUROBINDO,,45.0,YR,,M,Y,,,20210611.0,,HP,SE,ET,EFAVIRENZ.,Drug-induced liver injury,194012601.0,OT,,,,,,,,,194012601.0,1.0,HIV infection
19401277,194012771,1,I,,20210531.0,20210611,20210611,EXP,,ET-AUROBINDO-AUR-APL-2021-023209,AUROBINDO,,28.0,YR,,F,Y,,,20210611.0,,HP,SE,ET,EFAVIRENZ.,Cholestatic liver injury,194012771.0,OT,,,,,,,,,194012771.0,1.0,HIV infection
19401300,194013001,1,I,,20210531.0,20210611,20210611,EXP,,ET-AUROBINDO-AUR-APL-2021-023212,AUROBINDO,,30.0,YR,,F,Y,,,20210611.0,,HP,SE,ET,EFAVIRENZ.,Drug-induced liver injury,194013001.0,OT,,,,,,,,,194013001.0,1.0,HIV infection
19401360,194013601,1,I,,20210531.0,20210611,20210611,EXP,,ET-AUROBINDO-AUR-APL-2021-023215,AUROBINDO,,30.0,YR,,F,Y,,,20210611.0,,HP,SE,ET,EFAVIRENZ.,Cholestatic liver injury,194013601.0,OT,,,,,,,,,194013601.0,1.0,HIV infection
19401365,194013651,1,I,,20210531.0,20210611,20210611,EXP,,ET-AUROBINDO-AUR-APL-2021-023223,AUROBINDO,,49.0,YR,,M,Y,,,20210611.0,,HP,SE,ET,EFAVIRENZ.,Drug-induced liver injury,194013651.0,OT,,,,,,,,,194013651.0,1.0,HIV infection
19402851,194028511,1,I,,20210531.0,20210611,20210611,EXP,,ET-AUROBINDO-AUR-APL-2021-023211,AUROBINDO,,45.0,YR,,F,Y,,,20210611.0,,HP,ET,ET,EFAVIRENZ.,Cholestatic liver injury,194028511.0,OT,,,,,,,,,194028511.0,1.0,HIV infection
19405275,194052751,1,I,2019.0,20210603.0,20210611,20210611,EXP,,DK-MYLANLABS-2021M1034088,MYLAN,"GYNTHERSEN RMM, MENS H, WEGENER M, WAREHAM NE. INTRACRANIAL HYPERTENSION AND PAPILLOEDEMA AS A COMPLICATION TO LOW ANTIRETROVIRAL THERAPY ADHERENCE IN A MAN LIVING WITH CHRONIC HIV. BMJ?CASE?REP 2021?14(3):E237504.",61.0,YR,,M,Y,,,20210611.0,,MD,DK,DK,EFAVIRENZ.,Intracranial pressure increased;Leukocytosis;Macular oedema;Optic disc haemorrhage;Papilloedema;Pleocytosis;Retinal exudates;Retroviral rebound syndrome;Visual field defect,194052751.0,HO,,,194052751.0,1.0,2015.0,,,,194052751.0,1.0,HIV infection
19406148,194061484,4,F,20160101.0,20220304.0,20210611,20220315,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-054655,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,,,20220315.0,,CN,LV,LV,EFAVIRENZ,Blood cholesterol abnormal;Blood triglycerides abnormal;Coronary artery disease;Dizziness;High density lipoprotein abnormal;Hyperhidrosis;Hyperlipidaemia;Low density lipoprotein abnormal;Nightmare;Pulmonary hypertension,194061484.0,OT,,,194061484.0,1.0,2015.0,2016.0,,,194061484.0,1.0,HIV infection
19406684,194066841,1,I,2019.0,20210603.0,20210611,20210611,EXP,,DK-STRIDES ARCOLAB LIMITED-2021SP006368,STRIDES,"GYNTHERSEN RMM, MENS H, WEGENER M, WAREHAM NE. INTRACRANIAL HYPERTENSION AND PAPILLOEDEMA AS A COMPLICATION TO LOW ANTIRETROVIRAL THERAPY ADHERENCE IN A MAN LIVING WITH CHRONIC HIV. BMJ?CASE?REP. 2021?14(3):E237504",61.0,YR,,M,Y,,,20210611.0,,HP,DK,DK,EFAVIRENZ.,Retroviral rebound syndrome;Treatment noncompliance,194066841.0,HO,,,,,,,,,194066841.0,1.0,HIV infection
19407021,194070211,1,I,,20210607.0,20210611,20210611,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055687,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210611.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,194070211.0,OT,,,,,,,,,194070211.0,1.0,HIV infection
19408489,194084891,1,I,,20210531.0,20210612,20210612,EXP,,ET-AUROBINDO-AUR-APL-2021-023224,AUROBINDO,,38.0,YR,,F,Y,,,20210612.0,,HP,SE,ET,EFAVIRENZ.,Mixed liver injury,194084891.0,OT,,,,,,,,,194084891.0,1.0,HIV infection
19408490,194084901,1,I,,20210531.0,20210612,20210612,EXP,,ET-AUROBINDO-AUR-APL-2021-023206,AUROBINDO,,25.0,YR,,M,Y,,,20210612.0,,HP,SE,ET,EFAVIRENZ.,Drug-induced liver injury,194084901.0,OT,,,,,,,,,194084901.0,1.0,HIV infection
19408491,194084911,1,I,,20210531.0,20210612,20210612,EXP,,ET-AUROBINDO-AUR-APL-2021-023208,AUROBINDO,,37.0,YR,,F,Y,,,20210612.0,,HP,ET,ET,EFAVIRENZ.,Cholestatic liver injury,194084911.0,OT,,,,,,,,,194084911.0,1.0,HIV infection
19408495,194084951,1,I,,20210531.0,20210612,20210612,EXP,,ET-AUROBINDO-AUR-APL-2021-023207,AUROBINDO,,28.0,YR,,F,Y,,,20210612.0,,HP,SE,ET,EFAVIRENZ.,Cholestatic liver injury,194084951.0,OT,,,,,,,,,194084951.0,1.0,HIV infection
19408497,194084971,1,I,,20210531.0,20210612,20210612,EXP,,ET-AUROBINDO-AUR-APL-2021-023204,AUROBINDO,,34.0,YR,,F,Y,,,20210612.0,,HP,SE,ET,EFAVIRENZ.,Cholestatic liver injury,194084971.0,OT,,,,,,,,,194084971.0,1.0,HIV infection
19408509,194085091,1,I,,20210531.0,20210612,20210612,EXP,,ET-AUROBINDO-AUR-APL-2021-023222,AUROBINDO,,31.0,YR,,M,Y,,,20210612.0,,HP,SE,ET,EFAVIRENZ.,Mixed liver injury,194085091.0,OT,,,,,,,,,194085091.0,1.0,HIV infection
19410348,194103481,1,I,,20210531.0,20210614,20210614,EXP,,ET-AUROBINDO-AUR-APL-2021-023221,AUROBINDO,,30.0,YR,,F,Y,,,20210614.0,,HP,SE,ET,EFAVIRENZ.,Mixed liver injury,194103481.0,OT,,,,,,,,,194103481.0,1.0,HIV infection
19414929,194149291,1,I,,20210608.0,20210614,20210614,EXP,,GB-MYLANLABS-2021M1034524,MYLAN,,65.0,YR,,M,Y,,,20210614.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194149291.0,OT,,,194149291.0,1.0,20120601.0,,,,194149291.0,1.0,HIV infection
19415611,194156111,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055685,BRISTOL MYERS SQUIBB,,52.0,YR,,M,Y,,,20210614.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,194156111.0,OT,,,,,,,,,194156111.0,1.0,HIV infection
19417864,194178641,1,I,,20210518.0,20210615,20210615,EXP,,CN-GILEAD-2021-0532868,GILEAD,ZHENG W?ZHANG W?TANG H?ZHAO D?FENG Y. RENAL FUNCTION OF HIV/AIDS PATIENTS TREATED WITH TENOFOVIR AND ITS INFLUENCING FACTORS IN HUBEI PROVINCE. SOUTH CHINA J PREV MED. 2021?47(4):426?430. DOI:10.12183/J.SCJPM.2021.0426,,,A,,Y,,,20210615.0,,HP,CN,CN,EFAVIRENZ.,Chronic kidney disease,194178641.0,OT,,,194178641.0,1.0,20150101.0,20170930.0,,,194178641.0,1.0,HIV infection
19418003,194180031,1,I,,20210610.0,20210615,20210615,EXP,,CN-GILEAD-2021-0535563,GILEAD,ZHENG W?ZHANG W?TANG H?ZHAO D?FENG Y. RENAL FUNCTION OF HIV/AIDS PATIENTS TREATED WITH TENOFOVIR AND ITS INFLUENCING FACTORS IN HUBEI PROVINCE. SOUTH CHINA J PREV MED.. 2021?47(4):426?430. DOI:10.12183/J.SCJPM.2021.0426,,,A,,Y,,,20210615.0,,HP,CN,CN,EFAVIRENZ.,Blood creatinine abnormal;Chronic kidney disease,194180031.0,OT,,,,,,,,,194180031.0,1.0,HIV infection
19419932,194199321,1,I,,20210518.0,20210615,20210615,EXP,,CN-GILEAD-2021-0531381,GILEAD,"ZHENG W, ZHANG W, TANG H, ZHAO D, FENG Y. RENAL FUNCTION OF HIV/AIDS PATIENTS TREATED WITH TENOFOVIR AND ITS INFLUENCING FACTORS IN HUBEI PROVINCE. SOUTH CHINA J PREV MED.. 2021?47(4):426?430. DOI:10.12183/J.SCJPM.2021.0426",,,A,,Y,,,20210615.0,,HP,CN,CN,EFAVIRENZ.,Chronic kidney disease,194199321.0,OT,,,194199321.0,1.0,20150101.0,20170930.0,,,194199321.0,1.0,HIV infection
19422072,194220721,1,I,2019.0,20210603.0,20210616,20210616,EXP,,DK-LUPIN PHARMACEUTICALS INC.-2021-09481,LUPIN,,61.0,YR,,M,Y,,,20210616.0,,HP,DK,DK,EFAVIRENZ.,Intracranial pressure increased;Leukocytosis;Macular oedema;Optic disc haemorrhage;Papilloedema;Pleocytosis;Retinal exudates;Retroviral rebound syndrome;Visual field defect,194220721.0,HO,,,194220721.0,1.0,2015.0,,,,194220721.0,1.0,HIV infection
19422209,194222092,2,F,,20210609.0,20210616,20210616,EXP,,GB-ABBVIE-21K-167-3948768-00,ABBVIE,,61.0,YR,,M,Y,,,20210616.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,194222092.0,OT,,,194222092.0,1.0,20121101.0,,,,194222092.0,1.0,HIV infection
19425158,194251582,2,F,,20210619.0,20210616,20210625,EXP,,GB-ABBVIE-21K-167-3948725-00,ABBVIE,,76.0,YR,,M,Y,,,20210625.0,,HP,GB,GB,EFAVIRENZ.,Renal impairment,194251582.0,OT,,,194251582.0,1.0,20121101.0,,,,194251582.0,1.0,HIV infection
19425942,194259421,1,I,,20210606.0,20210617,20210617,EXP,,GB-AUROBINDO-AUR-APL-2021-024731,AUROBINDO,,62.0,YR,,M,Y,,,20210617.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194259421.0,OT,,,194259421.0,1.0,20150301.0,,,,194259421.0,1.0,HIV infection
19426212,194262121,1,I,,20210611.0,20210616,20210616,EXP,,GB-MYLANLABS-2021M1035494,MYLAN,,76.0,YR,,M,Y,,,20210616.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194262121.0,OT,,,194262121.0,1.0,20121101.0,,,,194262121.0,1.0,HIV infection
19426412,194264121,1,I,,20210609.0,20210616,20210616,EXP,,ES-MYLANLABS-2021M1034815,MYLAN,"ARAGON?S EROLES AM, SCHOENENBERGER ARNAIZ JA, CANOMARR?N SM, PUIG GANAU T, MORALES PORTILLO A, MANONELLES FERN?NDEZ A. RELACI?N ENTRE NIVELES PLASM?TICOS DE EFAVIRENZ Y ALTERACIONES LIP?MICAS. REV.OFIL?ILAPHAR. 2021?31 (1):64?69",,,A,,Y,,,20210616.0,,MD,ES,ES,EFAVIRENZ.,Hypertension;Thrombosis,194264121.0,OT,,,,,,,,,194264121.0,1.0,Antiretroviral therapy
19426431,194264311,1,I,,20210609.0,20210616,20210616,EXP,,ES-MYLANLABS-2021M1034808,MYLAN,"ARAGONES EROLES, AM ET AL.. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS.. REV.OFIL?ILAPHAR. 2021?31 (1):64?69",,,A,,Y,,,20210616.0,,MD,ES,ES,EFAVIRENZ.,Hypertension;Thrombosis,194264311.0,OT,,,,,,,,,194264311.0,1.0,Antiretroviral therapy
19426441,194264411,1,I,,20210609.0,20210616,20210616,EXP,,ES-MYLANLABS-2021M1034817,MYLAN,"ARAGON?S EROLES, AM ET AL.. RELACI?N ENTRE NIVELES PLASM?TICOS DE EFAVIRENZ Y ALTERACIONES LIP?MICAS. REV.OFIL?ILAPHAR. 2021?31 (1):64?69",,,A,,Y,,,20210616.0,,MD,ES,ES,EFAVIRENZ.,Thrombosis,194264411.0,OT,,,,,,,,,194264411.0,1.0,Antiretroviral therapy
19426505,194265051,1,I,,20210609.0,20210616,20210616,EXP,,ES-MYLANLABS-2021M1034836,MYLAN,"ARAGON?S EROLES, AM ET AL. RELACI?N ENTRE NIVELES PLASM?TICOS DE EFAVIRENZ Y ALTERACIONES LIP?MICAS. REV.OFIL?ILAPHAR. 2021?31 (1):64?69",,,A,,Y,,,20210616.0,,MD,ES,ES,EFAVIRENZ.,Thrombosis,194265051.0,OT,,,,,,,,,194265051.0,1.0,Antiretroviral therapy
19426507,194265071,1,I,,20210609.0,20210616,20210616,EXP,,ES-MYLANLABS-2021M1034837,MYLAN,"ARAGONES EROLES, AM ET AL.. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL?ILAPHAR. 2021?31(1):64?69",,,A,,Y,,,20210616.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194265071.0,OT,,,,,,,,,194265071.0,1.0,Antiretroviral therapy
19426520,194265201,1,I,,20210609.0,20210616,20210616,EXP,,ES-MYLANLABS-2021M1034838,MYLAN,"ARAGONES EROLES, AM ET AL.. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL?ILAPHAR. 2021?31(1):64?69",,,A,,Y,,,20210616.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194265201.0,OT,,,,,,,,,194265201.0,1.0,Antiretroviral therapy
19426533,194265331,1,I,,20210609.0,20210616,20210616,EXP,,ES-MYLANLABS-2021M1034839,MYLAN,"ARAGONES EROLES, AM ET AL.. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS.. REV.OFIL?ILAPHAR. 2021?31 (1):64?69",,,A,,Y,,,20210616.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194265331.0,OT,,,,,,,,,194265331.0,1.0,Antiretroviral therapy
19430373,194303735,5,F,20100924.0,20230610.0,20210617,20230614,EXP,,US-GILEAD-2021-0536679,GILEAD,,47.0,YR,A,M,Y,,,20230614.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Death;Emotional distress;Pain;Renal failure,194303735.0,DE,,,194303735.0,1.0,2010.0,20101024.0,,,194303735.0,1.0,HIV infection
19433699,194336993,3,F,20160501.0,20230720.0,20210617,20230726,PER,,US-GILEAD-2021-0536633,GILEAD,,59.0,YR,A,M,Y,77.11,KG,20230726.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Pollakiuria;Renal failure;Renal impairment,194336993.0,OT,,,194336993.0,1.0,2012.0,201605.0,,,194336993.0,1.0,HIV infection
19435745,194357453,3,F,20160101.0,20230808.0,20210618,20230815,EXP,,US-GILEAD-2021-0536637,GILEAD,,,,A,M,Y,,,20230815.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density abnormal;Cardiac disorder;Depression;Dysstasia;Emotional distress;Osteopenia;Osteoporosis;Pain;Protein urine present;Proteinuria;Renal impairment;Renal injury,194357453.0,OT,,,194357453.0,1.0,2007.0,201605.0,,,194357453.0,1.0,HIV infection
19435753,194357533,3,F,20160501.0,20230420.0,20210618,20230424,EXP,,US-GILEAD-2021-0536647,GILEAD,,62.0,YR,E,M,Y,81.646,KG,20230424.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Emotional distress;Osteoarthritis;Osteopenia;Osteoporosis;Pain,194357533.0,OT,,,194357533.0,1.0,200503.0,200505.0,,,194357533.0,1.0,HIV infection
19438156,194381561,1,I,,20210608.0,20210619,20210619,EXP,,GB-AUROBINDO-AUR-APL-2021-024928,AUROBINDO,,65.0,YR,,M,Y,,,20210619.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194381561.0,OT,,,194381561.0,1.0,20120601.0,,,,194381561.0,1.0,HIV infection
19439771,194397711,1,I,,20210607.0,20210620,20210620,EXP,,CN-LUPIN PHARMACEUTICALS INC.-2021-09731,LUPIN,,38.0,YR,,,Y,,,20210620.0,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Liver disorder;Virologic failure,194397711.0,OT,,,,,,,,,194397711.0,1.0,HIV infection
19441181,194411811,1,I,,20210611.0,20210621,20210621,EXP,,GB-TEVA-2021-GB-1923736,TEVA,,61.0,YR,A,M,Y,,,20210621.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,194411811.0,OT,,,194411811.0,1.0,20121101.0,,,,194411811.0,1.0,HIV infection
19443164,194431641,1,I,,20210611.0,20210621,20210621,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2021031584,MACLEODS,,,,,,Y,,,20210621.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194431641.0,OT,,,194431641.0,1.0,20121101.0,,,,194431641.0,1.0,HIV infection
19443903,194439031,1,I,,20210608.0,20210621,20210621,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-056478,BRISTOL MYERS SQUIBB,,65.0,YR,,M,Y,,,20210621.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,194439031.0,OT,,,194439031.0,1.0,20120601.0,,,,194439031.0,1.0,HIV infection
19445434,194454341,1,I,,20210610.0,20210622,20210622,EXP,,US-AUROBINDO-AUR-APL-2021-025301,AUROBINDO,,14.0,YR,,M,Y,,,20210622.0,,MD,US,US,EFAVIRENZ.,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,194454341.0,HO,,,,,,,,,194454341.0,1.0,HIV infection
19445505,194455051,1,I,,20210611.0,20210622,20210622,EXP,,GB-AUROBINDO-AUR-APL-2021-025556,AUROBINDO,,61.0,YR,,M,Y,,,20210622.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194455051.0,OT,,,194455051.0,1.0,20121101.0,,,,194455051.0,1.0,HIV infection
19445667,194456672,2,F,20160101.0,20220222.0,20210622,20220225,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2021EME131017,VIIV,,57.0,YR,,M,Y,,,20220225.0,,MD,LV,LV,EFAVIRENZ,Depression;Disease recurrence;Neurosyphilis,194456672.0,OT,,,194456672.0,1.0,2016.0,202009.0,,,194456672.0,1.0,HIV infection
19445668,194456682,2,F,,20220223.0,20210622,20220302,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2021EME131019,VIIV,,41.0,YR,,M,Y,,,20220302.0,,MD,LV,LV,EFAVIRENZ,Dizziness;Hyperlipidaemia;Nightmare;Pulmonary hypertension,194456682.0,OT,,,194456682.0,1.0,2018.0,2020.0,,,194456682.0,1.0,HIV infection
19445690,194456902,2,F,,20220223.0,20210622,20220302,EXP,,LV-GLAXOSMITHKLINE-LV2021EME131019,GLAXOSMITHKLINE,,41.0,YR,,M,Y,,,20220302.0,,MD,LV,LV,EFAVIRENZ,Dizziness;Hyperlipidaemia;Nightmare;Pulmonary hypertension,194456902.0,OT,,,194456902.0,1.0,2018.0,2020.0,,,194456902.0,1.0,HIV infection
19445706,194457062,2,F,20160101.0,20220222.0,20210622,20220225,EXP,,LV-GLAXOSMITHKLINE-LV2021EME131017,GLAXOSMITHKLINE,,57.0,YR,,M,Y,,,20220225.0,,MD,LV,LV,EFAVIRENZ,Depression;Disease recurrence;Neurosyphilis,194457062.0,OT,,,194457062.0,1.0,2016.0,202009.0,,,194457062.0,1.0,HIV infection
19451744,194517442,2,F,,20210624.0,20210623,20210706,EXP,,GB-AUROBINDO-AUR-APL-2021-025521,AUROBINDO,,76.0,YR,,M,Y,,,20210706.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194517442.0,OT,,,194517442.0,1.0,20121101.0,,,,194517442.0,1.0,HIV infection
19451767,194517673,3,F,2019.0,20210622.0,20210623,20210702,EXP,,DK-AUROBINDO-AUR-APL-2021-025770,AUROBINDO,,61.0,YR,,M,Y,,,20210702.0,,HP,DK,DK,EFAVIRENZ.,Dizziness;Drug ineffective;Headache;Intracranial pressure increased;Leukocytosis;Macular oedema;Nausea;Night sweats;Optic disc haemorrhage;Papilloedema;Pleocytosis;Pyrexia;Retinal exudates;Retroviral rebound syndrome;Vision blurred;Visual field defect;Vomiting;Weight decreased,194517673.0,OT,,,194517673.0,1.0,2015.0,,,,194517673.0,1.0,HIV infection
19451888,194518882,2,F,,20210624.0,20210623,20210705,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-057650,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,,,20210705.0,,MD,GB,GB,EFAVIRENZ.,Renal impairment,194518882.0,OT,,,194518882.0,1.0,20121101.0,,,,194518882.0,1.0,HIV infection
19453005,194530051,1,I,2019.0,20210614.0,20210623,20210623,EXP,,DK-TEVA-2021-DK-1924465,TEVA,"GYNTHERSEN RMM, MENS H, WEGENER M, WAREHAM NE. INTRACRANIAL HYPERTENSION AND PAPILLOEDEMA AS A COMPLICATION TO LOW ANTIRETROVIRAL THERAPY ADHERENCE IN A MAN LIVING WITH CHRONIC HIV. BMJ?CASE?REP 2021?14(3):E237504.",61.0,YR,A,M,Y,,,20210623.0,,MD,DK,DK,EFAVIRENZ.,Intracranial pressure increased;Leukocytosis;Macular oedema;Optic disc haemorrhage;Papilloedema;Pleocytosis;Retinal exudates;Retroviral rebound syndrome;Visual field defect,194530051.0,HO,,,194530051.0,1.0,2015.0,,,,194530051.0,1.0,HIV infection
19455704,194557041,1,I,,20210622.0,20210624,20210624,EXP,,GB-ABBVIE-21K-167-3963521-00,ABBVIE,,61.0,YR,,M,Y,,,20210623.0,,HP,GB,GB,EFAVIRENZ.,Renal impairment,194557041.0,OT,,,194557041.0,1.0,20121101.0,,,,194557041.0,1.0,HIV infection
19455856,194558564,4,F,20060101.0,20231013.0,20210624,20231016,EXP,,US-GILEAD-2021-0537460,GILEAD,,,,A,F,Y,60.317,KG,20231015.0,,LW,US,US,SUSTIVA,Abdominal pain lower;Anaemia;Anhedonia;Anxiety;Arthralgia;Back pain;Bone density decreased;Bone pain;Emotional distress;End stage renal disease;Fatigue;Osteopenia;Pain;Proteinuria;Renal failure;Renal pain;Urinary incontinence,194558564.0,OT,,,194558564.0,1.0,2004.0,201407.0,,,194558564.0,1.0,HIV infection
19455864,194558643,3,F,20080501.0,20230914.0,20210624,20230920,EXP,,US-GILEAD-2021-0537463,GILEAD,,41.0,YR,A,M,Y,100.69,KG,20230920.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Nephrogenic anaemia;Pain;Renal failure,194558643.0,OT,,,194558643.0,1.0,2006.0,200810.0,,,194558643.0,1.0,HIV infection
19455876,194558763,3,F,20140101.0,20230808.0,20210624,20230811,EXP,,US-GILEAD-2021-0537450,GILEAD,,,,A,M,Y,79.4,KG,20230811.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Bone density decreased;Dysstasia;Emotional distress;Gait disturbance;Hand fracture;Pain,194558763.0,OT,,,194558763.0,1.0,2009.0,201312.0,,,194558763.0,1.0,HIV infection
19455918,194559183,3,F,20130101.0,20230731.0,20210624,20230804,EXP,,US-GILEAD-2021-0537601,GILEAD,,41.0,YR,A,M,Y,90.703,KG,20230804.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Osteoporosis;Pain,194559183.0,OT,,,194559183.0,1.0,2009.0,2020.0,,,194559183.0,1.0,HIV infection
19456731,194567311,1,I,,20210609.0,20210624,20210624,PER,,GB-HORMOSAN PHARMA GMBH-2021-10051,LUPIN,,65.0,YR,,M,Y,,,20210624.0,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194567311.0,OT,,,194567311.0,1.0,20120601.0,,,,194567311.0,1.0,HIV infection
19457453,194574533,3,F,20140101.0,20230724.0,20210624,20230728,EXP,,US-GILEAD-2021-0537381,GILEAD,,,,A,F,Y,127.0,KG,20230728.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Arthritis;Bone density decreased;Dysstasia;Emotional distress;Foot fracture;Gait disturbance;Osteoporosis;Pain;Pain in extremity,194574533.0,OT,,,194574533.0,1.0,2001.0,2008.0,,,194574533.0,1.0,HIV infection
19457492,194574923,3,F,20170301.0,20231010.0,20210624,20231011,EXP,,US-GILEAD-2021-0537546,GILEAD,,41.0,YR,A,M,Y,88.435,KG,20231011.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;Emotional distress;Glomerular filtration rate decreased;Hypersensitivity;Pain;Renal impairment,194574923.0,OT,,,194574923.0,1.0,2012.0,201708.0,,,194574923.0,1.0,HIV infection
19461015,194610151,1,I,,20210617.0,20210625,20210625,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-059444,BRISTOL MYERS SQUIBB,"ARAGONES EROLES AM, SCHOENENBERGER ARNAIZ JA, CANO MARRON SM, PUIG GANAU T, MORALES PORTILLO A, MANONELLES FERNONDEZ A. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL.ILAPHAR. 2021?31(1):64?9",,,A,,Y,,,20210625.0,,MD,ES,ES,EFAVIRENZ.,Hypertension;Thrombosis,194610151.0,OT,,,,,,,,,194610151.0,1.0,Antiretroviral therapy
19461093,194610935,5,F,,20211216.0,20210625,20211223,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-059435,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20211223.0,,HP,ES,ES,EFAVIRENZ,Hypertension;Thrombosis,194610935.0,OT,,,,,,,,,194610935.0,1.0,Antiretroviral therapy
19462437,194624372,2,F,20110101.0,20220324.0,20210625,20220331,EXP,,US-GILEAD-2021-0537930,GILEAD,,,,A,M,Y,88.435,KG,20220331.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Mobility decreased;Multiple fractures;Osteoporosis;Pain,194624372.0,OT,,,194624372.0,1.0,2008.0,201903.0,,,194624372.0,1.0,HIV infection
19464464,194644642,2,F,,20210617.0,20210626,20210626,EXP,,ES-AUROBINDO-AUR-APL-2021-026743,AUROBINDO,,,,A,,Y,,,20210626.0,,HP,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194644642.0,OT,,,,,,,,,194644642.0,1.0,Antiretroviral therapy
19464465,194644654,4,F,,20211103.0,20210626,20211117,EXP,,ES-AUROBINDO-AUR-APL-2021-026748,AUROBINDO,"Aragon?s Eroles AM, Schoenenberger Arnaiz JA, Canomarr?n SM, Puig Ganau T, Morales Portillo A, Manonelles Fern?ndez A. Relaci?n entre niveles plasm?ticos de efavirenz y alteraciones lip?micas. Rev.OFIL?ILAPHAR. 2021;31 (1):64-69",,,A,,Y,,,20211117.0,,MD,ES,ES,EFAVIRENZ,Hypertension;No adverse event;Thrombosis,194644654.0,OT,,,,,,,,,194644654.0,1.0,Antiretroviral therapy
19464466,194644662,2,F,,20210617.0,20210626,20210626,EXP,,ES-AUROBINDO-AUR-APL-2021-026752,AUROBINDO,,,,A,,Y,,,20210626.0,,HP,ES,ES,EFAVIRENZ.,Hypertension;Thrombosis,194644662.0,OT,,,,,,,,,194644662.0,1.0,Antiretroviral therapy
19465057,194650571,1,I,,20210617.0,20210627,20210627,EXP,,ES-AUROBINDO-AUR-APL-2021-026744,AUROBINDO,ARAGON?S EROLES AM ET AL.. RELACI?N ENTRE NIVELES PLASM?TICOS DE EFAVIRENZ Y ALTERACIONES LIP?MICAS.. REV.OFIL?ILAPHAR. 2021?31(1):64?69,,,A,,Y,,,20210627.0,,MD,ES,ES,EFAVIRENZ.,Thrombosis,194650571.0,OT,,,,,,,,,194650571.0,1.0,Antiretroviral therapy
19465462,194654623,3,F,20070101.0,20230518.0,20210624,20230524,EXP,,US-GILEAD-2021-0537436,GILEAD,,,,A,M,Y,83.9,KG,20230524.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Arthralgia;Atrial fibrillation;Blood creatinine increased;Blood lactic acid increased;Chronic kidney disease;Depression;Dizziness;Dyspnoea;Emotional distress;Hypertension;Insomnia;Muscle fatigue;Muscle spasms;Pain;Palpitations;Pollakiuria;Renal injury;Swelling,194654623.0,OT,,,194654623.0,1.0,2007.0,201801.0,,,194654623.0,1.0,HIV infection
19465512,194655123,3,F,20120101.0,20230731.0,20210624,20230803,EXP,,US-GILEAD-2021-0537424,GILEAD,,,,A,F,Y,99.33,KG,20230803.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Gait disturbance;Hypertension;Osteopenia;Pain;Patella fracture;Renal injury;Rib fracture;Schizophrenia;Spinal fracture,194655123.0,OT,,,194655123.0,1.0,2009.0,2016.0,,,194655123.0,1.0,HIV infection
19465586,194655864,4,F,20111229.0,20230626.0,20210624,20230629,PER,,US-GILEAD-2021-0537451,GILEAD,,51.0,YR,A,M,Y,64.41,KG,20230629.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteopenia;Pain;Spinal compression fracture,194655864.0,OT,,,194655864.0,1.0,2006.0,201108.0,,,194655864.0,1.0,HIV infection
19466507,194665071,1,I,,20210617.0,20210628,20210628,EXP,,ES-AUROBINDO-AUR-APL-2021-026747,AUROBINDO,"ARAGON?S EROLES, AM ET AL.. RELACI?N ENTRE NIVELES PLASM?TICOS DE EFAVIRENZ Y ALTERACIONES LIP?MICAS.. REV.OFIL?ILAPHAR.. 2021?31(1):64?69.",,,A,,Y,,,20210628.0,,MD,ES,ES,EFAVIRENZ.,Thrombosis,194665071.0,OT,,,,,,,,,194665071.0,1.0,Antiretroviral therapy
19469199,194691992,2,F,20160101.0,20220228.0,20210628,20220310,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062115,BRISTOL MYERS SQUIBB,,57.0,YR,,M,Y,,,20220310.0,,CN,LV,LV,EFAVIRENZ,Depression;Disease recurrence;Neurosyphilis,194691992.0,OT,,,194691992.0,1.0,2016.0,,,,194691992.0,1.0,HIV infection
19469274,194692743,3,F,20130101.0,20230627.0,20210628,20230630,EXP,,US-GILEAD-2021-0537598,GILEAD,,53.0,YR,A,M,Y,78.005,KG,20230630.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Nephropathy;Osteoporosis;Pain;Proteinuria,194692743.0,OT,,,194692743.0,1.0,2007.0,201810.0,,,194692743.0,1.0,HIV infection
19469864,194698641,1,I,,20090923.0,20210629,20210629,EXP,,ZA-AUROBINDO-AUR-APL-2009-00718,AUROBINDO,REACTIONS WEEKLY. 2009?1270:7?8,11.0,YR,,F,Y,,,20210629.0,,HP,ZA,ZA,EFAVIRENZ.,Agitation;Confusional state;Delirium;Delusion;Dementia;Depression;General physical health deterioration;Hallucination;Hemiplegia;Intracranial pressure increased;Meningitis tuberculous;Mood altered,194698641.0,DE,,,,,,,,,194698641.0,1.0,HIV infection
19469985,194699851,1,I,,20210617.0,20210628,20210628,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-059445,BRISTOL MYERS SQUIBB,"ARAGONES EROLES AM, SCHOENENBERGER ARNAIZ JA, CANO MARRON SM, GANAU TP, MORALES PORTILLO A, FERNANDEZ AM. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL.LLAPHAR. 2021?31(1):64?9",,,A,,Y,,,20210628.0,,MD,ES,ES,EFAVIRENZ.,Thrombosis,194699851.0,OT,,,,,,,,,194699851.0,1.0,Antiretroviral therapy
19470019,194700191,1,I,,20210617.0,20210629,20210629,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-059448,BRISTOL MYERS SQUIBB,"ARAGONES EROLES AM, SCHOENENBERGER ARNAIZ JA, CANO MARRON SM, PUIG GANAU T, MORALES PORTILLO A, MANONELLES FERNONDEZ A. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL.ILAPHAR. 2021?31(1):64?9",,,A,,Y,,,20210629.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194700191.0,OT,,,,,,,,,194700191.0,1.0,Antiretroviral therapy
19472067,194720671,1,I,,20081215.0,20210629,20210629,EXP,,US-AUROBINDO-08-AUR-06867,AUROBINDO,,40.0,YR,,M,Y,,,20210629.0,,HP,US,US,EFAVIRENZ.,Apoptosis;Hepatic steatosis;Hepatotoxicity;Lipodystrophy acquired;Liver function test abnormal,194720671.0,OT,,,,,,,,,194720671.0,1.0,HIV infection
19472123,194721231,1,I,,20090923.0,20210629,20210629,EXP,,ZA-AUROBINDO-AUR-APL-2009-00715,AUROBINDO,,9.0,YR,,F,Y,16.0,KG,20210629.0,,MD,ZA,ZA,EFAVIRENZ.,"Agitation;Anxiety;Apathy;Confusional state;Delirium;Depression;Disinhibition;Euphoric mood;Fear;Feeling abnormal;Hallucinations, mixed;Lethargy;Nightmare;Poor quality sleep;Social avoidant behaviour",194721231.0,OT,,,,,,,,,194721231.0,1.0,HIV infection
19472747,194727471,1,I,,20210617.0,20210629,20210629,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-059414,BRISTOL MYERS SQUIBB,"ARAGONES EROLES AM,SCHOENENBERGER ARNAIZ JA, CANO MARRON SM, GANAU TP, MORALES PORTILLO A, FERNANDEZ AM. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL?ILAPHAR. 2021?31(1):64?9",,,A,,Y,,,20210629.0,,MD,ES,ES,EFAVIRENZ.,Thrombosis,194727471.0,OT,,,,,,,,,194727471.0,1.0,Antiretroviral therapy
19478851,194788511,1,I,,20210618.0,20210630,20210630,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-060288,BRISTOL MYERS SQUIBB,"ARAGONES EROLES AM, SCHOENENBERGER ARNAIZ JA, CANO MARRON SM, PUIG GANAU T, MORALES PORTILLO A, MANONELLES FERNANDEZ A. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL.ILAPHAR. 2021?31(1):64?9",,,A,,Y,,,20210630.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194788511.0,OT,,,,,,,,,194788511.0,1.0,Antiretroviral therapy
19478889,194788891,1,I,,20210618.0,20210630,20210630,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-060299,BRISTOL MYERS SQUIBB,"ARAGONES EROLES AM, SCHOENENBERGER ARNAIZ JA, CANO MARRON SM, PUIG GANAU T, MORALES PORTILLO A, MANONELLES FERNANDEZ A. RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL.ILAPHAR. 2021?31(1):64?9",,,A,,Y,,,20210630.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194788891.0,OT,,,,,,,,,194788891.0,1.0,Antiretroviral therapy
19480764,194807641,1,I,,20210621.0,20210701,20210701,EXP,,ES-AUROBINDO-AUR-APL-2021-027496,AUROBINDO,"ARAGONES EROLES, AM ET AL... RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL?ILAPHAR. 2021?31(1):64?69",,,A,,Y,,,20210701.0,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194807641.0,OT,,,,,,,,,194807641.0,1.0,Antiretroviral therapy
19480837,194808371,1,I,,20210616.0,20210701,20210701,EXP,,GB-CIPLA LTD.-2021GB04447,CIPLA,,,,,,Y,,,20210701.0,,HP,US,GB,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,194808371.0,OT,,,,,,,,,194808371.0,1.0,Antiretroviral therapy
19485086,194850861,1,I,,20210621.0,20210702,20210702,EXP,,ES-AUROBINDO-AUR-APL-2021-027495,AUROBINDO,,,,A,,Y,,,20210702.0,,HP,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194850861.0,OT,,,,,,,,,194850861.0,1.0,Antiretroviral therapy
19488470,194884701,1,I,,20210618.0,20210702,20210702,PER,,BR-LUPIN PHARMACEUTICALS INC.-2021-11310,LUPIN,,42.0,YR,,M,Y,,,20210703.0,,HP,BR,BR,EFAVIRENZ.,Treatment noncompliance,,,,,,,,,,,194884701.0,1.0,Antiretroviral therapy
19493342,194933421,1,I,,20210629.0,20210705,20210705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2021GSK000010,VIIV,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933421.0,OT,,,194933421.0,1.0,201501.0,,,,194933421.0,1.0,HIV infection
19493343,194933431,1,I,,20210629.0,20210705,20210705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2021GSK000011,VIIV,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933431.0,OT,,,194933431.0,1.0,201503.0,,,,194933431.0,1.0,HIV infection
19493348,194933481,1,I,,20210629.0,20210705,20210705,EXP,,IN-GLAXOSMITHKLINE-IN2021GSK000010,GLAXOSMITHKLINE,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933481.0,OT,,,194933481.0,1.0,201501.0,,,,194933481.0,1.0,HIV infection
19493349,194933491,1,I,,20210629.0,20210705,20210705,EXP,,IN-GLAXOSMITHKLINE-IN2021GSK000011,GLAXOSMITHKLINE,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933491.0,OT,,,194933491.0,1.0,201503.0,,,,194933491.0,1.0,HIV infection
19502163,195021634,4,F,20080527.0,20231024.0,20210707,20231025,EXP,,US-GILEAD-2021-0539466,GILEAD,,27.0,YR,A,M,Y,72.562,KG,20231025.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Fatigue;Osteopenia;Pain;Renal impairment;Urinary tract infection,195021634.0,OT,,,195021634.0,1.0,20040629.0,20060425.0,665.0,DAY,195021634.0,1.0,HIV infection
19503705,195037051,1,I,,20210705.0,20210707,20210707,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065804,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210707.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195037051.0,OT,,,,,,,,,195037051.0,1.0,HIV infection
19503738,195037382,2,F,,20211115.0,20210707,20211122,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065807,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20211122.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195037382.0,OT,,,,,,,,,195037382.0,1.0,HIV infection
19504053,195040533,3,F,20120101.0,20231024.0,20210707,20231025,EXP,,US-GILEAD-2021-0539504,GILEAD,,,,A,F,Y,74.84,KG,20231025.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Back pain;Blood creatinine increased;Chills;Chronic kidney disease;Depression;Dyspnoea exertional;Emotional distress;Insomnia;Mobility decreased;Pain;Pollakiuria;Pruritus;Renal failure,195040533.0,OT,,,195040533.0,1.0,2004.0,201610.0,,,195040533.0,1.0,HIV infection
19504686,195046862,2,F,20010101.0,20220118.0,20210707,20220125,EXP,,US-GILEAD-2021-0539470,GILEAD,,,,A,F,Y,68.027,KG,20220125.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Chronic kidney disease;Decreased appetite;Depression;Emotional distress;End stage renal disease;Fatigue;Hyperphosphataemia;Mobility decreased;Pain;Renal injury;Stress,195046862.0,OT,,,195046862.0,1.0,2001.0,201307.0,,,195046862.0,1.0,HIV infection
19507746,195077461,1,I,,20210623.0,20210708,20210708,EXP,,ZA-APPCO PHARMA LLC-2113602,APPCO PHARMA,,26.0,YR,,F,Y,,,20210708.0,,HP,ZA,ZA,EFAVIRENZ.,Drug ineffective;Respiratory failure,195077461.0,DE,,,,,,,,,195077461.0,1.0,HIV infection
19514964,195149641,1,I,200203.0,20210707.0,20210709,20210709,EXP,,FR-GLAXOSMITHKLINE-FR2021148241,GLAXOSMITHKLINE,,56.0,YR,,F,Y,56.0,KG,20210709.0,,HP,FR,FR,EFAVIRENZ.,Creatinine renal clearance decreased;Glycosuria;Hypophosphataemia;Myalgia;Nephropathy toxic;Pain in extremity;Proteinuria;Renal tubular dysfunction,195149641.0,OT,,,195149641.0,1.0,200105.0,2002.0,,,195149641.0,1.0,HIV infection
19514965,195149651,1,I,200203.0,20210707.0,20210709,20210709,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2021148241,VIIV,,56.0,YR,,F,Y,56.0,KG,20210709.0,,HP,FR,FR,EFAVIRENZ.,Creatinine renal clearance decreased;Glycosuria;Hypophosphataemia;Myalgia;Nephropathy toxic;Pain in extremity;Proteinuria;Renal tubular dysfunction,195149651.0,OT,,,195149651.0,1.0,200105.0,2002.0,,,195149651.0,1.0,HIV infection
19516890,195168904,4,F,20050101.0,20230807.0,20210711,20230809,EXP,,US-GILEAD-2021-0539492,GILEAD,,,,A,M,Y,83.914,KG,20230809.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Decreased interest;Depressed mood;Emotional distress;Multiple fractures;Pain;Stress;Tibia fracture,195168904.0,OT,,,195168904.0,1.0,2008.0,201908.0,,,195168904.0,1.0,HIV infection
19538738,195387381,1,I,,20210616.0,20210714,20210714,PER,,US-CIPLA LTD.-2021US04456,CIPLA,,,,,,Y,,,20210714.0,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;No adverse event,,,,,195387381.0,4.0,2019.0,,,,195387381.0,1.0,Antiretroviral therapy
19557806,195578061,1,I,,20210705.0,20210715,20210715,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065832,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210715.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195578061.0,OT,,,,,,,,,195578061.0,1.0,HIV infection
19557924,195579244,4,F,20101201.0,20241015.0,20210714,20241022,EXP,,US-GILEAD-2021-0539887,GILEAD,,49.0,YR,A,M,Y,120.18,KG,20241022.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density abnormal;Bone density decreased;Chronic kidney disease;Emotional distress;Gait disturbance;Pain;Tooth loss,195579244.0,OT,,,195579244.0,1.0,19980101.0,20201231.0,8400.0,DAY,195579244.0,1.0,HIV infection
19564559,195645591,1,I,,20210712.0,20210714,20210714,EXP,,DE-GILEAD-2021-0540451,GILEAD,"LUTZE S, RIEBE H, JUNGER M, ARNOLD A. THE COURSE OF KAPOSI^S SARCOMA, A MARKER DISEASE FOR THE INITIAL DIAGNOSIS OF AIDS, UNDER ONGOING CART. CLIN HEMORHEOL MICROCIRC.. 2020?76(2):263?277. DOI:10.3233/CH?209203",36.0,YR,A,M,Y,,,20210714.0,,HP,DE,DE,SUSTIVA,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma,195645591.0,OT,,,,,,,,,195645591.0,1.0,HIV infection
19565320,195653201,1,I,,20210705.0,20210714,20210714,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065851,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210714.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195653201.0,OT,,,,,,,,,195653201.0,1.0,HIV infection
19567906,195679062,2,F,,20211115.0,20210715,20211125,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065846,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20211125.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,195679062.0,OT,,,,,,,,,195679062.0,1.0,HIV infection
19568406,195684066,6,F,20090111.0,20230313.0,20210714,20230316,EXP,,US-GILEAD-2021-0540483,GILEAD,,43.0,YR,A,F,Y,108.84,KG,20230316.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthritis;Bone demineralisation;Bone density abnormal;Bone density decreased;Depression;Emotional distress;Foot fracture;Gait disturbance;Insomnia;Malaise;Multiple fractures;Nausea;Osteoporosis;Pain;Tooth loss,195684066.0,OT,,,195684066.0,1.0,2001.0,2015.0,,,195684066.0,1.0,HIV infection
19574736,195747361,1,I,,20210712.0,20210719,20210719,EXP,,BR-GILEAD-2021-0540861,GILEAD,"ABTIBOL?BERNARDINO M, DE AP, DE OG, DE AT, RODRIGUES G, OTANI R, CHAVES B, RODRIGUES C, DE AA, REDIVO E, FERNANDES S, CASTILHO M, BENZECRY S, BOTTO?MENEZES C., MARTINEZ?ESPINOSA F, ALECRIM M. NEUROLOGICAL FINDINGS IN CHILDREN WITHOUT CONGENITAL MICROCEPHALY EXPOSED TO ZIKA VIRUS IN UTERO: A CASE SERIES STUDY. VIRUSES.. 2020?12(11):UNK. DOI:10.3390/V12111335",,,I,M,Y,,,20210719.0,,HP,BR,BR,EFAVIRENZ.,Disturbance in attention;Epilepsy;Foetal exposure during pregnancy;Irritability;Language disorder;Macrocephaly;Motor dysfunction,195747361.0,OT,,,,,,,,,195747361.0,1.0,HIV infection
19578788,195787881,1,I,,20210308.0,20210719,20210719,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2021061971,VIIV,,,,,M,Y,,,20210719.0,,HP,PH,PH,EFAVIRENZ.,Brain herniation;Dizziness;Dysmetria;Encephalitis;Headache;Hydrocephalus;Immune reconstitution inflammatory syndrome;Nausea;Neck pain;Vomiting,195787881.0,OT,,,,,,,,,195787881.0,1.0,HIV infection
19578796,195787961,1,I,,20210308.0,20210719,20210719,EXP,,PH-GLAXOSMITHKLINE-PH2021061971,GLAXOSMITHKLINE,,,,,M,Y,,,20210719.0,,HP,PH,PH,EFAVIRENZ.,Brain herniation;Dizziness;Dysmetria;Encephalitis;Headache;Hydrocephalus;Immune reconstitution inflammatory syndrome;Nausea;Neck pain;Vomiting,195787961.0,HO,,,,,,,,,195787961.0,1.0,HIV infection
19584745,195847451,1,I,,20210712.0,20210720,20210720,EXP,,ID-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-069811,BRISTOL MYERS SQUIBB,"PONGBULAAN A, TRIYONO EA. GIGANTOMASTIA BILATERAL INDUCED EFAVIRENZ: A CASE REPORT. INDIAN JOURNAL OF FORENSIC MEDICINE AND TOXICOLOGY. 2021?15(3):956?60",25.0,YR,,F,Y,63.0,KG,20210720.0,,HP,ID,ID,EFAVIRENZ.,Breast enlargement,195847451.0,OT,,,,,,,,,195847451.0,1.0,HIV infection
19586522,195865221,1,I,,20090824.0,20210721,20210721,EXP,,ZA-AUROBINDO-AUR-APL-2009-00480,AUROBINDO,UNKNOWN ARTICLE. REACTIONS WEEKLY. 2009?30,32.0,YR,,F,Y,,,20210721.0,,MD,ZA,ZA,EFAVIRENZ.,Hepatic failure;Lactic acidosis;Maternal exposure during pregnancy;Tachypnoea;Toxicity to various agents,195865221.0,HO,,,195865221.0,1.0,200701.0,,,,195865221.0,1.0,Antiretroviral therapy
19593088,195930881,1,I,,20210719.0,20210722,20210722,EXP,,FR-GILEAD-2021-0541395,GILEAD,"FAURE C, CHASSERY M, OREAS R, AUDO I. DIDANOSINE?INDUCED RETINOPATHY: NEW INSIGHTS WITH LONG?TERM FOLLOW?UP. OCULAR IMMUNOLOGY + INFLAMMATION. 2021?UNK:1?8. DOI:10.1080/09273948.2021.1927117",56.0,YR,A,M,Y,,,20210722.0,,HP,FR,FR,EFAVIRENZ.,Drug interaction;Retinal toxicity,195930881.0,OT,,,,,,,,,195930881.0,1.0,HIV infection
19593176,195931763,3,F,20150101.0,20230810.0,20210722,20230815,PER,,US-GILEAD-2021-0541373,GILEAD,,,,A,M,Y,113.39,KG,20230815.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;Pain;Pollakiuria;Renal failure,195931763.0,OT,,,195931763.0,1.0,2002.0,2004.0,,,195931763.0,1.0,HIV infection
19604124,196041242,2,F,20141101.0,20210524.0,20210723,20230331,EXP,,HR-009507513-2107HRV006804,MERCK,,66.0,YR,,M,Y,,,20230331.0,,MD,HR,HR,EFAVIRENZ,Cardiac arrest;Hypertension;Myocardial infarction;Nephropathy,196041242.0,OT,,,196041242.0,1.0,200807.0,200808.0,,,196041242.0,1.0,HIV infection
19605568,196055683,3,F,20071001.0,20220112.0,20210723,20220120,PER,,US-GILEAD-2021-0541721,GILEAD,,43.0,YR,A,M,Y,,,20220120.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fatigue;Hypertension;Pain;Pollakiuria;Protein total abnormal;Renal impairment,196055683.0,OT,,,196055683.0,1.0,2008.0,20090219.0,493.0,DAY,196055683.0,1.0,HIV infection
19610462,196104622,2,F,20060601.0,20220117.0,20210726,20220124,EXP,,US-GILEAD-2021-0541777,GILEAD,,52.0,YR,A,M,Y,180.0,KG,20220124.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal impairment,196104622.0,OT,,,196104622.0,1.0,20061009.0,20091204.0,1152.0,DAY,196104622.0,1.0,HIV infection
19617759,196177591,1,I,,20210714.0,20210728,20210728,EXP,,CA-AUROBINDO-AUR-APL-2021-031431,AUROBINDO,,80.0,YR,,M,Y,,,20210728.0,,HP,CA,CA,EFAVIRENZ.,Depression;Diarrhoea;Drug resistance,196177591.0,OT,,,,,,,,,196177591.0,1.0,HIV infection
19634933,196349333,3,F,20110101.0,20230430.0,20210730,20230504,PER,,US-GILEAD-2021-0541785,GILEAD,,,,A,M,Y,,,20230504.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Emotional distress;Hypertension;Pain;Pollakiuria;Renal impairment,196349333.0,OT,,,196349333.0,1.0,2006.0,20180304.0,2330.0,DAY,196349333.0,1.0,HIV infection
19640051,196400513,3,F,20050101.0,20220217.0,20210730,20220221,EXP,,US-GILEAD-2021-0542435,GILEAD,,,,A,F,Y,81.633,KG,20220221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone pain;Emotional distress;Exercise tolerance decreased;Gait disturbance;Muscular weakness;Osteoporosis;Pain;Renal impairment,196400513.0,OT,,,196400513.0,1.0,2002.0,2008.0,,,196400513.0,1.0,HIV infection
19644204,196442043,3,F,20160414.0,20220122.0,20210801,20220128,PER,,US-GILEAD-2021-0542305,GILEAD,,59.0,YR,A,M,Y,83.447,KG,20220128.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Metabolic acidosis;Nausea;Nocturia;Pain;Sleep disorder;Urinary hesitation;Vomiting,196442043.0,HO,,,196442043.0,1.0,2016.0,201901.0,30.0,DAY,196442043.0,1.0,HIV infection
19645052,196450521,1,I,201411.0,20210726.0,20210802,20210802,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-073219,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20210802.0,,MD,HR,HR,EFAVIRENZ.,Cardiac arrest;Congenital cystic kidney disease;Hypertension;Myocardial infarction,196450521.0,OT,,,196450521.0,1.0,200807.0,201503.0,,,196450521.0,1.0,HIV infection
19648776,196487763,3,F,20130101.0,20220125.0,20210803,20220131,PER,,US-GILEAD-2021-0542370,GILEAD,,,,A,M,Y,94.331,KG,20220131.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bipolar disorder;Blood urine present;Chronic kidney disease;Decreased appetite;Dysuria;Emotional distress;Pain;Renal impairment;T-lymphocyte count increased;Therapeutic product effect decreased,196487763.0,OT,,,196487763.0,1.0,2012.0,2015.0,,,196487763.0,1.0,HIV infection
19649170,196491703,3,F,20180801.0,20240108.0,20210802,20240109,EXP,,US-GILEAD-2021-0542324,GILEAD,,49.0,YR,A,M,Y,151.95,KG,20240109.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Decreased activity;Dysstasia;Emotional distress;Foot fracture;Gait disturbance;Osteopenia;Osteoporosis;Pain;Peripheral swelling,196491703.0,OT,,,196491703.0,1.0,2011.0,201307.0,,,196491703.0,1.0,HIV infection
19654378,196543783,3,F,20080101.0,20230912.0,20210804,20230918,EXP,,US-GILEAD-2021-0542326,GILEAD,,,,A,M,Y,,,20230918.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Gout;Hypertension;Mobility decreased;Pain;Pneumonia;Seizure,196543783.0,OT,,,196543783.0,1.0,2001.0,201608.0,,,196543783.0,1.0,HIV infection
19654911,196549113,3,F,20100101.0,20230804.0,20210804,20230808,EXP,,US-GILEAD-2021-0542389,GILEAD,,,,A,F,Y,90.703,KG,20230808.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Gait disturbance;Impaired work ability;Osteoporosis;Pain;Protein urine present;Renal cyst;Renal impairment;Sitting disability,196549113.0,OT,,,196549113.0,1.0,2009.0,201406.0,,,196549113.0,1.0,HIV infection
19656612,196566123,3,F,20040101.0,20230613.0,20210804,20230615,EXP,,US-GILEAD-2021-0542302,GILEAD,,40.0,YR,A,M,Y,81.633,KG,20230615.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Depression;Emotional distress;Fractured sacrum;Mood swings;Osteoporosis;Pain;Pollakiuria;Psychiatric symptom;Renal failure;Renal impairment,196566123.0,OT,,,196566123.0,1.0,2001.0,2004.0,,,196566123.0,1.0,HIV infection
19658313,196583132,2,F,20100101.0,20211112.0,20210804,20211209,EXP,,US-GILEAD-2021-0542328,GILEAD,,45.0,YR,A,M,Y,78.458,KG,20211209.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Emotional distress;Exercise tolerance decreased;Gait disturbance;Hip arthroplasty;Osteoporosis;Pain,196583132.0,HO,,,196583132.0,1.0,200802.0,2010.0,,,196583132.0,1.0,HIV infection
19658691,196586912,2,F,20180309.0,20220215.0,20210804,20220221,EXP,,US-GILEAD-2021-0542308,GILEAD,,57.0,YR,A,M,Y,90.703,KG,20220221.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Pain,196586912.0,OT,,,196586912.0,1.0,2014.0,201803.0,,,196586912.0,1.0,HIV infection
19660115,196601152,2,F,20120401.0,20220116.0,20210805,20220121,EXP,,US-GILEAD-2021-0542448,GILEAD,,54.0,YR,A,M,Y,,,20220121.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Loss of personal independence in daily activities;Multiple fractures;Osteoporosis;Pain,196601152.0,OT,,,196601152.0,1.0,2006.0,201204.0,,,196601152.0,1.0,HIV infection
19660215,196602153,3,F,20180101.0,20230505.0,20210805,20230511,EXP,,US-GILEAD-2021-0542443,GILEAD,,,,A,M,Y,124.72,KG,20230511.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,196602153.0,OT,,,196602153.0,1.0,20130520.0,201306.0,129.0,DAY,196602153.0,1.0,HIV infection
19660525,196605253,3,F,20130101.0,20230611.0,20210805,20230614,EXP,,US-GILEAD-2021-0542310,GILEAD,,71.0,YR,E,M,Y,,,20230614.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Gastrointestinal haemorrhage;Hyperkalaemia;Loss of personal independence in daily activities;Pain;Renal impairment;Renal tubular disorder,196605253.0,HO,,,196605253.0,1.0,2005.0,20150821.0,,,196605253.0,1.0,HIV infection
19661898,196618983,3,F,,20211209.0,20210805,20211220,EXP,,CA-APOTEX-2021AP028481,APOTEX,,54.0,YR,,M,Y,,,20211220.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196618983.0,OT,,,,,,,,,196618983.0,1.0,HIV infection
19664910,196649103,3,F,20180101.0,20230512.0,20210805,20230517,EXP,,US-GILEAD-2021-0542366,GILEAD,,,,A,M,Y,86.0,KG,20230517.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Osteopenia;Pain,196649103.0,OT,,,196649103.0,1.0,2008.0,2015.0,,,196649103.0,1.0,HIV infection
19674222,196742221,1,I,,20210728.0,20210809,20210809,EXP,,CA-APOTEX-2021AP028482,APOTEX,,54.0,YR,,M,Y,,,20210809.0,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,196742221.0,OT,,,,,,,,,196742221.0,1.0,HIV infection
19687813,196878131,1,I,,20210809.0,20210811,20210811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079043,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20210811.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196878131.0,OT,,,,,,,,,196878131.0,1.0,HIV infection
19709900,197099001,1,I,,20210802.0,20210816,20210816,EXP,,US-VIIV HEALTHCARE LIMITED-US2021GSK164447,VIIV,"GALLARDO CM, WANG S, MONTIEL?GARCIA DJ, LITTLE SJ, SMITH DM, ROUTH AL ET AL. MRHAMER YIELDS HIGHLY ACCURATE SINGLE MOLECULE VIRAL SEQUENCES ENABLING ANALYSIS OF INTRA?HOST EVOLUTION. NUCLEIC ACIDS RESEARCH. 2021?49 (12)",,,,,Y,,,20210816.0,,HP,US,US,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Viral mutation identified;Virologic failure,197099001.0,OT,,,,,,,,,197099001.0,1.0,HIV infection
19709901,197099011,1,I,,20210802.0,20210816,20210816,EXP,,US-GLAXOSMITHKLINE-US2021GSK164447,GLAXOSMITHKLINE,"GALLARDO CM, WANG S, MONTIEL?GARCIA DJ, LITTLE SJ, SMITH DM, ROUTH AL ET AL. MRHAMER YIELDS HIGHLY ACCURATE SINGLE MOLECULE VIRAL SEQUENCES ENABLING ANALYSIS OF INTRA?HOST EVOLUTION. NUCLEIC ACIDS RESEARCH. 2021?49 (12)",,,,,Y,,,20210816.0,,HP,US,US,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Viral mutation identified;Virologic failure,197099011.0,OT,,,,,,,,,197099011.0,1.0,HIV infection
19711338,197113385,5,F,,20220711.0,20210817,20220715,EXP,,DE-MYLANLABS-2021M1052063,MYLAN,,57.0,YR,,M,Y,,,20220715.0,,MD,DE,DE,EFAVIRENZ,Drug resistance,197113385.0,OT,,,,,,,,,197113385.0,1.0,HIV infection
19711891,197118911,1,I,,20210803.0,20210816,20210816,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-081211,BRISTOL MYERS SQUIBB,"FAURE C, CHASSERY M, ORES R, AUDO I. DIDANOSINE?INDUCED RETINOPATHY: NEW INSIGHTS WITH LONG?TERM FOLLOW?UP. OCULAR IMMUNOLOGY AND INFLAMMATION. 2021?1?8",56.0,YR,,M,Y,,,20210816.0,,MD,FR,FR,EFAVIRENZ.,Retinopathy,197118911.0,OT,,,,,,,,,197118911.0,1.0,HIV infection
19711977,197119773,3,F,,20220110.0,20210816,20220124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079033,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20220124.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197119773.0,OT,,,,,,,,,197119773.0,1.0,HIV infection
19714944,197149442,2,F,20130101.0,20220304.0,20210818,20220309,PER,,US-GILEAD-2021-0544301,GILEAD,,,,A,F,Y,,,20220309.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Emotional distress;Pain;Renal failure;Renal impairment,197149442.0,DE,,,197149442.0,1.0,2006.0,201812.0,,,197149442.0,1.0,HIV infection
19716722,197167223,3,F,20180101.0,20220209.0,20210819,20220217,PER,,US-GILEAD-2021-0544308,GILEAD,,,,A,F,Y,70.748,KG,20220216.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Dysuria;Emotional distress;Pain;Renal failure;Urinary retention,197167223.0,OT,,,197167223.0,1.0,2013.0,2019.0,,,197167223.0,1.0,HIV infection
19720476,197204763,3,F,20111201.0,20230801.0,20210819,20230803,EXP,,US-GILEAD-2021-0544324,GILEAD,,42.0,YR,A,M,Y,49.887,KG,20230803.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Bone density decreased;Bone pain;Emotional distress;Hip fracture;Hypertension;Insomnia;Lower limb fracture;Lumbar vertebral fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal fracture;Wrist fracture,197204763.0,OT,,,197204763.0,1.0,2008.0,201904.0,,,197204763.0,1.0,HIV infection
19722738,197227381,1,I,,20210812.0,20210819,20210819,EXP,,ES-VIIV HEALTHCARE LIMITED-EC2021GSK174665,VIIV,"GARCIA?BOYANO M, VEGA W, PRIETO L, CHAVEZ?SOLORZANO N, MONTIEL DS, MINO?LEON G. PROGRESSIVE DISSEMINATED HISTOPLASMOSIS IN CHILDREN LIVING WITH HIV: A CASE SERIES STUDY. EUROPEAN JOURNAL OF PEDIATRICS. 2021?180 (6):1923?1931",,,C,M,Y,,,20210819.0,,MD,ES,EC,EFAVIRENZ.,Diarrhoea;Disease recurrence;Hepatomegaly;Histoplasmosis disseminated;Lymphadenopathy;Pyrexia;Splenomegaly;Treatment noncompliance;Virologic failure,197227381.0,DE,,,197227381.0,1.0,2015.0,,,,197227381.0,1.0,HIV infection
19722740,197227401,1,I,,20210812.0,20210819,20210819,EXP,,ES-GLAXOSMITHKLINE-EC2021GSK174665,GLAXOSMITHKLINE,"GARCIA?BOYANO M, VEGA W, PRIETO L, CHAVEZ?SOLORZANO N, MONTIEL DS, MINO?LEON G. PROGRESSIVE DISSEMINATED HISTOPLASMOSIS IN CHILDREN LIVING WITH HIV: A CASE SERIES STUDY. EUROPEAN JOURNAL OF PEDIATRICS. 2021?180 (6):1923?1931",,,C,M,Y,,,20210819.0,,MD,ES,EC,EFAVIRENZ.,Diarrhoea;Disease recurrence;Hepatomegaly;Histoplasmosis disseminated;Lymphadenopathy;Pyrexia;Splenomegaly;Treatment noncompliance;Virologic failure,197227401.0,OT,,,197227401.0,1.0,2015.0,,,,197227401.0,1.0,HIV infection
19724690,197246902,2,F,20050101.0,20220302.0,20210820,20220304,PER,,US-GILEAD-2021-0544464,GILEAD,,,,A,M,Y,92.986,KG,20220304.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Depression;Emotional distress;Loss of personal independence in daily activities;Lower limb fracture;Osteopenia;Pain;Renal failure;Renal impairment,197246902.0,OT,,,197246902.0,1.0,2004.0,2017.0,,,197246902.0,1.0,HIV infection
19725824,197258243,3,F,20130101.0,20231020.0,20210820,20231023,EXP,,US-GILEAD-2021-0544326,GILEAD,,50.0,YR,A,M,Y,95.057,KG,20231023.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Depression;Emotional distress;Gait disturbance;Hip arthroplasty;Multiple fractures;Osteopenia;Pain;Rib fracture,197258243.0,OT,,,197258243.0,1.0,2005.0,201805.0,,,197258243.0,1.0,HIV infection
19739652,197396521,1,I,,20210817.0,20210824,20210824,EXP,,GH-MYLANLABS-2021M1054459,MYLAN,"KUMBENI MT, APANGA PA, AYAMGA EA. NEXPLANON FAILURE IN A WOMAN WITH HIV INFECTION IN RURAL GHANA: A CASE REPORT. CLIN?CASE?REP 2020?8(12):2369?2372.",37.0,YR,,F,Y,68.0,KG,20210824.0,,HP,GH,GH,EFAVIRENZ.,Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy on contraceptive,197396521.0,OT,,,197396521.0,1.0,2014.0,,,,197396521.0,1.0,HIV infection
19744986,1974498611,11,F,,20230118.0,20210825,20230123,EXP,,CA-009507513-2108CAN005807,MERCK,,54.0,YR,,M,Y,,,20230123.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1974498611.0,DE,,,,,,,,,1974498611.0,1.0,HIV infection
19755697,197556973,3,F,20140901.0,20230807.0,20210827,20230810,EXP,,US-GILEAD-2021-0545324,GILEAD,,64.0,YR,A,M,Y,,,20230810.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Erectile dysfunction;Gout;Hypertension;Pain;Renal failure,197556973.0,OT,,,197556973.0,1.0,2006.0,2016.0,,,197556973.0,1.0,HIV infection
19759699,197596991,1,I,,20210817.0,20210830,20210830,EXP,,CA-AUROBINDO-AUR-APL-2021-036143,AUROBINDO,,32.0,YR,,M,Y,,,20210830.0,,HP,CA,CA,EFAVIRENZ.,Genotype drug resistance test positive;Therapeutic product effect incomplete,197596991.0,OT,,,,,,,,,197596991.0,1.0,HIV infection
19761315,197613151,1,I,,20210816.0,20210830,20210830,EXP,,ID-AUROBINDO-AUR-APL-2021-036283,AUROBINDO,,25.0,YR,,F,Y,63.0,KG,20210830.0,,HP,ID,ID,EFAVIRENZ.,Back pain;Breast enlargement;Breast pain,197613151.0,OT,,,,,,,,,197613151.0,1.0,HIV infection
19762415,197624151,1,I,,20210815.0,20210827,20210827,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-081286,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,,,20210827.0,,MD,GB,GB,EFAVIRENZ.,Viral load increased,197624151.0,OT,,,197624151.0,3.0,202104.0,,,,197624151.0,1.0,HIV infection
19764262,197642622,2,F,20100101.0,20220118.0,20210830,20220124,PER,,US-GILEAD-2021-0545395,GILEAD,,,,A,M,Y,98.413,KG,20220124.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Pollakiuria;Proteinuria;Renal impairment;Sleep disorder,,,,,197642622.0,1.0,2001.0,201010.0,,,197642622.0,1.0,HIV infection
19766166,197661667,7,F,20150301.0,20230914.0,20210831,20230928,PER,,US-GILEAD-2021-0545320,GILEAD,,63.0,YR,A,F,Y,58.957,KG,20230928.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Arthropathy;Asthenia;Body height decreased;Bone density decreased;Bone pain;Emotional distress;Fatigue;General physical health deterioration;Mobility decreased;Osteopenia;Osteoporosis;Pain;Therapy non-responder,197661667.0,OT,,,197661667.0,1.0,2007.0,20200901.0,2567.0,DAY,197661667.0,1.0,HIV infection
19766211,197662111,1,I,,20210817.0,20210831,20210831,PER,,GH-LUPIN PHARMACEUTICALS INC.-2021-15823,LUPIN,,37.0,YR,,F,Y,68.0,KG,20210831.0,,HP,GH,GH,EFAVIRENZ.,Exposure during pregnancy,,,,,197662111.0,1.0,2014.0,,,,197662111.0,1.0,HIV infection
19775312,197753121,1,I,,20210823.0,20210901,20210901,EXP,,CA-TEVA-2021-CA-1947158,TEVA,,54.0,YR,A,M,Y,,,20210901.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197753121.0,OT,,,,,,,,,197753121.0,1.0,HIV infection
19777664,197776641,1,I,,20190603.0,20210902,20210902,EXP,,IN-GILEAD-2021-0546329,GILEAD,"DESHWAL R, ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN J SEX TRANSM DIS AIDS.. 2019?40 (1):42?45. DOI:10.4103/IJSTD.IJSTD_23_18",55.0,YR,A,M,Y,,,20210902.0,,MD,IN,IN,EFAVIRENZ.,Drug ineffective;Renal tubular acidosis,197776641.0,OT,,,197776641.0,1.0,201501.0,,,,197776641.0,1.0,HIV infection
19777815,197778151,1,I,,20190603.0,20210902,20210902,EXP,,IN-GILEAD-2021-0546330,GILEAD,"DESHWAL R, ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY.. INDIAN J SEX TRANSM DIS AIDS.. 2019?40(1):42?45. DOI:10.4103/IJSTD.IJSTD_23_18",56.0,YR,A,M,Y,,,20210902.0,,MD,IN,IN,EFAVIRENZ.,Drug ineffective;Renal tubular acidosis,197778151.0,OT,,,197778151.0,1.0,201503.0,,,,197778151.0,1.0,HIV infection
19779111,197791111,1,I,,20210823.0,20210902,20210902,EXP,,CA-TEVA-2021-CA-1947077,TEVA,,54.0,YR,A,M,Y,,,20210902.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197791111.0,OT,,,,,,,,,197791111.0,1.0,HIV infection
19781509,197815092,2,F,,20210902.0,20210902,20210909,EXP,,SE-MYLANLABS-2021M1057698,MYLAN,"TYRBERG E., EDEN A., ERIKSEN J., NILSSON S., TREUTIGER CJ., THALME A, ET AL.. HIGHER PLASMA DRUG LEVELS IN ELDERLY PEOPLE LIVING WITH HIV TREATED WITH DARUNAVIR. PLOS ONE. 2021?16(2)",70.0,YR,,M,Y,75.0,KG,20210909.0,,HP,SE,SE,EFAVIRENZ.,Diabetes mellitus;Fat redistribution;Labelled drug-drug interaction issue;Sensory loss,197815092.0,OT,,,,,,,,,197815092.0,1.0,HIV infection
19781519,197815191,1,I,,20210830.0,20210902,20210902,EXP,,SE-MYLANLABS-2021M1057927,MYLAN,"TYRBERG E, EDEN A, ERIKSEN J, NILSSON S, TREUTIGER CJ, THALME A, ET AL... HIGHER PLASMA DRUG LEVELS IN ELDERLY PEOPLE LIVING WITH HIV TREATED WITH DARUNAVIR.. PLOS ONE. 2021?16 (2)",36.0,YR,,M,Y,79.0,KG,20210902.0,,HP,SE,SE,EFAVIRENZ.,Abnormal dreams;Coma;Erectile dysfunction,197815191.0,OT,,,,,,,,,197815191.0,1.0,HIV infection
19786994,197869942,2,F,20120101.0,20211124.0,20210903,20211203,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-084646,BRISTOL MYERS SQUIBB,,51.0,YR,,M,Y,,,20211203.0,,LW,US,US,SUSTIVA,Arthralgia;Arthropathy;Bone density abnormal;Bone density decreased;Multiple fractures;Musculoskeletal discomfort;Osteonecrosis;Osteoporosis;Tooth fracture;Tooth loss,197869942.0,OT,,,197869942.0,1.0,200807.0,2011.0,,,197869942.0,1.0,HIV infection
19793324,197933242,2,F,20140101.0,20220429.0,20210906,20220512,EXP,,US-GILEAD-2021-0547306,GILEAD,,,,A,M,Y,78.458,KG,20220512.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Fatigue;Pain;Protein urine present;Proteinuria;Renal impairment,197933242.0,OT,,,197933242.0,1.0,2006.0,201410.0,,,197933242.0,1.0,HIV infection
19795983,197959833,3,F,20090801.0,20230809.0,20210907,20230814,EXP,,US-GILEAD-2021-0547308,GILEAD,,54.0,YR,A,F,Y,105.67,KG,20230814.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Hyperlipidaemia;Mobility decreased;Osteopenia;Pain;Wrist fracture,197959833.0,OT,,,197959833.0,1.0,2003.0,200806.0,,,197959833.0,1.0,HIV infection
19798021,197980211,1,I,,20210830.0,20210907,20210907,EXP,,CA-TEVA-2021-CA-1950127,TEVA,,54.0,YR,A,M,Y,,,20210907.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197980211.0,OT,,,,,,,,,197980211.0,1.0,HIV infection
19798119,197981191,1,I,,20210830.0,20210907,20210907,EXP,,CA-TEVA-2021-CA-1950195,TEVA,,54.0,YR,A,M,Y,,,20210907.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197981191.0,OT,,,,,,,,,197981191.0,1.0,HIV infection
19800129,198001293,3,F,20160101.0,20230926.0,20210908,20230928,PER,,US-GILEAD-2021-0547348,GILEAD,,,,A,M,Y,98.413,KG,20230927.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Emotional distress;Gait disturbance;Osteopenia;Pain;Renal disorder;Somnolence,,,,,198001293.0,1.0,2015.0,201505.0,,,198001293.0,1.0,HIV infection
19800836,198008363,3,F,20170601.0,20231013.0,20210908,20231017,EXP,,US-GILEAD-2021-0547363,GILEAD,,59.0,YR,A,M,Y,83.9,KG,20231017.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Muscle spasms;Nocturia;Pain;Renal disorder;Renal impairment;Renal injury;Renal pain,198008363.0,OT,,,198008363.0,1.0,2006.0,201612.0,,,198008363.0,1.0,HIV infection
19802607,198026071,1,I,,20210830.0,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950206,TEVA,,54.0,YR,A,M,Y,,,20210908.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198026071.0,OT,,,,,,,,,198026071.0,1.0,HIV infection
19802647,198026471,1,I,,20210830.0,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950208,TEVA,,54.0,YR,A,M,Y,,,20210908.0,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,198026471.0,OT,,,,,,,,,198026471.0,1.0,HIV infection
19803160,198031602,2,F,,20220704.0,20210908,20220708,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN188941,GLAXOSMITHKLINE,"Nakamura H, Miyazaki N, Hosoya N, Koga M, Odawara T, Kikuchi T, et al.. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. Japanese Society of Chemotherapy and The Japanese Association for Infectious Dis. 2010;17:105-110",,,,,Y,,,20220708.0,,MD,JP,JP,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Rash;Viraemia,198031602.0,OT,,,,,,,,,198031602.0,1.0,HIV infection
19803165,198031652,2,F,,20220704.0,20210908,20220708,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN188941,VIIV,"Nakamura H, Miyazaki N, Hosoya N, Koga M, Odawara T, Kikuchi T, et al.. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. Japanese Society of Chemotherapy and The Japanese Association for Infectious Dis. 2010;17:105-110",,,,,Y,,,20220708.0,,MD,JP,JP,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Rash;Viraemia,198031652.0,OT,,,,,,,,,198031652.0,1.0,HIV infection
19804070,198040701,1,I,,20210831.0,20210908,20210908,EXP,,ZA-MYLANLABS-2021M1059873,MYLAN,"SEEDAT F, PATEL M, PHILLIP V, MOHAMED F, MARAIS AD, BLACKHURST DM, ET AL. HYPERLIPIDEMIC MYELOMA, A RARE FORM OF ACQUIRED DYSBETALIPOPROTEINEMIA, IN AN HIV SEROPOSITIVE AFRICAN FEMALE. CLIN?CHIM?ACTA 2021?520:71?75.",53.0,YR,,F,Y,,,20210908.0,,HP,ZA,ZA,EFAVIRENZ.,Type III hyperlipidaemia,198040701.0,HO,,,,,,,,,198040701.0,1.0,HIV infection
19806456,198064561,1,I,,20210830.0,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950156,TEVA,,54.0,YR,A,M,Y,,,20210908.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198064561.0,OT,,,,,,,,,198064561.0,1.0,HIV infection
19806457,198064571,1,I,,20210830.0,20210908,20210908,EXP,,CA-TEVA-2021-CA-1949398,TEVA,,54.0,YR,A,M,Y,,,20210908.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198064571.0,OT,,,,,,,,,198064571.0,1.0,HIV infection
19806583,198065831,1,I,,20210830.0,20210909,20210909,EXP,,IN-CIPLA (EU) LIMITED-2021IN06147,CIPLA,,,,,,Y,,,20210909.0,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198065831.0,OT,,,198065831.0,1.0,201209.0,,,,198065831.0,1.0,HIV infection
19806698,198066983,3,F,20080101.0,20230809.0,20210909,20230815,EXP,,US-GILEAD-2021-0547384,GILEAD,,,,A,F,Y,70.295,KG,20230815.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Arthritis;Back pain;Bone density decreased;Emotional distress;Osteopenia;Osteoporosis;Pain,198066983.0,OT,,,198066983.0,1.0,2003.0,201601.0,,,198066983.0,1.0,HIV infection
19809327,198093273,3,F,20100301.0,20230703.0,20210909,20230706,EXP,,US-GILEAD-2021-0547292,GILEAD,,44.0,YR,A,M,Y,80.272,KG,20230706.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Bone pain;Decreased activity;Depression;Emotional distress;Hyperlipidaemia;Osteoporosis;Pain,198093273.0,OT,,,198093273.0,1.0,2001.0,2004.0,,,198093273.0,1.0,HIV infection
19810653,198106531,1,I,,20210830.0,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950091,TEVA,,,,,M,Y,,,20210909.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198106531.0,DE,,,,,,,,,198106531.0,1.0,HIV infection
19810656,198106561,1,I,,20210830.0,20210909,20210909,EXP,,CA-TEVA-2021-CA-1949397,TEVA,,54.0,YR,A,M,Y,,,20210909.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198106561.0,OT,,,,,,,,,198106561.0,1.0,HIV infection
19811796,198117961,1,I,,20210830.0,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950170,TEVA,,54.0,YR,A,M,Y,,,20210909.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198117961.0,OT,,,,,,,,,198117961.0,1.0,HIV infection
19812559,198125593,3,F,20060101.0,20231013.0,20210910,20231016,PER,,US-GILEAD-2021-0547303,GILEAD,,,,A,F,Y,73.469,KG,20231016.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteopenia;Pain,,,,,198125593.0,1.0,2004.0,201607.0,,,198125593.0,1.0,HIV infection
19812616,198126163,3,F,20170101.0,20230612.0,20210910,20230614,EXP,,US-GILEAD-2021-0547373,GILEAD,,,,A,M,Y,76.19,KG,20230614.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Femur fracture;Hypertension;Pain;Renal impairment;Renal injury,198126163.0,OT,,,198126163.0,1.0,2005.0,202002.0,,,198126163.0,1.0,HIV infection
19812823,198128232,2,F,,20210907.0,20210910,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN190174,VIIV,,,,,,Y,,,20220624.0,,MD,JP,JP,EFAVIRENZ,Blood HIV RNA increased,198128232.0,OT,,,,,,,,,198128232.0,1.0,HIV infection
19815866,198158662,2,F,20150401.0,20220425.0,20210909,20220429,EXP,,US-GILEAD-2021-0547470,GILEAD,,50.0,YR,A,M,Y,77.098,KG,20220429.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Depression;Emotional distress;Gait disturbance;Hip fracture;Mobility decreased;Musculoskeletal pain;Osteopenia;Pain,198158662.0,OT,,,198158662.0,1.0,201501.0,201709.0,,,198158662.0,1.0,HIV infection
19816298,198162982,2,F,20190101.0,20220527.0,20210910,20220603,EXP,,US-GILEAD-2021-0547340,GILEAD,,,,A,F,Y,45.351,KG,20220603.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Dysstasia;Emotional distress;Gait disturbance;Impaired work ability;Insomnia;Mobility decreased;Multiple fractures;Osteoporosis;Pain;Rib fracture,198162982.0,OT,,,198162982.0,1.0,2011.0,201308.0,,,198162982.0,1.0,HIV infection
19816999,198169993,3,F,20161219.0,20230612.0,20210910,20230615,EXP,,US-GILEAD-2021-0547354,GILEAD,,58.0,YR,A,F,Y,57.15,KG,20230615.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Chronic kidney disease;Emotional distress;Fracture;Hip fracture;Osteopenia;Osteoporosis;Pain,198169993.0,OT,,,198169993.0,1.0,2006.0,2016.0,,,198169993.0,1.0,HIV infection
19818913,198189132,2,F,20170101.0,20220613.0,20210912,20220615,EXP,,US-GILEAD-2021-0547360,GILEAD,,,,A,F,Y,78.912,KG,20220615.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Exercise tolerance decreased;Gait disturbance;Mobility decreased;Pain,198189132.0,OT,,,198189132.0,1.0,2009.0,2019.0,,,198189132.0,1.0,HIV infection
19819308,198193081,1,I,,20210830.0,20210913,20210913,EXP,,IN-CIPLA LTD.-2021IN06149,CIPLA,,,,,,Y,,,20210913.0,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198193081.0,OT,,,198193081.0,1.0,200801.0,,,,198193081.0,1.0,HIV infection
19819331,198193311,1,I,,20210830.0,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06155,CIPLA,,,,,,Y,,,20210913.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,198193311.0,OT,,,198193311.0,1.0,201501.0,,,,198193311.0,1.0,HIV infection
19819354,198193541,1,I,,20210830.0,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06158,CIPLA,,,,,,Y,,,20210913.0,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198193541.0,OT,,,198193541.0,1.0,201410.0,,,,198193541.0,1.0,HIV infection
19819663,198196631,1,I,,20210830.0,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06156,CIPLA,,,,,,Y,,,20210913.0,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,198196631.0,OT,,,198196631.0,1.0,201503.0,,,,198196631.0,1.0,HIV infection
19819688,198196881,1,I,,20210830.0,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06160,CIPLA,,,,,,Y,,,20210913.0,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198196881.0,OT,,,198196881.0,1.0,201404.0,,,,198196881.0,1.0,HIV infection
19820307,198203071,1,I,,20210830.0,20210913,20210913,EXP,,IN-CIPLA LTD.-2021IN06150,CIPLA,,,,,,Y,,,20210913.0,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198203071.0,OT,,,198203071.0,1.0,201101.0,,,,198203071.0,1.0,HIV infection
19820769,198207691,1,I,,20210831.0,20210913,20210913,EXP,,ZA-STRIDES ARCOLAB LIMITED-2021SP027461,STRIDES,"SEEDAT F, PATEL M, PHILLIP V, MOHAMED F, MARAIS AD, BLACKHURST DM, ET AL.. HYPERLIPIDEMIC MYELOMA, A RARE FORM OF ACQUIRED DYSBETALIPOPROTEINEMIA, IN AN HIV SEROPOSITIVE AFRICAN FEMALE. CLIN?CHIM?ACTA.. 2021?52071?52075",53.0,YR,,F,Y,,,20210913.0,,HP,ZA,ZA,EFAVIRENZ.,Type III hyperlipidaemia,198207691.0,HO,,,,,,,,,198207691.0,1.0,HIV infection
19823132,198231324,4,F,20150701.0,20230824.0,20210913,20230830,EXP,,US-GILEAD-2021-0547356,GILEAD,,53.0,YR,A,M,Y,75.737,KG,20230830.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Compression fracture;Emotional distress;Gait disturbance;Mobility decreased;Multiple fractures;Osteopenia;Pain,198231324.0,OT,,,198231324.0,1.0,2010.0,201701.0,,,198231324.0,1.0,HIV infection
19824700,198247001,1,I,,20210831.0,20210914,20210914,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2021-17133,LUPIN,,53.0,YR,,F,Y,,,20210914.0,,HP,ZA,ZA,EFAVIRENZ.,Type III hyperlipidaemia,198247001.0,HO,,,,,,,,,198247001.0,1.0,HIV infection
19824774,198247741,1,I,,20210901.0,20210914,20210914,EXP,,IN-APPCO PHARMA LLC-2118328,APPCO PHARMA,"BELGAUMKAR VA, CHAVAN RB, SURYATALEY PR, SALUNKE AS, PATIL PP, BORADE SM. SYSTEMIC LUPUS ERYTHEMATOSUS IN HIV: AN INSIGHT INTO CLINICAL IMPLICATIONS AND MANAGEMENT. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019 JAN? 40(1):64 DOI: 10.4103/IJSTD.IJSTD_26_18.",47.0,YR,,F,Y,,,20210914.0,,HP,IN,IN,EFAVIRENZ.,Systemic lupus erythematosus,198247741.0,OT,,,,,,,,,198247741.0,1.0,HIV infection
19838200,198382001,1,I,,20210913.0,20210916,20210916,EXP,,CA-GILEAD-2021-0548506,GILEAD,,32.0,YR,A,M,Y,,,20210916.0,,HP,CA,CA,EFAVIRENZ.,Genotype drug resistance test positive;Therapeutic product effect incomplete,198382001.0,OT,,,,,,,,,198382001.0,1.0,HIV infection
19854662,198546622,2,F,,20210913.0,20210920,20210924,EXP,,ZA-AUROBINDO-AUR-APL-2021-038920,AUROBINDO,,53.0,YR,,F,Y,,,20210924.0,,HP,ZA,ZA,EFAVIRENZ.,Plasma cell myeloma;Type III hyperlipidaemia;Xanthoma,198546622.0,OT,,,,,,,,,198546622.0,1.0,HIV infection
19855115,198551153,3,F,20070101.0,20211203.0,20210920,20220107,EXP,,US-GILEAD-2021-0548468,GILEAD,,,,A,M,Y,,,20220107.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Dysstasia;Emotional distress;Exercise tolerance decreased;Pain;Renal injury;Skeletal injury,198551153.0,OT,,,198551153.0,1.0,2003.0,2011.0,,,198551153.0,1.0,HIV infection
19855618,198556183,3,F,20170101.0,20230810.0,20210920,20230816,EXP,,US-GILEAD-2021-0548487,GILEAD,,,,A,M,Y,,,20230816.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Femur fracture;Osteoporosis;Pain;Rib fracture,198556183.0,OT,,,198556183.0,1.0,2006.0,2019.0,,,198556183.0,1.0,HIV infection
19856529,198565291,1,I,202006.0,20210914.0,20210920,20210920,EXP,,DE-MYLANLABS-2021M1063808,MYLAN,,,,,M,Y,,,20210920.0,,HP,DE,DE,EFAVIRENZ.,Hypophosphataemia;Renal tubular dysfunction;Vitamin D deficiency,198565291.0,OT,,,198565291.0,1.0,200706.0,201704.0,,,198565291.0,1.0,HIV infection
19858950,198589501,1,I,2004.0,20210915.0,20210920,20210920,EXP,,ES-MYLANLABS-2021M1063042,MYLAN,,66.0,YR,,M,Y,,,20210920.0,,MD,ES,ES,EFAVIRENZ.,Drug ineffective;Treatment failure,198589501.0,OT,,,,,,,,,198589501.0,1.0,HIV infection
19864842,198648424,4,F,20080101.0,20231012.0,20210922,20231016,EXP,,US-GILEAD-2021-0548532,GILEAD,,49.0,YR,A,M,Y,63.5,KG,20231015.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood cholesterol increased;Blood creatinine increased;Chronic kidney disease;Depression;Emotional distress;Hypertension;Pain;Pollakiuria;Renal failure,198648424.0,OT,,,198648424.0,1.0,200708.0,200802.0,,,198648424.0,1.0,HIV infection
19865762,198657622,2,F,20160101.0,20211215.0,20210922,20211230,EXP,,US-GILEAD-2021-0548504,GILEAD,,60.0,YR,A,M,Y,,,20211230.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Hypertension;Joint injury;Nephropathy;Osteoarthritis;Osteopenia;Osteoporosis;Pain;Protein urine present,198657622.0,OT,,,198657622.0,1.0,2006.0,201701.0,,,198657622.0,1.0,HIV infection
19867567,198675672,2,F,,20231117.0,20210922,20231128,EXP,,CA-GLAXOSMITHKLINE-CA2021AMR196454,GLAXOSMITHKLINE,,,,,,Y,,,20231127.0,,HP,CA,CA,EFAVIRENZ,Chills;Disease recurrence;Drug ineffective;Nephropathy toxic,198675672.0,OT,,,198675672.0,10.0,,,4.0,WK,198675672.0,1.0,Antiretroviral therapy
19867673,198676732,2,F,,20231117.0,20210922,20231128,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021AMR196454,VIIV,,,,,,Y,,,20231127.0,,HP,CA,CA,EFAVIRENZ,Chills;Disease recurrence;Drug ineffective;Nephropathy toxic,198676732.0,OT,,,198676732.0,10.0,,,4.0,WK,198676732.0,1.0,Antiretroviral therapy
19876853,198768531,1,I,2004.0,20210920.0,20210923,20210923,EXP,,PT-MYLANLABS-2021M1064463,MYLAN,,55.0,YR,,F,Y,,,20210923.0,,MD,PT,PT,EFAVIRENZ.,Major depression;Neuropathy peripheral,198768531.0,OT,,,198768531.0,1.0,2011.0,2014.0,,,198768531.0,1.0,HIV infection
19882848,198828482,2,F,20210828.0,20210923.0,20210924,20211001,EXP,,RU-GILEAD-2021-0549987,GILEAD,,10.0,YR,C,M,Y,31.0,KG,20211001.0,,MD,RU,RU,EFAVIRENZ,Vomiting,198828482.0,DS,,,198828482.0,1.0,20210828.0,202109.0,3.0,WK,198828482.0,1.0,HIV infection
19884559,198845591,1,I,,20210915.0,20210927,20210927,EXP,,CA-AUROBINDO-AUR-APL-2021-039967,AUROBINDO,,10.0,YR,,F,Y,,,20210927.0,,HP,CA,CA,EFAVIRENZ.,Chills;Disease recurrence;Nephropathy toxic,198845591.0,OT,,,,,,,,,198845591.0,1.0,Antiretroviral therapy
19889360,198893601,1,I,202006.0,20210914.0,20210928,20210928,PER,,DE-LUPIN PHARMACEUTICALS INC.-2021-18149,LUPIN,,,,,M,Y,,,20210928.0,,HP,DE,DE,EFAVIRENZ.,Hypophosphataemia;Renal tubular dysfunction;Vitamin D deficiency,198893601.0,OT,,,198893601.0,1.0,2015.0,201704.0,,,198893601.0,1.0,HIV infection
19889985,198899851,1,I,,20210914.0,20210927,20210927,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2021GSK195185,VIIV,"SONEJA M, AGGARWAL A, KODAN P, GUPTA N. HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH MULTIPLE OPPORTUNISTIC INFECTIONS: LESSONS LEARNT FROM A NON?ADHERENT PATIENT. OXFORD MEDICAL CASE REPORTS. 2021?2021 (3):79?81",50.0,YR,,M,Y,,,20210927.0,,HP,IN,IN,EFAVIRENZ.,Blood electrolytes abnormal;Cachexia;Condition aggravated;Cryptosporidiosis infection;Cytomegalovirus oesophagitis;Dehydration;Diarrhoea;Dysphagia;Erythema;Ichthyosis;Oesophageal candidiasis;Oral candidiasis;Oral mucosal erythema;Punctate keratitis;SJS-TEN overlap;Skin lesion;Therapy non-responder;Treatment noncompliance,198899851.0,HO,,,,,,,,,198899851.0,1.0,HIV infection
19889986,198899861,1,I,,20210914.0,20210927,20210927,EXP,,IN-GLAXOSMITHKLINE-IN2021GSK195185,GLAXOSMITHKLINE,"SONEJA M, AGGARWAL A, KODAN P, GUPTA N. HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH MULTIPLE OPPORTUNISTIC INFECTIONS: LESSONS LEARNT FROM A NON?ADHERENT PATIENT. OXFORD MEDICAL CASE REPORTS. 2021?2021 (3):79?81",50.0,YR,,M,Y,,,20210927.0,,HP,IN,IN,EFAVIRENZ.,Blood electrolytes abnormal;Cachexia;Condition aggravated;Cryptosporidiosis infection;Cytomegalovirus oesophagitis;Dehydration;Diarrhoea;Dysphagia;Erythema;Ichthyosis;Oesophageal candidiasis;Oral candidiasis;Oral mucosal erythema;Punctate keratitis;SJS-TEN overlap;Skin lesion;Therapy non-responder;Treatment noncompliance,198899861.0,OT,,,,,,,,,198899861.0,1.0,HIV infection
19890987,198909871,1,I,,20210921.0,20210928,20210928,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME201026,VIIV,,58.0,YR,,M,Y,,,20210928.0,,CN,GB,GB,EFAVIRENZ.,Renal failure,198909871.0,OT,,,198909871.0,1.0,20120601.0,,,,198909871.0,1.0,HIV infection
19894699,198946993,3,F,,20240611.0,20210929,20240619,EXP,,CA-APOTEX-2021AP043233,APOTEX,,54.0,YR,,M,Y,,,20240619.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,198946993.0,OT,,,,,,,,,198946993.0,1.0,HIV infection
19895097,198950972,2,F,,20210927.0,20210929,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN202612,VIIV,,,,,,Y,,,20220624.0,,MD,JP,JP,EFAVIRENZ,Diarrhoea;Renal cancer;Renal impairment,198950972.0,OT,,,,,,,,,198950972.0,1.0,HIV infection
19895117,198951172,2,F,,20210927.0,20210929,20220714,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN202612,GLAXOSMITHKLINE,,,,,,Y,,,20220714.0,,MD,JP,JP,EFAVIRENZ,Diarrhoea;Renal cancer;Renal impairment,198951172.0,OT,,,,,,,,,198951172.0,1.0,HIV infection
19896069,198960691,1,I,,20210927.0,20210929,20210929,EXP,,CH-GILEAD-2021-0550396,GILEAD,,,,A,M,Y,,,20210929.0,,MD,CH,CH,EFAVIRENZ.,Blood creatinine increased;Disseminated leishmaniasis;Glycosuria;Haemoglobin decreased;Hepatosplenomegaly;Renal failure;Visceral leishmaniasis;Weight decreased,198960691.0,OT,,,,,,,,,198960691.0,1.0,HIV infection
19898315,198983151,1,I,,20210921.0,20210930,20210930,EXP,,CA-APOTEX-2021AP043204,APOTEX,,32.0,YR,,M,Y,,,20210930.0,,CN,CA,CA,EFAVIRENZ.,Genotype drug resistance test positive;Therapeutic product effect incomplete,198983151.0,OT,,,,,,,,,198983151.0,1.0,HIV infection
19901857,199018573,3,F,,20231102.0,20210930,20231116,EXP,,IN-CIPLA LTD.-2021IN06388,CIPLA,"Das S, Bhatia P. Treatment non-responsiveness in depression following Efavirenz administration. Indian Journal of Sexually Transmitted Diseases and AIDS. 2020;41 (1):113 to 115",,,,,Y,,,20231116.0,,HP,IN,IN,EFAVIRENZ,Depression;Drug interaction;Euphoric mood;Insomnia;Irritability;Logorrhoea;Therapy non-responder,199018573.0,OT,,,,,,,,,199018573.0,1.0,HIV infection
19903750,199037503,3,F,,20220518.0,20211001,20220527,EXP,,CA-APOTEX-2021AP043245,APOTEX,,54.0,YR,,M,Y,,,20220527.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199037503.0,OT,,,,,,,,,199037503.0,1.0,HIV infection
19904111,199041111,1,I,20170501.0,20210922.0,20211001,20211001,EXP,,GB-TEVA-2021-GB-1958742,TEVA,,57.0,YR,A,F,Y,,,20211001.0,,MD,GB,GB,EFAVIRENZ,Drug interaction;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,199041111.0,OT,,,199041111.0,1.0,20100901.0,,,,199041111.0,1.0,HIV infection
19904740,199047401,1,I,,20210927.0,20210930,20210930,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC203508,VIIV,,60.0,YR,,F,Y,62.8,KG,20210930.0,,MD,KR,KR,EFAVIRENZ.,Oesophageal candidiasis,199047401.0,OT,,,199047401.0,1.0,20140310.0,20140323.0,,,199047401.0,1.0,HIV infection
19904745,199047451,1,I,,20210927.0,20210930,20210930,EXP,,KR-GLAXOSMITHKLINE-KR2021APC203508,GLAXOSMITHKLINE,,60.0,YR,,F,Y,62.8,KG,20210930.0,,MD,KR,KR,EFAVIRENZ.,Oesophageal candidiasis,199047451.0,OT,,,199047451.0,1.0,20140310.0,20140323.0,,,199047451.0,1.0,HIV infection
19909900,199099002,2,F,,20220118.0,20211003,20220128,EXP,,CA-APOTEX-2021AP043243,APOTEX,,54.0,YR,,M,Y,,,20220128.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199099002.0,DE,,,,,,,,,199099002.0,1.0,HIV infection
19910547,199105471,1,I,20170501.0,20210922.0,20211004,20211004,EXP,,GB-AUROBINDO-AUR-APL-2021-040732,AUROBINDO,,57.0,YR,,F,Y,,,20211004.0,,MD,GB,GB,EFAVIRENZ,Drug interaction;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,199105471.0,OT,,,199105471.0,1.0,20100901.0,,,,199105471.0,1.0,HIV infection
19911577,199115771,1,I,20171015.0,20210927.0,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC204133,VIIV,,31.0,YR,,M,Y,67.0,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Appendicitis,199115771.0,HO,,,199115771.0,1.0,20170930.0,201511.0,,,199115771.0,1.0,HIV infection
19911589,199115891,1,I,20150904.0,20210927.0,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC203869,VIIV,,43.0,YR,,M,Y,64.5,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Lymphoma,199115891.0,HO,,,199115891.0,1.0,20150416.0,20150527.0,41.0,DAY,199115891.0,1.0,HIV infection
19911682,199116821,1,I,20150904.0,20210927.0,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC203869,GLAXOSMITHKLINE,,43.0,YR,,M,Y,64.5,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Lymphoma,199116821.0,HO,,,199116821.0,1.0,20150416.0,20150527.0,41.0,DAY,199116821.0,1.0,HIV infection
19911988,199119881,1,I,20130513.0,20210927.0,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC204139,GLAXOSMITHKLINE,,35.0,YR,,M,Y,56.7,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Conjunctivitis;Headache;Hyperbilirubinaemia;Myalgia;Pyrexia,199119881.0,OT,,,199119881.0,1.0,20130417.0,20130512.0,25.0,DAY,199119881.0,1.0,HIV infection
19911996,199119961,1,I,20130513.0,20210927.0,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC204139,VIIV,,35.0,YR,,M,Y,56.7,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Conjunctivitis;Headache;Hyperbilirubinaemia;Myalgia;Pyrexia,199119961.0,OT,,,199119961.0,1.0,20130417.0,20130512.0,25.0,DAY,199119961.0,1.0,HIV infection
19912698,199126981,1,I,20131007.0,20210927.0,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC203445,VIIV,,47.0,YR,,M,Y,64.7,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Cellulitis;Dyslipidaemia;Lipid metabolism disorder,199126981.0,OT,,,199126981.0,1.0,20130419.0,20131031.0,10.0,DAY,199126981.0,1.0,HIV infection
19912703,199127031,1,I,20131007.0,20210927.0,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC203445,GLAXOSMITHKLINE,,47.0,YR,,M,Y,64.7,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Cellulitis;Dyslipidaemia;Lipid metabolism disorder,199127031.0,OT,,,199127031.0,1.0,20130419.0,20131031.0,10.0,DAY,199127031.0,1.0,HIV infection
19913202,199132021,1,I,20160108.0,20210927.0,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC204117,VIIV,,53.0,YR,,M,Y,83.0,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Depression;Insomnia;Macular oedema;Periodontitis;Retinal detachment,199132021.0,OT,,,199132021.0,1.0,20121204.0,20160111.0,866.0,DAY,199132021.0,1.0,HIV infection
19913206,199132061,1,I,20160108.0,20210927.0,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC204117,GLAXOSMITHKLINE,,53.0,YR,,M,Y,83.0,KG,20211004.0,,MD,KR,KR,EFAVIRENZ,Depression;Insomnia;Macular oedema;Periodontitis;Retinal detachment,199132061.0,OT,,,199132061.0,1.0,20121204.0,20160111.0,866.0,DAY,199132061.0,1.0,HIV infection
19913795,199137951,1,I,20200701.0,20210927.0,20211004,20211004,EXP,,CH-VIIV HEALTHCARE LIMITED-CH2021EME203313,VIIV,,,,A,M,Y,,,20211004.0,,MD,CH,CH,EFAVIRENZ,Acute kidney injury;Hepatosplenomegaly;Immune system disorder;Pancytopenia;Peripheral sensory neuropathy;Visceral leishmaniasis;Weight decreased,199137951.0,OT,,,199137951.0,1.0,201911.0,202007.0,,,199137951.0,1.0,HIV infection
19913803,199138031,1,I,20200701.0,20210927.0,20211004,20211004,EXP,,CH-GLAXOSMITHKLINE-CH2021EME203313,GLAXOSMITHKLINE,,,,A,M,Y,,,20211004.0,,MD,CH,CH,EFAVIRENZ,Acute kidney injury;Hepatosplenomegaly;Immune system disorder;Pancytopenia;Peripheral sensory neuropathy;Visceral leishmaniasis;Weight decreased,199138031.0,OT,,,199138031.0,1.0,201911.0,202007.0,,,199138031.0,1.0,HIV infection
19930845,199308451,1,I,20201106.0,20210927.0,20211008,20211008,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-099507,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20211008.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,199308451.0,OT,,,199308451.0,1.0,20200910.0,20200909.0,1281.0,DAY,199308451.0,1.0,Antiretroviral therapy
19931364,199313641,1,I,20050101.0,20211004.0,20211007,20211007,EXP,,FR-MYLANLABS-2021M1069430,MYLAN,,65.0,YR,,M,Y,,,20211007.0,,MD,FR,FR,SUSTIVA,Drug resistance;Virologic failure,199313641.0,OT,,,199313641.0,1.0,20020701.0,20060601.0,46.0,MON,199313641.0,1.0,HIV infection
19934696,199346962,2,F,,20220308.0,20211008,20220310,EXP,,CA-ABBVIE-21K-028-4108072-00,ABBVIE,,54.0,YR,,M,Y,,,20220310.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,199346962.0,OT,,,,,,,,,199346962.0,1.0,HIV infection
19935668,199356682,2,F,,20220212.0,20211009,20220216,EXP,,CA-ABBVIE-21K-028-4109826-00,ABBVIE,,54.0,YR,,M,Y,,,20220216.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,199356682.0,OT,,,,,,,,,199356682.0,1.0,HIV infection
19940735,199407351,1,I,20020101.0,20210927.0,20211011,20211011,EXP,,FR-MYLANLABS-2021M1067533,MYLAN,"Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM et al... Renal Tubular Dysfunction Associated with Tenofovir Therapy: Report of 7 Cases.. J Acquir Immune Defic Syndr. 2004;35(3):269-73",48.0,YR,,F,Y,42.0,KG,20211011.0,,HP,FR,FR,EFAVIRENZ,Acquired aminoaciduria;Argininosuccinate synthetase deficiency;Creatinine renal clearance decreased;Hypophosphataemia;Myalgia;Nephropathy toxic;Paraesthesia;Proteinuria;Renal glycosuria;Renal tubular dysfunction,199407351.0,OT,,,199407351.0,1.0,200108.0,,,,199407351.0,1.0,HIV infection
19945467,199454672,2,F,,20220404.0,20211012,20220407,EXP,,LV-MYLANLABS-2021M1070855,MYLAN,,41.0,YR,,M,Y,,,20220407.0,,MD,LV,LV,EFAVIRENZ,Dizziness;Hyperlipidaemia;Nightmare;Pulmonary hypertension,199454672.0,OT,,,199454672.0,1.0,2018.0,2020.0,,,199454672.0,1.0,HIV infection
19945615,199456151,1,I,,20210930.0,20211012,20211012,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-101122,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20211012.0,,CN,GB,GB,EFAVIRENZ,Renal failure,199456151.0,OT,,,199456151.0,1.0,20120601.0,,,,199456151.0,1.0,HIV infection
19947437,199474373,3,F,20060705.0,20220427.0,20211012,20220504,EXP,,US-GILEAD-2021-0551913,GILEAD,,37.0,YR,A,M,Y,92.517,KG,20220503.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Cholelithiasis;Chronic kidney disease;Emotional distress;Pain;Renal failure;Renal impairment,199474373.0,OT,,,199474373.0,1.0,200608.0,200905.0,,,199474373.0,1.0,HIV infection
19947474,199474745,5,F,20160401.0,20230701.0,20211012,20230705,EXP,,US-GILEAD-2021-0551967,GILEAD,,50.0,YR,A,M,Y,82.54,KG,20230705.0,,LW,US,US,SUSTIVA,Abdominal discomfort;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Fatigue;Libido decreased;Loss of personal independence in daily activities;Nausea;Pain;Renal impairment,199474745.0,OT,,,199474745.0,1.0,2001.0,2004.0,,,199474745.0,1.0,HIV infection
19948549,199485491,1,I,,20211012.0,20211013,20211013,EXP,IS-IMA-4919,IS-GILEAD-2021-0552407,GILEAD,,,,A,M,Y,,,20211013.0,,PH,IS,IS,EFAVIRENZ,Abdominal pain;Acute kidney injury;Asthenia;Chest pain;Diarrhoea;Fanconi syndrome;Hypoaesthesia;Hypokalaemia;Hypophosphataemia;Metabolic acidosis;Osteoporosis;Rib fracture;Vitamin B12 deficiency;Vitamin D deficiency,199485491.0,DS,,,199485491.0,1.0,20050503.0,,,,199485491.0,1.0,HIV infection
19951029,199510291,1,I,,20210930.0,20211014,20211014,EXP,,GB-AUROBINDO-AUR-APL-2021-042245,AUROBINDO,,58.0,YR,,M,Y,,,20211014.0,,MD,GB,GB,EFAVIRENZ,Renal failure,199510291.0,OT,,,199510291.0,1.0,20120601.0,,,,199510291.0,1.0,HIV infection
19961937,199619371,1,I,,20211006.0,20211018,20211018,EXP,,MW-CIPLA LTD.-2021MW06795,CIPLA,"Brasher WP, Bvumbwe M, Kazembe PN.. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Medical Journal. 2020;32 (4):229 to 231",,,,,Y,,,20211018.0,,HP,MW,MW,EFAVIRENZ,Ataxia;Confusional state;Diplopia;Dysdiadochokinesis;Toxicity to various agents,199619371.0,HO,,,199619371.0,1.0,2012.0,,,,199619371.0,1.0,HIV infection
19964056,199640562,2,F,,20211026.0,20211018,20211102,EXP,,ZA-GILEAD-2021-0552643,GILEAD,"Loveday M., Hughes J., Sunkari B., Master I., Hlangu S., Reddy T., Chotoo S., Green N., Seddon J.. Maternal and Infant Outcomes among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis.. 2021;72:1158-1168. doi:10.1093/cid/ciaa189",,,I,M,Y,,,20211102.0,,HP,ZA,ZA,EFAVIRENZ,Ehlers-Danlos syndrome;Foetal exposure during pregnancy,199640562.0,CA,,,199640562.0,1.0,2015.0,,,,199640562.0,1.0,HIV infection
19964059,199640592,2,F,,20211026.0,20211018,20211102,EXP,,ZA-GILEAD-2021-0552640,GILEAD,"Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, Chotoo S, Green N, Seddon J. Maternal and Infant Outcomes among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis.. 2021;72:1158-1168. doi:10.1093/cid/ciaa189",,,I,,Y,,,20211102.0,,HP,ZA,ZA,EFAVIRENZ,Congenital umbilical hernia;Foetal exposure during pregnancy,199640592.0,CA,,,,,,,,,199640592.0,1.0,HIV infection
19967368,199673681,1,I,,20040719.0,20211019,20211019,EXP,,US-GILEAD-2004-0007278,GILEAD,,,,N,M,Y,,,20211019.0,,HP,US,US,SUSTIVA,Meningomyelocele,199673681.0,CA,,,199673681.0,1.0,20030310.0,20040219.0,347.0,DAY,199673681.0,1.0,HIV infection
19969617,199696172,2,F,,20231127.0,20211019,20231201,EXP,,FR-MYLANLABS-2021M1073241,MYLAN,"Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM et al.. Renal Tubular Dysfunction Associated with Tenofovir Therapy: Report of 7 Cases.. J Acquir Immune Defic Syndr. 2004;35(3):269-73",56.0,YR,,F,Y,56.0,KG,20231201.0,,MD,FR,FR,EFAVIRENZ,Creatinine renal clearance decreased;Glycosuria;Hypophosphataemia;Myalgia;Nephropathy toxic;Pain in extremity;Proteinuria;Renal tubular dysfunction,199696172.0,OT,,,199696172.0,1.0,202105.0,2002.0,11.0,MON,199696172.0,1.0,HIV infection
19974419,199744192,2,F,20210101.0,20211119.0,20211020,20220221,EXP,GB-MHRA-EYC 00263325,GB-MYLANLABS-2021M1073649,MYLAN,,71.0,YR,,M,Y,,,20220221.0,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199744192.0,OT,,,199744192.0,1.0,20191114.0,,,,199744192.0,1.0,HIV infection
19977951,199779515,5,F,20210101.0,20220420.0,20211020,20220422,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME212973,VIIV,"Bowman C, Ambrose A, Simoes P, Florman K, Kanitkar T, Katiyar A et al.. Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV",,,,M,Y,,,20220422.0,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199779515.0,OT,,,199779515.0,1.0,20191114.0,201911.0,,,199779515.0,1.0,HIV infection
19978643,199786435,5,F,20210101.0,20220420.0,20211020,20220422,EXP,,GB-GLAXOSMITHKLINE-GB2021EME212973,GLAXOSMITHKLINE,"Bowman C, Ambrose A, Simoes P, Florman K, Kanitkar T, Katiyar A et al.. Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV",,,,M,Y,,,20220422.0,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199786435.0,OT,,,199786435.0,1.0,20191114.0,201911.0,,,199786435.0,1.0,HIV infection
19987631,199876311,1,I,,20211017.0,20211022,20211022,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN214594,VIIV,,69.0,YR,,M,Y,,,20211022.0,,MD,JP,JP,EFAVIRENZ,Angina pectoris;Blood HIV RNA increased;Blood creatinine increased;Diabetes mellitus;Hypertension;Protein urine;Renal disorder,199876311.0,OT,,,,,,,,,199876311.0,1.0,Acquired immunodeficiency syndrome
19987636,199876361,1,I,,20211017.0,20211022,20211022,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN214594,GLAXOSMITHKLINE,,69.0,YR,,M,Y,,,20211022.0,,MD,JP,JP,EFAVIRENZ,Angina pectoris;Blood HIV RNA increased;Blood creatinine increased;Diabetes mellitus;Hypertension;Protein urine;Renal disorder,199876361.0,OT,,,,,,,,,199876361.0,1.0,Acquired immunodeficiency syndrome
20003856,200038562,2,F,20210101.0,20211119.0,20211028,20211203,EXP,,GB-AUROBINDO-AUR-APL-2021-043509,AUROBINDO,,71.0,YR,,M,Y,,,20211203.0,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,200038562.0,OT,,,200038562.0,1.0,20191114.0,201911.0,,,200038562.0,1.0,HIV infection
20010039,200100392,2,F,,20211113.0,20211028,20211123,EXP,,CA-TEVA-2021-CA-1969608,TEVA,,54.0,YR,A,M,Y,,,20211123.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,200100392.0,OT,,,,,,,,,200100392.0,1.0,HIV infection
20010155,200101551,1,I,,20211020.0,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969621,TEVA,,54.0,YR,A,M,Y,,,20211028.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200101551.0,HO,,,,,,,,,200101551.0,1.0,HIV infection
20010307,200103071,1,I,,20211020.0,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969604,TEVA,,54.0,YR,A,M,Y,,,20211028.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,200103071.0,OT,,,,,,,,,200103071.0,1.0,HIV infection
20010474,200104741,1,I,,20211020.0,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969615,TEVA,,54.0,YR,A,M,Y,,,20211028.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200104741.0,DE,,,,,,,,,200104741.0,1.0,HIV infection
20010477,200104771,1,I,,20211020.0,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969630,TEVA,,54.0,YR,A,M,Y,,,20211028.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,200104771.0,OT,,,,,,,,,200104771.0,1.0,HIV infection
20010478,200104781,1,I,,20211020.0,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969673,TEVA,,54.0,YR,A,M,Y,,,20211028.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,200104781.0,DE,,,,,,,,,200104781.0,1.0,HIV infection
20010924,200109241,1,I,,20211020.0,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969598,TEVA,,54.0,YR,A,M,Y,,,20211029.0,,HP,,CA,SUSTIVA,Depression;Drug interaction,200109241.0,OT,,,,,,,,,200109241.0,1.0,HIV infection
20030180,200301801,1,I,,20211022.0,20211103,20211103,EXP,,SA-GLAXOSMITHKLINE-SA2021GSK219680,GLAXOSMITHKLINE,,,,A,F,Y,,,20211103.0,,MD,SA,SA,EFAVIRENZ,Exposure during pregnancy;Live birth;Pathogen resistance,200301801.0,OT,,,,,,,,,200301801.0,1.0,HIV infection
20030181,200301811,1,I,,20211022.0,20211103,20211103,EXP,,SA-VIIV HEALTHCARE LIMITED-SA2021GSK219680,VIIV,,,,A,F,Y,,,20211103.0,,MD,SA,SA,EFAVIRENZ,Exposure during pregnancy;Live birth;Pathogen resistance,200301811.0,OT,,,,,,,,,200301811.0,1.0,HIV infection
20031273,200312731,1,I,,20211026.0,20211103,20211103,EXP,,TW-MYLANLABS-2021M1080284,MYLAN,"Kao S-W, Liu Z-H, Wu T-S, Ku SW-W, Tsai C-L, Shie S-S, et al. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: An observational study in a tertiary hospital in Northern Taiwan, 2017-19. J-Antimicrob-Chemother 2021;76(3):722-728.",,,,,Y,,,20211103.0,,HP,TW,TW,EFAVIRENZ,Drug resistance,200312731.0,OT,,,,,,,,,200312731.0,1.0,HIV infection
20041003,200410034,4,F,20070901.0,20230703.0,20211107,20230705,EXP,,US-GILEAD-2021-0555190,GILEAD,,42.0,YR,A,M,Y,81.633,KG,20230705.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fatigue;Osteopenia;Osteoporosis;Pain;Protein urine present;Renal failure;Renal impairment;Vitamin D deficiency,200410034.0,HO,,,200410034.0,1.0,2006.0,2018.0,,,200410034.0,1.0,HIV infection
20044841,200448411,1,I,,20211027.0,20211108,20211108,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2021GSK223294,VIIV,"Kouamou V, Mavetera J, Manasa J, Ndhlovu CE, Katzenstein D, Mcgregor AM et al.. Pretreatment HIV Drug Resistance among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?. AIDS Research and Human Retroviruses. 2021;37 (10):776-783",,,A,M,Y,,,20211108.0,,HP,ZW,ZW,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,200448411.0,OT,,,200448411.0,1.0,201001.0,201003.0,,,200448411.0,1.0,HIV infection
20044842,200448421,1,I,,20211027.0,20211108,20211108,EXP,,ZW-GLAXOSMITHKLINE-ZW2021GSK223294,GLAXOSMITHKLINE,"Kouamou V, Mavetera J, Manasa J, Ndhlovu CE, Katzenstein D, Mcgregor AM et al.. Pretreatment HIV Drug Resistance among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?. AIDS Research and Human Retroviruses. 2021;37 (10):776-783",,,A,M,Y,,,20211108.0,,HP,ZW,ZW,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,200448421.0,OT,,,200448421.0,1.0,201001.0,201003.0,,,200448421.0,1.0,HIV infection
20046628,200466282,2,F,20141001.0,20220519.0,20211109,20220524,EXP,,US-GILEAD-2021-0555234,GILEAD,,56.0,YR,A,F,Y,73.923,KG,20220524.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Discomfort;Emotional distress;Gait disturbance;Osteoporosis;Pain;Pain in extremity;Quality of life decreased,200466282.0,OT,,,200466282.0,1.0,200412.0,201601.0,,,200466282.0,1.0,HIV infection
20049700,200497001,1,I,,20211028.0,20211109,20211109,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-113592,BRISTOL MYERS SQUIBB,"Momen SE, Diaz-Cano S, Walsh S, Creamer D. Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms:facial edema aligns to the severe phenotype. Journal of the American Academy of Dermatology. 2021;85(3):645-52",50.0,YR,,M,Y,,,20211109.0,,MD,GB,GB,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,200497001.0,HO,,,,,,,,,200497001.0,1.0,HIV infection
20049732,200497323,3,F,20040101.0,20231029.0,20211109,20231031,EXP,,US-GILEAD-2021-0555302,GILEAD,,,,A,F,Y,81.646,KG,20231031.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Emotional distress;Loss of personal independence in daily activities;Muscular weakness;Osteopenia;Osteoporosis;Pain;Renal failure,200497323.0,OT,,,200497323.0,1.0,2004.0,201801.0,,,200497323.0,1.0,HIV infection
20057137,200571374,4,F,20020605.0,20220907.0,20211111,20220909,EXP,,JP-GLAXOSMITHKLINE-A20032850,GLAXOSMITHKLINE,,,,,,Y,,,20220909.0,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571374.0,HO,,,200571374.0,1.0,20010627.0,20030331.0,642.0,DAY,200571374.0,1.0,Acquired immunodeficiency syndrome
20057140,200571404,4,F,20020605.0,20220907.0,20211111,20220909,EXP,,JP-VIIV HEALTHCARE LIMITED-A20032850,VIIV,,,,,,Y,,,20220909.0,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571404.0,HO,,,200571404.0,1.0,20010627.0,20030331.0,642.0,DAY,200571404.0,1.0,Acquired immunodeficiency syndrome
20057395,200573951,1,I,,20211108.0,20211111,20211111,EXP,,UG-GILEAD-2021-0556212,GILEAD,"Kiragga AN, Twinomuhwezi E, Banturaki G, Achieng M, Nampala J, Bagaya I, Kigozi J, Castelnuovo B, Musick B, Hazra R., Yiannoutsos C, Wools-Kaloustian K. Outcomes of retained and disengaged pregnant women living with HIV in Uganda. PLoS One.. 2021;16(5):unk. doi:10.1371/journal.pone.0251413",,,A,F,Y,,,20211111.0,,HP,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,200573951.0,OT,,,,,,,,,200573951.0,1.0,HIV infection
20069912,200699121,1,I,,20211104.0,20211115,20211115,EXP,,KE-GLAXOSMITHKLINE-KE2021GSK233760,GLAXOSMITHKLINE,,,,,,Y,,,20211115.0,,MD,KE,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,200699121.0,OT,,,,,,,,,200699121.0,1.0,HIV infection
20069923,200699231,1,I,,20211104.0,20211115,20211115,EXP,,KE-VIIV HEALTHCARE LIMITED-KE2021GSK233760,VIIV,,,,,,Y,,,20211115.0,,MD,KE,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,200699231.0,OT,,,,,,,,,200699231.0,1.0,HIV infection
20073094,200730941,1,I,20030101.0,20211109.0,20211116,20211116,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2021EME232520,VIIV,,,,A,M,Y,,,20211116.0,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,200730941.0,OT,,,200730941.0,1.0,1997.0,,,,200730941.0,1.0,HIV infection
20073096,200730961,1,I,20080101.0,20211109.0,20211116,20211116,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2021EME232447,VIIV,,,,A,M,Y,,,20211116.0,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,200730961.0,OT,,,200730961.0,1.0,1997.0,,,,200730961.0,1.0,HIV infection
20073105,200731051,1,I,20030101.0,20211109.0,20211116,20211116,EXP,,DE-GLAXOSMITHKLINE-DE2021EME232520,GLAXOSMITHKLINE,,,,A,M,Y,,,20211116.0,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,200731051.0,OT,,,200731051.0,1.0,1997.0,,,,200731051.0,1.0,HIV infection
20073106,200731061,1,I,20080101.0,20211109.0,20211116,20211116,EXP,,DE-GLAXOSMITHKLINE-DE2021EME232447,GLAXOSMITHKLINE,,,,A,M,Y,,,20211116.0,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,200731061.0,OT,,,200731061.0,1.0,1997.0,,,,200731061.0,1.0,HIV infection
20076456,200764561,1,I,,20211105.0,20211116,20211116,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2021GSK193982,VIIV,"Garc?a-Ortiz J, Villamil-Morales IM, Lopez-Garcia JC. Nutritional status of pediatric patients living with human immunodeficiency virus in bogota, colombia. Infectio. 2021;26 (1):61-66",,,,M,Y,29.0,KG,20211116.0,,MD,CO,CO,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,200764561.0,OT,,,200764561.0,1.0,20150406.0,201508.0,,,200764561.0,2.0,HIV infection
20089476,200894762,2,F,20030101.0,20220629.0,20211119,20220705,EXP,,DE-ABBVIE-21K-062-4165446-00,ABBVIE,,,,A,M,Y,,,20220705.0,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,200894762.0,OT,,,200894762.0,1.0,1997.0,,,,200894762.0,1.0,HIV infection
20091164,200911641,1,I,,20211108.0,20211119,20211119,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2021-22433,LUPIN,"Kao S-W, Liu Z-H, Wu T-S, Ku SW-W, Tsai C-L, Shie S-S, et al. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: An observational study in a tertiary hospital in Northern Taiwan, 2017-19. Journal of Antimicrobial Chemotherapy. 2021;76(3):722-728",,,,,Y,,,20211119.0,,HP,TW,TW,EFAVIRENZ,Drug resistance,200911641.0,OT,,,,,,,,,200911641.0,1.0,HIV infection
20095219,200952192,2,F,20080101.0,20220629.0,20211122,20220704,EXP,,DE-ABBVIE-21K-062-4165442-00,ABBVIE,,,,A,M,Y,,,20220704.0,,CN,DE,DE,EFAVIRENZ,Pathogen resistance,200952192.0,OT,,,200952192.0,1.0,1997.0,,,,200952192.0,1.0,HIV infection
20095242,200952421,1,I,20170101.0,20211112.0,20211122,20211122,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2021EME234912,VIIV,,,,A,F,Y,,,20211122.0,,MD,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,200952421.0,OT,,,200952421.0,1.0,2015.0,2017.0,4.0,MON,200952421.0,1.0,HIV infection CDC category A
20095259,200952591,1,I,20170101.0,20211112.0,20211122,20211122,EXP,,LV-GLAXOSMITHKLINE-LV2021EME234912,GLAXOSMITHKLINE,,,,A,F,Y,,,20211122.0,,MD,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,200952591.0,OT,,,200952591.0,1.0,2015.0,2017.0,4.0,MON,200952591.0,1.0,HIV infection CDC category A
20099095,200990951,1,I,,20211116.0,20211122,20211122,EXP,,IN-MYLANLABS-2021M1086040,MYLAN,"Sirohi P, Dabas A, Nehara HR, Chhimpa AR, Barodia MK, Kumar R. Safety and efficacy of fixed drug combination tenofovir, lamivudine and efavirenz to prevent transmission of HIV. J-Clin-Diagnostic-Res 2021;15(7):OC01-OC05.",,,A,F,Y,,,20211122.0,,HP,IN,IN,EFAVIRENZ,Drug ineffective;Maternal exposure during pregnancy,200990951.0,OT,,,,,,,,,200990951.0,1.0,Prophylaxis against HIV infection
20105742,201057423,3,F,20090410.0,20220215.0,20211124,20220301,EXP,,US-VIIV HEALTHCARE LIMITED-US2020080421,VIIV,,33.0,YR,,M,Y,,,20220301.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Dental caries;Renal failure;Renal impairment;Renal injury;Skeletal injury;Tooth loss,201057423.0,OT,,,201057423.0,1.0,20090121.0,20160101.0,2536.0,DAY,201057423.0,1.0,HIV infection
20106011,201060113,3,F,20090410.0,20220215.0,20211124,20220301,EXP,,US-GLAXOSMITHKLINE-US2020080421,GLAXOSMITHKLINE,,33.0,YR,,M,Y,,,20220301.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Dental caries;Renal failure;Renal impairment;Renal injury;Skeletal injury;Tooth loss,201060113.0,OT,,,201060113.0,1.0,20090121.0,20160101.0,2536.0,DAY,201060113.0,1.0,HIV infection
20107504,201075042,2,F,,20211117.0,20211124,20211124,PER,,US-GILEAD-2021-0557833,GILEAD,,,,A,M,Y,,,20211124.0,,MD,US,US,EFAVIRENZ,Drug resistance,201075042.0,OT,,,,,,,,,201075042.0,1.0,HIV infection
20113711,201137112,2,F,,20220126.0,20211125,20220204,EXP,,RO-MYLANLABS-2021M1038036,MYLAN,,31.0,YR,,M,Y,,,20220204.0,,MD,RO,RO,EFAVIRENZ,Drug ineffective;Virologic failure,201137112.0,OT,,,,,,,,,201137112.0,1.0,HIV infection
20113979,201139793,3,F,20120101.0,20230813.0,20211125,20230817,EXP,,US-GILEAD-2021-0557438,GILEAD,,,,A,F,Y,68.481,KG,20230817.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Dysstasia;Emotional distress;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain,201139793.0,OT,,,201139793.0,1.0,2001.0,2004.0,,,201139793.0,1.0,HIV infection
20115964,201159644,4,F,20080101.0,20230610.0,20211126,20230614,EXP,,US-GILEAD-2021-0557151,GILEAD,,,,A,M,Y,79.37,KG,20230614.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Emotional distress;Mobility decreased;Osteoarthritis;Osteopenia;Osteoporosis;Pain,201159644.0,OT,,,201159644.0,1.0,2008.0,2007.0,,,201159644.0,1.0,HIV infection
20118031,201180311,1,I,,20211118.0,20211126,20211126,EXP,,CA-AstraZeneca-2021A820084,ASTRAZENECA,,54.0,YR,,M,Y,,,20211126.0,,MD,CA,,SUSTIVA,Depression;Drug interaction,201180311.0,OT,,,,,,,,,201180311.0,1.0,HIV infection
20118774,201187743,3,F,20100401.0,20230701.0,20211126,20230704,EXP,,US-GILEAD-2021-0557192,GILEAD,,51.0,YR,A,M,Y,100.23,KG,20230704.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Mobility decreased;Pain;Renal failure,201187743.0,HO,,,201187743.0,1.0,2004.0,200701.0,,,201187743.0,1.0,HIV infection
20119748,201197482,2,F,,20230123.0,20211126,20230130,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-121861,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20230131.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Off label use,201197482.0,OT,,,,,,,,,201197482.0,1.0,HIV infection
20120093,201200933,3,F,20060801.0,20230418.0,20211126,20230421,EXP,,US-GILEAD-2021-0557450,GILEAD,,45.0,YR,A,M,Y,79.365,KG,20230421.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Gait disturbance;Hyperlipidaemia;Loss of personal independence in daily activities;Micturition disorder;Mobility decreased;Osteopenia;Osteoporosis;Pain;Proteinuria;Rash,201200933.0,OT,,,201200933.0,1.0,200310.0,200401.0,,,201200933.0,1.0,HIV infection
20123708,201237082,2,F,20130601.0,20220513.0,20211129,20220516,EXP,,US-GILEAD-2021-0557125,GILEAD,,52.0,YR,A,M,Y,120.18,KG,20220516.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Emotional distress;Gait disturbance;Pain,201237082.0,OT,,,201237082.0,1.0,2004.0,2007.0,,,201237082.0,1.0,HIV infection
20123926,201239262,2,F,20210101.0,20220322.0,20211129,20220325,EXP,,GB-GILEAD-2021-0557694,GILEAD,,71.0,YR,E,M,Y,,,20220325.0,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,201239262.0,OT,,,201239262.0,1.0,20191114.0,201911.0,,,201239262.0,1.0,HIV infection
20124059,201240593,3,F,20160401.0,20230918.0,20211129,20230922,EXP,,US-GILEAD-2021-0557458,GILEAD,,50.0,YR,A,M,Y,76.644,KG,20230922.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Asthenia;Bone demineralisation;Emotional distress;Fatigue;Foot fracture;Loss of personal independence in daily activities;Osteoporosis;Pain,201240593.0,OT,,,201240593.0,1.0,2013.0,201703.0,,,201240593.0,1.0,HIV infection
20124538,201245381,1,I,20080101.0,20211119.0,20211129,20211129,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125098,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20211129.0,,CN,DE,DE,EFAVIRENZ,Pathogen resistance,201245381.0,OT,,,201245381.0,1.0,1997.0,,,,201245381.0,1.0,HIV infection
20125712,201257122,2,F,20160901.0,20220425.0,20211129,20220429,EXP,,US-GILEAD-2021-0557401,GILEAD,,52.0,YR,A,M,Y,136.05,KG,20220428.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Dysstasia;Emotional distress;Loss of personal independence in daily activities;Pain;Renal failure,201257122.0,OT,,,201257122.0,1.0,2005.0,2017.0,,,201257122.0,1.0,HIV infection
20128073,201280733,3,F,20090501.0,20230724.0,20211129,20230726,EXP,,US-GILEAD-2021-0557457,GILEAD,,40.0,YR,A,F,Y,68.027,KG,20230726.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Depression;Emotional distress;Fall;Gait disturbance;Hip fracture;Lower limb fracture;Mobility decreased;Osteonecrosis;Osteoporosis;Pain;Renal impairment,201280733.0,OT,,,201280733.0,1.0,2004.0,200906.0,,,201280733.0,1.0,HIV infection
20130013,201300131,1,I,20030101.0,20211118.0,20211130,20211130,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-124807,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20211130.0,,CN,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,201300131.0,OT,,,201300131.0,1.0,1997.0,,,,201300131.0,1.0,HIV infection
20132091,201320913,3,F,20170201.0,20230809.0,20211130,20230814,EXP,,US-GILEAD-2021-0557164,GILEAD,,51.0,YR,A,M,Y,90.703,KG,20230814.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Cardiac disorder;Chronic kidney disease;Dyspnoea;Emotional distress;Gait disturbance;Musculoskeletal disorder;Pain,201320913.0,OT,,,201320913.0,1.0,2006.0,2020.0,,,201320913.0,1.0,HIV infection
20132122,201321223,3,F,20121126.0,20231010.0,20211130,20231012,EXP,,US-GILEAD-2021-0557167,GILEAD,,52.0,YR,A,F,Y,59.41,KG,20231011.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Depression;Emotional distress;Foot fracture;Limb injury;Mobility decreased;Neck pain;Osteopenia;Osteoporosis;Pain;Spinal pain,201321223.0,OT,,,201321223.0,1.0,2010.0,201301.0,,,201321223.0,1.0,HIV infection
20132704,201327042,2,F,20070901.0,20220519.0,20211130,20220524,EXP,,US-GILEAD-2021-0557347,GILEAD,,43.0,YR,A,M,Y,54.422,KG,20220524.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Emotional distress;Foot fracture;Gait disturbance;Multiple fractures;Osteopenia;Osteoporosis;Pain;Pelvic fracture,201327042.0,OT,,,201327042.0,1.0,200510.0,201706.0,,,201327042.0,1.0,HIV infection
20138679,201386795,5,F,20170101.0,20230731.0,20211202,20230802,PER,,US-GILEAD-2021-0557128,GILEAD,,,,A,M,Y,92.971,KG,20230802.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;CD4 lymphocytes decreased;Chronic kidney disease;Emotional distress;Micturition disorder;Pain;Proteinuria;Renal impairment,201386795.0,OT,,,201386795.0,1.0,2001.0,2017.0,,,201386795.0,1.0,HIV infection
20140951,201409512,2,F,,20210609.0,20211202,20211214,EXP,,ES-MYLANLABS-2021M1089756,MYLAN,,,,A,,Y,,,20211214.0,,MD,ES,ES,EFAVIRENZ,Hypertension;Thrombosis,201409512.0,OT,,,,,,,,,201409512.0,1.0,Antiretroviral therapy
20141611,201416111,1,I,20170101.0,20211123.0,20211202,20211202,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-126077,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20211202.0,,CN,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,201416111.0,OT,,,201416111.0,1.0,2015.0,2017.0,4.0,MON,201416111.0,1.0,HIV infection CDC category A
20141744,201417441,1,I,,20211124.0,20211202,20211202,EXP,,CA-TEVA-2021-CA-1983097,TEVA,,54.0,YR,A,M,Y,,,20211202.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,201417441.0,OT,,,,,,,,,201417441.0,1.0,HIV infection
20143057,201430571,1,I,,20211123.0,20211202,20211202,EXP,,IR-STRIDES ARCOLAB LIMITED-2021SP030442,STRIDES,"Mardani M, Sharifi-Razavi A, Sheibani S, Baziboroun M.. Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report.. Curr-HIV-Res. 2021;19(4):377-382",61.0,YR,,M,Y,,,20211203.0,,HP,IR,IR,EFAVIRENZ,COVID-19,201430571.0,HO,,,201430571.0,1.0,2014.0,,,,201430571.0,1.0,HIV infection
20144068,201440681,1,I,20030101.0,20211122.0,20211203,20211203,EXP,,DE-ROCHE-2963337,ROCHE,,,,A,M,Y,,,20211203.0,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,201440681.0,OT,,,201440681.0,1.0,1997.0,,,,201440681.0,1.0,HIV infection
20145831,201458311,1,I,20080101.0,20211122.0,20211203,20211203,EXP,,DE-ROCHE-2963063,ROCHE,,,,A,M,Y,,,20211203.0,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,201458311.0,OT,,,201458311.0,1.0,1997.0,,,,201458311.0,1.0,HIV infection
20149844,201498443,3,F,20100901.0,20230712.0,20211206,20230717,EXP,,US-GILEAD-2021-0557165,GILEAD,,61.0,YR,A,M,Y,82.086,KG,20230717.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Dysuria;Emotional distress;Glomerulonephritis;Pain;Pollakiuria,201498443.0,OT,,,201498443.0,1.0,2001.0,2004.0,,,201498443.0,1.0,HIV infection
20150086,201500864,4,F,20131201.0,20230725.0,20211206,20230728,EXP,,US-GILEAD-2021-0557126,GILEAD,,55.0,YR,A,M,Y,79.37,KG,20230728.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone pain;Chronic kidney disease;Depression;Emotional distress;Insomnia;Osteopenia;Pain;Patella fracture;Pneumonia;Pollakiuria;Renal failure;Renal injury;Urinary tract infection;Weight increased,201500864.0,HO,,,201500864.0,1.0,2015.0,2017.0,,,201500864.0,1.0,HIV infection
20151279,201512793,3,F,20150513.0,20230609.0,20211206,20230612,PER,,US-GILEAD-2021-0557334,GILEAD,,52.0,YR,A,M,Y,57.0,KG,20230612.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Emotional distress;Muscular weakness;Osteopenia;Pain;Weight decreased;Wrist fracture,,,,,201512793.0,1.0,2011.0,201712.0,,,201512793.0,1.0,HIV infection
20152924,201529247,7,F,20170301.0,20230724.0,20211206,20230801,EXP,,US-GILEAD-2021-0557543,GILEAD,,54.0,YR,A,M,Y,99.773,KG,20230801.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Apathy;Chronic kidney disease;Drug ineffective;Emotional distress;Insomnia;Pain,201529247.0,OT,,,201529247.0,1.0,2003.0,200501.0,,,201529247.0,1.0,HIV infection
20154505,201545051,1,I,,20211123.0,20211207,20211207,EXP,,IR-LUPIN PHARMACEUTICALS INC.-2021-23894,LUPIN,"Mardani M, Sharifi-Razavi A, Sheibani S, Baziboroun M. Outcome of a HIV positive patient infected with COVID-19 after an autologous bone marrow transplantation: A case report. Current HIV Research. 2021;19(4):377-382",61.0,YR,,M,Y,,,20211207.0,,HP,IR,IR,EFAVIRENZ,COVID-19;Off label use,201545051.0,HO,,,201545051.0,1.0,2014.0,,,,201545051.0,1.0,HIV infection
20155343,201553433,3,F,20150901.0,20231011.0,20211207,20231013,EXP,,US-GILEAD-2021-0557188,GILEAD,,55.0,YR,A,M,Y,106.12,KG,20231013.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Nocturia;Pain;Renal impairment,201553433.0,OT,,,201553433.0,1.0,201106.0,201606.0,,,201553433.0,1.0,HIV infection
20158798,201587981,1,I,20080101.0,20211130.0,20211208,20211208,EXP,,DE-009507513-2111DEU010374,MERCK,,,,A,M,Y,,,20211208.0,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,201587981.0,OT,,,201587981.0,1.0,1997.0,,,,201587981.0,1.0,HIV infection
20159148,201591483,3,F,20141201.0,20230807.0,20211208,20230810,EXP,,US-GILEAD-2021-0557366,GILEAD,,52.0,YR,A,M,Y,58.05,KG,20230810.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;End stage renal disease;Hypertension;Pain;Weight decreased,201591483.0,OT,,,201591483.0,1.0,2006.0,2011.0,,,201591483.0,1.0,HIV infection
20160932,201609321,1,I,20030101.0,20211130.0,20211208,20211208,EXP,,DE-009507513-2111DEU010371,MERCK,,,,A,M,Y,,,20211208.0,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,201609321.0,OT,,,201609321.0,1.0,1997.0,,,,201609321.0,1.0,HIV infection
20161207,201612073,3,F,20180101.0,20230807.0,20211208,20230809,PER,,US-GILEAD-2021-0557433,GILEAD,,,,A,M,Y,97.506,KG,20230809.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Depression;Dysstasia;Emotional distress;Gait disturbance;General physical health deterioration;Mobility decreased;Osteopenia;Pain,,,,,201612073.0,1.0,2005.0,201306.0,,,201612073.0,1.0,HIV infection
20162635,201626352,2,F,20130401.0,20220519.0,20211208,20220524,PER,,US-GILEAD-2021-0557221,GILEAD,,54.0,YR,A,F,Y,64.853,KG,20220523.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Depression;Emotional distress;Loss of personal independence in daily activities;Mobility decreased;Nausea;Osteopenia;Pain;Skeletal injury;Vomiting,,,,,201626352.0,1.0,2004.0,201908.0,,,201626352.0,1.0,HIV infection
20164660,201646601,1,I,,20211206.0,20211209,20211209,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-114917,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20211209.0,,HP,CA,CA,SUSTIVA,Death,201646601.0,DE,,,,,,,,,201646601.0,1.0,HIV infection
20167539,201675394,4,F,20120901.0,20231009.0,20211209,20231011,EXP,,US-GILEAD-2021-0557448,GILEAD,,56.0,YR,A,M,Y,63.946,KG,20231011.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood test abnormal;Chronic kidney disease;Decreased activity;Emotional distress;Fanconi syndrome acquired;Hypophosphataemia;Pain;Proteinuria;Renal glycosuria,201675394.0,OT,,,201675394.0,1.0,20050308.0,201209.0,,,201675394.0,1.0,HIV infection
20168228,201682283,3,F,20080601.0,20231009.0,20211210,20231012,EXP,,US-GILEAD-2021-0557471,GILEAD,,25.0,YR,A,M,Y,77.098,KG,20231012.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Fatigue;General physical health deterioration;Hypertension;Medical diet;Pain;Renal impairment,201682283.0,HO,,,201682283.0,1.0,2007.0,201607.0,,,201682283.0,1.0,HIV infection
20168349,201683491,1,I,,20211201.0,20211210,20211210,EXP,,PT-AUROBINDO-AUR-APL-2021-050623,AUROBINDO,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F. et al.. Mono and dual therapies in human immunodeficiency virus infection.data from a district hospital.. unk. 2021;16 (2):56-65",,,A,,Y,,,20211210.0,,MD,PT,PT,EFAVIRENZ,Treatment failure,201683491.0,OT,,,,,,,,,201683491.0,1.0,HIV infection
20168471,201684711,1,I,,20211201.0,20211210,20211210,EXP,,PT-AUROBINDO-AUR-APL-2021-050618,AUROBINDO,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F et al. Mono and dual therapies in human immunodeficiency virus infection - data from a district hospital. 2021;16 (2):56-65",,,A,,Y,,,20211210.0,,MD,PT,PT,EFAVIRENZ,Genotype drug resistance test positive;Treatment failure,201684711.0,OT,,,,,,,,,201684711.0,1.0,HIV infection
20170766,201707662,2,F,20130901.0,20220713.0,20211210,20220721,EXP,,US-GILEAD-2021-0557388,GILEAD,,51.0,YR,A,M,Y,68.934,KG,20220721.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Pain;Renal impairment,201707662.0,OT,,,201707662.0,1.0,201212.0,201310.0,,,201707662.0,1.0,HIV infection
20171241,201712412,2,F,20191001.0,20220426.0,20211210,20220429,EXP,,US-GILEAD-2021-0557489,GILEAD,,57.0,YR,A,F,Y,35.374,KG,20220429.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Emotional distress;Foot fracture;Hand fracture;Liver disorder;Loss of personal independence in daily activities;Multiple fractures;Osteoporosis;Pain;Renal disorder;Skeletal injury;Spinal fracture,201712412.0,OT,,,201712412.0,1.0,2011.0,2018.0,,,201712412.0,1.0,HIV infection
20214238,202142384,4,F,,20221207.0,20211221,20221213,EXP,,US-GILEAD-2021-0560646,GILEAD,,,,A,M,Y,,,20221213.0,,LW,US,US,SUSTIVA,Chronic kidney disease;Renal failure,202142384.0,OT,,,202142384.0,1.0,2014.0,2018.0,,,202142384.0,1.0,HIV infection
20216631,202166311,1,I,,20211215.0,20211222,20211222,EXP,,GB-MYLANLABS-2021M1094901,MYLAN,"Patel N, Childs K. The legacy of older ART agents: Multiple consequences of decades of NRTI therapy. HIV-Med 2021;22 (Suppl. 3):308 (plus poster) abstr. CCP1/16.",34.0,YR,,F,Y,,,20211222.0,,HP,GB,GB,EFAVIRENZ,Condition aggravated;Dysarthria;Dysphagia;Dysphonia;Hypophosphataemia;Lactic acidosis;Loss of personal independence in daily activities;Myopathy;Neuropathy peripheral;Neurotoxicity;Weight decreased,202166311.0,HO,,,,,,,,,202166311.0,1.0,HIV infection
20217106,202171061,1,I,,20211215.0,20211222,20211222,EXP,,FR-MYLANLABS-2021M1095064,MYLAN,"Kherabi Y, De Castro N, Sellier P-O, Hamet G, Brun A, Digumber M, et al. Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection. A retrospective cohort study. HIV-Med 2021;22 (Suppl. 3):176 (plus poster) abstr. PE3/56.",,,,,Y,,,20211222.0,,HP,FR,FR,EFAVIRENZ,Pathogen resistance;Virologic failure,202171061.0,OT,,,,,,,,,202171061.0,1.0,Antiretroviral therapy
20217183,202171831,1,I,20170101.0,20211217.0,20211222,20211222,EXP,,LV-MYLANLABS-2021M1094387,MYLAN,,,,A,F,Y,,,20211222.0,,MD,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,202171831.0,OT,,,202171831.0,1.0,2015.0,2017.0,4.0,MON,202171831.0,1.0,HIV infection CDC category A
20220620,202206203,3,F,20100101.0,20230725.0,20211223,20230728,EXP,,US-GILEAD-2021-0561983,GILEAD,,,,A,M,Y,61.224,KG,20230728.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Degenerative bone disease;Emotional distress;Femoral neck fracture;Fracture;Hip fracture;Multiple fractures;Musculoskeletal procedural complication;Osteopenia;Osteoporosis;Pain;Shoulder fracture,202206203.0,OT,,,202206203.0,1.0,2006.0,2014.0,,,202206203.0,1.0,HIV infection
20222028,202220283,3,F,,20230810.0,20211223,20230816,EXP,,US-GILEAD-2021-0561992,GILEAD,,,,A,M,Y,57.143,KG,20230816.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Depression;Dysstasia;Emotional distress;Osteoporosis;Pain;Pain in extremity,202220283.0,OT,,,202220283.0,1.0,2014.0,201104.0,,,202220283.0,1.0,HIV infection
20224278,202242788,8,F,20080701.0,20231016.0,20211223,20231019,PER,,US-GILEAD-2021-0561994,GILEAD,,63.0,YR,A,F,Y,70.295,KG,20231019.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Drug interaction;Emotional distress;Fall;Foot fracture;Hand fracture;Humerus fracture;Joint contracture;Limb immobilisation;Loss of personal independence in daily activities;Lower limb fracture;Neuralgia;Osteopenia;Osteoporosis;Pain;Pain in extremity;Skeletal injury;Spinal osteoarthritis;Tibia fracture;Upper limb fracture,202242788.0,OT,,,202242788.0,1.0,2005.0,201401.0,,,202242788.0,1.0,HIV infection
20230602,202306023,3,F,20161201.0,20230815.0,20211227,20230817,EXP,,US-GILEAD-2021-0562338,GILEAD,,51.0,YR,A,M,Y,115.19,KG,20230817.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Back pain;Chronic kidney disease;Emotional distress;Gait disturbance;Oedema peripheral;Pain;Pollakiuria;Renal impairment;Renal injury,202306023.0,OT,,,202306023.0,1.0,2001.0,201210.0,,,202306023.0,1.0,HIV infection
20230640,202306402,2,F,20100901.0,20221121.0,20211227,20221129,EXP,,US-GILEAD-2021-0562277,GILEAD,,53.0,YR,A,M,Y,63.492,KG,20221129.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fatigue;Gait disturbance;Glomerular filtration rate decreased;Hyperparathyroidism;Osteopenia;Osteoporosis;Pain;Rib fracture,202306402.0,OT,,,202306402.0,1.0,200510.0,201611.0,,,202306402.0,1.0,HIV infection
20230921,202309213,3,F,20170101.0,20231010.0,20211227,20231013,EXP,,US-GILEAD-2021-0562335,GILEAD,,,,A,M,Y,86.168,KG,20231013.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone loss;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Metabolic acidosis;Osteomalacia;Pain;Renal injury,202309213.0,OT,,,202309213.0,1.0,200509.0,201801.0,,,202309213.0,1.0,HIV infection
20245780,202457801,1,I,,20211215.0,20211229,20211229,EXP,,GB-HORMOSAN PHARMA GMBH-2021-25819,LUPIN,"Patel N, Childs K. The legacy of older ART agents: Multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(3):308",52.0,YR,,F,Y,,,20211229.0,,HP,GB,GB,EFAVIRENZ,Dysarthria;Dysphagia;Dysphonia;Hypophosphataemia;Lactic acidosis;Loss of personal independence in daily activities;Myopathy;Neuropathy peripheral;Neurotoxicity;Weight decreased,202457801.0,HO,,,,,,,,,202457801.0,1.0,HIV infection
20247277,202472771,1,I,,20211222.0,20211229,20211229,EXP,,PT-MYLANLABS-2021M1095986,MYLAN,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F et al.. Mono and dual therapies in human immunodeficiency virus infection - data from a district hospital.. 2021;16(2):56-65",,,A,,Y,,,20211229.0,,MD,PT,PT,EFAVIRENZ,Genotype drug resistance test positive;Treatment failure,202472771.0,OT,,,,,,,,,202472771.0,1.0,HIV infection
20248402,202484021,1,I,,20211219.0,20211229,20211229,EXP,,CA-TEVA-2021-CA-1992471,TEVA,,54.0,YR,A,M,Y,,,20211229.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,202484021.0,OT,,,,,,,,,202484021.0,1.0,HIV infection
20248728,202487281,1,I,,20211219.0,20211229,20211229,EXP,,CA-TEVA-2021-CA-1992487,TEVA,,54.0,YR,A,M,Y,,,20211229.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,202487281.0,OT,,,,,,,,,202487281.0,1.0,HIV infection
20279046,202790461,1,I,,20211224.0,20220103,20220103,EXP,,FR-AUROBINDO-AUR-APL-2021-054104,AUROBINDO,"Kherabi Y, De Castro N, Sellier P-O, Hamet G, Brun A, Digumber M, et al.. Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection.. A retrospective cohort study. 2021;22 (Suppl. 3):176 (plus poster)",,,,,Y,,,20220103.0,,HP,FR,FR,EFAVIRENZ,Pathogen resistance;Virologic failure,202790461.0,OT,,,,,,,,,202790461.0,1.0,Antiretroviral therapy
20280183,202801831,1,I,,20211222.0,20220103,20220103,EXP,,PT-MYLANLABS-2021M1096034,MYLAN,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F. et al. Mono and dual therapies in human immunodeficiency virus infection. Data from a district hospital. 2021;16 (2):56-57",,,A,,Y,,,20220103.0,,MD,PT,PT,EFAVIRENZ,Treatment failure,202801831.0,OT,,,,,,,,,202801831.0,1.0,HIV infection
20296649,202966493,3,F,20060101.0,20230801.0,20220105,20230804,EXP,,US-GILEAD-2022-0563759,GILEAD,,,,A,M,Y,106.12,KG,20230804.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain,202966493.0,OT,,,202966493.0,1.0,2006.0,201707.0,,,202966493.0,1.0,HIV infection
20299652,202996523,3,F,20150501.0,20230606.0,20220105,20230608,PER,,US-GILEAD-2022-0563898,GILEAD,,62.0,YR,A,M,Y,82.086,KG,20230608.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Emotional distress;Mobility decreased;Osteopenia;Pain;Renal impairment;Upper limb fracture,202996523.0,OT,,,202996523.0,1.0,2006.0,201602.0,,,202996523.0,1.0,HIV infection
20301721,203017212,2,F,20160101.0,20221019.0,20220105,20221026,EXP,,US-GILEAD-2022-0563749,GILEAD,,,,A,M,Y,117.01,KG,20221026.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Depression;Emotional distress;Gait disturbance;General physical health deterioration;Pain;Thrombosis,203017212.0,OT,,,203017212.0,1.0,2014.0,201612.0,,,203017212.0,1.0,HIV infection
20302480,203024802,2,F,20181001.0,20220523.0,20220106,20220527,EXP,,US-GILEAD-2022-0563753,GILEAD,,57.0,YR,A,F,Y,63.492,KG,20220526.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Bone density decreased;Emotional distress;Intervertebral disc degeneration;Mobility decreased;Osteopenia;Osteoporosis;Pain,203024802.0,OT,,,203024802.0,1.0,2012.0,201811.0,,,203024802.0,1.0,HIV infection
20302666,203026663,3,F,20170201.0,20220802.0,20220106,20220804,PER,,US-GILEAD-2022-0563849,GILEAD,,64.0,YR,A,F,Y,48.98,KG,20220804.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Back pain;Chronic kidney disease;Emotional distress;Fatigue;Hypokalaemia;Memory impairment;Pain;Renal failure;Renal pain;Renal tubular necrosis,203026663.0,HO,,,203026663.0,1.0,2016.0,20170119.0,126.0,DAY,203026663.0,1.0,HIV infection
20303092,203030923,3,F,20080101.0,20230607.0,20220106,20230614,EXP,,US-GILEAD-2022-0563736,GILEAD,,53.0,YR,A,F,Y,81.646,KG,20230614.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Depression;Emotional distress;Feeding disorder;Foot fracture;Gait disturbance;General physical health deterioration;Lower limb fracture;Osteopenia;Osteoporosis;Pain;Renal impairment;Wrist fracture,203030923.0,OT,,,203030923.0,1.0,2008.0,201505.0,,,203030923.0,1.0,HIV infection
20303394,203033943,3,F,20170101.0,20230921.0,20220106,20230928,EXP,,US-GILEAD-2022-0563765,GILEAD,,45.0,YR,A,F,Y,88.904,KG,20230928.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Arthralgia;Chronic kidney disease;Depression;Emotional distress;Femur fracture;Gait disturbance;Loss of personal independence in daily activities;Mobility decreased;Nausea;Osteoporosis;Pain;Renal failure,203033943.0,HO,,,203033943.0,1.0,2009.0,201902.0,,,203033943.0,1.0,HIV infection
20303409,203034093,3,F,20140101.0,20230808.0,20220106,20230811,EXP,,US-GILEAD-2022-0563851,GILEAD,,,,A,F,Y,81.633,KG,20230811.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Osteoporosis;Pain,203034093.0,OT,,,203034093.0,1.0,2004.0,2016.0,,,203034093.0,1.0,HIV infection
20303504,203035043,3,F,20140101.0,20230707.0,20220106,20230712,EXP,,US-GILEAD-2022-0563909,GILEAD,,60.0,YR,A,F,Y,247.0,KG,20230712.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Balance disorder;Chronic kidney disease;Cognitive disorder;Depression;Emotional distress;Hyperparathyroidism;Pain;Renal injury;Skeletal injury,203035043.0,OT,,,203035043.0,1.0,2006.0,2013.0,,,203035043.0,1.0,HIV infection
20304149,203041493,3,F,20120120.0,20230721.0,20220106,20230727,EXP,,US-VIIV HEALTHCARE LIMITED-US2020262122,VIIV,,,,,,Y,,,20230727.0,,LW,COUNTRY NOT SPECIFIED,US,SUSTIVA,Blood creatinine increased;Nephropathy;Renal cyst;Renal failure,203041493.0,OT,,,203041493.0,1.0,20130129.0,20130314.0,44.0,DAY,203041493.0,1.0,HIV infection
20304292,203042923,3,F,20081101.0,20230605.0,20220106,20230607,PER,,US-GILEAD-2022-0563855,GILEAD,,42.0,YR,A,M,Y,122.45,KG,20230607.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Depression;Emotional distress;Hand fracture;Osteopenia;Pain;Tooth loss;Wrist fracture,,,,,203042923.0,1.0,2012.0,201606.0,,,203042923.0,1.0,HIV infection
20305983,203059833,3,F,20160101.0,20230804.0,20220106,20230809,EXP,,US-GILEAD-2022-0563902,GILEAD,,63.0,YR,A,M,Y,65.306,KG,20230809.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Chronic kidney disease;Emotional distress;Foot fracture;General physical health deterioration;Hypertension;Ill-defined disorder;Neck injury;Osteoporosis;Pain;Renal failure,203059833.0,OT,,,203059833.0,1.0,2004.0,201705.0,,,203059833.0,1.0,HIV infection
20306354,203063543,3,F,20141101.0,20231013.0,20220106,20231016,EXP,,US-GILEAD-2022-0563785,GILEAD,,39.0,YR,A,M,Y,77.551,KG,20231016.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Asthenia;Back pain;Bone demineralisation;Chronic kidney disease;Condition aggravated;Dysstasia;Emotional distress;End stage renal disease;Exercise tolerance decreased;Fatigue;Gait disturbance;Insomnia;Osteopenia;Pain;Pollakiuria;Renal pain,203063543.0,HO,,,203063543.0,1.0,2004.0,201703.0,,,203063543.0,1.0,HIV infection
20306374,203063743,3,F,20170801.0,20230920.0,20220106,20230924,EXP,,US-GILEAD-2022-0563771,GILEAD,,62.0,YR,A,M,Y,90.703,KG,20230924.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Enzyme level increased;Pain;Renal disorder;Renal injury,203063743.0,OT,,,203063743.0,1.0,2006.0,201812.0,,,203063743.0,1.0,HIV infection
20310738,203107381,1,I,,20211224.0,20220107,20220107,EXP,,CA-ABBVIE-22K-028-4224361-00,ABBVIE,,54.0,YR,,M,Y,,,20220107.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,203107381.0,DE,,,,,,,,,203107381.0,1.0,HIV infection
20311334,203113341,1,I,,20211231.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996525,TEVA,,54.0,YR,A,M,Y,,,20220108.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113341.0,OT,,,,,,,,,203113341.0,1.0,HIV infection
20311361,203113611,1,I,,20211231.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996533,TEVA,,54.0,YR,A,M,Y,,,20220108.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113611.0,OT,,,,,,,,,203113611.0,1.0,HIV infection
20311370,203113701,1,I,,20211231.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996518,TEVA,,54.0,YR,A,M,Y,,,20220108.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113701.0,DE,,,,,,,,,203113701.0,1.0,HIV infection
20317458,203174581,1,I,,20211228.0,20220110,20220110,EXP,,CN-GLAXOSMITHKLINE-CN2021APC264803,GLAXOSMITHKLINE,,,,,F,Y,,,20220110.0,,HP,CN,CN,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,203174581.0,OT,,,203174581.0,1.0,20180907.0,,,,203174581.0,1.0,Acquired immunodeficiency syndrome
20317460,203174601,1,I,,20211228.0,20220110,20220110,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2021APC264803,VIIV,,,,,F,Y,,,20220110.0,,HP,CN,CN,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,203174601.0,OT,,,203174601.0,1.0,20180907.0,,,,203174601.0,1.0,Acquired immunodeficiency syndrome
20324129,203241291,1,I,20080101.0,20220105.0,20220111,20220111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-144769,BRISTOL MYERS SQUIBB,"Patel N, Childs K. The legacy of older ART agents: multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(SUPPL 3):308",52.0,YR,,F,Y,,,20220111.0,,MD,GB,GB,EFAVIRENZ,Neurotoxicity,203241291.0,OT,,,203241291.0,1.0,2008.0,,,,203241291.0,1.0,HIV infection
20324157,203241571,1,I,20070101.0,20220105.0,20220111,20220111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-144768,BRISTOL MYERS SQUIBB,"Patel N, Childs K. The legacy of older ART agents: multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(SUPPL 3):308",52.0,YR,,F,Y,,,20220111.0,,MD,GB,GB,EFAVIRENZ,Hypophosphataemia,203241571.0,OT,,,203241571.0,1.0,2007.0,,,,203241571.0,1.0,HIV infection
20332604,203326041,1,I,,20220110.0,20220113,20220113,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-004967,BRISTOL MYERS SQUIBB,,54.0,YR,,M,Y,,,20220113.0,,HP,CA,CA,SUSTIVA,Death,203326041.0,OT,,,,,,,,,203326041.0,1.0,HIV infection
20333355,203333551,1,I,,20220107.0,20220113,20220113,EXP,,US-MYLANLABS-2022M1002777,MYLAN,"Brasher WP, Bvumbwe M, Kazembe PN. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi-Med-J 2020;32(4):229-231.",16.0,YR,,M,Y,,,20220113.0,,HP,US,US,EFAVIRENZ,Ataxia;Encephalopathy;Hypersensitivity;Toxicity to various agents,203333551.0,HO,,,203333551.0,1.0,2012.0,,,,203333551.0,1.0,HIV infection WHO clinical stage I
20338234,203382341,1,I,,20220104.0,20220115,20220115,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2022034048,MACLEODS,"Patel N, Childs K.. The legacy of older ART agents: Multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(3)",,,,,Y,,,20220115.0,,MD,GB,GB,EFAVIRENZ,Hepatic encephalopathy;Hypophosphataemia;Lactic acidosis;Neuropathy peripheral;Neurotoxicity;Portal hypertension;Portal vein thrombosis;Toxicity to various agents,203382341.0,HO,,,,,,,,,203382341.0,1.0,HIV infection
20339020,203390203,3,F,20140101.0,20230816.0,20220117,20230821,EXP,,US-GILEAD-2022-0565390,GILEAD,,,,E,M,Y,58.957,KG,20230821.0,,LW,US,US,SUSTIVA,Acidosis;Acute kidney injury;Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;General physical health deterioration;Osteoporosis;Pain,203390203.0,OT,,,203390203.0,1.0,2012.0,201612.0,,,203390203.0,1.0,HIV infection
20349004,203490043,3,F,20100101.0,20230725.0,20220119,20230728,EXP,,US-GILEAD-2022-0565450,GILEAD,,,,A,M,Y,64.399,KG,20230728.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Fatigue;Hypophosphataemia;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Vitamin D deficiency,203490043.0,OT,,,203490043.0,1.0,2007.0,2015.0,,,203490043.0,1.0,HIV infection
20349666,203496664,4,F,20160201.0,20231017.0,20220119,20231018,EXP,,US-GILEAD-2022-0565660,GILEAD,,45.0,YR,A,F,Y,102.04,KG,20231018.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Decreased activity;Depression;Emotional distress;Fear of falling;Osteoarthritis;Osteopenia;Osteoporosis;Pain,203496664.0,OT,,,203496664.0,1.0,2005.0,201003.0,,,203496664.0,1.0,HIV infection
20351646,203516463,3,F,20060101.0,20230803.0,20220119,20230808,EXP,,US-GILEAD-2022-0565657,GILEAD,,,,A,F,Y,74.376,KG,20230808.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Cardiac disorder;Chronic kidney disease;Degenerative bone disease;Emotional distress;Exercise tolerance decreased;Gait disturbance;Insomnia;Lipodystrophy acquired;Loss of personal independence in daily activities;Nephrolithiasis;Osteopenia;Pain;Pain in extremity;Urinary tract infection,203516463.0,HO,,,203516463.0,1.0,2001.0,2008.0,,,203516463.0,1.0,HIV infection
20353240,203532403,3,F,20120801.0,20230724.0,20220119,20230728,EXP,,US-GILEAD-2022-0565864,GILEAD,,55.0,YR,A,M,Y,48.98,KG,20230728.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Back pain;Blood creatinine increased;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Dysstasia;Emotional distress;Gait disturbance;Insomnia;Pain;Pollakiuria;Protein total increased;Renal impairment;Renal injury;Vitamin D deficiency,203532403.0,HO,,,203532403.0,1.0,2010.0,2010.0,,,203532403.0,1.0,HIV infection
20353321,203533213,3,F,20100101.0,20230712.0,20220119,20230717,EXP,,US-GILEAD-2022-0565796,GILEAD,,62.0,YR,A,F,Y,98.413,KG,20230717.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Bone pain;Emotional distress;Fatigue;Gait disturbance;Osteoporosis;Pain,203533213.0,OT,,,203533213.0,1.0,2015.0,2015.0,,,203533213.0,1.0,HIV infection
20354006,203540062,2,F,20140101.0,20220803.0,20220120,20220225,EXP,,US-GILEAD-2022-0565984,GILEAD,,,,A,M,Y,92.063,KG,20220808.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Foot fracture;Gait disturbance;Osteoporosis;Pain;Rib fracture,203540062.0,OT,,,203540062.0,1.0,200803.0,201609.0,,,203540062.0,1.0,HIV infection
20355563,203555633,3,F,20170601.0,20230609.0,20220120,20230616,EXP,,US-GILEAD-2022-0565913,GILEAD,,66.0,YR,E,M,Y,71.21,KG,20230616.0,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Emotional distress;Osteoporosis;Pain,203555633.0,OT,,,203555633.0,1.0,2006.0,2018.0,,,203555633.0,1.0,HIV infection
20357937,203579375,5,F,20110601.0,20231016.0,20220120,20231018,PER,,US-GILEAD-2022-0565950,GILEAD,,45.0,YR,A,M,Y,54.422,KG,20231018.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Ankle fracture;Anxiety;Bone demineralisation;Depression;Drug resistance;Emotional distress;General physical health deterioration;Hand fracture;Osteopenia;Osteoporosis;Pain,203579375.0,OT,,,203579375.0,1.0,2006.0,201405.0,,,203579375.0,1.0,HIV infection
20359299,203592991,1,I,20210615.0,20220114.0,20220121,20220121,EXP,,ZA-STRIDES ARCOLAB LIMITED-2022SP000446,STRIDES,,23.0,YR,,F,Y,,,20220121.0,,HP,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,203592991.0,OT,,,203592991.0,1.0,20210118.0,,,,203592991.0,1.0,HIV infection
20359439,203594392,2,F,20070801.0,20221115.0,20220121,20221118,EXP,,US-GILEAD-2022-0565923,GILEAD,,37.0,YR,A,F,Y,85.714,KG,20221118.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Bone demineralisation;Bone disorder;Depression;Emotional distress;Foot fracture;Gait disturbance;Hand fracture;Osteoarthritis;Osteoporosis;Pain,203594392.0,OT,,,203594392.0,1.0,2005.0,201806.0,,,203594392.0,1.0,HIV infection
20359529,203595294,4,F,20130601.0,20230830.0,20220121,20230906,EXP,,US-GILEAD-2022-0566167,GILEAD,,60.0,YR,A,M,Y,94.785,KG,20230906.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Osteopenia;Pain;Renal injury;Skeletal injury;Tooth injury;Tooth loss,203595294.0,OT,,,203595294.0,1.0,20160614.0,201706.0,2639.0,DAY,203595294.0,1.0,HIV infection
20359598,203595983,3,F,20070101.0,20230803.0,20220121,20230810,EXP,,US-GILEAD-2022-0565669,GILEAD,,,,A,M,Y,127.91,KG,20230810.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Bone demineralisation;Discomfort;Emotional distress;Fatigue;Intervertebral disc protrusion;Lumbar spinal stenosis;Osteoporosis;Pain;Renal impairment;Vitamin D deficiency,203595983.0,OT,,,203595983.0,1.0,2002.0,2007.0,,,203595983.0,1.0,HIV infection
20359796,203597963,3,F,20190606.0,20230820.0,20220121,20230823,EXP,,US-GILEAD-2022-0566034,GILEAD,,66.0,YR,E,F,Y,41.27,KG,20230823.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Balance disorder;Bone demineralisation;Dysstasia;Emotional distress;Gait disturbance;Musculoskeletal stiffness;Osteopenia;Osteoporosis;Pain,203597963.0,OT,,,203597963.0,1.0,2013.0,2018.0,,,203597963.0,1.0,HIV infection
20361137,203611374,4,F,20120101.0,20230911.0,20220121,20230914,EXP,,US-GILEAD-2022-0565857,GILEAD,,,,A,M,Y,79.365,KG,20230914.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;End stage renal disease;Loss of personal independence in daily activities;Pain;Pneumonia;Renal failure,203611374.0,HO,,,203611374.0,1.0,2004.0,2012.0,,,203611374.0,1.0,HIV infection
20361222,203612223,3,F,,20230709.0,20220121,20230712,EXP,,US-GILEAD-2022-0565664,GILEAD,,,,A,F,Y,87.543,KG,20230712.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Emotional distress;Gait disturbance;General physical health deterioration;Osteopenia;Osteoporosis;Pain,203612223.0,OT,,,203612223.0,1.0,2016.0,201903.0,,,203612223.0,1.0,HIV infection
20363820,203638202,2,F,20100101.0,20221013.0,20220121,20221018,EXP,,US-GILEAD-2022-0566013,GILEAD,,,,A,F,Y,85.714,KG,20221018.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Hip arthroplasty;Osteoporosis;Pain,203638202.0,OT,,,203638202.0,1.0,2004.0,2011.0,,,203638202.0,1.0,HIV infection
20364374,203643742,2,F,20181101.0,20221012.0,20220121,20221017,PER,,US-GILEAD-2022-0565684,GILEAD,,66.0,YR,E,M,Y,61.224,KG,20221017.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone disorder;Emotional distress;Gait disturbance;Osteopenia;Pain,,,,,203643742.0,1.0,2010.0,201804.0,,,203643742.0,1.0,HIV infection
20364389,203643895,5,F,20150901.0,20231013.0,20220121,20231017,EXP,,US-GILEAD-2022-0565663,GILEAD,,52.0,YR,A,M,Y,104.31,KG,20231016.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Pain;Renal impairment,203643895.0,OT,,,203643895.0,1.0,2011.0,201609.0,,,203643895.0,1.0,HIV infection
20365706,203657063,3,F,20180911.0,20230710.0,20220123,20230712,PER,,US-GILEAD-2022-0565899,GILEAD,,60.0,YR,A,F,Y,65.76,KG,20230712.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Arthropathy;Bone density decreased;Emotional distress;Gait disturbance;Musculoskeletal stiffness;Osteopenia;Pain,,,,,203657063.0,1.0,2007.0,201811.0,,,203657063.0,1.0,HIV infection
20365717,203657173,3,F,20090401.0,20230803.0,20220123,20230807,PER,,US-GILEAD-2022-0565891,GILEAD,,43.0,YR,A,F,Y,92.517,KG,20230807.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back injury;Back pain;Bone demineralisation;Bone density decreased;Chondropathy;Collagen disorder;Depression;Dysstasia;Emotional distress;Gait disturbance;Osteopenia;Pain;Therapeutic response decreased,,,,,203657173.0,1.0,2004.0,2012.0,,,203657173.0,1.0,HIV infection
20367048,203670483,3,F,20160101.0,20230530.0,20220123,20230531,PER,,US-GILEAD-2022-0566484,GILEAD,,,,A,M,Y,71.202,KG,20230531.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;General physical health deterioration;Pain,,,,,203670483.0,1.0,2010.0,201605.0,,,203670483.0,1.0,HIV infection
20367218,203672183,3,F,20120501.0,20230720.0,20220123,20230725,EXP,,US-GILEAD-2022-0566537,GILEAD,,54.0,YR,A,M,Y,70.295,KG,20230725.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone loss;Bone pain;Emotional distress;Fanconi syndrome acquired;Gait disturbance;Pain;Pain in extremity;Renal disorder;Renal impairment;Renal injury,203672183.0,OT,,,203672183.0,2.0,2009.0,20090722.0,12.0,DAY,203672183.0,1.0,HIV infection
20367543,203675433,3,F,20130101.0,20230622.0,20220124,20230627,EXP,,US-GILEAD-2022-0565789,GILEAD,,,,A,F,Y,93.424,KG,20230627.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Pain;Renal disorder,203675433.0,OT,,,203675433.0,1.0,2005.0,2017.0,,,203675433.0,1.0,HIV infection
20367792,203677923,3,F,20030101.0,20230706.0,20220124,20230712,EXP,,US-GILEAD-2022-0565861,GILEAD,,,,A,M,Y,77.098,KG,20230712.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Blood glucose increased;Chronic kidney disease;Diabetes mellitus;Emotional distress;Glomerular filtration rate decreased;Pain;Protein urine present;Renal failure;Renal injury,203677923.0,OT,,,203677923.0,1.0,2001.0,2004.0,,,203677923.0,1.0,HIV infection
20368213,203682133,3,F,20110101.0,20230824.0,20220124,20230830,EXP,,US-GILEAD-2022-0566426,GILEAD,,,,A,M,Y,61.23,KG,20230830.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone loss;Emotional distress;Multiple fractures;Osteoporosis;Pain;Renal injury,203682133.0,OT,,,203682133.0,1.0,2009.0,,,,203682133.0,1.0,HIV infection
20371223,203712233,3,F,20150301.0,20230802.0,20220124,20230807,EXP,,US-GILEAD-2022-0566467,GILEAD,,50.0,YR,A,F,Y,73.016,KG,20230807.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Depression;Emotional distress;Foot fracture;Gait disturbance;Multiple fractures;Osteoporosis;Pain;Pain in extremity;Proteinuria;Renal injury,203712233.0,OT,,,203712233.0,1.0,2005.0,201906.0,,,203712233.0,1.0,HIV infection
20371509,203715091,1,I,,20220116.0,20220124,20220124,EXP,,CA-TEVA-2022-CA-2001581,TEVA,,54.0,YR,A,M,Y,,,20220124.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,203715091.0,OT,,,,,,,,,203715091.0,1.0,HIV infection
20371513,203715131,1,I,,20220116.0,20220124,20220124,EXP,,CA-TEVA-2022-CA-2001358,TEVA,,54.0,YR,A,M,Y,,,20220124.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203715131.0,DE,,,,,,,,,203715131.0,1.0,HIV infection
20372264,203722643,3,F,20090515.0,20230809.0,20220124,20230814,EXP,,US-GILEAD-2022-0566378,GILEAD,,47.0,YR,A,F,Y,50.794,KG,20230814.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone demineralisation;Dysstasia;Emotional distress;Fall;Gait disturbance;Hand fracture;Multiple fractures;Musculoskeletal stiffness;Osteopenia;Osteoporosis;Pain;Rib fracture,203722643.0,OT,,,203722643.0,1.0,2008.0,2018.0,,,203722643.0,1.0,HIV infection
20372906,203729061,1,I,20210615.0,20220113.0,20220125,20220125,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-007273,BRISTOL MYERS SQUIBB,,23.0,YR,,F,Y,,,20220125.0,,HP,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,203729061.0,OT,,,203729061.0,1.0,20210301.0,,,,203729061.0,1.0,HIV infection
20372999,203729992,2,F,20210615.0,20220114.0,20220125,20220125,EXP,,ZA-CIPLA LTD.-2022ZA00255,CIPLA,,,,,,Y,,,20220125.0,,HP,ZA,ZA,EFAVIRENZ,Exposure during pregnancy;Stillbirth,203729992.0,OT,,,203729992.0,1.0,20210118.0,,,,203729992.0,1.0,HIV infection
20379763,203797634,4,F,20010101.0,20230609.0,20220126,20230613,PER,,US-GILEAD-2022-0566491,GILEAD,,,,A,M,Y,49.895,KG,20230613.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Bone density decreased;Emotional distress;Eye inflammation;Hypersensitivity;Lower limb fracture;Mobility decreased;Musculoskeletal disorder;Osteoporosis;Pain;Rib fracture,203797634.0,OT,,,203797634.0,1.0,2001.0,2003.0,,,203797634.0,1.0,HIV infection
20381382,203813822,2,F,,20220201.0,20220127,20220202,EXP,,CA-ABBVIE-22K-028-4247868-00,ABBVIE,,52.0,YR,,M,Y,,,20220202.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,203813822.0,OT,,,,,,,,,203813822.0,1.0,HIV infection
20381594,203815943,3,F,20140801.0,20230815.0,20220127,20230818,EXP,,US-GILEAD-2022-0566436,GILEAD,,59.0,YR,A,M,Y,96.599,KG,20230818.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Emotional distress;Osteoporosis;Pain,203815943.0,OT,,,203815943.0,1.0,2006.0,201701.0,,,203815943.0,1.0,HIV infection
20386757,203867572,2,F,20070101.0,20221129.0,20220127,20221202,EXP,,US-GILEAD-2022-0566508,GILEAD,,,,A,M,Y,51.256,KG,20221202.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Nocturia;Pain;Pollakiuria;Renal failure;Renal injury,203867572.0,OT,,,203867572.0,1.0,2004.0,2007.0,,,203867572.0,1.0,HIV infection
20394039,203940391,1,I,,20220117.0,20220129,20220129,EXP,,US-AUROBINDO-AUR-APL-2022-001768,AUROBINDO,"Brasher WP, Bvumbwe M, Kazembe PN.. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Medical Journal. 2020;32 (4):229-231",16.0,YR,,M,Y,,,20220129.0,,HP,US,US,EFAVIRENZ,Ataxia;Encephalopathy;Toxicity to various agents,203940391.0,OT,,,,,,,,,203940391.0,1.0,HIV infection
20411454,204114542,2,F,,20220210.0,20220201,20220223,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-010603,BRISTOL MYERS SQUIBB,How SARS-CoV-2 can evolve into a variant of concern in an immunocompromised individual. Le Monde.fr. 2022,4.0,DEC,,F,Y,,,20220223.0,,HP,ZA,ZA,EFAVIRENZ,COVID-19,204114542.0,HO,,,,,,,,,204114542.0,1.0,HIV infection
20414162,204141623,3,F,,20220317.0,20220201,20220330,EXP,,RO-AUROBINDO-AUR-APL-2018-040860,AUROBINDO,,26.0,YR,,M,Y,,,20220330.0,,MD,RO,RO,EFAVIRENZ,Lipodystrophy acquired;Virologic failure,204141623.0,OT,,,,,,,,,204141623.0,1.0,HIV infection
20414987,204149872,2,F,,20220201.0,20220202,20220211,EXP,,US-JNJFOC-20220149634,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20220211.0,,HP,US,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,204149872.0,OT,,,,,,,,,204149872.0,1.0,HIV infection
20427863,204278631,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00525,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204278631.0,OT,,,,,,,,,204278631.0,1.0,HIV infection
20427910,204279101,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00527,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204279101.0,OT,,,,,,,,,204279101.0,1.0,HIV infection
20427978,204279781,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00529,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204279781.0,OT,,,,,,,,,204279781.0,1.0,HIV infection
20428088,204280881,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00531,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):e026136:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204280881.0,OT,,,,,,,,,204280881.0,1.0,HIV infection
20428128,204281281,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00535,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T, et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204281281.0,OT,,,,,,,,,204281281.0,1.0,HIV infection
20428194,204281941,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00536,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204281941.0,OT,,,,,,,,,204281941.0,1.0,HIV infection
20428221,204282211,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00537,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204282211.0,OT,,,,,,,,,204282211.0,1.0,HIV infection
20428280,204282801,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00538,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204282801.0,OT,,,,,,,,,204282801.0,1.0,HIV infection
20428338,204283381,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00539,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204283381.0,OT,,,,,,,,,204283381.0,1.0,HIV infection
20428395,204283951,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00540,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T, et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204283951.0,OT,,,,,,,,,204283951.0,1.0,HIV infection
20428492,204284921,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00541,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204284921.0,OT,,,,,,,,,204284921.0,1.0,HIV infection
20428538,204285381,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00542,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204285381.0,OT,,,,,,,,,204285381.0,1.0,HIV infection
20428561,204285611,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00543,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204285611.0,OT,,,,,,,,,204285611.0,1.0,HIV infection
20428608,204286081,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00544,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204286081.0,OT,,,,,,,,,204286081.0,1.0,HIV infection
20428667,204286671,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00546,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204286671.0,OT,,,,,,,,,204286671.0,1.0,HIV infection
20429133,204291331,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00526,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204291331.0,OT,,,,,,,,,204291331.0,1.0,HIV infection
20429247,204292471,1,I,,20220125.0,20220204,20220204,EXP,,US-VIIV HEALTHCARE LIMITED-US2010000382,VIIV,,52.0,YR,,M,Y,,,20220204.0,,HP,CA,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,204292471.0,OT,,,204292471.0,3.0,,,9668.0,DAY,204292471.0,1.0,HIV infection
20429361,204293611,1,I,,20220125.0,20220204,20220204,EXP,,US-GLAXOSMITHKLINE-US2010000382,GLAXOSMITHKLINE,,52.0,YR,,M,Y,,,20220204.0,,HP,CA,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,204293611.0,OT,,,204293611.0,3.0,,,9668.0,DAY,204293611.0,1.0,HIV infection
20429398,204293981,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00532,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204293981.0,OT,,,,,,,,,204293981.0,1.0,HIV infection
20429400,204294001,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00533,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294001.0,OT,,,,,,,,,204294001.0,1.0,HIV infection
20429401,204294011,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00548,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294011.0,OT,,,,,,,,,204294011.0,1.0,HIV infection
20429402,204294021,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00528,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):e026136:1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294021.0,OT,,,,,,,,,204294021.0,1.0,HIV infection
20429403,204294031,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00530,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;6 (12):1 to15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294031.0,OT,,,,,,,,,204294031.0,1.0,HIV infection
20429405,204294051,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00547,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294051.0,OT,,,,,,,,,204294051.0,1.0,HIV infection
20429406,204294061,1,I,,20220124.0,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00549,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294061.0,OT,,,,,,,,,204294061.0,1.0,HIV infection
20432545,204325454,4,F,20130101.0,20240521.0,20220204,20240524,EXP,,TR-GILEAD-2022-0568528,GILEAD,,56.0,YR,A,M,Y,70.0,KG,20240524.0,,MD,TR,TR,EFAVIRENZ,Genotype drug resistance test positive;Osteonecrosis;Osteopenia;Osteoporosis;Viraemia,204325454.0,OT,,,204325454.0,1.0,2012.0,,,,204325454.0,1.0,HIV infection
20435782,204357821,1,I,,20220124.0,20220207,20220207,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00551,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220207.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204357821.0,OT,,,,,,,,,204357821.0,1.0,HIV infection
20435860,204358601,1,I,,20220124.0,20220207,20220207,EXP,,TZ-CIPLA LTD.-2022TZ00552,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220207.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204358601.0,OT,,,,,,,,,204358601.0,1.0,HIV infection
20435886,204358861,1,I,,20220124.0,20220207,20220207,EXP,,TZ-CIPLA LTD.-2022TZ00553,CIPLA,"Mapesi H, Paris DH, Okuma J, Franzeck F, Wilson HI, Senkoro E et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220207.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204358861.0,OT,,,,,,,,,204358861.0,1.0,HIV infection
20435983,204359831,1,I,,20220124.0,20220207,20220207,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00555,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220207.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204359831.0,OT,,,,,,,,,204359831.0,1.0,HIV infection
20436459,204364593,3,F,20180101.0,20220311.0,20220207,20220322,EXP,,MY-CIPLA (EU) LIMITED-2022MY00598,CIPLA,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iran J Dermatol. 2021;24:234 to 237",,,,,Y,,,20220322.0,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204364593.0,OT,,,204364593.0,1.0,20181101.0,2018.0,,,204364593.0,1.0,HIV infection
20436791,204367911,1,I,,20220131.0,20220207,20220207,EXP,,MY-GILEAD-2022-0568147,GILEAD,"Pazil S, Zulkifli M, Muhamad R., Chen L.. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology. 2021;24(3):234-237. doi:10.22034/ijd.2021.136582",39.0,YR,A,M,Y,,,20220207.0,,MD,MY,MY,EFAVIRENZ,Disorientation;Nausea;Vomiting,204367911.0,OT,,,204367911.0,1.0,201811.0,,,,204367911.0,1.0,HIV infection
20441868,204418681,1,I,,20220124.0,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00561,CIPLA,"Mapesi H, Paris DH, Okuma J, Franzeck F, Wilson HI, Senkoro E et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220208.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418681.0,OT,,,,,,,,,204418681.0,1.0,HIV infection
20441869,204418691,1,I,,20220124.0,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00558,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220208.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418691.0,OT,,,,,,,,,204418691.0,1.0,HIV infection
20441875,204418751,1,I,,20220124.0,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00562,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220208.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418751.0,OT,,,,,,,,,204418751.0,1.0,HIV infection
20441879,204418791,1,I,,20220124.0,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00556,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220208.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418791.0,OT,,,,,,,,,204418791.0,1.0,HIV infection
20441881,204418811,1,I,,20220124.0,20220208,20220208,EXP,,TZ-CIPLA LTD.-2022TZ00563,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220208.0,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418811.0,OT,,,,,,,,,204418811.0,1.0,HIV infection
20445774,204457741,1,I,20220119.0,20220124.0,20220208,20220208,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011151,BRISTOL MYERS SQUIBB,,4.0,YR,,F,Y,18.6,KG,20220208.0,,HP,US,US,SUSTIVA,Prescribed underdose;Product availability issue,,,,,204457741.0,1.0,20211215.0,,,,204457741.0,1.0,HIV infection
20445893,204458932,2,F,20200201.0,20220602.0,20220208,20220609,PER,,US-GILEAD-2022-0568978,GILEAD,,54.0,YR,A,F,Y,86.168,KG,20220609.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Emotional distress;Mobility decreased;Osteopenia;Pain,,,,,204458932.0,1.0,2006.0,201910.0,,,204458932.0,1.0,HIV infection
20448026,204480263,3,F,20120701.0,20230517.0,20220209,20230519,EXP,,US-GILEAD-2022-0569042,GILEAD,,56.0,YR,A,M,Y,81.647,KG,20230519.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Emotional distress;Fatigue;Osteoporosis;Pain,204480263.0,OT,,,204480263.0,1.0,2002.0,201302.0,,,204480263.0,1.0,HIV infection
20448824,204488241,1,I,20180101.0,20220201.0,20220209,20220209,EXP,,MY-STRIDES ARCOLAB LIMITED-2022SP001108,STRIDES,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian-J-Dermatol. 2021;24(3):234-237",39.0,YR,,M,Y,,,20220209.0,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Vomiting,204488241.0,OT,,,204488241.0,1.0,201811.0,,,,204488241.0,1.0,HIV infection
20449993,204499932,2,F,20141201.0,20220925.0,20220209,20220930,EXP,,US-GILEAD-2022-0569076,GILEAD,,54.0,YR,A,M,Y,96.599,KG,20220930.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Body height decreased;Emotional distress;Gait disturbance;General physical health deterioration;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal compression fracture;Upper limb fracture,204499932.0,OT,,,204499932.0,1.0,2003.0,2004.0,,,204499932.0,1.0,HIV infection
20451718,204517182,2,F,20120101.0,20220831.0,20220209,20220906,EXP,,US-GILEAD-2022-0569265,GILEAD,,,,A,F,Y,108.84,KG,20220906.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone demineralisation;Depression;Emotional distress;Foot fracture;Gait disturbance;Insomnia;Malaise;Nausea;Osteoporosis;Pain,204517182.0,OT,,,204517182.0,1.0,2001.0,2003.0,,,204517182.0,1.0,HIV infection
20452091,204520913,3,F,20120701.0,20231117.0,20220209,20231120,PER,,US-GILEAD-2022-0569147,GILEAD,,0.0,YR,A,M,Y,81.633,KG,20231120.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Body height decreased;Bone demineralisation;Bone pain;Emotional distress;Fatigue;Gait disturbance;Osteopenia;Pain;Proteinuria;Renal impairment,204520913.0,OT,,,204520913.0,1.0,2007.0,201903.0,,,204520913.0,1.0,HIV infection
20453658,204536583,3,F,,20220329.0,20220210,20220408,EXP,,GB-JNJFOC-20220209540,JOHNSON AND JOHNSON,,,,,,Y,,,20220408.0,,HP,GB,GB,EFAVIRENZ,Treatment failure,204536583.0,OT,,,,,,,,,204536583.0,1.0,HIV infection
20454381,204543813,3,F,20140101.0,20230727.0,20220210,20230802,EXP,,US-GILEAD-2022-0569129,GILEAD,,,,E,M,Y,63.5,KG,20230802.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Exercise tolerance decreased;Muscle atrophy;Pain,204543813.0,OT,,,204543813.0,1.0,2014.0,201509.0,,,204543813.0,1.0,HIV infection
20454920,204549201,1,I,20190101.0,20220201.0,20220210,20220210,EXP,,MY-MYLANLABS-2022M1011013,MYLAN,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian-J-Dermatol 2021;24(3):234-237.",39.0,YR,,M,Y,,,20220210.0,,MD,MY,MY,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoid leprosy,204549201.0,OT,,,204549201.0,1.0,201811.0,,,,204549201.0,1.0,HIV infection
20456732,204567323,3,F,20110701.0,20220901.0,20220210,20220908,PER,,US-GILEAD-2022-0569157,GILEAD,,53.0,YR,A,F,Y,107.0,KG,20220908.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Chronic kidney disease;Colitis;Depression;Emotional distress;Gait disturbance;Insomnia;Intervertebral disc degeneration;Nocturia;Osteopenia;Pain;Pollakiuria;Product dose omission issue;Renal failure;Renal impairment;Renal injury,204567323.0,OT,,,204567323.0,1.0,2004.0,201107.0,,,204567323.0,1.0,HIV infection
20456744,204567443,3,F,20091001.0,20240110.0,20220210,20240112,EXP,,US-GILEAD-2022-0569165,GILEAD,,38.0,YR,A,M,Y,126.98,KG,20240112.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Bone pain;Chronic kidney disease;Depressed mood;Depression;Emotional distress;Fatigue;Fracture pain;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Tibia fracture,204567443.0,HO,,,204567443.0,1.0,2006.0,2014.0,,,204567443.0,1.0,HIV infection
20456758,204567583,3,F,20130524.0,20230726.0,20220210,20230728,EXP,,US-GILEAD-2022-0569475,GILEAD,,55.0,YR,A,F,Y,108.84,KG,20230728.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Emotional distress;Mobility decreased;Osteopenia;Osteoporosis;Pain;Skeletal injury,204567583.0,OT,,,204567583.0,1.0,2006.0,201608.0,,,204567583.0,1.0,HIV infection
20456852,204568523,3,F,20100601.0,20231128.0,20220210,20231129,EXP,,US-GILEAD-2022-0569362,GILEAD,,50.0,YR,A,M,Y,,,20231129.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Hyperkalaemia;Hyperparathyroidism secondary;Metabolic acidosis;Pain;Renal impairment,204568523.0,DE,,,204568523.0,1.0,2003.0,201002.0,,,204568523.0,1.0,HIV infection
20457529,204575292,2,F,20080101.0,20221026.0,20220210,20221103,EXP,,US-GILEAD-2022-0569525,GILEAD,,,,A,M,Y,79.365,KG,20221103.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;Gait disturbance;Hip fracture;Hyperparathyroidism;Hypertension;Metabolic acidosis;Osteoporosis;Pain;Renal injury;Spinal fracture,204575292.0,OT,,,204575292.0,1.0,2004.0,201107.0,,,204575292.0,1.0,HIV infection
20460733,204607331,1,I,20190101.0,20220201.0,20220211,20220211,PER,,MY-LUPIN PHARMACEUTICALS INC.-2022-01590,LUPIN,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology. 2021;24(3):234-237",39.0,YR,,M,Y,,,20220211.0,,HP,MY,MY,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoid leprosy;Type 1 lepra reaction,204607331.0,OT,,,204607331.0,1.0,201811.0,,,,204607331.0,1.0,HIV infection
20467373,204673733,3,F,20180101.0,20220311.0,20220214,20220324,EXP,,MY-AUROBINDO-AUR-APL-2022-003868,AUROBINDO,"Zulkifli MM,Pazil SN, Muhamad R, Chen LK.. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome.. Iranian Journal of Dermatology.. 2021;24 (3):234-7",39.0,YR,,M,Y,66.5,KG,20220324.0,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204673733.0,HO,,,204673733.0,1.0,20181111.0,2018.0,,,204673733.0,1.0,HIV infection
20471020,204710202,2,F,20180101.0,20220314.0,20220214,20220324,EXP,,MY-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-015910,BRISTOL MYERS SQUIBB,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology 2021;24(3):234-7.",39.0,YR,A,M,Y,66.5,KG,20220324.0,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204710202.0,OT,,,204710202.0,1.0,201811.0,,,,204710202.0,1.0,HIV infection
20472901,204729012,2,F,20160101.0,20221028.0,20220215,20221103,PER,,US-GILEAD-2022-0569023,GILEAD,,53.0,YR,A,M,Y,95.254,KG,20221103.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Emotional distress;Fatigue;Pain;Renal impairment,204729012.0,OT,,,204729012.0,1.0,2009.0,200411.0,,,204729012.0,1.0,HIV infection
20472918,204729184,4,F,20160101.0,20230811.0,20220215,20230815,EXP,,US-GILEAD-2022-0569202,GILEAD,,,,A,M,Y,73.469,KG,20230815.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Emotional distress;General physical health deterioration;Glomerular filtration rate abnormal;Haematuria;Hypertension;Muscle spasms;Pain;Renal impairment;Renal injury,204729184.0,OT,,,204729184.0,1.0,2004.0,201708.0,,,204729184.0,1.0,HIV infection
20472920,204729203,3,F,20160101.0,20230802.0,20220215,20230807,PER,,US-GILEAD-2022-0569537,GILEAD,,,,A,M,Y,79.378,KG,20230807.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Gait disturbance;Haematuria;Hypotension;Mobility decreased;Pain;Renal impairment;Urinary tract disorder,204729203.0,OT,,,204729203.0,1.0,2006.0,2018.0,,,204729203.0,1.0,HIV infection
20474775,204747752,2,F,,20230721.0,20220215,20230804,EXP,,US-VIIV HEALTHCARE LIMITED-US2022AMR024542,VIIV,,,,,,Y,,,20230804.0,,CN,US,US,SUSTIVA,Blood creatinine increased;Nephropathy;Renal cyst;Renal failure,204747752.0,OT,,,204747752.0,1.0,20170321.0,20170925.0,188.0,DAY,204747752.0,1.0,HIV infection
20474789,204747892,2,F,20180101.0,20220311.0,20220215,20220324,EXP,,MY-MACLEODS PHARMACEUTICALS US LTD-MAC2022034353,MACLEODS,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK.. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology. 2021;24(3):234-7",,,,,Y,,,20220324.0,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204747892.0,HO,,,204747892.0,1.0,20181101.0,2018.0,,,204747892.0,1.0,HIV infection
20476272,204762722,2,F,20180401.0,20221209.0,20220215,20221215,EXP,,US-GILEAD-2022-0569123,GILEAD,,53.0,YR,A,M,Y,70.307,KG,20221215.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Emotional distress;Osteopenia;Osteoporosis;Pain,204762722.0,OT,,,204762722.0,1.0,2016.0,201611.0,,,204762722.0,1.0,HIV infection
20476575,204765752,2,F,20180701.0,20220629.0,20220215,20220704,PER,,US-GILEAD-2022-0569162,GILEAD,,54.0,YR,A,M,Y,,,20220704.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Decreased activity;Emotional distress;Gait disturbance;Hypoaesthesia;Mobility decreased;Osteopenia;Pain;Pain in extremity;Self esteem decreased;Skeletal injury;Weight increased,,,,,204765752.0,1.0,2011.0,2018.0,,,204765752.0,1.0,HIV infection
20477422,204774221,1,I,,20210616.0,20220215,20220215,PER,,US-CIPLA LTD.-2021US04453,CIPLA,,,,,,Y,,,20220216.0,,HP,US,US,EFAVIRENZ,Exposure during pregnancy;No adverse event,,,,,,,,,,,204774221.0,1.0,Antiretroviral therapy
20478539,204785392,2,F,20170101.0,20220802.0,20220216,20220804,PER,,US-GILEAD-2022-0569044,GILEAD,,,,A,M,Y,59.41,KG,20220804.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Bone density decreased;Cardiac disorder;Dehydration;Emotional distress;Foot fracture;Gait disturbance;Loss of personal independence in daily activities;Musculoskeletal disorder;Pain;Renal disorder,,,,,204785392.0,1.0,2005.0,201807.0,,,204785392.0,1.0,HIV infection
20479188,204791884,4,F,20110101.0,20230727.0,20220216,20230802,EXP,,US-GILEAD-2022-0569062,GILEAD,,51.0,YR,A,M,Y,72.562,KG,20230802.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Blood creatinine increased;Bone pain;Chronic kidney disease;Contusion;Depression;Emotional distress;Exercise tolerance decreased;Fatigue;Hand fracture;Hydronephrosis;Osteopenia;Pain;Renal failure;Renal impairment;Skull fracture,204791884.0,OT,,,204791884.0,1.0,2004.0,2015.0,,,204791884.0,1.0,HIV infection
20479484,204794843,3,F,20090101.0,20230623.0,20220216,20230626,PER,,US-GILEAD-2022-0569130,GILEAD,,46.0,YR,A,M,Y,78.458,KG,20230626.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Dysstasia;Emotional distress;Fractured coccyx;Impaired driving ability;Orthostatic hypotension;Osteopenia;Pain;Tinnitus;Tooth loss;Upper limb fracture,,,,,204794843.0,1.0,2006.0,201802.0,,,204794843.0,1.0,HIV infection
20479608,204796082,2,F,20190101.0,20220715.0,20220216,20220214,PER,,US-GILEAD-2022-0569302,GILEAD,,,,A,M,Y,325.0,KG,20220719.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Proteinuria;Renal impairment,204796082.0,OT,,,204796082.0,1.0,2007.0,2019.0,,,204796082.0,1.0,HIV infection
20481671,204816713,3,F,20170101.0,20230615.0,20220216,20230619,PER,,US-GILEAD-2022-0569116,GILEAD,,52.0,YR,A,M,Y,185.0,KG,20230619.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Balance disorder;Bone density decreased;Emotional distress;Gait disturbance;Osteopenia;Pain;Tooth loss,,,,,204816713.0,1.0,2011.0,2017.0,,,204816713.0,1.0,HIV infection
20481696,204816964,4,F,20130101.0,20230716.0,20220216,20230720,EXP,,US-GILEAD-2022-0569327,GILEAD,,70.0,YR,E,M,Y,93.878,KG,20230720.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Laboratory test abnormal;Pain;Renal impairment,204816964.0,OT,,,204816964.0,1.0,2004.0,2016.0,,,204816964.0,1.0,HIV infection
20482516,204825161,1,I,,20220207.0,20220217,20220217,EXP,,CO-HETERO-HET2022CO00367,HETERO,"Rojas Mejia DV, Zwiener RD, Cardona Villa R, Ramirez LF, Silva Espinosa DL, Serrano Reyes CD et al.,. Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study. J-Investig-Allergol-Clin-Immunol. 2021;31(4):322-331",,,,,Y,,,20220217.0,,HP,CO,CO,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,204825161.0,OT,,,,,,,,,204825161.0,1.0,Antiretroviral therapy
20484656,204846563,3,F,20170101.0,20230626.0,20220217,20230628,PER,,US-GILEAD-2022-0569088,GILEAD,,,,A,M,Y,77.098,KG,20230628.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;General physical health deterioration;Osteopenia;Pain,,,,,204846563.0,1.0,2005.0,2016.0,,,204846563.0,1.0,HIV infection
20486717,204867173,3,F,20160101.0,20230804.0,20220217,20230807,PER,,US-GILEAD-2022-0569381,GILEAD,,,,A,F,Y,79.819,KG,20230807.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Pain;Quality of life decreased,,,,,204867173.0,1.0,2007.0,201707.0,,,204867173.0,1.0,HIV infection
20491985,204919853,3,F,20090101.0,20230724.0,20220218,20230725,PER,,US-GILEAD-2022-0569392,GILEAD,,,,A,M,Y,83.9,KG,20230725.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Dysstasia;Emotional distress;Muscle spasms;Musculoskeletal stiffness;Osteopenia;Pain;Posture abnormal;Skeletal injury;Tooth loss;Wrist fracture,,,,,204919853.0,1.0,2008.0,2008.0,,,204919853.0,1.0,HIV infection
20496448,204964483,3,F,20190101.0,20220919.0,20220221,20220923,EXP,,US-GILEAD-2022-0569151,GILEAD,,,,A,M,Y,74.83,KG,20220923.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Diabetes mellitus;Emotional distress;Mobility decreased;Pain;Renal impairment,204964483.0,OT,,,204964483.0,1.0,2015.0,201907.0,,,204964483.0,1.0,HIV infection
20503440,205034401,1,I,,20220214.0,20220222,20220222,EXP,,CA-TEVA-2022-CA-2009488,TEVA,,54.0,YR,A,M,Y,,,20220222.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,205034401.0,DE,,,,,,,,,205034401.0,1.0,HIV infection
20508516,205085161,1,I,,20220217.0,20220223,20220223,EXP,,DK-VIIV HEALTHCARE LIMITED-DK2022GSK029896,VIIV,"Bang D, Fonager J, Johansen IS.. Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report. Journal of medical case reports. 2022;16 (62)",46.0,YR,,M,Y,,,20220223.0,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205085161.0,OT,,,,,,,,,205085161.0,1.0,HIV infection
20508520,205085201,1,I,,20220217.0,20220223,20220223,EXP,,DK-GLAXOSMITHKLINE-DK2022GSK029896,GLAXOSMITHKLINE,"Bang D, Fonager J, Johansen IS.. Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report. Journal of medical case reports. 2022;16 (62)",46.0,YR,,M,Y,,,20220223.0,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205085201.0,OT,,,,,,,,,205085201.0,1.0,HIV infection
20509882,205098821,1,I,,20220215.0,20220224,20220224,EXP,,FR-JNJFOC-20220237289,JOHNSON AND JOHNSON,,,,A,,Y,,,20220224.0,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Virologic failure,205098821.0,OT,,,,,,,,,205098821.0,1.0,HIV infection
20522073,205220735,5,F,,20220607.0,20220226,20220613,EXP,,CA-009507513-2202CAN006974,MERCK,,54.0,YR,,M,Y,,,20220613.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,205220735.0,DE,,,,,,,,,205220735.0,1.0,HIV infection
20527677,205276772,2,F,,20220620.0,20220228,20220708,EXP,,FR-GLAXOSMITHKLINE-FR2022035414,GLAXOSMITHKLINE,,,,,,Y,,,20220708.0,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Myocardial infarction,205276772.0,OT,,,,,,,,,205276772.0,1.0,HIV infection
20527678,205276782,2,F,,20220620.0,20220228,20220708,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2022035414,VIIV,,,,,,Y,,,20220708.0,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Myocardial infarction,205276782.0,OT,,,,,,,,,205276782.0,1.0,HIV infection
20532718,205327181,1,I,,20220221.0,20220301,20220301,EXP,,BR-GILEAD-2022-0570872,GILEAD,"Fioroti C, Distenhreft J, Paulino BB, Lacchine K, Ramos DR, Seguro AC, Luchi WM. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Rev Inst Med Trop Sao Paulo.. 2022;64e10:1-7. doi:10.1590/S1678-9946202264010",62.0,YR,A,F,Y,,,20220301.0,,HP,BR,BR,EFAVIRENZ,Acute kidney injury;Bone disorder;Chronic kidney disease;Fanconi syndrome acquired;Hyperparathyroidism secondary;Multiple fractures;Nephropathy toxic,205327181.0,HO,,,205327181.0,2.0,,,4.0,YR,205327181.0,1.0,HIV infection
20540104,205401042,2,F,,20220111.0,20220302,20220322,EXP,,CA-JNJFOC-20211128009,JOHNSON AND JOHNSON,,,,,,Y,,,20220323.0,,HP,CA,CA,EFAVIRENZ,Ascites;Hepatic encephalopathy;Hepatocellular carcinoma;Spontaneous bacterial peritonitis,205401042.0,OT,,,,,,,,,205401042.0,1.0,HIV infection
20557900,205579001,1,I,,20220224.0,20220307,20220307,EXP,,DK-AUROBINDO-AUR-APL-2022-006891,AUROBINDO,"Bang D, Fonager J, Johansen IS... Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.. Journal of medical case reports.. 2022;16 (62)",46.0,YR,,M,Y,,,20220307.0,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205579001.0,OT,,,,,,,,,205579001.0,1.0,HIV infection
20557964,205579641,1,I,,20220221.0,20220307,20220307,EXP,,IN-CIPLA (EU) LIMITED-2022IN01197,CIPLA,"Sinha P, Ayub A, Lekshmi Priya K, Madakshira MG, MN A, Koshy V.. AIDS-Associated psoriasiform dermatitis - An uncommonly reported entity occurring along with drug reaction with eosinophilia and systemic symptoms (DRESS). Indian journal of dermatology. 2021;66 (6):1 to 5",,,,,Y,,,20220307.0,,HP,IN,IN,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,205579641.0,OT,,,,,,,,,205579641.0,1.0,HIV infection
20569252,205692523,3,F,20090101.0,20230710.0,20220308,20230714,EXP,,US-GILEAD-2022-0572407,GILEAD,,,,A,F,Y,,,20230714.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Mobility decreased;Multiple fractures;Osteoporosis;Pain,205692523.0,OT,,,205692523.0,1.0,2007.0,2018.0,,,205692523.0,1.0,HIV infection
20570145,205701454,4,F,20130101.0,20230901.0,20220309,20230906,EXP,,US-GILEAD-2022-0572815,GILEAD,,50.0,YR,A,M,Y,99.79,KG,20230906.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Condition aggravated;Emotional distress;Pain;Renal failure,205701454.0,HO,,,205701454.0,1.0,2001.0,2008.0,,,205701454.0,1.0,HIV infection
20570688,205706883,3,F,20150701.0,20230811.0,20220309,20230815,EXP,,US-GILEAD-2022-0572922,GILEAD,,40.0,YR,A,M,Y,92.971,KG,20230815.0,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Blood creatinine increased;Depression;Dysstasia;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal impairment,205706883.0,OT,,,205706883.0,1.0,2002.0,201612.0,,,205706883.0,1.0,HIV infection
20570887,205708871,1,I,,20220223.0,20220309,20220309,EXP,,BR-MACLEODS PHARMACEUTICALS US LTD-MAC2022034677,MACLEODS,"Fioroti CEA, Distenhreft JIQ, Paulino BB, Lacchine K, Ramos DR, Seguro AC, Luchi WM.. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Journal of the s?o paulo institute of tropical medicine. 2022;64:7",,,,,Y,,,20220309.0,,HP,BR,BR,EFAVIRENZ,Acute kidney injury;Bone density decreased;Fanconi syndrome;Fracture;Hyperparathyroidism secondary;Musculoskeletal toxicity;Nephropathy toxic;Vitamin D deficiency,205708871.0,HO,,,,,,,,,205708871.0,1.0,HIV test positive
20571008,205710083,3,F,20060201.0,20231115.0,20220309,20231116,EXP,,US-GILEAD-2022-0572948,GILEAD,,40.0,YR,A,F,Y,90.703,KG,20231116.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;Hypertension;Osteopenia;Pain;Protein total increased;Renal impairment,205710083.0,HO,,,205710083.0,1.0,2005.0,200709.0,,,205710083.0,1.0,HIV infection
20571057,205710573,3,F,20100826.0,20230929.0,20220309,20231003,EXP,,US-GILEAD-2022-0572973,GILEAD,,49.0,YR,A,F,Y,53.977,KG,20231003.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Osteoporosis;Pain;Renal failure,205710573.0,HO,,,205710573.0,1.0,2004.0,201801.0,,,205710573.0,1.0,HIV infection
20571079,205710791,1,I,,20220228.0,20220309,20220309,EXP,,BR-STRIDES ARCOLAB LIMITED-2022SP002280,STRIDES,"Fioroti CEA, Distenhreft JIQ, Paulino BB, Lacchine K, Ramos DR, Seguro AC, et al.. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. [Review].. Rev-Inst-Med-Trop-Sao-Paulo. 2022",62.0,YR,,F,Y,,,20220309.0,,HP,BR,BR,EFAVIRENZ,Acute kidney injury;Bone density decreased;Chronic kidney disease;Fanconi syndrome;Fracture;Hyperparathyroidism secondary;Vitamin D deficiency,205710791.0,HO,,,,,,,,,205710791.0,1.0,HIV infection
20574147,205741475,5,F,20110501.0,20230518.0,20220309,20230524,PER,,US-GILEAD-2022-0572977,GILEAD,,48.0,YR,A,M,Y,,,20230524.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Drug ineffective;Emotional distress;Fall;Foot fracture;Loss of personal independence in daily activities;Osteoporosis;Pain;Renal impairment,205741475.0,OT,,,205741475.0,1.0,2010.0,202011.0,,,205741475.0,1.0,HIV infection
20574238,205742382,2,F,20060201.0,20230213.0,20220309,20230217,EXP,,US-GILEAD-2022-0573003,GILEAD,,37.0,YR,A,M,Y,80.73,KG,20230217.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Pain;Vitamin D deficiency,205742382.0,HO,,,205742382.0,1.0,2002.0,200606.0,,,205742382.0,1.0,HIV infection
20574834,205748343,3,F,,20220729.0,20220310,20220810,EXP,,FR-AUROBINDO-AUR-APL-2022-007338,AUROBINDO,"Landman R, de Truchis P, Assoumou L, Lambert S, Bellet J, Amat K, et al... A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.. The Lancet HIV.. 2022;9 (2):e79-90",,,A,,Y,,,20220810.0,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Pathogen resistance;Virologic failure,205748343.0,OT,,,,,,,,,205748343.0,1.0,HIV infection
20575030,205750303,3,F,20180101.0,20230926.0,20220310,20230928,EXP,,US-GILEAD-2022-0573075,GILEAD,,,,A,M,Y,,,20230928.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Emotional distress;Osteopenia;Pain;Renal impairment,205750303.0,OT,,,205750303.0,1.0,2006.0,201710.0,,,205750303.0,1.0,HIV infection
20575880,205758803,3,F,20170101.0,20230929.0,20220310,20231003,PER,,US-GILEAD-2022-0572849,GILEAD,,,,A,M,Y,,,20231003.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Emotional distress;Fatigue;Pain;Renal impairment,205758803.0,OT,,,205758803.0,1.0,2007.0,2019.0,,,205758803.0,1.0,HIV infection
20576327,205763273,3,F,20090501.0,20231002.0,20220310,20231004,EXP,,US-GILEAD-2022-0572953,GILEAD,,52.0,YR,A,M,Y,103.87,KG,20231003.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Emotional distress;Fatigue;Pain,205763273.0,OT,,,205763273.0,1.0,200904.0,200905.0,,,205763273.0,1.0,HIV infection
20579632,205796324,4,F,20120101.0,20230717.0,20220310,20230720,EXP,,US-GILEAD-2022-0572733,GILEAD,,,,A,M,Y,132.88,KG,20230720.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Hypertension;Insomnia;Nausea;Nocturia;Pain;Renal impairment,205796324.0,HO,,,205796324.0,1.0,2001.0,2002.0,,,205796324.0,1.0,HIV infection
20580300,205803002,2,F,20100201.0,20230302.0,20220310,20230307,PER,,US-GILEAD-2022-0572980,GILEAD,,41.0,YR,A,M,Y,127.0,KG,20230307.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Depression;Emotional distress;Pain;Proteinuria;Renal failure,205803002.0,OT,,,205803002.0,1.0,2007.0,201607.0,,,205803002.0,1.0,HIV infection
20580969,205809691,1,I,,20220301.0,20220311,20220311,EXP,,DK-009507513-2203DNK000839,MERCK,"Bang D, Fonager J, Johansen IS. Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report. Journal of medical case reports. 2022;16 (62)",46.0,YR,,M,Y,,,20220311.0,,HP,DK,DK,EFAVIRENZ,HIV-associated neurocognitive disorder;Pathogen resistance;Treatment noncompliance;Virologic failure,205809691.0,OT,,,,,,,,,205809691.0,1.0,HIV infection
20581656,205816561,1,I,,20220228.0,20220311,20220311,EXP,,IN-CIPLA LTD.-2022IN01512,CIPLA,Singh RK. Images in Clinical Tropical Medicine Diffuse Non-Genital Cutaneous Warts. Am. J. Trop. Med. Hyg. 2022;106(2):378 to 379,,,,,Y,,,20220311.0,,HP,IN,IN,EFAVIRENZ,Drug resistance;Therapeutic product effect decreased,205816561.0,OT,,,,,,,,,205816561.0,1.0,HIV infection
20582391,205823911,1,I,,20220228.0,20220311,20220311,EXP,,DK-JNJFOC-20220301083,JOHNSON AND JOHNSON,,46.0,YR,A,M,Y,,,20220311.0,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205823911.0,OT,,,,,,,,,205823911.0,1.0,HIV infection
20585003,205850035,5,F,20140101.0,20231206.0,20220311,20231208,EXP,,US-GILEAD-2022-0572812,GILEAD,,,,A,M,Y,,,20231208.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Fatigue;Gait disturbance;Hypertension;Loss of personal independence in daily activities;Pain;Renal impairment;Vitamin D deficiency,205850035.0,OT,,,205850035.0,1.0,2010.0,2019.0,,,205850035.0,1.0,HIV infection
20586647,205866473,3,F,20150601.0,20230815.0,20220313,20230818,EXP,,US-GILEAD-2022-0572813,GILEAD,,47.0,YR,A,M,Y,102.04,KG,20230818.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Multiple fractures;Osteopenia;Pain;Rib fracture,205866473.0,OT,,,205866473.0,1.0,2004.0,2006.0,,,205866473.0,1.0,HIV infection
20587130,205871302,2,F,,20220316.0,20220314,20220321,EXP,,US-CIPLA LTD.-2022US01631,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220321.0,,HP,US,US,EFAVIRENZ,Drug resistance;Treatment noncompliance,205871302.0,OT,,,205871302.0,1.0,2007.0,,,,205871302.0,1.0,HIV infection
20587147,205871471,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01632,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205871471.0,OT,,,,,,,,,205871471.0,1.0,HIV infection
20587173,205871731,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01633,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205871731.0,OT,,,,,,,,,205871731.0,1.0,HIV infection
20587176,205871761,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01634,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205871761.0,OT,,,,,,,,,205871761.0,1.0,HIV infection
20587178,205871781,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01635,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2021;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205871781.0,OT,,,,,,,,,205871781.0,1.0,HIV infection
20587182,205871821,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01636,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205871821.0,OT,,,,,,,,,205871821.0,1.0,HIV infection
20587186,205871861,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01637,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani SF, Howison M, Aung S, et.al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Infections Diseases Society of America. 2021;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205871861.0,OT,,,,,,,,,205871861.0,1.0,HIV infection
20587259,205872591,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01639,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205872591.0,OT,,,,,,,,,205872591.0,1.0,HIV infection
20587328,205873281,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01626,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205873281.0,OT,,,,,,,,,205873281.0,1.0,HIV infection
20587391,205873911,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01643,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2021;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205873911.0,OT,,,,,,,,,205873911.0,1.0,HIV infection
20587392,205873921,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01644,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205873921.0,OT,,,,,,,,,205873921.0,1.0,HIV infection
20587397,205873971,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01642,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205873971.0,OT,,,,,,,,,205873971.0,1.0,HIV infection
20587399,205873991,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01628,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205873991.0,OT,,,205873991.0,3.0,2007.0,,,,205873991.0,1.0,HIV infection
20587413,205874131,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01630,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.,. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Infectious Diseases Society of America. 2021;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205874131.0,OT,,,,,,,,,205874131.0,1.0,HIV infection
20587414,205874141,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01629,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205874141.0,OT,,,,,,,,,205874141.0,1.0,HIV infection
20587632,205876321,1,I,,20220302.0,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01638,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Statewide HIV Transmitted Resistance. 2021;1 to 16",,,,,Y,,,20220314.0,,HP,US,US,EFAVIRENZ,Drug resistance,205876321.0,OT,,,,,,,,,205876321.0,1.0,HIV infection
20591743,205917432,2,F,,20230731.0,20220314,20230807,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-036994,BRISTOL MYERS SQUIBB,"Ragni MV, Majerus E, Giermasz A, Fong S, Yates B, Scheeler S, et al. Valoctocogene roxaparvovec gene transfer in participants with HIV. Haemophilia. 2022 Feb 01;28(Suppl 1):101-2.",,,,M,Y,,,20230807.0,,HP,US,US,EFAVIRENZ,Drug interaction;Hepatocellular injury,205917432.0,OT,,,,,,,,,205917432.0,1.0,HIV infection
20592844,205928443,3,F,20200115.0,20220707.0,20220315,20220720,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-037237,BRISTOL MYERS SQUIBB,,18.0,YR,A,F,Y,,,20220720.0,,HP,ZW,ZW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,205928443.0,OT,,,205928443.0,1.0,20190122.0,20191217.0,330.0,DAY,205928443.0,1.0,HIV infection
20595035,205950351,1,I,20110101.0,20220302.0,20220315,20220315,EXP,,US-CIPLA (EU) LIMITED-2022US01627,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Statewide HIV Transmitted Resistance. 2022;1 to 11",,,,,Y,,,20220315.0,,HP,US,US,EFAVIRENZ,Drug resistance;Exposure during pregnancy;Toxicity to various agents;Viral load increased,205950351.0,OT,,,205950351.0,1.0,2012.0,2013.0,,,205950351.0,1.0,HIV infection
20601370,206013701,1,I,,20220307.0,20220316,20220316,EXP,,IL-STRIDES ARCOLAB LIMITED-2022SP002540,STRIDES,"David D, Kedem E, Turner D, Levy I, Elbirt DG, Shahar E, et al.. Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study.. PLOS-One.. 2021;16(10)",,,,F,Y,,,20220316.0,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Renal disorder,206013701.0,OT,,,,,,,,,206013701.0,1.0,HIV infection
20601438,206014384,4,F,,20240319.0,20220316,20240328,EXP,,ZA-CIPLA (EU) LIMITED-2022ZA01722,CIPLA,"Siddiqui N, Mansfield BS, Olmesdahl NP, Swart P, Nel J. A Severe Case of Molluscum Contagiosum Immune Reconstitution Inflammatory Syndrome in a Patient with Human Immunodeficiency Virus. European Journal of Case Reports in Internal Medicine. 2022;9 (1)",,,,,Y,,,20240328.0,,MD,ZA,ZA,EFAVIRENZ,Acute kidney injury;Condition aggravated;Immune reconstitution inflammatory syndrome;Molluscum contagiosum;Normocytic anaemia;Paradoxical drug reaction,206014384.0,DE,,,,,,,,,206014384.0,1.0,Antiretroviral therapy
20602073,206020731,1,I,,20220310.0,20220316,20220316,EXP,,SG-GILEAD-2022-0573423,GILEAD,,48.0,YR,A,M,Y,,,20220316.0,,CN,SG,SG,EFAVIRENZ,Liver injury,206020731.0,OT,,,206020731.0,1.0,2017.0,,,,206020731.0,1.0,HIV infection
20602708,206027084,4,F,20200115.0,20220708.0,20220316,20220711,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2022GSK047270,VIIV,,,,,,Y,,,20220711.0,,HP,ZW,ZW,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,206027084.0,OT,,,206027084.0,1.0,20190122.0,20191217.0,329.0,DAY,206027084.0,1.0,HIV infection
20602710,206027103,3,F,20200115.0,20220708.0,20220316,20220711,EXP,,ZW-GLAXOSMITHKLINE-ZW2022GSK047270,GLAXOSMITHKLINE,,,,,,Y,,,20220711.0,,HP,ZW,ZW,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,206027103.0,OT,,,206027103.0,1.0,20190122.0,20191217.0,329.0,DAY,206027103.0,1.0,HIV infection
20618184,206181841,1,I,20180101.0,20220316.0,20220321,20220321,EXP,,DE-GILEAD-2022-0574264,GILEAD,,29.0,YR,A,F,Y,,,20220321.0,,MD,DE,DE,EFAVIRENZ,Anxiety;COVID-19;Central nervous system lesion;Cervical dysplasia;Depressed mood;Depression;Fear of death;Hemiparesis;Herpes zoster;Iron deficiency anaemia;Loss of consciousness;Panic reaction;Peroneal nerve palsy;Sleep disorder;Thinking abnormal;Toxoplasmosis,206181841.0,OT,,,206181841.0,1.0,201812.0,201812.0,,,206181841.0,1.0,HIV infection
20641489,206414891,1,I,,20220315.0,20220328,20220328,EXP,,ZA-AUROBINDO-AUR-APL-2022-008940,AUROBINDO,"Siddiqui N, Mansfield BS, Olmesdahl NP, Swart P, Nel J.. A Severe Case of Molluscum Contagiosum Immune Reconstitution Inflammatory Syndrome in a Patient with Human Immunodeficiency Virus.. European Journal of Case Reports in Internal Medicine. 2022;9(1)",57.0,YR,,M,Y,,,20220328.0,,MD,ZA,ZA,EFAVIRENZ,Condition aggravated;Immune reconstitution inflammatory syndrome;Molluscum contagiosum;Paradoxical drug reaction,206414891.0,HO,,,,,,,,,206414891.0,1.0,HIV infection
20642663,206426631,1,I,,20220318.0,20220328,20220328,EXP,,CA-TEVA-2022-CA-2020215,TEVA,,54.0,YR,A,M,Y,,,20220328.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,206426631.0,OT,,,,,,,,,206426631.0,1.0,HIV infection
20643495,206434951,1,I,,20220315.0,20220328,20220328,EXP,,ZA-MACLEODS PHARMACEUTICALS US LTD-MAC2022034946,MACLEODS,"Siddiqui N, Mansfield BS, Olmesdahl NP, Swart P, Nel J.. A Severe Case of Molluscum Contagiosum Immune Reconstitution Inflammatory Syndrome in a Patient with Human Immunodeficiency Virus. European Journal of Case Reports in Internal Medicine. 2022;9(1)",,,,,Y,,,20220328.0,,MD,ZA,ZA,EFAVIRENZ,Condition aggravated;Death;Immune reconstitution inflammatory syndrome;Molluscum contagiosum;Paradoxical drug reaction,206434951.0,DE,,,,,,,,,206434951.0,1.0,HIV infection
20645596,206455961,1,I,,20220318.0,20220328,20220328,EXP,,CA-TEVA-2022-CA-2020214,TEVA,,54.0,YR,A,M,Y,,,20220328.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,206455961.0,DE,,,,,,,,,206455961.0,1.0,HIV infection
20645800,206458002,2,F,20211201.0,20220323.0,20220328,20220330,EXP,,BR-ORGANON-O2203BRA002402,ORGANON,,39.0,YR,,F,Y,,,20220330.0,,MD,BR,BR,EFAVIRENZ,Abortion of ectopic pregnancy;Ectopic pregnancy with contraceptive device;Unintended pregnancy,206458002.0,OT,,,206458002.0,1.0,202010.0,,,,206458002.0,2.0,Antiretroviral therapy
20646085,206460852,2,F,20100101.0,20230302.0,20220329,20230307,EXP,,US-GILEAD-2022-0575360,GILEAD,,,,A,M,Y,81.633,KG,20230307.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Fanconi syndrome acquired;Hyperlipidaemia;Osteoporosis;Pain,206460852.0,OT,,,206460852.0,1.0,2006.0,201105.0,,,206460852.0,1.0,HIV infection
20646717,206467172,2,F,20160101.0,20230130.0,20220329,20230201,EXP,,US-GILEAD-2022-0575246,GILEAD,,,,A,M,Y,74.8,KG,20230201.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Osteoporosis;Pain,206467172.0,OT,,,206467172.0,1.0,2006.0,2018.0,,,206467172.0,1.0,HIV infection
20649018,206490184,4,F,20130101.0,20230807.0,20220329,20230809,EXP,,US-GILEAD-2022-0575268,GILEAD,,,,A,M,Y,63.492,KG,20230809.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone pain;Emotional distress;Exercise tolerance decreased;Foot fracture;Multiple fractures;Osteonecrosis;Osteoporosis;Pain,206490184.0,OT,,,206490184.0,1.0,2005.0,2013.0,,,206490184.0,1.0,HIV infection
20649358,206493581,1,I,,20220322.0,20220329,20220329,EXP,,IL-JNJFOC-20220348654,JOHNSON AND JOHNSON,,,,E,,Y,,,20220329.0,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Drug interaction;Gastrointestinal disorder;Hyperlipidaemia;Hypersensitivity;Nervous system disorder;Osteoporosis;Renal disorder,206493581.0,OT,,,,,,,,,206493581.0,1.0,HIV infection
20649836,206498363,3,F,20110825.0,20231123.0,20220329,20231130,EXP,,FR-JNJFOC-20191209473,JOHNSON AND JOHNSON,,35.0,YR,A,F,Y,,,20231130.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,206498363.0,OT,,,,,,,,,206498363.0,1.0,HIV infection
20654193,206541931,1,I,,20220325.0,20220330,20220330,EXP,,DK-MYLANLABS-2022M1022948,MYLAN,"Bang D, Fonager J, Johansen IS... Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.. Journal of medical case reports. 2022;16(62)",46.0,YR,,M,Y,,,20220330.0,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,206541931.0,OT,,,,,,,,,206541931.0,1.0,HIV infection
20656948,206569483,3,F,20111201.0,20240301.0,20220331,20240304,EXP,,US-GILEAD-2022-0575369,GILEAD,,46.0,YR,A,M,Y,104.3,KG,20240304.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Condition aggravated;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Renal impairment,206569483.0,OT,,,206569483.0,1.0,2006.0,201209.0,,,206569483.0,1.0,HIV infection
20661241,206612412,2,F,20090618.0,20240117.0,20220401,20240123,EXP,,FR-AUROBINDO-AUR-APL-2022-010714,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design. 2018",47.0,YR,,M,Y,,,20240123.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,206612412.0,OT,,,,,,,,,206612412.0,1.0,HIV infection
20661387,206613873,3,F,20110101.0,20231121.0,20220401,20231123,EXP,,US-GILEAD-2022-0575284,GILEAD,,54.0,YR,A,M,Y,80.726,KG,20231123.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Dysstasia;Emotional distress;Pain,206613873.0,OT,,,206613873.0,1.0,2006.0,200901.0,,,206613873.0,1.0,HIV infection
20662386,206623864,4,F,20220121.0,20230119.0,20220401,20230130,EXP,,FR-AUROBINDO-AUR-APL-2022-007807,AUROBINDO,,,,A,M,Y,92.0,KG,20230130.0,,HP,FR,FR,EFAVIRENZ,Disease recurrence;Drug interaction;Hepatitis C,206623864.0,OT,,,206623864.0,2.0,20210528.0,20210820.0,84.0,DAY,206623864.0,1.0,HIV infection
20664467,206644672,2,F,20031101.0,20221116.0,20220401,20221121,EXP,,US-GILEAD-2022-0575243,GILEAD,,39.0,YR,A,M,Y,95.238,KG,20221121.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood creatinine increased;Chronic kidney disease;Dysstasia;Emotional distress;Hypertension;Pain,206644672.0,OT,,,206644672.0,1.0,200310.0,200610.0,,,206644672.0,1.0,HIV infection
20665752,206657522,2,F,20210528.0,20221108.0,20220402,20221117,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-034348,BRISTOL MYERS SQUIBB,,,,A,M,Y,92.0,KG,20221117.0,,HP,FR,FR,EFAVIRENZ,Drug interaction;Hepatitis C,206657522.0,OT,,,206657522.0,2.0,20210528.0,20210820.0,12.0,WK,206657522.0,1.0,HIV infection
20669823,206698233,3,F,,20220718.0,20220404,20220721,EXP,,FR-MYLANLABS-2022M1024088,MYLAN,"Yazdanpanah Y, Leibowitch J, Bellet J, Lefebvre B, Allavena C, Katlama C, et al.. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.. Lancet HIV. 2022;9:e79-e90",,,A,,Y,,,20220721.0,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Pathogen resistance;Virologic failure,206698233.0,OT,,,,,,,,,206698233.0,1.0,HIV infection
20672283,206722832,2,F,20090619.0,20231117.0,20220405,20231127,EXP,,FR-AUROBINDO-AUR-APL-2018-062546,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). Chemical biology + drug design. 2018",42.0,YR,,F,Y,,,20231127.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,206722832.0,OT,,,,,,,,,206722832.0,1.0,HIV infection
20677502,206775021,1,I,,20220328.0,20220406,20220406,EXP,,IN-CIPLA LTD.-2022IN02071,CIPLA,"Mani M, Kannagai R, Ramalingam V, Lionel J, Christina S, Sachithanandham J et.al.. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission. Indian Journal of Medical Microbiology. 2015;33(2):225 to 230",,,,,Y,,,20220406.0,,HP,IN,IN,EFAVIRENZ,Drug resistance;Exposure during pregnancy;Maternal exposure during delivery,206775021.0,OT,,,,,,,,,206775021.0,1.0,Prophylaxis against HIV infection
20677503,206775032,2,F,,20220328.0,20220406,20220407,EXP,,IN-CIPLA LTD.-2022IN02073,CIPLA,"Mani M, Kannangai R, Ramalingam VV, Lionel J, Christina SA, Sachithanandham J et.al. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission. Indian Journal of Medical Microbiology. 2015;33 (2):225 to 230",,,,,Y,,,20220407.0,,HP,IN,IN,EFAVIRENZ,Drug resistance;Exposure during pregnancy;Maternal exposure during delivery;No adverse event,206775032.0,OT,,,,,,,,,206775032.0,1.0,Prophylaxis against HIV infection
20678009,206780091,1,I,,20220404.0,20220406,20220406,EXP,,IN-GILEAD-2022-0576395,GILEAD,"Francis AK, Jacob M, Koshy JM, Finny P. Tenofovir Induced Fanconi Syndrome Complicated by Bilateral Neck of Femur Fractures. Indian J Endocr Metab.. 2021;25(6):569-571. doi:10.4103/ijem.ijem_363_21",56.0,YR,A,F,Y,,,20220406.0,,HP,IN,IN,EFAVIRENZ,Fanconi syndrome acquired;Multiple fractures;Osteoporosis,206780091.0,OT,,,,,,,,,206780091.0,1.0,HIV infection
20687035,206870353,3,F,20150101.0,20230407.0,20220407,20230414,EXP,,US-JNJFOC-20200934182,JOHNSON AND JOHNSON,,,,A,M,Y,68.027,KG,20230414.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone demineralisation;Decreased activity;Depression;Diarrhoea;Economic problem;Emotional distress;Fatigue;Headache;Hip arthroplasty;Left ventricular failure;Osteonecrosis;Osteoporosis;Pain,206870353.0,OT,,,206870353.0,2.0,20100802.0,20170729.0,2553.0,DAY,206870353.0,1.0,HIV infection
20688532,206885323,3,F,20120803.0,20231122.0,20220408,20231206,EXP,,FR-ROCHE-2232721,ROCHE,"Pouga L, Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). Doi: 10.1111/cbdd.13378. Chemical Biology + Drug Design. 2019;93 (1):50-9.",35.0,YR,,F,Y,,,20231206.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Treatment failure,,,,,,,,,,,206885323.0,1.0,HIV infection
20690928,206909281,1,I,,20220322.0,20220408,20220408,EXP,,IL-GLAXOSMITHKLINE-IL2022057522,GLAXOSMITHKLINE,,,,E,,Y,,,20220408.0,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Drug interaction;Gastrointestinal disorder;Hyperlipidaemia;Hypersensitivity;Nervous system disorder;Osteoporosis;Renal disorder,206909281.0,OT,,,,,,,,,206909281.0,1.0,HIV infection
20690931,206909311,1,I,,20220322.0,20220408,20220408,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2022057522,VIIV,,,,E,,Y,,,20220408.0,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Drug interaction;Gastrointestinal disorder;Hyperlipidaemia;Hypersensitivity;Nervous system disorder;Osteoporosis;Renal disorder,206909311.0,OT,,,,,,,,,206909311.0,1.0,HIV infection
20703217,207032171,1,I,,20220403.0,20220413,20220413,EXP,,IN-HETERO-HET2022IN00830,HETERO,"Francis AK, Jacob M, Koshy JM, Finny P. Tenofovir Induced Fanconi Syndrome Complicated by Bilateral Neck of Femur Fractures. Indian Journal of Endocrinology and Metabolism. 2021;25(6):569-571",56.0,YR,,F,Y,,,20220413.0,,HP,IN,IN,EFAVIRENZ,Fanconi syndrome;Osteomalacia;Osteoporosis,207032171.0,OT,,,,,,,,,207032171.0,1.0,HIV infection
20703717,207037171,1,I,,20220403.0,20220413,20220413,EXP,,IN-HETERO-HET2022IN00829,HETERO,"Sarma GR, Delon Dsouza SS, Prakash P. Efavirenz-Induced Delayed Onset Cerebellar Ataxia and Encephalopathyx. Annals of Indian Academy of Neurology. 2022;25(1):153-155",23.0,YR,,F,Y,28.0,KG,20220413.0,,MD,IN,IN,EFAVIRENZ,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,207037171.0,OT,,,207037171.0,1.0,2017.0,,,,207037171.0,1.0,HIV infection
20707501,207075011,1,I,,20220405.0,20220413,20220413,EXP,,CA-009507513-2204CAN002353,MERCK,,54.0,YR,,M,Y,,,20220413.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207075011.0,OT,,,,,,,,,207075011.0,1.0,HIV infection
20707845,207078451,1,I,,20220107.0,20220414,20220414,PER,,US-STRIDES ARCOLAB LIMITED-2021SP029351,STRIDES,"Brasher WP, Bvumbwe M, Kazembe PN.. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment.. Malawi-Med-J. 2020;32(4):229-231",16.0,YR,,M,Y,,,20220414.0,,HP,US,US,EFAVIRENZ,Ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,207078451.0,HO,,,207078451.0,1.0,2012.0,,3.0,DAY,207078451.0,1.0,HIV infection WHO clinical stage I
20713124,207131241,1,I,20220407.0,,20220414,20220414,DIR,FDA-CDER-CTU-2022-28781,,FDA-CTU,,68.0,YR,,M,N,,,20220414.0,N,PH,US,,EFAVIRENZ,Death,207131241.0,DE,207131241.0,HP,207131241.0,1.0,20211214.0,20220407.0,,,207131241.0,1.0,HIV infection
20724681,207246811,1,I,,20220411.0,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027446,TEVA,,54.0,YR,A,M,Y,,,20220419.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207246811.0,OT,,,,,,,,,207246811.0,1.0,HIV infection
20724688,207246881,1,I,,20220411.0,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027451,TEVA,,54.0,YR,A,M,Y,,,20220419.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207246881.0,OT,,,,,,,,,207246881.0,1.0,HIV infection
20728954,207289542,2,F,20170720.0,20230213.0,20220420,20230217,EXP,,US-GILEAD-2022-0577998,GILEAD,,50.0,YR,A,M,Y,26.122,KG,20230217.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Hip fracture;Osteopenia;Osteoporosis;Pain;Rib fracture,207289542.0,OT,,,207289542.0,1.0,2006.0,201611.0,,,207289542.0,1.0,HIV infection
20728978,207289784,4,F,20131201.0,20240205.0,20220420,20240207,EXP,,US-GILEAD-2022-0578499,GILEAD,,49.0,YR,A,M,Y,74.84,KG,20240207.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,207289784.0,OT,,,207289784.0,1.0,2012.0,201312.0,,,207289784.0,1.0,HIV infection
20729008,207290083,3,F,20130101.0,20230926.0,20220420,20230928,EXP,,US-GILEAD-2022-0578505,GILEAD,,,,A,M,Y,120.0,KG,20230928.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Compression fracture;Emotional distress;Femur fracture;Foot fracture;Hip fracture;Humerus fracture;Osteoporosis;Pain;Rib fracture;Shoulder fracture;Spinal fracture,207290083.0,OT,,,207290083.0,1.0,2006.0,201710.0,,,207290083.0,1.0,HIV infection
20729014,207290144,4,F,20120901.0,20230518.0,20220420,20230523,EXP,,US-GILEAD-2022-0578486,GILEAD,,55.0,YR,A,M,Y,97.522,KG,20230523.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Back pain;Dysstasia;Emotional distress;Fatigue;Gait disturbance;General physical health deterioration;Pain;Pollakiuria;Renal failure;Renal pain;Sepsis;Ureterolithiasis,207290144.0,OT,,,207290144.0,1.0,2006.0,2013.0,,,207290144.0,1.0,HIV infection
20729777,207297774,4,F,20120601.0,20230912.0,20220420,20230918,EXP,,US-GILEAD-2022-0578508,GILEAD,,51.0,YR,A,M,Y,94.331,KG,20230918.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal impairment;Vitamin D deficiency,207297774.0,OT,,,207297774.0,1.0,2007.0,2018.0,,,207297774.0,1.0,HIV infection
20732187,207321871,1,I,,20220413.0,20220420,20220420,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2022GSK065960,VIIV,"Badat A, Lowton K. Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen. South African Journal of Psychiatry. 2022;28(0)",32.0,YR,,M,Y,,,20220420.0,,HP,ZA,ZA,EFAVIRENZ,Aggression;Condition aggravated;Confusional state;Dizziness;Fall;Haemothorax;Humerus fracture;Insomnia;Neuropsychiatric symptoms;Pericardial effusion;Restlessness;Rib fracture;Sleep disorder;Soliloquy;Thinking abnormal,207321871.0,OT,,,,,,,,,207321871.0,1.0,HIV infection
20732862,207328623,3,F,20150102.0,20231205.0,20220420,20231207,EXP,,US-GILEAD-2022-0578558,GILEAD,,44.0,YR,A,M,Y,84.0,KG,20231207.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Dysstasia;Emotional distress;Gait disturbance;Pain,207328623.0,OT,,,207328623.0,1.0,2011.0,2013.0,,,207328623.0,1.0,HIV infection
20732933,207329333,3,F,20201001.0,20230725.0,20220420,20230728,EXP,,US-GILEAD-2022-0578571,GILEAD,,54.0,YR,A,M,Y,57.143,KG,20230728.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain;Renal failure,207329333.0,OT,,,207329333.0,1.0,2016.0,,,,207329333.0,1.0,HIV infection
20733486,207334862,2,F,20170101.0,20230225.0,20220421,20230301,EXP,,US-GILEAD-2022-0578540,GILEAD,,,,A,M,Y,116.1,KG,20230301.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Bone loss;Emotional distress;Osteoporosis;Pain;Tooth loss,207334862.0,OT,,,207334862.0,1.0,2004.0,201809.0,,,207334862.0,1.0,HIV infection
20737909,207379091,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02589,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207379091.0,OT,,,,,,,,,207379091.0,1.0,HIV infection WHO clinical stage I
20737937,207379371,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ02591,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207379371.0,OT,,,207379371.0,1.0,20100221.0,,,,207379371.0,1.0,HIV infection WHO clinical stage III
20738039,207380391,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02599,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380391.0,OT,,,207380391.0,1.0,20060626.0,,,,207380391.0,1.0,HIV infection WHO clinical stage III
20738089,207380891,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02605,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380891.0,OT,,,207380891.0,1.0,20070421.0,,,,207380891.0,1.0,HIV infection WHO clinical stage IV
20738093,207380931,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02537,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380931.0,OT,,,207380931.0,1.0,20120924.0,,,,207380931.0,1.0,HIV infection WHO clinical stage III
20738097,207380971,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02590,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380971.0,OT,,,207380971.0,1.0,20100423.0,,,,207380971.0,1.0,HIV infection WHO clinical stage III
20738155,207381551,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02607,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.,. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207381551.0,OT,,,207381551.0,2.0,20121106.0,,,,207381551.0,1.0,HIV infection WHO clinical stage IV
20738177,207381771,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02611,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207381771.0,OT,,,207381771.0,1.0,20060527.0,,,,207381771.0,1.0,HIV infection WHO clinical stage IV
20738205,207382051,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02615,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207382051.0,OT,,,207382051.0,1.0,20140131.0,,,,207382051.0,1.0,HIV infection WHO clinical stage I
20738237,207382371,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02621,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207382371.0,OT,,,207382371.0,1.0,20130520.0,,,,207382371.0,1.0,HIV infection WHO clinical stage I
20738390,207383901,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02625,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SS, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207383901.0,OT,,,207383901.0,1.0,20151019.0,,,,207383901.0,1.0,HIV infection WHO clinical stage III
20738438,207384381,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02598,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207384381.0,OT,,,207384381.0,1.0,20050411.0,,,,207384381.0,1.0,HIV infection WHO clinical stage IV
20738439,207384391,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02596,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial chemotherapy. 2022;77:483-491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207384391.0,OT,,,207384391.0,1.0,20070730.0,,,,207384391.0,1.0,HIV infection WHO clinical stage IV
20738440,207384401,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02629,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207384401.0,OT,,,207384401.0,1.0,20050725.0,,,,207384401.0,1.0,HIV infection WHO clinical stage II
20738760,207387601,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02614,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.,. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207387601.0,OT,,,207387601.0,1.0,20060629.0,,,,207387601.0,1.0,HIV infection WHO clinical stage III
20738762,207387621,1,I,,20220411.0,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02616,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207387621.0,OT,,,,,,,,,207387621.0,1.0,HIV infection WHO clinical stage III
20742958,207429581,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02620,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207429581.0,OT,,,207429581.0,1.0,20080327.0,,,,207429581.0,1.0,HIV infection WHO clinical stage III
20742959,207429591,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02626,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207429591.0,OT,,,207429591.0,1.0,20091013.0,,,,207429591.0,1.0,HIV infection CDC Group III
20742960,207429601,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02618,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207429601.0,OT,,,207429601.0,1.0,20160129.0,,,,207429601.0,1.0,HIV infection WHO clinical stage II
20743051,207430511,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02634,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430511.0,OT,,,207430511.0,1.0,20150121.0,,,,207430511.0,1.0,HIV infection
20743052,207430521,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02636,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430521.0,OT,,,207430521.0,1.0,20120517.0,,,,207430521.0,1.0,HIV infection WHO clinical stage II
20743053,207430531,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02628,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430531.0,OT,,,207430531.0,1.0,20090917.0,,,,207430531.0,1.0,HIV infection WHO clinical stage III
20743055,207430551,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02630,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430551.0,OT,,,207430551.0,1.0,20140709.0,,,,207430551.0,1.0,HIV infection CDC Group III
20743116,207431161,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02617,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431161.0,OT,,,207431161.0,1.0,20101021.0,,,,207431161.0,1.0,HIV infection WHO clinical stage II
20743129,207431291,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02631,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431291.0,OT,,,,,,,,,207431291.0,1.0,HIV infection WHO clinical stage III
20743149,207431491,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02633,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431491.0,OT,,,207431491.0,1.0,20120309.0,,,,207431491.0,1.0,HIV infection WHO clinical stage III
20743160,207431601,1,I,,20220411.0,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02745,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431601.0,OT,,,207431601.0,1.0,20130515.0,,,,207431601.0,1.0,HIV infection WHO clinical stage II
20748123,207481231,1,I,,20220411.0,20220426,20220426,EXP,,TZ-CIPLA LTD.-2022TZ02639,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220426.0,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207481231.0,OT,,,207481231.0,1.0,20090430.0,,,,207481231.0,1.0,HIV infection WHO clinical stage II
20762313,207623131,1,I,20220402.0,20220426.0,20220428,20220428,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC069574,VIIV,,22.0,YR,,M,Y,,,20220428.0,,HP,CN,CN,EFAVIRENZ,Abdominal discomfort;Abdominal distension;Granulocyte count decreased;Nausea,207623131.0,HO,,,207623131.0,1.0,20220328.0,20220407.0,10.0,DAY,207623131.0,1.0,Acquired immunodeficiency syndrome
20762345,207623451,1,I,20220402.0,20220426.0,20220428,20220428,EXP,,CN-GLAXOSMITHKLINE-CN2022APC069574,GLAXOSMITHKLINE,,22.0,YR,,M,Y,,,20220428.0,,HP,CN,CN,EFAVIRENZ,Abdominal discomfort;Abdominal distension;Granulocyte count decreased;Nausea,207623451.0,HO,,,207623451.0,1.0,20220328.0,20220407.0,10.0,DAY,207623451.0,1.0,Acquired immunodeficiency syndrome
20802683,2080268332,32,F,20120521.0,20221110.0,20220509,20221122,EXP,,GB-HORMOSAN PHARMA GMBH-2019-03347,LUPIN,,43.0,YR,,F,Y,43.0,KG,20221122.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Off label use,2080268332.0,HO,,,2080268332.0,2.0,20171006.0,20180205.0,4.0,MON,2080268332.0,1.0,HIV infection
20810420,208104201,1,I,,20220504.0,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK075381,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104201.0,OT,,,208104201.0,6.0,,,23.0,MON,208104201.0,1.0,HIV infection CDC category C
20810421,208104211,1,I,,20220504.0,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK075381,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104211.0,OT,,,208104211.0,6.0,,,23.0,MON,208104211.0,1.0,HIV infection CDC category C
20810470,208104701,1,I,,20220504.0,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK075399,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104701.0,OT,,,208104701.0,1.0,,,6.0,MON,208104701.0,1.0,HIV infection CDC category C
20810472,208104721,1,I,,20220504.0,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK075399,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104721.0,OT,,,208104721.0,1.0,,,6.0,MON,208104721.0,1.0,HIV infection CDC category C
20810474,208104741,1,I,,20220504.0,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK074567,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104741.0,OT,,,,,,,,,208104741.0,1.0,HIV infection CDC category C
20810477,208104771,1,I,,20220504.0,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK074567,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104771.0,OT,,,,,,,,,208104771.0,1.0,HIV infection CDC category C
20810744,208107441,1,I,,20220504.0,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK075600,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Drug interaction;Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208107441.0,OT,,,,,,,,,208107441.0,1.0,HIV infection CDC category C
20810745,208107451,1,I,,20220504.0,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK075600,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510.0,,HP,MW,MW,EFAVIRENZ,Drug interaction;Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208107451.0,OT,,,,,,,,,208107451.0,1.0,HIV infection CDC category C
20849982,208499821,1,I,,20220517.0,20220519,20220519,EXP,,GB-GILEAD-2022-0582191,GILEAD,,,,A,M,Y,,,20220519.0,,CN,GB,GB,EFAVIRENZ,Malaise,208499821.0,HO,,,,,,,,,208499821.0,1.0,HIV infection
20855923,208559232,2,F,,20220616.0,20220520,20220621,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2022GSK078393,VIIV,,,,,,Y,,,20220621.0,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,208559232.0,OT,,,208559232.0,2.0,200501.0,200501.0,,,208559232.0,1.0,HIV infection
20855924,208559242,2,F,,20220616.0,20220520,20220621,EXP,,ES-GLAXOSMITHKLINE-ES2022GSK078393,GLAXOSMITHKLINE,,,,,,Y,,,20220621.0,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,208559242.0,OT,,,208559242.0,2.0,200501.0,200501.0,,,208559242.0,1.0,HIV infection
20858432,2085843210,10,F,,20241029.0,20220521,20241031,EXP,,CA-009507513-2205CAN005476,MERCK,,54.0,YR,,M,Y,,,20241031.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,2085843210.0,HO,,,,,,,,,2085843210.0,1.0,HIV infection
20858945,208589452,2,F,20040601.0,20230226.0,20220522,20230301,EXP,,US-GILEAD-2022-0582563,GILEAD,,50.0,YR,A,M,Y,100.24,KG,20230301.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone loss;Chronic kidney disease;Emotional distress;Femur fracture;Foot fracture;Hypertension;Lymphoma;Multiple fractures;Nephrolithiasis;Osteoporosis;Pain;Radius fracture;Renal impairment;Renal injury,208589452.0,OT,,,208589452.0,1.0,2004.0,201609.0,,,208589452.0,1.0,HIV infection
20859131,208591313,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810.0,,LW,US,US,SUSTIVA,Abdominal pain lower;Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Depression;Emotional distress;Muscular weakness;Osteonecrosis;Osteoporosis;Pain;Pain in extremity;Periarthritis;Quality of life decreased,208591313.0,OT,,,208591313.0,1.0,2005.0,201703.0,,,208591313.0,1.0,HIV infection
20859502,208595023,3,F,20101001.0,20230614.0,20220523,20230619,EXP,,US-GILEAD-2022-0582516,GILEAD,,46.0,YR,A,M,Y,111.11,KG,20230619.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Dysstasia;Emotional distress;Gait disturbance;Pain;Renal failure,208595023.0,OT,,,208595023.0,1.0,2006.0,201904.0,,,208595023.0,1.0,HIV infection
20859527,208595274,4,F,20131201.0,20240210.0,20220523,20240212,EXP,,US-GILEAD-2022-0582524,GILEAD,,47.0,YR,A,M,Y,,,20240212.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Loss of personal independence in daily activities;Nephropathy toxic;Pain;Renal failure;Renal impairment,208595274.0,HO,,,208595274.0,1.0,2012.0,201403.0,,,208595274.0,1.0,HIV infection
20859661,208596613,3,F,20160801.0,20240207.0,20220523,20240209,PER,,US-GILEAD-2022-0582397,GILEAD,,55.0,YR,A,M,Y,72.57,KG,20240209.0,,LW,US,US,SUSTIVA,Abdominal discomfort;Acute kidney injury;Anhedonia;Anxiety;Asthenia;Depression;Emotional distress;Fatigue;Insomnia;Metabolic acidosis;Pain;Renal failure;Renal impairment;Tachyphrenia;Urine analysis abnormal,208596613.0,OT,,,208596613.0,1.0,2005.0,201612.0,,,208596613.0,1.0,HIV infection
20859947,208599473,3,F,20150101.0,20240207.0,20220523,20240208,EXP,,US-GILEAD-2022-0582540,GILEAD,,,,A,M,Y,98.866,KG,20240208.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Loss of personal independence in daily activities;Pain,208599473.0,OT,,,208599473.0,1.0,2005.0,201707.0,,,208599473.0,1.0,HIV infection
20859984,208599843,3,F,,20230911.0,20220523,20230914,EXP,,US-GILEAD-2022-0582560,GILEAD,,,,A,M,Y,99.79,KG,20230914.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Emotional distress;Insomnia;Pain;Pollakiuria,208599843.0,OT,,,208599843.0,1.0,2014.0,2009.0,,,208599843.0,1.0,HIV infection
20860647,208606473,3,F,20080101.0,20240109.0,20220523,20240111,PER,,US-GILEAD-2022-0582512,GILEAD,,,,A,F,Y,68.027,KG,20240111.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Foot fracture;Hyperlipidaemia;Hypertension;Intervertebral disc degeneration;Loss of personal independence in daily activities;Osteopenia;Pain;Wrist fracture,208606473.0,OT,,,208606473.0,1.0,2004.0,201512.0,,,208606473.0,1.0,HIV infection
20861199,208611994,4,F,,20240126.0,20220523,20240612,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039077,BRISTOL MYERS SQUIBB,Literature citation unavailable.,44.0,YR,A,M,Y,,,20240612.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208611994.0,OT,,,,,,,,,208611994.0,1.0,HIV infection
20862193,208621931,1,I,,20220510.0,20220523,20220523,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-045861,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20220523.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Death,208621931.0,DE,,,,,,,,,208621931.0,1.0,HIV infection
20862425,208624253,3,F,,20221130.0,20220523,20221202,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039291,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20221202.0,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Hospitalisation;Intentional product use issue;Loss of personal independence in daily activities,208624253.0,OT,,,,,,,,,208624253.0,1.0,HIV infection
20864130,208641302,2,F,20100101.0,20230304.0,20220523,20230309,EXP,,US-GILEAD-2022-0582593,GILEAD,,,,A,F,Y,64.0,KG,20230309.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Hand fracture;Osteopenia;Osteoporosis;Pain;Pneumothorax;Rib fracture;Skeletal injury;Wrist fracture,208641302.0,HO,,,208641302.0,1.0,2006.0,201806.0,,,208641302.0,1.0,HIV infection
20864134,208641342,2,F,20140101.0,20220714.0,20220523,20220718,EXP,,US-GILEAD-2022-0582465,GILEAD,,,,A,M,Y,134.69,KG,20220718.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Emotional distress;General physical health deterioration;Osteopenia;Osteoporosis;Pain,208641342.0,OT,,,208641342.0,1.0,2006.0,201410.0,,,208641342.0,1.0,HIV infection
20864139,208641393,3,F,20080101.0,20240115.0,20220523,20240117,EXP,,US-GILEAD-2022-0582671,GILEAD,,,,A,M,Y,106.58,KG,20240117.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Fatigue;Hypertension;Nephrolithiasis;Pain;Renal impairment,208641393.0,OT,,,208641393.0,1.0,2001.0,2013.0,,,208641393.0,1.0,HIV infection
20864227,208642273,3,F,20130101.0,20240111.0,20220523,20240114,PER,,US-GILEAD-2022-0582528,GILEAD,,,,A,M,Y,72.5,KG,20240114.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Emotional distress;Loss of personal independence in daily activities;Pain,208642273.0,HO,,,208642273.0,1.0,2012.0,2013.0,,,208642273.0,1.0,HIV infection
20864521,208645214,4,F,20160301.0,20230710.0,20220524,20230714,EXP,,US-GILEAD-2022-0582426,GILEAD,,55.0,YR,A,M,Y,109.75,KG,20230714.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Bone density decreased;Carotid artery disease;Chronic kidney disease;Constipation;Dysstasia;Emotional distress;Erectile dysfunction;Gait disturbance;Impaired work ability;Loss of personal independence in daily activities;Pain,208645214.0,OT,,,208645214.0,1.0,2014.0,201908.0,,,208645214.0,1.0,HIV infection
20865479,208654791,1,I,,20220517.0,20220524,20220524,EXP,,CA-GILEAD-2022-0582425,GILEAD,,52.0,YR,A,M,Y,,,20220524.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208654791.0,OT,,,,,,,,,208654791.0,1.0,HIV infection
20866089,208660893,3,F,20131101.0,20231004.0,20220524,20231005,EXP,,US-GILEAD-2022-0582630,GILEAD,,51.0,YR,A,F,Y,79.365,KG,20231005.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Back pain;Chronic kidney disease;Dysstasia;Emotional distress;Exercise tolerance decreased;Fatigue;Gait disturbance;Hyperparathyroidism;Insomnia;Osteopenia;Osteoporosis;Pain;Pollakiuria;Quality of life decreased;Renal failure;Renal impairment;Renal pain;Vitamin D deficiency,208660893.0,OT,,,208660893.0,1.0,2009.0,2009.0,40.0,MON,208660893.0,1.0,HIV infection
20866452,208664522,2,F,,20220530.0,20220524,20220601,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME080792,VIIV,,,,,,Y,,,20220601.0,,MD,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,208664522.0,OT,,,208664522.0,1.0,1998.0,,,,208664522.0,1.0,HIV infection
20868859,208688592,2,F,,20220516.0,20220524,20220613,EXP,,DK-GILEAD-2022-0582165,GILEAD,"Gulden T, Yahyavi S, Lodding I, Jensen J, Blomberg JM. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report. Bone Reports. 2021;15;101119:NI. doi:10.1016/j.bonr.2021.101119",67.0,YR,E,M,Y,,,20220613.0,,HP,DK,DK,EFAVIRENZ,Dehydration;Diarrhoea;Off label use;Vomiting,208688592.0,HO,,,,,,,,,208688592.0,1.0,HIV infection
20868953,208689533,3,F,20040401.0,20240108.0,20220524,20240110,EXP,,US-GILEAD-2022-0582604,GILEAD,,44.0,YR,A,F,Y,,,20240110.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Depression;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain,208689533.0,OT,,,208689533.0,1.0,2001.0,201711.0,,,208689533.0,1.0,HIV infection
20869041,208690412,2,F,20161001.0,20230218.0,20220524,20230222,EXP,,US-GILEAD-2022-0582682,GILEAD,,55.0,YR,A,M,Y,88.4,KG,20230222.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Emotional distress;Osteopenia;Pain,208690412.0,OT,,,208690412.0,1.0,2005.0,2006.0,,,208690412.0,1.0,HIV infection
20870910,208709101,1,I,,20220510.0,20220525,20220525,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039152,BRISTOL MYERS SQUIBB,,52.0,YR,A,M,Y,,,20220525.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,208709101.0,OT,,,,,,,,,208709101.0,1.0,HIV infection
20871852,2087185210,10,F,,20230424.0,20220525,20230428,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022082351,VIIV,,,,,,Y,,,20230428.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,2087185210.0,HO,,,,,,,,,2087185210.0,1.0,HIV infection
20871865,2087186510,10,F,,20230424.0,20220525,20230428,EXP,,CA-GLAXOSMITHKLINE-CA2022082351,GLAXOSMITHKLINE,,,,,,Y,,,20230428.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,2087186510.0,HO,,,,,,,,,2087186510.0,1.0,HIV infection
20871993,208719933,3,F,,20220715.0,20220525,20221028,EXP,,SE-VIIV HEALTHCARE LIMITED-SE2021267531,VIIV,,,,,,Y,,,20221028.0,,HP,SE,SE,EFAVIRENZ,Drug resistance,208719933.0,OT,,,,,,,,,208719933.0,1.0,HIV infection
20871996,208719963,3,F,,20220715.0,20220525,20221028,EXP,,SE-GLAXOSMITHKLINE-SE2021267531,GLAXOSMITHKLINE,,,,,,Y,,,20221028.0,,HP,SE,SE,EFAVIRENZ,Drug resistance,208719963.0,OT,,,,,,,,,208719963.0,1.0,HIV infection
20872212,208722121,1,I,,20220520.0,20220525,20220525,EXP,,CA-ROCHE-3101481,ROCHE,,54.0,YR,,M,Y,,,20220525.0,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,208722121.0,OT,,,,,,,,,208722121.0,1.0,HIV infection
20876174,208761742,2,F,20100101.0,20221010.0,20220526,20221012,PER,,US-GILEAD-2022-0582507,GILEAD,,51.0,YR,A,F,Y,65.76,KG,20221012.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Depression;Emotional distress;Foot fracture;Gait disturbance;Loss of personal independence in daily activities;Musculoskeletal disorder;Osteopenia;Pain;Pain in extremity;Patella fracture;Renal disorder,,,,,208761742.0,1.0,2002.0,2006.0,,,208761742.0,1.0,HIV infection
20877650,208776504,4,F,,20230713.0,20220526,20230725,EXP,,CA-APOTEX-2022AP008239,APOTEX,,54.0,YR,,M,Y,,,20230725.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208776504.0,HO,,,,,,,,,208776504.0,1.0,HIV infection
20879536,208795362,2,F,,20220914.0,20220526,20220919,EXP,,CA-009507513-2205CAN005187,MERCK,,52.0,YR,,M,Y,,,20220919.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208795362.0,OT,,,,,,,,,208795362.0,1.0,HIV infection
20884066,208840667,7,F,,20230424.0,20220527,20230426,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084848,VIIV,,,,,,Y,,,20230426.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840667.0,OT,,,,,,,,,208840667.0,1.0,HIV infection
20884074,208840747,7,F,,20230424.0,20220527,20230426,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084848,GLAXOSMITHKLINE,,,,,,Y,,,20230426.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840747.0,DE,,,,,,,,,208840747.0,1.0,HIV infection
20891017,208910172,2,F,20200101.0,20220601.0,20220530,20220606,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME082997,VIIV,,,,,,Y,,,20220606.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,208910172.0,OT,,,208910172.0,1.0,2013.0,2014.0,,,208910172.0,1.0,HIV infection
20891018,208910182,2,F,20200101.0,20220601.0,20220530,20220606,EXP,,PT-GLAXOSMITHKLINE-PT2022EME082997,GLAXOSMITHKLINE,,,,,,Y,,,20220606.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,208910182.0,OT,,,208910182.0,1.0,2013.0,2014.0,,,208910182.0,1.0,HIV infection
20891456,208914566,6,F,,20220715.0,20220530,20220722,EXP,,ES-JNJFOC-20220557464,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20220722.0,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,208914566.0,OT,,,208914566.0,4.0,200501.0,201501.0,,,208914566.0,1.0,HIV infection
20891666,208916661,1,I,,20220517.0,20220530,20220530,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022083222,VIIV,,,,,,Y,,,20220530.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208916661.0,OT,,,,,,,,,208916661.0,1.0,HIV infection
20891667,208916671,1,I,,20220517.0,20220530,20220530,EXP,,CA-GLAXOSMITHKLINE-CA2022083222,GLAXOSMITHKLINE,,,,,,Y,,,20220530.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208916671.0,OT,,,,,,,,,208916671.0,1.0,HIV infection
20892665,208926659,9,F,,20240923.0,20220531,20240927,EXP,,CA-ABBVIE-22K-028-4414704-00,ABBVIE,,54.0,YR,,M,Y,,,20240927.0,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208926659.0,OT,,,,,,,,,208926659.0,1.0,HIV infection
20893463,208934631,1,I,20090207.0,20220407.0,20220531,20220531,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2022-045158,BRISTOL MYERS SQUIBB,,36.0,YR,A,M,Y,,,20220531.0,,HP,JP,JP,EFAVIRENZ,COVID-19;Drug eruption;Herpes zoster;Insomnia;Spirochaetal infection,208934631.0,OT,,,208934631.0,1.0,20090208.0,20120821.0,1291.0,DAY,208934631.0,1.0,HIV infection
20895023,208950238,8,F,20100629.0,20220721.0,20220531,20241210,EXP,GB-EMA-DD-20180827-Ashwinihvp-120514,GB-GLAXOSMITHKLINE-GB2022083878,GLAXOSMITHKLINE,,,,,,Y,,,20241210.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Ultrasound antenatal screen,208950238.0,CA,,,208950238.0,1.0,20090101.0,20100110.0,374.0,DAY,208950238.0,1.0,Antiretroviral therapy
20895036,208950368,8,F,20100629.0,20220721.0,20220531,20241210,EXP,GB-EMA-DD-20180827-Ashwinihvp-120514,GB-VIIV HEALTHCARE LIMITED-GB2022083878,VIIV,,,,,,Y,,,20241210.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Ultrasound antenatal screen,208950368.0,HO,,,208950368.0,1.0,20090101.0,20100110.0,374.0,DAY,208950368.0,1.0,Antiretroviral therapy
20898424,2089842439,39,F,20180205.0,20221125.0,20220601,20230112,EXP,GB-EMA-DD-20190508-sahu_k-153427,GB-ABBVIE-22K-167-4414502-00,ABBVIE,,43.0,YR,,F,Y,43.0,KG,20230112.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Intentional product use issue;Maternal exposure during pregnancy;Off label use,2089842439.0,CA,,,2089842439.0,1.0,20100610.0,20180205.0,122.0,DAY,2089842439.0,1.0,HIV infection
20899782,208997821,1,I,20201129.0,20220525.0,20220601,20220601,EXP,,CN-GILEAD-2022-0583244,GILEAD,"Qing Z, Fang Z. A case of HIV infection complicated with toxic epidermal necrolysis. Chin J Diffic and Compl Cas. 2022;21:UNK. doi:10.3969 / j. issn.1671-6450.2022.05.019",20.0,YR,A,M,Y,,,20220601.0,,MD,CN,CN,EFAVIRENZ,Toxic epidermal necrolysis,208997821.0,HO,,,208997821.0,1.0,20201023.0,,,,208997821.0,1.0,HIV infection
20900824,209008241,1,I,,20220525.0,20220601,20220601,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084853,VIIV,,,,,,Y,,,20220601.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209008241.0,OT,,,,,,,,,209008241.0,1.0,HIV infection
20900836,209008361,1,I,,20220525.0,20220601,20220601,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084853,GLAXOSMITHKLINE,,,,,,Y,,,20220601.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209008361.0,HO,,,,,,,,,209008361.0,1.0,HIV infection
20907064,209070643,3,F,,20220628.0,20220602,20220705,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172602",BOEHRINGER INGELHEIM,,41.0,YR,A,M,Y,,,20220705.0,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,209070643.0,OT,,,209070643.0,1.0,1995.0,200501.0,73.0,MON,209070643.0,1.0,HIV infection
20907257,209072571,1,I,,20220602.0,20220602,20220602,EXP,,PT-ABBVIE-22K-130-4419333-00,ABBVIE,,56.0,YR,,M,Y,,,20220602.0,,CN,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,209072571.0,OT,,,209072571.0,1.0,1998.0,,,,209072571.0,1.0,HIV infection
20910420,209104206,6,F,,20220629.0,20220603,20220711,EXP,,ES-009507513-2205ESP007868,MERCK,"Puertas MC, Ploumidis G,Ploumidis M, Fumero E, Clotet B, Walworth CM et al.. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report.. The Lancet Microbe. 2020;1(3):e130-5",41.0,YR,,M,Y,,,20220711.0,,HP,ES,ES,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Therapy non-responder;Virologic failure,209104206.0,OT,,,209104206.0,1.0,200812.0,201501.0,,,209104206.0,1.0,HIV infection
20910771,209107716,6,F,,20240330.0,20220603,20240409,EXP,,CA-TEVA-2022-CA-2041639,TEVA,,54.0,YR,,M,Y,,,20240409.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209107716.0,OT,,,,,,,,,209107716.0,1.0,HIV infection
20910829,209108291,1,I,,20220524.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041644,TEVA,,54.0,YR,A,M,Y,,,20220603.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,209108291.0,OT,,,,,,,,,209108291.0,1.0,HIV infection
20911260,209112602,2,F,20220101.0,20220715.0,20220603,20220722,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2022EME086667,VIIV,,,,,,Y,,,20220722.0,,MD,RU,RU,EFAVIRENZ,Rash;Toxic skin eruption,209112602.0,OT,,,209112602.0,1.0,20220323.0,20220407.0,15.0,DAY,209112602.0,1.0,HIV infection
20916488,209164882,2,F,20100629.0,20220623.0,20220605,20220630,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173285",BOEHRINGER INGELHEIM,,43.0,YR,A,F,Y,,,20220630.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,209164882.0,CA,,,209164882.0,1.0,20090101.0,20100610.0,525.0,DAY,209164882.0,1.0,Antiretroviral therapy
20921192,209211921,1,I,,20220525.0,20220606,20220606,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-048190,BRISTOL MYERS SQUIBB,,56.0,YR,A,M,Y,,,20220606.0,,MD,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,209211921.0,OT,,,209211921.0,1.0,2002.0,,,,209211921.0,1.0,HIV infection
20922913,209229134,4,F,,20220713.0,20220607,20220727,EXP,,ES-AUROBINDO-AUR-APL-2022-020446,AUROBINDO,"Puertas MC, Ploumidis G,Ploumidis M, Fumero E, Clotet B, Walworth CM et al... Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report.. The Lancet Microbe. 2020;1(3):e130-e135",41.0,YR,,M,Y,,,20220727.0,,MD,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,209229134.0,OT,,,209229134.0,1.0,200501.0,200501.0,,,209229134.0,1.0,HIV infection
20923706,209237061,1,I,20200101.0,20220601.0,20220607,20220607,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-051945,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,,,20220607.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209237061.0,OT,,,209237061.0,1.0,2013.0,2014.0,1.0,YR,209237061.0,1.0,HIV infection
20927610,209276101,1,I,20200101.0,20220607.0,20220607,20220607,EXP,,PT-ABBVIE-22K-130-4424610-00,ABBVIE,,73.0,YR,,F,Y,,,20220607.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209276101.0,OT,,,209276101.0,1.0,2014.0,2018.0,,,209276101.0,1.0,HIV infection
20929239,209292391,1,I,,20220526.0,20220608,20220608,EXP,,PT-AUROBINDO-AUR-APL-2022-020016,AUROBINDO,,56.0,YR,,M,Y,,,20220608.0,,MD,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,209292391.0,OT,,,209292391.0,1.0,2002.0,,,,209292391.0,1.0,HIV infection
20929340,209293402,2,F,20171006.0,20240715.0,20220608,20240722,EXP,,GB-AUROBINDO-AUR-APL-2022-020239,AUROBINDO,,43.0,YR,,F,Y,,,20240722.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,209293402.0,OT,,,209293402.0,1.0,20171006.0,20180205.0,4.0,MON,209293402.0,1.0,HIV infection
20942966,209429662,2,F,,20221018.0,20220610,20221028,EXP,,CA-TEVA-2022-CA-2043060,TEVA,,52.0,YR,A,M,Y,,,20221028.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,209429662.0,OT,,,,,,,,,209429662.0,1.0,HIV infection
20946959,209469591,1,I,,20220531.0,20220610,20220610,EXP,,CA-ROCHE-3109643,ROCHE,,54.0,YR,,M,Y,,,20220610.0,,HP,CA,,SUSTIVA,Depression;Drug interaction,209469591.0,OT,,,,,,,,,209469591.0,1.0,HIV infection
20949197,209491972,2,F,20200101.0,20220606.0,20220613,20220616,EXP,,PT-JNJFOC-20220621625,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220617.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209491972.0,OT,,,209491972.0,1.0,2018.0,2018.0,,,209491972.0,1.0,HIV infection
20950372,209503721,1,I,,20220606.0,20220613,20220613,EXP,,FR-GILEAD-2022-0584949,GILEAD,"Laparra A, Lerolle N, Gerin M, Cheret A, De CN, Gallien S, Pourcher V, Lanternier F, Bourgarit A, Goujard C. Tumor necrosis factor-alpha inhibitors for extended or severe neurological immune reconstitution inflammatory syndrome in HIV-infected patients. AIDS.. 2021;35:995-997. doi:10.1097/QAD.0000000000002823",37.0,YR,A,M,Y,,,20220613.0,,HP,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome,209503721.0,OT,,,,,,,,,209503721.0,1.0,HIV infection
20951752,209517522,2,F,,20221012.0,20220613,20221014,EXP,,CA-ROCHE-3111593,ROCHE,,52.0,YR,,M,Y,,,20221014.0,,HP,CA,,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,209517522.0,OT,,,,,,,,,209517522.0,1.0,HIV infection
20952372,209523722,2,F,,20220609.0,20220613,20220617,EXP,,DK-MYLANLABS-2022M1043471,MYLAN,"Gulden T, Yahyavi SK, Lodding IP, Jensen J-EB, Blomberg Jensen M. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report.. Bone Reports. 2021;101119",67.0,YR,,M,Y,,,20220617.0,,HP,DK,DK,EFAVIRENZ,Acute kidney injury;Dehydration;Diarrhoea;Gait disturbance;Hypocalcaemia;Myalgia;Nausea;Off label use;Vomiting,209523722.0,HO,,,,,,,,,209523722.0,1.0,HIV infection
20954014,209540141,1,I,20200101.0,20220531.0,20220614,20220614,EXP,,PT-AUROBINDO-AUR-APL-2022-021508,AUROBINDO,,73.0,YR,,F,Y,,,20220614.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209540141.0,OT,,,209540141.0,1.0,2013.0,2014.0,,,209540141.0,1.0,HIV infection
20959265,209592651,1,I,20200101.0,20220608.0,20220614,20220614,EXP,,PT-MYLANLABS-2022M1044308,MYLAN,,73.0,YR,,F,Y,,,20220614.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209592651.0,OT,,,209592651.0,1.0,2013.0,2014.0,,,209592651.0,1.0,HIV infection
20965915,209659152,2,F,,20220620.0,20220616,20220702,EXP,,DK-AUROBINDO-AUR-APL-2022-019522,AUROBINDO,"Gulden T, Yahyavi SK, Lodding IP, Jensen JB, Blomberg Jensen M.. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report. Bone Reports. 2021;15:101119",67.0,YR,,M,Y,,,20220702.0,,HP,DK,DK,EFAVIRENZ,Dehydration;Diarrhoea;Hypocalcaemia;Myalgia;Nausea;Off label use;Vomiting,209659152.0,HO,,,,,,,,,209659152.0,1.0,HIV infection
20966859,2096685928,28,F,20100629.0,20230605.0,20220616,20230615,EXP,GB-AUROBINDO-AUR-APL-2018-033634,GB-STRIDES ARCOLAB LIMITED-2018SP005378,STRIDES,,43.0,YR,,F,Y,43.0,KG,20230615.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Drug abuse;Hepatic cytolysis;Hydrops foetalis;Intentional product misuse;Intentional product use issue;Maternal exposure during pregnancy;Off label use,2096685928.0,CA,,,2096685928.0,1.0,20100610.0,20180205.0,4.0,MON,2096685928.0,1.0,HIV infection
20966864,209668642,2,F,,20220609.0,20220616,20230113,EXP,,DK-STRIDES ARCOLAB LIMITED-2022SP007262,STRIDES,"Gulden T, Yahyavi SK, Lodding IP, Jensen J-EB, Blomberg Jensen M.. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report.. Bone-Rep.. 2021",67.0,YR,,M,Y,,,20230109.0,,HP,DK,DK,EFAVIRENZ,Acute kidney injury;Dehydration;Diarrhoea;Gait disturbance;Hypocalcaemia;Myalgia;Nausea;Vomiting,209668642.0,HO,,,,,,,,,209668642.0,1.0,HIV infection
20972674,209726741,1,I,20101201.0,20220602.0,20220617,20220617,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-052226,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20220617.0,,MD,PT,PT,EFAVIRENZ,Drug ineffective;Maternal exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,209726741.0,OT,,,209726741.0,1.0,200905.0,201012.0,19.0,MON,209726741.0,1.0,HIV infection
20975946,209759461,1,I,,20220608.0,20220617,20220617,EXP,,FR-SAMSUNG BIOEPIS-SB-2022-14242,SAMSUNG BIOEPIS,"Laparra A, Lerolle N, Gerin M, Cheret A, Castro N, Gallien S, Pourcher V, Lanternie F, Bourgarit A, Goujard C. Tumor necrosis factor-alpha inhibitors for extended or severe neurological immune reconstitution inflammatory syndrome in HIV-infected patients. AIDS. 2021;35(6):995-1001. doi:10.1097/QAD.0000000000002823",37.0,YR,A,M,Y,,,20220617.0,,HP,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Off label use,209759461.0,OT,,,209759461.0,1.0,,,16.0,DAY,209759461.0,1.0,Immune reconstitution inflammatory syndrome associated tuberculosis
20986261,209862611,1,I,,20220608.0,20220621,20220621,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-2022-055712,BRISTOL MYERS SQUIBB,Acquired immunodeficiency syndrome-related acute longitudinal myelitis involving the entire spinal cord. Neurological Sciences. 2022; 43: 4045-48. 10.1007/s10072-022-06034-7,45.0,YR,A,M,Y,,,20220621.0,,HP,CN,CN,EFAVIRENZ,Drug eruption;Hepatic function abnormal,209862611.0,HO,,,209862611.0,1.0,,2022.0,,,209862611.0,1.0,Acquired immunodeficiency syndrome
20994170,209941705,5,F,,20220718.0,20220622,20220721,EXP,,ES-MYLANLABS-2022M1045944,MYLAN,"Puertas MC, Ploumidis G,Ploumidis M, Fumero E, Clotet B, Walworth CM et al.. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report.. The Lancet Microbe.. 2020;1(3):e130-e135",41.0,YR,,M,Y,,,20220721.0,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,209941705.0,OT,,,209941705.0,2.0,200501.0,200501.0,,,209941705.0,1.0,HIV infection
20999389,209993891,1,I,,20220617.0,20220623,20220623,EXP,,JP-GLAXOSMITHKLINE-JP2022JPN094266,GLAXOSMITHKLINE,,,,,,Y,,,20220623.0,,MD,JP,JP,EFAVIRENZ,Anaemia;Diarrhoea;Malaise;Off label use;Palpitations;Pathogen resistance;Prescribed underdose;Product use issue;Renal cancer;Virologic failure,209993891.0,OT,,,,,,,,,209993891.0,1.0,HIV infection
20999390,209993901,1,I,,20220617.0,20220623,20220623,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022JPN094266,VIIV,,,,,,Y,,,20220623.0,,MD,JP,JP,EFAVIRENZ,Anaemia;Diarrhoea;Malaise;Off label use;Palpitations;Pathogen resistance;Prescribed underdose;Product use issue;Renal cancer;Virologic failure,209993901.0,OT,,,,,,,,,209993901.0,1.0,HIV infection
21000351,210003511,1,I,,20220616.0,20220623,20220623,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2022GSK093790,VIIV,"John MT, Venter M, Vaughan J, Black M, Prince D, Luke AM et al. Multiple opportunistic infections (pulmonary tuberculosis, Mycobacterium avium complex and parvovirus B19) in a single patient. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20220623.0,,HP,ZA,ZA,EFAVIRENZ,Drug resistance;Pathogen resistance,210003511.0,OT,,,210003511.0,1.0,2019.0,2020.0,3.0,DAY,210003511.0,1.0,HIV infection
21000353,210003531,1,I,,20220616.0,20220623,20220623,EXP,,ZA-GLAXOSMITHKLINE-ZA2022GSK093790,GLAXOSMITHKLINE,"John MT, Venter M, Vaughan J, Black M, Prince D, Luke AM et al. Multiple opportunistic infections (pulmonary tuberculosis, Mycobacterium avium complex and parvovirus B19) in a single patient. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20220623.0,,HP,ZA,ZA,EFAVIRENZ,Drug resistance;Pathogen resistance,210003531.0,OT,,,210003531.0,1.0,2019.0,2020.0,3.0,DAY,210003531.0,1.0,HIV infection
21004856,210048561,1,I,,20220621.0,20220624,20220624,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK096493,VIIV,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Current Drug Safety. 2022;17 (1):40-46",,,,,Y,,,20220624.0,,MD,IN,IN,EFAVIRENZ,Death;SJS-TEN overlap,210048561.0,DE,,,210048561.0,1.0,,,30.0,DAY,210048561.0,1.0,Acquired immunodeficiency syndrome
21004858,210048581,1,I,,20220621.0,20220624,20220624,EXP,,IN-GLAXOSMITHKLINE-IN2022GSK096493,GLAXOSMITHKLINE,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Current Drug Safety. 2022;17 (1):40-46",,,,,Y,,,20220624.0,,MD,IN,IN,EFAVIRENZ,Death;SJS-TEN overlap,210048581.0,DE,,,210048581.0,1.0,,,30.0,DAY,210048581.0,1.0,Acquired immunodeficiency syndrome
21020997,210209971,1,I,20120101.0,20220617.0,20220629,20220629,EXP,,GB-AUROBINDO-AUR-APL-2022-023415,AUROBINDO,,59.0,YR,,F,Y,,,20220629.0,,CN,GB,GB,EFAVIRENZ,Arthritis;Knee operation,210209971.0,OT,,,,,,,,,210209971.0,1.0,HIV infection
21021504,2102150428,28,F,20100629.0,20230109.0,20220629,20230118,EXP,,GB-HORMOSAN PHARMA GMBH-2022-08992,LUPIN,,16.0,WK,,M,Y,,,20230118.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,2102150428.0,DE,,,2102150428.0,1.0,20171006.0,20180205.0,4.0,MON,2102150428.0,1.0,HIV infection
21023783,210237831,1,I,,20220622.0,20220629,20220629,EXP,,NA-VIIV HEALTHCARE LIMITED-NA2022GSK097227,VIIV,"Kakubu MAM, Bikinesi T, Liswaniso ES, Katoto P DMC. A case of undisclosed prior exposure to antiretroviral therapy (ART) and early virologic failure that improved on a pre-emptive third-line ART regimen. GERMS. 2022;12 (1):102-106",,,,,Y,,,20220629.0,,MD,,,EFAVIRENZ,Drug resistance;Immunosuppression;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure;Weight decreased,210237831.0,OT,,,210237831.0,1.0,201903.0,,,,210237831.0,1.0,HIV infection WHO clinical stage I
21023785,210237851,1,I,,20220622.0,20220629,20220629,EXP,,NA-GLAXOSMITHKLINE-NA2022GSK097227,GLAXOSMITHKLINE,"Kakubu MAM, Bikinesi T, Liswaniso ES, Katoto P DMC. A case of undisclosed prior exposure to antiretroviral therapy (ART) and early virologic failure that improved on a pre-emptive third-line ART regimen. GERMS. 2022;12 (1):102-106",,,,,Y,,,20220629.0,,MD,,,EFAVIRENZ,Drug resistance;Immunosuppression;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure;Weight decreased,210237851.0,OT,,,210237851.0,1.0,201903.0,,,,210237851.0,1.0,HIV infection WHO clinical stage I
21032324,210323241,1,I,20090618.0,20220623.0,20220701,20220701,EXP,,FR-ROCHE-2233267,ROCHE,"Reporter known company, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design.. 2018;:-.",47.0,YR,,M,Y,,,20220701.0,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,210323241.0,OT,,,,,,,,,210323241.0,1.0,HIV infection
21033786,210337861,1,I,20010101.0,20220624.0,20220701,20220701,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME097938,VIIV,,,,,,Y,,,20220701.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210337861.0,OT,,,210337861.0,1.0,2018.0,202107.0,,,210337861.0,1.0,HIV infection
21033830,210338301,1,I,20010101.0,20220624.0,20220701,20220701,EXP,,PT-GLAXOSMITHKLINE-PT2022EME097938,GLAXOSMITHKLINE,,,,,,Y,,,20220701.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210338301.0,HO,,,210338301.0,1.0,2018.0,202107.0,,,210338301.0,1.0,HIV infection
21036366,210363662,2,F,20120101.0,20220617.0,20220702,20220702,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2022036261,MACLEODS,,,,,,Y,,,20220702.0,,CN,GB,GB,EFAVIRENZ,Arthritis;Knee operation,210363662.0,OT,,,,,,,,,210363662.0,1.0,HIV infection
21039057,2103905714,14,F,20100629.0,20240119.0,20220704,20240125,EXP,,GB-CIPLA LTD.-2022GB04083,CIPLA,,,,,,Y,,,20240125.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,2103905714.0,CA,,,2103905714.0,1.0,20171006.0,20180205.0,4.0,MON,2103905714.0,1.0,HIV infection
21047238,210472381,1,I,,20220627.0,20220706,20220706,EXP,,FR-MYLANLABS-2022M1050473,MYLAN,"Joharjy H, Pisella PJ, Audo I, Le-Lez ML. A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation. Medicina-Kaunas 2022;58(6):1-8.",42.0,YR,,F,Y,51.0,KG,20220706.0,,HP,FR,FR,EFAVIRENZ,Retinopathy,210472381.0,OT,,,210472381.0,1.0,2004.0,2011.0,,,210472381.0,1.0,HIV infection
21047694,210476941,1,I,,20220701.0,20220706,20220706,EXP,,DE-GLAXOSMITHKLINE-DE2021EME035635,GLAXOSMITHKLINE,,,,,,Y,,,20220706.0,,MD,DE,DE,EFAVIRENZ,Drug resistance,210476941.0,OT,,,,,,,,,210476941.0,1.0,HIV infection
21047773,210477731,1,I,,20220701.0,20220706,20220706,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2021EME035635,VIIV,,,,,,Y,,,20220706.0,,MD,DE,DE,EFAVIRENZ,Drug resistance,210477731.0,OT,,,,,,,,,210477731.0,1.0,HIV infection
21054689,210546892,2,F,20050801.0,20230410.0,20220707,20230417,EXP,,PT-MYLANLABS-2022M1050688,MYLAN,,54.0,YR,,M,Y,,,20230417.0,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,210546892.0,OT,,,210546892.0,1.0,200607.0,200504.0,,,210546892.0,1.0,HIV infection
21061351,210613511,1,I,,20220630.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2052424,TEVA,,54.0,YR,A,M,Y,,,20220709.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,210613511.0,DE,,,,,,,,,210613511.0,1.0,HIV infection
21071580,210715801,1,I,,20220629.0,20220712,20220712,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2022-066770,BRISTOL MYERS SQUIBB,"Joharjy H, Pisella P, Audo I, Le-Lez M. A rare case of didanosine-induced mid-peripheral chorioretinal atrophy identified incidentally 11 Years after the drug cessation. Medicina. 2022; 1-8. 10.3390/medicina58060735",42.0,YR,A,F,Y,51.0,KG,20220712.0,,HP,FR,FR,EFAVIRENZ,Retinal degeneration,210715801.0,OT,,,210715801.0,3.0,201112.0,202110.0,118.0,MON,210715801.0,1.0,HIV infection
21073285,210732851,1,I,20050801.0,20220704.0,20220712,20220712,EXP,,PT-JNJFOC-20220708498,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220713.0,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,210732851.0,OT,,,210732851.0,2.0,200209.0,200504.0,,,210732851.0,1.0,HIV infection
21073704,210737041,1,I,,20220705.0,20220713,20220713,EXP,,FR-CELLTRION INC.-2022FR010788,CELLTRION,"Laparra A, Lerolle N, Gerin M, Cheret A, Castro N, Gallien S, et al.. Tumor necrosis factor-alpha inhibitors for extended or severe neurological immune reconstitution inflammatory syndrome in HIV-infected patients. AIDS. 2021;35(6):995-1001",,,,,Y,,,20220713.0,,HP,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Off label use,210737041.0,OT,,,210737041.0,2.0,,,16.0,DAY,210737041.0,1.0,Immune reconstitution inflammatory syndrome associated tuberculosis
21080303,210803033,3,F,20050801.0,20230404.0,20220714,20230415,EXP,,PT-AUROBINDO-AUR-APL-2022-025665,AUROBINDO,,54.0,YR,,M,Y,,,20230415.0,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,210803033.0,OT,,,210803033.0,2.0,200209.0,,,,210803033.0,1.0,HIV infection
21081693,210816931,1,I,20010101.0,20220711.0,20220714,20220714,EXP,,PT-MYLANLABS-2022M1077749,MYLAN,,46.0,YR,,M,Y,,,20220714.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210816931.0,HO,,,210816931.0,1.0,2012.0,2018.0,,,210816931.0,1.0,HIV infection
21081813,210818131,1,I,20220101.0,20220707.0,20220714,20220714,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2022AMR104745,VIIV,,,,,,Y,,,20220714.0,,MD,CO,CO,EFAVIRENZ,Hypertension;Myocardial infarction,210818131.0,OT,,,210818131.0,1.0,20220502.0,2022.0,,,210818131.0,1.0,HIV infection
21086868,210868681,1,I,,20220708.0,20220715,20220715,EXP,,DE-ABBVIE-21K-062-3784915-00,ABBVIE,,57.0,YR,,M,Y,,,20220715.0,,CN,DE,DE,EFAVIRENZ,Drug resistance,210868681.0,OT,,,,,,,,,210868681.0,1.0,HIV infection
21086894,210868941,1,I,,20220630.0,20220715,20220715,EXP,,DE-MACLEODS PHARMACEUTICALS US LTD-MAC2022036410,MACLEODS,,,,,,Y,,,20220714.0,,MD,DE,DE,EFAVIRENZ,Drug resistance,210868941.0,OT,,,,,,,,,210868941.0,1.0,HIV infection
21092489,210924891,1,I,20010101.0,20220706.0,20220718,20220718,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-069835,BRISTOL MYERS SQUIBB,,46.0,YR,A,M,Y,,,20220718.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210924891.0,HO,,,210924891.0,1.0,2012.0,2018.0,6.0,YR,210924891.0,1.0,HIV infection
21112325,211123251,1,I,20220720.0,,20220721,20220721,DIR,623970,,FDA-CTU,,50.0,YR,,M,N,,,20220721.0,N,PH,US,,EFAVIRENZ,Hospitalisation,211123251.0,HO,211123251.0,HP,211123251.0,1.0,20181113.0,,,,211123251.0,1.0,HIV infection
21138033,211380331,1,I,,20220720.0,20220727,20220727,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022AMR109217,VIIV,,,,,,Y,,,20220727.0,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,211380331.0,OT,,,211380331.0,1.0,2020.0,,,,211380331.0,1.0,HIV infection
21138061,211380611,1,I,,20220720.0,20220727,20220727,EXP,,CA-GSK-CA2022AMR109217,GLAXOSMITHKLINE,,,,,,Y,,,20220727.0,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,211380611.0,OT,,,211380611.0,1.0,2020.0,,,,211380611.0,1.0,HIV infection
21141067,211410672,2,F,20060701.0,20220725.0,20220728,20230323,EXP,,PT-GILEAD-2022-0591091,GILEAD,,54.0,YR,A,M,Y,,,20230322.0,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211410672.0,OT,,,211410672.0,1.0,200607.0,200504.0,,,211410672.0,1.0,HIV infection
21142753,211427531,1,I,,20220509.0,20220728,20220728,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2022-041051,BRISTOL MYERS SQUIBB,"Mangal V, Murari T, Someshwar , Gaikwad N, Kaur K. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - a case report. Indian Journal of Nephrology. 2022 Mar 11; 32(2): 175-8. 10.4103/ijn.IJN_456_20",54.0,YR,A,F,Y,,,20220728.0,,MD,IN,IN,EFAVIRENZ,Hydronephrosis;Nephrolithiasis,211427531.0,OT,,,,,,,,,211427531.0,1.0,Antiretroviral therapy
21145130,211451301,1,I,,20220719.0,20220729,20220729,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-081043,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20220729.0,,CN,CA,CA,SUSTIVA,Death,211451301.0,DE,,,,,,,,,211451301.0,1.0,HIV infection
21158239,211582392,2,F,20060701.0,20220725.0,20220801,20230327,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022112005,VIIV,,,,,,Y,,,20230327.0,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211582392.0,OT,,,211582392.0,1.0,200607.0,200504.0,,,211582392.0,1.0,HIV infection
21158241,211582412,2,F,20060701.0,20220725.0,20220801,20230327,EXP,,PT-GSK-PT2022112005,GLAXOSMITHKLINE,,,,,,Y,,,20230327.0,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211582412.0,OT,,,211582412.0,1.0,200607.0,200504.0,,,211582412.0,1.0,HIV infection
21161923,211619231,1,I,,20220719.0,20220802,20220802,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-083119,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20220802.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Death,211619231.0,DE,,,,,,,,,211619231.0,1.0,HIV infection
21167110,211671101,1,I,20200801.0,20220727.0,20220803,20220803,EXP,,DK-GSK-DK2022GSK113937,GLAXOSMITHKLINE,"Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports. 2022;14(4):501-504",,,,,Y,,,20220803.0,,HP,DK,DK,EFAVIRENZ,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,211671101.0,OT,,,,,,,,,211671101.0,1.0,HIV infection
21167111,211671111,1,I,20200801.0,20220727.0,20220803,20220803,EXP,,DK-VIIV HEALTHCARE LIMITED-DK2022GSK113937,VIIV,"Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports. 2022;14(4):501-504",,,,,Y,,,20220803.0,,HP,DK,DK,EFAVIRENZ,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,211671111.0,OT,,,,,,,,,211671111.0,1.0,HIV infection
21177192,211771921,1,I,20050801.0,20220728.0,20220805,20220805,EXP,,PT-TEVA-2022-PT-2061184,TEVA,,54.0,YR,A,M,Y,,,20220805.0,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211771921.0,OT,,,211771921.0,2.0,200607.0,200504.0,2.0,YR,211771921.0,1.0,HIV infection
21193496,211934962,2,F,,20220816.0,20220810,20220829,EXP,,UG-AUROBINDO-AUR-APL-2022-031724,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica... 2020;109:2706-16",10.0,YR,,,Y,,,20220829.0,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,211934962.0,OT,,,,,,,,,211934962.0,1.0,HIV infection
21193504,211935041,1,I,,20220803.0,20220810,20220810,EXP,,UG-AUROBINDO-AUR-APL-2022-031762,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al.. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",3.0,YR,,,Y,,,20220810.0,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,211935041.0,OT,,,,,,,,,211935041.0,1.0,HIV infection
21199407,211994071,1,I,,20220803.0,20220811,20220811,EXP,,UG-AUROBINDO-AUR-APL-2022-031750,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",9.0,YR,,,Y,,,20220811.0,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,211994071.0,OT,,,,,,,,,211994071.0,1.0,HIV infection
21211499,212114991,1,I,,20220803.0,20220815,20220815,EXP,,UG-MYLANLABS-2022M1086623,MYLAN,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",9.0,YR,,M,Y,,,20220815.0,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212114991.0,OT,,,,,,,,,212114991.0,1.0,HIV infection
21213971,212139711,1,I,,20220803.0,20220816,20220816,EXP,,UG-AUROBINDO-AUR-APL-2022-031760,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica.. 2020;109:2706-16",3.0,YR,,,Y,,,20220816.0,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212139711.0,OT,,,,,,,,,212139711.0,1.0,HIV infection
21213977,212139771,1,I,,20220803.0,20220816,20220816,EXP,,UG-AUROBINDO-AUR-APL-2022-031765,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica... 2020;109:2706-16",3.0,YR,,,Y,,,20220816.0,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212139771.0,OT,,,,,,,,,212139771.0,1.0,HIV infection
21213995,212139952,2,F,,20230506.0,20220816,20230515,EXP,,SE-AUROBINDO-AUR-APL-2022-031768,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706?2716",9.0,YR,,,Y,,,20230515.0,,HP,SE,UG,EFAVIRENZ,Pathogen resistance,212139952.0,OT,,,,,,,,,212139952.0,1.0,HIV infection
21214005,212140053,3,F,,20230506.0,20220816,20230515,EXP,,UG-AUROBINDO-AUR-APL-2022-031771,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica.. Acta Paediatrica.. 2020;109:2706-2716",5.0,YR,,,Y,,,20230515.0,,HP,SE,UG,EFAVIRENZ,Pathogen resistance,212140053.0,OT,,,,,,,,,212140053.0,1.0,HIV infection
21214633,212146331,1,I,,20220803.0,20220816,20220816,EXP,,SE-AUROBINDO-AUR-APL-2022-031763,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica.. 2020;109:2706-16.",5.0,YR,,,Y,,,20220816.0,,HP,SE,UG,EFAVIRENZ,Pathogen resistance,212146331.0,OT,,,,,,,,,212146331.0,1.0,HIV infection
21214650,212146501,1,I,,20220803.0,20220816,20220816,EXP,,SE-AUROBINDO-AUR-APL-2022-031769,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al.. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",4.0,YR,,,Y,,,20220816.0,,HP,SE,UG,EFAVIRENZ,Pathogen resistance,212146501.0,OT,,,,,,,,,212146501.0,1.0,HIV infection
21214670,212146701,1,I,,20220803.0,20220816,20220816,EXP,,UG-AUROBINDO-AUR-APL-2022-031767,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al.. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica. 2020;109:2706-16",7.0,YR,,,Y,,,20220816.0,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212146701.0,OT,,,,,,,,,212146701.0,1.0,HIV infection
21217161,212171612,2,F,20050101.0,20221108.0,20220816,20221116,EXP,,US-GILEAD-2022-0593520,GILEAD,,,,A,M,Y,154.0,KG,20221116.0,,CN,US,US,SUSTIVA,Anxiety;Arm amputation;Bone deformity;Bone disorder;Dental caries;Depression;Dysgraphia;Emotional distress;Feelings of worthlessness;Gait disturbance;Immobile;Impaired work ability;Kyphosis;Monoparesis;Multiple fractures;Osteogenesis imperfecta;Osteomyelitis;Pain;Paralysis;Scoliosis;Spinal cord infection;Spinal osteoarthritis;Tooth loss;Wheelchair user,212171612.0,OT,,,212171612.0,1.0,2004.0,20140407.0,,,212171612.0,1.0,HIV infection
21217772,212177722,2,F,,20220823.0,20220816,20220901,EXP,,ES-TEVA-2022-ES-2064395,TEVA,,,,,M,Y,,,20220901.0,,HP,ES,ES,EFAVIRENZ,Cushing's syndrome;Drug ineffective;Drug interaction;Tertiary adrenal insufficiency,212177722.0,OT,,,212177722.0,11.0,,,5.0,YR,212177722.0,1.0,HIV infection
21220297,212202978,8,F,20100629.0,20221125.0,20220817,20221210,EXP,,GB-AUROBINDO-AUR-APL-2018-044992,AUROBINDO,,43.0,YR,,F,Y,,,20221210.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,212202978.0,OT,,,212202978.0,1.0,20171006.0,20180205.0,4.0,MON,212202978.0,1.0,HIV infection
21220860,212208604,4,F,20200801.0,20230202.0,20220817,20230210,EXP,,DK-AUROBINDO-AUR-APL-2022-032254,AUROBINDO,"Mens H, Fjordside L, Fonager J, Gerstoft J.. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports.. 2022;14(4):501-504.",50.0,YR,,M,Y,,,20230210.0,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,212208604.0,OT,,,,,,,,,212208604.0,1.0,HIV infection
21227585,212275851,1,I,,20220815.0,20220818,20220818,EXP,,IN-GILEAD-2022-0594043,GILEAD,"Yadav R, Chopra K, Jaiswal N. Study of impact of WHO option B+ on maternal and perinatal outcome in HIV-positive women delivering at a tertiary care hospital, Delhi. Indian J Sex Transm Dis AIDS.. 2022;43(1):90-91. doi:10.4103/ijstd.ijstd_24_21",,,A,F,Y,,,20220818.0,,HP,IN,IN,EFAVIRENZ,Ectopic pregnancy;Maternal exposure during pregnancy,212275851.0,OT,,,,,,,,,212275851.0,1.0,HIV infection
21227749,212277491,1,I,,20220815.0,20220818,20220818,EXP,,IN-GILEAD-2022-0593738,GILEAD,"Yadav R, Chopra K, Jaiswal N. Study of impact of WHO option B+ on maternal and perinatal outcome in HIV-positive women delivering at a tertiary care hospital, Delhi. Indian J Sex Transm Dis AIDS.. 2022;43(1):90-91. doi:10.4103/ijstd.ijstd_24_21",,,A,F,Y,,,20220818.0,,HP,IN,IN,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,212277491.0,OT,,,,,,,,,212277491.0,1.0,HIV infection
21229955,212299551,1,I,,20220812.0,20220818,20220818,EXP,,IN-GSK-IN2022GSK118227,GLAXOSMITHKLINE,,,,,,Y,,,20220818.0,,MD,IN,IN,EFAVIRENZ,Apoptosis;Drug eruption;Erythema;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Lymphadenopathy;Lymphocytic infiltration;Non-scarring alopecia;Parakeratosis;Rash;Secondary syphilis;Skin exfoliation;Skin hyperpigmentation;Skin lesion;Skin plaque,212299551.0,OT,,,,,,,,,212299551.0,1.0,HIV infection
21229958,212299581,1,I,,20220812.0,20220818,20220818,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK118227,VIIV,,,,,,Y,,,20220818.0,,MD,IN,IN,EFAVIRENZ,Apoptosis;Drug eruption;Erythema;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Lymphadenopathy;Lymphocytic infiltration;Non-scarring alopecia;Parakeratosis;Rash;Secondary syphilis;Skin exfoliation;Skin hyperpigmentation;Skin lesion;Skin plaque,212299581.0,OT,,,,,,,,,212299581.0,1.0,HIV infection
21233347,212333471,1,I,20170530.0,20220817.0,20220819,20220819,EXP,,ZA-GILEAD-2022-0594267,GILEAD,,30.0,YR,A,F,Y,,,20220819.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,212333471.0,OT,,,212333471.0,1.0,20170224.0,,,,212333471.0,1.0,HIV infection
21234412,212344121,1,I,,20220812.0,20220820,20220820,EXP,,IT-STRIDES ARCOLAB LIMITED-2022SP010540,STRIDES,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633",71.0,YR,,M,Y,,,20220820.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212344121.0,OT,,,,,,,,,212344121.0,1.0,HIV infection
21236182,212361821,1,I,,20220809.0,20220822,20220822,EXP,,CA-AUROBINDO-AUR-APL-2022-033204,AUROBINDO,,54.0,YR,,M,Y,,,20220822.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212361821.0,OT,,,,,,,,,212361821.0,1.0,HIV infection
21236359,212363592,2,F,,20230417.0,20220822,20230430,EXP,,CA-AUROBINDO-AUR-APL-2022-033209,AUROBINDO,,54.0,YR,,M,Y,,,20230429.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212363592.0,HO,,,,,,,,,212363592.0,1.0,HIV infection
21238262,212382622,2,F,,20230124.0,20220822,20230202,EXP,,IT-MYLANLABS-2022M1087630,MYLAN,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract 2021;11(5):E627-E633.",71.0,YR,,M,Y,,,20230202.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212382622.0,OT,,,,,,,,,212382622.0,1.0,HIV infection
21239988,212399881,1,I,20170822.0,20220816.0,20220822,20220822,EXP,,ZA-MYLANLABS-2022M1087832,MYLAN,,30.0,YR,,F,Y,,,20220822.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous,212399881.0,OT,,,212399881.0,1.0,20170224.0,,,,212399881.0,1.0,HIV infection
21242990,212429901,1,I,,20220817.0,20220823,20220823,EXP,,IN-MYLANLABS-2022M1088396,MYLAN,"Pangti R, Gupta S, Bhari N, Dhawan B, Gupta S. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus-positive patient. India-J-Sex-Transm-Dis 2022;43(1):86-87.",32.0,YR,,M,Y,,,20220823.0,,MD,IN,IN,EFAVIRENZ,Genital herpes;Herpes simplex;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Paradoxical drug reaction;Syphilis,212429901.0,OT,,,,,,,,,212429901.0,1.0,HIV infection
21244489,212444891,1,I,,20220817.0,20220823,20220823,EXP,,CN-GSK-CN2022GSK119896,GLAXOSMITHKLINE,,,,,,Y,,,20220823.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance,212444891.0,OT,,,212444891.0,1.0,20190629.0,,,,212444891.0,1.0,HIV infection
21244491,212444911,1,I,,20220817.0,20220823,20220823,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK119896,VIIV,,,,,,Y,,,20220823.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance,212444911.0,OT,,,212444911.0,1.0,20190629.0,,,,212444911.0,1.0,HIV infection
21258149,212581491,1,I,,20220815.0,20220826,20220826,EXP,,IN-CIPLA LTD.-2022IN05113,CIPLA,"Pangti R, Gupta S, Gupta S, Bhari N, Dhawan B.. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus-positive patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43:86 to 87",32.0,YR,,M,Y,,,20220826.0,,HP,IN,IN,EFAVIRENZ,Genital herpes;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Secondary syphilis,212581491.0,OT,,,,,,,,,212581491.0,1.0,HIV infection
21259121,212591211,1,I,,20220815.0,20220826,20220826,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022123308,VIIV,,,,,,Y,,,20220826.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,212591211.0,OT,,,,,,,,,212591211.0,1.0,HIV infection
21259140,212591401,1,I,,20220815.0,20220826,20220826,EXP,,CN-GSK-CN2022123308,GLAXOSMITHKLINE,,,,,,Y,,,20220826.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,212591401.0,OT,,,,,,,,,212591401.0,1.0,HIV infection
21260524,212605241,1,I,,20220328.0,20220826,20220826,EXP,,AL-GSK-AL2022GSK122512,GLAXOSMITHKLINE,"Muco E, Karruli A, Hoxha N, Hoxhaj A, Kokici M. Visceral Leishmaniasis and Herpes Zoster as a Component of Syndrome of Immune Reconstitution Inflammatory Syndrome in an HIV-Positive Patient. Case reports in infectious diseases. 2022;2022",,,,,Y,,,20220826.0,,HP,AL,AL,EFAVIRENZ,Abdominal distension;Blister;Fatigue;Hepatomegaly;Hepatosplenomegaly;Herpes zoster;Hyperhidrosis;Immune reconstitution inflammatory syndrome;Lethargy;Lymphadenopathy;Pancytopenia;Pustule;Pyrexia;Rash maculo-papular;Scab;Skin lesion;Splenomegaly;Visceral leishmaniasis;Weight decreased,212605241.0,OT,,,,,,,,,212605241.0,1.0,HIV infection CDC category C
21260528,212605281,1,I,,20220328.0,20220826,20220826,EXP,,AL-VIIV HEALTHCARE LIMITED-AL2022GSK122512,VIIV,"Muco E, Karruli A, Hoxha N, Hoxhaj A, Kokici M. Visceral Leishmaniasis and Herpes Zoster as a Component of Syndrome of Immune Reconstitution Inflammatory Syndrome in an HIV-Positive Patient. Case reports in infectious diseases. 2022;2022",,,,,Y,,,20220826.0,,HP,AL,AL,EFAVIRENZ,Abdominal distension;Blister;Fatigue;Hepatomegaly;Hepatosplenomegaly;Herpes zoster;Hyperhidrosis;Immune reconstitution inflammatory syndrome;Lethargy;Lymphadenopathy;Pancytopenia;Pustule;Pyrexia;Rash maculo-papular;Scab;Skin lesion;Splenomegaly;Visceral leishmaniasis;Weight decreased,212605281.0,OT,,,,,,,,,212605281.0,1.0,HIV infection CDC category C
21264010,212640101,1,I,,20220819.0,20220829,20220829,EXP,,FR-AUROBINDO-AUR-APL-2022-033883,AUROBINDO,,,,A,M,Y,,,20220829.0,,MD,FR,FR,SUSTIVA,Virologic failure,212640101.0,OT,,,212640101.0,1.0,20060615.0,20090615.0,3.0,YR,212640101.0,1.0,HIV infection
21264035,212640351,1,I,,20220819.0,20220829,20220829,EXP,,ES-AUROBINDO-AUR-APL-2022-033954,AUROBINDO,"Gomez AS, Garcia MJA, Maria Rafael Saponi Cortes J, Ruiz CM.. Cushing^s syndrome secondary to inhaled fluticasone.. Endocrinol-Diabetes-Nutr. 2022;69(6):442-444",,,,M,Y,,,20220829.0,,HP,ES,ES,EFAVIRENZ,Cushing's syndrome;Drug ineffective;Drug interaction;Tertiary adrenal insufficiency,212640351.0,OT,,,212640351.0,14.0,,,5.0,YR,212640351.0,1.0,HIV infection
21264121,212641211,1,I,20170822.0,20220816.0,20220829,20220829,EXP,,ZA-AUROBINDO-AUR-APL-2022-033761,AUROBINDO,,30.0,YR,,F,Y,,,20220829.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,212641211.0,OT,,,212641211.0,1.0,20170224.0,,,,212641211.0,1.0,HIV infection
21264327,212643271,1,I,,20220817.0,20220829,20220829,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2022-092170,BRISTOL MYERS SQUIBB,"Gupta S, Gupta S, Bhari N, Dhawan B, Pangti R. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus-positive patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022; 43(1): 86-7. 10.4103/ijstd.ijstd_110_20",32.0,YR,A,M,Y,,,20220829.0,,HP,IN,IN,EFAVIRENZ,Genital herpes;Lichenoid keratosis;Secondary syphilis,212643271.0,OT,,,,,,,,,212643271.0,1.0,HIV test positive
21264423,212644231,1,I,20170822.0,20220816.0,20220829,20220829,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-093269,BRISTOL MYERS SQUIBB,,30.0,YR,A,F,Y,,,20220829.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Prescribed overdose,212644231.0,OT,,,212644231.0,1.0,20170224.0,,,,212644231.0,1.0,HIV infection
21265092,212650922,2,F,20170822.0,20230804.0,20220829,20230818,EXP,,ZA-CIPLA LTD.-2022ZA05102,CIPLA,,,,,,Y,,,20230818.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,212650922.0,OT,,,212650922.0,1.0,20170224.0,,,,212650922.0,1.0,HIV infection
21265636,212656361,1,I,,20220823.0,20220829,20220829,EXP,,NA-MYLANLABS-2022M1089621,MYLAN,"Kakubu MAM, Kalonji M, Katoto PDMC. A Case Report of Multiclass HIV Drug-Resistance After an Inappropriate Switch of ARVs with Persistent Unsuppressed Viral Load. J-Int-Assoc-Provid-AIDS-Care 2022;null:null.",48.0,YR,,F,Y,,,20220829.0,,MD,,,EFAVIRENZ,Drug resistance,212656361.0,OT,,,212656361.0,1.0,200906.0,201404.0,,,212656361.0,1.0,HIV test positive
21266482,212664821,1,I,,20220817.0,20220829,20220829,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022036934,MACLEODS,,,,,,Y,,,20220829.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,212664821.0,OT,,,212664821.0,1.0,20170224.0,,,,212664821.0,1.0,HIV infection
21280548,212805482,2,F,,20230818.0,20220901,20230828,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK125136,VIIV,,,,,,Y,,,20230828.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,212805482.0,OT,,,,,,,,,212805482.0,1.0,HIV infection
21280549,212805491,1,I,,20220825.0,20220901,20220901,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK125134,VIIV,,,,,,Y,,,20220901.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212805491.0,OT,,,,,,,,,212805491.0,1.0,HIV infection
21280558,212805582,2,F,,20230818.0,20220901,20230828,EXP,,CA-GSK-CA2022GSK125136,GLAXOSMITHKLINE,,,,,,Y,,,20230828.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,212805582.0,DE,,,,,,,,,212805582.0,1.0,HIV infection
21280563,212805631,1,I,,20220825.0,20220901,20220901,EXP,,CA-GSK-CA2022GSK125134,GLAXOSMITHKLINE,,,,,,Y,,,20220901.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212805631.0,OT,,,,,,,,,212805631.0,1.0,HIV infection
21281891,212818911,1,I,,20220822.0,20220901,20220901,EXP,,IT-TEVA-2022-IT-2068488,TEVA,,71.0,YR,E,M,Y,,,20220901.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212818911.0,OT,,,,,,,,,212818911.0,1.0,HIV infection
21285914,212859142,2,F,20220628.0,20221205.0,20220902,20221219,30DAY,,US-VIIV HEALTHCARE LIMITED-US2022AMR124211,VIIV,,50.0,YR,,M,Y,87.528,KG,20221214.0,,HP,US,US,SUSTIVA,Product use in unapproved therapeutic environment;Treatment failure;Viral load increased,,,,,212859142.0,1.0,20220421.0,20220819.0,1.0,MON,212859142.0,1.0,HIV infection CDC category B
21290056,212900561,1,I,20020201.0,20220826.0,20220902,20220902,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2022EME124553,VIIV,"Nabiullina DR, Mazus AI, Litivinova NG, Khamatova AA, Nagibina MV, Chebotareva TA, et.al.. Practical aspects of human immunodeficiency virus multiresistance in modern clinical practice. Epidemiology and Infectious Diseases. 2021;26 (3):113-126",,,,,Y,,,20220902.0,,MD,RU,RU,EFAVIRENZ,Drug ineffective;Hepatitis toxic;Nausea;Pathogen resistance;Virologic failure;Vomiting,212900561.0,OT,,,212900561.0,1.0,1999.0,200202.0,4.0,MON,212900561.0,1.0,HIV infection
21290057,212900571,1,I,20020201.0,20220826.0,20220902,20220902,EXP,,RU-GSK-RU2022EME124553,GLAXOSMITHKLINE,"Nabiullina DR, Mazus AI, Litivinova NG, Khamatova AA, Nagibina MV, Chebotareva TA, et.al.. Practical aspects of human immunodeficiency virus multiresistance in modern clinical practice. Epidemiology and Infectious Diseases. 2021;26 (3):113-126",,,,,Y,,,20220902.0,,MD,RU,RU,EFAVIRENZ,Drug ineffective;Hepatitis toxic;Nausea;Pathogen resistance;Virologic failure;Vomiting,212900571.0,OT,,,212900571.0,1.0,1999.0,200202.0,4.0,MON,212900571.0,1.0,HIV infection
21290630,212906301,1,I,,20220823.0,20220903,20220903,EXP,,IT-AUROBINDO-AUR-APL-2022-034347,AUROBINDO,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633.",71.0,YR,,M,Y,,,20220903.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212906301.0,OT,,,,,,,,,212906301.0,1.0,HIV infection
21290780,212907801,1,I,,20220822.0,20220903,20220903,EXP,,IN-HETERO-HET2022IN02049,HETERO,"Pangti R, Gupta S, Bhari N, Dhawan B, Gupta S. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus?positive patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(1):86-87",32.0,YR,,M,Y,,,20220903.0,,HP,IN,IN,EFAVIRENZ,Genital herpes;Immune reconstitution inflammatory syndrome;Secondary syphilis,212907801.0,OT,,,,,,,,,212907801.0,1.0,HIV infection
21291596,212915962,2,F,20220628.0,20221205.0,20220903,20221215,PER,,US-JNJFOC-20220904524,JOHNSON AND JOHNSON,,46.0,YR,A,M,Y,,,20221215.0,,HP,US,US,SUSTIVA,Product use in unapproved therapeutic environment;Treatment failure;Viral load increased,,,,,212915962.0,1.0,20220421.0,20220819.0,31.0,DAY,212915962.0,1.0,HIV infection CDC category B
21293953,212939531,1,I,,20220825.0,20220905,20220905,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK124460,VIIV,,,,,,Y,,,20220905.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212939531.0,OT,,,,,,,,,212939531.0,1.0,HIV infection
21293975,212939751,1,I,,20220825.0,20220905,20220905,EXP,,CA-GSK-CA2022GSK124460,GLAXOSMITHKLINE,,,,,,Y,,,20220905.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212939751.0,OT,,,,,,,,,212939751.0,1.0,HIV infection
21306338,213063383,3,F,20210618.0,20230829.0,20220908,20230909,EXP,,ES-AUROBINDO-AUR-APL-2022-032121,AUROBINDO,,22.0,YR,,M,Y,,,20230909.0,,MD,ES,ES,EFAVIRENZ,Off label use;Treatment noncompliance;Virologic failure,213063383.0,OT,,,213063383.0,2.0,20220218.0,20220218.0,246.0,DAY,213063383.0,1.0,HIV infection
21308901,213089011,1,I,20210927.0,20220904.0,20220908,20220908,EXP,,GB-MYLANLABS-2022M1091635,MYLAN,,31.0,YR,,F,Y,,,20220908.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213089011.0,OT,,,,,,,,,213089011.0,1.0,HIV infection
21332236,213322361,1,I,,20220901.0,20220914,20220914,EXP,,IN-Appco Pharma LLC-2132840,APPCO PHARMA,"Patra P, Samal P, Bhola R, Pradhan S. An event of Evans even in HIV. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022 JUN 07;43(1):64-6. DOI: 10.4103/ijstd.ijstd_113_20",32.0,YR,,F,Y,,,20220914.0,,MD,IN,IN,EFAVIRENZ,Evans syndrome,213322361.0,OT,,,,,,,,,213322361.0,1.0,HIV infection
21333037,213330371,1,I,20150101.0,20220907.0,20220914,20220914,EXP,,PT-GSK-PT2022EME129711,GLAXOSMITHKLINE,,,,,,Y,,,20220914.0,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213330371.0,OT,,,213330371.0,1.0,201504.0,2015.0,,,213330371.0,1.0,Antiretroviral therapy
21333097,213330971,1,I,20150101.0,20220907.0,20220914,20220914,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME129711,VIIV,,,,,,Y,,,20220914.0,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213330971.0,OT,,,213330971.0,1.0,201504.0,2015.0,,,213330971.0,1.0,Antiretroviral therapy
21334238,213342381,1,I,20210927.0,20220904.0,20220914,20220914,EXP,,GB-TEVA-2022-GB-2071405,TEVA,,31.0,YR,A,F,Y,,,20220914.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213342381.0,OT,,,,,,,,,213342381.0,1.0,HIV infection
21335490,213354901,1,I,20210927.0,20220904.0,20220915,20220915,EXP,,GB-AUROBINDO-AUR-APL-2022-035997,AUROBINDO,,31.0,YR,,F,Y,,,20220915.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213354901.0,OT,,,,,,,,,213354901.0,1.0,HIV infection
21336659,213366591,1,I,,20220902.0,20220915,20220915,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022037174,MACLEODS,"Isaacs T, Ngwanya MR, Dlamini S, Lehloenya RJ. Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases. Journal of Antimicrobial Chemotherapy. 2013;68(12):2871-2874",,,,,Y,,,20220915.0,,HP,ZA,ZA,EFAVIRENZ,Erythema annulare;Maternal exposure during pregnancy;Photosensitivity reaction,213366591.0,HO,,,,,,,,,213366591.0,1.0,HIV infection
21337663,213376631,1,I,,20220911.0,20220915,20220915,EXP,,IN-GILEAD-2022-0597688,GILEAD,"Sarkar A, Rohilla M, Kumari S. Concurrence of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Journal of Obstetrics and Gynaecolog. 2022;42(5):747-750. doi:10.1080/01443615.2021.2024157",,,N,,Y,,,20220915.0,,HP,IN,IN,EFAVIRENZ,Death neonatal;Foetal exposure during pregnancy;Neural tube defect,213376631.0,DE,,,,,,,,,213376631.0,1.0,HIV infection
21338119,213381191,1,I,,20220908.0,20220915,20220915,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK131647,VIIV,"Sarkar A, Rohilla M, Kumari S. Concurrence of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Journal of Obstetrics and Gynaecology. 2022;42(5):747-750",,,,,Y,,,20220915.0,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213381191.0,CA,,,,,,,,,213381191.0,1.0,HIV infection
21338120,213381201,1,I,,20220908.0,20220915,20220915,EXP,,IN-GSK-IN2022GSK131647,GLAXOSMITHKLINE,"Sarkar A, Rohilla M, Kumari S. Concurrence of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Journal of Obstetrics and Gynaecology. 2022;42(5):747-750",,,,,Y,,,20220915.0,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213381201.0,CA,,,,,,,,,213381201.0,1.0,HIV infection
21342601,213426011,1,I,20210927.0,20220904.0,20220916,20220916,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2022037190,MACLEODS,,,,,,Y,,,20220916.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213426011.0,OT,,,,,,,,,213426011.0,1.0,HIV infection
21350279,213502791,1,I,,20220916.0,20220919,20220919,EXP,,IT-GSK-IT2022133577,GLAXOSMITHKLINE,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV.. Neurol-Clin-Pract. 2021;11(5):E627-E633",,,,,Y,,,20220919.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213502791.0,OT,,,,,,,,,213502791.0,1.0,HIV infection
21350280,213502801,1,I,,20220916.0,20220919,20220919,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2022133577,VIIV,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV.. Neurol-Clin-Pract. 2021;11(5):E627-E633",,,,,Y,,,20220919.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213502801.0,OT,,,,,,,,,213502801.0,1.0,HIV infection
21350741,213507411,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107980,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507411.0,OT,,,,,,,,,213507411.0,1.0,HIV test positive
21350742,213507421,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107982,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507421.0,HO,,,,,,,,,213507421.0,1.0,HIV test positive
21350786,213507861,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107983,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507861.0,HO,,,,,,,,,213507861.0,1.0,HIV test positive
21350787,213507871,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107985,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507871.0,HO,,,,,,,,,213507871.0,1.0,HIV test positive
21350827,213508271,1,I,,20220912.0,20220919,20220919,EXP,,EG-VIIV HEALTHCARE LIMITED-EG2022GSK134151,VIIV,"Gaballah A, Ghazal A, Metwally D, Emad R, Essam G, Attia NM et al. Mutation patterns, cross resistance and virological failure among HIV type-1 patients in Alexandria, Egypt. Future Virology. 2022;17(7):441-454",,,,,Y,,,20220919.0,,HP,EG,EG,EFAVIRENZ,Pathogen resistance;Viral mutation identified,213508271.0,OT,,,,,,,,,213508271.0,1.0,HIV infection
21350903,213509031,1,I,,20220912.0,20220919,20220919,EXP,,EG-VIIV HEALTHCARE LIMITED-EG2022GSK134150,VIIV,"Gaballah A, Ghazal A, Metwally D, Emad R, Essam G, Attia NM et al. Mutation patterns, cross resistance and virological failure among HIV type-1 patients in Alexandria, Egypt. Future Virology. 2022;17(7):441-454",,,,,Y,,,20220919.0,,HP,EG,EG,EFAVIRENZ,Pathogen resistance;Viral mutation identified,213509031.0,OT,,,,,,,,,213509031.0,1.0,HIV infection
21350943,213509431,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107978,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213509431.0,HO,,,,,,,,,213509431.0,1.0,HIV test positive
21350944,213509441,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107979,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213509441.0,HO,,,,,,,,,213509441.0,1.0,HIV test positive
21350958,213509581,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107975,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213509581.0,HO,,,,,,,,,213509581.0,1.0,HIV test positive
21351716,213517161,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107987,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220920.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213517161.0,HO,,,,,,,,,213517161.0,1.0,HIV test positive
21351747,213517471,1,I,,20220908.0,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-055611,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220920.0,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213517471.0,HO,,,,,,,,,213517471.0,1.0,HIV test positive
21352750,213527501,1,I,,20220914.0,20220920,20220920,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-107110,BRISTOL MYERS SQUIBB,,52.0,YR,A,M,Y,,,20220920.0,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,213527501.0,OT,,,,,,,,,213527501.0,1.0,HIV infection
21354782,213547821,1,I,20150101.0,20220915.0,20220920,20220920,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-107544,BRISTOL MYERS SQUIBB,,45.0,YR,A,M,Y,,,20220920.0,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213547821.0,OT,,,213547821.0,1.0,200307.0,201511.0,6.0,MON,213547821.0,1.0,Antiretroviral therapy
21356659,213566591,1,I,20100101.0,20220915.0,20220920,20220920,PER,,US-GILEAD-2022-0598029,GILEAD,,48.0,YR,A,M,Y,,,20220920.0,,MD,US,US,EFAVIRENZ,Drug intolerance;Genotype drug resistance test positive;Treatment failure;Vomiting,,,,,,,,,,,213566591.0,1.0,HIV infection
21364311,213643112,2,F,,20230124.0,20220922,20230201,EXP,,DK-MYLANLABS-2022M1095642,MYLAN,"Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infect-Dis-Rep 2022;14(4):501-504.",50.0,YR,,M,Y,,,20230201.0,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance,213643112.0,OT,,,,,,,,,213643112.0,1.0,HIV infection
21366083,213660832,2,F,,20220922.0,20220922,20220926,EXP,,IT-GILEAD-2022-0598645,GILEAD,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633",71.0,YR,E,M,Y,,,20220926.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213660832.0,OT,,,,,,,,,213660832.0,1.0,HIV infection
21367727,213677271,1,I,,20220913.0,20220923,20220923,EXP,,CA-TEVA-2022-CA-2074579,TEVA,,54.0,YR,A,M,Y,,,20220923.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,213677271.0,OT,,,,,,,,,213677271.0,1.0,HIV infection
21368218,213682181,1,I,,20220913.0,20220923,20220923,EXP,,CA-TEVA-2022-CA-2074597,TEVA,,54.0,YR,A,M,Y,,,20220923.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,213682181.0,OT,,,,,,,,,213682181.0,1.0,HIV infection
21368770,213687701,1,I,,20220914.0,20220923,20220923,EXP,,CA-009507513-2209CAN005857,MERCK,,54.0,YR,,M,Y,,,20220923.0,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,213687701.0,OT,,,213687701.0,11.0,,,2.0,DAY,213687701.0,1.0,HIV infection
21369015,213690152,2,F,,20221006.0,20220923,20221013,EXP,,US-CIPLA LTD.-2019US02860,CIPLA,"Ali MS, Kooragayalu S, Mba BI, Olsen FC.. Isolated myopathy: An unusual manifestation of inhaled Fluticasone Propionate and Ritonavir interaction. Archivos de Bronconeumologia. 2017;55 (4):223 to 225",58.0,YR,,M,Y,,,20221013.0,,MD,US,US,EFAVIRENZ,Drug interaction;Fall;Myopathy,213690152.0,HO,,,213690152.0,2.0,,,5.0,MON,213690152.0,1.0,HIV infection
21373970,213739701,1,I,20150101.0,20220919.0,20220926,20220926,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192778",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20220926.0,,CN,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213739701.0,OT,,,213739701.0,1.0,200404.0,201504.0,11.0,YR,213739701.0,1.0,Antiretroviral therapy
21376989,213769891,1,I,,20220920.0,20220926,20220926,EXP,,ES-MYLANLABS-2022M1096244,MYLAN,"Gomez AS, Garcia MJA, Maria Rafael Saponi Cortes J, Ruiz CM. Cushing^s syndrome secondary to inhaled fluticasone.. Endocrinol-Diabetes-Nutr. 2022;69(6):442-444",,,,M,Y,,,20220926.0,,HP,ES,ES,EFAVIRENZ,Cushing's syndrome;Drug ineffective;Drug interaction;Tertiary adrenal insufficiency,213769891.0,OT,,,213769891.0,14.0,,,5.0,YR,213769891.0,1.0,HIV infection
21377221,213772211,1,I,,20220919.0,20220926,20220926,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK134599,VIIV,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Epiretinal membrane;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772211.0,OT,,,213772211.0,1.0,,,8.0,WK,213772211.0,1.0,HIV infection
21377222,213772221,1,I,,20220919.0,20220926,20220926,EXP,,CN-GSK-CN2022GSK134599,GLAXOSMITHKLINE,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Epiretinal membrane;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772221.0,OT,,,213772221.0,1.0,,,8.0,WK,213772221.0,1.0,HIV infection
21377271,213772711,1,I,,20220919.0,20220926,20220926,EXP,,CN-GSK-CN2022GSK136018,GLAXOSMITHKLINE,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772711.0,OT,,,213772711.0,1.0,,,4.0,WK,213772711.0,1.0,HIV infection
21377272,213772721,1,I,,20220919.0,20220926,20220926,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK136019,VIIV,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitreous haemorrhage;Vitritis,213772721.0,OT,,,213772721.0,1.0,,,8.0,WK,213772721.0,1.0,HIV infection
21377273,213772731,1,I,,20220919.0,20220926,20220926,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK136018,VIIV,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772731.0,OT,,,213772731.0,1.0,,,4.0,WK,213772731.0,1.0,HIV infection
21377274,213772741,1,I,,20220919.0,20220926,20220926,EXP,,CN-GSK-CN2022GSK136019,GLAXOSMITHKLINE,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitreous haemorrhage;Vitritis,213772741.0,OT,,,213772741.0,1.0,,,8.0,WK,213772741.0,1.0,HIV infection
21378124,213781241,1,I,,20220914.0,20220926,20220926,EXP,,IT-CIPLA LTD.-2022IT05586,CIPLA,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV.. Neurol-Clin-Pract. 2021;11 (5):E627 to E633",71.0,YR,,M,Y,,,20220927.0,,HP,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213781241.0,OT,,,,,,,,,213781241.0,1.0,HIV infection
21379974,213799742,2,F,,20221011.0,20220927,20221014,EXP,,IN-GILEAD-2022-0598900,GILEAD,,,,N,,Y,,,20221014.0,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213799742.0,CA,,,,,,,,,213799742.0,1.0,HIV infection
21383905,213839051,1,I,20150101.0,20220915.0,20220928,20220928,EXP,,PT-AUROBINDO-AUR-APL-2022-037937,AUROBINDO,,45.0,YR,,M,Y,,,20220928.0,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213839051.0,OT,,,213839051.0,1.0,200307.0,201504.0,,,213839051.0,1.0,Antiretroviral therapy
21385809,213858092,2,F,,20221010.0,20220928,20221017,EXP,,IN-MYLANLABS-2022M1096459,MYLAN,,,,,,Y,,,20221017.0,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213858092.0,CA,,,,,,,,,213858092.0,1.0,HIV infection
21387525,213875251,1,I,,20220913.0,20220928,20220928,EXP,,CA-JNJFOC-20220953572,JOHNSON AND JOHNSON,,,,,,Y,,,20220928.0,,MD,CA,CA,EFAVIRENZ,Amylase increased;Blood cholesterol increased;Low density lipoprotein;Neutropenia,213875251.0,OT,,,213875251.0,1.0,2014.0,,,,213875251.0,1.0,HIV infection
21390191,213901911,1,I,20150101.0,20220919.0,20220929,20220929,EXP,,PT-009507513-2209PRT006906,MERCK,,45.0,YR,,M,Y,,,20220929.0,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213901911.0,OT,,,213901911.0,1.0,201505.0,201511.0,,,213901911.0,1.0,Antiretroviral therapy
21390251,213902511,1,I,,20220926.0,20220929,20220929,EXP,,CA-AstraZeneca-2022A330116,ASTRAZENECA,,54.0,YR,,M,Y,,,20220929.0,,MD,CA,,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,213902511.0,OT,,,,,,,,,213902511.0,1.0,HIV infection
21391532,213915321,1,I,,20220926.0,20220929,20220929,EXP,,CN-GILEAD-2022-0599382,GILEAD,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, Lu H, Wang Z. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;unk:unk. doi:10.3389/fmed.2022.807013",50.0,YR,A,M,Y,,,20220929.0,,HP,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,213915321.0,OT,,,,,,,,,213915321.0,1.0,HIV infection
21391585,213915851,1,I,,20220926.0,20220929,20220929,EXP,,CN-GILEAD-2022-0599385,GILEAD,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, Lu H, Wang Z.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;unk:unk. doi:10.3389/fmed.2022.807013",40.0,YR,A,M,Y,,,20220929.0,,HP,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,213915851.0,OT,,,,,,,,,213915851.0,1.0,HIV infection
21395180,213951805,5,F,20100629.0,20230131.0,20220930,20230209,EXP,,GB-AUROBINDO-AUR-APL-2022-021223,AUROBINDO,,43.0,YR,,F,Y,43.0,KG,20230209.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,213951805.0,CA,,,213951805.0,1.0,20171006.0,20180205.0,4.0,MON,213951805.0,1.0,HIV infection
21400770,214007701,1,I,,20220923.0,20221003,20221003,EXP,,IN-HETERO-HET2022IN02383,HETERO,,,,,,Y,,,20221003.0,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,214007701.0,OT,,,,,,,,,214007701.0,1.0,HIV infection
21408781,214087811,1,I,20160101.0,20220927.0,20221004,20221004,EXP,,CN-GSK-CN2022APC138426,GLAXOSMITHKLINE,,,,,,Y,,,20221004.0,,HP,CN,CN,EFAVIRENZ,Ascites;Cholecystitis;Cholelithiasis;Collateral circulation;Faeces discoloured;Haemoglobin decreased;Hepatic cirrhosis;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Portal vein embolism;Splenomegaly;Varices oesophageal,214087811.0,OT,,,214087811.0,1.0,2015.0,,,,214087811.0,1.0,HIV infection
21408782,214087821,1,I,20160101.0,20220927.0,20221004,20221004,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC138426,VIIV,,,,,,Y,,,20221004.0,,HP,CN,CN,EFAVIRENZ,Ascites;Cholecystitis;Cholelithiasis;Collateral circulation;Faeces discoloured;Haemoglobin decreased;Hepatic cirrhosis;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Portal vein embolism;Splenomegaly;Varices oesophageal,214087821.0,OT,,,214087821.0,1.0,2015.0,,,,214087821.0,1.0,HIV infection
21409265,214092651,1,I,20210101.0,20220927.0,20221004,20221004,EXP,,CN-GSK-CN2022GSK141511,GLAXOSMITHKLINE,,,,,,Y,,,20221004.0,,HP,CN,CN,EFAVIRENZ,Abdominal distension;Abdominal pain;Bile duct stent insertion;Bile duct stone;Biliary dilatation;Duodenal ulcer;Hepatic mass;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Post cholecystectomy syndrome;Splenomegaly;Varices oesophageal,214092651.0,OT,,,214092651.0,1.0,2019.0,,,,214092651.0,1.0,HIV infection
21409266,214092661,1,I,20210101.0,20220927.0,20221004,20221004,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK141511,VIIV,,,,,,Y,,,20221004.0,,HP,CN,CN,EFAVIRENZ,Abdominal distension;Abdominal pain;Bile duct stent insertion;Bile duct stone;Biliary dilatation;Duodenal ulcer;Hepatic mass;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Post cholecystectomy syndrome;Splenomegaly;Varices oesophageal,214092661.0,OT,,,214092661.0,1.0,2019.0,,,,214092661.0,1.0,HIV infection
21411094,214110941,1,I,20160101.0,20220927.0,20221005,20221005,EXP,,CN-GILEAD-2022-0599697,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/j.issn.1001-5256.2022.09.028",46.0,YR,A,M,Y,,,20221005.0,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214110941.0,OT,,,214110941.0,1.0,2015.0,,,,214110941.0,1.0,HIV infection
21411176,214111761,1,I,20160101.0,20220927.0,20221005,20221005,EXP,,CN-GILEAD-2022-0600272,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/ j. issn.1001 -5256. 2022. 09. 028",40.0,YR,A,M,Y,,,20221005.0,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214111761.0,OT,,,214111761.0,1.0,2013.0,,,,214111761.0,1.0,HIV infection
21411267,214112671,1,I,20200101.0,20220927.0,20221005,20221005,EXP,,CN-GILEAD-2022-0600274,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/ j. issn.1001 -5256. 2022. 09. 028",67.0,YR,E,F,Y,,,20221005.0,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214112671.0,OT,,,214112671.0,1.0,2015.0,,,,214112671.0,1.0,HIV infection
21411370,214113701,1,I,20210101.0,20220927.0,20221005,20221005,EXP,,CN-GILEAD-2022-0600275,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/ j. issn.1001 -5256. 2022. 09. 028",43.0,YR,A,M,Y,,,20221005.0,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214113701.0,OT,,,214113701.0,1.0,2019.0,,,,214113701.0,1.0,HIV infection
21411508,214115081,1,I,20160101.0,20220927.0,20221005,20221005,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK140964,VIIV,,,,,,Y,,,20221005.0,,HP,CN,CN,EFAVIRENZ,Cholecystitis chronic;Chronic gastritis;Faeces discoloured;Gastric varices;Haemoglobin decreased;Hepatic lesion;Non-cirrhotic portal hypertension;Renal cyst;Splenic fibrosis;Splenomegaly,214115081.0,HO,,,214115081.0,1.0,2013.0,,,,214115081.0,1.0,HIV infection
21411511,214115111,1,I,20160101.0,20220927.0,20221005,20221005,EXP,,CN-GSK-CN2022GSK140964,GLAXOSMITHKLINE,,,,,,Y,,,20221005.0,,HP,CN,CN,EFAVIRENZ,Cholecystitis chronic;Chronic gastritis;Faeces discoloured;Gastric varices;Haemoglobin decreased;Hepatic lesion;Non-cirrhotic portal hypertension;Renal cyst;Splenic fibrosis;Splenomegaly,214115111.0,OT,,,214115111.0,1.0,2013.0,,,,214115111.0,1.0,HIV infection
21412923,214129232,2,F,20200801.0,20221005.0,20221005,20221012,EXP,,DK-GILEAD-2022-0600376,GILEAD,"Mens H, Fjordside L, Fonager J, Gerstoft J.. Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.. Emergence of the G118R Pan-Integrase. 2022;14 (4):501-504. doi:10.3390/idr14040053",50.0,YR,A,M,Y,,,20221012.0,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,214129232.0,OT,,,,,,,,,214129232.0,1.0,HIV infection
21415835,214158351,1,I,,20220923.0,20221006,20221006,EXP,,US-AUROBINDO-AUR-APL-2022-040323,AUROBINDO,,,,I,,Y,,,20221006.0,,HP,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,214158351.0,OT,,,,,,,,,214158351.0,1.0,HIV infection
21418024,214180242,2,F,,20221020.0,20221006,20221025,EXP,,JP-GSK-JP2022141732,GLAXOSMITHKLINE,,,,,,Y,,,20221025.0,,PH,JP,JP,EFAVIRENZ,Renal impairment,214180242.0,OT,,,,,,,,,214180242.0,1.0,HIV infection
21418037,214180372,2,F,,20221020.0,20221006,20221025,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022141732,VIIV,,,,,,Y,,,20221025.0,,PH,JP,JP,EFAVIRENZ,Renal impairment,214180372.0,OT,,,,,,,,,214180372.0,1.0,HIV infection
21419292,214192922,2,F,,20221010.0,20221006,20221019,EXP,,DK-TEVA-2022-DK-2079789,TEVA,,50.0,YR,A,M,Y,,,20221019.0,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Treatment noncompliance,214192922.0,OT,,,,,,,,,214192922.0,1.0,HIV infection
21423307,214233071,1,I,,20221005.0,20221007,20221007,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2022EME137684,VIIV,,,,,,Y,,,20221007.0,,MD,FR,FR,SUSTIVA,Cerebral venous thrombosis;Logorrhoea;Vascular dementia;Vertigo;White matter lesion,214233071.0,HO,,,214233071.0,1.0,20210414.0,,,,214233071.0,1.0,HIV infection
21435862,214358621,1,I,20200101.0,20220927.0,20221010,20221010,EXP,,CN-GSK-CN2022GSK141118,GLAXOSMITHKLINE,,,,,,Y,,,20221010.0,,HP,CN,CN,EFAVIRENZ,Abdominal pain;Adrenal adenoma;Aspartate aminotransferase increased;Biliary dilatation;Collateral circulation;Duodenal ulcer;Gastric varices;Gastritis erosive;Haematemesis;Haemoglobin decreased;Hepatic cirrhosis;Intra-abdominal fluid collection;Non-cirrhotic portal hypertension;Pancreatic duct dilatation;Pelvic fluid collection;Platelet count decreased;Portal hypertensive gastropathy;Splenomegaly;Varices oesophageal,214358621.0,OT,,,214358621.0,1.0,2015.0,,,,214358621.0,1.0,HIV infection
21435863,214358631,1,I,20200101.0,20220927.0,20221010,20221010,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK141118,VIIV,,,,,,Y,,,20221010.0,,HP,CN,CN,EFAVIRENZ,Abdominal pain;Adrenal adenoma;Aspartate aminotransferase increased;Biliary dilatation;Collateral circulation;Duodenal ulcer;Gastric varices;Gastritis erosive;Haematemesis;Haemoglobin decreased;Hepatic cirrhosis;Intra-abdominal fluid collection;Non-cirrhotic portal hypertension;Pancreatic duct dilatation;Pelvic fluid collection;Platelet count decreased;Portal hypertensive gastropathy;Splenomegaly;Varices oesophageal,214358631.0,HO,,,214358631.0,1.0,2015.0,,,,214358631.0,1.0,HIV infection
21437515,214375151,1,I,,20220926.0,20221011,20221011,EXP,,DK-AUROBINDO-AUR-APL-2022-040749,AUROBINDO,"Mens H, Fjordside L, Fonager J, Gerstoft J.. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.. Infect-Dis-Rep. 2022;14(4):501-504.",50.0,YR,,M,Y,,,20221011.0,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance,214375151.0,OT,,,,,,,,,214375151.0,1.0,HIV infection
21439002,214390022,2,F,20210618.0,20230913.0,20221011,20230919,EXP,,ES-MYLANLABS-2022M1096222,MYLAN,,22.0,YR,,M,Y,,,20230919.0,,MD,ES,ES,EFAVIRENZ,Off label use;Treatment noncompliance;Virologic failure,,,,,214390022.0,2.0,20210618.0,20220218.0,246.0,DAY,214390022.0,1.0,HIV infection
21441301,214413011,1,I,,20220510.0,20221011,20221011,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-045768,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20221011.0,,HP,CA,CA,SUSTIVA,Death,214413011.0,DE,,,,,,,,,214413011.0,1.0,HIV infection
21445143,214451431,1,I,,20221004.0,20221012,20221012,EXP,,IN-MYLANLABS-2022M1112866,MYLAN,"Das S, Bhatia P. Treatment non-responsiveness in depression following Efavirenz administration. India-J-Sex-Transm-Dis 2020;41(1):113-115.",,,,M,Y,,,20221012.0,,MD,IN,IN,EFAVIRENZ,Bipolar I disorder;Psychotic symptom,214451431.0,OT,,,,,,,,,214451431.0,1.0,HIV infection
21449775,214497751,1,I,,20221004.0,20221013,20221013,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP013319,STRIDES,"Das S, Bhatia P.. Treatment non-responsiveness in depression following Efavirenz administration.. India-J-Sex-Transm-Dis. 2020;41(1):113-115",,,,M,Y,,,20221013.0,,MD,IN,IN,EFAVIRENZ,Bipolar I disorder;Condition aggravated;Psychotic symptom,214497751.0,OT,,,,,,,,,214497751.0,1.0,HIV infection
21454326,214543261,1,I,20120101.0,20221010.0,20221013,20221013,EXP,,PT-GILEAD-2022-0601266,GILEAD,,64.0,YR,A,M,Y,,,20221013.0,,MD,PT,PT,EFAVIRENZ,Headache;Hepatic steatosis;Hepatitis C;Insomnia;Magnetic resonance elastography;Malaise;Medication error;Treatment noncompliance,214543261.0,OT,,,214543261.0,1.0,202012.0,202012.0,12.0,WK,214543261.0,1.0,HIV infection
21454509,214545091,1,I,,20221011.0,20221013,20221013,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-119966,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20221014.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214545091.0,HO,,,,,,,,,214545091.0,1.0,HIV infection
21464395,214643951,1,I,,20221005.0,20221017,20221017,EXP,,US-CIPLA LTD.-2022US06095,CIPLA,"Boyce CL, Frenkel LM, Beck IA, Styrchak SM, Hardy SR, Wallner JJ et al.. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term. PLoS ONE. 2022;17(9): e0275254:1 to 10",,,A,F,Y,,,20221017.0,,HP,US,US,EFAVIRENZ,Drug resistance;Exposure during pregnancy;No adverse event,214643951.0,OT,,,214643951.0,1.0,,,30.0,DAY,214643951.0,1.0,HIV infection
21464396,214643961,1,I,,20221005.0,20221017,20221017,EXP,,US-CIPLA LTD.-2022US06096,CIPLA,"Boyce CL, Frenkel LM, Beck IA, Styrchak SM, Hardy SR, Wallner JJ et al.. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term. PLoS ONE. 2022;17 (9):1 to 10",,,,F,Y,,,20221017.0,,HP,US,US,EFAVIRENZ,Drug resistance;Exposure during pregnancy;No adverse event,214643961.0,OT,,,214643961.0,1.0,,,99.0,DAY,214643961.0,1.0,HIV infection
21465026,214650262,2,F,,20221016.0,20221017,20221026,EXP,,CA-TEVA-2022-CA-2816836,TEVA,,54.0,YR,A,M,Y,,,20221026.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214650262.0,OT,,,,,,,,,214650262.0,1.0,HIV infection
21466450,214664501,1,I,,20221007.0,20221017,20221017,EXP,,CA-TEVA-2022-CA-2816840,TEVA,,54.0,YR,A,M,Y,,,20221017.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,214664501.0,OT,,,,,,,,,214664501.0,1.0,HIV infection
21467853,214678531,1,I,,20221009.0,20221017,20221017,EXP,,CN-GSK-CN2022APC144715,GLAXOSMITHKLINE,,,,,,Y,,,20221017.0,,MD,CN,CN,EFAVIRENZ,Acute kidney injury;Back pain;Chromaturia;Face oedema;Myalgia;Oedema;Oedema peripheral;Rhabdomyolysis,214678531.0,OT,,,,,,,,,214678531.0,1.0,HIV infection
21467856,214678561,1,I,,20221009.0,20221017,20221017,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC144715,VIIV,,,,,,Y,,,20221017.0,,MD,CN,CN,EFAVIRENZ,Acute kidney injury;Back pain;Chromaturia;Face oedema;Myalgia;Oedema;Oedema peripheral;Rhabdomyolysis,214678561.0,HO,,,,,,,,,214678561.0,1.0,HIV infection
21474222,214742221,1,I,20220101.0,20221012.0,20221018,20221018,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2022GSK146995,VIIV,"Ortiz-Martinez Y, Cabeza-Ruiz LD, Henao-Martinez AF, Rodriguez-Morales AJ. Clinical challenges of managing advanced AIDS in the tropics: Histoplasmosis, COVID-19, and shigellosis coinfections. New Microbes and New Infections. 2022;49-50",,,,,Y,,,20221018.0,,HP,CO,CO,EFAVIRENZ,Abdominal pain;Abdominal tenderness;Anaemia;Bronchiectasis;COVID-19;Cachexia;Chills;Cough;Diarrhoea;Dyspnoea;Hepatomegaly;Histoplasmosis;Hypertransaminasaemia;Hypoalbuminaemia;Hypoxia;Leukopenia;Lung consolidation;Lung opacity;Lymphopenia;Night sweats;Pulmonary septal thickening;Pyrexia;Rales;Shigella infection;Tachycardia;Treatment noncompliance;Virologic failure;Wheezing,214742221.0,OT,,,,,,,,,214742221.0,1.0,HIV infection
21485943,214859431,1,I,,20221011.0,20221020,20221020,EXP,,GB-MYLANLABS-2022M1115278,MYLAN,"Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Lancet-HIV 2022;9(8):e534-e543.",,,A,F,Y,,,20221020.0,,HP,GB,GB,EFAVIRENZ,Hepatic cirrhosis;Maternal exposure during pregnancy,214859431.0,OT,,,,,,,,,214859431.0,1.0,HIV infection
21487384,214873841,1,I,20100629.0,20221011.0,20221020,20221020,EXP,,US-009507513-2210GBR007626,MERCK,,43.0,YR,,F,Y,,,20221020.0,,HP,US,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Off label use,214873841.0,CA,,,214873841.0,1.0,20171006.0,20180205.0,4.0,MON,214873841.0,1.0,HIV infection
21496247,214962471,1,I,,20221010.0,20221022,20221022,EXP,,IN-AUROBINDO-AUR-APL-2022-044158,AUROBINDO,"Das S, Bhatia P. Treatment non-responsiveness in depression following Efavirenz administration. Indian Journal of Sexually Transmitted Diseases and AIDS Volume. 2020;41(1):113-115",23.0,YR,,M,Y,,,20221022.0,,MD,IN,IN,EFAVIRENZ,Abnormal behaviour;Bipolar disorder;Crying;Decreased appetite;Depressed mood;Depression;Insomnia;Social problem,214962471.0,OT,,,,,,,,,214962471.0,1.0,HIV infection
21507282,215072821,1,I,,20221019.0,20221026,20221026,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK153360,VIIV,,,,,,Y,,,20221026.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215072821.0,HO,,,,,,,,,215072821.0,1.0,HIV infection
21507298,215072981,1,I,,20221019.0,20221026,20221026,EXP,,CA-GSK-CA2022GSK153360,GLAXOSMITHKLINE,,,,,,Y,,,20221026.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215072981.0,OT,,,,,,,,,215072981.0,1.0,HIV infection
21507379,215073791,1,I,,20220607.0,20221026,20221026,EXP,,US-GSK-NA2022152666,GLAXOSMITHKLINE,,,,,,Y,,,20221026.0,,HP,US,,EFAVIRENZ,Drug resistance,215073791.0,OT,,,,,,,,,215073791.0,1.0,HIV infection
21507380,215073801,1,I,,20220607.0,20221026,20221026,EXP,,US-VIIV HEALTHCARE LIMITED-NA2022152666,VIIV,,,,,,Y,,,20221026.0,,HP,US,,EFAVIRENZ,Drug resistance,215073801.0,OT,,,,,,,,,215073801.0,1.0,HIV infection
21518479,215184791,1,I,20220401.0,20221020.0,20221028,20221028,EXP,,RU-HETERO-HET2022RU02643,HETERO,,21.0,YR,,M,Y,68.0,KG,20221028.0,,MD,RU,RU,EFAVIRENZ,Asthenia;Mental impairment;Sleep disorder;Somnolence,215184791.0,OT,,,215184791.0,1.0,20220404.0,20220516.0,43.0,DAY,215184791.0,1.0,HIV infection
21527023,215270231,1,I,,20221018.0,20221031,20221031,EXP,,IN-CIPLA LTD.-2022IN06311,CIPLA,"Lad SG, Pandey V, Kolhe K, Chauhan S, Gattani M, Sethiya P et.al. AIH in HIV: A Very Much Possible Entity. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY. 2022;12 (5):1388 to 1392",48.0,YR,,F,Y,,,20221031.0,,HP,IN,IN,EFAVIRENZ,Acute on chronic liver failure;Anaemia;Autoimmune hepatitis;Gastric disorder;Hepatic cirrhosis;Nephropathy toxic;Portal hypertension;Thrombocytopenia;Varices oesophageal,215270231.0,OT,,,,,,,,,215270231.0,1.0,HIV infection
21532531,215325315,5,F,,20240410.0,20221101,20240424,EXP,,IN-CIPLA (EU) LIMITED-2022IN06312,CIPLA,"Lad SG, Pandey V, Kolhe K, Chauhan S, Gattani M, Sethiya P et.al. AIH in HIV: A Very Much Possible Entity. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY. 2022;12 (5):1388 to 1392",,,,,Y,,,20240424.0,,HP,IN,IN,EFAVIRENZ,Autoimmune hepatitis;Drug-induced liver injury,215325315.0,OT,,,,,,,,,215325315.0,1.0,HIV infection
21542652,215426522,2,F,20150101.0,20230905.0,20221102,20230906,PER,,US-GILEAD-2022-0603542,GILEAD,,,,A,M,Y,,,20230906.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Emotional distress;Hypertension;Pain,,,,,215426522.0,1.0,2004.0,201805.0,,,215426522.0,1.0,HIV infection
21548316,215483161,1,I,,20221026.0,20221103,20221103,EXP,,ET-MYLANLABS-2022M1120452,MYLAN,"Hirigo AT, Gutema S, Eifa A, Ketema W. Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus. SAGE-Open-Med-Case-Rep 2022;null:null.",47.0,YR,,M,Y,,,20221103.0,,HP,ET,ET,EFAVIRENZ,Type 2 diabetes mellitus,215483161.0,OT,,,215483161.0,2.0,20140716.0,,,,215483161.0,1.0,HIV infection
21549976,215499764,4,F,,20230203.0,20221103,20230828,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-2022-128597,BRISTOL MYERS SQUIBB,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: case report. HIV and AIDS Review. 2017 Oct 13;16(3):198-203.doi:10.5114/hivar.2017.70947.",43.0,YR,A,M,Y,,,20230828.0,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,215499764.0,OT,,,215499764.0,1.0,2011.0,,,,215499764.0,1.0,Acquired immunodeficiency syndrome
21552956,215529563,3,F,20170101.0,20230627.0,20221104,20230630,EXP,,US-GILEAD-2022-0603472,GILEAD,,47.0,YR,A,F,Y,108.84,KG,20230630.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Blood cholesterol increased;Blood glucose increased;Bone demineralisation;Depression;Emotional distress;Gait disturbance;Hypertension;Osteopenia;Osteoporosis;Pain;Type 2 diabetes mellitus,215529563.0,OT,,,215529563.0,1.0,2001.0,201311.0,,,215529563.0,1.0,HIV infection
21554065,215540653,3,F,20201001.0,20231124.0,20221104,20231127,EXP,,US-GILEAD-2022-0603518,GILEAD,,58.0,YR,A,M,Y,76.19,KG,20231126.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Gait disturbance;Osteopenia;Osteoporosis;Pain;Radius fracture,215540653.0,OT,,,215540653.0,1.0,2012.0,202201.0,,,215540653.0,1.0,HIV infection
21556815,215568152,2,F,20060601.0,20231030.0,20221104,20231031,EXP,,US-GILEAD-2022-0603555,GILEAD,,10.0,YR,A,M,Y,,,20231031.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;End stage renal disease;Fanconi syndrome acquired;Hyperkalaemia;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Pain;Renal transplant,215568152.0,OT,,,215568152.0,1.0,2004.0,200606.0,,,215568152.0,1.0,HIV infection
21557666,215576667,7,F,20120101.0,20240125.0,20221106,20240204,EXP,,PL-JNJFOC-20221056107,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20240204.0,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neuropsychological symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,215576667.0,OT,,,215576667.0,3.0,2011.0,,,,215576667.0,1.0,Acquired immunodeficiency syndrome
21559678,215596781,1,I,,20221028.0,20221107,20221107,EXP,,PL-GSK-PL2022EME156810,GLAXOSMITHKLINE,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV-AIDS-Rev. 2017;16(3):198-203",,,,,Y,,,20221107.0,,MD,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract inflammation,215596781.0,OT,,,215596781.0,8.0,201112.0,,,,215596781.0,1.0,HIV infection
21559679,215596791,1,I,,20221028.0,20221107,20221107,EXP,,PL-VIIV HEALTHCARE LIMITED-PL2022EME156810,VIIV,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV-AIDS-Rev. 2017;16(3):198-203",,,,,Y,,,20221107.0,,MD,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract inflammation,215596791.0,OT,,,215596791.0,8.0,201112.0,,,,215596791.0,1.0,HIV infection
21561611,215616111,1,I,20221103.0,,20221104,20221104,DIR,637338,,FDA-CTU,,41.0,YR,,UNK,N,,,20221104.0,N,PH,US,,EFAVIRENZ,Somnolence,,,215616111.0,HP,215616111.0,1.0,20220330.0,20221102.0,,,215616111.0,1.0,HIV infection
21577560,215775602,2,F,,20230124.0,20221110,20230201,EXP,,IT-MYLANLABS-2022M1122353,MYLAN,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633",71.0,YR,,M,Y,,,20230201.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,215775602.0,OT,,,,,,,,,215775602.0,1.0,HIV infection
21577958,215779581,1,I,,20221103.0,20221110,20221110,EXP,,IN-GSK-IN2022GSK159630,GLAXOSMITHKLINE,"Sil A, Bhanja DB, Panigrahi A, Biswas S. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian Journal of Dermatology. 2022;67(3):316",,,,,Y,,,20221110.0,,HP,IN,IN,EFAVIRENZ,Acanthosis;Epidermodysplasia verruciformis;Hyperkeratosis;Koebner phenomenon;Papilloma;Papule;Rash;Skin hypopigmentation;Skin lesion;Skin plaque,215779581.0,OT,,,,,,,,,215779581.0,1.0,HIV infection
21577960,215779601,1,I,,20221103.0,20221110,20221110,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK159630,VIIV,"Sil A, Bhanja DB, Panigrahi A, Biswas S. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian Journal of Dermatology. 2022;67(3):316",,,,,Y,,,20221110.0,,HP,IN,IN,EFAVIRENZ,Acanthosis;Epidermodysplasia verruciformis;Hyperkeratosis;Koebner phenomenon;Papilloma;Papule;Rash;Skin hypopigmentation;Skin lesion;Skin plaque,215779601.0,OT,,,,,,,,,215779601.0,1.0,HIV infection
21582714,215827141,1,I,20220101.0,20221031.0,20221111,20221111,EXP,,ZM-CIPLA LTD.-2022ZM06539,CIPLA,"Kaweme NM, Mantina HM, Butress SNM. Long-Term Zidovudine Therapy and Whether It is a Trigger of Vitamin B12 Deficiency: A Case Study of Megaloblastic Anemia at the University of Zambia Teaching Hospital. Case Reports in Hematology. 2022;1 to 6",52.0,YR,,M,Y,,,20221111.0,,HP,ZM,ZM,EFAVIRENZ,Anaemia folate deficiency,215827141.0,HO,,,215827141.0,1.0,2017.0,,,,215827141.0,1.0,HIV infection
21583473,215834731,1,I,20150101.0,20221107.0,20221111,20221111,EXP,,PT-MYLANLABS-2022M1123746,MYLAN,,45.0,YR,,M,Y,,,20221111.0,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,215834731.0,OT,,,215834731.0,1.0,200307.0,201504.0,,,215834731.0,1.0,Antiretroviral therapy
21594096,215940961,1,I,,20221108.0,20221115,20221115,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP015194,STRIDES,"Sil A, Bhanja DB, Panigrahi A, Biswas SK.. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian-J-Dermatol. 2022;67(3)",42.0,YR,,M,Y,,,20221115.0,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,215940961.0,OT,,,,,,,,,215940961.0,1.0,HIV infection
21596620,215966201,1,I,,20221101.0,20221115,20221115,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK160027,VIIV,,,,,,Y,,,20221115.0,,HP,CN,CN,EFAVIRENZ,Pathogen resistance,215966201.0,OT,,,215966201.0,1.0,,,2.0,YR,215966201.0,1.0,HIV infection
21596621,215966211,1,I,,20221101.0,20221115,20221115,EXP,,CN-GSK-CN2022GSK160027,GLAXOSMITHKLINE,,,,,,Y,,,20221115.0,,HP,CN,CN,EFAVIRENZ,Pathogen resistance,215966211.0,OT,,,215966211.0,1.0,,,2.0,YR,215966211.0,1.0,HIV infection
21596656,215966561,1,I,,20221108.0,20221115,20221115,EXP,,IN-MYLANLABS-2022M1125136,MYLAN,"Sil A, Bhanja DB, Panigrahi A, Biswas SK. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian-J-Dermatol 2022;67:No. 3.",42.0,YR,,M,Y,,,20221115.0,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,215966561.0,OT,,,,,,,,,215966561.0,1.0,HIV infection
21601033,216010331,1,I,,20221107.0,20221116,20221116,EXP,,IN-CIPLA LTD.-2022IN06662,CIPLA,"Sil A, Bhanja DB, Panigrahi A, Biswas SK. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian J Dermatol. 2022;67(3):316",42.0,YR,,M,Y,,,20221116.0,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis,216010331.0,OT,,,,,,,,,216010331.0,1.0,HIV infection
21606753,216067537,7,F,,20231121.0,20221117,20231201,EXP,,PL-GILEAD-2022-0603189,GILEAD,,43.0,YR,A,M,Y,,,20231201.0,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neuropsychological symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216067537.0,HO,,,216067537.0,1.0,2011.0,,,,216067537.0,1.0,HIV infection
21609769,216097691,1,I,20180101.0,20221103.0,20221117,20221117,EXP,,CN-GSK-CN2022APC160306,GLAXOSMITHKLINE,,,,,,Y,,,20221117.0,,MD,CN,CN,EFAVIRENZ,Alopecia;Amnesia;Hepatomegaly;Kidney enlargement;Mitochondrial cytopathy;Renal cyst;Therapy cessation,216097691.0,OT,,,216097691.0,1.0,201607.0,20180218.0,13.0,MON,216097691.0,1.0,HIV infection
21609774,216097741,1,I,20180101.0,20221103.0,20221117,20221117,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC160306,VIIV,,,,,,Y,,,20221117.0,,MD,CN,CN,EFAVIRENZ,Alopecia;Amnesia;Hepatomegaly;Kidney enlargement;Mitochondrial cytopathy;Renal cyst;Therapy cessation,216097741.0,OT,,,216097741.0,1.0,201607.0,20180218.0,13.0,MON,216097741.0,1.0,HIV infection
21615178,216151783,3,F,,20230227.0,20221118,20240202,EXP,,KE-VIIV HEALTHCARE LIMITED-KE2022GSK165931,VIIV,"Koech MK, Ali SM, Karoney MJ, Kigen G. Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. Journal of medical case reports.. 2022;16(1):407",,,,,Y,,,20240202.0,,HP,KE,KE,EFAVIRENZ,Abdominal discomfort;Abdominal pain;Abdominal tenderness;Acute kidney injury;Blood HIV RNA increased;Chest discomfort;Chest pain;Chills;Confusional state;Cough;Decreased appetite;Diarrhoea;Generalised oedema;Headache;Hepatic function abnormal;Hepatitis viral;Hyperhidrosis;Hypersensitivity;Hypotension;Intentional product misuse;Malaise;Myalgia;Nausea;Neuropathy peripheral;Nosocomial infection;Oropharyngeal pain;Pain;Palpitations;Paraesthesia;Pharyngeal inflammation;Pharyngitis;Pyrexia;Rash;Respiratory alkalosis;Self-medication;Stomatitis;Tachycardia;Virologic failure;Vomiting,216151783.0,HO,,,216151783.0,8.0,,,2.0,MON,216151783.0,1.0,HIV infection
21619349,216193491,1,I,,20221111.0,20221120,20221120,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-137995,BRISTOL MYERS SQUIBB,,62.0,YR,A,F,Y,43.09,KG,20221121.0,,CN,US,US,SUSTIVA,Amnesia;Arthritis;Arthropathy;Bipolar disorder;Bone disorder;Limb discomfort;Post-traumatic stress disorder;Renal disorder;Spinal fracture;Weight decreased,216193491.0,OT,,,216193491.0,1.0,1999.0,20220930.0,8673.0,DAY,216193491.0,1.0,HIV test positive
21630149,216301493,3,F,,20221128.0,20221122,20221213,EXP,,IN-GILEAD-2022-0604339,GILEAD,Sil A. Bhanja D. Panigrahi A. Biswas S. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian Journal of Dermatology.. 2022;67 (3):316. doi:10.4103/ijd.IJD_747_20,42.0,YR,A,M,Y,,,20221213.0,,HP,IN,IN,EFAVIRENZ,Drug ineffective;Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,216301493.0,OT,,,,,,,,,216301493.0,1.0,HIV infection
21634299,216342991,1,I,20190101.0,20220608.0,20221123,20221123,EXP,,RU-GSK-RU2022GSK164326,GLAXOSMITHKLINE,"Morgunova TB, Maloletkina ES, Amergulov II, Glinkina IV, Pavlova MG, Fadeyev VV. Panhypopituitarism in HIV patient receiving antiretroviral therapy. Russian Open Medical Journal. 2021;10(4)",,,,,Y,,,20221123.0,,MD,RU,RU,EFAVIRENZ,Androgen deficiency;Asthenia;Central hypothyroidism;Condition aggravated;Empty sella syndrome;Erectile dysfunction;Fatigue;Growth hormone deficiency;Hypopituitarism;Hypotrichosis;Libido decreased;Osteopenia;Performance status decreased;Secondary adrenocortical insufficiency;Secondary hypogonadism;Weight decreased,216342991.0,HO,,,,,,,,,216342991.0,1.0,HIV infection
21634300,216343001,1,I,20190101.0,20220608.0,20221123,20221123,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2022GSK164326,VIIV,"Morgunova TB, Maloletkina ES, Amergulov II, Glinkina IV, Pavlova MG, Fadeyev VV. Panhypopituitarism in HIV patient receiving antiretroviral therapy. Russian Open Medical Journal. 2021;10(4)",,,,,Y,,,20221123.0,,MD,RU,RU,EFAVIRENZ,Androgen deficiency;Asthenia;Central hypothyroidism;Condition aggravated;Empty sella syndrome;Erectile dysfunction;Fatigue;Growth hormone deficiency;Hypopituitarism;Hypotrichosis;Libido decreased;Osteopenia;Performance status decreased;Secondary adrenocortical insufficiency;Secondary hypogonadism;Weight decreased,216343001.0,OT,,,,,,,,,216343001.0,1.0,HIV infection
21636380,216363801,1,I,,20221110.0,20221124,20221124,EXP,,UG-CIPLA (EU) LIMITED-2022UG06732,CIPLA,"Kiggundu R, Nabeta HW, Okia R, Rhein J, Lukande R.. Unmasking histoplasmosis immune reconstitution inflammatory syndrome in a patient recently started on antiretroviral therapy. Autopsy and Case Reports. 2016;6 (4):27 to 33",43.0,YR,,M,Y,,,20221124.0,,HP,UG,UG,EFAVIRENZ,Histoplasmosis cutaneous;Immune reconstitution inflammatory syndrome,216363801.0,OT,,,,,,,,,216363801.0,1.0,HIV infection
21644169,216441691,1,I,,20221118.0,20221125,20221125,EXP,,JP-GSK-JP2022JPN172504,GLAXOSMITHKLINE,Kashiwabara Y. TR5-2 A case of an AIDS patient with multiple drug-resistant mutant viruses whose dolutegravir was administered by simple suspension method and its blood concentration was measured. The 36th Annual Meeting of the Japanese Society for AIDS Research HIV Infectious. 2022,,,,,Y,,,20221125.0,,PH,JP,JP,EFAVIRENZ,Anaemia;Dysphagia;Gastrostomy;Hepatic function abnormal;Hypopharyngeal cancer stage II;Off label use;Pathogen resistance;Product use issue;Renal impairment,216441691.0,OT,,,,,,,,,216441691.0,1.0,Acquired immunodeficiency syndrome
21644170,216441701,1,I,,20221118.0,20221125,20221125,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022JPN172504,VIIV,Kashiwabara Y. TR5-2 A case of an AIDS patient with multiple drug-resistant mutant viruses whose dolutegravir was administered by simple suspension method and its blood concentration was measured. The 36th Annual Meeting of the Japanese Society for AIDS Research HIV Infectious. 2022,,,,,Y,,,20221125.0,,PH,JP,JP,EFAVIRENZ,Anaemia;Dysphagia;Gastrostomy;Hepatic function abnormal;Hypopharyngeal cancer stage II;Off label use;Pathogen resistance;Product use issue;Renal impairment,216441701.0,OT,,,,,,,,,216441701.0,1.0,Acquired immunodeficiency syndrome
21646702,216467021,1,I,,20221113.0,20221127,20221127,EXP,,CA-TEVA-2022-CA-2828583,TEVA,,54.0,YR,A,M,Y,,,20221126.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,216467021.0,HO,,,,,,,,,216467021.0,1.0,HIV infection
21647398,216473981,1,I,20170822.0,20220817.0,20221128,20221128,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022036934,MACLEODS,,,,,,Y,,,20221125.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,216473981.0,OT,,,216473981.0,1.0,20170224.0,,,,216473981.0,1.0,HIV infection
21651342,216513422,2,F,,20240117.0,20221128,20240123,EXP,,PL-AUROBINDO-AUR-APL-2022-049669,AUROBINDO,"Aksak-Was BJ, et al. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV and AIDS Review. 2017;16:198-203",43.0,YR,,M,Y,,,20240123.0,,MD,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neuropsychological symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216513422.0,OT,,,216513422.0,6.0,201112.0,,,,216513422.0,1.0,HIV infection
21652667,216526673,3,F,,20230118.0,20221128,20230123,EXP,,CA-MYLANLABS-2022M1132690,MYLAN,,52.0,YR,,M,Y,,,20230123.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,216526673.0,OT,,,,,,,,,216526673.0,1.0,HIV infection
21652898,216528981,1,I,,20221121.0,20221128,20221128,EXP,,JP-GSK-JP2022GSK177053,GLAXOSMITHKLINE,,,,,,Y,,,20221128.0,,HP,JP,JP,EFAVIRENZ,Altered state of consciousness;Aphasia;Central nervous system lesion;Cognitive disorder;Condition aggravated;Epilepsy;Hemiparesis;Immune reconstitution inflammatory syndrome;Inflammation;Meningitis cryptococcal;Sensory disturbance,216528981.0,OT,,,,,,,,,216528981.0,1.0,HIV infection
21652900,216529001,1,I,,20221121.0,20221128,20221128,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022GSK177053,VIIV,,,,,,Y,,,20221128.0,,HP,JP,JP,EFAVIRENZ,Altered state of consciousness;Aphasia;Central nervous system lesion;Cognitive disorder;Condition aggravated;Epilepsy;Hemiparesis;Immune reconstitution inflammatory syndrome;Inflammation;Meningitis cryptococcal;Sensory disturbance,216529001.0,OT,,,,,,,,,216529001.0,1.0,HIV infection
21653751,2165375116,16,F,20120521.0,20230327.0,20221129,20230405,EXP,,GB-HORMOSAN PHARMA GMBH-2019-09098,LUPIN,,,,,,Y,,,20230405.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,2165375116.0,CA,,,2165375116.0,2.0,20171006.0,20180205.0,4.0,MON,2165375116.0,1.0,HIV infection
21654524,216545242,2,F,,20221205.0,20221129,20221219,EXP,,IN-AUROBINDO-AUR-APL-2022-050424,AUROBINDO,"Sil A, Bhanja DB, Panigrahi A, Biswas SK.. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian-J-Dermatol. 2022;67No. 3.:316",42.0,YR,,M,Y,,,20221219.0,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,216545242.0,OT,,,,,,,,,216545242.0,1.0,HIV infection
21660043,216600431,1,I,,20221121.0,20221130,20221130,EXP,,CA-APOTEX-2022AP015893,APOTEX,,63.0,YR,,F,Y,,,20221130.0,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,216600431.0,OT,,,,,,,,,216600431.0,1.0,HIV infection
21666597,216665971,1,I,,20221121.0,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06920,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201.0,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216665971.0,OT,,,,,,,,,216665971.0,1.0,HIV infection
21666598,216665981,1,I,,20221121.0,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06918,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201.0,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216665981.0,OT,,,,,,,,,216665981.0,1.0,HIV infection WHO clinical stage I
21666604,216666041,1,I,,20221121.0,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06922,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201.0,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216666041.0,OT,,,,,,,,,216666041.0,1.0,HIV infection WHO clinical stage III
21666705,216667051,1,I,,20221121.0,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06919,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201.0,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216667051.0,OT,,,,,,,,,216667051.0,1.0,HIV infection WHO clinical stage I
21666706,216667061,1,I,,20221121.0,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06916,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes.. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201.0,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216667061.0,OT,,,,,,,,,216667061.0,1.0,HIV infection
21666707,216667071,1,I,,20221121.0,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06921,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",18.0,YR,,F,Y,,,20221201.0,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216667071.0,OT,,,,,,,,,216667071.0,1.0,HIV infection WHO clinical stage I
21668271,216682711,1,I,,20221121.0,20221201,20221201,EXP,,TW-GSK-TW2022APC173392,GLAXOSMITHKLINE,Chong YB. Immune reconstitution inflammatory syndrome: case report. Adis Insight. 2022,,,,,Y,,,20221201.0,,HP,TW,TW,EFAVIRENZ,Abscess limb;Adrenal neoplasm;Epstein-Barr virus infection;Extradural neoplasm;Febrile neutropenia;Hypoaesthesia;Immune reconstitution inflammatory syndrome;Leiomyoma;Malaise;Paraplegia;Schwannoma;Septic shock;Smooth muscle cell neoplasm;Spinal cord compression;Spinal cord neoplasm,216682711.0,OT,,,,,,,,,216682711.0,1.0,HIV infection
21668329,216683291,1,I,,20221121.0,20221201,20221201,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2022APC173392,VIIV,Chong YB. Immune reconstitution inflammatory syndrome: case report. Adis Insight. 2022,,,,,Y,,,20221201.0,,HP,TW,TW,EFAVIRENZ,Abscess limb;Adrenal neoplasm;Epstein-Barr virus infection;Extradural neoplasm;Febrile neutropenia;Hypoaesthesia;Immune reconstitution inflammatory syndrome;Leiomyoma;Malaise;Paraplegia;Schwannoma;Septic shock;Smooth muscle cell neoplasm;Spinal cord compression;Spinal cord neoplasm,216683291.0,OT,,,,,,,,,216683291.0,1.0,HIV infection
21675341,216753411,1,I,,20221128.0,20221202,20221202,EXP,,JP-GSK-JP2022JPN178225,GLAXOSMITHKLINE,Kanai O. Review of two cases of cerebrovascular events in young HIV-positive patients despite low risk of lifestyle disease. The Journal of AIDS Research/The 36th Annual Meeting of the Japanese Society for. 2022;24 (4):459(335),,,,,Y,,,20221202.0,,MD,JP,JP,EFAVIRENZ,Altered state of consciousness;Diplopia;Dysarthria;Hemiparesis;Sensory disturbance;Thrombotic cerebral infarction,216753411.0,HO,,,,,,,,,216753411.0,1.0,HIV infection
21675344,216753441,1,I,,20221128.0,20221202,20221202,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022JPN178225,VIIV,Kanai O. Review of two cases of cerebrovascular events in young HIV-positive patients despite low risk of lifestyle disease. The Journal of AIDS Research/The 36th Annual Meeting of the Japanese Society for. 2022;24 (4):459(335),,,,,Y,,,20221202.0,,MD,JP,JP,EFAVIRENZ,Altered state of consciousness;Diplopia;Dysarthria;Hemiparesis;Sensory disturbance;Thrombotic cerebral infarction,216753441.0,OT,,,,,,,,,216753441.0,1.0,HIV infection
21691095,216910954,4,F,20130101.0,20230726.0,20221207,20230728,EXP,,US-GILEAD-2022-0607706,GILEAD,,,,A,M,Y,99.79,KG,20230728.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Blood creatinine increased;Bone density abnormal;Bone density decreased;Chronic kidney disease;Emotional distress;Pain;Tooth loss,216910954.0,OT,,,216910954.0,1.0,2007.0,2011.0,,,216910954.0,1.0,HIV infection
21697546,216975461,1,I,,20221130.0,20221208,20221208,EXP,,CA-TEVA-2022-CA-2832794,TEVA,,,,,M,Y,,,20221208.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,216975461.0,HO,,,,,,,,,216975461.0,1.0,HIV infection
21698004,216980041,1,I,,20221130.0,20221208,20221208,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-148214,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20221208.0,,HP,CA,CA,SUSTIVA,Death,216980041.0,DE,,,,,,,,,216980041.0,1.0,HIV infection
21699720,216997202,2,F,20200801.0,20230124.0,20221208,20230207,EXP,,DK-MYLANLABS-2022M1135462,MYLAN,"Mens H, Fjordside L, Fonager J, Gerstoft J... Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.. Emergence of the G118R Pan-Integrase.. 2022;14 (4):501-504",50.0,YR,,M,Y,,,20230207.0,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,216997202.0,OT,,,,,,,,,216997202.0,1.0,HIV infection
21699735,216997357,7,F,,20230619.0,20221208,20230623,EXP,,NVSC2022CA283120,NOVARTIS,,54.0,YR,,M,Y,,,20230621.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Prescribed overdose;Product use in unapproved indication,216997357.0,OT,,,,,,,,,216997357.0,1.0,HIV infection
21699859,216998591,1,I,20080901.0,20221202.0,20221208,20221208,EXP,,IN-MYLANLABS-2022M1137164,MYLAN,"Raja K, Chandrasekar C, Krishnarajasekhar O, Manoharan G. Zero CD4 count: A case of discordant CD4 response in a patient with well suppressed viral load. Indian-J-Med-Microbiol 2013;31(3):298-302.",5.0,DEC,,M,Y,,,20221208.0,,MD,IN,IN,EFAVIRENZ,Treatment failure,216998591.0,OT,,,216998591.0,4.0,200802.0,,,,216998591.0,1.0,HIV infection
21706848,217068481,1,I,20100101.0,20221205.0,20221209,20221209,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME183265,VIIV,,,,,,Y,,,20221209.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217068481.0,HO,,,217068481.0,1.0,2003.0,2011.0,,,217068481.0,1.0,Antiretroviral therapy
21706849,217068491,1,I,20100101.0,20221205.0,20221209,20221209,EXP,,PT-GSK-PT2022EME183265,GLAXOSMITHKLINE,,,,,,Y,,,20221209.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217068491.0,HO,,,217068491.0,1.0,2003.0,2011.0,,,217068491.0,1.0,Antiretroviral therapy
21718480,217184801,1,I,,20221202.0,20221212,20221212,EXP,,CN-STRIDES ARCOLAB LIMITED-2022SP016657,STRIDES,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series.. Front-Med. 2022;9:807013",40.0,YR,,M,Y,,,20221213.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vitritis,217184801.0,OT,,,,,,,,,217184801.0,1.0,Antiretroviral therapy
21718481,217184811,1,I,,20221202.0,20221212,20221212,EXP,,CN-STRIDES ARCOLAB LIMITED-2022SP016659,STRIDES,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series.. Front-Med. 2022;9807013.",50.0,YR,,M,Y,,,20221213.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vitritis,217184811.0,OT,,,,,,,,,217184811.0,1.0,HIV infection
21718653,217186531,1,I,,20221128.0,20221213,20221213,EXP,,GB-CIPLA LTD.-2022GH07091,CIPLA,"Villa G, Gerett AM, Owusu D, Smith C, Azumah M, Abdullahi A et al.. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatology Communications. 2022;6:3036 to 3051",61.0,YR,,M,Y,,,20221213.0,,HP,GB,GH,EFAVIRENZ,Drug resistance,217186531.0,OT,,,,,,,,,217186531.0,1.0,HIV infection
21718656,217186561,1,I,,20221128.0,20221213,20221213,EXP,,GB-CIPLA LTD.-2022GH07089,CIPLA,"Villa G, Geretti AM, Owusu D, Smith C, Azumah M, Abdullahi A et al.. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatology Communications. 2022;6:3036 to 3051",48.0,YR,,M,Y,,,20221213.0,,HP,GB,GH,EFAVIRENZ,Drug resistance,217186561.0,OT,,,,,,,,,217186561.0,1.0,HIV infection
21718713,217187131,1,I,,20221128.0,20221213,20221213,EXP,,GB-CIPLA LTD.-2022GH07090,CIPLA,"Villa G, Geretti AM, Owusu D, Smith C, Azumah M, Abdullahi A et al.. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatology Communications. 2022;6:3036 to 3051",48.0,YR,,F,Y,,,20221213.0,,HP,GB,GH,EFAVIRENZ,Drug resistance,217187131.0,OT,,,,,,,,,217187131.0,1.0,HIV infection
21720436,217204361,1,I,,20221202.0,20221213,20221213,EXP,,CN-STRIDES ARCOLAB LIMITED-2022SP016660,STRIDES,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series.. Front-Med. 2022;9807013",54.0,YR,,M,Y,,,20221213.0,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vitritis,217204361.0,OT,,,,,,,,,217204361.0,1.0,HIV infection
21730259,217302591,1,I,,20221207.0,20221214,20221214,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-152236,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20221215.0,,CN,US,US,SUSTIVA,Panic attack,,,,,217302591.0,1.0,2005.0,,,,217302591.0,1.0,HIV infection
21738851,217388511,1,I,,20221205.0,20221216,20221216,EXP,,US-CIPLA (EU) LIMITED-2022US07153,CIPLA,"Kilcrease C, Agwu AL, Yusuf H, Park J, Powell A, James L et al.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19:56:1 to 6",,,,F,Y,,,20221216.0,,HP,US,US,EFAVIRENZ,Drug resistance;Immunosuppression;Molluscum contagiosum;Mycobacterium avium complex infection;Pneumonia;Treatment noncompliance;Vaginal infection;Virologic failure,217388511.0,HO,,,,,,,,,217388511.0,1.0,HIV infection
21738852,217388523,3,F,,20240723.0,20221216,20240805,EXP,,US-CIPLA LTD.-2022US07155,CIPLA,"Kilcrease C, Agwu AL, Yusuf H, Park J, Powell A, James L et al.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19 (56):1 to 6",,,,,Y,,,20240805.0,,HP,US,US,EFAVIRENZ,Adverse drug reaction;Drug resistance;Immunosuppression;Infection;Mucocutaneous candidiasis;Nausea;Onychomycosis;Oral candidiasis;Pneumonia;Product use complaint;Pyelonephritis;Somnolence;Treatment noncompliance;Varicella;Virologic failure,217388523.0,OT,,,,,,,,,217388523.0,1.0,HIV infection
21739924,217399241,1,I,,20221212.0,20221216,20221216,EXP,,IN-GILEAD-2022-0609375,GILEAD,"Parvez S., Goel P., Sarna M, Rijhwani P... HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. Indian Academy of Clinical Medicine. 2022;23(3-4):154-156. doi:Unk",30.0,YR,A,M,Y,,,20221216.0,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,217399241.0,OT,,,,,,,,,217399241.0,1.0,HIV infection
21744610,217446101,1,I,,20221209.0,20221218,20221218,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP016970,STRIDES,"Samukawa S, Yoshimi R, Kojitani N, Uzawa Y, Takase-Minegishi K, Kirino Y, et al.. Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.. J-Infect-Chemother. 2022;no pagination.",5.0,DEC,,M,Y,,,20221219.0,,HP,JP,JP,EFAVIRENZ,Altered state of consciousness;Aphasia;Cognitive disorder;Epilepsy;Hemiparesis;Immune reconstitution inflammatory syndrome;Sensory disturbance,217446101.0,OT,,,217446101.0,4.0,,,6.0,MON,217446101.0,1.0,HIV infection
21749395,217493951,1,I,,20221205.0,20221219,20221219,EXP,,ES-GSK-PA2022GSK183682,GLAXOSMITHKLINE,,,,,,Y,,,20221219.0,,HP,ES,PA,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,217493951.0,OT,,,,,,,,,217493951.0,1.0,Perinatal HIV infection
21749399,217493991,1,I,,20221205.0,20221219,20221219,EXP,,ES-VIIV HEALTHCARE LIMITED-PA2022GSK183682,VIIV,,,,,,Y,,,20221219.0,,HP,ES,PA,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,217493991.0,OT,,,,,,,,,217493991.0,1.0,Perinatal HIV infection
21749543,217495431,1,I,20221204.0,20221207.0,20221219,20221219,EXP,,CN-GSK-CN2022APC184665,GLAXOSMITHKLINE,,,,,,Y,,,20221214.0,,HP,CN,CN,EFAVIRENZ,Decreased appetite;Pathogen resistance,217495431.0,OT,,,217495431.0,1.0,20221202.0,20221205.0,3.0,DAY,217495431.0,1.0,HIV infection
21749564,217495641,1,I,20221204.0,20221207.0,20221219,20221219,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC184665,VIIV,,,,,,Y,,,20221214.0,,HP,CN,CN,EFAVIRENZ,Decreased appetite;Pathogen resistance,217495641.0,OT,,,217495641.0,1.0,20221202.0,20221205.0,3.0,DAY,217495641.0,1.0,HIV infection
21754551,217545511,1,I,,20221214.0,20221220,20221220,EXP,,CA-APOTEX-2022AP016890,APOTEX,,54.0,YR,,M,Y,,,20221220.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,217545511.0,OT,,,,,,,,,217545511.0,1.0,HIV infection
21760342,217603421,1,I,,20221214.0,20221221,20221221,EXP,,CA-APOTEX-2022AP016900,APOTEX,,54.0,YR,,M,Y,,,20221221.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,217603421.0,OT,,,,,,,,,217603421.0,1.0,HIV infection
21762630,217626301,1,I,,20221212.0,20221221,20221221,EXP,,IN-GSK-IN2022GSK186259,GLAXOSMITHKLINE,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. Journal, Indian Academy of Clinical Medicine. 2022;23(3-4):154-156",,,,,Y,,,20221221.0,,MD,IN,IN,EFAVIRENZ,Gingival hypertrophy;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Rash;Skin hyperpigmentation;Skin lesion;Skin mass;Skin plaque,217626301.0,OT,,,,,,,,,217626301.0,1.0,HIV infection
21762631,217626311,1,I,,20221212.0,20221221,20221221,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK186259,VIIV,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. Journal, Indian Academy of Clinical Medicine. 2022;23(3-4):154-156",,,,,Y,,,20221221.0,,MD,IN,IN,EFAVIRENZ,Gingival hypertrophy;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Rash;Skin hyperpigmentation;Skin lesion;Skin mass;Skin plaque,217626311.0,OT,,,,,,,,,217626311.0,1.0,HIV infection
21769521,217695211,1,I,,20221214.0,20221223,20221223,EXP,,CA-APOTEX-2022AP016931,APOTEX,,54.0,YR,,M,Y,,,20221223.0,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,217695211.0,OT,,,,,,,,,217695211.0,1.0,HIV infection
21770839,217708391,1,I,,20221212.0,20221223,20221223,EXP,,IN-CIPLA LTD.-2022IN07290,CIPLA,"Parvez S, Goel P, Sarna MK, Rijhwani P.. HIV-Associated Cutaneous Kaposi?s Sarcoma induced by IRIS following Antiretroviral Therapy. Journal, Indian Academy of Clinical Medicine. 2022;23 (3 to 4):154 to 156",30.0,YR,,M,Y,,,20221223.0,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma,217708391.0,OT,,,,,,,,,217708391.0,1.0,HIV infection
21771945,217719451,1,I,20100101.0,20221215.0,20221223,20221223,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-154808,BRISTOL MYERS SQUIBB,,77.0,YR,E,M,Y,,,20221223.0,,CN,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217719451.0,OT,,,217719451.0,1.0,2003.0,2017.0,6.0,YR,217719451.0,1.0,Antiretroviral therapy
21773178,217731781,1,I,,20221215.0,20221223,20221223,EXP,,US-PFIZER INC-PV202200125940,PFIZER,"Kilcrease, C.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19(1):10.1186/s12981-022-00477-w",37.0,YR,,F,Y,,,20221223.0,,HP,US,US,EFAVIRENZ,Treatment noncompliance,217731781.0,OT,,,,,,,,,217731781.0,1.0,HIV infection
21778231,217782311,1,I,,20221216.0,20221226,20221226,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2022GSK188297,VIIV,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. Southern African journal of HIV medicine. 2022;23(1)",,,,,Y,,,20221226.0,,MD,ZW,ZW,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,217782311.0,OT,,,,,,,,,217782311.0,1.0,HIV infection
21778275,217782751,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016932,APOTEX,,54.0,YR,,M,Y,,,20221226.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,217782751.0,OT,,,,,,,,,217782751.0,1.0,HIV infection
21781145,217811451,1,I,,20221212.0,20221227,20221227,EXP,,IN-AUROBINDO-AUR-APL-2022-054276,AUROBINDO,"Raja K, Chandrasekar C, Krishnarajasekhar O, Manoharan G.. Zero CD4 count: A case of discordant CD4 response in a patient with well suppressed viral load. Indian-J-Med-Microbiol. 2013;31(3):298-302",49.0,YR,,M,Y,59.0,KG,20221227.0,,HP,IN,IN,EFAVIRENZ,Treatment failure,217811451.0,OT,,,217811451.0,3.0,200802.0,,,,217811451.0,1.0,HIV infection
21787127,217871273,3,F,,20230310.0,20221228,20230321,EXP,,ES-AUROBINDO-AUR-APL-2022-054940,AUROBINDO,"Holguin A, Ventosa-Cubillo J, Pinzon R, Gonzalez-Alba JM, Estripeaut D, Navarro ML.. Drug resistance in children and adolescents with HIV in Panama. The Journal of antimicrobial chemotherapy. 2023;78:423-435",15.0,YR,,,Y,,,20230321.0,,HP,ES,ES,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,217871273.0,OT,,,,,,,,,217871273.0,1.0,Perinatal HIV infection
21791687,217916871,1,I,20221207.0,20221220.0,20221229,20221229,EXP,,RU-HETERO-HET2022RU03177,HETERO,,34.0,YR,,F,Y,,,20221229.0,,CN,RU,RU,EFAVIRENZ,Pruritus;Rash;Swelling face,217916871.0,HO,,,217916871.0,1.0,20221128.0,20221207.0,10.0,DAY,217916871.0,1.0,HIV infection
21793519,217935191,1,I,20100101.0,20221215.0,20221229,20221229,EXP,,PT-AUROBINDO-AUR-APL-2022-055163,AUROBINDO,,77.0,YR,,M,Y,,,20221229.0,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217935191.0,HO,,,217935191.0,1.0,2011.0,2017.0,,,217935191.0,1.0,Antiretroviral therapy
21807743,218077431,1,I,,20221220.0,20230103,20230103,EXP,,CA-AUROBINDO-AUR-APL-2022-056016,AUROBINDO,,63.0,YR,,F,Y,,,20230103.0,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,218077431.0,OT,,,,,,,,,218077431.0,1.0,HIV infection
21812941,218129411,1,I,20220101.0,20221226.0,20230103,20230103,EXP,,BY-MYLANLABS-2022M1148509,MYLAN,Gvozdeliuk V O. BONE MINERAL DENSITY IN PATIENTS WITH HIV INFECTION,68.0,YR,,F,Y,,,20230103.0,,HP,BY,BY,EFAVIRENZ,Osteoporosis,218129411.0,DS,,,218129411.0,1.0,2017.0,,,,218129411.0,1.0,HIV infection
21816784,218167841,1,I,,20221228.0,20230104,20230104,EXP,,NA-VIIV HEALTHCARE LIMITED-NA2022GSK193544,VIIV,"Kakubu MAM, Frans K, Gibutai N, Katoto PD. A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions. SAGE Open Medical Case Reports. 2022;10",,,,,Y,,,20230104.0,,HP,,,EFAVIRENZ,Acquired immunodeficiency syndrome;Disease recurrence;Immunosuppression;Malaise;Oesophageal candidiasis;Treatment noncompliance;Virologic failure,218167841.0,OT,,,218167841.0,1.0,20150129.0,20170406.0,210.0,DAY,218167841.0,1.0,HIV infection
21816785,218167851,1,I,,20221228.0,20230104,20230104,EXP,,NA-GSK-NA2022GSK193544,GLAXOSMITHKLINE,"Kakubu MAM, Frans K, Gibutai N, Katoto PD. A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions. SAGE Open Medical Case Reports. 2022;10",,,,,Y,,,20230104.0,,HP,,,EFAVIRENZ,Acquired immunodeficiency syndrome;Disease recurrence;Immunosuppression;Malaise;Oesophageal candidiasis;Treatment noncompliance;Virologic failure,218167851.0,OT,,,218167851.0,1.0,20150129.0,20170406.0,210.0,DAY,218167851.0,1.0,HIV infection
21820307,218203071,1,I,,20221228.0,20230105,20230105,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP000095,STRIDES,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M.. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.. Curr-Drug-Saf. 2022;17(1):40-46.",44.0,YR,,F,Y,,,20230105.0,,HP,IN,IN,EFAVIRENZ,Off label use;SJS-TEN overlap,218203071.0,OT,,,218203071.0,1.0,,,30.0,DAY,218203071.0,1.0,Acquired immunodeficiency syndrome
21822389,218223891,1,I,20220110.0,20230101.0,20230105,20230105,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2023EME000250,VIIV,,,,,,Y,,,20230105.0,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218223891.0,OT,,,218223891.0,1.0,20220101.0,,,,218223891.0,1.0,HIV infection
21822400,218224001,1,I,20220110.0,20230101.0,20230105,20230105,EXP,,FR-GSK-FR2023EME000250,GLAXOSMITHKLINE,,,,,,Y,,,20230105.0,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218224001.0,OT,,,218224001.0,1.0,20220101.0,,,,218224001.0,1.0,HIV infection
21830307,218303071,1,I,,20221228.0,20230106,20230106,EXP,,IN-MYLANLABS-2022M1141448,MYLAN,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Curr-Drug-Saf 2022;17(1):40-46.",44.0,YR,,F,Y,,,20230106.0,,HP,IN,IN,EFAVIRENZ,SJS-TEN overlap,218303071.0,OT,,,,,,,,,218303071.0,1.0,Acquired immunodeficiency syndrome
21830862,218308621,1,I,,20230102.0,20230106,20230106,EXP,,ES-GSK-ES2023GSK000216,GLAXOSMITHKLINE,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308621.0,OT,,,,,,,,,218308621.0,1.0,HIV infection
21830863,218308631,1,I,,20230102.0,20230106,20230106,EXP,,ES-GSK-ES2023GSK000520,GLAXOSMITHKLINE,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308631.0,OT,,,,,,,,,218308631.0,1.0,HIV infection
21830867,218308671,1,I,,20230102.0,20230106,20230106,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2023GSK000216,VIIV,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308671.0,OT,,,,,,,,,218308671.0,1.0,HIV infection
21830869,218308691,1,I,,20230102.0,20230106,20230106,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2023GSK000520,VIIV,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308691.0,OT,,,,,,,,,218308691.0,1.0,HIV infection
21838351,218383511,1,I,,20221230.0,20230109,20230109,EXP,,CA-TEVA-2023-CA-2842697,TEVA,,63.0,YR,A,F,Y,,,20230109.0,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,218383511.0,OT,,,,,,,,,218383511.0,1.0,HIV infection
21844263,218442632,2,F,20080301.0,20231113.0,20230110,20231115,PER,,US-GILEAD-2023-0611855,GILEAD,,50.0,YR,A,M,Y,65.0,KG,20231115.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Emotional distress;Loss of personal independence in daily activities;Pain;Renal failure,218442632.0,OT,,,218442632.0,1.0,2006.0,200610.0,,,218442632.0,1.0,HIV infection
21844827,218448274,4,F,,20231220.0,20230110,20231221,PER,,US-GILEAD-2023-0611873,GILEAD,,,,A,F,Y,,,20231221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Drug ineffective;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Osteoporosis;Pain,218448274.0,OT,,,218448274.0,1.0,2011.0,201812.0,,,218448274.0,1.0,HIV infection
21844837,218448373,3,F,20071001.0,20240313.0,20230110,20240315,EXP,,US-GILEAD-2023-0611874,GILEAD,,43.0,YR,A,M,Y,72.562,KG,20240315.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,218448373.0,OT,,,218448373.0,1.0,2001.0,200609.0,,,218448373.0,1.0,HIV infection
21844859,218448594,4,F,20110101.0,20240322.0,20230110,20240329,EXP,,US-GILEAD-2023-0611875,GILEAD,,,,A,M,Y,183.0,KG,20240326.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Gout;Pain;Pollakiuria;Renal failure;Renal impairment,218448594.0,OT,,,218448594.0,1.0,2014.0,201202.0,,,218448594.0,1.0,HIV infection
21844892,218448923,3,F,20160301.0,20240115.0,20230110,20240117,EXP,,US-GILEAD-2023-0611878,GILEAD,,53.0,YR,A,M,Y,77.098,KG,20240117.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back injury;Bone demineralisation;Chronic kidney disease;Dizziness;Emotional distress;Loss of personal independence in daily activities;Osteoporosis;Pain;Vitamin D deficiency,218448923.0,OT,,,218448923.0,1.0,2004.0,201212.0,,,218448923.0,1.0,HIV infection
21844921,218449213,3,F,20150101.0,20231219.0,20230110,20231221,EXP,,US-GILEAD-2023-0611880,GILEAD,,,,A,M,Y,,,20231220.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Depression;Emotional distress;Fatigue;Osteoporosis;Pain;Renal failure;Rib fracture;Wrist fracture,218449213.0,OT,,,218449213.0,1.0,2012.0,201511.0,,,218449213.0,1.0,HIV infection
21849306,218493061,1,I,20220110.0,20230109.0,20230111,20230111,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-004508,BRISTOL MYERS SQUIBB,,41.0,YR,A,F,Y,,,20230111.0,,CN,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218493061.0,OT,,,218493061.0,1.0,20220101.0,,,,218493061.0,1.0,HIV infection
21864157,218641572,2,F,,20230110.0,20230116,20230120,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-004599,BRISTOL MYERS SQUIBB,,44.0,YR,A,M,Y,,,20230120.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,218641572.0,OT,,,,,,,,,218641572.0,1.0,HIV infection
21878572,218785722,2,F,,20230731.0,20230118,20231018,PER,,US-CIPLA LTD.-2022US07389,CIPLA,,,,,,Y,,,20231018.0,,HP,US,US,EFAVIRENZ,Exposure during pregnancy;No adverse event,,,,,,,,,,,218785722.0,1.0,Antiretroviral therapy
21878649,218786491,1,I,,20230112.0,20230118,20230118,EXP,,ZA-GSK-ZA2023GSK004630,GLAXOSMITHKLINE,"Botha JC, Steegen K, Edoo M, Nel J, van Zyl GU. Low-level viraemia despite emergence of dolutegravir-resistant variants. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20230118.0,,HP,ZA,ZA,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Treatment noncompliance;Viraemia;Viral mutation identified;Virologic failure,218786491.0,OT,,,218786491.0,1.0,2015.0,2015.0,,,218786491.0,1.0,HIV infection
21878650,218786501,1,I,,20230112.0,20230118,20230118,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2023GSK004630,VIIV,"Botha JC, Steegen K, Edoo M, Nel J, van Zyl GU. Low-level viraemia despite emergence of dolutegravir-resistant variants. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20230118.0,,HP,ZA,ZA,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Treatment noncompliance;Viraemia;Viral mutation identified;Virologic failure,218786501.0,OT,,,218786501.0,1.0,2015.0,2015.0,,,218786501.0,1.0,HIV infection
21881778,218817781,1,I,20220110.0,20230107.0,20230119,20230119,EXP,,FR-AUROBINDO-AUR-APL-2023-001519,AUROBINDO,,41.0,YR,,F,Y,,,20230119.0,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218817781.0,OT,,,218817781.0,1.0,20220101.0,,,,218817781.0,1.0,HIV infection
21881972,218819721,1,I,,20230107.0,20230119,20230119,EXP,,ES-AUROBINDO-AUR-APL-2023-001536,AUROBINDO,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.. Frontiers in Microbiology. 2022;13",18.0,YR,,F,Y,,,20230119.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218819721.0,OT,,,,,,,,,218819721.0,1.0,HIV infection
21882800,218828001,1,I,,20230107.0,20230119,20230119,EXP,,ES-AUROBINDO-AUR-APL-2023-001530,AUROBINDO,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM.. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.. Frontiers in Microbiology. 2022;13",31.0,YR,,M,Y,,,20230119.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218828001.0,OT,,,,,,,,,218828001.0,1.0,HIV infection
21891583,218915832,2,F,20121212.0,20240204.0,20230120,20240206,PER,,US-GILEAD-2023-0613241,GILEAD,,45.0,YR,A,M,Y,79.0,KG,20240206.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Emotional distress;Osteopenia;Pain,,,,,218915832.0,1.0,2006.0,201709.0,,,218915832.0,1.0,HIV infection
21892134,218921342,2,F,20190325.0,20240210.0,20230120,20240212,EXP,,US-GILEAD-2023-0613263,GILEAD,,62.0,YR,A,M,Y,,,20240212.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure,218921342.0,OT,,,218921342.0,1.0,2006.0,201903.0,,,218921342.0,1.0,HIV infection
21892749,218927493,3,F,20190101.0,20231124.0,20230120,20231127,EXP,,US-GILEAD-2023-0613231,GILEAD,,57.0,YR,A,M,Y,77.1,KG,20231127.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Clavicle fracture;Emotional distress;Foot fracture;Osteopenia;Osteoporosis;Pain,218927493.0,OT,,,218927493.0,1.0,2006.0,2005.0,,,218927493.0,1.0,HIV infection
21892932,218929323,3,F,20080601.0,20230831.0,20230120,20230906,PER,,US-GILEAD-2023-0613298,GILEAD,,46.0,YR,A,M,Y,97.52,KG,20230906.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Gait disturbance;Pain;Renal impairment,218929323.0,OT,,,218929323.0,1.0,2010.0,201812.0,,,218929323.0,1.0,HIV infection
21892989,218929893,3,F,20180101.0,20240116.0,20230120,20240118,PER,,US-GILEAD-2023-0613303,GILEAD,,,,A,F,Y,,,20240118.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Drug ineffective;Drug resistance;Emotional distress;Loss of personal independence in daily activities;Osteoporosis;Pain,218929893.0,OT,,,218929893.0,1.0,2005.0,2006.0,,,218929893.0,1.0,HIV infection
21893014,218930143,3,F,20121101.0,20231114.0,20230120,20231115,EXP,,US-GILEAD-2023-0613315,GILEAD,,65.0,YR,A,M,Y,72.0,KG,20231115.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Depression;Emotional distress;Foot fracture;Gait disturbance;Osteopenia;Osteoporosis;Pain,218930143.0,OT,,,218930143.0,1.0,2001.0,2011.0,,,218930143.0,1.0,HIV infection
21898448,218984483,3,F,,20230317.0,20230123,20230323,EXP,,ES-MYLANLABS-2023M1006058,MYLAN,"Ventosa-Cubillo J, Pinzon R, Gonzalez-Alba JM, Estripeaut D, Navarro ML, Holguin A. Drug resistance in children and adolescents with HIV in Panama.. The Journal of antimicrobial chemotherapy. 2022",15.0,YR,,,Y,,,20230323.0,,HP,ES,ES,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,218984483.0,OT,,,,,,,,,218984483.0,1.0,Perinatal HIV infection
21900229,219002292,2,F,20110101.0,20231227.0,20230123,20231228,EXP,,US-GILEAD-2023-0613331,GILEAD,,,,A,M,Y,86.0,KG,20231228.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Emotional distress;Osteopenia;Osteoporosis;Pain;Systemic lupus erythematosus,219002292.0,OT,,,219002292.0,1.0,2005.0,2012.0,,,219002292.0,1.0,HIV infection
21900412,219004122,2,F,20131010.0,20240220.0,20230123,20240222,EXP,,US-GILEAD-2023-0613335,GILEAD,,31.0,YR,A,F,Y,,,20240222.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Emotional distress;Impaired work ability;Osteoporosis;Pain;Renal impairment,219004122.0,OT,,,219004122.0,1.0,2006.0,201703.0,,,219004122.0,1.0,HIV infection
21901036,219010363,3,F,20051001.0,20230907.0,20230123,20230912,PER,,US-GILEAD-2023-0613355,GILEAD,,38.0,YR,A,M,Y,57.596,KG,20230912.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Malaise;Pain;Pyrexia;Renal failure;Renal tubular necrosis;Weight decreased,219010363.0,HO,,,219010363.0,1.0,2001.0,200510.0,,,219010363.0,1.0,HIV infection
21901292,219012924,4,F,20111101.0,20231125.0,20230123,20231201,EXP,,US-GILEAD-2023-0613431,GILEAD,,46.0,YR,A,M,Y,63.502,KG,20231201.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,219012924.0,OT,,,219012924.0,1.0,2006.0,200801.0,,,219012924.0,1.0,HIV infection
21901298,219012984,4,F,20140101.0,20231218.0,20230123,20231220,EXP,,US-GILEAD-2023-0613437,GILEAD,,59.0,YR,A,M,Y,107.03,KG,20231220.0,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Emotional distress;End stage renal disease;Pain;Renal failure,219012984.0,HO,,,219012984.0,1.0,2007.0,201308.0,,,219012984.0,1.0,HIV infection
21901315,219013152,2,F,20130601.0,20231011.0,20230123,20231013,EXP,,US-GILEAD-2023-0613443,GILEAD,,55.0,YR,A,M,Y,81.633,KG,20231013.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,219013152.0,OT,,,219013152.0,1.0,200310.0,201601.0,,,219013152.0,1.0,HIV infection
21901336,219013365,5,F,20060101.0,20231218.0,20230123,20231220,PER,,US-GILEAD-2023-0613337,GILEAD,,,,A,M,Y,,,20231220.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Drug ineffective;Emotional distress;End stage renal disease;Fatigue;Hypertension;Loss of personal independence in daily activities;Nephrogenic anaemia;Pain;Pollakiuria;Poor quality sleep;Renal failure;Sexual dysfunction,219013365.0,HO,,,219013365.0,1.0,2001.0,,,,219013365.0,1.0,HIV infection
21909664,219096641,1,I,,20230119.0,20230125,20230125,EXP,,MW-VIIV HEALTHCARE LIMITED-US2023GSK008325,VIIV,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y et al.. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Frontiers in Oncology. 2022;12",,,,,Y,,,20230125.0,,HP,MW,MW,EFAVIRENZ,Anaemia;Castleman's disease;Condition aggravated;Fatigue;Human herpesvirus 8 infection;Immune reconstitution inflammatory syndrome;Lymphadenitis viral;Lymphadenopathy;Malaise;Myalgia;Night sweats;Pyrexia;Virologic failure;Weight decreased,219096641.0,OT,,,,,,,,,219096641.0,1.0,HIV infection
21909665,219096651,1,I,,20230119.0,20230125,20230125,EXP,,MW-GSK-US2023GSK008325,GLAXOSMITHKLINE,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y et al.. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Frontiers in Oncology. 2022;12",,,,,Y,,,20230125.0,,HP,MW,MW,EFAVIRENZ,Anaemia;Castleman's disease;Condition aggravated;Fatigue;Human herpesvirus 8 infection;Immune reconstitution inflammatory syndrome;Lymphadenitis viral;Lymphadenopathy;Malaise;Myalgia;Night sweats;Pyrexia;Virologic failure;Weight decreased,219096651.0,OT,,,,,,,,,219096651.0,1.0,HIV infection
21911786,219117861,1,I,,20230123.0,20230125,20230125,EXP,,IN-GILEAD-2023-0614073,GILEAD,"Barman B, Jamil M, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229-230. doi:10.4103/ijstd.ijstd_99_21",28.0,YR,A,M,Y,,,20230125.0,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,219117861.0,OT,,,,,,,,,219117861.0,1.0,HIV infection
21918755,219187551,1,I,,20230116.0,20230127,20230127,EXP,,US-CIPLA LTD.-2023US00317,CIPLA,"Church LWP, Judson MA, Chopra A. Paradoxical Reactions and the Immune Reconstitution In?ammatory Syndrome. Microbiol Spectrum. 2017;5 (2):1 to 15",39.0,YR,,F,Y,,,20230127.0,,HP,US,US,EFAVIRENZ,Disease recurrence;Sarcoidosis;Treatment noncompliance,219187551.0,HO,,,,,,,,,219187551.0,1.0,HIV infection
21920283,219202835,5,F,20100629.0,20230223.0,20230127,20230306,EXP,,GB-HORMOSAN PHARMA GMBH-2022-15144,LUPIN,,3.0,MON,,M,Y,,,20230306.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,219202835.0,HO,,,219202835.0,1.0,20171006.0,20180205.0,4.0,MON,219202835.0,1.0,HIV infection
21923583,219235833,3,F,,20240927.0,20230130,20241007,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-013331,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20241007.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Death,219235833.0,DE,,,,,,,,,219235833.0,1.0,HIV infection
21924600,219246002,2,F,,20230206.0,20230130,20230220,EXP,,ZA-CIPLA (EU) LIMITED-2023ZA00314,CIPLA,"Botha JC, Steegen K, Edoo M, Nel J, Van Zyl GU.. Low-level viraemia despite emergence of dolutegravir-resistant variants. Southern African Journal of HIV Medicine. 2022;23 (1):1 to 4",,,,,Y,,,20230220.0,,MD,ZA,ZA,EFAVIRENZ,Diarrhoea;Drug resistance;Treatment noncompliance;Viral load increased;Virologic failure,219246002.0,HO,,,219246002.0,1.0,2012.0,2015.0,,,219246002.0,1.0,HIV infection
21935581,219355811,1,I,,20230125.0,20230201,20230201,EXP,,FR-MYLANLABS-2023M1010955,MYLAN,"Faure C, Chassery M, Ores R, Audo I. Didanosine-induced Retinopathy: New Insights with Long-term Follow-up. Ocular-Immunol-Inflamm 2022;30(7):1625-1632.",56.0,YR,,M,Y,,,20230201.0,,MD,FR,FR,EFAVIRENZ,Labelled drug-disease interaction medication error;Retinopathy,219355811.0,OT,,,,,,,,,219355811.0,1.0,HIV infection
21944224,219442241,1,I,,20230123.0,20230202,20230202,EXP,,CA-TEVA-2023-CA-2850572,TEVA,,54.0,YR,A,M,Y,,,20230202.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,219442241.0,OT,,,,,,,,,219442241.0,1.0,HIV infection
21944229,219442291,1,I,,20230123.0,20230202,20230202,EXP,,CA-TEVA-2023-CA-2850580,TEVA,,54.0,YR,A,M,Y,,,20230202.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219442291.0,OT,,,,,,,,,219442291.0,1.0,HIV infection
21948224,219482241,1,I,,20230123.0,20230203,20230203,EXP,,CA-TEVA-2023-CA-2850542,TEVA,,54.0,YR,A,M,Y,,,20230202.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,219482241.0,HO,,,,,,,,,219482241.0,1.0,HIV infection
21948227,219482271,1,I,,20230123.0,20230203,20230203,EXP,,CA-TEVA-2023-CA-2850536,TEVA,,54.0,YR,A,M,Y,,,20230202.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219482271.0,OT,,,,,,,,,219482271.0,1.0,HIV infection
21948229,219482291,1,I,,20230123.0,20230203,20230203,EXP,,CA-TEVA-2023-CA-2850541,TEVA,,54.0,YR,A,M,Y,,,20230202.0,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,219482291.0,OT,,,,,,,,,219482291.0,1.0,HIV infection
21949113,219491132,2,F,20120521.0,20230213.0,20230203,20230215,EXP,,NVSC2019GB122185,NOVARTIS,,43.0,YR,,F,Y,,,20230215.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Ultrasound antenatal screen,219491132.0,OT,,,219491132.0,3.0,20180205.0,20180205.0,1.0,DAY,219491132.0,1.0,HIV infection
21952729,219527291,1,I,,20230125.0,20230204,20230204,EXP,,IN-HETERO-HET2023IN00198,HETERO,"Barman B, Jamil Md, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229-230",28.0,YR,,M,Y,,,20230204.0,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,219527291.0,OT,,,,,,,,,219527291.0,1.0,Antiretroviral therapy
21958982,219589822,2,F,,20230125.0,20230206,20230209,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2023-010569,BRISTOL MYERS SQUIBB,"Barman B, Jamil M, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022 Nov 17;43(2):229-30.doi:10.4103/ijstd.ijstd_99_21.",28.0,YR,A,M,Y,,,20230210.0,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,219589822.0,OT,,,,,,,,,219589822.0,1.0,Antiretroviral therapy
21960652,219606521,1,I,,20230123.0,20230207,20230207,EXP,,MW-CIPLA (EU) LIMITED-2023MW00432,CIPLA,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y et.al. Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Frontiers in oncology. 2022;12:969135:01 to 06",,,,,Y,,,20230207.0,,HP,MW,MW,EFAVIRENZ,Castleman's disease;Haemoglobin decreased;Immune reconstitution inflammatory syndrome;Platelet count decreased;Virologic failure,219606521.0,OT,,,,,,,,,219606521.0,1.0,HIV infection
21962089,219620891,1,I,20201228.0,20230130.0,20230207,20230207,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK014191,VIIV,"Cui X, Su F, Ye H, Jiang Y, Guo X. Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report. BMC Infectious Diseases. 2022;22 (1)",,,,,Y,,,20230207.0,,HP,CN,CN,EFAVIRENZ,Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Discomfort;Drug interaction;Faeces discoloured;Gastrointestinal haemorrhage;Gastrointestinal inflammation;Hypotension;Liver function test abnormal;Myelosuppression;Pathogen resistance;Penicillium infection;Rash papular;Shock haemorrhagic;Skin lesion;Skin necrosis;Ulcer;Virologic failure,219620891.0,OT,,,219620891.0,1.0,,,5.0,YR,219620891.0,1.0,HIV infection
21962092,219620921,1,I,20201228.0,20230130.0,20230207,20230207,EXP,,CN-GSK-CN2023GSK014191,GLAXOSMITHKLINE,"Cui X, Su F, Ye H, Jiang Y, Guo X. Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report. BMC Infectious Diseases. 2022;22 (1)",,,,,Y,,,20230207.0,,HP,CN,CN,EFAVIRENZ,Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Discomfort;Drug interaction;Faeces discoloured;Gastrointestinal haemorrhage;Gastrointestinal inflammation;Hypotension;Liver function test abnormal;Myelosuppression;Pathogen resistance;Penicillium infection;Rash papular;Shock haemorrhagic;Skin lesion;Skin necrosis;Ulcer;Virologic failure,219620921.0,OT,,,219620921.0,1.0,,,5.0,YR,219620921.0,1.0,HIV infection
21962826,219628261,1,I,,20230201.0,20230207,20230207,EXP,,ES-MYLANLABS-2023M1012000,MYLAN,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology.. 2022;13",18.0,YR,,F,Y,,,20230207.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,219628261.0,OT,,,,,,,,,219628261.0,1.0,HIV infection
21964425,219644251,1,I,20220110.0,20230201.0,20230207,20230207,EXP,,FR-MYLANLABS-2023M1011801,MYLAN,,41.0,YR,,F,Y,,,20230207.0,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,219644251.0,OT,,,219644251.0,1.0,20220101.0,,,,219644251.0,1.0,HIV infection
21964445,219644451,1,I,,20230201.0,20230207,20230207,EXP,,ES-MYLANLABS-2023M1012004,MYLAN,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM.. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.. Frontiers in Microbiology.. 2022;13",31.0,YR,,M,Y,,,20230207.0,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,219644451.0,OT,,,,,,,,,219644451.0,1.0,HIV infection
21965274,219652741,1,I,,20230125.0,20230208,20230208,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2023039666,MACLEODS,"Barman B, Jamil Md, Dey B, Ish P.. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229-30",,,,,Y,,,20230208.0,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,219652741.0,OT,,,,,,,,,219652741.0,1.0,Antiretroviral therapy
21970432,219704321,1,I,,20230125.0,20230209,20230209,EXP,,IN-CIPLA (EU) LIMITED-2023IN00390,CIPLA,"Barman B, Jamil M, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229 to 230",,,,,Y,,,20230209.0,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,219704321.0,OT,,,,,,,,,219704321.0,1.0,HIV infection
21981649,219816491,1,I,,20230203.0,20230212,20230212,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-2022-094992,BRISTOL MYERS SQUIBB,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer dementia in people living with HIV. Neurology: Clinical Practice. 2021; 11(5): e627-33. 10.1212/CPJ.0000000000001060",71.0,YR,E,M,Y,,,20230212.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,219816491.0,OT,,,,,,,,,219816491.0,1.0,HIV infection
21984954,219849545,5,F,20211101.0,20240531.0,20230213,20240607,EXP,,US-VIIV HEALTHCARE LIMITED-US2023AMR018948,VIIV,,,,,,Y,,,20240607.0,,HP,US,US,SUSTIVA,Gun shot wound;Hypokinesia;Paralysis;Pyrexia;Skin laceration;Thrombocytopenia;Wound infection,219849545.0,DS,,,219849545.0,1.0,2019.0,2019.0,,,219849545.0,1.0,HIV infection
21987515,219875151,1,I,20201201.0,20230131.0,20230214,20230214,EXP,,CN-CIPLA LTD.-2023CN00833,CIPLA,"Cui X, Su F, Ye H, Jiang Y, Guo X.. Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report. BMC Infectious Diseases. 2022;22:238:1 to 6",,,,,Y,,,20230214.0,,HP,CN,CN,EFAVIRENZ,Discomfort;Virologic failure,219875151.0,OT,,,219875151.0,1.0,2015.0,202011.0,4.0,DAY,219875151.0,1.0,HIV infection
21990501,219905011,1,I,,20230208.0,20230214,20230214,EXP,,ZA-MYLANLABS-2023M1015516,MYLAN,"Botha JC, Steegen K, Edoo M, Nel J, van Zyl GU. Low-level viraemia despite emergence of dolutegravir-resistant variants. South-Afr-J-HIV-Med 2022;23(1):a1398.",,,A,M,Y,,,20230214.0,,HP,ZA,ZA,EFAVIRENZ,Diarrhoea;Pathogen resistance;Virologic failure,219905011.0,OT,,,,,,,,,219905011.0,1.0,HIV infection
21996663,219966631,1,I,,20230208.0,20230215,20230215,EXP,,IN-MYLANLABS-2023M1016669,MYLAN,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. J-Indian-Acad-Clin-Med 2022;23(3):154-156.",30.0,YR,,M,Y,,,20230215.0,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Paradoxical drug reaction,219966631.0,OT,,,,,,,,,219966631.0,1.0,HIV infection
21998557,219985571,1,I,,20230208.0,20230216,20230216,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP002348,STRIDES,"Parvez S, Goel P, Sarna MK, Rijhwani P.. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy.. J-Indian-Acad-Clin-Med.. 2022;23(3):154-156.",30.0,YR,,M,Y,,,20230216.0,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Paradoxical drug reaction,219985571.0,OT,,,,,,,,,219985571.0,1.0,HIV infection
21999608,219996081,1,I,,20230206.0,20230216,20230216,EXP,,FR-TEVA-2023-FR-2855921,TEVA,,56.0,YR,A,M,Y,,,20230216.0,,MD,FR,FR,EFAVIRENZ,Drug interaction;Retinopathy,219996081.0,OT,,,,,,,,,219996081.0,1.0,HIV infection
22005246,220052461,1,I,,20230210.0,20230217,20230217,EXP,,ES-GSK-ES2023GSK022581,GLAXOSMITHKLINE,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018. BMC Infectious Diseases. 2022;22(1)",,,,,Y,,,20230217.0,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220052461.0,OT,,,,,,,,,220052461.0,1.0,HIV infection
22005247,220052471,1,I,,20230210.0,20230217,20230217,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2023GSK022581,VIIV,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018. BMC Infectious Diseases. 2022;22(1)",,,,,Y,,,20230217.0,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220052471.0,OT,,,,,,,,,220052471.0,1.0,HIV infection
22006388,220063883,3,F,,20230217.0,20230217,20230302,EXP,,CN-GILEAD-2023-0616851,GILEAD,"Hengli L, Xia L, Xinping Y, Cuixian Y, Mi Z, Huiqin L, et al.. Analysis on clinical characteristics of tenofovir disoproxil fumarate-related Fanconi syndrome in patients with HIV infection/AIDS. ADRJ. 2023;25(1):Unk. doi:10.3760/cma.j.cn114015?20220603?00491",19.0,YR,A,F,Y,38.0,KG,20230302.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220063883.0,HO,,,,,,,,,220063883.0,1.0,HIV infection
22011038,220110383,3,F,,20230217.0,20230220,20230309,EXP,,CN-GSK-CN2023026500,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220110383.0,HO,,,,,,,,,220110383.0,1.0,HIV infection
22011039,220110393,3,F,,20230217.0,20230220,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023026500,VIIV,,,,,,Y,,,20230309.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220110393.0,HO,,,,,,,,,220110393.0,1.0,HIV infection
22014511,220145111,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00980,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et al.. Efficacy of Efavirenz-Based Regimen in Antiretroviral-Naive Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145111.0,OT,,,,,,,,,220145111.0,1.0,HIV infection
22014512,220145121,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00982,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145121.0,OT,,,,,,,,,220145121.0,1.0,HIV infection
22014515,220145151,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00983,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145151.0,OT,,,,,,,,,220145151.0,1.0,HIV infection
22014516,220145161,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00981,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral Naive Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145161.0,OT,,,,,,,,,220145161.0,1.0,HIV infection
22014517,220145171,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00986,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral Naive Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145171.0,OT,,,,,,,,,220145171.0,1.0,HIV infection
22015137,220151371,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00985,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et al.. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245-55",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220151371.0,OT,,,,,,,,,220151371.0,1.0,HIV infection
22015139,220151391,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00979,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et al.. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220151391.0,OT,,,,,,,,,220151391.0,1.0,HIV infection
22015141,220151411,1,I,,20230208.0,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00984,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221.0,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220151411.0,OT,,,,,,,,,220151411.0,1.0,HIV infection
22017801,220178012,2,F,,20230213.0,20230221,20230327,EXP,,AU-GILEAD-2023-0617264,GILEAD,,,,A,F,Y,,,20230327.0,,CN,AU,AU,EFAVIRENZ,Feeling abnormal;Lipodystrophy acquired;Nightmare;Sleep disorder;Weight increased,220178012.0,OT,,,220178012.0,1.0,200808.0,201908.0,,,220178012.0,1.0,HIV infection
22020669,220206691,1,I,,20230214.0,20230222,20230222,EXP,,MW-MYLANLABS-2023M1018835,MYLAN,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y, et al. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Front-Oncol 2022;12:969135.",36.0,YR,,F,Y,,,20230222.0,,HP,MW,MW,EFAVIRENZ,Castleman's disease;Human herpesvirus 8 infection;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Treatment failure;Unmasking of previously unidentified disease,220206691.0,OT,,,,,,,,,220206691.0,1.0,HIV infection
22021503,220215033,3,F,,20230217.0,20230222,20230309,EXP,,CN-GSK-CN2023029276,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220215033.0,OT,,,,,,,,,220215033.0,1.0,HIV infection
22021504,220215043,3,F,,20230217.0,20230222,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023029276,VIIV,,,,,,Y,,,20230309.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220215043.0,OT,,,,,,,,,220215043.0,1.0,HIV infection
22022496,220224961,1,I,,20230213.0,20230222,20230222,EXP,,US-GSK-US2023GSK027765,GLAXOSMITHKLINE,"Horner M, Hazra R, Barnholtz-Sloan JS, Shiels MS, Engels EA. Cancer risk among HIV-exposed uninfected children in the United States. AIDS. 2023;37 (3):549-551",,,,,Y,,,20230222.0,,HP,US,US,EFAVIRENZ,Ependymoma;Foetal exposure during pregnancy,220224961.0,OT,,,,,,,,,220224961.0,1.0,Prophylaxis against HIV infection
22023930,220239301,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003777,APOTEX,,54.0,YR,,M,Y,,,20230223.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,220239301.0,OT,,,,,,,,,220239301.0,1.0,HIV infection
22026640,220266401,1,I,,20230223.0,20230223,20230223,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-220660",BOEHRINGER INGELHEIM,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018. BMC Infectious Diseases. 2022;22(1):doi:10.1186/s12879-022-07311-8",4.0,YR,C,,Y,,,20230223.0,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220266401.0,OT,,,,,,,,,220266401.0,1.0,HIV infection
22027059,220270591,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003784,APOTEX,,54.0,YR,,M,Y,,,20230223.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,220270591.0,DE,,,,,,,,,220270591.0,1.0,HIV infection
22027340,220273401,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003787,APOTEX,,54.0,YR,,M,Y,,,20230223.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220273401.0,OT,,,,,,,,,220273401.0,1.0,HIV infection
22027879,220278791,1,I,,20230213.0,20230223,20230223,EXP,,US-VIIV HEALTHCARE LIMITED-US2023GSK027765,VIIV,"Horner M, Hazra R, Barnholtz-Sloan JS, Shiels MS, Engels EA. Cancer risk among HIV-exposed uninfected children in the United States. AIDS. 2023;37 (3):549-551",,,,,Y,,,20230223.0,,HP,US,US,EFAVIRENZ,Ependymoma;Foetal exposure during pregnancy,220278791.0,OT,,,,,,,,,220278791.0,1.0,Prophylaxis against HIV infection
22029095,220290952,2,F,,20230217.0,20230223,20230303,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023029360,VIIV,,,,,,Y,,,20230303.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220290952.0,OT,,,,,,,,,220290952.0,1.0,HIV infection
22029096,220290962,2,F,,20230217.0,20230223,20230303,EXP,,CN-GSK-CN2023029360,GLAXOSMITHKLINE,,,,,,Y,,,20230303.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220290962.0,OT,,,,,,,,,220290962.0,1.0,HIV infection
22032938,220329381,1,I,,20230214.0,20230224,20230224,EXP,,MW-STRIDES ARCOLAB LIMITED-2023SP002539,STRIDES,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y, et al.. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi.. Front-Oncol. 2022;12969135.",36.0,YR,,F,Y,,,20230224.0,,HP,MW,MW,EFAVIRENZ,Castleman's disease;Herpes virus infection;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Treatment failure;Unmasking of previously unidentified disease,220329381.0,OT,,,,,,,,,220329381.0,1.0,HIV infection
22034775,220347752,2,F,,20230214.0,20230224,20230303,EXP,,CN-GSK-CN2023030319,GLAXOSMITHKLINE,"Hengli L, Xia L, Xinping Y, Cuixian Y, Mi Z ,Huiqin L. etal. Analysis on clinical characteristics of tenofovir disoproxil fumarate-related Fanconi syndrome in patients with HIV infection/AIDS. ADRJ. 2023;25(1):unk",,,,,Y,,,20230303.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220347752.0,HO,,,,,,,,,220347752.0,1.0,HIV infection
22034776,220347762,2,F,,20230214.0,20230224,20230303,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023030319,VIIV,"Hengli L, Xia L, Xinping Y, Cuixian Y, Mi Z ,Huiqin L. etal. Analysis on clinical characteristics of tenofovir disoproxil fumarate-related Fanconi syndrome in patients with HIV infection/AIDS. ADRJ. 2023;25(1):unk",,,,,Y,,,20230303.0,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220347762.0,HO,,,,,,,,,220347762.0,1.0,HIV infection
22039184,220391841,1,I,,20230215.0,20230227,20230227,EXP,,CA-APOTEX-2023AP003773,APOTEX,,54.0,YR,,M,Y,,,20230227.0,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,220391841.0,OT,,,,,,,,,220391841.0,1.0,HIV infection
22043195,220431951,1,I,,20230220.0,20230228,20230228,EXP,,CA-009507513-2302CAN007028,MERCK,,54.0,YR,,M,Y,,,20230228.0,,CN,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,220431951.0,OT,,,,,,,,,220431951.0,1.0,HIV infection
22043323,220433231,1,I,,20230217.0,20230228,20230228,EXP,,IN-AUROBINDO-AUR-APL-2023-002010,AUROBINDO,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M.. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.. Current Drug Safety. 2022;17(1):40-46",44.0,YR,,F,Y,,,20230228.0,,HP,IN,IN,EFAVIRENZ,SJS-TEN overlap;Stevens-Johnson syndrome;Toxic epidermal necrolysis,220433231.0,OT,,,,,,,,,220433231.0,1.0,Acquired immunodeficiency syndrome
22046308,220463082,2,F,20080301.0,20240210.0,20230228,20240212,PER,,US-GILEAD-2023-0618197,GILEAD,,49.0,YR,A,M,Y,111.11,KG,20240212.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Arthritis;Blood creatinine increased;Emotional distress;Pain;Renal impairment,220463082.0,OT,,,220463082.0,1.0,200606.0,200803.0,,,220463082.0,1.0,HIV infection
22046312,220463122,2,F,20130801.0,20240221.0,20230228,20240222,EXP,,US-GILEAD-2023-0618200,GILEAD,,48.0,YR,A,M,Y,95.0,KG,20240221.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Dysstasia;Emotional distress;Nephrolithiasis;Osteoporosis;Pain;Renal impairment,220463122.0,OT,,,220463122.0,1.0,2001.0,20150707.0,340.0,DAY,220463122.0,1.0,HIV infection
22046340,220463403,3,F,20150101.0,20231114.0,20230228,20231116,EXP,,US-GILEAD-2023-0618228,GILEAD,,,,A,M,Y,,,20231116.0,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bipolar disorder;Depression;Emotional distress;Pain;Renal failure;Schizophrenia,220463403.0,OT,,,220463403.0,1.0,2008.0,201901.0,,,220463403.0,1.0,HIV infection
22056108,220561082,2,F,20210913.0,20230221.0,20230302,20230303,EXP,,CN-GILEAD-2023-0617948,GILEAD,,30.0,YR,A,M,Y,80.0,KG,20230303.0,,HP,CN,CN,EFAVIRENZ,Angina pectoris,220561082.0,OT,,,220561082.0,1.0,20140730.0,20210224.0,2401.0,DAY,220561082.0,1.0,HIV infection
22058305,220583052,2,F,,20230803.0,20230303,20230817,EXP,,CO-CIPLA LTD.-2023CO01159,CIPLA,"Ardila-Suarez OM, Oriz-Benjumea L, Arteta AA, Guevara-Casallas LG. Drug-induced liver injury: Relation between the R ratio and histopathology. Journal of Gastroenterology of Mexico. 2023;88 (1):19 to 27",,,,,Y,,,20230817.0,,HP,CO,CO,EFAVIRENZ,Chronic hepatitis;Drug-induced liver injury;Hepatocellular injury,220583052.0,OT,,,,,,,,,220583052.0,1.0,HIV infection
22061346,220613461,1,I,,20230220.0,20230304,20230304,EXP,,IN-AUROBINDO-AUR-APL-2023-009426,AUROBINDO,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. J-Indian-Acad-Clin-Med. 2022;23(3):154-156",30.0,YR,,M,Y,,,20230304.0,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,220613461.0,OT,,,,,,,,,220613461.0,1.0,HIV infection
22062007,220620071,1,I,,20230221.0,20230304,20230304,EXP,,ES-AUROBINDO-AUR-APL-2023-008823,AUROBINDO,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al.. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018.. BMC Infectious Diseases. 2022;22(1)",4.0,YR,,,Y,,,20230304.0,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220620071.0,OT,,,,,,,,,220620071.0,1.0,HIV infection
22063544,220635442,2,F,,20230803.0,20230306,20230817,EXP,,CO-CIPLA LTD.-2023CO01160,CIPLA,"Ardila-Suarez OM, Oriz-Benjumea L, Arteta AA, Guevara-Casallas LG.. Drug-induced liver injury: Relation between the R ratio and histopathology.. Journal of Gastroenterology of Mexico. 2023;88 (1):19 to 27",,,,,Y,,,20230817.0,,HP,CO,CO,EFAVIRENZ,Chronic hepatitis;Drug-induced liver injury;Hepatocellular injury,220635442.0,HO,,,,,,,,,220635442.0,1.0,HIV infection
22065473,220654731,1,I,,20230222.0,20230306,20230306,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-027227,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20230306.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220654731.0,OT,,,,,,,,,220654731.0,1.0,HIV infection
22066492,220664922,2,F,,20230803.0,20230306,20230817,EXP,,CO-CIPLA LTD.-2023CO01161,CIPLA,"Ardila-Suarez OM, Oriz-Benjumea L, Arteta AA, Guevara-Casallas LG. Drug-induced liver injury: Relation between the R ratio and histopathology. Journal of Gastroenterology of Mexico. 2023;88 (1):19 to 27",,,,,Y,,,20230817.0,,HP,CO,CO,EFAVIRENZ,Drug-induced liver injury;Mixed liver injury,220664922.0,OT,,,,,,,,,220664922.0,1.0,HIV infection
22073905,220739051,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK036255,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220739051.0,OT,,,,,,,,,220739051.0,1.0,HIV infection CDC category B
22073906,220739061,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036255,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220739061.0,OT,,,,,,,,,220739061.0,1.0,HIV infection CDC category B
22074186,220741861,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035121,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741861.0,OT,,,,,,,,,220741861.0,1.0,HIV infection
22074188,220741881,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035120,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220741881.0,OT,,,,,,,,,220741881.0,1.0,HIV infection
22074189,220741891,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035121,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741891.0,OT,,,,,,,,,220741891.0,1.0,HIV infection
22074190,220741901,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035120,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220741901.0,OT,,,,,,,,,220741901.0,1.0,HIV infection
22074191,220741911,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035119,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220741911.0,OT,,,,,,,,,220741911.0,1.0,HIV infection
22074192,220741921,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035119,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220741921.0,OT,,,,,,,,,220741921.0,1.0,HIV infection
22074193,220741931,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035122,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741931.0,OT,,,,,,,,,220741931.0,1.0,HIV infection
22074194,220741941,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035122,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741941.0,OT,,,,,,,,,220741941.0,1.0,HIV infection
22074234,220742341,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035123,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742341.0,OT,,,,,,,,,220742341.0,1.0,HIV infection
22074235,220742351,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035124,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742351.0,OT,,,,,,,,,220742351.0,1.0,HIV infection CDC category B
22074236,220742361,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036253,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742361.0,OT,,,,,,,,,220742361.0,1.0,HIV infection
22074237,220742371,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035123,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742371.0,OT,,,,,,,,,220742371.0,1.0,HIV infection
22074238,220742381,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK036253,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742381.0,OT,,,,,,,,,220742381.0,1.0,HIV infection
22074239,220742391,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK036254,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742391.0,OT,,,,,,,,,220742391.0,1.0,HIV infection
22074240,220742401,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036254,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742401.0,OT,,,,,,,,,220742401.0,1.0,HIV infection
22074241,220742411,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035124,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742411.0,OT,,,,,,,,,220742411.0,1.0,HIV infection CDC category B
22074711,220747111,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035771,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220747111.0,OT,,,,,,,,,220747111.0,1.0,HIV infection CDC category A
22074712,220747121,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035772,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220747121.0,OT,,,,,,,,,220747121.0,1.0,HIV infection
22074715,220747151,1,I,,20230302.0,20230308,20230308,EXP,,CN-GSK-CN2023GSK035771,GLAXOSMITHKLINE,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220747151.0,OT,,,,,,,,,220747151.0,1.0,HIV infection CDC category A
22074716,220747161,1,I,,20230302.0,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035772,VIIV,,,,,,Y,,,20230308.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220747161.0,OT,,,,,,,,,220747161.0,1.0,HIV infection
22075622,220756221,1,I,20090101.0,20230306.0,20230308,20230308,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2023-033362,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20230308.0,,CN,PT,PT,EFAVIRENZ,Lipodystrophy acquired,220756221.0,OT,,,220756221.0,1.0,2001.0,,,,220756221.0,1.0,HIV infection
22077693,220776931,1,I,20210913.0,20230222.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023033979,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,Angina pectoris,220776931.0,OT,,,220776931.0,1.0,20140730.0,20210224.0,2401.0,DAY,220776931.0,1.0,HIV infection
22077726,220777261,1,I,20210913.0,20230222.0,20230309,20230309,EXP,,CN-GSK-CN2023033979,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,Angina pectoris,220777261.0,OT,,,220777261.0,1.0,20140730.0,20210224.0,2401.0,DAY,220777261.0,1.0,HIV infection
22077813,220778131,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036087,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778131.0,OT,,,,,,,,,220778131.0,1.0,HIV infection
22077815,220778151,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036087,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778151.0,OT,,,,,,,,,220778151.0,1.0,HIV infection
22077871,220778711,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036212,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778711.0,OT,,,,,,,,,220778711.0,1.0,HIV infection
22077872,220778721,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036210,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220778721.0,OT,,,,,,,,,220778721.0,1.0,HIV infection
22077873,220778731,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036235,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778731.0,OT,,,,,,,,,220778731.0,1.0,HIV infection
22077874,220778741,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036236,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778741.0,OT,,,,,,,,,220778741.0,1.0,HIV infection
22077877,220778771,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036212,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778771.0,OT,,,,,,,,,220778771.0,1.0,HIV infection
22077878,220778781,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036235,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778781.0,OT,,,,,,,,,220778781.0,1.0,HIV infection
22077879,220778791,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036210,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220778791.0,OT,,,,,,,,,220778791.0,1.0,HIV infection
22077880,220778801,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036236,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778801.0,OT,,,,,,,,,220778801.0,1.0,HIV infection
22077881,220778811,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036211,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778811.0,OT,,,,,,,,,220778811.0,1.0,HIV infection
22077882,220778821,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036211,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778821.0,OT,,,,,,,,,220778821.0,1.0,HIV infection
22078372,220783721,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036208,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220783721.0,OT,,,,,,,,,220783721.0,1.0,HIV infection
22078373,220783731,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036208,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220783731.0,OT,,,,,,,,,220783731.0,1.0,HIV infection
22078612,220786121,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036209,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220786121.0,OT,,,,,,,,,220786121.0,1.0,HIV infection
22078614,220786141,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036209,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220786141.0,OT,,,,,,,,,220786141.0,1.0,HIV infection
22078944,220789441,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036089,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220789441.0,OT,,,,,,,,,220789441.0,1.0,HIV infection
22078945,220789451,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036089,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220789451.0,OT,,,,,,,,,220789451.0,1.0,HIV infection
22078946,220789461,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036088,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220789461.0,OT,,,,,,,,,220789461.0,1.0,HIV infection CDC category B
22078947,220789471,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036088,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220789471.0,OT,,,,,,,,,220789471.0,1.0,HIV infection CDC category B
22079007,220790071,1,I,,20230302.0,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036090,VIIV,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220790071.0,OT,,,,,,,,,220790071.0,1.0,HIV infection
22079008,220790081,1,I,,20230302.0,20230309,20230309,EXP,,CN-GSK-CN2023GSK036090,GLAXOSMITHKLINE,,,,,,Y,,,20230309.0,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220790081.0,OT,,,,,,,,,220790081.0,1.0,HIV infection
22088611,220886111,1,I,20180829.0,20230308.0,20230313,20230313,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2023JPN036936,VIIV,,,,,,Y,,,20230313.0,,MD,JP,JP,EFAVIRENZ,Insomnia;Syphilis,220886111.0,OT,,,220886111.0,1.0,20170130.0,20220611.0,1958.0,DAY,220886111.0,1.0,HIV infection
22090734,220907341,1,I,,20230310.0,20230313,20230313,EXP,,US-GILEAD-2023-0620036,GILEAD,,64.0,YR,A,M,Y,,,20230313.0,,CN,US,US,SUSTIVA,Anxiety;Autonomic neuropathy;Brain neoplasm;Fatigue;Headache;Muscle atrophy;Terminal state;Unevaluable event,220907341.0,OT,,,,,,,,,220907341.0,1.0,HIV infection
22096710,220967101,1,I,,20230305.0,20230315,20230315,EXP,,IN-HETERO-HET2023IN00534,HETERO,"Joseph A, Cherian KE, Kapoor N, Paul TV. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density trabecular bone score and proximal hip geometry change with treatment?. Endocrinology, Diabetes + Metabolism Case Reports.. 2023;2023(1):1-5",46.0,YR,,F,Y,,,20230315.0,,HP,IN,IN,EFAVIRENZ,Hypophosphataemic osteomalacia;Renal tubular acidosis,220967101.0,OT,,,,,,,,,220967101.0,1.0,HIV infection
22100706,221007062,2,F,,20230421.0,20230316,20230506,EXP,,IN-MACLEODS PHARMA EU LTD-MAC2023040244,MACLEODS,"Joseph A, Cherian KE, Kapoor N, Paul TV.. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density, trabecular bone score and proximal hip geometry change with treatment?. Endocrinology Diabetes Metabolism Case Reports. 2023;22:0259",,,,,Y,,,20230505.0,,MD,IN,IN,EFAVIRENZ,Femoral neck fracture;Femur fracture;Hypokalaemia;Hypophosphataemic osteomalacia;Osteopenia;Osteoporosis;Renal tubular acidosis;Stress fracture,221007062.0,OT,,,221007062.0,1.0,,,12.0,YR,221007062.0,1.0,Antiretroviral therapy
22107824,221078241,1,I,20090101.0,20230306.0,20230317,20230317,EXP,,PT-AUROBINDO-AUR-APL-2023-011203,AUROBINDO,,,,A,F,Y,,,20230317.0,,MD,PT,PT,EFAVIRENZ,Lipodystrophy acquired,221078241.0,OT,,,221078241.0,1.0,2001.0,,,,221078241.0,1.0,HIV infection
22114454,221144542,2,F,,20230317.0,20230320,20230323,EXP,FR-AFSSAPS-PC2023000309,FR-VIIV HEALTHCARE LIMITED-FR2023041159,VIIV,,,,,,Y,,,20230323.0,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221144542.0,OT,,,221144542.0,1.0,20221215.0,20230130.0,46.0,DAY,221144542.0,1.0,HIV infection
22117303,221173031,1,I,,20230310.0,20230320,20230320,EXP,,CA-TEVA-2023-CA-2868081,TEVA,,54.0,YR,A,M,Y,,,20230321.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,221173031.0,OT,,,,,,,,,221173031.0,1.0,HIV infection
22117321,221173211,1,I,,20230310.0,20230320,20230320,EXP,,CA-TEVA-2023-CA-2868085,TEVA,,54.0,YR,A,M,Y,,,20230321.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,221173211.0,OT,,,,,,,,,221173211.0,1.0,HIV infection
22118387,221183871,1,I,,20230306.0,20230321,20230321,EXP,,ZA-CIPLA LTD.-2023ZA01640,CIPLA,"Munsami L, Schutte CM, De Villiers M, Hiesgen J. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa. Southern African Journal of HIV Medicine. 2023;24(1):01 to 06",,,,,Y,,,20230321.0,,HP,ZA,ZA,EFAVIRENZ,Ataxia;Cerebellar atrophy;Loss of personal independence in daily activities;Mobility decreased;Toxicity to various agents;Wheelchair user,221183871.0,HO,,,,,,,,,221183871.0,1.0,HIV infection
22122696,221226961,1,I,20120521.0,20230208.0,20230321,20230321,EXP,GB-NOVPHSZ-PHHY2018GB086977,GB-ABBVIE-4300293,ABBVIE,,43.0,YR,,F,Y,43.0,KG,20230321.0,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Maternal exposure during pregnancy;Off label use,221226961.0,DE,,,221226961.0,1.0,20100610.0,20180205.0,19.0,DAY,221226961.0,1.0,HIV infection
22127079,221270791,1,I,20221205.0,20230317.0,20230322,20230322,EXP,FR-AFSSAPS-PC2023000309,FR-GILEAD-2023-0620940,GILEAD,,57.0,YR,A,F,Y,114.0,KG,20230322.0,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221270791.0,OT,,,221270791.0,1.0,20220817.0,20230130.0,119.0,DAY,221270791.0,1.0,HIV infection
22127657,221276571,1,I,,20230313.0,20230323,20230323,EXP,,IN-AUROBINDO-AUR-APL-2023-012008,AUROBINDO,"Barman B, Jamil M, Dey B, Ish. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome.. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43 (2):229-230",28.0,YR,,F,Y,,,20230323.0,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,221276571.0,OT,,,,,,,,,221276571.0,1.0,HIV infection
22134042,221340421,1,I,20221205.0,20230314.0,20230324,20230324,EXP,,FR-AUROBINDO-AUR-APL-2023-012688,AUROBINDO,,57.0,YR,,F,Y,114.0,KG,20230324.0,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221340421.0,OT,,,221340421.0,1.0,20220817.0,20221214.0,119.0,DAY,221340421.0,1.0,HIV infection
22138807,221388072,2,F,,20230411.0,20230327,20230426,EXP,,ES-MACLEODS PHARMACEUTICALS US LTD-MAC2023040379,MACLEODS,,,,,,Y,,,20230424.0,,HP,ES,ES,EFAVIRENZ,Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,221388072.0,OT,,,,,,,,,221388072.0,1.0,Antiretroviral therapy
22139887,221398871,1,I,,20230321.0,20230327,20230327,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP004390,STRIDES,"Simon M, Meah A. Tenofovir as a cause of acquired fanconi^s syndrome. Ann-Afr-Med. 2023;22(1):128-130",53.0,YR,,F,Y,,,20230327.0,,HP,IN,IN,EFAVIRENZ,Fanconi syndrome,221398871.0,HO,,,,,,,,,221398871.0,1.0,HIV infection
22140030,221400302,2,F,20140101.0,20230327.0,20230327,20230410,EXP,,ZW-CIPLA LTD.-2023ZW01605,CIPLA,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S.. Emergent dolutegravir resistance in integrase-na?ve, treatment experienced patients from Zimbabwe. Southern African Journal of HIV Medicine. 2022;26;23(1):1435:1 to 3",,,,,Y,,,20230410.0,,HP,ZW,ZW,EFAVIRENZ,Multiple-drug resistance;Treatment noncompliance;Virologic failure,221400302.0,OT,,,221400302.0,1.0,201009.0,201501.0,,,221400302.0,1.0,HIV infection
22140031,221400311,1,I,,20230313.0,20230327,20230327,EXP,,ZW-CIPLA LTD.-2023ZW01606,CIPLA,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. Southern African Journal of HIV Medicine. 2022;23(1) a1435:1 to 3",,,,,Y,,,20230327.0,,HP,ZW,ZW,EFAVIRENZ,Drug interaction;Drug level below therapeutic;Multiple-drug resistance;Treatment noncompliance;Virologic failure,221400311.0,OT,,,221400311.0,1.0,202008.0,202006.0,,,221400311.0,1.0,HIV infection
22141984,221419841,1,I,20221205.0,20230320.0,20230327,20230327,EXP,FR-AFSSAPS-PC2023000309,FR-MYLANLABS-2023M1030294,MYLAN,,57.0,YR,,F,Y,114.0,KG,20230327.0,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221419841.0,HO,,,221419841.0,1.0,20220817.0,20230130.0,46.0,DAY,221419841.0,1.0,HIV infection
22144261,221442611,1,I,,20230315.0,20230328,20230328,EXP,,GH-CIPLA LTD.-2023GH01635,CIPLA,"Puplampu P, Ganu V, Asamoah I, Asare BO, Berko KP, Oladele O et al.. Cryptococcal meningitis among perinatally HIV-infected adolescents: Case series on presentation and management challenges. Clin Case Rep. 2023;11 (e6995):1 to 6",,,,,Y,,,20230328.0,,HP,GH,GH,EFAVIRENZ,Treatment noncompliance,221442611.0,OT,,,,,,,,,221442611.0,1.0,HIV infection
22153588,221535881,1,I,20230206.0,20230321.0,20230330,20230330,EXP,,PT-AUROBINDO-AUR-APL-2023-013663,AUROBINDO,,31.0,YR,,F,Y,,,20230330.0,,MD,PT,PT,EFAVIRENZ,Agitation;Insomnia;Irritability,221535881.0,DS,,,221535881.0,1.0,,20230316.0,,,221535881.0,1.0,HIV infection
22165012,221650121,1,I,20050801.0,20230323.0,20230403,20230403,EXP,,PT-JNJFOC-20230359036,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20230403.0,,HP,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,221650121.0,OT,,,221650121.0,2.0,200607.0,200504.0,,,221650121.0,1.0,HIV infection
22173828,221738281,1,I,20230101.0,20230323.0,20230404,20230404,EXP,,IT-009507513-2302ITA007959,MERCK,,59.0,YR,,F,Y,,,20230404.0,,MD,IT,IT,EFAVIRENZ,Pathogen resistance;Viral load increased;Viral mutation identified,221738281.0,OT,,,221738281.0,1.0,20210111.0,20210130.0,20.0,DAY,221738281.0,1.0,HIV infection
22176584,221765841,1,I,,20230327.0,20230405,20230405,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2023-044903,BRISTOL MYERS SQUIBB,"Maharaj M, Levin M. Adverse drug reactions to antiretroviral combination treatments in a child. Current Allergy and Clinical Immunology. 2022 Sep 01;35(3): 180-1.",4.0,YR,C,F,Y,,,20230405.0,,HP,ZA,ZA,EFAVIRENZ,Type IV hypersensitivity reaction,221765841.0,OT,,,,,,,,,221765841.0,1.0,HIV infection
22183781,221837814,4,F,20131023.0,20241004.0,20230406,20241009,PER,,US-GILEAD-2023-0622978,GILEAD,,48.0,YR,A,F,Y,76.19,KG,20241009.0,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Depression;Emotional distress;Osteoporosis;Pain;Renal failure;Renal impairment,221837814.0,HO,,,221837814.0,1.0,2005.0,200608.0,,,221837814.0,1.0,HIV infection
22188584,221885841,1,I,,20230327.0,20230409,20230409,EXP,,ZA-STRIDES ARCOLAB LIMITED-2023SP004808,STRIDES,"Munsami L, Schutte CM, de Villiers M, Hiesgen J.. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa.. South-Afr-J-HIV-Med. 2023;24(1)",,,,,Y,,,20230409.0,,HP,ZA,ZA,EFAVIRENZ,Encephalopathy;Quadriparesis;Toxicity to various agents,221885841.0,OT,,,,,,,,,221885841.0,1.0,HIV infection
22188585,221885851,1,I,,20230327.0,20230409,20230409,EXP,,ZA-STRIDES ARCOLAB LIMITED-2023SP004818,STRIDES,"Munsami L, Schutte CM, de Villiers M, Hiesgen J.. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa.. South-Afr-J-HIV-Med. 2023;24 (1)",,,,,Y,,,20230409.0,,HP,ZA,ZA,EFAVIRENZ,Cerebellar ataxia;Psychotic disorder;Toxicity to various agents,221885851.0,DE,,,,,,,,,221885851.0,1.0,HIV infection
22188586,221885861,1,I,,20230327.0,20230409,20230409,EXP,,ZA-STRIDES ARCOLAB LIMITED-2023SP004807,STRIDES,"Munsami L, Schutte CM, de Villiers M, Hiesgen J.. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa.. South-Afr-J-HIV-Med. 2023;24 (1)",,,,,Y,,,20230409.0,,HP,ZA,ZA,EFAVIRENZ,Cerebellar ataxia;Hemiparesis;Toxicity to various agents,221885861.0,OT,,,,,,,,,221885861.0,1.0,HIV infection
22192025,221920251,1,I,20210601.0,20230403.0,20230410,20230410,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK049343,VIIV,"Zhang C, Qian C, Wang W, Chen Z, Lin Y, Sun M. AIDS with obesity, hypothyroidism and elevated serum creatinine: A case report. Frontiers in Medicine. 2023;10",,,,,Y,,,20230410.0,,HP,CN,CN,EFAVIRENZ,Asthenia;Blood creatinine increased;Bradykinesia;Chills;Condition aggravated;Constipation;Decreased appetite;Dry skin;Fatigue;Hypothyroidism;Left atrial enlargement;Left ventricular enlargement;Memory impairment;Muscular weakness;Oedema peripheral;Pallor;Pericardial effusion;Pleural effusion;Slow response to stimuli;Slow speech;Snoring;Somnolence;Thirst,221920251.0,HO,,,,,,,,,221920251.0,1.0,HIV infection
22192026,221920261,1,I,20190201.0,20230403.0,20230410,20230410,EXP,,NA-GSK-NA2023GSK048878,GLAXOSMITHKLINE,"Kakubu MAM, Bikinesi T, Katoto PDMC. Lamivudine induced pure red cell aplasia and HIV-1 drug resistance-associated mutations: a case report. Oxford Medical Case Reports. 2023;3:106-109",,,,,Y,,,20230410.0,,MD,,,EFAVIRENZ,Acquired immunodeficiency syndrome;Anaemia;Aplasia pure red cell;Fatigue;Oesophageal candidiasis;Pathogen resistance;Renal impairment;Renal injury;Therapy interrupted;Toxicity to various agents;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,221920261.0,OT,,,221920261.0,1.0,201207.0,202002.0,,,221920261.0,1.0,HIV infection
22192027,221920271,1,I,20190201.0,20230403.0,20230410,20230410,EXP,,NA-VIIV HEALTHCARE LIMITED-NA2023GSK048878,VIIV,"Kakubu MAM, Bikinesi T, Katoto PDMC. Lamivudine induced pure red cell aplasia and HIV-1 drug resistance-associated mutations: a case report. Oxford Medical Case Reports. 2023;3:106-109",,,,,Y,,,20230410.0,,MD,,,EFAVIRENZ,Acquired immunodeficiency syndrome;Anaemia;Aplasia pure red cell;Fatigue;Oesophageal candidiasis;Pathogen resistance;Renal impairment;Renal injury;Therapy interrupted;Toxicity to various agents;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,221920271.0,OT,,,221920271.0,1.0,201207.0,202002.0,,,221920271.0,1.0,HIV infection
22192030,221920301,1,I,20210601.0,20230403.0,20230410,20230410,EXP,,CN-GSK-CN2023GSK049343,GLAXOSMITHKLINE,"Zhang C, Qian C, Wang W, Chen Z, Lin Y, Sun M. AIDS with obesity, hypothyroidism and elevated serum creatinine: A case report. Frontiers in Medicine. 2023;10",,,,,Y,,,20230410.0,,HP,CN,CN,EFAVIRENZ,Asthenia;Blood creatinine increased;Bradykinesia;Chills;Condition aggravated;Constipation;Decreased appetite;Dry skin;Fatigue;Hypothyroidism;Left atrial enlargement;Left ventricular enlargement;Memory impairment;Muscular weakness;Oedema peripheral;Pallor;Pericardial effusion;Pleural effusion;Slow response to stimuli;Slow speech;Snoring;Somnolence;Thirst,221920301.0,HO,,,,,,,,,221920301.0,1.0,HIV infection
22206619,222066191,1,I,20141101.0,20230403.0,20230413,20230413,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-047779,BRISTOL MYERS SQUIBB,,66.0,YR,E,M,Y,,,20230413.0,,MD,HR,HR,EFAVIRENZ,Cardiac arrest;Condition aggravated;Hypertension;Myocardial infarction;Nephropathy,222066191.0,OT,,,222066191.0,1.0,200807.0,200808.0,1.0,MON,222066191.0,1.0,HIV infection
22209688,222096882,2,F,,20230523.0,20230414,20230603,EXP,,ZA-AUROBINDO-AUR-APL-2023-029515,AUROBINDO,"Munsami L, Schutte CM, de Villiers M, Hiesgen J. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa. South-Afr-J-HIV-Med. 2023;24No. 1.:1-6",,,A,,Y,,,20230603.0,,HP,ZA,ZA,EFAVIRENZ,Cerebellar ataxia;Psychotic disorder;Toxicity to various agents,222096882.0,DE,,,,,,,,,222096882.0,1.0,HIV infection
22214213,222142132,2,F,20170901.0,20230410.0,20230414,20230418,EXP,,PT-009507513-2304PRT004178,MERCK,,47.0,YR,,M,Y,,,20230418.0,,MD,PT,PT,EFAVIRENZ,Hyperphosphaturia;Hypertriglyceridaemia;Perforated ulcer;Proteinuria,222142132.0,OT,,,222142132.0,1.0,201308.0,,,,222142132.0,1.0,HIV infection
22216204,222162043,3,F,20120521.0,20230614.0,20230417,20230627,EXP,,GB-LUPIN EUROPE GMBH-2019-09099,LUPIN,,,,,,Y,,,20230627.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,222162043.0,CA,,,222162043.0,2.0,20171006.0,20180205.0,4.0,MON,222162043.0,1.0,HIV infection
22220716,222207161,1,I,20150101.0,20230411.0,20230418,20230418,EXP,,LV-JNJFOC-20201021251,JOHNSON AND JOHNSON,,45.0,YR,A,F,Y,,,20230418.0,,CN,LV,LV,EFAVIRENZ,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,222207161.0,OT,,,222207161.0,1.0,2019.0,,,,222207161.0,1.0,HIV infection
22223425,222234251,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055711,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222234251.0,OT,,,,,,,,,222234251.0,1.0,HIV infection
22223426,222234261,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055711,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222234261.0,OT,,,,,,,,,222234261.0,1.0,HIV infection
22223512,222235121,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055725,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222235121.0,OT,,,,,,,,,222235121.0,1.0,HIV infection
22223513,222235131,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055725,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222235131.0,OT,,,,,,,,,222235131.0,1.0,HIV infection
22225062,222250621,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055726,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222250621.0,OT,,,,,,,,,222250621.0,1.0,HIV infection
22225063,222250631,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055726,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222250631.0,OT,,,,,,,,,222250631.0,1.0,HIV infection
22225111,222251111,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055732,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222251111.0,OT,,,,,,,,,222251111.0,1.0,HIV infection
22225112,222251121,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055732,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222251121.0,OT,,,,,,,,,222251121.0,1.0,HIV infection
22225402,222254021,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055750,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254021.0,OT,,,,,,,,,222254021.0,1.0,HIV infection
22225403,222254031,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055750,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254031.0,OT,,,,,,,,,222254031.0,1.0,HIV infection
22225469,222254691,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056209,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254691.0,OT,,,,,,,,,222254691.0,1.0,HIV infection
22225472,222254721,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055751,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254721.0,OT,,,,,,,,,222254721.0,1.0,HIV infection
22225473,222254731,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055761,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254731.0,OT,,,,,,,,,222254731.0,1.0,HIV infection
22225474,222254741,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK055760,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254741.0,OT,,,,,,,,,222254741.0,1.0,HIV infection
22225476,222254761,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055751,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254761.0,OT,,,,,,,,,222254761.0,1.0,HIV infection
22225477,222254771,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055761,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254771.0,OT,,,,,,,,,222254771.0,1.0,HIV infection
22225479,222254791,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK056209,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254791.0,OT,,,,,,,,,222254791.0,1.0,HIV infection
22225480,222254801,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK055760,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222254801.0,OT,,,,,,,,,222254801.0,1.0,HIV infection
22225507,222255071,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056211,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255071.0,OT,,,,,,,,,222255071.0,1.0,HIV infection
22225508,222255081,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056210,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255081.0,OT,,,,,,,,,222255081.0,1.0,HIV infection
22225509,222255091,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056272,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255091.0,OT,,,,,,,,,222255091.0,1.0,HIV infection
22225510,222255101,1,I,,20230413.0,20230418,20230418,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056212,VIIV,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255101.0,OT,,,,,,,,,222255101.0,1.0,HIV infection
22225511,222255111,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK056210,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255111.0,OT,,,,,,,,,222255111.0,1.0,HIV infection
22225512,222255121,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK056272,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255121.0,OT,,,,,,,,,222255121.0,1.0,HIV infection
22225513,222255131,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK056212,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255131.0,OT,,,,,,,,,222255131.0,1.0,HIV infection
22225514,222255141,1,I,,20230413.0,20230418,20230418,EXP,,BR-GSK-BR2023GSK056211,GLAXOSMITHKLINE,,,,,,Y,,,20230418.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222255141.0,OT,,,,,,,,,222255141.0,1.0,HIV infection
22227810,222278101,1,I,,20230413.0,20230419,20230419,EXP,,BR-GSK-BR2023GSK056273,GLAXOSMITHKLINE,,,,,,Y,,,20230419.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222278101.0,OT,,,,,,,,,222278101.0,1.0,HIV infection
22227811,222278111,1,I,,20230413.0,20230419,20230419,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056273,VIIV,,,,,,Y,,,20230419.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222278111.0,OT,,,,,,,,,222278111.0,1.0,HIV infection
22227976,222279761,1,I,,20230413.0,20230419,20230419,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056275,VIIV,,,,,,Y,,,20230419.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222279761.0,OT,,,,,,,,,222279761.0,1.0,HIV infection
22227977,222279771,1,I,,20230413.0,20230419,20230419,EXP,,BR-GSK-BR2023GSK056275,GLAXOSMITHKLINE,,,,,,Y,,,20230419.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222279771.0,OT,,,,,,,,,222279771.0,1.0,HIV infection
22228079,222280791,1,I,,20230413.0,20230419,20230419,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK056377,VIIV,,,,,,Y,,,20230419.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222280791.0,OT,,,,,,,,,222280791.0,1.0,HIV infection
22228080,222280801,1,I,,20230413.0,20230419,20230419,EXP,,BR-GSK-BR2023GSK056377,GLAXOSMITHKLINE,,,,,,Y,,,20230419.0,,HP,BR,BR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,222280801.0,OT,,,,,,,,,222280801.0,1.0,HIV infection
22230708,222307081,1,I,20210101.0,20230417.0,20230420,20230420,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-2023-055143,BRISTOL MYERS SQUIBB,"Zhang C, Qian C, Wang W, Chen Z, Lin Y, Sun M. AIDS with obesity, hypothyroidism and elevated serum creatinine: a case report. Frontiers in Medicine. 2023 Mar 14;10:1-4. doi:10.3389/fmed.2023.1090659.",30.0,YR,A,M,Y,,,20230420.0,,HP,CN,CN,EFAVIRENZ,Blood creatinine increased;Hypothyroidism;Obesity,222307081.0,OT,,,,,,,,,222307081.0,1.0,Acquired immunodeficiency syndrome
22230901,222309011,1,I,,20230405.0,20230420,20230420,EXP,,NA-MACLEODS PHARMACEUTICALS US LTD-MAC2023040810,MACLEODS,"Kakubu MA, Bikinesi T, Katoto PD. Lamivudine induced pure red cell aplasia and HIV-1 drug resistance-associated mutations: a case report. Oxford Medical Case Reports. 2023;3:106-109",,,,,Y,,,20230418.0,,HP,,,EFAVIRENZ,Aplasia pure red cell;Drug resistance mutation;Renal injury;Treatment failure;Treatment noncompliance,222309011.0,OT,,,,,,,,,222309011.0,1.0,HIV infection
22237729,222377293,3,F,20170901.0,20230518.0,20230421,20230523,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2023-055121,BRISTOL MYERS SQUIBB,,47.0,YR,A,M,Y,,,20230523.0,,MD,PT,PT,EFAVIRENZ,Hyperphosphaturia;Hypertriglyceridaemia;Perforated ulcer;Proteinuria,222377293.0,OT,,,222377293.0,1.0,201308.0,,,,222377293.0,1.0,HIV infection
22245412,222454121,1,I,,20230410.0,20230424,20230424,EXP,,DE-drreddys-LIT/GER/23/0164301,DR REDDYS,"Evers S, Buchheister A, Reichelt D, Husstedt I, Frese A. Botulinum Toxin A Treatment in HIV Infected Patients-A Long-Term Observational Study. J Clin Med. 2022;11:2197-2197. doi:10.3390/jcm11082197",54.0,YR,A,M,Y,,,20230424.0,,HP,DE,DE,EFAVIRENZ,Drug ineffective for unapproved indication;Head titubation;Hemiparesis;Product use in unapproved indication;Progressive multifocal leukoencephalopathy,222454121.0,OT,,,,,,,,,222454121.0,1.0,HIV infection CDC category C
22245877,222458771,1,I,20160101.0,20230417.0,20230424,20230424,EXP,,PT-GSK-PT2023EME057134,GLAXOSMITHKLINE,,,,,,Y,,,20230424.0,,MD,PT,PT,EFAVIRENZ,Dyslipidaemia;Glomerular filtration rate increased;Lipids increased;Nervous system disorder;Renal impairment,222458771.0,OT,,,222458771.0,1.0,2012.0,2016.0,,,222458771.0,1.0,HIV infection
22245878,222458781,1,I,20160101.0,20230417.0,20230424,20230424,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2023EME057134,VIIV,,,,,,Y,,,20230424.0,,MD,PT,PT,EFAVIRENZ,Dyslipidaemia;Glomerular filtration rate increased;Lipids increased;Nervous system disorder;Renal impairment,222458781.0,OT,,,222458781.0,1.0,2012.0,2016.0,,,222458781.0,1.0,HIV infection
22246460,222464602,2,F,,20230417.0,20230424,20230503,EXP,,IN-GILEAD-2023-0624846,GILEAD,"Joseph A., Cherian K, Kapoor N., Paul T. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density, trabecular bone score and proximal hip geometry change with treatment?. Endocrinology, Diabetes and Metabolism Case Reports. 2023;2023(1):unk. doi:10.1530/EDM-22-0259",46.0,YR,A,F,Y,,,20230503.0,,HP,IN,IN,EFAVIRENZ,Hypophosphataemic osteomalacia;Renal tubular acidosis,222464602.0,OT,,,,,,,,,222464602.0,1.0,HIV infection
22255608,222556081,1,I,,20230421.0,20230426,20230426,EXP,,GB-MYLANLABS-2023M1044100,MYLAN,,,,A,F,Y,,,20230426.0,,CN,GB,GB,EFAVIRENZ,Suicidal ideation,222556081.0,OT,,,,,,,,,222556081.0,1.0,HIV infection
22258654,222586541,1,I,20210101.0,20230420.0,20230427,20230427,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2023EME058556,VIIV,,,,,,Y,,,20230427.0,,MD,PT,PT,EFAVIRENZ,Benign prostatic hyperplasia;Hypertension;Lipids increased;Renal function test abnormal;Urinary retention,222586541.0,OT,,,222586541.0,1.0,2015.0,,,,222586541.0,1.0,HIV infection
22258677,222586771,1,I,20210101.0,20230420.0,20230427,20230427,EXP,,PT-GSK-PT2023EME058556,GLAXOSMITHKLINE,,,,,,Y,,,20230427.0,,MD,PT,PT,EFAVIRENZ,Benign prostatic hyperplasia;Hypertension;Lipids increased;Renal function test abnormal;Urinary retention,222586771.0,OT,,,222586771.0,1.0,2015.0,,,,222586771.0,1.0,HIV infection
22259303,222593031,1,I,,20230420.0,20230427,20230427,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2023EME058634,VIIV,,,,,,Y,,,20230427.0,,MD,PT,PT,EFAVIRENZ,Diabetes mellitus;Dyslipidaemia;Gastric disorder;Hypersensitivity;Hypertension;Lipodystrophy acquired;Paraesthesia,222593031.0,OT,,,222593031.0,1.0,1996.0,,,,222593031.0,1.0,HIV infection
22259304,222593041,1,I,,20230420.0,20230427,20230427,EXP,,PT-GSK-PT2023EME058634,GLAXOSMITHKLINE,,,,,,Y,,,20230427.0,,MD,PT,PT,EFAVIRENZ,Diabetes mellitus;Dyslipidaemia;Gastric disorder;Hypersensitivity;Hypertension;Lipodystrophy acquired;Paraesthesia,222593041.0,OT,,,222593041.0,1.0,1996.0,,,,222593041.0,1.0,HIV infection
22262511,222625111,1,I,,20230419.0,20230428,20230428,EXP,,CA-009507513-2304CAN008438,MERCK,,54.0,YR,,M,Y,,,20230428.0,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,222625111.0,DE,,,,,,,,,222625111.0,1.0,HIV infection
22262576,222625761,1,I,20160101.0,20230427.0,20230428,20230428,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2023-060819,BRISTOL MYERS SQUIBB,,,,E,M,Y,,,20230428.0,,MD,PT,PT,EFAVIRENZ,Dyslipidaemia;Glomerular filtration rate increased;Lipids increased;Nervous system disorder;Renal impairment,222625761.0,OT,,,222625761.0,1.0,2012.0,2016.0,,,222625761.0,1.0,HIV infection
22263785,222637851,1,I,,20230421.0,20230428,20230428,EXP,,FR-GSK-FR2023059022,GLAXOSMITHKLINE,,,,,,Y,,,20230428.0,,CN,FR,FR,EFAVIRENZ,Cardiac discomfort;Choking;Dyspnoea;Labelled drug-drug interaction issue;Product use in unapproved indication,222637851.0,OT,,,,,,,,,222637851.0,1.0,HIV infection
22264846,222648461,1,I,,20230423.0,20230428,20230428,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023APC059135,VIIV,,,,,,Y,,,20230428.0,,MD,CN,CN,EFAVIRENZ,Pathogen resistance;Virologic failure,222648461.0,OT,,,,,,,,,222648461.0,1.0,HIV infection
22264848,222648481,1,I,,20230423.0,20230428,20230428,EXP,,CN-GSK-CN2023APC059135,GLAXOSMITHKLINE,,,,,,Y,,,20230428.0,,MD,CN,CN,EFAVIRENZ,Pathogen resistance;Virologic failure,222648481.0,OT,,,,,,,,,222648481.0,1.0,HIV infection
22267571,222675712,2,F,20170901.0,20230518.0,20230430,20230528,EXP,,PT-AUROBINDO-AUR-APL-2023-031894,AUROBINDO,,47.0,YR,,M,Y,,,20230528.0,,MD,PT,PT,EFAVIRENZ,Hyperphosphaturia;Hypertriglyceridaemia;Perforated ulcer;Proteinuria,222675712.0,OT,,,222675712.0,1.0,201308.0,,,,222675712.0,1.0,HIV infection
22271438,222714381,1,I,20160101.0,20230427.0,20230501,20230501,EXP,,PT-ABBVIE-4744607,ABBVIE,,,,,M,Y,,,20230501.0,,MD,PT,PT,EFAVIRENZ,Dyslipidaemia;Glomerular filtration rate increased;Lipids increased;Nervous system disorder;Renal impairment,222714381.0,OT,,,222714381.0,1.0,2016.0,2016.0,,,222714381.0,1.0,HIV infection
22271844,222718442,2,F,,20230505.0,20230502,20230511,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2023-061732,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20230511.0,,CN,PT,PT,EFAVIRENZ,Diabetes mellitus;Dyslipidaemia;Gastric disorder;Hypersensitivity;Hypertension;Lipodystrophy acquired;Paraesthesia,222718442.0,OT,,,222718442.0,1.0,2001.0,,,,222718442.0,1.0,HIV infection
22271913,222719131,1,I,20210101.0,20230428.0,20230502,20230502,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2023-061750,BRISTOL MYERS SQUIBB,,,,E,M,Y,,,20230502.0,,MD,PT,PT,EFAVIRENZ,Benign prostatic hyperplasia;Hypertension;Lipids increased;Renal function test abnormal;Urinary retention,222719131.0,OT,,,222719131.0,1.0,2015.0,,,,222719131.0,1.0,HIV infection
22278422,222784221,1,I,,20230424.0,20230503,20230503,EXP,,CA-APOTEX-2023AP007606,APOTEX,,44.0,YR,,M,Y,,,20230503.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,222784221.0,OT,,,,,,,,,222784221.0,1.0,HIV infection
22281625,222816251,1,I,,20230501.0,20230504,20230504,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-062619,BRISTOL MYERS SQUIBB,,60.0,YR,A,M,Y,,,20230504.0,,CN,FR,FR,EFAVIRENZ,Cardiac discomfort;Choking;Dyspnoea;Labelled drug-drug interaction issue,222816251.0,OT,,,,,,,,,222816251.0,1.0,HIV infection
22286583,222865831,1,I,,20230421.0,20230505,20230505,EXP,,GB-AUROBINDO-AUR-APL-2023-032945,AUROBINDO,,,,A,F,Y,,,20230505.0,,CN,GB,GB,EFAVIRENZ,Suicidal ideation,222865831.0,OT,,,,,,,,,222865831.0,1.0,HIV infection
22291479,222914791,1,I,,20230421.0,20230506,20230506,EXP,,GB-MACLEODS PHARMA EU LTD-MAC2023041115,MACLEODS,,,,,,Y,,,20230506.0,,CN,GB,GB,EFAVIRENZ,Suicidal ideation,222914791.0,OT,,,,,,,,,222914791.0,1.0,HIV infection
22294280,222942801,1,I,20160101.0,20230501.0,20230508,20230508,EXP,,PT-JNJFOC-20230503835,JOHNSON AND JOHNSON,,,,E,M,Y,,,20230508.0,,MD,PT,PT,EFAVIRENZ,Dyslipidaemia;Glomerular filtration rate increased;Lipids increased;Nervous system disorder;Renal impairment,222942801.0,OT,,,222942801.0,1.0,2012.0,2016.0,,,222942801.0,1.0,HIV infection
22298122,222981225,5,F,,20240126.0,20230509,20240612,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-107208,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20240612.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,222981225.0,HO,,,,,,,,,222981225.0,1.0,HIV infection
22300406,223004061,1,I,,20230502.0,20230509,20230509,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-063721,BRISTOL MYERS SQUIBB,,44.0,YR,A,M,Y,,,20230509.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Hospitalisation;Off label use;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,223004061.0,HO,,,,,,,,,223004061.0,1.0,HIV infection
22302723,223027231,1,I,20210101.0,20230428.0,20230510,20230510,EXP,,PT-AUROBINDO-AUR-APL-2023-034899,AUROBINDO,,,,E,M,Y,,,20230510.0,,MD,PT,PT,EFAVIRENZ,Benign prostatic hyperplasia;Hypertension;Lipids increased;Renal function test abnormal;Urinary retention,223027231.0,OT,,,223027231.0,1.0,2015.0,,,,223027231.0,1.0,HIV infection
22305380,223053801,1,I,,20230504.0,20230510,20230510,EXP,,PT-MYLANLABS-2023M1048151,MYLAN,,,,,F,Y,,,20230510.0,,MD,PT,PT,EFAVIRENZ,Diabetes mellitus;Dyslipidaemia;Gastric disorder;Hypersensitivity;Hypertension;Lipodystrophy acquired;Paraesthesia,223053801.0,OT,,,223053801.0,1.0,2001.0,,,,223053801.0,1.0,HIV infection
22305831,223058311,1,I,,20230428.0,20230511,20230511,EXP,,PT-AUROBINDO-AUR-APL-2023-034901,AUROBINDO,,,,,F,Y,,,20230511.0,,MD,PT,PT,EFAVIRENZ,Diabetes mellitus;Dyslipidaemia;Gastric disorder;Hypersensitivity;Hypertension;Lipodystrophy acquired;Paraesthesia,223058311.0,OT,,,223058311.0,1.0,2001.0,,,,223058311.0,1.0,HIV infection
22305946,223059461,1,I,,20230429.0,20230511,20230511,EXP,,FR-AUROBINDO-AUR-APL-2023-035329,AUROBINDO,,60.0,YR,,M,Y,,,20230511.0,,CN,FR,FR,EFAVIRENZ,Cardiac discomfort;Choking;Dyspnoea;Labelled drug-drug interaction issue;Product use in unapproved indication,223059461.0,OT,,,,,,,,,223059461.0,1.0,HIV infection
22310847,223108471,1,I,,20230505.0,20230511,20230511,EXP,,FR-MYLANLABS-2023M1048249,MYLAN,,60.0,YR,,M,Y,,,20230511.0,,CN,FR,FR,EFAVIRENZ,Cardiac discomfort;Choking;Dyspnoea;Labelled drug-drug interaction issue;Product use in unapproved indication,223108471.0,OT,,,,,,,,,223108471.0,1.0,HIV infection
22312570,223125701,1,I,,20230510.0,20230512,20230512,EXP,,GB-CIPLA LTD.-2023GB02522,CIPLA,,,,,,Y,,,20230512.0,,CN,GB,GB,EFAVIRENZ,Suicidal ideation,223125701.0,OT,,,,,,,,,223125701.0,1.0,HIV infection
22313066,223130664,4,F,,20230630.0,20230512,20230704,EXP,,JP-GILEAD-2023-0627751,GILEAD,,8.0,DEC,E,F,Y,35.0,KG,20230704.0,,PH,JP,JP,EFAVIRENZ,Femoral neck fracture;Rectal perforation;Tubulointerstitial nephritis,223130664.0,OT,,,,,,,,,223130664.0,1.0,HIV infection
22313201,223132011,1,I,,20230511.0,20230512,20230512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-236859",BOEHRINGER INGELHEIM,,61.0,YR,A,M,Y,,,20230512.0,,CN,DE,DE,EFAVIRENZ,Major depression;Nervous system disorder;Viral mutation identified,223132011.0,OT,,,223132011.0,1.0,20001115.0,20010115.0,2.0,MON,223132011.0,1.0,HIV infection CDC category B
22320046,223200461,1,I,,20230511.0,20230515,20230515,EXP,,NVSC2023DE108062,NOVARTIS,,61.0,YR,,M,Y,,,20230515.0,,MD,DE,DE,EFAVIRENZ,Major depression;Nervous system disorder;Viral mutation identified,223200461.0,OT,,,223200461.0,1.0,20000601.0,20010115.0,229.0,DAY,223200461.0,1.0,HIV infection CDC category B
22321206,223212061,1,I,,20230503.0,20230515,20230515,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2023GSK064336,VIIV,"Anuroj K, Chongbanyatcharoen S, Chiencharoenthanakij R. Severe Anemia: A Case Report of an Uncommon Precipitant of Schizophrenia Relapse. Journal of Blood Medicine. 2023;14:329-336",,,,,Y,,,20230510.0,,HP,TH,TH,EFAVIRENZ,Anaemia;Aplasia pure red cell;Fatigue;Headache;Irritability;Psychotic disorder;Schizophrenia;Slow response to stimuli;Somatic symptom disorder;Temperature intolerance,223212061.0,OT,,,223212061.0,5.0,2014.0,,,,223212061.0,1.0,HIV infection
22335379,223353791,1,I,,20230509.0,20230518,20230518,EXP,,TZ-STRIDES ARCOLAB LIMITED-2023SP007053,STRIDES,"Mandari S, Aslan S, Deodatus S, Nyundo A.. Delusional Infestation: A case of Ekbom syndrome in an elderly woman with a long history of HIV.. Clin-Case-Rep.. 2023;11(3):no pagination",70.0,YR,,F,Y,,,20230518.0,,HP,TZ,TZ,EFAVIRENZ,Delusion of parasitosis,223353791.0,OT,,,,,,,,,223353791.0,1.0,HIV infection
22335823,223358231,1,I,,20230508.0,20230518,20230518,EXP,,DE-AUROBINDO-AUR-APL-2023-036404,AUROBINDO,,61.0,YR,,M,Y,,,20230518.0,,MD,DE,DE,EFAVIRENZ,Major depression;Nervous system disorder;Viral mutation identified,223358231.0,OT,,,223358231.0,1.0,20000601.0,20001115.0,167.0,DAY,223358231.0,1.0,HIV infection CDC category B
22347410,223474101,1,I,20210124.0,20230515.0,20230521,20230521,EXP,,RU-009507513-2305RUS004835,MERCK,,,,,F,Y,78.0,KG,20230521.0,,MD,RU,RU,EFAVIRENZ,Diarrhoea;Headache;Pruritus;Rash,223474101.0,OT,,,223474101.0,1.0,20220208.0,20221228.0,324.0,DAY,223474101.0,1.0,HIV infection
22349713,223497131,1,I,,20230510.0,20230522,20230522,EXP,,IT-MACLEODS PHARMACEUTICALS US LTD-MAC2023041403,MACLEODS,"Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C. Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. Journal of Medical Case Reports.. 2009;3:8136",,,,,Y,,,20230522.0,,HP,IT,IT,EFAVIRENZ,Fanconi syndrome;Hypophosphataemic osteomalacia,223497131.0,HO,,,223497131.0,1.0,200402.0,,,,223497131.0,1.0,HIV infection
22350512,223505121,1,I,,20230516.0,20230522,20230522,EXP,,GB-MYLANLABS-2023M1042673,MYLAN,,52.0,YR,,M,Y,,,20230522.0,,MD,GB,GB,EFAVIRENZ,Drug interaction;Nervous system disorder,223505121.0,OT,,,223505121.0,1.0,2008.0,,,,223505121.0,1.0,HIV infection
22355223,223552231,1,I,,20230515.0,20230523,20230523,EXP,,VN-MYLANLABS-2023M1051611,MYLAN,"Pham, D T; Truong, D T.. THE REDUCTION OF DRUG-INDUCED GYNECOMASTIA IN HIV-POSITIVE ADULT MAN: A CASE REPORT. JOURNAL OF MEDICAL RESEARCH. 2023;165 (4)",25.0,YR,,M,Y,53.0,KG,20230523.0,,HP,VN,VN,EFAVIRENZ,Gynaecomastia,223552231.0,OT,,,,,,,,,223552231.0,1.0,HIV infection
22356213,223562138,8,F,20230101.0,20240514.0,20230523,20240522,EXP,,AR-009507513-2305ARG006540,MERCK,,,,,M,Y,,,20240522.0,,CN,AR,AR,EFAVIRENZ,Abnormal dreams;Anxiety;Arrhythmia;Drug effect less than expected;Drug hypersensitivity;Drug intolerance;Fear;Nervous system disorder;Product supply issue;Somnolence,223562138.0,OT,,,223562138.0,1.0,2008.0,202302.0,,,223562138.0,1.0,HIV infection
22359677,223596771,1,I,,20220822.0,20230524,20230524,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-2022-094585,BRISTOL MYERS SQUIBB,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C. et al. Alzheimer dementia in people living with HIV. Neurology: Clinical Practice. 2021 Oct; 11(5): e627-33. 10.1212/CPJ.0000000000001060",71.0,YR,E,M,Y,,,20230524.0,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,223596771.0,OT,,,,,,,,,223596771.0,1.0,HIV infection
22370029,223700291,1,I,,20230515.0,20230526,20230526,EXP,,TZ-AUROBINDO-AUR-APL-2023-037867,AUROBINDO,"Mandari S, Aslan S, Deodatus S, Nyundo A.. Delusional Infestation: A case of Ekbom syndrome in an elderly woman with a long history of HIV. Clinical Case Reports. 2023;11(3):1-4",70.0,YR,,F,Y,,,20230526.0,,HP,TZ,TZ,EFAVIRENZ,Delusion of parasitosis,223700291.0,OT,,,,,,,,,223700291.0,1.0,HIV infection
22370972,223709721,1,I,,20230516.0,20230526,20230526,EXP,,GB-AUROBINDO-AUR-APL-2023-032577,AUROBINDO,,52.0,YR,,M,Y,,,20230526.0,,MD,GB,GB,EFAVIRENZ,Drug interaction;Nervous system disorder,223709721.0,OT,,,223709721.0,1.0,2008.0,,,,223709721.0,1.0,HIV infection
22381016,223810161,1,I,,20230516.0,20230530,20230530,EXP,,GB-MACLEODS PHARMA EU LTD-MAC2023041052,MACLEODS,,,,,,Y,,,20230529.0,,MD,GB,GB,EFAVIRENZ,Drug interaction;Nervous system disorder,223810161.0,OT,,,223810161.0,1.0,2008.0,,,,223810161.0,1.0,HIV infection
22383335,223833352,2,F,,20230602.0,20230530,20230612,EXP,,IT-PFIZER INC-2002050690,PFIZER,,33.0,YR,,F,Y,,,20230612.0,,MD,IT,IT,EFAVIRENZ,Maternal exposure during pregnancy;Unevaluable event,223833352.0,OT,,,223833352.0,2.0,20000112.0,20000217.0,37.0,DAY,223833352.0,1.0,HIV infection
22384819,223848191,1,I,,20230529.0,20230530,20230530,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2023-075568,BRISTOL MYERS SQUIBB,"Oliveira A, Taylor C, Agarwal K, Childs K. First description of efavirenz as a cause of drug-induced autoimmune hepatitis: compelling evidence from two cases. HIV Medicine. 2023 Apr 01;24(Supplement 3):61-2. doi:10.1111/hiv.13478.",33.0,YR,A,F,Y,,,20230530.0,,HP,GB,GB,EFAVIRENZ,Autoimmune hepatitis,223848191.0,OT,,,223848191.0,1.0,202004.0,202206.0,26.0,MON,223848191.0,1.0,HIV infection
22385851,223858511,1,I,,20230523.0,20230530,20230530,EXP,,CH-VIIV HEALTHCARE LIMITED-CH2023GSK073019,VIIV,"Erba A, Marzolini C, Rentsch K, Stoeckle M, Battegay M, Mayr M et al. Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient. Virology Journal. 2023;20 (1)",,,,,Y,,,20230530.0,,HP,CH,CH,EFAVIRENZ,Drug resistance;HIV viraemia;Pathogen resistance;Viral mutation identified,223858511.0,OT,,,223858511.0,6.0,1997.0,,,,223858511.0,1.0,HIV infection
22385852,223858521,1,I,,20230523.0,20230530,20230530,EXP,,CH-GSK-CH2023GSK073019,GLAXOSMITHKLINE,"Erba A, Marzolini C, Rentsch K, Stoeckle M, Battegay M, Mayr M et al. Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient. Virology Journal. 2023;20 (1)",,,,,Y,,,20230530.0,,HP,CH,CH,EFAVIRENZ,Drug resistance;HIV viraemia;Pathogen resistance;Viral mutation identified,223858521.0,OT,,,223858521.0,6.0,1997.0,,,,223858521.0,1.0,HIV infection
22386446,223864461,1,I,20221129.0,20230521.0,20230531,20230531,EXP,,GB-AUROBINDO-AUR-APL-2022-055907,AUROBINDO,,,,A,M,Y,,,20230531.0,,HP,GB,GB,EFAVIRENZ,Death,223864461.0,DE,,,,,,,,,223864461.0,1.0,HIV infection
22389441,223894412,2,F,,20230602.0,20230531,20230612,EXP,,IT-PFIZER INC-039-1343-M0200001,PFIZER,"FUNDARO, C.. MYELOMENINGOCELE IN A CHILD WITH INTRAUTERINE EXPOSURE TO EFAVIRENZ. AIDS. 2001;16(2):299-300",24.0,WK,,M,Y,3.45,KG,20230612.0,,MD,IT,IT,SUSTIVA,HIV test positive;Hydrocephalus;Maternal exposure during pregnancy;Meningomyelocele,223894412.0,CA,,,223894412.0,2.0,20000112.0,20000217.0,37.0,DAY,223894412.0,1.0,HIV infection
22390441,223904412,2,F,20170901.0,20230525.0,20230531,20230601,EXP,,PT-MYLANLABS-2023M1055358,MYLAN,,47.0,YR,,M,Y,,,20230601.0,,MD,PT,PT,EFAVIRENZ,Hyperphosphaturia;Hypertriglyceridaemia;Perforated ulcer;Proteinuria,223904412.0,OT,,,223904412.0,1.0,201308.0,,,,223904412.0,1.0,HIV infection
22391768,223917682,2,F,,20230528.0,20230601,20230610,EXP,,GB-MACLEODS PHARMA EU LTD-MAC2023041169,MACLEODS,,,,,,Y,,,20230609.0,,MD,GB,GB,EFAVIRENZ,Agitation;Diabetes mellitus;Insomnia;Weight increased,223917682.0,OT,,,223917682.0,1.0,2013.0,,,,223917682.0,1.0,HIV infection
22399171,223991711,1,I,,20230525.0,20230602,20230602,EXP,,UY-GSK-UY2023GSK077550,GLAXOSMITHKLINE,"Gonzalez Castro AV, Sande V, Pardo Casaretto LV, Gutierrez Rodriguez SI. Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay. Archivos Argentinos De Pediatria. 2023",,,,,Y,,,20230602.0,,HP,UY,UY,EFAVIRENZ,Drug interaction;Pathogen resistance;Viral mutation identified;Virologic failure,223991711.0,OT,,,,,,,,,223991711.0,1.0,HIV infection
22399172,223991721,1,I,,20230525.0,20230602,20230602,EXP,,UY-VIIV HEALTHCARE LIMITED-UY2023GSK077550,VIIV,"Gonzalez Castro AV, Sande V, Pardo Casaretto LV, Gutierrez Rodriguez SI. Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay. Archivos Argentinos De Pediatria. 2023",,,,,Y,,,20230602.0,,HP,UY,UY,EFAVIRENZ,Drug interaction;Pathogen resistance;Viral mutation identified;Virologic failure,223991721.0,OT,,,,,,,,,223991721.0,1.0,HIV infection
22399604,223996041,1,I,,20230525.0,20230602,20230602,EXP,,UY-GSK-UY2023GSK077527,GLAXOSMITHKLINE,"Gonzalez Castro AV, Sande V, Pardo Casaretto LV, Gutierrez Rodriguez SI. Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay. Archivos Argentinos De Pediatria. 2023",,,,,Y,,,20230602.0,,HP,UY,UY,EFAVIRENZ,Pathogen resistance;Virologic failure,223996041.0,OT,,,,,,,,,223996041.0,1.0,HIV infection
22399605,223996051,1,I,,20230525.0,20230602,20230602,EXP,,UY-VIIV HEALTHCARE LIMITED-UY2023GSK077527,VIIV,"Gonzalez Castro AV, Sande V, Pardo Casaretto LV, Gutierrez Rodriguez SI. Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay. Archivos Argentinos De Pediatria. 2023",,,,,Y,,,20230602.0,,HP,UY,UY,EFAVIRENZ,Pathogen resistance;Virologic failure,223996051.0,OT,,,,,,,,,223996051.0,1.0,HIV infection
22517361,225173611,1,I,,20230523.0,20230603,20230603,EXP,,ZA-AUROBINDO-AUR-APL-2023-029518,AUROBINDO,"Munsami L, Schutte CM, de Villiers M, Hiesgen J.. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa. South-Afr-J-HIV-Med. 2023;24No. 1.:1-6",,,A,,Y,,,20230603.0,,HP,ZA,ZA,EFAVIRENZ,Encephalopathy;Quadriparesis;Toxicity to various agents,225173611.0,OT,,,,,,,,,225173611.0,1.0,HIV infection
22517365,225173651,1,I,,20230523.0,20230603,20230603,EXP,,ZA-AUROBINDO-AUR-APL-2023-029519,AUROBINDO,"Munsami L, Schutte CM, de Villiers M, Hiesgen J.. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa. South-Afr-J-HIV-Med. 2023;24No. 1:1-6",,,A,,Y,,,20230603.0,,HP,ZA,ZA,EFAVIRENZ,Cerebellar ataxia;Hemiparesis;Toxicity to various agents,225173651.0,OT,,,,,,,,,225173651.0,1.0,HIV infection
22525100,225251002,2,F,,20230528.0,20230606,20230607,EXP,,GB-AUROBINDO-AUR-APL-2023-034068,AUROBINDO,,,,,M,Y,,,20230607.0,,MD,GB,GB,EFAVIRENZ,Agitation;Diabetes mellitus;Insomnia;Weight increased,225251002.0,OT,,,225251002.0,1.0,2013.0,2013.0,2920.0,DAY,225251002.0,1.0,HIV infection
22525206,225252061,1,I,,20230529.0,20230606,20230606,EXP,,FR-MYLANLABS-2023M1059146,MYLAN,"Kherabi Y, de Castro N, Sellier PO, Hamet G, Brun A, Mechai F, et al. Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. J-Acquir-Immune-Defic-Syndr 2022;91(1):85-90.",,,,,Y,,,20230606.0,,HP,FR,FR,EFAVIRENZ,Virologic failure,225252061.0,OT,,,,,,,,,225252061.0,1.0,Antiretroviral therapy
22525207,225252071,1,I,,20230529.0,20230606,20230606,EXP,,FR-MYLANLABS-2023M1059114,MYLAN,"Kherabi Y, de Castro N, Sellier PO, Hamet G, Brun A, Mechai F, et al. Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. J-Acquir-Immune-Defic-Syndr 2022;91(1):85-90.",,,,,Y,,,20230606.0,,HP,FR,FR,EFAVIRENZ,Virologic failure,225252071.0,OT,,,,,,,,,225252071.0,1.0,Antiretroviral therapy
22525208,225252081,1,I,,20230529.0,20230606,20230606,EXP,,FR-MYLANLABS-2023M1059145,MYLAN,"Kherabi Y, de Castro N, Sellier PO, Hamet G, Brun A, Mechai F, et al. Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. J-Acquir-Immune-Defic-Syndr 2022;91(1):85-90.",,,,,Y,,,20230606.0,,HP,FR,FR,EFAVIRENZ,Virologic failure,225252081.0,OT,,,,,,,,,225252081.0,1.0,Antiretroviral therapy
22525212,225252121,1,I,,20230529.0,20230606,20230606,EXP,,FR-MYLANLABS-2023M1059066,MYLAN,"Kherabi Y, de Castro N, Sellier PO, Hamet G, Brun A, Mechai F, et al. Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. J-Acquir-Immune-Defic-Syndr 2022;91(1):85-90.",,,,,Y,,,20230606.0,,HP,FR,FR,EFAVIRENZ,Virologic failure,225252121.0,OT,,,,,,,,,225252121.0,1.0,Antiretroviral therapy
22525300,225253001,1,I,,20230529.0,20230606,20230606,EXP,,FR-MYLANLABS-2023M1059060,MYLAN,"Kherabi Y, de Castro N, Sellier PO, Hamet G, Brun A, Mechai F, et al. Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. J-Acquir-Immune-Defic-Syndr 2022;91(1):85-90.",,,,,Y,,,20230606.0,,HP,FR,FR,EFAVIRENZ,Virologic failure,225253001.0,OT,,,,,,,,,225253001.0,1.0,Antiretroviral therapy
22526709,225267091,1,I,,20230531.0,20230606,20230606,EXP,,ZA-MYLANLABS-2023M1059226,MYLAN,"Maponga TG, Jeffries M, Tegally H, Sutherland A, Wilkinson E, Lessells RJ, et al. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection. Clin-Infect-Dis 2023;76(3):E522-E525.",22.0,YR,,F,Y,,,20230606.0,,HP,ZA,ZA,EFAVIRENZ,Intentional product misuse;Treatment noncompliance,225267091.0,OT,,,,,,,,,225267091.0,1.0,HIV infection
22529946,225299461,1,I,,20230531.0,20230607,20230607,EXP,,IT-JNJFOC-20230611912,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20230607.0,,HP,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,225299461.0,OT,,,,,,,,,225299461.0,1.0,HIV infection
22532673,225326731,1,I,20131001.0,20200226.0,20230607,20230607,EXP,,NVSC2020GB056080,NOVARTIS,"Kanellopoulos A, Kaparou M, Xenou E, Paneesha S, Kishore B, Lovell R et al.. Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia. BONE MARROW TRANSPLANTATION. 2018;53(12):1518-21",39.0,YR,,M,Y,,,20230607.0,,HP,GB,GB,EFAVIRENZ,Acute myeloid leukaemia;Product use in unapproved indication,225326731.0,HO,,,225326731.0,4.0,200308.0,200311.0,3.0,MON,225326731.0,1.0,HIV infection CDC category C
22533286,225332861,1,I,20210901.0,20230531.0,20230607,20230607,EXP,,ZA-STRIDES ARCOLAB LIMITED-2023SP009080,STRIDES,"Maponga TG, Jeffries M, Tegally H, Sutherland A, Wilkinson E, Lessells RJ, et al.. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection.. Clin-Infect-Dis.. 2023;76(3):E522-E525.",22.0,YR,,F,Y,,,20230608.0,,HP,ZA,ZA,EFAVIRENZ,Intentional product misuse;Treatment noncompliance,225332861.0,OT,,,225332861.0,2.0,202109.0,,,,225332861.0,1.0,HIV infection
22590557,225905571,1,I,,20230603.0,20230612,20230612,EXP,,UG-GSK-UG2023080820,GLAXOSMITHKLINE,,,,,,Y,,,20230612.0,,MD,UG,UG,EFAVIRENZ,Hospitalisation,225905571.0,HO,,,225905571.0,1.0,20060705.0,,,,225905571.0,1.0,HIV infection
22590558,225905581,1,I,,20230603.0,20230612,20230612,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2023080820,VIIV,,,,,,Y,,,20230612.0,,MD,UG,UG,EFAVIRENZ,Hospitalisation,225905581.0,HO,,,225905581.0,1.0,20060705.0,,,,225905581.0,1.0,HIV infection
22591196,225911961,1,I,,20230601.0,20230612,20230612,EXP,,IT-GSK-IT2023GSK079465,GLAXOSMITHKLINE,"Labate L, Bruzzone B, Spagnuolo V, Zazzi M, Santoro MM, Di Biagio A et al. Prestigio ring: ^A 59-year-old HIV-1 positive, highly treatment-experienced women failing darunavir/ritonavir plus raltegravir.^. The New Microbiologica. 2023;46(2):226-230",,,,,Y,,,20230612.0,,HP,IT,IT,EFAVIRENZ,Immune system disorder;Insomnia;Neuropathy peripheral;Pathogen resistance;Toxicity to various agents;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,225911961.0,OT,,,225911961.0,1.0,19960711.0,19990505.0,1028.0,DAY,225911961.0,1.0,HIV infection
22591202,225912021,1,I,,20230601.0,20230612,20230612,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK079465,VIIV,"Labate L, Bruzzone B, Spagnuolo V, Zazzi M, Santoro MM, Di Biagio A et al. Prestigio ring: ^A 59-year-old HIV-1 positive, highly treatment-experienced women failing darunavir/ritonavir plus raltegravir.^. The New Microbiologica. 2023;46(2):226-230",,,,,Y,,,20230612.0,,HP,IT,IT,EFAVIRENZ,Immune system disorder;Insomnia;Neuropathy peripheral;Pathogen resistance;Toxicity to various agents;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,225912021.0,OT,,,225912021.0,1.0,19960711.0,19990505.0,1028.0,DAY,225912021.0,1.0,HIV infection
22595211,225952111,1,I,,20230605.0,20230613,20230613,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK080298,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230613.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,225952111.0,OT,,,,,,,,,225952111.0,1.0,HIV infection
22596572,225965721,1,I,,20230605.0,20230613,20230613,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK080574,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230613.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,225965721.0,OT,,,,,,,,,225965721.0,1.0,HIV infection
22596597,225965971,1,I,,20230605.0,20230613,20230613,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK080599,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230613.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,225965971.0,OT,,,,,,,,,225965971.0,1.0,HIV infection
22597265,225972651,1,I,,20230531.0,20230614,20230614,EXP,,CA-CIPLA LTD.-2023TZ03098,CIPLA,"Lopez A, Campbell L, Bacha J, Kovarik C.. Successful use of multidisciplinary palliative care in the outpatient treatment of disseminated histoplasmosis in an HIV positive child. Children. 2021;8:1 to 10",,,,,Y,,,20230614.0,,HP,CA,TZ,EFAVIRENZ,Histoplasmosis;Treatment failure,225972651.0,HO,,,,,,,,,225972651.0,1.0,Antiretroviral therapy
22603892,226038921,1,I,,20230604.0,20230615,20230615,EXP,,IN-HETERO-HET2023IN01158,HETERO,"Subith S, Tungenwar S, Avhad T, Apte T, Dakhode S.. Anti-retroviral Therapy-Induced Multiple Pathological Fractures in a  HIV-Positive Young Female: A Case Report and Review of Literature. Journal of Orthopaedic Case Reports.. 2023;13(5):111",38.0,YR,,F,Y,,,20230615.0,,MD,IN,IN,EFAVIRENZ,Multiple fractures;Osteoporosis;Pathological fracture,226038921.0,OT,,,,,,,,,226038921.0,1.0,HIV infection
22605939,226059391,1,I,,20230605.0,20230615,20230615,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK081824,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230615.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226059391.0,OT,,,,,,,,,226059391.0,1.0,HIV infection
22606090,226060901,1,I,,20230605.0,20230615,20230615,EXP,,IT-GSK-IT2023GSK080786,GLAXOSMITHKLINE,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230615.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226060901.0,OT,,,,,,,,,226060901.0,1.0,HIV infection
22606091,226060911,1,I,,20230605.0,20230615,20230615,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK080786,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230615.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226060911.0,OT,,,,,,,,,226060911.0,1.0,HIV infection
22608597,226085971,1,I,,20230607.0,20230616,20230616,EXP,,CH-STRIDES ARCOLAB LIMITED-2023SP009479,STRIDES,"Erba A, Marzolini C, Rentsch K, Stoeckle M, Battegay M, Mayr M, et al. Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient. Virol-J. 2023;20(1)",5.0,DEC,,M,Y,,,20230616.0,,HP,CH,CH,EFAVIRENZ,Diabetes mellitus;Diabetic foot infection;Drug interaction;Drug level decreased;Drug level increased;Drug resistance;Erysipelas;Neuropathy peripheral;Peripheral arterial occlusive disease,226085971.0,OT,,,,,,,,,226085971.0,1.0,HIV infection
22610097,226100971,1,I,,20230605.0,20230616,20230616,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK080716,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230616.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226100971.0,OT,,,,,,,,,226100971.0,1.0,HIV infection
22610860,226108601,1,I,,20230605.0,20230616,20230616,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK080739,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230616.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226108601.0,OT,,,,,,,,,226108601.0,1.0,HIV infection
22611023,226110231,1,I,,20230605.0,20230616,20230616,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK080779,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230616.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226110231.0,OT,,,,,,,,,226110231.0,1.0,HIV infection
22611239,226112391,1,I,,20230605.0,20230616,20230616,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK081378,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230616.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226112391.0,OT,,,,,,,,,226112391.0,1.0,HIV infection
22612470,226124701,1,I,,20230606.0,20230617,20230617,EXP,,ZA-AUROBINDO-AUR-APL-2023-030969,AUROBINDO,"Maharaj M, Levin M.. ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL COMBINATION TREATMENTS IN A CHILD. Curr-All-Clinical-Immunol. 2022;35(3):180-181",4.0,YR,,F,Y,,,20230617.0,,HP,ZA,ZA,EFAVIRENZ,Drug hypersensitivity;Eosinophilia;Flushing;Pyrexia;Rash;Transaminases increased;Vomiting,226124701.0,OT,,,,,,,,,226124701.0,1.0,HIV infection
22614164,226141641,1,I,,20230616.0,20230619,20230619,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244516",BOEHRINGER INGELHEIM,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422. doi:10.1093/jac/dkad101",,,A,,Y,,,20230619.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226141641.0,OT,,,,,,,,,226141641.0,1.0,HIV infection
22614402,226144021,1,I,,20230612.0,20230619,20230619,EXP,,MY-STRIDES ARCOLAB LIMITED-2023SP009585,STRIDES,"Chua KY, Tey KE.. Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.. Int-J-STD-AIDS. 2022;33(9):812-820.",,,,,Y,,,20230619.0,,HP,MY,MY,EFAVIRENZ,Photodermatosis,226144021.0,OT,,,,,,,,,226144021.0,1.0,HIV infection
22614420,226144201,1,I,,20230612.0,20230619,20230619,EXP,,MY-STRIDES ARCOLAB LIMITED-2023SP009542,STRIDES,"Chua KY, Tey KE.. Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.. Int-J-STD-AIDS.. 2022;33(9):812-820",,,,,Y,,,20230619.0,,HP,MY,MY,EFAVIRENZ,Angioedema,226144201.0,OT,,,,,,,,,226144201.0,1.0,HIV infection
22614583,226145831,1,I,,20230608.0,20230619,20230619,EXP,,FR-AUROBINDO-AUR-APL-2022-036099,AUROBINDO,"Kherabi Y, de Castro N, Sellier P, Hamet G, Brun A, Mecha? F et al. Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. Journal of acquired immune deficiency syndromes. 2022;91(1):85-90",,,A,,Y,,,20230619.0,,HP,FR,FR,EFAVIRENZ,Virologic failure,226145831.0,OT,,,,,,,,,226145831.0,1.0,HIV infection
22615007,226150071,1,I,,20230616.0,20230619,20230619,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244515",BOEHRINGER INGELHEIM,,,,A,,Y,,,20230619.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226150071.0,OT,,,,,,,,,226150071.0,1.0,HIV infection
22615020,226150201,1,I,,20230616.0,20230619,20230619,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244517",BOEHRINGER INGELHEIM,,,,A,,Y,,,20230619.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226150201.0,OT,,,,,,,,,226150201.0,1.0,HIV infection
22615086,226150861,1,I,,20230616.0,20230619,20230619,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244513",BOEHRINGER INGELHEIM,,,,A,,Y,,,20230619.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226150861.0,OT,,,,,,,,,226150861.0,1.0,HIV infection
22616479,226164791,1,I,,20230605.0,20230619,20230619,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2023GSK081308,VIIV,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,,,Y,,,20230619.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226164791.0,OT,,,,,,,,,226164791.0,1.0,HIV infection
22617714,226177141,1,I,,20230524.0,20230620,20230620,PER,,US-APOTEX-2022AP016966,APOTEX,,45.0,YR,,F,Y,,,20230620.0,,HP,US,US,EFAVIRENZ,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,226177141.0,1.0,Antiretroviral therapy
22618751,226187512,2,F,,20230703.0,20230620,20230710,EXP,IT-ViiV Healthcare Limited-IT2023GSK079465,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243515",BOEHRINGER INGELHEIM,"Labate L, Bruzzone B, Spagnuolo V, Zazzi M, Santoro MM, Di Biagio A et al. Prestigio ring: ?A 59-year-old HIV-1 positive, highly treatment-experienced women failing darunavir/ritonavir plus raltegravir.^. The New Microbiologica. 2023;46(2):226-230",59.0,YR,A,F,Y,150.0,KG,20230710.0,,HP,IT,IT,EFAVIRENZ,Immune system disorder;Insomnia;Neuropathy peripheral;Pathogen resistance;Toxicity to various agents;Viral mutation identified;Virologic failure,226187512.0,OT,,,226187512.0,1.0,19990505.0,20000120.0,260.0,DAY,226187512.0,1.0,HIV infection
22620007,226200071,1,I,,20230616.0,20230620,20230620,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244507",BOEHRINGER INGELHEIM,,,,A,,Y,,,20230620.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226200071.0,OT,,,,,,,,,226200071.0,1.0,HIV infection
22620756,226207561,1,I,,20230613.0,20230620,20230620,EXP,,MY-MYLANLABS-2023M1063215,MYLAN,,34.0,YR,,M,Y,,,20230620.0,,PH,MY,MY,EFAVIRENZ,Headache;Mouth ulceration;Pyrexia;Rash;Somnolence,226207561.0,OT,,,,,,,,,226207561.0,1.0,Antiretroviral therapy
22625269,226252691,1,I,,20230616.0,20230621,20230621,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244526",BOEHRINGER INGELHEIM,,,,A,,Y,,,20230621.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226252691.0,OT,,,,,,,,,226252691.0,1.0,HIV infection
22627955,226279552,2,F,,20230628.0,20230622,20230710,EXP,,VN-MYLANLABS-2023M1064470,MYLAN,"Doan thu T, Do duy C.. Changes in liver enzymes and glomerular filtration rate in persons with hiv/aids after antiretroviral treatment at the center for tropical diseases, bach mai hospital. VIETNAM MEDICAL JOURNAL. 2023;2:526",,,,,Y,,,20230710.0,,HP,VN,VN,EFAVIRENZ,Glomerular filtration rate decreased;Hepatic enzyme increased,226279552.0,OT,,,,,,,,,226279552.0,1.0,Acquired immunodeficiency syndrome
22628043,226280431,1,I,,20230616.0,20230622,20230622,EXP,,IT-JNJFOC-20230641963,JOHNSON AND JOHNSON,,,,A,,Y,,,20230622.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226280431.0,OT,,,,,,,,,226280431.0,1.0,HIV infection
22628900,226289002,2,F,,20230616.0,20230622,20230630,EXP,,IT-JNJFOC-20230642011,JOHNSON AND JOHNSON,,,,A,,Y,,,20230630.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226289002.0,OT,,,,,,,,,226289002.0,1.0,HIV infection
22630182,226301824,4,F,20220101.0,20230704.0,20230622,20230712,EXP,,IT-JNJFOC-20230631223,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,150.0,KG,20230712.0,,HP,IT,IT,EFAVIRENZ,Immune system disorder;Immunodeficiency;Insomnia;Multiple drug therapy;Neuropathy peripheral;Pathogen resistance;Toxicity to various agents;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,226301824.0,OT,,,226301824.0,3.0,20040402.0,20080321.0,473.0,DAY,226301824.0,1.0,HIV infection
22633180,226331802,2,F,,20230616.0,20230623,20230630,EXP,,IT-JNJFOC-20230641762,JOHNSON AND JOHNSON,,,,A,,Y,,,20230630.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226331802.0,OT,,,,,,,,,226331802.0,1.0,HIV infection
22633993,226339931,1,I,,20230619.0,20230623,20230623,EXP,,IT-ROCHE-3371846,ROCHE,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. doi:10.1093/jac/dkad101 2023;78(6):1415-1422.",,,A,,Y,,,20230623.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226339931.0,OT,,,,,,,,,226339931.0,1.0,HIV infection
22635354,226353541,1,I,20230415.0,20230620.0,20230623,20230623,EXP,,GB-MYLANLABS-2023M1065474,MYLAN,,,,,M,Y,,,20230623.0,,HP,GB,GB,EFAVIRENZ,Death,226353541.0,DE,,,,,,,,,226353541.0,1.0,HIV infection
22638289,226382891,1,I,,20230619.0,20230626,20230626,EXP,,IT-ROCHE-3371844,ROCHE,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy 2023;78(6):1415-1422.",,,A,,Y,,,20230624.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226382891.0,OT,,,,,,,,,226382891.0,1.0,HIV infection
22639017,226390171,1,I,,20230619.0,20230626,20230626,EXP,,IT-ROCHE-3371830,ROCHE,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422.",,,A,,Y,,,20230626.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226390171.0,OT,,,,,,,,,226390171.0,1.0,HIV infection
22639410,226394101,1,I,,20230614.0,20230626,20230626,EXP,,IT-AUROBINDO-AUR-APL-2023-043610,AUROBINDO,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,A,,Y,,,20230626.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226394101.0,OT,,,,,,,,,226394101.0,1.0,HIV infection
22639426,226394262,2,F,,20240527.0,20230626,20240606,EXP,,IT-AUROBINDO-AUR-APL-2023-043613,AUROBINDO,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;1415-1422:78(6)",,,A,,Y,,,20240606.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226394262.0,OT,,,,,,,,,226394262.0,1.0,HIV infection
22639531,226395313,3,F,,20240415.0,20230626,20240429,EXP,,IT-AUROBINDO-AUR-APL-2023-043201,AUROBINDO,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,A,,Y,,,20240429.0,,HP,IT,IT,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viraemia;Viral mutation identified;Virologic failure,226395313.0,OT,,,,,,,,,226395313.0,1.0,HIV infection
22641965,226419651,1,I,20210901.0,20230615.0,20230626,20230626,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023APC084075,VIIV,,,,,,Y,,,20230626.0,,MD,CN,CN,EFAVIRENZ,Abdominal pain upper;Depression;Diarrhoea;Fatigue;Heart rate decreased;Hepatic failure;Non-alcoholic fatty liver;Tongue coated;Toxicity to various agents,226419651.0,OT,,,,,,,,,226419651.0,1.0,HIV infection
22641971,226419711,1,I,20210901.0,20230615.0,20230626,20230626,EXP,,CN-GSK-CN2023APC084075,GLAXOSMITHKLINE,,,,,,Y,,,20230626.0,,MD,CN,CN,EFAVIRENZ,Abdominal pain upper;Depression;Diarrhoea;Fatigue;Heart rate decreased;Hepatic failure;Non-alcoholic fatty liver;Tongue coated;Toxicity to various agents,226419711.0,OT,,,,,,,,,226419711.0,1.0,HIV infection
22646443,226464432,2,F,,20240405.0,20230627,20240415,EXP,,IT-MYLANLABS-2023M1066778,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,A,,Y,,,20240415.0,,HP,IT,IT,EFAVIRENZ,Treatment failure,226464432.0,OT,,,,,,,,,226464432.0,1.0,HIV infection
22646473,226464732,2,F,,20240405.0,20230627,20240415,EXP,,IT-MYLANLABS-2023M1066729,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,A,,Y,,,20240415.0,,HP,IT,IT,EFAVIRENZ,Treatment failure,226464732.0,OT,,,,,,,,,226464732.0,1.0,HIV infection
22646768,226467682,2,F,,20240405.0,20230627,20240415,EXP,,IT-MYLANLABS-2023M1066665,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy.. 2023;78(6):1415-1422",,,A,,Y,,,20240415.0,,HP,IT,IT,EFAVIRENZ,Treatment failure,226467682.0,OT,,,,,,,,,226467682.0,1.0,HIV infection
22646769,226467692,2,F,,20240405.0,20230627,20240418,EXP,,IT-MYLANLABS-2023M1066656,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy.. 2023;78(6):1415-1422",,,A,,Y,,,20240418.0,,HP,IT,IT,EFAVIRENZ,Treatment failure,226467692.0,OT,,,,,,,,,226467692.0,1.0,HIV infection
22646883,226468831,1,I,,20230621.0,20230627,20230627,EXP,,IT-MYLANLABS-2023M1066376,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,A,,Y,,,20230627.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226468831.0,OT,,,,,,,,,226468831.0,1.0,HIV infection
22646957,226469571,1,I,,20230621.0,20230627,20230627,EXP,,IT-MYLANLABS-2023M1066336,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy.. 2023;78(6):1415-1422.",,,A,,Y,,,20230627.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226469571.0,OT,,,,,,,,,226469571.0,1.0,HIV infection
22646984,226469841,1,I,,20230621.0,20230627,20230627,EXP,,IT-MYLANLABS-2023M1066339,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy.. 2023;78(6):1415-1422",,,A,,Y,,,20230627.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226469841.0,OT,,,,,,,,,226469841.0,1.0,HIV infection
22646990,226469901,1,I,,20230621.0,20230627,20230627,EXP,,IT-MYLANLABS-2023M1066296,MYLAN,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy.. 2023;78(6):1415-1422",,,A,,Y,,,20230627.0,,HP,IT,IT,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,226469901.0,OT,,,,,,,,,226469901.0,1.0,HIV infection
22662983,226629833,3,F,20131227.0,20240520.0,20230703,20240527,EXP,,JP-JNJFOC-20181027661,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,,,20240527.0,,MD,JP,JP,EFAVIRENZ,Amoebic dysentery;Beta 2 microglobulin urine increased;Irritable bowel syndrome;Protein urine present,226629833.0,OT,,,226629833.0,1.0,20121018.0,20181231.0,7.0,YR,226629833.0,1.0,HIV infection
22663153,226631532,2,F,20220101.0,20230626.0,20230703,20230710,EXP,,IT-AUROBINDO-AUR-APL-2023-044527,AUROBINDO,"Labate L, Bruzzone B, Spagnuolo V, Zazzi M, Santoro MM, Di Biagio a, et al... PRESTIGIO RING: ^A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir^. The new microbiologica.. 2023;46 (2):226-30",59.0,YR,,F,Y,43.0,KG,20230710.0,,HP,IT,IT,EFAVIRENZ,Immune system disorder;Insomnia;Multiple drug therapy;Neuropathy peripheral;Pathogen resistance;Toxicity to various agents;Treatment noncompliance;Viral mutation identified;Virologic failure,226631532.0,OT,,,226631532.0,1.0,20080321.0,20080605.0,76.0,DAY,226631532.0,1.0,HIV infection
22666415,226664151,1,I,,20230621.0,20230703,20230703,EXP,,SE-VIIV HEALTHCARE LIMITED-SE2023GSK088940,VIIV,"Elvstam O, Malmborn K, Elen S, Marrone G, Garcia F, Zazzi M et al. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort. Clinical Infectious Diseases. 2023;76(1):25-31",,,,,Y,,,20230703.0,,HP,SE,SE,EFAVIRENZ,HIV viraemia,226664151.0,OT,,,,,,,,,226664151.0,1.0,HIV infection
22666416,226664161,1,I,,20230621.0,20230703,20230703,EXP,,SE-GSK-SE2023GSK088940,GLAXOSMITHKLINE,"Elvstam O, Malmborn K, Elen S, Marrone G, Garcia F, Zazzi M et al. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort. Clinical Infectious Diseases. 2023;76(1):25-31",,,,,Y,,,20230703.0,,HP,SE,SE,EFAVIRENZ,HIV viraemia,226664161.0,OT,,,,,,,,,226664161.0,1.0,HIV infection
22667420,226674201,1,I,,20230627.0,20230704,20230704,EXP,,CA-009507513-2306CAN013580,MERCK,,54.0,YR,,M,Y,,,20230704.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,226674201.0,HO,,,,,,,,,226674201.0,1.0,HIV infection
22672219,226722192,2,F,,20240927.0,20230705,20241008,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-092636,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20241008.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,226722192.0,HO,,,,,,,,,226722192.0,1.0,HIV infection
22676416,226764161,1,I,20230417.0,20230614.0,20230706,20230706,EXP,,RU-GSK-RU2023EME088178,GLAXOSMITHKLINE,,,,,,Y,,,20230706.0,,CN,RU,RU,EFAVIRENZ,Anaemia;Blood pressure increased;Cerebral haematoma;Cerebral haemorrhage;Haemorrhagic stroke;Hemiataxia;Hypertension;Subarachnoid haemorrhage,226764161.0,HO,,,226764161.0,1.0,20141027.0,20150205.0,101.0,DAY,226764161.0,1.0,HIV infection
22676417,226764171,1,I,20230417.0,20230614.0,20230706,20230706,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2023EME088178,VIIV,,,,,,Y,,,20230706.0,,CN,RU,RU,EFAVIRENZ,Anaemia;Blood pressure increased;Cerebral haematoma;Cerebral haemorrhage;Haemorrhagic stroke;Hemiataxia;Hypertension;Subarachnoid haemorrhage,226764171.0,HO,,,226764171.0,1.0,20141027.0,20150205.0,101.0,DAY,226764171.0,1.0,HIV infection
22676695,226766951,1,I,,20230626.0,20230706,20230706,EXP,,CA-TEVA-2023-CA-2904043,TEVA,,44.0,YR,A,M,Y,,,20230706.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,226766951.0,OT,,,,,,,,,226766951.0,1.0,HIV infection
22680635,226806351,1,I,20230526.0,20230703.0,20230707,20230707,EXP,FR-AFSSAPS-TS2023000845,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-094446,BRISTOL MYERS SQUIBB,,78.0,YR,E,M,Y,72.0,KG,20230707.0,,MD,FR,FR,EFAVIRENZ,Retinopathy,226806351.0,OT,,,226806351.0,1.0,20001001.0,20140312.0,4910.0,DAY,226806351.0,1.0,HIV infection
22686456,226864561,1,I,20230526.0,20230705.0,20230710,20230710,EXP,FR-AFSSAPS-TS2023000845,FR-VIIV HEALTHCARE LIMITED-FR2023092168,VIIV,,,,,,Y,,,20230710.0,,MD,FR,FR,EFAVIRENZ,Retinopathy,226864561.0,OT,,,226864561.0,1.0,20001001.0,20150325.0,5288.0,DAY,226864561.0,1.0,HIV infection
22686474,226864741,1,I,20230526.0,20230705.0,20230710,20230710,EXP,FR-AFSSAPS-TS2023000845,FR-GSK-FR2023092168,GLAXOSMITHKLINE,,,,,,Y,,,20230710.0,,MD,FR,FR,EFAVIRENZ,Retinopathy,226864741.0,OT,,,226864741.0,1.0,20001001.0,20150325.0,5288.0,DAY,226864741.0,1.0,HIV infection
22687920,226879201,1,I,,20230629.0,20230710,20230710,EXP,,GB-MYLANLABS-2023M1070629,MYLAN,,,,,M,Y,,,20230710.0,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident;Hemiplegia,226879201.0,HO,,,,,,,,,226879201.0,1.0,HIV infection
22693568,226935681,1,I,,20230704.0,20230711,20230711,EXP,,TH-MYLANLABS-2023M1073833,MYLAN,"Anuroj K, Chongbanyatcharoen S, Chiencharoenthanakij R. Severe Anemia: A Case Report of an Uncommon Precipitant of Schizophrenia Relapse. J-Blood-Med 2023;14:329-336.",48.0,YR,,F,Y,,,20230711.0,,HP,TH,TH,EFAVIRENZ,Anaemia;Intentional product misuse;Schizophrenia;Treatment noncompliance;Vitamin B12 deficiency,226935681.0,HO,,,226935681.0,1.0,2020.0,202206.0,,,226935681.0,1.0,HIV infection
22694160,226941601,1,I,20220101.0,20230710.0,20230711,20230711,EXP,FR-AFSSAPS-RS2023000486,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-097466,BRISTOL MYERS SQUIBB,,72.0,YR,E,M,Y,,,20230711.0,,MD,FR,FR,EFAVIRENZ,Drug interaction;Hyperthyroidism,226941601.0,OT,,,226941601.0,1.0,2013.0,202201.0,,,226941601.0,1.0,HIV infection
22696312,226963121,1,I,,20230703.0,20230712,20230712,EXP,,US-MYLANLABS-2023M1072590,MYLAN,"Lopez A, Bacha J, Kovarik C, Campbell L. Successful use of multidisciplinary palliative care in the outpatient treatment of disseminated histoplasmosis in an hiv positive child. Children-(Basel) 2021;8(4):no pagination.",10.0,YR,,F,Y,,,20230712.0,,HP,US,US,EFAVIRENZ,Drug ineffective,226963121.0,OT,,,,,,,,,226963121.0,1.0,HIV infection
22699078,226990781,1,I,,20230630.0,20230713,20230713,EXP,,SE-AUROBINDO-AUR-APL-2023-046499,AUROBINDO,"Elvstam O, Malmborn K, Elen S, Marrone G, Garcia F, Zazzi M et al.. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort. Clinical Infectious Diseases. 2023;76(1):25-31",,,A,,Y,,,20230713.0,,HP,SE,SE,EFAVIRENZ,HIV viraemia,226990781.0,OT,,,,,,,,,226990781.0,1.0,HIV infection
22699553,226995531,1,I,,20230629.0,20230713,20230713,EXP,,IN-MACLEODS PHARMA EU LTD-MAC2023042282,MACLEODS,"Sridhar S, Sangumani J.. Highly Active Antiretroviral Therapy-associated Lipodystrophy: Pseudo-Cushing^s Syndrome. The Journal of the Association of Physicians of India. 2023;71(2):11-12",,,,,Y,,,20230713.0,,HP,IN,IN,EFAVIRENZ,Cushing's syndrome;Dyslipidaemia;Lipodystrophy acquired,226995531.0,OT,,,,,,,,,226995531.0,1.0,HIV infection
22714660,227146601,1,I,,20230706.0,20230718,20230718,EXP,,GB-AUROBINDO-AUR-APL-2023-047489,AUROBINDO,,,,,M,Y,,,20230718.0,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident;Hemiplegia,227146601.0,HO,,,,,,,,,227146601.0,1.0,HIV infection
22714911,227149111,1,I,,20230710.0,20230718,20230718,EXP,,IN-HETERO-HET2023IN02036,HETERO,"Lad SG, Kolhe K, Chauhan S, Gattani M, Sethiya P, Singh GK, et al.. AIH in HIV: A Very Much Possible Entity. Journal of Clinical and Experimental Hepatology.. 2022;12(5):1388-1392",48.0,YR,,F,Y,,,20230718.0,,HP,IN,IN,EFAVIRENZ,Acute kidney injury,227149111.0,OT,,,,,,,,,227149111.0,1.0,HIV infection
22722094,227220942,2,F,,20230711.0,20230719,20230719,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP011546,STRIDES,"Kilcrease C, Yusuf H, Park J, Powell A, Rn LJ, Rn JO, et al.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.. AIDS-Res-Ther. 2022;19(1)",,,,F,Y,,,20230719.0,,HP,US,US,EFAVIRENZ,Intentional product misuse;Treatment noncompliance;Virologic failure,227220942.0,OT,,,,,,,,,227220942.0,1.0,Perinatal HIV infection
22726133,227261331,1,I,,20230710.0,20230720,20230720,EXP,,IN-HETERO-HET2023IN02037,HETERO,"Lad S G,Kolhe K, Chauhan S,Gattani M,Sethiya P,Singh G K et al. AIH in HIV: A Very Much Possible Entity. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY. 2022;12:1388-1392",42.0,YR,,F,Y,,,20230720.0,,HP,IN,IN,EFAVIRENZ,Autoimmune hepatitis;Drug-induced liver injury,227261331.0,OT,,,,,,,,,227261331.0,1.0,HIV infection
22728690,227286901,1,I,,20230719.0,20230720,20230720,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2023-102263,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20230720.0,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident;Hemiplegia,227286901.0,HO,,,,,,,,,227286901.0,1.0,HIV infection
22734045,227340451,1,I,,20230711.0,20230721,20230721,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP011619,STRIDES,"Kilcrease C, Yusuf H, Park J, Powell A, Rn LJ, n JO, et al.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.. AIDS-Res-Ther. 2022;19 (1)",,,,F,Y,,,20230721.0,,HP,US,US,EFAVIRENZ,Intentional product misuse;Treatment noncompliance;Virologic failure,227340451.0,OT,,,,,,,,,227340451.0,1.0,Perinatal HIV infection
22739450,227394501,1,I,20220101.0,20230710.0,20230722,20230722,EXP,,FR-AUROBINDO-AUR-APL-2023-047837,AUROBINDO,,72.0,YR,,M,Y,,,20230722.0,,MD,FR,FR,EFAVIRENZ,Drug interaction;Hyperthyroidism,227394501.0,OT,,,227394501.0,1.0,2013.0,202201.0,,,227394501.0,1.0,HIV infection
22739852,227398522,2,F,,20240405.0,20230722,20240420,EXP,,CA-AUROBINDO-AUR-APL-2023-048696,AUROBINDO,"Lopez A, Bacha J, Kovarik C, Campbell L. Successful use of multidisciplinary palliative care in the outpatient treatment of disseminated histoplasmosis in an hiv positive child. Children-(Basel). 2021;8(4)",10.0,YR,,F,Y,,,20240420.0,,HP,CA,CA,EFAVIRENZ,Drug ineffective,227398522.0,OT,,,,,,,,,227398522.0,1.0,HIV infection
22745383,227453832,2,F,,20240408.0,20230725,20240417,EXP,,CA-APOTEX-2023AP010583,APOTEX,,54.0,YR,,M,Y,,,20240417.0,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,227453832.0,OT,,,,,,,,,227453832.0,1.0,HIV infection
22752200,227522001,1,I,,20230719.0,20230726,20230726,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2023GSK099979,VIIV,"Kemp SA, Charles OJ, Derache A, Smidt W, Martin DP, Iwuji C et al. HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy. mBio. 2022;13 (3)",,,,,Y,,,20230726.0,,HP,GB,ZA,EFAVIRENZ,Antiviral drug level below therapeutic;Pathogen resistance;Treatment failure;Treatment noncompliance;Viraemia;Viral mutation identified;Virologic failure,227522001.0,OT,,,,,,,,,227522001.0,1.0,HIV infection
22752201,227522011,1,I,,20230719.0,20230726,20230726,EXP,,GB-GSK-ZA2023GSK099979,GLAXOSMITHKLINE,"Kemp SA, Charles OJ, Derache A, Smidt W, Martin DP, Iwuji C et al. HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy. mBio. 2022;13 (3)",,,,,Y,,,20230726.0,,HP,GB,ZA,EFAVIRENZ,Antiviral drug level below therapeutic;Pathogen resistance;Treatment failure;Treatment noncompliance;Viraemia;Viral mutation identified;Virologic failure,227522011.0,OT,,,,,,,,,227522011.0,1.0,HIV infection
22770988,227709881,1,I,,20230724.0,20230801,20230801,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012365,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11",,,A,M,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227709881.0,OT,,,,,,,,,227709881.0,1.0,HIV infection
22770990,227709901,1,I,,20230724.0,20230801,20230801,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012291,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One.. 2022;17(3):1-11",,,A,F,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227709901.0,OT,,,,,,,,,227709901.0,1.0,HIV infection
22771012,227710121,1,I,,20230724.0,20230801,20230801,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012363,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11",,,A,M,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227710121.0,OT,,,,,,,,,227710121.0,1.0,HIV infection
22771104,227711041,1,I,,20230724.0,20230801,20230801,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012324,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One.. 2022;17(3):1-11",,,A,F,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227711041.0,OT,,,,,,,,,227711041.0,1.0,HIV infection
22771661,227716611,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1080981,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Nervous system disorder,227716611.0,OT,,,,,,,,,227716611.0,1.0,HIV infection
22771669,227716691,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1081024,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Treatment failure,227716691.0,OT,,,,,,,,,227716691.0,1.0,HIV infection
22771670,227716701,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1080995,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Treatment failure,227716701.0,OT,,,,,,,,,227716701.0,1.0,HIV infection
22771830,227718301,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1080944,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Treatment failure,227718301.0,OT,,,,,,,,,227718301.0,1.0,HIV infection
22771831,227718311,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1080957,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227718311.0,OT,,,,,,,,,227718311.0,1.0,HIV infection
22771832,227718321,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1081101,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Treatment failure,227718321.0,OT,,,,,,,,,227718321.0,1.0,HIV infection
22773866,227738661,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1081055,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ,Treatment failure,227738661.0,OT,,,,,,,,,227738661.0,1.0,HIV infection
22774471,227744711,1,I,,20230719.0,20230802,20230802,EXP,,GB-AUROBINDO-AUR-APL-2023-050100,AUROBINDO,,,,,M,Y,,,20230802.0,,HP,GB,GB,EFAVIRENZ,Cerebrovascular accident;Hemiplegia,227744711.0,HO,,,,,,,,,227744711.0,1.0,HIV infection
22774512,227745121,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012401,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One.. 2022;17(3):1-11",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227745121.0,OT,,,,,,,,,227745121.0,1.0,HIV infection
22774515,227745151,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012362,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227745151.0,OT,,,,,,,,,227745151.0,1.0,HIV infection
22774518,227745181,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012290,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One.. 2022;17(3):1-11",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Maternal exposure during pregnancy,227745181.0,OT,,,,,,,,,227745181.0,1.0,HIV infection
22774885,227748851,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012422,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Nervous system disorder,227748851.0,OT,,,,,,,,,227748851.0,1.0,HIV infection
22774936,227749361,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012393,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Nervous system disorder,227749361.0,OT,,,,,,,,,227749361.0,1.0,HIV infection
22775804,227758041,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012380,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227758041.0,OT,,,,,,,,,227758041.0,1.0,HIV infection
22775818,227758181,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012432,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One.. 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227758181.0,OT,,,,,,,,,227758181.0,1.0,HIV infection
22775845,227758451,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012400,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Nervous system disorder,227758451.0,OT,,,,,,,,,227758451.0,1.0,HIV infection
22775857,227758571,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012409,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Nervous system disorder,227758571.0,OT,,,,,,,,,227758571.0,1.0,HIV infection
22775883,227758831,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012270,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227758831.0,OT,,,,,,,,,227758831.0,1.0,HIV infection
22775952,227759521,1,I,,20230724.0,20230802,20230802,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012374,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227759521.0,OT,,,,,,,,,227759521.0,1.0,HIV infection
22776215,227762151,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081166,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227762151.0,OT,,,,,,,,,227762151.0,1.0,HIV infection
22776216,227762161,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1080947,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227762161.0,OT,,,,,,,,,227762161.0,1.0,HIV infection
22776226,227762261,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1080959,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Maternal exposure during pregnancy,227762261.0,OT,,,,,,,,,227762261.0,1.0,HIV infection
22776227,227762271,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081185,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227762271.0,OT,,,,,,,,,227762271.0,1.0,HIV infection
22776228,227762281,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081061,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227762281.0,OT,,,,,,,,,227762281.0,1.0,HIV infection
22776234,227762341,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1080970,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227762341.0,OT,,,,,,,,,227762341.0,1.0,HIV infection
22778542,227785421,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081155,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227785421.0,OT,,,,,,,,,227785421.0,1.0,HIV infection
22778543,227785431,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081051,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227785431.0,OT,,,,,,,,,227785431.0,1.0,HIV infection
22778549,227785491,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081083,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227785491.0,OT,,,,,,,,,227785491.0,1.0,HIV infection
22778550,227785501,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081007,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227785501.0,OT,,,,,,,,,227785501.0,1.0,HIV infection
22778551,227785511,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1080993,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Nervous system disorder;Treatment failure,227785511.0,OT,,,,,,,,,227785511.0,1.0,HIV infection
22778553,227785531,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081190,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Anaemia,227785531.0,OT,,,,,,,,,227785531.0,1.0,HIV infection
22778761,227787611,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081058,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Treatment failure,227787611.0,OT,,,,,,,,,227787611.0,1.0,HIV infection
22778763,227787631,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081201,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ,Treatment failure,227787631.0,OT,,,,,,,,,227787631.0,1.0,HIV infection
22780101,227801011,1,I,,20230724.0,20230803,20230803,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012430,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11",,,A,F,Y,,,20230803.0,,HP,ET,ET,EFAVIRENZ,Nervous system disorder,227801011.0,OT,,,,,,,,,227801011.0,1.0,HIV infection
22780117,227801171,1,I,,20230724.0,20230803,20230803,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012268,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One. 2022;17(3):1-11.",,,A,F,Y,,,20230803.0,,HP,ET,ET,EFAVIRENZ,Nervous system disorder,227801171.0,OT,,,,,,,,,227801171.0,1.0,HIV infection
22781039,227810391,1,I,,20230724.0,20230803,20230803,EXP,,ET-STRIDES ARCOLAB LIMITED-2023SP012428,STRIDES,"Fentie Wendie T, Mengistu G.. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.. PLOS-One.. 2022;17(3):1-11",,,A,F,Y,,,20230803.0,,HP,ET,ET,EFAVIRENZ,Nervous system disorder,227810391.0,OT,,,,,,,,,227810391.0,1.0,HIV infection
22781139,227811391,1,I,,20230724.0,20230803,20230803,EXP,,ET-MYLANLABS-2023M1081116,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230803.0,,HP,ET,ET,EFAVIRENZ,Anaemia;Treatment failure,227811391.0,OT,,,,,,,,,227811391.0,1.0,HIV infection
22797484,227974841,1,I,20210601.0,20230731.0,20230808,20230808,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2023GSK105024,VIIV,"Knobel H, Canas-Ruano E, Guelar A, Knobel P, Villar-Garcia J, Gonzalez-Mena A et al. Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study. HIV Research and Clinical Practice. 2023;24 (1)",,,,,Y,,,20230808.0,,HP,ES,ES,EFAVIRENZ,Insomnia;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,227974841.0,OT,,,227974841.0,1.0,202012.0,202012.0,,,227974841.0,1.0,HIV infection
22797491,227974911,1,I,20210601.0,20230731.0,20230808,20230808,EXP,,ES-GSK-ES2023GSK105024,GLAXOSMITHKLINE,"Knobel H, Canas-Ruano E, Guelar A, Knobel P, Villar-Garcia J, Gonzalez-Mena A et al. Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study. HIV Research and Clinical Practice. 2023;24 (1)",,,,,Y,,,20230808.0,,HP,ES,ES,EFAVIRENZ,Insomnia;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,227974911.0,OT,,,227974911.0,1.0,202012.0,202012.0,,,227974911.0,1.0,HIV infection
22818822,228188222,2,F,20170101.0,20240615.0,20230814,20240628,EXP,,ZA-CIPLA (EU) LIMITED-2023ZA04764,CIPLA,,,,,,Y,,,20240628.0,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,228188222.0,OT,,,228188222.0,1.0,20170224.0,,,,228188222.0,1.0,Antiretroviral therapy
22821496,228214962,2,F,,20230822.0,20230814,20230829,EXP,,US-MYLANLABS-2023M1085726,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",37.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228214962.0,OT,,,,,,,,,228214962.0,1.0,HIV infection
22826740,228267402,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085746,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",36.0,YR,,M,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267402.0,OT,,,,,,,,,228267402.0,1.0,HIV infection
22826742,228267421,1,I,,20230807.0,20230816,20230816,EXP,,US-MYLANLABS-2023M1085697,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",,,,,Y,,,20230816.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267421.0,OT,,,,,,,,,228267421.0,1.0,HIV infection
22826743,228267432,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085700,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",33.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267432.0,OT,,,,,,,,,228267432.0,1.0,HIV infection
22826745,228267451,1,I,,20230807.0,20230816,20230816,EXP,,US-MYLANLABS-2023M1085744,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",,,,,Y,,,20230816.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267451.0,OT,,,,,,,,,228267451.0,1.0,HIV infection
22826746,228267462,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085739,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",34.0,YR,,M,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267462.0,OT,,,,,,,,,228267462.0,1.0,HIV infection
22826747,228267472,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085698,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",39.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267472.0,OT,,,,,,,,,228267472.0,1.0,HIV infection
22826748,228267482,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085702,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",26.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267482.0,OT,,,,,,,,,228267482.0,1.0,HIV infection
22826750,228267501,1,I,,20230807.0,20230816,20230816,EXP,,US-MYLANLABS-2023M1085735,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",,,,,Y,,,20230816.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267501.0,OT,,,,,,,,,228267501.0,1.0,HIV infection
22826752,228267521,1,I,,20230807.0,20230816,20230816,EXP,,US-MYLANLABS-2023M1085695,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",,,,,Y,,,20230816.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267521.0,OT,,,,,,,,,228267521.0,1.0,HIV infection
22826755,228267552,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085713,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",43.0,YR,,M,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267552.0,OT,,,,,,,,,228267552.0,1.0,HIV infection
22826759,228267592,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085699,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",40.0,YR,,M,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267592.0,OT,,,,,,,,,228267592.0,1.0,HIV infection
22826792,228267921,1,I,,20230807.0,20230816,20230816,EXP,,US-MYLANLABS-2023M1085709,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",,,,,Y,,,20230816.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267921.0,OT,,,,,,,,,228267921.0,1.0,HIV infection
22826793,228267932,2,F,,20230822.0,20230816,20230830,EXP,,US-MYLANLABS-2023M1085761,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",52.0,YR,,F,Y,,,20230830.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228267932.0,OT,,,,,,,,,228267932.0,1.0,HIV infection
22827213,228272132,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085728,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",47.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228272132.0,OT,,,,,,,,,228272132.0,1.0,HIV infection
22827214,228272142,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085730,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",39.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228272142.0,OT,,,,,,,,,228272142.0,1.0,HIV infection
22827216,228272162,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085743,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",47.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228272162.0,OT,,,,,,,,,228272162.0,1.0,HIV infection
22827220,228272202,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085708,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",49.0,YR,,F,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228272202.0,OT,,,,,,,,,228272202.0,1.0,HIV infection
22827307,228273072,2,F,,20230822.0,20230816,20230829,EXP,,US-MYLANLABS-2023M1085715,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",38.0,YR,,M,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228273072.0,OT,,,,,,,,,228273072.0,1.0,HIV infection
22827704,228277042,2,F,,20230822.0,20230816,20230828,EXP,,US-MYLANLABS-2023M1085755,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",52.0,YR,,F,Y,,,20230828.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228277042.0,OT,,,,,,,,,228277042.0,1.0,HIV infection
22831518,228315183,3,F,,20230822.0,20230817,20230829,EXP,,US-MYLANLABS-2023M1085732,MYLAN,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS 2022;36(14):2057-2062.",35.0,YR,,M,Y,,,20230829.0,,HP,US,ZA,EFAVIRENZ,Drug ineffective,228315183.0,OT,,,,,,,,,228315183.0,1.0,HIV infection
22872934,228729342,2,F,,20230821.0,20230828,20231106,EXP,,GB-GILEAD-2023-0640941,GILEAD,"Ali M, Lee N, French P, Miller R and Ahmed N. Effective prolonged suppression of HIV-1 viral load using tenofovir alafenamide, emtricitabine and efavirenz in an adult with BMI }59 kg/m2. International Journal of STD + AIDS. 2023;0 (0):1-3. doi:https://doi.org/10.1177/09564624231195088",59.0,YR,A,F,Y,,,20231106.0,,HP,GB,GB,EFAVIRENZ,Acute kidney injury;Diabetic ketoacidosis,228729342.0,OT,,,228729342.0,1.0,2019.0,,,,228729342.0,1.0,HIV infection
22875985,228759851,1,I,,20230823.0,20230829,20230829,EXP,,US-VIIV HEALTHCARE LIMITED-KE2023GSK116810,VIIV,,,,,,Y,,,20230829.0,,HP,US,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,228759851.0,OT,,,,,,,,,228759851.0,1.0,HIV infection
22875990,228759901,1,I,,20230823.0,20230829,20230829,EXP,,US-VIIV HEALTHCARE LIMITED-KE2023GSK116811,VIIV,,,,,,Y,,,20230829.0,,HP,US,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,228759901.0,OT,,,,,,,,,228759901.0,1.0,HIV infection
22875993,228759931,1,I,,20230823.0,20230829,20230829,EXP,,US-GSK-KE2023GSK116811,GLAXOSMITHKLINE,,,,,,Y,,,20230829.0,,HP,US,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,228759931.0,OT,,,,,,,,,228759931.0,1.0,HIV infection
22875994,228759941,1,I,,20230823.0,20230829,20230829,EXP,,US-GSK-KE2023GSK116810,GLAXOSMITHKLINE,,,,,,Y,,,20230829.0,,HP,US,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,228759941.0,OT,,,,,,,,,228759941.0,1.0,HIV infection
22944890,229448901,1,I,,20230907.0,20230914,20230914,EXP,,CN-GSK-CN2023GSK123510,GLAXOSMITHKLINE,"Li J, Wen Z, Chen Y, Yin S. R263K Mutation Leading to Failure of Dolutegravir-Based Treatment in a HIV Patient also Receiving Rifampicin A Case Report. Re:GEN Open. 2023;3 (1):34-39",,,,,Y,,,20230914.0,,HP,CN,CN,EFAVIRENZ,Cough;Drug interaction;Haemoptysis;Night sweats;Pathogen resistance;Productive cough;Treatment failure;Viral mutation identified;Virologic failure;Weight decreased,229448901.0,OT,,,229448901.0,1.0,20191021.0,20210128.0,465.0,DAY,229448901.0,1.0,HIV infection
22944900,229449004,4,F,,20231208.0,20230914,20231214,EXP,,PL-JNJFOC-20230908054,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20231214.0,,MD,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neuropsychological symptoms;Neutropenia;Off label use;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,229449004.0,HO,,,229449004.0,2.0,2011.0,,,,229449004.0,1.0,HIV infection
22944901,229449011,1,I,,20230907.0,20230914,20230914,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK123510,VIIV,"Li J, Wen Z, Chen Y, Yin S. R263K Mutation Leading to Failure of Dolutegravir-Based Treatment in a HIV Patient also Receiving Rifampicin A Case Report. Re:GEN Open. 2023;3 (1):34-39",,,,,Y,,,20230914.0,,HP,CN,CN,EFAVIRENZ,Cough;Drug interaction;Haemoptysis;Night sweats;Pathogen resistance;Productive cough;Treatment failure;Viral mutation identified;Virologic failure;Weight decreased,229449011.0,OT,,,229449011.0,1.0,20191021.0,20210128.0,465.0,DAY,229449011.0,1.0,HIV infection
22947191,229471911,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058424,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057?2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229471911.0,OT,,,,,,,,,229471911.0,1.0,HIV infection
22947250,229472501,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058429,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057?2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229472501.0,OT,,,,,,,,,229472501.0,1.0,HIV infection
22947357,229473571,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058434,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057-2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229473571.0,OT,,,,,,,,,229473571.0,1.0,HIV infection
22947459,229474591,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058435,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057?2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229474591.0,OT,,,,,,,,,229474591.0,1.0,HIV infection
22947501,229475011,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058437,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229475011.0,OT,,,,,,,,,229475011.0,1.0,HIV infection
22947542,229475421,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058438,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229475421.0,OT,,,,,,,,,229475421.0,1.0,HIV infection
22947546,229475461,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058441,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057?2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229475461.0,OT,,,,,,,,,229475461.0,1.0,HIV infection
22947825,229478251,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058421,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057?2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229478251.0,OT,,,,,,,,,229478251.0,1.0,HIV infection
22947850,229478501,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058426,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229478501.0,OT,,,,,,,,,229478501.0,1.0,HIV infection
22947916,229479161,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058430,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057?2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229479161.0,OT,,,,,,,,,229479161.0,1.0,HIV infection
22947995,229479951,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058440,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057-2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229479951.0,OT,,,,,,,,,229479951.0,1.0,HIV infection
22948390,229483901,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058431,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229483901.0,OT,,,,,,,,,229483901.0,1.0,HIV infection
22948414,229484141,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058436,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229484141.0,OT,,,,,,,,,229484141.0,1.0,HIV infection
22948417,229484171,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058422,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.. AIDS. 2022;36(14):2057-2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229484171.0,OT,,,,,,,,,229484171.0,1.0,HIV infection
22948432,229484321,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058427,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229484321.0,OT,,,,,,,,,229484321.0,1.0,HIV infection
22948445,229484451,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058432,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229484451.0,OT,,,,,,,,,229484451.0,1.0,HIV infection
22948456,229484561,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058439,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057-2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229484561.0,OT,,,,,,,,,229484561.0,1.0,HIV infection
22949145,229491451,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058425,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229491451.0,OT,,,,,,,,,229491451.0,1.0,HIV infection
22949152,229491521,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058423,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057?2062",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229491521.0,OT,,,,,,,,,229491521.0,1.0,HIV infection
22949153,229491531,1,I,,20230904.0,20230915,20230915,EXP,,ZA-AUROBINDO-AUR-APL-2023-058442,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14)",,,,,Y,,,20230915.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective;Virologic failure,229491531.0,OT,,,,,,,,,229491531.0,1.0,HIV infection
22950719,229507191,1,I,,20230904.0,20230916,20230916,EXP,,ZA-AUROBINDO-AUR-APL-2023-058428,AUROBINDO,"van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Gandhi M, et al.. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens. AIDS. 2022;36 (14):2057-2062",,,,,Y,,,20230916.0,,HP,ZA,ZA,EFAVIRENZ,Drug ineffective,229507191.0,OT,,,,,,,,,229507191.0,1.0,HIV infection
22964190,229641902,2,F,,20230918.0,20230921,20230929,EXP,,CN-GILEAD-2023-0643503,GILEAD,"Tang J , Liu Y. A Case Report of Efavirenz Induced Gynecomastia. Chinese Journal of Pharmacovigilance. 2023;unk:unk. doi:10.19803/j.1672- 8629.20230041",72.0,YR,E,M,Y,,,20230929.0,,HP,CN,CN,EFAVIRENZ,Gynaecomastia,229641902.0,HO,,,,,,,,,229641902.0,1.0,HIV infection
22967702,229677024,4,F,,20231222.0,20230921,20231228,EXP,,PL-ABBVIE-5411496,ABBVIE,,43.0,YR,,M,Y,,,20231228.0,,HP,PL,PL,EFAVIRENZ,Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychological symptoms;Neutropenia;Off label use;Pancreatitis;Pathogen resistance;Urinary tract infection bacterial,229677024.0,OT,,,229677024.0,7.0,201104.0,,,,229677024.0,1.0,HIV infection
22970289,229702891,1,I,,20230918.0,20230922,20230922,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-2023-132965,BRISTOL MYERS SQUIBB,,43.0,YR,A,M,Y,,,20230922.0,,HP,PL,PL,EFAVIRENZ,Diarrhoea;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection,229702891.0,HO,,,229702891.0,1.0,2011.0,,,,229702891.0,1.0,HIV infection
23006300,230063001,1,I,,20230918.0,20230929,20230929,EXP,,GB-CIPLA LTD.-2023GB05771,CIPLA,"Ali M, Lee N, French P, Miller R, Ahmed N. Effective prolonged suppression of HIV-1 viral load using Tenofovir alafenamide, emtricitabine and efavirenz in an adult with BMI }59 kg/m2. NA",,,,,Y,,,20230929.0,,HP,GB,GB,EFAVIRENZ,Acute kidney injury;Diabetic ketoacidosis,230063001.0,OT,,,230063001.0,1.0,2019.0,,,,230063001.0,1.0,Antiretroviral therapy
23011647,230116471,1,I,20110101.0,20230919.0,20230929,20230929,EXP,,GB-009507513-2309GBR007192,MERCK,"Obeng L, Patel A, Villa G, Mourad A, Whibley M, Gilleece Y, et al.. Autoimmune hepatitis in people living with HIV: A case series and review of literature. Open AIDS Journal. 2023;17",47.0,YR,,F,Y,,,20230929.0,,HP,GB,GB,EFAVIRENZ,Autoimmune hepatitis,230116471.0,OT,,,230116471.0,1.0,201001.0,201101.0,,,230116471.0,1.0,HIV infection
23022257,230222572,2,F,,20240410.0,20231003,20240412,EXP,,CA-SANDOZ INC.-NVSC2023CA037206,SANDOZ,,54.0,YR,,M,Y,,,20240412.0,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,230222572.0,HO,,,,,,,,,230222572.0,1.0,HIV infection
23023866,230238661,1,I,20230808.0,20230929.0,20231003,20231003,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-139731,BRISTOL MYERS SQUIBB,,,,,,Y,,,20231004.0,,PH,US,US,SUSTIVA,Wrong technique in product usage process,,,,,230238661.0,1.0,20230808.0,,,,230238661.0,1.0,HIV infection
23029234,230292344,4,F,,20240507.0,20231004,20240508,EXP,,CA-SANDOZ INC.-SDZ2023CA035416,SANDOZ,,54.0,YR,,M,Y,,,20240508.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,230292344.0,OT,,,,,,,,,230292344.0,1.0,HIV infection
23035650,230356501,1,I,,20230927.0,20231006,20231006,EXP,,FR-AUROBINDO-AUR-APL-2023-061194,AUROBINDO,"Laparra A, Lerolle N, Gerin M, Cheret A, De Castro N, Gallien S, et al.. Tumor necrosis factor-alpha inhibitors for extended or severe neurological immune reconstitution inflammatory syndrome in HIV-infected patients.. AIDS.. 2021;35(6):995-997",37.0,YR,,F,Y,,,20231006.0,,HP,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome,230356501.0,OT,,,,,,,,,230356501.0,1.0,HIV infection
23053149,230531492,2,F,,20231206.0,20231011,20231212,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2023GSK138370,VIIV,"Marcon CEM, Schlindwein AD, Schuelter-Trevisol F. Longitudinal Assessment of Virological Failure and Antiretroviral Drug Resistance among Treatment-naive Subjects Living with HIV. Current HIV Research. 2023;21(3):213-219",,,,,Y,,,20231212.0,,HP,BR,BR,EFAVIRENZ,Drug resistance;Pathogen resistance;Virologic failure,230531492.0,OT,,,,,,,,,230531492.0,1.0,HIV infection
23053158,230531582,2,F,,20231206.0,20231011,20231212,EXP,,BR-GSK-BR2023GSK138370,GLAXOSMITHKLINE,"Marcon CEM, Schlindwein AD, Schuelter-Trevisol F. Longitudinal Assessment of Virological Failure and Antiretroviral Drug Resistance among Treatment-naive Subjects Living with HIV. Current HIV Research. 2023;21(3):213-219",,,,,Y,,,20231212.0,,HP,BR,BR,EFAVIRENZ,Drug resistance;Pathogen resistance;Virologic failure,230531582.0,OT,,,,,,,,,230531582.0,1.0,HIV infection
23057980,230579801,1,I,,20231009.0,20231012,20231012,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-143633,BRISTOL MYERS SQUIBB,"Shah DM, Poor A. The art of anaphylaxis: rare case of anaphylactic reaction to efavirenz. Chest. 2023 Oct;164(4S):114A. doi:10.1016/j.chest.2023.07.127.",40.0,YR,A,M,Y,,,20231012.0,,HP,US,US,EFAVIRENZ,Anaphylactic reaction,230579801.0,LT,,,,,,,,,230579801.0,1.0,HIV infection
23104947,231049471,1,I,,20231018.0,20231025,20231025,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2023EME145159,VIIV,,,,,,Y,,,20231025.0,,MD,PT,PT,EFAVIRENZ,Inappropriate schedule of product administration;Product prescribing error;Product use in unapproved therapeutic environment;Tuberculosis,231049471.0,OT,,,,,,,,,231049471.0,1.0,Acquired immunodeficiency syndrome
23109595,231095951,1,I,,20231016.0,20231026,20231026,EXP,,CA-TEVA-2023-CA-2938481,TEVA,,54.0,YR,A,M,Y,,,20231026.0,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,231095951.0,OT,,,,,,,,,231095951.0,1.0,HIV infection
23131537,231315377,7,F,20231001.0,20240702.0,20231031,20241127,EXP,,US-THERATECHNOLOGIES INC.-2023-THE-IBA-000432,Unknown Manufacturer,,,,,,Y,,,20241127.0,,CN,US,US,SUSTIVA,Abdominal pain upper;Decreased appetite;Depression;Fatigue;Hypoaesthesia;Paraesthesia;Scar,,,,,231315377.0,1.0,202310.0,202310.0,,,231315377.0,1.0,HIV infection
23146842,231468421,1,I,,20231025.0,20231105,20231105,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP016319,STRIDES,"Singh A, Raka MS, Rukhiyana RH, Thadiboina O. Sepsis in a Seropositive Pregnant Woman With Early Preterm Labor Pains: A Case Study of a Near Miss.. Cureus. 2022;14(10):e29815",35.0,YR,,F,Y,,,20231106.0,,HP,IN,IN,EFAVIRENZ,Maternal exposure during pregnancy;Premature delivery,231468421.0,OT,,,231468421.0,1.0,2015.0,,,,231468421.0,1.0,HIV infection
23185148,231851481,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-160490,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231851481.0,OT,,,,,,,,,231851481.0,1.0,HIV infection
23186243,231862431,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-163893,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231862431.0,DE,,,,,,,,,231862431.0,1.0,HIV infection
23186433,231864331,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-163894,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231864331.0,DE,,,,,,,,,231864331.0,1.0,HIV infection
23186819,231868191,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-163895,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231868191.0,DE,,,,,,,,,231868191.0,1.0,HIV infection
23187175,231871751,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-163896,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231871751.0,DE,,,,,,,,,231871751.0,1.0,HIV infection
23187220,231872201,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-163897,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231872201.0,OT,,,,,,,,,231872201.0,1.0,HIV infection
23187560,231875601,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-163898,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231875601.0,DE,,,,,,,,,231875601.0,1.0,HIV infection
23187653,231876531,1,I,,20231104.0,20231115,20231115,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-163899,BRISTOL MYERS SQUIBB,"Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk of suicidal ideation, attempted, or completed suicide. Ann Intern Med. 2014 Jul 01;16(1):1-20.doi:10.7326/M14-0293.",,,,M,Y,,,20231115.0,,HP,US,US,EFAVIRENZ,Completed suicide,231876531.0,DE,,,,,,,,,231876531.0,1.0,HIV infection
23202653,232026531,1,I,,20231108.0,20231120,20231120,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP016897,STRIDES,"Subith S, Tungenwar S, Avhad T, Apte T, Dakhode S.. Anti-retroviral Therapy-Induced Multiple Pathological Fractures in a HIV-Positive Young Female: A Case Report and Review of Literature. Journal of Orthopaedic Case Reports. 2023;13(5):111-115",38.0,YR,,F,Y,,,20231120.0,,HP,IN,IN,EFAVIRENZ,Fanconi syndrome;Osteoporosis;Pathological fracture,232026531.0,OT,,,,,,,,,232026531.0,1.0,HIV infection
23206116,232061161,1,I,,20231113.0,20231120,20231120,EXP,,JP-GILEAD-2023-0651349,GILEAD,"Isoda A, Mihara M, Matsumoto M, Sawamura M. Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient. BMJ Case Reports. 2023;16(11):unk. doi:10.1136/bcr-2023-255751",7.0,DEC,E,F,Y,36.0,KG,20231120.0,,MD,JP,JP,EFAVIRENZ,Drug resistance mutation;Lactic acidosis;Mitochondrial toxicity;Off label use;Renal impairment,232061161.0,HO,,,,,,,,,232061161.0,1.0,HIV infection
23209004,232090041,1,I,,20231113.0,20231121,20231121,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2023-167207,BRISTOL MYERS SQUIBB,"Coovadia A, Abrams EJ, Strehlau R, Shiau S, Pinillos F, Martens L, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in south africa: a randomized clinical trial. JAMA. 2015 Nov 03;314(17):1808-17. doi:10.1001/jama.2015.13631.",,,C,,Y,,,20231121.0,,HP,ZA,ZA,EFAVIRENZ,Generalised tonic-clonic seizure,232090041.0,OT,,,,,,,,,232090041.0,1.0,HIV infection
23209588,232095881,1,I,,20231113.0,20231121,20231121,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2023-167169,BRISTOL MYERS SQUIBB,"Coovadia A, Abrams EJ, Strehlau R, Shiau S, Pinillos F, Martens L, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in south africa: a randomized clinical trial. JAMA. 2015 Nov 03;314(17):1808-17. doi:10.1001/jama.2015.13631.",,,C,,Y,,,20231121.0,,HP,ZA,ZA,EFAVIRENZ,Petit mal epilepsy,232095881.0,OT,,,,,,,,,232095881.0,1.0,HIV infection
23213773,232137731,1,I,,20231108.0,20231121,20231121,EXP,,SA-STRIDES ARCOLAB LIMITED-2023SP017057,STRIDES,"Almangour TA, Skersick PT, Corbett A, Rodgers JE, Chang PP, Farel CE. Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report. AIDS Research and Therapy. 2023;20(1):55",58.0,YR,,M,Y,,,20231121.0,,HP,SA,SA,EFAVIRENZ,Drug interaction;Rash;Therapy non-responder;Transplant rejection,232137731.0,OT,,,232137731.0,1.0,2006.0,2015.0,6.0,MON,232137731.0,1.0,HIV infection
23226332,232263321,1,I,20190101.0,20231115.0,20231124,20231124,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2023EME162956,VIIV,,,,,,Y,,,20231124.0,,HP,RU,RU,EFAVIRENZ,Abdominal pain upper;Blood pressure increased;COVID-19;Dyspepsia;Face oedema;Hypertensive crisis;Malaise;Metabolic nephropathy;Nausea;Oedema peripheral;Renal cyst,232263321.0,OT,,,232263321.0,1.0,201908.0,,,,232263321.0,1.0,HIV infection
23226333,232263331,1,I,20190101.0,20231115.0,20231124,20231124,EXP,,RU-GSK-RU2023EME162956,GLAXOSMITHKLINE,,,,,,Y,,,20231124.0,,HP,RU,RU,EFAVIRENZ,Abdominal pain upper;Blood pressure increased;COVID-19;Dyspepsia;Face oedema;Hypertensive crisis;Malaise;Metabolic nephropathy;Nausea;Oedema peripheral;Renal cyst,232263331.0,OT,,,232263331.0,1.0,201908.0,,,,232263331.0,1.0,HIV infection
23227250,232272501,1,I,20180601.0,20231115.0,20231124,20231124,EXP,,RU-GSK-RU2023EME162948,GLAXOSMITHKLINE,,,,,,Y,,,20231124.0,,HP,RU,RU,EFAVIRENZ,Astigmatism;Brain contusion;COVID-19;Contusion;Craniocerebral injury;Discomfort;Fall;Fibrosis;Headache;Hepatic fibrosis;Hyperaemia;Myopia;Onychomycosis;Oral candidiasis;Oral discomfort;Rash vesicular;Red blood cell count decreased;Renal cyst;Varicella zoster virus infection;Viral load increased,232272501.0,OT,,,232272501.0,1.0,20150616.0,,,,232272501.0,1.0,HIV infection
23227251,232272511,1,I,20180601.0,20231115.0,20231124,20231124,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2023EME162948,VIIV,,,,,,Y,,,20231124.0,,HP,RU,RU,EFAVIRENZ,Astigmatism;Brain contusion;COVID-19;Contusion;Craniocerebral injury;Discomfort;Fall;Fibrosis;Headache;Hepatic fibrosis;Hyperaemia;Myopia;Onychomycosis;Oral candidiasis;Oral discomfort;Rash vesicular;Red blood cell count decreased;Renal cyst;Varicella zoster virus infection;Viral load increased,232272511.0,HO,,,232272511.0,1.0,20150616.0,,,,232272511.0,1.0,HIV infection
23232512,232325121,1,I,20020301.0,20231117.0,20231128,20231128,EXP,,FR-AUROBINDO-AUR-APL-2023-074381,AUROBINDO,"Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM et al... Renal Tubular Dysfunction Associated with Tenofovir Therapy: Report of 7 Cases.. J Acquir Immune Defic Syndr.. 2004;35(3):269-73",56.0,YR,,F,Y,56.0,KG,20231128.0,,MD,FR,FR,EFAVIRENZ,Creatinine renal clearance decreased;Glycosuria;Hypophosphataemia;Myalgia;Nephropathy toxic;Pain in extremity;Proteinuria;Renal tubular dysfunction,232325121.0,OT,,,232325121.0,1.0,202105.0,2002.0,11.0,MON,232325121.0,1.0,HIV infection
23239306,232393061,1,I,,20231115.0,20231129,20231129,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP017807,STRIDES,Hiremath G.. Gynaecomastia in HIV Positive Patient on Highly Active Antiretroviral Therapy (Haart): Case Report.. Indian-J-Pharmacol. 2021;53 (Suppl.) (7):S146.,40.0,YR,,M,Y,,,20231129.0,,HP,IN,IN,EFAVIRENZ,Gynaecomastia,232393061.0,OT,,,,,,,,,232393061.0,1.0,HIV infection
23241067,232410671,1,I,,20231115.0,20231129,20231129,EXP,,IN-MYLANLABS-2023M1125654,MYLAN,Hiremath G. Gynaecomastia in HIV Positive Patient on Highly Active Antiretroviral Therapy (Haart): Case Report. Indian-J-Pharmacol 2021; 53 (Suppl.) (7): S146.,40.0,YR,,M,Y,,,20231127.0,,HP,IN,IN,EFAVIRENZ,Gynaecomastia;Mental disorder,232410671.0,OT,,,,,,,,,232410671.0,1.0,HIV infection
23244289,232442891,1,I,,20231120.0,20231130,20231130,EXP,,CA-APOTEX-2023AP016881,APOTEX,,54.0,YR,,M,Y,,,20231130.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,232442891.0,HO,,,,,,,,,232442891.0,1.0,HIV infection
23281445,232814451,1,I,,20231127.0,20231211,20231211,EXP,,IN-AUROBINDO-AUR-APL-2023-076393,AUROBINDO,Hiremath G. Gynaecomastia in HIV Positive Patient on Highly Active Antiretroviral Therapy (Haart): Case Report. Indian-J-Pharmacol. 2021;53 (Suppl.)(7):S146,40.0,YR,,M,Y,,,20231211.0,,HP,IN,IN,EFAVIRENZ,Gynaecomastia,232814451.0,OT,,,,,,,,,232814451.0,1.0,HIV infection
23287292,232872921,1,I,,20230711.0,20231212,20231212,PER,,US-APOTEX-2023AP010725,APOTEX,"Kilcrease C, Yusuf H, Park J, Powell A, Rn LJ, Rn JO, et al.. Realizing the promise of long-acting antiretroviral treatment strategies  for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19 (1):56",37.0,YR,,F,Y,,,20231212.0,,HP,US,US,EFAVIRENZ,Treatment noncompliance,,,,,232872921.0,1.0,,202008.0,,,232872921.0,1.0,Perinatal HIV infection
23299339,232993391,1,I,20231001.0,20231206.0,20231215,20231215,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023APC171236,VIIV,,,,,,Y,,,20231215.0,,HP,CN,CN,EFAVIRENZ,Cheilitis;Conjunctivitis;Erythema multiforme;Foreign body sensation in eyes;Mouth ulceration;Ocular discomfort;Rash;Stevens-Johnson syndrome;Tongue ulceration,232993391.0,OT,,,232993391.0,1.0,20230922.0,20231206.0,75.0,DAY,232993391.0,1.0,Acquired immunodeficiency syndrome
23302889,233028891,1,I,20190901.0,20231206.0,20231215,20231215,EXP,,IT-009507513-2312ITA003034,MERCK,"Carmillo L, Congedo P, Caggiula M, Nuzzo MM, Fasano A. MuSK myasthenia gravis as a manifestation of immune reconstitution inflammatory syndrome in an HIV-positive patient: a challenging diagnosis and therapeutic approach. Neurological Sciences. 2023;44:4575-7",44.0,YR,,F,Y,,,20231215.0,,HP,IT,IT,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Immune-mediated myasthenia gravis,233028891.0,HO,,,233028891.0,1.0,2010.0,,,,233028891.0,1.0,HIV infection
23311748,233117481,1,I,20190101.0,20231208.0,20231219,20231219,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2023-179660,BRISTOL MYERS SQUIBB,,43.0,YR,A,M,Y,,,20231219.0,,MD,PT,PT,EFAVIRENZ,Aphthous ulcer;Diarrhoea;Drug resistance;Insomnia;Irritability;Respiratory tract infection;Secondary syphilis;Treatment noncompliance,233117481.0,OT,,,233117481.0,1.0,2009.0,2019.0,10.0,YR,233117481.0,1.0,HIV infection
23318861,233188612,2,F,20190101.0,20231225.0,20231220,20240105,EXP,,PT-AUROBINDO-AUR-APL-2023-078766,AUROBINDO,,43.0,YR,,M,Y,,,20240105.0,,MD,PT,PT,EFAVIRENZ,Aphthous ulcer;Diarrhoea;Drug resistance mutation;Insomnia;Irritability;Respiratory tract infection;Secondary syphilis;Treatment noncompliance,233188612.0,OT,,,233188612.0,1.0,2009.0,2019.0,,,233188612.0,1.0,HIV infection
23320164,233201641,1,I,,20231213.0,20231220,20231220,EXP,,MY-MYLANLABS-2023M1134744,MYLAN,,21.0,YR,,M,Y,,,20231220.0,,PH,MY,MY,EFAVIRENZ,Burning sensation;Rash;Skin exfoliation,233201641.0,OT,,,,,,,,,233201641.0,1.0,Antiretroviral therapy
23320492,233204921,1,I,,20231213.0,20231220,20231220,EXP,,CN-GSK-CN2023GSK175165,GLAXOSMITHKLINE,,,,,,Y,,,20231220.0,,MD,CN,CN,EFAVIRENZ,Drug resistance;HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,233204921.0,OT,,,233204921.0,1.0,201804.0,,19.0,MON,233204921.0,1.0,HIV infection
23320493,233204931,1,I,,20231213.0,20231220,20231220,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK175165,VIIV,,,,,,Y,,,20231220.0,,MD,CN,CN,EFAVIRENZ,Drug resistance;HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,233204931.0,OT,,,233204931.0,1.0,201804.0,,19.0,MON,233204931.0,1.0,HIV infection
23335742,233357421,1,I,,20231212.0,20231225,20231225,EXP,,NP-MACLEODS PHARMACEUTICALS US LTD-MAC2023044949,MACLEODS,"Dhonju K, Gautam A, Dahal A, Sharma NK, Adhikari D, Devkota L, et.al.. Dolutegravir-induced acquired sideroblastic anemia in a HIV positive patient: A challenging hematologic complication. Clinical Case Reports. 2023;11(12):e8301",,,,,Y,,,20231225.0,,HP,NP,NP,EFAVIRENZ,Rash;Sideroblastic anaemia,233357421.0,OT,,,233357421.0,2.0,20170316.0,,,,233357421.0,1.0,HIV infection
23352513,233525131,1,I,20190901.0,20231218.0,20231229,20231229,EXP,,IT-AUROBINDO-AUR-APL-2023-080136,AUROBINDO,"Carmillo L, Congedo P, Caggiula M, Nuzzo MM, Fasano A. MuSK. myasthenia gravis as a manifestation of immune reconstitution inflammatory syndrome in an HIV-positive patient: a challenging diagnosis and therapeutic approach. Neurological Sciences.. 2023;4575-7",44.0,YR,,F,Y,,,20231230.0,,HP,IT,IT,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Immune-mediated myasthenia gravis,233525131.0,OT,,,233525131.0,1.0,2010.0,,,,233525131.0,1.0,HIV infection
23373106,233731061,1,I,20030101.0,20231228.0,20240105,20240105,EXP,,CH-009507513-2401CHE001068,MERCK,,46.0,YR,,F,Y,,,20240105.0,,MD,CH,CH,EFAVIRENZ,Acute psychosis;CD4 lymphocytes abnormal;Drug reaction with eosinophilia and systemic symptoms;Hypertension;Lipodystrophy acquired;Malnutrition;Metabolic syndrome;Pneumocystis jirovecii infection;Product use issue;Therapeutic product effect incomplete;Therapy interrupted;Transaminases increased;Treatment noncompliance;Viral load abnormal,233731061.0,OT,,,233731061.0,1.0,200906.0,200910.0,,,233731061.0,1.0,HIV infection
23377700,233777001,1,I,,20240104.0,20240108,20240108,EXP,,CA-SANDOZ INC.-SDZ2024CA001185,SANDOZ,,54.0,YR,,M,Y,,,20240108.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,233777001.0,HO,,,,,,,,,233777001.0,1.0,HIV infection
23380635,233806352,2,F,,20240415.0,20240109,20240429,EXP,,IT-AUROBINDO-AUR-APL-2023-043261,AUROBINDO,"Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V et al.. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.. The Journal of antimicrobial chemotherapy. 2023;78(6):1415-1422",,,A,,Y,,,20240429.0,,HP,IT,IT,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viraemia;Viral mutation identified;Virologic failure,233806352.0,OT,,,,,,,,,233806352.0,1.0,HIV infection
23395840,233958401,1,I,20210701.0,20240103.0,20240112,20240112,EXP,,TN-MACLEODS PHARMACEUTICALS US LTD-MAC2024045249,MACLEODS,"Aouam A, Bougossa R, Abroug N, Soua Y, Chakroun M.. HIV-associated autoimmune blistering and connective tissue disorders: a case report. HIV and AIDS Review. 2023;22(4):357-60",,,,,Y,,,20240112.0,,MD,TN,TN,EFAVIRENZ,Acute kidney injury;Metabolic acidosis;Nephropathy toxic;Renal atrophy,233958401.0,DE,,,233958401.0,1.0,20200816.0,202107.0,,,233958401.0,1.0,Antiretroviral therapy
23398575,233985751,1,I,,20240108.0,20240112,20240112,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024GSK004849,VIIV,,,,,,Y,,,20240112.0,,HP,CN,CN,EFAVIRENZ,Atypical mycobacterial infection;Cough;Fatigue;Immune reconstitution inflammatory syndrome;Nausea;Night sweats;Pyrexia,233985751.0,OT,,,233985751.0,6.0,,,14.0,MON,233985751.0,1.0,HIV infection
23398576,233985761,1,I,,20240108.0,20240112,20240112,EXP,,CN-GSK-CN2024GSK004849,GLAXOSMITHKLINE,,,,,,Y,,,20240112.0,,HP,CN,CN,EFAVIRENZ,Atypical mycobacterial infection;Cough;Fatigue;Immune reconstitution inflammatory syndrome;Nausea;Night sweats;Pyrexia,233985761.0,HO,,,233985761.0,6.0,,,14.0,MON,233985761.0,1.0,HIV infection
23403060,234030601,1,I,20210927.0,20240102.0,20240115,20240115,EXP,,GB-CIPLA LTD.-2024GB00095,CIPLA,,,,,,Y,,,20240116.0,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,234030601.0,OT,,,,,,,,,234030601.0,1.0,HIV infection
23409047,234090471,1,I,,20240115.0,20240117,20240117,EXP,,IN-GILEAD-2024-0658595,GILEAD,"Misri R., Bambroo M., Gupta D... Uncommon manifestation of discoid lupus erythematosus in a human immunodeficiency virus patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2023;44(2):186-187. doi:10.4103/ijstd.ijstd_42_23",61.0,YR,A,M,Y,,,20240117.0,,MD,IN,IN,EFAVIRENZ,Chronic cutaneous lupus erythematosus;Immune reconstitution inflammatory syndrome,234090471.0,OT,,,,,,,,,234090471.0,1.0,HIV infection
23427093,234270931,1,I,,20240116.0,20240122,20240122,EXP,,NA-MYLANLABS-2024M1006036,MYLAN,"Kakubu MAM, Bikinesi T, Katoto PDMC. Lamivudine induced pure red cell aplasia and HIV-1 drug resistance-associated mutations: a case report. Oxf-Med-Case-Reports 2023; 2023 (3): 106-109.",44.0,YR,,F,Y,,,20240122.0,,HP,,,EFAVIRENZ,Creatinine renal clearance decreased;Intentional product misuse;Treatment failure;Treatment noncompliance,234270931.0,OT,,,234270931.0,1.0,201207.0,202002.0,,,234270931.0,1.0,HIV infection
23436697,234366971,1,I,20180101.0,20240116.0,20240124,20240124,EXP,,NA-STRIDES ARCOLAB LIMITED-2024SP000874,STRIDES,"Kakubu MAM, Bikinesi T, Katoto PDMC.. Lamivudine induced pure red cell aplasia and HIV-1 drug resistance-associated mutations: a case report.. Oxf-Med-Case-Reports. 2023;2023 (3):106-109",50.0,YR,,F,Y,,,20240124.0,,HP,,,EFAVIRENZ,Aplasia pure red cell;Creatinine renal clearance decreased;Gene mutation;Oesophageal candidiasis;Treatment failure;Treatment noncompliance,234366971.0,OT,,,234366971.0,1.0,201207.0,202002.0,,,234366971.0,1.0,HIV infection
23441801,234418011,1,I,,20240115.0,20240125,20240125,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2024-010353,BRISTOL MYERS SQUIBB,"Misri R, Bambroo M, Gupta D. Uncommon manifestation of discoid lupus erythematosus in a human immunodeficiency virus patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2023 Dec 06;44(2):186-7. doi:10.4103/ijstd.ijstd_42_23.",61.0,YR,A,M,Y,,,20240125.0,,MD,IN,IN,EFAVIRENZ,Chronic cutaneous lupus erythematosus,234418011.0,OT,,,,,,,,,234418011.0,1.0,HIV test
23442468,234424681,1,I,,20240119.0,20240125,20240125,EXP,,ZA-MYLANLABS-2024M1007960,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",31.0,YR,,F,Y,,,20240125.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234424681.0,OT,,,,,,,,,234424681.0,1.0,HIV infection
23442469,234424691,1,I,,20240119.0,20240125,20240125,EXP,,ZA-MYLANLABS-2024M1007958,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",49.0,YR,,F,Y,,,20240125.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234424691.0,OT,,,,,,,,,234424691.0,1.0,HIV infection
23442471,234424711,1,I,,20240119.0,20240125,20240125,EXP,,ZA-MYLANLABS-2024M1007949,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",39.0,YR,,M,Y,,,20240125.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234424711.0,OT,,,,,,,,,234424711.0,1.0,HIV infection
23443565,234435651,1,I,,20240119.0,20240125,20240125,EXP,,ZA-MYLANLABS-2024M1007965,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",36.0,YR,,F,Y,,,20240125.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234435651.0,OT,,,,,,,,,234435651.0,1.0,HIV infection
23444780,234447801,1,I,,20240119.0,20240125,20240125,EXP,,ZA-MYLANLABS-2024M1007954,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",31.0,YR,,F,Y,,,20240125.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Neurotoxicity;Seizure,234447801.0,OT,,,,,,,,,234447801.0,1.0,HIV infection
23444785,234447851,1,I,,20240119.0,20240125,20240125,EXP,,ZA-MYLANLABS-2024M1007967,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11).",35.0,YR,,F,Y,,,20240125.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234447851.0,OT,,,,,,,,,234447851.0,1.0,HIV infection
23444786,234447861,1,I,,20240119.0,20240125,20240125,EXP,,ZA-MYLANLABS-2024M1007952,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",30.0,YR,,F,Y,,,20240125.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234447861.0,OT,,,,,,,,,234447861.0,1.0,HIV infection
23449504,234495041,1,I,,20240115.0,20240129,20240129,EXP,,IN-CIPLA LTD.-2024IN00795,CIPLA,"Misri R, Bambroo M, Gupta D. Uncommon manifestation of discoid lupus erythematosus in a human immunodeficiency virus patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2023;44 (Issue 2):186 to 187",,,,,Y,,,20240129.0,,MD,IN,IN,EFAVIRENZ,Chronic cutaneous lupus erythematosus,234495041.0,OT,,,,,,,,,234495041.0,1.0,HIV infection
23450703,234507031,1,I,,20240119.0,20240129,20240129,EXP,,ZA-MYLANLABS-2024M1007953,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11).",33.0,YR,,F,Y,,,20240129.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Neurotoxicity;Seizure,234507031.0,OT,,,,,,,,,234507031.0,1.0,HIV infection
23450704,234507041,1,I,,20240119.0,20240129,20240129,EXP,,ZA-MYLANLABS-2024M1007968,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",23.0,YR,,F,Y,,,20240129.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234507041.0,OT,,,,,,,,,234507041.0,1.0,HIV infection
23450712,234507121,1,I,,20240119.0,20240129,20240129,EXP,,ZA-MYLANLABS-2024M1007970,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",38.0,YR,,F,Y,,,20240129.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234507121.0,OT,,,,,,,,,234507121.0,1.0,HIV infection
23450713,234507131,1,I,,20240119.0,20240129,20240129,EXP,,ZA-MYLANLABS-2024M1007966,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",21.0,YR,,F,Y,,,20240129.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234507131.0,OT,,,,,,,,,234507131.0,1.0,HIV infection
23450714,234507141,1,I,,20240119.0,20240129,20240129,EXP,,ZA-MYLANLABS-2024M1007959,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11).",36.0,YR,,F,Y,,,20240129.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Encephalopathy;Neurotoxicity,234507141.0,OT,,,,,,,,,234507141.0,1.0,HIV infection
23450715,234507151,1,I,,20240119.0,20240129,20240129,EXP,,ZA-MYLANLABS-2024M1007955,MYLAN,"Nightingale S, Ssemmanda S, Tucker LM, Eastman RW, Lee Pan EB. Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. PLOS-One 2023; 18 (11):.",30.0,YR,,F,Y,,,20240129.0,,HP,ZA,ZA,EFAVIRENZ,Drug level above therapeutic;Neurotoxicity;Seizure,234507151.0,OT,,,,,,,,,234507151.0,1.0,HIV infection
23465138,234651382,2,F,,20231204.0,20240201,20240208,EXP,,IT-GILEAD-2024-0660385,GILEAD,"Carmillo L., Congedo P., Caggiula M., Nuzzo M, Fasano A. MuSK myasthenia gravis as a manifestation of immune reconstitution inflammatory syndrome in an HIV-positive patient: a challenging diagnosis and therapeutic approach. Neurological Sciences. 2023;44(12):4575-4577. doi:10.1007/s10072-023-07002-5",44.0,YR,A,F,Y,,,20240208.0,,HP,IT,IT,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Myasthenia gravis;Viral load increased,234651382.0,OT,,,,,,,,,234651382.0,1.0,HIV infection
23473618,234736182,2,F,20200101.0,20240122.0,20240203,20240327,EXP,,NA-AUROBINDO-AUR-APL-2024-003788,AUROBINDO,"Kakubu MAM, Bikinesi T, Katoto PDMC. Lamivudine induced pure red cell aplasia and HIV-1 drug resistance-associated mutations: a case report. Oxf-Med-Case-Reports. 2023;2023(3):106-109",50.0,YR,,F,Y,,,20240327.0,,HP,,,EFAVIRENZ,Aplasia pure red cell;Creatinine renal clearance decreased;HIV associated nephropathy;Treatment failure;Viral mutation identified,234736182.0,OT,,,,,,,,,234736182.0,1.0,HIV infection
23480824,234808242,2,F,,20240206.0,20240205,20240209,EXP,,AR-ABBVIE-5616860,ABBVIE,"Kobashigawa CJ, Rousseau MN. Pharmaceutical care in patients with acquired immunodeficiency and/or tuberculosis in the outpatient department of a pediatric hospital. Pediatr Med. 2023;4:346-357.; Kobashigawa CJ, Rousseau MN. ATENCION FARMACEUTICA EN PACIENTES CON INMUNODEFICIENCIA ADQUIRIDA Y/O TUBERCULOSIS EN EL AREA AMBULATORIA DE UN HOSPITAL PEDIATRICO. Medicina Infantil. 2023;XXX(4):346-357.",18.0,YR,,M,Y,,,20240209.0,,PH,AR,AR,EFAVIRENZ,Breast hyperplasia;Gynaecomastia,234808242.0,OT,,,,,,,,,234808242.0,1.0,Human immunodeficiency virus transmission
23481183,234811831,1,I,,20240115.0,20240205,20240205,EXP,,CN-GILEAD-2024-0659630,GILEAD,"Guo Y., Li X., Xiao Q., Yang J., Tao R., Xu L., etal. Mycobacterium colombiense Pneumonia in HIV-Infected Patients: Three Case Reports and a Literature Review. Infection and Drug Resistance. 2023;16:7767-7773. doi:10.2147/IDR.S441083",36.0,YR,A,M,Y,,,20240205.0,,HP,CN,CN,EFAVIRENZ,Atypical mycobacterial infection;Immune reconstitution inflammatory syndrome,234811831.0,OT,,,,,,,,,234811831.0,1.0,HIV infection
23503895,235038951,1,I,20240126.0,20240202.0,20240209,20240209,EXP,,RU-HETERO-HET2024RU00349,HETERO,,34.0,YR,,M,Y,69.0,KG,20240209.0,,CN,RU,RU,EFAVIRENZ,Dizziness postural,235038951.0,OT,,,235038951.0,1.0,20240126.0,20240128.0,3.0,DAY,235038951.0,1.0,HIV infection
23509330,235093301,1,I,,20240201.0,20240210,20240210,EXP,,CN-STRIDES ARCOLAB LIMITED-2024SP001443,STRIDES,"Zhang C, Qian C, Wang W, Chen Z, Lin Y, Sun M.. AIDS with obesity, hypothyroidism and elevated serum creatinine: A case report.. Front-Med. 2023;10",30.0,YR,,M,Y,102.0,KG,20240210.0,,HP,CN,CN,EFAVIRENZ,Condition aggravated;Hypothyroidism,235093301.0,HO,,,,,,,,,235093301.0,1.0,Acquired immunodeficiency syndrome
23522239,235222391,1,I,,20240212.0,20240214,20240214,EXP,,BR-GILEAD-2024-0661959,GILEAD,"Muller P, Coelho A, da CV, Barros D, Bertolini D. PERFIL DO AMBULATORIO DE PRE NATAL (CIS E TRANS) DE PESSOAS GESTANTES QUE VIVEM COM HIV (PGVHIV) OU PESSOAS GESTANTES DE PARCERIAS SORODIFERENTES (PGPSD), INCLUINDO HOMENS TRANSEXUAIS NO CRT DST-AIDS SP E SEU IMPACTO SOBRE A TRANSMISSAO VERTICAL. Brazilian Journal of Infectious Diseases. 2023;27(1):Unk. doi:10.1016/j.bjid.2023.103039",,,,F,Y,,,20240214.0,,HP,BR,BR,EFAVIRENZ,Ectopic pregnancy;Maternal exposure during pregnancy,235222391.0,OT,,,,,,,,,235222391.0,1.0,HIV infection
23530473,235304731,1,I,,20240213.0,20240216,20240216,EXP,,BR-GSK-BR2024019806,GLAXOSMITHKLINE,,,,,,Y,,,20240216.0,,HP,BR,BR,EFAVIRENZ,Ectopic pregnancy;Exposure during pregnancy,235304731.0,OT,,,,,,,,,235304731.0,1.0,HIV infection
23530474,235304741,1,I,,20240213.0,20240216,20240216,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2024019806,VIIV,,,,,,Y,,,20240216.0,,HP,BR,BR,EFAVIRENZ,Ectopic pregnancy;Exposure during pregnancy,235304741.0,OT,,,,,,,,,235304741.0,1.0,HIV infection
23535335,235353353,3,F,,20241115.0,20240218,20241128,EXP,,PT-AUROBINDO-AUR-APL-2024-007326,AUROBINDO,"Mariana Dias Pais, Fernando Godinho Pereira, Helena Pires, Ana Messias, Cristina Santos. FROM SUSCEPTIBILITY TO INSULT, A CASE OF ACUTE INTERSTITIAL NEPHRITIS. Portuguese Journal of Nephrology and Hypertension. Abstract No. 104",58.0,YR,,M,Y,,,20241128.0,,MD,PT,PT,EFAVIRENZ,Anaemia macrocytic;Fanconi syndrome;Renal tubular injury;Tubulointerstitial nephritis,235353353.0,OT,,,,,,,,,235353353.0,1.0,HIV infection
23558646,235586461,1,I,,20240218.0,20240223,20240223,EXP,,GB-JNJFOC-20151006327,JOHNSON AND JOHNSON,,,,A,,Y,,,20240223.0,,HP,SG,GB,EFAVIRENZ,AIDS related complication;Adverse event;Anal cancer;Breast cancer recurrent;Cerebrovascular accident;Completed suicide;Cytomegalovirus colitis;Drug ineffective;Dysarthria;Encephalopathy;Extrapulmonary tuberculosis;Facial wasting;Glioblastoma;Memory impairment;Metastatic neoplasm;Myocardial infarction;Neoplasm malignant;Oesophageal adenocarcinoma;Pancreatitis;Pulmonary embolism;Renal failure;Small cell lung cancer;Toxicity to various agents;Visual impairment,235586461.0,DE,,,,,,,,,235586461.0,1.0,HIV infection
23635595,236355951,1,I,20170512.0,20240308.0,20240315,20240315,EXP,,RU-AMAROX PHARMA-HET2024RU00683,HETERO,,,,,M,Y,,,20240315.0,,MD,RU,RU,EFAVIRENZ,Neurotoxicity,236355951.0,OT,,,236355951.0,1.0,20170512.0,20170518.0,7.0,DAY,236355951.0,1.0,HIV infection
23637492,236374921,1,I,,20240311.0,20240315,20240315,EXP,,SA-GILEAD-2024-0665529,GILEAD,"Qorban GN, Alyami J, Samargandy S, Madani TA.. Delayed Irreversible Fanconi Syndrome Associated With Vertebral Fracture After Tenofovir Discontinuation. Cureus. 2024;16(1):unk. doi:10.7759/cureus.53280",40.0,YR,A,F,Y,25.0,KG,20240315.0,,HP,SA,SA,EFAVIRENZ,Fanconi syndrome acquired;Pancreatitis acute;Spinal fracture,236374921.0,OT,,,236374921.0,1.0,20150405.0,201612.0,,,236374921.0,1.0,HIV infection
23638487,236384871,1,I,,20240304.0,20240315,20240315,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2024-041086,BRISTOL MYERS SQUIBB,"Casado JL, Santos Id, Palacio Md, Garcia-Fraile L, Perez-Elias MJ, Sanz J, et al. Lipid-lowering effect and efficacy after switching to etravirine in hiv-infected patients with intolerance to suppressive haart. HIV Clinical Trials. 2015 Jan 06;14(1):1-9. doi:10.1310/hct1401-1.",,,,,Y,,,20240315.0,,HP,ES,ES,EFAVIRENZ,Lipodystrophy acquired,236384871.0,OT,,,,,,,,,236384871.0,1.0,HIV infection
23638847,236388471,1,I,,20240311.0,20240315,20240315,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2024GSK032145,VIIV,"Arbune M, Padurariu-Covit M, Tiutiuca C, Mihailov R, Niculet E, Arbune A, et al. Unusual Localization of AIDS-Related Kaposi^s Sarcoma in a Heterosexual Male during the COVID-19 Pandemic: A Case Report. Tropical Medicine and Infectious Disease. 2024;9(2)",,,,,Y,,,20240315.0,,HP,RO,RO,EFAVIRENZ,Gastroenteritis;Meningitis meningococcal;Treatment noncompliance;Virologic failure,236388471.0,OT,,,236388471.0,5.0,2013.0,,,,236388471.0,1.0,HIV infection
23638849,236388491,1,I,,20240311.0,20240315,20240315,EXP,,RO-GSK-RO2024GSK032145,GLAXOSMITHKLINE,"Arbune M, Padurariu-Covit M, Tiutiuca C, Mihailov R, Niculet E, Arbune A, et al. Unusual Localization of AIDS-Related Kaposi^s Sarcoma in a Heterosexual Male during the COVID-19 Pandemic: A Case Report. Tropical Medicine and Infectious Disease. 2024;9(2)",,,,,Y,,,20240315.0,,HP,RO,RO,EFAVIRENZ,Gastroenteritis;Meningitis meningococcal;Treatment noncompliance;Virologic failure,236388491.0,OT,,,236388491.0,5.0,2013.0,,,,236388491.0,1.0,HIV infection
23639510,236395101,1,I,20161201.0,20240306.0,20240316,20240316,EXP,,SA-MACLEODS PHARMACEUTICALS US LTD-MAC2024046300,MACLEODS,"Qorban GN, Alyami J, Samargandy S, Madani TA.. Delayed Irreversible Fanconi Syndrome Associated With Vertebral Fracture After Tenofovir Discontinuation. Cureus. 2024;16(1):e53280",,,,,Y,,,20240316.0,,HP,SA,SA,EFAVIRENZ,Anaemia;COVID-19 pneumonia;Pancreatitis acute,236395101.0,DE,,,236395101.0,1.0,201605.0,201612.0,,,236395101.0,1.0,HIV infection
23686289,236862892,2,F,,20240326.0,20240329,20240402,EXP,,RO-MYLANLABS-2024M1027744,MYLAN,"Arbune M, Padurariu-Covit M, Tiutiuca C, Mihailov R, Niculet E, Arbune A, et al.. Unusual localization of aids-related kaposi?s sarcoma in a heterosexual male during the covid-19 pandemic: a case report.. Tropical Medicine and Infectious Disease. 2024;9(2):47",30.0,YR,,M,Y,,,20240402.0,,HP,RO,RO,EFAVIRENZ,Febrile neutropenia;Gastroenteritis;Meningitis meningococcal;Staphylococcal infection;Treatment noncompliance;Virologic failure,236862892.0,OT,,,,,,,,,236862892.0,1.0,HIV infection
23686732,236867321,1,I,,20240325.0,20240329,20240329,EXP,,ES-MYLANLABS-2024M1028311,MYLAN,"Casado JL, Santos Id, Palacio Md, Garcia-Fraile L, Perez-Elias MJ, Sanz J, et al.. Lipid-lowering effect and efficacy after switching to etravirine in hiv-infected patients with intolerance to suppressive haart.. HIV Clinical Trials. 2015;14(1):1-9",,,,,Y,,,20240329.0,,HP,ES,ES,EFAVIRENZ,Lipodystrophy acquired,236867321.0,OT,,,,,,,,,236867321.0,1.0,HIV infection
23690188,236901881,1,I,,20240316.0,20240401,20240401,EXP,,RO-AUROBINDO-AUR-APL-2024-013763,AUROBINDO,"Arbune M, Padurariu-Covit MD, Tiutiuca C, Mihailov R, Niculet E, Arbune AA, et al.. Unusual localization of aids-related kaposi?s sarcoma in a heterosexual male during the covid-19 pandemic: a case report.. Topical Medicine and Infectious Disease.. 2024;9(2):47",30.0,YR,,M,Y,,,20240330.0,,HP,RO,RO,EFAVIRENZ,Drug ineffective;Febrile neutropenia;Gastroenteritis;Meningitis meningococcal;Staphylococcal infection;Treatment noncompliance;Virologic failure,236901881.0,OT,,,236901881.0,10.0,2013.0,,,,236901881.0,1.0,HIV infection
23695703,236957031,1,I,,20240326.0,20240402,20240402,EXP,,CN-MACLEODS PHARMACEUTICALS US LTD-MAC2024046617,MACLEODS,"Chen Z, Si T, Ying L, Guiying C, Ping XJ, Wang M. A case of multiple ART intolerance responds to Albuvirtide and Dolutegravir: Case report and literature review. Heliyon. 2024;10(6):e27219",,,,,Y,,,20240402.0,,HP,CN,CN,EFAVIRENZ,Abdominal discomfort;Arthralgia;Decreased appetite;Diarrhoea;Drug intolerance;Drug-induced liver injury;Fatigue;Nausea;Rash;Vomiting,236957031.0,HO,,,236957031.0,1.0,201412.0,,,,236957031.0,1.0,Antiretroviral therapy
23700122,237001221,1,I,,20240319.0,20240403,20240403,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-004631,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,,,20240403.0,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,237001221.0,OT,,,,,,,,,237001221.0,1.0,HIV infection
23706834,237068341,1,I,,20240328.0,20240404,20240404,EXP,,DE-MYLANLABS-2024M1030198,MYLAN,"Foerster Y, Sollfrank L, Rechtien L, Harrer T, Berking C, Sticherling M. Case report: Bullous pemphigoid in HIV-1-positive patients: interplay or coincidence? A case series and review of the literature. Front-Immunol 2023; 14 1-6.",74.0,YR,,F,Y,,,20240404.0,,HP,DE,DE,EFAVIRENZ,Pemphigoid,237068341.0,HO,,,,,,,,,237068341.0,1.0,HIV infection
23710640,237106402,2,F,20220601.0,20240412.0,20240405,20240419,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024APC040288,VIIV,,,,,,Y,,,20240419.0,,CN,CN,CN,EFAVIRENZ,Chronic kidney disease;Dizziness;Fatigue;Hypertension;Hyperuricaemia;Product use in unapproved therapeutic environment;Renal impairment;Treatment failure,237106402.0,OT,,,237106402.0,1.0,202206.0,,,,237106402.0,1.0,HIV infection
23710641,237106412,2,F,20220601.0,20240412.0,20240405,20240419,EXP,,CN-GSK-CN2024APC040288,GLAXOSMITHKLINE,,,,,,Y,,,20240419.0,,CN,CN,CN,EFAVIRENZ,Chronic kidney disease;Dizziness;Fatigue;Hypertension;Hyperuricaemia;Product use in unapproved therapeutic environment;Renal impairment;Treatment failure,237106412.0,OT,,,237106412.0,1.0,202206.0,,,,237106412.0,1.0,HIV infection
23757286,237572861,1,I,,20240403.0,20240418,20240418,EXP,,DE-AUROBINDO-AUR-APL-2024-017247,AUROBINDO,"Foerster Y, Sollfrank L, Rechtien L, Harrer T, Berking C, Sticherling M. Case report: Bullous pemphigoid in HIV-1-positive patients: interplay or coincidence? A case series and review of the literature. Frontiers-in Immunology. 2023;14:1-6",74.0,YR,,F,Y,,,20240418.0,,HP,DE,DE,EFAVIRENZ,Pemphigoid,237572861.0,HO,,,,,,,,,237572861.0,1.0,HIV infection
23758447,237584472,2,F,,20240424.0,20240418,20240503,EXP,,DE-TEVA-VS-3183881,TEVA,"Foerster Y, Sollfrank L, Rechtien L, Harrer T, Berking C, Sticherling M. Case report: Bullous pemphigoid in HIV-1-positive patients: interplay or coincidence? A case series and review of the literature. Front-Immunol 2023; 14 1-6.; Foerster Y, Sollfrank L, Rechtien L, Harrer T, Berking C, Sticherling M. Case report: Bullous pemphigoid in HIV-1-positive patients: interplay or coincidence? A case series and review of the literature. Front-Immunol 2023; 14 1-6.",74.0,YR,,F,Y,,,20240503.0,,HP,DE,DE,EFAVIRENZ,Pemphigoid,237584472.0,HO,,,,,,,,,237584472.0,1.0,HIV infection
23760545,237605452,2,F,20001023.0,20240619.0,20240419,20240621,EXP,,JP-VIIV HEALTHCARE LIMITED-A20017641,VIIV,,,,,,Y,,,20240621.0,,MD,JP,JP,EFAVIRENZ,Intracranial aneurysm;Liver function test abnormal;Osteoporosis;Progressive multifocal leukoencephalopathy;Spinal compression fracture,237605452.0,DE,,,237605452.0,1.0,20000619.0,20110925.0,4115.0,DAY,237605452.0,1.0,HIV infection
23770220,237702201,1,I,,20240412.0,20240422,20240422,EXP,,MY-MYLANLABS-2024M1035230,MYLAN,"Rahman RA, Hashim SM , Jalal JIA. Implant Failure Resulting In An Unintended Pregnancy In A Woman Living With Hiv: A Case Report. Brunei-Int-Med-J 2024; 20 24-28.",32.0,YR,,F,Y,,,20240422.0,,HP,MY,MY,EFAVIRENZ,Abortion spontaneous;Drug interaction;Maternal exposure during pregnancy;Pregnancy with injectable contraceptive,237702201.0,OT,,,,,,,,,237702201.0,1.0,HIV infection
23776671,237766712,2,F,,20240827.0,20240424,20240902,EXP,,US-CIPLA (EU) LIMITED-2024US03893,CIPLA,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K.. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: A case series. The American Journal of the Medical Science. 2024;367 (S1):S9 to S10",,,,,Y,,,20240902.0,,MD,US,US,EFAVIRENZ,Endocrine ophthalmopathy;Graves' disease,237766712.0,OT,,,,,,,,,237766712.0,1.0,HIV infection
23778979,237789791,1,I,,20240318.0,20240424,20240424,EXP,,BR-GILEAD-2024-0670573,GILEAD,"Coelho L, Chazallon C., Laureillard D., Escada R., N^Takpe J, Timana I etal. Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial. Open Forum Infectious Diseases. 2024;11(3):unk. doi:10.1093/ofid/ofae035",,,A,,Y,,,20240424.0,,HP,BR,BR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,237789791.0,OT,,,,,,,,,237789791.0,1.0,HIV infection
23779122,237791221,1,I,,20240318.0,20240424,20240424,EXP,,BR-GILEAD-2024-0670576,GILEAD,"Coelho L, Chazallon C., Laureillard D., Escada R., N^Takpe J, Timana I.. Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial. Open Forum Infectious Diseases. 2024;11(3):unk. doi:10.1093/ofid/ofae035",,,A,,Y,,,20240424.0,,HP,BR,BR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,237791221.0,DE,,,,,,,,,237791221.0,1.0,HIV infection
23779226,237792261,1,I,,20240318.0,20240424,20240424,EXP,,BR-GILEAD-2024-0670577,GILEAD,"Coelho L, Chazallon C., Laureillard D., Escada R., N^Takpe J, Timana I etal. Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial. Open Forum Infectious Diseases. 2024;11(3):Unk. doi:10.1093/ofid/ofae035",,,A,,Y,,,20240424.0,,HP,BR,BR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,237792261.0,DE,,,,,,,,,237792261.0,1.0,HIV infection
23800135,238001351,1,I,20170701.0,20240423.0,20240430,20240430,EXP,,CN-GSK-CN2024APC051498,GLAXOSMITHKLINE,,,,,,Y,,,20240430.0,,HP,CN,CN,EFAVIRENZ,Dermatitis allergic;Discomfort;Disease recurrence;Drug eruption;Erythema;Pruritus;Rash;Rash maculo-papular;Skin exfoliation;Skin warm,238001351.0,HO,,,238001351.0,1.0,20240415.0,20240419.0,4.0,DAY,238001351.0,1.0,HIV infection
23800136,238001361,1,I,20170701.0,20240423.0,20240430,20240430,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024APC051498,VIIV,,,,,,Y,,,20240430.0,,HP,CN,CN,EFAVIRENZ,Dermatitis allergic;Discomfort;Disease recurrence;Drug eruption;Erythema;Pruritus;Rash;Rash maculo-papular;Skin exfoliation;Skin warm,238001361.0,HO,,,238001361.0,1.0,20240415.0,20240419.0,4.0,DAY,238001361.0,1.0,HIV infection
23808977,238089772,2,F,,20240429.0,20240502,20240513,EXP,,IN-GILEAD-2024-0671242,GILEAD,"Ranade R, Desai A., Mayya M, Patil S, Rani H., Revanasiddappa M. Clinicopathological study of pigment induced nephropathy; a retrospective study. Journal of Nephropathology. 2024;13(2):Unk. doi:10.34172/jnp.2022.17362",61.0,YR,A,M,Y,,,20240513.0,,HP,IN,IN,EFAVIRENZ,Acute kidney injury;Rhabdomyolysis,238089772.0,OT,,,,,,,,,238089772.0,1.0,HIV infection
23830638,238306382,2,F,20190101.0,20241008.0,20240508,20241016,EXP,,BE-MYLANLABS-2024M1039683,MYLAN,"Martin C, Moretti M, Stoffels K, Van Laethem K, Verhofstede C, Van Den Wijngaert S. The challenge of adherence to a complex antiretroviral therapy regimen in an individual with multidrug-resistant HIV. Topics in Antiviral Medicine. 2024;32 (2):437-444",35.0,YR,,F,Y,,,20241016.0,,MD,BE,BE,EFAVIRENZ,Acute kidney injury;Cachexia;Depression;Drug intolerance;Gene mutation;Multiple-drug resistance;Mycobacterium avium complex infection;Myocarditis;Pneumocystis jirovecii pneumonia;Progressive multifocal leukoencephalopathy;Virologic failure,238306382.0,OT,,,238306382.0,4.0,2009.0,,,,238306382.0,1.0,HIV infection
23868149,238681491,1,I,20240503.0,20240507.0,20240517,20240517,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024APC058005,VIIV,,,,,,Y,,,20240517.0,,HP,CN,CN,EFAVIRENZ,Agitation;Insomnia;Myelosuppression;Nausea;Palpitations;Vomiting,238681491.0,OT,,,238681491.0,1.0,20240502.0,20240502.0,,,238681491.0,1.0,Antiretroviral therapy
23868154,238681541,1,I,20240503.0,20240507.0,20240517,20240517,EXP,,CN-GSK-CN2024APC058005,GLAXOSMITHKLINE,,,,,,Y,,,20240517.0,,HP,CN,CN,EFAVIRENZ,Agitation;Insomnia;Myelosuppression;Nausea;Palpitations;Vomiting,238681541.0,OT,,,238681541.0,1.0,20240502.0,20240502.0,,,238681541.0,1.0,Antiretroviral therapy
23870431,238704311,1,I,20240328.0,20240511.0,20240518,20240518,EXP,,RU-AMAROX PHARMA-HET2024RU01436,HETERO,,,,,M,Y,51.0,KG,20240518.0,,MD,RU,RU,EFAVIRENZ,Renal impairment,238704311.0,OT,,,238704311.0,1.0,20240221.0,20240328.0,37.0,DAY,238704311.0,1.0,HIV infection
23896240,238962401,1,I,20240501.0,20240520.0,20240523,20240523,DIR,FDA-CDER-CTU-2024-37182,,FDA-CTU,,52.0,YR,,M,N,,,20240520.0,N,HP,US,,EFAVIRENZ,Viral infection,238962401.0,HO,238962401.0,HP,238962401.0,1.0,202404.0,,,,238962401.0,1.0,HIV infection
23921652,239216521,1,I,20200312.0,20240520.0,20240530,20240530,EXP,,RU-GILEAD-2024-0674846,GILEAD,,41.0,YR,A,F,Y,77.0,KG,20240530.0,,HP,RU,RU,EFAVIRENZ,Dermatitis allergic,239216521.0,OT,,,239216521.0,1.0,20200212.0,20200313.0,30.0,DAY,239216521.0,1.0,HIV infection
23921891,239218911,1,I,20160101.0,20240520.0,20240530,20240530,EXP,,RO-009507513-2405ROU006794,MERCK,,28.0,YR,,F,Y,,,20240530.0,,MD,RO,RO,EFAVIRENZ,Aortic arteriosclerosis;Blood HIV RNA increased;CD4 lymphocytes decreased;Coeliac artery stenosis;Drug resistance mutation;Duodenitis;Lymphadenopathy;Mental fatigue;Mesenteric artery stenosis;Psychotherapy;Renal artery stenosis;Treatment noncompliance,239218911.0,OT,,,,,,,,,239218911.0,1.0,HIV infection
23956005,239560051,1,I,,20240529.0,20240610,20240610,EXP,,KE-MACLEODS PHARMA-MAC2024047519,MACLEODS,"Odhiambo F, Nareeba S, Mwangeka G, Njambi A, Nyakebati V..Tenofovir induced Fanconi syndrome in a middle age African female from Kenya, East Africa: Case report and brief literature review.Clinical Case Reports.24-MAY-2024;12(6):e8889:1-5",,,,,Y,,,20240610.0,,HP,KE,KE,EFAVIRENZ,Fanconi syndrome;Nephropathy toxic,239560051.0,HO,,,239560051.0,2.0,2011.0,2019.0,,,239560051.0,1.0,HIV infection
23961478,239614781,1,I,,20240606.0,20240611,20240611,EXP,,GH-MYLANLABS-2024M1052645,MYLAN,"Puplampu P, Asamoah I, Asare BO, Berko KP, Oladele O, Amankwa E, et al. Cryptococcal meningitis among perinatally HIV-infected adolescents: Case series on presentation and management challenges. Clin-Case-Rep 2023; 11 (2): e6995.",,,,F,Y,,,20240611.0,,HP,GH,GH,EFAVIRENZ,Meningitis cryptococcal;Treatment noncompliance,239614781.0,HO,,,,,,,,,239614781.0,1.0,Perinatal HIV infection
23966342,239663421,1,I,,20240606.0,20240612,20240612,EXP,,GH-MYLANLABS-2024M1052744,MYLAN,"Puplampu P, Asamoah I, Asare BO, Berko KP, Oladele O, Amankwa E, et al. Cryptococcal meningitis among perinatally HIV-infected adolescents: Case series on presentation and management challenges. Clin-Case-Rep 2023; 11 (2): e6995.",,,T,F,Y,,,20240612.0,,HP,GH,GH,EFAVIRENZ,Meningitis cryptococcal;Treatment noncompliance,239663421.0,DE,,,,,,,,,239663421.0,1.0,Perinatal HIV infection
23971329,239713291,1,I,,20240606.0,20240613,20240613,EXP,,GH-STRIDES ARCOLAB LIMITED-2024SP006673,STRIDES,"Puplampu P, Asamoah I, Asare BO, Berko KP, Oladele O, Amankwa E, et al. Cryptococcal meningitis among perinatally HIV-infected adolescents: Case series on presentation and management challenges.. Clin-Case-Rep. 2023;11(2):e6995",,,,F,Y,,,20240613.0,,HP,GH,GH,EFAVIRENZ,Meningitis cryptococcal;Treatment noncompliance,239713291.0,DE,,,,,,,,,239713291.0,1.0,Perinatal HIV infection
23971351,239713511,1,I,,20240606.0,20240613,20240613,EXP,,GH-STRIDES ARCOLAB LIMITED-2024SP006675,STRIDES,"Puplampu P, Asamoah I, Asare BO, Berko KP, Oladele O, Amankwa E, et al.. Cryptococcal meningitis among perinatally HIV-infected adolescents: Case series on presentation and management challenges. Clin-Case-Rep. 2023;11(2):e6995",,,T,F,Y,,,20240613.0,,HP,GH,GH,EFAVIRENZ,Meningitis cryptococcal;Treatment noncompliance,239713511.0,DE,,,,,,,,,239713511.0,1.0,Perinatal HIV infection
23978611,239786111,1,I,20150101.0,20240605.0,20240614,20240614,EXP,,RO-009507513-2406ROU001779,MERCK,,41.0,YR,,F,Y,,,20240614.0,,MD,RO,RO,EFAVIRENZ,Carotid arteriosclerosis;Cerebrovascular accident;Coma;Coronary artery disease;Dyslipidaemia;Hypertension;Transient ischaemic attack;Treatment failure;Weight increased,239786111.0,HO,,,239786111.0,1.0,2015.0,2013.0,,,239786111.0,1.0,Antiretroviral therapy
24012609,240126091,1,I,,20240621.0,20240626,20240626,EXP,,CA-SANDOZ INC.-SDZ2024CA059990,SANDOZ,,54.0,YR,,M,Y,,,20240626.0,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,240126091.0,OT,,,,,,,,,240126091.0,1.0,HIV infection
24018029,240180291,1,I,20150101.0,20240617.0,20240627,20240627,EXP,,RO-AUROBINDO-AUR-APL-2024-030588,AUROBINDO,,41.0,YR,,F,Y,,,20240627.0,,MD,RO,RO,EFAVIRENZ,Carotid arteriosclerosis;Cerebrovascular accident;Coma;Coronary artery disease;Dyslipidaemia;Hypertension;Transient ischaemic attack;Treatment failure;Weight increased,240180291.0,HO,,,240180291.0,1.0,201205.0,2013.0,,,240180291.0,1.0,Antiretroviral therapy
24020251,240202511,1,I,,20240620.0,20240627,20240627,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024APC077427,VIIV,,,,,,Y,,,20240627.0,,HP,CN,CN,EFAVIRENZ,Arthralgia;Condition aggravated;Pruritus;Rash;Skin infection;Skin ulcer,240202511.0,HO,,,240202511.0,1.0,20100501.0,20240601.0,169.0,MON,240202511.0,1.0,Acquired immunodeficiency syndrome
24029098,240290981,1,I,,20240625.0,20240628,20240628,EXP,,MY-MYLANLABS-2024M1060440,MYLAN,,25.0,YR,,M,Y,,,20240628.0,,MD,MY,MY,EFAVIRENZ,Erectile dysfunction,240290981.0,OT,,,,,,,,,240290981.0,1.0,Antiretroviral therapy
24040572,240405721,1,I,,20240619.0,20240702,20240702,EXP,,US-CIPLA LTD.-2024US06678,CIPLA,"Nguyen NV, Kim L, Collins LF, Ofotokun I, Fernandes A, Yeh S et al. Retinopathy associated with Ritonavir treatment for HIV infection: a case series reappraisal in the COVID-19 era.. Journal of vitreoretinal diseases. 2024;8(1):111 to 116",,,,,Y,,,20240702.0,,HP,US,US,EFAVIRENZ,Maculopathy,240405721.0,OT,,,,,,,,,240405721.0,1.0,Antiretroviral therapy
24053207,240532071,1,I,,20240627.0,20240705,20240705,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2024-103202,BRISTOL MYERS SQUIBB,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et al. Drug-induced systemic lupus erythematosus in a child living with HIV. Indian Journal of Sexually Transmitted Diseases and AIDS. 2024 Jun 06;45(1):59-61. doi:10.4103/ijstd.ijstd_69_23.",12.0,YR,T,M,Y,,,20240705.0,,HP,IN,IN,EFAVIRENZ,Lupus-like syndrome,240532071.0,HO,,,240532071.0,1.0,2019.0,,,,240532071.0,1.0,HIV infection
24059186,240591861,1,I,,20240624.0,20240708,20240708,EXP,,IN-CIPLA LTD.-2024IN06905,CIPLA,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et.al. Drug-induced systemic lupus erythematosus in a child living with HIV. Indian Journal of Sexually Transmitted Diseases and AIDS. 2024;45 (1):59 to 61",,,,,Y,,,20240708.0,,HP,IN,IN,EFAVIRENZ,Lupus-like syndrome,240591861.0,HO,,,,,,,,,240591861.0,1.0,HIV infection
24075720,240757201,1,I,,20240703.0,20240710,20240710,EXP,,DK-GSK-DK2024GSK083765,GLAXOSMITHKLINE,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment. BMJ Case Reports. 2024;17 (6)",,,,,Y,,,20240710.0,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,240757201.0,OT,,,,,,,,,240757201.0,1.0,HIV infection
24075728,240757281,1,I,,20240703.0,20240710,20240710,EXP,,DK-VIIV HEALTHCARE LIMITED-DK2024GSK083765,VIIV,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment. BMJ Case Reports. 2024;17 (6)",,,,,Y,,,20240710.0,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,240757281.0,HO,,,,,,,,,240757281.0,1.0,HIV infection
24104618,241046181,1,I,,20240710.0,20240717,20240717,EXP,,IN-MYLANLABS-2024M1065941,MYLAN,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et al. Drug-induced systemic lupus erythematosus in a child living with HIV. India-J-Sex-Transm-Dis 2024; 45 (1): 59-61.",12.0,YR,,M,Y,,,20240717.0,,MD,IN,IN,EFAVIRENZ,Systemic lupus erythematosus,241046181.0,HO,,,,,,,,,241046181.0,1.0,HIV infection
24114771,241147711,1,I,,20240710.0,20240721,20240721,EXP,,IN-STRIDES ARCOLAB LIMITED-2024SP008730,STRIDES,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et al.. Drug-induced systemic lupus erythematosus in a child living with HIV.. India-J-Sex-Transm-Dis. 2024;45(1):59-61",12.0,YR,,M,Y,,,20240719.0,,MD,IN,IN,EFAVIRENZ,Systemic lupus erythematosus,241147711.0,HO,,,,,,,,,241147711.0,1.0,HIV infection
24118659,241186591,1,I,,20240715.0,20240722,20240722,EXP,,IN-HETERO-HET2024IN02386,HETERO,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et.al.. Drug-induced systemic lupus erythematosus in a child living with HIV. Indian Journal of Sexually Transmitted Diseases and AIDS.. 2024;45(1):59-61",12.0,YR,,M,Y,,,20240722.0,,HP,IN,IN,EFAVIRENZ,Systemic lupus erythematosus,241186591.0,HO,,,,,,,,,241186591.0,1.0,HIV infection
24125317,241253171,1,I,,20240710.0,20240723,20240723,EXP,,US-MACLEODS PHARMA-MAC2024048349,MACLEODS,"Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D Agati VD, Markowitz GS.Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.Kidney international.2010;78(11):1171-7",63.0,YR,A,M,Y,,,20240723.0,,HP,US,US,EFAVIRENZ,Post infection glomerulonephritis;Renal tubular necrosis,241253171.0,OT,,,241253171.0,1.0,,,8.0,,241253171.0,1.0,HIV infection
24125324,241253241,1,I,,20240710.0,20240723,20240723,EXP,,US-MACLEODS PHARMA-MAC2024048352,MACLEODS,"Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D^Agati VD, Markowitz GS.Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.Kidney international.01-DEC-2010;78(11):1171-7",,,,,Y,,,20240723.0,,HP,US,US,EFAVIRENZ,Intercapillary glomerulosclerosis;Renal tubular disorder,241253241.0,OT,,,241253241.0,1.0,,,8.0,,241253241.0,1.0,HIV infection
24125664,241256641,1,I,,20240712.0,20240723,20240723,EXP,,DK-AUROBINDO-AUR-APL-2024-035672,AUROBINDO,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F.. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment.. BMJ Case Reports.. 2024;17 (6)",,,A,F,Y,,,20240723.0,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,241256641.0,HO,,,,,,,,,241256641.0,1.0,HIV infection
24131625,241316251,1,I,,20240717.0,20240724,20240724,EXP,,DK-MYLANLABS-2024M1067358,MYLAN,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F.. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment.. BMJ Case Reports.. 2024;17 (6)",,,A,F,Y,,,20240724.0,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,241316251.0,OT,,,,,,,,,241316251.0,1.0,HIV infection
24154539,241545391,1,I,,20240723.0,20240731,20240731,EXP,,BR-STRIDES ARCOLAB LIMITED-2024SP009362,STRIDES,"Muller PR, Coelho ADC, da Cruz VIF, Barros DDO, Bertolini DV.. PERFIL DO AMBULATORIO DE PRE NATAL (CIS E TRANS) DE PESSOAS GESTANTES QUE VIVEM COM HIV (PGVHIV) OU PESSOAS GESTANTES DE PARCERIAS SORODIFERENTES (PGPSD), INCLUINDO HOMENS TRANSEXUAIS NO CRT DST-AIDS SP E SEU IMPACTO SOBRE A TRANSMISSAO VERTICAL.. Brazil-J-Infect-Dis. 2023;27 (Suppl.):no pagination",,,,F,Y,,,20240731.0,,HP,BR,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,241545391.0,OT,,,,,,,,,241545391.0,1.0,HIV infection
24155899,241558991,1,I,,20240720.0,20240731,20240731,EXP,,US-AUROBINDO PHARMA GMBH-AUR-APL-2014-05905,AUROBINDO,803103150,12.0,YR,,M,Y,,,20240731.0,,HP,US,US,EFAVIRENZ,Dyspnoea;Immune reconstitution inflammatory syndrome;Neuropathy peripheral;Pericardial effusion;Skin lesion,241558991.0,OT,,,,,,,,,241558991.0,1.0,Antiretroviral therapy
24214385,242143851,1,I,,20240805.0,20240815,20240815,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2024GSK099062,VIIV,,,,,,Y,,,20240815.0,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242143851.0,OT,,,242143851.0,1.0,201402.0,201506.0,,,242143851.0,1.0,HIV infection
24214388,242143881,1,I,,20240805.0,20240815,20240815,EXP,,IT-GSK-IT2024GSK099062,GLAXOSMITHKLINE,,,,,,Y,,,20240815.0,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242143881.0,OT,,,242143881.0,1.0,201402.0,201506.0,,,242143881.0,1.0,HIV infection
24229546,242295461,1,I,20240517.0,20240813.0,20240820,20240820,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024APC100933,VIIV,,,,,,Y,,,20240820.0,,HP,CN,CN,EFAVIRENZ,Condition aggravated;Drug hypersensitivity;Osteoporosis;Petechiae;Pruritus;Rash erythematous;Rash pruritic,242295461.0,HO,,,242295461.0,1.0,20240701.0,20240705.0,4.0,DAY,242295461.0,1.0,Acquired immunodeficiency syndrome
24229548,242295481,1,I,20240517.0,20240813.0,20240820,20240820,EXP,,CN-GSK-CN2024APC100933,GLAXOSMITHKLINE,,,,,,Y,,,20240820.0,,HP,CN,CN,EFAVIRENZ,Condition aggravated;Drug hypersensitivity;Osteoporosis;Petechiae;Pruritus;Rash erythematous;Rash pruritic,242295481.0,HO,,,242295481.0,1.0,20240701.0,20240705.0,4.0,DAY,242295481.0,1.0,Acquired immunodeficiency syndrome
24230742,242307421,1,I,20180602.0,20240813.0,20240821,20240821,EXP,,UG-DEXPHARM-2024-2866,DEXCEL,"Lubega, G.; Lutaakome, J.; Kibirige, M.; Opoka, D.; Atukunda, I.; Ruzagira, E.  Vitamin B12 deficiency presenting as progressive blindness in a 33-year- old HIV-positive female patient on Efavirenz-based regimen: case report. Pan African Medical Journal 2024, V47, P164",33.0,YR,A,F,Y,,,20240821.0,,HP,UG,UG,EFAVIRENZ,Optic neuritis;Vitamin B12 deficiency,242307421.0,HO,,,242307421.0,1.0,201301.0,,2.0,WK,242307421.0,1.0,HIV infection
24235546,242355461,1,I,,20240819.0,20240822,20240822,EXP,,IT-JNJFOC-20240850285,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20240822.0,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242355461.0,OT,,,242355461.0,1.0,200910.0,202007.0,,,242355461.0,1.0,HIV infection
24254578,242545782,2,F,,20240821.0,20240827,20240830,EXP,,IT-MYLANLABS-2024M1077815,MYLAN,"Monti B, Soria A, Saladini F, Lapadula G, Squillace N, Giammarino F, et al.. Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests.. Journal of Medical Virology.. 2024;96(8)",60.0,YR,,F,Y,,,20240830.0,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242545782.0,OT,,,242545782.0,1.0,201805.0,201909.0,,,242545782.0,1.0,HIV infection
24257651,242576512,2,F,20221201.0,20240830.0,20240828,20240910,EXP,,IT-AUROBINDO-AUR-APL-2024-042100,AUROBINDO,"Monti B, Soria A, Saladini F, Lapadula G, Squillace N, Giammarino F, et al. Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests. Journal of Medical Virology. 2024;96(8):1-3.",60.0,YR,,F,Y,,,20240910.0,,HP,IT,IT,EFAVIRENZ,Drug resistance;Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242576512.0,OT,,,242576512.0,1.0,200901.0,200910.0,,,242576512.0,1.0,HIV infection
24355635,243556351,1,I,,20240918.0,20240924,20240924,EXP,,ZW-CIPLA LTD.-2024ZW08707,CIPLA,"Bishop MD, Frenkel LM, Korutaro V, Boyce CL, Beck IA, Styrchak SM et al.. Characterizing HIV drug resistance in cases of vertical transmission in the VesTed randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024;96 (4):385 to 392",,,,,Y,,,20240924.0,,HP,ZW,ZW,EFAVIRENZ,Drug ineffective;Exposure during pregnancy;HIV viraemia;Treatment noncompliance,243556351.0,OT,,,,,,,,,243556351.0,1.0,Antiretroviral therapy
24386863,243868631,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689521,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243868631.0,OT,,,,,,,,,243868631.0,1.0,HIV infection
24386872,243868721,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689478,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243868721.0,OT,,,,,,,,,243868721.0,1.0,HIV infection
24387341,243873411,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689511,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243873411.0,OT,,,,,,,,,243873411.0,1.0,HIV infection
24387344,243873441,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689509,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243873441.0,OT,,,,,,,,,243873441.0,1.0,HIV infection
24387447,243874471,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689513,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243874471.0,OT,,,,,,,,,243874471.0,1.0,HIV infection
24387464,243874641,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689517,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243874641.0,OT,,,,,,,,,243874641.0,1.0,HIV infection
24387516,243875161,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689508,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243875161.0,OT,,,,,,,,,243875161.0,1.0,HIV infection
24387527,243875271,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689510,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243875271.0,OT,,,,,,,,,243875271.0,1.0,HIV infection
24387854,243878541,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689516,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243878541.0,OT,,,,,,,,,243878541.0,1.0,HIV infection
24387856,243878561,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689512,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243878561.0,OT,,,,,,,,,243878561.0,1.0,HIV infection
24388086,243880861,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689520,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243880861.0,OT,,,,,,,,,243880861.0,1.0,HIV infection
24388099,243880991,1,I,,20240930.0,20241002,20241002,EXP,,ZA-GILEAD-2024-0689518,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241002.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243880991.0,OT,,,,,,,,,243880991.0,1.0,HIV infection
24390748,243907481,1,I,,20240930.0,20241003,20241003,EXP,,ZA-GILEAD-2024-0689519,GILEAD,"Moseki R, Barber D, Du BE, Shey M., Van DP, Wilkinson R, et al.. Phenotypic Profile of Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses in People with Advanced Human Immunodeficiency Virus Who Develop  Tuberculosis-Associated Immune Reconstitution  Inflammatory Syndrome. Open Forum Infectious Diseases. 2023;10(1):UNK. doi:10.1093/ofid/ofac546",,,A,,Y,,,20241003.0,,HP,ZA,ZA,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,243907481.0,OT,,,,,,,,,243907481.0,1.0,HIV infection
24393005,243930051,1,I,20240913.0,20240927.0,20241003,20241003,EXP,,CN-GSK-CN2024APC119543,GLAXOSMITHKLINE,,,,,,Y,,,20241003.0,,HP,CN,CN,EFAVIRENZ,Renal injury,243930051.0,HO,,,243930051.0,1.0,20171105.0,20240913.0,2504.0,DAY,243930051.0,1.0,HIV infection
24393006,243930061,1,I,20240913.0,20240927.0,20241003,20241003,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024APC119543,VIIV,,,,,,Y,,,20241003.0,,HP,CN,CN,EFAVIRENZ,Renal injury,243930061.0,OT,,,243930061.0,1.0,20171105.0,20240913.0,2504.0,DAY,243930061.0,1.0,HIV infection
24446663,244466631,1,I,20190117.0,20241008.0,20241016,20241016,EXP,,RU-GSK-RU2024EME125831,GLAXOSMITHKLINE,,,,,,Y,,,20241016.0,,HP,RU,RU,EFAVIRENZ,Acrochordon;Aortic arteriosclerosis;Aortic valve sclerosis;Arthralgia;Arthritis;Asthenia;Balanoposthitis;Blood HIV RNA increased;Bone lesion;Burning sensation;Candida infection;Carotid arteriosclerosis;Condition aggravated;Diarrhoea;Disease recurrence;Drug ineffective;Drug interaction;Drug intolerance;Dry mouth;Dysuria;Electrocardiogram repolarisation abnormality;Exostosis;Foot deformity;General physical health deterioration;HIV infection;Hepatic steatosis;Hepatitis C;Hepatitis toxic;Hepatomegaly;Hyperaemia;Hypertension;Immunosuppression;Infection reactivation;Lymphadenopathy;Mitral valve sclerosis;Oral candidiasis;Oropharyngeal plaque;Osteochondrosis;Pancreatic disorder;Pathogen resistance;Penile plaque;Penile swelling;Psoriasis;Psoriatic arthropathy;Respiratory tract infection;Retinopathy hypertensive;Skin papilloma;Synovitis;Vertebrobasilar insufficiency;Viral mutation identified;Weight decreased,244466631.0,OT,,,244466631.0,1.0,2012.0,20200205.0,411.0,DAY,244466631.0,1.0,HIV infection
24446664,244466641,1,I,20190117.0,20241008.0,20241016,20241016,EXP,,RU-VIIV HEALTHCARE-RU2024EME125831,VIIV,,,,,,Y,,,20241016.0,,HP,RU,RU,EFAVIRENZ,Acrochordon;Aortic arteriosclerosis;Aortic valve sclerosis;Arthralgia;Arthritis;Asthenia;Balanoposthitis;Blood HIV RNA increased;Bone lesion;Burning sensation;Candida infection;Carotid arteriosclerosis;Condition aggravated;Diarrhoea;Disease recurrence;Drug ineffective;Drug interaction;Drug intolerance;Dry mouth;Dysuria;Electrocardiogram repolarisation abnormality;Exostosis;Foot deformity;General physical health deterioration;HIV infection;Hepatic steatosis;Hepatitis C;Hepatitis toxic;Hepatomegaly;Hyperaemia;Hypertension;Immunosuppression;Infection reactivation;Lymphadenopathy;Mitral valve sclerosis;Oral candidiasis;Oropharyngeal plaque;Osteochondrosis;Pancreatic disorder;Pathogen resistance;Penile plaque;Penile swelling;Psoriasis;Psoriatic arthropathy;Respiratory tract infection;Retinopathy hypertensive;Skin papilloma;Synovitis;Vertebrobasilar insufficiency;Viral mutation identified;Weight decreased,244466641.0,OT,,,244466641.0,1.0,2012.0,20200205.0,411.0,DAY,244466641.0,1.0,HIV infection
24567979,245679791,1,I,,20190610.0,20241031,20241031,EXP,,GB-SANDOZ INC.-PHHY2018GB161759,SANDOZ,,,,,,Y,,,20241031.0,,HP,GB,GB,EFAVIRENZ,Congenital toxoplasmosis;Foetal exposure during pregnancy,245679791.0,CA,,,,,,,,,245679791.0,1.0,HIV infection
24573261,245732612,2,F,20240928.0,20241026.0,20241101,20241108,EXP,,CN-VIIV HEALTHCARE-CN2024APC133330,VIIV,,,,,,Y,,,20241108.0,,HP,CN,CN,EFAVIRENZ,Anaemia;Chills;Dyspnoea;Full blood count decreased;Myelosuppression,245732612.0,OT,,,245732612.0,1.0,20220101.0,20240928.0,1001.0,DAY,245732612.0,1.0,Acquired immunodeficiency syndrome
24603736,246037361,1,I,20240301.0,20241110.0,20241110,20241110,DIR,726795,,FDA-CTU,,52.0,YR,,M,N,110.0,KG,20241110.0,N,CN,GB,,EFAVIRENZ,Angina pectoris;Aspartate aminotransferase increased;Gamma-glutamyltransferase increased;Rash,246037361.0,OT,246037361.0,CSM,246037361.0,1.0,,,10.0,WK,246037361.0,1.0,HIV infection
24625982,246259821,1,I,,20241108.0,20241115,20241115,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2024-176909,BRISTOL-MYERS SQUIBB COMPANY,"Laurenda O, Anneka P, Giovanni V, Adele M, Max W, Yvonne G, et al. Autoimmune hepatitis in people living with HIV: a case series and review of literature. The Open AIDS Journal. 2023;17:1-7. doi:10.2174/18746136-v17-230825-2023-15.",47.0,YR,A,F,Y,,,20241115.0,,HP,GB,GB,EFAVIRENZ,Drug-induced liver injury,246259821.0,OT,,,246259821.0,1.0,201001.0,,,,246259821.0,1.0,HIV infection
24627476,246274762,2,F,20110101.0,20241120.0,20241116,20241129,EXP,,GB-MACLEODS PHARMA-MAC2024050246,MACLEODS,,,,,,Y,,,20241129.0,,HP,GB,GB,EFAVIRENZ,Autoimmune hepatitis;Portal fibrosis,246274762.0,OT,,,246274762.0,1.0,201001.0,201101.0,,,246274762.0,1.0,HIV infection
24677350,246773501,1,I,,20241121.0,20241129,20241129,EXP,,JP-GSK-JP2024JPN146263,GLAXOSMITHKLINE,Yoshida K. EACS LIVE! - Interactive case-based discussion -. The 38th Annual Meeting of the Japanese for AIDS Research,,,,,Y,,,20241129.0,,MD,JP,JP,EFAVIRENZ,Abscess limb;Ascites;CD4 lymphocytes abnormal;Cytomegalovirus colitis;Cytomegalovirus oesophagitis;Cytomegalovirus pancreatitis;Depression;Disseminated mycobacterium avium complex infection;Heart failure with reduced ejection fraction;Ileus paralytic;Immune reconstitution inflammatory syndrome;Liver abscess;Muscular weakness;Pneumocystis jirovecii pneumonia;Staphylococcal infection;Therapy interrupted,246773501.0,HO,,,,,,,,,246773501.0,1.0,HIV infection
24677351,246773511,1,I,,20241121.0,20241129,20241129,EXP,,JP-VIIV HEALTHCARE-JP2024JPN146263,VIIV,Yoshida K. EACS LIVE! - Interactive case-based discussion -. The 38th Annual Meeting of the Japanese for AIDS Research,,,,,Y,,,20241129.0,,MD,JP,JP,EFAVIRENZ,Abscess limb;Ascites;CD4 lymphocytes abnormal;Cytomegalovirus colitis;Cytomegalovirus oesophagitis;Cytomegalovirus pancreatitis;Depression;Disseminated mycobacterium avium complex infection;Heart failure with reduced ejection fraction;Ileus paralytic;Immune reconstitution inflammatory syndrome;Liver abscess;Muscular weakness;Pneumocystis jirovecii pneumonia;Staphylococcal infection;Therapy interrupted,246773511.0,HO,,,,,,,,,246773511.0,1.0,HIV infection
24681754,246817541,1,I,20241111.0,20241120.0,20241130,20241130,EXP,,RU-AMAROX PHARMA-HET2024RU04375,HETERO,,,,,M,Y,75.0,KG,20241130.0,,CN,RU,RU,EFAVIRENZ,Rash pruritic,246817541.0,OT,,,246817541.0,1.0,20241103.0,20241111.0,9.0,DAY,246817541.0,1.0,HIV infection
24714767,247147671,1,I,20190101.0,20241202.0,20241210,20241210,EXP,,RO-VIIV HEALTHCARE-RO2024EME151507,VIIV,,,,,,Y,,,20241210.0,,MD,RO,RO,EFAVIRENZ,Dyslipidaemia;Gallbladder cholesterolosis;Goitre;Hepatic steatosis;Obesity;Premature menopause,247147671.0,OT,,,247147671.0,1.0,20040101.0,,,,247147671.0,1.0,HIV infection
24718305,247183051,1,I,20101001.0,20241202.0,20241210,20241210,EXP,,RO-GSK-RO2024EME151506,GLAXOSMITHKLINE,,,,,,Y,,,20241210.0,,MD,RO,RO,EFAVIRENZ,Anaemia;Depression;Dyslipidaemia;Hepatitis toxic;Hyperglycaemia;Hypertension;Intervertebral disc degeneration;Myocardial ischaemia;Overweight,247183051.0,OT,,,247183051.0,1.0,20100911.0,20211010.0,4047.0,DAY,247183051.0,1.0,HIV infection
24718306,247183061,1,I,20101001.0,20241202.0,20241210,20241210,EXP,,RO-VIIV HEALTHCARE-RO2024EME151506,VIIV,,,,,,Y,,,20241210.0,,MD,RO,RO,EFAVIRENZ,Anaemia;Depression;Dyslipidaemia;Hepatitis toxic;Hyperglycaemia;Hypertension;Intervertebral disc degeneration;Myocardial ischaemia;Overweight,247183061.0,OT,,,247183061.0,1.0,20100911.0,20211010.0,4047.0,DAY,247183061.0,1.0,HIV infection
24724291,247242911,1,I,,20241204.0,20241212,20241212,EXP,,CO-STRIDES ARCOLAB LIMITED-2024SP016429,STRIDES,"Grajales-Urrego DM, Mantilla-Sylvain F, Rolon-Cadena MC, Basto-Borbon WM, Alvarez-Figueroa J.. Venous intestinal ischemia of fungal origin as a cause of intestinal obstruction in immunocompromised patients: case report and literature review.. Gut-Path. 2024;16 (1)",48.0,YR,,M,Y,,,20241212.0,,HP,CO,CO,EFAVIRENZ,Acute myeloid leukaemia;Gastrointestinal mucormycosis;Intestinal obstruction,247242911.0,HO,,,,,,,,,247242911.0,1.0,HIV infection
24726181,247261811,1,I,,20241204.0,20241212,20241212,EXP,,CO-MYLANLABS-2024M1111101,MYLAN,"Grajales-Urrego DM, Mantilla-Sylvain F, Rolon-Cadena MC, Basto-Borbon WM, Alvarez-Figueroa J. Venous intestinal ischemia of fungal origin as a cause of intestinal obstruction in immunocompromised patients: case report and literature review. Gut-Path 2024; 16 (1):.",48.0,YR,,M,Y,,,20241212.0,,HP,CO,CO,EFAVIRENZ,Acute myeloid leukaemia;Gastrointestinal mucormycosis;Intestinal obstruction,247261811.0,DE,,,,,,,,,247261811.0,1.0,HIV infection
24750479,247504792,2,F,,20241218.0,20241218,20241224,EXP,,CN-GILEAD-2024-0696989,GILEAD,"Niya H, Caiqiong Z, Zhiqing Z. Tenofovir disoproxil fumarate induced Fanconi syndrome with renal diabetes insipidus a case report. Chin J Hosp Pharm. 2024;44(22):2670-2672. doi:10.13286/j.1001-5213.2024.22.18",44.0,YR,A,M,Y,58.0,KG,20241224.0,,HP,CN,CN,EFAVIRENZ,Azotaemia;Fanconi syndrome acquired,247504792.0,OT,,,,,,,,,247504792.0,1.0,HIV infection
24752300,247523001,1,I,20241121.0,20241128.0,20241219,20241219,EXP,,CN-JNJFOC-20241242349,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,66.0,KG,20241219.0,,HP,CN,CN,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood bilirubin increased;Gamma-glutamyltransferase increased,247523001.0,HO,,,247523001.0,1.0,20240903.0,20241126.0,84.0,DAY,247523001.0,1.0,HIV infection
24788646,247886461,1,I,,20241216.0,20241230,20241230,EXP,,CO-AUROBINDO-AUR-APL-2024-062898,AUROBINDO,"Grajales-Urrego DM, Mantilla-Sylvain F, Rolon-Cadena MC, Basto-Borbon WM, Alvarez-Figueroa J.. Venous intestinal ischemia of fungal origin as a cause of intestinal obstruction in immunocompromised patients: case report and literature review. Gut Pathogens. 2024;16:66",48.0,YR,,M,Y,,,20241230.0,,HP,CO,CO,EFAVIRENZ,Acute myeloid leukaemia;Gastrointestinal mucormycosis,247886461.0,HO,,,,,,,,,247886461.0,1.0,HIV infection
